Authors,Title,Year,Source title,Volume,Issue,Art. No.,Page start,Page end,Page count,Cited by,DOI,Link,Affiliations,Authors with affiliations,Abstract,Author Keywords,References,Document Type,Source,EID
"Fan Y., Wang K., Xu S., Chen G., Di H., Cao M., Liu C.","Association between adipoq +45t>G polymorphism and type 2 diabetes: A systematic review and meta-analysis",2015,"International Journal of Molecular Sciences","16","1",,"704","723",,,10.3390/ijms16010704,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920275968&partnerID=40&md5=11f9dc5d1330e321711fb93bc71b1c47","Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese MedicineNanjing, China","Fan, Y., Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese MedicineNanjing, China; Wang, K., Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese MedicineNanjing, China; Xu, S., Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese MedicineNanjing, China; Chen, G., Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese MedicineNanjing, China; Di, H., Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese MedicineNanjing, China; Cao, M., Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese MedicineNanjing, China; Liu, C., Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese MedicineNanjing, China","Recently, a number of studies have reported the association between the single nucleotide polymorphisms (SNPs) +45T>G polymorphism in the adiponectin (ADIPOQ) gene and type 2 diabetes mellitus (T2DM) risk, though the results are inconsistent. In order to obtain a more precise estimation of the relationship, a meta-analysis was performed. In this current study, the Medline, Embase, Pubmed, ISI Web of Knowledge, Ovid, Science Citation Index Expanded Database, Wanfang Database, and China National Knowledge Infrastructure were searched for eligible studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to estimate the strength of association. Forty-five publications were included in the final meta-analysis with 9986 T2DM patients and 16,222 controls for ADIPOQ +45T>G polymorphism according to our inclusion and exclusion criteria. The +45T>G polymorphism was associated with an overall significantly increased risk of T2DM (G vs. T: OR = 1.18, 95% CI = 1.06–1.32; The dominant model: OR = 1.18, 95% CI = 1.03–1.33; The recessive model: OR = 1.47, 95% CI = 1.20–1.78; The homozygous model: OR = 1.62, 95% CI = 1.25–2.09; Except the heterozygous model: OR = 1.11, 95% CI = 0.98–1.24). Subgroup analysis revealed a significant association between the +45T>G polymorphism and T2D in an Asian population. Thus, this meta-analysis indicates that the G allele of the ADIPOQ +45T>G polymorphisms associated with a significantly increased risk of T2DM in the Asian population. © 2014 by the authors; licensee MDPI, Basel, Switzerland.","ADIPOQ; Meta-analysis; References; Single nucleotide polymorphisms (SNPs); Type 2 diabetes mellitus","Matharoo, K., Arora, P., Bhanwer, A.J., Association of adiponectin (ADIPOQ) and sulphonylurea receptor (ABCC8) gene polymorphisms with Type 2 diabetes in North Indian population of Punjab (2013) Gene, 527, pp. 228-234; Abbasi, F., Chu, J.W., Lamendola, C., McLaughlin, T., Hayden, J., Reaven, G.M., Reaven, P.D., Discrimination between obesity and insulin resistance in the relationship with adiponectin (2004) Diabetes, 53, pp. 585-590; Kern, P.A., Di Gregorio, G.B., Lu, T., Rassouli, N., Ranganathan, G., Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-α expression (2003) Diabetes, 52, pp. 1779-1785; Tschritter, O., Fritsche, A., Thamer, C., Haap, M., Shirkavand, F., Rahe, S., Staiger, H., Stumvoll, M., Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism (2003) Diabetes, 52, pp. 239-243; Takahashi, M., Arita, Y., Yamagata, K., Matsukawa, Y., Okutomi, K., Horie, M., Shimomura, I., Kihara, S., Genomic structure and mutations in adipose-specific gene, adiponectin (2000) Int. J. Obes. Relat. Metab. Disord, 24, pp. 861-868; Wang, Y., Zhang, D., Liu, Y., Yang, Y., Zhao, T., Xu, J., Li, S., He, L., Association study of the single nucleotide polymorphisms in adiponectin-associated genes with type 2 diabetes in Han Chinese (2009) J. Genet. Genomics, 36, pp. 417-423; Suriyaprom, K., Phonrat, B., Namjuntra, P., Harnroongroj, T., Tungtrongchitr, R., The –11377C>G adiponectin gene polymorphism alters the adiponectin concentration and the susceptibility to type 2 diabetes in Thais (2010) Int. J. Vitam. Nutr. Res, 80, pp. 216-224; Gupta, V., Khadqawat, R., Nq, H.K., Kumar, S., Aggarwal, A., Rao, V.R., Sachdeva, M., Validation study of type 2 diabetes-related variants of the TCF7L2, HHEX, KCNJ11, and ADIPOQ genes in one endogamous ethnic group of North India (2010) Ann. Hum. Genet, 74, pp. 361-368; Mousavinasab, F., Tahtinen, T., Jokelainen, J., Koskela, P., Vanhala, M., Oikarinen, J., Keinänen-Kiukaanniemi, S., Laakso, M., Common polymorphisms (Single-nucleotide polymorphisms SNP+45 and SNP+276) of the adiponectin gene regulate serum adiponectin concentrations and blood pressure in young Finnish men (2006) Mol. Genet. Metab, 87, pp. 147-151; Arikoglu, H., Ozdemir, H., Kaya, D.E., Ipekci, S.H., Arslan, A., Kayis, S.A., Gonen, M.S., The Adiponectin variants contribute to the genetic background of type 2 diabetes in Turkish population (2014) Gene, 534, pp. 10-16; Peters, K.E., Beilby, J., Cadby, G., Warrington, N.M., Bruce, D.G., Davis, W.A., Davis, T.M., McQuillan, B.M., A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome (2013) BMC. Med. Genet, 14, p. 15; Chiodini, B.D., Specchia, C., Gori, F., Barlera, S., D’Orazio, A., Pietri, S., Crociati, L., Signorini, S., Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: An association study in an Italian population (2010) Ther. Adv. Cardiovasc. Dis, 4, pp. 223-230; Hara, K., Boutin, P., Mori, Y., Tobe, K., Dina, C., Yasuda, K., Yamauchi, T., Eto, K., Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population (2002) Diabetes, 51, pp. 536-540; Populaire, C., Mori, Y., Dina, C., Vasseur, F., Vaxillaire, M., Kadowaki, T., Froguel, P., Does the -11377 promoter variant of APM1 gene contribute to the genetic risk for type 2 diabetes mellitus in Japanese families? (2003) Diabetologia, 46, pp. 443-445; Dong, Y., Li, G., Luo, T.H., Wu, G., Huang, W., Luo, M., Relationship between adiponectin gene polymorphisms and type 2 diabetes (2004) Acad. J. Shanghai Second. Med. Univ, 12, p. 008; Xia, H., Mo, Y.Z., Bian, R.W., Correlation between single nucleotide polymorphism of adiponectin gene and type 2 diabetes in Chinese (2004) Chin. J. Endocrinol. Metab, 20, pp. 236-237; Lee, Y.Y., Lee, N.S., Cho, Y.M., Moon, M.K., Jung, H.S., Park, Y.J., Park, H.J., Park, K.S., Genetic association study of adiponectin polymorphisms with risk of type 2 diabetes mellitus in Korean population (2005) Diabet. Med, 22, pp. 569-575; Wang, Z.X., (2005) Study on Serum Adiponectin Level and Its Gene Polymorphism in Different Glucose Tolerance Humans, , Master’s Thesis, Hebei Medical University, Shijiazhuang, China, 10 March; Su, Q.J., (2005) Association of the T-G Polymorphism in Adiponectin (Exon 2) with Diabetes and Related Risk Factors, , Master’s Thesis, Guangxi Medical University, Nanning, China, 25 May; Zhai, B., Ye, L., Liu, J.W., Interaction of adiponectin and peroxisome proliferator-activated receptor γ 2 gene polymorphisms and their relationship with type 2 diabetes in population from Beijing communities (2006) Chin. J. Clin. Rehabil, 10, pp. 28-31; Li, L.L., Kang, X.L., Ran, X.J., Wang, Y., Wang, C.H., Huang, L., Ren, J., Mao, X.M., Associations between 45T/G polymorphism of the adiponectin gene and plasma adiponectin levels with type 2 diabetes (2007) Clin. Exp. Pharmacol. Physiol, 34, pp. 1287-1290; Zhang, J., (2007) Correlation between Single Nucleotide Polymorphism (+45, 276) of Adiponectin Gene and Type 2 Diabetes in Xinjiang Uigur Population, , Master’s Thesis, Shihezi University, Shihezi, China, 15 June; Wang, Y., He, L., Huang, C.L., Correlation of adiponectin gene polymorphism and type 2 diabetes Mellitusin Han Population of Guangdong (2007) J. Trop. Med, 7, pp. 651-653; Wei, Y.L., Huo, Z.H., Zhao, W., The relationship of the adiponectin +45 nucleotide T/G polymorphism with insulin resistance, obesity and type 2 diabetes (2007) Chin. J. Diabetes, 15, pp. 583-585; Cheng, W., Yi, H.Z., Ma, X.W., Single nucleotide polymorphism of adiponectin gene 45 site in patientswith type 2 diabetes in the south of Henan province (2007) J. Zhengzhou Univ, 42, pp. 1145-1147; Shi, X.H., Jin, F., Sun, L., Li, H., Wang, L., Yang, Z., Association of the polymorphism of SNP+45 (T/G) in adiponectin gene with type 2 diabetes (2007) J. Clin. Rehabil. Tissue Eng. Res, 11, pp. 4941-4944; Wang, S.F., Zhao, J.J., Jiang, Q., The correlation between adiponectin gene polymorphism and type 2 diabetes (2007) Chin. J. Endocrinol. Metab, 23, pp. 51-52; Wu, W.J., Bu, R.F., Liu, G.P., Study on serum adiponectin level and SNP45 in adiponectin gene in type 2 diabetes patients with hypertriglyceridemia (2008) Chin. J. Diabetes, 16, pp. 402-404; Sun, H., Gong, Z.C., Yin, J.Y., Liu, H.L., Liu, Y.Z., Guo, Z.W., Zhou, H.H., Liu, Z.Q., The association of adiponectin allele 45T/G and –11377C/G polymorphisms with type 2 diabetes and rosiglitazone response in Chinese patients (2008) Br. J. Clin. Pharmacol, 65, pp. 917-926; Kang, Z., Sun, C.K., Zhao, H.Z., Sha, Y., Yu, D., Liu, D., Yan, X., Xue, Y., Correlation between polymorphism of adiponectin gene and type 2 diabetes mellitus in Bai and Han population at Daliarea (2008) Chin. J. Diabetes, 16, pp. 718-720; Chen, Q.Y., Su, Q.J., Tan, W.W., Association of the T–G polymorphism in adiponectin (Exon 2) with diabetes in Zhuang people in Guangxi (2008) J. Guangxi Med. Univ, 25, pp. 821-824; Wang, Y., Wang, T., Zhong, H.T., An association research of adiponectin gene SNP45 T/G polymorphism and type 2 diabetes mellitus (2008) Prog. Mod. Biomed, 8, pp. 84-86; Hao, J.M., Diao, Z.H., Liu, J.X., Correlation between single nucleotide polymorphism of adiponectin gene and type 2 diabetes in Han population of Hainan (2009) Hainan Med. J, 20, pp. 1-3; Zhou, Q., Yang, J., Luo, M.S., Research on adiponectin’s single nucleotide polymorphism (SNP+45) site expression in type 2 diabetes mellitus (2009) Int. J. Lab. Med, 30, pp. 105-107; Ye, H., Zhuang, J., Association research of adiponectin gene T45G polymorphism and type 2 diabetes mellitusin Han Chinese (2009) Pharm. Care. Res, 9, pp. 158-160. , (In Chinese); Wang, Y.X., Zhao, L., Yu, S.G., Correlation of adiponectin gene polymorphism and type 2 diabetes mellitus (2010) Shandong Med. J, 50, pp. 1-2; Wang, B., Wang, C., Wei, D., Zhang, J., He, H., Ma, M., Li, X., Xue, F., Jonasson, J.M.; et al. An association study of SNP +45T>G of the ADIPOQ gene with type 2 diabetes in Yi and Han people in China (2011) Int. J. Vitam. Nutr. Res, 81, pp. 392-397; He, H.J., Wei, D.Y., Wang, C.X., Association between single nucleotide polymorphism of adiponectin gene and type 2 diabetes in Han people in Liangshan, Sichuan province (2012) Chin. J. Public Health, 28, pp. 302-304; Kang, X.L., Kang, X.L., He, C.H., Correlation of 45T/G polymorphism adiponectin gene with type 2 diabetes in Kazaks of Xinjiang (2012) J. China Med. Univ, 41, pp. 454-457; Nv, Y., Ye, S.D., Hu, H.L., The association of between the polymorphism of the adiponectin gene rs2241766 and rs1501299 and the metabolic traits of type 2 diabetes in Han Chinese (2012) Chin. J. Clin. Healthc, 15, pp. 337-339; Kang, Z., Su, H., Zhang, Y., Genetic association analysis of the adiponectin polymorphisms in type 2 diabetes of Bai nationality at Dali area (2013) Lab. Med. Clin, 10, pp. 3122-3124; Menzaghi, C., Ercolino, T., Di Paola, R., Berg, A.H., Warram, J.H., Scherer, P.E., Trischitta, V., Doria, A., A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome (2002) Diabetes, 51, pp. 2306-2312; Fumeron, F., Aubert, R., Siddig, A., Betoulle, D., Péan, F., Hadjadj, S., Tichet, J., Balkau, B., Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: The epidemiologic data on the insulin resistance syndrome prospective study (2004) Diabetes, 53, pp. 1150-1157; Ukkola, O., Santaniemi, M., Rankinen, T., Leon, A.S., Skinner, J.S., Wilmore, J.H., Rao, D.C., Bouchard, C., Adiponectin polymorphisms, adiposity and insulin metabolism: HERITAGE family study and Oulu diabetic study (2005) Ann. Med, 37, pp. 141-150; González-Sánchez, J.L., Zabena, C.A., Martínez-Larrad, M.T., Fernández-Pérez, C., Pérez-Barba, M., Laakso, M., Serrano-Ríos, M., An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance (2005) Obes. Res, 13, pp. 807-812; Nannipieri, M., Posadas, R., Bonotti, A., Williams, K., Gonzalez-Villalpando, C., Stern, M.P., Ferrannini, E., Polymorphism of the 3'-untranslated region of the leptin receptor gene, but not the adiponectin SNP45 polymorphism, predicts type 2 diabetes (2006) Diabetes Care, 29, pp. 2509-2511; Schwarz, P.E., Govindarajalu, S., Towers, W., Schwanebeck, U., Fischer, S., Vasseur, F., Bornstein, S.R., Schulze, J., Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population (2006) Horm. Metab. Res, 38, pp. 447-451; Gable, D.R., Matin, J., Whittall, R., Cakmak, H., Li, K.W., Cooper, J., Miller, G.J., Investigators, H., Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetesin European subjects (2007) Ann. Hum. Genet, 71, pp. 453-466; Potapov, V.A., Chistiakov, D.A., Dubinina, A., Shamkhalova, M.S., Shestakova, M.V., Nosikov, V.V., Adiponectin andadiponectin receptor gene variants in relation to type 2 diabetes and insulin resistance related phenotypes (2008) Rev. Diabet. Stud, 5, pp. 28-37; Szopa, M., Malczewska-Malec, M., Kiec-Wilk, B., Skupien, J., Wolkow, P., Malecki, M.T., Sieradzki, J., Variants of the adiponectin gene and type 2 diabetes in a Polish population (2009) Acta Diabetol, 46, pp. 317-322; Mohammadzadeh, G., Zarghami, N., Associations between single nucleotide polymorphisms of the adiponectin gene, serum adiponectin levels and increased risk of type 2 diabetes mellitus in Iranian obese individuals (2009) Scand. J. Clin. Lab. Investig, 69, pp. 764-771; Vendramini, M.F., Pereira, A.C., Ferreira, S.R., Kasamatsu, T.S., Moisés, R.S., Japanese Brazilian Diabetes Study Group. Association of genetic variants in the adiponectin encoding gene (ADIPOQ) with type 2 diabetes in Japanese Brazilians (2010) J. Diabetes Complicat, 24, pp. 115-120; Tabatabaei-Malazy, O., Hasani-Ranjbar, S., Amoli, M.M., Heshmat, R., Sajadi, M., Derakhshan, R., Amiri, P., Tavakkoly-Bazzaz, J., Genderspecific differences in the association of adiponectin gene polymorphisms with body mass index (2010) Rev. Diabet. Stud, 7, pp. 241-246; Al-Daghri, N.M., Al-Attas, O.S., Alokail, M.S., Alkharfy, K.M., Hussain, T., Yakout, S., Vinodson, B., Sabico, S., Adiponectin gene polymorphisms (T45G and G276T), adiponectin levels and risk formetabolic diseases in an Arab population (2012) Gene, 493, pp. 142-147; Vionnet, N., Hani, E.H., Dupont, S., Gallina, S., Francke, S., Dotte, S., De Matos, F., Lecoeur, C., Genomewide search for type 2 diabetes-susceptibility genes in French whites: Evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21–q24 (2000) Am. J. Genet, 67, pp. 1470-1480; Mori, Y., Otabe, S., Dina, C., Yasuda, K., Populaire, C., Lecoeur, C., Vatin, V., Okada, T., Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p (2002) Diabetes, 51, pp. 1247-1255; Kissebah, A.H., Sonnenberg, G.E., Myklebust, J., Goldstein, M., Broman, K., James, R.G., Marks, J.A., Weber, J., Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome (2000) Proc. Natl. Acad. Sci. USA, 97, pp. 14478-14483; Borges, A.P., Guidoni, C.M., Freitas, O.D., Pereira, L.R., Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service (2011) Arg. Bras. Endocrinol. Metabol, 55, pp. 686-691; Lin, Y., Sun, Z., Current views on type 2 diabetes (2010) J. Endocrinol, 204, pp. 1-11; Gong, M., Long, J., Liu, Q., Deng, H.C., Association of the ADIPOQ rs17360539 and rs266729 polymorphisms with type 2 diabetes: A meta-analysis (2010) Mol. Cell. Endocrinol, 325, pp. 78-83; Han, L.Y., Wu, Q.H., Jiao, M.L., Kumar, S., Aggarwal, A., Rao, V.R., Sachdeva, M.P., Associations between single-nucleotide polymorphisms (+45T>G, +276G>T, –11377C>G, –11391G>A) of adiponectin gene and type 2 diabetes mellitus: A systematic review and meta-analysis (2011) Diabetologia, 54, pp. 2303-2314; Menzaghi, C., Trischitta, V., Doria, A., Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease (2007) Diabetes, 56, pp. 1198-1209; Li, Y., Li, X., Shi, L., Yang, M., Yang, Y., Tao, W., Shi, L., Yao, Y., Association of adiponectin SNP+45 and SNP+276 with type 2 diabetes in Han Chinese populations: A meta-Analysis of 26 case-control studies (2011) PLoS One, 6, p. 19686; Thompson, S.G., Why sources of heterogeneity in meta-analysis should be investigated (1994) BMJ, 309, pp. 1351-1355; Munafò, M.R., Flint, J., Meta-analysis of genetic association studies (2004) Trends Genet, 20, pp. 439-444; Nair, M., Diabetes mellitus, part 1: Physiology and complications (2007) Br. J. Nurs, 16, pp. 184-188; Liao, N., Xie, Z.K., Huang, J., Xie, Z.F., Association between the ghrelin Leu72Met polymorphism and type 2 diabetes risk: A meta-analysis (2013) Gene, 517, pp. 179-183; Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K., Tobe, K., Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome (2006) J. Clin. Investig, 116, pp. 1784-1792; Xita, N., Tsatsoulis, A. Adiponectin in diabetes mellitus (2012) Curr. Med. Chem, 19, pp. 5451-5458; Heidemann, C., Sun, Q., Van Dam, R.M., Meigs, J.B., Zhang, C., Tworoger, S.S., Mantzoros, C., Hu, F.B., Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women (2008) Ann. Intern. Med, 149, pp. 307-316; Von Eynatten, M., Humpert, P.M., Bluemm, A., Lepper, P.M., Hamann, A., Allolio, B., Nawroth, P.P., Dugi, K.A., High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men (2008) Atherosclerosis, 199, pp. 123-128; Seino, Y., Hirose, H., Saito, I., Itoh, H., High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: A population-based 6-year follow-up study in Japanese men (2009) Metabolism, 58, pp. 355-360; Fasshauer, M., Klein, J., Neumann, S., Eszlinger, M., Paschke, R., Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes (2002) Biochem. Biophys. Res. Commun, 290, pp. 1084-1089; Koerner, A., Kratzsch, J., Kiess, W., Adipocytokines: Leptin—the classical, resistin—the controversical, adiponectin—the promising, and more to come (2005) Best Pract. Res. Clin. Endocrinol. Metab, 19, pp. 525-546; Cochran, W.G., The effectiveness of adjustment by subclassification in removing bias in observational studies (1968) Biometrics, 24, pp. 295-313; Dersimonian, R., Laird, N., Meta-analysis in clinical trials (1986) Control. Clin. Trials, 7, pp. 177-188; Mantel, N., Haenszel, W., Statistical aspects of the analysis of data from retrospective studies of disease (1959) J. Natl. Cancer Inst, 22, pp. 719-748",Article,Scopus,2-s2.0-84920275968
"Muoio D.M., Newgard C.B.","Diabetes: The good in fat",2014,"Nature","516","7529",,"49","50",,,10.1038/nature14070,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929058834&partnerID=40&md5=7a6ce96518f5daa28f346d688f4e5e8b","Duke Molecular Physiology Institute, Departments of Pharmacology and Cancer Biology and Medicine, Duke University Medical CenterDurham, NC, United States","Muoio, D.M., Duke Molecular Physiology Institute, Departments of Pharmacology and Cancer Biology and Medicine, Duke University Medical CenterDurham, NC, United States; Newgard, C.B., Duke Molecular Physiology Institute, Departments of Pharmacology and Cancer Biology and Medicine, Duke University Medical CenterDurham, NC, United States",[No abstract available],,"Yore, M.M., (2014) Cell, 159, pp. 318-332; Abel, E.D., (2001) Nature, 409, pp. 729-733; Shepherd, P.R., (1993) J. Biol. Chem., 268, pp. 22243-22246; Herman, M.A., (2012) Nature, 484, pp. 333-338; Cao, H., (2008) Cell, 134, pp. 933-944; Oh, D.Y., (2010) Cell, 142, pp. 687-698",Short Survey,Scopus,2-s2.0-84929058834
"Benbenek-Klupa T., Matejko B., Klupa T.","Metabolic control in type 1 diabetes patients practicing combat sports: at least two-year follow-up study",2015,"SpringerPlus","4","1",,"","",5,,10.1186/s40064-015-0919-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925873879&partnerID=40&md5=939e0f0d7cc08d30e9076911e929b157","DiabWay Educational EnterpriseKrakow, Poland; Department of Metabolic Diseases, Jagiellonian University Medical College, Kopernika 15Krakow, Poland; University HosptalKrakow, Poland","Benbenek-Klupa, T., DiabWay Educational EnterpriseKrakow, Poland; Matejko, B., Department of Metabolic Diseases, Jagiellonian University Medical College, Kopernika 15Krakow, Poland, University HosptalKrakow, Poland; Klupa, T., Department of Metabolic Diseases, Jagiellonian University Medical College, Kopernika 15Krakow, Poland, University HosptalKrakow, Poland","Background: It is well recognized that physical activity should be an integral part of the management of diabetes. It remains controversial, however, whether combat sports, often preferred by young individuals type 1 diabetes mellitus (T1DM), may be performed without high risk of metabolic decompensation. The aim of this observational study was to summarize a two-year follow-up period of five young male patients with T1DM practicing combat sports under the care of a physical-activity oriented specialist diabetes outpatient clinic. Of the five patients, three mixed martial arts and two kick-boxing competitors were included in the study. To control glucose in each patient, an individual approach was used that took into consideration the type of training, the sequence of the exercises, and the relative proportion of different forms of exercise.Findings: During the follow-up, glycemic control was improved and maintained in all individuals. Neither an episode of hospitalization-requiring diabetic ketoacidosis nor severe hypoglycemia occurred in these patients during the follow-up.Conclusions: In conclusion, an individual approach for T1DM patients practicing combat sports may result in achieving and maintaining satisfactory glycemic control without increased risk of metabolic decompensation. © 2015, Benbenek-Klupa et al.; licensee Springer.","Combat sports; CSII; Diabetes; Insulin pump","Bridge, C.A., Jones, M.A., Drust, B., Physiological responses and perceived exertion during international Taekwondo competition (2009) Int J Sports Physiol Perform, 4, pp. 485-493; Bussau, V.A., Ferreira, L.D., Jones, T.W., The 10-s maximal sprint: a novel approach to counter an exercise-mediated fall in glycemia in individuals with type 1 diabetes (2006) Diabetes Care, 29, pp. 601-606; Campaigne, B.N., Wallberg-Henriksson, H., Gunnarsson, R., Glucose and insulin responses in relation to insulin dose and caloric intake 12 h after acute physical exercise in men with IDDM (1987) Diabetes Care, 10, pp. 716-721; Chaabène, H., Mkaouer, B., Franchini, E., Souissi, N., Selmi, M.A., Nagra, Y., Chamari, K., Physiological Responses and Performance Analysis Difference between Official and Simulated Karate Combat Conditions (2014) Asian J Sports Med, 5, pp. 21-29; Chiang, J.L., Kirkman, M.S., Laffel, L.M., Peters, A.L., Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Type 1 Diabetes Sourcebook Authors (2014) Diabetes Care, 37, pp. 2034-2054; Davey, R.J., Bussau, V.A., Paramalingam, N., Ferreira, L.D., Lim, E.M., Davis, E.A., Jones, T.W., Fournier, P.A., A 10-s sprint performed after moderate-intensity exercise neither increases nor decreases the glucose requirement to prevent late-onset hypoglycemia in individuals with type 1 diabetes (2013) Diabetes Care, 36 (12), pp. 4163-4165; Francescato, M.P., Fusi, S., Stupar, G., Noacco, C., Cattin, L., Carbohydrate requirement and insulin concentration during moderate exercise in type 1 diabetic patients (2004) Metab, 53, pp. 1126-1130; Guelfi, K.J., Jones, T.W., Fournier, P.A., The decline in blood glucose levels is less with intermittent high-intensity compared with moderate exercise in individuals with type 1 diabetes (2005) Diabetes Care, 28, pp. 1289-1294; Guelfi, K.J., Ratnam, N., Smythe, G.A., Jones, T.W., Fournier, P.A., Effect of intermittent high-intensity compared with continuous moderate exercise on glucose production and utilization in individuals with type 1 diabetes (2007) Am J Physiol Endocrinol Metab, 292, pp. 865-870; Harmer, A.R., Chisholm, D.J., McKenna, M.J., Morris, N.R., Thom, J.M., Bennett, G., Flack, J.R., High-intensity training improves plasma glucose and acid–base regulation during intermittent maximal exercise in type 1 diabetes (2007) Diabetes Care, 30 (5), pp. 1269-1271; Jimenez, C.C., Corcoran, M.H., Crawley, J.T., Guyton Hornsby, W., Peer, K.S., Philbin, R.D., Riddell, M.C., National athletic trainers’ association position statement: management of the athlete with type 1 diabetes mellitus (2007) J Athl Train, 42, pp. 536-545; Klonoff, D.C., Bergenstal, R., Blonde, L., Boren, S.A., Church, T.S., Gaffaney, J., Jovanovic, L., Wollitzer, A.O., Consensus report of the coalition for clinical research-self-monitoring of blood glucose (2008) J Diabetes Sci Technol, 2, pp. 1030-1053; Macknight, J.M., Mistry, D.J., Pastors, J.G., Holmes, V., Rynders, C.A., The daily management of athletes with diabetes (2009) Clin Sports Med, 28, pp. 479-495; Matejko, B., Grzanka, M., Kieć-Wilk, B., Małecki, M.T., Klupa, T., Clinical factors affecting the perception of hypoglycemia in type 1 diabetes patients treated with personal insulin pumps (2013) Ann Agric Environ Med, 20, pp. 152-154; Matejko, B., Skupien, J., Mrozińska, S., Grzanka, M., Cyganek, K., Kiec-Wilk, B., Malecki, M.T., Klupa, T., Factors associated with glycemic control in adult type 1 diabetes patients treated with insulin pump therapy (2015) Endocrine, 48, pp. 164-169; Murillo, S., Brugnara, L., Novials, A., One year follow-up in a group of half-marathon runners with type-1 diabetes treated with insulin analogues (2010) J Sports Med Phys Fitness, 50, pp. 506-510; Sigal, R.J., Armstrong, M.J., Colby, P., Kenny, G.P., Plotnikoff, R.C., Reichert, S.M., Riddell, M.C., Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Physical activity and diabetes (2013) Can J Diabetes, 37, pp. 40-44; Turner, D., Luzio, S., Gray, B.J., Dunseath, G., Rees, E.D., Kilduff, L.P., Campbell, M.D., Bracken, R.M., Impact of single and multiple sets of resistance exercise in type 1 diabetes (2015) Scand J Med Sci Sports, 25 (1), pp. 99-109; Yardley, J.E., Kenny, G.P., Perkins, B.A., Riddell, M.C., Malcolm, J., Boulay, P., Khandwala, F., Sigal, R.J., Effects of performing resistance exercise before versus after aerobic exercise on glycemia in type 1 diabetes (2012) Diabetes Care, 35, pp. 669-675; Yardley, J.E., Iscoe, K.E., Sigal, R.J., Kenny, G.P., Perkins, B.A., Riddell, M.C., Insulin pump therapy is associated with less post-exercise hyperglycemia than multiple daily injections: an observational study of physically active type 1 diabetes patients (2013) Diabetes Technol Ther, 15, pp. 84-88; Yardley, J.E., Kenny, G.P., Perkins, B.A., Riddell, M.C., Balaa, N., Malcolm, J., Boulay, P., Sigal, R.J., Resistance versus aerobic exercise. Acute effects on glycemia in type 1 diabetes (2013) Diabetes Care, 36, pp. 537-542",Article,Scopus,2-s2.0-84925873879
"Tseng C.-L., Lafrance J.-P., Lu S.-E., Soroka O., Miller D.R., Maney M., Pogach L.M.","Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes",2015,"BMC Nephrology","16","1", 34,"","",,,10.1186/s12882-015-0025-52015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927778499&partnerID=40&md5=58e63f8fef73064c7d518f85ca4e8cb0","Department of Veteran Affairs-New Jersey Health Care System, 385 Tremont Avenue, Mail Stop#15East Orange, NJ, United States; Department of Preventive Medicine and Community Health, Rutgers University, New Jersey Medical SchoolNewark, NJ, United States; Department of Medicine, University of MontrealMontreal, QC, Canada; Department of Biostatistics, Rutgers School of Public HealthPiscataway, NJ, United States; Bedford VA Medical Center, Center for Health Quality, Outcomes and Economic ResearchBedford, MA, United States; Boston University, School of Public HealthBoston, MA, United States","Tseng, C.-L., Department of Veteran Affairs-New Jersey Health Care System, 385 Tremont Avenue, Mail Stop#15East Orange, NJ, United States, Department of Preventive Medicine and Community Health, Rutgers University, New Jersey Medical SchoolNewark, NJ, United States; Lafrance, J.-P., Department of Medicine, University of MontrealMontreal, QC, Canada; Lu, S.-E., Department of Biostatistics, Rutgers School of Public HealthPiscataway, NJ, United States; Soroka, O., Department of Veteran Affairs-New Jersey Health Care System, 385 Tremont Avenue, Mail Stop#15East Orange, NJ, United States; Miller, D.R., Bedford VA Medical Center, Center for Health Quality, Outcomes and Economic ResearchBedford, MA, United States, Boston University, School of Public HealthBoston, MA, United States; Maney, M., Department of Veteran Affairs-New Jersey Health Care System, 385 Tremont Avenue, Mail Stop#15East Orange, NJ, United States; Pogach, L.M., Department of Veteran Affairs-New Jersey Health Care System, 385 Tremont Avenue, Mail Stop#15East Orange, NJ, United States, Department of Preventive Medicine and Community Health, Rutgers University, New Jersey Medical SchoolNewark, NJ, United States","Background: It is unknown whether variability of estimated Glomerular Filtration Rate (eGFR) is a risk factor for dialysis or death in patients with chronic kidney disease (CKD). This study aimed to evaluate variability of estimated Glomerular Filtration Rate (eGFR) as a risk factor for dialysis or death to facilitate optimum care among high risk patients. Methods: A longitudinal retrospective cohort study of 70,598 Veterans Health Administration veteran patients with diabetes and CKD (stage 3-4) in 2000 with up to 5 years of follow-up. VHA and Medicare files were linked to derive study variables. We used Cox proportional hazards models to evaluate association between time to initial dialysis/death and key independent variables: time-varying eGFR variability (measured by standard deviation (SD)) and eGFR means and slopes while adjusting for prior hospitalizations, and comorbidities. Results: There were 76.7% older than 65 years, 97.5% men, and 81.9% Whites. Patients were largely in early stage 3 (61.2%), followed by late stage 3 (28.9%), and stage 4 (9.9%); 29.1%, 46.8%, and 73.3%, respectively, died or had dialysis during the follow-up. eGFR SDs (median: 5.8, 5.1, and 4.0 ml/min/1.73 m2) and means (median: 54.1, 41.0, 27.2 ml/min/1.73 m2) from all two-year moving intervals decreased as CKD advanced; eGFR variability (relative to the mean) increased when CKD progressed (median coefficient of variation: 10.9, 12.8, and 15.4). Cox regressions revealed that one unit increase in a patient's standard deviation of eGFRs from prior two years was significantly associated with about 7% increase in risk of dialysis/death in the current year, similarly in all three CKD stages. This was after adjusting for concurrent means and slopes of eGFRs, demographics, prior hospitalization, and comorbidities. For example, the hazard of dialysis/death increased by 7.2% (hazard ratio:1.072; 95% CI = 1.067, 1.080) in early stage 3. Conclusion: eGFR variability was independently associated with elevated risk of dialysis/death even after controlling for eGFR means and slopes. © 2015 Tseng et al.; licensee BioMed Central.","Chronic kidney disease; Diabetes; Dialysis; Glomerular filtration rate; Mortality","Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E., Hsu, C., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization (2004) N Engl J Med, 351 (13), pp. 1296-1305; U.S. Renal Data System, (2011) USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, , Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Levin, A., Djurdjev, O., Beaulieu, M., Er, L., Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort (2008) Am J Kidney Dis, 52 (4), pp. 661-671; Onuigbo, M.A., The natural history of chronic kidney disease revisited-a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: A call for circumspection (2009) Adv Perit Dial, 25, pp. 85-88; Zhang, A.H., Tam, P., LeBlanc, D., Zhong, H., Chan, C.T., Bargman, J.M., Natural history of CKD stage 4 and 5 patients following referral to renal management clinic (2009) Int Urol Nephrol, 41 (4), pp. 977-982; Barrett, B.J., Garg, A.X., Goeree, R., Levin, A., Molzahn, A., Rigatto, C., A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: A randomized controlled trial (2011) Clin J Am Soc Nephrol, 6 (6), pp. 1241-1247; Al-Aly, Z., Zeringue, A., Fu, J., Rauchman, M.I., McDonald, J.R., El-Achkar, T.M., Rate of kidney function decline associates with mortality (2010) J Am Soc Nephrol, 21 (11), pp. 1961-1969; Hoefield, R.A., Kalra, P.A., Baker, P., Lane, B., New, J.P., O'Donoghue, D.J., Factors associated with kidney disease progression and mortality in a referred CKD population (2010) Am J Kidney Dis, 56 (6), pp. 1072-1081; Tangri, N., Stevens, L.A., Griffith, J., Tighiouart, H., Djurdjev, O., Naimark, D., A predictive model for progression of chronic kidney disease to kidney failure (2011) JAMA, 305 (15), pp. 1553-1559; Ambrogi, V., Thilly, N., Boini, S., Virion, J.M., Kessler, M., Briancon, S., Patterns and predictors of kidney function decline in the last year prior to dialysis (2009) Nephron Clin Pract, 111 (12), pp. c95-c101; Heaf, J.G., Mortensen, L.S., Uraemia progression in chronic kidney disease stages 3-5 is not constant (2011) Nephron Clin Pract, 118 (4), pp. c367-c374; Li, L., Astor, B.C., Lewis, J., Appel, L.J., Lipkowitz, M.S., Toto, R.D., Longitudinal Progression Trajectory of GFR Among Patients With CKD (2012) Am J Kidney Dis, 59 (4), pp. 504-512; Ali, T., Khan, I., Simpson, W., Prescott, G., Townend, J., Smith, W., Incidence and outcomes in acute kidney injury: A comprehensive population-based study (2007) J Am Soc Nephrol, 18 (4), pp. 1292-1298; Ishani, A., Xue, J.L., Himmelfarb, J., Prescott, G., Townend, J., Smith, W., Acute kidney injury increases risk of ESRD among elderly (2009) J Am Soc Nephrol, 20 (1), pp. 223-228; Lafrance, J.P., Djurdjev, O., Levin, A., Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort (2010) Nephrol Dial Transplant, 25 (7), pp. 2203-2209; Klahr, S., Levey, A.S., Beck, G.J., Caggiula, A.W., Hunsicker, L., Kusek, J.W., The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease (1994) N Engl J Med, 330 (13), pp. 877-884. , Modification of Diet in Renal Disease Study Group; Wright, J., Barkis, G., Greene, T., Agodoa, L.Y., Appel, L.J., Charleston, J., Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial (2002) JAMA, 288 (19), pp. 2421-2431; Gassman, J.J., Greene, T., Wright, J.T., Jr., Agodoa, L., Bakris, G., Beck, G.J., Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK) (2003) J Am Soc Nephrol, 14, pp. S154-S165; Al-Aly, Z., Balasubramanian, S., McDonald, J.R., Scherrer, J.F., O'Hare, A.M., Greater variability in kidney function is associated with an increased risk of death (2012) Kidney Int, 82 (11), pp. 1208-2014; Moen, M.F., Zhan, M., Hsu, V.D., Walker, L.D., Einhorn, L.M., Seliger, S.L., Frequency of hypoglycemia and its significance in chronic kidney disease (2009) Clin J Am Soc Nephrol, 4 (6), pp. 1121-1127; Miller, D.R., Safford, M.M., Pogach, L.M., Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data (2004) Diabetes Care, 27, pp. B10-B21; Kern, E.F.O., Maney, M., Miller, D.R., Tseng, C.L., Tiwari, A., Rajan, M., Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes (2006) Health Serv Res, 41 (2), pp. 564-580; Tseng, C.L., Kern, E.F.O., Miller, D., Tiwari, A., Maney, M., Rajan, M., Survival Benefit of Nephrologic Care in Patients with Diabetes and Chronic Kidney Disease (2008) Arch Intern Med, 168 (1), pp. 55-62; National Kidney Foundation, K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification (2002) Am J Kidney Dis, 39 (2), pp. S1-S266; Levey, A.S., Coresh, J., Greene, T., Stevens, L.A., Zhang, Y.L., Hendriksen, S., Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate (2006) Ann Intern Med, 145 (4), pp. 247-254; VA Information Resource Center (VIReC), VHA Vital Status File, , http://www.hsrd.research.va.gov/for_researchers/cyber_seminars/archives/694-notes.pdf, Accessed January 20, 2015; Health Benefits: Priority Group Table, , http://www.va.gov/healthbenefits/resources/priority_groups.asp, Accessed January 20, 2015; Selim, A.J., Fincke, G., Ren, X.S., Lee, A., Rogers, W.H., Miller, D.R., Comorbidity assessments based on patient report: Results from the Veterans Health Study (2004) J Ambul Care Manage, 27 (3), pp. 281-295; Yang, W., Israni, R.K., Brunelli, S.M., Hemoglobin variability and mortality in ESRD (2007) J Am Soc Nephrol, 18 (12), pp. 3164-3170; Muntner, P., Shimbo, D., Tonelli, M., Reynolds, K., Arnett, D.K., Oparil, S., The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: Findings from NHANES III, 1988 to 1994 (2011) Hypertension, 57 (2), pp. 160-166; Mazzeo, A.T., La Monaca, E., Di Leo, R., Vita, G., Santamaria, L.B., Heart rate variability: A diagnostic and prognostic tool in anesthesia and intensive care (2011) Acta Anaesthesiol Scand, 55 (7), pp. 797-811; Johansson, J.K., Niiranen, T.J., Puukka, P.J., Jula, A.M., Prognostic value of the variability in home-measured blood pressure and heart rate: The Finn-Home Study (2012) Hypertension, 59 (2), pp. 212-218; Takao, T., Matsuyama, Y., Yanagisawa, H., Kikuchi, M., Kawazu, S., Association between HbA1c variability and mortality in patients with type 2 diabetes (2014) J Diabetes Complications, 28 (4), pp. 494-499; Wadén, J., Forsblom, C., Thorn, L.M., Gordin, D., Saraheimo, M., Groop, P.H., A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes (2009) Diabetes, 58 (11), pp. 2649-2655; Musso, C.G., Renal reserve test: Its methodology and significance (2011) Saudi J Kidney Dis Transpl, 22 (5), pp. 990-993; Barai, S., Gambhir, S., Prasad, N., Sharma, R.K., Ora, M., Functional renal reserve capacity in different stages of chronic kidney disease (2010) Nephrology (Carlton), 15 (3), pp. 350-353; Schell, J.O., Patel, U.D., Steinhauser, K.E., Ammarell, N., Tulsky, J.A., Discussions of the kidney disease trajectory by elderly patients and nephrologists: A qualitative study (2012) Am J Kidney Dis, 59 (4), pp. 495-503; Levin, A., Djurdjev, O., On being better kidney doctors: Understanding trajectories, probabilities, predictability, and people (2012) Am J Kidney Dis, 59 (4), pp. 475-477; Matsushita, K., Selvin, E., Bash, L.D., Franceschini, N., Astor, B.C., Coresh, J., Change in estimated GFR associates with coronary heart disease and mortality (2009) J Am Soc Nephrol, 20, pp. 2617-2624; Turin, T.C., Coresh, J., Tonelli, M., Stevens, P.E., De Jong, P.E., Farmer, C.K., Change in the estimated glomerular filtration rate over time and risk of all-cause mortality (2013) Kidney Int, 83 (4), pp. 684-691; Perkins, R.M., Tang, X., Bengier, A.C., Kirchner, H.L., Bucaloiu, I.D., Variability in estimated glomerular filtration rate is an independent risk factor for death among patients with stage 3 chronic kidney disease (2012) Kidney Int, 82 (12), pp. 1332-1338; Turin, T.C., Coresh, J., Tonelli, M., Stevens, P.E., De Jong, P.E., Farmer, C.K., Short-term change in kidney function and risk of end-stage renal disease (2012) Nephrol Dial Transplant, 27 (10), pp. 3835-3843; Perkins, R.M., Kirchner, H.L., Hartle, J.E., Bucaloiu, I.D., Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease (2013) Clin Nephrol, 80 (4), pp. 256-262",Article,Scopus,2-s2.0-84927778499
"Heng B.C., Aubel D., Fussenegger M.","Prosthetic gene networks as an alternative to standard pharmacotherapies for metabolic disorders",2015,"Current Opinion in Biotechnology","35",,,"37","45",,,10.1016/j.copbio.2015.01.010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922422820&partnerID=40&md5=b101592fed9be10253fc82d3600febee","Department of Biological Sciences, Sunway University, Bandar SunwaySelangor Darul Ehsan, Malaysia; Department of Biosystems Science and Engineering (D-BSSE), ETH Zurich, Mattenstrasse 26Basel, Switzerland; IUTA Département Génie Biologique, Université Claude Bernard Lyon 1, Boulevard du 11 Novembre 1918Villeurbanne Cedex, France; Faculty of Science, University of Basel, Mattenstrasse 26Basel, Switzerland","Heng, B.C., Department of Biological Sciences, Sunway University, Bandar SunwaySelangor Darul Ehsan, Malaysia, Department of Biosystems Science and Engineering (D-BSSE), ETH Zurich, Mattenstrasse 26Basel, Switzerland; Aubel, D., IUTA Département Génie Biologique, Université Claude Bernard Lyon 1, Boulevard du 11 Novembre 1918Villeurbanne Cedex, France; Fussenegger, M., Department of Biosystems Science and Engineering (D-BSSE), ETH Zurich, Mattenstrasse 26Basel, Switzerland, Faculty of Science, University of Basel, Mattenstrasse 26Basel, Switzerland","Synthetic biology makes inroads into clinical therapy with the debut of closed-loop prosthetic gene networks specifically designed to treat human diseases. Prosthetic networks are synthetic sensor/effector devices that could functionally integrate and interface with host metabolism to monitor disease states and coordinate appropriate therapeutic responses in a self-sufficient, timely and automatic manner. Prosthetic networks hold particular promise for the current global epidemic of closely interrelated metabolic disorders encompassing obesity, type 2 diabetes, hypertension and hyperlipidaemia, which arise from the unhealthy lifestyle and dietary factors in the modern urbanised world. This review will critically examine the various attempts at constructing prosthetic gene networks for the treatment of these metabolic disorders, as well as provide insight into future developments in the field. © 2015 Elsevier Ltd.",,"Wang, Y.H., Wei, K.Y., Smolke, C.D., Synthetic biology: advancing the design of diverse genetic systems (2013) Annu Rev Chem Biomol Eng, 4, pp. 69-102; Lim, W.A., Lee, C.M., Tang, C., Design principles of regulatory networks: searching for the molecular algorithms of the cell (2013) Mol Cell, 49, pp. 202-212; Brophy, J.A., Voigt, C.A., Principles of genetic circuit design (2014) Nat Methods, 11, pp. 508-520; Singh, V., Recent advancements in synthetic biology: current status and challenges (2014) Gene, 535, pp. 1-11; Weber, W., Fussenegger, M., Molecular diversity - the toolbox for synthetic gene switches and networks (2011) Curr Opin Chem Biol, 15, pp. 414-420; Endo, K., Hayashi, K., Inoue, T., Saito, H., A versatile cis-acting inverter module for synthetic translational switches (2013) Nat Commun, 4, p. 2393; Minaba, M., Kato, Y., High-yield, zero-leakage expression system with a translational switch using site-specific unnatural amino Acid incorporation (2014) Appl Environ Microbiol, 80, pp. 1718-1725; Rhodius, V.A., Segall-Shapiro, T.H., Sharon, B.D., Ghodasara, A., Orlova, E., Tabakh, H., Burkhardt, D.H., Voigt, C.A., Design of orthogonal genetic switches based on a crosstalk map of σs, anti-σs, and promoters (2013) Mol Syst Biol, 9, p. 702; Shi, C., Zhou, T., Yuan, Z., Functional tunability of biological circuits from additional toggle switches (2013) IET Syst Biol, 7, pp. 126-134; Chen, S., Zhang, H., Shi, H., Ji, W., Feng, J., Gong, Y., Yang, Z., Ouyang, Q., Automated design of genetic toggle switches with predetermined bistability (2012) ACS Synth Biol, 1, pp. 284-290; Ryback, B.M., Odoni, D.I., van Heck, R.G., van Nuland, Y., Hesselman, M.C., Martins Dos Santos, V.A., van Passel, M.W., Hugenholtz, F., Design and analysis of a tunable synchronized oscillator (2013) J Biol Eng, 7, p. 26; Lomnitz, J.G., Savageau, M.A., Strategy revealing phenotypic differences among synthetic oscillator designs (2014) ACS Synth Biol, 3, pp. 686-701; Hellen, E.H., Dana, S.K., Zhurov, B., Volkov, E., Electronic implementation of a repressilator with quorum sensing feedback (2013) PLOS ONE, 8, p. e62997; Chang, Y.C., Lin, C.L., Jennawasin, T., Design of synthetic genetic oscillators using evolutionary optimization (2013) Evol Bioinform Online, 9, pp. 137-150; Osella, M., Lagomarsino, M.C., Growth-rate-dependent dynamics of a bacterial genetic oscillator (2013) Phys Rev E Stat Nonlin Soft Matter Phys, 87, p. 012726; Padirac, A., Fujii, T., Estévez-Torres, A., Rondelez, Y., Spatial waves in synthetic biochemical networks (2013) J Am Chem Soc, 135, pp. 14586-14592; Potapov, I., Zhurov, B., Volkov, E., 'Quorum sensing' generated multistability and chaos in a synthetic genetic oscillator (2012) Chaos, 22, p. 023117; Wang, B., Barahona, M., Buck, M., A modular cell-based biosensor using engineered genetic logic circuits to detect and integrate multiple environmental signals (2013) Biosens Bioelectron, 40, pp. 368-376; Davidson, E.A., Basu, A.S., Bayer, T.S., Programming microbes using pulse width modulation of optical signals (2013) J Mol Biol, 425, pp. 4161-4166; Häkkinen, A., Tran, H., Yli-Harja, O., Ribeiro, A.S., Effects of rate-limiting steps in transcription initiation on genetic filter motifs (2013) PLOS ONE, 8, p. e70439; Greber, D., Fussenegger, M., An engineered mammalian band-pass network (2010) Nucleic Acids Res, 38, p. e174; Sohka, T., Heins, R.A., Phelan, R.M., Greisler, J.M., Townsend, C.A., Ostermeier, M., An externally tunable bacterial band-pass filter (2009) Proc Natl Acad Sci U S A, 106, pp. 10135-10140; Muranaka, N., Yokobayashi, Y., A synthetic riboswitch with chemical band-pass response (2010) Chem Commun (Camb), 46, pp. 6825-6827; Sohka, T., Heins, R.A., Ostermeier, M., Morphogen-defined patterning of Escherichia coli enabled by an externally tunable band-pass filter (2009) J Biol Eng, 3, p. 10; Prindle, A., Selimkhanov, J., Li, H., Razinkov, I., Tsimring, L.S., Hasty, J., Rapid and tunable post-translational coupling of genetic circuits (2014) Nature, 508, pp. 387-391; Bacchus, W., Fussenegger, M., Engineering of synthetic intercellular communication systems (2013) Metab Eng, 16, pp. 33-41; Hoffman-Sommer, M., Supady, A., Klipp, E., Cell-to-cell communication circuits: quantitative analysis of synthetic logic gates (2012) Front Physiol, 3, p. 287; Chuang, J.S., Engineering multicellular traits in synthetic microbial populations (2012) Curr Opin Chem Biol, 16, pp. 370-378; Bacchus, W., Lang, M., El-Baba, M.D., Weber, W., Stelling, J., Fussenegger, M., Synthetic two-way communication between mammalian cells (2012) Nat Biotechnol, 30, pp. 991-996; Bacchus, W., Aubel, D., Fussenegger, M., Biomedically relevant circuit-design strategies in mammalian synthetic biology (2013) Mol Syst Biol, 9, p. 691; Ye, H., Aubel, D., Fussenegger, M., Synthetic mammalian gene circuits for biomedical applications (2013) Curr Opin Chem Biol, 17, pp. 910-917; Wu, K., Rao, C.V., Computational methods in synthetic biology: towards computer-aided part design (2012) Curr Opin Chem Biol, 16, pp. 318-322; Lux, M.W., Bramlett, B.W., Ball, D.A., Peccoud, J., Genetic design automation: engineering fantasy or scientific renewal? (2012) Trends Biotechnol, 30, pp. 120-126; Ye, H., Charpin-El Hamri, G., Zwicky, K., Christen, M., Folcher, M., Fussenegger, M., Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome (2013) Proc Natl Acad Sci U S A, 110, pp. 141-146; Ye, H., Daoud-El Baba, M., Peng, R.W., Fussenegger, M., A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice (2011) Science, 332, pp. 1565-1568; Stanley, S.A., Gagner, J.E., Damanpour, S., Yoshida, M., Dordick, J.S., Friedman, J.M., Radio-wave heating of iron oxide nanoparticles can regulate plasma glucose in mice (2012) Science, 336, pp. 604-608; Lam, D.W., LeRoith, D., The worldwide diabetes epidemic (2012) Curr Opin Endocrinol Diabetes Obes, 19, pp. 93-96; Wang, X., Chen, X., Yang, Y., Spatiotemporal control of gene expression by a light-switchable transgene system (2012) Nat Methods, 9, pp. 266-269; Ma, Z., Du, Z., Chen, X., Wang, X., Yang, Y., Fine tuning the LightOn light-switchable transgene expression system (2013) Biochem Biophys Res Commun, 440, pp. 419-423; Stanley, S.A., Sauer, J., Kane, R.S., Dordick, J.S., Friedman, J.M., Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles (2015) Nat Med, 21, pp. 92-98; Folcher, M., Oesterle, S., Zwicky, K., Thekkottil, T., Heymoz, J., Hohmann, M., Christen, M., Fussenegger, M., Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant (2014) Nat Commun, 5, p. 5392; Rössger, K., Charpin-El Hamri, G., Fussenegger, M., Reward-based hypertension control by a synthetic brain-dopamine interface (2013) Proc Natl Acad Sci U S A, 110, pp. 18150-18155; Singh, M., Mood, food, and obesity (2014) Front Psychol, 5, p. 925; Blum, K., Chen, A.L., Giordano, J., Borsten, J., Chen, T.J., Hauser, M., Simpatico, T., Barh, D., The addictive brain: all roads lead to dopamine (2012) J Psychoactive Drugs, 44, pp. 134-143; Baradaran, A., Nasri, H., Rafieian-Kopaei, M., Oxidative stress and hypertension: possibility of hypertension therapy with antioxidants (2014) J Res Med Sci, 19, pp. 358-367; Symonides, B., Holas, P., Schram, M., Sleszycka, J., Bogaczewicz, A., Gaciong, Z., Does the control of negative emotions influence blood pressure control and its variability? (2014) Blood Press, 23, pp. 323-329; Kemmer, C., Gitzinger, M., Daoud-El Baba, M., Djonov, V., Stelling, J., Fussenegger, M., Self-sufficient control of urate homeostasis in mice by a synthetic circuit (2010) Nat Biotechnol, 28, pp. 355-360; Karis, E., Crittenden, D.B., Pillinger, M.H., Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street (2014) South Med J, 107, pp. 235-241; Takai, M., Yamauchi, T., Fujita, K., Lee, S., Ookura, M., Kishi, S., Urasaki, Y., Ueda, T., Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome (2014) Oncol Lett, 8, pp. 1523-1527; Rössger, K., Charpin-El-Hamri, G., Fussenegger, M., A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice (2013) Nat Commun, 4, p. 2825; Pandey, R.P., Li, T.F., Kim, E.H., Yamaguchi, T., Park, Y.I., Kim, J.S., Sohng, J.K., Enzymatic synthesis of novel phloretin glucosides (2013) Appl Environ Microbiol, 79, pp. 3516-3521; Ausländer, D., Ausländer, S., Charpin-El Hamri, G., Sedlmayer, F., Müller, M., Frey, O., Hierlemann, A., Fussenegger, M., A synthetic multifunctional mammalian pH sensor and CO2 transgene-control device (2014) Mol Cell, 55, pp. 397-408; Gosmanov, A.R., Gosmanova, E.O., Dillard-Cannon, E., Management of adult diabetic ketoacidosis (2014) Diabetes Metab Syndr Obes, 7, pp. 255-264; Greco, S.J., Rameshwar, P., Mesenchymal stem cells in drug/gene delivery: implications for cell therapy (2012) Ther Deliv, 3, pp. 997-1004; Sanz, L., Compte, M., Guijarro-Muñoz, I., Álvarez-Vallina, L., Non-hematopoietic stem cells as factories for in vivo therapeutic protein production (2012) Gene Ther, 19, pp. 1-7; Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., Induction of pluripotent stem cells from adult human fibroblasts by defined factors (2007) Cell, 131, pp. 861-872; Turner, M., Leslie, S., Martin, N.G., Peschanski, M., Rao, M., Taylor, C.J., Trounson, A., Wilmut, I., Toward the development of a global induced pluripotent stem cell library (2013) Cell Stem Cell, 13, pp. 382-384",Review,Scopus,2-s2.0-84922422820
"Assaad-Khalil S.H., Najem R., Sison J., Kitchlew A.R., Cho B., Ueng K.-C., Ditommaso S., Shete A.","Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups",2015,"Vascular Health and Risk Management","11",,,"71","78",,,10.2147/VHRM.S76599,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921860898&partnerID=40&md5=77e86d5df324f0abd15038b1f481e877","Department of Diabetology, Lipidology and Metabolism, Alexandria UniversityAlexandria, Egypt; Lebanese University HospitalBeirut, Lebanon; Medical Center ManilaManila, Philippines; Pakistan Institute of Medical SciencesIslamabad, Pakistan; Seoul National University College of MedicineSeoul, South Korea; Chung Shan Medical University HospitalTaichung City, Taiwan; Novartis Pharma AGAGBasel, Switzerland","Assaad-Khalil, S.H., Department of Diabetology, Lipidology and Metabolism, Alexandria UniversityAlexandria, Egypt; Najem, R., Lebanese University HospitalBeirut, Lebanon; Sison, J., Medical Center ManilaManila, Philippines; Kitchlew, A.R., Pakistan Institute of Medical SciencesIslamabad, Pakistan; Cho, B., Seoul National University College of MedicineSeoul, South Korea; Ueng, K.-C., Chung Shan Medical University HospitalTaichung City, Taiwan; Ditommaso, S., Novartis Pharma AGAGBasel, Switzerland; Shete, A., Novartis Pharma AGAGBasel, Switzerland","Background: The clinical EXCITE (EXperienCe of amlodIpine and valsarTan in hypErtension) study reported clinically relevant blood pressure (BP) reductions across all doses of amlodipine/valsartan (Aml/Val) and Aml/Val/hydrochlorothiazide (HCT) single-pill combinations. The study prospectively observed a multiethnic population of hypertensive patients for 26 weeks who were treated according to routine clinical practice. Here, we present the results in high-risk subgroups including the elderly, obese patients, and patients with diabetes or isolated systolic hypertension. In addition, we present a post hoc analysis as per prior antihypertensive monotherapy and dual therapy. Methods: Patients prescribed Aml/Val or Aml/Val/HCT were assessed in this 26±8 week, noninterventional, multicenter study across 13 countries in the Middle East and Asia. Changes in mean sitting systolic BP, mean sitting diastolic BP, and overall safety were assessed. Results: Of a total of 9,794 patients analyzed, 8,603 and 1,191 patients were prescribed Aml/Val and Aml/Val/HCT, respectively. Among these, 15.5% were elderly, 32.5% were obese, 31.3% had diabetes, and 9.8% had isolated systolic hypertension. Both Aml/Val and Aml/Val/HCT single-pill combinations, respectively, were associated with clinically relevant and significant mean sitting systolic/diastolic BP reductions across all subgroups: elderly patients (−32.2/−14.3 mmHg and −38.5/−16.5 mmHg), obese patients (−32.2/−17.9 mmHg and −38.5/−18.4 mmHg), diabetic patients (−30.3/−16.1 mmHg and −34.4/−16.6 mmHg), and patients with isolated systolic hypertension (−25.5/−4.1 mmHg and −30.2/−5.9 mmHg). Incremental BP reductions with Aml/Val or Aml/Val/HCT single-pill combinations were also observed in patients receiving prior monotherapy or dual therapy for hypertension. Overall, both Aml/Val and Aml/Val/HCT were generally well tolerated. Conclusion: This large, multiethnic study supports the evidence that Aml/Val and Aml/Val/HCT single-pill combinations are effective in diverse and clinically important subgroups of patients with hypertension. © 2015 Assaad-Khalil et al.","Amlodipine; Hydrochlorothiazide; Real world; Single-pill combinations; Valsartan","Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J., Global burden of hypertension: Analysis of worldwide data (2005) Lancet, 365, pp. 217-223; Chow, C.K., Teo, K.K., Rangarajan, S., Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries (2013) JAMA, 310, pp. 959-968; Gradman, A.H., Managing high-risk patients with hypertension: Focus on the renin-angiotensin system (2004) J Clin Hypertens (Greenwich), 6, pp. 501-508; Mancia, G., Fagard, R., Narkiewicz, K., ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) J Hypertens. 2013;31, pp. 1281-1357; Bramlage, P., Pittrow, D., Wittchen, H.U., Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled (2004) Am J Hypertens, 17, pp. 904-910; Eguchi, K., Pickering, T.G., Kario, K., Why is blood pressure so hard to control in patients with type 2 diabetes? (2007) J Cardiometab Syndr, 2, pp. 114-118; Stokes, G.S., Management of hypertension in the elderly patient (2009) Clin Interv Aging, 4, pp. 379-389; Chobanian, A.V., Bakris, G.L., Black, H.R., Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (2003) Hypertension, 42, pp. 1206-1252; Duprez, D., Treatment of isolated systolic hypertension in the elderly (2012) Expert Rev Cardiovasc Ther, 10, pp. 1367-1373; Kidambi, S., Kotchen, T.A., Treatment of hypertension in obese patients (2013) Am J Cardiovasc Drugs, 13, pp. 163-175; Mallat, S.G., Itani, H.S., Tanios, B.Y., Current perspectives on combination therapy in the management of hypertension (2013) Integr Blood Press Control, 6, pp. 69-78; Chiang, C.E., Wang, T.D., Li, Y.H., Guidelines of the Taiwan Society of Cardiology for the management of hypertension (2010) J Formos Med Assoc, 109, pp. 740-773; Chung, N., Baek, S., Chen, M.F., Expert recommendations on the challenges of hypertension in Asia (2008) Int J Clin Pract, 62, pp. 1306-1312; Fujita, T., Wu, Z., Park, J.-B., Chen, M.-F., Briefings on JHS, CHS, KHS and THS guidelines and their difference from JNC VII and ESC/ESH (2006) Int J Clin Pract, 60, pp. 3-6; Sison, J., Assaad-Khalil, S.H., Najem, R., Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: The EXCITE study (2014) Curr Med Res Opin, 30, pp. 1937-1945; Pistrosch, F., Natali, A., Hanefeld, M., Is hyperglycemia a cardiovascular risk factor? (2011) Diabetes Care, 34, pp. S128-S131; Stearne, M.R., Palmer, S.L., Hammersley, M.S., Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group (1998) BMJ, 317, pp. 703-713; Singer, G.M., Setaro, J.F., Secondary hypertension: Obesity and the metabolic syndrome (2008) J Clin Hypertens (Greenwich), 10, pp. 567-574; Landsberg, L., Aronne, L.J., Beilin, L.J., Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment – a position paper of the The Obesity Society and The American Society of Hypertension (2013) Obesity (Silver Spring), 21, pp. 8-24; Chobanian, A.V., Bakris, G.L., Black, H.R., The Seventh Report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report (2003) JAMA, 289, pp. 2560-2572; Weber, M.A., Schiffrin, E.L., White, W.B., Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension (2014) J Clin Hypertens (Greenwich), 16, pp. 14-26; Izzo, J.L., Jr., Levy, D., Black, H.R., Clinical Advisory Statement. Importance of systolic blood pressure in older Americans (2000) Hypertension, 35, pp. 1021-1024; Calhoun, D.A., Lacourciere, Y., Crikelair, N., Jia, Y., Glazer, R.D., Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension (2013) Curr Med Res Opin, 29, pp. 901-910; Smith, T.R., Philipp, T., Vaisse, B., Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: Subgroup analyses of 2 randomized, placebo-controlled studies (2007) J Clin Hypertens (Greenwich), 9, pp. 355-364; Flack, J.M., Calhoun, D.A., Satlin, L., Barbier, M., Hilkert, R., Brunel, P., Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: The EX-STAND study (2009) J Hum Hypertens, 23, pp. 479-489; Allemann, Y., Fraile, B., Lambert, M., Barbier, M., Ferber, P., Izzo, J.L., Jr., Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The Exforge in Failure after Single Therapy (EX-FAST) study (2008) J Clin Hypertens (Greenwich), 10, pp. 185-194; Destro, M., Luckow, A., Samson, M., Kandra, A., Brunel, P., Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: A randomized, double-blind, multicenter study: The EX-EFFeCTS Study (2008) J am Soc Hypertens, 2, pp. 294-302; Calhoun, D.A., Crikelair, N.A., Yen, J., Glazer, R.D., Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety (2009) Adv Ther, 26, pp. 1012-1023; Poldermans, D., Glazes, R., Kargiannis, S., Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension (2007) Clin Ther, 29, pp. 279-289; Eckert, S., Freytag, S.B., Muller, A., Klebs, S.H., Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors (2013) Blood Press, 22, pp. 11-21; Kizilirmak, P., Berktas, M., Yalcin, M.R., Boyaci, B., Efficacy and safety of valsartan and amlodipine single-pill combination in hypertensive patients (PEAK study) (2013) Turk Kardiyol Dern Ars, 41, pp. 406-417; Hu, D., Liu, L., Li, W., Efficacy and safety of valsartan/amlodipine single-pill Combination in 11,422 Chinese patients with hypertension: An observational study (2014) Adv Ther, 31, pp. 762-775; Dusing, R., Optimizing blood pressure control through the use of fixed combinations (2010) Vasc Health Risk Manag, 6, pp. 321-325",Article,Scopus,2-s2.0-84921860898
"Wright Nunes J.A., Anderson C.A.M., Greene J.H., Ikizler T.A., Cavanaugh K.L.","Results of a novel screening tool measuring dietary sodium knowledge in patients with chronic kidney disease",2015,"BMC Nephrology","16","1",,"","",,,10.1186/s12882-015-0027-3,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927771938&partnerID=40&md5=7fb9d59a0147f808f8a486e6d502f0e7","Department of Internal Medicine, Division of Nephrology, University of Michigan Health System, Simpson Memorial Building, Room 311 102 ObservatoryAnn Arbor, MI, United States; San Diego, Division of Preventive Medicine, University of CaliforniaSan Diego, CA, United States; Vanderbilt University Medical Center, Division of NephrologyNashville, TN, United States; Vanderbilt University Medical Center, Vanderbilt Center for Kidney DiseaseNashville, TN, United States","Wright Nunes, J.A., Department of Internal Medicine, Division of Nephrology, University of Michigan Health System, Simpson Memorial Building, Room 311 102 ObservatoryAnn Arbor, MI, United States; Anderson, C.A.M., San Diego, Division of Preventive Medicine, University of CaliforniaSan Diego, CA, United States; Greene, J.H., Vanderbilt University Medical Center, Division of NephrologyNashville, TN, United States; Ikizler, T.A., Vanderbilt University Medical Center, Division of NephrologyNashville, TN, United States, Vanderbilt University Medical Center, Vanderbilt Center for Kidney DiseaseNashville, TN, United States; Cavanaugh, K.L., Vanderbilt University Medical Center, Division of NephrologyNashville, TN, United States, Vanderbilt University Medical Center, Vanderbilt Center for Kidney DiseaseNashville, TN, United States","Background: Reducing dietary sodium has potential to benefit patients with chronic kidney disease (CKD). Little research is available defining dietary sodium knowledge gaps in patients with pre-dialysis CKD. We designed a brief screening tool to rapidly identify patient knowledge gaps related to dietary sodium for patients with CKD not yet on dialysis. Methods: A Short Sodium Knowledge Survey (SSKS) was developed and administered to patients with pre-dialysis CKD. We also asked patients if they received counseling on dietary sodium reduction and about recommended intake limits. We performed logistic regression to examine the association between sodium knowledge and patient characteristics. Characteristics of patients who answered all SSKS questions correctly were compared to those who did not. Results: One-hundred fifty-five patients were surveyed. The mean (SD) age was 56.6 (15.1) years, 84 (54%) were men, and 119 (77%) were white. Sixty-seven patients (43.2%) correctly identified their daily intake sodium limit. Fifty-eight (37.4%) were unable to answer all survey questions correctly. In analysis adjusted for age, sex, race, education, health literacy, CKD stage, self-reported hypertension and attendance in a kidney education class, women and patients of non-white race had lower odds of correctly answering survey questions (0.36 [0.16,0.81]; p = 0.01 women versus men and 0.33 [0.14,0.76]; p = 0.01 non-white versus white, respectively). Conclusions: Our survey provides a mechanism to quickly identify dietary sodium knowledge gaps in patients with CKD. Women and patients of non-white race may have knowledge barriers impeding adherence to sodium reduction advice. © 2015 Nunes et al.; licensee BioMed Central.","Dietary sodium; Kidney disease; Patient knowledge; Survey","Fotherby, M.D., Potter, J.F., Effects of moderate sodium restriction on clinic and twenty-four-hour ambulatory blood pressure in elderly hypertensive subjects (1993) J Hypertens, 11 (6), pp. 657-663; McMahon, E.J., Campbell, K.L., Mudge, D.W., Bauer, J.D., Achieving salt restriction in chronic kidney disease (2012) Int J Nephrol, 2012, p. 720429; He, F.J., Li, J., Macgregor, G.A., Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials (2013) BMJ, 346, p. f1325; Arora, P., Vasa, P., Brenner, D., Iglar, K., McFarlane, P., Morrison, H., Prevalence estimates of chronic kidney disease in Canada: Results of a nationally representative survey (2013) CMAJ, 185 (9), pp. E417-E423; Kearns, B., Gallagher, H., De Lusignan, S., Predicting the prevalence of chronic kidney disease in the English population: A cross-sectional study (2013) BMC Nephrol, 14, p. 49; Singh, A.K., Farag, Y.M., Mittal, B.V., Subramanian, K.K., Reddy, S.R., Acharya, V.N., Epidemiology and risk factors of chronic kidney disease in India - Results from the SEEK (screening and early evaluation of kidney disease) study (2013) BMC Nephrol, 14, p. 114; U.S. Renal Data System, (2013) USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, , National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; Mc Causland, F.R., Waikar, S.S., Brunelli, S.M., Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients (2012) Kidney Int, 82 (2), pp. 204-211; Vegter, S., Perna, A., Postma, M.J., Navis, G., Remuzzi, G., Ruggenenti, P., Sodium intake, ACE inhibition, and progression to ESRD (2012) J Am Soc Nephrol, 23 (1), pp. 165-173; Agarwal, R., Resistant hypertension and the neglected antihypertensive: Sodium restriction (2012) Nephrol Dial Transplant, 27 (11), pp. 4041-4045; K/DOQI clinical practice guidelines for nutrition in chronic renal failure (2000) Am J Kidney Dis, 35 (6), pp. S1-S140; K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease (2004) Am J Kidney Dis, 43 (5), pp. S1-S290; Nishida, C., Uauy, R., Kumanyika, S., Shetty, P., The joint WHO/FAO expert consultation on diet, nutrition and the prevention of chronic diseases: Process, product and policy implications (2004) Public Health Nutr, 7 (1), pp. 245-250. , SPI; Kutlugun, A.A., Arici, M., Yildirim, T., Turgut, D., Yilmaz, R., Altindal, M., Daily sodium intake in chronic kidney disease patients during nephrology clinic follow-up: An observational study with 24-hour urine sodium measurement (2011) Nephron Clin Pract, 118 (4), pp. c361-c366; Wright, J.A., Cavanaugh, K.L., Dietary sodium in chronic kidney disease: A comprehensive approach (2010) Semin Dial, 23 (4), pp. 415-421; Cobb, L.K., Appel, L.J., Anderson, C.A., Strategies to reduce dietary sodium intake (2012) Curr Treat Options Cardiovasc Med, 14 (4), pp. 425-434; Van Der Wal, M.H., Jaarsma, T., Adherence in heart failure in the elderly: Problem and possible solutions (2008) Int J Cardiol, 125 (2), pp. 203-208; Smith, K., Coston, M., Glock, K., Elasy, T.A., Wallston, K.A., Ikizler, T.A., Patient perspectives on fluid management in chronic hemodialysis (2010) J Ren Nutr, 20 (5), pp. 334-341; Clark-Cutaia, M.N., Ren, D., Hoffman, L.A., Burke, L.E., Sevick, M.A., Adherence to hemodialysis dietary sodium recommendations: Influence of patient characteristics, self-efficacy, and perceived barriers (2014) J Ren Nutr, 24 (2), pp. 92-99; Cavanaugh, K.L., Wingard, R.L., Hakim, R.M., Elasy, T.A., Ikizler, T.A., Patient dialysis knowledge is associated with permanent arteriovenous access use in chronic hemodialysis (2009) Clin J Am Soc Nephrol, 4 (5), pp. 950-956; Finkelstein, F.O., Story, K., Firanek, C., Barre, P., Takano, T., Soroka, S., Perceived knowledge among patients cared for by nephrologists about chronic kidney disease and end-stage renal disease therapies (2008) Kidney Int, 74 (9), pp. 1178-1184; Agondi Rde, F., Gallani, M.C., Rodrigues, R.C., Cornelio, M.E., Relationship between beliefs regarding a low salt diet in chronic renal failure patients on dialysis (2011) J Ren Nutr, 21 (2), pp. 160-168; Cupisti, A., Ferretti, V., D'Alessandro, C., Petrone, I., Di Giorgio, A., Meola, M., Nutritional knowledge in hemodialysis patients and nurses: Focus on phosphorus (2012) J Ren Nutr, 22 (6), pp. 541-546; Park, K.A., Choi-Kwon, S., Sim, Y.M., Kim, S.B., Comparison of dietary compliance and dietary knowledge between older and younger Korean hemodialysis patients (2008) J Ren Nutr, 18 (5), pp. 415-423; Pollock, J.B., Jaffery, J.B., Knowledge of phosphorus compared with other nutrients in maintenance dialysis patients (2007) J Ren Nutr, 17 (5), pp. 323-328; Davis, T.C., Long, S.W., Jackson, R.H., Mayeaux, E.J., George, R.B., Murphy, P.W., Rapid estimate of adult literacy in medicine: A shortened screening instrument (1993) Fam Med, 25 (6), pp. 391-395; Wright Nunes, J., Greene, J.H., Wallston, K., Eden, S., Shintani, A., Elasy, T., Pilot study of a physician-delivered education tool to increase patient knowledge about CKD (2013) Am J Kidney Dis, 62 (1), pp. 23-32; KDOQI, Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease (2007) Am J Kidney Dis, 49 (2), pp. S12-S154; Levey, A.S., Coresh, J., Balk, E., Kausz, A.T., Levin, A., Steffes, M.W., National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification (2003) Ann Intern Med, 139 (2), pp. 137-147; Cavanaugh, K.L., Merkin, S.S., Plantinga, L.C., Fink, N.E., Sadler, J.H., Powe, N.R., Accuracy of patients' reports of comorbid disease and their association with mortality in ESRD (2008) Am J Kidney Dis, 52 (1), pp. 118-127; McMahon, E.J., Bauer, J.D., Hawley, C.M., Isbel, N.M., Stowasser, M., Johnson, D.W., A randomized trial of dietary sodium restriction in CKD (2013) J Am Soc Nephrol, 24 (12), pp. 2096-2103; Vermeire, E., Hearnshaw, H., Van Royen, P., Denekens, J., Patient adherence to treatment: Three decades of research. A comprehensive review (2001) J Clin Pharm Ther, 26 (5), pp. 331-342; Rees, K., Dyakova, M., Ward, K., Thorogood, M., Brunner, E., Dietary advice for reducing cardiovascular risk (2013) Cochrane Database Syst Rev, 3, p. CD002128; Wright-Nunes, J.A., Luther, J.M., Ikizler, T.A., Cavanaugh, K.L., Patient knowledge of blood pressure target is associated with improved blood pressure control in chronic kidney disease (2012) Patient Educ Couns, 88 (2), pp. 184-188; Sevick, M.A., Stone, R.A., Novak, M., Piraino, B., Snetselaar, L., Marsh, R.M., A PDA-based dietary self-monitoring intervention to reduce sodium intake in an in-center hemodialysis patient (2008) Patient Prefer Adherence, 2, pp. 177-184; Tan, A.U., Hoffman, B., Rosas, S.E., Patient perception of risk factors associated with chronic kidney disease morbidity and mortality (2010) Ethn Dis, 20 (2), pp. 106-110; Flack, J.M., Grimm, R.H., Jr., Staffileno, B.A., Elmer, P., Yunis, C., New salt-sensitivity metrics: Variability-adjusted blood pressure change and the urinary sodium-to-creatinine ratio (2002) Ethn Dis, 12 (1), pp. 10-19; Wong, M., Gucciardi, E., Li, L., Grace, S.L., Gender and nutrition management in type 2 diabetes (2005) Can J Diet Pract Res, 66 (4), pp. 215-220; Wright, J.A., Wallston, K.A., Elasy, T.A., Ikizler, T.A., Cavanaugh, K.L., Development and results of a kidney disease knowledge survey given to patients with CKD (2011) Am J Kidney Dis, 57 (3), pp. 387-395; Green, J.A., Mor, M.K., Shields, A.M., Sevick, M.A., Palevsky, P.M., Fine, M.J., Prevalence and demographic and clinical associations of health literacy in patients on maintenance hemodialysis (2011) Clin J Am Soc Nephrol, 6 (6), pp. 1354-1360; Abdel-Kader, K., Dew, M.A., Bhatnagar, M., Argyropoulos, C., Karpov, I., Switzer, G., Numeracy skills in CKD: Correlates and outcomes (2010) Clin J Am Soc Nephrol, 5 (9), pp. 1566-1573; U.S. Renal Data System, (2010) USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, , National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD",Article,Scopus,2-s2.0-84927771938
"Messa P., Cozzolino M., Brancaccio D., Cannella G., Malberti F., Costanzo A.M., Paparatti U.D.L., Festa V., Gualberti G., Mazzaferro S.","Effect of VDRA on survival in incident hemodialysis patients: Results of the FARO-2 observational study",2015,"BMC Nephrology","16","1", 11,"","",,,10.1186/s12882-015-0006-8,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927714379&partnerID=40&md5=23669daad9f12897699ba56506980064","Nephrology, Dialysis and Renal Transplant, Fondazione Ca' Granda IRCCS-PoliclinicoMilan, Italy; Department of Health Sciences, University of Milan, San Paolo HospitalMilan, Italy; Dialysis Unit, Simone MartiniMilan, Italy; Department of Nephrology, San Martino HospitalGenoa, Italy; Divisione di Nefrologia E Dialisi, Azienda Ospedaliera Istituti Ospitalieri di CremonaCremona, Italy; AbbVie Italy, CampoverdeLatina, Italy; Dipartimento di Scienze Cardiovascolari Respiratorie Nefrologiche E Geriatriche, Sapienza Università di RomaRoma, Italy","Messa, P., Nephrology, Dialysis and Renal Transplant, Fondazione Ca' Granda IRCCS-PoliclinicoMilan, Italy; Cozzolino, M., Department of Health Sciences, University of Milan, San Paolo HospitalMilan, Italy; Brancaccio, D., Dialysis Unit, Simone MartiniMilan, Italy; Cannella, G., Department of Nephrology, San Martino HospitalGenoa, Italy; Malberti, F., Divisione di Nefrologia E Dialisi, Azienda Ospedaliera Istituti Ospitalieri di CremonaCremona, Italy; Costanzo, A.M., AbbVie Italy, CampoverdeLatina, Italy; Paparatti, U.D.L., AbbVie Italy, CampoverdeLatina, Italy; Festa, V., AbbVie Italy, CampoverdeLatina, Italy; Gualberti, G., AbbVie Italy, CampoverdeLatina, Italy; Mazzaferro, S., Dipartimento di Scienze Cardiovascolari Respiratorie Nefrologiche E Geriatriche, Sapienza Università di RomaRoma, Italy","Background: Mortality rate among patients with stage five chronic kidney disease (CKD) maintained on hemodialysis (HD) is high. Although evidence suggests that use of Vitamin D Receptor Activators (VDRA) in CKD patients increases survival, few studies have examined the effect of VDRA in incident HD patients. The FARO-2 study evaluated the clinical outcome of VDRA therapy on mortality in incident HD patients. Methods: FARO-2 was a longitudinal epidemiological study performed on 568 incident HD patients followed prospectively from 26 dialysis centers over a 3-year period. Data were collected every 6 months using a questionnaire, obtaining clinical, biochemical and therapeutic parameters. Kaplan-Meier curves and Cox proportional hazard regression models were used to determine cumulative probability of time-to-death and adjusted hazard ratios. Results: 568 patients (68% male) with an average age of 65.5 years were followed up. Mean dialysis duration at study entry was 3 months. VDRA use increased from 46% at 6 months to 54.7% at 36 months of follow-up (p = 0.08). No difference was observed in the presence of comorbid diseases at baseline in patients with and without VDRA therapy. Cumulative probability of survival at 24 months was 74.5% (95% CI: 70.2-78.3). Patients receiving VDRA therapy showed a significant increase in survival at 24 months (80.7%; 95% CI: 75.7-84.8) compared to those without (63.3%; 95% CI: 54.8-70.7, p <0.01). The presence of vascular disease, decreased hemoglobin, increased P and lack of VDRA treatment were significantly associated with an increased risk of mortality. Lack of VDRA treatment still remained significant as a predictor of mortality after adjusting for levels of PTH, P and Ca (HR = 2.16, 95% CI: 1.09-4.30, p = 0.03). Conclusions: Findings from FARO-2 indicate that in incident HD patients VDRA therapy was associated with increased survival. © 2015 Messa et al.; licensee BioMed Central.","Calcitriol; CKD-MBD; Hemodialysis; Paricalcitol; PTH","Foley, R.N., Parfrey, P.S., Sarnak, M.J., Clinical epidemiology of cardiovascular disease in chronic renal disease (1998) Am J Kidney Dis, 32, pp. S112-S119; Iseki, K., Shinzato, T., Nagura, Y., Akiba, T., Factors influencing long-term survival in patients on chronic dialysis (2004) Clin Exp Nephrol, 8, pp. 89-97; Block, G.A., Hulbert-Shearon, T.E., Levin, N.W., Port, F.K., Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study (1998) Am J Kidney Dis, 31, pp. 607-617; Stevens, L.A., Djurdjev, O., Cardew, S., Cameron, E.C., Levin, A., Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes (2004) J Am Soc Nephrol, 15, pp. 770-779; Block, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G., Chertow, G.M., Mineral metabolism, mortality, and morbidity in maintenance hemodialysis (2004) J Am Soc Nephrol, 15, pp. 2208-2218; Slinin, Y., Foley, R.N., Collins, A.J., Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study (2005) J Am Soc Nephrol, 16, pp. 1788-1793; Kestenbaum, B., Sampson, J.N., Rudser, K.D., Patterson, D.J., Seliger, S.L., Young, B., Serum phosphate levels and mortality risk among people with chronic kidney disease (2005) J Am Soc Nephrol, 16, pp. 520-528; Young, E.W., Albert, J.M., Satayathum, S., Goodkin, D.A., Pisoni, R.L., Akiba, T., Predictors and consequences of altered mineral metabolism: The dialysis outcomes and practice patterns study (2005) Kidney Int, 67, pp. 1179-1187; Kalantar-Zadeh, K., Kuwae, N., Regidor, D.L., Kovesdy, C.P., Kilpatrick, R.D., Shinaberger, C.S., Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients (2006) Kidney Int, 70, pp. 771-780; Wald, R., Sarnak, M.J., Tighiouart, H., Cheung, A.K., Levey, A.S., Eknoyan, G., Disordered mineral metabolism in hemodialysis patients: An analysis of cumulative effects in the Hemodialysis (HEMO) Study (2008) Am J Kidney Dis, 52, pp. 531-540; Tentori, F., Blayney, M.J., Albert, J.M., Gillespie, B.W., Kerr, P.G., Bommer, J., Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The dialysis outcomes and practice patterns study (DOPPS) (2008) Am J Kidney Dis, 52, pp. 519-530; Floege, J., Kim, J., Ireland, E., Chazot, C., Drueke, T., De Francisco, A., Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population (2011) Nephrol Dial Transplant, 26, pp. 1948-1955; Nakai, S., Akiba, T., Kazama, J., Yokoyama, K., Fukagawa, M., Tominaga, Y., Patient registration committee of the Japanese society for dialysis therapy, Tokyo, Japan: Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan (2010) Ther Apher Dial, 12, pp. 49-54; Naves-Díaz, M., Passlick-Deetjen, J., Guinsburg, A., Marelli, C., Fernández-Martín, J.L., Rodríguez-Puyol, D., Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America the CORES study (2011) Nephrol Dial Transplant, 26, pp. 1938-1947; Cozzolino, M., Brancaccio, D., Cannella, G., Messa, P., Gesualdo, L., Marangella, M., VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: Results of the Italian FARO Survey (2012) Nephrol Dial Transplant, 27, pp. 3588-3594; Martin, K.J., Gonzalez, E.A., Metabolic bone disease in chronic kidney disease (2007) J Am Soc Nephrol, 18, pp. 875-885; Levin, A., Bakris, G.L., Molitch, M., Smulders, M., Tian, J., Williams, L.A., Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease (2007) Kidney Int, 71, pp. 31-38; Wolf, M., Thadhani, R., Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward (2007) J Steroid Biochem Mol Biol, 103, pp. 487-490; Salusky, I.B., Goodman, W.G., Cardiovascular calcification in end-stage renal disease (2002) Nephrol Dial Transplant, 17, pp. 336-339; Wolisi, G.O., Moe, S.M., The role of vitamin D in vascular calcification in chronic kidney disease (2005) Semin Dial, 18, pp. 307-314; Brown, A.J., Slatopolsky, E., Drug insight: Vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (2007) Nat Clin Pract Endocrinol Metab, 3, pp. 134-144; Ronco, C., Cozzolino, M., Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes (2012) Heart Fail Rev, 17, pp. 211-220; Khan, S., Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease (2007) Am J Med Sci, 333, pp. 201-207; Lund, R.J., Andress, D.L., Amdahl, M., Williams, L.A., Heaney, R.P., Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients (2010) Am J Nephrol, 31, pp. 165-170; Greenbaum, L.A., Benador, N., Goldstein, S.L., Paredes, A., Melnick, J.Z., Mattingly, S., Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis (2007) Am J Kidney Dis, 49, pp. 814-823; Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J.M., Thadhani, R., Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy (2003) N Engl J Med, 349, pp. 446-456; Teng, M., Wolf, M., Ofsthun, M.N., Lazarus, J.M., Hernán, M.A., Camargo, C.A., Jr., Activated injectable vitamin D and hemodialysis survival: A historical cohort study (2005) J Am Soc Nephrol, 16, pp. 1115-1125; Naves-Díaz, M., Alvarez-Hernández, D., Passlick-Deetjen, J., Guinsburg, A., Marelli, C., Rodriguez-Puyol, D., Oral active vitamin D is associated with improved survival in hemodialysis patients (2008) Kidney Int, 74, pp. 1070-1078; Wolf, M., Betancourt, J., Chang, Y., Shah, A., Teng, M., Tamez, H., Impact of activated vitamin D and race on survival among hemodialysis patients (2008) J Am Soc Nephrol, 19, pp. 1379-1388; Tentori, F., Albert, J.M., Young, E.W., Blayney, M.J., Robinson, B.M., Pisoni, R.L., The survival advantage for HD patients taking vitamin D is questioned: Findings from the dialysis outcomes and practice patterns study (2009) Nephrol Dial Transplant, 24, pp. 963-972; Ogawa, T., Kyono, A., Sato, M., Sugimoto, H., Otsuka, K., Nitta, K., Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients (2012) Clin Exp Nephrol, 16, pp. 779-785; Brancaccio, D., Cozzolino, M., Cannella, G., Messa, P., Bonomini, M., Cancarini, G., Secondary hyperparathyroidism in chronic dialysis patients: Results of the Italian FARO survey on treatment and mortality (2011) Blood Purif, 32, pp. 124-132; Iseki, K., Tozawa, M., Takishita, S., Effect of the duration of dialysis on survival in a cohort of chronic hemodialysis patients (2003) Nephrol Dial Transplant, 18, pp. 782-787; Mazzaferro, S., Brancaccio, D., Messa, P., Andreucci, V.E., Bellinghieri, G., Bigazzi, R., Management of secondary hyperparathyroidism in Italy: Results of the Italian FARO survey (2011) J Nephrol, 24, pp. 225-235; National Kidney Foundation, K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease (2003) Am J Kidney Dis, 42, pp. S1-S202; Cozzolino, M., Messa, P., Brancaccio, D., Cannella, G., Mazzaferro, S., Achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in incident haemodialysis patients: Results of the FARO-2 cohort (2012) Nephrol Dial Transplant, 27, pp. ii1-ii536. , Abstracts of the 49th ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) Congress. May 24-27, 2012. Paris, France Abstract number 565; Moeschberger, M.L., Klein, J.P., (2003) Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed., , Springer Science and Business Media, Inc: New York, NY; Tentori, F., Hunt, W.C., Stidley, C.A., Rohrscheib, M.R., Bedrick, E.J., Meyer, K.B., Mortality risk among hemodialysis patients receiving different vitamin D analogs (2006) Kidney Int, 70, pp. 1858-1865; Dobrez, D.G., Mathes, A., Amdahl, M., Marx, S.E., Melnick, J.Z., Sprague, S.M., Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings (2004) Nephrol Dial Transplant, 19, pp. 1174-1181; Longenecker, J.C., Coresh, J., Powe, N.R., Levey, A.S., Fink, N.E., Martin, A., Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study (2002) J Am Soc Nephrol, 13, pp. 1918-1927; Miguel, S.B., Miguel, J.B., Velarde, L.G., Sampaio, E.D.A., Matos, J.P., Lugon, J.R., Prevalence and correlates of vascular disease at ultrasound examination in patients on hemodialysis (2011) Arq Bras Cardiol, 96, pp. 260-265; Thadhani, R., Appelbaum, E., Pritchett, Y., Chang, Y., Wenger, J., Tamez, H., Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial (2012) JAMA, 15 (307), pp. 674-684; Tamez, H., Zoccali, C., Packham, D., Wenger, J., Bhan, I., Appelbaum, E., Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease (2012) Am Heart J, 164, pp. 902.e2-909.e2",Article,Scopus,2-s2.0-84927714379
"Takai M., Kaneto H., Kamei S., Mune T., Kaku K.","A case of hypothalamic hypopituitarism accompanied by recurrent severe hypoglycemia",2015,"SpringerPlus","4","1",,"","",5,,10.1186/s40064-015-0934-6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928412508&partnerID=40&md5=dfa825feed8c21e2ca08801a91c44b43","Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, 577 MatsushimaKurashiki, Japan","Takai, M., Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, 577 MatsushimaKurashiki, Japan; Kaneto, H., Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, 577 MatsushimaKurashiki, Japan; Kamei, S., Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, 577 MatsushimaKurashiki, Japan; Mune, T., Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, 577 MatsushimaKurashiki, Japan; Kaku, K., Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, 577 MatsushimaKurashiki, Japan","Introduction: Hypothalamic hypopituitarism is relatively rare cause of secondary adrenal deficiency which is often accompanied by severe hypoglycemia. Hydrocortisone replacement therapy is essential for this condition, but gastrointestinal symptom such as nausea and vomiting is not well-recognized adverse effect of hydrocortisone. Case description: A 64-year-old-woman was referred to our hospital because of frequent severe hypoglycemia. She was diagnosed as type 2 diabetes when she was 58 years old but had not been treated since she was 60. We ruled out the possibility of exogenous administration of insulin or other anti-diabetic drugs, insulinoma and insulin autoimmune syndrome. After glucose injection, she once became conscious, but severe hypoglycemia was often observed even after that. In addition, counter-regulatory hormone levels were not increased even at the time of hypoglycemia. We conducted several hormone load tests. In corticotropin-releasing hormone (CRH) load test, excess and delayed reaction of ACTH was observed. In thyrotropin-releasing hormone (TRH) load test, TSH and prolactin were normally secreted in response to TRH. In luteinizing hormone-releasing hormone (LHRH) load test, delayed reaction of LH and FSH was observed. Based on such hormone loading tests, we diagnosed this patient as idiopathic hypothalamic hypopituitarism and consequent adrenal deficiency. We immediately intravenously injected hydrocortisone and started oral hydrocortisone therapy. However, just after taking hydrocortisone, vomiting was often observed which disturbed sufficient steroid hormone replacement, leading to recurrent hypoglycemia. Therefore, we stopped hydrocortisone and instead started an alternative treatment with prednisolone. After that, vomiting and hypoglycemia were not observed at all. Discussion and Evaluation: We diagnosed this subject as hypothalamic hypopituitarism mainly by the following two findings: (1) excess and delayed reaction of ACTH in CRH load test, (2) delayed reaction of LH and FSH in LHRH load test. Conclusions: We should be aware of the possibility of hypothalamic hypopituitarism as a cause of recurrent severe hypoglycemia. Also, we should be aware that hydrocortisone could induce gastrointestinal symptom and that in such a case we should stop hydrocortisone and start prednisolone to sufficiently replace steroid hormone and avoid recurrent hypoglycemia. © 2015, Takai et al.; licensee Springer.","Hydrocortisone; Hypoglycemia; Hypothalamic hypopituitarism","Barendse, S., Singh, H., Frier, B.M., Speight, J., The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative review (2012) Diabet Med, 29, pp. 293-392; Frier, B.M., Schernthaner, G., Heller, S.R., Hypoglycemia and cardiovascular risks (2011) Diabetes Care, 34, pp. 132-137; Glezer, A., Bronstein, M.D., Pituitary autoimmune disease: nuances in clinical presentation (2012) Endocrine, 42, pp. 74-79; Greco, D.S., Pituitary deficiencies (2012) Top Companion Anim Med, 27, pp. 2-7; Kaneto, H., Ikeda, M., Kishimoto, M., Iida, M., Hoshi, A., Watarai, T., Kubota, M., Hori, M., Dramatic recovery of counterregulatory hormone response to hypoglycemia after intensive insulin therapy in poorly controlled type 1 diabetes (1998) Diabetologia, 41, pp. 982-983; Kinsley, B.T., Widom, B., Simonson, D.C., Differential regulation of counterregulatory hormone secretion and symptoms during hypoglycemia in IDDM (1995) Diabetes Care, 18, pp. 17-26; Lingenfelser, T., Buettner, U., Martin, J., Tobis, M., Renn, W., Kaschel, R., Jakober, B., Improvement of impaired counterregulatory hormone response and symptom perception by short-term avoidance of hypoglycemia in IDDM (1995) Diabetes Care, 18, pp. 321-325; Saito, T., Sato, N., Kimoto, M., Asano, T., Aoki, A., Ikoma, A., Toyoshima, H., Ishikawa, S.E., Incomplete deficiency of hypothalamic hormones in hypothalamic hypopituitarism associated with an old traumatic brain injury (2009) Endocr J, 56, pp. 945-950; Sharma, O.P., Sharma, A.M., Sarcoidosis of the nervous system. A clinical approach (1991) Arch Intern Med, 151, pp. 1317-1321; http://square.umin.ac.jp/kasuitai/doctor/guidance.html, The hypothalamic-pituitary dysfunction study group of the Ministry of Health Labour and Welfare, Japan (2009) The guideline for the diagnosis and treatment of adult GH deficiency. Accessed June 20, 2012 (In Japanese)Widom, B., Simonson, D.C., Intermittent hypoglycemia impairs glucose counterregulation (1992) Diabetes, 41, pp. 1597-1602",Article,Scopus,2-s2.0-84928412508
"Simon L., Nalliah R.P., Seymour B.","Lack of dental insurance is correlated with edentulism",2015,"Journal of the Massachusetts Dental Society","63","4",,"28","31",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929032632&partnerID=40&md5=0627b8c4aa262071a64900dd27df149b",,"Simon, L.; Nalliah, R.P.; Seymour, B.","PURPOSE: The correlation between insurance status and edentulism has not previously been reported in a population with known access to a dentist, and little is known about patient demographics in corporate dental settings. This study investigated patient demographics of a former dental franchise in Chicopee, Massachusetts, and examined a correlation between dental insurance and edentulism in this group. The correlation of edentulism with age, gender, and dental risk factors (diabetes, temporomandibular disorder, trouble with previous dental work, or oral sores and ulcers) was also examined.MATERIALS AND METHODS: This was a retrospective case study. Age, gender, and presence of dental risk factors were recorded from the patient medical history intake form. Dentate status was recorded from patient odontograms. Dental insurance status was obtained from billing records. Data was aggregated and deidentified. Descriptive and bivariate statistics and logistic regression models were used to identify associations (p-value ≤ 0.05 significance).RESULTS: Of 1,123 records meeting inclusion criteria, 52.54 percent of patients had dental insurance, 26.27 percent had at least one dental risk factor, and 18.17 percent were edentulous. Age and insurance status were significantly correlated with edentulism. Correcting for age, individuals without insurance were 1.56 times as likely to be edentulous.CONCLUSION: This case study provides insight into patient demographics that might seek care in a corporate setting and suggests that access to a dentist alone may not be adequate in preserving the adult dentition; dental insurance may also be important to health. As the corporate dental practice model continues to grow, these topics deserve further study.",,,Article,Scopus,2-s2.0-84929032632
"Ozawa S., Ueda S., Li Y., Mori K., Asanuma K., Yanagita M., Nakagawa T.","Fatty acid binding protein 3 as a potential mediator for diabetic nephropathy in eNOS deficient mouse",2014,"Biochemical and Biophysical Research Communications","454","4",,"531","536",,,10.1016/j.bbrc.2014.10.121,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84910641622&partnerID=40&md5=870b046dbb4622654523276b43e364d5","TMK Project, Medical Innovation Center, Kyoto University, 53 Shogoin Kawahara-choSakyo-ku, Kyoto, Japan; Pharmacology Research Laboratories II, Mitsubishi Tanabe Pharma CorporationSaitama, Japan; Department of Internal Medicine, Teikyo University School of MedicineTokyo, Japan; Department of Nephrology, Kyoto University Graduate School of MedicineKyoto, Japan","Ozawa, S., TMK Project, Medical Innovation Center, Kyoto University, 53 Shogoin Kawahara-choSakyo-ku, Kyoto, Japan, Pharmacology Research Laboratories II, Mitsubishi Tanabe Pharma CorporationSaitama, Japan; Ueda, S., TMK Project, Medical Innovation Center, Kyoto University, 53 Shogoin Kawahara-choSakyo-ku, Kyoto, Japan, Department of Internal Medicine, Teikyo University School of MedicineTokyo, Japan; Li, Y., TMK Project, Medical Innovation Center, Kyoto University, 53 Shogoin Kawahara-choSakyo-ku, Kyoto, Japan; Mori, K., TMK Project, Medical Innovation Center, Kyoto University, 53 Shogoin Kawahara-choSakyo-ku, Kyoto, Japan; Asanuma, K., TMK Project, Medical Innovation Center, Kyoto University, 53 Shogoin Kawahara-choSakyo-ku, Kyoto, Japan; Yanagita, M., TMK Project, Medical Innovation Center, Kyoto University, 53 Shogoin Kawahara-choSakyo-ku, Kyoto, Japan, Department of Nephrology, Kyoto University Graduate School of MedicineKyoto, Japan; Nakagawa, T., TMK Project, Medical Innovation Center, Kyoto University, 53 Shogoin Kawahara-choSakyo-ku, Kyoto, Japan","In human diabetic nephropathy, glomerular injury was found to comprise lipid droplets, suggesting that abnormal lipid metabolism might take place in the development of diabetic glomerular injury. However, its precise mechanism remains unclear. Fatty acid binding protein (FABP) is currently considered as a key molecule for lipid metabolism. Since diabetic eNOS knockout (KO) mouse is considered to be a good model for human diabetic nephropathy, we here investigated whether FABP could mediate glomerular injury in this model. We found that glomerular injuries were associated with inflammatory processes, such as macrophage infiltration and MCP-1 induction. Microarray assay with isolated glomeruli revealed that among 10 isoforms in FABP family, FABP3 mRNA was most highly expressed in diabetic eNOSKO mice compared to non-diabetic eNOSKO mice. FABP3 protein was found to be located in the mesangial cells. Overexpression of FABP3 resulted in a greater response to palmitate, a satulated FA, to induce MCP-1 in the rat mesangial cells. In turn, the heart, a major organ for FABP3 protein in normal condition, failed to alter its expression level under diabetic condition in either wild type or eNOSKO mice. In conclusion, FABP3 is induced in the mesangial cells and likely a mediator to induce MCP-1 in the diabetic nephropathy. © 2014 The Authors.","Advanced diabetic nephropathy; Endothelial; FABP; Fatty acid; Inflammation; Nitric oxide","Defronzo, R.A., Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009 (2010) Diabetologia, 53, pp. 1270-1287; Klein-Platat, C., Drai, J., Oujaa, M., Schlienger, J.L., Simon, C., Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents (2005) Am. J. Clin. Nutr., 82, pp. 1178-1184; Soumura, M., Kume, S., Isshiki, K., Takeda, N., Araki, S., Tanaka, Y., Sugimoto, T., Uzu, T., Oleate and eicosapentaenoic acid attenuate palmitate-induced inflammation and apoptosis in renal proximal tubular cell (2010) Biochem. Biophys. Res. Commun., 402, pp. 265-271; Yamamoto, T., Yamamoto, A., Watanabe, M., Matsuo, T., Yamazaki, N., Kataoka, M., Terada, H., Shinohara, Y., Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues (2009) Biotechnol. Lett., 31, pp. 1695-1701; Glatz, J.F., Storch, J., Unravelling the significance of cellular fatty acid-binding proteins (2001) Curr. Opin. Lipidol., 12, pp. 267-274; Grone, H.J., Glomerular lipids in non-hereditary forms of glomerulopathy/glomerulonephritis (1999) Nephrol. Dial. Transplant., 14, pp. 1595-1598; Nakagawa, T., Sato, W., Glushakova, O., Heinig, M., Clarke, T., Campbell-Thompson, M., Yuzawa, Y., Croker, B., Diabetic eNOS knockout mice develop advanced diabetic nephropathy (2007) J. Am. Soc. Nephrol., 18, pp. 539-550; Tanabe, K., Lanaspa, M.A., Kitagawa, W., Rivard, C.J., Miyazaki, M., Klawitter, J., Schreiner, G.F., Nakagawa, T., Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse (2012) Am. J. Physiol. Renal. Physiol., 302, pp. 1151-F1160; Daniel, C., Ludke, A., Wagner, A., Todorov, V.T., Hohenstein, B., Hugo, C., Transgelin is a marker of repopulating mesangial cells after injury and promotes their proliferation and migration (2012) Lab. Invest., 92, pp. 812-826; Proctor, G., Jiang, T., Iwahashi, M., Wang, Z., Li, J., Levi, M., Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes (2006) Diabetes, 55, pp. 2502-2509; Wang, Z., Jiang, T., Li, J., Proctor, G., McManaman, J.L., Lucia, S., Chua, S., Levi, M., Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes (2005) Diabetes, 54, pp. 2328-2335; Coll, T., Eyre, E., Rodriguez-Calvo, R., Palomer, X., Sanchez, R.M., Merlos, M., Laguna, J.C., Vazquez-Carrera, M., Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells (2008) J. Biol. Chem., 283, pp. 11107-11116; Maatman, R.G., Van Kuppevelt, T.H., Veerkamp, J.H., Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization (1991) Biochem. J., 273 (3), pp. 759-766; Nauta, F.L., Boertien, W.E., Bakker, S.J., Van Goor, H., Van Oeveren, W., De Jong, P.E., Bilo, H., Gansevoort, R.T., Glomerular and tubular damage markers are elevated in patients with diabetes (2011) Diabetes Care, 34, pp. 975-981",Article,Scopus,2-s2.0-84910641622
"Landecker H.","Pregnancy: Study the mother's DNA as well",2014,"Nature","513","7517",,"172","",,,10.1038/513172b,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84907275441&partnerID=40&md5=59453a8b10eea82ff213d4b3a7bd72c1","University of CaliforniaLos Angeles, United States","Landecker, H., University of CaliforniaLos Angeles, United States",[No abstract available],,,Letter,Scopus,2-s2.0-84907275441
"Gouveia-Figueira S.C., Castilho P.C.","Phenolic screening by HPLC-DAD-ESI/MSn and antioxidant capacity of leaves, flowers and berries of Rubus grandifolius Lowe",2015,"Industrial Crops and Products","73",,,"28","40",,,10.1016/j.indcrop.2015.03.022,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928569448&partnerID=40&md5=75c044eb0bc5d4910e1dd7b05b6f9697","Department of Chemistry, Umeå University, Sweden; Centro de Química da Madeira, CCCEE, Universidade da Madeira Campus Universitário da Penteada, Piso 0Funchal, Portugal","Gouveia-Figueira, S.C., Department of Chemistry, Umeå University, Sweden, Centro de Química da Madeira, CCCEE, Universidade da Madeira Campus Universitário da Penteada, Piso 0Funchal, Portugal; Castilho, P.C., Centro de Química da Madeira, CCCEE, Universidade da Madeira Campus Universitário da Penteada, Piso 0Funchal, Portugal","In Madeira Island (Macaronesia Island), Rubus grandifolius Lowe berries, locally known by amoras, are widely consumed fresh or processed as jam, juice or liquor. Folk medicine describes R. grandifolius Lowe fruits and leaves being used to treat diabetes, as depurative, diuretic and to relieve sore throat.The aim of this study was to investigate phenolic composition and antioxidant capacity of the different edible parts of the plant (berries, leaves and flowers). HPLC-DAD-ESI/MS. n was used to establish the phenolic profile. Phenolic monomers such as flavonol O-glycosilated (quercetin and kaempferol), quinic acid and caffeic acid conjugates were characterized using the electrospray source in the negative mode; while positive mode was employed to detect glycosylated anthocyanins (cyanidin, delphinin and petunidin).The berries presented a higher radical scavenger capacity (DPPH and ABTS assays) and reducing properties (FRAP) than the leaves and the flowers. Ethanolic extracts showed highest antioxidant capacity when compared with water based extracts: DPPH values of 147.9. ±. 0.7. μmol eq Trolox/g DM; ABTS value of 255.8. ±. 1.9. μmol eq Trolox/g DM and FRAP value 9455. ±. 29. mmol Fe(II)/mgDM). © 2015 Elsevier B.V.","Antioxidant; Berries; HPLC-DAD-ESI/MSn; Phenolic compounds; Rubus","Abdel-Aal, E.-S.M., Young, J.C., Rabalski, I., Anthocyanin composition in black, blue, pink, purple, and red cereal grains (2006) J. Agric. Food Chem., 54, pp. 4696-4704; Ablajan, K., Abliz, Z., Shang, X.-Y., He, J.-M., Zhang, R.-P., Shi, J.-G., Structural characterization of flavonol 3,7-di-O-glycosides and determination of theglycosylation position by using negative ion electrospray ionization tandem mass spectrometry (2006) J. Mass Spectrom., 41, pp. 352-360; Alothman, M., Bhat, R., Karim, A.A., Effects of radiation processing on phytochemicals and antioxidants in plant produce (2009) Trends Food Sci. Technol., 20, pp. 201-212; Bobinaite, R., Viškelis, P., Venskutonis, P.R., Variation of total phenolics anthocyanins, ellagic acid and radical scavenging capacity in various raspberry (Rubus spp.) cultivars (2012) Food Chem., 132, pp. 1495-1501; Bradish, C.M., Perkins-Veazie, P., Fernandez, G.E., Xie, G., Jia, W., Comparison of flavonoid composition of red raspberries (Rubus idaeus L.) Grown in the Southern United States (2011) J. Agric. Food Chem., 60, pp. 5779-5786; Clifford, M.N., Knight, S., Kuhnert, N., Discriminating between the six isomers of dicaffeoylquinic acid by LC-MSn (2005) J. Agric. Food Chem., 53, pp. 3821-3832; Cuyckens, F., Claeys, M., Mass spectrometry in the structural analysis of flavonoids (2004) J. Mass Spectrom., 39, pp. 1-15; Cuyckens, F., Claeys, M., Determination of the glycosylation site in flavonoid mono-O-glycosides by collision-induced dissociation of electrospray-generated deprotonated and sodiated molecules (2005) J. Mass Spectrom., 40, pp. 364-372; Deighton, N., Brennan, R., Finn, C., Davies, H.V., Antioxidant properties of domesticated and wild Rubus species (2000) J. Sci. Food Agric., 80, pp. 1307-1313; Downey, M.O., Rochfort, S., Simultaneous separation by reversed-phase high-performance liquid chromatography and mass spectral identification of anthocyanins and flavonols in Shiraz grape skin (2008) J. Chromatogr. A, 1201, pp. 43-47; Felgines, C., Talavera, S., Texier, O., Gil-Izquierdo, A., Lamaison, J.-L., Remesy, C., Blackberry anthocyanins are mainly recovered from urine as methylated and glucuronidated conjugates in humans (2005) J. Agric. Food Chem., 53, pp. 7721-7727; Gao, J., Shi, J., Lu, X., Sun, C., Pan, Y., Differentiation of common diastereoisomeric ursane-type triterpenoids by high-performance liquid chromatography/tandem mass spectrometry (2011) Rapid Commun. Mass Spectrom., 25, pp. 1349-1355; Gouveia-Figueira, S., Gouveia, C., Carvalho, M., Rodrigues, A., Nording, M., Castilho, P., Antioxidant capacity, cytotoxicity and antimycobacterial activity of madeira archipelago endemic Helichrysum dietary and medicinal plants (2014) Antioxidants, 3, pp. 713-729; Gouveia, S.C., Castilho, P.C., Analysis of phenolic compounds from different morphological parts of Helichrysum devium by liquid chromatography with on-line UV and electrospray ionization mass spectrometric detection (2009) Rapid Commun. Mass Spectrom., 23, pp. 3939-3953; Gouveia, S.C., Castilho, P.C., Characterization of phenolic compounds in Helichrysum melaleucum by high-performance liquid chromatography with on-line ultraviolet and mass spectrometry detection (2010) Rapid Commun. Mass Spectrom., 24, pp. 1851-1868; Gouveia, S.C., Castilho, P.C., Antioxidant potential of Artemisia argentea L'Hér alcoholic extract and its relation with the phenolic composition (2011) Food Res. Int., 44, pp. 1620-1631; Gouveia, S.C., Castilho, P.C., Characterisation of phenolic acid derivatives and flavonoids from different morphological parts of Helichrysum obconicum by a RP-HPLC-DAD-(-)-ESI-MSn method (2011) Food Chem., 129, pp. 333-344; Gouveia, S., Castilho, P.C., Helichrysum monizii Lowe: phenolic composition and antioxidant potential (2012) Phytochem. Anal., 23, pp. 72-83; Gouveia, S.C., Castilho, P.C., Helichrysum monizii Lowe: phenolic composition and antioxidant potential (2012) Phytochem. Anal., 23, pp. 72-83; Gouveia, S.C., Castilho, P.C., Phenolic composition and antioxidant capacity of cultivated artichoke, Madeira cardoon and artichoke-based dietary supplements (2012) Food Res. Int., 48, pp. 712-724; Hummer, K.E., Rubus pharmacology: antiquity to the present (2010) HortScience, 45, pp. 1587-1591; Jaakkola, M., Korpelainen, V., Hoppula, K., Virtanen, V., Chemical composition of ripe fruits of Rubus chamaemorus L. grown in different habitats (2012) J. Sci. Food Agric., 92, pp. 1324-1330; Kajdžanoska, M., Gjamovski, V., Stefova, M., HPLC-DAD-ESI-MSn identification of phenolic compounds in cultivated strawberries from Macedonia (2010) Maced. J. Chem. Chem. Eng., 29, pp. 181-194; Kusznierewicz, B., Piekarska, A., Mrugalska, B., Konieczka, P., Namieśnik, J., Bartoszek, A., Phenolic composition and antioxidant properties of polish blue-berried honeysuckle genotypes by HPLC-DAD-MS, HPLC postcolumn derivatization with ABTS or FC, and TLC with DPPH visualization (2012) J. Agric. Food Chem., 60, pp. 1755-1763; Chen, Y.-H., Wang, Z.-T., Tao, X.-Y., Tyrosinase inhibitory effect and inhibitory mechanism of tiliroside from raspberry (2009) J. Enzyme Inhib. Med. Chem., 24, pp. 1154-1160; Mabry, T.J., Markham, K.R., Thomas, M.B., The ultraviolet spectra of flavones and flavonols, isoflavones, dihydroxyflavonols (1970) The Systematics Identification of Flavonoids, , Springer-Verlag, New York, NY, Springer-Verlag (Ed.); Olsen, H., Aaby, K., Borge, G.I.A., Characterization and quantification of flavonoids and hydroxycinnamic acids in curly kale (Brassica oleracea L. Convar. acephala Var. sabellica) by HPLC-DAD-ESI-MSn (2009) J. Agric. Food Chem., 57, pp. 2816-2825; Pereira, O.R., Silva, A.M.S., Domingues, M.R.M., Cardoso, S.M., Identification of phenolic constituents of Cytisus multiflorus (2012) Food Chem., 131, pp. 652-659; Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., Rice-Evans, C., Antioxidant activity applying an improved ABTS radical cation decolorization assay (1999) Free Radical Bio. Med., 26, pp. 1231-1237; Rivera, D., Obón, C., The ethnopharmacology of Madeira and Porto Santo Islands, a review (1995) J. Ethnopharm., 46, pp. 73-93; Scordino, M., Sabatino, L., Characterization of polyphenolic profile of citrus fruit by HPLC/PDA/ESI/MS-MS (2014) Polyphenols in Plants, pp. 187-199. , Academic Press, San Diego, (Chapter 9), R.R. Watson (Ed.); Sejali, S.N.F., Anuar, M.S., Effect of drying methods on phenolic contents of neem (Azadirachta indica) leaf powder (2011) J. Herbs Spices Med. Plants, 17, pp. 119-131; Simirgiotis, M.J., Theoduloz, C., Caligari, P.D.S., Schmeda-Hirschmann, G., Comparison of phenolic composition and antioxidant properties of two native Chilean and one domestic strawberry genotypes (2009) Food Chem., 113, pp. 377-385; Soong, Y.Y., Barlow, P.J., Isolation and structure elucidation of phenolic compounds from longan (Dimocarpus longan Lour.) seed by high-performance liquid chromatography-electrospray ionization mass spectrometry (2005) J. Chromatogr. A, 1085, pp. 270-277; Tang, J., Zhao, M., Wang, Y., Kang, G., Wu, J., Zheng, M., Peng, S., One single HPLC-PDA/(-)ESI-MS/MS analysis to simultaneously determine 30 components of the aqueous extract of Rabdosia rubescens (2011) J. Chromatogr. B, 879, pp. 2783-2793; Turland, N.J., (1994) Flora da Madeira, HMSO Publications Center, , first ed., London; Vallverdú-Queralt, A., Jáuregui, O., Di Lecce, G., Andrés-Lacueva, C., Lamuela-Raventós, R.M., Screening of the polyphenol content of tomato-based products through accurate-mass spectrometry (HPLC-ESI-QTOF) (2011) Food Chem., 129, pp. 877-883; Wang, H., Feng, F., Identification of components in Zhi-Zi-Da-Huang decoction by HPLC coupled with electrospray ionization tandem mass spectrometry, photodiode array and fluorescence detectors (2009) J. Pharm. Biomed. Anal., 49, pp. 1157-1165; Winkel-Shirley, B., Biosynthesis of flavonoids and effects of stress (2002) Curr. Opin. Plant Biol., 5, pp. 218-223; Yang, M., Wang, X., Guan, S., Xia, J., Sun, J., Guo, H., Guo, D.-A., Analysis of triterpenoids in Ganoderma lucidum using liquid chromatography coupled with electrospray ionization mass spectrometry (2007) J. Am. Soc. Mass Spectrom., 18, pp. 927-939",Article,Scopus,2-s2.0-84928569448
"Lopez-Sanz S., Montilla A., Moreno F.J., Villamiel M.","Stability of oligosaccharides derived from lactulose during the processing of milk and apple juice",2015,"Food Chemistry","183",,,"64","71",,,10.1016/j.foodchem.2015.03.020,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925449688&partnerID=40&md5=e68078e745d7a7bf50a771971091948e","Instituto de Investigacion en Ciencias de la Alimentacion (CIAL) (CSIC-UAM) CEI (CSIC+UAM), Campus de la Universidad Autónoma de Madrid, Nicolás Cabrera, 9Madrid, Spain","López-Sanz, S., Instituto de Investigacion en Ciencias de la Alimentacion (CIAL) (CSIC-UAM) CEI (CSIC+UAM), Campus de la Universidad Autónoma de Madrid, Nicolás Cabrera, 9Madrid, Spain; Montilla, A., Instituto de Investigacion en Ciencias de la Alimentacion (CIAL) (CSIC-UAM) CEI (CSIC+UAM), Campus de la Universidad Autónoma de Madrid, Nicolás Cabrera, 9Madrid, Spain; Moreno, F.J., Instituto de Investigacion en Ciencias de la Alimentacion (CIAL) (CSIC-UAM) CEI (CSIC+UAM), Campus de la Universidad Autónoma de Madrid, Nicolás Cabrera, 9Madrid, Spain; Villamiel, M., Instituto de Investigacion en Ciencias de la Alimentacion (CIAL) (CSIC-UAM) CEI (CSIC+UAM), Campus de la Universidad Autónoma de Madrid, Nicolás Cabrera, 9Madrid, Spain","The scientific evidence on the bioactivity of oligosaccharides from lactulose has encouraged us to study their physicochemical modifications during the processing of milk and apple juice. The carbohydrate fraction with a degree of polymerization ≥3 was stable in milk heated at temperatures up to 100°C for 30 min and in apple juice heated up to 90°C for 15 min. An assessment of the Maillard reaction in heated milk pointed out a higher formation of furosine in milk with oligosaccharides from lactulose as compared to its counterpart without this ingredient, due to a higher presence of galactose. The organoleptic properties of juice with oligosaccharides from lactulose were acceptable and similar to those of apple juice with commercial galactooligosaccharides. The results presented herein demonstrate that oligosaccharides from lactulose can be used as prebiotic ingredients in a wide range of functional foods, including those intended for diabetics and lactose intolerant individuals. © 2015 Elsevier Ltd. All rights reserved.","Apple juice; Milk; Oligosaccharides derived from lactulose; Prebiotic; Processing","Algieri, F., Rodriguez-Nogales, A., Garrido-Mesa, N., Vezza, T., Garrido-Mesa, J., Utrilla, M.P., Intestinal anti-inflammatory effects of oligosaccharides derived from lactulose in the trinitrobenzenesulfonic acid model of rat colitis (2014) Journal of Agricultural and Food Chemistry, 62, pp. 4285-4297; Anadon, A., Martinez, M.A., Ares, I., Castellano, V., Martinez-Larranaga, M.R., Corzo, N., Acute and repeated dose (28 days) oral safety studies of ALIBIRD in rats (2013) Journal of Food Protection, 76, pp. 1226-1239; Berg, H.E., (1993) Reactions of Lactose during Heat Treatment of Milk: A Quantitative Study, , Ph.D. Thesis Agricultural University, Wageningen; Cardelle-Cobas, A., Corzo, N., Villamiel, M., Olano, A., Isomerization of lactose-derived oligosaccharides: A case study using sodium aluminate (2008) Journal of Agricultural and Food Chemistry, 56, pp. 10954-10959; Cardelle-Cobas, A., Martinez-Villaluenga, C., Villamiel, M., Olano, A., Corzo, N., Synthesis of oligosaccharides derived from lactulose and Pectinex Ultra SP-L (2008) Journal of Agricultural and Food Chemistry, 56, pp. 3328-3333; Cardelle-Cobas, A., Fernandez, M., Salazar, N., Martinez-Villaluenga, C., Villamiel, M., Ruas-Madiedo, P., Bifidogenic effect and stimulation of short chain fatty acid production in human faecal slurry cultures by oligosaccharides derived from lactose and lactulose (2009) Journal of Dairy Research, 76, pp. 317-325; Cardelle-Cobas, A., Corzo, N., Martinez-Villaluenga, C., Olano, A., Villamiel, M., Effect of reaction conditions on lactulose-derived trisaccharides obtained by transgalactosylation with beta-galactosidase of Kluyveromyces lactis (2011) European Food Research and Technology, 233, pp. 89-94; Cardelle-Cobas, A., Corzo, N., Olano, A., Pelaez, C., Requena, T., Avila, M., Galactooligosaccharides derived from lactose and lactulose: Influence of structure on Lactobacillus, Streptococcus and Bifidobacterium growth (2011) International Journal of Food Microbiology, 149, pp. 81-87; Cardelle-Cobas, A., Olano, A., Corzo, N., Villamiel, M., Collins, M., Kolida, S., In vitro fermentation of lactulose-derived oligosaccharides by mixed fecal microbiota (2012) Journal of Agricultural and Food Chemistry, 60, pp. 2024-2032; Corzo-Martinez, M., Hernandez-Hernandez, O., Villamiel, M., Rastall, R.A., Moreno, F.J., In vitro bifidogenic effect of Maillard-type milk protein-galactose conjugates on the human intestinal microbiota (2013) International Dairy Journal, 31, pp. 127-131; De Rafael, D., Villamiel, M., Olano, A., Formation of lactulose and furosine during heat treatment of milk at temperatures of 100-120°C (1997) Milchwissenschaft-Milk Science International, 52, pp. 76-78; Erbersdobler, H.F., Somoza, V., Forty years of furosine-forty years using Maillard reaction products as indicators of the nutritional quality of foods (2007) Molecular Nutrition and Food Research, 51, pp. 423-430; Evangelisti, F., Calcagno, C., Nardi, S., Zunin, P., Deterioration of protein fraction by Maillard reaction in dietetic milks (1999) Journal of Dairy Research, 66, pp. 237-243; Guerra-Hernandez, E., Gomez, C.L., Garcia-Villanova, B., Sanchez, N.C., Gomez, J.M.R., Effect of storage on non-enzymatic browning of liquid infant milk formulae (2002) Journal of the Science of Food and Agriculture, 82, pp. 587-592; Hernandez-Hernandez, O., Montanes, F., Clemente, A., Moreno, F.J., Sanz, M.L., Characterization of galactooligosaccharides derived from lactulose (2011) Journal of Chromatography A, 1218, pp. 7691-7696; Hernandez-Hernandez, O., Sanz, M.L., Kolida, S., Rastall, R.A., Moreno, F.J., In vitro fermentation by human gut bacteria of proteolytically digested caseinomacropeptide nonenzymatically glycosylated with prebiotic carbohydrates (2011) Journal of Agricultural and Food Chemistry, 59, pp. 11949-11955; Hernandez-Hernandez, O., Marin-Manzano, M.C., Rubio, L.A., Moreno, E.J., Sanz, M.L., Clemente, A., Monomer and linkage type of galacto-oligosaccharides affect their resistance to ileal digestion and prebiotic properties in rats (2012) Journal of Nutrition, 142, pp. 1232-1239; Ibarz, A., Garza, S., Garvin, A., Pagan, J., Degradation of mandarin juice concentrates treated at high temperatures (2011) Journal of Food Process Engineering, 34, pp. 682-696; Klewicki, R., The stability of gal-polyols and oligosaccharides during pasteurization at a low pH (2007) LWT-Food Science and Technology, 40, pp. 1259-1265; Lamsal, B.P., Production, health aspects and potential food uses of dairy prebiotic galactooligosaccharides (2012) Journal of the Science of Food and Agriculture, 92, pp. 2020-2028; Laparra, J.M., Diez-Municio, M., Herrero, M., Moreno, F.J., Structural differences of prebiotic oligosaccharides influence their capability to enhance iron absorption in deficient rats (2014) Food & Function, 5, pp. 2430-2437; Marin-Manzano, M.C., Abecia, L., Hernandez-Hernandez, O., Sanz, M.L., Montilla, A., Olano, A., Galacto-oligosaccharides derived from lactulose exert a selective stimulation on the growth of bifidobacterium animals in the large intestine of growing rats (2013) Journal of Agricultural and Food Chemistry, 61, pp. 7560-7567; Martinez-Villaluenga, C., Cardelle-Cobas, A., Olano, A., Corzo, N., Villamiel, M., Jimeno, M.L., Enzymatic synthesis and identification of two trisaccharides produced from lactulose by transgalactosylation (2008) Journal of Agricultural and Food Chemistry, 56, pp. 557-563; Matusek, A., Meresz, P., Le, T.K.D., Orsi, F., Fructo-oligosaccharide degradation in apple pulp matrix (2011) Acta Alimentaria, 40, pp. 182-193; Moreno, F.J., Villamiel, M., Olano, A., Effect of high pressure on isomerization and degradation of lactose in alkaline media (2003) Journal of Agricultural and Food Chemistry, 51, pp. 1894-1896; Moreno, F.J., Montilla, A., Villamiel, M., Corzo, N., Olano, A., Analysis, structural characterization, and bioactivity of oligosaccharides derived from lactose (2014) Electrophoresis, 35, pp. 1519-1534; Olano, A., Corzo, N., Lactulose as a food ingredient (2009) Journal of the Science of Food and Agriculture, 89, pp. 1987-1990; Patel, S., Goyal, A., The current trends and future perspectives of prebiotics research: A review (2012) 3 Biotechnology, 2, pp. 115-125; Ruiz-Matute, A.I., Corzo-Martinez, M., Montilla, A., Olano, A., Copovi, P., Corzo, N., Presence of mono-, di- and galactooligosaccharides in commercial lactose-free UHT dairy products (2012) Journal of Food Composition and Analysis, 28, pp. 164-169; Sancho, J., Bota, E., De Castro, J.J., (2002) Introducción Al Análisis Sensorial de Los Alimentos, p. 145. , Alfaomega Mexico D.F; Sangwan, V., Tomar, S.K., Singh, R.R.B., Singh, A.K., Ali, B., Galactooligosaccharides: Novel components of designer foods (2011) Journal of Food Science, 76, pp. R103-R111; Sanz, M.L., Polemis, N., Morales, V., Corzo, N., Drakoularakou, A., Gibson, G.R., In vitro investigation into the potential prebiotic activity of honey oligosaccharides (2005) Journal of Agricultural and Food Chemistry, 53, pp. 2914-2921; Ting, S.V., Rouseff, R.L., (1986) Citrus Fruits and Their Products. Analysis and Technology, , Marcel Dekker Inc New York; Troyano, E., Villamiel, M., Olano, A., Sanz, J., Martinez-Castro, I., Monosaccharides and myo-inositol in commercial milks (1996) Journal of Agricultural and Food Chemistry, 44, pp. 815-817; Van Leusen, E., Torringa, E., Groenink, P., Kortleve, P., Geene, R., Schoterman, M., Industrial applications of galactooligosaccharides (2014) Food Oligosaccharides: Production, Analysis and Bioactivity, pp. 470-491. , F.J. Moreno, M.L. Sanz (Eds.), Wiley Blackwell Chichester, England; Villamiel, M., Corzo, N., Martinez-Castro, I., Olano, A., Chemical changes during microwave treatment of milk (1996) Food Chemistry, 56, pp. 385-388; Walton, G.E., Van Den Heuvel, E., Kosters, M.H.W., Rastall, R.A., Tuohy, K.M., Gibson, G.R., A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age (2012) British Journal of Nutrition, 107, pp. 1466-1475; Watts, B.M., Ylimaki, G.L., Jeffery, L.E., Elías, L.G., (1992) Métodos Sensoriales Básicos para la Evaluación de Alimentos, p. 89. , Centro internacional de investigaciones para el desarrollo Ottawa, Canadá; Whisner, C.M., Martin, B.R., Schoterman, M.H.C., Nakatsu, C.H., McCabe, L.D., McCabe, G.P., Galacto-oligosaccharides increase calcium absorption and gut bifidobacteria in young girls: A double-blind cross-over trial (2013) British Journal of Nutrition, 110, pp. 1292-1303; Zuluaga, J., Rodriguez, N., Rivas-Ramirez, I., De La Fuente, V., Rufo, L., Amils, R., An improved semiquantitative method for elemental analysis of plants using inductive coupled plasma mass spectrometry (2011) Biological Trace Element Research, 144, pp. 1302-1317",Article,Scopus,2-s2.0-84925449688
"Kong Y., Li X., Zheng T., Lv L.","Glycation of β-lactoglobulin and antiglycation by genistein in different reactive carbonyl model systems",2015,"Food Chemistry","183",, 17221,"36","42",,,10.1016/j.foodchem.2015.02.122,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925086201&partnerID=40&md5=8ceb5432841968ed66d5ae870a86210e","Department of Food Science and Technology, Nanjing Normal University, 122# Ninghai RoadNanjing, China","Kong, Y., Department of Food Science and Technology, Nanjing Normal University, 122# Ninghai RoadNanjing, China; Li, X., Department of Food Science and Technology, Nanjing Normal University, 122# Ninghai RoadNanjing, China; Zheng, T., Department of Food Science and Technology, Nanjing Normal University, 122# Ninghai RoadNanjing, China; Lv, L., Department of Food Science and Technology, Nanjing Normal University, 122# Ninghai RoadNanjing, China","Abstract Advanced glycation end products (AGEs), which are formed in β-lactoglobulin (β-lg) glycation systems via the Maillard reaction, have been implicated in diabetes-related long-term complications. In the present study, we found that reaction conditions, including temperature, time, pH, reactant type and molar ratio of beta-lg to a sugar/MGO/GO, can significantly affect the formation of AGEs. Using SDS-PAGE, we further demonstrated that genistein, a natural isoflavone found in a number of plants including soybeans and kudzu, can efficiently inhibit cross-links of the glycated β-lg, and suppress the formation AGEs in a dose-dependent manner by trapping reactive dicarbonyl compounds. The products formed from genistein and methylglyoxal (MGO) in the β-lg-MGO assay were analyzed using LC/MS. Both mono-MGO and di-MGO adducts of genistein were detected with this method. © 2015 Elsevier Ltd. All rights reserved.","Advanced glycation end products (AGEs); Antiglycation; Genistein; Glyoxal; Methylglyoxal; β-Lactoglobulin","Akselrod, S., Gordon, D., Ubel, F.A., Shannon, D.C., Berger, A., Cohen, R.J., Power spectrum analysis of heart rate fluctuation: A quantitative probe of beat-to-beat cardiovascular control (1981) Science, 213, pp. 220-222; Ames, J.M., Control of the Maillard reaction in food systems (1990) Trends in Food Science & Technology, 1, pp. 150-154; Baynes, J.W., The role of AGEs in aging: Causation or correlation (2001) Experimental Gerontology, 36, pp. 1527-1537; Bouhallab, S., Morgan, F., Henry, G., Molle, D., Leonil, J., Formation of stable covalent dimer explains the high solubility at pH 4.6 of lactose-beta-lactoglobulin conjugates heated near neutral pH (1999) Journal of Agricultural and Food Chemistry, 47 (4), pp. 1489-1494; Broersen, K., Voragen, A.G., Hamer, R.J., De Jongh, H.H., Glycoforms of β-lactoglobulin with improved thermostability and preserved structural packing (2004) Biotechnology and Bioengineering, 86, pp. 78-87; Bunn, H.F., Higgins, P.J., Reaction of monosaccharides with proteins: Possible evolutionary significance (1981) Science, 213, pp. 222-224; Chen, X.M., Kitts, D.D., Determining conditions for nitric oxide synthesis in Caco-2 cells using Taguchi and factorial experimental designs (2008) Analytical Biochemistry, 381, pp. 185-192; Chevalier, F., Chobert, J.M., Dalgalarrondo, M., Choiset, Y., Haertle, T., Maillard glycation of beta-lactoglobulin induces conformation changes (2002) Nahrung, 46, pp. 58-63; Chuyen, N., Maillard reaction and food processing (1998) Process-induced chemical changes in food, pp. 213-235. , Springer; Corzo-Martínez, M., Moreno, F.J., Olano, A., Villamiel, M., Structural characterization of bovine β-lactoglobulin- galactose/tagatose Maillard complexes by electrophoretic, chromatographic, and spectroscopic methods (2008) Journal of Agricultural and Food Chemistry, 56, pp. 4244-4252; Docena, G., Fernandez, R., Chirdo, F., Fossati, C., Identification of casein as the major allergenic and antigenic protein of cow's milk (1996) Allergy, 51, pp. 412-416; Fox, P.F., Heat-Induced Changes in Milk Preceding Coagulation (1981) Journal of Dairy Science, 64, pp. 2127-2137; Furth, A.J., Methods for assaying nonenzymatic glycosylation (1988) Analytical Biochemistry, 175, pp. 347-360; Garcia-Amezquita, L., Martinez-Alvarenga, M., Olivas, G., Zamudio-Flores, P., Acosta-Muñiz, C., Sepulveda, D., Effect of Maillard reaction conditions on the degree of glycation and functional properties of whey protein isolate-Maltodextrin conjugates (2014) Food Hydrocolloids, 38, pp. 110-118; Gaudin, J.C., Rabesona, H., Choiset, Y., Yeretssian, G., Chobert, J.M., Sakanyan, V., Assessment of the immunoglobulin E-mediated immune response to milk-specific proteins in allergic patients using microarrays (2008) Clinical & Experimental Allergy, 38, pp. 686-693; Gerrard, J.A., Protein-protein crosslinking in food: Methods, consequences, applications (2002) Trends in Food Science & Technology, 13, pp. 391-399; Goldin, A., Beckman, J.A., Schmidt, A.M., Creager, M.A., Advanced glycation end products sparking the development of diabetic vascular injury (2006) Circulation, 114, pp. 597-605; Guyomarc'h, F., Warin, F., Donald Muir, D., Leaver, J., Lactosylation of milk proteins during the manufacture and storage of skim milk powders (2000) International Dairy Journal, 10, pp. 863-872; Hattori, M., Nagasawa, K., Ohgata, K., Sone, N., Fukuda, A., Matsuda, H., Reduced immunogenicity of β-lactoglobulin by conjugation with carboxymethyl dextran (2000) Bioconjugate Chemistry, 11, pp. 84-93; Havea, P., Singh, H., Creamer, L.K., Characterization of heat-induced aggregates of beta-lactoglobulin, alpha-lactalbumin and bovine serum albumin in a whey protein concentrate environment (2001) Journal of Dairy Research, 68, pp. 483-497; Hofmann, T., Schieberle, P., Chemical interactions between odor-active thiols and melanoidins involved in the aroma staling of coffee beverages (2002) Journal of Agricultural and Food Chemistry, 50, pp. 319-326; Kim, S., Seo, I., Khan, M., Ki, K., Lee, W., Lee, H., Enzymatic hydrolysis of heated whey: Iron-binding ability of peptides and antigenic protein fractions (2007) Journal of Dairy Science, 90, pp. 4033-4042; Kontopidis, G., Holt, C., Sawyer, L., Invited review: beta-lactoglobulin: Binding properties, structure, and function (2004) Journal of Dairy Science, 87, pp. 785-796; Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4 (1970) Nature, 227, pp. 680-685; Ledl, F., Schleicher, E., New aspects of the Maillard reaction in foods and in the human body (1990) Angewandte Chemie International Edition in English, 29, pp. 565-594; Lo, T.W., Westwood, M.E., McLellan, A.C., Selwood, T., Thornalley, P.J., Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin (1994) Journal of Biological Chemistry, 269, pp. 32299-32305; Lv, L., Shao, X., Chen, H., Ho, C.T., Sang, S., Genistein inhibits advanced glycation end product formation by trapping methylglyoxal (2011) Chemical Research in Toxicology, 24, pp. 579-586; Maillard, L., Action of amino acids on sugars. Formation of melanoidins in a methodical way (1912) Comptes Rendus Chimie, 154, pp. 66-68; Martins, S.I., Van Boekel, M.A., A kinetic model for the glucose/glycine Maillard reaction pathways (2005) Food Chemistry, 90, pp. 257-269; Meltretter, J., Seeber, S., Humeny, A., Becker, C.M., Pischetsrieder, M., Site-specific formation of Maillard, oxidation, and condensation products from whey proteins during reaction with lactose (2007) Journal of Agricultural and Food Chemistry, 55, pp. 6096-6103; Natale, M., Bisson, C., Monti, G., Peltran, A., Perono Garoffo, L., Valentini, S., Cow's milk allergens identification by two-dimensional immunoblotting and mass spectrometry (2004) Molecular Nutrition & Food Research, 48, pp. 363-369; O'Brien, J., Morrissey, P., Ames, J., Nutritional and toxicological aspects of the Maillard browning reaction in foods (1989) Critical Reviews in Food Science & Nutrition, 28, pp. 211-248; Peppa, M., Uribarri, J., Vlassara, H., Glucose, advanced glycation end products, and diabetes complications: what is new and what works (2003) Clinical Diabetes, 21, pp. 186-187; Poulsen, M.W., Hedegaard, R.V., Andersen, J.M., De Courten, B., Bügel, S., Nielsen, J., Advanced glycation endproducts in food and their effects on health (2013) Food and Chemical Toxicology, 60, pp. 10-37; Rabbani, N., Thornalley, P.J., Dicarbonyls linked to damage in the powerhouse: Glycation of mitochondrial proteins and oxidative stress (2008) Biochemical Society Transitions, 36, pp. 1045-1050; Sang, S., Shao, X., Bai, N., Lo, C.Y., Yang, C.S., Ho, C.T., Tea polyphenol (-)-epigallocatechin-3-gallate: A new trapping agent of reactive dicarbonyl species (2007) Chemical Research in Toxicology, 20, pp. 1862-1870; Shao, X., Bai, N., He, K., Ho, C.T., Yang, C.S., Sang, S., Apple polyphenols, phloretin and phloridzin: New trapping agents of reactive dicarbonyl species (2008) Chemical Research in Toxicology, 21, pp. 2042-2050; Singh, R., Barden, A., Mori, T., Beilin, L., Advanced glycation end-products: A review (2001) Diabetologia, 44, pp. 129-146; Taheri-Kafrani, A., Gaudin, J.C., Rabesona, H., Nioi, C., Agarwal, D., Drouet, M., Effects of heating and glycation of β-lactoglobulin on its recognition by IgE of sera from cow milk allergy patients (2009) Journal of Agricultural and Food Chemistry, 57, pp. 4974-4982; Van Boekel, M.A.J.S., Effect of heating on Maillard reactions in milk (1998) Food Chemistry, 62, pp. 403-414; Van Boekel, M.A., Kinetic aspects of the Maillard reaction: A critical review (2001) Nahrung, 45, pp. 150-159; Wooster, T.J., Augustin, M.A., The emulsion flocculation stability of protein-carbohydrate diblock copolymers (2007) Journal of Colloid and Interface Science, 313, pp. 665-675; Wu, C.-H., Yen, G.-C., Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts (2005) Journal of Agricultural and Food Chemistry, 53, pp. 3167-3173; Zeng, J., Davies, M.J., Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins (2005) Chemical Research in Toxicology, 18 (8), pp. 1232-1241",Article,Scopus,2-s2.0-84925086201
"McLean M.H., Dieguez D., Miller L.M., Young H.A.","Does the microbiota play a role in the pathogenesis of autoimmune diseases?",2015,"Gut","64","2",,"332","341",,,10.1136/gutjnl-2014-308514,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920971304&partnerID=40&md5=f841679f76b3f595118bd4493c13d5c9","Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, National Cancer Institute, 1050 Boyles StreetFrederick, MD, United States; Society for Women's Health Research, Scientific AffairsWashington, D.C., United States","McLean, M.H., Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, National Cancer Institute, 1050 Boyles StreetFrederick, MD, United States; Dieguez, D., Jr., Society for Women's Health Research, Scientific AffairsWashington, D.C., United States; Miller, L.M., Society for Women's Health Research, Scientific AffairsWashington, D.C., United States; Young, H.A., Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, National Cancer Institute, 1050 Boyles StreetFrederick, MD, United States","The microbiota of the human metaorganism is not a mere bystander. These microbes have coevolved with us and are pivotal to normal development and homoeostasis. Dysbiosis of the GI microbiota is associated with many disease susceptibilities, including obesity, malignancy, liver disease and GI pathology such as IBD. It is clear that there is direct and indirect crosstalk between this microbial community and host immune response. However, the precise mechanism of this microbial influence in disease pathogenesis remains elusive and is now a major research focus. There is emerging literature on the role of the microbiota in the pathogenesis of autoimmune disease, with clear and increasing evidence that changes in the microbiota are associated with some of these diseases. Examples include type 1 diabetes, coeliac disease and rheumatoid arthritis, and these contribute significantly to global morbidity and mortality. Understanding the role of the microbiota in autoimmune diseases may offer novel insight into factors that initiate and drive disease progression, stratify patient risk for complications and ultimately deliver new therapeutic strategies. This review summarises the current status on the role of the microbiota in autoimmune diseases.",,"Turnbaugh, P.J., Ley, R.E., Hamady, M., The human microbiome project: Exploring the microbial part of ourselves in a changing world (2007) Nature, 449, pp. 804-810; Guarner, F., Malagelada, J.R., Gut flora in health and disease (2003) Lancet, 361, pp. 512-519; Hollister, E.B., Gao, C., Versalovic, J., Compositional and functional features of the gastrointestinal microbiome and their effects on human health (2014) Gastroenterology, 146, pp. 1449-1458; Cox, A.J., West, N.P., Cripps, A.W., Obesity, inflammation, and the gut microbiota (2014) Lancet Diabetes Endocrinol, , Published Online First: 21 Jul; Shapiro, H., Thaiss, C.A., Levy, M., The cross talk between microbiota and the immune system: Metabolites take center stage (2014) Curr Opin Immunol, 30, pp. 54-62; Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Diversity, stability and resilience of the human gut microbiota (2012) Nature, 489, pp. 220-230; Yatsunenko, T., Rey, F.E., Manary, M.J., Human gut microbiome viewed across age and geography (2012) Nature, 486, pp. 222-228; Zeissig, S., Blumberg, R.S., Life at the beginning: Perturbation of the microbiota by antibiotics in early life and its role in health and disease (2014) Nat Immunol, 15, pp. 307-310; Structure, function and diversity of the healthy human microbiome (2012) Nature, 486, pp. 207-214; Joscelyn, J., Kasper, L.H., Digesting the emerging role for the gut microbiome in central nervous system demyelination Mult Scler, 20, pp. 1553-1559; Schwabe, R.F., Jobin, C., The microbiome and cancer (2013) Nat Rev Cancer, 13, pp. 800-812; Abreu, M.T., Peek, R.M., Jr., Gastrointestinal malignancy and the microbiome (2014) Gastroenterology, 146, pp. 1534-1546; Bultman, S.J., Emerging roles of the microbiome in cancer (2014) Carcinogenesis, 35, pp. 249-255; Roderburg, C., Luedde, T., The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma (2014) Gut Microbes, 5, pp. 441-445; Schnabl, B., Brenner, D.A., Interactions between the intestinal microbiome and liver diseases (2014) Gastroenterology, 146, pp. 1513-1524; Kostic, A.D., Xavier, R.J., Gevers, D., The microbiome in inflammatory bowel disease: Current status and the future ahead (2014) Gastroenterology, 146, pp. 1489-1499; Dabelea, D., The accelerating epidemic of childhood diabetes (2009) Lancet, 373, pp. 1999-2000; Vehik, K., Ajami, N.J., Hadley, D., The changing landscape of type 1 diabetes: Recent developments and future frontiers (2013) Curr Diab Rep, 13, pp. 642-650; Hakonarson, H., Grant, S.F., GWAS and its impact on elucidating the etiology of diabetes (2011) Diabetes Metab Res Rev, 27, pp. 685-696; Steck, A.K., Rewers, M.J., Genetics of type 1 diabetes (2011) Clin Chem, 57, pp. 176-185; Bakay, M., Pandey, R., Hakonarson, H., Genes involved in type 1 diabetes (2013) Genes (Basel), 4, pp. 499-521; Alper, C.A., Husain, Z., Larsen, C.E., Incomplete penetrance of susceptibility genes for MHC-determined immunoglobulin deficiencies in monozygotic twins discordant for type 1 diabetes (2006) J Autoimmun, 27, pp. 89-95; Oilinki, T., Otonkoski, T., Ilonen, J., Prevalence and characteristics of diabetes among Somali children and adolescents living in Helsinki, Finland (2012) Pediatr Diabetes, 13, pp. 176-180; Nielsen, D.S., Krych, L., Buschard, K., Beyond genetics. Influence of dietary factors on gut microbiota on type 1 diabetes (2014) FEBS Lett, 588, pp. 4234-4243; Kondrashova, A., Hyöty, H., Role of viruses and other microbes in the pathogenesis of type 1 diabetes (2014) Int Rev Immunol, 33, pp. 284-295; Boerner, B.P., Sarvetnick, N.E., Type 1 diabetes: Role of intestinal microbiome in humans and mice (2011) Ann N Y Acad Sci, 1243, pp. 103-118; Atkinson, M.A., Chervonsky, A., Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease (2012) Diabetologia, 55, pp. 2868-2877; Hara, N., Alkanani, A.K., Ir, D., The role of the intestinal microbiota in type 1 diabetes (2013) Clin Immunol, 146, pp. 112-119; Zipris, D., The interplay between the gut microbiota and the immune system in the mechanism of type 1 diabetes (2013) Curr Opin Endocrinol Diabetes Obes, 20, pp. 265-270; Dunne, J.L., Triplett, E.W., Geyers, D., The intestinal microbiome in type 1 diabetes (2014) Clin Exp Immunol, 177, pp. 30-37; Brehm, M.A., Powers, A.C., Shultz, L.D., Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice (2012) Cold Spring Harb Perspect Med, 2; Wen, L., Ley, R.E., Volchkov, P.Y., Innate immunity and intestinal microbiota in the development of Type 1 diabetes (2008) Nature, 455, pp. 1109-1113; Hansen, C.H., Krych, L., Nielsen, D.S., Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse (2012) Diabetologia, 55, pp. 2285-2294; Alkanani, A.K., Hara, N., Lien, E., Induction of diabetes in the RIP-B7.1 mouse model is critically dependent on TLR3 and MyD88 pathways and is associated with alterations in the intestinal microbiome (2014) Diabetes, 63, pp. 619-631; Tormo-Badia, N., Hakansson, A., Vasudevan, K., Antibiotic treatment of pregnant non-obese diabetic (NOD) mice leads to altered gut microbiota and intestinal immunological changes in the offspring (2014) Scand J Immunol, 80, pp. 250-260; Sofi, M.H., Gudi, R., Karumuthil-Melethil, S., pH of drinking water influences the composition of gut microbiome and type 1 diabetes incidence (2014) Diabetes, 63, pp. 632-644; Wolf, K.J., Daft, J.G., Tanner, S.M., Consumption of acidic water alters the gut microbiome and decreases the risk of diabetes in NOD mice (2014) J Histochem Cytochem, 62, pp. 237-250; Kriegel, M.A., Sefik, E., Hill, J.A., Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice (2011) Proc Natl Acad Sci USA, 108, pp. 11548-11553; Markle, J.G., Frank, D.N., Adeli, K., Microbiome manipulation modifies sex-specific risk for autoimmunity (2014) Gut Microbes, 5, pp. 485-493; Peng, J., Narasimhan, S., Marchesi, J.R., Long term effect of gut microbiota transfer on diabetes development (2014) Journal of Autoimmunity, 53, pp. 85-94; King, C., Sarvetnick, N., The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions (2011) PLoS ONE, 6; Zipris, D., Toll-like receptors and type 1 diabetes (2010) Adv Exp Med Biol, 654, pp. 585-610; Brugman, S., Klatter, F.A., Visser, J.T., Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes prone rat. Is the gut flora involved in the development of type 1 diabetes? (2006) Diabetologia, 49, pp. 2105-2108; Schwartz, R.F., Neu, J., Schatz, D., Comment on: Brugman S et al. (2007) Diabetologia, 50, pp. 220-221; Vaarala, O., Human intestinal microbiota and type 1 diabetes (2013) Curr Diab Rep, 13, pp. 601-607; De Goffau, M.C., Fuentes, S., Van Den Bogert, B., Aberrant gut microbiota composition at the onset of type 1 diabetes in young children (2014) Diabetologia, 57, pp. 1569-1577; Brown, C.T., Davis-Richardson, A.G., Giongo, A., Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes (2011) PLoS ONE, 610; Giongo, A., Gano, K.A., Crabb, D.B., Toward defining the autoimmune microbiome for type 1 diabetes (2011) ISME J, 5, pp. 82-91; Murri, M., Leiva, I., Gomez-Zumaquero, J.M., Gut microbiota in children with type 1 diabetes differs from that in healthy children: A case-control study (2013) BMC Med, 11, p. 46; Endesfelder, D., Zu Castell, W., Ardissone, A., Compromised gut microbiota networks in children with anti-islet cell autoimmunity (2014) Diabetes, 63, pp. 2006-2014; Mejía-León, M.E., Petrosino, J.F., Ajami, N.J., Fecal microbiota imbalance in Mexican children with type 1 diabetes (2014) Sci Rep, 4, p. 3814; Cardwell, C.R., Stene, L.C., Joner, G., Caesarean section is associated with an increased risk of childhood onset type 1 diabetes: A meta-analysis of observational studies (2008) Diabetologia, 51, pp. 726-735; Phillips, J., Gill, N., Sikdar, K., History of cesarean section associated with childhood onset of T1DM in Newfoundland and Labrador, Canada (2012) J Environ Public Health, 2012, p. 635097; Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns (2010) Proc Natl Acad Sci USA, 107, pp. 11971-11975; Wallberg, M., Cooke, A., Immune mechanisms in type 1 diabetes (2013) Trends Immunol, 34, pp. 583-591; Lau, K., Benitez, P., Ardissone, A., Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias (2011) J Immunol, 186, pp. 3538-3546; Bedoya, S.K., Lam, B., Lau, K., Th17 cells in immunity and autoimmunity (2013) Clin Dev Immunol, 2013, p. 986789; Bosi, E., Molteni, L., Radaelli, M.G., Increased intestinal permeability precedes clinical onset of type 1 diabetes (2006) Diabetologia, 49, pp. 2824-2827; Secondulfo, M., Iafusco, D., Carratù, R., Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type 1 diabetic patients (2004) Dig Liver Dis, 36, pp. 35-45; Vaarala, O., Leaking gut in type 1 diabetes (2008) Curr Opin Gastroenterol, 24, pp. 701-706; Visser, J., Rozing, J., Sapone, A., Tight junctions, intestinal permeability, and autoimmunity: Celiac disease and type 1 diabetes paradigms (2009) Ann N Y Acad Sci, 1165, pp. 195-205; Kupfer, S.S., Jabri, B., Pathophysiology of celiac disease (2012) Gastrointest Endosc Clin N Am, 22, pp. 639-660; Guandalini, S., Assiri, A., Celiac disease: A review (2014) JAMA Pediatr, 168, pp. 272-278; Meresse, B., Malamut, G., Cerf-Bensussan, N., Celiac disease: An immunological jigsaw (2012) Immunity, 36, pp. 907-919; Abadie, V., Jabri, B., IL-15: A central regulator of celiac disease immunopathology (2014) Immunol Rev, 260, pp. 221-234; Mooney, P.D., Hadjivassiliou, M., Sanders, D.S., Coeliac disease (2014) BMJ, 348, p. g156; Greco, L., Romino, R., Coto, I., The first large population based twin study of coeliac disease (2002) Gut, 50, pp. 624-628; Nisticò, L., Fagnani, C., Coto, I., Concordance, disease progression, and heritability of coeliac disease in Italian twins (2006) Gut, 55, pp. 803-808; Dubois, P.C., Trynka, G., Franke, L., Multiple common variants for celiac disease influencing immune gene expression (2010) Nat Genet, 42, pp. 295-302; Trynka, G., Hunt, K.A., Bockett, N.A., Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease (2011) Nat Genet, 43, pp. 1193-1201; Wijmenga, C., Gutierrez-Achury, J., Celiac disease genetics: Past, present and future challenges (2014) J Pediatr Gastroenterol Nutr, 59, pp. S4-S7; Lohi, S., Mustalahti, K., Kaukinen, K., Increasing prevalence of coeliac disease over time (2007) Aliment Pharmacol Ther, 26, pp. 1217-1225; Rubio-Tapia, A., Kyle, R.A., Kaplan, E.L., Increased prevalence and mortality in undiagnosed celiac disease (2009) Gastroenterology, 137, pp. 88-93; De Sousa Moraes, L.F., Grzeskowiak, L.M., De Sales Teixeira, T.F., Intestinal microbiota and probiotics in celiac disease (2014) Clin Microbiol Rev, 27, pp. 482-489; Ou, G., Hedberg, M., Hörstedt, P., Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease (2009) Am J Gastroenterol, 104, pp. 3058-3067; Nistal, E., Caminero, A., Herran, A.R., Differences of small intestinal bacteria populations in adults and children with/without celiac disease: Effect of age, gluten diet, and disease (2012) Inflamm Bowel Dis, 18, pp. 649-656; Cheng, J., Kalliomäki, M., Heilig, H.G., Duodenal microbiota composition and mucosal homeostasis in pediatric celiac disease (2013) BMC Gastroenterol, 13, p. 113; De Meij, T.G., Budding, A.E., Grasman, M.E., Composition and diversity of the duodenal mucosa-associated microbiome in children with untreated coeliac disease (2013) Scand J Gastroenterol, 48, pp. 530-536; Collado, M.C., Calabuig, M., Sanz, Y., Differences between the fecal microbiota of coeliac infants and healthy controls (2007) Curr Issues Intest Microbiol, 8, pp. 9-14; Nadal, I., Donat, E., Ribes-Koninckx, C., Imbalance in the composition of the duodenal microbiota of children with coeliac disease (2007) J Med Microbiol, 56, pp. 1669-1674; Sanz, Y., Sanchez, E., Marzotto, M., Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis (2007) FEMS Immunol Med Microbiol, 51, pp. 562-568; Collado, M.C., Donat, E., Ribes-Koninckx, C., Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease (2009) J Clin Pathol, 62, pp. 264-269; Schippa, S., Iebba, V., Barbato, M., A distinctive 'microbial signature' in celiac pediatric patients (2010) BMC Microbiol, 10, p. 175; Di Cagno, R., De Angelis, M., De Pasquale, I., Duodenal and faecal microbiota of celiac children: Molecular, phenotype and metabolome characterization (2011) BMC Microbiol, 11, p. 219; Sanchez, E., Laparra, J.M., Sanz, Y., Discerning the role of Bacteroides fragilis in celiac disease pathogenesis (2012) Appl Environ Microbiol, 78, pp. 6507-6515; De Palma, G., Kamanova, J., Cinova, J., Modulation of phenotypic and functional maturation of dendritic cells by intestinal bacteria and gliadin: Relevance for celiac disease (2012) J Leukoc Biol, 92, pp. 1043-1054; Stoven, S., Murray, J.A., Marietta, E.V., Latest in vitro and in vivo models of celiac disease (2013) Expert Opin Drug Discov, 8, pp. 445-457; Laparra, J.M., Olivares, M., Gallina, O., Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model (2012) PLoS ONE, 7; Olivares, M., Laparra, M., Sanz, Y., Oral administration of Bifidobacterium longum CECT 7347 modulates jejuna proteome in an in vivo gliadin induced enteropathy animal model (2012) J Proteomics, 77, pp. 310-320; Freitag, T.L., Rietdijk, S., Junker, Y., Gliadin-primed CD4 +CD45RBlowCD25-T cells drive gluten-dependent small intestinal damage after adoptive transfer into lymphopenic mice (2009) Gut, 58, pp. 1597-1605; Olivares, M., Neef, A., Castillejo, G., The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease (2014) Gut, , Published Online First: 17 Jun; Sellitto, M., Bai, G., Serena, G., Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants (2012) PLoS ONE, 7; Wacklin, P., Kaukinen, K., Tuovinen, E., The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease (2013) Inflamm Bowel Dis, 19, pp. 934-941; Fernandez-Feo, M., Wei, G., Blumenkranz, G., The cultivable human oral gluten-degrading microbiome and its potential implications in coeliac disease and gluten sensitivity (2013) Clin Microbiol Infect, 19, pp. E386-E394; Lähdeaho, M.L., Kaukinen, K., Laurila, K., Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease (2014) Gastroenterology, 146, pp. 1649-1658; Francavilla, R., Ercolini, D., Piccolo, M., Salivary microbiota and metabolome associated with celiac disease (2014) Appl Environ Microbiol, 80, pp. 3416-3425; McInnes, I.B., Schett, G., The pathogenesis of rheumatoid arthritis (2011) N Engl J Med, 365, pp. 2205-2219; Scher, J.U., Abramson, S.B., The microbiome and rheumatoid arthritis (2011) Nat Rev Rheumatol, 7, pp. 569-578; Luckey, D., Gomez, A., Murray, J., Bugs & us: The role of the gut in autoimmunity (2013) Indian J Med Res, 138, pp. 732-743; Nielen, M.M., Van Schaardenburg, D., Reesink, H.W., Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis (2004) Arthritis Rheum, 50, pp. 2423-2427; Kochi, Y., Suzuki, A., Yamamoto, K., Genetic basis of rheumatoid arthritis: A current review (2014) Biochem Biophys Res Commun, 452, pp. 254-262; MacGregor, A.J., Snieder, H., Rigby, A.S., Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins (2000) Arthritis Rheum, 43, pp. 30-37; Bogdanos, D.P., Smyk, D.S., Rigopoulou, E.I., Twin studies in autoimmune disease: Genetics, gender and environment (2012) J Autoimmun, 38, pp. J156-J169; Paget, S.A., The microbiome, autoimmunity, and arthritis: Cause and effect: An historical perspective (2012) Trans Am Clin Climatol Assoc, 123, pp. 257-266; Sato, N., Oizumi, T., Kinbara, M., Promotion of arthritis and allergy in mice by aminoglycoglycerophospholipid, a membrane antigen specific to Mycoplasma fermentans (2010) FEMS Immunol Med Microbiol, 59, pp. 33-41; Newkirk, M.M., Zbar, A., Baron, M., Distinct bacterial colonization patterns of Escherichia coli subtypes associate with rheumatoid factor status in early inflammatory arthritis (2010) Rheumatology (Oxford), 49, pp. 1311-1316; Ebringer, A., Ptaszynska, T., Corbett, M., Antibodies to proteus in rheumatoid arthritis (1985) Lancet, 2, pp. 305-307; Ebringer, A., Rashid, T., Wilson, C., Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper (2010) Autoimmun Rev, 9, pp. 216-223; Hunter, W., Oral sepsis as a cause of disease (1900) Br Med J, 2, pp. 215-216; De Aquino, S.G., Abdollahi-Roodsaz, S., Koenders, M.I., Periodontal pathogens directly promote autoimmune experimental arthritis by inducing a TLR2- and IL-1-driven Th17 response (2014) J Immunol, 192, pp. 4103-4111; Scher, J.U., Ubeda, C., Equinda, M., Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis (2012) Arthritis Rheum, 64, pp. 3083-3094; Wolff, B., Berger, T., Frese, C., Oral status in patients with early rheumatoid arthritis: A prospective, case-control study (2014) Rheumatology (Oxford), 53, pp. 526-531; Al-Katma, M.K., Bissada, N.F., Bordeaux, J.M., Control of periodontal infection reduces the severity of active rheumatoid arthritis (2007) J Clin Rheumatol, 13, pp. 134-137; Pischon, N., Pischon, T., Kröger, J., Association among rheumatoid arthritis, oral hygiene, and periodontitis (2008) J Periodontol, 79, pp. 979-986; Mikuls, T.R., Payne, J.B., Yu, F., Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis (2014) Arthritis Rheumatol, 66, pp. 1090-1100; Okada, M., Kobayashi, T., Ito, S., Periodontal treatment decreases levels of antibodies to Porphyromonas gingivalis and citrulline in patients with rheumatoid arthritis and periodontitis (2013) J Periodontol, 84, pp. e74-e84; Ortiz, P., Bissada, N.F., Palomo, L., Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors (2009) J Periodontol, 80, pp. 535-540; Hitchon, C.A., Chandad, F., Ferucci, E.D., Antibodies to Porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives (2010) J Rheumatol, 37, pp. 1105-1112; Martinez-Martinez, R.E., Abud-Mendoza, C., Patiño-Marin, N., Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients (2009) J Clin Periodontol, 36, pp. 1004-1010; Moen, K., Brun, J.G., Valen, M., Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs (2006) Clin Exp Rheumatol, 24, pp. 656-663; Marchesan, J.T., Gerow, E.A., Schaff, R., Porphyromonas gingivalis oral infection exacerbates the development and severity of collagen-induced arthritis (2013) Arthritis Res Ther, 15, p. R186; Wegner, N., Lundberg, K., Kinloch, A., Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis (2010) Immunol Rev, 233, pp. 34-54; Brusca, S.B., Abramson, S.B., Scher, J.U., Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity (2014) Curr Opin Rheumatol, 26, pp. 101-107; Hilty, M., Burke, C., Pedro, H., Disordered microbial communities in asthmatic airways (2010) PLoS One, 5; Segal, L.N., Alekseyenko, A.V., Clemente, J.C., Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation (2013) Microbiome, 1, p. 19; Makrygiannakis, D., Hermansson, M., Ulfgren, A.K., Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells (2008) Ann Rheum Dis, 67, pp. 1488-1492; Demoruelle, M.K., Weisman, M.H., Simonian, P.L., Brief report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity? (2012) Arthritis Rheum, 64, pp. 1756-1761; Fung, I., Garrett, J.P., Shahane, A., Do bugs control our fate? The influence of the microbiome on autoimmunity (2012) Curr Allergy Asthma Rep, 12, pp. 511-519; Yeoh, N., Burton, J.P., Suppiah, P., The role of the microbiome in rheumatic diseases (2013) Curr Rheumatol Rep, 15, p. 314; Taneja, V., Arthritis susceptibility and the gut microbiome (2014) FEBS Lett, , Published Online First; Abdollahi-Roodsaz, S., Joosten, L.A., Koenders, M.I., Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis (2008) J Clin Invest, 118, pp. 205-216. , http://www.ncbi.nlm.nih.gov/pubmed/?term=Stimulation+of+TLR2+and+TLR4+differentially+skews+the+balance+of+T+cells+in+a+mouse+model+of+arthritis; Wu, H.J., Ivanov, I.I., Darce, J., Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells (2010) Immunity, 32, pp. 815-827; Gomez, A., Luckey, D., Yeoman, C.J., Loss of sex and age driven differences in the gut microbiome characterize arthritis-susceptible 0401 mice but not arthritis-resistant 0402 mice (2012) PLoS ONE, 7; Dorozyńska, I., Majewska-Szczepanik, M., Marcińska, K., Partial depletion of natural gut fl ora by antibiotic aggravates collagen induced arthritis (CIA) in mice (2014) Pharmacol Rep, 66, pp. 250-255; Vaahtovuo, J., Munukka, E., Korkeamäki, M., Fecal microbiota in early rheumatoid arthritis (2008) J Rheumatol, 35, pp. 1500-1505; Scher, J.U., Sczesnak, A., Longman, R.S., Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis (2013) Elife, 2; Zhou, L., Li, X., Ahmed, A., Gut microbe analysis between hyperthyroid and healthy individuals (2014) Curr Microbiol, 69, pp. 675-680; Penhale, W.J., Young, P.R., The influence of the normal microbial flora on the susceptibility of rats to experimental autoimmune thyroiditis (1988) Clin Exp Immunol, 72, pp. 288-292; Szymula, A., Rosenthal, J., Szczerba, B.M., T cell epitope mimicry between Sjögren's syndrome Antigen A (SSA)/Ro60 and oral, gut, skin and vaginal bacteria (2014) Clin Immunol, 152, pp. 1-9; Vieira, S.M., Pagovich, O.E., Kriegel, M.A., Diet, microbiota and autoimmune diseases (2014) Lupus, 23, pp. 518-526; Costello, M.E., Elewaut, D., Kenna, T.J., Microbes, the gut and ankylosing spondylitis (2013) Arthritis Res Ther, 15, p. 214; Schaeverbeke, T., Truchetet, M.E., Richez, C., Gut metagenome and spondyloarthritis (2013) Joint Bone Spine, 80, pp. 349-352; Wallis, D., Asaduzzaman, A., Weisman, M., Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: An observational study (2013) Arthritis Res Ther, 15, p. R166; Hacquard-Bouder, C., Ittah, M., Breban, M., Animal models of HLA-B27-associated diseases: New outcomes (2006) Joint Bone Spine, 73, pp. 132-138; Stebbings, S., Munro, K., Simon, M.A., Comparison of the faecal microfl ora of patients with ankylosing spondylitis and controls using molecular methods of analysis (2002) Rheumatology (Oxford), 41, pp. 1395-1401; Stebbings, S.M., Taylor, C., Tannock, G.W., The immune response to autologous bacteroides in ankylosing spondylitis is characterized by reduced interleukin 10 production (2009) J Rheumatol, 36, pp. 797-800; Lin, P., Bach, M., Asquith, M., HLA-B27 and Human β2-Microglobulin Affect the Gut Microbiota of Transgenic Rats (2014) PLoS ONE, 9; Wang, Y., Kasper, L.H., The role of microbiome in central nervous system disorders (2014) Brain Behav Immun, 38, pp. 1-12; Bhargava, P., Mowry, E.M., Gut microbiome and multiple sclerosis (2014) Curr Neurol Neurosci Rep, 14, p. 492; Berer, K., Krishnamoorthy, G., Microbial view of central nervous system autoimmunity (2014) FEBS Lett, 588, pp. 4207-4213; Lee, Y.K., Menezes, J.S., Umesaki, Y., Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis (2011) Proc Natl Acad Sci USA, 108, pp. 4615-4622; Yokote, H., Miyake, S., Croxford, J.L., NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora (2008) Am J Pathol, 173, pp. 1714-1723; Ochoa-Repáraz, J., Mielcarz, D.W., Ditrio, L.E., Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis (2009) J Immunol, 183, pp. 6041-6050; Ochoa-Repáraz, J., Mielcarz, D.W., Haque-Begum, S., Induction of a regulatory B cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora (2010) Gut Microbes, 1, pp. 103-108; Berer, K., Mues, M., Koutrolos, M., Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination (2011) Nature, 479, pp. 538-541; Ochoa-Reparaz, J., Mielcarz, D.W., Ditrio, L.E., Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression (2010) J Immunol, 185, pp. 4101-4108; Ochoa-Reparaz, J., Mielcarz, D.W., Wang, Y., A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease (2010) Mucosal Immunol, 3, pp. 487-495; Mao, Y.-K., Kasper, D.L., Wang, B., Bacteroides fragilis polysaccharide A is necessary and sufficient for acute activation of intestinal sensory neurons (2013) Nat Commun, 4, p. 1465; Wang, Y., Telesford, K.M., Ochoa-Repáraz, J., An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signalling (2014) Nat Commun, 5, p. 4432",Article,Scopus,2-s2.0-84920971304
"Han Y., Jung H.W., Park Y.-K.","Effects of Icariin on insulin resistance via the activation of AMPK pathway in C2C12 mouse muscle cells",2015,"European Journal of Pharmacology","758",,,"60","63",,,10.1016/j.ejphar.2015.03.059,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927772678&partnerID=40&md5=5da446bef65d67e53fc1c2c4895ba454","Korean Medicine RandD Center, Dongguk UniversityGyeongju, South Korea; Department of Herbology, College of Korean Medicine, Dongguk UniversityGyeongju, South Korea","Han, Y., Korean Medicine RandD Center, Dongguk UniversityGyeongju, South Korea; Jung, H.W., Korean Medicine RandD Center, Dongguk UniversityGyeongju, South Korea, Department of Herbology, College of Korean Medicine, Dongguk UniversityGyeongju, South Korea; Park, Y.-K., Korean Medicine RandD Center, Dongguk UniversityGyeongju, South Korea, Department of Herbology, College of Korean Medicine, Dongguk UniversityGyeongju, South Korea","Insulin resistance in skeletal muscle is a major risk factor for the development of type 2 diabetes (T2D). In this study, we investigated the effect of icariin on insulin resistance in C2C12 mouse skeletal muscle cells. C2C12 myoblasts were differentiated into myotubes for five days, then treated with icariin (50 and 100 μM) or metformin (1 mM) in the presence of 100 nM insulin for 24 h. Adiponectin production was measured in culture media by ELISA, and AMP-activated protein kinase (AMPK)/insulin signaling pathway activation was assessed by the western blot analysis. Icariin significantly increased adiponectin production in C2C12 myotubes. Moreover, icariin markedly promoted the phosphorylation of AMPK and acetyl-CoA carboxylase (ACC). Icariin up-regulated the expression of phosphatidylinositol 3-kinase (PI3K) and the phosphorylation of insulin receptor substrate-1 (IRS-1) in C2C12 myotubes. These results suggest that icariin has therapeutic potential for the treatment of T2D via the regulation of insulin resistance in skeletal muscle. © 2015 Elsevier B.V. All rights reserved.","AMPK pathway; C2C12 cells; Icariin; Insulin resistance; Skeletal muscle; Type 2 diabetes","Aguer, C., Harper, M., Skeletal muscle mitochondrial energetic in obesity and type 2 diabetes mellitus: Endocrine aspects (2012) Best Pract. Res. Clin. Endocrinol. Metab., 26, pp. 805-819; Bijland, S., Mancini, S.J., Salt, I.P., Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation (2013) Clin. Sci., 124, pp. 491-507; Bojic, L.A., Telford, D.E., Fullerton, M.D., Ford, R.H., Sutherland, B.G., Edwards, J.Y., Sawyez, C.G., Huff, M.W., PPARδ actication attenuates hepatic steatosis in ldlr-/-mice by enhanced fat oxidation, reduced lipogenesis and improved insulin sensitivity (2014) J. Lipid. Res., 55, pp. 1254-1266; Bruckbauer, A., Zemel, M.B., Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity (2013) Diabetes Metab. Syndr. Obes., 6, pp. 93-102; Burén, J., Liu, H.X., Lauritz, J., Erilsson, J.W., High glucose and insulin in combination cause insulin receptor substrate-1 and -2 depletion and protein kinase B desensitization in primary cultured rat adipocytes: Possible implications for insulin resistance in type 2 diabetes (2003) Eur. J. Endocrinol., 148, pp. 157-167; Chellan, N., Muller, C.J.F., Beer, D., Joubert, E., Page, B.J., Louw, J., An in vitro assessment of the effect of athrixia phylicoides DC. Aqueous extract on glucose metabolism (2012) Phytomedicine, 19, pp. 730-736; Chen, M., Hao, J., Yang, Q., Li, G., Effects of icariin on reproductive functions in male rats (2014) Molecules, 19, pp. 9502-9514; Delaigle, A.M., Senou, M., Guiot, Y., Many, M.C., Brichard, S.M., Induction of adiponectin in skeletal muscle of type 2 diabetic mice: In vivo and in vitro studies (2006) Diabetologia, 49, pp. 1311-1323; Deng, Y.T., Chang, T.W., Lee, M.S., Lin, J.K., Suppression of free fatty acid-induced insulin resistance by phytopolyphenols in c2c12 mouse skeletal muscle cells (2012) J. Agric. Food Chem., 60, pp. 1059-1066; Han, Y., Jung, H.W., Bae, H.S., Park, Y.K., Wen-pi-tang-hab-wu-ling-san, a polyherbal medicine, attenuates er stress in 3T3-L1 preadipocytes by promoting the insuling signaling pathway (2013) Evid. Based Complement. Altern. Med., 2013, p. 825814; Hao, C., Hao, J., Wang, W., Han, Z., Li, G., Zhang, L., Zhao, X., Yu, G., Insulin sensitizing effects of oligomannuronate-chromium (III) complexes in C2C12 skeletal muscle cells (2011) PLoS. ONE, 6, pp. 1-10; Ji, D.B., Ye, J., Li, C.L., Wang, Y.H., Zhao, J., Cai, S.Q., Antiaging effect of cordyceps sinensis extract (2009) Phytother. Res., 23, pp. 116-122; Kim, D., Park, K.K., Lee, S.K., Lee, S.E., Hwang, J.K., Cornus kousa f.buerger ex miquel increases glucose uptake through activation of peroxisome proliferator-activated receptor γ and insulin sensitization (2011) J. Ethnopharmacol., 133, pp. 803-809; Kimura, T., Kato, E., MacHikawa, T., Kimura, S., Katayama, S., Kawabata, J., Hydroxylamine enhances glucose uptake in C2C12 skeletal muscle cells through the activation of insulin receptor substrate 1 (2014) Biochem. Biophys. Res. Commun., 445, pp. 6-9; Lee, H.M., Lee, O.H., Kim, K.J., Lee, B.Y., Ginsenoside rg1 promotes glucose uptake through activated ampk pathway in insulin-resistant muscle cells (2012) Phytother. Res., 26, pp. 1017-1022; Mor, A., Aizman, E., George, J., Kloog, Y., Ras inhibition induces insulin sensitivity and glucose uptake (2011) PLoS. One, 6, pp. 1-11; Oliver, E., McGillicuddy, F., Phillips, C., Toomey, S., Roche, H.M., The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA (2010) Proc. Nutr. Soc., 69, pp. 232-243; Pan, Y., Hong, Y., Zhang, Q.Y., Kong, L.D., Impaired hypothalamic insulin signaling in cums rats: Restored by icariin and fluoxetine through inhibiting crf system (2013) Psychoneuroendocrinology, 38, pp. 122-134; Park, S.Y., Kim, M.H., Ahn, J.H., Lee, S.J., Lee, J.H., Eum, W.S., Choi, S.Y., Kwon, H.Y., The stimulatory effect of essential fatty acids on glucose uptake involves both akt and ampk activation in C2C12 skeletal muscle cells (2014) Korean J. Pharmacol., 18, pp. 255-261; Qi, M.Y., Kai, C., Liu, H.R., Su, Y.H., Yu, S.Q., Protective effect of icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats (2011) J. Ethnopharmacol., 138, pp. 731-736; Qiao, L., Kinney, B., Schaack, J., Shao, J., Adiponectin inhibits lipolysis in mouse adipocytes (2011) Diabetes, 60, pp. 1519-1527; Shen, Y., Honma, N., Kobayashi, K., Jia, L.N., Hosono, T., Shindo, K., Ariga, T., Seki, T., Cinnamon extract enhances glucose uptake in 3T3-L1 adipocytes and c2c12 myocytes by inducing lkb1-amp-activated protein kinase signaling (2014) PLoS. One, 9, pp. 1-9; Song, Y.H., Cai, H., Gu, N., Qian, C.F., Cao, S.P., Zhao, Z.M., Icariin attenuates cardiac remodeling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure (2011) J. Pharm. Pharmacol., 63, pp. 541-549; Turban, S., Stretton, C., Drouin, O., Green, C.J., Watson, M.L., Gray, A., Ross, F., Hundal, H.S., Defining the contribution of amp-activated protein kinase (ampk) and protein kinase c (pkc) in regulation of glucose uptake by metformin in skeletal muscle cells (2012) J. Biol. Chem., 287, pp. 20088-20099; Veliça, P., Bunce, C.M., A quick, simple and unbiased method to quantify C2C12 myogenic differentiation (2011) Muscle Nerve, 44, pp. 366-370; Zhang, B.B., Zhou, G., Li, C., AMPK: An emerging drug target for diabetes and the metabolic syndrome (2009) Cell Metab., 9, pp. 407-416; Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Moller, D.E., Role of amp-activated protein kinase in mechanism of metformin action (2001) J. Clin. Invest., 108, pp. 1167-1174; Zhou, J., Wu, J., Chen, X., Fortenbery, N., Eksioglu, E., Kodumudi, K.N., Pk, E.B., Wei, S., Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (mdscs) functions (2011) Int. Immunopharmacol., 11, pp. 890-898",Article,Scopus,2-s2.0-84927772678
"Ahmad Raston N.H., Gu M.B.","Highly amplified detection of visceral adipose tissue-derived serpin (vaspin) using a cognate aptamer duo",2015,"Biosensors and Bioelectronics","70",,,"261","267",,,10.1016/j.bios.2015.03.042,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925727238&partnerID=40&md5=f0a08fe99951595dcb0df121b7476e3f","College of Life Sciences and Biotechnology, Korea UniversityAnam-dong, Seongbuk-Gu, Seoul, South Korea","Ahmad Raston, N.H., College of Life Sciences and Biotechnology, Korea UniversityAnam-dong, Seongbuk-Gu, Seoul, South Korea; Gu, M.B., College of Life Sciences and Biotechnology, Korea UniversityAnam-dong, Seongbuk-Gu, Seoul, South Korea","A cognate aptamer duo for visceral adipose tissue-derived serpin (vaspin) which distinctively bind to two different sites on vaspin with high affinity and specificity were successfully developed by using graphene oxide-based systematic evolution of ligands by exponential enrichment (GO-SELEX), which offers immobilization-free screening of aptamers. The specific and simultaneous bindings of this aptamer duo (V1 and V49 aptamers) to the different sites of vaspin were confirmed by circular dichroism (CD) analysis and both sandwich-type surface plasmon resonance (SPR) and quantum dot labelled fluorescence imaging analysis (V1 aptamer serves as primary capturing aptamer and V49 aptamer as secondary signalling aptamer or vice versa). With this vaspin cognate aptamer duo on SPR platform, the detection of the target vaspin were improved to the limit of detection down to 3.5. ng/ml in buffer and 4.7. ng/ml in human serum samples. This cognate aptamer duo based biosensor could be utilized in the early diagnosis of type-2 diabetes. © 2015 The Authors.",,"Bluher, M., Vaspin in obesity and diabetes: pathophysiological and clinical significance (2012) Endocrine, 41 (2), pp. 176-182; Gong, Q., Wang, J., Ahmad, K.M., Csordas, A.T., Zhou, J., Nie, J., Stewart, R., Soh, H.T., Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets (2012) Anal. Chem., 84 (12), pp. 5365-5371; Hida, K., Wada, J., Eguchi, J., Zhang, H., Baba, M., Seida, A., Hashimoto, I., Kanwar, Y.S., Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity (2005) Proc. Natl. Acad. Sci. USA, 102 (30), pp. 10610-10615; Jo, H., Youn, H., Lee, S., Ban, C., Ultra-effective photothermal therapy for prostate cancer cells using dual aptamer-modified gold nanostars (2014) J. Mater. Chem. B, 2 (30), pp. 4862-4867; Kim, I.A., (2010) In Vitro Selection of DNA Aptamers for Vaspin and Aptasensor Development, , Korea University, Seoul, Korea; Kim, Y.S., Chung, J., Song, M.Y., Jurng, J., Kim, B.C., Aptamer cocktails: enhancement of sensing signals compared to single use of aptamers for detection of bacteria (2014) Biosens. Bioelectron., 54, pp. 195-198; Kim, Y.S., Kim, B.C., Lee, J.H., Kim, J., Gu, M.B., Specific detection of DNA using quantum dots and magnetic beads for large volume samples (2006) Biotechnol. Bioprocess Eng., 11 (5), pp. 449-454; Kloting, N., Graham, T.E., Berndt, J., Kralisch, S., Kovacs, P., Wason, C.J., Fasshauer, M., Kahn, B.B., Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass (2007) Cell Metab., 6 (1), pp. 79-87; Lee, J.E., Kim, J.H., Lee, S.H., Kim, J.Y., Mah, S.J., Gu, M.B., In-situ on-fabric one-touch colorimetric detection using aptamer-conjugated gold nanoparticles (2013) Biochip J., 7 (2), pp. 180-187; Lee, S.J., Park, J.W., Kim, I.A., Youn, B.S., Gu, M.B., Sensitive detection of adipokines for early diagnosis of type 2 diabetes using enzyme-linked antibody-aptamer sandwich (ELAAS) assays (2012) Sens. Actuators B-Chem., 168, pp. 243-248; Lee, S.J., Youn, B.S., Park, J.W., Niazi, J.H., Kim, Y.S., Gu, M.B., SsDNA aptamer-based surface plasmon resonance biosensor for the detection of retinol binding protein 4 for the early diagnosis of type 2 diabetes (2008) Anal. Chem., 80 (8), pp. 2867-2873; Li, Q., Chen, R., Moriya, J., Yamakawa, J., Sumino, H., Kanda, T., Takahashi, T., A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity (2008) J. Int. Med. Res., 36 (4), pp. 625-629; Liu, J.B., Yang, X.H., Wang, K.M., Wang, Q., Liu, W., Wang, D., Solid-phase single molecule biosensing using dual-color colocalization of fluorescent quantum dot nanoprobes (2013) Nanoscale, 5 (22), pp. 11257-11264; Liu, L., Deng, D.H., Xing, Y., Li, S.J., Yuan, B.Q., Chen, J., Xia, N., Activity analysis of the carbodiimide-mediated amine coupling reaction on self-assembled monolayers by cyclic voltammetry (2013) Electrochim. Acta, 89, pp. 616-622; Luo, Y., Liu, X., Jiang, T., Liao, P., Fu, W., Dual-aptamer-based biosensing of toxoplasma antibody (2013) Anal. Chem., 85 (17), pp. 8354-8360; Park, J.W., Jin Lee, S., Choi, E.J., Kim, J., Song, J.Y., Bock, G.M., An ultra-sensitive detection of a whole virus using dual aptamers developed by immobilization-free screening (2014) Biosens. Bioelectron., 51, pp. 324-329; Park, J.W., Tatavarty, R., Kim, D.W., Jung, H.T., Gu, M.B., Immobilization-free screening of aptamers assisted by graphene oxide (2012) Chem. Commun., 48 (15), pp. 2071-2073; Rinker, S., Ke, Y., Liu, Y., Chhabra, R., Yan, H., Self-assembled DNA nanostructures for distance-dependent multivalent ligand-protein binding (2008) Nat. Nanotechnol., 3 (7), pp. 418-422; Shi, H., Fan, X., Sevilimedu, A., Lis, J.T., RNA aptamers directed to discrete functional sites on a single protein structural domain (2007) Proc. Natl. Acad. Sci. USA, 104 (10), pp. 3742-3746; Tasset, D.M., Kubik, M.F., Steiner, W., Oligonucleotide inhibitors of human thrombin that bind distinct epitopes (1997) J. Mol. Biol., 272 (5), pp. 688-698; Van Harmelen, V., Reynisdottir, S., Eriksson, P., Thorne, A., Hoffstedt, J., Lonnqvist, F., Arner, P., Leptin secretion from subcutaneous and visceral adipose tissue in women (1998) Diabetes, 47 (6), pp. 913-917; Vinkenborg, J.L., Karnowski, N., Famulok, M., Aptamers for allosteric regulation (2011) Nat. Chem. Biol., 7 (8), pp. 519-527; Youn, B.S., Kloting, N., Kratzsch, J., Lee, N., Park, J.W., Song, E.S., Ruschke, K., Bluher, M., Serum vaspin concentrations in human obesity and type 2 diabetes (2008) Diabetes, 57 (2), pp. 372-377; Zhang, H.Q., Li, X.F., Le, X.C., Differentiation and detection of PDGF isomers and their receptors by tunable aptamer capillary electrophoresis (2009) Anal. Chem., 81 (18), pp. 7795-7800; Zhao, J., Zhang, Y., Li, H., Wen, Y., Fan, X., Lin, F., Tan, L., Yao, S., Ultrasensitive electrochemical aptasensor for thrombin based on the amplification of aptamer-AuNPs-HRP conjugates (2011) Biosens. Bioelectron., 26 (5), pp. 2297-2303",Article,Scopus,2-s2.0-84925727238
"Romano M., Cianci E., Simiele F., Recchiuti A.","Lipoxins and aspirin-triggered lipoxins in resolution of inflammation",2015,"European Journal of Pharmacology","760",,,"49","63",,,10.1016/j.ejphar.2015.03.083,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928580559&partnerID=40&md5=69da086a27878a296f3bd24dff10c9dd","Department of Medical, Oral and Biotechnological Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Medicine and Aging Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy","Romano, M., Department of Medical, Oral and Biotechnological Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy, Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Cianci, E., Medicine and Aging Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy, Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Simiele, F., Department of Medical, Oral and Biotechnological Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy, Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Recchiuti, A., Department of Medical, Oral and Biotechnological Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy, Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy","The resolution of the inflammatory response is highly regulated by the timely biosynthesis of a number of endogenous lipid mediators. Among these, lipoxins (LX) and their 15-epimers, aspirin triggered lipoxins (ATL) derived by the lipoxygenase (LO) route of arachidonic acid metabolism. In particular, they are formed and released by cells expressing 5-, 12- and 15-LO such as leukocytes, platelets, vascular endothelium and epithelium, alone or during transcellular interactions. ATL biosynthesis requires cyclooxygenase-2 acetylation by aspirin. LX and ATL exert potent bioactions on leukocytes, vascular and epithelial cells to stop inflammation and promote resolution. They have shown to be beneficial in a broad spectrum of preclinical models of disease as well as in some clinical trials. Counter-regulatory signaling by LXA<inf>4</inf> and 15-epi-LXA<inf>4</inf> follows the activation of a G protein-coupled receptor, termed ALX/FPR2, which is emerging as a key anti-inflammatory receptor. © 2015 Elsevier B.V. All rights reserved.","Efferocytosis; Inflammation; Lipoxin; Lipoxygenase; microRNA; Polymorphysm; Promoter; Receptor; Resolution","Abdelmoaty, S., Wigerblad, G., Bas, D.B., Codeluppi, S., Fernandez-Zafra, T., El, E.-A., Moustafa, S., Svensson, C.I.E., Spinal actions of Lipoxin A4 and 17(R)-Resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release (2013) PLoS One, 8, p. e75543; Al-Alawi, M., Buchanan, P., Verriere, V., Higgins, G., McCabe, O., Costello, R.W., McNally, P., Harvey, B.J., Physiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epithelium (2014) Physiol. Rep., 2, p. e12093; Aliberti, J., Hieny, S., Reis Sousa E, C., Serhan, C.N., Sher, A., Lipoxin-mediated inhibition of IL-12 production by DCs: A mechanism for regulation of microbial immunity (2002) Nat Immunol., 3, pp. 76-82; Aliberti, J., Serhan, C., Sher, A., Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection (2002) J. Exp. Med., 196, pp. 1253-1262; Ariel, A., Chiang, N., Arita, M., Petasis, N.A., Serhan, C.N., Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells (2003) J. Immunol., 170, pp. 6266-6272; Ariel, A., Fredman, G., Sun, Y.-P., Kantarci, A., Van Dyke, T.E., Luster, A.D., Serhan, C.N., Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression (2006) Nat. Immunol., 7, pp. 1209-1216; Badr, K.F., Deboer, D.K., Schwartzberg, M., Serhan, C.N., Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: Evidence for competition at a common receptor (1989) Proc. Natl. Acad. Sci. USA, 86, pp. 3438-3442; Bafica, A., Scanga, C.A., Serhan, C., Machado, F., White, S., Sher, A., Aliberti, J., Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production (2005) J. Clinic.Investig., 115, pp. 1601-1606; Baker, N., Omeara, S.J., Scannell, M., Maderna, P., Godson, C., Lipoxin A4: Anti-inflammatory and anti-angiogenic impact on endothelial cells (2009) J. Immunol., 182, pp. 3819-3826; Bandeira-Melo, C., Serra, M.F., Diaz, B.L., Cordeiro, R.S., Silva, P.M., Lenzi, H.L., Bakhle, Y.S., Martins, M.A., Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: Relationship with concurrent eosinophilia (2000) J. Immunol., 164, pp. 1029-1036; Bannenberg, G.L., Aliberti, J., Hong, S., Sher, A., Serhan, C., Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis (2004) J. Exp. Med., 199, pp. 515-523; Bannenberg, G.L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K.H., Hong, S., Serhan, C.N., Molecular circuits of resolution: Formation and actions of resolvins and protectins (2005) J. Immunol., 174, pp. 4345-4355; Barnig, C., Cernadas, M., Dutile, S., Liu, X., Perrella, M.A., Kazani, S., Wechsler, M.E., Levy, B.D., Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma (2013) Sci. Transl. Med., 5, p. 174ra126; Biteman, B., Hassan, I.R., Walker, E., Leedom, A.J., Dunn, M., Seta, F., Laniado-Schwartzman, M., Gronert, K., Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing (2007) FASEB J., 21, pp. 2257-2266; Bonnans, C., Fukunaga, K., Levy, M.A., Levy, B.D., Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury (2006) Am. J. Pathol., 168, pp. 1064-1072; Borgeson, E., Docherty, N.G., Murphy, M., Rodgers, K., Ryan, A., Osullivan, T.P., Guiry, P.J., Godson, C., Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis (2011) FASEB J., 25, pp. 2967-2979; Borgeson, E., Godson, C., Resolution of inflammation: Therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications (2012) Front. Immunol., 3, p. 318; Borgeson, E., Lonn, J., Bergstrom, I., Brodin, V.P., Ramstrom, S., Nayeri, F., Sarndahl, E., Bengtsson, T., Lipoxin A(4) inhibits Porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression (2011) Infect. Immun., 79, pp. 1489-1497; Borgeson, E., McGillicuddy, F.C., Harford, K.A., Corrigan, N., Higgins, D.F., Maderna, P., Roche, H.M., Godson, C., Lipoxin A4 attenuates adipose inflammation (2012) FASEB J., 26, pp. 4287-4294; Brady, H.R., Persson, U., Ballermann, B.J., Brenner, B.M., Serhan, C.N., Leukotrienes stimulate neutrophil adhesion to mesangial cells: Modulation with lipoxins (1990) Am. J. Physiol., 259, pp. F809-815; Brancaleone, V., Gobbetti, T., Cenac, N., Le Faouder, P., Colom, B., Flower, R.J., Vergnolle, N., Perretti, M., A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation (2013) Blood, 122, pp. 608-617; Brennan, E.P., Nolan, K.A., Borgeson, E., Gough, O.S., McEvoy, C.M., Docherty, N.G., Higgins, D.F., Godson, C., Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFbetaR1 (2013) J. Am. Soc. Nephrol., 24, pp. 627-637; Brezinski, D.A., Nesto, R.W., Serhan, C.N., Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy (1992) Circulation, 86, pp. 56-63; Brezinski, D.A., Serhan, C.N., Characterization of lipoxins by combined gas chromatography and electron-capture negative ion chemical ionization mass spectrometry: Formation of lipoxin A4 by stimulated human whole blood (1991) Biol. Mass Spectrom., 20, pp. 45-52; Brezinski, M.E., Gimbrone, Jr.M.A., Nicolaou, K.C., Serhan, C.N., Lipoxins stimulate prostacyclin generation by human endothelial cells (1989) FEBS Lett., 245, pp. 167-172; Buchanan, P.J., McNally, P., Harvey, B.J., Urbach, V., Lipoxin A4-mediated KATP potassium channel activation results in cystic fibrosis airway epithelial repair (2013) Am. J. Physiol. Lung Cell. Mol. Physiol., 305, pp. L193-201; Carlo, T., Kalwa, H., Levy, B.D., 15-Epi-lipoxin A4 inhibits human neutrophil superoxide anion generation by regulating polyisoprenyl diphosphate phosphatase 1 (2013) FASEB J., 27, pp. 2733-2741; Celik, G.E., Erkekol, F.O., Misirligil, Z., Melli, M., Lipoxin A4 levels in asthma: Relation with disease severity and aspirin sensitivity (2007) Clin. Exp. Allergy, 37, pp. 1494-1501; Cezar-De-Mello, P.F., Nascimento-Silva, V., Villela, C.G., Fierro, I.M., Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly (2006) Oncogene, 25, pp. 122-129; Cezar-De-Mello, P.F., Vieira, A.M., Nascimento-Silva, V., Villela, C.G., Barja-Fidalgo, C., Fierro, I.M., ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor (2008) Br. J. Pharmacol., 153, pp. 956-965; Chan, M.M., Moore, A.R., Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production (2010) J. Immunol, 184, pp. 6418-6426; Chen, M., Divangahi, M., Gan, H., Shin, D.S., Hong, S., Lee, D.M., Serhan, C.N., Remold, H.G., Lipid mediators in innate immunity against tuberculosis: Opposing roles of PGE2 and LXA4 in the induction of macrophage death (2008) J. Exp. Med., 205, pp. 2791-2801; Chen, X.Q., Wu, S.H., Zhou, Y., Tang, Y.R., Involvement of K+ channel-dependant pathways in lipoxin A4-induced protective effects on hypoxia/reoxygenation injury of cardiomyocytes (2013) Prostaglandins Leuk. Essent. Fatty Acids, 88, pp. 391-397; Chen, X.Q., Wu, S.H., Zhou, Y., Tang, Y.R., Lipoxin A4-induced heme oxygenase-1 protects cardiomyocytes against hypoxia/reoxygenation injury via p38 MAPK activation and Nrf2/ARE complex (2013) PLoS One, 8, p. e67120; Chen, Y., Hao, H., He, S., Cai, L., Li, Y., Hu, S., Ye, D., Chen, X., Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: The role of antiangiogenesis (2010) Mol. Cancer Ther., 9, pp. 2164-2174; Chiang, N., Bermudez, E.A., Ridker, P.M., Hurwitz, S., Serhan, C.N., Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial (2004) Proc. Natl. Acad. Sci. USA, 101, pp. 15178-15183; Chiang, N., Gronert, K., Clish, C.B., Obrien, J.A., Freeman, M.W., Serhan, C.N., Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion (1999) J. Clin. Investig., 104, pp. 309-316; Chiang, N., Hurwitz, S., Ridker, P.M., Serhan, C.N., Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: A randomized human trial (2006) Arterioscler. Thromb. Vasc. Biol., 26, pp. e14-17; Chiang, N., Takano, T., Arita, M., Watanabe, S., Serhan, C.N., A novel rat lipoxin A4 receptor that is conserved in structure and function (2003) Br. J. Pharmacol., 139, pp. 89-98; Christie, P.E., Spur, B.W., Lee, T.H., The effects of lipoxin A4 on airway responses in asthmatic subjects (1992) Am. Rev. Respir. Dis., 145, pp. 1281-1284; Cilloniz, C., Pantin-Jackwood, M.J., Ni, C., Goodman, A.G., Peng, X., Proll, S.C., Carter, V.S., Katze, M.G., Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection (2010) J. Virol., 84, pp. 7613-7624; Claria, J., Lee, M.H., Serhan, C.N., Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation (1996) Mol. Med., 2, pp. 583-596; Claria, J., Serhan, C.N., Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions (1995) Proc. Natl. Acad. Sci. USA, 92, pp. 9475-9479; Clish, C.B., Levy, B.D., Chiang, N., Tai, H.H., Serhan, C.N., Oxidoreductases in lipoxin A4 metabolic inactivation: A novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation (2000) J. Biol. Chem., 275, pp. 25372-25380; Clish, C.B., Obrien, J.A., Gronert, K., Stahl, G.L., Petasis, N.A., Serhan, C.N., Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo (1999) Proc. Natl. Acad. Sci. USA, 96, pp. 8247-8252; Colgan, S.P., Serhan, C.N., Parkos, C.A., Delp-Archer, C., Madara, J.L., Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers (1993) J. Clin. Investig., 92, pp. 75-82; Conte, F.P., Menezes-De-Lima, Jr.O., Verri, Jr.W.A., Cunha, F.Q., Penido, C., Henriques, M.G., Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects (2010) Br. J. Pharmacol., 161, pp. 911-924; Cooray, S.N., Gobbetti, T., Montero-Melendez, T., McArthur, S., Thompson, D., Clark, A.J.L., Flower, R.J., Perretti, M., Ligand-specific conformational change of the G-protein coupled receptor ALX/FPR2 determines proresolving functional responses (2013) Proc. Natl. Acad. Sci. USA, 110, pp. 18232-18237; Dalli, J., Colas, R.A., Serhan, C.N., Novel n-3 immunoresolvents: Structures and actions (2013) Sci. Rep., 3, p. 1940; Dalli, J., Winkler, J.W., Colas, R.A., Arnardottir, H., Cheng, C.Y., Chiang, N., Petasis, N.A., Serhan, C.N., Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents (2013) Chem. Biol., 20, pp. 188-201; Das, U.N., Arachidonic acid and lipoxin A4 as possible endogenous anti-diabetic molecules (2013) Prostaglandins Leukot. Essent. Fatty Acids, 88, pp. 201-210; Das, U.N., Lipoxins, resolvins, and protectins in the prevention and treatment of diabetic macular edema and retinopathy (2013) Nutrition, 29, pp. 1-7; Deng, X., Ueda, H., Su, S.B., Gong, W., Dunlop, N.M., Gao, J.L., Murphy, P.M., Wang, J.M., A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R (1999) Blood, 94, pp. 1165-1173; Devchand, P.R., Arita, M., Hong, S., Bannenberg, G., Moussignac, R.L., Gronert, K., Serhan, C.N., Human ALX receptor regulates neutrophil recruitment in transgenic mice: Roles in inflammation and host defense (2003) FASEB J., 17, pp. 652-659; Devchand, P.R., Schmidt, B.A., Primo, V.C., Zhang, Q.-Y., Arnaout, M.A., Serhan, C.N., Nikolic, B., A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils (2005) FASEB J., 19, pp. 203-210; Duffy, C.D., Maderna, P., McCarthy, C., Loscher, C.E., Godson, C., Guiry, P., Synthesis and biological evaluation of pyridine-containing lipoxin A4 analogues (2010) Chem. Med. Chem., 5, pp. 517-522; Dufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H.B., Gray, M., Dacquisto, F., Flower, R.J., Anti-inflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation (2010) J. Immunol., 184, pp. 2611-2619; Dunn, H.C., Ager, R.R., Baglietto-Vargas, D., Cheng, D., Kitazawa, M., Cribbs, D.H., Medeiros, R., Restoration of Lipoxin A4 Signaling Reduces Alzheimers Disease-Like Pathology in the 3xTg-AD Mouse Model (2015) J. Alzheimers Dis., 43, pp. 893-903; Edenius, C., Haeggstrom, J., Lindgren, J.A., Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions (1988) Biochem. Biophys. Res. Commun., 157, pp. 801-807; Edenius, C., Kumlin, M., Bjork, T., Anggard, A., Lindgren, J.A., Lipoxin formation in human nasal polyps and bronchial tissue (1990) FEBS Lett., 272, pp. 25-28; Eke Gungor, H., Tahan, F., Gokahmetoglu, S., Saraymen, B., Decreased levels of lipoxin A4 and annexin A1 in wheezy infants (2014) Int. Arch. Allergy Immunol., 163, pp. 193-197; El Kebir, D., Jozsef, L., Pan, W., Wang, L., Petasis, N.A., Serhan, C.N., Filep, J.G., 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury (2009) Am. J. Respir. Crit. Care Med., 180, pp. 311-319; Fierro, I.M., Colgan, S.P., Bernasconi, G., Petasis, N.A., Clish, C.B., Arita, M., Serhan, C.N., Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: Comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells (2003) J. Immunol., 170, pp. 2688-2694; Fierro, I.M., Kutok, J.L., Serhan, C.N., Novel lipid mediator regulators of endothelial cell proliferation and migration: Aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4) (2002) J. Pharmacol. Exp. Ther., 300, pp. 385-392; Fiore, S., Ryeom, S.W., Weller, P.F., Serhan, C.N., Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils (1992) J. Biol. Chem., 267, pp. 16168-16176; Fiore, S., Serhan, C.N., Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils (1990) J. Exp. Med., 172, pp. 1451-1457; Fiore, S., Serhan, C.N., Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: Inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction (1995) Biochemistry, 34, pp. 16678-16686; Fiorucci, S., De Lima, Jr.O.M., Mencarelli, A., Palazzetti, B., Distrutti, E., McKnight, W., Dicay, M., Wallace, J.L., Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage (2002) Gastroenterology, 123, pp. 1598-1606; Fiorucci, S., Distrutti, E., De Lima, O.M., Romano, M., Mencarelli, A., Barbanti, M., Palazzini, E., Wallace, J.L., Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin (2003) FASEB J., 17, pp. 1171-1173; Fiorucci, S., Santucci, L., Wallace, J.L., Sardina, M., Romano, M., Del Soldato, P., Morelli, A., Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa (2003) Proc. Natl. Acad. Sci. USA, 100, pp. 10937-10941; Fiorucci, S., Wallace, J.L., Mencarelli, A., Distrutti, E., Rizzo, G., Farneti, S., Morelli, A., Parkinson, J.F., A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction (2004) Proc. Natl. Acad. Sci. USA, 101, pp. 15736-15741; Gangemi, S., Luciotti, G., D'Urbano, E., Mallamace, A., Santoro, D., Bellinghieri, G., Davi, G., Romano, M., Physical exercise increases urinary excretion of lipoxin A4 and related compounds (2003) J. Appl. Physiol. (1985), 94, pp. 2237-2240; Gangemi, S., Patella, V., Cianci, E., Saitta, S., Lattanzio, S., Florio, G., Romano, M., Ultrarush venom immunotherapy and the lipoxin a4 inflammation resolution pathway (2012) Ann. Allergy Asthma Immunol., 109, pp. 226-227; Genis, P., Jett, M., Bernton, E.W., Boyle, T., Gelbard, H.A., Dzenko, K., Keane, R.W., Volsky, D.J., Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: Implications for the neuropathogenesis of HIV disease (1992) J. Exp. Med., 176, pp. 1703-1718; Gewirtz, A.T., Collier-Hyams, L.S., Young, A.N., Kucharzik, T., Guilford, W.J., Parkinson, J.F., Williams, I.R., Madara, J.L., Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis (2002) J. Immunol., 168, pp. 5260-5267; Gewirtz, A.T., Fokin, V.V., Petasis, N.A., Serhan, C.N., Madara, J.L., LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation (1999) Am. J. Physiol., 276, pp. C988-994; Gil-Villa, A.M., Norling, L.V., Serhan, C.N., Cordero, D., Rojas, M., Cadavid, A., Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma (2012) Prostaglandins Leukot. Essent. Fatty Acids, 87, pp. 127-134; Gobbetti, T., Coldewey, S.M., Chen, J., McArthur, S., Le Faouder, P., Cenac, N., Flower, R.J., Perretti, M., Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis (2014) Proc. Natl. Acad. Sci. USA, 111, pp. 18685-18690; Godson, C., Mitchell, S., Harvey, K., Petasis, N.A., Hogg, N., Brady, H.R., Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages (2000) J. Immunol., 164, pp. 1663-1667; Goh, J., Baird, A.W., Okeane, C., Watson, R.W., Cottell, D., Bernasconi, G., Petasis, N.A., Mac Mathuna, P., Lipoxin A(4) and aspirin-triggered 15-epi-lipoxin A(4) antagonize TNF-alpha-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-alpha-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo (2001) J. Immunol., 167, pp. 2772-2780; Gronert, K., Maheshwari, N., Khan, N., Hassan, I.R., Dunn, M., Laniado Schwartzman, M., A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense (2005) J. Biol. Chem., 280, pp. 15267-15278; Grumbach, Y., Quynh, N.V., Chiron, R., Urbach, V., LXA4 stimulates ZO-1 expression and transepithelial electrical resistance in human airway epithelial (16HBE14o-) cells (2009) Am. J. Physiol. Lung Cell. Mol. Physiol., 296, pp. L101-108; Guilford, W.J., Bauman, J.G., Skuballa, W., Bauer, S., Wei, G.P., Davey, D., Schaefer, C., Parkinson, J.F., Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo (2004) J. Med. Chem., 47, pp. 2157-2165; Guilherme, R.F., Xisto, D.G., Kunkel, S.L., Freire-De-Lima, C.G., Rocco, P.R., Neves, J.S., Fierro, I.M., Benjamim, C.F., Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog (2013) Am. J. Respir. Cell Mol. Biol., 49, pp. 1029-1037; Gutierrez, A.D., Sathyanarayana, P., Konduru, S., Ye, Y., Birnbaum, Y., Bajaj, M., The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes (2012) Atherosclerosis, 223, pp. 204-208; Hao, H., Liu, M., Wu, P., Cai, L., Tang, K., Yi, P., Li, Y., Ye, D., Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment (2011) Cancer Lett., 309, pp. 85-94; Hashimoto, A., Hayashi, I., Murakami, Y., Sato, Y., Kitasato, H., Matsushita, R., Iizuka, N., Endo, H., Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis (2007) J. Rheumatol., 34, pp. 2144-2153; Higgins, G., Buchanan, P., Perriere, M., Al-Alawi, M., Costello, R.W., Verriere, V., McNally, P., Urbach, V., Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis (2014) Am. J. Respir. Cell Mol. Biol., 51, pp. 178-190; Ho, K.J., Spite, M., Owens, C.D., Lancero, H., Kroemer, A.H., Pande, R., Creager, M.A., Conte, M.S., Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis (2010) Am. J. Pathol., 177, pp. 2116-2123; Hu, S., Mao-Ying, Q.L., Wang, J., Wang, Z.F., Mi, W.L., Wang, X.W., Jiang, J.W., Wang, Y.Q., Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines (2012) J. Neuroinflammation, p. 278; Janakiram, N.B., Mohammed, A., Rao, C.V., Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer (2011) Cancer Metastasis Rev., 30, pp. 507-523; Jin, H., Li, Y.H., Xu, J.S., Guo, G.Q., Chen, D.L., Bo, Y., Lipoxin A4 analog attenuates morphine antinociceptive tolerance, withdrawal-induced hyperalgesia, and glial reaction and cytokine expression in the spinal cord of rat (2012) Neuroscience, 208, pp. 1-10; Jin, S.W., Zhang, L., Lian, Q.Q., Liu, D., Wu, P., Yao, S.L., Ye, D.Y., Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: The role of heme oxygenase-1 (2007) Anesth. Analg., 104, pp. 369-377; Jin, W., Jia, Y., Huang, L., Wang, T., Wang, H., Dong, Y., Zhang, H., Lv, P., Lipoxin A4 methyl ester ameliorates cognitive deficits induced by chronic cerebral hypoperfusion through activating ERK/Nrf2 signaling pathway in rats (2014) Pharmacol. Biochem. Behav., 124, pp. 145-152; Jin, Y., Arita, M., Zhang, Q., Saban, D.R., Chauhan, S.K., Chiang, N., Serhan, C.N., Dana, R., Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators (2009) Investig. Ophthalmol. Vis. Sci., 50, pp. 4743-4752; Jozsef, L., Zouki, C., Petasis, N.A., Serhan, C.N., Filep, J.G., Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes (2002) Proc. Natl. Acad. Sci. USA, 99, pp. 13266-13271; Kakazu, A., He, J., Kenchegowda, S., Bazan, H.E., Lipoxin A(4) inhibits platelet-activating factor inflammatory response and stimulates corneal wound healing of injuries that compromise the stroma (2012) Exp. Eye Res., 103, pp. 9-16; Karp, C.L., Flick, L.M., Park, K.W., Softic, S., Greer, T.M., Keledjian, R., Yang, R., Petasis, N.A., Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway (2004) Nat. Immunol., 5, pp. 388-392; Kieran, N.E., Doran, P.P., Connolly, S.B., Greenan, M.C., Higgins, D.F., Leonard, M., Godson, C., Brady, H.R., Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog (2003) Kidney Int., 64, pp. 480-492; Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., Serhan, C.N., Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs (2012) Am. J. Pathol., 180, pp. 2018-2027; Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C.H., Yang, R., Petasis, N.A., Serhan, C.N., Resolvin D1 binds human phagocytes with evidence for proresolving receptors (2010) Proc. Natl. Acad. Sci. USA, 107, pp. 1660-1665; Kumar, R., Clerc, A.C., Gori, I., Russell, R., Pellegrini, C., Govender, L., Wyss, J.C., Canny, G.O., Lipoxin A(4) prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E(2) production and estrogen signaling (2014) PLoS One, 9, p. e89742; Kure, I., Nishiumi, S., Nishitani, Y., Tanoue, T., Ishida, T., Mizuno, M., Fujita, T., Yoshida, M., Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation (2010) J. Pharmacol. Exp. Ther., 332, pp. 541-548; Le, Y., Gong, W., Tiffany, H.L., Tumanov, A., Nedospasov, S., Shen, W., Dunlop, N.M., Wang, J.M., Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1 (2001) J. Neurosci., 21, p. RC123; Leedom, A.J., Sullivan, A.B., Dong, B., Lau, D., Gronert, K., Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury (2010) Am. J. Pathol., 176, pp. 74-84; Leibovich, S.J., Ross, R., The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum (1975) Am. J. Pathol., 78, pp. 71-100; Leonard, M.O., Hannan, K., Burne, M.J., Lappin, D.W., Doran, P., Coleman, P., Stenson, C., Brady, H.R., 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure (2002) J. Am. Soc. Nephrol., 13, pp. 1657-1662; Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., Serhan, C.N., Lipid mediator class switching during acute inflammation: Signals in resolution (2001) Nat. Immunol., 2, pp. 612-619; Levy, B.D., De Sanctis, G.T., Devchand, P.R., Kim, E., Ackerman, K., Schmidt, B.A., Szczeklik, W., Serhan, C.N., Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4) (2002) Nat. Med., 8, pp. 1018-1023; Levy, B.D., Fokin, V.V., Clark, J.M., Wakelam, M.J., Petasis, N.A., Serhan, C.N., Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: A 'stop' signaling switch for aspirin-triggered lipoxin A4 (1999) FASEB J., 13, pp. 903-911; Levy, B.D., Lukacs, N.W., Berlin, A.A., Schmidt, B., Guilford, W.J., Serhan, C.N., Parkinson, J.F., Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism (2007) FASEB J., 21, pp. 3877-3884; Levy, B.D., Romano, M., Chapman, H.A., Reilly, J.J., Drazen, J., Serhan, C.N., Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins (1993) J. Clin. Investig., 92, pp. 1572-1579; Levy, B.D., Zhang, Q.Y., Bonnans, C., Primo, V., Reilly, J.J., Perkins, D.L., Liang, Y., Serhan, C.N., The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection (2011) Prostaglandins Leukot. Essent. Fatty Acids, 84, pp. 43-50; Li, Q., Tian, Y., Wang, Z.F., Liu, S.B., Mi, W.L., Ma, H.J., Wu, G.C., Wang, Y.Q., Involvement of the spinal NALP1 inflammasome in neuropathic pain and aspirin-triggered-15-epi-lipoxin A4 induced analgesia (2013) Neuroscience, 254, pp. 230-240; Lucas, T., Waisman, A., Ranjan, R., Roes, J., Krieg, T., Muller, W., Roers, A., Eming, S.A., Differential roles of macrophages in diverse phases of skin repair (2010) J. Immunol., 184, pp. 3964-3977; Luo, C.L., Li, Q.Q., Chen, X.P., Zhang, X.M., Li, L.L., Li, B.X., Zhao, Z.Q., Tao, L.Y., Lipoxin A4 attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury (2013) Brain Res., 1502, pp. 1-10; Maddox, J.F., Colgan, S.P., Clish, C.B., Petasis, N.A., Fokin, V.V., Serhan, C.N., Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: Design of stable lipoxin B4 analogs with increased biologic activity (1998) FASEB J., 12, pp. 487-494; Maddox, J.F., Hachicha, M., Takano, T., Petasis, N.A., Fokin, V.V., Serhan, C.N., Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor (1997) J. Biol. Chem., 272, pp. 6972-6978; Maddox, J.F., Serhan, C.N., Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: Selective inactivation by dehydrogenation and reduction (1996) J. Exp. Med., 183, pp. 137-146; Majno, G., Joris, I., (2004) Cells, Tissues, and Disease: Principles of General Pathology: Principles of General Pathology, , Oxford University Press USA; Maldonado-Perez, D., Golightly, E., Denison, F.C., Jabbour, H.N., Norman, J.E., A role for lipoxin A4 as anti-inflammatory and proresolution mediator in human parturition (2011) FASEB J., 25, pp. 569-575; Martins, V., Valenca, S.S., Farias-Filho, F.A., Molinaro, R., Simoes, R.L., Ferreira, T.P., Silva P M, E., Benjamim, C.F., ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis (2009) J. Immunol., 182, pp. 5374-5381; Mattoscio, D., Evangelista, V., De Cristofaro, R., Recchiuti, A., Pandolfi, A., Di Silvestre, S., Manarini, S., Romano, M., Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response (2010) FASEB J., 24, pp. 3970-3980; McMahon, B., Mitchell, D., Shattock, R., Martin, F., Brady, H.R., Godson, C., Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation (2002) FASEB J., 16, pp. 1817-1819; McMahon, B., Stenson, C., McPhillips, F., Fanning, A., Brady, H.R., Godson, C., Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors (2000) J. Biol. Chem., 275, pp. 27566-27575; Medeiros, R., Kitazawa, M., Passos, G.F., Baglietto-Vargas, D., Cheng, D., Cribbs, D.H., Laferla, F.M., Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice (2013) Am. J. Pathol., 182, pp. 1780-1789; Medeiros, R., Rodrigues, G.B., Figueiredo, C.P., Rodrigues, E.B., Grumman, Jr.A., Menezes-De-Lima, Jr.O., Passos, G.F., Calixto, J.B., Molecular mechanisms of topical anti-inflammatory effects of lipoxin A(4) in endotoxin-induced uveitis (2008) Mol. Pharmacol., 74, pp. 154-161; Merched, A.J., Ko, K., Gotlinger, K.H., Serhan, C.N., Chan, L., Atherosclerosis: Evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators (2008) FASEB J., 22, pp. 3595-3606; Mitchell, D., Omeara, S.J., Gaffney, A., Crean, J.K.G., Kinsella, B.T., Godson, C., The Lipoxin A4 Receptor Is Coupled to SHP-2 Activation: Implications for regulation of receptor tyrosine kinases (2007) J. Biol. Chem., 282, pp. 15606-15618; Mitchell, D., Rodgers, K., Hanly, J., McMahon, B., Brady, H.R., Martin, F., Godson, C., Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells (2004) Am. J. Pathol., 164, pp. 937-946; Molina-Berrios, A., Campos-Estrada, C., Henriquez, N., Faundez, M., Torres, G., Castillo, C., Escanilla, S., Maya, J.D., Protective role of acetylsalicylic acid in experimental Trypanosoma cruzi infection: Evidence of a 15-epi-lipoxin A(4)-mediated effect (2013) PLoS Negl. Trop. Dis., 7, p. e2173; Morris, T., Stables, M., Hobbs, A., De Souza, P., Colville-Nash, P., Warner, T., Newson, J., Gilroy, D.W., Effects of low-dose aspirin on acute inflammatory responses in humans (2009) J. Immunol., 183, pp. 2089-2096; Munger, K.A., Montero, A., Fukunaga, M., Uda, S., Yura, T., Imai, E., Kaneda, Y., Badr, K.F., Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis (1999) Proc. Natl. Acad. Sci. USA, 96, pp. 13375-13380; Murphy, P.M., Ozcelik, T., Kenney, R.T., Tiffany, H.L., McDermott, D., Francke, U., A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family (1992) J. Biol. Chem., 267, pp. 7637-7643; Nascimento-Silva, V., Arruda, M.A., Barja-Fidalgo, C., Fierro, I.M., Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: A novel antioxidative mechanism (2007) Thromb. Haemost., 97, pp. 88-98; Nascimento-Silva, V., Arruda, M.A., Barja-Fidalgo, C., Villela, C.G., Fierro, I.M., Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells (2005) Am. J. Physiol. Cell Physiol., 289, pp. C557-563; Nathan, C., Ding, A., Nonresolving inflammation (2010) Cell, 140, pp. 871-882; Norling, L.V., Spite, M., Yang, R., Flower, R.J., Perretti, M., Serhan, C.N., Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing (2011) J. Immunol., 186, pp. 5543-5547; Norris, P.C., Gosselin, D., Reichart, D., Glass, C.K., Dennis, E.A., Phospholipase A2 regulates eicosanoid class switching during inflammasome activation (2014) Proc. Natl. Acad. Sci. USA, 111, pp. 12746-12751; O'Sullivan, T.P., Vallin, K.S., Shah, S.T., Fakhry, J., Maderna, P., Scannell, M., Sampaio, A.L., Guiry, P.J., Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities (2007) J. Med. Chem., 50, pp. 5894-5902; Ono, E., Dutile, S., Kazani, S., Wechsler, M.E., Yang, J., Hammock, B.D., Douda, D.N., Levy, B.D., Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma (2014) Am. J. Respir. Crit. Care Med., 190, pp. 886-897; Ortiz-Munoz, G., Mallavia, B., Bins, A., Headley, M., Krummel, M.F., Looney, M.R., Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice (2014) Blood, 124, pp. 2625-2634; Papayianni, A., Serhan, C.N., Brady, H.R., Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells (1996) J. Immunol., 156, pp. 2264-2272; Papayianni, A., Serhan, C.N., Phillips, M.L., Rennke, H.G., Brady, H.R., Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis (1995) Kidney Int., 47, pp. 1295-1302; Park, S.W., Lee, E.H., Lee, E.J., Kim, H.J., Bae, D.J., Han, S., Kim, D., Park, C.S., Apolipoprotein A1 potentiates lipoxin A4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium (2013) Clin. Exp. Allergy, 43, pp. 914-927; Paul-Clark, M.J., Van Cao, T., Moradi-Bidhendi, N., Cooper, D., Gilroy, D.W., 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation (2004) J. Exp. Med., 200, pp. 69-78; Perretti, M., Chiang, N., La, M., Fierro, I.M., Marullo, S., Getting, S.J., Solito, E., Serhan, C.N., Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor (2002) Nat. Med., 8, pp. 1296-1302; Peskar, B.M., Ehrlich, K., Schuligoi, R., Peskar, B.A., Role of lipoxygenases and lipoxin A(4)/annexin-1 receptor in gastric protection induced by 20% ethanol or sodium salicylate in rats (2009) Pharmacology, 84, pp. 310-313; Peskar, B.M., Ehrlich, K., Schuligoi, R., Peskar, B.A., Role of lipoxygenases and the lipoxin A(4)/annexin 1 receptor in ischemia-reperfusion-induced gastric mucosal damage in rats (2009) Pharmacology, 84, pp. 294-299; Petri, M.H., Laguna-Fernandez, A., Tseng, C.N., Hedin, U., Perretti, M., Back, M., Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation (2014) Int. J. Cardiol., 179, pp. 370-372; Pierdomenico, A.M., Recchiuti, A., Simiele, F., Codagnone, M., Mari, V.C., Davi, G., Romano, M., MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages (2015) J. Biol. Chem., 290, pp. 3592-3600; Planaguma, A., Kazani, S., Marigowda, G., Haworth, O., Mariani, T.J., Israel, E., Bleecker, E.R., Levy, B.D., Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma (2008) Am. J. Respir. Crit. Care Med., 178, pp. 574-582; Pouliot, M., Clish, C.B., Petasis, N.A., Van Dyke, T.E., Serhan, C.N., Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: A role for cyclooxygenase-2 and lipoxins in periodontal disease (2000) Biochemistry, 39, pp. 4761-4768; Prescott, D., McKay, D.M., Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production (2011) Am. J. Physiol. Gastrointest. Liver Physiol., 301, pp. G487-497; Ramon, S., Bancos, S., Serhan, C.N., Phipps, R.P., Lipoxin A modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism (2013) Eur. J. Immunol., 44, pp. 357-369; Ramstedt, U., Ng, J., Wigzell, H., Serhan, C.N., Samuelsson, B., Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: Effects on intracellular cAMP and target cell binding (1985) J. Immunol., 135, pp. 3434-3438; Ramstedt, U., Serhan, C.N., Nicolaou, K.C., Webber, S.E., Wigzell, H., Samuelsson, B., Lipoxin A-induced inhibition of human natural killer cell cytotoxicity: Studies on stereospecificity of inhibition and mode of action (1987) J. Immunol., 138, pp. 266-270; Reina-Couto, M., Carvalho, J., Valente, M.J., Vale, L., Afonso, J., Carvalho, F., Bettencourt, P., Albino-Teixeira, A., Impaired resolution of inflammation in human chronic heart failure (2014) Eur. J. Clin. Investig., 44, pp. 527-538; Renda, G., Zurro, M., Romano, M., De Caterina, R., Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. Nonselective COX-2 inhibitors (2010) Br. J. Clin. Pharmacol., 69, pp. 303-306; Ringholz, F.C., Buchanan, P.J., Clarke, D.T., Millar, R.G., McDermott, M., Linnane, B., Harvey, B.J., Urbach, V., Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis (2014) Eur. Respir. J., 44, pp. 394-404; Rodgers, K., McMahon, B., Mitchell, D., Sadlier, D., Godson, C., Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells (2005) Am. J. Pathol., 167, pp. 683-694; Romano, M., Lipid mediators: Lipoxin and aspirin-triggered 15-epi-lipoxins (2006) Inflamm. Allergy Drug Targets, 5, pp. 81-90; Romano, M., Chen, X.S., Takahashi, Y., Yamamoto, S., Funk, C.D., Serhan, C.N., Lipoxin synthase activity of human platelet 12-lipoxygenase (1993) Biochem. J., 296, pp. 127-133; Romano, M., Maddox, J.F., Serhan, C.N., Activation of human monocytes and the acute monocytic leukemia cell line (THP-1) by lipoxins involves unique signaling pathways for lipoxin A4 versus lipoxin B4: Evidence for differential Ca2+ mobilization (1996) J. Immunol., 157, pp. 2149-2154; Romano, M., Recchia, I., Recchiuti, A., Lipoxin receptors (2007) ScientificWorldJournal, 7, pp. 1393-1412; Romano, M., Serhan, C.N., Lipoxin generation by permeabilized human platelets (1992) Biochemistry, 31, pp. 8269-8277; Russell, R., Gori, I., Pellegrini, C., Kumar, R., Achtari, C., Canny, G.O., Lipoxin A4 is a novel estrogen receptor modulator (2011) FASEB J., 25, pp. 4326-4337; Sanak, M., Levy, B.D., Clish, C.B., Chiang, N., Gronert, K., Mastalerz, L., Serhan, C.N., Szczeklik, A., Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics (2000) Eur. Respir. J., 16, pp. 44-49; Scalia, R., Gefen, J., Petasis, N.A., Serhan, C.N., Lefer, A.M., Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: Role of P-selectin (1997) Proc. Natl. Acad. Sci. USA, 94, pp. 9967-9972; Schottelius, A.J., Giesen, C., Asadullah, K., Fierro, I.M., Colgan, S.P., Bauman, J., Guilford, W., Parkinson, J.F., An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile (2002) J. Immunol., 169, pp. 7063-7070; Schwab, J.M., Chiang, N., Arita, M., Serhan, C.N., Resolvin E1 and protectin D1 activate inflammation-resolution programmes (2007) Nature, 447, pp. 869-874; Serhan, C.N., A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: Missing links to resolution (2004) Histochem. Cell Biol., 122, pp. 305-321; Serhan, C.N., Chiang, N., Resolution phase lipid mediators of inflammation: Agonists of resolution (2013) Curr. Opin. Pharmacol., 13, pp. 632-640; Serhan, C.N., Chiang, N., Van Dyke, T.E., Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators (2008) Nat. Rev. Immunol., 8, pp. 349-361; Serhan, C.N., Clish, C.B., Brannon, J., Colgan, S.P., Chiang, N., Gronert, K., Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing (2000) J. Exp. Med., 192, pp. 1197-1204; Serhan, C.N., Hamberg, M., Samuelsson, B., Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes (1984) Proc. Natl. Acad. Sci. USA, 81, pp. 5335-5339; Serhan, C.N., Hamberg, M., Samuelsson, B., Trihydroxytetraenes: A novel series of compounds formed from arachidonic acid in human leukocytes (1984) Biochem. Biophys. Res. Commun., 118, pp. 943-949; Serhan, C.N., Hamberg, M., Samuelsson, B., Morris, J., Wishka, D.G., On the stereochemistry and biosynthesis of lipoxin B (1986) Proc. Natl. Acad. Sci. USA, 83, pp. 1983-1987; Serhan, C.N., Hirsch, U., Palmblad, J., Samuelsson, B., Formation of lipoxin A by granulocytes from eosinophilic donors (1987) FEBS Lett., 217, pp. 242-246; Serhan, C.N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S.P., Van Dyke, T.E., Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators (2003) J. Immunol., 171, pp. 6856-6865; Serhan, C.N., Maddox, J.F., Petasis, N.A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H.R., Colgan, S.P., Madara, J.L., Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils (1995) Biochemistry, 34, pp. 14609-14615; Serhan, C.N., Savill, J., Resolution of inflammation: The beginning programs the end (2005) Nat. Immunol., 6, pp. 1191-1197; Sheppard, K.A., Greenberg, S.M., Funk, C.D., Romano, M., Serhan, C.N., Lipoxin generation by human megakaryocyte-induced 12-lipoxygenase (1992) Biochim. Biophys. Acta, 1133, pp. 223-234; Shryock, N., McBerry, C., Salazar Gonzalez, R.M., Janes, S., Costa, F.T., Aliberti, J., Lipoxin A(4) and 15-epi-lipoxin A(4) protect against experimental cerebral malaria by inhibiting IL-12/IFN-gamma in the brain (2013) PLoS One, 8, p. e61882; Simiele, F., Recchiuti, A., Mattoscio, D., De Luca, A., Cianci, E., Franchi, S., Gatta, V., Romano, M., Transcriptional regulation of the human FPR2/ALX gene: Evidence of a heritable genetic variant that impairs promoter activity (2012) FASEB J., 26, pp. 1323-1333; Sodin-Semrl, S., Taddeo, B., Tseng, D., Varga, J., Fiore, S., Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases (2000) J. Immunol., 164, pp. 2660-2666; Souza, M.C., Padua, T.A., Torres, N.D., Souza Costa, M.F., Candea, A.P., Maramaldo, T., Seito, L.N., Henriques, M.G., Lipoxin A4 attenuates endothelial dysfunction during experimental cerebral malaria (2015) Int. Immunopharmacol., 24, pp. 400-407; Soyombo, O., Spur, B.W., Lee, T.H., Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-l-methionyl-l-leucyl-l-phenylalanine (1994) Allergy, 49, pp. 230-234; Sun, Y.P., Tjonahen, E., Keledjian, R., Zhu, M., Yang, R., Recchiuti, A., Pillai, P.S., Serhan, C.N., Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs (2009) Prostaglandins Leukot. Essent. Fatty Acids, 81, pp. 357-366; Svensson, C.I., Zattoni, M., Serhan, C.N., Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing (2007) J. Exp. Med., 204, pp. 245-252; Takano, T., Fiore, S., Maddox, J.F., Brady, H.R., Petasis, N.A., Serhan, C.N., Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors (1997) J. Exp. Med., 185, pp. 1693-1704; Titos, E., Chiang, N., Serhan, C.N., Romano, M., Gaya, J., Pueyo, G., Claria, J., Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4) (1999) Am. J. Physiol., 277, pp. C870-877; Tobin, D.M., Roca, F.J., Oh, S.F., McFarland, R., Vickery, T.W., Ray, J.P., Ko, D.C., Ramakrishnan, L., Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections (2012) Cell, 148, pp. 434-446; Ueda, T., Fukunaga, K., Seki, H., Miyata, J., Arita, M., Miyasho, T., Obata, T., Takeda, J., Combination therapy of 15-epi-lipoxin A4 with antibiotics protects mice from Escherichia coli-induced sepsis∗ (2014) Crit. Care Med., 42, pp. e288-295; Verriere, V., Higgins, G., Al-Alawi, M., Costello, R.W., McNally, P., Chiron, R., Harvey, B.J., Urbach, V., Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia (2012) PLoS One, 7, p. e37746; Vong, L., Ferraz, J.G., Dufton, N., Panaccione, R., Beck, P.L., Sherman, P.M., Perretti, M., Wallace, J.L., Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis (2012) PLoS One, 7, p. e39244; Waechter, V., Schmid, M., Herova, M., Weber, A., Gunther, V., Marti-Jaun, J., Wust, S., Hersberger, M., Characterization of the promoter and the transcriptional regulation of the lipoxin A4 receptor (FPR2/ALX) gene in human monocytes and macrophages (2012) J. Immunol., 188, pp. 1856-1867; Walker, J., Dichter, E., Lacorte, G., Kerner, D., Spur, B., Rodriguez, A., Yin, K., Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis (2011) Shock, 36, pp. 410-416; Wang, Q., Lian, Q.Q., Li, R., Ying, B.Y., He, Q., Chen, F., Zheng, X., Jin, S.W., Lipoxin A(4) activates alveolar epithelial sodium channel, Na,K-ATPase, and increases alveolar fluid clearance (2013) Am. J. Respir. Cell Mol. Biol., 48, pp. 610-618; Wang, Z.F., Li, Q., Liu, S.B., Mi, W.L., Hu, S., Zhao, J., Tian, Y., Wu, G.C., Aspirin-triggered Lipoxin A4 attenuates mechanical allodynia in association with inhibiting spinal JAK2/STAT3 signaling in neuropathic pain in rats (2014) Neuroscience, 273, pp. 65-78; Winkler, J.W., Uddin, J., Serhan, C.N., Petasis, N.A., Stereocontrolled total synthesis of the potent anti-inflammatory and pro-resolving lipid mediator resolvin D3 and its aspirin-triggered 17R-epimer (2013) Org. Lett., 15, pp. 1424-1427; Wu, H., Yang, J., Su, E.M., Li, L., Zhao, C., Yang, X., Gao, Z., Su, X., Lipoxin A4 and platelet activating factor are involved in E. Coli or LPS-induced lung inflammation in CFTR-deficient mice (2014) PLoS One, 9, p. e93003; Wu, J., Wang, A., Min, Z., Xiong, Y., Yan, Q., Zhang, J., Xu, J., Zhang, S., Lipoxin A4 inhibits the production of proinflammatory cytokines induced by beta-amyloid in vitro and in vivo (2011) Biochem. Biophys. Res. Commun., 408, pp. 382-387; Wu, L., Miao, S., Zou, L.B., Wu, P., Hao, H., Tang, K., Zeng, P., Ye, D.Y., Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury (2012) J. Mol. Neurosci., 48, pp. 185-200; Wu, R., Zhou, W., Chen, S., Shi, Y., Su, L., Zhu, M., Chen, Q., Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway (2014) Br. J. Pharmacol., 171, pp. 4927-4940; Wu, S.H., Liu, B., Dong, L., Wu, H.J., NF-kappaB is involved in inhibition of lipoxin A4 on dermal inflammation and hyperplasia induced by mezerein (2010) Exp. Dermatol., 19, pp. e286-288; Wu, S.H., Wu, X.H., Lu, C., Dong, L., Chen, Z.Q., Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor (2006) Am. J. Respir. Cell Mol. Biol., 34, pp. 65-72; Wu, S.H., Wu, X.H., Lu, C., Dong, L., Zhou, G.P., Chen, Z.Q., Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells (2006) Kidney Int., 69, pp. 248-256; Xiong, J., Zeng, P., Ye, D., Lipoxins: A novel regulator in embryo implantation (2011) ScientificWorldJournal, 11, pp. 235-241; Xu, Z., Zhao, F., Lin, F., Chen, J., Huang, Y., Lipoxin A4 inhibits the development of endometriosis in mice: The role of anti-inflammation and anti-angiogenesis (2012) Am. J. Reprod. Immunol., 67, pp. 491-497; Yamaguchi, H., Higashi, N., Mita, H., Ono, E., Komase, Y., Nakagawa, T., Miyazawa, T., Taniguchi, M., Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma (2011) Clin. Exp. Allergy, 41, pp. 1711-1718; Yang, F., Xie, J., Wang, W., Xie, Y., Sun, H., Jin, Y., Xu, D., Zhou, M., Regional arterial infusion with lipoxin A4 attenuates experimental severe acute pancreatitis (2014) PLoS One, 9, p. e108525; Yang, J., Eiserich, J.P., Cross, C.E., Morrissey, B.M., Hammock, B.D., Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients (2012) Free Radic. Biol. Med., 53, pp. 160-171; Ye, R.D., Boulay, F., Wang, J.M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C.N., Murphy, P.M., International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family (2009) Pharmacol. Rev., 61, pp. 119-161; Zhang, B., Jia, H., Liu, J., Yang, Z., Jiang, T., Tang, K., Li, D., Huang, B., Depletion of regulatory T cells facilitates growth of established tumors: A mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4 (2010) J. Immunol., 185, pp. 7199-7206; Zhang, L., Zhang, X., Wu, P., Li, H., Jin, S., Zhou, X., Li, Y., Wan, J., BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis (2008) Inflamm. Res., 57, pp. 157-162; Zhou, H.Y., Hao, J.L., Bi, M.M., Wang, S., Zhang, H., Zhang, W.S., Molecular mechanism of the inhibition effect of Lipoxin A4 on corneal dissolving pathology process (2013) Int. J. Ophthalmol., 6, pp. 39-43; Zhou, M., Chen, B., Sun, H., Deng, Z., Andersson, R., Zhang, Q., The protective effects of Lipoxin A4 during the early phase of severe acute pancreatitis in rats (2011) Scand. J. Gastroenterol., 46, pp. 211-219; Zhou, X.L., Yang, Q.S., Ni, S.Z., Tu, X.P., Zhao, Y., Xu, B., Pan, Z.Q., Shen, J., Protective effects of lipoxin A4 in testis injury following testicular torsion and detorsion in rats (2014) Mediat. Inflamm., 2014, p. 898056",Review,Scopus,2-s2.0-84928580559
"Challier C., Beassoni P., Boetsch C., Garcia N.A., Biasutti M.A., Criado S.","Interaction between Human Serum Albumin and antidiabetic compounds and its influence on the O2(1Δg)-mediated degradation of the protein",2015,"Journal of Photochemistry and Photobiology B: Biology","142",,,"20","28",,,10.1016/j.jphotobiol.2014.10.019,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84915747507&partnerID=40&md5=6e9b039380ca8fd9ecc6b54857988991","Departamento de Química, Universidad Nacional de Río CuartoCórdoba, Argentina; Departamento de Biología Molecular, Universidad Nacional de Río CuartoCórdoba, Argentina","Challier, C., Departamento de Química, Universidad Nacional de Río CuartoCórdoba, Argentina; Beassoni, P., Departamento de Biología Molecular, Universidad Nacional de Río CuartoCórdoba, Argentina; Boetsch, C., Departamento de Biología Molecular, Universidad Nacional de Río CuartoCórdoba, Argentina; García, N.A., Departamento de Química, Universidad Nacional de Río CuartoCórdoba, Argentina; Biasutti, M.A., Departamento de Química, Universidad Nacional de Río CuartoCórdoba, Argentina; Criado, S., Departamento de Química, Universidad Nacional de Río CuartoCórdoba, Argentina","The complexity depicted by disease scenarios as diabetes mellitus, constitutes a very interesting field of study when drugs and biologically relevant components may be affected by such environments. In this report, the interaction between the protein Human Serum Albumin (HSA) and two antidiabetics (Andb), Gliclazide (Gli) and Glipizide (Glip) was studied through fluorescence and docking assays, in order to characterize these systems. On the basis that HSA and Andb can be exposed in vivo at high Reactive Oxygen Species (ROS) concentrations in diabetic patients, the degradative process of the protein free and bound to Andb, in presence of the species singlet molecular oxygen (O2(1Δg)), was evaluated. Fluorescence and docking assays indicated that Gli, as well as Glip bind to HSA on two sites, with binding constants values in the order of 104-105 M-1. Likewise, docking assays revealed that the location of Gli or Glip on the protein may be the HSA binding sites II and III. Thermodynamic parameters showed that the interaction between HSA and Glip is a favored, enthalpically-controlled process. Oxygen uptake experiments indicated that Glip is less photooxidizable than Gli through a O2(1Δg)-mediated process. Besides, the protein-Andb binding produced a decrease in the overall rate constant for O2(1Δg) quenching as compared to the value for the free protein. This fact could be interpreted in terms of a reduction in the availability of Tyrosine residues in the bonded protein, with a concomitant decrease in the physical quenching deactivation of the oxidative species. © 2014 Elsevier B.V.",,"Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, W., (2002) Molecular Biology of the Cell, , 4th ed. Garland Science New York; Roberts, J.A., Pea, F., Lipman, J., The clinical relevance of plasma protein binding changes (2013) Clin. Pharmacokinet., 52, pp. 1-8; Roche, M., Rondeau, P., Singh, N.R., Tarnues, E., Bourdon, E., The antioxidant properties of serum albumin (2008) FEBS Lett., 582, pp. 1783-1787; Diabetes Association, A., Diagnosis and classification of diabetes mellitus (2010) Diabetes Care, 33, pp. 62-S69; Brownlee, M., Negative consequences of glycation (2000) Metab. Clin. Exp., 49, pp. 9-13; Gribble, F.M., Riemann, F., Sulphonylurea action revisited: The post-cloning era (2003) Diabetologia, 46, pp. 875-891; Griffith Hardman, J., Limbird, L.E., Gilman, A.G., (2001) Las Bases Farmacológicas de la Terapéutica Goodman & Gilman, , 9th ed. McGraw-Hill/Interamericana de España S.A. Madrid; Baynes, J.W., Role of oxidative stress in development of complications in diabetes (1991) Diabetes, 40, pp. 405-412; Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Brownlee, M., Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage (2000) Nature, 404, pp. 787-790; Tiedge, M., Lortz, S., Drinkgern, J., Lenzen, S., Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells (1997) Diabetes, 46, pp. 1733-1742; Maechler, P., Jornot, L., Wollheim, C.B., Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells (1999) J. Biol. Chem., 274, pp. 27905-27913; Sirotkin, V.A., Borisover, M.D., Solomonov, B.N., Effect of chain length on interactions of aliphatic alcohols with suspended human serum albumin (1997) Binphys. Chem., 69, pp. 239-248; Kragh-Hansen, U., Chuang, V.T.G., Otagiri, M., Practical aspects of the ligand-binding and enzymatic properties of human serum albumin (2002) Biol. Pharm. Bull, 25, pp. 695-704; Groemping, Y., Hellmann, N., Spectroscopic methods for the determination of protein interactions (2005) Curr. Protocol Protein Sci., 39, pp. 1-27. , 20.8; Klotzt, I.M., Hunston, D.L., Properties of graphical representations of multiple classes of binding sites (1971) Biochemistry, 10, pp. 3065-3069; Stinson, R., Holbrook, J.J., Equilibrium binding of nicofinamide nucleotides to lactate dehydrogenases (1973) J. Biochem., 1319, pp. 719-728; Ward, L.D., Measurement of ligand binding to proteins by fluorescence spectroscopy (1985) Methods Enzymol., 117, pp. 400-414; Origin, , OriginLab, Northampton, MA; Beassoni, P., Otero, L.H., Boetsch, C., Domenech, C.E., González-Nilo, F.D., Lisa, A.T., Site-directed mutations and kinetic studies show key residues involved in alkylammonium interactions and reveal two sites for phosphorylcholine in Pseudomonas aeruginosa phosphorylcholine phosphatase (2011) Biochim. Biophys. Acta, 1814, pp. 858-863; Abagyan, R., Trotov, M., Kuznetsov, D., A new method for structure modeling and design: Applications to docking and structure prediction from the distorted native conformation (1994) J. Comput. Chem., 15, pp. 488-506; http://pubchem.ncbi.nlm.nih.gov/Sudlow, G., Birkett, D.J., Wade, D.N., The characterization of two specific drug binding sites on human serum albumin (1975) Mol. Pharmacol., 11, pp. 824-832; Bertolotti, S.G., Arguello, G.A., García, N.A., Effect of the peptide bond on the singlet molecular oxygen mediated photooxidation of tyrosine and tryptophan dipeptides (1991) J. Photochem. Photobiol. B, 10, pp. 57-70; Schweitzer, C., Schmidt, R., Physical mechanisms of generation and deactivation of singlet oxygen (2003) Chem. Rev., 103, pp. 1685-1757; Miskoski, S., Bertolotti, S., Arguello, G., Garcia, N.A., On the O2(1Δg)-mediated photooxidative behaviour of tripeptideglycyltyrosyl-alanine in alkaline medium: A kinetic study (1993) Amino Acids, 4, pp. 101-103; Nonell, S.L., Moncayo, F., Trull, F., Amat-Guerri, F., Lissi, E., Soltermann, A.T., Criado, S., Garcia, N.A., Solvent influence on the kinetics of the photodynamic degradation of Trolox, a water-soluble model compound for vitamin e (1995) J. Photoch. Photobiol. B., 29, pp. 157-162; Remko, M., Theoretical study of molecular structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some hypoglycemic agents (2009) J. Mol. Struct. Theochem., 897, pp. 73-82; Seedher, N., Kanojia, M., Mechanism of interaction of hypoglycemic agents glimepiride and glipizide with human serum albumin (2009) Central Eur. J. Chem., 7, pp. 96-104; Seedher, N., Kanojia, M., Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin (2008) Chem. Biol. Drug Des., 72, pp. 290-296; Ross, P.D., Subramanian, S., Thermodynamics of protein association (1981) Biochemistry, 20, pp. 3096-3102; Ghuman, J., Zunszain, P.A., Petitpas, I., Bhattacharya, A.A., Otagiri, M., Curry, S., Structural basis of the drug-binding specificity of human serum albumin (2005) J. Mol. Biol., 353, pp. 38-52; Sevilla, P., Rivas, J.M., García-Blanco, F., García-Ramos, J.V., Sánchez-Cortés, S., Identification of the antitumoral drug emodin binding sites in bovine serum albumin by spectroscopic methods (2007) Biochim. Biophys. Acta, 1774, pp. 1359-1369; Tushar, K.M., Kalyan, S.G., Anirban, S., Swagata, D., The interaction of silibinin with human serum albumin: A spectroscopic investigation (2008) J. Photochem. Photobiol. A: Chem., 194, pp. 297-307; Seedher, N., Bhatia, S., Reversible binding of celecoxib and valdecoxib with human serum albumin using fluorescence spectroscopic technique (2006) Pharmacol. Res., 54, pp. 77-84; Keshavarz, F., Alavianmher, M.M., Yousefi, R., Molecular dynamics simulation and docking studies on the binding properties of several anticancer drugs to human serum albumin (2012) Mol. Biol. Res. Commun., 1, pp. 65-73; Davies, M.J., Singlet oxygen-mediated damage to proteins and its consequences (2003) Biochem. Biophys. Res. Commun., 305, pp. 761-770",Article,Scopus,2-s2.0-84915747507
"Scholtes V.P.W., Peeters W., van Lammeren G.W., Howard D.P.J., de Vries J.P.P.M., de Borst G.J., Redgrave J.N., Kemperman H., Schalkwijk C.G., den Ruijter H.M., de Kleijn D.P.V., Moll F.L., Rothwell P.M., Pasterkamp G.","Type 2 diabetes is not associated with an altered plaque phenotype among patients undergoing carotid revascularization. A histological analysis of 1455 carotid plaques",2015,"Atherosclerosis","235","2",,"418","423",,,10.1016/j.atherosclerosis.2014.05.941,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921447893&partnerID=40&md5=956e6280dbeedbac2db779166570e2d4","Experimental Cardiology Laboratory, University Medical Center Utrecht, Heidelberglaan 100Utrecht, Netherlands; Department of Clinical Neurology, Stroke Prevention Research Unit, Radcliffe InfirmaryOxford, United Kingdom; Department of Vascular Surgery, St Antonius HospitalNieuwegein, Netherlands; Department of Vascular Surgery, University Medical Center UtrechtUtrecht, Netherlands; Department of Clinical Chemistry, University Medical Center UtrechtUtrecht, Netherlands; Department of Internal Medicine, Laboratory of Metabolism and Vascular MedicineMaastricht, Netherlands; Cardiovascular Research Institute, Maastricht University Medical CenterMaastricht, Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center UtrechtUtrecht, Netherlands","Scholtes, V.P.W., Experimental Cardiology Laboratory, University Medical Center Utrecht, Heidelberglaan 100Utrecht, Netherlands; Peeters, W., Experimental Cardiology Laboratory, University Medical Center Utrecht, Heidelberglaan 100Utrecht, Netherlands; van Lammeren, G.W., Experimental Cardiology Laboratory, University Medical Center Utrecht, Heidelberglaan 100Utrecht, Netherlands; Howard, D.P.J., Department of Clinical Neurology, Stroke Prevention Research Unit, Radcliffe InfirmaryOxford, United Kingdom; de Vries, J.P.P.M., Department of Vascular Surgery, St Antonius HospitalNieuwegein, Netherlands; de Borst, G.J., Department of Vascular Surgery, University Medical Center UtrechtUtrecht, Netherlands; Redgrave, J.N., Department of Clinical Neurology, Stroke Prevention Research Unit, Radcliffe InfirmaryOxford, United Kingdom; Kemperman, H., Department of Clinical Chemistry, University Medical Center UtrechtUtrecht, Netherlands; Schalkwijk, C.G., Department of Internal Medicine, Laboratory of Metabolism and Vascular MedicineMaastricht, Netherlands, Cardiovascular Research Institute, Maastricht University Medical CenterMaastricht, Netherlands; den Ruijter, H.M., Experimental Cardiology Laboratory, University Medical Center Utrecht, Heidelberglaan 100Utrecht, Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center UtrechtUtrecht, Netherlands; de Kleijn, D.P.V., Experimental Cardiology Laboratory, University Medical Center Utrecht, Heidelberglaan 100Utrecht, Netherlands; Moll, F.L., Department of Vascular Surgery, University Medical Center UtrechtUtrecht, Netherlands; Rothwell, P.M., Department of Clinical Neurology, Stroke Prevention Research Unit, Radcliffe InfirmaryOxford, United Kingdom; Pasterkamp, G., Experimental Cardiology Laboratory, University Medical Center Utrecht, Heidelberglaan 100Utrecht, Netherlands","Aims: Diabetes accelerates progression of atherosclerotic disease, but data on associations between diabetes and advanced atherosclerotic plaque composition are scarce. Methods and results: We used one of the largest biobanks, the Athero-Express study (n= 1455) at carotid endarterectomy (CEA). All plaques were subjected to histological analysis to assess lipid core size, collagen, macrophages, smooth muscle cells, micro-vessel density and calcifications. In addition, within a subset of patients cytokines and chemokines were assessed.The 295 patients (20%) with type-2 diabetes showed a higher proportion of previous cardiovascular interventions and more stringent treatment for hypertension and hypercholesterolaemia compared with patients without type-2 diabetes. Surprisingly, no associations between diabetes and histological plaque characteristics were observed. In addition, no differences were observed in the expression of inflammatory chemokines, cytokines or advanced glycation end products in plaques of diabetic and non-diabetic patients. Conclusion: In patients suffering from significant carotid artery disease, diabetes does not appear to be associated with specific atherosclerotic plaque characteristics. © 2014 Elsevier Ireland Ltd.","Carotid endarterectomy; Carotid plaque; Diabetes; Histology","Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., Heart disease and stroke statistics - 2013 update: a report from the American Heart Association (2013) Circulation, 127, pp. e6-e245; Mokdad, A.H., Ford, E.S., Bowman, B.A., Dietz, W.H., Vinicor, F., Bales, V.S., Prevalence of obesity, diabetes, and obesity-related health risk factors (2001) JAMA, 2003 (289), pp. 76-79; Fox, C.S., Coady, S., Sorlie, P.D., D'Agostino, R.B., Pencina, M.J., Vasan, R.S., Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study (2007) Circulation, 115, pp. 1544-1550; Beckman, J.A., Creager, M.A., Libby, P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management (2002) JAMA, 287, pp. 2570-2581; Bhatt, D.L., Eagle, K.A., Ohman, E.M., Hirsch, A.T., Goto, S., Mahoney, E.M., Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis (2010) JAMA, 304, pp. 1350-1357; Cho, E., Rimm, E.B., Stampfer, M.J., Willett, W.C., Hu, F.B., The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men (2002) JAm Coll Cardiol, 40, pp. 954-960; Jamrozik, K., Broadhurst, R.J., Forbes, S., Hankey, G.J., Anderson, C.S., Predictors of death and vascular events in the elderly: the Perth Community Stroke Study (2000) Stroke, 31, pp. 863-868; Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., Laakso, M., Type 2 diabetes as a ""coronary heart disease equivalent"": an 18-year prospective population-based study in Finnish subjects (2005) Diab Care, 28, pp. 2901-2907; Verhoeven, B.A.N., Velema, E., Schoneveld, A.H., de Vries, J.P.P.M., de Bruin, P., Seldenrijk, C.A., Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design (2004) Eur J Epidemiol, 19, pp. 1127-1133; Hellings, W.E., Pasterkamp, G., Vollebregt, A., Seldenrijk, C.A., De Vries, J.-P.P.M., Velema, E., Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens (2007) JVasc Surg, 46, pp. 1147-1154; Teerlink, T., Barto, R., Ten Brink, H.J., Schalkwijk, C.G., Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry (2004) Clin Chem, 50, pp. 1222-1228; Teerlink, T., Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance (2005) Clin Chem Lab Med, 43, pp. 1130-1138; Verhoeven, B.A.N., Moll, F.L., Koekkoek, J.A.F., van der Wal, A.C., de Kleijn, D.P.V., de Vries, J.P.P.M., Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy (2006) Stroke, 37, pp. 2054-2060; Hellings, W.E., Pasterkamp, G., Verhoeven, B.A.N., De Kleijn, D.P.V., De Vries, J.-P.P.M., Seldenrijk, K.A., Gender-associated differences in plaque phenotype of patients undergoing carotid endarterectomy (2007) JVasc Surg, 45, pp. 289-296. , discussion 296-7; Redgrave, J.N., Lovett, J.K., Syed, A.B., Rothwell, P.M., Histological features of symptomatic carotid plaques in patients with impaired glucose tolerance and diabetes (oxford plaque study) (2008) Cerebrovasc Dis, 26, pp. 79-86; Kanter, J.E., Johansson, F., LeBoeuf, R.C., Bornfeldt, K.E., Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? (2007) Circ Res, 100, pp. 769-781; Pasterkamp, G., Methods of accelerated atherosclerosis in diabetic patients (2013) Heart, 99, pp. 743-749; Spagnoli, L.G., Mauriello, A., Palmieri, G., Santeusanio, G., Amante, A., Taurino, M., Relationships between risk factors and morphological patterns of human carotid atherosclerotic plaques. A multivariate discriminant analysis (1994) Atherosclerosis, 108, pp. 39-60; Cipollone, F., Iezzi, A., Fazia, M., Zucchelli, M., Pini, B., Cuccurullo, C., The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control (2003) Circulation, 108, pp. 1070-1077; Burke, A.P., Kolodgie, F.D., Zieske, A., Fowler, D.R., Weber, D.K., Varghese, P.J., Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study (2004) Arterioscler Thromb Vasc Biol, 24, pp. 1266-1271; Moreno, P.R., Murcia, A.M., Palacios, I.F., Leon, M.N., Bernardi, V.H., Fuster, V., Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus (2000) Circulation, 102, pp. 2180-2184; Hellings, W.E., Peeters, W., Moll, F.L., Piers, S.R.D., van Setten, J., Van der Spek, P.J., Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study (2010) Circulation, 121, pp. 1941-1950; Kolodgie, F.D., Gold, H.K., Burke, A.P., Fowler, D.R., Kruth, H.S., Weber, D.K., Intraplaque hemorrhage and progression of coronary atheroma (2003) NEngl J Med, 349, pp. 2316-2325; Golledge, J., Greenhalgh, R.M., Davies, A.H., The symptomatic carotid plaque (2000) Stroke, 31, pp. 774-781; Achterberg, S., Cramer, M.J.M., Kappelle, L.J., de Borst, G.J., Visseren, F.L.J., van der Graaf, Y., Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study (2010) Eur J Cardiovasc Prev Rehab, 17, pp. 424-430; Bernhagen, J., Calandra, T., Bucala, R., Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features (1998) JMol Med (Berl), 76, pp. 151-161; Bernhagen, J., Krohn, R., Lue, H., Gregory, J.L., Zernecke, A., Koenen, R.R., MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment (2007) Nat Med, 13, pp. 587-596; De Kleijn, D.P.V., Moll, F.L., Hellings, W.E., Ozsarlak-Sozer, G., de Bruin, P., Doevendans, P.A., Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events (2010) Arterioscler Thromb Vasc Biol, 30, pp. 612-619; Dandona, P., Aljada, A., Ghanim, H., Mohanty, P., Tripathy, C., Hofmeyer, D., Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin (2004) JClin Endocrinol Metab, 89, pp. 5043-5047; Brown, A., Reynolds, L.R., Bruemmer, D., Intensive glycemic control and cardiovascular disease: an update (2010) Nat Rev Cardiol, 7, pp. 369-375; Camafort, M., Alvarez-Rodríguez, L.R., Muñoz-Torrero, J.F.S., Sahuquillo, J.C., López-Jiménez, L., Coll, R., Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry (2011) Diabet Med, 28, pp. 73-80",Article,Scopus,2-s2.0-84921447893
"Fandino-Vaquero R., Fernandez-Trasancos A., Alvarez E., Ahmad S., Batista-Oliveira A.L., Adrio B., Fernandez T.L., Gonzalez-Juanatey J.R., Eiras S.","Orosomucoid secretion levels by epicardial adipose tissue as possible indicator of endothelial dysfunction in diabetes mellitus or inflammation in coronary artery disease",2015,"Atherosclerosis","235","2",,"281","288",,2,10.1016/j.atherosclerosis.2014.05.921,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908217682&partnerID=40&md5=eb24b3d47bd7c395b0e0d3bfc78230f6","Department of Cardiology and Coronary Unit, Clinical Hospital of Santiago de Compostela, Spain; Health Research Institute, Spain; Department of Cardiac Surgery, Clinical Hospital of Santiago de Compostela, Spain","Fandiño-Vaquero, R., Department of Cardiology and Coronary Unit, Clinical Hospital of Santiago de Compostela, Spain; Fernández-Trasancos, A., Health Research Institute, Spain; Álvarez, E., Health Research Institute, Spain; Ahmad, S., Health Research Institute, Spain; Batista-Oliveira, A.L., Health Research Institute, Spain; Adrio, B., Department of Cardiac Surgery, Clinical Hospital of Santiago de Compostela, Spain; Fernández, T.L., Department of Cardiac Surgery, Clinical Hospital of Santiago de Compostela, Spain; González-Juanatey, J.R., Department of Cardiology and Coronary Unit, Clinical Hospital of Santiago de Compostela, Spain, Health Research Institute, Spain; Eiras, S., Health Research Institute, Spain","Objective: Type 2 diabetes mellitus (T2DM) is associated with fat and autonomic system dysfunction. Epicardial adipose tissue (EAT) plays an endocrine role over the heart. Since orosomucoid (ORM) has local actions around the coronaries, our aim was to assess the relationship between its secretion profile by EAT and its catecholaminergic regulation in patients with T2DM and coronary artery disease (CAD). Methods: We obtained EAT, subcutaneous adipose tissue (SAT) and plasma from 55 patients undergoing cardiac surgery. Fat explants were stimulated with isoproterenol (ISO) 1μM for 6h. After, the fat explants released-ORM and plasma levels were analyzed by ELISA. mRNA or protein expression was analyzed by real time PCR or western blot, respectively. The effects of ORM on endothelial cells were analyzed by impedance and wound healing assays. Results: We observed that EAT-released ORM levels were higher than SAT (328±185 vs 58±45ng/mL; p<0.001). Interestingly, EAT secretion was lower in patients with than those without T2DM (260±141 vs 370±194ng/mL; p<0.05) and this difference was enhanced after ISO stimulation (. p<0.01). However, plasma levels (412±119 vs 594±207μg/mL) and EAT-released ORM levels were higher in patients with than those without CAD (384±195 vs 279±159ng/mL; p<0.05). ISO stimulation, also reduced the EAT released-ORM levels in patients with CAD. On human endothelial cells, ORM induced an increase of healing and proliferation in a dose-dependent manner. Conclusion: EAT-released ORM levels in patients with T2DM or CAD and its regulation by catecholamines might be the mirror of local endothelium dysfunction or inflammatory process in different cardiovascular disorders. © 2014 Elsevier Ireland Ltd.","Epicardial adipose tissue; Orosomucoid; Type 2 diabetes mellitus","Iacobellis, G., Corradi, D., Sharma, A.M., Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart (2005) Nat Clin Pract Cardiovasc Med, 2, pp. 536-543; Sacks, H.S., Fain, J.N., Human epicardial adipose tissue: a review (2007) Am Heart J, 153, pp. 907-917; Gorter, P.M., de Vos, A.M., van der Graaf, Y., Stella, P.R., Doevendans, P.A., Meijs, M.F., Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography (2008) Am J Cardiol, 102, pp. 380-385; Iozzo, P., Myocardial, perivascular, and epicardial fat (2011) Diabetes Care, 34 (Suppl.2), pp. S371-S379; Shimabukuro, M., Hirata, Y., Tabata, M., Dagvasumberel, M., Sato, H., Kurobe, H., Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis (2013) Arterioscler Thromb Vasc Biol, 33, pp. 1077-1084; Mazurek, T., Zhang, L., Zalewski, A., Mannion, J.D., Diehl, J.T., Arafat, H., Human epicardial adipose tissue is a source of inflammatory mediators (2003) Circulation, 108, pp. 2460-2466; Silaghi, A., Achard, V., Paulmyer-Lacroix, O., Scridon, T., Tassistro, V., Duncea, I., Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status (2007) Am J Physiol Endocrinol Metab, 293, pp. E1443-E1450; Salgado-Somoza, A., Teijeira-Fernandez, E., Fernandez, A.L., Gonzalez-Juanatey, J.R., Eiras, S., Changes in lipid transport-involved proteins of epicardial adipose tissue associated with coronary artery disease (2012) Atherosclerosis, 224, pp. 492-499; Karastergiou, K., Evans, I., Ogston, N., Miheisi, N., Nair, D., Kaski, J.C., Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells (2010) Arterioscler Thromb Vasc Biol, 30, pp. 1340-1346; Wang, C.P., Hsu, H.L., Hung, W.C., Yu, T.H., Chen, Y.H., Chiu, C.A., Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis (2009) Clin Endocrinol (Oxf), 70, pp. 876-882; Galvez-Monton, C., Prat-Vidal, C., Roura, S., Farre, J., Soler-Botija, C., Llucia-Valldeperas, A., Transposition of a pericardial-derived vascular adipose flap for myocardial salvage after infarct (2011) Cardiovasc Res, 91, pp. 659-667; Gao, Y.J., Zeng, Z.H., Teoh, K., Sharma, A.M., Abouzahr, L., Cybulsky, I., Perivascular adipose tissue modulates vascular function in the human internal thoracic artery (2005) JThorac Cardiovasc Surg, 130, pp. 1130-1136; Greulich, S., Maxhera, B., Vandenplas, G., Herzfeld de Wiza, D., Smiris, K., Mueller, H., Secretory products from epicardial adipose tissue of patients with type 2 diabetes induce cardiomyocyte dysfunction (2012) Circulation, 126, pp. 2324-2334; Aksakal, E., Tanboga, I.H., Kurt, M., Predictors of coronary lesions complexity in patients with stable coronary artery disease (2013) Angiology, 64, p. 313; Costello, M.J., Gewurz, H., Siegel, J.N., Inhibition of neutrophil activation by alpha1-acid glycoprotein (1984) Clin Exp Immunol, 55, pp. 465-472; Sorensson, J., Matejka, G.L., Ohlson, M., Haraldsson, B., Human endothelial cells produce orosomucoid, an important component of the capillary barrier (1999) Am J Phys, 276, pp. H530-H534; Lee, Y.S., Choi, J.W., Hwang, I., Lee, J.W., Lee, J.H., Kim, A.Y., Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation (2010) JBiol Chem, 285, pp. 22174-22185; Teijeira-Fernandez, E., Eiras, S., Grigorian-Shamagian, L., Fernandez, A., Adrio, B., Gonzalez-Juanatey, J.R., Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension (2008) JHum Hypertens, 22, pp. 856-863; Teijeira-Fernandez, E., Eiras, S., Grigorian-Shamagian, L., Salgado-Somoza, A., Martinez-Comendador, J.M., Gonzalez-Juanatey, J.R., Diabetic and nondiabetic patients express similar adipose tissue adiponectin and leptin levels (2010) Int J Obes (Lond), 34, pp. 1200-1208; Eiras, S., Teijeira-Fernandez, E., Shamagian, L.G., Fernandez, A.L., Vazquez-Boquete, A., Gonzalez-Juanatey, J.R., Extension of coronary artery disease is associated with increased IL-6 and decreased adiponectin gene expression in epicardial adipose tissue (2008) Cytokine, 43, pp. 174-180; Catapano, A.L., Reiner, Z., De Backer, G., Graham, I., Taskinen, M.R., Wiklund, O., ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) Atherosclerosis, 217, pp. 3-46; Scriba, D., Aprath-Husmann, I., Blum, W.F., Hauner, H., Catecholamines suppress leptin release from invitro differentiated subcutaneous human adipocytes in primary culture via beta1- and beta2-adrenergic receptors (2000) Eur J Endocrinol, 143, pp. 439-445; Rodino-Janeiro, B.K., Gonzalez-Peteiro, M., Ucieda-Somoza, R., Gonzalez-Juanatey, J.R., Alvarez, E., Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy (2010) Diabetes Metab Res Rev, 26, pp. 550-558; Jiang, A., Gao, H., Kelley, M.R., Qiao, X., Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis invitro and invivo (2010) Vision Res, 51, pp. 93-100; Dessy, C., Balligand, J.L., Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives (2010) Adv Pharmacol, 59, pp. 135-163; Boncela, J., Smolarczyk, K., Wyroba, E., Cierniewski, C.S., Binding of PAI-1 to endothelial cells stimulated by thymosin beta4 and modulation of their fibrinolytic potential (2006) JBiol Chem, 281, pp. 1066-1072; Correale, M., Brunetti, N.D., De Gennaro, L., Di Biase, M., Acute phase proteins in atherosclerosis (acute coronary syndrome) (2008) Cardiovasc Hematol Agents Med Chem, 6, pp. 272-277; Agra, R.M., Teijeira-Fernandez, E., Pascual-Figal, D., Jesus, S.M., Fernandez-Trasancos, A., Sierra, J., Differential behavior between S100A9 and adiponectin in coronary artery disease. Plasma or epicardial fat (2014) Life Sci, 100, pp. 147-151; Alexopoulos, N., Katritsis, D., Raggi, P., Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis (2014) Atherosclerosis, 233, pp. 104-112; Ligresti, G., Aplin, A.C., Dunn, B.E., Morishita, A., Nicosia, R.F., The acute phase reactant orosomucoid-1 is a bimodal regulator of angiogenesis with time- and context-dependent inhibitory and stimulatory properties (2012) PLoS One, 7, p. e41387; Kuebler, J.F., Toth, B., Yokoyama, Y., Bland, K.I., Rue, L.W., Chaudry, I.H., Alpha1-acid-glycoprotein protects against trauma-hemorrhagic shock (2004) JSurg Res, 119, pp. 21-28; Hjalmarsson, C., Lidell, M.E., Haraldsson, B., Beneficial effects of orosomucoid on the glomerular barrier in puromycin aminonucleoside-induced nephrosis (2006) Nephrol Dial Transplant, 21, pp. 1223-1230; Gunnarsson, P., Levander, L., Pahlsson, P., Grenegard, M., Alpha(1)-acid glycoprotein (AGP)-induced platelet shape change involves the Rho/Rho kinase signalling pathway (2009) Thromb Haemost, 102, pp. 694-703; Manfrini, O., Pizzi, C., Trere, D., Fontana, F., Bugiardini, R., Parasympathetic failure and risk of subsequent coronary events in unstable angina and non-ST-segment elevation myocardial infarction (2003) Eur Heart J, 24, pp. 1560-1566; Licht, C.M., de Geus, E.J., Penninx, B.W., Dysregulation of the autonomic nervous system predicts the development of the metabolic syndrome (2013) JClin Endocrinol Metab, 98, pp. 2484-2493",Article,Scopus,2-s2.0-84908217682
"Lipinski M.J., Pendyala L.K., Torguson R., Chen F., Waksman R.","Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin",2015,"Atherosclerosis","235","2",,"295","298",,,10.1016/j.atherosclerosis.2014.05.919,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921442608&partnerID=40&md5=ac50f30e0a674418533d7cfb1f607aaa","Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States","Lipinski, M.J., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States; Pendyala, L.K., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States; Torguson, R., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States; Chen, F., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States; Waksman, R., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States","Objective: Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis. Therefore, we assessed the impact of metformin on stent thrombosis and major adverse cardiovascular events (MACE) in non-insulin-dependent diabetes mellitus (NIDDM) patients who receive drug-eluting stents (DES). Methods: We assessed the impact of metformin and stent type on stent thrombosis, MACE, and death in NIDDM patients following DES placement. Of the 1201 patients included, 74.8% received LES, 25.2% received paclitaxel-eluting stents (PES), and 55% were taking metformin. Results: There was no difference in stent thrombosis, regardless of stent type or metformin use. While Kaplan-Meier curves demonstrated reduced MACE (. p=0.007) and death (. p=0.006) with metformin use, multivariate analysis demonstrated that stent type and metformin use were not associated with outcome. Conclusion: In NIDDM patients, metformin use or stent type following DES placement did not increase stent thrombosis and MACE rates. © 2014 Elsevier Ireland Ltd.","Diabetes mellitus; Drug-eluting stents; Metformin; Outcomes; Percutaneous coronary intervention","Donahoe, S.M., Stewart, G.C., McCabe, C.H., Mohanavelu, S., Murphy, S.A., Cannon, C.P., Diabetes and mortality following acute coronary syndromes (2007) JAm Med Assoc, 298, pp. 765-775; Stettler, C., Allemann, S., Wandel, S., Kastrati, A., Morice, M.C., Schomig, A., Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis (2008) BMJ, 337, p. a1331; De Luca, G., Dirksen, M.T., Spaulding, C., Kelbaek, H., Schalij, M., Thuesen, L., Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention (2013) Am J Cardiol, 111, pp. 1295-1304; Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group (1998) Lancet, 352, pp. 854-865; Isoda, K., Young, J.L., Zirlik, A., MacFarlane, L.A., Tsuboi, N., Gerdes, N., Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells (2006) Arterioscler Thromb Vasc Biol, 26, pp. 611-617; Li, Y., Xu, S., Mihaylova, M.M., Zheng, B., Hou, X., Jiang, B., AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice (2011) Cell Metab, 13, pp. 376-388; Habib, A., Karmali, V., Polavarapu, R., Akahori, H., Nakano, M., Yazdani, S., Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation (2013) JAm Coll Cardiol, 61, pp. 971-980; Habib, A., Karmali, V., Polavarapu, R., Akahori, H., Pachura, K., Finn, A.V., Metformin impairs endothelialization after placement of newer generation drug eluting stents (2013) Atherosclerosis, 229, pp. 385-387; DeFronzo, R.A., Goodman, A.M., Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group (1995) NEngl J Med, 333, pp. 541-549; Huang, N.L., Chiang, S.H., Hsueh, C.H., Liang, Y.J., Chen, Y.J., Lai, L.P., Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation (2009) Int J Cardiol, 134, pp. 169-175; Ewart, M.A., Kennedy, S., AMPK and vasculoprotection (2011) Pharmacol Ther, 131, pp. 242-253; Barbash, I.M., Minha, S., Torguson, R., Ben-Dor, I., Badr, S., Loh, J.P., Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice (2014) JInvasive Cardiol, 26, pp. 154-160; Kim, W.J., Lee, S.W., Park, S.W., Kim, Y.H., Yun, S.C., Lee, J.Y., Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial (2011) Circulation, 124, pp. 886-892",Article,Scopus,2-s2.0-84921442608
"Katakami N., Kaneto H., Matsuoka T.-A., Takahara M., Osonoi T., Saitou M., Kawai K., Ishibashi F., Kashiwagi A., Kawamori R., Shimomura I., Yamasaki Y.","Accumulation of oxidative stress-related gene polymorphisms and the risk of coronary heart disease events in patients with type 2 diabetes - An 8-year prospective study",2015,"Atherosclerosis","235","2",,"408","414",,,10.1016/j.atherosclerosis.2014.05.936,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921473820&partnerID=40&md5=cd07ea00a9655908c946009645c3ef6a","Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, Japan; Naka Memorial Clinic, Japan; Kawai Clinic, Japan; Ishibashi Clinic, Japan; Department of Medicine, Shiga University of Medical Science, Japan; Sportology Center, Juntendo University School of Medicine, Japan","Katakami, N., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan, Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, Japan; Kaneto, H., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Matsuoka, T.-A., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Takahara, M., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Osonoi, T., Naka Memorial Clinic, Japan; Saitou, M., Naka Memorial Clinic, Japan; Kawai, K., Kawai Clinic, Japan; Ishibashi, F., Ishibashi Clinic, Japan; Kashiwagi, A., Department of Medicine, Shiga University of Medical Science, Japan; Kawamori, R., Sportology Center, Juntendo University School of Medicine, Japan; Shimomura, I., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Yamasaki, Y., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan","Objective: Oxidative stress, which is provoked in patients with diabetes, plays critical roles in the pathogenesis of coronary heart disease (CHD). We simultaneously determined 5 relatively common genetic variants related to oxidative stress and evaluated the combined effect on CHD. Methods: We enrolled 1977 Japanese type 2 diabetic subjects without history of CVD (males 66.1%, 59.5±10.0 years old), determined their genotypes regarding glutamate-cysteine ligase modifier subunit (GCLM) C-588T, manganese superoxide dismutase (SOD2) Val16Ala, endothelial nitric oxide synthase (NOS3) G894T, NAD(P)H oxidase p22phox (CYBA) C242T, and myeloperoxidase (MPO) G-463A polymorphisms, and prospectively evaluated the association between these polymorphisms and CHD events. Results: The median follow-up period was 7.5 years and there were 85 new CHD events. The single association analysis revealed that there were no statistically significant associations between each polymorphism and the prevalence of CHD. Interestingly, the risk of CHD event was higher with the increase of the total number of 10 concomitant unfavorable ""pro-oxidant alleles"" in each subject (p for trend=0.018, log-rank test). Especially, the carriers of <8 pro-oxidant alleles had a significantly increased risk as compared to the carriers of <8 pro-oxidant alleles, whether the other clinical variables were adjusted (HR 2.92 with 95%CI 1.50-5.67, p=0.002) or not (HR 2.89 with 95%CI 1.49-5.59, p=0.002). Conclusions: Accumulation of gene polymorphisms related to oxidative stress is likely associated with the development of CHD in patients with type 2 diabetes, suggesting that the combined information about these variants is useful to assess the risk of CHD. © 2014 Elsevier Ireland Ltd.","Atherosclerosis; Coronary heart disease; Diabetes; Oxidative stress; Polymorphism","Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H., Keen, H., Mortality and causes of death in the WHO multinational study of vascular disease in diabetes (2001) Diabetologia, 44 (Suppl.2), pp. S14-S21; Eckel, R.H., Kahn, R., Robertson, R.M., Rizza, R.A., Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association (2006) Circulation, 113, pp. 2943-2946; Khot, U.N., Khot, M.B., Bajzer, C.T., Sapp, S.K., Ohman, E.M., Brener, S.J., Prevalence of conventional risk factors in patients with coronary heart disease (2003) JAm Med Assoc, 290, pp. 898-904; Greenland, P., Knoll, M.D., Stamler, J., Neaton, J.D., Dyer, A.R., Garside, D.B., Major risk factors as antecedents of fatal and nonfatal coronary heart disease events (2003) JAm Med Assoc, 290, pp. 891-897; West, I.C., Radicals in oxidative stress in diabetes (2002) Diabet Med, 17, pp. 171-180; Meister, A., Anderson, M.E., Glutathione (1983) Annu Rev Biochem, 52, pp. 711-760; Minova, H.R., Mulcahy, R.T., An electrophile responsive element (EpRE) regulates gamma-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory subunit gene (1998) JBiol Chem, 273, pp. 14683-14689; Nakamura, S., Kugiyama, K., Sugiyama, S., Miyamoto, S., Koide, S., Fukushima, H., Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction (2002) Circulation, 105, pp. 2968-2973; Lebovitz, R.M., Zhang, H., Vogel, H., Cartwright, J., Dionne, L., Lu, N., Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice (1996) Proc Natl Acad Sci U S A, 93, pp. 9782-9787; Shimoda-Matsubayashi, S., Matsumine, H., Kobayashi, T., Nakagawa-Hattori, Y., Shimizu, Y., Mizuno, Y., Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease (1996) Biochem Biophys Res Commun, 226, pp. 561-565; Sutton, A., Khoury, H., Prip-Buus, C., Cepanec, C., Pessayre, D., Degoul, F., The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria (2003) Pharmacogenetics, 13, pp. 145-157; Shimoda-Matsubayashi, S., Hattori, T., Matsumine, H., Shinohara, A., Yoritaka, A., Mori, H., MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson' disease and control (1997) Neurology, 49, pp. 1257-1262; Tesauro, M., Thompson, W.C., Rogliani, P., Qi, L., Chaudhary, P.P., Moss, J., Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298 (2000) Proc Natl Acad Sci U S A, 97, pp. 2832-2835; Wang, X.L., Sim, A.S., Wang, M.X., Murrell, G.A., Trudinger, B., Wang, J., Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity (2000) FEBS Lett, 471, pp. 45-50; Veldman, B.A., Spiering, W., Doevendans, P.A., Vervoort, G., Kroon, A.A., de Leeuw, P.W., The Glu298Asp polymorphism of the NOS3 gene as a determinant of the baseline production of nitric oxide (2002) JHypertens, 20, pp. 2023-2027; Noiri, E., Satoh, H., Taguchi, J., Brodsky, S.V., Nakao, A., Ogawa, Y., Association of eNOS Glu298Asp polymorphism with end-stage renal disease (2002) Hypertension, 40, pp. 535-540; Azumi, H., Inoue, N., Takeshita, S., Rikitake, Y., Kawashima, S., Hayashi, Y., Expression of NADH/NADPH oxidase p22phox in human coronary arteries (1999) Circulation, 100, pp. 1494-1498; Guzik, T.J., West, N.E., Black, E., McDonald, D., Ratnatunga, C., Pillai, R., Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis (2000) Circulation, 102, pp. 1744-1747; Daugherty, A., Dunn, J.L., Rateri, D.L., Heinecke, J.W., Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions (1994) JClin Invest, 94, pp. 437-444; Reynolds, W.F., Chang, E., Douer, E., Ball, E.D., Kanda, V., An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia (1997) Blood, 90, pp. 2730-2737; Piedrafita, F.J., Molander, R.B., Vansant, G., Orlova, E.A., Pfhal, M., Reynolds, W.F., An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element (1996) JBiol Chem, 271, pp. 14412-14420; Katakami, N., Kume, S., Kaneto, H., Uzu, T., Kashiwagi, A., Yamasaki, Y., Association of myeloperoxidase G-463A gene polymorphism with diabetic nephropathy in Japanese type 2 diabetic subjects (2013) Endocr J, 60, pp. 457-471; Katakami, N., Kaneto, H., Matsuoka, T.A., Takahara, M., Imamura, K., Ishibashi, F., Accumulation of gene polymorphisms related to oxidative stress is associated with myocardial infarction in Japanese type 2 diabetic patients (2010) Atherosclerosis, 212, pp. 534-538; Yamada, Y., Izawa, H., Ichihara, S., Takatsu, F., Ishihara, H., Hirayama, H., Prediction of the risk of myocardial infarction from polymorphisms in candidate genes (2002) NEngl J Med, 347, pp. 1916-1923; Yang, Q., Khoury, M.J., Botto, L., Friedman, J.M., Flanders, W.D., Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes (2003) Am J Hum Genet, 72, pp. 636-649; Cam, S.F., Sekuri, C., Tengiz, I., Ecran, E., Sagcan, A., Akin, M., The G894T polymorphism on endothelial nitric oxide synthase gene is associated with premature coronary artery disease in a Turkish population (2005) Thromb Res, 116, pp. 278-292; Tamemoto, H., Ishikawa, S.E., Kawakami, M., Association of the Glu298Asp polymorphism of the eNOS gene with ischemic heart disease in Japanese diabetic subjects (2008) Diabetes Res Clin Pract, 80, pp. 275-279; Jaramillo, P.C., Munoz, M.A., Lanas, M.C., Lanas, Z.F., Salazar, L.A., Endothelial nitric oxide synthase G894T gene polymorphism in Chilean subjects with coronary artery disease and controls (2006) Clin Chim Acta, 371, pp. 102-106; Inoue, N., Kawashima, S., Kanazawa, K., Yamada, S., Akita, H., Yokoyama, M., Polymorphism of the NADH/NADPH oxidase p22phox gene in patients with coronary artery disease (1998) Circulation, 97, pp. 135-137; Soccio, M., Toniato, E., Evangelista, V., Carluccio, M., De Caterina, R., Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants (2005) Eur J Clin Invest, 35, pp. 305-314; Nikpoor, B., Turecki, G., Fournier, C., Theroux, P., Rouleau, G.A., Afunctional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians (2001) Am Heart J, 142, pp. 336-339; Makela, R., Loimaala, A., Nenonen, A., Mercuri, M., Vuori, I., Huhtala, H., The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes (2008) Clin Biochem, 41, pp. 532-553; Wainstein, R.V., Wainstein, M.V., Riberio, J.P., Dornelles, L.V., Tozzati, P., Ashton-Prolla, P., Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease (2010) Clin Biochem, 43, pp. 57-62; Fujimoto, H., Taguchi, J., Imai, Y., Ayabe, S., Hashimoto, H., Kobayashi, H., Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease (2008) Eur Heart J, 29, pp. 1267-1274; Dalager, S., Paaske, W.P., Kristensen, I.B., Laurberg, J.M., Falk, E., Artery-related differences in atherosclerosis expression. Implications for atherogenesis and dynamics in intima-media thickness (2007) Stroke, 38, pp. 2698-2705; Glagov, S., Zarins, C., Giddens, D.P., Ku, D.N., Hemodynamics and atherosclerosis: insights and perspectives gained from studies of human arteries (1988) Arch Pathol Lab Med, 112, pp. 1018-1031; Sone, H., Tanaka, S., Tanaka, S., Iimuro, S., Oida, K., Yamasaki, Y., Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS) (2011) JClin Endocrinol Metab, 96, pp. 3448-3456. , Japan Diabetes Complications Study Group; van der Heijden, A.A., Ortegon, M.M., Niessen, L.W., Nijpels, G., Dekker, J.M., Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions (2009) Diabetes Care, 32, pp. 2094-2098; Mulnier, H.E., Seaman, H.E., Raleigh, V.S., Soedamah-Muthu, S.S., Colhoun, H.M., Lawrenson, R.A., Risk of stroke in people with type 2 diabetes in the UK: a study using the general practice research database (2006) Diabetologia, 49, pp. 2859-2865; Sone, H., Mizuno, S., Fujii, H., Yoshimura, Y., Yamasaki, Y., Ishibashi, S., Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study (2005) Diabetes Care, 28, pp. 1463-1471; Sone, H., Ito, H., Ohashi, Y., Akanuma, Y., Yamada, N., Obesity and type 2 diabetes in Japanese patients (2003) Lancet, 361, p. 85",Article,Scopus,2-s2.0-84921473820
"Brings S., Zhang S., Choong Y.S., Hogl S., Middleditch M., Kamalov M., Brimble M.A., Gong D., Cooper G.J.S.","Diabetes-induced alterations in tissue collagen and carboxymethyllysine in rat kidneys: Association with increased collagen-degrading proteinases and amelioration by Cu(II)-selective chelation",2015,"Biochimica et Biophysica Acta - Molecular Basis of Disease","1852","8",,"1610","1618",,,10.1016/j.bbadis.2015.04.014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928958184&partnerID=40&md5=8c26aca5a3eccd8e586f02fc5ce1c356","The School of Biological Sciences, Faculty of Science, University of AucklandAuckland, New Zealand; The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of AucklandAuckland, New Zealand; The School of Chemical Sciences, University of AucklandAuckland, New Zealand; Centre for Advanced Discovery and Experimental Therapeutics, NIHR Manchester Biomedical Research Centre, Central Manchester Univ. Hospitals NHS Foundation Trust, School of Biomedicine, Faculty of Medical and Human Sciences, University of ManchesterManchester, United Kingdom; Department of Pharmacology, Division of Medical Sciences, University of OxfordOxford, United Kingdom","Brings, S., The School of Biological Sciences, Faculty of Science, University of AucklandAuckland, New Zealand; Zhang, S., The School of Biological Sciences, Faculty of Science, University of AucklandAuckland, New Zealand, The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of AucklandAuckland, New Zealand; Choong, Y.S., The School of Biological Sciences, Faculty of Science, University of AucklandAuckland, New Zealand; Hogl, S., The School of Biological Sciences, Faculty of Science, University of AucklandAuckland, New Zealand; Middleditch, M., The School of Biological Sciences, Faculty of Science, University of AucklandAuckland, New Zealand, The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of AucklandAuckland, New Zealand; Kamalov, M., The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of AucklandAuckland, New Zealand, The School of Chemical Sciences, University of AucklandAuckland, New Zealand; Brimble, M.A., The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of AucklandAuckland, New Zealand, The School of Chemical Sciences, University of AucklandAuckland, New Zealand; Gong, D., The School of Biological Sciences, Faculty of Science, University of AucklandAuckland, New Zealand; Cooper, G.J.S., The School of Biological Sciences, Faculty of Science, University of AucklandAuckland, New Zealand, The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of AucklandAuckland, New Zealand, Centre for Advanced Discovery and Experimental Therapeutics, NIHR Manchester Biomedical Research Centre, Central Manchester Univ. Hospitals NHS Foundation Trust, School of Biomedicine, Faculty of Medical and Human Sciences, University of ManchesterManchester, United Kingdom, Department of Pharmacology, Division of Medical Sciences, University of OxfordOxford, United Kingdom","Advanced glycation end-products (AGEs) comprise a group of non-enzymatic post-translational modifications of proteins and are elevated in diabetic tissues. AGE-modification impairs the digestibility of collagen in vitro but little is known about its relation to collagen-degrading proteinases in vivo. Nε-carboxymethyllysine (CML) is a stable AGE that forms on lysyl side-chains in the presence of glucose, probably via a transition metal-catalysed mechanism.Here, rats with streptozotocin-induced diabetes and non-diabetic controls were treated for 8. weeks with placebo or the Cu(II)-selective chelator, triethylenetetramine (TETA), commencing 8. weeks after disease induction. Actions of diabetes and drug treatment were measured on collagen and collagen-degrading proteinases in kidney tissue.The digestibility and CML content of collagen, and corresponding levels of mRNAs and collagen, were related to changes in collagen-degrading-proteinases. Collagen-degrading proteinases, cathepsin L (CTSL) and matrix metalloproteinase-2 (MMP-2) were increased in diabetic rats. CTSL-levels correlated strongly and positively with increased collagen-CML levels and inversely with decreased collagen digestibility in diabetes. The collagen-rich mesangium displayed a strong increase of CTSL in diabetes. TETA treatment normalised kidney collagen content and partially normalised levels of CML and CTSL.These data provide evidence for an adaptive proteinase response in diabetic kidneys, affected by excessive collagen-CML formation and decreased collagen digestibility. The normalisation of collagen and partial normalisation of CML- and CTSL-levels by TETA treatment supports the involvement of Cu(II) in CML formation and altered collagen metabolism in diabetic kidneys. Cu(II)-chelation by TETA may represent a treatment option to rectify collagen metabolism in diabetes independent of alterations in blood glucose levels. © 2015 Elsevier B.V.","Advanced glycation end-product; Autoxidative glycation; Cathepsin L; Collagen; Matrix metalloproteinase-2; Triethylenetetramine","Baynes, J.W., Thorpe, S.R., Role of oxidative stress in diabetic complications: a new perspective on an old paradigm (1999) Diabetes, 48, pp. 1-9; Wolff, S.P., Dean, R.T., Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes (1987) Biochem. J., 245, pp. 243-250; Thornalley, P.J., Battah, S., Ahmed, N., Karachalias, N., Agalou, S., Babaei-Jadidi, R., Dawnay, A., Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry (2003) Biochem. J., 375, pp. 581-592; Schnider, S.L., Kohn, R.R., Effects of age and diabetes mellitus on the solubility and nonenzymatic glucosylation of human skin collagen (1981) J. Clin. Invest., 67, pp. 1630-1635; Sell, D.R., Biemel, K.M., Reihl, O., Lederer, M.O., Strauch, C.M., Monnier, V.M., Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes (2005) J. Biol. Chem., 280, pp. 12310-12315; Ozdemir, A.M., Hopfer, U., Rosca, M.V., Fan, X.J., Monnier, V.M., Weiss, M.F., Effects of advanced glycation end product modification on proximal tubule epithelial cell processing of albumin (2008) Am. J. Nephrol., 28, pp. 14-24; Uchiki, T., Weikel, K.A., Jiao, W., Shang, F., Caceres, A., Pawlak, D., Handa, J.T., Taylor, A., Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics) (2012) Aging Cell, 11, pp. 1-13; Thornalley, P.J., Rabbani, N., Highlights and hotspots of protein glycation in end-stage renal disease (2009) Semin. Dial., 22, pp. 400-404; Everts, V., van der Zee, E., Creemers, L., Beertsen, W., Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling (1996) Histochem. J., 28, pp. 229-245; Creemers, L.B., Jansen, I.D., Docherty, A.J., Reynolds, J.J., Beertsen, W., Everts, V., Gelatinase A (MMP-2) and cysteine proteinases are essential for the degradation of collagen in soft connective tissue (1998) Matrix Biol., 17, pp. 35-46; Leber, R., Knecht, R., Hasslacher, C., Degradation of glomerular basement membrane in diabetes. II. Proteolytic activity of diabetic and nondiabetic glomeruli (1987) Res. Exp. Med. (Berl.), 187, pp. 347-352; Reckelhoff, J.F., Tygart, V.L., Mitias, M.M., Walcott, J.L., STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats (1993) Diabetes, 42, pp. 1425-1432; Peres, G.B., Juliano, M.A., Simões, M.J., Michelacci, Y.M., Lysosomal enzymes are decreased in the kidney of diabetic rats (2013) Biochim. Biophys. Acta Mol. Basis Dis., 1832, pp. 85-95; Olbricht, C.J., Geissinger, B., Renal hypertrophy in streptozotocin diabetic rats: role of proteolytic lysosomal enzymes (1992) Kidney Int., 41, pp. 966-972; Cooper, G.J.S., Phillips, A.R.J., Choong, S.Y., Leonard, B.L., Crossman, D.J., Brunton, D.H., Saafi, L., Baker, J.R., Regeneration of the heart in diabetes by selective copper chelation (2004) Diabetes, 53, pp. 2501-2508; Gong, D., Lu, J., Chen, X., Reddy, S., Crossman, D.J., Glyn-Jones, S., Choong, Y.S., Cooper, G.J.S., A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes (2008) Diabetologia, 51, pp. 1741-1751; Kilkenny, C., Browne, W.J., Cuthill, I.C., Emerson, M., Altman, D.G., Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research (2010) PLoS Biol., 8, p. e1000412; Neuhoff, V., Arold, N., Taube, D., Ehrhardt, W., Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250 (1988) Electrophoresis, 9, pp. 255-262; Choe, Y., Leonetti, F., Greenbaum, D.C., Lecaille, F., Bogyo, M., Bromme, D., Ellman, J.A., Craik, C.S., Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities (2006) J. Biol. Chem., 281, pp. 12824-12832; Avery, N.C., Bailey, A.J., An efficient method for the isolation of intramuscular collagen (1995) Meat Sci., 41, pp. 97-100; Bergman, I., Loxley, R., Two improved and simplified methods for the spectrophotometric determination of hydroxyproline (1963) Anal. Chem., 35, pp. 1961-1965; Woods, T.M., Kamalov, M., Harris, P.W.R., Cooper, G.J.S., Brimble, M.A., Synthesis of monolysyl advanced glycation endproducts and their incorporation into collagen model peptides (2012) Org. Lett., 14, pp. 5740-5743; Lloyd, C.M., Phillips, A.R., Cooper, G.J., Dunbar, P.R., Three-colour fluorescence immunohistochemistry reveals the diversity of cells staining for macrophage markers in murine spleen and liver (2008) J. Immunol. Methods, 334, pp. 70-81; Sun, Y., Yu, H., Zheng, D., Cao, Q., Wang, Y., Harris, D., Wang, Y., Sudan black B reduces autofluorescence in murine renal tissue (2011) Arch. Pathol. Lab. Med., 135, pp. 1335-1342; Chace, K.V., Carubelli, R., Nordquist, R.E., The role of nonenzymatic glycosylation, transition metals, and free radicals in the formation of collagen aggregates (1991) Arch. Biochem. Biophys., 288, pp. 473-480; Miller, E.J., Rhodes, R.K., Preparation and characterization of the different types of collagen (1982) Methods Enzymol., 82, pp. 33-64; Aimes, R.T., Quigley, J.P., Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments (1995) J. Biol. Chem., 270, pp. 5872-5876; Erickson, A., Isidoro, C., Mach, L., Mort, J., Cathepsins: getting in shape for lysosomal proteolysis (2013) Proteases: Structure and Function, pp. 127-173. , Springer, Vienna, K. Brix, W. Stöcker (Eds.); Mason, R.W., Wilcox, D., Wikstrom, P., Shaw, E.N., The identification of active forms of cysteine proteinases in Kirsten-virus-transformed mouse fibroblasts by use of a specific radiolabelled inhibitor (1989) Biochem. J., 257, pp. 125-129; Bohlender, J.M., Franke, S., Stein, G., Wolf, G., Advanced glycation end products and the kidney (2005) Am. J. Physiol. Renal Physiol., 289, pp. F645-F659; Knecht, R., Leber, R., Hasslacher, C., Degradation of glomerular basement membrane in diabetes. I. Susceptibility of diabetic and nondiabetic basement membrane to proteolytic degradation of isolated glomeruli (1987) Res. Exp. Med. (Berl.), 187, pp. 323-328; Sever, S., Altintas, M.M., Nankoe, S.R., Moller, C.C., Ko, D., Wei, C., Henderson, J., Reiser, J., Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease (2007) J. Clin. Invest., 117, pp. 2095-2104; Yaddanapudi, S., Altintas, M.M., Kistler, A.D., Fernandez, I., Moller, C.C., Wei, C., Peev, V., Reiser, J., CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival (2011) J. Clin. Invest., 121, pp. 3965-3980; Abboud-Jarrous, G., Atzmon, R., Peretz, T., Palermo, C., Gadea, B.B., Joyce, J.A., Vlodavsky, I., Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment (2008) J. Biol. Chem., 283, pp. 18167-18176; Huang, L., Haylor, J.L., Hau, Z., Jones, R.A., Vickers, M.E., Wagner, B., Griffin, M., Johnson, T.S., Transglutaminase inhibition ameliorates experimental diabetic nephropathy (2009) Kidney Int., 76, pp. 383-394; Forbes, J.M., Thallas, V., Thomas, M.C., Founds, H.W., Burns, W.C., Jerums, G., Cooper, M.E., The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes (2003) FASEB J., 17, pp. 1762-1764; Kamalov, M., Harris, P.W.R., Hartinger, C.G., Miskelly, G.M., Cooper, G.J.S., Brimble, M.A., Physicochemical studies on the copper(II) binding by glycated collagen telopeptides (2015) Org. Biomol. Chem., 13, pp. 3058-3063; Eaton, J.W., Qian, M., Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy (2002) Mol. Cell. Biochem., pp. 135-142; Saxena, A.K., Saxena, P., Wu, X., Obrenovich, M., Weiss, M.F., Monnier, V.M., Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress (1999) Biochem. Biophys. Res. Commun., 260, pp. 332-338; Laurent, G.J., Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass (1987) Am. J. Physiol., 252, pp. C1-C9; Verzijl, N., DeGroot, J., Thorpe, S.R., Bank, R.A., Shaw, J.N., Lyons, T.J., Bijlsma, J.W., TeKoppele, J.M., Effect of collagen turnover on the accumulation of advanced glycation end products (2000) J. Biol. Chem., 275, pp. 39027-39031; Sun, S.Z., Wang, Y., Li, Q., Tian, Y.J., Liu, M.H., Yu, Y.H., Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats (2006) Chin. Med. J., 119, pp. 814-821; Singh, R., Song, R.H., Alavi, N., Pegoraro, A.A., Singh, A.K., Leehey, D.J., High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1 (2001) Exp. Nephrol., 9, pp. 249-257; McLennan, S.V., Martell, S.Y., Yue, D.K., High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: possible role in mesangium accumulation (2000) Diabetologia, 43, pp. 642-648; Inada, A., Nagai, K., Arai, H., Miyazaki, J., Nomura, K., Kanamori, H., Toyokuni, S., Seino, Y., Establishment of a diabetic mouse model with progressive diabetic nephropathy (2005) Am. J. Pathol., 167, pp. 327-336; Chang, K., Uitto, J., Rowold, E.A., Grant, G.A., Kilo, C., Williamson, J.R., Increased collagen cross-linkages in experimental diabetes: reversal by beta-aminopropionitrile and d-penicillamine (1980) Diabetes, 29, pp. 778-781; Robins, S.P., Biochemistry and functional significance of collagen cross-linking (2007) Biochem. Soc. Trans., 35, pp. 849-852; Rucker, R.B., Kosonen, T., Clegg, M.S., Mitchell, A.E., Rucker, B.R., Uriu-Hare, J.Y., Keen, C.L., Copper, lysyl oxidase, and extracellular matrix protein cross-linking (1998) Am. J. Clin. Nutr., 67, pp. 996S-1002S; Genuth, S., Sun, W., Cleary, P., Gao, X., Sell, D.R., Lachin, J., Group, D.E.R., Monnier, V.M., Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes (2015) Diabetes, 64, pp. 266-278; Seifert, S.T., Krause, R., Gloe, K., Helne, T., Metal complexation by the peptide-bound Maillard reaction products N-ε-fructoselysine and N-ε-carboxymethyllysine (2004) J. Agric. Food Chem., 52, pp. 2347-2350; Ito, S., Fujita, H., Narita, T., Yaginuma, T., Kawarada, Y., Kawagoe, M., Sugiyama, T., Urinary copper excretion in type 2 diabetic patients with nephropathy (2001) Nephron, 88, pp. 307-312; Cooper, G.J.S., Selective divalent copper chelation for the treatment of diabetes mellitus (2012) Curr. Med. Chem., 19, pp. 2828-2860; Cooper, G.J.S., Chan, Y.K., Dissanayake, A.M., Leahy, F.E., Keogh, G.F., Frampton, C.M., Gamble, G.D., Poppitt, S.D., Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals (2005) Diabetes, 54, pp. 1468-1476; Hébert, C.D., Elwell, M.R., Travlos, G.S., Fitz, C.J., Bucher, J.R., Subchronic toxicity of cupric sulfate administered in drinking water and feed to rats and mice (1993) Fundam. Appl. Toxicol., 21, pp. 461-475; Cooper, G.J.S., Young, A.A., Gamble, G.D., Occleshaw, C.J., Dissanayake, A.M., Cowan, B.R., Brunton, D.H., Doughty, R.N., A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study (2009) Diabetologia, 52, pp. 715-722; Cooper, G.J.S., Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes and Alzheimer's disease (2011) Drugs, 71, pp. 1281-1320; Nurchi, V.M., Crisponi, G., Crespo-Alonso, M., Lachowicz, J.I., Cooper, G.J.S., Complex formation equilibria of Cu(II) and Zn(II) with triethylenetetramine and its mono- and di-acetyl metabolites (2013) J. Chem. Soc. Dalton Trans., 42, pp. 6161-6170; Siegemund, R., Lößner, J., Günther, K., Kühn, H.J., Bachmann, H., Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease (1991) Acta Neurol. Scand., 83, pp. 364-366; de Bie, P., Muller, P., Wijmenga, C., Klomp, L.W.J., Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes (2007) J. Med. Genet., 44, pp. 673-688",Article,Scopus,2-s2.0-84928958184
"Lim S., Oh P.C., Sakuma I., Koh K.K.","How to balance cardiorenometabolic benefits and risks of statins",2015,"Atherosclerosis","235","2",,"644","648",,1,10.1016/j.atherosclerosis.2014.06.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921534753&partnerID=40&md5=21d2e0ba9237b0c16a458efd60fa9285","Division of Endocrinology, Seoul National University Bundang Hospital, Seoul National University College of MedicineSeongnam, South Korea; Cardiology, Gachon University, Gil Medical CenterIncheon, South Korea; Gachon Cardiovascular Research InstituteIncheon, South Korea; Cardiovascular Medicine, Hokko Memorial ClinicSapporo, Japan","Lim, S., Division of Endocrinology, Seoul National University Bundang Hospital, Seoul National University College of MedicineSeongnam, South Korea; Oh, P.C., Cardiology, Gachon University, Gil Medical CenterIncheon, South Korea, Gachon Cardiovascular Research InstituteIncheon, South Korea; Sakuma, I., Cardiovascular Medicine, Hokko Memorial ClinicSapporo, Japan; Koh, K.K., Cardiology, Gachon University, Gil Medical CenterIncheon, South Korea, Gachon Cardiovascular Research InstituteIncheon, South Korea","Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are important for preventing adverse cardiovascular events not only in patients with a high risk of vascular disease but also in those with a low risk, by reducing the levels of low-density lipoprotein cholesterol. Statin is associated with deteriorating glucose homeostasis and an increased risk of diabetes mellitus. Moreover, these off-target effects are dose-dependent; it has also been suggested that renal insult can be caused dose-dependently by statin treatment, in contrast to previous studies showing a renoprotective effect. The 2013 American College of Cardiology/American Heart Association guidelines recommend the use of high-intensity statin therapy, and extend its use to more people at risk of vascular diseases. However, a European committee has expressed concerns about the potential side effects of using statins in a large fraction of the population for extended periods. This is true of Asian people, for whom the disease burden from cardiovascular disorders is not as great as among Western ethnic groups. There are still many unanswered questions on how to balance the cardiovascular benefits with the potential renometabolic risks of statins. Therefore, genetic or pharmacogenetic approaches are needed to define who is more vulnerable to developing diabetes mellitus or acute kidney injury. In particular, more information is required regarding the metabolism of statins, and their off-target or unknown actions and overall impact. These different renometabolic effects of statins should help in formulating optimal therapeutic strategies for patients for reducing overall morbidity and mortality and not just those associated with cardiovascular diseases. © 2014 Elsevier Ireland Ltd.","Benefits and risks; Cardiovascular disease; Diabetes; Renal injury; Statins","Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials (2010) Lancet, 376, pp. 1670-1681; Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S) (1994) Lancet, 344, pp. 1383-1389; Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial (2004) Lancet, 364, pp. 685-696; Ford, I., Murray, H., Packard, C.J., Shepherd, J., Macfarlane, P.W., Cobbe, S.M., Long-term follow-up of the west of scotland coronary prevention study (2007) NEngl J Med, 357, pp. 1477-1486; Koh, K.K., Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability (2000) Cardiovasc Res, 47, pp. 648-657; Koh, K.K., Effects of HMG-CoA reductase inhibitor on hemostasis (2000) Int J Cardiol, 76, pp. 23-32; Sparrow, C.P., Burton, C.A., Hernandez, M., Mundt, S., Hassing, H., Patel, S., Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering (2001) Arterioscler Thromb Vasc Biol, 21, pp. 115-121; Joo, S.J., Anti-inflammatory effects of statins beyond cholesterol lowering (2012) Korean Circ J, 42, pp. 592-594; Koh, K.K., Quon, M.J., Han, S.H., Chung, W.J., Ahn, J.Y., Seo, Y.H., Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients (2004) Circulation, 110, pp. 3687-3692; Koh, K.K., Han, S.H., Oh, P.C., Shin, E.K., Quon, M.J., Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction (2010) Atherosclerosis, 209, pp. 307-313; Tolman, K.G., The liver and lovastatin (2002) Am J Cardiol, 89, pp. 1374-1380; Ucar, M., Mjorndal, T., Dahlqvist, R., HMG-CoA reductase inhibitors and myotoxicity (2000) Drug Saf, 22, pp. 441-457; Goldstein, L.B., Amarenco, P., Szarek, M., Callahan, A., Hennerici, M., Sillesen, H., Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study (2008) Neurology, 70, pp. 2364-2370; Sheikh-Ali, A.A., Maddukuri, P.V., Han, H., Karas, R.H., Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials (2007) JAm Coll Cardiol, 50, pp. 409-418; Dale, K.M., Coleman, C.I., Henyan, N.N., Kluger, J., White, C.M., Statins and cancer risk: a meta-analysis (2006) JAMA, 295, pp. 74-80; Desai, P., Chlebowski, R., Cauley, J.A., Manson, J.E., Wu, C., Martin, L.W., Prospective analysis of association between statin use and breast cancer risk in the women's health initiative (2013) Cancer Epidemiol Biomarkers Prev, 22, pp. 1868-1876; Singh, P.P., Singh, S., Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis (2013) Ann Oncol, 24, pp. 1721-1730; Tsan, Y.T., Lee, C.H., Wang, J.D., Chen, P.C., Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection (2012) JClin Oncol, 30, pp. 623-630; Nielsen, S.F., Nordestgaard, B.G., Bojesen, S.E., Statin use and reduced cancer-related mortality (2012) NEngl J Med, 367, pp. 1792-1802; Lan, S., Bimal, R.S., Eric, M.R., Thomas, L., Wojdyla, D., Diem, P., Role of diuretics, beta-blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study (2013) BMJ, 347; Preiss, D., Seshasai, S.R., Welsh, P., Murphy, S.A., Ho, J.E., Waters, D.D., Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis (2011) JAMA, 305, pp. 2556-2564; Ridker, P.M., Pradhan, A., MacFadyen, J.G., Libby, P., Glynn, R.J., Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial (2012) Lancet, 380, pp. 565-571; Carter, A.A., Gomes, T., Camacho, X., Juurlink, D.N., Shah, B.R., Mamdani, M.M., Risk of incident diabetes among patients treated with statins: population based study (2013) BMJ, 346; Culver, A.L., Ockene, I.S., Balasubramanian, R., Olendzki, B.C., Sepavich, D.M., Wactawski-Wende, J., Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative (2012) Arch Intern Med, 172, pp. 144-152; Koh, K.K., Quon, M.J., Han, S.H., Lee, Y., Ahn, J.Y., Kim, S.J., Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulinsensitivity in hypercholesterolemic patients (2008) Diabetes Care, 31, pp. 776-782; Koh, K.K., Quon, M.J., Han, S.H., Lee, Y., Kim, S.J., Shin, E.K., Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients (2010) JAm Coll Cardiol, 55, pp. 1209-1216; Sattar, N., Preiss, D., Murray, H.M., Welsh, P., Buckley, B.M., de Craen, A.J., Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (2010) Lancet, 375, pp. 735-742; Waters, D.D., Ho, J.E., Boekholdt, S.M., DeMicco, D.A., Kastelein, J.J., Messig, M., Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes (2013) JAm Coll Cardiol, 61, pp. 148-152; Dormuth, C.R., Hemmelgarn, B.R., Paterson, J.M., James, M.T., Teare, G.F., Raymond, C.B., Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases (2013) BMJ, 346; Koh, K.K., Quon, M.J., Han, S.H., Lee, Y., Kim, S.J., Park, J.B., Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients (2009) Atherosclerosis, 204, pp. 483-490; Koh, K.K., Quon, M.J., Sakuma, I., Han, S.H., Choi, H., Lee, K., Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients (2013) Int J Cardiol, 166, pp. 509-515; Coleman, C.I., Reinhart, K., Kluger, J., White, C.M., The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials (2008) Curr Med Res Opin, 24, pp. 1359-1362; Yoon, J.S., Lee, H.W., Diabetogenic effect of statins: a double-edged sword? (2013) Diabetes Metab J, 37, pp. 415-422; Yada, T., Nakata, M., Shiraishi, T., Kakei, M., Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells (1999) Br J Pharmacol, 126, pp. 1205-1213; Liao, J.K., Isoprenoids as mediators of the biological effects of statins (2002) JClin Invest, 110, pp. 285-288; Chamberlain, L.H., Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes (2001) FEBS Lett, 507, pp. 357-361; Koh, K.K., Sakuma, I., Quon, M.J., Differential metabolic effects of distinct statins (2011) Atherosclerosis, 215, pp. 1-8; Kanda, M., Satoh, K., Ichihara, K., Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin (2003) Biol Pharm Bull, 26, pp. 1681-1684; Mallinson, J.E., Constantin-Teodosiu, D., Sidaway, J., Westwood, F.R., Greenhaff, P.L., Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy (2009) JPhysiol, 587, pp. 219-230; Nakata, M., Nagasaka, S., Kusaka, I., Matsuoka, H., Ishibashi, S., Yada, T., Effects ofstatins on the adipocyte maturation and expression of glucose transporter 4(SLC2A4): implications in glycaemic control (2006) Diabetologia, 49, pp. 1881-1892; Coritsidis, G., Rifici, V., Gupta, S., Rie, J., Shan, Z.H., Neugarten, J., Preferential binding of oxidized LDL to rat glomeruli invivo and cultured mesangial cells invitro (1991) Kidney Int, 39, pp. 858-866; Kramer-Guth, A., Nauck, M., Pavenstädt, H., Königer, M., Wieland, H., Schollmeyer, P., Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells (1994) JAm Soc Nephrol, 5, pp. 1081-1090; Rovin, B.H., Tan, L.C., LDL stimulates mesangial fibronectin production and chemoattractant expression (1993) Kidney Int, 43, pp. 218-225; Kim, S.I., Kim, H.J., Han, D.C., Lee, H.B., Effect of lovastatin on small GTP binding proteins and on TGF-beta1 and fibronectin expression (2000) Kidney Int Suppl, 77, pp. S88-S92; Rikitake, Y., Liao, J.K., Rho GTPases, statins, and nitric oxide (2005) Circ Res, 97, pp. 1232-1235; Collins, R., Armitage, J., Parish, S., Sleigh, P., Peto, R., MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial (2003) Lancet, 361, pp. 2005-2016; Tonelli, M., Moye, L., Sacks, F.M., Cole, T., Curhan, G.C., Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease (2003) JAm Soc Nephrol, 14, pp. 1605-1613; Athyros, V.G., Mikhailidis, D.P., Papageorgiou, A.A., Symeonidis, A.N., Pehlivanidis, A.N., Bouloukos, V.I., The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study (2004) JClin Pathol, 57, pp. 728-734; Kuwabara, M., Kubo, T., Bando, K., Hirakawa, Y., Kitaoka, H., Nishinaga, M., 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the progression of renal dysfunction in Japanese hypertensive patients (2010) Geriatr Gerontol Int, 10, pp. 219-224; Wolfe, S.M., Dangers of rosuvastatin identified before and after FDA approval (2004) Lancet, 363, pp. 2189-2190; Kiortsis, D.N., Filippatos, T.D., Mikhailidis, D.P., Elisaf, M.S., Liberopoulos, E.N., Statin-associated adverse effects beyond muscle and liver toxicity (2007) Atherosclerosis, 195, pp. 7-16; Hippisley-Cox, J., Coupland, C., Unintended effects of statins in men and women in England and wales: population based cohort study using the QResearch database (2010) BMJ, 340; McMurray, J.J., Dunselman, P., Wedel, H., Cleland, J.G., Lindberg, M., Hjalmarson, A., Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure) (2010) JAm Coll Cardiol, 56, pp. 1196-1204; Marcoff, L., Thompson, P.D., The role of coenzyme Q10 in statin-associated myopathy: a systematic review (2007) JAm Coll Cardiol, 49, pp. 2231-2237; Sourris, K.C., Harcourt, B.E., Tang, P.H., Morley, A.L., Huynh, K., Penfold, S.A., Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes (2012) Free Radic Biol Med, 52, pp. 716-723; Peerapanyasut, W., Thamprasert, K., Wongmekiat, O., Ubiquinol supplementation protects against renal ischemia and reperfusion injury in rats (2014) Free Radic Res, 48, pp. 180-189; Sheikh-Ali, A.A., Ambrose, M.S., Kuvin, J.T., Karas, R.H., The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis (2005) Circulation, 111, pp. 3051-3057; Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E.H., The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials (2012) Lancet, 380, pp. 581-590; Catapano, A.L., Reiner, Z., De Backer, G., Graham, I., Taskinen, M.R., Wiklund, O., ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) Atherosclerosis, 217, pp. 1-44; Stone, N.J., Robinson, J., Lichtenstein, A.H., Bairey Merz, C.N., Lloyd-Jones, D.M., Blum, C.B., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (2013) Circulation, , [Epub a head of print]; Koh, K.K., Quon, M.J., The importance of considering alternative or combination strategies for lowering LDL-C (2009) Int J Cardiol, 136, pp. 115-119; Koh, K.K., Quon, M.J., Targeting converging therapeutic pathways to overcome hypertension (2009) Int J Cardiol, 132, pp. 297-299; Koh, K.K., Lim, S., Sakuma, I., Quon, M.J., Caveats to aggressive lowering of lipids by specific statins (2012) Int J Cardiol, 154, pp. 97-101; Lim, S., Sakuma, I., Quon, M.J., Koh, K.K., Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality (2013) Int J Cardiol, 167, pp. 1696-1702; Lim, S., Sakuma, I., Quon, M.J., Koh, K.K., Differential metabolic actions of specific statins: clinical and therapeutic considerations (2013) Antioxid Redox Signal, 20, pp. 1286-1299; Lim, S., Park, Y.M., Sakuma, I., Koh, K.K., How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol (2012) Int J Cardiol, 166, pp. 8-14; Lee, B.S., Choi, J.Y., Kim, J.Y., Han, S.H., Park, J.E., Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein E-/- mice (2012) Korean Circ J, 42, pp. 543-550; Lee, H.Y., Sakuma, I., Ihm, S.H., Goh, C.W., Koh, K.K., Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease (2014) Circ J, 78, pp. 281-287; Goldstein, M.R., Mascitelli, L., Do statins cause diabetes? (2013) Curr Diab Rep, 13, pp. 381-390; Huseyin, N., John, P.A.I., Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study (2013) BMJ, 347",Review,Scopus,2-s2.0-84921534753
"Fadini G.P., Iori E., Marescotti M.C., Vigili de Kreutzenberg S., Avogaro A.","Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in type 2 diabetic patients",2015,"Atherosclerosis","235","2",,"415","417",,,10.1016/j.atherosclerosis.2014.05.942,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921526044&partnerID=40&md5=a2794277d6ce51bbe60ea2c931660e62","Department of Medicine, University of PadovaPadova, Italy; Venetian Institute of Molecular MedicinePadova, Italy","Fadini, G.P., Department of Medicine, University of PadovaPadova, Italy, Venetian Institute of Molecular MedicinePadova, Italy; Iori, E., Department of Medicine, University of PadovaPadova, Italy; Marescotti, M.C., Department of Medicine, University of PadovaPadova, Italy; Vigili de Kreutzenberg, S., Department of Medicine, University of PadovaPadova, Italy; Avogaro, A., Department of Medicine, University of PadovaPadova, Italy, Venetian Institute of Molecular MedicinePadova, Italy","Type 2 diabetes (T2D) is characterized by low HDL cholesterol (HDL-C) and HDL dysfunction. We herein tested whether lowering HbA1c affects HDL-C and reverse cholesterol transport (RCT). Forty-two uncontrolled T2D patients initiating basal insulin were included. HbA1c, HDL-C and RCT were assessed at baseline and after 6 months. At baseline, HDL-C and RCT were directly correlated (r=0.50; p<0.001). After 6 months of insulin therapy, HbA1c dropped from 8.8±0.16% to 7.1±0.1%, while average HDL-C and RCT did not change. Follow-up HDL-C and RCT were still correlated (r=0.31; p=0.033) and δHDL-C correlated with δRCT (r=0.32; p=0.029). δHbA1c correlated with δHDL-C (r=0.43, p=0.001), but not with δRCT. In patients with δHbA1c above the median value (1.3%), HDL-C (but not RCT) increased significantly. In conclusion, glucose control correlates with increased HDL-C, but not with improved RCT. Thus, persistent HDL dysfunction despite improved HbA1c and HDL-C can contribute to residual cardiovascular risk in T2D. © 2014 Elsevier Ireland Ltd.","Atherosclerosis; Cardiovascular risk; Cholesterol; Diabetes; HDL","Seshasai, S.R., Kaptoge, S., Thompson, A., Diabetes mellitus, fasting glucose, and risk of cause-specific death (2011) NEngl J Med, 364, pp. 829-841; Avogaro, A., de Kreutzenberg, S.V., Fadini, G.P., Endothelial dysfunction: causes and consequences in patients with diabetes mellitus (2008) Diabetes Res Clin Pract, pp. S94-S101; Avogaro, A., Albiero, M., Menegazzo, L., de Kreutzenberg, S., Fadini, G.P., Endothelial dysfunction in diabetes: the role of reparatory mechanisms (2011) Diabetes Care, 2 (34 Suppl), pp. S285-S290; Schaper, N.C., Havekes, B., Diabetes: impaired damage control (2012) Diabetologia, 55, pp. 18-20; Fadini, G.P., de Kreutzenberg, S.V., Boscaro, E., An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy (2013) Diabetologia, 56, pp. 1856-1866; Fadini, G.P., Areappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications, (2014) Diabetologia, 57, pp. 4-15; Besler, C., Luscher, T.F., Landmesser, U., Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease (2012) EMBO Mol Med, 4, pp. 251-268; Farbstein, D., Levy, A.P., HDL dysfunction in diabetes: causes and possible treatments (2012) Expert Rev Cardiovasc Ther, 10, pp. 353-361; Luscher, T.F., Landmesser, U., von Eckardstein, A., Fogelman, A.M., High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target (2014) Circ Res, 114, pp. 171-182; Fadini, G.P., de Kreutzenberg, S.V., Mariano, V., Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine (2011) Diabetes Obes Metab, 13, pp. 718-725; Khera, A.V., Cuchel, M., de la Llera-Moya, M., Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis (2011) NEngl J Med, 364, pp. 127-135",Article,Scopus,2-s2.0-84921526044
"Li W., Maloney R.E., Aw T.Y.","High glucose, glucose fluctuation and carbonyl stress enhance brain microvascular endothelial barrier dysfunction: Implications for diabetic cerebral microvasculature",2015,"Redox Biology","5",,,"80","90",,,10.1016/j.redox.2015.03.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926464959&partnerID=40&md5=2ff33391615e76097467e032a9be1e22","Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences CenterShreveport, LA, United States; Center for Cardiovascular Disease and Sciences, Louisiana State University Health Sciences CenterShreveport, LA, United States; DepartmentofGeriatrics,UnionHospital, TongiMedical College, Huazhong University of Science and oTechnologyWuhan, China","Li, W., Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences CenterShreveport, LA, United States, DepartmentofGeriatrics,UnionHospital, TongiMedical College, Huazhong University of Science and oTechnologyWuhan, China; Maloney, R.E., Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences CenterShreveport, LA, United States; Aw, T.Y., Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences CenterShreveport, LA, United States, Center for Cardiovascular Disease and Sciences, Louisiana State University Health Sciences CenterShreveport, LA, United States","We previously demonstrated that in normal glucose (5 mM), methylglyoxal (MG, a model of carbonyl stress) induced brain microvascular endothelial cell (IHEC) dysfunction that was associated with occludin glycation and prevented by N-acetylcysteine (NAC). Herein, we investigated the impact of high glucose and low GSH, conditions that mimicked the diabetic state, on MG-induced IHEC dysfunction. MG-induced loss of transendothelial electrical resistance (TEER) was potentiated in IHECs cultured for 7 or 12days in 25. mM glucose (hyperglycemia); moreover, barrier function remained disrupted 6. h after cell transfer to normal glucose media (acute glycemic fluctuation). Notably, basal occludin glycation was elevated under these glycemic states. TEER loss was exaggerated by inhibition of glutathione (GSH) synthesis and abrogated by NAC, which corresponded to GSH decreases and increases, respectively. Significantly, glyoxalase II activity was attenuated in hyperglycemic cells. Moreover, hyperglycemia and GSH inhibition increased MG accumulation, consistent with a compromised capacity for MG elimination. α-Oxoaldehydes (MG plus glyoxal) levels were elevated in streptozotocin-induced diabetic rat plasma. Immunohistochemistry revealed a prevalence of MG-positive, but fewer occludin-positive microvessels in the diabetic brain in vivo, and Western analysis confirmed an increase in MG-occludin adducts. These results provide the first evidence that hyperglycemia and acute glucose fluctuation promote MG-occludin formation and exacerbate brain microvascular endothelial dysfunction. Low occludin expression and high glycated-occludin contents in diabetic brain in vivo are factors that would contribute to the dysfunction of the cerebral microvasculature during diabetes. © 2015 The Authors.","Carbonyl stress & endothelial GSH; Diabetic brain microvascular dysfunction; Hyperglycemia & methylglyoxal; N-acetylcysteine & endothelial barrier function; Occludin glycation & brain endothelial barrier function; Streptozotocin & diabetes","Li, W., Maloney, R.E., Circu, M.L., Alexander, J.S., Aw, T.Y., Acute carbonyl stress induces occludin glycation and brain microvascular endothelial barrier dysfunction: role for glutathione-dependent metabolism of methylglyoxal (2013) Free Radical Biology and Medicine, 54, pp. 51-61. , http://www.ncbi.nlm.nih.gov/pubmed/23108103; Huber, J.D., VanGilder, R.L., Houser, K.A., Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats (2006) American Journal of Physiology-Heart and Circulatory Physiology, 291 (6), pp. H2660-H2668. , http://www.ncbi.nlm.nih.gov/pubmed/16951046; Bechmann, I., Galea, I., Perry, V.H., What is the blood-brain barrier (not)? (2007) Trends in Immunology, 28 (1), pp. 5-11. , http://www.ncbi.nlm.nih.gov/pubmed/17140851; Shusta, E.V., Blood-brain barrier (2005) Endothelial Cells in Health and Disease, pp. 33-63. , Taylor and Francis, New York, W.C. Aird (Ed.); Romero, I.A., Radewicz, K., Jubin, E., Michel, C.C., Greenwood, J., Couraud, P.O., Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells (2003) Neuroscience Letters, 344 (2), pp. 112-116. , http://www.ncbi.nlm.nih.gov/pubmed/12782340; Agarwal, R., Shukla, G.S., Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat (1999) Neurochemical Research, 24 (12), pp. 1507-1514. , http://www.ncbi.nlm.nih.gov/pubmed/10591399; Ulusu, N.N., Sahilli, M., Avci, A., Canbolat, O., Ozansoy, G., Ari, N., Pentose phosphate pathway, glutathione-dependent enzymes and antioxidant defense during oxidative stress in diabetic rodent brain and peripheral organs: effects of stobadine and vitamin E (2003) Neurochemical Research, 28 (6), pp. 815-823. , http://www.ncbi.nlm.nih.gov/pubmed/12718433; Okouchi, M., Okayama, N., Alexander, J.S., Aw, T.Y., NRF2-dependent glutamate-l-cysteine ligase catalytic subunit expression mediates insulin protection against hyperglycemia-induced brain endothelial cell apoptosis (2006) Current Neurovascular Research, 3 (4), pp. 249-261. , http://www.ncbi.nlm.nih.gov/pubmed/17109620; Okouchi, M., Okayama, N., Aw, T.Y., Preservation of cellular glutathione status and mitochondrial membrane potential by N-acetylcysteine and insulin sensitizers prevent carbonyl stress-induced human brain endothelial cell apoptosis (2009) Current Neurovascular Research, 6 (4), pp. 267-278. , http://www.ncbi.nlm.nih.gov/pubmed/19807652; Thornalley, P.J., Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems -role in ageing and disease (2008) Drug Metabolism and Drug Interactions, 23 (1-2), pp. 125-150. , http://www.ncbi.nlm.nih.gov/pubmed/18533367; Thornalley, P.J., Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors (1998) Chemico-Biological Interactions, pp. 137-151. , http://www.ncbi.nlm.nih.gov/pubmed/9679550; Stitt, A.W., Jenkins, A.J., Cooper, M.E., Advanced glycation end products and diabetic complications (2002) Expert Opinion on Investigational Drugs, 11 (9), pp. 1205-1223. , http://www.ncbi.nlm.nih.gov/pubmed/12225243; Li, W., Prakash, R., Kelly-Cobbs, A.I., Ogbi, S., Kozak, A., El-Remessy, A.B., Schreihofer, D.A., Ergul, A., Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia (2010) Diabetes, 59 (1), pp. 228-235. , http://www.ncbi.nlm.nih.gov/pubmed/19808897; Reed, D.J., Babson, J.R., Beatty, P.W., Brodie, A.E., Ellis, W.W., Potter, D.W., High-performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide, and related thiols and disulfides (1980) Analytical Biochemistry, 106 (1), pp. 55-62. , http://www.ncbi.nlm.nih.gov/pubmed/7416469; Dhar, A., Desai, K., Liu, J., Wu, L., Methylglyoxal, protein binding and biological samples: are we getting the true measure? (2009) Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 877 (11-12), pp. 1093-1100. , http://www.ncbi.nlm.nih.gov/pubmed/19299210; Shinohara, M., Thornalley, P.J., Giardino, I., Beisswenger, P., Thorpe, S.R., Onorato, J., Brownlee, M., Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis (1998) Journal of Clinical Investigation, 101 (5), pp. 1142-1147. , http://www.ncbi.nlm.nih.gov/pubmed/9486985; Talesa, V., Uotila, L., Koivusalo, M., Principato, G., Giovannini, E., Rosi, G., Demonstration of glyoxalase II in rat liver mitochondria. Partial purification and occurrence in multiple forms (1988) Biochimica et Biophysica Acta, 955 (1), pp. 103-110. , http://www.ncbi.nlm.nih.gov/pubmed/3382669; Hawkins, B.T., Lundeen, T.F., Norwood, K.M., Brooks, H.L., Egleton, R.D., Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases (2007) Diabetologia, 50 (1), pp. 202-211. , http://www.ncbi.nlm.nih.gov/pubmed/17143608; Okouchi, M., Okayama, N., Aw, T.Y., Hyperglycemia potentiates carbonyl stress-induced apoptosis in naïve PC-12 cells: relationship to cellular redox and activator protease factor-1 expression (2005) Current Neurovascular Research, 2 (5), pp. 375-386. , http://www.ncbi.nlm.nih.gov/pubmed/16375719; Hsieh, M.S., Chan, W.H., Impact of methylglyoxal and high glucose co-treatment on human mononuclear cells (2009) International Journal of Molecular Sciences, 10 (4), pp. 1445-1464. , http://www.ncbi.nlm.nih.gov/pubmed/19468318; Chan, W.H., Wu, H.J., Methylglyoxal and high glucose co-treatment induces apoptosis or necrosis in human umbilical vein endothelial cells (2008) Journal of Cellular Biochemistry, 103 (4), pp. 1144-1157. , http://www.ncbi.nlm.nih.gov/pubmed/17721990; Hawkins, B.T., Davis, T.P., The blood-brain barrier/neurovascular unit in health and disease (2005) Pharmacological Reviews, 57 (2), pp. 173-185. , http://www.ncbi.nlm.nih.gov/pubmed/15914466; Chen, Y., Lu, Q., Schneeberger, E.E., Goodenough, D.A., Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells (2000) Molecular Biology of the Cell, 11 (3), pp. 849-862. , http://www.ncbi.nlm.nih.gov/pubmed/10712504; Li, W., Prakash, R., Kelly-Cobbs, A.I., Ogbi, S., Kozak, A., El-Remessy, A.B., Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia (2010) Diabetes, 59 (1), pp. 228-235. , http://www.ncbi.nlm.nih.gov/pubmed/19808897; Antonetti, D.A., Barber, A.J., Khin, S., Lieth, E., Tarbell, J.M., Gardner, T.W., Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group (1998) Diabetes, 47 (12), pp. 1953-1959. , http://www.ncbi.nlm.nih.gov/pubmed/9836530; Barber, A.J., Antonetti, D.A., Gardner, T.W., Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group (2000) Investigative Ophthalmology & Visual Science, 41 (11), pp. 3561-3568. , http://www.ncbi.nlm.nih.gov/pubmed/11006253; Bennett, J., Basivireddy, J., Kollar, A., Biron, K.E., Reickmann, P., Jefferies, W.A., McQuaid, S., Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE (2010) Journal of Neuroimmunology, 229 (1-2), pp. 180-191. , http://www.ncbi.nlm.nih.gov/pubmed/20832870; Kanmogne, G.D., Primeaux, C., Grammas, P., HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia (2005) Journal of Neuropathology & Experimental Neurology, 64 (6), pp. 498-505. , http://www.ncbi.nlm.nih.gov/pubmed/15977641; Biron, K.E., Dickstein, D.L., Gopaul, R., Jefferies, W.A., Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease (2011) PLOS One, 6 (8), p. e23789. , http://www.ncbi.nlm.nih.gov/pubmed/21909359; Chen, X., Lan, X., Roche, I., Liu, R., Geiger, J.D., Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum (2008) Journal of Neurochemistry, 107 (4), pp. 1147-1157. , http://www.ncbi.nlm.nih.gov/pubmed/18808450; Rigau, V., Morin, M., Rousset, M.C., de Bock, F., Lebrun, A., Coubes, P., Picot, M.C., Lerner-Natoli, M., Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy (2007) Brain, 130 (7), pp. 1942-1956. , http://www.ncbi.nlm.nih.gov/pubmed/17533168; Fukumoto, K., Takagi, N., Yamamoto, R., Moriyama, Y., Takeo, S., Tanonaka, K., Prostanoid EP1 receptor antagonist reduces blood-brain barrier leakage after cerebral ischemia (2010) European Journal of Pharmacology, 640 (1-3), pp. 82-86. , http://www.ncbi.nlm.nih.gov/pubmed/20470769; Rosenberg, G.A., Estrada, E.Y., Dencoff, J.E., Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain (1998) Stroke, 29 (10), pp. 2189-2195. , http://www.ncbi.nlm.nih.gov/pubmed/9756602; Yang, Y., Estrada, E.Y., Thompson, J.F., Liu, W., Rosenberg, G.A., Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat (2007) Journal of Cerebral Blood Flow & Metabolism, 27 (4), pp. 697-709. , http://www.ncbi.nlm.nih.gov/pubmed/16850029; Jin, R., Song, Z., Yu, S., Piazza, A., Nanda, A., Penninger, J.M., Granger, D.N., Li, G., Phosphatidylinositol-3-kinase gamma plays a central role in blood-brain barrier dysfunction in acute experimental stroke (2011) Stroke, 42 (7), pp. 2033-2044. , http://www.ncbi.nlm.nih.gov/pubmed/21546487; Murakami, T., Felinski, E.A., Antonetti, D.A., Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability (2009) Journal of Biological Chemistry, 284 (31), pp. 21036-21046. , http://www.ncbi.nlm.nih.gov/pubmed/19478092; Zeng, J., Davies, M.J., Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins (2005) Chemical Research in Toxicology, 18 (8), pp. 1232-1241. , http://www.ncbi.nlm.nih.gov/pubmed/16097796; Rabbani, N., Thornalley, P.J., Glyoxalase in diabetes, obesity and related disorders (2011) Seminars in Cell and Developmental Biology, 22 (3), pp. 309-317. , http://www.ncbi.nlm.nih.gov/pubmed/21335095; Thornalley, P.J., Glyoxalase I -structure, function and a critical role in the enzymatic defence against glycation (2003) Biochemical Society Transactions, 31 (6), pp. 1343-1348. , http://www.ncbi.nlm.nih.gov/pubmed/14641060; Koc, B., Erten, V., Yilmaz, M.I., Sonmez, A., Kocar, I.H., The relationship between red blood cell Na/K-ATPase activities and diabetic complications in patients with type 2 diabetes mellitus (2003) Endocrine, 21 (3), pp. 273-278. , http://www.ncbi.nlm.nih.gov/pubmed/14515013; Turk, Z., Nemet, I., Varga-Defteardarović, L., Car, N., Elevated level of methylglyoxal during diabetic ketoacidosis and its recovery phase (2006) Diabetes & Metabolism, 32 (2), pp. 176-180. , http://www.ncbi.nlm.nih.gov/pubmed/16735968",Article,Scopus,2-s2.0-84926464959
"Smani T., Shapovalov G., Skryma R., Prevarskaya N., Rosado J.A.","Functional and physiopathological implications of TRP channels",2015,"Biochimica et Biophysica Acta - Molecular Cell Research","1853","8",,"1772","1782",,,10.1016/j.bbamcr.2015.04.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928911195&partnerID=40&md5=439b5c2e0365999cfdf52bfa587beb72","Department of Medical Physiology and Biophysic, Institute of Biomedicine of SevillaSevilla, Spain; Inserm U1003, Equipe Labellisee par la Ligue Nationale Contre le Cancer; Lab. of Excellence Ion Channel Science, Therapeutics; Universite de Lille 1, Sciences et TechnologiesVilleneuve d'Ascq, France; Department of Physiology (Cell Physiology Research Group), University of ExtremaduraCáceres, Spain","Smani, T., Department of Medical Physiology and Biophysic, Institute of Biomedicine of SevillaSevilla, Spain; Shapovalov, G., Inserm U1003, Equipe Labellisee par la Ligue Nationale Contre le Cancer; Lab. of Excellence Ion Channel Science, Therapeutics; Universite de Lille 1, Sciences et TechnologiesVilleneuve d'Ascq, France; Skryma, R., Inserm U1003, Equipe Labellisee par la Ligue Nationale Contre le Cancer; Lab. of Excellence Ion Channel Science, Therapeutics; Universite de Lille 1, Sciences et TechnologiesVilleneuve d'Ascq, France; Prevarskaya, N., Inserm U1003, Equipe Labellisee par la Ligue Nationale Contre le Cancer; Lab. of Excellence Ion Channel Science, Therapeutics; Universite de Lille 1, Sciences et TechnologiesVilleneuve d'Ascq, France; Rosado, J.A., Department of Physiology (Cell Physiology Research Group), University of ExtremaduraCáceres, Spain","Transient Receptor Potential (TRP) channel proteins are a diverse family of proteins that are expressed in many organisms, tissues and cell types. TRP channels respond to a variety of stimuli, including light, mechanical or chemical stimuli, temperature, pH or osmolarity. In addition, several TRP family members have been identified as downstream molecules in the G protein-coupled receptor signaling pathway. TRP proteins are involved in a variety of cell functions both in non-excitable and excitable cells due to their diverse permeability to cations and their ability to modulate intracellular Ca2+ signaling. Emerging evidence suggests that TRP channel dysfunction significantly contributes to the physiopathology of a number of diseases, including cardiovascular, neurological, metabolic or neoplastic disorders. This review focuses on the implication of TRP proteins in the pathogenesis of some of the most prevalent disorders in human. We summarize the current findings regarding the role of TRP proteins in the development of cardiovascular disease, diabetes mellitus as well as diabetic complications, and tumorigenesis and present TRP proteins as targets of potential diagnostic and therapeutic strategies. © 2015 Elsevier B.V.","Cancer cells; Cardiovascular disorders; Diabetes mellitus; TRP channels; Tumorigenesis","Montell, C., Rubin, G.M., Molecular characterization of the Drosophila trp locus: a putative integral membrane protein required for phototransduction (1989) Neuron, 2, pp. 1313-1323; Hardie, R.C., Minke, B., The trp gene is essential for a light-activated Ca2+ channel in Drosophila photoreceptors (1992) Neuron, 8, pp. 643-651; Montell, C., Physiology, phylogeny, and functions of the TRP superfamily of cation channels (2001) Sci. STKE, 2001, p. re1; Moiseenkova-Bell, V., Wensel, T.G., Functional and structural studies of TRP channels heterologously expressed in budding yeast (2011) Adv. Exp. Med. Biol., 704, pp. 25-40; Harteneck, C., Klose, C., Krautwurst, D., Synthetic modulators of TRP channel activity (2011) Adv. Exp. Med. Biol., 704, pp. 87-106; Salido, G.M., Sage, S.O., Rosado, J.A., TRPC channels and store-operated Ca2+ entry (2009) Biochim. Biophys. Acta, 1793, pp. 223-230; Clapham, D.E., TRP channels as cellular sensors (2003) Nature, 426, pp. 517-524; Nilius, B., Owsianik, G., Voets, T., Peters, J.A., Transient receptor potential cation channels in disease (2007) Physiol. Rev., 87, pp. 165-217; Nilius, B., Szallasi, A., Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine (2014) Pharmacol. Rev., 66, pp. 676-814; Yue, Z., Xie, J., Yu, A.S., Stock, J., Du, J., Yue, L., Role of TRP channels in the cardiovascular system (2015) Am. J. Physiol. Heart Circ. Physiol., 308, pp. H157-H182; Beech, D.J., Characteristics of transient receptor potential canonical calcium-permeable channels and their relevance to vascular physiology and disease (2013) Circ. J., 77, pp. 570-579; Gonzalez-Cobos, J.C., Trebak, M., TRPC channels in smooth muscle cells (2010) Front. Biosci. (Landmark Ed.), 15, pp. 1023-1039; Vennekens, R., Emerging concepts for the role of TRP channels in the cardiovascular system (2011) J. Physiol., 589, pp. 1527-1534; Bergdahl, A., Gomez, M.F., Dreja, K., Xu, S.Z., Adner, M., Beech, D.J., Broman, J., Sward, K., Cholesterol depletion impairs vascular reactivity to endothelin-1 by reducing store-operated Ca2+ entry dependent on TRPC1 (2003) Circ. Res., 93, pp. 839-847; Kunichika, N., Yu, Y., Remillard, C.V., Platoshyn, O., Zhang, S., Yuan, J.X., Overexpression of TRPC1 enhances pulmonary vasoconstriction induced by capacitative Ca2+ entry (2004) Am. J. Physiol. Lung Cell. Mol. Physiol., 287, pp. L962-L969; Dietrich, A., Kalwa, H., Gudermann, T., TRPC channels in vascular cell function (2010) Thromb. Haemost., 103, pp. 262-270; Dietrich, A., Kalwa, H., Storch, U., Mederos y Schnitzler, M., Salanova, B., Pinkenburg, O., Dubrovska, G., Gudermann, T., Pressure-induced and store-operated cation influx in vascular smooth muscle cells is independent of TRPC1 (2007) Pflugers Arch., 455, pp. 465-477; Saleh, S.N., Albert, A.P., Peppiatt, C.M., Large, W.A., Angiotensin II activates two cation conductances with distinct TRPC1 and TRPC6 channel properties in rabbit mesenteric artery myocytes (2006) J. Physiol., 577, pp. 479-495; Peppiatt-Wildman, C.M., Albert, A.P., Saleh, S.N., Large, W.A., Endothelin-1 activates a Ca2+-permeable cation channel with TRPC3 and TRPC7 properties in rabbit coronary artery myocytes (2007) J. Physiol., 580, pp. 755-764; Inoue, R., Okada, T., Onoue, H., Hara, Y., Shimizu, S., Naitoh, S., Ito, Y., Mori, Y., The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel (2001) Circ. Res., 88, pp. 325-332; Jung, S., Strotmann, R., Schultz, G., Plant, T.D., TRPC6 is a candidate channel involved in receptor-stimulated cation currents in A7r5 smooth muscle cells (2002) Am. J. Physiol. Cell Physiol., 282, pp. C347-C359; Weissmann, N., Dietrich, A., Fuchs, B., Kalwa, H., Ay, M., Dumitrascu, R., Olschewski, A., Gudermann, T., Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange (2006) Proc. Natl. Acad. Sci. U. S. A., 103, pp. 19093-19098; Sel, S., Rost, B.R., Yildirim, A.O., Sel, B., Kalwa, H., Fehrenbach, H., Renz, H., Dietrich, A., Loss of classical transient receptor potential 6 channel reduces allergic airway response (2008) Clin. Exp. Allergy, 38, pp. 1548-1558; Dietrich, A., Mederos, Y.S.M., Gollasch, M., Gross, V., Storch, U., Dubrovska, G., Obst, M., Birnbaumer, L., Increased vascular smooth muscle contractility in TRPC6-/- mice (2005) Mol. Cell. Biol., 25, pp. 6980-6989; Inoue, R., Jian, Z., Kawarabayashi, Y., Mechanosensitive TRP channels in cardiovascular pathophysiology (2009) Pharmacol. Ther., 123, pp. 371-385; Earley, S., TRPA1 channels in the vasculature (2012) Br. J. Pharmacol., 167, pp. 13-22; Welsh, D.G., Morielli, A.D., Nelson, M.T., Brayden, J.E., Transient receptor potential channels regulate myogenic tone of resistance arteries (2002) Circ. Res., 90, pp. 248-250; Mathar, I., Vennekens, R., Meissner, M., Kees, F., Van der Mieren, G., Camacho Londono, J.E., Uhl, S., Freichel, M., Increased catecholamine secretion contributes to hypertension in TRPM4-deficient mice (2010) J. Clin. Invest., 120, pp. 3267-3279; Sharif-Naeini, R., Folgering, J.H., Bichet, D., Duprat, F., Lauritzen, I., Arhatte, M., Jodar, M., Honore, E., Polycystin-1 and -2 dosage regulates pressure sensing (2009) Cell, 139, pp. 587-596; Wamhoff, B.R., Bowles, D.K., Owens, G.K., Excitation-transcription coupling in arterial smooth muscle (2006) Circ. Res., 98, pp. 868-878; Rodriguez-Moyano, M., Diaz, I., Dionisio, N., Zhang, X., Avila-Medina, J., Calderon-Sanchez, E., Trebak, M., Smani, T., Urotensin-II promotes vascular smooth muscle cell proliferation through store operated calcium entry and EGFR transactivation (2013) Cardiovasc. Res., 100, pp. 297-306; Kumar, B., Dreja, K., Shah, S.S., Cheong, A., Xu, S.Z., Sukumar, P., Naylor, J., Beech, D.J., Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia (2006) Circ. Res., 98, pp. 557-563; Takahashi, Y., Watanabe, H., Murakami, M., Ohba, T., Radovanovic, M., Ono, K., Iijima, T., Ito, H., Involvement of transient receptor potential canonical 1 (TRPC1) in angiotensin II-induced vascular smooth muscle cell hypertrophy (2007) Atherosclerosis, 195, pp. 287-296; Berra-Romani, R., Mazzocco-Spezzia, A., Pulina, M.V., Golovina, V.A., Ca2+ handling is altered when arterial myocytes progress from a contractile to a proliferative phenotype in culture (2008) Am. J. Physiol. Cell Physiol., 295, pp. C779-C790; Yu, Y., Keller, S.H., Remillard, C.V., Safrina, O., Nicholson, A., Zhang, S.L., Jiang, W., Yuan, J.X., A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension (2009) Circulation, 119, pp. 2313-2322; Koenig, S., Schernthaner, M., Maechler, H., Kappe, C.O., Glasnov, T.N., Hoefler, G., Braune, M., Groschner, K., A TRPC3 blocker, ethyl-1-(4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-c arboxylate (Pyr3), prevents stent-induced arterial remodeling (2013) J. Pharmacol. Exp. Ther., 344, pp. 33-40; Schleifer, H., Doleschal, B., Lichtenegger, M., Oppenrieder, R., Derler, I., Frischauf, I., Glasnov, T.N., Groschner, K., Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca(2+) entry pathways (2012) Br. J. Pharmacol., 167, pp. 1712-1722; Wang, Y.X., Wang, J., Wang, C., Liu, J., Shi, L.P., Xu, M., Functional expression of transient receptor potential vanilloid-related channels in chronically hypoxic human pulmonary arterial smooth muscle cells (2008) J. Membr. Biol., 223, pp. 151-159; Martin, E., Dahan, D., Cardouat, G., Gillibert-Duplantier, J., Marthan, R., Savineau, J.P., Ducret, T., Involvement of TRPV1 and TRPV4 channels in migration of rat pulmonary arterial smooth muscle cells (2012) Pflugers Arch., 464, pp. 261-272; Naylor, J., Li, J., Milligan, C.J., Zeng, F., Sukumar, P., Hou, B., Sedo, A., Beech, D.J., Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction (2010) Circ. Res., 106, pp. 1507-1515; Zhang, Z., Wang, M., Fan, X.H., Chen, J.H., Guan, Y.Y., Tang, Y.B., Upregulation of TRPM7 channels by angiotensin II triggers phenotypic switching of vascular smooth muscle cells of ascending aorta (2012) Circ. Res., 111, pp. 1137-1146; Kaneko, Y., Szallasi, A., Transient receptor potential (TRP) channels: a clinical perspective (2014) Br. J. Pharmacol., 171, pp. 2474-2507; Inoue, R., Jensen, L.J., Shi, J., Morita, H., Nishida, M., Honda, A., Ito, Y., Transient receptor potential channels in cardiovascular function and disease (2006) Circ. Res., 99, pp. 119-131; Sabourin, J., Robin, E., Raddatz, E., A key role of TRPC channels in the regulation of electromechanical activity of the developing heart (2011) Cardiovasc. Res., 92, pp. 226-236; Abriel, H., Syam, N., Sottas, V., Amarouch, M.Y., Rougier, J.S., TRPM4 channels in the cardiovascular system: physiology, pathophysiology, and pharmacology (2012) Biochem. Pharmacol., 84, pp. 873-881; Kruse, M., Schulze-Bahr, E., Corfield, V., Beckmann, A., Stallmeyer, B., Kurtbay, G., Ohmert, I., Pongs, O., Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I (2009) J. Clin. Invest., 119, pp. 2737-2744; Liu, H., El Zein, L., Kruse, M., Guinamard, R., Beckmann, A., Bozio, A., Kurtbay, G., Bouvagnet, P., Gain-of-function mutations in TRPM4 cause autosomal dominant isolated cardiac conduction disease (2010) Circ. Cardiovasc. Genet., 3, pp. 374-385; Stallmeyer, B., Zumhagen, S., Denjoy, I., Duthoit, G., Hebert, J.L., Ferrer, X., Maugenre, S., Guicheney, P., Mutational spectrum in the Ca(2+)-activated cation channel gene TRPM4 in patients with cardiac conductance disturbances (2012) Hum. Mutat., 33, pp. 109-117; Du, J., Xie, J., Zhang, Z., Tsujikawa, H., Fusco, D., Silverman, D., Liang, B., Yue, L., TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation (2010) Circ. Res., 106, pp. 992-1003; Harada, M., Luo, X., Qi, X.Y., Tadevosyan, A., Maguy, A., Ordog, B., Ledoux, J., Nattel, S., Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation (2012) Circulation, 126, pp. 2051-2064; Eder, P., Molkentin, J.D., TRPC channels as effectors of cardiac hypertrophy (2011) Circ. Res., 108, pp. 265-272; Watanabe, H., Murakami, M., Ohba, T., Takahashi, Y., Ito, H., TRP channel and cardiovascular disease (2008) Pharmacol. Ther., 118, pp. 337-351; Wu, X., Eder, P., Chang, B., Molkentin, J.D., TRPC channels are necessary mediators of pathologic cardiac hypertrophy (2010) Proc. Natl. Acad. Sci. U. S. A., 107, pp. 7000-7005; Seth, M., Zhang, Z.S., Mao, L., Graham, V., Burch, J., Stiber, J., Tsiokas, L., Rosenberg, P., TRPC1 channels are critical for hypertrophic signaling in the heart (2009) Circ. Res., 105, pp. 1023-1030; Nakayama, H., Wilkin, B.J., Bodi, I., Molkentin, J.D., Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart (2006) FASEB J., 20, pp. 1660-1670; Kuwahara, K., Wang, Y., McAnally, J., Richardson, J.A., Bassel-Duby, R., Hill, J.A., Olson, E.N., TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling (2006) J. Clin. Invest., 116, pp. 3114-3126; Onohara, N., Nishida, M., Inoue, R., Kobayashi, H., Sumimoto, H., Sato, Y., Mori, Y., Kurose, H., TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy (2006) EMBO J., 25, pp. 5305-5316; Buckley, C.L., Stokes, A.J., Mice lacking functional TRPV1 are protected from pressure overload cardiac hypertrophy (2011) Channels (Austin), 5, pp. 367-374; Anyatonwu, G.I., Estrada, M., Tian, X., Somlo, S., Ehrlich, B.E., Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2 (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 6454-6459; MacDonald, P.E., Rorsman, P., Oscillations, intercellular coupling, and insulin secretion in pancreatic beta cells (2006) PLoS Biol., 4, p. e49; Colsoul, B., Vennekens, R., Nilius, B., Transient receptor potential cation channels in pancreatic beta cells (2011) Rev. Physiol. Biochem. Pharmacol., 161, pp. 87-110; Henquin, J.C., Nenquin, M., Ravier, M.A., Szollosi, A., Shortcomings of current models of glucose-induced insulin secretion (2009) Diabetes Obes. Metab., 11, pp. 168-179; Jacobson, D.A., Philipson, L.H., TRP channels of the pancreatic beta cell (2007) Handb. Exp. Pharmacol., pp. 409-424; Drews, G., Krippeit-Drews, P., Dufer, M., Electrophysiology of islet cells (2010) Adv. Exp. Med. Biol., 654, pp. 115-163; Islam, M.S., Calcium signaling in the islets (2010) Adv. Exp. Med. Biol., 654, pp. 235-259; Diaz-Garcia, C.M., The TRPA1 channel and oral hypoglycemic agents: is there complicity in beta-cell exhaustion? (2013) Channels (Austin), 7, pp. 420-422; Numazawa, S., Takase, M., Ahiko, T., Ishii, M., Shimizu, S., Yoshida, T., Possible involvement of transient receptor potential channels in electrophile-induced insulin secretion from RINm5F cells (2012) Biol. Pharm. Bull., 35, pp. 346-354; Roe, M.W., Worley, J.F., Qian, F., Tamarina, N., Mittal, A.A., Dralyuk, F., Blair, N.T., Dukes, I.D., Characterization of a Ca2+ release-activated nonselective cation current regulating membrane potential and [Ca2+]i oscillations in transgenically derived beta-cells (1998) J. Biol. Chem., 273, pp. 10402-10410; Freichel, M., Philipp, S., Cavalie, A., Flockerzi, V., TRPC4 and TRPC4-deficient mice (2004) Novartis Found. Symp., 258, pp. 189-199. , (discussion 199-203, 263-186); Park, S.H., Ryu, S.Y., Yu, W.J., Han, Y.E., Ji, Y.S., Oh, K., Sohn, J.W., Ho, W.K., Leptin promotes K(ATP) channel trafficking by AMPK signaling in pancreatic beta-cells (2013) Proc. Natl. Acad. Sci. U. S. A., 110, pp. 12673-12678; Colsoul, B., Schraenen, A., Lemaire, K., Quintens, R., Van Lommel, L., Segal, A., Owsianik, G., Vennekens, R., Loss of high-frequency glucose-induced Ca2+ oscillations in pancreatic islets correlates with impaired glucose tolerance in Trpm5-/- mice (2010) Proc. Natl. Acad. Sci. U. S. A., 107, pp. 5208-5213; Brixel, L.R., Monteilh-Zoller, M.K., Ingenbrandt, C.S., Fleig, A., Penner, R., Enklaar, T., Zabel, B.U., Prawitt, D., TRPM5 regulates glucose-stimulated insulin secretion (2010) Pflugers Arch., 460, pp. 69-76; Hofmann, T., Chubanov, V., Gudermann, T., Montell, C., TRPM5 is a voltage-modulated and Ca(2+)-activated monovalent selective cation channel (2003) Curr. Biol., 13, pp. 1153-1158; Oike, H., Wakamori, M., Mori, Y., Nakanishi, H., Taguchi, R., Misaka, T., Matsumoto, I., Abe, K., Arachidonic acid can function as a signaling modulator by activating the TRPM5 cation channel in taste receptor cells (2006) Biochim. Biophys. Acta, 1761, pp. 1078-1084; Nakagawa, Y., Nagasawa, M., Yamada, S., Hara, A., Mogami, H., Nikolaev, V.O., Lohse, M.J., Kojima, I., Sweet taste receptor expressed in pancreatic beta-cells activates the calcium and cyclic AMP signaling systems and stimulates insulin secretion (2009) PLoS One, 4, p. e5106; Cheng, H., Beck, A., Launay, P., Gross, S.A., Stokes, A.J., Kinet, J.P., Fleig, A., Penner, R., TRPM4 controls insulin secretion in pancreatic beta-cells (2007) Cell Calcium, 41, pp. 51-61; Marigo, V., Courville, K., Hsu, W.H., Feng, J.M., Cheng, H., TRPM4 impacts on Ca2+ signals during agonist-induced insulin secretion in pancreatic beta-cells (2009) Mol. Cell. Endocrinol., 299, pp. 194-203; Vennekens, R., Olausson, J., Meissner, M., Bloch, W., Mathar, I., Philipp, S.E., Schmitz, F., Freichel, M., Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonselective cation channel TRPM4 (2007) Nat. Immunol., 8, pp. 312-320; Herson, P.S., Ashford, M.L., Activation of a novel non-selective cation channel by alloxan and H2O2 in the rat insulin-secreting cell line CRI-G1 (1997) J. Physiol., 501, pp. 59-66; Togashi, K., Hara, Y., Tominaga, T., Higashi, T., Konishi, Y., Mori, Y., Tominaga, M., TRPM2 activation by cyclic ADP-ribose at body temperature is involved in insulin secretion (2006) EMBO J., 25, pp. 1804-1815; Uchida, K., Dezaki, K., Damdindorj, B., Inada, H., Shiuchi, T., Mori, Y., Yada, T., Tominaga, M., Lack of TRPM2 impaired insulin secretion and glucose metabolisms in mice (2011) Diabetes, 60, pp. 119-126; Lange, I., Yamamoto, S., Partida-Sanchez, S., Mori, Y., Fleig, A., Penner, R., TRPM2 functions as a lysosomal Ca2+-release channel in beta cells (2009) Sci. Signal., 2, p. ra23; Razavi, R., Chan, Y., Afifiyan, F.N., Liu, X.J., Wan, X., Yantha, J., Tsui, H., Dosch, H.M., TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes (2006) Cell, 127, pp. 1123-1135; Hisanaga, E., Nagasawa, M., Ueki, K., Kulkarni, R.N., Mori, M., Kojima, I., Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic beta-cells (2009) Diabetes, 58, pp. 174-184; Kottgen, M., Buchholz, B., Garcia-Gonzalez, M.A., Kotsis, F., Fu, X., Doerken, M., Boehlke, C., Walz, G., TRPP2 and TRPV4 form a polymodal sensory channel complex (2008) J. Cell Biol., 182, pp. 437-447; Grapengiesser, E., Gylfe, E., Dansk, H., Hellman, B., Stretch activation of Ca2+ transients in pancreatic beta cells by mobilization of intracellular stores (2003) Pancreas, 26, pp. 82-86; Cao, D.S., Zhong, L., Hsieh, T.H., Abooj, M., Bishnoi, M., Hughes, L., Premkumar, L.S., Expression of transient receptor potential ankyrin 1 (TRPA1) and its role in insulin release from rat pancreatic beta cells (2012) PLoS One, 7, p. e38005; Wang, P., Fiaschi-Taesch, N.M., Vasavada, R.C., Scott, D.K., Garcia-Ocana, A., Stewart, A.F., Diabetes mellitus-advances and challenges in human beta-cell proliferation (2015) Nat. Rev. Endocrinol., 11, pp. 201-212; Ashcroft, F.M., Rorsman, P., Molecular defects in insulin secretion in type-2 diabetes (2004) Rev. Endocr. Metab. Disord., 5, pp. 135-142; Ketterer, C., Mussig, K., Heni, M., Dudziak, K., Randrianarisoa, E., Wagner, R., Machicao, F., Staiger, H., Genetic variation within the TRPM5 locus associates with prediabetic phenotypes in subjects at increased risk for type 2 diabetes (2011) Metabolism, 60, pp. 1325-1333; McCoy, D.D., Zhou, L., Nguyen, A.K., Watts, A.G., Donovan, C.M., McKemy, D.D., Enhanced insulin clearance in mice lacking TRPM8 channels (2013) Am. J. Physiol. Endocrinol. Metab., 305, pp. E78-E88; Babes, A., Fischer, M.J., Filipovic, M., Engel, M.A., Flonta, M.L., Reeh, P.W., The anti-diabetic drug glibenclamide is an agonist of the transient receptor potential Ankyrin 1 (TRPA1) ion channel (2013) Eur. J. Pharmacol., 704, pp. 15-22; Graham, S., Yuan, J.P., Ma, R., Canonical transient receptor potential channels in diabetes (2012) Exp. Biol. Med. (Maywood), 237, pp. 111-118; Chung, A.W., Yeung, K., Chum, E., Okon, E.B., van Breemen, C., Diabetes modulates capacitative calcium entry and expression of transient receptor potential canonical channels in human saphenous vein (2009) Eur. J. Pharmacol., 613, pp. 114-118; Mita, M., Ito, K., Taira, K., Nakagawa, J., Walsh, M.P., Shoji, M., Attenuation of store-operated Ca2+ entry and enhanced expression of TRPC channels in caudal artery smooth muscle from Type 2 diabetic Goto-Kakizaki rats (2010) Clin. Exp. Pharmacol. Physiol., 37, pp. 670-678; Bishara, N.B., Ding, H., Glucose enhances expression of TRPC1 and calcium entry in endothelial cells (2010) Am. J. Physiol. Heart Circ. Physiol., 298, pp. H171-H178; Sobol, A.B., Watala, C., The role of platelets in diabetes-related vascular complications (2000) Diabetes Res. Clin. Pract., 50, pp. 1-16; Rosado, J.A., Saavedra, F.R., Redondo, P.C., Hernandez-Cruz, J.M., Salido, G.M., Pariente, J.A., Reduced plasma membrane Ca2+-ATPase function in platelets from patients with non-insulin-dependent diabetes mellitus (2004) Haematologica, 89, pp. 1142-1144; Saavedra, F.R., Redondo, P.C., Hernandez-Cruz, J.M., Salido, G.M., Pariente, J.A., Rosado, J.A., Store-operated Ca2+ entry and tyrosine kinase pp60src hyperactivity are modulated by hyperglycemia in platelets from patients with non insulin-dependent diabetes mellitus (2004) Arch. Biochem. Biophys., 432, pp. 261-268; Zbidi, H., Lopez, J.J., Amor, N.B., Bartegi, A., Salido, G.M., Rosado, J.A., Enhanced expression of STIM1/Orai1 and TRPC3 in platelets from patients with type 2 diabetes mellitus (2009) Blood Cells Mol. Dis., 43, pp. 211-213; Liu, D., Maier, A., Scholze, A., Rauch, U., Boltzen, U., Zhao, Z., Zhu, Z., Tepel, M., High glucose enhances transient receptor potential channel canonical type 6-dependent calcium influx in human platelets via phosphatidylinositol 3-kinase-dependent pathway (2008) Arterioscler. Thromb. Vasc. Biol., 28, pp. 746-751; Redondo, P.C., Jardin, I., Hernandez-Cruz, J.M., Pariente, J.A., Salido, G.M., Rosado, J.A., Hydrogen peroxide and peroxynitrite enhance Ca2+ mobilization and aggregation in platelets from type 2 diabetic patients (2005) Biochem. Biophys. Res. Commun., 333, pp. 794-802; Liu, J., Fitzgerald, M.E., Berndt, M.C., Jackson, C.W., Gartner, T.K., Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo (2006) Blood, 108, pp. 2596-2603; Redondo, P.C., Ben-Amor, N., Salido, G.M., Bartegi, A., Pariente, J.A., Rosado, J.A., Ca2+-independent activation of Bruton's tyrosine kinase is required for store-mediated Ca2+ entry in human platelets (2005) Cell. Signal., 17, pp. 1011-1021; Bose, R., Li, Y., Woo, V., Sodium-calcium exchange in platelets of diabetics (2001) Proc. West. Pharmacol. Soc., 44, pp. 183-184; Jardin, I., Lopez, J.J., Zbidi, H., Bartegi, A., Salido, G.M., Rosado, J.A., Attenuated store-operated divalent cation entry and association between STIM1, Orai1, hTRPC1 and hTRPC6 in platelets from type 2 diabetic patients (2011) Blood Cells Mol. Dis., 46, pp. 252-260; Jardin, I., Lopez, J.J., Salido, G.M., Rosado, J.A., Orai1 mediates the interaction between STIM1 and hTRPC1 and regulates the mode of activation of hTRPC1-forming Ca2+ channels (2008) J. Biol. Chem., 283, pp. 25296-25304; Jardin, I., Salido, G.M., Rosado, J.A., Role of lipid rafts in the interaction between hTRPC1, Orai1 and STIM1 (2008) Channels (Austin), 2, pp. 401-403; Zhang, D., Freedman, B.I., Flekac, M., Santos, E., Hicks, P.J., Bowden, D.W., Efendic, S., Gu, H.F., Evaluation of genetic association and expression reduction of TRPC1 in the development of diabetic nephropathy (2009) Am. J. Nephrol., 29, pp. 244-251; Niehof, M., Borlak, J., HNF4 alpha and the Ca-channel TRPC1 are novel disease candidate genes in diabetic nephropathy (2008) Diabetes, 57, pp. 1069-1077; He, F., Peng, F., Xia, X., Zhao, C., Luo, Q., Guan, W., Li, Z., Huang, F., MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1 (2014) Diabetologia, 57, pp. 1726-1736; Graham, S., Ding, M., Sours-Brothers, S., Yorio, T., Ma, J.X., Ma, R., Downregulation of TRPC6 protein expression by high glucose, a possible mechanism for the impaired Ca2+ signaling in glomerular mesangial cells in diabetes (2007) Am. J. Physiol. Ren. Physiol., 293, pp. F1381-F1390; Graham, S., Gorin, Y., Abboud, H.E., Ding, M., Lee, D.Y., Shi, H., Ding, Y., Ma, R., Abundance of TRPC6 protein in glomerular mesangial cells is decreased by ROS and PKC in diabetes (2011) Am. J. Physiol. Cell Physiol., 301, pp. C304-C315; Jung, J.H., Kim, B.J., Chae, M.R., Kam, S.C., Jeon, J.H., So, I., Chung, K.H., Lee, S.W., Gene transfer of TRPC6 (dominant negative) restores erectile function in diabetic rats (2010) J. Sex. Med., 7, pp. 1126-1138; Sung, H.H., Choo, S.H., Ko, M., Kang, S.J., Chae, M.R., Kam, S.C., Han, D.H., Lee, S.W., Increased expression of TRPC4 channels associated with erectile dysfunction in diabetes (2014) Andrology, 2, pp. 550-558; Koivisto, A., Hukkanen, M., Saarnilehto, M., Chapman, H., Kuokkanen, K., Wei, H., Viisanen, H., Pertovaara, A., Inhibiting TRPA1 ion channel reduces loss of cutaneous nerve fiber function in diabetic animals: sustained activation of the TRPA1 channel contributes to the pathogenesis of peripheral diabetic neuropathy (2012) Pharmacol. Res., 65, pp. 149-158; Naziroglu, M., Dikici, D.M., Dursun, S., Role of oxidative stress and Ca(2)(+) signaling on molecular pathways of neuropathic pain in diabetes: focus on TRP channels (2012) Neurochem. Res., 37, pp. 2065-2075; Yao, X., Kwan, H.Y., Huang, Y., Regulation of TRP channels by phosphorylation (2005) Neurosignals, 14, pp. 273-280; Roderick, H.L., Cook, S.J., Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival (2008) Nat. Rev. Cancer, 8, pp. 361-375; Pedersen, S.F., Owsianik, G., Nilius, B., TRP channels: an overview (2005) Cell Calcium, 38, pp. 233-252; Monteith, G.R., McAndrew, D., Faddy, H.M., Roberts-Thomson, S.J., Calcium and cancer: targeting Ca2+ transport (2007) Nat. Rev. Cancer, 7, pp. 519-530; Berridge, M.J., Bootman, M.D., Roderick, H.L., Calcium signalling: dynamics, homeostasis and remodelling (2003) Nat. Rev. Mol. Cell Biol., 4, pp. 517-529; Orrenius, S., Zhivotovsky, B., Nicotera, P., Regulation of cell death: the calcium-apoptosis link. Nature reviews (2003) Mol. Cell. Biol., 4, pp. 552-565; Pinton, P., Giorgi, C., Siviero, R., Zecchini, E., Rizzuto, R., Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis (2008) Oncogene, 27, pp. 6407-6418; Prevarskaya, N., Skryma, R., Shuba, Y., Ion channels and the hallmarks of cancer (2010) Trends Mol. Med., 16, pp. 107-121; Cook, S.J., Lockyer, P.J., Recent advances in Ca(2+)-dependent Ras regulation and cell proliferation (2006) Cell Calcium, 39, pp. 101-112; Whitfield, J.F., Calcium signals and cancer (1992) Crit. Rev. Oncog., 3, pp. 55-90; Hoyer-Hansen, M., Jaattela, M., Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium (2007) Cell Death Differ., 14, pp. 1576-1582; Johnson, J.D., Han, Z., Otani, K., Ye, H., Zhang, Y., Wu, H., Horikawa, Y., Polonsky, K.S., RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets (2004) J. Biol. Chem., 279, pp. 24794-24802; Leanza, L., Biasutto, L., Manago, A., Gulbins, E., Zoratti, M., Szabo, I., Intracellular ion channels and cancer (2013) Front. Physiol., 4, p. 227; Zeng, X., Sikka, S.C., Huang, L., Sun, C., Xu, C., Jia, D., Abdel-Mageed, A.B., Li, M., Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferation (2010) Prostate Cancer Prostatic Dis., 13, pp. 195-201; Bidaux, G., Beck, B., Zholos, A., Gordienko, D., Lemonnier, L., Flourakis, M., Roudbaraki, M., Prevarskaya, N., Regulation of activity of transient receptor potential melastatin 8 (TRPM8) channel by its short isoforms (2012) J. Biol. Chem., 287, pp. 2948-2962; Yamauchi, T., Neuronal Ca2+/calmodulin-dependent protein kinase II-discovery, progress in a quarter of a century, and perspective: implication for learning and memory (2005) Biol. Pharm. Bull., 28, pp. 1342-1354; McGargill, M.A., Sharp, L.L., Bui, J.D., Hedrick, S.M., Calbo, S., Active Ca2+/calmodulin-dependent protein kinase II gamma B impairs positive selection of T cells by modulating TCR signaling (2005) J. Immunol., 175, pp. 656-664; Lin, M.Y., Zal, T., Ch'en, I.L., Gascoigne, N.R., Hedrick, S.M., A pivotal role for the multifunctional calcium/calmodulin-dependent protein kinase II in T cells: from activation to unresponsiveness (2005) J. Immunol., 174, pp. 5583-5592; Chandel, N.S., Trzyna, W.C., McClintock, D.S., Schumacker, P.T., Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin (2000) J. Immunol., 165, pp. 1013-1021; Renard, P., Zachary, M.D., Bougelet, C., Mirault, M.E., Haegeman, G., Remacle, J., Raes, M., Effects of antioxidant enzyme modulations on interleukin-1-induced nuclear factor kappa B activation (1997) Biochem. Pharmacol., 53, pp. 149-160; Wu, H.Y., Tomizawa, K., Matsui, H., Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder (2007) Acta Med. Okayama, 61, pp. 123-137; Heit, J.J., Apelqvist, A.A., Gu, X., Winslow, M.M., Neilson, J.R., Crabtree, G.R., Kim, S.K., Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function (2006) Nature, 443, pp. 345-349; Premkumar, L.S., Abooj, M., TRP channels and analgesia (2013) Life Sci., 92, pp. 415-424; Yue, L., Peng, J.B., Hediger, M.A., Clapham, D.E., CaT1 manifests the pore properties of the calcium-release-activated calcium channel (2001) Nature, 410, pp. 705-709; Bodding, M., Flockerzi, V., Ca2+ dependence of the Ca2+-selective TRPV6 channel (2004) J. Biol. Chem., 279, pp. 36546-36552; Bolanz, K.A., Hediger, M.A., Landowski, C.P., The role of TRPV6 in breast carcinogenesis (2008) Mol. Cancer Ther., 7, pp. 271-279; Wissenbach, U., Niemeyer, B.A., Fixemer, T., Schneidewind, A., Trost, C., Cavalie, A., Reus, K., Flockerzi, V., Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer (2001) J. Biol. Chem., 276, pp. 19461-19468; Peng, J.B., Zhuang, L., Berger, U.V., Adam, R.M., Williams, B.J., Brown, E.M., Hediger, M.A., Freeman, M.R., CaT1 expression correlates with tumor grade in prostate cancer (2001) Biochem. Biophys. Res. Commun., 282, pp. 729-734; Vanden Abeele, F., Roudbaraki, M., Shuba, Y., Skryma, R., Prevarskaya, N., Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1 (2003) J. Biol. Chem., 278, pp. 15381-15389; Zhuang, L., Peng, J.B., Tou, L., Takanaga, H., Adam, R.M., Hediger, M.A., Freeman, M.R., Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies (2002) Lab. Investig., 82, pp. 1755-1764; Fixemer, T., Wissenbach, U., Flockerzi, V., Bonkhoff, H., Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression (2003) Oncogene, 22, pp. 7858-7861; Peters, A.A., Simpson, P.T., Bassett, J.J., Lee, J.M., Da Silva, L., Reid, L.E., Song, S., Monteith, G.R., Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer (2012) Mol. Cancer Ther., 11, pp. 2158-2168; Bodding, M., Fecher-Trost, C., Flockerzi, V., Store-operated Ca2+ current and TRPV6 channels in lymph node prostate cancer cells (2003) J. Biol. Chem., 278, pp. 50872-50879; Raphael, M., Lehen'kyi, V., Vandenberghe, M., Beck, B., Khalimonchyk, S., Vanden Abeele, F., Farsetti, L., Prevarskaya, N., TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival (2014) Proc. Natl. Acad. Sci. U. S. A., 111, pp. E3870-E3879; Monet, M., Lehen'kyi, V., Gackiere, F., Firlej, V., Vandenberghe, M., Roudbaraki, M., Gkika, D., Prevarskaya, N., Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance (2010) Cancer Res., 70, pp. 1225-1235; Nabissi, M., Morelli, M.B., Santoni, M., Santoni, G., Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents (2013) Carcinogenesis, 34, pp. 48-57; Fan, H., Shen, Y.X., Yuan, Y.F., Expression and prognostic roles of TRPV5 and TRPV6 in non-small cell lung cancer after curative resection (2014) Asian Pac. J. Cancer Prev., 15, pp. 2559-2563; Ariano, P., Dalmazzo, S., Owsianik, G., Nilius, B., Lovisolo, D., TRPC channels are involved in calcium-dependent migration and proliferation in immortalized GnRH neurons (2011) Cell Calcium, 49, pp. 387-394; Fabian, A., Fortmann, T., Bulk, E., Bomben, V.C., Sontheimer, H., Schwab, A., Chemotaxis of MDCK-F cells toward fibroblast growth factor-2 depends on transient receptor potential canonical channel 1 (2011) Pflugers Arch. - Eur. J. Physiol., 461, pp. 295-306; Fabian, A., Fortmann, T., Dieterich, P., Riethmuller, C., Schon, P., Mally, S., Nilius, B., Schwab, A., TRPC1 channels regulate directionality of migrating cells (2008) Pflugers Arch. - Eur. J. Physiol., 457, pp. 475-484; Zanou, N., Shapovalov, G., Louis, M., Tajeddine, N., Gallo, C., Van Schoor, M., Anguish, I., Gailly, P., Role of TRPC1 channel in skeletal muscle function (2010) Am. J. Physiol. Cell Physiol., 298, pp. C149-C162; He, B., Liu, F., Ruan, J., Li, A., Chen, J., Li, R., Shen, J., Luo, R., Silencing TRPC1 expression inhibits invasion of CNE2 nasopharyngeal tumor cells (2012) Oncol. Rep., 27, pp. 1548-1554; Tajeddine, N., Gailly, P., TRPC1 protein channel is major regulator of epidermal growth factor receptor signaling (2012) J. Biol. Chem., 287, pp. 16146-16157; Bomben, V.C., Turner, K.L., Barclay, T.T., Sontheimer, H., Transient receptor potential canonical channels are essential for chemotactic migration of human malignant gliomas (2011) J. Cell. Physiol., 226, pp. 1879-1888; Bon, R.S., Beech, D.J., In pursuit of small molecule chemistry for calcium-permeable non-selective TRPC channels - mirage or pot of gold? (2013) Br. J. Pharmacol., 170, pp. 459-474; Cai, R., Ren, G., Ding, X., Wang, Y.Z., Jin, Y.N., Essential role of TRPC6 in the proliferation of gastric cancer and its mechanism (2012) Zhonghua Zhong Liu Za Zhi, 34, pp. 577-581; Thebault, S., Flourakis, M., Vanoverberghe, K., Vandermoere, F., Roudbaraki, M., Lehen'kyi, V., Slomianny, C., Prevarskaya, N., Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells (2006) Cancer Res., 66, pp. 2038-2047; El Boustany, C., Bidaux, G., Enfissi, A., Delcourt, P., Prevarskaya, N., Capiod, T., Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation (2008) Hepatology, 47, pp. 2068-2077; Ma, X., Cai, Y., He, D., Zou, C., Zhang, P., Lo, C.Y., Xu, Z., Yao, X., Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells (2012) Proc. Natl. Acad. Sci. U. S. A., 109, pp. 16282-16287; Aydar, E., Yeo, S., Djamgoz, M., Palmer, C., Abnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy (2009) Cancer Cell Int., 9, p. 23; Guilbert, A., Dhennin-Duthille, I., Hiani, Y.E., Haren, N., Khorsi, H., Sevestre, H., Ahidouch, A., Ouadid-Ahidouch, H., Expression of TRPC6 channels in human epithelial breast cancer cells (2008) BMC Cancer, 8, p. 125; Dhennin-Duthille, I., Gautier, M., Faouzi, M., Guilbert, A., Brevet, M., Vaudry, D., Ahidouch, A., Ouadid-Ahidouch, H., High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters (2011) Cell. Physiol. Biochem., 28, pp. 813-822; Prawitt, D., Enklaar, T., Klemm, G., Gartner, B., Spangenberg, C., Winterpacht, A., Higgins, M., Zabel, B., Identification and characterization of MTR1, a novel gene with homology to melastatin (MLSN1) and the trp gene family located in the BWS-WT2 critical region on chromosome 11p15.5 and showing allele-specific expression (2000) Hum. Mol. Genet., 9, pp. 203-216; Suguro, M., Tagawa, H., Kagami, Y., Okamoto, M., Ohshima, K., Shiku, H., Morishima, Y., Seto, M., Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature (2006) Cancer Sci., 97, pp. 868-874; Singh, J., Manickam, P., Shmoish, M., Natik, S., Denyer, G., Handelsman, D., Gong, D.W., Dong, Q., Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate (2006) Cancer Lett., 237, pp. 298-304; Schinke, E.N., Bii, V., Nalla, A., Rae, D.T., Tedrick, L., Meadows, G.G., Trobridge, G.D., A novel approach to identify driver genes involved in androgen-independent prostate cancer (2014) Mol. Cancer, 13, p. 120; Armisen, R., Marcelain, K., Simon, F., Tapia, J.C., Toro, J., Quest, A.F., Stutzin, A., TRPM4 enhances cell proliferation through up-regulation of the beta-catenin signaling pathway (2011) J. Cell. Physiol., 226, pp. 103-109; Guilbert, A., Gautier, M., Dhennin-Duthille, I., Haren, N., Sevestre, H., Ouadid-Ahidouch, H., Evidence that TRPM7 is required for breast cancer cell proliferation (2009) Am. J. Physiol. Cell Physiol., 297, pp. C493-C502; Kim, B.J., Involvement of melastatin type transient receptor potential 7 channels in ginsenoside Rd-induced apoptosis in gastric and breast cancer cells (2013) J. Ginseng Res., 37, pp. 201-209; Rybarczyk, P., Gautier, M., Hague, F., Dhennin-Duthille, I., Chatelain, D., Kerr-Conte, J., Pattou, F., Ouadid-Ahidouch, H., Transient receptor potential melastatin-related 7 channel is overexpressed in human pancreatic ductal adenocarcinomas and regulates human pancreatic cancer cell migration (2012) Int. J. Cancer, 131, pp. E851-E861; Yee, N.S., Kazi, A.A., Li, Q., Yang, Z., Berg, A., Yee, R.K., Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis (2015) Biol. Open, 4, pp. 507-514; Dou, Y., Li, Y., Chen, J., Wu, S., Xiao, X., Xie, S., Tang, L., Yan, G., Inhibition of cancer cell proliferation by midazolam by targeting transient receptor potential melastatin 7 (2013) Oncol. Lett., 5, pp. 1010-1016; Chen, J.P., Wang, J., Luan, Y., Wang, C.X., Li, W.H., Zhang, J.B., Sha, D., Wang, W.B., TRPM7 promotes the metastatic process in human nasopharyngeal carcinoma (2015) Cancer Lett., 356, pp. 483-490; Sun, Y., Selvaraj, S., Varma, A., Derry, S., Sahmoun, A.E., Singh, B.B., Increase in serum Ca2+/Mg2+ ratio promotes proliferation of prostate cancer cells by activating TRPM7 channels (2013) J. Biol. Chem., 288, pp. 255-263; Visser, D., Langeslag, M., Kedziora, K.M., Klarenbeek, J., Kamermans, A., Horgen, F.D., Fleig, A., Jalink, K., TRPM7 triggers Ca2+ sparks and invadosome formation in neuroblastoma cells (2013) Cell Calcium, 54, pp. 404-415; Lange, I., Koomoa, D.L., MycN promotes TRPM7 expression and cell migration in neuroblastoma through a process that involves polyamines (2014) FEBS Open Bio, 4, pp. 966-975; Middelbeek, J., Visser, D., Henneman, L., Kamermans, A., Kuipers, A.J., Hoogerbrugge, P.M., Jalink, K., van Leeuwen, F.N., TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation (2015) Oncotarget, 6, pp. 8760-8776; Pigozzi, D., Ducret, T., Tajeddine, N., Gala, J.L., Tombal, B., Gailly, P., Calcium store contents control the expression of TRPC1, TRPC3 and TRPV6 proteins in LNCaP prostate cancer cell line (2006) Cell Calcium, 39, pp. 401-415; Misra, U.K., Mowery, Y.M., Gawdi, G., Pizzo, S.V., Loss of cell surface TFII-I promotes apoptosis in prostate cancer cells stimulated with activated alpha(2) -macroglobulin (2011) J. Cell. Biochem., 112, pp. 1685-1695; Zhang, H., Zhou, L., Shi, W., Song, N., Yu, K., Gu, Y., A mechanism underlying the effects of polyunsaturated fatty acids on breast cancer (2012) Int. J. Mol. Med., 30, pp. 487-494; Tao, X., Zhao, N., Jin, H., Zhang, Z., Liu, Y., Wu, J., Bast, R.C., Feng, Y., FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3 (2013) Endocr. Relat. Cancer, 20, pp. 415-429; Deeds, J., Cronin, F., Duncan, L.M., Patterns of melastatin mRNA expression in melanocytic tumors (2000) Hum. Pathol., 31, pp. 1346-1356; Duncan, L.M., Deeds, J., Hunter, J., Shao, J., Holmgren, L.M., Woolf, E.A., Tepper, R.I., Shyjan, A.W., Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis (1998) Cancer Res., 58, pp. 1515-1520; Lazzeri, M., Vannucchi, M.G., Spinelli, M., Bizzoco, E., Beneforti, P., Turini, D., Faussone-Pellegrini, M.S., Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder (2005) Eur. Urol., 48, pp. 691-698; Sanchez, M.G., Sanchez, A.M., Collado, B., Malagarie-Cazenave, S., Olea, N., Carmena, M.J., Prieto, J.C., Diaz-Laviada, I.I., Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue (2005) Eur. J. Pharmacol., 515, pp. 20-27; Ziglioli, F., Frattini, A., Maestroni, U., Dinale, F., Ciufifeda, M., Cortellini, P., Vanilloid-mediated apoptosis in prostate cancer cells through a TRPV-1 dependent and a TRPV-1-independent mechanism (2009) Acta Biomed., 80, pp. 13-20; Sung, B., Prasad, S., Ravindran, J., Yadav, V.R., Aggarwal, B.B., Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors (2012) Free Radic. Biol. Med., 53, pp. 1977-1987; Shen, Y., Rampino, M.A., Carroll, R.C., Nawy, S., G-protein-mediated inhibition of the Trp channel TRPM1 requires the Gbetagamma dimer (2012) Proc. Natl. Acad. Sci. U. S. A., 109, pp. 8752-8757; Fleig, A., Penner, R., The TRPM ion channel subfamily: molecular, biophysical and functional features (2004) Trends Pharmacol. Sci., 25, pp. 633-639; Duncan, L.M., Deeds, J., Cronin, F.E., Donovan, M., Sober, A.J., Kauffman, M., McCarthy, J.J., Melastatin expression and prognosis in cutaneous malignant melanoma (2001) J. Clin. Oncol., 19, pp. 568-576; Fang, D., Setaluri, V., Expression and Up-regulation of alternatively spliced transcripts of melastatin, a melanoma metastasis-related gene, in human melanoma cells (2000) Biochem. Biophys. Res. Commun., 279, pp. 53-61; Bodding, M., TRP proteins and cancer (2007) Cell. Signal., 19, pp. 617-624; Miller, A.J., Du, J., Rowan, S., Hershey, C.L., Widlund, H.R., Fisher, D.E., Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma (2004) Cancer Res., 64, pp. 509-516; Erickson, L.A., Letts, G.A., Shah, S.M., Shackelton, J.B., Duncan, L.M., TRPM1 (Melastatin-1/MLSN1) mRNA expression in Spitz nevi and nodular melanomas (2009) Mod. Pathol., 22, pp. 969-976; Guo, H., Carlson, J.A., Slominski, A., Role of TRPM in melanocytes and melanoma (2012) Exp. Dermatol., 21, pp. 650-654; Xia, B., Yang, S., Liu, T., Lou, G., MiR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6 (2015) Mol. Cancer, 14, p. 322; Lis, A., Wissenbach, U., Philipp, S.E., Transcriptional regulation and processing increase the functional variability of TRPM channels (2005) Naunyn Schmiedeberg's Arch. Pharmacol., 371, pp. 315-324; Xu, X.Z., Moebius, F., Gill, D.L., Montell, C., Regulation of melastatin, a TRP-related protein, through interaction with a cytoplasmic isoform (2001) Proc. Natl. Acad. Sci. U. S. A., 98, pp. 10692-10697; Zhang, W., Hirschler-Laszkiewicz, I., Tong, Q., Conrad, K., Sun, S.C., Penn, L., Barber, D.L., Miller, B.A., TRPM2 is an ion channel that modulates hematopoietic cell death through activation of caspases and PARP cleavage (2006) Am. J. Physiol. Cell Physiol., 290, pp. C1146-C1159; Hara, Y., Wakamori, M., Ishii, M., Maeno, E., Nishida, M., Yoshida, T., Yamada, H., Mori, Y., LTRPC2 Ca2+-permeable channel activated by changes in redox status confers susceptibility to cell death (2002) Mol. Cell, 9, pp. 163-173; Cao, Q.F., Qian, S.B., Wang, N., Zhang, L., Wang, W.M., Shen, H.B., TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells (2015) Cancer Biother. Radiopharm., 30, pp. 87-93; Zhang, W., Chu, X., Tong, Q., Cheung, J.Y., Conrad, K., Masker, K., Miller, B.A., A novel TRPM2 isoform inhibits calcium influx and susceptibility to cell death (2003) J. Biol. Chem., 278, pp. 16222-16229; Middelbeek, J., Kuipers, A.J., Henneman, L., Visser, D., Eidhof, I., van Horssen, R., Wieringa, B., Jalink, K., TRPM7 is required for breast tumor cell metastasis (2012) Cancer Res., 72, pp. 4250-4261; Meng, X., Cai, C., Wu, J., Cai, S., Ye, C., Chen, H., Yang, Z., Zou, F., TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway (2013) Cancer Lett., 333, pp. 96-102; Guilbert, A., Gautier, M., Dhennin-Duthille, I., Rybarczyk, P., Sahni, J., Sevestre, H., Scharenberg, A.M., Ouadid-Ahidouch, H., Transient receptor potential melastatin 7 is involved in oestrogen receptor-negative metastatic breast cancer cells migration through its kinase domain (2013) Eur. J. Cancer, 49, pp. 3694-3707; Yu, H., Zhang, Z., Lis, A., Penner, R., Fleig, A., TRPM7 is regulated by halides through its kinase domain (2013) Cell. Mol. Life Sci., 70, pp. 2757-2771; Davis, F.M., Azimi, I., Faville, R.A., Peters, A.A., Jalink, K., Putney, J.W., Goodhill, G.J., Monteith, G.R., Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent (2014) Oncogene, 33, pp. 2307-2316; Tsavaler, L., Shapero, M.H., Morkowski, S., Laus, R., Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins (2001) Cancer Res., 61, pp. 3760-3769; Bidaux, G., Roudbaraki, M., Merle, C., Crepin, A., Delcourt, P., Slomianny, C., Thebault, S., Prevarskaya, N., Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement (2005) Endocr. Relat. Cancer, 12, pp. 367-382; Zhang, L., Barritt, G.J., Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells (2004) Cancer Res., 64, pp. 8365-8373; Okamoto, Y., Ohkubo, T., Ikebe, T., Yamazaki, J., Blockade of TRPM8 activity reduces the invasion potential of oral squamous carcinoma cell lines (2012) Int. J. Oncol., 40, pp. 1431-1440; Cucu, D., Chiritoiu, G., Petrescu, S., Babes, A., Stanica, L., Duda, D.G., Horii, A., Popescu, I., Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells (2014) Pancreas, 43, pp. 795-800; Du, G.J., Li, J.H., Liu, W.J., Liu, Y.H., Zhao, B., Li, H.R., Hou, X.D., Duan, Y.J., The combination of TRPM8 and TRPA1 expression causes an invasive phenotype in lung cancer (2014) Tumour Biol., 35, pp. 1251-1261; Yang, Z.H., Wang, X.H., Wang, H.P., Hu, L.Q., Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells (2009) Asian J. Androl., 11, pp. 157-165; Gkika, D., Lemonnier, L., Shapovalov, G., Gordienko, D., Poux, C., Bernardini, M., Bokhobza, A., Prevarskaya, N., TRP channel-associated factors are a novel protein family that regulates TRPM8 trafficking and activity (2015) J. Cell Biol., 208, pp. 89-107; Monet, M., Gkika, D., Lehen'kyi, V., Pourtier, A., Vanden Abeele, F., Bidaux, G., Juvin, V., Prevarsakaya, N., Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation (2009) Biochim. Biophys. Acta, 1793, pp. 528-539",Review,Scopus,2-s2.0-84928911195
"Purwar A., Singh S.K.","Hybrid prediction model with missing value imputation for medical data",2015,"Expert Systems with Applications","42","13",,"5621","5631",,,10.1016/j.eswa.2015.02.050,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926648585&partnerID=40&md5=912eaeee215bc6d196e60fc9f07808a9","Department of Computer Science and Information Technology, JIIT Noida, India","Purwar, A., Department of Computer Science and Information Technology, JIIT Noida, India; Singh, S.K., Department of Computer Science and Information Technology, JIIT Noida, India","Accurate prediction in the presence of large number of missing values in the data set has always been a challenging problem. Most of hybrid models to address this challenge have either deleted the missing instances from the data set (popularly known as case deletion) or have used some default way to fill the missing values. This paper, presents a novel hybrid prediction model with missing value imputation (HPM-MI) that analyze various imputation techniques using simple K-means clustering and apply the best one to a data set. The proposed hybrid model is the first one to use combination of K-means clustering with Multilayer Perceptron. K-means clustering is also used to validate class labels of given data (incorrectly classified instances are deleted i.e. pattern extracted from original data) before applying classifier. The proposed system has significantly improved data quality by use of best imputation technique after quantitative analysis of eleven imputation approaches. The efficiency of proposed model as predictive classification system is investigated on three benchmark medical data sets namely Pima Indians Diabetes, Wisconsin Breast Cancer, and Hepatitis from the UCI Repository of Machine Learning. In addition to accuracy, sensitivity, specificity; kappa statistics and the area under ROC are also computed. The experimental results show HPM-MI has produced accuracy, sensitivity, specificity, kappa and ROC as 99.82%, 100%, 99.74%, 0.996 and 1.0 respectively for Pima Indian Diabetes data set, 99.39%, 99.31%, 99.54%, 0.986, and 1.0 respectively for breast cancer data set and 99.08%, 100%, 96.55%, 0.978 and 0.99 respectively for Hepatitis data set. Results are best in comparison with existing methods. Further, the performance of our model is measured and analyzed as function of missing rate and train-test ratio using 2D synthetic data set and Wisconsin Diagnostics Breast Cancer Data Sets. Results are promising and therefore the proposed model will be very useful in prediction for medical domain especially when numbers of missing value are large in the data set. © 2015 Elsevier Ltd. All rights reserved.","Data mining; K-means clustering; Missing value imputation; Multilayer Perceptron (MLP)","Alcalá-Fdez, J., Sánchez, L., García, S., Del Jesus, M.J., Ventura, S., Garrell, J.M., KEEL: A software tool to assess evolutionary algorithms for data mining problems (2009) Soft Computing, 13, pp. 307-318; Aussem, A., De Morais, S.R., A conservative feature subset selection algorithm with missing data (2008) Data Mining, 2008. ICDM '08. Eighth IEEE International Conference on, pp. 725-730; Bellazzi, R., Zupan, B., Predictive data mining in clinical medicine: Current issues and guidelines (2008) International Journal of Medical Informatics, 77, pp. 81-97; Bennett, K.P., Blue, J.A., (1998) A support vector machine approach to decision trees, 3, pp. 2396-2401. , Neural networks proceedings, 1998. IEEE world congress on computational intelligence. The 1998 IEEE international joint conference on; Bioch, J.C., Meer, O., Potharst, R., (1996) Classification using Bayesian neural nets, pp. 1488-1493. , International conference on neural networks; Carpenter, G.A., Markuzon, N., ARTMAP-IC and medical diagnosis: Instance counting and inconsistent cases (1998) Neural Networks, 11, pp. 323-336; Chen, H., Liu, D., Yang, B., Liu, J., Wang, G., A new hybrid method based on local fisher discriminant analysis and support vector machines for hepatitis disease diagnosis (2011) Expert Systems with Applications, 38 (9), pp. 11796-11803; Chen, H., Yang, B., Wang, G., Wang, S., Liu, J., Liu, D., Support vector machine based diagnostic system for breast cancer using swarm intelligence (2012) Journal of Medical Systems, pp. 2505-2519; Cibenko, G., Approximation by superpositions of a sigmoidal function (1989) Mathematics of Control, Signal and Systems, 2 (4), pp. 303-314; David, W., On classification with incomplete data (2007) IEEE Transactions on Pattern Analysis and Machine Intelligence, 29, pp. 427-436; Delen, D., Walker, G., Kadam, A., Predicting breast cancer survivability: A comparison of three data mining methods (2005) Artificial Intelligence in Medicine, 34 (2), pp. 113-127; Dogantekin, E., Dogantekin, A., Avci, D., Automatic hepatitis diagnosis system based on linear discriminant analysis and adaptive network based on fuzzy inference system (2009) Expert Systems with Applications, 36 (8), pp. 11282-11286; Downs, J., Harrison, R.F., Kennedy, R.L., Cross, S.S., Application of the fuzzy ARTMAP neural network model to medical pattern classification tasks (1996) Artificial Intelligence in Medicine, 8, pp. 403-428; Hammer, P., Bonates, T., Logical analysis of data - An overview: From combinatorial optimization to medical applications (2006) Annals of Operations Research, 148, pp. 203-225; Han, J., Kamber, M., (2006) Data Mining: Concepts and Techniques, , 2nd ed. Morgan Kaufmann Publishers; Hathaway, R.J., Bezdek, J.C., Clustering incomplete relational data using the non-Euclidean relational fuzzy c-means algorithm (2002) Pattern Recognition Letters, 23, pp. 151-160; Kahramanli, H., Allahverdi, N., Design of a hybrid system for the diabetes and heart diseases (2008) Expert Systems with Applications, 35, pp. 82-89; Kanungo, T., Mount, D.M., Netanyahu, N.S., Piatko, C.D., Silverman, R., Wu, A.Y., An efficient k-means clustering algorithm: Analysis and implementation (2002) IEEE Transactions on Pattern Analysis and Machine Intelligence, 24, pp. 881-892; Koren, Y., Bell, R., Volinsky, C., Matrix factorization techniques for recommender systems (2009) Computer, 42 (8), pp. 30-37; Llango, S.B., Ramaraj, N., A hybrid prediction model with F-score feature selection for type II Diabetes databases (2010) 1st Amrita ACM-W Celebration on Women in Computing in India, pp. 1-4. , Coimbatore, India; Luengo, J., García, S., Herrera, F., On the choice of the best imputation methods for missing values considering three groups of classification methods (2011) Knowledge and Information Systems, 32, pp. 77-108; Luukka, P., Classification based on fuzzy robust PCA algorithms and similarity classifier (2009) Expert Systems with Applications, 36 (4), pp. 7463-7468; Luukka, P., Feature selection using fuzzy entropy measures with similarity classifier (2011) Expert Systems with Applications, 38, pp. 4600-4607; Meesad, P., Yen, G.G., Combined numerical and linguistic knowledge representation and its application to medical diagnosis (2003) IEEE Transactions on Systems, Man and Cybernetics, Part A: Systems and Humans, 33, pp. 206-222; Michie, D., Spiegelhalter, D.J., Taylor, C.C., (1994) Machine Learning, Neural and Statistical Classification, , Ellis Horwoo; Mukhopadhyay, S., Changhong, T., Huang, J., Mulong, Y., Palakal, M., A comparative study of genetic sequence classification algorithms (2002) Neural Networks for Signal Processing, pp. 57-66; Newman, D.J., Hettich, S., Blake, C.L., Merz, C.J., (2007) UCI Repository of Machine Learning Databases, , Irvine, CA: University of California, Department of Information and Computer Science; Örkcü, H.H., Bal, H., Comparing performances of backpropagation and genetic algorithms in the data classification (2011) Expert Systems with Applications, 38, pp. 3703-3709; Patil, B.M., Joshi, R.C., Toshniwal, D., Hybrid prediction model for type-2 diabetic patients (2010) Expert Systems with Applications, 37, pp. 8102-8108; Polat, K., Güneş, S., Hepatitis disease diagnosis using a new hybrid system based on feature selection (FS) and artificial immune recognition system with fuzzy resource allocation (2006) Digital Signal Processing, 16 (6), pp. 889-901; Polat, K., Güneş, S., Prediction of hepatitis disease based on principal component analysis and artificial immune recognition system (2007) Applied Mathematics and Computation, 189 (2), pp. 1282-1291; Polat, K., Sahan, S., Kodaz, H., Güneş, S., Breast cancer and liver disorders classification using artificial immune recognition system (AIRS) with performance evaluation by fuzzy resource allocation mechanism (2007) Expert Systems with Applications, 32 (1), pp. 172-183; Qin, Y., Zhang, S., Zhu, X., Zhang, J., Zhang, C., Semi-parametric optimization for missing data imputation (2007) Applied Intelligence, 27, pp. 79-88; Quinlan, J., Improved use of continuous attribute in C4.5 (1996) Journal of Artificial Intelligence Research, 4, pp. 77-90; Rumelhart, D.E., Hinton, G.E., Williams, R.J., (1986) Learning Internal Representations by Error Propagation, 1. , MIT Press; Saar-Tsechansky, M.P.F., Handling missing values when applying classification models (2007) The Journal of Machine Learning Research, 8, pp. 1625-1657; Saastamoinen, K., Ketola, J., Medical data classification using logical similarity based measures (2006) IEEE Conference on Cybernetics and Intelligent Systems, pp. 1-5; Scholz, M., Kaplan, F., Guy, C.L., Kopka, J., Selbig, J., Non-linear PCA: A missing data approach (2005) Bioinformatics, 21, pp. 3887-3895. , Springer; Seera, M., Lim, C.P., A hybrid intelligent system for medical data classification (2014) Expert Systems with Applications, 41, pp. 2239-2249; Ster, B., Dobinkar, A., Neural Networks in medical diagnosis: Comparison with others methods (1996) Proceeding of International Conference on Engineering Applications of Neural Networks, pp. 427-430; Stoean, R., Stoean, C., Modeling medical decision making by support vector machines, explaining by rules of evolutionary algorithms with feature selection (2013) Expert Systems with Applications, 40 (7), pp. 2677-2686; Takács, G., Matrix factorization and neighbor based algorithms for the Netflix prize problem (2008) ACM Conference on Recommender Systems, pp. 267-274; Thora, J., Ebba, T., Helgi, S., Sven, S., The feasibility of constructing a predictive outcome model for breast cancer using the tools of data mining (2008) Expert Systems with Applications, 34, pp. 108-118; Tsirogiannis, G.L., Frossyniotis, D., Stoitsis, J., Golemati, S., Stafylopatis, A., Nikita, K.S., Classification of medical data with a robust multi-level combination scheme (2004) Neural Networks Proceedings. IEEE International Joint Conference on, 3, pp. 2483-2487; Witten, I.H., Frank, E., (2000) Data Mining: Practical Machine Learning Tools and Techniques with Java Implementations, , Morgan Kaufman San Francisco; Zangooei, M.H., Habibi, J., Alizadehsani, R., Disease diagnosis with a hybrid method SVR using NSGA-II (2014) Neurocomputing, 136, pp. 14-29",Article,Scopus,2-s2.0-84926648585
"Zhao S., Wang Y., Mu Y., Yu B., Ye P., Yan X., Li Z., Wei Y., Ambegaonakr B.M., Hu D., Er B.A.J, Guiwen C., Buxing C., Hong C., Jin C., Jing C., Liefeng C., Min C., Qiong C., Shaoliang C., Tielong C., Xiaofei C., Xiaohong C., You C., Guoli C., Mei C., Hongliang C., Qin C., Shiwei C., Yong C., Shudong D., Henghua D., Xiaomei D., Yirong D., Xiaoyan D., Birong D., Yumei D., Yugang D., Ping D., Lei D., Limei F., Ningyuan F., Lixia F., Lie F., Jun G., GeWeihong, Hongmin G., Minxia G., Qinghua H., Fengchang H., Dayi H., Lingzhi H., Xueqiang H., Yaojun H., Yiming H., Zhiping H., Fei H., Qi H., Dejia H., Gewen H., Hongman H., Liming H., Qiong H., Ruowen H., Taifu H., Bin J., Kai J., Hui J., Huigen J., Jinsong K., Bao L., Chengjiang L., Hongjuan L., Li Jun X., Li Jun J., Nanfang L., Qifu L., Qiang L., Xin L., Xueyou L., Yanbing L., Yanping L., Yansheng L., Yong L., Yuling L., Zhanquan L., Zhengfang L., Li L., Yongxue L., Zerong L., Yuhua L., Fan L., Hong L., Hui L., Minling L., Qiang L., Qingsong L., Shaokui L., Weidong L., Xueping L., Xinjian L., Benyan L., Shaonian L., Suxin L., Hong L., LvYun, Aiqun M., Jianhua M., Qiang M., Yan M., Changsheng M., Yide M., Yiming M., NieXiaoli, NiuXiaoyuan, Hongtao P., Mingkang P., Qiaoqing P., Huifen Q., Qiumin Q., Lijie Q., Liqun R., Jingshan S., Qiang S., Jing H., Xiuyun S., Yongquan S., Liangyi S., Zhi S., Zhiyuan S., Yufeng S., Chunyan T., TengXiaochun, Haoming T., Wenhua T., Qinwei T., TuQiuyun, Keying W., Aihong W., Chaohui W., Chunning W., Dezhao W., Guixia W., Hanqiao W., Jianan W., Jianjun W., Lan W., Xiaoming W., Yaping W., Yangwei W., Yongjun W., Meifang W., Yidong W., Hongyun W., Chun W., Dongmei W., Jiang W., Jun W., Xiaolin W., Zonggui W., XiGuangxia, Yi X., Qian X., Xiaoping X., Yulong X., Anding X., Yuanming X., Chuanzhu Y., Tao Y., Xiaowei Y., Gangyi Y., Jian Y., Xiaosu Y.W.Y., Xinchun Y., Yifang Y., Yu Y., Mingyu Y., Min Y., Ping Y., Bo Y., Jiangyi Y., Jinming Y., Yan Y., Ling Z., Longyi Z., Xiaoyun Z., Baorong Z., Bei Z., Chaoxin Z., Xuelian Z., Dadong Z., Dongping Z., Fuchun Z., Hong Z., Huifang Z., Liping Z., Liyang Z., Rufu Z., Saidan Z., Weijuan Z., Dong Z., Gang Z., Shuiping Z., Xiuxin Z., Qiangsun Z., Yang Z., Xiaohui Z., Yali Z., Yujie Z., Yi Z., Yulan Z., Xiangping Z.","Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS)",2015,"Atherosclerosis","235","2",,"463","469",,3,10.1016/j.atherosclerosis.2014.05.916,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84905822472&partnerID=40&md5=80728ef72c0a2ae875c2345e2cf0353b","Department of Cardiology, Second Xiangya Hospital, Central South University, No.139, People Street (M.)Changsha, China; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 6, Tiantan Xi LiDongcheng District, Beijing, China; Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing RdHaidian District, Beijing, China; Department of Geriatric Cardiology, Chinese PLA General Hospital, No.28, Fuxing RdHaidian District, Beijing, China; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1, Shuai Fu YuanDongcheng District, Beijing, China; Department of Cardiology, The People's Hospital of Liaoning Province, No. 33, Wen Yi Rd.Shenhe District, Shenyang, China; Department of Cardiology, Tenth People's Hospital of Tongji University, No. 301, Yanchang Rd. (M)Shanghai, China; Merck and Co. Inc.Whitehouse Station, NJ, United States; Department of Cardiology, Peking University People's Hospital, No.11, Xi Zhi Men Nan Da JieXicheng District, Beijing, China","Zhao, S., Department of Cardiology, Second Xiangya Hospital, Central South University, No.139, People Street (M.)Changsha, China; Wang, Y., Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 6, Tiantan Xi LiDongcheng District, Beijing, China; Mu, Y., Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing RdHaidian District, Beijing, China; Yu, B., Department of Geriatric Cardiology, Chinese PLA General Hospital, No.28, Fuxing RdHaidian District, Beijing, China; Ye, P., Department of Geriatric Cardiology, Chinese PLA General Hospital, No.28, Fuxing RdHaidian District, Beijing, China; Yan, X., Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1, Shuai Fu YuanDongcheng District, Beijing, China; Li, Z., Department of Cardiology, The People's Hospital of Liaoning Province, No. 33, Wen Yi Rd.Shenhe District, Shenyang, China; Wei, Y., Department of Cardiology, Tenth People's Hospital of Tongji University, No. 301, Yanchang Rd. (M)Shanghai, China; Ambegaonakr, B.M., Merck and Co. Inc.Whitehouse Station, NJ, United States; Hu, D., Department of Cardiology, Peking University People's Hospital, No.11, Xi Zhi Men Nan Da JieXicheng District, Beijing, China; Er, B.A.J; Guiwen, C.; Buxing, C.; Hong, C.; Jin, C.; Jing, C.; Liefeng, C.; Min, C.; Qiong, C.; Shaoliang, C.; Tielong, C.; Xiaofei, C.; Xiaohong, C.; You, C.; Guoli, C.; Mei, C.; Hongliang, C.; Qin, C.; Shiwei, C.; Yong, C.; Shudong, D.; Henghua, D.; Xiaomei, D.; Yirong, D.; Xiaoyan, D.; Birong, D.; Yumei, D.; Yugang, D.; Ping, D.; Lei, D.; Limei, F.; Ningyuan, F.; Lixia, F.; Lie, F.; Jun, G.; GeWeihong; Hongmin, G.; Minxia, G.; Qinghua, H.; Fengchang, H.; Dayi, H.; Lingzhi, H.; Xueqiang, H.; Yaojun, H.; Yiming, H.; Zhiping, H.; Fei, H.; Qi, H.; Dejia, H.; Gewen, H.; Hongman, H.; Liming, H.; Qiong, H.; Ruowen, H.; Taifu, H.; Bin, J.; Kai, J.; Hui, J.; Huigen, J.; Jinsong, K.; Bao, L.; Chengjiang, L.; Hongjuan, L.; Li Jun, X.; Li Jun, J.; Nanfang, L.; Qifu, L.; Qiang, L.; Xin, L.; Xueyou, L.; Yanbing, L.; Yanping, L.; Yansheng, L.; Yong, L.; Yuling, L.; Zhanquan, L.; Zhengfang, L.; Li, L.; Yongxue, L.; Zerong, L.; Yuhua, L.; Fan, L.; Hong, L.; Hui, L.; Minling, L.; Qiang, L.; Qingsong, L.; Shaokui, L.; Weidong, L.; Xueping, L.; Xinjian, L.; Benyan, L.; Shaonian, L.; Suxin, L.; Hong, L.; LvYun; Aiqun, M.; Jianhua, M.; Qiang, M.; Yan, M.; Changsheng, M.; Yide, M.; Yiming, M.; NieXiaoli; NiuXiaoyuan; Hongtao, P.; Mingkang, P.; Qiaoqing, P.; Huifen, Q.; Qiumin, Q.; Lijie, Q.; Liqun, R.; Jingshan, S.; Qiang, S.; Jing, H.; Xiuyun, S.; Yongquan, S.; Liangyi, S.; Zhi, S.; Zhiyuan, S.; Yufeng, S.; Chunyan, T.; TengXiaochun; Haoming, T.; Wenhua, T.; Qinwei, T.; TuQiuyun; Keying, W.; Aihong, W.; Chaohui, W.; Chunning, W.; Dezhao, W.; Guixia, W.; Hanqiao, W.; Jianan, W.; Jianjun, W.; Lan, W.; Xiaoming, W.; Yaping, W.; Yangwei, W.; Yongjun, W.; Meifang, W.; Yidong, W.; Hongyun, W.; Chun, W.; Dongmei, W.; Jiang, W.; Jun, W.; Xiaolin, W.; Zonggui, W.; XiGuangxia; Yi, X.; Qian, X.; Xiaoping, X.; Yulong, X.; Anding, X.; Yuanming, X.; Chuanzhu, Y.; Tao, Y.; Xiaowei, Y.; Gangyi, Y.; Jian, Y.; Xiaosu, Y.W.Y.; Xinchun, Y.; Yifang, Y.; Yu, Y.; Mingyu, Y.; Min, Y.; Ping, Y.; Bo, Y.; Jiangyi, Y.; Jinming, Y.; Yan, Y.; Ling, Z.; Longyi, Z.; Xiaoyun, Z.; Baorong, Z.; Bei, Z.; Chaoxin, Z.; Xuelian, Z.; Dadong, Z.; Dongping, Z.; Fuchun, Z.; Hong, Z.; Huifang, Z.; Liping, Z.; Liyang, Z.; Rufu, Z.; Saidan, Z.; Weijuan, Z.; Dong, Z.; Gang, Z.; Shuiping, Z.; Xiuxin, Z.; Qiangsun, Z.; Yang, Z.; Xiaohui, Z.; Yali, Z.; Yujie, Z.; Yi, Z.; Yulan, Z.; Xiangping, Z.","Background: Despite clear guideline recommendations, there is a paucity of data regarding the prevalence and type of persistent lipid profile abnormalities in patients on stable lipid-lowering therapy in China. Methods: This cross-sectional trial included 25,697 patients treated with lipid-lowering agents from 122 centres between April 2012 and October 2012; all underwent clinical examination and had their latest fasting lipid profiles while on lipid-lowering therapy recorded. Logistic regression was performed to assess predictors for lipid abnormalities classified according to current Chinese guidelines. Findings: Overall, 29.1% of patients had no lipid abnormalities, and 38.5% of patients did not achieve the therapeutic goal for low-density lipoprotein cholesterol (LDL-C), either as a single lipid anomaly or associated with low high-density lipoprotein cholesterol (HDL-C), elevated triglycerides, or both. Subjects with low risk were more likely than those with very high and high risk to be at target LDL-C levels. Furthermore, 10.4% of very high-risk patients and 11.1% of high-risk patients who attained the LDL-C goal failed to attain non-HDL-C goals. Diabetes was shown to be a strong predictor of failure in attaining non-HDL-C and both goals (OR 3.03; 3.22, 95% CI 2.58-3.55; 2.73-3.79, respectively). Conclusion: Although great improvements have been made over the past decade, the large majority of very high-risk and high-risk patients treated with lipid-lowing agents still had one or more manifestations of dyslipidaemia. Further clinical evidence is needed to clarify whether adding other lipid-lowering agents to a statin will be associated with additional cardiovascular risk reduction. © 2014 Elsevier Ireland Ltd.","Cardiovascular diseases; Dyslipidaemia; LDL cholesterol; Lipid-lowering agents; Non-HDL cholesterol; Statin","He, J., Gu, D., Reynolds, K., Wu, X., Duan, X., Yao, C., Major causes of death among men and women in China (2005) N Engl J Med, 353, pp. 1124-1134; Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (2004) Lancet, 364, pp. 937-952; Yang, W., Xiao, J., Yang, Z., Ji, L., Jia, W., Weng, J., Serum lipids and lipoproteins in Chinese men and women (2012) Circulation, 125, pp. 2212-2221; Dyslipidemia management in adults with diabetes (2004) Diabetes Care, 27, pp. S68-S71. , 90001; Snow, V., Aronson, M.D., Hornbake, E.R., Mottur-Pilson, C., Weiss, K.B., Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American college of physicians (2004) Ann Intern Med, 140, pp. 644-649; Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., Dawber, T.R., High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study (1977) Am J Med, 62, pp. 707-714; Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies (2007) Circulation, 115, pp. 450-458; Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins (2005) Lancet, 366, pp. 1267-1278; Fruchart, J.C., Sacks, F.M., Hermans, M.P., Assmann, G., Brown, W.V., Ceska, R., The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient (2008) Diab Vasc Dis Res, 5, pp. 319-335; Treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (2001) JAm Med Assoc, 285, pp. 2486-2497; Reiner, Z., Catapano, A.L., ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) Eur Heart J, 32, pp. 1769-1818; Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report (2002) Circulation, 106, pp. 3143-3421; Hu, D.Y., Ding, R.J., Guidelines for management of adult dyslipidemia in China (2007) Zhonghua Xin Xue Guan Bing Za Zhi, 35, pp. 390-410; Yu, B.L., Zhao, S.P., Peng, D.Q., Huo, Y., Hu, L., Acomparison of non-HDL and LDL cholesterol goal attainment in the CHILLAS trial (2013) Int J Cardiol, 9 (168), pp. 4340-4342; Amulti-center study of current status on clinical control of hypercholesterolemia in China: success rate and related factors (2002) Zhonghua Xin Xue Guan Bing Za Zhi, 30, pp. 109-114; Wu, Y.F., The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors (2007) Zhonghua Xin Xue Guan Bing Za Zhi, 35, pp. 420-427; Gitt, A.K., Drexel, H., Feely, J., Ferrières, J., Gonzalez-Juanatey, J.R., Thomsen, K.K., Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada (2012) Eur J Prev Cardiol, 19, pp. 221-230; Goodman, S.G., Langer, A., Bastien, N.R., McPherson, R., Francis, G.A., Genest, J.J., Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS) (2010) Can J Cardiol, 26, pp. e330-e335; Yusuf, S., Islam, S., Chow, C.K., Rangarajan, S., Dagenais, G., Diaz, R., Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey (2011) Lancet, 378, pp. 1231-1243; Gitt, A.K., Jünger, C., Smolka, W., Bestehorn, K., Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany (2010) Clin Res Cardiol, 99, pp. 723-733; Hwang, J.Y., Jung, C.H., Lee, W.J., Park, C.Y., Kim, S.R., Yoon, K.H., Low density lipoprotein cholesterol target goal attainment rate and physician perceptions about target goal achievement in Korean patients with diabetes (2011) Diabetes Metab J, 35, pp. 628-636; Kennedy, A.G., MacLean, C.D., Littenberg, B., Ades, P.A., Pinckney, R.G., The challenge of achieving national cholesterol goals in patients with diabetes (2005) Diabetes Care, 28, pp. 1029-1034; Yan, A.T., Yan, R.T., Tan, M., Hackam, D.G., Leblanc, K.L., Kertland, H., Vascular Protection (VP) and guidelines oriented approach to lipid lowering (GOALL) registries investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met (2006) Am J Med, 119, pp. 676-683; Teoh, H., Mendelsohn, A.A., Goodman, S.G., Jaffer, S., Chen, R.Y., Tjia, S., Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease (2009) Am J Cardiol, 104, pp. 798-804; Maron, D.J., Hartigan, P.M., Neff, D.R., Weintraub, W.S., W.E. Boden; COURAGE Trial Investigators. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the clinical outcomes utilizing revascularization and aggressive drug evaluation [COURAGE] trial) (2013) Am J Cardiol, 111, pp. 1557-1562; Chin, C.W., Gao, F., Le, T., Tan, R., Lipid goal attainment and prescription behavior in asian patients with acute coronary syndromes: experience from a tertiary hospital (2013) Clin Med Insights Cardiol, 7, pp. 51-57; Gao, F., Zhou, Y.J., Hu, D.Y., Zhao, Y.X., Liu, Y.Y., Wang, Z.J., Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China (2013) PLoS One, 8. , e47681; Leiter, L.A., Lundman, P., da Silva, P.M., Drexel, H., Jünger, C., Gitt, A.K., Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study (2011) Diabet Med, 28, pp. 1343-1351; Robinson, J.G., Want, S., Smith, B.J., Jacobson, T.A., Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease (2009) JAm Coll Cardiol, 53, pp. 316-322",Article,Scopus,2-s2.0-84905822472
"Charles P.G.P., Uckay I., Kressmann B., Emonet S., Lipsky B.A.","The role of anaerobes in diabetic foot infections",2015,"Anaerobe","34",,,"8","13",,,10.1016/j.anaerobe.2015.03.009,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926665067&partnerID=40&md5=35fe1cf93bd7b3078718df188dd95e75","Infectious Diseases Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland; Department of Infectious Diseases, Austin HealthHeidelberg, Australia; Department of Medicine, University of MelbourneParkville, Australia; Orthopaedic Surgery Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland; Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland; Laboratory of Bacteriology, Geneva University HospitalsGeneva, Switzerland; Division of Medical Sciences (Infectious Diseases), University of OxfordOxford, United Kingdom","Charles, P.G.P., Infectious Diseases Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland, Department of Infectious Diseases, Austin HealthHeidelberg, Australia, Department of Medicine, University of MelbourneParkville, Australia; Uçkay, I., Infectious Diseases Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland, Orthopaedic Surgery Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland; Kressmann, B., Infectious Diseases Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland, Orthopaedic Surgery Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland; Emonet, S., Infectious Diseases Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland, Laboratory of Bacteriology, Geneva University HospitalsGeneva, Switzerland; Lipsky, B.A., Infectious Diseases Service, Geneva University Hospitals and Faculty of MedicineGeneva, Switzerland, Division of Medical Sciences (Infectious Diseases), University of OxfordOxford, United Kingdom","Diabetic foot infections (DFI) are a common cause of morbidity and, on occasion, even mortality. Infection can be either mono- or polymicrobial, with a wide variety of potential pathogens. Anaerobes may be involved, particularly in wounds that are deeper or more chronic, and are more frequently identified when using modern molecular techniques, such as 16s PCR and pyrosequencing. It remains unclear whether the presence of anaerobes in DFI leads to more severe manifestations, or if these organisms are largely colonizers associated with the presence of greater degrees of tissue ischemia and necrosis. Commonly used empiric antibiotic therapy for diabetic foot infections is generally broad-spectrum and usually has activity against the most frequently identified anaerobes, such as Peptostreptococcus and Bacteroides species. Adequate surgical debridement and, when needed, foot revascularization may be at least as important as the choice of antibiotic to achieve a successful treatment outcome. © 2015 Elsevier Ltd.","Anaerobes; Bacteria; Diabetes mellitus; Diabetic foot infection; Infection; Ulcer","Singh, N., Armstrong, D.G., Lipsky, B.A., Preventing foot ulcers in patients with diabetes (2005) JAMA, 293, pp. 217-228; Raspovic, K.M., Wukich, D.K., Self-reported quality of life and diabetic foot infections (2014) J.Foot Ankle Surg., 53, pp. 716-719; Lipsky, B.A., Berendt, A.R., Cornia, P.B., 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections (2012) Clin. Infect. Dis., 54, pp. e132-e173; Louie, T.J., Bartlett, J.G., Tally, F.P., Gorbach, S.L., Aerobic and anaerobic bacteria in diabetic foot ulcers (1976) Ann. Intern. Med., 85, pp. 461-463; Gerding, D.N., Foot infections in diabetic patients: the role of anaerobes (1995) Clin. Infect. Dis., 20, pp. S283-S288; Uçkay, I., Gariani, K., Pataky, Z., Lipsky, B.A., Diabetic foot infections: state-of-the-art (2014) Diabetes Obes. Metab., 16, pp. 305-316; Bowler, P.G., Duerden, B.I., Armstrong, D.G., Wound microbiology and associated approaches to wound management (2001) Clin. Microbiol. Rev., 14, pp. 244-269; Lavery, L.A., Peters, E.J., Armstrong, D.G., Wendel, C.S., Murdoch, D.P., Lipsky, B.A., Risk factors for developing osteomyelitis in patients with diabetic foot wounds (2009) Diabetes Res. Clin. Pract., 83, pp. 347-352; Prompers, L., Schaper, N., Apelqvist, J., Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE study (2008) Diabetologia, 51, pp. 747-755; Gardner, S.E., Hillis, S.L., Heilmann, K., Segre, J.A., Grice, E.A., The neuropathic diabetic foot ulcer microbiome is associated with clinical factors (2013) Diabetes, 62, pp. 923-930; Chakraborti, C., Le, C., Yanofsky, A., Sensitivity of superficial cultures in lower extremity wounds (2010) J.Hosp. Med., 5, pp. 415-420; Sotto, A., Richard, J.L., Jourdan, N., Miniaturized oligonucleotide arrays: a new tool for discriminating colonization from infection due to Staphylococcus aureus in diabetic foot ulcers (2007) Diabetes Care, 30, pp. 2051-2056; Senneville, E., Melliez, H., Beltrand, E., Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures (2006) Clin. Infect. Dis., 42, pp. 57-62; Senneville, E., Morant, H., Descamps, D., Needle puncture and transcutaneous bone biopsy cultures are inconsistent in patients with diabetes and suspected osteomyelitis of the foot (2009) Clin. Infect. Dis., 48, pp. 888-893; Dowd, S.E., Wolcott, R.D., Sun, Y., McKeehan, T., Smith, E., Rhoads, D., Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP) (2008) PLoS One, 3, p. e3326; Dowd, S.E., Sun, Y., Secor, P.R., Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing (2008) BMC Microbiol., 8, p. 43; Lavigne, J.P., Sotto, A., Dunyach-Remy, C., Lipsky, B.A., New molecular techniques to study the skin microbiota of diabetic foot ulcers (2015) Adv. Wound Care (New Rochelle), 4, pp. 38-49; Spichler, A., Hurwitz, B.L., Armstrong, D.G., Lipsky, B.A., Microbiology of diabetic foot infections: from Louis Pasteur to 'crime scene investigation' (2015) BMC Med., 13, p. 2; Lipsky, B.A., Richard, J.L., Lavigne, J.P., Diabetic foot ulcer microbiome: one small step for molecular microbiology. . . One giant leap for understanding diabetic foot ulcers? (2013) Diabetes, 62, pp. 679-681; Zenelaj, B., Bouvet, C., Lipsky, B.A., Uçkay, I., Do diabetic foot infections with methicillin-resistant Staphylococcus aureus differ from those with other pathogens? (2014) Int. J. Low Extrem. Wounds, 13, pp. 263-272; Hsu, Y.M., Burnham, C.A., MALDI-TOF MS identification of anaerobic bacteria: assessment of pre-analytical variables and specimen preparation techniques (2014) Diagn. Microbiol. Infect. Dis., 79, pp. 144-148; Nagy, E., Schuetz, A., Is there a need for the antibiotic susceptibility testing of anaerobic bacteria? (2015) Anaerobe, 31, pp. 2-3; Jamal, W., Shahin, M., Rotimi, V.O., Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007 (2010) Anaerobe, 16, pp. 1-5; Bahebeck, J., Sobgui, E., Loic, F., Nonga, B.N., Mbanya, J.C., Sosso, M., Limb-threatening and life-threatening diabetic extremities: clinical patterns and outcomes in 56 patients (2010) J.Foot Ankle Surg., 49, pp. 43-46; Lipsky, B.A., Sheehan, P., Armstrong, D.G., Tice, A.D., Polis, A.B., Abramson, M.A., Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial (2007) Int. Wound J., 4, pp. 30-38; Lipsky, B.A., Armstrong, D.G., Citron, D.M., Tice, A.D., Morgenstern, D.E., Abramson, M.A., Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial (2005) Lancet, 366, pp. 1695-1703; Lauf, L., Ozsvar, Z., Mitha, I., Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis (2014) Diagn. Microbiol. Infect. Dis., 78, pp. 469-480; Vardakas, K.Z., Horianopoulou, M., Falagas, M.E., Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials (2008) Diabetes Res. Clin. Pract., 80, pp. 344-351; Clay, P.G., Graham, M.R., Lindsey, C.C., Lamp, K.C., Freeman, C., Glaros, A., Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males (2004) Am. J. Geriatr. Pharmacother., 2, pp. 181-189; Lipsky, B.A., Baker, P.D., Landon, G.C., Fernau, R., Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens (1997) Clin. Infect. Dis., 24, pp. 643-648; Lipsky, B.A., Giordano, P., Choudhri, S., Song, J., Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate (2007) J.Antimicrob. Chemother., 60, pp. 370-376; Lipsky, B.A., Itani, K., Norden, C., Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate (2004) Clin. Infect. Dis., 38, pp. 17-24. , Linezolid Diabetic Foot Infections Study G; Lipsky, B.A., Pecoraro, R.E., Larson, S.A., Hanley, M.E., Ahroni, J.H., Outpatient management of uncomplicated lower-extremity infections in diabetic patients (1990) Arch. Intern. Med., 150, pp. 790-797; Peterson, L.R., Lissack, L.M., Canter, K., Fasching, C.E., Clabots, C., Gerding, D.N., Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both (1989) Am. J. Med., 86, pp. 801-808; Schaper, N.C., Dryden, M., Kujath, P., Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study (2013) Infection, 41, pp. 175-186; Lipsky, B.A., Peters, E.J., Senneville, E., Expert opinion on the management of infections in the diabetic foot (2012) Diabetes Metab. Res. Rev., 28, pp. 163-178; Anandi, C., Alaguraja, D., Natarajan, V., Bacteriology of diabetic foot lesions (2004) Indian J. Med. Microbiol., 22, pp. 175-178; Unachukwu, C.N., Obunge, O.K., Odia, O.J., The bacteriology of diabetic foot ulcers in Port Harcourt, Nigeria (2005) Niger. J. Med., 14, pp. 173-176; Senneville, E., Antimicrobial interventions for the management of diabetic foot infections (2005) Expert Opin. Pharmacother., 6, pp. 263-273; Abdulrazak, A., Bitar, Z.I., Al-Shamali, A.A., Mobasher, L.A., Bacteriological study of diabetic foot infections (2005) J.Diabetes Complicat., 19, pp. 138-141; Shankar, E.M., Mohan, V., Premalatha, G., Srinivasan, R.S., Usha, A.R., Bacterial etiology of diabetic foot infections in South India (2005) Eur. J. Intern. Med., 16, pp. 567-570; Raja, N.S., Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases (2007) J.Microbiol. Immunol. Infect., 40, pp. 39-44; Cetin, M., Ocak, S., Kuvandik, G., Aslan, B., Comparison of bacterial isolates cultured from hemodialysis patients and other patients with diabetic foot and their antimicrobial resistance (2007) Ren. Fail., 29, pp. 973-978; Sotto, A., Bouziges, N., Jourdan, N., Richard, J.L., Lavigne, J.P., Invitro activity of tigecycline against strains isolated from diabetic foot ulcers (2007) Pathol. Biol., 55, pp. 398-406; Umadevi, S., Kumar, S., Joseph, N.M., Microbiological study of diabetic foot infections (2007) Indian J. Med. Spec., 2, pp. 12-17; Ozkara, A., DelibasI, T., Selcoki, Y., Arikan, M.F., The major clinical outcomes of diabetic foot infections: one center experience (2008) Cent. Eur. J. Med., 3, pp. 464-469; Aragón-Sánchez, F.J., Cabrera-Galván, J.J., Quintana-Marrero, Y., Outcomes of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement (2008) Diabetalogia, 51, pp. 1962-1970; Ng, L.S., Kwang, L.L., Yeow, S.C., Tan, T.Y., Anaerobic culture of diabetic foot infections: organisms and antimicrobial susceptibilities (2008) Ann. Acad. Med. Singap., 37, pp. 936-939; Khoharo, H.K., Ansari, S., Qureshi, F., Diabetic foot ulcers (2009) Prof. Med. J., 16, pp. 53-60; Martinez-Gomez Dde, A., Ramirez-Almagro, C., Campillo-Soto, A., Morales-Cuenca, G., Pagan-Ortiz, J., Aguayo-Albasini, J.L., Diabetic foot infections. Prevalence and antibiotic sensitivity of the causative microorganisms (2009) Enferm. Infecc. Microbiol. Clin., 27, pp. 317-321; Lipsky, B.A., Tabak, Y.P., Johannes, R.S., Vo, L., Hyde, L., Weigelt, J.A., Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost (2010) Diabetologia, 53, pp. 914-923; Girish, M.B., Kumar, T.N., Srinivas, R., Pattern of antimicrobials used to treat infected diabetic foot in a tertiary care hospital in Kolar (2010) Int. J. Pharm. Biomed. Res., 1, pp. 48-52; Zubair, M., Malik, A., Ahmad, J., Clinico-microbiological study and antimicrobial drug resistance profile of diabetic foot infections in North India (2011) Foot (Edinb.), 21, pp. 6-14; Hayat, A.S., Khan, A.H., Masood, N., Shaikh, N., Study for microbiological pattern and invitro antibiotic susceptibility in patients having diabetic foot infections at tertiary care hospital in Abbottabad (2011) World Appl. Sci. J., 12, pp. 123-131; Bozkurt, F., Gülsün, S., Tekin, R., Hoşoğlu, S., Acemoğlu, H., Comparison of microbiological results of deep tissue biopsy and superficial swab in diabetic foot infections (2011) J.Microbiol. Infect. Dis., 1, pp. 122-127; Pappu, A.K., Sinha, A., Johnson, A., Microbiological profile of diabetic foot ulcer (2011) Calicut Med. J., 9, pp. 1-4; Tascini, C., Piaggesi, A., Tagliaferri, E., Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy (2011) Diabetes Res. Clin. Pract., 94, pp. 133-139; Aziz, Z., Lin, W.K., Nather, A., Huak, C.Y., Predictive factors for lower extremity amputations in diabetic foot infections (2011) Diabet. Foot Ankle, 2; Dezfulian, A., Salehian, M.T., Amini, V., Bacteriological study of diabetic foot infections in an Iranian hospital (2011) Iran Red Crescent Med. J., 13, pp. 590-591; Swarna, S.R.M.R., Gomathi, S., Thamaraiselvi, D., Thamaraiselvi, S., Astudy of biofilm in diabetic foot ulcer (2012) Int. J. Res. Pharma Biomed. Sci., 3, pp. 1809-1814; Mendes, J.J., Marques-Costa, A., Vilela, C., Clinical and bacteriological survey of diabetic foot infections in Lisbon (2012) Diabetes Res. Clin. Pract., 95, pp. 153-161; Bano, I., Chaudhary, W.A., Hameed, A., Invitro bacteriologic study and empiric antibiotic regimens for diabetic foot ulcers (2012) Afr. J. Microbiol. Res., 6, pp. 5568-5573; Parvez, N., Dutta, P., Ray, P., Microbial profile and utility of soft tissue, pus, and bone cultures in diagnosing diabetic foot infections (2012) Diabetes Technol. Ther., 14, pp. 669-674; Al Benwan, K., Al Mulla, A., Rotimi, V.O., Astudy of the microbiology of diabetic foot infections in a teaching hospital in Kuwait (2012) J.Infect. Public Health, 5, pp. 1-8; Osariemen, I.J., Olowu, S.S., Adevbo, E., Aerobic bacteria associated with diabetic wounds in patients attending clinic in a rural community in Nigeria (2013) Glob. Res. J. Microbiol., 3, pp. 8-11; Djahmi, N., Messad, N., Nedjai, S., Molecular epidemiology of Staphylococcus aureus strains isolated from inpatients with infected diabetic foot ulcers in an Algerian University Hospital (2013) Clin. Microbiol. Infect., 19, pp. E398-E404; Jasmine, J., Sekkizhar, G., Kumpatla, S., Viswanathan, V., Bioburden vs. antibiogram of diabetic foot infection (2013) Clin. Res. Foot Ankle, 1, p. 121; Islam, S., Cawich, S.O., Budhooram, S., Microbial profile of diabetic foot infections in Trinidad and Tobago (2013) Prim. Care Diabetes, 7, pp. 303-308; Ahmed, M.B., Said, A.M.I., Naira, E.A., Fatani, A.J., Emad, E.M., Soma, A.E., Infection in diabetic foot (2013) Menoufia Med. J., 26, pp. 49-53; Malone, M., Bowling, F.L., Gannass, A., Jude, E.B., Boulton, A.J., Deep wound cultures correlate well with bone biopsy culture in diabetic foot osteomyelitis (2013) Diabetes Metab. Res. Rev., 29, pp. 546-550; Claros, M., Citron, D.M., Goldstein, E.J., Merriam, C.V., Tyrrell, K.L., Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections (2013) Diagn. Microbiol. Infect. Dis., 76, pp. 546-548; de Vries, M.G., Ekkelenkamp, M.B., Peters, E.J., Are clindamycin and ciprofloxacin appropriate for the empirical treatment of diabetic foot infections? (2014) Eur. J. Clin. Microbiol. Infect. Dis., 33, pp. 453-456; Hatipoglu, M., Mutluoglu, M., Uzun, G., Karabacak, E., Turhan, V., Lipsky, B.A., The microbiologic profile of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections in Turkey (2014) Eur. J. Clin. Microbiol. Infect. Dis., 33, pp. 871-878; Akhi, M.T., Ghotaslou, R., Asgharzadeh, M., Bacterial etiology and antibiotic susceptibility pattern of diabetic foot infections in Tabriz, Iran (2015) GMS Hyg. Infect. Control, 10. , http://www.egms.de/static/pdf/journals/dgkh/2015-10/dgkh000245.pdf",Review,Scopus,2-s2.0-84926665067
"Zuliani G., Morieri M.L., Volpato S., Maggio M., Cherubini A., Francesconi D., Bandinelli S., Paolisso G., Guralnik J.M., Ferrucci L.","Insulin resistance and systemic inflammation, but not metabolic syndrome phenotype, predict 9 years mortality in older adults",2015,"Atherosclerosis","235","2",,"538","545",,1,10.1016/j.atherosclerosis.2014.05.959,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84910059901&partnerID=40&md5=a92ff117e0fc9aa1bbe16b749e9940cc","Department of Medical Sciences, Section of Internal and CardioRespiratory Medicine, University of Ferrara, Italy; Department of Internal Medicine and Biomedical Sciences, Section of Geriatrics, University of Parma, Italy; Institute of Gerontology and Geriatrics, INNRCAAncona, Italy; ASF Geriatric RehabilitationFlorence, Italy; Tuscany Regional Health Agency, I.O.T.Florence, Italy; Department of Gerontology, Geriatrics and Metabolic Diseases, Second University of Naples, Italy; Department of Epidemiology and Public Health, University of Maryland School of MedicineBaltimore, MD, United States; Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, NIHBaltimore, MD, United States","Zuliani, G., Department of Medical Sciences, Section of Internal and CardioRespiratory Medicine, University of Ferrara, Italy; Morieri, M.L., Department of Medical Sciences, Section of Internal and CardioRespiratory Medicine, University of Ferrara, Italy; Volpato, S., Department of Medical Sciences, Section of Internal and CardioRespiratory Medicine, University of Ferrara, Italy; Maggio, M., Department of Internal Medicine and Biomedical Sciences, Section of Geriatrics, University of Parma, Italy; Cherubini, A., Institute of Gerontology and Geriatrics, INNRCAAncona, Italy; Francesconi, D., Department of Medical Sciences, Section of Internal and CardioRespiratory Medicine, University of Ferrara, Italy; Bandinelli, S., ASF Geriatric RehabilitationFlorence, Italy, Tuscany Regional Health Agency, I.O.T.Florence, Italy; Paolisso, G., Department of Gerontology, Geriatrics and Metabolic Diseases, Second University of Naples, Italy; Guralnik, J.M., Department of Epidemiology and Public Health, University of Maryland School of MedicineBaltimore, MD, United States; Ferrucci, L., Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, NIHBaltimore, MD, United States","Background: Although metabolic syndrome (MS) is a typical condition of middle-aged/older person, the association between MS and mortality risk has not been confirmed in people over 65 years. We hypothesized that while in the elderly MS phenotype might lose its value in predicting mortality risk, the two core factors of MS, i.e. insulin resistance (IR) and low grade systemic inflammation (LGSI) would not. Methods: 1011 community-dwelling older individuals (InCHIANTI study) were included. MS phenotype was defined by NCEP-ATP-III criteria. IR was calculated by HOMA; high-sensitivity C reactive protein was measured by ELISA. Subjects were divided into four groups based on presence/absence of IR (HOMA ≥ 2.27) and LGSI (hs-CRP≥3g/L): Group 1: no IR/LGSI (reference); Group 2: LGSI only; Group 3: IR only; Group 4: IR+LGSI. Hazard Ratios (HR) for 9-years cardiovascular (CVD) and total mortality, according to IR/LGSI groups, were estimated in subjects with (n.311) and without MS by Cox model. Results: 31.8% of subjects with MS phenotype had no IR, 45.3% had no LGSI; moreover, 51% of subjects with both IR and LGSI didn't display the MS phenotype. MS phenotype was not associated with CVD (HR: 1.29; 95%C.I.:0.92-1.81) or total (HR: 1.07; 95%C.I.:0.86-1.34) mortality risk, whereas the presence of IR plus LGSI was associated with increased CVD (no MS: HR 2.07, 95%CI: 1.12-3.72; MS: HR 9.88, 95%CI: 2.18-4), and overall (no MS: HR 1.72, 95%CI: 1.001-3.17; MS: HR 1.51, 95%CI: 1.02-2.28) mortality risk. The presence of IR (HR: 6.90, 95%CI: 1.45-32) or LGSI (HR 7.56, 95%CI: 1.63-35) was associated with CVD mortality, only among individuals with MS phenotype. Conclusions: Among community-dwelling older individuals, IR and LGSI, but not MS phenotype, was associated with 9-years overall and CVD mortality risk. Since a reduced ""overlap"" between MS phenotype and its physiopathological core (IR and LGSI) might be present with aging, we suggest that the definition of MS might be more holistic in advanced age, and probably comprise the measurement of IR and LGSI. © 2014 Elsevier Ireland Ltd.","C reactive protein; Elderly; Insulin resistance; Metabolic syndrome; Mortality","Reaven, G.M., Banting lecture 1988. Role of insulin resistance in human disease (1988) Diabetes, 37 (12), pp. 1595-1607; Malik, S., Wong, N.D., Franklin, S.S., Kamath, T.V., L'Italien, G.J., Pio, J.R., Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults (2004) Circulation, 110 (10), pp. 1245-1250; Mottillo, S., Filion, K.B., Genest, J., Joseph, L., Pilote, L., Poirier, P., The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis (2010) JAm Coll Cardiol, 56 (14), pp. 1113-1132; Ford, E.S., Giles, W.H., Dietz, W.H., Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey (2002) JAMA, 287 (3), pp. 356-359; Mozaffarian, D., Kamineni, A., Prineas, R.J., Siscovick, D.S., Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study (2008) Arch Intern Med, 168 (9), pp. 969-978; Zambon, S., Zanoni, S., Romanato, G., Corti, M.C., Noale, M., Sartori, L., Metabolic syndrome and all-cause and cardiovascular mortality in an Italian elderly population: the Progetto Veneto Anziani (Pro.V.A.) Study (2009) Diabetes Care, 32 (1), pp. 153-159; Akbaraly, T.N., Kivimaki, M., Ancelin, M.L., Barberger-Gateau, P., Mura, T., Tzourio, C., Metabolic syndrome, its components, and mortality in the elderly (2010) JClin Endocrinol Metab, 95 (11), pp. E327-E332; Rachas, A., Raffaitin, C., Barberger-Gateau, P., Helmer, C., Ritchie, K., Tzourio, C., Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study (2012) Heart, 98 (8), pp. 650-655; Wang, J., Ruotsalainen, S., Moilanen, L., Lepisto, P., Laakso, M., Kuusisto, J., The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic finns (2007) Eur Heart J, 28 (7), pp. 857-864; Sattar, N., McConnachie, A., Shaper, A.G., Blauw, G.J., Buckley, B.M., de Craen, A.J., Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies (2008) Lancet, 371 (9628), pp. 1927-1935; Butler, J., Rodondi, N., Zhu, Y., Figaro, K., Fazio, S., Vaughan, D.E., Metabolic syndrome and the risk of cardiovascular disease in older adults (2006) JAm Coll Cardiol, 47 (8), pp. 1595-1602; Hildrum, B., Mykletun, A., Dahl, A.A., Midthjell, K., Metabolic syndrome and risk of mortality in middle-aged versus elderly individuals: the Nord-Trondelag Health Study (HUNT) (2009) Diabetologia, 52 (4), pp. 583-590; Thomas, F., Pannier, B., Benetos, A., Vischer, U.M., The impact of the metabolic syndrome-but not of hypertension-on all-cause mortality disappears in the elderly (2011) JHypertens, 29 (4), pp. 663-668; Sundstrom, J., Riserus, U., Byberg, L., Zethelius, B., Lithell, H., Lind, L., Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study (2006) BMJ, 332 (7546), pp. 878-882; Ausk, K.J., Boyko, E.J., Ioannou, G.N., Insulin resistance predicts mortality in nondiabetic individuals in the U.S (2010) Diabetes Care, 33 (6), pp. 1179-1185; Perseghin, G., Calori, G., Lattuada, G., Ragogna, F., Dugnani, E., Garancini, M.P., Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up (2012) Acta Diabetol, 49 (6), pp. 421-428; Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., Meigs, J.B., Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study (2007) Diabetes Care, 30 (2), pp. 318-324; de Boer, I.H., Katz, R., Chonchol, M.B., Fried, L.F., Ix, J.H., Kestenbaum, B., Insulin resistance, cystatin C, and mortality among older adults (2012) Diabetes Care, 35 (6), pp. 1355-1360; Festa, A., D'Agostino, R., Howard, G., Mykkanen, L., Tracy, R.P., Haffner, S.M., Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study (2000) Kidney Int, 58 (4), pp. 1703-1710; Hassinen, M., Lakka, T.A., Komulainen, P., Gylling, H., Nissinen, A., Rauramaa, R., C-reactive protein and metabolic syndrome in elderly women: a 12-year follow-up study (2006) Diabetes Care, 29 (4), pp. 931-932; Libby, P., Ridker, P.M., Maseri, A., Inflammation and atherosclerosis (2002) Circulation, 105 (9), pp. 1135-1143; Libby, P., Inflammation in atherosclerosis (2002) Nature, 420 (6917), pp. 868-874; Buckley, D.I., Fu, R., Freeman, M., Rogers, K., Helfand, M., C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force (2009) Ann Intern Med, 151 (7), pp. 483-495; Rutter, M.K., Meigs, J.B., Sullivan, L.M., D'Agostino, R.B., Wilson, P.W., C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study (2004) Circulation, 110 (4), pp. 380-385; Elkind, M.S., Luna, J.M., Moon, Y.P., Liu, K.M., Spitalnik, S.L., Paik, M.C., High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study (2009) Neurology, 73 (16), pp. 1300-1307; Harris, T.B., Ferrucci, L., Tracy, R.P., Corti, M.C., Wacholder, S., Ettinger, W.H., Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly (1999) Am J Med, 106 (5), pp. 506-512; Cushman, M., Arnold, A.M., Psaty, B.M., Manolio, T.A., Kuller, L.H., Burke, G.L., C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study (2005) Circulation, 112 (1), pp. 25-31; Giovannini, S., Onder, G., Liperoti, R., Russo, A., Carter, C., Capoluongo, E., Interleukin-6, C-reactive protein, and tumor necrosis factor-alpha as predictors of mortality in frail, community-living elderly individuals (2011) JAm Geriatr Soc, 59 (9), pp. 1679-1685; Ferrucci, L., Bandinelli, S., Benvenuti, E., Di, I.A., Macchi, C., Harris, T.B., Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study (2000) JAm Geriatr Soc, 48 (12), pp. 1618-1625; Zuliani, G., Galvani, M., Maggio, M., Volpato, S., Bandinelli, S., Corsi, A.M., Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance (2010) Atherosclerosis, 213 (1), pp. 319-324; Pearson, T.A., Bazzarre, T.L., Daniels, S.R., Fair, J.M., Fortmann, S.P., Franklin, B.A., American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science (2003) Circulation, 107 (4), pp. 645-651; Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) Circulation, 112 (17), pp. 2735-2752; Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report (2002) Circulation, 106 (25), pp. 3143-3421; Barnett, K.N., McMurdo, M.E., Ogston, S.A., Morris, A.D., Evans, J.M., Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review (2006) Age Ageing, 35 (5), pp. 463-468; Lee, J.K., Bettencourt, R., Brenner, D., Le, T.A., Barrett-Connor, E., Loomba, R., Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study (2012) PLoS One, 7 (4), p. e34218; Laaksonen, D.E., Niskanen, L., Nyyssonen, K., Punnonen, K., Tuomainen, T.P., Salonen, J.T., C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study (2005) Eur Heart J, 26 (17), pp. 1783-1789; Despres, J.P., Lemieux, I., Abdominal obesity and metabolic syndrome (2006) Nature, 444 (7121), pp. 881-887; Boren, J., Taskinen, M.R., Olofsson, S.O., Levin, M., Ectopic lipid storage and insulin resistance: a harmful relationship (2013) JIntern Med, 274 (1), pp. 25-40; Bonora, E., Targher, G., Alberiche, M., Bonadonna, R.C., Saggiani, F., Zenere, M.B., Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity (2000) Diabetes Care, 23 (1), pp. 57-63",Article,Scopus,2-s2.0-84910059901
"Gocke C., Holtfreter B., Meisel P., Grotevendt A., Jablonowski L., Nauck M., Markus M.R.P., Kocher T.","Abdominal obesity modifies long-term associations between periodontitis and markers of systemic inflammation",2015,"Atherosclerosis","235","2",,"351","357",,,10.1016/j.atherosclerosis.2014.05.926,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921480162&partnerID=40&md5=7a9da4bc2301b3e3bd755536a97aba18","Unit of Periodontology, Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany; Department Study of Health in Pomerania/Clinical-Epidemiological Research, Institute for Community Medicine, University Medicine GreifswaldGreifswald, Germany","Gocke, C., Unit of Periodontology, Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany; Holtfreter, B., Unit of Periodontology, Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany; Meisel, P., Unit of Periodontology, Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany; Grotevendt, A., Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany; Jablonowski, L., Unit of Periodontology, Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany; Nauck, M., Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany; Markus, M.R.P., Department Study of Health in Pomerania/Clinical-Epidemiological Research, Institute for Community Medicine, University Medicine GreifswaldGreifswald, Germany; Kocher, T., Unit of Periodontology, Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Ernst Moritz Arndt University of GreifswaldGreifswald, Germany","Objective: Periodontitis is considered to promote atherosclerosis and cardiovascular diseases through increased low-grade systemic inflammation. However, there is no information on the long-term impact of periodontitis on systemic inflammation from cohort studies. Thus, this study aims to assess the impact of periodontitis on systemic inflammation (fibrinogen and white blood cells (WBC)) in a population-based longitudinal survey in north-eastern Germany. Methods: The study sample comprised 2622 subjects from the Study of Health in Pomerania with complete 5- and 11-year follow-ups. Periodontitis was assessed by probing depth and clinical attachment level. Multilevel regression analyses were applied to evaluate associations between periodontitis measures and i) fibrinogen/WBC count using 11-year follow-up data and ii) respective z-scores of fibrinogen/WBC count using 5- and 11-year follow-up data. We adjusted for common cardiovascular risk factors and stratified analyses by abdominal obesity (. P for interaction <0.10). Results: In lean subjects, beta-coefficients of mean probing depth were B=0.13 (0.08-0.019; P<0.001) for fibrinogen and B=0.50 (0.37-0.64; P<0.001) for WBC count using 11-year follow-up data only. For lean subjects, models using z-scores confirmed that increased mean probing depths were associated with increased fibrinogen z-scores (. B=0.14 (0.09-0.18; P<0.001)) and increased WBC z-scores (. B=0.16 (0.11-0.20; P<0.001)). Consistent results were found for mean clinical attachment levels. For abdominally obese subjects, relations between periodontitis measures and levels of inflammation markers were less pronounced or non-significant. Conclusion: Modified by abdominal obesity, periodontitis affected systemic inflammation in a significant dose-dependent manner. Results contribute to the discussion on how periodontitis is linked to atherosclerosis and cardiovascular diseases. © 2014 Elsevier Ireland Ltd.","Cohort study; Fibrinogen; Obesity; Periodontitis; Study of health in Pomerania; Systemic inflammation; White blood cell count","(2013) The top 10 causes of death, , http://who.int/mediacentre/factsheets/fs310/en/index.html, Available from:, [accessed 07.10.13]; Holtfreter, B., Schwahn, C., Biffar, R., Kocher, T., Epidemiology of periodontal diseases in the Study of Health in Pomerania (2009) JClin Periodontol, 36 (2), pp. 114-123; Tonetti, M.S., Van Dyke, T.E., Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases (2013) JPeriodontol, 84 (4 SUPPL), pp. S24-S29; Dietrich, T., Sharma, P., Walter, C., Weston, P., Beck, J., The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease (2013) JPeriodontol, 84 (4 SUPPL), pp. S70-S84; Bahekar, A.A., Singh, S., Saha, S., Molnar, J., Arora, R., The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis (2007) Am Heart J, 154 (5), pp. 830-837; Dietrich, T., Jimenez, M., Krall Kaye, E.A., Vokonas, P.S., Garcia, R.I., Age-dependent associations between chronic periodontitis/edentulism and risk of coronary heart disease (2008) Circulation, 117 (13), pp. 1668-1674; Van Dyke, T.E., van Winkelhoff, A.J., Infection and inflammatory mechanisms (2013) JClin Periodontol, 40 (Suppl.14), pp. S1-S7; Schenkein, H.A., Loos, B.G., Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases (2013) JClin Periodontol, 40 (Suppl.14), pp. S51-S69; Kebschull, M., Demmer, R.T., Papapanou, P.N., ""Gum bug, leave my heart alone!"" - epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis (2010) JDent Res, 89 (9), pp. 879-902; Forner, L., Larsen, T., Kilian, M., Holmstrup, P., Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation (2006) JClin Periodontol, 33 (6), pp. 401-407; Lafaurie, G.I., Mayorga-Fayad, I., Torres, M.F., Castillo, D.M., Aya, M.R., Baron, A., Periodontopathic microorganisms in peripheric blood after scaling and root planing (2007) JClin Periodontol, 34 (10), pp. 873-879; Kozarov, E., Sweier, D., Shelburne, C., Progulske-Fox, A., Lopatin, D., Detection of bacterial DNA in atheromatous plaques by quantitative PCR (2006) Microbes Infect, 8 (3), pp. 687-693; Monteiro, A.M., Jardini, M.A.N., Alves, S., Giampaoli, V., Aubin, E.C.Q., Figueiredo Neto, A.M., Cardiovascular disease parameters in periodontitis (2009) JPeriodontol, 80 (3), pp. 378-388; Shi, D., Meng, H., Xu, L., Zhang, L., Chen, Z., Feng, X., Systemic inflammation markers in patients with aggressive periodontitis: a pilot study (2008) JPeriodontol, 79 (12), pp. 2340-2346; Buhlin, K., Hultin, M., Norderyd, O., Persson, L., Pockley, A.G., Rabe, P., Risk factors for atherosclerosis in cases with severe periodontitis (2009) JClin Periodontol, 36 (7), pp. 541-549; Salzberg, T.N., Overstreet, B.T., Rogers, J.D., Califano, J.V., Best, A.M., Schenkein, H.A., C-reactive protein levels in patients with aggressive periodontitis (2006) JPeriodontol, 77 (6), pp. 933-939; Slade, G.D., Ghezzi, E.M., Heiss, G., Beck, J.D., Riche, E., Offenbacher, S., Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study (2003) Arch Intern Med, 163 (10), pp. 1172-1179; Vidal, F., Figueredo, C.M.S., Cordovil, I., Fischer, R.G., Periodontal therapy reduces plasma levels of interleukin-6, C-reactive protein, and fibrinogen in patients with severe periodontitis and refractory arterial hypertension (2009) JPeriodontol, 80 (5), pp. 786-791; Radafshar, G., Shad, B., Ariamajd, E., Geranmayeh, S., Effect of intensive non-surgical treatment on the level of serum inflammatory markers in advanced periodontitis (2010) JDent (Tehran), 7 (1), pp. 24-30; Offenbacher, S., Beck, J.D., Moss, K., Mendoza, L., Paquette, D.W., Barrow, D.A., Results from the Periodontitis and Vascular Events (PAVE) Study: a pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease (2009) JPeriodontol, 80 (2), pp. 190-201; Demmer, R.T., Trinquart, L., Zuk, A., Fu, B.C., Blomkvist, J., Michalowicz, B.S., The influence of anti-infective periodontal treatment on C-reactive protein: a systematic review and meta-analysis of randomized controlled trials (2013) PLoS One, 8 (10), p. e77441; Teeuw, W.J., Slot, D.E., Susanto, H., Gerdes, V.E., Abbas, F., D'Aiuto, F., Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis (2014) JClin Periodontol, 41 (1), pp. 70-79; Paraskevas, S., Huizinga, J.D., Loos, B.G., Asystematic review and meta-analyses on C-reactive protein in relation to periodontitis (2008) JClin Periodontol, 35 (4), pp. 277-290; Volzke, H., Alte, D., Schmidt, C.O., Radke, D., Lorbeer, R., Friedrich, N., Cohort profile: the study of health in Pomerania (2011) Int J Epidemiol, 40 (2), pp. 294-307; Hensel, E., Gesch, D., Biffar, R., Bernhardt, O., Kocher, T., Splieth, C., Study of Health in Pomerania (SHIP): a health survey in an East German region. Objectives and design of the oral health section (2003) Quintessence Int, 34 (5), pp. 370-378; John, U., Greiner, B., Hensel, E., Ludemann, J., Piek, M., Sauer, S., Study of Health in Pomerania (SHIP): a health examination survey in an east German region: objectives and design (2001) Soz Praventivmed, 46 (3), pp. 186-194; Alte, D., Ludemann, J., Piek, M., Adam, C., Rose, H.J., John, U., Distribution and dose response of laboratory markers to alcohol consumption in a general population: results of the Study of Health in Pomerania (SHIP) (2003) JStud Alcohol, 64 (1), pp. 75-82; Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity (2009) Circulation, 120 (16), pp. 1640-1645; Adamu, A.N., Comparative performance of HbA1c 6.5% for FPG ≥7.0 vs 2hr PG≥11.1 criteria for diagnosis of type 2 diabetes (2011) Afr Health Sci, 11 (3), pp. 421-426; Demmer, R.T., Kocher, T., Schwahn, C., Volzke, H., Jacobs, D.R., Desvarieux, M., Refining exposure definitions for studies of periodontal disease and systemic disease associations (2008) Community Dent Oral Epidemiol, 36 (6), pp. 493-502; Gatke, D., Holtfreter, B., Biffar, R., Kocher, T., Five-year change of periodontal diseases in the Study of Health in Pomerania (SHIP) (2012) JClin Periodontol, 39 (4), pp. 357-367; Salazar, M.G., Jehmlich, N., Murr, A., Dhople, V.M., Holtfreter, B., Hammer, E., Identification of periodontitis associated changes in the proteome of whole human saliva by mass spectrometric analysis (2013) JClin Periodontol, 40 (9), pp. 825-832; Holtfreter, B., Alte, D., Schwahn, C., Desvarieux, M., Kocher, T., Effects of different manual periodontal probes on periodontal measurements (2012) JClin Periodontol, 39 (11), pp. 1032-1041; Greenland, S., Brumback, B., An overview of relations among causal modelling methods (2002) Int J Epidemiol, 31 (5), pp. 1030-1037; Textor, J., Hardt, J., Knuppel, S., DAGitty: a graphical tool for analyzing causal diagrams (2011) Epidemiology, 22 (5), p. 745; Hopkins, M.H., Owen, J., Ahearn, T., Fedirko, V., Flanders, W.D., Jones, D.P., Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial (2011) Cancer Prev Res (Phila), 4 (10), pp. 1645-1654; (2013) Stata statistical software: release 13, , StataCorp LP, College Station, TX; Sinning, J.M., Bickel, C., Messow, C.M., Schnabel, R., Lubos, E., Rupprecht, H.J., Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study (2006) Eur Heart J, 27 (24), pp. 2962-2968; Ridker, P.M., Clinical application of C-reactive protein for cardiovascular disease detection and prevention (2003) Circulation, 107 (3), pp. 363-369; Wheeler, J.G., Mussolino, M.E., Gillum, R.F., Danesh, J., Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals (2004) Eur Heart J, 25 (15), pp. 1287-1292; Brown, D.W., Giles, W.H., Croft, J.B., White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort (2001) JClin Epidemiol, 54 (3), pp. 316-322; Beck, J.D., Offenbacher, S., Relationships among clinical measures of periodontal disease and their associations with systemic markers (2002) Ann Periodontol, 7 (1), pp. 79-89; Fantuzzi, G., Adipose tissue, adipokines, and inflammation (2005) JAllergy Clin Immunol, 115 (5), pp. 911-919. , quiz 920",Article,Scopus,2-s2.0-84921480162
"Wohlfahrt P., Somers V.K., Cifkova R., Filipovsky J., Seidlerova J., Krajcoviechova A., Sochor O., Kullo I.J., Lopez-Jimenez F.","Relationship between measures of central and general adiposity with aortic stiffness in the general population",2015,"Atherosclerosis","235","2",,"625","631",,2,10.1016/j.atherosclerosis.2014.05.958,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84910133705&partnerID=40&md5=a23e5ddf25aca377e19b4c5fd36f253e","Division of Cardiovascular Diseases, Mayo ClinicRochester, MN, United States; International Clinical Research Center, St. Anne's University Hospital, Masaryk UniversityBrno, Czech Republic; Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer HospitalPrague, Czech Republic; Department of Preventive Cardiology, Institute for Clinical and Experimental MedicinePrague, Czech Republic; 2nd Department of Internal Medicine, Charles University, Center for HypertensionPilsen, Czech Republic","Wohlfahrt, P., Division of Cardiovascular Diseases, Mayo ClinicRochester, MN, United States, International Clinical Research Center, St. Anne's University Hospital, Masaryk UniversityBrno, Czech Republic, Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer HospitalPrague, Czech Republic, Department of Preventive Cardiology, Institute for Clinical and Experimental MedicinePrague, Czech Republic; Somers, V.K., Division of Cardiovascular Diseases, Mayo ClinicRochester, MN, United States; Cifkova, R., International Clinical Research Center, St. Anne's University Hospital, Masaryk UniversityBrno, Czech Republic, Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer HospitalPrague, Czech Republic; Filipovsky, J., 2nd Department of Internal Medicine, Charles University, Center for HypertensionPilsen, Czech Republic; Seidlerova, J., 2nd Department of Internal Medicine, Charles University, Center for HypertensionPilsen, Czech Republic; Krajcoviechova, A., Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer HospitalPrague, Czech Republic; Sochor, O., Division of Cardiovascular Diseases, Mayo ClinicRochester, MN, United States, International Clinical Research Center, St. Anne's University Hospital, Masaryk UniversityBrno, Czech Republic; Kullo, I.J., Division of Cardiovascular Diseases, Mayo ClinicRochester, MN, United States; Lopez-Jimenez, F., Division of Cardiovascular Diseases, Mayo ClinicRochester, MN, United States","Objective: Increased aortic stiffness may be one of the mechanisms by which obesity increases cardiovascular risk independently of traditional risk factors. While body mass index (BMI) is generally used to define excess adiposity, several studies have suggested that measures of central obesity may be better predictors of cardiovascular risk. However, data comparing the association between several measures of central and general obesity with aortic stiffness in the general population are inconclusive. Methods: In 1031 individuals (age 53±13 years, 45% men) without manifest cardiovascular disease randomly selected from population, we tested the association between parameters of central obesity (waist circumference - WC, waist-to-hip-ratio - WHR, waist-to-height ratio - WHtR) and general obesity (BMI) with carotid-femoral pulse wave velocity (cfPWV). Results: In univariate analysis, WC and WHtR were more strongly associated with cfPWV than BMI in both genders, while WHR showed a stronger association with cfPWV only in women. WHtR was more closely associated with cfPVW than WHR. This difference between obesity measures remained after multivariate adjustment. When the fully adjusted hierarchical regression was used, among central obesity measures, WHtR had the largest additive value on top of BMI, while there was no additive value of BMI on top of WHtR. Conclusion: Central obesity parameters are more closely associated with aortic stiffness than BMI. Of central adiposity measures, WHtR has the strongest association with aortic stiffness beyond body mass index and cardiovascular risk factors. Our results suggest that WHtR may be the best anthropometric measure of excess adiposity in the general population. © 2014 Elsevier Ireland Ltd.","Aortic stiffness; Body mass index; Obesity; Pulse wave velocity; Waist circumference; Waist-to-height ratio; Waist-to-hip ratio","Adams, K.F., Schatzkin, A., Harris, T.B., Kipnis, V., Mouw, T., Ballard-Barbash, R., Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old (2006) NEngl J Med, 355, pp. 763-778; Calle, E.E., Thun, M.J., Petrelli, J.M., Rodriguez, C., Heath, C.W., Body-mass index and mortality in a prospective cohort of U.S. adults (1999) NEngl J Med, 341, pp. 1097-1105; Jee, S.H., Sull, J.W., Park, J., Lee, S.Y., Ohrr, H., Guallar, E., Body-mass index and mortality in Korean men and women (2006) NEngl J Med, 355, pp. 779-787; Wilson, P.W., D'Agostino, R.B., Sullivan, L., Parise, H., Kannel, W.B., Overweight and obesity as determinants of cardiovascular risk: the Framingham experience (2002) Arch Intern Med, 162, pp. 1867-1872; Poirier, P., Giles, T.D., Bray, G.A., Hong, Y., Stern, J.S., Pi-Sunyer, F.X., Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss (2006) Arterioscler Thromb Vasc Biol, 26, pp. 968-976; Ounpuu, S., Negassa, A., Yusuf, S., INTER-HEART: a global study of risk factors for acute myocardial infarction (2001) Am Heart J, 141, pp. 711-721; Laurent, S., Boutouyrie, P., Arterial stiffness: a new surrogate end point for cardiovascular disease? (2007) JNephrol, 20 (Suppl.12), pp. S45-S50; Asmar, R.G., Pannier, B., Santoni, J.P., Laurent, S., London, G.M., Levy, B.I., Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension (1988) Circulation, 78, pp. 941-950; London, G.M., Pannier, B., Guerin, A.P., Marchais, S.J., Safar, M.E., Cuche, J.L., Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade (1994) Circulation, 90, pp. 2786-2796; Tuttolomondo, A., Di Sciacca, R., Di Raimondo, D., Serio, A., D'Aguanno, G., Pinto, A., Arterial stiffness indexes in acute ischemic stroke: relationship with stroke subtype (2010) Atherosclerosis, 211, pp. 187-194; Hashimoto, J., Aikawa, T., Imai, Y., Large artery stiffening as a link between cerebral lacunar infarction and renal albuminuria (2008) Am J Hypertens, 21, pp. 1304-1309; Wohlfahrt, P., Krajcoviechova, A., Jozifova, M., Mayer, O., Vanek, J., Filipovsky, J., Large artery stiffness and carotid flow pulsatility in stroke survivors (2014) JHypertens, 32 (5), pp. 1097-1103; O'Rourke, M.F., Safar, M.E., Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy (2005) Hypertension, 46, pp. 200-204; Wildman, R.P., Mackey, R.H., Bostom, A., Thompson, T., Sutton-Tyrrell, K., Measures of obesity are associated with vascular stiffness in young and older adults (2003) Hypertension, 42, pp. 468-473; Wohlfahrt, P., Krajcoviechova, A., Seidlerova, J., Galovcova, M., Bruthans, J., Filipovsky, J., Lower-extremity arterial stiffness vs. aortic stiffness in the general population (2013) Hypertens Res, 36, pp. 718-724; van Popele, N.M., Westendorp, I.C., Bots, M.L., Reneman, R.S., Hoeks, A.P., Hofman, A., Variables of the insulin resistance syndrome are associated with reduced arterial distensibility in healthy non-diabetic middle-aged women (2000) Diabetologia, 43, pp. 665-672; Sutton-Tyrrell, K., Newman, A., Simonsick, E.M., Havlik, R., Pahor, M., Lakatta, E., Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition (2001) Hypertension, 38, pp. 429-433; Rodrigues, S.L., Baldo, M.P., Lani, L., Nogueira, L., Mill, J.G., Sa Cunha, R., Body mass index is not independently associated with increased aortic stiffness in a Brazilian population (2012) Am J Hypertens, 25, pp. 1064-1069; Ohnishi, H., Saitoh, S., Takagi, S., Ohata, J., Isobe, T., Kikuchi, Y., Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study (2003) Diabetes Care, 26, pp. 437-440; Czernichow, S., Bertrais, S., Oppert, J.M., Galan, P., Blacher, J., Ducimetiere, P., Body composition and fat repartition in relation to structure and function of large arteries in middle-aged adults (the SU.VI.MAX study) (2005) Int J Obes (Lond), 29, pp. 826-832; Oren, A., Vos, L.E., Uiterwaal, C.S., Grobbee, D.E., Bots, M.L., Aortic stiffness and carotid intima-media thickness: two independent markers of subclinical vascular damage in young adults? (2003) Eur J Clin Invest, 33, pp. 949-954; Pischon, T., Boeing, H., Hoffmann, K., Bergmann, M., Schulze, M.B., Overvad, K., General and abdominal adiposity and risk of death in Europe (2008) NEngl J Med, 359, pp. 2105-2120; Despres, J.P., Moorjani, S., Lupien, P.J., Tremblay, A., Nadeau, A., Bouchard, C., Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease (1990) Arteriosclerosis, 10, pp. 497-511; Nieves, D.J., Cnop, M., Retzlaff, B., Walden, C.E., Brunzell, J.D., Knopp, R.H., The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat (2003) Diabetes, 52, pp. 172-179; Larsson, B., Svardsudd, K., Welin, L., Wilhelmsen, L., Bjorntorp, P., Tibblin, G., Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913 (1984) Br Med J (Clin Res Ed), 288, pp. 1401-1404; Cifkova, R., Skodova, Z., Bruthans, J., Adamkova, V., Jozifova, M., Galovcova, M., Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA (2010) Atherosclerosis, 211, pp. 676-681; Cifkova, R., Skodova, Z., Bruthans, J., Holub, J., Adamkova, V., Jozifova, M., Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008 (2010) JHypertens, 28, pp. 2196-2203; Laurent, S., Cockcroft, J., Van Bortel, L., Boutouyrie, P., Giannattasio, C., Hayoz, D., Expert consensus document on arterial stiffness: methodological issues and clinical applications (2006) Eur Heart J, 27, pp. 2588-2605; Wohlfahrt, P., Palous, D., Ingrischova, M., Krajcoviechova, A., Seidlerova, J., Galovcova, M., Ahigh ankle-brachial index is associated with increased aortic pulse wave velocity: the Czech post-MONICA study (2011) Eur J Cardiovasc Prev Rehabil, 18, pp. 790-796; Wohlfahrt, P., Krajcoviechova, A., Seidlerova, J., Mayer, O., Bruthans, J., Filipovsky, J., Arterial stiffness parameters: how do they differ? (2013) Atherosclerosis, 231, pp. 359-364; Recio-Rodriguez, J.I., Gomez-Marcos, M.A., Patino-Alonso, M.C., Agudo-Conde, C., Rodriguez-Sanchez, E., Garcia-Ortiz, L., Abdominal obesity vs general obesity for identifying arterial stiffness, subclinical atherosclerosis and wave reflection in healthy, diabetics and hypertensive (2012) BMC Cardiovasc Disord, 12, p. 3; Teoh, W.L., Price, J.F., Williamson, R.M., Payne, R.A., Van Look, L.A., Reynolds, R.M., Metabolic parameters associated with arterial stiffness in older adults with Type 2 diabetes: the Edinburgh Type 2 diabetes study (2013) JHypertens, 31, pp. 1010-1017; Hansen, T.W., Jeppesen, J., Rasmussen, S., Ibsen, H., Torp-Pedersen, C., Relation between insulin and aortic stiffness: a population-based study (2004) JHum Hypertens, 18, pp. 1-7; Mackey, R.H., Sutton-Tyrrell, K., Vaitkevicius, P.V., Sakkinen, P.A., Lyles, M.F., Spurgeon, H.A., Correlates of aortic stiffness in elderly individuals: a subgroup of the Cardiovascular Health Study (2002) Am J Hypertens, 15, pp. 16-23; Cornier, M.A., Despres, J.P., Davis, N., Grossniklaus, D.A., Klein, S., Lamarche, B., Assessing adiposity: a scientific statement from the American Heart Association (2011) Circulation, 124, pp. 1996-2019; Okorodudu, D.O., Jumean, M.F., Montori, V.M., Romero-Corral, A., Somers, V.K., Erwin, P.J., Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis (2010) Int J Obes (Lond), 34, pp. 791-799; Romero-Corral, A., Montori, V.M., Somers, V.K., Korinek, J., Thomas, R.J., Allison, T.G., Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies (2006) Lancet, 368, pp. 666-678; Coutinho, T., Goel, K., Correa de Sa, D., Carter, R.E., Hodge, D.O., Kragelund, C., Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of ""normal weight central obesity"" (2013) JAm Coll Cardiol, 61, pp. 553-560; Coutinho, T., Goel, K., Correa de Sa, D., Kragelund, C., Kanaya, A.M., Zeller, M., Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data (2011) JAm Coll Cardiol, 57, pp. 1877-1886; Czernichow, S., Kengne, A.P., Stamatakis, E., Hamer, M., Batty, G.D., Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies (2011) Obes Rev, 12, pp. 680-687; Schneider, H.J., Klotsche, J., Silber, S., Stalla, G.K., Wittchen, H.U., Measuring abdominal obesity: effects of height on distribution of cardiometabolic risk factors risk using waist circumference and waist-to-height ratio (2011) Diabetes Care, 34, p. e7; Taylor, A.E., Ebrahim, S., Ben-Shlomo, Y., Martin, R.M., Whincup, P.H., Yarnell, J.W., Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts (2010) Am J Clin Nutr, 91, pp. 547-556; Freiberg, M.S., Pencina, M.J., D'Agostino, R.B., Lanier, K., Wilson, P.W., Vasan, R.S., BMI vs. waist circumference for identifying vascular risk (2008) Obesity (Silver Spring), 16, pp. 463-469; Boffetta, P., McLerran, D., Chen, Y., Inoue, M., Sinha, R., He, J., Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium (2011) PLoS One, 6, p. e19930; Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) JAMA, 285, pp. 2486-2497; Scuteri, A., Cunha, P.G., Rosei, E.A., Badariere, J., Bekaert, S., Cockcroft, J.R., Arterial stiffness and influences of the metabolic syndrome: a cross-countries study (2014) Atherosclerosis, 233, pp. 654-660; Salomaa, V., Riley, W., Kark, J.D., Nardo, C., Folsom, A.R., Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study (1995) Circulation, 91, pp. 1432-1443; Webb, D.R., Khunti, K., Silverman, R., Gray, L.J., Srinivasan, B., Lacy, P.S., Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity (2010) Diabetologia, 53, pp. 1190-1198; Dandona, P., Aljada, A., Bandyopadhyay, A., Inflammation: the link between insulin resistance, obesity and diabetes (2004) Trends Immunol, 25, pp. 4-7",Article,Scopus,2-s2.0-84910133705
"Feng Y., Huang X., Sun H., Liu C., Zhang B., Zhang Z., Sharma Tengur V., Chen W., Wu T., Yuan J., Zhang X.","Framingham risk score modifies the effect of PM<inf>10</inf> on heart rate variability",2015,"Science of the Total Environment","523",,,"146","151",,,10.1016/j.scitotenv.2015.04.009,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926332767&partnerID=40&md5=994b002be718b16b13cbb721932f519a","Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China","Feng, Y., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Huang, X., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Sun, H., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Liu, C., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Zhang, B., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Zhang, Z., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Sharma Tengur, V., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Chen, W., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Wu, T., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Yuan, J., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Zhang, X., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China","Health conditions may greatly modify the association between particulate matter (PM) and heart rate variability (HRV), but whether the modification of PM effect by coronary artery disease (CAD) risk status depends on the PM levels remains unknown. We investigated the associations between personal exposures to PM with aerodynamic diameter of ≤10μm (PM<inf>10</inf>) and ≤2.5μm (PM<inf>2.5</inf>) and concurrent HRV, and whether the effect of PM on HRV was modified by Framingham risk score (FRS) in healthy subjects with different PM exposure levels. Personal exposures to PM<inf>10</inf> and PM<inf>2.5</inf> were measured for 24h in 152 volunteers of community residents who were free of cardiovascular disease in two cities (Zhuhai and Wuhan) that differ in air quality. Simultaneously, 24h HRV indices were obtained from 3-channel Holter monitor. FRS was calculated based on age, sex, lipid profiles, blood pressure, diabetes, and smoking status. Linear regression models were constructed after adjusting for potential confounders. We found significant decrease in total power (TP) and low power (LF) with increased PM<inf>10</inf> concentrations (P for trend<0.05) in the high PM levels city (Wuhan) and total population, but not in the low PM levels city (Zhuhai). We also observed significant modification of FRS on PM<inf>10</inf> effect in Wuhan. Interestingly, elevated PM<inf>10</inf> was associated in a greater decreased HRV in the low FRS subgroup, but not in the high FRS subgroup. However, we did not find any significant main effects of PM<inf>2.5</inf> or PM<inf>2.5</inf>-FRS interactions on HRV in city-specified or city-combined analyses. Overall, the findings indicate that individual coronary risk profiles may modulate the association between particulate air pollution and HRV in high PM exposure levels. © 2015 Elsevier B.V.","Framingham risk score; Heart rate variability; Particulate matter","Diagnosis and classification of diabetes mellitus (2012) Diabetes Care, 35, pp. S64-S71; Baccarelli, A., Cassano, P.A., Litonjua, A., Park, S.K., Suh, H., Sparrow, D., Cardiac autonomic dysfunction: effects from particulate air pollution and protection by dietary methyl nutrients and metabolic polymorphisms (2008) Circulation, 117, pp. 1802-1809; Brook, R.D., Franklin, B., Cascio, W., Hong, Y., Howard, G., Lipsett, M., Air pollution and cardiovascular disease: a statement for healthcare professionals from the expert panel on Population and Prevention Science of the American Heart Association (2004) Circulation, 109, pp. 2655-2671; Cavallari, J.M., Eisen, E.A., Chen, J.C., Fang, S.C., Dobson, C.B., Schwartz, J., Night heart rate variability and particulate exposures among boilermaker construction workers (2007) Environ. Health Perspect., 115, pp. 1046-1051; Chahine, T., Baccarelli, A., Litonjua, A., Wright, R.O., Suh, H., Gold, D.R., Particulate air pollution, oxidative stress genes, and heart rate variability in an elderly cohort (2007) Environ. Health Perspect., 115, pp. 1617-1622; Chen, J.C., Stone, P.H., Verrier, R.L., Nearing, B.D., MacCallum, G., Kim, J.Y., Personal coronary risk profiles modify autonomic nervous system responses to air pollution (2006) J. Occup. Environ. Med., 48, pp. 1133-1142; Chen, J.C., Cavallari, J.M., Stone, P.H., Christiani, D.C., Obesity is a modifier of autonomic cardiac responses to fine metal particulates (2007) Environ. Health Perspect., 115, pp. 1002-1006; Chen, R., Wang, X., Meng, X., Hua, J., Zhou, Z., Chen, B., Communicating air pollution-related health risks to the public: an application of the Air Quality Health Index in Shanghai, China (2013) Environ. Int., 51, pp. 168-173; Feng, Y., Sun, H., Song, Y., Bao, J., Huang, X., Ye, J., A community study of the effect of polycyclic aromatic hydrocarbon metabolites on heart rate variability based on the Framingham risk score (2014) Occup. Environ. Med., 71, pp. 338-345; Folino, A.F., Scapellato, M.L., Canova, C., Maestrelli, P., Bertorelli, G., Simonato, L., Individual exposure to particulate matter and the short-term arrhythmic and autonomic profiles in patients with myocardial infarction (2009) Eur. Heart J., 30, pp. 1614-1620; Ford, E.S., The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study (2004) Atherosclerosis, 173, pp. 309-314; Gold, D.R., Litonjua, A., Schwartz, J., Lovett, E., Larson, A., Nearing, B., Ambient pollution and heart rate variability (2000) Circulation, 101, pp. 1267-1273; Grundy, S.M., Pasternak, R., Greenland, P., Smith, S., Fuster, V., Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology (1999) Circulation, 100, pp. 1481-1492; Holguin, F., Tellez-Rojo, M.M., Hernandez, M., Cortez, M., Chow, J.C., Watson, J.G., Air pollution and heart rate variability among the elderly in Mexico City (2003) Epidemiology, 14, pp. 521-527; Huang, W., Zhu, T., Pan, X., Hu, M., Lu, S.E., Lin, Y., Air pollution and autonomic and vascular dysfunction in patients with cardiovascular disease: interactions of systemic inflammation, overweight, and gender (2012) Am. J. Epidemiol., 176, pp. 117-126; Jedrychowski, W.A., Perera, F.P., Maugeri, U., Spengler, J., Mroz, E., Flak, E., Prohypertensive effect of gestational personal exposure to fine particulate matter. Prospective cohort study in non-smoking and non-obese pregnant women (2012) Cardiovasc. Toxicol., 12, pp. 216-225; Jia, X., Song, X., Shima, M., Tamura, K., Deng, F., Guo, X., Effects of fine particulate on heart rate variability in Beijing: a panel study of healthy elderly subjects (2012) Int. Arch. Occup. Environ. Health, 85, pp. 97-107; Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men (2002) JAMA, 288, pp. 2709-2716; Li, L., Qian, J., Ou, C.Q., Zhou, Y.X., Guo, C., Guo, Y., Spatial and temporal analysis of Air Pollution Index and its timescale-dependent relationship with meteorological factors in Guangzhou, China, 2001-2011 (2014) Environ. Pollut., 190, pp. 75-81; Luttmann-Gibson, H., Suh, H.H., Coull, B.A., Dockery, D.W., Sarnat, S.E., Schwartz, J., Systemic inflammation, heart rate variability and air pollution in a cohort of senior adults (2010) Occup. Environ. Med., 67, pp. 625-630; Maestrelli, P., Canova, C., Scapellato, M.L., Visentin, A., Tessari, R., Bartolucci, G.B., Personal exposure to particulate matter is associated with worse health perception in adult asthma (2011) J. Investig. Allergol. Clin. Immunol., 21, pp. 120-128; Magari, S.R., Hauser, R., Schwartz, J., Williams, P.L., Smith, T.J., Christiani, D.C., Association of heart rate variability with occupational and environmental exposure to particulate air pollution (2001) Circulation, 104, pp. 986-991; Magari, S.R., Schwartz, J., Williams, P.L., Hauser, R., Smith, T.J., Christiani, D.C., The association of particulate air metal concentrations with heart rate variability (2002) Environ. Health Perspect., 110, pp. 875-880; Determination of atmospheric articles PM<inf>10</inf> and PM<inf>2.5</inf> in ambient air by gravimetric method (HJ 618-2011), , http://kjs.mep.gov.cn/hjbhbz/bzwb/dqhjbh/jcgfffbz/201109/t20110914_217272.htm, (accessed on July 24, 2014); Ambient air quality standards (GB 3095-2012), , http://kjs.mep.gov.cn/hjbhbz/bzwb/dqhjbh/dqhjzlbz/201203/t20120302_224165.htm, Available online:, (accessed on July 24, 2014); Air quality in 2013, , http://www.mep.gov.cn/zhxx/hjyw/201403/t20140326_269702.htm, Available online:, (accessed on June 14, 2014); Park, S.K., O'Neill, M.S., Vokonas, P.S., Sparrow, D., Schwartz, J., Effects of air pollution on heart rate variability: the VA normative aging study (2005) Environ. Health Perspect., 113, pp. 304-309; Park, S.K., Auchincloss, A.H., O'Neill, M.S., Prineas, R., Correa, J.C., Keeler, J., Particulate air pollution, metabolic syndrome, and heart rate variability: the Multi-Ethnic Study of Atherosclerosis (MESA) (2010) Environ. Health Perspect., 118, pp. 1406-1411; Pieters, N., Plusquin, M., Cox, B., Kicinski, M., Vangronsveld, J., Nawrot, T.S., An epidemiological appraisal of the association between heart rate variability and particulate air pollution: a meta-analysis (2012) Heart, 98, pp. 1127-1135; Pope, C.A., Hansen, M.L., Long, R.W., Nielsen, K.R., Eatough, N.L., Wilson, W.E., Ambient particulate air pollution, heart rate variability, and blood markers of inflammation in a panel of elderly subjects (2004) Environ. Health Perspect., 112, pp. 339-345; Qian, Z., He, Q., Lin, H.M., Kong, L., Liao, D., Dan, J., Association of daily cause-specific mortality with ambient particle air pollution in Wuhan, China (2007) Environ. Res., 105, pp. 380-389; Riediker, M., Cascio, W.E., Griggs, T.R., Herbst, M.C., Bromberg, P.A., Neas, L., Particulate matter exposure in cars is associated with cardiovascular effects in healthy young men (2004) Am. J. Respir. Crit. Care Med., 169, pp. 934-940; Sarnat, J.A., Koutrakis, P., Suh, H.H., Assessing the relationship between personal particulate and gaseous exposures of senior citizens living in Baltimore, MD (2000) J. Air Waste Manag. Assoc., 50, pp. 1184-1198; Schwartz, J., Park, S.K., O'Neill, M.S., Vokonas, P.S., Sparrow, D., Weiss, S., Glutathione-S-transferase M1, obesity, statins, and autonomic effects of particles: gene-by-drug-by-environment interaction (2005) Am. J. Respir. Crit. Care Med., 172, pp. 1529-1533; Report on the state of the environment in China 2006, , http://english.mep.gov.cn/down_load/Documents/200710/P020071023479580153243.pdf, Available online:, (accessed on June 10, 2014); Sullivan, J.H., Schreuder, A.B., Trenga, C.A., Liu, S.L., Larson, T.V., Koenig, J.Q., Association between short term exposure to fine particulate matter and heart rate variability in older subjects with and without heart disease (2005) Thorax, 60, pp. 462-466; Timonen, K.L., Vanninen, E., de Hartog, J., Ibald-Mulli, A., Brunekreef, B., Gold, D.R., Effects of ultrafine and fine particulate and gaseous air pollution on cardiac autonomic control in subjects with coronary artery disease: the ULTRA study (2006) J. Expo. Sci. Environ. Epidemiol., 16, pp. 332-341; Wannamethee, S.G., Shaper, A.G., Lennon, L., Morris, R.W., Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus (2005) Arch. Intern. Med., 165, pp. 2644-2650; Wheeler, A., Zanobetti, A., Gold, D.R., Schwartz, J., Stone, P., Suh, H.H., The relationship between ambient air pollution and heart rate variability differs for individuals with heart and pulmonary disease (2006) Environ. Health Perspect., 114, pp. 560-566; Whitsel, E.A., Quibrera, P.M., Christ, S.L., Liao, D., Prineas, R.J., Anderson, G.L., Heart rate variability, ambient particulate matter air pollution, and glucose homeostasis: the environmental epidemiology of arrhythmogenesis in the women's health initiative (2009) Am. J. Epidemiol., 169, pp. 693-703; Wilson, P.W., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B., Prediction of coronary heart disease using risk factor categories (1998) Circulation, 97, pp. 1837-1847; Environment and people's health in China (2001), , http://www.wpro.who.int/environmental_health/documents/docs/CHNEnvironmentalHealth.pdf, Available online:, (accessed on June 10, 2014); Wu, S., Deng, F., Niu, J., Huang, Q., Liu, Y., Guo, X., Association of heart rate variability in taxi drivers with marked changes in particulate air pollution in Beijing in 2008 (2010) Environ. Health Perspect., 118, pp. 87-91; Wu, S., Deng, F., Niu, J., Huang, Q., Liu, Y., Guo, X., Exposures to PM<inf>2.5</inf> components and heart rate variability in taxi drivers around the Beijing 2008 Olympic Games (2011) Sci. Total Environ., 409, pp. 2478-2485; Wu, S., Deng, F., Liu, Y., Shima, M., Niu, J., Huang, Q., Temperature, traffic-related air pollution, and heart rate variability in a panel of healthy adults (2013) Environ. Res., 120, pp. 82-89; Xiang, H., Mertz, K.J., Arena, V.C., Brink, L.L., Xu, X., Bi, Y., Estimation of short-term effects of air pollution on stroke hospital admissions in Wuhan, China (2013) PLoS One, 8, p. e61168",Article,Scopus,2-s2.0-84926332767
"Liu C., Xiang W., Yu Y., Shi Z.-Q., Huang X.-Z., Xu L.","Comparative analysis of 1-deoxynojirimycin contribution degree to α-glucosidase inhibitory activity and physiological distribution in Morus alba L",2015,"Industrial Crops and Products","70",,,"309","315",,,10.1016/j.indcrop.2015.02.046,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925715275&partnerID=40&md5=f8b43051ec8c510170bea3fb4604509c","College of Biotechnology, Southwest UniversityChongqing, China","Liu, C., College of Biotechnology, Southwest UniversityChongqing, China; Xiang, W., College of Biotechnology, Southwest UniversityChongqing, China; Yu, Y., College of Biotechnology, Southwest UniversityChongqing, China; Shi, Z.-Q., College of Biotechnology, Southwest UniversityChongqing, China; Huang, X.-Z., College of Biotechnology, Southwest UniversityChongqing, China; Xu, L., College of Biotechnology, Southwest UniversityChongqing, China","Natural α-glucosidase inhibitors offer an attractive strategy to manage postprandial hyperglycemia in patients with type 2 diabetes. 1-Deoxynojirimycin (DNJ), the main hypoglycemic constituents in Morus alba L., has been extensively researched. Here, for different parts of the mulberry tree, the DNJ content and the IC<inf>50</inf> values of DNJ and ethanol extracts have been determined and compared. Possible metabolic pathways and storage sites for DNJ in mulberry trees have been investigated, and the kinetics of inhibition of α-glucosidase by DNJ and ethanol extracts of different parts of the mulberry tree have been measured. DNJ content was found to be highest in trunk bark, whereas α-glucosidase inhibitory activity was highest in both twig and trunk bark. Buds and roots are likely to be the topmost and bottommost sites of DNJ biosynthesis. DNJ is an insect antifeedant (not including silkworms) and may itself have antiviral activity, or be the precursor to a compound with antiviral activity. Ethanol extracts of twig, trunk and root bark are mixed-type inhibitors of α-glucosidase; extracts from other parts of the tree are competitive inhibitors. The study provides useful information about the physiological distribution of important active components, especially DNJ, in the mulberry tree and suggests how best to develop and use the crude drug resources provided by the tree. © 2015 Elsevier B.V.","1-Deoxynojirimycin; Ethanol extracts; Mulberry; Physiological distribution; α-Glucosidase inhibitory activity","Abdel, N.B.S., Hesham, A.E., Makiko, Y., Taro, N., Toshio, F., Hypoglycemic effect of Egyptian Morus alba root bark extract: effect on diabetes and lipid peroxidation of streptozotocin-induced diabetic rats (2005) J. Ethnopharmacol., 100, pp. 333-338; Asano, N., Oseki, K., Tomioka, E., Kizu, H., Matsui, K., N-containing sugars from Morus alba and their glycosidase inhibitory activities (1994) Carbohydr. Res., 259, pp. 243-255; Asano, N., Yamashita, T., Polyhydroxylated alkaloids isolated from mulberry trees and silkworms (2001) J. Agric. Food Chem., 49, pp. 4208-4213; Ding, Y., Jiang, M.X., Zhou, Y.J., Song, S.J., Active constituents of lowering blood sugars frrom Morus alba L (2007) Chin. J. Med. Chem., 17, pp. 386-389; Eike, S., Thomas, W., Stephanie, K., Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus (2007) Hepatology, 46, pp. 330-338; Fang, M., Huang, A.Q., Zhang, Y.Q., The correlation between 1-deoxynojirimycin content and α-glucosidase inhibitory activity in the bark ethanol extract from Ramulus mori (2012) The 1st International Conference on Biomedical Engineering and Biotechnology (iCBEB2012), IEEE Xplore, pp. 1795-1798; Fenouillet, E., Papandréou, M.J., Jones, I.M., Recombinant HIV envelope expressed in an α-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional (1997) Virology, 231, pp. 89-95; Flanagan, J.J., Rossi, B., Tang, K., Wu, X.Y., Mascioli, K., Donaudy, F., Tuzzi, M.R., Porto, C., The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase (2009) Hum. Mutat., 30, pp. 1683-1692; Hirayama, C., Konno, K., Wasano, N., Nakamura, M., Differential effects of sugar-mimic alkaloids in mulberry latex on sugar metabolism and disaccharidases of Eri and domesticated silkworms: enzymatic adaptation of Bombyx mori to mulberry defense (2007) Insect Biochem. Mol. Biol., 37, pp. 1348-1358; Hiroyuki, I., Osami, T., Iwao Sa Susumu, T., Shuichi, T., Hiroshi, S., Inhibitory effects of compounds from Anemarrhenae rhizoma on α-glucosidase and aldose reductase and its contents by drying conditions (2007) J. Nat. Med., 61, pp. 146-153; Hong, D.Z., Shi, L.G., Hypoglycemic effect of polysaccharides in Ramulus Mori on diabetic model mice (2012) Chin J. Pharmacol. Toxicol., 26, pp. 806-809; Kazuhisa, Y., Masatoshi, I., Satoshi, O., The relationship between 1-deoxynojirimycin content and α-glucosidase inhibitory activity in leaves of 276 mulberry cultivars (Morus spp.) in Kyoto (2008) Jpn. J. Nat. Med., 62, pp. 63-66; Kim, H.S., Kim, Y.H., Alpha-glucosidase inhibitors from Commelina communis (1999) Planta Med., 65, pp. 437-439; Kim, J.S., Kwon, Y.S., Chun, W.J., Kim, T.Y., Sun, J., Yu, C.Y., Kim, M.J., Rhus verniciflua stokes flavonoid extracts have anti-oxidant: anti-microbial and α-glucosidase inhibitory effect (2010) Food Chem., 120, pp. 539-543; Kim, J.W., Kim, S.U., Lee, H.S., Kim, I., Ahn, M.Y., Ryu, K.S., Determination of 1-deoxynojirimycin in Morus alba L. leaves by derivatization with 9-fluorenylmethyl chloroformate followed by reversed-phase high-performance liquid chromatography (2003) J. Chromatogr. A, 1002, pp. 93-99; Kim, J.Y., Chung, H.I., Jung, K.O., Wee, J.H., Kwon, O., Chemical profiles and hypoglycemic activities of mulberry leaf extracts vary with ethanol concentration (2013) Food Sci. Biotechnol., 22, pp. 1443-1447; Kimura, M., Chen, F.J., Nakashima, N., Kimura, I., Asano, N., Koya, S., Antihyperglycemic effects of N-containing sugars derived from mulberry leaves in streptozocin-induced diabetic mice (1995) J. Trad. Med., 12, pp. 214-219; Kimura, T., Nakagawa, K., Saito, Y., Yamagishi, K., Suzuki, M., Yamaki, K., Shinmoto, H., Miyazawa, T., Determination of 1-deoxynojirimycin in mulberry leaves using hydrophilic interaction chromatography with evaporative light scattering detection (2004) J. Agric. Food. Chem., 52, pp. 1415-1418; King, H., Aubert, R.E., Herman, W.H., Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections (1998) Diabetes Care, 21, pp. 1414-1431; Kotaro, K., Hiroshi, O., Masatoshi, N., Ken, T., Chikara, H., Yasumori, T., Makoto, H., Katsuyuki, K., Mulberry latex rich in antidiabetic sugar-mimic alkaloids forces dieting on catepillars (2006) Proc. Natl. Acad. Sci. U. S. A., 103, pp. 1337-1341; Lee, H.J., Lee, H.S., Choi, J.W., Ra, K.S., Kim, J.M., Suh, H.J., Novel tripeptides with α-glucosidase inhibitory activity isolated from silk cocoon hydrolysate (2011) J. Agric. Food. Chem., 59, pp. 11522-11525; Liu, C., Wang, C.H., Liu, J., Xu, L., Xiang, W., Wang, Y.C., Optimization of microwave-assisted technology for extracting 1-deoxynojirimycin from mulberry tea by response surface methodology (2014) Food Sci. Technol. Res., 20, pp. 599-605; Li, Y.G., Ji, D.F., Zhong, S., Lv, Z.Q., Lin, T.B., Cooperative anti-diabetic effects of deoxynojirimycin-polysaccharide by inhibiting glucose absorption and modulating glucose metabolism in streptozotocin-induced diabetic mice (2013) PLoS One, 8, pp. 1-14; Luc, M.M., Herve, M.P., Jean, D.W., Jean, A.L., Shamsun, N.K., Muhammad, C.I., Bonaventure, T.N., Hartmut, L., α-Glucosidase inhibitory pentacyclic triterpenes from the stem bark of Fagara tessmannii (Rutaceae) (2007) Phytochemistry, 68, pp. 591-595; Luo, L.P., Wang, R.H., Wang, X.J., Ma, Z.J., Li, N., Compounds from Angelica keiskei with NQO1 induction: DPPH scavenging and a-glucosidase inhibitory activities (2012) Food Chem., 131, pp. 992-998; Luo, J.J., Wang, W., Cao, X.L., Isolation: purification and anti-α-glucosidase activity of polysaccharides from mulberry leaves (2011) Food sci., 32, pp. 112-116; Ma, H.Y., Gao, H.Y., Sun, L., Huang, J., Xu, X.M., Wu, L.J., Constituents with α-glucosidase and advanced glycation end-product formation inhibitory activities from Salvia miltiorrhiza Bge (2011) J. Nat. Med., 65, pp. 37-42; Makio, S., Koji, K., Masahik, O.T., Masahide, Y., Kimiye, B., Antioxidant constituents in the dayflower (Commelina communis L.) and their α-glucosidase-inhibitory activity (2008) J. Nat. Med., 62, pp. 349-353; Meng, X., Ouyang, Z., Chang, Y., Yang, Y., Contrast of 1-deoxynojirimycin content in mulberry leaves from different habitats (2008) J. Chin. Med. Mater., 31, pp. 8-10; Nojima, H., Kimura, I., Chen, F.J., Sugihara, Y., Haruno, M., Kato, A., Asano, N., Antihyperglycemic effects of N-containing sugars from Xanthocercis zambesiaca, Morus bombycis, Aglaonema treubii, and Castanospermum austral in streptozotocin-diabetic mice (1998) J. Nat. Prod., 61, pp. 397-400; Ouyang, Z., Meng, X., Chang, Y., Yang, Y., Study on changes of contents of 1-deoxynojirimycin in Bombyx mori and their byproducts (2009) J. Chin. Med. Mater., 32, pp. 182-185; Pan, C.Y., Yang, W.Y., Jia, W.P., Weng, J.P., Tian, H., Management of Chinese patients with type 2 diabetes, 1998-2006: the diabcare-China surveys (2009) Curr. Med. Res. Opin., 25, pp. 39-45; Rahman, A., Zareen, S., Choudhary, M.I., Akhtar, M.N., Khan, S.N., α-Glucosidase inhibitory activity of triterpenoids from Cichorium intybus (2008) J. Nat. Prod., 71, pp. 910-913; Sheng, Z.W., Dai, H.F., Pan, S.Y., Wang, H., Hu, Y.Y., Ma, W.H., Isolation and characterization of an α-glucosidase inhibitor from Musa spp. (Baxijiao) flowers (2014) Molecules, 19, pp. 10563-10573; Shibano, M., Fujimoto, Y., Kushino, K., Kusano, G., Baba, K., Biosynthesis of 1-deoxynojirimycin in Commelina communis: a difference between the microorganisms and plants (2004) Phytochemistry, 65, pp. 2661-2665; Shi, Y., Hu, F.B., The global implications of diabetes and cancer (2014) Lancet, 383, pp. 1947-1948; Shlomo, M., Kenneth, S.P., Larsen, P.R., Henry, M.K., (2011) Williams Textbook of Endocrinology, pp. 1371-1435. , Elsevier/Saunders, Philadelphia; Sridhar, R.A., Ramesh, D., Ramchander, M., Sreenivasulu, B., Madhusudana, R.J., New icetexane diterpenes with intestinal α-glucosidase inhibitory and free-radical scavenging activity isolated from Premna tomentosa roots (2012) Fitoterapia, 83, pp. 88-92; Tsuruoka, T., Fukuyasu, H., Ishii, M., Usui, T., Shibahara, S., Inouye, S., Inhibition of mouse tumor metastasis with nojirimycin-related compounds (1996) J. Antibiot., 49, pp. 155-161; Vichasilp, C., Nakagawa, K., Sookwong, P., Higuchi, O., Luemunkong, S., Miyazawa, T., Development of high 1-deoxynojirimycin (DNJ) content mulberry tea and use of response surface methodology to optimize tea-making conditions for highest DNJ extraction (2012) LWT-Food Sci. Technol., 45, pp. 226-232; Wang, F., Li, J.R., Research progress on chemical constituents: physiological function and applicafion of mulberry leaves (2005) Food Sci., 26, pp. 111-117; Yagi, M., Kouno, T., Aoyagi, Y., Murai, H., The structure of moranoline,a piperidine alkaloid from Morus species (1976) Nippin Nougei Kagaku Kaishi, 50, pp. 571-572; Yang, Z.Z., Wang, Y.C., Wang, Y., Zhang, Y.F., Bioassay-guided screening and isolation of α-glucosidase and tyrosinase inhibitors from leaves of Morus alba (2012) Food Chem., 131, pp. 617-625; Zhang, Y.L., Luo, J.G., Wan, C.X., Zhou, Z.B., Kong, L.Y., Geranylated 2-arylbenzofurans from Morus alba var. tatarica and their α-glucosidase and protein tyrosine phosphatase 1B inhibitory activities (2014) Fitoterapia, 92, pp. 116-126",Article,Scopus,2-s2.0-84925715275
"Liu C., Sheng Y., Sun Y., Feng J., Wang S., Zhang J., Xu J., Jiang D.","A glucose oxidase-coupled DNAzyme sensor for glucose detection in tears and saliva",2015,"Biosensors and Bioelectronics","70",,,"455","461",,,10.1016/j.bios.2015.03.070,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926334582&partnerID=40&md5=62233662f7560c2bea69fa43d70b3de5","Key Lab for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Qianjin Street 2699Changchun, China; Department of Biochemistry, University of WisconsinMadison, WI, United States","Liu, C., Key Lab for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Qianjin Street 2699Changchun, China; Sheng, Y., Key Lab for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Qianjin Street 2699Changchun, China; Sun, Y., Key Lab for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Qianjin Street 2699Changchun, China; Feng, J., Key Lab for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Qianjin Street 2699Changchun, China; Wang, S., Key Lab for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Qianjin Street 2699Changchun, China; Zhang, J., Key Lab for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Qianjin Street 2699Changchun, China; Xu, J., Department of Biochemistry, University of WisconsinMadison, WI, United States; Jiang, D., Key Lab for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Qianjin Street 2699Changchun, China","Biosensors have been widely investigated and utilized in a variety of fields ranging from environmental monitoring to clinical diagnostics. Glucose biosensors have triggered great interest and have been widely exploited since glucose determination is essential for diabetes diagnosis. In here, we designed a novel dual-enzyme biosensor composed of glucose oxidase (GOx) and pistol-like DNAzyme (PLDz) to detect glucose levels in tears and saliva. First, GOx, as a molecular recognition element, catalyzes the oxidation of glucose forming H<inf>2</inf>O<inf>2</inf>; then PLDz recognizes the produced H<inf>2</inf>O<inf>2</inf> as a secondary signal and performs a self-cleavage reaction promoted by Mn2+, Co2+ and Cu2+. Thus, detection of glucose could be realized by monitoring the cleavage rate of PLDz. The slope of the cleavage rate of PLDz versus glucose concentration curve was fitted with a Double Boltzmann equation, with a range of glucose from 100nM to 10mM and a detection limit of 5μM. We further applied the GOx-PLDz 1.0 biosensor for glucose detection in tears and saliva, glucose levels in which are 720±81μM and 405±56μM respectively. Therefore, the GOx-PLDz 1.0 biosensor is able to determine glucose levels in tears and saliva as a noninvasive glucose biosensor, which is important for diabetic patients with frequent/continuous glucose monitoring requirements. In addition, induction of DNAzyme provides a new approach in the development of glucose biosensors. © 2015 Elsevier B.V.","Glucose; Glucose oxidase; Non-invasive technology; Pistol-like DNAzyme; Saliva; Tear","Baca, J.T., Finegold, D.N., Asher, S.A., (2007) Clin. Sci., 5, pp. 280-293; Bankar, S.B., Bule, M.V., Singhal, R.S., Ananthanarayan, L., (2009) Biotechnol. Adv., 27, pp. 489-501; Berman, E.R., (1991) Biochemistry of the Eye, p. 70. , New York; Breaker, R.R., Joyce, G.F., (1994) Chem. Biol., 1, pp. 223-229; Calcutt, N.A., Cooper, M.E., Kern, T.S., Schmidt, A.M., (2009) Nat. Rev. Drug Discov., 8, pp. 417-429; Carmi, N., Balkhi, S.R., Breaker, R.R., (1998) Proc. Natl. Acad. Sci. USA, 95, pp. 2233-2237; Carmi, N., Breaker, R.R., (2001) Bioorg. Med. Chem., 9, pp. 2589-2600; Chaturvedi, P., Vanegas, D.C., Taguchi, M., Burrs, S.L., Sharma, P., McLamore, E.S., (2014) Biosens. Bioelectron., 58, pp. 179-185; Chen, X., Wang, Y., Liu, Q., Zhang, Z., Fan, C., He, L., (2006) Angew. Chem. Int. Ed., 45, pp. 1759-1762; Cui, J., Adeloju, S.B., Wu, Y., (2014) Anal. Chim. Acta, 809, pp. 134-140; Gao, L., Zhang, H., Cui, H., (2014) Biosens. Bioelectron., 57, pp. 65-70; Gibson, Q.H., Swoboda, B.E., Massey, V., (1964) J. Biol. Chem., 239, pp. 3927-3934; Gifford, R., (2013) ChemPhysChem, 14, pp. 2032-2044; Gruhl, F.J., Rapp, B.E., Länge, K., (2013) Adv. Biochem. Eng. Biotechnol., 133, pp. 115-148; Guascito, M.R., Malitesta, C., Mazzotta, E., Turco, A., (2008) Sens. Actuators B Chem., 131, pp. 394-402; He, Y., Wang, X., Sun, J., Jiao, S., Chen, H., Gao, F., Wang, L., (2014) Anal. Chim. Acta, 810, pp. 71-78; Höbartner, C., Silverman, S.K., Recent advances in DNA catalysis (2007) Biopolymers, 87, pp. 279-292; Jiang, D., Xu, J., Sheng, Y., Sun, Y., Zhang, J., (2010) FEBS J., 277, pp. 2543-2549; Jurysta, C., Bulur, N., Oguzhan, B., Satman, I., Yilmaz, T.M., Malaisse, W.J., Sener, A., (2009) J. Biomed. Biotechnol., 2009, p. 430426; Khan, M., Park, S.Y., (2014) Anal. Chem., 86, pp. 1493-1501; Koppenol, W.H., (2001) Redox Rep., 6, pp. 229-234; Lawal, A.T., (2015) Talanta, 131, pp. 424-443; Leng, J., Wang, W.M., Lu, L.M., Bai, L., Qiu, X.L., (2014) Nanoscale Res. Lett., 9, p. 99; Leskovac, V., Trivic, S., Wohlfahrt, G., Kandrac, J., Pericin, D., (2005) Int. J. Biochem. Cell Biol., 37, pp. 731-750; Liang, H., Zhang, X., Lv, Y., Gong, L., Wang, R., Zhu, X., Yang, R., Tan, W., (2014) Acc. Chem. Res., 47, pp. 1891-1901; Lin, Y., Ren, J., Qu, X., (2014) Acc. Chem. Res., 47, pp. 1097-1105; Lin, Y., Ren, J., Qu, X., (2014) Adv. Mater., 26, pp. 4200-4217; Liu, J., Cao, Z., Lu, Y., (2009) Chem. Rev., 109, pp. 1948-1998; Lu, Y., Liu, J., (2006) Curr. Opin. Biotechnol., 17, pp. 580-588; Makaram, P., Owens, D., Aceros, J., (2014) Diagnostics, 4, pp. 27-46; Malashikhina, N., Pavlov, V., (2012) Biosens. Bioelectron., 33, pp. 241-246; Miao, X., Ling, L., Cheng, D., Shuai, X., (2012) Analyst, 137, pp. 3064-3069; Scognamiglio, V., (2013) Biosens. Bioelectron., 47, pp. 12-25; Sen, D.K., Sarin, G.S., (1980) Br. J. Ophthalmol., 64, pp. 693-695; Sun, Y., Ma, R., Liu, C., Wang, S., Sheng, Y., Feng, J., Zhang, J., Jiang, D., (2015), (in preparation)Tram, K., Kanda, P., Salena, B.J., Huan, S., Li, Y., (2014) Angew. Chem. Int. Ed., 53, pp. 1-5; Wohlfahrt, G., Witt, S., Hendle, J., Schomburg, D., Kalisz, H.M., Hecht, H.J., (1999) Acta Crystallogr. D Biol. Crystallogr., 55, pp. 969-977; Xu, J., Sun, Y., Sheng, Y., Fei, Y., Zhang, J., Jiang, D., (2014) Anal. Bioanal. Chem., 406, pp. 3025-3029; Xiang, Y., Lu, Y., (2011) Nat. Chem., 3, pp. 697-703; Yamaguchi, M., Mitsumori, M., Kano, Y., (1998) IEEE Eng. Med. Biol. Mag., 17, pp. 59-63; Yoo, E., Lee, S., (2010) Sensors, 10, pp. 4558-4576; Zadran, S., Standley, S., Wong, K., Otiniano, E., Amighi, A., Baudry, M., (2012) Appl. Microbiol. Biotechnol., 96, pp. 895-902; Zeng, D., Luo, W., Li, J., Liu, H., Ma, H., Huang, Q., Fan, C., (2012) Analyst, 137, pp. 4435-4439; Zhang, X., Kong, R., Lu, Y., (2011) Annu. Rev. Anal. Chem., 4, pp. 105-128; Zhuang, J., Lai, W., Chen, G., Tang, D., (2014) Chem. Commun., 50, pp. 2935-2938",Article,Scopus,2-s2.0-84926334582
"Piwkowska A., Rogacka D., Audzeyenka I., Kasztan M., Angielski S., Jankowski M.","Insulin increases glomerular filtration barrier permeability through PKGIα-dependent mobilization of BK<inf>Ca</inf> channels in cultured rat podocytes",2015,"Biochimica et Biophysica Acta - Molecular Basis of Disease","1852","8",,"1599","1609",,,10.1016/j.bbadis.2015.04.024,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928978788&partnerID=40&md5=0b7311f52d5b403cb1ab1c5c88f6ad94","Mossakowski Medical Research Centre, Polish Academy of Sciences, Laboratory of Molecular and Cellular NephrologyGdańsk, Poland; Medical University of Gdańsk, Department of Therapy Monitoring and Pharmacogenetics, Poland; Medical University of Gdańsk, Department of Clinical Chemistry, Poland","Piwkowska, A., Mossakowski Medical Research Centre, Polish Academy of Sciences, Laboratory of Molecular and Cellular NephrologyGdańsk, Poland; Rogacka, D., Mossakowski Medical Research Centre, Polish Academy of Sciences, Laboratory of Molecular and Cellular NephrologyGdańsk, Poland; Audzeyenka, I., Mossakowski Medical Research Centre, Polish Academy of Sciences, Laboratory of Molecular and Cellular NephrologyGdańsk, Poland; Kasztan, M., Medical University of Gdańsk, Department of Therapy Monitoring and Pharmacogenetics, Poland; Angielski, S., Mossakowski Medical Research Centre, Polish Academy of Sciences, Laboratory of Molecular and Cellular NephrologyGdańsk, Poland; Jankowski, M., Mossakowski Medical Research Centre, Polish Academy of Sciences, Laboratory of Molecular and Cellular NephrologyGdańsk, Poland, Medical University of Gdańsk, Department of Clinical Chemistry, Poland","Podocytes are highly specialized cells that wrap around glomerular capillaries and comprise a key component of the glomerular filtration barrier. They are uniquely sensitive to insulin; like skeletal muscle and fat cells, they exhibit insulin-stimulated glucose uptake and express glucose transporters. Podocyte insulin signaling is mediated by protein kinase G type I (PKGI), and it leads to changes in glomerular permeability to albumin. Here, we investigated whether large-conductance Ca2+-activated K+ channels (BK<inf>Ca</inf>) were involved in insulin-mediated, PKGIα-dependent filtration barrier permeability.Insulin-induced glomerular permeability was measured in glomeruli isolated from Wistar rats. Transepithelial albumin flux was measured in cultured rat podocyte monolayers. Expression of BK<inf>Ca</inf> subunits was detected by RT-PCR. BK<inf>Ca</inf>, PKGIα, and upstream protein expression were examined in podocytes with Western blotting and immunofluorescence. The BK<inf>Ca</inf>-PKGIα interaction was assessed with co-immunoprecipitation.RT-PCR showed that primary cultured rat podocytes expressed mRNAs that encoded the pore-forming α subunit and four accessory β subunits of BK<inf>Ca</inf>. The BK<inf>Ca</inf> inhibitor, iberiotoxin (ibTX), abolished insulin-dependent glomerular albumin permeability and PKGI-dependent transepithelial albumin flux. Insulin-evoked albumin permeability across podocyte monolayers was also blocked with BK<inf>Ca</inf> siRNA. Moreover, ibTX blocked insulin-induced disruption of the actin cytoskeleton and changes in the phosphorylation of PKG target proteins, MYPT1 and RhoA.These results indicated that insulin increased filtration barrier permeability through mobilization of BK<inf>Ca</inf> channels via PKGI in cultured rat podocytes. This molecular mechanism may explain podocyte injury and proteinuria in diabetes. © 2015 Elsevier B.V.","Constriction apparatus; Filtration barrier permeability; Insulin; Large-conductance Ca2+-activated K+ channels; Podocyte","Pavenstädt, H., Kriz, W., Kretzler, M., Cell biology of the glomerular podocyte (2003) Physiol. Rev., 83 (1), pp. 253-307; Holthöfer, H., Ahola, H., Solin, M.L., Wang, S., Palmen, T., Luimula, P., Miettinen, A., Kerjaschki, D., Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney (1999) Am. J. Pathol., 155, pp. 1681-1687; Saleem, M.A., Ni, L., Witherden, I., Tryggvason, K., Ruotsalainen, V., Mundel, P., Mathieson, P.W., Co-localization of nephrin, podocin, and the actin cytoskeleton: evidence for a role in podocyte foot process formation (2002) Am. J. Pathol., 161, pp. 1459-1466; Morton, M.J., Hutchinson, K., Mathieson, P.W., Witherden, I.R., Saleem, M.A., Hunter, M., Human podocytes possess a stretch-sensitive, Ca2+-activated K+ channel: potential implications for the control of glomerular filtration (2004) J. Am. Soc. Nephrol., 15, pp. 2981-2987; Greka, A., Mundel, P., Balancing calcium signals through TRPC5 and TRPC6 in podocytes (2011) J. Am. Soc. Nephrol., 22 (11), pp. 1969-1980; Drenckhahn, D., Franke, R.P., Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man (1988) Lab. Investig., 59, pp. 673-682; Saleem, M.A., Zavadil, J., Bailly, M., McGee, K., Witherden, I.R., Pavenstadt, H., Hsu, H., Mathieson, P.W., The molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cells (2008) Am. J. Physiol. Renal Physiol., 295, pp. F959-F970; Endlich, N., Kress, K.R., Reiser, J., Uttenweiler, D., Kriz, W., Mundel, P., Endlich, K., Podocytes respond to mechanical stress in vitro (2001) J. Am. Soc. Nephrol., 12 (3), pp. 413-422; Sharma, R., Lovell, H.B., Wiegmann, T.B., Savin, V.J., Vasoactive substances induce cytoskeletal changes in cultured rat glomerular epithelial cells (1992) J. Am. Soc. Nephrol., 3, pp. 1131-1138; Surks, H.K., Mochizuki, N., Kasai, Y., Georgescu, S.P., Tang, K.M., Ito, M., Lincoln, T.M., Mendelsohn, M.E., Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase I alpha (1999) Science, 286, pp. 1583-1587; Gao, Y., Portugal, A.D., Negash, S., Zhou, W., Longo, L.D., Usha Raj, J., Role of Rho kinases in PKG-mediated relaxation of pulmonary arteries of fetal lambs exposed to chronic high altitude hypoxia (2007) Am. J. Physiol. Lung Cell. Mol. Physiol., 292, pp. L678-L684; Surks, H.K., CGMP-dependent protein kinase I and smooth muscle relaxation: a tale of two isoforms (2007) Circ. Res., 101, pp. 1078-1080; Sauzeau, V., Le Jeune, H., Cario-Toumaniantz, C., Smolenski, A., Lohmann, S.M., Bertoglio, J., Chardin, P., Loirand, G., Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle (2000) J. Biol. Chem., 275, pp. 21722-21729; Stockand, J.D., Sansom, S.C., Mechanism of activation by cGMP-dependent protein kinase of large Ca(2+)-activated K+ channels in mesangial cells (1996) Am. J. Physiol., 271, pp. C1669-C1677; Kim, E.Y., Choi, K.J., Dryer, S.E., Nephrin binds to the COOH terminus of a large-conductance Ca2+-activated K+ channel isoform and regulates its expression on the cell surface (2008) Am. J. Physiol. Renal Physiol., 295 (1), pp. F235-F246; Kim, E.Y., Chiu, Y.H., Dryer, S.E., Neph1 regulates steady-state surface expression of Slo1 Ca(2+)-activated K(+) channels: different effects in embryonic neurons and podocytes (2009) Am. J. Physiol. Cell Physiol., 297 (6), pp. C1379-C1388; Kim, E.Y., Suh, J.M., Chiu, Y.H., Dryer, S.E., Regulation of podocyte BK(Ca) channels by synaptopodin, Rho, and actin microfilaments (2010) Am. J. Physiol. Renal Physiol., 299 (3), pp. F594-F604; Kim, E.Y., Alvarez-Baron, C.P., Dryer, S.E., Canonical transient receptor potential channel (TRPC)3 and TRPC6 associate with large-conductance Ca2+-activated K+ (BK<inf>Ca</inf>) channels: role in BK<inf>Ca</inf> trafficking to the surface of cultured podocytes (2009) Mol. Pharmacol., 75 (3), pp. 466-477; Kim, E.Y., Dryer, S.E., Effects of insulin and high glucose on mobilization of slo1 BK<inf>Ca</inf> channels in podocytes (2011) J. Cell. Physiol., 226 (9), pp. 2307-2315; Welsh, G.I., Hale, L.J., Eremina, V., Jeansson, M., Maezawa, Y., Lennon, R., Pons, D.A., Coward, R.J., Insulin signaling to the glomerular podocyte is critical for normal kidney function (2010) Cell Metab., 12 (4), pp. 329-340; Piwkowska, A., Rogacka, D., Kasztan, M., Angielski, S., Jankowski, M., Insulin increases glomerular filtration barrier permeability through dimerization of protein kinase G type Iα subunits (2013) Biochim. Biophys. Acta, 1832 (6), pp. 791-804; Piwkowska, A., Rogacka, D., Jankowski, M., Kocbuch, K., Angielski, S., Hydrogen peroxide induces dimerization of protein kinase G type Iα subunits and increases albumin permeability in cultured rat podocytes (2012) J. Cell. Physiol., 227 (3), pp. 1004-1016; Misra, R.P., Isolation of glomeruli from mammalian kidneys by graded sieving (1972) Am. J. Clin. Pathol., 58, pp. 135-139; Pubill, D., Dayanithi, G., Siatka, C., Andrés, M., Dufour, M.N., Guillon, G., Mendre, C., ATP induces intracellular calcium increases and actin cytoskeleton disaggregation via P2x receptors (2001) Cell Calcium, 29, pp. 299-309; Oshima, T., Laroux, F.S., Coe, L.L., Morise, Z., Kawachi, S., Bauer, P., Grisham, M.B., Alexander, J.S., Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function (2001) Microvasc. Res., 61, pp. 130-143; Savin, V.J., Sharma, R., Lovell, H.B., Welling, D.J., Measurement of albumin reflection coefficient with isolated rat glomeruli (1992) J. Am. Soc. Nephrol., 3 (6), pp. 1260-1269; Kriz, W., Hackenthal, E., Nobiling, R., Sakai, T., Elger, M., Hähnel, B., A role for podocytes to counteract capillary wall distension (1994) Kidney Int., 45 (2), pp. 369-376; Cohen, A.J., McCarthy, D.M., Stoff, J.S., Direct hemodynamic effect of insulin in the isolated perfused kidney (1989) Am. J. Physiol., 257 (4), pp. F580-F585; Hayashi, K., Fujiwara, K., Oka, K., Nagahama, T., Matsuda, H., Saruta, T., Effects of insulin on rat renal microvessels: studies in the isolated perfused hydronephrotic kidney (1997) Kidney Int., 51 (5), pp. 1507-1513; ter Maaten, J.C., Bakker, S.J., Serné, E.H., ter Wee, P.M., Donker, A.J., Gans, R.O., Insulin's acute effects on glomerular filtration rate correlate with insulin sensitivity whereas insulin's acute effects on proximal tubular sodium reabsorption correlation with salt sensitivity in normal subjects (1999) Nephrol. Dial. Transplant., 14 (10), pp. 2357-2363; Tucker, B.J., Mendonca, M.M., Blantz, R.C., Contrasting effects of acute insulin infusion on renal function in awake nondiabetic and diabetic rats (1993) J. Am. Soc. Nephrol., 3 (10), pp. 1686-1693; Song, Y., Wang, P., Ma, J., Xue, Y., C-terminus of human BK<inf>Ca</inf> channel alpha subunit enhances the permeability of the brain endothelial cells by interacting with caveolin-1 and triggering caveolin-1 intracellular trafficking (2014) Neruomol. Med., 16 (2), pp. 499-509; Nakamura, K., Koga, Y., Sakai, H., Homma, K., Ikebe, M., CGMP-dependent relaxation of smooth muscle is coupled with the change in the phosphorylation of myosin phosphatase (2007) Circ. Res., 101 (7), pp. 712-722; Etienne-Manneville, S., Hall, A., Rho GTPases in cell biology (2002) Nature, 420, pp. 629-635; Hunt, J.L., Pollak, M.R., Denker, B.M., Cultured podocytes establish a size-selective barrier regulated by specific signaling pathways and demonstrate synchronized barrier assembly in a calcium switch model of junction formation (2005) J. Am. Soc. Nephrol., 16, pp. 1593-1602; Dimitropoulou, C., Han, G., Miller, A.W., Molero, M., Fuchs, L.C., White, R.E., Carrier, G.O., Potassium (BK(Ca)) currents are reduced in microvascular smooth muscle cells from insulin-resistant rats (2002) Am. J. Physiol. Heart Circ. Physiol., 282 (3), pp. H908-H917; Foutz, R.M., Grimm, P.R., Sansom, S.C., Insulin increases the activity of mesangial BK channels through MAPK signaling (2008) Am. J. Physiol. Renal Physiol., 294 (6), pp. F1465-F1472",Article,Scopus,2-s2.0-84928978788
"Riza Erbay A., Turhan H., Yasar A.S., Ayaz S., Sahin O., Senen K., Sasmaz H., Yetkin E.","Elevated level of plasma homocysteine in patients with slow coronary flow",2005,"International Journal of Cardiology","102","3",,"419","423",,1,10.1016/j.ijcard.2004.05.064,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928485346&partnerID=40&md5=5f5d9b94cbfe0da7667bfaab24517801","Department of Cardiology, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Department of Biochemistry, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Department of Cardiology, Inonu University Medical FacultyMalatya, Turkey","Riza Erbay, A., Department of Cardiology, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Turhan, H., Department of Cardiology, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Yasar, A.S., Department of Cardiology, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Ayaz, S., Department of Biochemistry, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Sahin, O., Department of Cardiology, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Senen, K., Department of Cardiology, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Sasmaz, H., Department of Cardiology, Turkiye Yuksek Ihtisas HospitalAnkara, Turkey; Yetkin, E., Department of Cardiology, Inonu University Medical FacultyMalatya, Turkey","Background Elevated plasma levels of homocysteine are currently considered a major, independent risk factor for cardiovascular diseases. Recently, several investigators have suggested that even mild elevation in plasma homocysteine level can severely disturb vascular endothelial function and subsequently impair coronary blood flow. Accordingly, we investigated plasma homocysteine level in patients with slow coronary flow. Method Study population included 53 patients with angiographically proven normal coronary arteries and slow coronary flow in all three coronary vessels (group I, 21 females, 32 males, mean age=48±9 years), and 50 subjects with angiographically proven normal coronary arteries without associated slow coronary flow (group II, 22 females, 28 males, mean age=50±8 years). Coronary flow rates of all patients and control subjects were documented by Thrombolysis In Myocardial Infarction frame count (TIMI frame count). All patients in group I had TIMI frame counts greater than two standard deviations above those of control subjects (group II) and, therefore, were accepted as exhibiting slow coronary flow. The mean TIMI frame count for each patient and control subject was calculated by adding the TIMI frame counts for each major epicardial coronary artery and then dividing the obtained value into 3. Plasma homocysteine level was measured in all patients and control subjects using commercially available homocysteine kits. Results There was no statistically significant difference between two groups in respect to age, gender, hypertension, diabetes mellitus, hyperlipidemia and cigarette smoking (p>0.05). Plasma homocysteine level of patients with slow coronary flow were found to be significantly higher than those of control subjects (15.5±5.7 vs. 8.7±4.2 μM/l, respectively, p<0.001). Moreover, we found a significant positive correlation between plasma homocysteine level and mean TIMI frame count (r=0.660, p<0.001). Conclusion We have shown that patients with slow coronary flow have raised level of plasma homocysteine compared to control subjects with normal coronary flow. This data suggests that elevated level of plasma homocysteine may play a role in the pathogenesis of slow coronary flow. © 2004 Elsevier Ireland Ltd. All rights reserved.","Endothelial dysfunction; Homocysteine; Slow coronary flow","Tambe, A.A., Demany, M.A., Zimmerman, H.A., Mascarenhas, E., Angina pectoris and slow flow velocity of dye in coronary arteries. A new angiographic finding (1972) Am. Heart J., 84, pp. 66-71; Mangieri, E., Macchiarelli, G., Ciavolella, M., Barilla, F., Avella, A., Martinotti, A., Slow coronary flow: Clinical and histopathological features in patients with otherwise normal epicardial coronary arteries (1996) Catheter. Cardiovasc. Diagn., 37, pp. 375-381; Mosseri, M., Yarom, R., Gotsman, M.S., Hasin, Y., Histologic evidence for small vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries (1986) Circulation, 74, pp. 964-972; Christensen, B., Refsum, H., Vintermyr, O., Ueland, P.M., Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: Methionine loading of nontransformed, transformed, proliferating and quiescent cells in culture (1991) J. Cell Biol., 146, pp. 52-62; Selhub, J., Jacques, P.F., Wilson, P.W., Rush, D., Rosenberg, I.H., Vitamin status and intake as primary determinants of homocysteinemia in an elderly population (1993) JAMA, 270, pp. 2693-2698; Kang, S.-S., Passen, E.L., Ruggie, N., Wang, P.W., Sora, H., Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease (1993) Circulation, 88, pp. 1463-1469; Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattstrom, L.E., Ueland, P.M., Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project (1997) JAMA, 277, pp. 1775-1778; Boushey, C.J., Beresford, S.A.A., Omenn, G.S., Motulsky, A.G., A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes (1995) JAMA, 274, pp. 1049-1056; Woo, K.S., Chook, P., Lolin, Y.I., Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans (1997) Circulation, 96, pp. 2542-2544; Tawakol, A., Omland, T., Gerhard, M., Wu, J.T., Creager, M.A., Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans (1997) Circulation, 95, pp. 1119-1121; Stamler, J.S., Osborn, J.A., Jaraji, O., Adverse effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen (1993) J. Clin. Invest., 91, pp. 308-318; Gibson, C.M., TIMI frame count: A quantitative method of assessing coronary artery flow (1996) Circulation, 93, pp. 879-888. , for the TIMI 4 Study Group; Dodge, J.T., Brown, B.G., Bolson, E.L., Dodge, H.T., Intrathoracic spatial location of specified coronary segments on the normal human heart: Application in quantitative arteriography, assessment of regional risk and contraction, and anatomic display (1988) Circulation, 78, pp. 1167-1180; Epstein, S.E., Cannon, O., Talbot, T.L., Hemodynamic principles in the control of coronary blood flow (1985) Am. J. Cardiol., 56, pp. 4E-10E; Kurtoglu, N., Akcay, A., Dindar, I., Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow (2001) Am. J. Cardiol., 87, pp. 777-779; Beltrame, J.F., Limaye, S.B., Wuttke, R.D., Horowitz, J.D., Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon (2003) Am. Heart J., 146, pp. 84-90; Camsari, A., Pekdemir, H., Cicek, D., Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow (2003) Circ. J., 67, pp. 1022-1028; Cin, V.G., Pekdemir, H., Camsari, A., Diffuse intimal thickening of coronary arteries in slow coronary flow (2003) Jpn. Heart J., 44, pp. 907-919; Senen, K., Yetkin, E., Turhan, H., Increased thrombolysis in myocardial infarction frame counts in patients with isolated coronary artery ectasia (2004) Heart Vessels, 19, pp. 23-26; Chambers, J.C., McGregor, A., Jean-Marie, J., Kooner, J.S., Acute hyperhomocysteinemia and endothelial dysfunction (1998) Lancet, 351, pp. 36-37; Constans, J., Blann, A.D., Resplandy, F., Endothelial dysfunction during acute methionine load in hyperhomocysteinemic patients (1999) Atherosclerosis, 147, pp. 411-413; Sezgin, A.T., Sigirci, A., Barutcu, I., Vascular endothelial function in patients with slow coronary flow (2003) Coron. Artery Dis., 14, pp. 155-161; Starkebaum, G., Harlan, J.M., Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine (1986) J. Clin. Invest., 77, pp. 1370-1376; Welch, G.N., Upchurch, G., Loscalzo, J., Hyperhomocysteinemia and atherothrombosis (1997) Ann. N. Y. Acad. Sci. U. S. A., 811, pp. 48-58; Upchurch, G.R., Welch, G.N., Ramdev, N., The effect of homocysteine on endothelial cell nitric oxide production (1995) FASEB J., 9, p. A876; Upchurch, G.R., Welch, G.N., Freedman, J.F., Loscalzo, J., Homocysteine attenuates endothelial glutathione peroxidase and thereby potentiates peroxide-mediated cell injury (1995) Circulation, 92, pp. I-228; Upchurch, G.R., Welch, G.N., Fabian, A.J., Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase (1997) J. Biol. Chem., 272, pp. 17012-17017; Stanger, O., Semmelrock, H.J., Wonisch, W., Bos, U., Pabst, E., Wascher, T.C., Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects (2002) J. Pharmacol. Exp. Ther., 303, pp. 158-162; Willems, F.F., Aengevaeren, W.R., Boers, G.H., Blom, H.J., Verheugt, F.W., Coronary endothelial function in hyperhomocysteinemia: Improvement after treatment with folic acid and cobalamin in patients with coronary artery disease (2002) J. Am. Coll. Cardiol., 40, pp. 766-772; Arnett, E.N., Isner, J.M., Redwood, D.R., Coronary artery narrowing in coronary heart disease: Comparison of cineangiographic and necropsy findings (1979) Ann. Intern. Med., 91, pp. 350-356; Chemarin-Alibelli, M.J., Pieraggi, M.T., Elbaz, M., Identification of coronary thrombus after myocardial infarction by intracoronary ultrasound compared with histology of tissues sampled by atherectomy (1996) Am. J. Cardiol., 77, pp. 344-349; Potkin, B.N., Bartorelli, A.L., Gessert, J.M., Coronary artery imaging with intravascular high-frequency ultrasound (1990) Circulation, 81, pp. 1575-1585",Article,Scopus,2-s2.0-84928485346
"Wu S.-H., Yao C.-H., Hsieh C.-J., Liu Y.-W., Chao Y.-S., Song J.-S., Lee J.-C.","Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors",2015,"European Journal of Pharmaceutical Sciences","74",,,"40","44",,,10.1016/j.ejps.2015.03.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928499272&partnerID=40&md5=182cc8dedb23802e5d19ab136d093640","Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan RoadZhunan Town, Miaoli County, Taiwan; TPV Technology Group, Top Victory Electronics (Taiwan) Co.,Ltd, 12F-1, No. 186, Jian 1st Rd.Zhonghe Dist., New Taipei City, Taiwan; Diamond BioFund Inc, 5F., No. 3, Sec. 1, Dunhua S. Rd.Taipei City, Taiwan","Wu, S.-H., Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan RoadZhunan Town, Miaoli County, Taiwan; Yao, C.-H., Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan RoadZhunan Town, Miaoli County, Taiwan; Hsieh, C.-J., TPV Technology Group, Top Victory Electronics (Taiwan) Co.,Ltd, 12F-1, No. 186, Jian 1st Rd.Zhonghe Dist., New Taipei City, Taiwan; Liu, Y.-W., Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan RoadZhunan Town, Miaoli County, Taiwan; Chao, Y.-S., Diamond BioFund Inc, 5F., No. 3, Sec. 1, Dunhua S. Rd.Taipei City, Taiwan; Song, J.-S., Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan RoadZhunan Town, Miaoli County, Taiwan; Lee, J.-C., Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan RoadZhunan Town, Miaoli County, Taiwan","Sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors are of current interest as a treatment for type 2 diabetes. Efforts have been made to discover phlorizin-related glycosides with good SGLT2 inhibitory activity. To increase structural diversity and better understand the role of non-glycoside SGLT2 inhibitors on glycemic control, we initiated a research program to identify non-glycoside hits from high-throughput screening. Here, we report the development of a novel, fluorogenic probe-based glucose uptake system based on a Cu(I)-catalyzed [3 + 2] cycloaddition. The safer processes and cheaper substances made the developed assay our first priority for large-scale primary screening as compared to the well-known [14C]-labeled α-methyl-d-glucopyranoside ([14C]-AMG) radioactive assay. This effort culminated in the identification of a benzimidazole, non-glycoside SGLT2 hit with an EC<inf>50</inf> value of 0.62 μM by high-throughput screening of 41,000 compounds. © 2015 Elsevier B.V. All rights reserved.","Click chemistry; High-throughput screening; Non-glycoside; Sodium-dependent glucose co-transporter; Type 2 diabetes mellitus","Abdul-Ghani, M.A., Norton, L., Defronzo, R.A., Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes (2011) Endocr. Rev., 32, pp. 515-531; Best, M.D., Click chemistry and bioorthogonal reactions: Unprecedented selectivity in the labeling of biological molecules (2009) Biochemistry, 48, pp. 6571-6584; Castaneda, F., Kinne, R.K., A 96-Well automated method to study inhibitors of human sodium-dependent d-glucose transport (2005) Mol. Cell. Biochem., 280, pp. 91-98; Ehrenkranz, J.R.L., Lewis, N.G., Kahn, C.R., Roth, J., Phlorizin: A review (2005) Diabetes Metab. Res. Rev., 21, pp. 31-38; Elkinson, S., Scott, L.J., Canagliflozin: First global approval (2013) Drugs, 73, pp. 979-988; Fujita, Y., Inagaki, N., Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action (2014) J. Diabetes Invest., 5, pp. 265-275; Hertzberg, R.P., Pope, A.J., High-throughput screening: New technology for the 21st century (2000) Curr. Opin. Chem. Biol., 4, pp. 445-451; Ho, L.T., Kulkarni, S.S., Lee, J.C., Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics (2011) Curr. Top. Med. Chem., 11, pp. 1476-1512; Li, A.R., Zhang, J., Greenberg, J., Lee, T., Liu, J., Discovery of non-glucoside SGLT2 inhibitors (2011) Bioorg. Med. Chem. Lett., 21, pp. 2472-2475; Liu, B., Li, S., Hu, J., Technological advances in high-throughput screening (2004) Am. J. Pharmacogenomics, 4, pp. 263-276; Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes (2014) Drug Des. Devel. Ther., 8, pp. 1335-1380; Neumiller, J.J., Empagliflozin: A new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes (2014) Drugs Context, 3, p. 212262; Poole, R.M., Dungo, R.T., Ipragliflozin: First global approval (2014) Drugs, 74, pp. 611-617; Poole, R.M., Prossler, J.E., Tofogliflozin: First global approval (2014) Drugs, 74, pp. 939-944; Rostovtsev, V.V., Green, L.G., Fokin, V.V., Sharpless, K.B., A stepwise Huisgen cycloaddition process: Copper(I)-catalyzed regioselective ""ligation"" of azides and terminal alkynes (2002) Angew. Chem. Int. Ed., 41, pp. 2596-2599; Sawa, M., Hsu, T.L., Itoh, T., Sugiyama, M., Hanson, S.R., Vogt, P.K., Wong, C.H., Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo (2006) Proc. Natl. Acad. Sci. U.S.A., 103, pp. 12371-12376; Traynor, K., Dapagliflozin approved for type 2 diabetes (2014) Am. J. Health Syst. Pharm., 71, p. 263; Wright, E.M., Renal Na+-glucose cotransporters (2001) Am. J. Physiol. Ren. Physiol., 280, pp. F10-F18; Wright, E.M., Turk, E., The sodium/glucose cotransport family SLC5 (2004) Pflugers Arch., 447, pp. 510-518; Zhang, X., Zhang, Y., Applications of azide-based bioorthogonal click chemistry in glycobiology (2013) Molecules, 18, pp. 7145-7159; Zhang, J.H., Chung, T.D.Y., Oldenburg, K.R., A simple statistical parameter for use in evaluation and validation of high throughput screening assays (1999) J. Biomol. Screen., 4, pp. 67-73; Zhou, Z., Fahrni, C.J., A fluorogenic probe for the copper(I)-catalyzed azide-alkyne ligation reaction: Modulation of the fluorescence emission via 3(n, pi)-1(pi, pi) inversion (2004) J. Am. Chem. Soc., 126, pp. 8862-8863",Article,Scopus,2-s2.0-84928499272
"Kosacka J., Kern M., Kloting N., Paeschke S., Rudich A., Haim Y., Gericke M., Serke H., Stumvoll M., Bechmann I., Nowicki M., Bluher M.","Autophagy in adipose tissue of patients with obesity and type 2 diabetes",2015,"Molecular and Cellular Endocrinology","409",,,"21","32",,,10.1016/j.mce.2015.03.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927629824&partnerID=40&md5=6a905b7f7bfbc7b82b54eeea0a3d8d9c","Department of Medicine, University of Leipzig, Liebigstraße 21Leipzig, Germany; Integrated Research and Treatment Center (IFB) Adiposity Diseases, Liebigstraße 21Leipzig, Germany; Department of Clinical Biochemistry and Pharmacology, National Institute of Biotechnology in the Negev, Ben-Gurion University of the NegevBeer-Sheva, Israel; Institute of Anatomy, University of Leipzig, Liebigstraße 13Leipzig, Germany","Kosacka, J., Department of Medicine, University of Leipzig, Liebigstraße 21Leipzig, Germany; Kern, M., Department of Medicine, University of Leipzig, Liebigstraße 21Leipzig, Germany; Klöting, N., Department of Medicine, University of Leipzig, Liebigstraße 21Leipzig, Germany, Integrated Research and Treatment Center (IFB) Adiposity Diseases, Liebigstraße 21Leipzig, Germany; Paeschke, S., Department of Medicine, University of Leipzig, Liebigstraße 21Leipzig, Germany; Rudich, A., Department of Clinical Biochemistry and Pharmacology, National Institute of Biotechnology in the Negev, Ben-Gurion University of the NegevBeer-Sheva, Israel; Haim, Y., Department of Clinical Biochemistry and Pharmacology, National Institute of Biotechnology in the Negev, Ben-Gurion University of the NegevBeer-Sheva, Israel; Gericke, M., Institute of Anatomy, University of Leipzig, Liebigstraße 13Leipzig, Germany; Serke, H., Institute of Anatomy, University of Leipzig, Liebigstraße 13Leipzig, Germany; Stumvoll, M., Department of Medicine, University of Leipzig, Liebigstraße 21Leipzig, Germany; Bechmann, I., Institute of Anatomy, University of Leipzig, Liebigstraße 13Leipzig, Germany; Nowicki, M., Institute of Anatomy, University of Leipzig, Liebigstraße 13Leipzig, Germany; Blüher, M., Department of Medicine, University of Leipzig, Liebigstraße 21Leipzig, Germany","Background: Pathophysiology of obesity is closely associated with enhanced autophagy in adipose tissue (AT). Autophagic process can promote survival or activate cell death. Therefore, we examine the occurrence of autophagy in AT of type 2 diabetes (T2D) patients in comparison to obese and lean individuals without diabetes. Methodology/principal findings: Numerous autophagosomes accumulated within adipocytes were visualized by electron transmission microscopy and by immunofluorescence staining for autophagy marker LC3 in obese and T2D patients. Increased autophagy was demonstrated by higher LC3-II/LC3-I ratio, up-regulated expression of LC3 and Atg5 mRNA, along with decreased p62 and mTOR protein levels. Increased autophagy occurred together with AT inflammation. Conclusions: Our data suggest fat depot-related differences in autophagy regulation. In subcutaneous AT, increased autophagy is accompanied by increased markers of apoptosis in patients with obesity independently of T2D. In contrast, in visceral AT only in T2D patients increased autophagy was related to higher markers of apoptosis. © 2015 Elsevier Ireland Ltd.","Adipose tissue; Autophagy; Inflammation; Obesity; T2D","Alkhouri, N., Gornicka, A., Berk, M.P., Thapaliya, S., Dixon, L.J., Kashyap, S., Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis (2010) J. Biol. Chem, 5, pp. 3428-3438; Blüher, M., Clinical relevance of adipokines (2012) Diabetes Metab. J., 36, pp. 317-327; Blüher, M., Adipose tissue dysfunction contributes to obesity related metabolic diseases (2013) Best Pract. Res. Clin. Endocrinol. Metab, 27, pp. 163-177; Blüher, M., Bashan, N., Shai, I., Harman-Boehm, I., Tarnovscki, T., Avinaoch, E., Activated Ask1-MKK4-p38MAPK/JNK stress signaling pathway in human omental fat tissue may link macrophage infiltration to whole-body Insulin sensitivity (2009) J. Clin. Endocrinol. Metab, 94, pp. 2507-2515; Booth, L.A., Tavallai, S., Hamed, H.A., Cruickshanks, N., Dent, P., The role of cell signalling in the crosstalk between autophagy and apoptosis (2014) Cell. Signal, 26, pp. 549-555; Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss (2005) Diabetes, 54, pp. 2277-2286; Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans (2005) J. Lipid Res, 46, pp. 2347-2355; Codogno, P., Meijer, A.J., Autophagy: a potential link between obesity and insulin resistance (2010) Cell Metab, 5, pp. 449-451; Crişan, T.O., Plantinga, T.S., van de Veerdonk, F.L., Farcaş, M.F., Stoffels, M., Kullberg, B.J., Inflammasome-independent modulation of cytokine response by autophagy in human cells (2011) PLoS ONE, 6, p. e18666; Cummins, T.D., Holden, C.R., Sansbury, B.E., Gibb, A.A., Shah, J., Zafar, N., Metabolic remodeling of white adipose tissue in obesity (2014) Am. J. Physiol. Endocrinol. Metab, , ajpendo.00271.2013 [pii]; Eisenberg, T., Büttner, S., Kroemer, G., Madeo, F., The mitochondrial pathway in yeast apoptosis (2007) Apoptosis, 12, pp. 1011-1023; Eskelinen, E.L., Saftig, P., Autophagy: a lysosomal degradation pathway with a central role in health and disease (2009) Biochim. Biophys. Acta, 1793, pp. 664-673; Goldman, S., Zhang, Y., Jin, S., Autophagy and adipogenesis: implications in obesity and type II diabetes (2010) Autophagy, 6, pp. 179-181; Harris, J., Autophagy and cytokines (2011) Cytokine, 56, pp. 140-144; Harris, J., Hartman, M., Roche, C., Zeng, S.G., O'Shea, A., Sharp, F.A., Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation (2011) J. Biol. Chem, 286, pp. 9587-9597; Jain, M.V., Paczulla, A.M., Klonisch, T., Dimgba, F.N., Rao, S.B., Roberg, K., Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development (2013) J. Cell. Mol. Med, 17, pp. 12-29; Klionsky, D.J., Abdalla, F.C., Abeliovich, H., Abraham, R.T., Acevedo-Arozena, A., Adeli, K., Guidelines for the use and interpretation of assays for monitoring autophagy (2012) Autophagy, 8, pp. 445-544; Klöting, N., Fasshauer, M., Dietrich, A., Kovacs, P., Schön, M.R., Kern, M., Insulin-sensitive obesity (2010) Am. J. Physiol. Endocrinol. Metab, 299, pp. E506-E515; Koren, I., Reem, E., Kimchi, A., Autophagy gets a brake: DAP1, a novel mTOR substrate, is activated to suppress the autophagic process (2010) Autophagy, 6, pp. 1179-1180; Kosacka, J., Koch, K., Gericke, M., Nowicki, M., Heiker, J.T., Klöting, I., The polygenetically inherited metabolic syndrome of male WOKW rats is associated with enhanced autophagy in adipose tissue (2013) Diabetol. Metab. Syndr, 5, p. 23; Kovsan, J., Blüher, M., Tarnovscki, T., Klöting, N., Kirshtein, B., Madar, L., Altered autophagy in human adipose tissues in obesity (2011) J. Clin. Endocrinol. Metab, 96, pp. E268-E277; Kroemer, G., Galluzzi, L., Brenner, C., Mitochondrial membrane permeabilization in cell death (2007) Physiol. Rev, 87, pp. 99-163; Levine, B., Klionsky, D.J., Development by self-digestion: molecular mechanisms and biological functions of autophagy (2004) Dev. Cell, 6, pp. 463-477; Levine, B., Mizushima, N., Virgin, H.W., Autophagy in immunity and inflammation (2011) Nature, 469, pp. 323-335; Liu, K., Zhao, E., Ilyas, G., Lalazar, G., Lin, Y., Haseeb, M., Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization (2015) Autophagy, 4, p. 0. , Epub ahead of print]. PMID:25650776; Lumeng, C.N., Bodzin, J.L., Saltiel, A.R., Obesity induces a phenotypic switch in adipose tissue macrophage polarization (2007) J. Clin. Invest, 117, pp. 175-184; Makki, K., Froguel, P., Wolowczuk, I., Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines (2013) ISRN Inflamm, , Review; Mazumder, S., Plesca, D., Almasan, A., Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis (2008) Methods Mol. Biol, 414, pp. 13-21; Meng, Q., Cai, D., Defective hypothalamic autophagy directs the central pathogenesis of obesity via the IkappaB kinase beta (IKKbeta)/NF-kappaB pathway (2011) J. Biol. Chem, 286, pp. 32324-32332; Menzies, F.M., Moreau, K., Puri, C., Renna, M., Rubinsztein, D.C., Measurement of autophagic activity in mammalian cells (2012) Current Protocols in Cell Biology, , Chapter 15, Unit 15.16; Miwa, K., Asano, M., Horai, R., Iwakura, Y., Nagata, S., Suda, T., Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand (1998) Nat. Med, 4, pp. 1287-1292; Mizushima, N., Methods for monitoring autophagy (2004) Int. J. Biochem. Cell Biol, 36, pp. 2491-2502; Mizushima, N., Levine, B., Cuervo, A.M., Klionsky, D.J., Autophagy fights disease through cellular self-digestion (2008) Nature, 451, pp. 1069-1075; Öst, A., Svensson, K., Ruishalme, I., Brännmark, C., Franck, N., Krook, H., Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes (2010) Mol. Med, 16, pp. 235-246; Porter, A.G., Jänicke, R.U., Emerging roles of caspase-3 in apoptosis (1999) Cell Death Differ, 6, pp. 99-104; Rouschop, K.M., van den Beucken, T., Dubois, L., Niessen, H., Bussink, J., Savelkouls, K., The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5 (2010) J. Clin. Invest, 120, pp. 127-141; Rubinstein, A.D., Kimchi, A., Life in the balance - a mechanistic view of the crosstalk between autophagy and apoptosis (2012) J. Cell Sci, 125, pp. 5259-5268; Stienstra, R., Haim, Y., Riahi, Y., Netea, M., Rudich, A., Leibowitz, G., Autophagy in adipose tissue and the beta cell: implications for obesity and diabetes (2014) Diabetologia, 57, pp. 1505-1516; Wajchenberg, B.L., Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome (2000) Endocr. Rev, 21, pp. 697-738; Wang, Y., Li, Y.B., Yin, J.J., Wang, Y., Zhu, L.B., Xie, G.Y., Autophagy regulates inflammation following oxidative injury in diabetes (2013) Autophagy, 9, pp. 272-277; Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W., Obesity is associated with macrophage accumulation in adipose tissue (2003) J. Clin. Invest, 112, pp. 1796-1808; Wellen, K.E., Hotamisligil, G.S., Inflammation, stress, and diabetes (2005) J. Clin. Invest, 115, pp. 1111-1119; Yousefi, S., Perozzo, R., Schmid, I., Ziemiecki, A., Schaffner, T., Scapozza, L., Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis (2006) Nat. Cell Biol, 8, pp. 1124-1132",Article,Scopus,2-s2.0-84927629824
"Guo W., Zheng B., Guo D., Cai Z., Wang Y.","Association of AluYb8 insertion/deletion polymorphism in the MUTYH gene with mtDNA maintain in the type 2 diabetes mellitus patients",2015,"Molecular and Cellular Endocrinology","409",,,"33","40",,,10.1016/j.mce.2015.03.019,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928016018&partnerID=40&md5=3fac5a833ca8558801420927a9de1efe","Jiangsu Key Laboratory of Molecular Medicine, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China; Department of Medical Genetics, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China; Clinical Molecular Diagnostic Center, Second Hospital, Nanjing Medical University, No.121 Jiangjiayuan RoadNanjing, China","Guo, W., Jiangsu Key Laboratory of Molecular Medicine, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China, Department of Medical Genetics, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China, Clinical Molecular Diagnostic Center, Second Hospital, Nanjing Medical University, No.121 Jiangjiayuan RoadNanjing, China; Zheng, B., Jiangsu Key Laboratory of Molecular Medicine, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China, Department of Medical Genetics, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China; Guo, D., Jiangsu Key Laboratory of Molecular Medicine, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China, Department of Medical Genetics, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China; Cai, Z., Jiangsu Key Laboratory of Molecular Medicine, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China, Department of Medical Genetics, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China; Wang, Y., Jiangsu Key Laboratory of Molecular Medicine, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China, Department of Medical Genetics, Nanjing University School of Medicine, No.22 HanKou RoadNanjing, China","A common AluYb8-element insertion/deletion polymorphism of the MUTYH gene (AluYb8MUTYH) is a novel genetic risk factor for type 2 diabetes mellitus (T2DM). In the present study, mtDNA sequencing analysis indicated that the mtDNA sequence heteroplasmy was not associated with AluYb8MUTYH polymorphism. To better understand the genetic risk for T2DM, we investigated the association of this polymorphism with mtDNA content, mtDNA breakage and mtDNA transcription in the leukocytes of T2DM patients. The mtDNA content and unbroken mtDNA were significantly increased in the mutant patients than in the wild-type patients (P <. 0.05, respectively). However, no association between mtDNA transcription and AluYb8MUTYH variant was observed. The results suggested that the AluYb8MUTYH variant was associated with an altered mtDNA maintain in T2DM patients. The high level of mtDNA content observed in the mutant patients may have resulted from inefficient base excision repair of mitochondrial MUTYH and a compensatory mechanism that is triggered by elevated oxidative stress. © 2015 Elsevier Ireland Ltd.","AluYb8 element; Base excision repair; MtDNA content; MtDNA maintain; MUTYH; Type 2 diabetes mellitus","Al-Tassan, N., Chmiel, N.H., Maynard, J., Fleming, N., Livingston, A.L., Williams, G.T., Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors (2002) Nat. Genet, 30 (2), pp. 227-232; Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation (1998) Diabet. Med, 15 (7), pp. 539-553; Beckman, K.B., Ames, B.N., The free radical theory of aging matures (1998) Physiol. Rev, 78 (2), pp. 547-581; Boesch, P., Weber-Lotfi, F., Ibrahim, N., Tarasenko, V., Cosset, A., Paulus, F., DNA repair in organelles: pathways, organization, regulation, relevance in disease and aging (2011) Biochim. Biophys. Acta, 1813 (1), pp. 186-200; Carling, P.J., Cree, L.M., Chinnery, P.F., The implications of mitochondrial DNA copy number regulation during embryogenesis (2011) Mitochondrion, 11 (5), pp. 686-692; Chen, H., Sun, C., Guo, W., Meng, R., Du, H., Qi, Q., AluYb8 insertion in the MUTYH gene is related to increased 8-OHdG in genomic DNA and could be a risk factor for type 2 diabetes in a Chinese population (2011) Mol. Cell. Endocrinol, 332 (1-2), pp. 301-305; Choi, Y.S., Kim, S., Pak, Y.K., Mitochondrial transcription factor A (mtTFA) and diabetes (2001) Diabetes Res. Clin. Pract, 54, pp. S3-S9; Clay Montier, L.L., Deng, J.J., Bai, Y., Number matters: control of mammalian mitochondrial DNA copy number (2009) J. Genet. Genomics, 36 (3), pp. 125-131; Cooke, M.S., Olinski, R., Evans, M.D., Does measurement of oxidative damage to DNA have clinical significance? (2006) Clin. Chim. Acta, 365 (1-2), pp. 30-49; Droge, W., Free radicals in the physiological control of cell function (2002) Physiol. Rev, 82 (1), pp. 47-95; Goto, M., Shinmura, K., Nakabeppu, Y., Tao, H., Yamada, H., Tsuneyoshi, T., Adenine DNA glycosylase activity of 14 human MutY homolog (MUTYH) variant proteins found in patients with colorectal polyposis and cancer (2010) Hum. Mutat, 31 (11), pp. E1861-E1874; Guo, W., Zheng, B., Cai, Z., Xu, L., Guo, D., Cao, L., The polymorphic AluYb8 insertion in the MUTYH gene is associated with reduced type 1 protein expression and reduced mitochondrial DNA content (2013) PLoS ONE, 8 (8). , e70718; Halsne, R., Esbensen, Y., Wang, W., Scheffler, K., Suganthan, R., Bjoras, M., Lack of the DNA glycosylases MYH and OGG1 in the cancer prone double mutant mouse does not increase mitochondrial DNA mutagenesis (2012) DNA Repair (Amst), 11 (3), pp. 278-285; Hamanaka, R.B., Chandel, N.S., Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) Trends Biochem. Sci, 35 (9), pp. 505-513; Harman, D., The biologic clock: the mitochondria? (1972) J. Am. Geriatr. Soc, 20 (4), pp. 145-147; Hsieh, C.J., Weng, S.W., Liou, C.W., Lin, T.K., Chen, J.B., Tiao, M.M., Tissue-specific differences in mitochondrial DNA content in type 2 diabetes (2011) Diabetes Res. Clin. Pract, 92 (1), pp. 106-110; Huang, H.E., Yang, Y.C., Wu, J.S., Wang, R.H., Lu, F.H., Chang, C.J., The relationship between different glycemic statuses and colon polyps in a Taiwanese population (2014) J. Gastroenterol, 49 (7), pp. 1145-1151; Jones, S., Emmerson, P., Maynard, J., Best, J.M., Jordan, S., Williams, G.T., Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C→T:A mutations (2002) Hum. Mol. Genet, 11 (23), pp. 2961-2967; Kakimoto, M., Inoguchi, T., Sonta, T., Yu, H.Y., Imamura, M., Etoh, T., Accumulation of 8-hydroxy-2'-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats (2002) Diabetes, 51 (5), pp. 1588-1595; Kazak, L., Reyes, A., Holt, I.J., Minimizing the damage: repair pathways keep mitochondrial DNA intact (2012) Nat. Rev. Mol. Cell Biol, 13 (10), pp. 659-671; Lee, H.C., Wei, Y.H., Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress (2005) Int. J. Biochem. Cell Biol, 37 (4), pp. 822-834; Lee, H.C., Yin, P.H., Lu, C.Y., Chi, C.W., Wei, Y.H., Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells (2000) Biochem. J., 348, pp. 425-432; Lee, H.K., Song, J.H., Shin, C.S., Park, D.J., Park, K.S., Lee, K.U., Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus (1998) Diabetes Res. Clin. Pract, 42 (3), pp. 161-167; Lipton, L., Halford, S.E., Johnson, V., Novelli, M.R., Jones, A., Cummings, C., Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway (2003) Cancer Res, 63 (22), pp. 7595-7599; Minowa, O., Arai, T., Hirano, M., Monden, Y., Nakai, S., Fukuda, M., Mmh/Ogg1 gene inactivation results in accumulation of 8-hydroxyguanine in mice (2000) Proc. Natl. Acad. Sci. U.S.A., 97 (8), pp. 4156-4161; Molatore, S., Russo, M.T., D'Agostino, V.G., Barone, F., Matsumoto, Y., Albertini, A.M., MUTYH mutations associated with familial adenomatous polyposis: functional characterization by a mammalian cell-based assay (2010) Hum. Mutat, 31 (2), pp. 159-166; Moraes, C.T., What regulates mitochondrial DNA copy number in animal cells? (2001) Trends Genet, 17 (4), pp. 199-205; Oka, S., Nakabeppu, Y., DNA glycosylase encoded by MUTYH functions as a molecular switch for programmed cell death under oxidative stress to suppress tumorigenesis (2011) Cancer Sci, 102 (4), pp. 677-682; Oka, S., Ohno, M., Tsuchimoto, D., Sakumi, K., Furuichi, M., Nakabeppu, Y., Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAs (2008) EMBO J., 27 (2), pp. 421-432; Oka, S., Leon, J., Tsuchimoto, D., Sakumi, K., Nakabeppu, Y., MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death (2014) Oncogenesis, 3. , e121; Out, A.A., Tops, C.M., Nielsen, M., Weiss, M.M., van Minderhout, I.J., Fokkema, I.F., Leiden open variation database of the MUTYH gene (2010) Hum. Mutat, 31 (11), pp. 1205-1215; Santos, J.H., Meyer, J.N., Mandavilli, B.S., Van Houten, B., Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells (2006) Methods Mol. Biol, 314, pp. 183-199; Shay, J.W., Pierce, D.J., Werbin, H., Mitochondrial DNA copy number is proportional to total cell DNA under a variety of growth conditions (1990) J. Biol. Chem, 265 (25), pp. 14802-14807; Shen, G.X., Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase (2010) Can. J. Physiol. Pharmacol, 88 (3), pp. 241-248; Sheng, Z., Oka, S., Tsuchimoto, D., Abolhassani, N., Nomaru, H., Sakumi, K., 8-Oxoguanine causes neurodegeneration during MUTYH-mediated DNA base excision repair (2012) J. Clin. Invest, 122 (12), pp. 4344-4361; Shokolenko, I., Venediktova, N., Bochkareva, A., Wilson, G.L., Alexeyev, M.F., Oxidative stress induces degradation of mitochondrial DNA (2009) Nucleic Acids Res, 37 (8), pp. 2539-2548; Sivitz, W.I., Yorek, M.A., Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities (2010) Antioxid. Redox Signal, 12 (4), pp. 537-577; Sun, C., Chen, H., Guo, W., Zhang, K., Qi, Q., Gu, X., A common mutation of the MYH gene is associated with increased DNA oxidation and age-related diseases (2010) Free Radic. Biol. Med, 48 (3), pp. 430-436; Takao, M., Zhang, Q.M., Yonei, S., Yasui, A., Differential subcellular localization of human MutY homolog (hMYH) and the functional activity of adenine:8-oxoguanine DNA glycosylase (1999) Nucleic Acids Res, 27 (18), pp. 3638-3644; van Loon, B., Markkanen, E., Hubscher, U., Oxygen as a friend and enemy: how to combat the mutational potential of 8-oxo-guanine (2010) DNA Repair (Amst), 9 (6), pp. 604-616; Wang, J., Armour, T., Geiss, L.S., Engelgau, M.M., Obesity and diabetes: dual epidemics on the rise (2005) Curr. Opin. Endocrinol. Diabetes Obes, 12 (2), pp. 174-180; Weng, S.W., Lin, T.K., Liou, C.W., Chen, S.D., Wei, Y.H., Lee, H.C., Peripheral blood mitochondrial DNA content and dysregulation of glucose metabolism (2009) Diabetes Res. Clin. Pract, 83 (1), pp. 94-99; Williams, R.S., Mitochondrial gene expression in mammalian striated muscle. Evidence that variation in gene dosage is the major regulatory event (1986) J. Biol. Chem, 261 (26), pp. 12390-12394; Wilson, D.M., Bohr, V.A., The mechanics of base excision repair, and its relationship to aging and disease (2007) DNA Repair (Amst), 6 (4), pp. 544-559; Wong, J., McLennan, S.V., Molyneaux, L., Min, D., Twigg, S.M., Yue, D.K., Mitochondrial DNA content in peripheral blood monocytes: relationship with age of diabetes onset and diabetic complications (2009) Diabetologia, 52 (9), pp. 1953-1961; Xie, L., Zhu, X., Hu, Y., Li, T., Gao, Y., Shi, Y., Mitochondrial DNA oxidative damage triggering mitochondrial dysfunction and apoptosis in high glucose-induced HRECs (2008) Invest. Ophthalmol. Vis. Sci, 49 (9), pp. 4203-4209; Xie, Y., Yang, H., Cunanan, C., Okamoto, K., Shibata, D., Pan, J., Deficiencies in mouse Myh and Ogg1 result in tumor predisposition and G to T mutations in codon 12 of the K-ras oncogene in lung tumors (2004) Cancer Res, 64 (9), pp. 3096-3102",Article,Scopus,2-s2.0-84928016018
"Kim K.M., Lee K.-S., Lee G.Y., Jin H., Durrance E.S., Park H.S., Choi S.H., Park K.S., Kim Y.-B., Jang H.C., Lim S.","Anti-diabetic efficacy of KICG1338, a novel glycogen synthase kinase-3β inhibitor, and its molecular characterization in animal models of type 2 diabetes and insulin resistance",2015,"Molecular and Cellular Endocrinology","409",,,"1","10",,,10.1016/j.mce.2015.03.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926486779&partnerID=40&md5=476055de86d72ae78ea44200bd75b35d","Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea; Biomedical Research Institute, Seoul National University Bundang HospitalSeongnam, South Korea; Department of Internal Medicine, Seoul National University College of MedicineSeoul, South Korea; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine Seoul National UniversitySeoul, South Korea; Division of Endocrinology, Metabolism and Diabetes, Beth Israel Deaconess Medical Center and Harvard Medical SchoolBoston, MA, United States","Kim, K.M., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea; Lee, K.-S., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea, Biomedical Research Institute, Seoul National University Bundang HospitalSeongnam, South Korea; Lee, G.Y., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea, Biomedical Research Institute, Seoul National University Bundang HospitalSeongnam, South Korea; Jin, H., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea, Biomedical Research Institute, Seoul National University Bundang HospitalSeongnam, South Korea; Durrance, E.S., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea, Biomedical Research Institute, Seoul National University Bundang HospitalSeongnam, South Korea; Park, H.S., Department of Internal Medicine, Seoul National University College of MedicineSeoul, South Korea; Choi, S.H., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea; Park, K.S., Department of Internal Medicine, Seoul National University College of MedicineSeoul, South Korea, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine Seoul National UniversitySeoul, South Korea; Kim, Y.-B., Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine Seoul National UniversitySeoul, South Korea, Division of Endocrinology, Metabolism and Diabetes, Beth Israel Deaconess Medical Center and Harvard Medical SchoolBoston, MA, United States; Jang, H.C., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea; Lim, S., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang HospitalSeongnam, South Korea","Selective inhibition of glycogen synthase kinase-3 (GSK3) has been targeted as a novel therapeutic strategy for diabetes mellitus. We investigated the anti-diabetic efficacy and molecular mechanisms of KICG1338 (2-(4-fluoro-phenyl)-3. H-imidazo[4,5-b]pyridine-7-carboxylic acid(4-methyl-pyridin-3-yl)-amide), a GSK3β inhibitor, in three animal models: Otsuka Long-Evans Tokushima Fatty (OLETF) rats, leptin receptors-deficient db/. db mice, and diet-induced obese (DIO) mice. Biochemical parameters including glucose tolerance tests and gene expressions associated with glucose metabolism were investigated. Glucose excursion decreased significantly by KICG1338-treated OLETF rats, accompanied by increase in insulin receptor substrate-1 and glucose transporter (GLUT)-4 expressions in muscle and decreased GLUT-2 expression in liver. Glucose-lowering effects were similarly observed in KICG1338-treated db/. db and DIO mice. KICG1338 treatment increased adiponectin levels and decreased TNF-α levels. KICG1338 therapy also led to greater β-cell preservation and less hepatic fat infiltration with decreased expressions of genes involved in inflammation and endoplasmic reticulum stress. These data demonstrate anti-diabetic efficacy of KICG1338, a novel GSK3β inhibitor. © 2015 Elsevier Ireland Ltd.","Diabetes; Diet-induced obese mice; GLUT; Glycogen synthase kinase-3; Obesity; OLETF rat","Allagnat, F., Christulia, F., Ortis, F., Pirot, P., Lortz, S., Lenzen, S., Sustained production of spliced X-box binding protein 1 (XBP1) induces pancreatic beta cell dysfunction and apoptosis (2010) Diabetologia, 53 (6), pp. 1120-1130; Asano, T., Katagiri, H., Tsukuda, K., Lin, J.L., Ishihara, H., Yazaki, Y., Upregulation of GLUT2 mRNA by glucose, mannose, and fructose in isolated rat hepatocytes (1992) Diabetes, 41 (1), pp. 22-25; Azevedo, M.F., Camsari, C., Sa, C.M., Lima, C.F., Fernandes-Ferreira, M., Pereira-Wilson, C., Ursolic acid and luteolin-7-glucoside improve lipid profiles and increase liver glycogen content through glycogen synthase kinase-3 (2010) Phytother. Res, 24, pp. S220-S224; Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormo, M., Nilsson, Y., Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 (2003) J. Biol. Chem, 278 (46), pp. 45937-45945; Burcelin, R., Dolci, W., Thorens, B., Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice (2000) Diabetes, 49 (10), pp. 1643-1648; Cao, J., Feng, X., Yao, L., Ning, B., Yang, Z.X., Fang, D.L., Saturated free fatty acid sodium palmitate-induced lipoapoptosis by targeting glycogen synthase kinase-3beta activation in human liver cells (2014) Dig. Dis. Sci, 59 (2), pp. 346-357; Coghlan, M.P., Culbert, A.A., Cross, D.A., Corcoran, S.L., Yates, J.W., Pearce, N.J., Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription (2000) Chem. Biol, 7 (10), pp. 793-803; Cohen, P., Frame, S., The renaissance of GSK3 (2001) Nat. Rev. Mol. Cell Biol, 2 (10), pp. 769-776; Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., Hemmings, B.A., Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B (1995) Nature, 378 (6559), pp. 785-789; Eldar-Finkelman, H., Krebs, E.G., Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action (1997) Proc. Natl. Acad. Sci. U.S.A., 94 (18), pp. 9660-9664; Eldar-Finkelman, H., Schreyer, S.A., Shinohara, M.M., LeBoeuf, R.C., Krebs, E.G., Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice (1999) Diabetes, 48 (8), pp. 1662-1666; Embi, N., Rylatt, D.B., Cohen, P., Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase (1980) Eur. J. Biochem, 107 (2), pp. 519-527; Flamment, M., Hajduch, E., Ferré, P., Foufelle, F., New insights into ER stress-induced insulin resistance (2012) Trends Endocrinol. Metab, 23 (8), pp. 381-390; Foretz, M., Ancellin, N., Andreelli, F., Saintillan, Y., Grondin, P., Kahn, A., Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver (2005) Diabetes, 54 (5), pp. 1331-1339; Gibbs, E.M., Stock, J.L., McCoid, S.C., Stukenbrok, H.A., Pessin, J.E., Stevenson, R.W., Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4) (1995) J. Clin. Invest, 95 (4), pp. 1512-1518; Grimes, C.A., Jope, R.S., The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling (2001) Prog. Neurobiol, 65 (4), pp. 391-426; Hagberg, C.E., Mehlem, A., Falkevall, A., Muhl, L., Fam, B.C., Ortsater, H., Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes (2012) Nature, 490 (7420), pp. 426-430; Hanley, A.J., Williams, K., Festa, A., Wagenknecht, L.E., D'Agostino, R.B., Haffner, S.M., Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study (2005) Diabetes, 54 (11), pp. 3140-3147; Hashimoto, E., Taniai, M., Tokushige, K., Characteristics and diagnosis of NAFLD/NASH (2013) J. Gastroenterol. Hepatol, 28, pp. 64-70; Henriksen, E., Dysregulation of glycogen synthase kinase-3 in skeletal muscle and the etiology of insulin resistance and type 2 diabetes (2010) Curr. Diabetes Rev, 6 (5), pp. 285-293; Hoeflich, K.P., Luo, J., Rubie, E.A., Tsao, M.S., Jin, O., Woodgett, J.R., Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation (2000) Nature, 406 (6791), pp. 86-90; Ibrahim, S.H., Akazawa, Y., Cazanave, S.C., Bronk, S.F., Elmi, N.A., Werneburg, N.W., Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis (2011) J. Hepatol, 54 (4), pp. 765-772; Im, S.S., Kang, S.Y., Kim, S.Y., Kim, H.I., Kim, J.W., Kim, K.S., Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes (2005) Diabetes, 54 (6), pp. 1684-1691; Irimia, J.M., Meyer, C.M., Peper, C.L., Zhai, L., Bock, C.B., Previs, S.F., Impaired glucose tolerance and predisposition to the fasted state in liver glycogen synthase knock-out mice (2010) J. Biol. Chem, 285 (17), pp. 12851-12861; Kahn, B.B., Rossetti, L., Lodish, H.F., Charron, M.J., Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle of diabetic rats (1991) J. Clin. Invest, 87 (6), pp. 2197-2206; Kaidanovich, O., Eldar-Finkelman, H., The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes (2002) Expert Opin. Ther. Targets, 6 (5), pp. 555-561; Kaidanovich-Beilin, O., Eldar-Finkelman, H., Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle (2006) J. Pharmacol. Exp. Ther, 316 (1), pp. 17-24; Kim, Y.M., Song, I., Seo, Y.H., Yoon, G., Glycogen synthase kinase 3 inactivation induces cell senescence through sterol regulatory element binding protein 1-mediated lipogenesis in chang cells (2013) Endocrinol. Metab. (Seoul), 28 (4), pp. 297-308; Laybutt, D.R., Preston, A.M., Akerfeldt, M.C., Kench, J.G., Busch, A.K., Biankin, A.V., Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes (2007) Diabetologia, 50 (4), pp. 752-763; Lee, S.C., Kim, H.T., Park, C.H., Lee, D.Y., Chang, H.J., Park, S., Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3beta inhibitors (2012) Bioorg. Med. Chem. Lett, 22 (13), pp. 4221-4224; Lee, S.C., Shin, D., Cho, J.M., Ro, S., Suh, Y.G., Structure-activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3beta inhibitor (2012) Bioorg. Med. Chem. Lett, 22 (5), pp. 1891-1894; Leng, S., Zhang, W., Zheng, Y., Liberman, Z., Rhodes, C.J., Eldar-Finkelman, H., Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1 (2010) J. Endocrinol, 206 (2), pp. 171-181; Liberman, Z., Eldar-Finkelman, H., Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling (2005) J. Biol. Chem, 280 (6), pp. 4422-4428; Lim, S., Ectopic fat assessment focusing on cardiometabolic and renal risk (2014) Endocrinol. Metab. (Seoul), 29 (1), pp. 1-4; Lim, S., Moon, M.K., Shin, H., Kim, T.H., Cho, B.J., Kim, M., Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats (2011) Cardiovasc. Res, 90 (2), pp. 383-393; Mackenzie, R.W., Elliott, B.T., Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes (2014) Diabetes Metab. Syndr. Obes, 7, pp. 55-64; Martinez, A., Castro, A., Dorronsoro, I., Alonso, M., Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation (2002) Med. Res. Rev, 22 (4), pp. 373-384; Nikoulina, S.E., Ciaraldi, T.P., Mudaliar, S., Mohideen, P., Carter, L., Henry, R.R., Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes (2000) Diabetes, 49 (2), pp. 263-271; Osawa, Y., Seki, E., Kodama, Y., Suetsugu, A., Miura, K., Adachi, M., Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression (2011) FASEB J., 25 (4), pp. 1133-1144; Pearce, N.J., Arch, J.R., Clapham, J.C., Coghlan, M.P., Corcoran, S.L., Lister, C.A., Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter (2004) Metabolism, 53 (10), pp. 1322-1330; Postic, C., Burcelin, R., Rencurel, F., Pegorier, J.P., Loizeau, M., Girard, J., Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: studies in vivo and in vitro (1993) Biochem. J., 293, pp. 119-124; Rao, R., Hao, C.M., Redha, R., Wasserman, D.H., McGuinness, O.P., Breyer, M.D., Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice (2007) Diabetologia, 50 (2), pp. 452-460; Ring, D.B., Johnson, K.W., Henriksen, E.J., Nuss, J.M., Goff, D., Kinnick, T.R., Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo (2003) Diabetes, 52 (3), pp. 588-595; Ruderman, N.B., Carling, D., Prentki, M., Cacicedo, J.M., AMPK, insulin resistance, and the metabolic syndrome (2013) J. Clin. Invest, 123 (7), pp. 2764-2772; Schwabe, R.F., Brenner, D.A., Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes (2002) Am. J. Physiol. Gastrointest. Liver Physiol, 283 (1), pp. G204-G211; Seto, S., Yumoto, K., Okada, K., Asahina, Y., Iwane, A., Iwago, M., Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3beta (GSK-3beta) inhibitors for type 2 diabetics (2012) Bioorg. Med. Chem, 20 (3), pp. 1188-1200; Wang, Y., Feng, W., Xue, W., Tan, Y., Hein, D.W., Li, X.K., Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling (2009) Diabetes, 58 (6), pp. 1391-1402; Zhande, R., Mitchell, J., Wu, J., Sun, X., Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1 (2002) Mol. Cell. Biol, 22 (4), pp. 1016-1026; Zisman, A., Peroni, O.D., Abel, E.D., Michael, M.D., Mauvais-Jarvis, F., Lowell, B.B., Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance (2000) Nat. Med, 6 (8), pp. 924-928",Article,Scopus,2-s2.0-84926486779
"Hellmann M., Roustit M., Gaillard-Bigot F., Cracowski J.-L.","Cutaneous iontophoresis of treprostinil, a prostacyclin analog, increases microvascular blood flux in diabetic malleolus area",2015,"European Journal of Pharmacology","758",,,"123","128",,,10.1016/j.ejphar.2015.03.066,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928016077&partnerID=40&md5=fcfe705c0c1782f23df4ebcfd829d01e","Inserm CIC1406, Centre DInvestigation Clinique de Grenoble, CHU de GrenobleGrenoble Cedex 09, France; Noninvasive Cardiac Diagnostics Department, Medical UniversityGdansk, Poland; Inserm HP2Grenoble, France; Univ. Grenoble-Alpes, HP2Grenoble, France","Hellmann, M., Inserm CIC1406, Centre DInvestigation Clinique de Grenoble, CHU de GrenobleGrenoble Cedex 09, France, Noninvasive Cardiac Diagnostics Department, Medical UniversityGdansk, Poland; Roustit, M., Inserm CIC1406, Centre DInvestigation Clinique de Grenoble, CHU de GrenobleGrenoble Cedex 09, France, Inserm HP2Grenoble, France, Univ. Grenoble-Alpes, HP2Grenoble, France; Gaillard-Bigot, F., Inserm CIC1406, Centre DInvestigation Clinique de Grenoble, CHU de GrenobleGrenoble Cedex 09, France; Cracowski, J.-L., Inserm CIC1406, Centre DInvestigation Clinique de Grenoble, CHU de GrenobleGrenoble Cedex 09, France, Inserm HP2Grenoble, France, Univ. Grenoble-Alpes, HP2Grenoble, France","Diabetic foot ulcers are one of the most common and serious complications of diabetes mellitus. Few drugs are effective in enhancing the healing of microvascular skin ulcers. The main objective of the present study was to determine whether iontophoresis of treprostinil, a prostacyclin analog, increases skin microvascular blood flux in the malleolus area of healthy subjects and diabetic patients. We recruited 12 healthy subjects and 12 type 2 diabetic patients. Cathodal iontophoresis (40 mC/cm) of treprostinil 250 μM and NaCl 0.9% was performed in the malleolus area. Skin hyperemia was quantified using non-invasive laser speckle contrast imaging, and expressed as the area under the curve (AUC) of cutaneous vascular conductance (CVC). In healthy controls and diabetic patients, treprostinil 250 μM induced a significant increase in CVC compared with NaCl (for diabetic patients, AUC<inf>0-6 h</inf> was 19970±8697; versus 2893±5481%BL.min, respectively; P=0.002). In both groups, the peak flux was obtained between 30 min and 1 h after the end of treprostinil iontophoresis and flux remained higher than baseline up to 6 h after ending of iontophoresis. No significant side-effect occurred. Cutaneous iontophoresis of 250 μM treprostinil increases microvascular blood flux in the malleolus area in healthy volunteers and diabetic patients, without inducing systemic or local side-effects. Treprostinil cathodal iontophoresis should be further investigated as a new local therapy for diabetic ulcers. © 2015 Elsevier B.V. All rights reserved.","Diabetic foot ulcers; Iontophoresis; Laser speckle contrast imaging; Microcirculation; Prostacyclin; Treprostinil","Aso, Y., Inukai, T., Takemura, Y., Evaluation of microangiopathy of the skin in patients with non-insulin-dependent diabetes mellitus by laser Doppler fluxmetry; Microvasodilatory responses to beraprost sodium (1997) Diabetes Res. Clin. Pract., 36, pp. 19-26; Baltzis, D., Eleftheriadou, I., Veves, A., Pathogenesis and treatment of impaired wound healing in diabetes mellitus: New insights (2014) Adv. Ther., 31, pp. 817-836; Blaise, S., Roustit, M., Millet, C., Ribuot, C., Boutonnat, J., Cracowski, J.L., Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats (2011) Br. J. Pharmacol., 162, pp. 557-565; Blaise, S., Roustit, M., Hellmann, M., Millet, C., Cracowski, J.L., Cathodal iontophoresis of treprostinil induces a sustained increase in cutaneous blood flux in healthy volunteers (2013) J. Clin. Pharmacol., 53, pp. 58-66; Brock, F.E., Abri, O., Baitsch, G., Bechara, G., Beck, K., Corovic, D., Diehm, C., Scheffler, P., Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative (1990) Schweiz. Med. Wochenschr., 120, pp. 1477-1482; Caselli, A., Rich, J., Hanane, T., Uccioli, L., Veves, A., Role of C-nociceptive fibers in the nerve axon reflex-related vasodilation in diabetes (2003) Neurology, 60, pp. 297-300; Daeschlein, G., Assadian, O., Kloth, L.C., Meinl, C., Ney, F., Kramer, A., Antibacterial activity of positive and negative polarity low-voltage pulsed current (LVPC) on six typical Gram-positive and Gram-negative bacterial pathogens of chronic wounds (2007) Wound Repair Regen., 15, pp. 399-403; Gohin, S., Sigaudo-Roussel, D., Conjard-Duplany, A., Dubourg, L., Saumet, J.L., Fromy, B., What can current stimulation tell us about the vascular function of endogenous prostacyclin in healthy rat skin in vivo? (2011) J. Investig. Dermatol, 131, pp. 237-244; Huttenlocher, A., Horwitz, A.R., Wound healing with electric potential (2007) New Engl. J. Med., 356, pp. 303-304; Kalia, Y.N., Naik, A., Garrison, J., Guy, R.H., Iontophoretic drug delivery (2004) Adv. Drug Deliv. Rev., 56, pp. 619-658; Ko, S.H., Cao, W., Liu, Z., Hypertension management and microvascular insulin resistance in diabetes (2010) Curr. Hypertens. Rep., 12, pp. 243-251; Laliberte, K., Arneson, C., Jeffs, R., Hunt, T., Wade, M., Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers (2004) J. Cardiovasc. Pharmacol., 44, pp. 209-214; Murray, A.K., Herrick, A.L., Gorodkin, R.E., Moore, T.L., King, T.A., Possible therapeutic use of vasodilator iontophoresis (2005) Microvasc Res., 69, pp. 89-94; O'Meara, S., Cullum, N., Majid, M., Sheldon, T., Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration (2001) Health Technol Assess., 4, pp. 1-237; Roustit, M., Millet, C., Blaise, S., Dufournet, B., Cracowski, J.L., Excellent reproducibility of laser speckle contrast imaging to assess skin microvascular reactivity (2010) Microvasc. Res., 80, pp. 505-511; Roustit, M., Cracowski, J.L., Non-invasive assessment of skin microvascular function in humans: An insight into methods (2012) Microcirculation., 19, pp. 47-64; Roustit, M., Cracowski, J.L., Assessment of endothelial and neurovascular function in human skin microcirculation (2013) Trends Pharmacol. Sci., 34, pp. 373-384; Roustit, M., Blaise, S., Cracowski, J.L., Trials and tribulations of skin iontophoresis in therapeutics (2014) Br. J. Clin. Pharmacol., 77, pp. 63-71; Roustit, M., Gaillard-Bigot, F., Blaise, S., Stanke-Labesque, F., Cracowski, C., Seinturier, C., Jourdil, J.F., Cracowski, J.L., Cutaneous iontophoresis of treprostinil in systemic sclerosis: A proof-of-concept study (2014) Clin. Pharmacol. Ther., 95, pp. 439-445; Veves, A., Akbari, C.M., Primavera, J., Donaghue, V.M., Zacharoulis, D., Chrzan, J.S., Degirolami, U., Freeman, R., Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration (1998) Diabetes, 47, pp. 457-463; Whittle, B.J., Silverstein, A.M., Mottola, D.M., Clapp, L.H., Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist (2012) Biochem. Pharmacol., 84, pp. 68-75; Woodward, D.F., Jones, R.L., Narumiya, S., International union of basic and clinical pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress (2011) Pharmacol. Rev., 63, pp. 471-538; Yamamoto, T., Horikawa, N., Komuro, Y., Hara, Y., Effect of topical application of a stable prostacyclin analog, SM-10902 on wound healing in diabetic mice (1996) Eur. J. Pharmacol., 302, pp. 53-60; Zhao, M., Song, B., Pu, J., Wada, T., Reid, B., Tai, G., Wang, F., Penninger, J.M., Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN (2006) Nature, 442, pp. 457-460",Article,Scopus,2-s2.0-84928016077
"Han Y., Chen J., Pan T., Liu G.","Determination of glycated hemoglobin using near-infrared spectroscopy combined with equidistant combination partial least squares",2015,"Chemometrics and Intelligent Laboratory Systems","145",,,"84","92",,,10.1016/j.chemolab.2015.04.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929000999&partnerID=40&md5=cc88ee8f65aa12c6cdf4b6f43142d0a1","Department of Optoelectronic Engineering, Jinan University, Huangpu Road West 601Tianhe District, Guangzhou, China; Department of Biological Engineering, Jinan University, Huangpu Road West 601Tianhe District, Guangzhou, China; Department of Mathematics, Jinan University, Huangpu Road West 601Tianhe District, Guangzhou, China","Han, Y., Department of Optoelectronic Engineering, Jinan University, Huangpu Road West 601Tianhe District, Guangzhou, China; Chen, J., Department of Biological Engineering, Jinan University, Huangpu Road West 601Tianhe District, Guangzhou, China; Pan, T., Department of Optoelectronic Engineering, Jinan University, Huangpu Road West 601Tianhe District, Guangzhou, China; Liu, G., Department of Mathematics, Jinan University, Huangpu Road West 601Tianhe District, Guangzhou, China","A novel near-infrared-spectroscopy-based quantification method for glycated hemoglobin (HbA1c), a major clinical diagnosis indicator of diabetes, was developed on the basis of simultaneous determination of hemoglobin (Hb) and absolute HbA1c content (Hb•HbA1c) in human hemolysate samples. Equidistant combination partial least squares (EC-PLS) method was proposed to perform wavelengths selection. Competitive adaptive reweighted sampling PLS (CARS-PLS) and Monte Carlo uninformative variable elimination PLS (MC-UVE-PLS) methods were also conducted for comparison. A randomness and stability dependent rigorous process of calibration, prediction, and validation was performed to produce objective and stable models. The search range covered the unsaturated region (780-1880. nm, 2090-2330. nm). For Hb and Hb•HbA1c, only 6 and 14 wavelengths were selected with EC-PLS, 23 and 30 wavelengths were selected with CARS-PLS, and 100 and 120 wavelengths were selected with MC-UVE-PLS, respectively.The predicted values of relative percentage HbA1c were calculated from the predicted Hb and Hb•HbA1c values. The sensitivity and specificity for diabetes were 93.5% and 97.1% with EC-PLS, 91.3% and 94.1% with CARS-PLS, and 89.1% and 76.5% with MC-UVE-PLS, respectively. In three methods, EC-PLS not only employed the least wavelengths but also produced the best quantification accuracy for HbA1c. EC-PLS also achieved the highest classification accuracy for negative and positive samples for diabetes.The results confirm the feasibility of HbA1c quantification based on the simultaneous analysis of Hb and Hb•HbA1c with NIR spectroscopy. This technique is rapid and simple when compared with conventional methods, and is a promising tool for screening diabetes in large populations. © 2015 Elsevier B.V.","Competitive adaptive reweighted sampling combined with PLS; Equidistant combination PLS; Glycated hemoglobin; Monte Carlo uninformative variable elimination by PLS; Near-infrared spectroscopic analysis","Zhernovaya, O.S., Tuchin, V.V., Meglinski, I.V., Monitoring of blood proteins glycation by refractive index and spectral measurements (2008) Laser Phys. Lett., 6, pp. 460-464; Standards of medical care for patients with diabetes mellitus (2003) Diabetes Care, 26, pp. 33-50; Stott, A., Casson, I.F., Higgins, G.J., Glycated haemoglobin assays. Approaches to standardization of results (2001) Diabet. Med., 18, pp. 274-279; Hazen, K.H., Arnold, M.A., Small, G.W., Measurement of glucose and other analytes in undiluted human serum with near-infrared transmission spectroscopy (1998) Anal. Chim. Acta, 371, pp. 255-267; Jiang, J.H., Berry, R.J., Siesler, H.W., Ozaki, Y., Wavelength interval selection in multicomponent spectral analysis by moving window partial least-squares regression with applications to mid-infrared and near-infrared spectroscopic data (2002) Anal. Chem., 74, pp. 3555-3565; Xie, J., Pan, T., Chen, J.M., Chen, H.Z., Ren, X.H., Joint optimization of Savitzky-Golay smoothing models and partial least squares factors for near-infrared spectroscopic analysis of serum glucose (2010) Chin. J. Anal. Chem., 38, pp. 342-346; Istvan, V.N., Karoly, J.K., Janos, M.J., Éva, G., Gyula, D., Application of near infrared spectroscopy to the determination of haemoglobin (1997) Clin. Chem. Acta, 264, pp. 117-125; Lee, Y., Lee, S., In, J.Y., Chung, S.H., Yon, J.H., Prediction of plasma hemoglobin concentration by near-infrared spectroscopy (2008) J. Korean Med. Sci., 23, pp. 674-677; Yin, H., Pan, T., Tian, P.L., Han, Y., Wei, X.C., Zhang, Q.J., Fang, J.Y., Feng, H., The rapid quantitative analysis for the human blood hemoglobin applied through the FTIR/ATR spectrum (2009) Chin. J. Spectrosc. Lab., 26, pp. 431-436; Pan, T., Liu, J.M., Chen, J.M., Zhang, G.P., Zhao, Y., Rapid determination of preliminary thalassaemia screening indicators based on near-infrared spectroscopy with wavelength selection stability (2013) Anal. Methods, 5, pp. 4355-4362; Du, Y.P., Liang, Y.Z., Jiang, J.H., Berry, R.J., Ozaki, Y., Spectral regions selection to improve prediction ability of PLS models by changeable size moving window partial least squares and searching combination moving window partial least squares (2004) Anal. Chim. Acta, 501, pp. 183-191; Chen, H.Z., Pan, T., Chen, J.M., Lu, Q.P., Waveband selection for NIR spectroscopy analysis of soil organic matter based on SG smoothing and MWPLS methods (2011) Chemometr. Intell. Lab., 107, pp. 139-146; Pan, T., Chen, Z.H., Chen, J.M., Liu, Z.Y., Near-Infrared spectroscopy with waveband selection stability for the determination of COD in sugar refinery wastewater (2012) Anal. Methods, 4, pp. 1046-1052; Pan, T., Wu, Z.T., Chen, J.M., Waveband optimization for near-infrared spectroscopic analysis of total nitrogen in soil (2012) Chin. J. Anal. Chem., 40, pp. 920-924; Liu, Z.Y., Liu, B., Pan, T., Yang, J.D., Determination of amino acid nitrogen in tuber mustard using near-infrared spectroscopy with waveband selection stability (2013) Spectrochim. Acta A, 102, pp. 269-274; Ni, W.D., Brown, S.D., Man, R.L., Stacked PLS for calibration transfer without standards (2011) J. Chemom., 25, pp. 130-137; Pan, T., Xie, J., Chen, H.Z., Yin, H., Chen, X.D., Equidistant combination moving window MLR method for wavenumbers selection of NIR analysis (2010) Near infrared spectroscopy: Proceedings of the 14th international conference, pp. 867-870. , IM Publications LLP, Chichester, UK, S. Saranwong, S. Kasemsumran, W. Thanapase, P. Williams (Eds.); Pan, T., Li, M.M., Chen, J.M., Selection method of quasi-continuous wavelength combination with applications to the near-infrared spectroscopic analysis of soil organic matter (2014) Appl. Spectrosc., 68, pp. 263-271; Li, H.D., Liang, Y.Z., Xu, Q.S., Cao, D.S., Key wavelengths screening using competitive adaptive reweighted sampling method for multivariate calibration (2009) Ana. Chim. Acta, 648, pp. 77-84; Cai, W.S., Li, Y.K., Shao, X.G., A variable selection method based on uninformative variable elimination for multivariate calibration of near-infrared spectra (2008) Chemometr. Intell. Lab., 90, pp. 188-194",Article,Scopus,2-s2.0-84929000999
"Zhang Y., Bai J., Wu H., Ying J.Y.","Trapping cells in paper for white blood cell count",2015,"Biosensors and Bioelectronics","69",,,"121","127",,,10.1016/j.bios.2015.02.019,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923262281&partnerID=40&md5=c85c4ab9e8fd9ab05b27438c30b2b150","Institute of Bioengineering and Nanotechnology, 31 Biopolis WayThe Nanos, Singapore, Singapore","Zhang, Y., Institute of Bioengineering and Nanotechnology, 31 Biopolis WayThe Nanos, Singapore, Singapore; Bai, J., Institute of Bioengineering and Nanotechnology, 31 Biopolis WayThe Nanos, Singapore, Singapore; Wu, H., Institute of Bioengineering and Nanotechnology, 31 Biopolis WayThe Nanos, Singapore, Singapore; Ying, J.Y., Institute of Bioengineering and Nanotechnology, 31 Biopolis WayThe Nanos, Singapore, Singapore","White blood cell count is an important indicator of each individual's health condition. An abnormal white blood cell count usually results from an infection, cancer, or other conditions that trigger systemic inflammation responses. White blood cell count also provides predictive information on the incidence of cardiovascular diseases and Type 2 diabetes. Therefore, monitoring white blood cell count on a regular basis can potentially help individuals to take preventive measures and improve healthcare outcomes. Currently, white blood cell count is primarily conducted in centralized laboratories, and it requires specialized equipment and dedicated personnel to perform the test and interpret the results. So far there has been no rapid test that allows white blood cell count in low-resource settings. In this study, we have demonstrated a vertical flow platform that quantifies white blood cells by trapping them in the paper. White blood cells were tagged with gold nanoparticles, and flowed through the paper via a small orifice. The white blood cell count was determined by measuring the colorimetric intensity of gold nanoparticles on the surface of white blood cells that were trapped in the paper mesh. Using this platform, we were able to quantify white blood cells in 15. μL of blood, and visually differentiate the abnormal count of white blood cells from the normal count. The proposed platform enabled rapid white blood cell count in low resource settings with a small sample volume requirement. Its low-cost, instrument-free operations would be attractive for point-of-care applications. © 2015 Elsevier B.V.","Flow-through; Gold nanoparticle; Immunoassay; Paper microfluidics; Vertical flow; White blood cell count","Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P., (2002) Molecular Biology of the Cell, , Garland Science, New York; Berliner, N., (2011) Cecil Medicine, , Elsevier, Philadelphia; Buttarello, M., Plebani, M., (2008) Am. J. Clin. Pathol., 130, pp. 104-116; Cheng, X., Irimia, D., Dixon, M., Sekine, K., Demirci, U., Zamir, L., Tompkins, R.G., Toner, M., (2007) Lab Chip, 7, pp. 170-178; Esfandiari, J., Brook, S., Dual path immunoassay device, US Patent 13/965, 2013, 829Friedman, G.D., Klatsky, A.L., Siegelaub, A.B., (1974) N. Engl. J. Med., 290, pp. 1275-1278; Fu, L.-M., Yang, R.-J., Lin, C.-H., Pan, Y.-J., Lee, G.-B., (2004) Anal. Chim. Acta, 507, pp. 163-169; Glynn, M.T., Kinahan, D.J., Ducree, J., (2014) Lab Chip, 14, pp. 2844-2851; Goldmann, F., Bauer, N., Moritz, A., (2013) Comp. Clin. Path, 22, pp. 855-868; Graham, M.D., (2003) J. Lab. Autom., 8, pp. 72-81; Grimm, R.H., Neaton, J.D., Ludwig, W., (1985) JAMA, 254, pp. 1932-1937; Gwo-Bin, L., Che-Hsin, L., Shen-Chie, C., (2005) J. Micromech. Microeng., 15, p. 447; Holmes, D., Pettigrew, D., Reccius, C.H., Gwyer, J.D., van Berkel, C., Holloway, J., Davies, D.E., Morgan, H., (2009) Lab Chip, 9, pp. 2881-2889; Horne, B.D., Anderson, J.L., John, J.M., Weaver, A., Bair, T.L., Jensen, K.R., Renlund, D.G., Muhlestein, J.B., (2005) J. Am. Coll. Cardiol., 45, pp. 1638-1643; Hyun, B.H., Gulati, G.L., Ashton, J.K., (1991) Yonsei Med. J., 32, pp. 283-291; Kannel, W.B., Anderson, K., Wilson, P.F., (1992) JAMA, 267, pp. 1253-1256; Liu, G., Mao, X., Phillips, J.A., Xu, H., Tan, W., Zeng, L., (2009) Anal. Chem., 81, pp. 10013-10018; Mao, X., Ma, Y., Zhang, A., Zhang, L., Zeng, L., Liu, G., (2009) Anal. Chem., 81, pp. 1660-1668; Ngom, B., Guo, Y., Wang, X., Bi, D., (2010) Anal. Bioanal. Chem., 397, pp. 1113-1135; Ohshita, K., Yamane, K., Hanafusa, M., Mori, H., Mito, K., Okubo, M., Hara, H., Kohno, N., (2004) Diabetes Care, 27, pp. 491-496; Pickup, J.C., Crook, M.A., (1998) Diabetologia, 41, pp. 1241-1248; Sung-Yi, Y., Suz-Kai, H., Yung-Ching, H., Chen-Min, C., Teh-Lu, L., Gwo-Bin, L., (2006) Meas. Sci. Technol., 17, p. 2001; Tefferi, A., Hanson, C.A., Inwards, D.J., (2005) Mayo. Clin. Proc., 80, pp. 923-936; Terstappen, L.W.M.M., DeGrooth, B.G., Visscher, K., VanKouterik, F.A., Greve, J., (1988) Cytometry, 9, pp. 39-43; Tortora, G.J., Grabowski, S.R., (2002) Principles of Anatomy and Physiology, , John Wiley & Sons Inc., Canada; Verso, M.L., (1964) Med. Hist., 8, pp. 149-158; Vozarova, B., Weyer, C., Lindsay, R.S., Pratley, R.E., Bogardus, C., Tataranni, P.A., (2002) Diabetes, 51, pp. 455-461; Weijenberg, M.P., Feskens, E.J.M., Kromhout, D., (1996) Arterioscler. Thromb. Vasc. Biol., 16, pp. 499-503; Wong, A.P., Gupta, M., Shevkoplyas, S.S., Whitesides, G.M., (2008) Lab Chip, 8, pp. 2032-2037; Wu, W., Yu, L., Fang, Z., Lie, P., Zeng, L., (2013) Anal. Biochem., 436, pp. 160-164",Article,Scopus,2-s2.0-84923262281
"Haight T.J., Bryan R.N., Erus G., Davatzikos C., Jacobs D.R., D'Esposito M., Lewis C.E., Launer L.J.","Vascular risk factors, cerebrovascular reactivity, and the default-mode brain network",2015,"NeuroImage","115",,,"7","16",,,10.1016/j.neuroimage.2015.04.039,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928888984&partnerID=40&md5=98ea63953e885138651657f9353cc2c1","Laboratory of Epidemiology and Population Sciences, National Institute on Aging, 7201 Wisconsin AvenueBethesda, MD, United States; Department of Radiology, University of Pennsylvania, 3600 Market St.Philadelphia, PA, United States; Division of Epidemiology and Community Health, University of Minnesota, 1300 S. 2nd Street, Suite 300Minneapolis, MN, United States; Helen Wills Neuroscience Institute, University of California-Berkeley, 132 Barker HallBerkeley, CA, United States; Department of Medicine, Division of Preventive Medicine, University of Alabama, Medical Towers 614, 1717 11th Avenue SouthBirmingham, AL, United States","Haight, T.J., Laboratory of Epidemiology and Population Sciences, National Institute on Aging, 7201 Wisconsin AvenueBethesda, MD, United States; Bryan, R.N., Department of Radiology, University of Pennsylvania, 3600 Market St.Philadelphia, PA, United States; Erus, G., Department of Radiology, University of Pennsylvania, 3600 Market St.Philadelphia, PA, United States; Davatzikos, C., Department of Radiology, University of Pennsylvania, 3600 Market St.Philadelphia, PA, United States; Jacobs, D.R., Division of Epidemiology and Community Health, University of Minnesota, 1300 S. 2nd Street, Suite 300Minneapolis, MN, United States; D'Esposito, M., Helen Wills Neuroscience Institute, University of California-Berkeley, 132 Barker HallBerkeley, CA, United States; Lewis, C.E., Department of Medicine, Division of Preventive Medicine, University of Alabama, Medical Towers 614, 1717 11th Avenue SouthBirmingham, AL, United States; Launer, L.J., Laboratory of Epidemiology and Population Sciences, National Institute on Aging, 7201 Wisconsin AvenueBethesda, MD, United States","Cumulating evidence from epidemiologic studies implicates cardiovascular health and cerebrovascular function in several brain diseases in late life. We examined vascular risk factors with respect to a cerebrovascular measure of brain functioning in subjects in mid-life, which could represent a marker of brain changes in later life. Breath-hold functional MRI (fMRI) was performed in 541 women and men (mean age 50.4. years) from the Coronary Artery Risk Development in Young Adults (CARDIA) Brain MRI sub-study. Cerebrovascular reactivity (CVR) was quantified as percentage change in blood-oxygen level dependent (BOLD) signal in activated voxels, which was mapped to a common brain template and log-transformed. Mean CVR was calculated for anatomic regions underlying the default-mode network (DMN) - a network implicated in AD and other brain disorders - in addition to areas considered to be relatively spared in the disease (e.g. occipital lobe), which were utilized as reference regions. Mean CVR was significantly reduced in the posterior cingulate/precuneus (β. =. -. 0.063, 95% CI: -. 0.106, -. 0.020), anterior cingulate (β. =. -. 0.055, 95% CI: -. 0.101, -. 0.010), and medial frontal lobe (β. =. -. 0.050, 95% CI: -. 0.092, -. 0.008) relative to mean CVR in the occipital lobe, after adjustment for age, sex, race, education, and smoking status, in subjects with pre-hypertension/hypertension compared to normotensive subjects. By contrast, mean CVR was lower, but not significantly, in the inferior parietal lobe (β. =. -. 0.024, 95% CI: -. 0.062, 0.014) and the hippocampus (β. =. -. 0.006, 95% CI: -. 0.062, 0.050) relative to mean CVR in the occipital lobe. Similar results were observed in subjects with diabetes and dyslipidemia compared to those without these conditions, though the differences were non-significant. Reduced CVR may represent diminished vascular functionality for the DMN for individuals with prehypertension/hypertension in mid-life, and may serve as a preclinical marker for brain dysfunction in later life. © 2015 Elsevier Inc.","Alzheimer's disease; Neurophysiology; Vascular risk factors","Alsop, D.C., Detre, J.A., Grossman, M., Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging (2000) Ann. Neurol., 47, pp. 93-100; Alsop, D.C., Dai, W., Grossman, M., Detre, J.A., Arterial spin labeling blood flow MRI: its role in theearly characterization of Alzheimer's disease (2010) J. Alzheimers Dis., 20, pp. 871-880; Diagnosis and classification of diabetes mellitus (2011) Diabetes Care, 34, pp. S62-S69; Bandettini, P.A., Wong, E.C., A hypercapnia-based normalization method for improved spatial localization of human brain activation with fMRI (1997) NMR Biomed., 10, pp. 197-203; Beason-Held, L.L., Thambisetty, M., Deib, G., Sojkova, J., Landman, B.A., Zonderman, A.B., Ferrucci, L., Resnick, S.M., Baseline cardiovascular risk predicts subsequent changes in resting brain function (2012) Stroke, 43, pp. 1542-1547; Benarroch, E.E., Neurovascular unit dysfunction: a vascular component of Alzheimer disease? (2007) Neurology, 68, pp. 1730-1732; Bendlin, B.B., Carlsson, C.M., Gleason, C.E., Johnson, S.C., Sodhi, A., Gallagher, C.L., Puglielli, L., Asthana, S., Midlife predictors of Alzheimer's disease (2010) Maturitas, 65, pp. 131-137; Bondi, M.W., Houston, W.S., Eyler, L.T., Brown, G.G., FMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease (2005) Neurology, 64, pp. 501-508; Bookheimer, S.Y., Strojwas, M.H., Cohen, M.S., Saunders, A.M., Pericak-Vance, M.A., Mazziotta, J.C., Small, G.W., Patterns of brain activation in people at risk for Alzheimer's disease (2000) N. Engl. J. Med., 343, pp. 450-456; Brier, M.R., Thomas, J.B., Ances, B.M., Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis (2014) Brain Connect., 4, pp. 299-311; Buckner, R.L., Andrews-Hanna, J.R., Schacter, D.L., The brain's default network: anatomy, function, and relevance to disease (2008) Ann. N. Y. Acad. Sci., 1124, pp. 1-38; Celone, K.A., Calhoun, V.D., Dickerson, B.C., Atri, A., Chua, E.F., Miller, S.L., DePeau, K., Sperling, R.A., Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis (2006) J. Neurosci., 26, pp. 10222-10231; Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jones, D.W., Roccella, E.J., Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (2003) Hypertension, 42, pp. 1206-1252; Claus, J.J., Breteler, M.M., Hasan, D., Krenning, E.P., Bots, M.L., Grobbee, D.E., Van Swieten, J.C., Hofman, A., Regional cerebral blood flow and cerebrovascular risk factors in the elderly population (1998) Neurobiol. Aging, 19, pp. 57-64; Convit, A., Wolf, O.T., Tarshish, C., de Leon, M.J., Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly (2003) Proc. Natl. Acad. Sci. U. S. A., 100, pp. 2019-2022; Dai, W., Lopez, O.L., Carmichael, O.T., Becker, J.T., Kuller, L.H., Gach, H.M., Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension (2008) Stroke, 39, pp. 349-354; Dai, W., Lopez, O.L., Carmichael, O.T., Becker, J.T., Kuller, L.H., Gach, H.M., Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging (2009) Radiology, 250, pp. 856-866; Damoiseaux, J.S., Greicius, M.D., Greater than the sum of its parts: a review of studies combining structural connectivity and resting-state functional connectivity (2009) Brain Struct. Funct., 213, pp. 525-533; Damoiseaux, J.S., Prater, K.E., Miller, B.L., Greicius, M.D., Functional connectivity tracks clinical deterioration in Alzheimer's disease (2012) Neurobiol. Aging, 33 (828), pp. e819-e830; Daselaar, S.M., Prince, S.E., Cabeza, R., When less means more: deactivations during encoding that predict subsequent memory (2004) NeuroImage, 23, pp. 921-927; Dickerson, B.C., Salat, D.H., Greve, D.N., Chua, E.F., Rand-Giovannetti, E., Rentz, D.M., Bertram, L., Sperling, R.A., Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD (2005) Neurology, 65, pp. 404-411; Dunn, C.J., Duffy, S.L., Hickie, I.B., Lagopoulos, J., Lewis, S.J., Naismith, S.L., Shine, J.M., Deficits in episodic memory retrieval reveal impaired default mode network connectivity in amnestic mild cognitive impairment (2014) NeuroImage Clin., 4, pp. 473-480; Duschek, S., Schandry, R., Reduced brain perfusion and cognitive performance due to constitutional hypotension (2007) Clin. Auton. Res., 17, pp. 69-76; Friedman, G.D., Cutter, G.R., Donahue, R.P., Hughes, G.H., Hulley, S.B., Jacobs, D.R., Liu, K., Savage, P.J., CARDIA: study design, recruitment, and some characteristics of the examined subjects (1988) J. Clin. Epidemiol., 41, pp. 1105-1116; FSL software for BOLD analysis, , http://www.fmrib.ox.ac.uk/fsl/, [cited 2013 June 27 2013]; Available from; Gazzaley, A., D'Esposito, M., BOLD fMRI and cognitive aging (2005) Cognitive Neuroscience of Aging, pp. 107-131. , Oxford University Press, New York, R. Cabeza, L. Nyberg, D. Park (Eds.); Glodzik, L., Rusinek, H., Brys, M., Tsui, W.H., Switalski, R., Mosconi, L., Mistur, R., de Leon, M.J., Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia (2011) J. Cereb. Blood Flow Metab., 31, pp. 671-679; Goldszal, A.F., Davatzikos, C., Pham, D.L., Yan, M.X., Bryan, R.N., Resnick, S.M., An image-processing system for qualitative and quantitative volumetric analysis of brain images (1998) J. Comput. Assist. Tomogr., 22, pp. 827-837; Greicius, M.D., Srivastava, G., Reiss, A.L., Menon, V., Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI (2004) Proc. Natl. Acad. Sci. U. S. A., 101, pp. 4637-4642; Handwerker, D.A., Gazzaley, A., Inglis, B.A., D'Esposito, M., Reducing vascular variability of fMRI data across aging populations using a breathholding task (2007) Hum. Brain Mapp., 28, pp. 846-859; Hedden, T., Gabrieli, J.D., Insights into the ageing mind: a view from cognitive neuroscience (2004) Nat. Rev. Neurosci., 5, pp. 87-96; Hedden, T., Van Dijk, K., Becker, A., Mehta, A., Sperling, R., Johnson, K., Buckner, R.L., Disruption of functional connectivity in clinically normal older adults harboring amyloid burden (2009) J. Neurosci., 29, pp. 12686-12694; Ishii, K., Soma, T., Kono, A.K., Sofue, K., Miyamoto, N., Yoshikawa, T., Mori, E., Murase, K., Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer's disease (2007) J. Nucl. Med., 48, pp. 704-711; Jack, C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) Lancet Neurol., 9, pp. 119-128; Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, L.M., Trojanowski, J.Q., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers (2013) Lancet Neurol., 12, pp. 207-216; (2009) Imaging the Aging Brain, , Oxford University Press, New York, W.J. Jagust, M. D'Esposito (Eds.); Jennings, J.R., Muldoon, M.F., Ryan, C., Price, J.C., Greer, P., Sutton-Tyrrell, K., van der Veen, F.M., Meltzer, C.C., Reduced cerebral blood flow response and compensation among patients with untreated hypertension (2005) Neurology, 64, pp. 1358-1365; Johnson, N.A., Jahng, G.H., Weiner, M.W., Miller, B.L., Chui, H.C., Jagust, W.J., Gorno-Tempini, M.L., Schuff, N., Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience (2005) Radiology, 234, pp. 851-859; Kabani, N.J., Collins, D.L., Evans, A.C., A 3D neuroanatomical atlas (1998) Fourth International Conference on Functional Mapping of the Human Brain; Kastrup, A., Kruger, G., Glover, G.H., Neumann-Haefelin, T., Moseley, M.E., Regional variability of cerebral blood oxygenation response to hypercapnia (1999) NeuroImage, 10, pp. 675-681; Kastrup, A., Kruger, G., Neumann-Haefelin, T., Moseley, M.E., Assessment of cerebrovascular reactivity with functional magnetic resonance imaging: comparison of CO<inf>2</inf> and breath holding (2001) Magn. Reson. Imaging, 19, pp. 13-20; Kivipelto, M., Helkala, E.L., Hanninen, T., Laakso, M.P., Hallikainen, M., Alhainen, K., Soininen, H., Nissinen, A., Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study (2001) Neurology, 56, pp. 1683-1689; Lao, Z., Shen, D., Liu, D., Jawad, A.F., Melhem, E.R., Launer, L.J., Bryan, R.N., Davatzikos, C., Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine (2008) Acad. Radiol., 15, pp. 300-313; Last, D., Alsop, D.C., Abduljalil, A.M., Marquis, R.P., de Bazelaire, C., Hu, K., Cavallerano, J., Novak, V., Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity (2007) Diabetes Care, 30, pp. 1193-1199; Launer, L.J., Masaki, K., Petrovitch, H., Foley, D., Havlik, R.J., The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study (1995) JAMA, 274, pp. 1846-1851; Launer, L.J., Ross, G.W., Petrovitch, H., Masaki, K., Foley, D., White, L.R., Havlik, R.J., Midlife blood pressure and dementia: the Honolulu-Asia aging study (2000) Neurobiol. Aging, 21, pp. 49-55; Launer, L.J., Lewis, C.E., Schreiner, P.J., Sidney, S., Battapady, H., Jacobs, D.R., Lim, K.O., Bryan, R.N., Vascular factors and multiple measures of early brain health: CARDIA Brain MRI Study (2015) PLoS One, 10 (3), p. e0122138; Littell, R.C., Milliken, G.A., Stroup, W.W., Wolfinger, R.D., (1996) SAS System for Mixed Models, , SAS Institute, Cary, NC; Mayda, A.B., Westphal, A., Carter, C.S., DeCarli, C., Late life cognitive control deficits are accentuated by white matter disease burden (2011) Brain, 134, pp. 1673-1683; Miller, S.L., Celone, K., DePeau, K., Diamond, E., Dickerson, B.C., Rentz, D., Pihlajamaki, M., Sperling, R.A., Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation (2008) Proc. Natl. Acad. Sci. U. S. A., 105, pp. 2181-2186; Miller, M., Stone, N.J., Ballantyne, C., Bittner, V., Criqui, M.H., Ginsberg, H.N., Goldberg, A.C., Pennathur, S., Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association (2011) Circulation, 123, pp. 2292-2333; Muller, M., van der Graaf, Y., Visseren, F.L., Mali, W.P., Geerlings, M.I., Group, S.S., Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study (2012) Ann. Neurol., 71, pp. 825-833; Murphy, K., Harris, A.D., Wise, R.G., Robustly measuring vascular reactivity differences with breath-hold: normalising stimulus-evoked and resting state BOLD fMRI data (2011) NeuroImage, 54, pp. 369-379; Novak, V., Cognition and hemodynamics (2012) Curr. Cardiovasc. Risk Rep., 6, pp. 380-396; Papma, J., den Heijer, T., de Koning, I., Mattace-Raso, F., van der Lugt, A., van der Lijn, F., van Swieten, J., Prins, N., The influence of cerebral small vessel disease on default mode network deactivation in mild cognitive impairment (2013) NeuroImage Clin., 2, pp. 33-42; Pillai, J.J., Milkulis, D.J., Cerebrovascular reactivity mapping: an evolving standard for clinical functional imaging (2015) AJNR, 36, pp. 7-13; Raichle, M.E., MacLeod, A.M., Snyder, A.Z., Powers, W.J., Gusnard, D.A., Shulman, G.L., A default mode of brain function (2001) Proc. Natl. Acad. Sci. U. S. A., 98, pp. 676-682; Resnick, S.M., Pham, D.L., Kraut, M.A., Zonderman, A.B., Davatzikos, C., Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain (2003) J. Neurosci., 23, pp. 3295-3301; Riecker, A., Grodd, W., Klose, U., Schulz, J.B., Groschel, K., Erb, M., Ackermann, H., Kastrup, A., Relation between regional functional MRI activation and vascular reactivity to carbon dioxide during normal aging (2003) J. Cereb. Blood Flow Metab., 23, pp. 565-573; Roberts, R.O., Knopman, D.S., Przybelski, S.A., Mielke, M.M., Kantarci, K., Preboske, G.M., Senjem, M.L., Jack, C.R., Association of type 2 diabetes with brain atrophy and cognitive impairment (2014) Neurology, 82, pp. 1132-1141; Rossini, P.M., Altamura, C., Ferretti, A., Vernieri, F., Zappasodi, F., Caulo, M., Pizzella, V., Tecchio, F., Does cerebrovascular disease affect the coupling between neuronal activity and local haemodynamics? (2004) Brain, 127, pp. 99-110; Schuff, N., Matsumoto, S., Kmiecik, J., Studholme, C., Du, A., Ezekiel, F., Miller, B.L., Weiner, M.W., Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging (2009) Alzheimers Dement., 5, pp. 454-462; Sheline, Y.I., Raichle, M.E., Resting state functional connectivity in preclinical Alzheimer's disease (2013) Biol. Psychiatry, 74, pp. 340-347; Shen, D., Davatzikos, C., HAMMER: hierarchical attribute matching mechanism for elastic registration (2002) IEEE Trans. Med. Imaging, 21, pp. 1421-1439; Silvestrini, M., Vernieri, F., Pasqualetti, P., Matteis, M., Passarelli, F., Troisi, E., Caltagirone, C., Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis (2000) JAMA, 283, pp. 2122-2127; Sorond, F.A., Galica, A., Serrador, J.M., Kiely, D.K., Iloputaife, I., Cupples, L.A., Lipsitz, L.A., Cerebrovascular hemodynamics, gait, and falls in an elderly population: MOBILIZE Boston Study (2010) Neurology, 74, pp. 1627-1633; Sperling, R., Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease (2007) Ann. N. Y. Acad. Sci., 1097, pp. 146-155; Stefani, A., Sancesario, G., Pierantozzi, M., Leone, G., Galati, S., Hainsworth, A.H., Diomedi, M., CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia (2009) J. Neurol. Sci., 283, pp. 109-115; Thompson, P.M., Mega, M.S., Woods, R.P., Zoumalan, C.I., Lindshield, C.J., Blanton, R.E., Moussai, J., Toga, A.W., Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas (2001) Cereb. Cortex, 11, pp. 1-16; Vernieri, F., Pasqualetti, P., Passarelli, F., Rossini, P.M., Silvestrini, M., Outcome of carotid artery occlusion is predicted by cerebrovascular reactivity (1999) Stroke, 30, pp. 593-598; Wang, Z., Aguirre, G., Rao, H., Wang, J., Fernández-Seara, M., Childress, A., Detre, J., Empirical optimization of of ASL data analysis using an ASL data processing toolbox: ALS tbx (2008) Magn. Reson. Imaging, 26, pp. 261-269; Wu, W., Brickman, A.M., Luchsinger, J., Ferrazzano, P., Pichiule, P., Yoshita, M., Brown, T., Small, S.A., The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life (2008) Ann. Neurol., 64, pp. 698-706; Yakushev, I., Landvogt, C., Buchholz, H.G., Fellgiebel, A., Hammers, A., Scheurich, A., Schmidtmann, I., Bartenstein, P., Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18 (2008) Psychiatry Res., 164, pp. 143-153; Zacharaki, E.I., Kanterakis, S., Bryan, R.N., Davatzikos, C., Measuring brain lesion progression with a supervised tissue classification system (2008) Med. Image Comput. Comput. Assist. Interv., 11, pp. 620-627",Article,Scopus,2-s2.0-84928888984
"Turyk M., Fantuzzi G., Persky V., Freels S., Lambertino A., Pini M., Rhodes D.H., Anderson H.A.","Persistent organic pollutants and biomarkers of diabetes risk in a cohort of Great Lakes sport caught fish consumers",2015,"Environmental Research","140",,,"335","344",,,10.1016/j.envres.2015.03.037,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928154827&partnerID=40&md5=8a7d98e66faf739965eb29444cd98290","University of Illinois at Chicago, Division of Epidemiology and Biostatistics, School of Public Health, 1603 W. Taylor StreetChicago, IL, United States; University of Illinois at Chicago, Department of Kinesiology and Nutrition, College of Applied Health Sciences, 1919 W. Taylor StreetChicago, IL, United States; Université Pierre et Marie Curie-Paris6, Centre de Recherche des Cordeliers, UMRS 872Paris, France; Institute of Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière HospitalParis, France; Department of Human Nutrition, Kansas State UniversityManhattan, KS, United States; Wisconsin Division of Public Health, 1 W. Wilson St., Room 150Madison, WI, United States","Turyk, M., University of Illinois at Chicago, Division of Epidemiology and Biostatistics, School of Public Health, 1603 W. Taylor StreetChicago, IL, United States; Fantuzzi, G., University of Illinois at Chicago, Department of Kinesiology and Nutrition, College of Applied Health Sciences, 1919 W. Taylor StreetChicago, IL, United States; Persky, V., University of Illinois at Chicago, Division of Epidemiology and Biostatistics, School of Public Health, 1603 W. Taylor StreetChicago, IL, United States; Freels, S., University of Illinois at Chicago, Division of Epidemiology and Biostatistics, School of Public Health, 1603 W. Taylor StreetChicago, IL, United States; Lambertino, A., University of Illinois at Chicago, Division of Epidemiology and Biostatistics, School of Public Health, 1603 W. Taylor StreetChicago, IL, United States; Pini, M., University of Illinois at Chicago, Department of Kinesiology and Nutrition, College of Applied Health Sciences, 1919 W. Taylor StreetChicago, IL, United States, Université Pierre et Marie Curie-Paris6, Centre de Recherche des Cordeliers, UMRS 872Paris, France, Institute of Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière HospitalParis, France; Rhodes, D.H., University of Illinois at Chicago, Department of Kinesiology and Nutrition, College of Applied Health Sciences, 1919 W. Taylor StreetChicago, IL, United States, Department of Human Nutrition, Kansas State UniversityManhattan, KS, United States; Anderson, H.A., Wisconsin Division of Public Health, 1 W. Wilson St., Room 150Madison, WI, United States","Background: Exposure to persistent organic pollutants (POPs) is associated with increased diabetes risk, although the mechanism of action is not well delineated. Methods: We investigated established diabetes biomarkers that could implicate potential mechanistic pathways, including C-reactive protein (CRP), a marker of systemic inflammation; gamma glutamyl transferase (GGT), a liver enzyme associated with oxidative stress; and adiponectin, an adipokine modulating glucose regulation and fatty acid oxidation. These biomarkers as well as hemoglobin A1c (HA1c), and POPs [polychlorinated biphenyls (PCBs), p,p-dichlorodiphenyldichloroethylene (DDE) and polybrominated diphenyl ethers (PBDEs)] were measured in a cohort of Great Lakes sport caught fish (GLSCF) consumers. We examined associations of POPs and fish consumption with HA1c and incident diabetes, and evaluated mediation and moderation by the diabetes biomarkers. Results: Odds of incident diabetes were elevated with exposure to DDE and PCBs. DDE and PCB 118 were positively, and fish meals were inversely, associated with HA1c. CRP was inversely associated with saltwater and total fish meals, particularly in persons with higher adiposity, but did not mediate the associations of fish meals with HA1c. There were few associations of POPs with adiponectin, CRP and GGT, with the exception of positive associations of PCB 118 with GGT, PBDEs with GGT in older persons, and PBDEs with adiponectin. Adiponectin, CRP and GGT did not mediate associations of DDE and PCBs with HA1c or incident diabetes. However, the association of DDE with HA1c was stronger in persons with higher CRP, GGT and BMI, and lower adiponectin, while the association of PCB 118 with HA1c was stronger in persons with higher GGT. Conclusions: These findings suggest that adiponectin, CRP and GGT did not mediate effects of POPs on diabetes or HA1c. However, POPs may have stronger effects on blood glucose in persons at higher risk for diabetes. © 2015 Elsevier Inc.","Adiponectin; C-reactive protein; DDE; Diabetes; Fish consumption; Gamma glutamyl transferase; PCBs; Persistent organic pollutants","Akinkuolie, A.O., Ngwa, J.S., Meigs, J.B., Djousse, L., Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials (2011) Clin. Nutr., 30, pp. 702-707; Standards of medical care in diabetes - 2010 (2010) Diabetes Care, 33, pp. S11-S61; Anderson, H., Falk, C., Fiore, B., Hanrahan, L., Humphrey, H.E., Kanarek, M., Consortium for the health assessment of great lakes sport fish consumption (1996) Toxicol. Ind. Health, 12, pp. 369-373; Anderson, H.A., Imm, P., Knobeloch, L., Turyk, M., Mathew, J., Buelow, C., Polybrominated diphenyl ethers (PBDE) in serum: findings from a US cohort of consumers of sport-caught fish (2008) Chemosphere, 73, pp. 187-194; Boeing, H., Weisgerber, U.M., Jeckel, A., Rose, H.J., Kroke, A., Association between glycated hemoglobin and diet and other lifestyle factors in a nondiabetic population: cross-sectional evaluation of data from the Potsdam cohort of the European Prospective Investigation into Cancer and Nutrition Study (2000) Am. J. Clin. Nutr., 71, pp. 1115-1122; Brand, J.S., Wareham, N.J., Dowsett, M., Folkerd, E., van der Schouw, Y.T., Luben, R.N., Associations of endogenous testosterone and SHBG with glycated haemoglobin in middle-aged and older men (2011) Clin. Endocrinol., 74, pp. 572-578; Calvert, G.M., Sweeney, M.H., Deddens, J., Wall, D.K., Evaluation of diabetes mellitus, serum glucose, and thyroid function among United States workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (1999) Occup. Environ. Med., 56, pp. 270-276; Carpentier, Y.A., Portois, L., Malaisse, W.J., N-3 fatty acids and the metabolic syndrome (2006) Am. J. Clin. Nutr., 83, pp. 1499S-1504S; Chen, H.L., Su, H.J., Guo, Y.L., Liao, P.C., Hung, C.F., Lee, C.C., Biochemistry examinations and health disorder evaluation of Taiwanese living near incinerators and with low serum PCDD/Fs levels (2006) Sci. Total Environ., 366, pp. 538-548; Codru, N., Schymura, M.J., Negoita, S., Rej, R., Carpenter, D.O., Diabetes in relation to serum levels of polychlorinated biphenyls and chlorinated pesticides in adult Native Americans (2007) Environ. Health Perspect., 115, pp. 1442-1447; De Tata, V., Association of dioxin and other persistent organic pollutants (POPs) with diabetes: epidemiological evidence and new mechanisms of beta cell dysfunction (2014) Int. J. Mol. Sci., 15, pp. 7787-7811; Dehghan, A., Kardys, I., de Maat, M.P., Uitterlinden, A.G., Sijbrands, E.J., Bootsma, A.H., Genetic variation, C-reactive protein levels, and incidence of diabetes (2007) Diabetes, 56, pp. 872-878; Duncan, B.B., Schmidt, M.I., The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes (2006) Diabetes Technol. Ther., 8, pp. 7-17; Everett, C.J., Matheson, E.M., Biomarkers of pesticide exposure and diabetes in the 1999-2004 national health and nutrition examination survey (2010) Environ. Int., 36, pp. 398-401; Everett, C.J., Thompson, O.M., Associations of dioxins, furans and dioxin-like PCBs with diabetes and pre-diabetes: is the toxic equivalency approach useful? (2012) Environ. Res., 118, pp. 107-111; Fallah, S., Sanjary, P.M., Rabbani, C.A., Korani, M., Adiponectin, leptin and lipid profiles evaluation in oral contraceptive pill consumers (2012) Arch. Gynecol. Obstet., 285, pp. 1747-1752; Fantuzzi, G., Adipose tissue, adipokines, and inflammation (2005) J. Allergy Clin. Immunol., 115, pp. 911-919; Fedor, D., Kelley, D.S., Prevention of insulin resistance by n-3 polyunsaturated fatty acids (2009) Curr. Opin. Clin. Nutr. Metab. Care, 12, pp. 138-146; Fujiyoshi, P.T., Michalek, J.E., Matsumura, F., Molecular epidemiologic evidence for diabetogenic effects of dioxin exposure in U.S. Air force veterans of the Vietnam war (2006) Environ. Health Perspect., 114, pp. 1677-1683; Grandjean, P., Henriksen, J.E., Choi, A.L., Petersen, M.S., Dalgard, C., Nielsen, F., Marine food pollutants as a risk factor for hypoinsulinemia and type 2 diabetes (2011) Epidemiology, 22, pp. 410-417; Ha, M.H., Lee, D.H., Jacobs, D.R., Association between serum concentrations of persistent organic pollutants and self-reported cardiovascular disease prevalence: results from the National Health and Nutrition Examination Survey, 1999-2002 (2007) Environ. Health Perspect., 115, pp. 1204-1209; Hanrahan, L.P., Falk, C., Anderson, H.A., Draheim, L., Kanarek, M.S., Olson, J., Serum PCB and DDE levels of frequent Great Lakes sport fish consumers-a first look. The Great Lakes Consortium (1999) Environ. Res., 80, pp. S26-S37; Harding, A.H., Day, N.E., Khaw, K.T., Bingham, S.A., Luben, R.N., Welsh, A., Habitual fish consumption and glycated haemoglobin: the EPIC-Norfolk study (2004) Eur. J. Clin. Nutr., 58, pp. 277-284; He, K., Liu, K., Daviglus, M.L., Jenny, N.S., Mayer-Davis, E., Jiang, R., Associations of dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the Multi-Ethnic Study of Atherosclerosis [MESA]) (2009) Am. J. Cardiol., 103, pp. 1238-1243; Henriksen, G.L., Ketchum, N.S., Michalek, J.E., Swaby, J.A., Serum dioxin and diabetes mellitus in veterans of Operation Ranch Hand (1997) Epidemiology, 8, pp. 252-258; Hoppe, A.A., Carey, G.B., Polybrominated diphenyl ethers as endocrine disruptors of adipocyte metabolism (2007) Obesity, 15, pp. 2942-2950; Howell, G., Mangum, L., Exposure to bioaccumulative organochlorine compounds alters adipogenesis, fatty acid uptake, and adipokine production in NIH3T3-L1 cells (2011) Toxicol. In Vitro, 25, pp. 394-402; Imbeault, P., Findlay, C.S., Robidoux, M.A., Haman, F., Blais, J.M., Tremblay, A., Dysregulation of cytokine response in Canadian First Nations communities: is there an association with persistent organic pollutant levels? (2012) PLoS One, 7, p. e39931; Jorgensen, M.E., Borch-Johnsen, K., Bjerregaard, P., A cross-sectional study of the association between persistent organic pollutants and glucose intolerance among Greenland Inuit (2008) Diabetologia, 51, pp. 1416-1422; Kern, P.A., Said, S., Jackson, W.G., Michalek, J.E., Insulin sensitivity following agent orange exposure in Vietnam veterans with high blood levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin (2004) J. Clin. Endocrinol. Metab., 89, pp. 4665-4672; Kim, K.S., Hong, N.S., Jacobs, D.R., Lee, D.H., Interaction between persistent organic pollutants and C-reactive protein in estimating insulin resistance among non-diabetic adults (2012) J. Prev. Med. Public Health, 45, pp. 62-69; Kondo, K., Morino, K., Nishio, Y., Kondo, M., Fuke, T., Ugi, S., Effects of a fish-based diet on the serum adiponectin concentration in young, non-obese, healthy Japanese subjects (2010) J. Atheroscler. Thromb., 17, pp. 628-637; Kumar, J., Lind, L., Salihovic, S., van, B.B., Ingelsson, E., Lind, P.M., Persistent organic pollutants and liver dysfunction biomarkers in a population-based human sample of men and women (2014) Environ. Res., 134, pp. 251-256; Kumar, J., Lind, P.M., Salihovic, S., van, B.B., Ingelsson, E., Lind, L., Persistent organic pollutants and inflammatory markers in a cross-sectional study of elderly swedish people: the PIVUS cohort (2014) Environ. Health Perspect., 122, pp. 977-983; Kuo, C.C., Moon, K., Thayer, K.A., Navas-Acien, A., Environmental chemicals and type 2 diabetes: an updated systematic review of the epidemiologic evidence (2013) Curr. Diabetes Rep., 13, pp. 831-849; Kuwatsuka, Y., Shimizu, K., Akiyama, Y., Koike, Y., Ogawa, F., Furue, M., Yusho patients show increased serum IL-17, IL-23, IL-1beta, and TNFalpha levels more than 40 years after accidental polychlorinated biphenyl poisoning (2014) J. Immunotoxicol., 11, pp. 246-249; Langer, P., Tajtakova, M., Guretzki, H.J., Kocan, A., Petrik, J., Chovancova, J., High prevalence of anti-glutamic acid decarboxylase (anti-GAD) antibodies in employees at a polychlorinated biphenyl production factory (2002) Arch. Environ. Health, 57, pp. 412-415; Langer, P., Ukropec, J., Kocan, A., Drobna, B., Radikova, Z., Huckova, M., Obesogenic and diabetogenic impact of high organochlorine levels (HCB, p,p'-DDE, PCBs) on inhabitants in the highly polluted Eastern Slovakia (2014) Endocr. Regul., 48, pp. 17-24; Lara, J.J., Economou, M., Wallace, A.M., Rumley, A., Lowe, G., Slater, C., Benefits of salmon eating on traditional and novel vascular risk factors in young, non-obese healthy subjects (2007) Atherosclerosis, 193, pp. 213-221; Lee, D.H., Jacobs, D.R., Association between serum concentrations of persistent organic pollutants and gamma glutamyltransferase: results from the National Health and Examination Survey 1999-2002 (2006) Clin. Chem., 52, pp. 1825-1827; Lee, D.H., Lind, P.M., Jacobs, D.R., Salihovic, S., van, B.B., Lind, L., Polychlorinated biphenyls and organochlorine pesticides in plasma predict development of type 2 diabetes in the elderly: the prospective investigation of the vasculature in Uppsala Seniors (PIVUS) study (2011) Diabetes Care, 34, pp. 1778-1784; Lee, D.H., Porta, M., Jacobs, D.R., Vandenberg, L.N., Chlorinated persistent organic pollutants, obesity, and type 2 diabetes (2014) Endocr. Rev., 35, pp. 557-601; Lee, D.H., Steffes, M.W., Jacobs, D.R., Can persistent organic pollutants explain the association between serum gamma-glutamyltransferase and type 2 diabetes? (2008) Diabetologia, 51, pp. 402-407; Lee, D.H., Steffes, M.W., Sjodin, A., Jones, R.S., Needham, L.L., Jacobs, D.R., Low dose of some persistent organic pollutants predicts type 2 diabetes: a nested case-control study (2010) Environ. Health Perspect., 118, pp. 1235-1242; Lee, H.K., Mitochondrial dysfunction and insulin resistance: the contribution of dioxin-like substances (2011) Diabetes Metab. J., 35, pp. 207-215; Lee, K.L., Yoon, E.H., Lee, H.M., Hwang, H.S., Park, H.K., Relationship between food-frequency and glycated hemoglobin in Korean diabetics: using data from the 4th Korea National Health and Nutrition Examination Survey (2012) Korean J. Fam. Med., 33, pp. 280-286; Li, S., Shin, H.J., Ding, E.L., van Dam, R.M., Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis (2009) JAMA, 302, pp. 179-188; Lim, J.E., Jee, S.H., Association between 'serum levels of adiponectin and polychlorinated biphenyls in Korean men and women (2014) Endocrine; Michalek, J.E., Akhtar, F.Z., Kiel, J.L., Serum dioxin, insulin, fasting glucose, and sex hormone-binding globulin in veterans of Operation Ranch Hand (1999) J. Clin. Endocrinol. Metab., 84, pp. 1540-1543; Mullerova, D., Kopecky, J., Matejkova, D., Muller, L., Rosmus, J., Racek, J., Negative association between plasma levels of adiponectin and polychlorinated biphenyl 153 in obese women under non-energy-restrictive regime (2008) Int. J. Obes., 32, pp. 1875-1878; Nakanishi, N., Nishina, K., Li, W., Ssato, M., Suzuki, M., Tatara, K., Serum?-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men (2003) J. Intern. Med., 254, pp. 287-295; Nakanishi, N., Suzuki, K., Tatara, K., Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men (2004) Diabetes Care, 27, pp. 1427-1432; Neale, E.P., Muhlhausler, B., Probst, Y.C., Batterham, M.J., Fernandez, F., Tapsell, L.C., Short-term effects of fish and fish oil consumption on total and high molecular weight adiponectin levels in overweight and obese adults (2013) Metabolism, 62, pp. 651-660; Ouellet, V., Weisnagel, S.J., Marois, J., Bergeron, J., Julien, P., Gougeon, R., Dietary cod protein reduces plasma C-reactive protein in insulin-resistant men and women (2008) J. Nutr., 138, pp. 2386-2391; Persky, V., Piorkowski, J., Turyk, M., Freels, S., Chatterton, R., Dimos, J., Associations of polychlorinated biphenyl exposure and endogenous hormones with diabetes in post-menopausal women previously employed at a capacitor manufacturing plant (2011) Environ. Res., 111, pp. 817-824; Persky, V., Piorkowski, J., Turyk, M., Freels, S., Chatterton, R., Dimos, J., Polychlorinated biphenyl exposure, diabetes and endogenous hormones: a cross-sectional study in men previously employed at a capacitor manufacturing plant (2012) Environ. Health, 11, p. 57; Persky, V., Turyk, M., Anderson, H.A., Hanrahan, L.P., Falk, C., Steenport, D.N., The effects of PCB exposure and fish consumption on endogenous hormones (2001) Environ. Health Perspect., 109, pp. 1275-1283; Philibert, A., Schwartz, H., Mergler, D., An exploratory study of diabetes in a First Nation community with respect to serum concentrations of p,p'-DDE and PCBs and fish consumption (2009) Int. J. Environ. Res. Public Health, 6, pp. 3179-3189; Prynne, C.J., Mander, A., Wadsworth, M.E., Stephen, A.M., Diet and glycosylated haemoglobin in the 1946 British birth cohort (2009) Eur. J. Clin. Nutr., 63, pp. 1084-1090; Ramel, A., Martinez, J.A., Kiely, M., Bandarra, N.M., Thorsdottir, I., Effects of weight loss and seafood consumption on inflammation parameters in young, overweight and obese European men and women during 8 weeks of energy restriction (2010) Eur. J. Clin. Nutr., 64, pp. 987-993; Remillard, R.B., Bunce, N.J., Linking dioxins to diabetes: epidemiology and biologic plausibility (2002) Environ. Health Perspect., 110, pp. 853-858; Rignell-Hydbom, A., Lidfeldt, J., Kiviranta, H., Rantakokko, P., Samsioe, G., Agardh, C.D., Exposure to p,p'-DDE: a risk factor for type 2 diabetes (2009) PLoS One, 4, p. e7503; Sargeant, L.A., Wareham, N.J., Khaw, K.T., Hormone replacement therapy and glucose tolerance in EPIC-Norfolk: a population-based study (2000) Diabetes Metab. Res. Rev., 16, pp. 20-25; Smith, K.M., Barraj, L.M., Kantor, M., Sahyoun, N.R., Relationship between fish intake, n-3 fatty acids, mercury and risk markers of CHD (National Health and Nutrition Examination Survey 1999-2002) (2009) Public Health Nutr., 12, pp. 1261-1269; Suarez-Lopez, J.R., Lee, D.H., Porta, M., Steffes, M.W., Jacobs, D.R., Persistent organic pollutants in young adults and changes in glucose related metabolism over a 23-year follow-up (2015) Environ. Res., 137, pp. 485-494; Sweeney, M.H., Mocarelli, P., Human health effects after exposure to 2,3,7,8-TCDD (2000) Food Addit. Contam., 17, pp. 303-316; Tabak, A.G., Herder, C., Rathmann, W., Brunner, E.J., Kivimaki, M., Prediabetes: a high-risk state for diabetes development (2012) Lancet, 379, pp. 2279-2290; Taxvig, C., Dreisig, K., Boberg, J., Nellemann, C., Schelde, A.B., Pedersen, D., Differential effects of environmental chemicals and food contaminants on adipogenesis, biomarker release and PPARgamma activation (2012) Mol. Cell. Endocrinol.; Taylor, K.W., Novak, R.F., Anderson, H.A., Birnbaum, L.S., Blystone, C., Devito, M., Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiological studies: a national toxicology program workshop review (2013) Environ. Health Perspect., 121, pp. 774-783; Turunen, A.W., Jula, A., Suominen, A.L., Mannisto, S., Marniemi, J., Kiviranta, H., Fish consumption, omega-3 fatty acids, and environmental contaminants in relation to low-grade inflammation and early atherosclerosis (2013) Environ. Res., 120, pp. 43-54; Turyk, M., Anderson, H., Knobeloch, L., Imm, P., Persky, V., Organochlorine exposure and incidence of diabetes in a cohort of Great Lakes sport fish consumers (2009) Environ. Health Perspect., 117, pp. 1076-1082; Turyk, M., Anderson, H.A., Knobeloch, L., Imm, P., Persky, V.W., Prevalence of diabetes and body burdens of polychlorinated biphenyls, polybrominated diphenyl ethers, and p,p'-diphenyldichloroethene in Great Lakes sport fish consumers (2009) Chemosphere, 75, pp. 674-679; Turyk, M.E., Bhavsar, S.P., Bowerman, W., Boysen, E., Clark, M., Diamond, M., Risks and benefits of consumption of Great Lakes fish (2012) Environ. Health Perspect., 120, pp. 11-18; Vasiliu, O., Cameron, L., Gardiner, J., Deguire, P., Karmaus, W., Polybrominated biphenyls, polychlorinated biphenyls, body weight, and incidence of adult-onset diabetes mellitus (2006) Epidemiology, 17, pp. 352-359; Wu, H., Bertrand, K.A., Choi, A.L., Hu, F.B., Laden, F., Grandjean, P., Persistent organic pollutants and type 2 diabetes: a prospective analysis in the nurses' health study and meta-analysis (2013) Environ. Health Perspect., 121, pp. 153-161; Wu, J.H., Micha, R., Imamura, F., Pan, A., Biggs, M.L., Ajaz, O., Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis (2012) Br. J. Nutr., 107, pp. S214-S227; Zani, C., Donato, F., Magoni, M., Feretti, D., Covolo, L., Vassallo, F., Polychlorinated biphenyls, glycaemia and diabetes in a population living in a highly polychlorinated biphenyls-polluted area in Northern Italy: a cross-sectional and cohort study (2013) J. Public Health Res., 2, pp. 2-8; Zhang, J., Wang, C., Li, L., Man, Q., Meng, L., Song, P., Dietary inclusion of salmon, herring and pompano as oily fish reduces CVD risk markers in dyslipidaemic middle-aged and elderly Chinese women (2012) Br. J. Nutr., 108, pp. 1455-1465; Zhang, M., Picard-Deland, E., Marette, A., Fish and marine omega-3 polyunsatured fatty acid consumption and incidence of type 2 diabetes: a systematic review and meta-analysis (2013) Int. J. Endocrinol., 2013, p. 501015",Article,Scopus,2-s2.0-84928154827
"Stoeckel M., Duke D.","Diabetes and Behavioral Learning Principles: Often Neglected yet Well-Known and Empirically Validated Means of Optimizing Diabetes Care Behavior",2015,"Current Diabetes Reports","15","7",,"","",8,,10.1007/s11892-015-0615-4,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929001147&partnerID=40&md5=43cc2000ceeeb6925fbd1ea514006f5c","Division of Psychology, Child Development and Rehabilitation Center, Oregon Health and Science University, 707 SW Gaines StreetPortland, OR, United States","Stoeckel, M., Division of Psychology, Child Development and Rehabilitation Center, Oregon Health and Science University, 707 SW Gaines StreetPortland, OR, United States; Duke, D., Division of Psychology, Child Development and Rehabilitation Center, Oregon Health and Science University, 707 SW Gaines StreetPortland, OR, United States","Managing diabetes is known to be invasive, pervasive, and unrelenting, making adherence to the treatment regimen difficult to accomplish. Ongoing clinical and research efforts have attempted to address the struggles faced by youth and adults with diabetes. Recent research supports the integration of behavioral interventions into clinical practice to assist patients and families with the goal of improving health outcomes. Empirically supported and well-documented behavioral learning principles, particularly positive reinforcement, are often underutilized in modern diabetes care. We posit that most diabetes care providers are aware of these principles. However, the constraints of today’s medical systems have become significant barriers to purposefully and consistently applying them to promote improved diabetes care. We provide a brief overview of basic behavioral principles and common barriers to implementation, discuss relevant interventions, and present several examples of applications in clinical settings. We conclude with recommendations to raise awareness regarding the importance of consistently integrating relevant behavioral learning principles and interventions into diabetes care settings. © 2015, Springer Science+Business Media New York.","Behavior; Diabetes; Healthcare; Learning; Psychology","Gil, G., Nayak, A.U., Wilkins, J., Hankey, J., Raffeeq, P., Varughese, G.I., Challenges of emerging adulthood-transition from paediatric to adult diabetes (2014) World J Diabetes, 5, pp. 630-635; Kurtz, S.M.S., Adherence to diabetes regimens: empirical status and clinical applications (1990) Diabetes Educ, 16, pp. 50-56. , COI: 1:STN:280:DyaK3c7otlOjtg%3D%3D, PID: 2178896; Diabetes Control and Complications Trial Research Group, Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial (1994) J Pediatr, 125, pp. 177-188; Benjamin, R.M., Medication adherence: helping patients take their medicines as directed (2012) Public Health Rep, 127, pp. 2-3. , PID: 22298918; Avoidable costs in U.S (2013) health care, , http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Institute/RUOM-2013/IHII_Responsible_Use_Medicines_2013.pdf; Lewis, A., Noncompliance: a $100 billion problem (1997) Remington Rep, 5, pp. 14-15; Renders, C.M., Valk, G.D., Griffin, S.J., Wagner, E., van Eijk, J.T., Assendelft, W.J.J., Interventions to improve the management of diabetes mellitus in primary care, outpatient, and community settings (Review) (2009) The Cochrane Collaboration: John Wiley & Sons; Kaplan, S.H., Greenfield, S., Ware, J.E., Jr., Assessing the effects of physician-patient interactions on the outcomes of chronic disease (1989) Med Care, 27, pp. 110-127. , COI: 1:STN:280:DyaL1M7lvVeitw%3D%3D, PID: 2646486; Stewart, M.A., Effective physician-patient communication and health outcomes: a review (1995) CMAJ, 152, pp. 1423-1433. , COI: 1:STN:280:DyaK2M3ksF2mug%3D%3D, PID: 7728691; Roter, D.L., Hall, J.A., Merisca, R., Effectiveness of interventions to improve patient compliance (1998) Med Care, 36, pp. 1138-1161. , COI: 1:STN:280:DyaK1cznt1aqsQ%3D%3D, PID: 9708588; Graber, A.L., Davidson, P., Brown, A.W., McRae, J.R., Wooldridge, K., Dropout and relapse during diabetes care (1992) Diabetes Care, 15, pp. 1477-1483. , COI: 1:STN:280:DyaK3s7gsFOmtQ%3D%3D, PID: 1468274; Dunbar, J.M., Marshall, G.D., Hovell, M.F., Behavioral strategies for improving compliance (1979) Compliance in health care, , Haynes RB, Taylor DW, Sackett DC, (eds), The Johns Hopkins University Press, Baltimore:; Shelton, J.L., Levy, R.L., (1981) Behavioral assignment and treatment compliance: a handbook of clinical strategies, , Research Press, Champaign, Illinois:; Fisher, L., Glasgow, R.E., A call for more effectively integrating behavioral and social science principles into comprehensive diabetes care (2007) Diabetes Care, 30, pp. 2746-2749. , PID: 17901532; Glasgow, R.E., Hiss, R.G., Anderson, R.M., Friedman, N.M., Hayward, R.A., Marrero, D.G., Report of the health care delivery work group: behavioral research related to the establishment of a chronic disease model for diabetes care (2001) Diabetes Care, 24, pp. 124-130. , COI: 1:STN:280:DC%2BD3MzgtVantQ%3D%3D, PID: 11194217; Glasgow, R.E., Fisher, E.B., Anderson, B.J., LaGreca, A., Marrero, D., Johnson, S.B., Behavioral science in diabetes: contributions and opportunities (1999) Diabetes Care, 22, pp. 832-843. , COI: 1:STN:280:DyaK1M3msFSqtw%3D%3D, PID: 10332691; Watson, J., Psychology as the behaviorist views it (1913) Psychol Rev, 20, pp. 158-177; Watson, J., (1928) The ways of behaviorism, , Harper & Brothers Pub, New York:; Skinner, B.F., (1938) The behavior of organisms: an experimental analysis, , Appleton-Century, New York:; Thorndike, E.L., (1905) The elements of psychology, , A.G. Seiler, New York:; Randall, L., Begovic, J., Hudson, M., Smiley, D., Peng, L., Pitre, N., Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors (2011) Diabetes Care, 34, pp. 1891-1896. , PID: 21775761, This study presents examples of common barriers to optimal adherence in diabetes; Hoey, H., Psychosocial factors are associated with metabolic control in adolescents: research from the Hvidoere study group on childhood diabetes (2009) Pediatr Diabetes, 10, pp. 9-14. , PID: 19930221; Peyrot, M., Rubin, R.R., Behavioral and psychosocial interventions in diabetes: a conceptual review (2007) Diabetes Care, 30, pp. 2433-2440. , PID: 17666457; Petry, N.M., Cengiz, E., Wagner, J.A., Hood, K.K., Carria, L., Tamborlane, W.V., Incentivizing behaviour change to improve diabetes care (2013) Diabetes Obes Metab, 15, pp. 1071-1076. , COI: 1:STN:280:DC%2BC3srktVGrtw%3D%3D, PID: 23574494; Petry, N.M., Martin, B., Finocche, C., Contingency management in group treatment: a demonstration project in an HIV drop-in center (2001) J Subst Abuse Treat, 21, pp. 89-96. , COI: 1:STN:280:DC%2BD3MrgtlWgsA%3D%3D, PID: 11551737; Petry, N.M., Andrade, L.F., Barry, D., Byrne, S., A randomized study of reinforcing ambulatory exercise in older adults (2013) Psychol Aging, 28, pp. 1164-1173. , PID: 24128075, This study provides another critical example of the application of reinforcement to promote behavioral change; Petry, N.M., Rash, C.J., Byrne, S., Ashraf, S., White, W.B., Financial reinforcers for improving medication adherence: findings from a meta-analysis (2012) Am J Med, 125, pp. 888-896. , PID: 22800876, This study provides a useful summary of the use of incentives to promote behavioral change, specifically medication adherence; Raiff, B.R., Dallery, J., Internet-based contingency management to improve adherence with blood glucose testing recommendations for teens with type 1 diabetes (2010) J Appl Behav Anal, 43, pp. 487-491. , PID: 21358907; Long, J.A., Jahnle, E.C., Richardson, D.M., Loewenstein, G., Volpp, K.G., Peer mentoring and financial incentives to improve glucose control in African American veterans: a randomized trial (2012) Ann Intern Med, 156, pp. 416-424. , PID: 22431674; Miltenberger, R.G., Behavioral modification: principles and procedures (2008) Thomson/Wadsworth, p. 86; Wysocki, T., Harris, M., Buckloh, L., Mertlich, D., Lochrie, A., Taylor, A., Randomized, controlled trial of behavioral family systems therapy for diabetes: maintenance and generalization of effects on parent-adolescent communication (2007) Behav Ther, 39, pp. 33-46. , PID: 18328868; Wysocki, T., Greco, P., Harris, M.A., Bubb, J., White, N.H., Behavior therapy for families of adolescents with diabetes: maintenance of treatment effects (2001) Diabetes Care, 24, pp. 441-444. , COI: 1:STN:280:DC%2BD3M7pslCnuw%3D%3D, PID: 11289465; Wysocki, T., Harris, M.A., Buckloh, L.M., Effects of behavioral family systems therapy for diabetes on adolescents’ family relationships, treatment adherence and metabolic control (2006) J Pediatr Psychol, 31, pp. 928-938. , PID: 16401678; Hood, K.K., Rohan, J.M., Peterson, C.M., Drotar, D., Interventions with adherence-promoting components in pediatric type 1 diabetes (2010) Diabetes Care, 33, pp. 1658-1664. , PID: 20587726; Polonsky, W.H., (1999) Diabetes burnout: what to do when you can’t take it anymore, , American Diabetes Association, Alexandria, Virginia:; Anderson, L.A., Health-care communication and selected psychosocial correlates of adherence in diabetes management (1990) Diabetes Care, 13, pp. 66-76; Lowes, L., Eddy, D., Channon, S., McNamara, R., Robling, M., Gregory, J.W., The experience of living with type 1 diabetes and attending clinic from the perception of children, adolescents and carers: analysis of qualitative data from the DEPICTED study (2015) J Pediatr Nurs, 30, pp. 54-62. , PID: 25308399; Maslach, C., Schaufeli, W.B., Leiter, M.P., Job burnout (2001) Annu Rev Psychol, 52, pp. 397-422. , COI: 1:STN:280:DC%2BD3Mzptlartg%3D%3D, PID: 11148311; Chopra, S., Sotile, W., Sotile, M., Physician burnout (2004) JAMA, 291, p. 633. , COI: 1:CAS:528:DC%2BD2cXhtVyks70%3D, PID: 14762045; Whittemore, R., Jaser, S.S., Jeon, S., Liberti, L., Delameter, A., Murphy, K., An internet coping skills training program for youth with type 1 diabetes: six-month outcomes (2012) Nurs Res, 61, pp. 395-404. , PID: 22960587; Franklin, V.L., Waller, A., Pagliari, C., Greene, S.A., A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes (2006) Diabet Med, 23, pp. 1332-1338. , COI: 1:STN:280:DC%2BD28nnvFCrtg%3D%3D, PID: 17116184; Siemer, C.P., Fogel, J., Van Voorhees, B.W., Telemental health and web-based applications in children and adolescents (2011) Child Adolesc Psychiatr Clin N Am, 20, pp. 135-153. , PID: 21092918",Review,Scopus,2-s2.0-84929001147
"Malmqvist E., Elding Larsson H., Jonsson I., Rignell-Hydbom A., Ivarsson S.-A., Tinnerberg H., Stroh E., Rittner R., Jakobsson K., Swietlicki E., Rylander L.","Maternal exposure to air pollution and type 1 diabetes - Accounting for genetic factors",2015,"Environmental Research","140",,,"268","274",,,10.1016/j.envres.2015.03.024,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927549487&partnerID=40&md5=99044fec265d8c43cd767d9f400e0d24","Division of Occupational and Environmental Medicine, Lund UniversityLund, Sweden; Department of Clinical Sciences-Paediatrics, University Hospital MASMalmö, Sweden; Division of Nuclear Physics, Lund UniversityLund, Sweden","Malmqvist, E., Division of Occupational and Environmental Medicine, Lund UniversityLund, Sweden; Elding Larsson, H., Department of Clinical Sciences-Paediatrics, University Hospital MASMalmö, Sweden; Jönsson, I., Department of Clinical Sciences-Paediatrics, University Hospital MASMalmö, Sweden; Rignell-Hydbom, A., Division of Occupational and Environmental Medicine, Lund UniversityLund, Sweden; Ivarsson, S.-A., Department of Clinical Sciences-Paediatrics, University Hospital MASMalmö, Sweden; Tinnerberg, H., Division of Occupational and Environmental Medicine, Lund UniversityLund, Sweden; Stroh, E., Division of Occupational and Environmental Medicine, Lund UniversityLund, Sweden; Rittner, R., Division of Occupational and Environmental Medicine, Lund UniversityLund, Sweden; Jakobsson, K., Division of Occupational and Environmental Medicine, Lund UniversityLund, Sweden; Swietlicki, E., Division of Nuclear Physics, Lund UniversityLund, Sweden; Rylander, L., Division of Occupational and Environmental Medicine, Lund UniversityLund, Sweden","Background: Genetic and non-genetic factors probably act together to initiate and accelerate development of type 1 diabetes [T1D]. One suggested risk factor contributing to development of T1D is air pollution. Objective: The aim of the study was to investigate whether maternal exposure during pregnancy to air pollution, measured as nitrogen oxides [NO<inf>x</inf>] and ozone, in a low-dose exposure area was associated with the child developing T1D. Method: In Scania (Skåne), the most southern county in Sweden, 84,039 infants were born during the period 1999-2005. By the end of April 2013, 324 of those children had been diagnosed with T1D. For each of those T1D children three control children were randomly selected and matched for HLA genotype and birth year. Individually modelled exposure data at residence during pregnancy were assessed for nitrogen oxides [NO<inf>x</inf>], traffic density and ozone. Results: Ozone as well as NO<inf>x</inf> exposures were associated with T1D. When the highest exposure group was compared to the lowest group an odds ratios of 1.62 (95% confidence interval [CI] 0.99-2.65) was observed for ozone in the second trimester and 1.58 (95% CI 1.06-2.35) for NO<inf>x</inf> in the third trimester. Conclusion: This study indicates that living in an area with elevated levels of air pollution during pregnancy may be a risk factor for offspring T1D. © 2015 Elsevier Inc.","Air pollution; Diabetes mellitus type 1; Maternal exposure; Nitrogen oxides; Ozone; Type 1 diabetes mellitus","Abbey, D.E., Estimating cumulative ambient concentrations of air pollutants: description and precision of methods used for an epidemiological study (1991) Arch. Environ. Health, 46 (5), pp. 281-287; Executive summary: Standards of Medical Care in Diabetes-2011 (2011) Diabetes Care, 34. , S4-10; Borchers, A., Uibo, R., Gershwin, M.E., The geoepidemiology of type 1 diabetes (2010) Autoimmun. Rev., 9, pp. A355-A365; Dahlquist, G., Bennich, S.S., Kallen, B., Intrauterine growth pattern and risk of childhood onset insulin dependent (type I) diabetes: population based case-control study (1996) BMJ, 313, pp. 1174-1177; Dahlquist, G.G., Patterson, C., Soltesz, G., Perinatal risk factors for childhood type 1 diabetes in Europe. The EURODIAB Substudy 2 Study Group (1999) Diabetes Care, 22, pp. 1698-1702; Daneman, D., Type 1 Diabetes (2006) Lancet, 367, pp. 847-858; Green, A., Patterson, C.C., Trends in the incidence of childhood onset diabetes in Europe 1989-1998 (2001) Diabetologia, 44, pp. B3-B8; Hathout, E.H., Beeson, W.L., Ischander, M., Rao, R., Mace, J.W., Air pollution and type 1 diabetes in children (2006) Pediatr. Diabetes, 7, pp. 81-87; Hathout, E.H., Beeson, W.L., Nahab, F., Rabadi, A., Thomas, W., Mace, J.W., Role of exposure to air pollutants in the development of type1 diabetes before and after 5 yr of age (2002) Pediatr. Diabetes, 3, pp. 184-188; Hjern, A., Söderström, U., Parental country of birth is a major determinant of childhood type 1 diabetes in Sweden (2008) Pediatr. Diabetes, 9, pp. 35-39; Howard, S.G., Heindel, J.J., Thayer, K.A., Porta, M., Environmental pollutants and beta cell function: relevance for type 1 and gestational diabetes (2011) Diabetologia, 54, pp. 3168-3169; Ilonen, J., Sjöroos, M., Knip, M., Veijola, R., Simell, O., Estimation of genetic risk for type 1 diabetes (2002) Am. J. Med. Genet., 115 (1), pp. 30-36; Jones, M., Swerdlow, A.J., Leicester, E.G., Goldacre, M.J., Prenatal and early life risk factors for childhood onset diabetes mellitus: a record linkage study (1998) Int. J. Epidemiol., 27, pp. 444-449; Joss-Moore, L.A., Lane, R.H., The developmental origins of adult disease (2009) Curr. Opin. Pediatr., 21, pp. 230-234; Karvonen, M., Viik-Kajander, M., Moltchanova, E., Libman, I., LaPorte, R., Tuomilehto, J., Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group (2000) Diabetes Care, 23, pp. 1516-1526; Kristensson, A., Dal Maso, M., Swietlicki, E., Hussein, T., Zhou, J., Characterization of new particle formation events at a background site in southern Sweden: relation to air mass history (2008) Tellus, 60 B, pp. 330-344; Larsson, K., Elding-Larsson, H., Cederwall, E., Kockum, K., Neiderud, J., Sjöblad, S., Lindberg, B., Genetic and perinatal factors as risk for childhood type 1 diabetes (2004) Diabetes Metab. Res. Rev., 20 (6), pp. 429-437; Lernmark, A., Type 1 diabetes (1999) Clin. Chem., 45, pp. 1331-1338; Locatelli, M., Buzzetti, R., Galgani, A., Montemari, A.L., Khazrai, M., Petrone, A., Length of gestation and gender are associated with HLA genotypes at risk for Type 1 diabetes (Italian DIABFIN 3) (2007) Diabet. Med., 24, pp. 916-919; Malmqvist, E., Jakobsson, K., Tinnerberg, H., Rignell-Hydbom, A., Rylander, L., Gestational diabetes and preeclampsia in association with air pollution at levels below current air quality guidelines (2013) Environ. Health Perspect., 121, pp. 488-493; Malmqvist, E., Rignell-Hydbom, A., Tinnerberg, H., Björk, J., Stroh, E., Jakobsson, K., Maternal exposure to air pollution and birth outcomes (2011) Environ. Health Perspect., 119, pp. 553-558; Malmqvist, E., Olsson, D., Hagenbjörk-Gustafsson, A., Forsberg, B., Mattisson, K., Stroh, E., Strömgren, M., Modig, L., (2014) Assessing ozone exposure for long term epidemiological studies, , [Epub ahead of print 2014 May 16]; Marshall, A.L., Chetwynd, A., Morris, J.A., Placzek, M., Smith, C., Type1 diabetes mellitus in childhood: a matched case control study in Lancashire and Cumbria, UK (2004) Diabet. Med., 21, pp. 1035-1040; Mattsson, K., Jönsson, I., Malmqvist, E., Elding Larsson, H., Rylander, L., Maternal smoking during pregnancy and offspring Type 1 diabetes mellitus risk: accounting for HLA haplotypes (2015) Eur. J. Epidemiol., 30 (3), pp. 231-238; Mehers, K.L., Gillespie, K.M., The genetic basis for Type1 diabetes (2008) Br. Med. Bull., 88 (1), pp. 115-129. , 2008; Regnéll, S.E., Lernmark, Å., The environment and the origins of islet autoimmunity and Type 1 diabetes (2013) Diabet. Med., 30, p. 2; Ritz, S.A., Air pollution as potential contributor to the 'epidemic' of autoimmune disease (2010) Med. Hypotheses, 74, pp. 110-117; Sjöberg, K., Persson, K., Pihl Karlsson, G., Brodin, Y., Air quality in cities 2005 (2006), IVL [Swedish Environmental Research Institute] SwedenEvaluation of the Swedish Medical Birth Registry (2002), SwedenStroh, E., Harrie, L., Gustafsson, S., A study of spatial resolution in pollution exposure modeling (2007) Int. J. Health Geogr., 6, p. 19; Stroh, E., Oudin, A., Gustafsson, S., Pilesjö, P., Harrie, L., Strömberg, U., Jakobsson, K., Are associations between socio-economic characteristics and exposure to air pollution a question of study area size? An example from Scania, Sweden (2005) Int. J. Health Geogr., 4, p. 30; Stroh, E., Rittner, R., Oudin, A., Ardö, J., Jakobsson, K., Björk, J., Tinnerberg, H., Measured and modeled personal and environmental NO<inf>2</inf>-exposure (2012) Popul. Health Metr., 10, p. 10; Svensson, J., Carstensen, B., Mortensen, H.B., Borch-Johnsen, K., Early childhood risk factors associated with type 1 diabetes-is gender important? (2005) Eur. J. Epidemiol., 20, pp. 429-434; (2004), Description of model formulation Washington D.C. Environmental Protection AgencyAir quality guidelines. Global update 2005 (2006) Particulate matter, ozone, nitrogen dioxide and sulphur dioxide, , http://www.euro.who.int/Document/E90038.pdf",Article,Scopus,2-s2.0-84927549487
"Mieczkowska A., Mansur S.A., Irwin N., Flatt P.R., Chappard D., Mabilleau G.","Alteration of the bone tissue material properties in type 1 diabetes mellitus: A Fourier transform infrared microspectroscopy study",2015,"Bone","76",,,"31","39",,,10.1016/j.bone.2015.03.010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925872153&partnerID=40&md5=3ac8fff1f8e50b56352b4b5f24b49774","LUNAM Université, GEROM-LHEA, Institut de Biologie en SantéAngers, France; LUNAM Université, SCIAM, Institut de Biologie en SantéAngers, France; School of Biomedical Sciences, University of UlsterColeraine, United Kingdom; University Tun Hussein Onn MalaysiaJohor, Malaysia","Mieczkowska, A., LUNAM Université, GEROM-LHEA, Institut de Biologie en SantéAngers, France; Mansur, S.A., School of Biomedical Sciences, University of UlsterColeraine, United Kingdom, University Tun Hussein Onn MalaysiaJohor, Malaysia; Irwin, N., School of Biomedical Sciences, University of UlsterColeraine, United Kingdom; Flatt, P.R., School of Biomedical Sciences, University of UlsterColeraine, United Kingdom; Chappard, D., LUNAM Université, GEROM-LHEA, Institut de Biologie en SantéAngers, France, LUNAM Université, SCIAM, Institut de Biologie en SantéAngers, France; Mabilleau, G., LUNAM Université, GEROM-LHEA, Institut de Biologie en SantéAngers, France, LUNAM Université, SCIAM, Institut de Biologie en SantéAngers, France","Type 1 diabetes mellitus (T1DM) is a severe disorder characterized by hyperglycemia and hypoinsulinemia. A higher occurrence of bone fractures has been reported in T1DM, and although bone mineral density is reduced in this disorder, it is also thought that bone quality may be altered in this chronic pathology. Vibrational microscopies such as Fourier transform infrared microspectroscopy (FTIRM) represent an interesting approach to study bone quality as they allow investigation of the collagen and mineral compartment of the extracellular matrix in a specific bone location. However, as spectral feature arising from the mineral may overlap with those of the organic component, the demineralization of bone sections should be performed for a full investigation of the organic matrix. The aims of the present study were to (i) develop a new approach, based on the demineralization of thin bone tissue section to allow a better characterization of the bone organic component by FTIRM, (ii) to validate collagen glycation and collagen integrity in bone tissue and (iii) to better understand what alterations of tissue material properties in newly forming bone occur in T1DM.The streptozotocin-injected mouse (150mg/kg body weight, injected at 8weeks old) was used as T1DM model. Animals were randomly allocated to control (n=8) or diabetic (n=10) groups and were sacrificed 4weeks post-STZ injection. Bones were collected at necropsy, embedded in polymethylmethacrylate and sectioned prior to examination by FTIRM. FTIRM collagen parameters were collagen maturity (area ratio between 1660 and 1690cm-1 subbands), collagen glycation (area ratio between the 1032cm-1 subband and amide I) and collagen integrity (area ratio between the 1338cm-1 subband and amide II).No significant differences in the mineral compartment of the bone matrix could be observed between controls and STZ-injected animals. On the other hand, as compared with controls, STZ-injected animals presented with significant higher value for collagen maturity (17%, p= 0.0048) and collagen glycation (99%, p= 0.0121), while collagen integrity was significantly lower by 170% (p= 0.0121).This study demonstrated the profound effect of early T1DM on the organic compartment of the bone matrix in newly forming bone. Further studies in humans are required to ascertain whether T1DM also lead to similar effect on the quality of the bone matrix. © 2015 Elsevier Inc.","Collagen glycation; Collagen integrity; Fourier transform infrared microspectroscopy; Type 1 diabetes mellitus","Kemink, S.A., Hermus, A.R., Swinkels, L.M., Lutterman, J.A., Smals, A.G., Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology (2000) J Endocrinol Invest, 23, pp. 295-303; Krakauer, J.C., McKenna, M.J., Buderer, N.F., Rao, D.S., Whitehouse, F.W., Parfitt, A.M., Bone loss and bone turnover in diabetes (1995) Diabetes, 44, pp. 775-782; Forsen, L., Meyer, H.E., Midthjell, K., Edna, T.H., Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey (1999) Diabetologia, 42, pp. 920-925; Vestergaard, P., Rejnmark, L., Mosekilde, L., Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes (2009) Calcif Tissue Int, 84, pp. 45-55; Tuominen, J.T., Impivaara, O., Puukka, P., Ronnemaa, T., Bone mineral density in patients with type 1 and type 2 diabetes (1999) Diabetes Care, 22, pp. 1196-1200; Danielson, K.K., Elliott, M.E., LeCaire, T., Binkley, N., Palta, M., Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes (2009) Osteoporos Int, 20, pp. 923-933; Strotmeyer, E.S., Cauley, J.A., Schwartz, A.V., Nevitt, M.C., Resnick, H.E., Bauer, D.C., Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study (2005) Arch Intern Med, 165, pp. 1612-1617; Strotmeyer, E.S., Cauley, J.A., Diabetes mellitus, bone mineral density, and fracture risk (2007) Curr Opin Endocrinol Diabetes Obes, 14, pp. 429-435; Tang, S.Y., Allen, M.R., Phipps, R., Burr, D.B., Vashishth, D., Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate (2009) Osteoporos Int, 20, pp. 887-894; Tang, S.Y., Zeenath, U., Vashishth, D., Effects of non-enzymatic glycation on cancellous bone fragility (2007) Bone, 40, pp. 1144-1151; Szkudelski, T., The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas (2001) Physiol Res, 50, pp. 537-546; Reddy, G.K., Stehno-Bittel, L., Hamade, S., Enwemeka, C.S., The biomechanical integrity of bone in experimental diabetes (2001) Diabetes Res Clin Pract, 54, pp. 1-8; Zhang, S.Q., Chen, G.H., Lu, W.L., Zhang, Q., Effects on the bones of vanadyl acetylacetonate by oral administration: a comparison study in diabetic rats (2007) J Bone Miner Metab, 25, pp. 293-301; Silva, M.J., Brodt, M.D., Lynch, M.A., McKenzie, J.A., Tanouye, K.M., Nyman, J.S., Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life (2009) J Bone Miner Res, 24, pp. 1618-1627; Facchini, D.M., Yuen, V.G., Battell, M.L., McNeill, J.H., Grynpas, M.D., The effects of vanadium treatment on bone in diabetic and non-diabetic rats (2006) Bone, 38, pp. 368-377; Nyman, J.S., Even, J.L., Jo, C.H., Herbert, E.G., Murry, M.R., Cockrell, G.E., Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone (2011) Bone, 48, pp. 733-740; Boskey, A., Mendelsohn, R., Infrared analysis of bone in health and disease (2005) J Biomed Opt, 10, p. 031102; Carden, A., Morris, M.D., Application of vibrational spectroscopy to the study of mineralized tissues (review) (2000) J Biomed Opt, 5, pp. 259-268; Miller, L.M., Dumas, P., Chemical imaging of biological tissue with synchrotron infrared light (2006) Biochim Biophys Acta, 1758, pp. 846-857; Boskey, A., Pleshko, C.N., FT-IR imaging of native and tissue-engineered bone and cartilage (2007) Biomaterials, 28, pp. 2465-2478; Rieppo, L., Saarakkala, S., Narhi, T., Helminen, H.J., Jurvelin, J.S., Rieppo, J., Application of second derivative spectroscopy for increasing molecular specificity of Fourier transform infrared spectroscopic imaging of articular cartilage (2012) Osteoarthritis Cartilage, 20, pp. 451-459; Roy, R., Boskey, A., Bonassar, L.J., Processing of type I collagen gels using nonenzymatic glycation (2010) J Biomed Mater Res A, 93, pp. 843-851; Mabilleau, G., Chappard, D., Sabokbar, A., Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis (2011) J Biol Chem, 286, pp. 3242-3249; Aparicio, S., Doty, S.B., Camacho, N.P., Paschalis, E.P., Spevak, L., Mendelsohn, R., Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy (2002) Calcif Tissue Int, 70, pp. 422-429; Roschger, P., Fratzl, P., Eschberger, J., Klaushofer, K., Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies (1998) Bone, 23, pp. 319-326; Mabilleau, G., Mieczkowska, A., Irwin, N., Flatt, P.R., Chappard, D., Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor (2013) J Endocrinol, 219, pp. 59-68; Camacho, N.P., West, P., Torzilli, P.A., Mendelsohn, R., FTIR microscopic imaging of collagen and proteoglycan in bovine cartilage (2001) Biopolymers, 62, pp. 1-8; Jackson, M., Choo, L.P., Watson, P.H., Halliday, W.C., Mantsch, H.H., Beware of connective tissue proteins: assignment and implications of collagen absorptions in infrared spectra of human tissues (1995) Biochim Biophys Acta, 1270, pp. 1-6; Guilbert, M., Said, G., Happillon, T., Untereiner, V., Garnotel, R., Jeannesson, P., Probing non-enzymatic glycation of type I collagen: a novel approach using Raman and infrared biophotonic methods (1830) Biochim Biophys Acta, 2013, pp. 3525-3531; West, P.A., Bostrom, M.P., Torzilli, P.A., Camacho, N.P., Fourier transform infrared spectral analysis of degenerative cartilage: an infrared fiber optic probe and imaging study (2004) Appl Spectrosc, 58, pp. 376-381; West, P.A., Torzilli, P.A., Chen, C., Lin, P., Camacho, N.P., Fourier transform infrared imaging spectroscopy analysis of collagenase-induced cartilage degradation (2005) J Biomed Opt, 10, p. 14015; Byler, D.M., Susi, H., Examination of the secondary structure of proteins by deconvolved FTIR spectra (1986) Biopolymers, 25, pp. 469-487; Pelton, J.T., McLean, L.R., Spectroscopic methods for analysis of protein secondary structure (2000) Anal Biochem, 277, pp. 167-176; Brodsky, B., Ramshaw, J.A., The collagen triple-helix structure (1997) Matrix Biol, 15, pp. 545-554; Hamada, Y., Kitazawa, S., Kitazawa, R., Fujii, H., Kasuga, M., Fukagawa, M., Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress (2007) Bone, 40, pp. 1408-1414; Saito, M., Fujii, K., Mori, Y., Marumo, K., Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats (2006) Osteoporos Int, 17, pp. 1514-1523; Paschalis, E.P., Verdelis, K., Doty, S.B., Boskey, A.L., Mendelsohn, R., Yamauchi, M., Spectroscopic characterization of collagen cross-links in bone (2001) J Bone Miner Res, 16, pp. 1821-1828; Ning, R., Chopp, M., Yan, T., Zacharek, A., Zhang, C., Roberts, C., Tissue plasminogen activator treatment of stroke in type-1 diabetes rats (2012) Neuroscience, 222, pp. 326-332; Ryan, M.E., Ramamurthy, N.S., Sorsa, T., Golub, L.M., MMP-mediated events in diabetes (1999) Ann N Y Acad Sci, 878, pp. 311-334; Silva, J.A., Ferrucci, D.L., Peroni, L.A., Abrahao, P.G., Salamene, A.F., Rossa-Junior, C., Sequential IL-23 and IL-17 and increased MMP8 and MMP14 expression characterize the progression of an experimental model of periodontal disease in type 1 diabetes (2012) J Cell Physiol, 227, pp. 2441-2450; Symeonidis, C., Papakonstantinou, E., Galli, A., Tsinopoulos, I., Mataftsi, A., Batzios, S., Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes (2013) Graefes Arch Clin Exp Ophthalmol, 251, pp. 741-749; Takahashi, N., Takasu, S., A close relationship between type 1 diabetes and vitamin A-deficiency and matrix metalloproteinase and hyaluronidase activities in skin tissues (2011) Exp Dermatol, 20, pp. 899-904",Article,Scopus,2-s2.0-84925872153
"Yousefi A., Yousefi R., Panahi F., Sarikhani S., Zolghadr A.R., Bahaoddini A., Khalafi-Nezhad A.","Novel curcumin-based pyrano[2,3-d]pyrimidine anti-oxidant inhibitors for α-amylase and α-glucosidase: Implications for their pleiotropic effects against diabetes complications",2015,"International Journal of Biological Macromolecules","78",,,"46","55",,,10.1016/j.ijbiomac.2015.03.060,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927609289&partnerID=40&md5=4f6f95ae855be2226e6171526cdf1fe4","Protein Chemistry Laboratory (PCL), Department of Biology, College of Sciences, Shiraz UniversityShiraz, Iran; Department of Chemistry, College of Sciences, Shiraz UniversityShiraz, Iran; Department of Biology, College of Sciences, Shiraz UniversityShiraz, Iran","Yousefi, A., Protein Chemistry Laboratory (PCL), Department of Biology, College of Sciences, Shiraz UniversityShiraz, Iran; Yousefi, R., Protein Chemistry Laboratory (PCL), Department of Biology, College of Sciences, Shiraz UniversityShiraz, Iran; Panahi, F., Department of Chemistry, College of Sciences, Shiraz UniversityShiraz, Iran; Sarikhani, S., Department of Chemistry, College of Sciences, Shiraz UniversityShiraz, Iran; Zolghadr, A.R., Department of Chemistry, College of Sciences, Shiraz UniversityShiraz, Iran; Bahaoddini, A., Department of Biology, College of Sciences, Shiraz UniversityShiraz, Iran; Khalafi-Nezhad, A., Department of Chemistry, College of Sciences, Shiraz UniversityShiraz, Iran","Curcumin (bis-α,β-unsaturated β-diketone), the chief constituent of turmeric plant (Curcuma longa), plays significant role in prevention of various diseases including diabetes. The research objective in the current study was to synthesize novel anti-diabetic curcumin derivatives with inhibitory properties against α-amylase (α-Amy) and α-glucosidase (α-Gls), as these two carbohydrate-hydrolysing enzymes are known to be important molecular targets for attenuation of postprandial hyperglycemia. The curcumin-based pyrano[2,3-d]pyrimidine derivatives were synthesized in the presence of curcumin, barbituric acids and aldehydes, using a multi-component reaction (MCR). Also, their inhibitory properties against α-Amy and α-Gls were evaluated spectroscopically. The curcumin-derived compounds with two invariant substructures (curcumin-based subunit and barbituric acid moiety) and one variable aryl (Ar) group demonstrated inhibitory action against α-Amy and α-Gls. Moreover, the synthetic compounds revealed prominent antioxidant activities, when examined by a 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) decolorization assay system. Overall, these antioxidant inhibitors are potentially important anti-diabetic drugs, not only to restore euglysemic condition, but also to limit activity of the major reactive oxygen species (ROS) producing pathways in diabetic patients. © 2015 Elsevier B.V.","Anti-diabetic compounds; Curcumin; Multi-component reaction; Reactive oxygen species; α-Glucosidase","Baynes, J.W., Thorpe, S.R., (1999) Diabetes, 48, pp. 1-9; Lee, H.B., Ha, H., King, G.L., (2003) J. Am. Soc. Nephrol., 14, pp. S209-S210; Callaghan, M.J., Ceradini, D.J., Gurtner, G.C., (2005) Antioxid. Redox. Signal, 7, pp. 1476-1482; Rolo, A.P., Palmeira, C.M., (2006) Toxicol. Appl. Pharmacol., 212, pp. 167-178; Sesti, F., Tsitsilonis, O.E., Kotsinas, A., Trougakos, I.P., (2012) In Vivo, 26, pp. 395-402; Basta, G., Schmidt, A.M., De Caterina, R., (2004) Cardiovasc. Res., 63, pp. 582-592; Maritim, A., Sanders, R., Watkins, R., (2003) J. Biochem. Mol. Toxicol., 17, pp. 24-38; Kajaria, D., Ranjana, J.T., Tripathi, Y.B., Tiwari, S., (2013) J. Adv. Pharm. Technol. Res., 4, p. 206; Kuppusamy, A., Muthusamy, U., Andichetiar Thirumalaisamy, S., Varadharajan, S., Ramasamy, K., Ramanathan, S., (2011) J. Complement Integr. Med., 8; Senger, M.R., Gomes, L., Ferreira, S.B., Kaiser, C.R., Ferreira, V.F., Silva, F.P., (2012) ChemBioChem, 13, pp. 1584-1593; Bachhawat, J.A., Shihabudeen, M.S., Thirumurugan, K., (2011) Int. J. Pharm. Pharm. Sci., 3; Standl, E., Schnell, O., (2012) Diab. Vasc. Dis. Res., 9, pp. 163-169; Zhang, L., Hogan, S., Li, J., Sun, S., Canning, C., Zheng, S.J., Zhou, K., (2011) Food Chem., 126, pp. 466-471; Konya, H., Miuchi, M., Konishi, K., Nagai, E., Ueyama, T., Kusunoki, Y., Kimura, Y., Inokuchi, C., (2009) J. Int. Med. Res., 37, pp. 1904-1912; Yagi, S., Drouart, N., Bourgaud, F., Henry, M., Chapleur, Y., Laurain-Mattar, D., (2013) S. Afr. J. Bot., 84, pp. 124-127; Kowluru, R.A., Kanwar, M., (2007) Nutr. Metab. (Lond), 4, p. 8; Gupta, S.C., Patchva, S., Aggarwal, B.B., (2013) AAPS J., 15, pp. 195-218; Du, Z.Y., Liu, R.R., Shao, W.Y., Mao, X.P., Ma, L., Gu, L.Q., Huang, Z.S., Chan, A.S.C., (2006) Eur. J. Med. Chem., 41, pp. 213-218; Li, M., Liu, Z., Zhang, Z., Ma, L., (2006) Front. Chem. China, 1, pp. 227-231; Lin, J., Tang, Y., Kang, Q., Feng, Y., Chen, A., (2012) Br. J. Pharmacol., 166, pp. 2212-2227; Muthenna, P., Suryanarayana, P., Gunda, S.K., Petrash, J.M., Reddy, G.B., (2009) FEBS Lett., 583, pp. 3637-3642; Mahmoud, A.A., Nor El-Din, A.K.A., (2013) J. Biomarkers, 2013, p. 7; Menon, V.P., Sudheer, A.R., Antioxidant and anti-inflammatory properties of curcumin (2007) The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, pp. 105-125. , Springer; Aziz, M.T.A., El-Asmar, M.F., Rezq, A.M., Wassef, M.A.A., Fouad, H., Roshdy, N.K., Ahmed, H.H., Taha, F.M., (2014) Chin. Med., 9, p. 3; Yousefi, R., Alavian-Mehr, M.M., Mokhtari, F., Panahi, F., Mehraban, M.H., Khalafi-Nezhad, A., (2013) J. Enzyme Inhib. Med. Chem., 28, pp. 1228-1235; Aggarwal, B.B., Surh, Y.J., Shishodia, S., (2007) The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, , Springer; Panahi, F., Yousefi, R., Mehraban, M.H., Khalafi-Nezhad, A., (2013) Carbohydr. Res., 380, pp. 81-91; Cortes, A., Cascante, M., Cardenas, M., Cornish-Bowden, A., (2001) Biochem. J., 357, pp. 263-268; Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., Rice-Evans, C., (1999) Free Radic. Biol. Med., 26, pp. 1231-1237; Gupta, S.C., Prasad, S., Kim, J.H., Patchva, S., Webb, L.J., Priyadarsini, I.K., Aggarwal, B.B., (2011) Nat. Prod. Rep., 28, pp. 1937-1955; Qiu, X., Du, Y., Lou, B., Zuo, Y., Shao, W., Huo, Y., Huang, J., Du, J., (2010) J. Med. Chem., 53, pp. 8260-8273; Lenhart, J.A., Ling, X., Gandhi, R., Guo, T.L., Gerk, P.M., Brunzell, D.H., Zhang, S., (2010) J. Med. Chem., 53, pp. 6198-6209; Li, W., Wu, W., Yu, F., Huang, H., Liang, X., Ye, J., (2011) Org. Biomol. Chem., 9, pp. 2505-2511; Safavy, A., Raisch, K.P., Mantena, S., Sanford, L.L., Sham, S.W., Krishna, N.R., Bonner, J.A., (2007) J. Med. Chem., 50, pp. 6284-6288; Lin, L., Shi, Q., Nyarko, A.K., Bastow, K.F., Wu, C.C., Su, C.Y., Shih, C.C.Y., Lee, K.H., (2006) J. Med. Chem., 49, pp. 3963-3972; Valentini, A., Conforti, F., Crispini, A., De Martino, A., Condello, R., Stellitano, C., Rotilio, G., Bernardini, S., (2008) J. Med. Chem., 52, pp. 484-491; Caruso, F., Rossi, M., Benson, A., Opazo, C., Freedman, D., Monti, E., Gariboldi, M.B., Pettinari, R., (2012) J. Med. Chem., 55, pp. 1072-1081; Sagnou, M., Benaki, D., Triantis, C., Tsotakos, T., Psycharis, V., Raptopoulou, C.P., Pirmettis, I., Pelecanou, M., (2011) Inorg. Chem., 50, pp. 1295-1303; Sahu, P.K., Sahu, P.K., Gupta, S.K., Agarwal, D.D., (2013) Catal. Sci. Technol., 3, pp. 1520-1530; Lal, J., Gupta, S., Thavaselvam, D., Agarwal, D., (2012) Bioorg. Med. Chem. Lett., 22, pp. 2872-2876; Ding, K., Dai, L.-X., (2012) Organic Chemistry-Breakthroughs and Perspectives, pp. 413-476. , Wiley-VCH, Weinheim, Germany, (Eds.); Toure, B.B., Hall, D.G., (2009) Chem. Rev., 109, pp. 4439-4486; Dömling, A., (2006) Chem. Rev., 106, pp. 17-89; Khalafi-Nezhad, A., Sarikhani, S., Shahidzadeh, E.S., Panahi, F., (2012) Green Chem., 14, pp. 2876-2884; Khalafi-Nezhad, A., Shahidzadeh, E.S., Sarikhani, S., Panahi, F., (2013) J. Mol. Catal. A: Chem., 379, pp. 1-8; Panoutsopoulos, G.I., Beedham, C., (2005) Cell Physiol. Biochem., 15, pp. 89-98; Reuter, S., Charlet, J., Juncker, T., Teiten, M.H., Dicato, M., Diederich, M., (2009) Ann. NY Acad Sci, 1171, pp. 436-447; López-Lázaro, M., (2008) Mol. Nutr. Food Res., 52, pp. S103-S127; Xie, L., Li, X.-K., Takahara, S., (2011) Int. Immunopharmacol., 11, pp. 323-330; Funk, J.L., Oyarzo, J.N., Frye, J.B., Chen, G., Lantz, R.C., Jolad, S.D., Sólyom, A.M., Timmermann, B.N., (2006) J. Nat. Prod., 69, pp. 351-355; Sui, Z., Salto, R., Li, J., Craik, C., Ortiz de Montellano, P.R., (1993) Bioorg. Med. Chem., 1, pp. 415-422; Rivera-Espinoza, Y., Muriel, P., (2009) Liver Int., 29, pp. 1457-1466; Mishra, S., Palanivelu, K., (2008) Ann. Indian Acad. Neurol., 11, p. 13; Punithavathi, D., Venkatesan, N., Babu, M., (2000) Br. J. Pharmacol., 131, pp. 169-172; Saleheen, D., Ali, S.A., Ashfaq, K., Siddiqui, A.A., Agha, A., Yasinzai, M.M., (2002) Biol. Pharm. Bull., 25, pp. 386-389; Wang, N.P., Wang, Z.F., Tootle, S., Philip, T., Zhao, Z.Q., (2012) Br. J. Pharmacol., 167, pp. 1550-1562; Suryanarayana, P., Saraswat, M., Mrudula, T., Krishna, T.P., Krishnaswamy, K., Reddy, G.B., (2005) Invest. Ophthalmol. Vis. Sci., 46, pp. 2092-2099; Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C., Jirawatnotai, S., (2012) Diab. Care, 35, pp. 2121-2127; Cheppudira, B., Fowler, M., McGhee, L., Greer, A., Mares, A., Petz, L., Devore, D., Clifford, J.L., (2013) Expert Opin. Invest. Drugs, 22, pp. 1295-1303; Mahmmoud, Y.A., (2007) Br. J. Pharmacol., 150, pp. 200-208; Aldebasi, Y.H., Aly, S.M., Rahmani, A.H., (2013) Int. J. Physiol. Pathophysiol. Pharmacol., 5, p. 194; Singh, U., Barik, A., Singh, B.G., Priyadarsini, K.I., (2011) Free Radic. Res., 45, pp. 317-325; Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Montgomery Jr, J.A., Pople, J.A., (2004), Gaussian, Inc., Wallingford, CTButterworth, P.J., Warren, F.J., Ellis, P.R., (2011) Starch-Stärke, 63, pp. 395-405; Sales, P.M., Souza, P.M., Simeoni, L.A., Magalhães, P.O., Silveira, D., (2012) J. Pharm. Pharm. Sci., 15, pp. 141-183; Hong, J., Bose, M., Ju, J., Ryu, J.-H., Chen, X., Sang, S., Lee, M.-J., Yang, C.S., (2004) Carcinogenesis, 25, pp. 1671-1679",Article,Scopus,2-s2.0-84927609289
"Tunna T.S., Zaidul I.S.M., Ahmed Q.U., Ghafoor K., Al-Juhaimi F.Y., Uddin M.S., Hasan M., Ferdous S.","Analyses and profiling of extract and fractions of neglected weed Mimosa pudica Linn. traditionally used in Southeast Asia to treat diabetes",2015,"South African Journal of Botany","99",,,"144","152",,,10.1016/j.sajb.2015.02.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928660018&partnerID=40&md5=d5b265879f7b65550337a71b89a671ef","Faculty of Pharmacy, International Islamic University Malaysia, Kuantan CampusKuantan, Pahang, Malaysia; Department of Food Science and Nutrition, King Saud UniversityRiyadh, Saudi Arabia; Faculty of Science, International Islamic University Malaysia, Kuantan CampusKuantan, Pahang, Malaysia","Tunna, T.S., Faculty of Pharmacy, International Islamic University Malaysia, Kuantan CampusKuantan, Pahang, Malaysia; Zaidul, I.S.M., Faculty of Pharmacy, International Islamic University Malaysia, Kuantan CampusKuantan, Pahang, Malaysia; Ahmed, Q.U., Faculty of Pharmacy, International Islamic University Malaysia, Kuantan CampusKuantan, Pahang, Malaysia; Ghafoor, K., Department of Food Science and Nutrition, King Saud UniversityRiyadh, Saudi Arabia; Al-Juhaimi, F.Y., Department of Food Science and Nutrition, King Saud UniversityRiyadh, Saudi Arabia; Uddin, M.S., Faculty of Pharmacy, International Islamic University Malaysia, Kuantan CampusKuantan, Pahang, Malaysia; Hasan, M., Faculty of Pharmacy, International Islamic University Malaysia, Kuantan CampusKuantan, Pahang, Malaysia; Ferdous, S., Faculty of Science, International Islamic University Malaysia, Kuantan CampusKuantan, Pahang, Malaysia","Mimosa pudica Linn. var. hispida Bren. (Family: Fabaceae) a neglected weed has been studied for its antidiabetic potential to propose alternative medicinal source against the global threat of diabetes mellitus. This study aimed to investigate in vitro inhibitory activity against diabetic enzymes (i.e. α-amylase & α-glucosidase) and three anti-oxidant assays were conducted to evaluate anti-diabetic potential of M. pudica's methanol extract (MeOH<inf>i</inf>) and its sub-fractions (Hexane<inf>f</inf>, EtOAc<inf>f</inf>, Acetone<inf>f</inf> and MeOH<inf>f</inf>). In depth chemical profiling using GC Q-TOF MS was also performed for the first time for this weed, to assess the probable compounds present in the extract and sub fractions that could be linked to anti-diabetic activity. Results showed the lowest (7.18±0.0005) and highest (158.4±0.0004) IC<inf>50</inf> for DPPH assay by MeOH<inf>i</inf> and MeOH<inf>f</inf>, respectively. Acetone<inf>f</inf> and MeOH<inf>i</inf> showed the highest TPC (60.07±1.066) and TFC (16.97±1.472), respectively. Three and two fold higher inhibitory activity than the standard acarbose at 1mg/ mL was manifested by MeOH<inf>i</inf> (95.65±0.911) & EtOAc<inf>f</inf> (51.87±3.106), respectively. Hexane<inf>f</inf> did not show inhibitory activity against both the enzymes. α-glucosidase results for the extract and sub fractions were found to be significant (p<0.05). GC Q-TOF MS analysis identified organic acids, quinolones, quinone, phenolic compounds and dodecaborane as major constituents. Presence of highly radical scavenging dodecaborane is being reported for the first time in M. pudica. High TPC and TFC values could be attributed to exert enzyme inhibitory action by M. pudica that can help in the regulation of glucose absorption and consequently glucose homeostasis. Results show that M. pudica can be proposed as an excellent alternative for future anti-diabetic implications. © 2015 South African Association of Botanists.","Alternative medicinal source; Anti-diabetic activity; Dodecaborane; GC Q-TOF MS analysis; Mimosa pudica; α-Amylase & α-glucosidase","Abdou, M.M., Chemistry of 4-Hydroxy-2(1H)-quinolone. Part 1: Synthesis and reactions (2014) Arabian Journal of Chemistry, , (in press); Allegretti, P., Choi, S.K., Gendron, R., Fatheree, P.R., Jendza, K., McKinnell, R.M., McMurtrie, D., Olson, B., (2013) Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity. Patent: US 8569351 B2. Publication number: 8569351 B2; Dyslipidemia management in adults with diabetes (2004) Diabetes Care, 27, pp. 68-71; Apostolidis, E., Kwon, Y.I., Shetty, K., Inhibitory potential of herb, fruit, and fungal enriched cheese against key enzymes linked to type 2 diabetes and hypertension (2007) Innovative Food Science and Emerging Technology, 8, pp. 46-54; Bezakova, L., Misik, V., Malekova, L., Svajdlenka, E., Kostalova, D., Lipoxygenase inhibition and antioxidant properties of bisbenzylisoquinoline alkaloids isolated from Mahonia aquifolium (1996) Pharmazie, 51, pp. 758-761; Bhandari, M.J., Kawabata, J., Organic acid, phenolic content and antioxidant activity of wild yam (Dioscorea spp) tubers of Nepal (2004) Food Chemistry, 88, pp. 163-168; Blainsky, A., Lopes, G.C., Palazzo de Mello, J.C., Application and analysis of the Folin Ciocalteu method for the determination of the total phenolic content from Limonium brasiliense L (2013) Molecules, 18, pp. 6852-6865; Buckingham, J., Macdonald, F., (1996) Dictionary of Organic Chemistry, , Chapman & Hall., London, UK; Cai, Y., Hu, X., Huang, M., Sun, F., Bo Yang, B., Juying He, J., Wang, X., Chen, J., Characterization of the Antibacterial Activity and the Chemical Components of the Volatile Oil of the Leaves of Rubus parvifolius L (2012) Molecules, 17, pp. 7758-7768; Dayam, R., Deng, J., Neamati, N., HIV-1 integrase inhibitors: 2003-2004 update (2006) Medical Research and Review, 26, pp. 271-309; Djeridane, A., Hamdi, A., Bensania, W., Cheifa, K., Lakhdari, I., Yousfi, M., The in vitro evaluation of antioxidative activity, alpha glucosidase and alpha amylase enzyme inhibitory of natural phenolic extracts (2013) Diabetes-Metabolic Syndrome and Clinical Research Review; Gandhiraja, N., Sriram, S., Meenaa, V., Srilakshmi, K., Sasikumar, C., Rajeswari, R., Phytochemical screening and antimicrobial activity of the plant extracts of Mimosa pudica L. against selected microbes (2009) Ethnobotanical leaflet, 13, pp. 618-624; Ghosh, A.K., Dutta, M., Mitra, E., Panigrahy, A., Chowdhury, U.R., Chattopadhayay, A., Bandyopadhayay, D., Ethyl acetate partitioning positively modulates antioxidant efficacy of aqueous bark extract of Terminalia arjuna (2014) Journal of Pharmacy Research, 8, pp. 452-465; Grever, M.R., Schepartz, S.A., Chabner, B.A., The National Cancer Institute: cancer drug discovery and development program (1992) Seminars in Oncology, 6, pp. 622-638; Grover, J.K., Yadav, S., Vats, V., Medicinal plants of India with anti-diabetic potential (2002) Journal of Ethnopharmacology, 81, pp. 81-100; Grycova, L., Dostal, J., Marek, R., Quaternary protoberberine alkaloids (2007) Phytochemistry, 68, pp. 150-175; Harborne, J.B., (1984) Phytochemical Methods: A guide to modern techniques of plant analysis, , (London New York); Hayouni, E.A., Abedrabba, M., Bouix, M., Hamdi, M., The effects of solvents and extraction method on the phenolic contents and biological activities in vitro of Tunisian Quercus coccifera L. and Juniperus phoenicea L. fruit extracts (2007) Food Chemistry, 105, pp. 1126-1134; Hulin, B., (1997) 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents, , Publication number, EP0533781 B1; Javanmardi, J., Stushnoff, C., Locke, E., Vivanco, J.M., Antioxidant activity and total phenolic content of Iranian Ocimum accessions (2003) Food Chemistry, 83, pp. 547-550; Jinshun, L., Xinfeng, W., Yingying, B., Chemical Composition and Antimicrobial Activity of the Volatile and Semi-Volatile Components of Paeonia veitchii Roots (2009) Scientia Silvae Sinica, 45, pp. 161-166; Khare, C.P., (2004) Encyclopedia of Indian Medicinal Plants, pp. 313-314. , Springer, Germany; Kukula-Koch, W., Aligiannis, N., Halabalaki, M., Skaltsounis, A.L., Glowniak, K., Kalpoutzakis, E., Influence of extraction procedures on phenolic content andantioxidant activity of Cretan barberry herb (2013) Food Chemistry, 138, pp. 406-413; Kumar, D., Gupta, N., Ghosh, R., Gaonkara, R.H., Pala, B.C., Alpha glucosidase and alpha amylase inhibitory constituent of Carexbaccans: Bio-assay guided isolation Andquantification by validated RP-HPLC-DAD (2013) Journal of Functional Foods, 5, pp. 211-218; Lee, B.M., Lee, S.K., Kim, H.S., Inhibition of oxidative DNA damage, 8-OHdG, and carbonyl contents in smokers treated with antioxidants (vitamin E, vitamin C, β- carotene and red ginseng) (1998) Cancer Letters, 132, pp. 219-227; Loliger, J., The use of anti-oxidants in foods (1991) Freeradical and food additives, pp. 121-150. , Taylor Francis, London, O.I. Arouma, B. Halliwell (Eds); Mai, T.T., Thu, N.N., Tien, P.G., Van Chuyen, N., Alpha-glucosidase inhibitory and antioxidant activities of Vietnamese edible plants and their relationships with polyphenol contents (2007) Journal of Nutritional Science and Vitaminology, 53, pp. 267-276; Manosroi, J., Moses, Z.Z., Manosroi, W., Manosroi, A., Hypoglycemic activity of Thai medicinal plants selected from the Thai/Lanna medicinal recipe database MANOSROI II (2011) Journal of Ethnopharmacology, 138, pp. 92-98; Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030 (2006) PLoS Medicine, 3, p. 442; Matsui, T., Ueda, T., Oki, T., Sugita, K., Terahara, N., Matsumoto, K., A-Glucosidase inhibitory action of natural acylated anthocyanins. 1. Survey of natural pigments with potent inhibitory activity (2001) Journal of Agriculture and Food Chemistry, 49, pp. 1948-1951; Miro-Casas, E., Covas, M., Farre, M., Fito, M., Ortuño, J., Weinbrenner, T., Roset, T., Torre, R., Hydroxytyrosol Disposition in Humans (2003) Clinical Chemistry, 49, pp. 945-952; Mukai, K., Okabe, K., Hosose, H., Synthesis and stopped flow investigation of antioxidant activity of tocopherols finding of new tocopherol derivatives having the highest antioxidant activity among phenolic antioxidants (1989) Journal of Organic Chemistry, 54, pp. 557-560; Murad, H., Shamban, A.T., Premo, P.S., The use of glycolic acid as a peeling agent (1995) Dermatologic Clinics, 2, pp. 285-307; Namiki, M., Antioxidant/antimutagens in food (1990) Critical Reviews in Food Science, 29, pp. 272-300; Nickavar, B., Kamalinejad, M., Izadpanah, H., Free radical and food additives in vitrofree radical scavenging activity of five Salvia species (2006) Pakistan Journal of Pharmaceutical Sciences, 20, pp. 291-294; Noda, Y., Ogata, K., Mori, A., Antioxidant activities of novel alpha-lipoic acid derivatives: N-(6, 8-dimercaptooctanoyl)-2-aminoethanesulfonate- and N-(6, 8-dimercaptooctanoyl)-L-aspartate-zinc complex (2003) Research Communications in Molecular Pathology and Pharmacology, pp. 133-147; Oboh, G., Ademiluyi, A.O., Akinyemi, A.J., Henle, T.H., Saliu, J.A., Schwarzenbolz, U., Inhibitory effect of polyphenol rich extracts of jute leaf (Corchorus olitorius) on key enzyme linked to type 2 diabetes (alpha amylase and alpha glucosidase) and hypertension (angiotensin I converting) in vitro (2012) Journal of Functional Foods, 4, pp. 450-458; Olorunnisola, O.S., Bradley, G., Afolayan, A.J., Chemical composition, antioxidant activity and toxicity evaluation of essential oil of Tulbaghia violacea Harv (2012) Journal of Medicinal Plants Research, 6, pp. 2769-2776; Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A., Keogh, J.P., Hammar, S., Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (1996) New England Journal of Medicine, 334, pp. 1150-1155; Paul, G., Klaus, B., Rifat, P., (1998) Esters and amides of substituted pyrrole acetic acids. Patent: US 5721347 A. Publication number: US 5721347 A; Pereira, D.F., Cazarolli, L.H., Lavado, C., Mengatto, V., Figueiredo, M.S.R.B., Guedes, A., Pizzolatti, M.G., Silva, F.R.M.B., Effects of flavonoids on α-glucosidase activity: Potential targets for glucose homeostasis (2011) Nutrition, 27, pp. 1161-1167; Poyrazoglu, E., Gokmen, V., Artik, N., Organic acids and phenolic compounds in pomegranates (Punicagranatum L) grown in Turkey (2002) Journal of Food Composition and Analysis, 14, pp. 567-575; Proestos, C., Komaitis, M., Analysis of naturally occurring phenolic compounds in aromatic plants by RP-HPLC coupled to diode array detector (DAD) and GC-MS after silylation (2013) Foods, 2, pp. 90-99; Shim, Y.J., Doo, H.K., Ahn, S.Y., Kim, Y.S., Seong, J.K., Park, I.S., Inhibitory effect of aqueous extract from the gal of Rhuzchinesis on alpha glucosidaseactivities and postprandial blood glucose (2003) Journal of Enthopharmacology, 85, pp. 283-287; Sigmundová, I., Zahradník, P., Magdolen, P., Bujdáková, H., Synthesis and study of new antimicrobial benzothiazoles substituted on heterocyclic ring (2008) ARKIVOC, 8, pp. 183-192; Singleton, V.L., Rossi, J.A., Colorimetry of total phenolics with phosphotungstic acidreagents (1965) American Journal of Enology and Viticulture, 16, pp. 144-158; Smeulders, D.E., Wilson, M.A., Armstrong, L., Poisoning of aluminium hydroxide precipitation by high-molecular-weight fractions of Bayer organics (2001) Industrial and Engineering Chemistry Research, 40, pp. 5901-5907; Stepp, J.R., The role of weeds as sources of pharmaceuticals (2004) Journal of Ethnopharmacology, 92, pp. 163-166; Stepp, J.R., Moerman, D.E., The importance of weeds in ethnopharmacology (2001) Journal of Ethnopharmacology, 75, pp. 19-23; Suganthi, J., Devi, U.P., Kanmari, S., Free radical scavenging potential and HPTLC profile of Mimosa pudica (2011) Research Journal of Pharmaceutical Technology, 4, pp. 1090-1094; Sutar, N.G., Sutar, U.N., Behera, B.C., Antidiabetic activity of Mimosa pudica Linn onalbino rats (2009) Journal of Herbal Medicine and Toxicology, 3, pp. 123-126; Tadera, K., Minami, Y., Takamatsu, K., Matsuoka, T., Inhibition of alpha-glucosidase and alpha-amylase by flavonoids (2006) Journal of Nutritional Science and Vitaminology, 52, pp. 149-153; Tamilarasi, T., Ananthi, T., Phytochemical analysis and anti-microbial activity of Mimosa pudica Linn (2012) Research Journal of Chemical Science, 2, pp. 72-74; Umamaheswari, S., Prince, P.S., Antihyperglycaemic effect of 'Ilogen-Excel', an ayurvedic herbal formulation in streptozotocin-induced diabetes mellitus (2007) Acta Poloniae Pharmaceutica, 64, pp. 53-61; Umar, A., Ahmed, Q.U., Muhammad, B.Y., Bashar, B.S., Dogaraia, B.B.S., Zaiton, S., Anti-hyperglycemic activity of the leaves of Tetracera scandens Linn. Merr. (Dilleniaceae) in alloxan induced diabetic rats (2010) Journal of Ethnopharmacology, 131, pp. 140-145; Valliant, J.F., Guenther, K.J., King, A.S., Pierre Morel, P., Paul Schaffer, P., Sogbein, O.O., Karin, A., The medicinal chemistry of carboranes (2012) Coordination Chemistry Reviews, 232, pp. 173-230; Wang, Y., Huang, S., Shao, S., Qian, L., Xu, P., Studies on bioactivities of tea (Camellia sinensis L) fruit peel extracts: Antioxidant activity and inhibitory potential against alpha-glucosidase and a-amylase in vitro (2012) Industrial Crop Production, 37, pp. 520-526; at:whqlibdoc.who.int/hq/2002/who_edm_trm_2002.1.pdf (2002) Traditional Medicine Strategy, , World Health Organisation, Geneva,Switzerland; Diabetes Mellitus, , http://who.int/mediacentre/factsheets/fs312/en/index.html; Worthington, V., Alpha amylase (1993) Worthington enzyme manual, pp. 36-41. , Worthington Biochemical Corporation, Freehold, NJ, V. Worthington (Ed); Yao, X., Ling Zhu, L., Chen, Y., Tian, J., Wanga, Y., In vivo and in vitro antioxidant activity and a-glucosidase, a-amylase inhibitory effects of flavonoids from Cichorium glandulosum seeds (2013) Food Chemistry, 139, pp. 59-66; Zadernowski, R., Czaplicki, S., Naczk, M., Phenolic acid profiles of mangosteen fruits (Garcinia mangostana) (2009) Food Chemistry, 112, pp. 685-689; Zhang, J., Yuan, K., Zhou, W.L., Zhou, J., Yang, P., Studies on the active components and antioxidant activities of the extracts of Mimosa pudicaLinn.from southern China (2011) Pharmacogocnosy Magazine, 7, pp. 35-39; Zhishen, J., Tang Mengcheng, T., Jianming, W., The determination of flavonoid contents in mulberry and their scavenging effects on superoxide radicals (1999) Food Chemistry, 64, pp. 555-559; Zhong, Z., Wheeler, M.D., Li, X., Froh, M., Schemmer, P., Yin, M., Bunzendaul, H., Lemasters, J.J., L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent (2003) Current Opinion in Clinical Nutrition and Metabolic Care, 6, pp. 229-240",Article,Scopus,2-s2.0-84928660018
"Stadler K., Goldberg I.J., Susztak K.","The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease",2015,"Current Diabetes Reports","15","7",,"","",8,,10.1007/s11892-015-0611-8,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929000506&partnerID=40&md5=1adcb3675afa16a19cd8b2e49fa7a9a4","Oxidative Stress and Disease Laboratory, Pennington Biomedical Research CenterBaton Rouge, LA, United States; Division of Endocrinology, Diabetes, and Metabolism, New York University School of MedicineNew York, NY, United States; Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, 405 Clinical Research Building, 415 CRB, 415 Curie BlvdPhiladelphia, PA, United States","Stadler, K., Oxidative Stress and Disease Laboratory, Pennington Biomedical Research CenterBaton Rouge, LA, United States; Goldberg, I.J., Division of Endocrinology, Diabetes, and Metabolism, New York University School of MedicineNew York, NY, United States; Susztak, K., Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, 405 Clinical Research Building, 415 CRB, 415 Curie BlvdPhiladelphia, PA, United States","Although diabetes is mainly diagnosed based on elevated glucose levels, dyslipidemia is also observed in these patients. Chronic kidney disease (CKD), a frequent occurrence in patients with diabetes, is associated with major abnormalities in circulating lipoproteins and renal lipid metabolism. At baseline, most renal epithelial cells rely on fatty acids as their energy source. CKD, including that which occurs in diabetes, is characterized by tubule epithelial lipid accumulation. Whether this is due to increased uptake or greater local fatty acid synthesis is unknown. We have recently shown that CKD also leads to decreased fatty acid oxidation, which might be an additional mechanism leading to lipid accumulation. Defective fatty acid utilization causes energy depletion resulting in increased apoptosis and dedifferentiation, which in turn contributes to fibrosis and CKD progression. Enhanced fatty acid oxidation in the kidney induced by fenofibrate, a peroxisomal proliferator-activated receptor (PPAR)-α agonist, showed benefit in mouse models of CKD. Fenofibrate treatment also reduced albuminuria in patients with diabetes in multiple clinical trials. Taken together, these findings suggest that further understanding of lipid metabolism in diabetic kidney disease may lead to novel therapeutic approaches. © 2015, Springer Science+Business Media New York.","Chronic renal failure; Diabetes; Fatty acid metabolism; Triglyceride","Aon, M.A., Bhatt, N., Cortassa, S.C., Mitochondrial and cellular mechanisms for managing lipid excess (2014) Front Physiol, 5, p. 282. , PID: 25132820; Goldberg, I.J., Trent, C.M., Schulze, P.C., Lipid metabolism and toxicity in the heart (2012) Cell Metab, 15 (6), pp. 805-812. , COI: 1:CAS:528:DC%2BC38Xot12gsb4%3D, PID: 22682221, This paper provides a thorough review of fatty acid metabolism in the heart and highlights diabetic or obese conditions, alterations in lipid metabolism and possible treatments to alleviate lipid-related pathology; Barkoudah, E., Skali, H., Uno, H., Solomon, S.D., Pfeffer, M.A., Mortality rates in trials of subjects with type 2 diabetes (2012) J Am Heart Assoc, 1 (1), pp. 8-15. , PID: 23130114; Jiang, T., Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway (2005) J Biol Chem, 280 (37), pp. 32317-32325. , COI: 1:CAS:528:DC%2BD2MXpvVyqsbc%3D, PID: 16046411; Wang, W., Deletion of scavenger receptor A protects mice from progressive nephropathy independent of lipid control during diet-induced hyperlipidemia (2012) Kidney Int, 81 (10), pp. 1002-1014. , COI: 1:CAS:528:DC%2BC38XmsFaktbk%3D, PID: 22377830, This study highlights the important role of a transmembrane receptor in hyperlipidemic kidney and tubular cell injury; Weinberg, J.M., Lipotoxicity (2006) Kidney Int, 70 (9), pp. 1560-1566. , COI: 1:CAS:528:DC%2BD28XhtV2gsrrJ, PID: 16955100; Kimmelstiel, P., Wilson, C., Intercapillary lesions in the glomeruli of the kidney (1936) Am J Pathol, 12 (1), pp. 83-98. , COI: 1:STN:280:DC%2BC3critFCgsw%3D%3D, PID: 19970254; Chajek, T., Stein, O., Stein, Y., Pre- and post-natal development of lipoprotein lipase and hepatic triglyceride hydrolase activity in rat tissues (1977) Atherosclerosis, 26, pp. 549-561. , COI: 1:CAS:528:DyaE2sXktF2lsrw%3D, PID: 857810; Goldberg, I.J., Localization of lipoprotein lipase mRNA in selected rat tissues (1989) J Lipid Res, 30 (10), pp. 1569-1577. , COI: 1:CAS:528:DyaL1MXmt12nu7k%3D, PID: 2614260; Coburn, C.T., Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice (2000) J Biol Chem, 275 (42), pp. 32523-32529. , COI: 1:CAS:528:DC%2BD3cXnslOitrY%3D, PID: 10913136; Bobulescu, I.A., Dubree, M., Zhang, J., McLeroy, P., Moe, O.W., Effect of renal lipid accumulation on proximal tubule Na+/H+ exchange and ammonium secretion (2008) Am J Physiol Renal Physiol, 294 (6), pp. 1315-1322. , COI: 1:CAS:528:DC%2BD1cXnsVarsb8%3D, PID: 18417539; Bobulescu, I.A., Renal lipid metabolism and lipotoxicity (2010) Curr Opin Nephrol Hypertens, 19 (4), pp. 393-402. , COI: 1:CAS:528:DC%2BC3cXnvVOhs78%3D, PID: 20489613; Ginsberg, H.N., Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels (1996) Diabetes, 45, pp. 27-30. , COI: 1:CAS:528:DyaK28XjvFartLs%3D, PID: 8674885; Haemmerle, G., Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase (2006) Science, 312 (5774), pp. 734-737. , COI: 1:CAS:528:DC%2BD28XktVGntL4%3D, PID: 16675698; Eckel, R.H., Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases (1989) N Engl J Med, 320 (16), pp. 1060-1068. , COI: 1:CAS:528:DyaL1MXitVyiuro%3D, PID: 2648155; Taskinen, M.R., Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects (2011) Arterioscler Thromb Vasc Biol, 31 (9), pp. 2144-2150. , COI: 1:CAS:528:DC%2BC3MXhtVaktrnI, PID: 21778423; Vaziri, N.D., Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences (2006) Am J Physiol Renal Physiol, 290 (2), pp. 262-272. , COI: 1:CAS:528:DC%2BD28XhsFKit7k%3D, PID: 16403839; Chauhan, V., Vaid, M., Dyslipidemia in chronic kidney disease: managing a high-risk combination (2009) Postgrad Med, 121 (6), pp. 54-61. , PID: 19940417; Arici, M., Fatty acids carried on albumin modulate proximal tubular cell fibronectin production: a role for protein kinase C (2002) Nephrol Dial Transplant, 17 (10), pp. 1751-1757. , COI: 1:CAS:528:DC%2BD38Xot1CisLw%3D, PID: 12270980; Thomas, M.E., Harris, K.P., Walls, J., Furness, P.N., Brunskill, N.J., Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria (2002) Am J Physiol Renal Physiol, 283 (4), pp. 640-647. , PID: 12217854; Susztak, K., Ciccone, E., McCue, P., Sharma, K., Bottinger, E.P., Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy (2005) PLoS Med, 2 (2), p. 45. , PID: 15737001; Ruggiero, C., Albumin-bound fatty acids but not albumin itself alter redox balance in tubular epithelial cells and induce a peroxide-mediated redox-sensitive apoptosis (2014) Am J Physiol Renal Physiol, 306 (8), pp. 896-906. , COI: 1:CAS:528:DC%2BC2cXns1Grtbk%3D, PID: 24500687; Sun, L., Halaihel, N., Zhang, W., Rogers, T., Levi, M., Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus (2002) J Biol Chem, 277 (21), pp. 18919-18927. , COI: 1:CAS:528:DC%2BD38XktFChtrk%3D, PID: 11875060; Wang, Z., Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes (2005) Diabetes, 54 (8), pp. 2328-2335. , COI: 1:CAS:528:DC%2BD2MXnt1yntr4%3D, PID: 16046298; Jiang, T., Liebman, S.E., Lucia, M.S., Li, J., Levi, M., Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease (2005) Kidney Int, 68 (6), pp. 2608-2620. , COI: 1:CAS:528:DC%2BD28XhslSrtg%3D%3D, PID: 16316337; Kang, H.M., Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development (2015) Nat Med, 21 (1), pp. 37-46. , COI: 1:CAS:528:DC%2BC2cXhvF2js7jJ, PID: 25419705, This novel study provides evidence for the first time that it is not necessarily the increase in fatty acid levels but its defective oxidation that may play a key role in kidney fibrosis; Ledo, N., Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD (2015) J Am Soc Nephrol, 26 (3), pp. 692-714. , COI: 1:CAS:528:DC%2BC2MXktl2ru74%3D, PID: 25231882; Reidy, K., Kang, H.M., Hostetter, T., Susztak, K., Molecular mechanisms of diabetic kidney disease (2014) J Clin Invest, 124 (6), pp. 2333-2340. , COI: 1:CAS:528:DC%2BC2cXpvFaitbk%3D, PID: 24892707; Muoio, D.M., Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility (2012) Cell Metab, 15 (5), pp. 764-777. , COI: 1:CAS:528:DC%2BC38XmsVektrc%3D, PID: 22560225, This study provides key evidence for the lipid overload theory in skeletal muscle in contrast to the lipotoxicity theory; Markwell, M.A., McGroarty, E.J., Bieber, L.L., Tolbert, N.E., The subcellular distribution of carnitine acyltransferases in mammalian liver and kidney. A new peroxisomal enzyme (1973) J Biol Chem, 248 (10), pp. 3426-3432. , COI: 1:CAS:528:DyaE3sXkt12ksb8%3D, PID: 4702872; Haynie, K.R., Vandanmagsar, B., Wicks, S.E., Zhang, J., Mynatt, R.L., Inhibition of carnitine palymitoyltransferase1b induces cardiac hypertrophy and mortality in mice (2014) Diabetes Obes Metab, 16 (8), pp. 757-760. , COI: 1:CAS:528:DC%2BC2cXhtFOlt7bF, PID: 24330405; Vickers, A.E., Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors (2009) Toxicol Pathol, 37 (1), pp. 78-88. , COI: 1:CAS:528:DC%2BD1MXjtVyisb8%3D, PID: 19234235; Son, N.H., PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation (2010) J Clin Invest, 120 (10), pp. 3443-3454. , COI: 1:CAS:528:DC%2BC3cXht1GgtLbO, PID: 20852389; Liu, L., DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity (2009) J Biol Chem, 284 (52), pp. 36312-36323. , COI: 1:CAS:528:DC%2BD1MXhsFyiurvI, PID: 19778901; Muoio, D.M., Neufer, P.D., Lipid-induced mitochondrial stress and insulin action in muscle (2012) Cell Metab, 15 (5), pp. 595-605. , COI: 1:CAS:528:DC%2BC38XmsVCjtbs%3D, PID: 22560212, This paper discusses mitochondrial lipid overload and its potential role in insulin sensitivity and emphasizes the advances of this hypothesis; Goodpaster, B.H., He, J., Watkins, S., Kelley, D.E., Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes (2001) J Clin Endocrinol Metab, 86 (12), pp. 5755-5761. , COI: 1:CAS:528:DC%2BD3MXptVylurs%3D, PID: 11739435; Wang, Z., Resting energy expenditure-fat-free mass relationship: new insights provided by body composition modeling (2000) Am J Physiol Endocrinol Metab, 279 (3), pp. 539-545. , COI: 1:CAS:528:DC%2BD3cXmvVGrs7Y%3D, PID: 10950820; Nieth, H., Schollmeyer, P., Substrate-utilization of the human kidney (1966) Nature, 209 (5029), pp. 1244-1245. , COI: 1:CAS:528:DyaF28Xps1WisA%3D%3D, PID: 5956318; Milne, G.L., Musiek, E.S., Morrow, J.D., F2-isoprostanes as markers of oxidative stress in vivo: an overview (2005) Biomark Biochem Indic Expo Response Susceptibility Chem, 10 (1), pp. 10-23. , COI: 1:CAS:528:DC%2BD2MXht1eltLfI; Morrow, J.D., Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans (2005) Arterioscler Thromb Vasc Biol, 25 (2), pp. 279-286. , COI: 1:CAS:528:DC%2BD2MXmtFClug%3D%3D, PID: 15591226; Stadler, K., Involvement of inducible nitric oxide synthase in hydroxyl radical-mediated lipid peroxidation in streptozotocin-induced diabetes (2008) Free Radic Biol Med, 45 (6), pp. 866-874. , COI: 1:CAS:528:DC%2BD1cXhtVylsbfN, PID: 18620046; Higdon, A., Diers, A.R., Oh, J.Y., Landar, A., Darley-Usmar, V.M., Cell signalling by reactive lipid species: new concepts and molecular mechanisms (2012) Biochem J, 442 (3), pp. 453-464. , COI: 1:CAS:528:DC%2BC38XivV2itbo%3D, PID: 22364280, This study highlights that reactive lipids are not only deleterious, but they play major roles in signaling pathways as well due to their reactive, electrophile nature; Cooper, C.E., Patel, R.P., Brookes, P.S., Darley-Usmar, V.M., Nanotransducers in cellular redox signaling: modification of thiols by reactive oxygen and nitrogen species (2002) Trends Biochem Sci, 27 (10), pp. 489-492. , COI: 1:CAS:528:DC%2BD38XnsVWqsL8%3D, PID: 12368076; Rudolph TK, Freeman BA. Transduction of redox signaling by electrophile-protein reactions. Sci Signal. 2009; 2(90 re7)Morton, J., Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study (2012) Diabetes Care, 35 (11), pp. 2201-2206. , COI: 1:CAS:528:DC%2BC38XhvFShs7nL, PID: 22891258; The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group (1993) N Engl J Med, 329 (14), pp. 977-986; Baigent, C., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial (2011) Lancet, 377 (9784), pp. 2181-2192. , COI: 1:CAS:528:DC%2BC3MXotVejsb0%3D, PID: 21663949; Portilla, D., Mandel, L.J., Bar-Sagi, D., Millington, D.S., Anoxia induces phospholipase A2 activation in rabbit renal proximal tubules (1992) Am J Physiol, 262, pp. 354-360. , COI: 1:CAS:528:DyaK38Xitleiu7c%3D, PID: 1558154; Davis, T.M., Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study (2011) Diabetologia, 54 (2), pp. 280-290. , COI: 1:CAS:528:DC%2BC3MXjtVehtQ%3D%3D, PID: 21052978; Ting, R.D., Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study (2012) Diabetes Care, 35 (2), pp. 218-225. , COI: 1:CAS:528:DC%2BC38Xjt1ajtbg%3D, PID: 22210576, The studies described in this paper collectively summarize the advantages and potential disadvantages of fenofibrate therapy in diabetic kidney disease patients; Kostapanos, M.S., Florentin, M., Elisaf, M.S., Fenofibrate and the kidney: an overview (2013) Eur J Clin Investig, 43 (5), pp. 522-531. , COI: 1:CAS:528:DC%2BC3sXmt1OhtLw%3D",Review,Scopus,2-s2.0-84929000506
"Mark L., Vallejo-Vaz A.J., Reiber I., Paragh G., Kondapally Seshasai S.R., Ray K.K.","Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals inHungary",2015,"Atherosclerosis","241","1",,"62","68",,,10.1016/j.atherosclerosis.2015.04.810,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928884892&partnerID=40&md5=f879d8da723987b3f8b929251726cdcd","2nd Department of Medicine - Cardiology, Pandy Kalman Bekes County HospitalGyula, Hungary; Cardiovascular and Cell Sciences Research Institute, St George's, University of LondonLondon, United Kingdom; 4th Department of Medicine, St George Fejer County HospitalSzekesfehervar, Hungary; 1st Department of Medicine, Medical and Health Science Centre, University of DebrecenDebrecen, Hungary; Department of Primary Care and Public Health, School of Public Health, Imperial College LondonLondon, United Kingdom","Mark, L., 2nd Department of Medicine - Cardiology, Pandy Kalman Bekes County HospitalGyula, Hungary; Vallejo-Vaz, A.J., Cardiovascular and Cell Sciences Research Institute, St George's, University of LondonLondon, United Kingdom; Reiber, I., 4th Department of Medicine, St George Fejer County HospitalSzekesfehervar, Hungary; Paragh, G., 1st Department of Medicine, Medical and Health Science Centre, University of DebrecenDebrecen, Hungary; Kondapally Seshasai, S.R., Cardiovascular and Cell Sciences Research Institute, St George's, University of LondonLondon, United Kingdom; Ray, K.K., Department of Primary Care and Public Health, School of Public Health, Imperial College LondonLondon, United Kingdom","Aims: Non-HDL cholesterol represents the pro-atherogenic, apo-B-containing lipoprotein fraction of circulating lipids, and represents a secondary target for CVD prevention in people with diabetes. We therefore assessed the proportion of individuals with diabetes and CVD who attain a non-HDL-C goal of <2.6mmol/L, the extent to which triglycerides influence this goal attainment, and their relationship with HDL-C and triglyceride-rich lipoproteins (TRL). Methods and results: Of 2674 diabetic subjects with baseline CVD in the Hungarian MULTI-GAP programme (mean age 64.8 years, mean HbA1c 7.2%), an LDL-C goal <1.8 and non-HDL-C goal <2.6mmol/L was attained in 13.5% and 17.7% individuals, respectively. Non-HDL-C goal attainment declined at higher triglyceride concentrations; and graphically this relationship appeared to be continuously and inversely associated with triglyceride concentrations. In contrast, the relationship between LDL-C goal attainment was inversely and continuously associated with triglyceride levels up to about 2.5mmol/L, after which the graphical appearance plateaued such that no further difference in LDL-C were observed beyond triglyceride levels of 2.5mmol/L. With increasing triglyceride concentrations, non-HDL-C increased continuously, HDL-C decreased initially but later plateaued (at 1.5-2.0 [men] or 2.0-2.5mmol/L [women]), LDL-C levels plateaued at about 2.0-2.5mmol/L, and TRL-cholesterol (non-HDL-C minus LDL-C) rose continuously. In multivariable-adjusted models, elevated triglyceride concentrations, non-specialist care and uncontrolled blood pressure were inversely associated with non-HDL-C goal attainment. Triglyceride levels were more strongly associated with non-HDL-C than with LDL-C goal attainment (ORs per 1-SD increase in log-triglycerides was 0.74, 95% CI 0.61-0.89, for LDL-C goal attainment, and 0.49, 95% CI 0.38-0.61, for non-HDL-C goal attainment). Conclusion: Non-HDL-C goal attainment was suboptimal in people with diabetes and co-existing CVD. This was most marked at higher triglyceride levels, possibly due to higher levels of TRL. © 2015 .","Cardiovascular disease; Diabetes mellitus; LDL cholesterol; Non-HDL cholesterol; Remnants; Triglyceride-rich lipoproteins; Triglycerides","Diabetes mellitus, fasting glucose, and risk of cause-Specific Death (2011) N.Engl. J. Med., 364, pp. 829-841; (2010) Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries, , National Academies Press (US), Washington (DC), V. Fuster, B.B. Kelly (Eds.); Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, W.M.M., Albus, C., Zannad, F., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) Eur. Heart J., 33, pp. 1635-1701; Reiner, Z., Catapano, A.L., De Backer, G., Graham, I., Taskinen, M.R., Wiklund, O., Agewall, S., Wood, D., ESC/EAS guidelines for the management of dyslipidaemias (2011) Eur. Heart J., 32, pp. 1769-1818; Rydén, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Zamorano, J.L., ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (2013) Eur. Heart J., 34, pp. 3035-3087; Ray, K.K., Kastelein, J.J.P., Boekholdt, S.M., Nicholls, S.J., Khaw, K.T., Ballantyne, C.M., Catapano, A.L., Luscher, T.F., The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011 (2014) Eur. Heart J., 35, pp. 960-968; Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B., Clark, L.T., Hunninghake, D.B., Pasternak, R.C., Stone, N.J., Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines (2004) Circulation, 110 (2), pp. 227-239; Mark, L., Paragh, G., Karadi, I., Reiber, I., Pados, G., Changes in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004-2008 (2010) Arch. Med. Sci., 6 (5), pp. 695-700; Mark, L., Paragh, G., Karadi, I., Reiber, I., Pados, G., Kiss, Z., An attempt to make lipid-lowering therapy more effective in Hungary. The results of MULTI GAP 2010 and the PLUS (2011) Program. Arch. Med. Sci., 7 (5), pp. 760-766; Mark, L., Paragh, G., Karadi, I., Reiber, I., Pados, G., Kiss, Z., How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines? (2012) Arch. Med. Sci., 8 (4), pp. 608-613; Varbo, A., Benn, M., Nordestgaard, B.G., Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment (2014) Pharmacol. Ther., 141 (3), pp. 358-367; Janosi, A., Ostor, E., Borbas, S., Kazinczy, R., Kali, A., Vamos, I., Bradak, A., Podmaniczky, M., Data on secondary prevention of coronary artery disease in Hungary and some changes in the last ten years (EUROASPIRE 1995-2005) (2010) Orv. Hetil., 151 (43), pp. 1776-1782; Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyorala, K., Keil, U., Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II AND III surveys in eight European countries (2009) Lancet, 373, pp. 929-940; Li, M., Ong, K.L., Tse, H.F., Cheung, B.M.Y., Utilization of lipid lowering medications among adults in the United States 1999-2006 (2010) Atherosclerosis, 208, pp. 456-460; Gaede, P., Lund-Andersen, H., Parving, H.H., Pedersen, O., Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) N.Engl. J. Med., 358 (6), pp. 580-591; Anselmino, M., Malmberg, K., Ohrvik, J., Rydén, L., Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart (2008) Eur. J. Cardiovasc Prev. Rehabil., 15 (2), pp. 216-223; Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Simes, R., Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins (2005) Lancet, 366 (9493), pp. 1267-1278; Gould, A.L., Davies, G.M., Alemao, E., Yin, D.D., Cook, J.R., Cholesterol reduction yields clinical benefits: meta-analysis including recent trials (2007) Clin. Ther., 29 (5), pp. 778-794; Major lipids, apolipoproteins, and risk of vascular disease (2009) JAMA, 302 (18), pp. 1993-2000; Robinson, J.G., Wang, S., Smith, B.J., Jacobson, T.A., Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk (2009) J.Am. Coll. Cardiol., 53 (4), pp. 316-322; Boekholdt, S.M., Arsenault, B.J., Mora, S., Pedersen, T.R., LaRosa, J.C., Nestel, P.J., Simes, R.J., Kastelein, J.J., Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins (2012) JAMA, 307 (12), pp. 1302-1309; Chapman, M.J., Ginsberg, H.N., Amarenco, P., Andreotti, F., Borén, J.C., Catapano, A.L., Descamps, O.S., Watts, G.F., Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011) Eur. Heart J., 32, pp. 1345-1361; Varbo, A., Benn, M., Tybjaerg-Hansen, A., Jorgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Remnant cholesterol as a causal risk factor for ischemic heart disease (2013) J.Am. Coll. Cardiol., 61, pp. 427-436; Davis, C.E., Williams, D.H., Oganov, R.G., Tao, S.C., Rywik, S.L., Stein, Y., Little, J.A., Sex difference in high density lipoprotein cholesterol in six countries (1996) Am. J. Epidemiol., 143 (11), pp. 1100-1106; Norata, G.D., Tibolla, G., Catapano, A.L., PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges (2014) Vasc. Pharmacol., 62 (2), pp. 103-111. , pii:S1537-1891(14)00107-4; Jun, K.R., Park, H.I., Chun, S., Park, H., Min, W.K., Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula (2008) Clin. Chem. Lab. Med., 46 (3), pp. 371-375; Scharnagl, H., Nauck, M., Wieland, H., März, W., The Friedewald formula underestimates LDL cholesterol at low concentrations (2001) Clin. Chem. Lab. Med., 39 (5), pp. 426-431",Article,Scopus,2-s2.0-84928884892
"Skarbaliene J., Secher T., Jelsing J., Ansarullah, Neerup T.S.R., Billestrup N., Fosgerau K.","The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats",2015,"Peptides","69",,,"47","55",,,10.1016/j.peptides.2015.03.024,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928011579&partnerID=40&md5=79f7158bed4b19cc0b1911ddaf677b77","Research and Development, Zealand Pharma A/S, Smedeland 36Glostrup, Denmark; Gubra ApS, Hørsholm, Denmark; Sanford Project, Children Health Research Center, Sanford Research/USDSioux Falls, SD, United States; Department of Biomedical Sciences, University of Copenhagen, Denmark; Total Potential Cells Pvt LtdVadodra, Gujarat, India; Bionor Pharma ASAOslo, Norway","Skarbaliene, J., Research and Development, Zealand Pharma A/S, Smedeland 36Glostrup, Denmark; Secher, T., Gubra ApS, Hørsholm, Denmark; Jelsing, J., Gubra ApS, Hørsholm, Denmark; Ansarullah, Sanford Project, Children Health Research Center, Sanford Research/USDSioux Falls, SD, United States, Total Potential Cells Pvt LtdVadodra, Gujarat, India; Neerup, T.S.R., Research and Development, Zealand Pharma A/S, Smedeland 36Glostrup, Denmark, Bionor Pharma ASAOslo, Norway; Billestrup, N., Department of Biomedical Sciences, University of Copenhagen, Denmark; Fosgerau, K., Research and Development, Zealand Pharma A/S, Smedeland 36Glostrup, Denmark","Aims/hypothesis Combination treatment with exendin-4 and gastrin has proven beneficial in treatment of diabetes and preservation of beta cell mass in diabetic mice. Here, we examined the chronic effects of a GLP-1-gastrin dual agonist ZP3022 on glycemic control and beta cell dysfunction in overtly diabetic Zucker Diabetic Fatty (ZDF) rats. Methods ZDF rats aged 11 weeks were dosed s.c., b.i.d. for 8 weeks with vehicle, ZP3022, liraglutide, exendin-4, or gastrin-17 with or without exendin-4. Glycemic control was assessed by measurements of HbA1c and blood glucose levels, as well as glucose tolerance during an oral glucose tolerance test (OGTT). Beta cell dynamics were examined by morphometric analyses of beta and alpha cell fractions. Results ZP3022 improved glycemic control as measured by terminal HbA1c levels (6.2 ± 0.12 (high dose) vs. 7.9 ± 0.07% (vehicle), P < 0.001), as did all treatments, except gastrin-17 monotherapy. In contrast, only ZP3022, exendin-4 and combination treatment with exendin-4 and gastrin-17 significantly improved glucose tolerance and increased insulin levels during an OGTT. Moreover, only ZP3022 significantly enhanced the beta cell fraction in ZDF rats, a difference of 41%, when compared to the vehicle group (0.31 ± 0.03 vs. 0.22 ± 0.02%, respectively, P < 0.05). Conclusion These data suggest that ZP3022 may have therapeutic potential in the prevention/delay of beta cell dysfunction in type 2 diabetes. © 2015 Elsevier Inc.All rights reserved.","Dual agonist; Gastrin; Glucagon-like peptide-1; Pancreatic beta cell; Type 2 diabetes; Zucker diabetic fatty rats","Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants (2011) Lancet, pp. 31-40; Ferrannini, E., The stunned beta cell: A brief history (2010) Cell Metab, pp. 349-352; U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group (1995) Diabetes, pp. 1249-1258; Buse, J.B., Drucker, D.J., Taylor, K.L., Kim, T., Walsh, B., Hu, H., DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks (2010) Diabetes Care, pp. 1255-1261; Garber, A., Henry, R.R., Ratner, R., Hale, P., Chang, C.T., Bode, B., Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes (2011) Diabetes Obes Metab, pp. 348-356; Toso, C., McCall, M., Emamaullee, J., Merani, S., Davis, J., Edgar, R., Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture (2010) Transpl Int, pp. 259-265; Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats (2002) Endocrinology, pp. 4397-4408; Kwon, D.Y., Kim, Y.S., Ahn, I.S., Ds, K., Kang, S., Hong, S.M., Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats (2009) J Pharmacol Sci, pp. 361-371; Xu, G., Stoffers, D.A., Habener, J.F., Bonner-Weir, S., Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (1999) Diabetes, pp. 2270-2276; Finan, B., Ma, T., Ottaway, N., Muller, T.D., Habegger, K.M., Heppner, K.M., Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans (2013) Sci Transl Med, , 209ra151; Fosgerau, K., Jessen, L., Tolborg, J.L., Osterlund, T., Larsen, K.S., Rolsted, K., The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice (2013) Diabetes Obes Metab, pp. 62-71; Dufresne, M., Seva, C., Fourmy, D., Cholecystokinin and gastrin receptors (2006) Physiol Rev, pp. 805-847; Crouch, M.A., Mefford, I.N., Wade, E.U., Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes (2012) J Am Board Fam Med, pp. 50-54; Hove, K.D., Faerch, K., Bodvarsdottir, T.B., Karlsen, A.E., Petersen, J.S., Vaag, A., Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - A retrospective analysis (2010) Diabetes Res Clin Pract, pp. e72-e74; Brand, S.J., Fuller, P.J., Differential gastrin gene expression in rat gastrointestinal tract and pancreas during neonatal development (1988) J Biol Chem, pp. 5341-5347; Morisset, J., Laine, J., Mimeau-Worthington, T., Hormonal control of rat fetal pancreas development (1999) Biol Neonate, pp. 327-336; Rooman, I., Lardon, J., Bouwens, L., Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue (2002) Diabetes, pp. 686-690; Suarez-Pinzon, W.L., Power, R.F., Yan, Y., Wasserfall, C., Atkinson, M., Rabinovitch, A., Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice (2008) Diabetes, pp. 3281-3288; Suarez-Pinzon, W.L., Lakey, J.R., Rabinovitch, A., Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice (2008) Cell Transplant, pp. 631-640; Suarez-Pinzon, W.L., Rabinovitch, A., Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice (2011) Cell Transplant, pp. 1343-1349; Dalboge, L.S., Almholt, D.L., Neerup, T.S., Vrang, N., Jelsing, J., Fosgerau, K., The novel GLP-1-gastrin dual agonist, ZP3022, improves glucose homeostasis and increases beta cell mass without affecting islet number in db/db mice (2014) J Pharmacol Exp Ther, pp. 353-360; Brand, C.L., Galsgaard, E.D., Tornehave, D., Romer, J., Gotfredsen, C.F., Wassermann, K., Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats (2009) Diabetes Obes Metab, pp. 795-803; Vrang, N., Jelsing, J., Simonsen, L., Jensen, A.E., Thorup, I., Soeborg, H., The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: A quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis (2012) Am J Physiol Endocrinol Metab, pp. E253-E264; Larsen, P.J., Wulff, E.M., Gotfredsen, C.F., Brand, C.L., Sturis, J., Vrang, N., Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats (2008) Diabetes Obes Metab, pp. 301-311; Sturis, J., Gotfredsen, C.F., Romer, J., Rolin, B., Ribel, U., Brand, C.L., GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics (2003) Br J Pharmacol, pp. 123-132; Tamaki, M., Fujitani, Y., Uchida, T., Hirose, T., Kawamori, R., Watada, H., Combination treatment of db/db mice with exendin-4 and gastrin preserves b-cell mass by stimulating b-cell growth and differentiation (2010) J Diabetes Invest, pp. 172-183; Tellez, N., Joanny, G., Escoriza, J., Vilaseca, M., Montanya, E., Gastrin treatment stimulates beta-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats (2011) Endocrinology, pp. 2580-2588; Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat (1998) Diabetes, pp. 358-364; Petersen, B., Christiansen, J., Rehfeld, J.F., Acid secretory potency and elimination of the 15-leucine gastrin-17 analogue in man (1981) Scand J Gastroenterol, pp. 437-440; Koole, C., Wootten, D., Simms, J., Valant, C., Sridhar, R., Woodman, O.L., Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: Implications for drug screening (2010) Mol Pharmacol, pp. 456-465; Pocai, A., Carrington, P.E., Adams, J.R., Wright, M., Eiermann, G., Zhu, L., Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice (2009) Diabetes, pp. 2258-2266; Rooman, I., Lardon, J., Flamez, D., Schuit, F., Bouwens, L., Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas (2001) Gastroenterology, pp. 940-949; Morisset, J., Julien, S., Laine, J., Localization of cholecystokinin receptor subtypes in the endocine pancreas (2003) J Histochem Cytochem, pp. 1501-1513; Buteau, J., Foisy, S., Joly, E., Prentki, M., Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor (2003) Diabetes, pp. 124-132; Miyazaki, Y., Shinomura, Y., Tsutsui, S., Zushi, S., Higashimoto, Y., Kanayama, S., Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor (1999) Gastroenterology, pp. 78-89; Suarez-Pinzon, W.L., Lakey, J.R., Brand, S.J., Rabinovitch, A., Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass (2005) J Clin Endocrinol Metab, pp. 3401-3409; Suarez-Pinzon, W.L., Yan, Y., Power, R., Brand, S.J., Rabinovitch, A., Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice (2005) Diabetes, pp. 2596-2601; Rolin, B., Larsen, M.O., Gotfredsen, C.F., Deacon, C.F., Carr, R.D., Wilken, M., The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice (2002) Am J Physiol Endocrinol Metab, pp. E745-E752; Clerc, P., Coll Constans, M.G., Lulka, H., Broussaud, S., Guigne, C., Leung-Theung-Long, S., Involvement of cholecystokinin 2 receptor in food intake regulation: Hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice (2007) Endocrinology, pp. 1039-1049; Levetan, C.S., Pierce, S.M., Distinctions between the islets of mice and men: Implications for new therapies for type 1 and 2 diabetes (2013) Endocr Pract, pp. 301-312",Article,Scopus,2-s2.0-84928011579
"George S., Ajikumaran Nair S., Johnson A.J., Venkataraman R., Baby S.","O-prenylated flavonoid, an antidiabetes constituent in Melicope lunu-ankenda",2015,"Journal of Ethnopharmacology","168",,,"158","163",,,10.1016/j.jep.2015.03.060,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928409252&partnerID=40&md5=9db6b9b2427fc82cea6013901ac7be04","Phytochemistry and Phytopharmacology Division, Jawaharlal Nehru Tropical Botanic Garden and Research InstitutePacha-Palode, Thiruvananthapuram, Kerala, India; Department of Chemistry, Sri Paramakalyani College (Manonmaniam Sundaranar University Tirunelveli)Alwarkurichi, Tamil Nadu, India","George, S., Phytochemistry and Phytopharmacology Division, Jawaharlal Nehru Tropical Botanic Garden and Research InstitutePacha-Palode, Thiruvananthapuram, Kerala, India; Ajikumaran Nair, S., Phytochemistry and Phytopharmacology Division, Jawaharlal Nehru Tropical Botanic Garden and Research InstitutePacha-Palode, Thiruvananthapuram, Kerala, India; Johnson, A.J., Phytochemistry and Phytopharmacology Division, Jawaharlal Nehru Tropical Botanic Garden and Research InstitutePacha-Palode, Thiruvananthapuram, Kerala, India; Venkataraman, R., Department of Chemistry, Sri Paramakalyani College (Manonmaniam Sundaranar University Tirunelveli)Alwarkurichi, Tamil Nadu, India; Baby, S., Phytochemistry and Phytopharmacology Division, Jawaharlal Nehru Tropical Botanic Garden and Research InstitutePacha-Palode, Thiruvananthapuram, Kerala, India","Ethnopharmacological relevance: Melicope lunu-ankenda leaves are used to treat diabetes in folklore medicinal practices in India and Malaysia. Here we report the isolation of an O-prenylated flavonoid (3,5,4′-trihydroxy-8,3′-dimethoxy-7-(3-methylbut-2-enoxy)flavone; OPF) from the leaves of M. lunu-ankenda and its antidiabetes activity against type-2 diabetes mellitus (T2DM). Materials and methods OPF was isolated from M. lunu-ankenda leaves by extraction and repeated column chromatography and its structure was elucidated by IR, UV-vis, 1D-, 2D-NMR and mass spectral analyses. Blood glucose lowering activity of OPF was tested in normal rats by oral glucose tolerance test and its efficacy was tested in STZ-induced type-2 diabetic rats. SGOT, SGPT, ALP, serum urea, total triglycerides, total cholesterol and reduction in HDLC, protein and serum insulin levels in normal rats and STZ-induced type-2 diabetic rats were measured. Acute toxicity of OPF was tested at 500 mg/kg dose. Mechanism of antidiabetes action of OPF was elucidated by insulin release from RIN 5F cells. Results OPF isolated from M. lunu-ankenda showed significant blood glucose lowering activity in oral glucose tolerance test on overnight fasted, glucose loaded normal rats and the optimum activity was observed at a dose of 10 mg/kg body weight. In neonatal streptozotocin (STZ) induced diabetic rats, the OPF treatment for 20 days significantly ameliorated the derailed blood glucose levels, liver glycogen and serum biological parameters including insulin to normal levels. OPF on acute toxicity evaluation did not show any conspicuous toxic symptoms even at a higher dose of 500 mg/kg body weight in mice. On evaluating the mechanism of antidiabetes action, it was observed that, OPF induced insulin release from cultured RIN 5F cells in vitro from which it was evident that the OPF acts on pancreatic β-cells for insulin release thereby correcting the derailed blood glucose levels, serum biochemical parameters and ameliorate various diabetic complications in STZ-induced diabetic rats. Conclusions This study shows the potent antidiabetes activity of OPF and describes its mechanism of action. OPF is a promising candidate for the development of new generation anti-DM drugs. Isolation of the O-prenylated flavonoid justifies the use of M. lunu-ankenda for diabetic treatments in folklore practices. © 2015 Elsevier Ireland Ltd.","Melicope lunu-ankenda; O-prenylated flavonoid; RIN 5F cells; Streptozotocin; Type 2 diabetes mellitus","Ab. Karim, M.S., Nasouddin, S.S., Othman, M., Mohd Adzahan, N., Hussin, S.R., Khozirah, S., Consumers' knowledge and perception towards Melicope ptelefolia (Daun Tenggek Burung): A preliminary qualitative study (2011) Int. Food Res. J., 18, pp. 1481-1488; Ajikumaran, N.S., Sabulal, B., Radhika, J., Arun, K.R., Subramoniam, A., Promising anti-diabetes mellitus activity in rats of β-amyrin palmitate isolated from Hemidesmus indicus roots (2014) Eur. J. Pharmacol., 734, pp. 77-82; Ajikumaran, N.S., Subramoniam, A., Indian medicinal plants with anti-diabetes properties (2005) Modern and Alternative Medicine for Diabetes, pp. 43-193. , Khanum, A. Khan, A. Khan, A.A. (Eds.), Ukaaz Publications Hyderabad; Anil, J.J., Arun, K.R., Sherin, A.R., Sreeja, P.C., Arun, C., Sabulal, B., Subramoniam, A., Antipyretic, analgesic, anti-inflammatory and antioxidant activities of two major chromenes from Melicope lunu-ankenda (2010) J. Ethnopharmacol., 130, pp. 267-271; Arulmozhi, D.K., Veeranjaneyulu, A., Bodhankar, S.L., Neonatal streptozotocin-induced rat model of Type-2 diabetes mellitus: A glance (2004) Indian. J. Pharmacol., 36, pp. 217-221; Botta, B., Vitali, A., Menendez, P., Misiti, D., Delle, M.G., Prenylated flavonoids: Pharmacology and biotechnology (2005) Curr. Med. Chem., 12, pp. 713-739; Caroll, N.V., Longly, W., Joseph, H.R., Determination of glycogen in liver and muscle by use of anthrone reagent (1956) J. Biol. Chem., 220, pp. 583-593; Choi, J., Kim, M.Y., Cha, B.C., Yoo, E.S., Yoon, K., Lee, J., Rho, H.S., Cho, J.Y., ZYM-201 Sodium succinate ameliorates streptozotocin-induced hyperlipidemic condition (2012) Planta Med., 78, pp. 12-17; Gray, A.M., Flatt, P.R., Insulin-secreting activity of the traditional antidiabetic plant Viscum album (mistletoe) (1999) J. Endocrinol., 160, pp. 409-414; Guasch, L., Sala, E., Mulero, M., Valls, C., Salvadó, M.J., Pujadas, G., Garcia-Vallvé, S., Identification of PPARgamma partial agonists of natural origin (II): In silico prediction in natural extracts with known antidiabetic activity (2013) PLoS ONE, 8, p. e55889; Guasch, L., Sala, E., Ojeda, M.J., Valls, C., Blade, C., Mulero, M., Blay, M., Pujadas, G., Identification of novel human dipeptidyl peptidase-iv inhibitors of natural origin (Part II): In silico prediction in antidiabetic extracts (2012) PLoS ONE, 7, p. e44972; Hajra, P.K., Nair, V.J., Daniel, P., (1997) Flora of India, 4, p. 369. , Botanic Survey of India Calcutta; Hashim, N.M., Rahmani, M., Ismail, H.B.M., Sukari, M.A., Ali, A.M., Lian, G.E.C., Biological activities of four Melicope species (2009) Sains Malays., 38, pp. 767-771; Hossain, M.A., Ismail, Z., New prenylated flavonoids of Orthosiphon stamineus grown in Malaysia (2011) Asian J. Biotechnol., 3, pp. 200-205; Huseini, H.F., Kianbakht, S., Hajiaghaee, R., Dabaghian, F.H., Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial (2012) Planta Med., 78, pp. 311-316; Ikeoka, D., Krusinova, E., Insulin resistance and lipid metabolism (2009) Rev. Assoc. Med. Bras., 55, p. 234; Ivorra, M.D., Paya, M., Villar, A., A review of natural products and plants as potential antidiabetic drugs (1989) J. Ethnopharmacol., 27, pp. 243-275; Jia, S., Hu, C., Pharmacological effects of rutaecarpine as a cardiovascular protective agent (2010) Molecules, 15, pp. 1873-1881; Kasetti, R.B., Rajasekhar, M.D., Kondeti, V.K., Fatima, S.S., Kumar, E.G., Swapna, S., Ramesh, B., Rao, C.A., Antihyperglycemic and antihyperlipidemic activities of methanol:water (4:1) fraction isolated from aqueous extract of Syzygium alternifolium seeds in streptozotocin induced diabetic rats (2010) Food Chem. Toxicol., 48, pp. 1078-1084; Kato, A., Yasuko, H., Goto, H., Hollinshead, J., Nash, R.J., Adachi, I., Inhibitory effect of rhetsinine isolated from Evodia rutaecarpa on aldose reductase activity (2009) Phytomedicine, 16, pp. 258-261; Kind, P.R.N., King, E.J., Estimation of plasma phosphatases by determination of hydrolysed phenol with antipyrine (1954) J. Clin. Pathol., 70, pp. 322-330; Kumar, V., Karunaratne, V., Sanath, M.R., Meegalle, K., MacLeod, J.K., Two fungicidal phenylethanones from Euodia lunu-ankenda root bark (1990) Phytochemistry, 29, pp. 243-245; Lalitha, K.G., Venkatachalam, T., Rathinavel, G., Kishor, K.V., Kalaiselvi, P., Evaluation of analgesic activity of Evodia lunu-ankenda (Gaertn) Merr. bark (2010) Der Pharm. Sin., 1, pp. 7-10; Liao, J.-F., Chiou, W.-F., Shen, Y.-C., Wang, G.-J., Chen, C.-F., Anti-inflammatory and anti-infectious effects of Evodia rutaecarpa (Wuzhuyu) and its major bioactive components (2011) Chin. Med., 6, p. 6; Nicolle, E., Souard, F., Faure, P., Boumendjel, A., Flavonoids as promising lead compounds in type 2 diabetes mellitus: Molecules of interest and structure-activity relationship (2011) Curr. Med. Chem., 18, pp. 2661-2672; Olivier, B., Daniele, B., Portha, B., Relation of insulin deficiency to impaired insulin action in NIDDM adult rats given streptozocin as neonates (1989) Diabetes, 38, pp. 610-617; Othman, A., Mukhtar, N.J., Ismail, N.S., Chang, S.K., Phenolics, flavonoids content and antioxidant activities of 4 Malaysian herbal plants (2014) Int. Food Res. J., 21, pp. 759-766; Qi, L.W., Liu, E.H., Chu, C., Peng, Y.B., Cai, H.X., Li, P., Anti-diabetic agents from natural products-an update from 2004 to 2009 (2010) Curr. Top. Med. Chem., 10, pp. 434-457; Rajasekaran, S., Ravi, K., Sivagnanam, K., Subramanian, S., Beneficial effects of Aloe vera leaf gel extract on lipid profile status in rats with streptozotocin diabetes (2006) Clin. Exp. Pharmacol. Physiol., 33, pp. 232-237; Reed, M.J., Meszaros, K., Entes, L.J., Claypool, M.D., Pinkett, J.G., Gadbois, T.M., Reaven, G.M., A new rat model of type 2 diabetes, the fat-fed, streptozotocin treated rat (2000) Metabolism, 49, pp. 1390-1394; Reitman, S., Frankel, S., A colorimetric method for the determination of serum glutamate oxalo-acetate and glutamate pyruvate transaminase (1957) Am. J. Clin. Pathol., 28, pp. 56-63; Sabulal, B., George, V., Shiburaj, S., Volatile constituents and antibacterial activity of the flower oil of Evodia lunu-ankenda (Gaertn.) Merr (2006) J. Essent. Oil Res., 18, pp. 462-464; Sidhu, M.C., Sharma, T., Medicinal plants from twelve families having antidiabetic activity: A review (2013) Am. J. PharmTech Res., 3, pp. 36-52; Sultana, N., Hartley, T.G., Waterman, P.G., Two novel prenylated flavones from the aerial parts of Melicope micrococca (1999) Phytochemistry, 50, pp. 1249-1253; Tan, L.Y., Yin, W.F., Chan, K.G., Silencing quorum sensing through extracts of Melicope lunu-ankenda (2012) Sensors, 12, pp. 4339-4351; Vats, V., Yadav, S.P., Grover, J.K., Ethanolic extract of Ocimum sanctum leaves partially attenuates streptozotocin-induced alterations in glycogen content and carbohydrate metabolism in rats (2004) J. Ethnopharmacol., 90, pp. 155-160; Verspohl, E.J., Recommended testing in diabetes research (2002) Planta Med., 68, pp. 581-591; Waltner-Law, M.E., Wang, X.L., Law, B.K., Hall, R.K., Nawano, M., Granner, D.K., Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production (2002) J. Biol. Chem., 277, pp. 34933-34940; Wang, T., Kusudo, T., Takeuchi, T., Yamashita, Y., Kontani, Y., Okamatsu, Y., Saito, M., Yamashita, H., Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice (2013) PLoS ONE, 8, p. e83264; Yeo, J., Kang, Y.-M., Cho, S.-I., Jung, M.-H., Effects of a multi-herbal extract on type 2 diabetes (2011) Chin. Med., 6, p. 10",Article,Scopus,2-s2.0-84928409252
"Alrefaie Z., Alhayani A.","Vitamin D<inf>3</inf> improves decline in cognitive function and cholinergic transmission in prefrontal cortex of streptozotocin-induced diabetic rats",2015,"Behavioural Brain Research","287",,,"156","162",,,10.1016/j.bbr.2015.03.050,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926483484&partnerID=40&md5=de2a39a2f382603c7980e89d812a0720","Physiology Department, Faculty of Medicine, King Abdulaziz UniversityJeddah, Saudi Arabia; Anatomy Department, Faculty of Medicine, King Abdulaziz UniversityJeddah, Saudi Arabia","Alrefaie, Z., Physiology Department, Faculty of Medicine, King Abdulaziz UniversityJeddah, Saudi Arabia; Alhayani, A., Anatomy Department, Faculty of Medicine, King Abdulaziz UniversityJeddah, Saudi Arabia","Complications of diabetes mellitus include cognitive impairments and functional changes in the brain. The present study aimed to investigate the possible beneficial effect of vitamin D<inf>3</inf> on episodic memory and cholinergic transmission in the prefrontal cortex of streptozotocin-induced diabetic rats.Thirty male Wistar rats (150-200g) were included into control, diabetic and diabetic supplemented with vitamin D<inf>3</inf> groups. Diabetes was induced by single intraperitoneal injection of streptozotocin 45mg/kg in citrate buffer. Vitamin D<inf>3</inf> was administered orally in a dose of 500IU/kg/day in corn oil for 10 weeks. Then rats were subjected to novel object recognition test to examine for episodic memory. Animals were sacrificed under diethyl ether anesthesia and prefrontal cortices were dissected to measure the activity of choline acetyl transferase (CAT) and acetyle choline esterase (ACE) enzymes to assess for cholinergic transmission.Diabetic rats spent significantly less time exploring the novel object compared to control animals. Vitamin D<inf>3</inf> significantly attenuated the diabetes-induced impairment so that animals again spent significantly more time exploring the novel object. The CAT activity was significantly decreased in diabetic animals while the ACE activity was significantly increased compared to control non-diabetic animals. Diabetes-induced alterations in enzyme activity in the prefrontal cortex were mitigated by vitamin D<inf>3</inf> supplementation.The present findings demonstrate the potential effect of vitamin D<inf>3</inf> supplementation on cognitive function in diabetic animals. It is possible that this effect is mediated through enhancing the prefrontal cortex cholinergic transmission. © 2015 Elsevier B.V.","Acetyle choline esterase; Choline acetyl transferase; Diabetes mellitus; Episodic memory; Prefrontal cortex","Eyles, D.W., Smith, S., Kinobe, R., Hewison, M., McGrath, J.J., Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain (2005) J Chem Neuroanat, 29, pp. 21-30; Grant, W.B., Does vitamin D reduce the risk of dementia? (2009) J Alzheimers Dis, 17, pp. 151-159; Soni, M., Kos, K., Lang, I.A., Jones, K., Melzer, D., Llewllyn, D.J., Vitamin D and cognitive function (2012) Scand J Clin Lab Inv, 72 (243), pp. 79-82; Kumar, P.T., Paul, J., Antony, S., Paulose, C.S., Expression of cholinergic, insulin, vitamin D receptors and GLUT 3 in the brainstem of streptozotocin induced diabetic rats: effect of treatment with vitamin D3 (2011) Neurochem Res, 36 (11), pp. 2116-2126; Sims-Robinson, C., Zhao, S., Hur, J., Feldman, E.L., Central nervous system endoplasmic reticulum stressin a murine model of type 2 diabetes (2012) Diabetologia, 55 (8), pp. 2276-2284; Currais, A., Prior, M., Lo, D., Jolivalt, C., Schubert, D., Maher, P., Diabetes exacerbates amyloid and neurovascular pathology in aging-accelerated mice (2012) Aging Cell, 11 (6), pp. 1017-1026; Zhang, W.J., Tan, Y.F., Yue, J.T., Vranic, M., Wojtowicz, J.M., Impairment of hippocampal neurogenesis in streptozotocin-treated diabetic rats (2008) Acta Neurol Scand, 117 (3), pp. 205-210; Reis, H.J., Guatimosim, C., Paquet, M., Santos, M., Ribeiro, F.M., Kummer, A., Neuro-transmitters in the central nervous system and their implication in learning and memory processes (2009) Curr Med Chem, 16 (7), pp. 796-840; Xiong, L., Zhang, J.J., Sun, D., Liu, H., Therapeutic benefit of Yangxue Qingnao granule on cognitive impairment induced by chronic cerebral hypoperfusion in rats (2011) Chin J Integr Med, 17 (2), pp. 134-140; Gao, Y., Li, C., Yin, J., Shen, J., Wang, H., Wu, Y., Fucoidan, a sulfated polysaccharide from brown algae, improves cognitive impairment induced by infusion of Aβ peptide in rats (2012) Environ Toxicol Pharmacol, 33 (2), pp. 304-311; Biessels, G.J., Kerssen, A., de Haan, E.H., Kappelle, L.J., Cognitive dysfunction and diabetes: implications for primary care (2007) Prim Care Diabetes, 1, pp. 187-193; Pari, L., Sankaranarayanan, C., Beneficial effects of thymoquinone on hepatic key enzymes in streptozotocin- induced diabetic rats (2009) Life Sci, 85 (26), pp. 830-834; Salum, E., Kampus, P., Zilmer, M., Eha, J., Butlin, M., Avolio, A.P., Effect of vitamin D on aortic remodeling in streptozotocin-induced diabetes (2012) Cardiovasc Diabetol, 11, pp. 58-62; Aggleton, J.P., One-trial object recognition by rats (1985) Q J Exp Psychol, 37, pp. 279-294; Ennaceur, A., Delacour, J., A new one-trial test for neurobiological studies of memory in rats. 1. Behavioral data (1988) Behav Brain Res, 31 (1), pp. 47-59; Bertaina-Anglade, V., Enjuanes, E., Morillon, D., Drieu la Rochelle, C., The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity (2006) J Pharmacol Toxicol Methods, 54, pp. 99-105; Grayson, B., Idris, N.F., Neill, J.C., Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat (2007) Behav Brain Res, 184, pp. 31-38; Chao, L., Spectrophotomertic determination of choline acetyl transferase in the presence of dithiotheritol (1978) Anal Biochem, 85 (1), pp. 20-24; Ellman, G., Gurteny, K., Andre, J., Feathestone, R., A new and rapid colorimetric determination of acetylcholine esterase activity (1969) Biochem Pharmacol, 7, pp. 88-95; Tulving, E., Schacter, D.L., Priming and human memory systems (1990) Science, 247, pp. 301-306; Tulving, E., Markowitsch, H.J., Episodic and declarative memory: role of the hippocampus (1998) Hippocampus, 8, pp. 198-204; Tulving, E., Episodic memory and common sense: how far apart (2001) Phil Trans R Soc Lond B, 356, pp. 1505-1515; Tiehuis, A., van der Meer, F., Mali, W., Pleizier, M., Biessels, G.J., Kappelle, J., MR spectroscopy of cerebral white matter in type 2 diabetes; no association with clinical variables and cognitive performance (2010) Neuroradiology, 52 (2), pp. 155-161; Kálcza-Jánosi, K., Lukács, A., Barkai, L., Szamosközi, I., Cognitive functions in type 1 and type 2 diabetes. Meta-analysis (2013) Orv Hetil, 154 (18), pp. 694-699; Zhao, B., Pan, B.S., Shen, S.W., Sun, X., Hou, Z.Z., Yan, R., Diabetes-induced central neuritic dystrophy and cognitive deficits are associated with the formation of oligomeric reticulon-3 via oxidative stress (2013) J Biol Chem, 288 (22), pp. 15590-15599; Huang, X., Wang, F., Chen, W., Chen, Y., Wang, N., von Maltzan, K., Possible link between the cognitive dysfunction associated with diabetes mellitus and the neurotoxicity of methylglyoxal (2012) Brain Res, 1469, pp. 82-91; Sima, A.F., Kamlya, H., Lia, Z.G., Insulin C-peptide, hyperglycemia and central nervous system complications in diabetes (2004) Eur J Pharmacol, 490, pp. 187-197; Dere, E., Huston, J.P., De Souza Silva, M.A., The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents (2007) Neurosci Biobehav Rev, 31, pp. 673-704; Bhutada, P., Mundhada, Y., Bansod, K., Tawari, S., Patil, S., Dixit, P., Protection of cholinergic and antioxidant system contribute to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes (2011) Behav Brain Res, 220, pp. 30-41; Sarter, M., Bruno, J.P., Cortical cholinergic inputs mediating arousal, attentional processing and dreaming, differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents (2000) Neuroscience, 95, pp. 933-952; Wallacea, T.L., Bertrand, D., Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex (2013) Biochem Pharmacol, 85, pp. 1713-1720; Sarter, M., Bruno, J.P., Cognitive functions of cortical acetylcholine, toward a unifying hypothesis (1997) Brain Res Rev, 23, pp. 28-46; Bartus, R.T., On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis (2000) Exp Neurol, 163, pp. 495-529; Obermann, K.R., Morris, J.C., Roe, C.M., Exploration of 100 commonly used drugs and supplements on cognition in older adults (2013) Alzheimers Dement, 6, pp. 724-732; Annweiler, C., Montero-Odasso, M., Llewellyn, D.J., Richard-Devantoy, S., Duque, G., Beauchet, O., Meta-analysis of memory and executive dysfunctions in relation to vitamin D (2013) J Alzheimer Dis, 37 (1), pp. 147-171; Littlejohns, T.J., Henley, W.E., Lang, I.A., Annweiler, C., Beauchet, O., Chaves, P.H., Vitamin D and the risk of dementia and Alzheimer disease (2014) Neurology, 83 (10), pp. 920-928; De Neree Tot Babberich, E., Gourdeau, C., Pointel, S., Lamarchant, B., Beauchet, O., Annweiler, C., Biology of subjective cognitive complaint amongst geriatric patients: vitamin D involvement (2015) Curr Alzheimer Res, , [Epub ahead of print]; Moon, Y., Moon, W.J., Kwon, H., Lee, J.M., Han, S.H., Vitamin D deficiency disrupts neural integrity in cognitively impaired patients (2015) J Alzheimer Dis, , [Epub ahead of print]; Annweiler, C., Annweiler, T., Bartha, R., Herrmann, F.R., Camicioli, R., Beauchet, O., Vitamin D and white matter abnormalities in older adults: a cross-sectional neuroimaging study (2014) Eur J Neurol, 21 (12), pp. 1436-1495; Latimer, C.S., Brewer, L.D., Searcy, J.L., Chen, K.C., Popovic, J., Kraner, S.D., Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats (2014) Proc Natl Acad Sci U S A, 111 (41), pp. E4359-E4366; Dursun, E., Gezen-Ak, D., Yilmazzer, S., A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid beta and preventing the amyloid beta-induced alterations by vitamin D in cortical neurons (2011) J Alzheimers Dis, 23, pp. 207-219; Fernandes de Areu, D.A., Eyles, D., Feron, F., Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases (2009) Psychneuroendocrinology, 34 (1), pp. S265-S277; Briones, T.L., Darwish, H., Vitamin D mitigates age-related cognitive decline through modulation of pro-inflammatory state and decrease in amyloid burden (2012) J Neuroinflammation, 9, p. 244",Article,Scopus,2-s2.0-84926483484
"Wang C., Chen R., Zhao Z., Cai J., Lu J., Ha S., Xu X., Chen X., Kan H.","Particulate air pollution and circulating biomarkers among type 2 diabetic mellitus patients: The roles of particle size and time windows of exposure",2015,"Environmental Research","140",,,"112","118",,,10.1016/j.envres.2015.03.026,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926195308&partnerID=40&md5=753462a9d76d132d46e232920a5b6744","School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China; Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP), Fudan UniversityShanghai, China; Tianping Community Health Center, Xuhui DistrictShanghai, China","Wang, C., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China, Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP), Fudan UniversityShanghai, China; Chen, R., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China, Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP), Fudan UniversityShanghai, China; Zhao, Z., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China; Cai, J., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China, Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP), Fudan UniversityShanghai, China; Lu, J., Tianping Community Health Center, Xuhui DistrictShanghai, China; Ha, S., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China, Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP), Fudan UniversityShanghai, China, Tianping Community Health Center, Xuhui DistrictShanghai, China; Xu, X., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China, Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP), Fudan UniversityShanghai, China, Tianping Community Health Center, Xuhui DistrictShanghai, China; Chen, X., Tianping Community Health Center, Xuhui DistrictShanghai, China; Kan, H., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China, Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP), Fudan UniversityShanghai, China","Background: Short-term associations between size-fractionated particulate matter (PM) air pollution and circulating biomarkers are not well established, especially among diabetes patients. Methods: We conducted a longitudinal panel study involving 6 repeated measurements of 12 circulating biomarkers among 35 diabetes patients from April to June, 2013 in Shanghai, China. Real-time number and mass concentrations of PM with multiple size fractions between 0.25 and 10. μm were measured. Linear mixed-effect models were used to explore the associations between size-fractionated PM concentrations and blood biomarkers at different time windows. Results: Short-term exposure to PM was significantly associated with elevated levels of 5 biomarkers of inflammation, 3 biomarkers of coagulation and 1 vasoconstrictor. The effects varied considerably by particle size and time windows. Overall, PM with smaller size had stronger associations, and the most significant size fractions were 0.25-0.40μm. Even 2h exposure to PM can lead to a significant increase in biomarkers. The effects on biomarkers of inflammation and vasoconstriction were restricted to the first 12h after exposure, but the effects on coagulation persisted for 24-72h. For example, an interquartile range increase in 2h average exposure to PM<inf>0.25-0.40</inf> was associated with 6-20% increase in biomarkers of inflammation, 19-38% in coagulation and 17% in vasoconstriction. PM had a stronger effect among male patients than female patients. Conclusions: Our results provided important evidence on the roles of the size and time windows of exposure in the PM-mediated effects on circulating biomarkers of inflammation, coagulation and vasoconstriction in diabetes patients in China. © 2015 Elsevier Inc.","Biomarker; Epidemiology; Particle size; Particulate matter; Time window; Type 2 diabetic mellitus","Adar, S.D., Ambient coarse particulate matter and human health: a systematic review and meta-analysis (2014) Curr. Environ. Health Rep., 1, pp. 258-274; Aso, Y., Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis (2007) Front. Biosci., 12, pp. 2957-2966; Delfino, R.J., Circulating biomarkers of inflammation, antioxidant activity, and platelet activation are associated with primary combustion aerosols in subjects with coronary artery disease (2008) Environ. Health Perspect., 116, pp. 898-906; Dominici, F., Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases (2006) JAMA, 295, pp. 1127-1134; Dubowsky, S.D., Diabetes, obesity, and hypertension may enhance associations between air pollution and markers of systemic inflammation (2006) Environ. Health Perspect., 114, pp. 992-998; Ensor, K.B., A case-crossover analysis of out-of-hospital cardiac arrest and air pollution (2013) Circulation, 127, pp. 1192-1199; Franklin, M., Association between PM2.5 and all-cause and specific-casue mortality in 27 US communities (2007) J. Expo. Sci. Environ. Epidemiol., 17, pp. 279-287; Gabay, C., Kushner, I., Acute-phase proteins and other systemic responses to inflammation (1999) N. Engl. J. Med., 340, pp. 448-454; Guariguata, L., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 103, 137-49.Kan, H., et al., 2012. Ambient air pollution, climate change, and population health in China (2014) Environ. Int., 42, pp. 10-19; Leitte, A.M., Size-segregated particle number concentrations and respiratory emergency room visits in Beijing, China (2011) Environ. Health Perspect., 119, pp. 508-513; Lerman, A., Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans (1995) Circulation, 92, pp. 2426-2431; Liao, D., Association of criteria pollutants with plasma hemostatic/inflammatory markers: a population-based study (2005) J. Expo. Anal. Environ. Epidemiol., 15, pp. 319-328; Lim, S.S., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) Lancet, 380, pp. 2224-2260; Link, M.S., Acute exposure to air pollution triggers atrial fibrillation (2013) J. Am. Coll. Cardiol., 62, pp. 816-825; Liu, C., Epidemiological and experimental links between air pollution and type 2 diabetes (2013) Toxicol. Pathol., 41, pp. 361-373; Liu, L., Size-fractioned particulate air pollution and cardiovascular emergency room visits in Beijing, China (2013) Environ. Res., 121, pp. 52-63; Meng, X., Size-fractionated particle number concentrations and daily mortality in a Chinese city (2013) Environ. Health Perspect., 121, pp. 1174-1178; Mustafic, H., Main air pollutants and myocardial infarction: a systematic review and meta-analysis (2012) JAMA, 307, pp. 713-721; O'Neill, M.S., Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility (2007) Occup. Environ. Med., 64, pp. 373-379; Rich, D.Q., Association between changes in air pollution levels during the beijing olympics and biomarkers of inflammation and thrombosis in healthy young adults (2012) JAMA, 307, pp. 2068-2078; Ruckerl, R., Ultrafine particles and platelet activation in patients with coronary heart disease-results from a prospective panel study (2007) Part Fiber Toxicol., 4, pp. 1-14; Ruckerl, R., Associations between ambient air pollution and blood markers of inflammation and coagulation/fibrinolysis in susceptible populations (2014) Environ. Int., 70, pp. 32-49; Sacks, J.D., Particulate matter-induced health effects: who is susceptible? (2011) Environ. Health Perspect., 119, pp. 446-454; Samoli, E., Acute effects of ambient particulate matter on mortality in Europe and North America: results from the APHENA study (2008) Environ. Health Perspect., 116, pp. 1480-1486; Schauble, C.L., Short-term effects of air temperature on blood markers of coagulation and inflammation in potentially susceptible individuals (2012) Occup. Environ. Med., 69, pp. 670-678; Schneider, A., Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals (2008) Environ. Health Perspect., 116, pp. 1666-1674; Shah, A.S., Global association of air pollution and heart failure: a systematic review and meta-analysis (2013) Lancet, 382, pp. 1039-1048; Tian, L.W., Ambient carbon monoxide and the risk of hospitalization due to chronic obstructive pulmonary disease (2014) Am. J. Epidemiol., 180, pp. 1159-1167; Verbeke, G., Molenberghs, G., (2009) Linear Mixed Models for Longitudinal Data, , Springer, New York; Wellenius, G.A., Ambient air pollution and the risk of acute ischemic stroke (2012) Arch. Int. Med., 172, pp. 229-234; (2014), http://www.who.int/mediacentre/factsheets/fs312/en/Xu, Y., Prevalence and control of diabetes in Chinese adults (2013) JAMA, 310, pp. 948-959; Yanagisawa, M., A novel potent vasoconstrictor peptide produced by vascular endothelial cells (1988) Nature, 332, pp. 411-415; Zeka, A., Individual-level modifiers of the effects of particulate matter on daily mortality (2005) Am. J. Epidemiol., 163, pp. 849-859; Zhou, M., The associations between ambient air pollution and adult respiratory mortality in 32 major Chinese cities, 2006-2010 (2015) Environ. Res., 137, pp. 278-286",Article,Scopus,2-s2.0-84926195308
"D'Onofrio N., Vitiello M., Casale R., Servillo L., Giovane A., Balestrieri M.L.","Sirtuins in vascular diseases: Emerging roles and therapeutic potential",2015,"Biochimica et Biophysica Acta - Molecular Basis of Disease","1852","7",,"1311","1322",,,10.1016/j.bbadis.2015.03.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929060305&partnerID=40&md5=99bb6c8ab140fd4ab1ba3ae974147008","Department of Biochemistry, Biophysics and General Pathology, School of Medicine and Surgery, Second University of Naples, via L. De Crecchio 7Naples, Italy","D'Onofrio, N., Department of Biochemistry, Biophysics and General Pathology, School of Medicine and Surgery, Second University of Naples, via L. De Crecchio 7Naples, Italy; Vitiello, M., Department of Biochemistry, Biophysics and General Pathology, School of Medicine and Surgery, Second University of Naples, via L. De Crecchio 7Naples, Italy; Casale, R., Department of Biochemistry, Biophysics and General Pathology, School of Medicine and Surgery, Second University of Naples, via L. De Crecchio 7Naples, Italy; Servillo, L., Department of Biochemistry, Biophysics and General Pathology, School of Medicine and Surgery, Second University of Naples, via L. De Crecchio 7Naples, Italy; Giovane, A., Department of Biochemistry, Biophysics and General Pathology, School of Medicine and Surgery, Second University of Naples, via L. De Crecchio 7Naples, Italy; Balestrieri, M.L., Department of Biochemistry, Biophysics and General Pathology, School of Medicine and Surgery, Second University of Naples, via L. De Crecchio 7Naples, Italy","Silent information regulator-2 (Sir-2) proteins, or sirtuins, are a highly conserved protein family of histone deacetylases that promote longevity by mediating many of the beneficial effects of calorie restriction which extends life span and reduces the incidence of cancer, cardiovascular disease (CVD), and diabetes. Here, we review the role of sirtuins (SIRT1-7) in vascular homeostasis and diseases by providing an update on the latest knowledge about their roles in endothelial damage and vascular repair mechanisms. Among all sirtuins, in the light of the numerous functions reported on SIRT1 in the vascular system, herein we discuss its roles not only in the control of endothelial cells (EC) functionality but also in other cell types beyond EC, including endothelial progenitor cells (EPC), smooth muscle cells (SMC), and immune cells. Furthermore, we also provide an update on the growing field of compounds under clinical evaluation for the modulation of SIRT1 which, at the state of the art, represents the most promising target for the development of novel drugs against CVD, especially when concomitant with type 2 diabetes. © 2015.","Cardiovascular disease; Endothelial progenitor cell; Endothelium; Sirtuins; Vascular dysfunction","El Assar, M., Angulo, J., Vallejo, S., Peiro, C., Sanchez-Ferrer, C.F., Rodriguez-Manas, L., Mechanisms involved in the aging-induced vascular dysfunction (2012) Front. Physiol., 3, p. 132; Ignarro, L.J., Balestrieri, M.L., Napoli, C., Nutrition, physical activity, and cardiovascular disease: an update (2007) Cardiovasc. Res., 73, pp. 326-340; Versari, D., Daghini, E., Virdis, A., Ghiadoni, L., Taddei, S., Endothelial dysfunction as a target for prevention of cardiovascular disease (2009) Diabetes Care, 32, pp. S314-S321; Kolluru, G.K., Bir, S.C., Kevil, C.G., Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing (2012) Int. J. Vasc. Med., 2012, p. 918267; Evora, P.R., Baldo, C.F., Celotto, A.C., Capellini, V.K., Endothelium dysfunction classification: why is it still an open discussion? (2009) Int. J. Cardiol., 137, pp. 175-176; Milne, J.C., Lambert, P.D., Schenk, S., Carney, D.P., Smith, J.J., Gagne, D.J., Jin, L., Westphal, C.H., Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes (2007) Nature, 450, pp. 712-716; Lavu, S., Boss, O., Elliott, P.J., Lambert, P.D., Sirtuins-novel therapeutic targets to treat age-associated diseases (2008) Nat. Rev. Drug Discov., 7, pp. 841-853; Balestrieri, M.L., Servillo, L., Esposito, A., D'Onofrio, N., Giovane, A., Casale, R., Barbieri, M., Marfella, R., Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation (2013) Diabetologia, 56, pp. 162-172; Oellerich, M.F., Potente, M., FOXOs and sirtuins in vascular growth, maintenance, and aging (2012) Circ. Res., 110, pp. 1238-1251; Viswanathan, M., Guarente, L., Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes (2011) Nature, 477, pp. E1-E2; Lombard, D.B., Pletcher, S.D., Canto, C., Auwerx, J., Ageing: longevity hits a roadblock (2011) Nature, 477, pp. 410-411; Kaeberlein, M., Powers, R.W., Sir2 and calorie restriction in yeast: a skeptical perspective (2007) Ageing Res. Rev., 6, pp. 128-140; Guarente, L., Franklin, H., Epstein lecture: sirtuins, aging, and medicine (2011) N. Engl. J. Med., 364, pp. 2235-2244; Herranz, D., Munoz-Martin, M., Canamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., Serrano, M., Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer (2010) Nat. Commun., 1, p. 3; Haigis, M.C., Sinclair, D.A., Mammalian sirtuins: biological insights and disease relevance (2010) Annu. Rev. Pathol., 5, pp. 253-295; Frye, R.A., Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins (2000) Biochem. Biophys. Res. Commun., 273, pp. 793-798; Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., Horio, Y., Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1 (2007) J. Biol. Chem., 282, pp. 6823-6832; Vaquero, A., Scher, M.B., Lee, D.H., Sutton, A., Cheng, H.L., Alt, F.W., Serrano, L., Reinberg, D., SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis (2006) Genes Dev., 20, pp. 1256-1261; Huang, J.Y., Hirschey, M.D., Shimazu, T., Ho, L., Verdin, E., Mitochondrial sirtuins (2010) Biochim. Biophys. Acta, 1804, pp. 1645-1651; Liszt, G., Ford, E., Kurtev, M., Guarente, L., Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase (2005) J. Biol. Chem., 280, pp. 21313-21320; Ford, E., Voit, R., Liszt, G., Magin, C., Grummt, I., Guarente, L., Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription (2006) Genes Dev., 20, pp. 1075-1080; Bordo, D., Structure and evolution of human sirtuins (2013) Curr. Drug Targets, 14, pp. 662-665; Kugel, S., Mostoslavsky, R., Chromatin and beyond: the multitasking roles for SIRT6 (2014) Trends Biochem. Sci., 39, pp. 72-81; Mathias, R.A., Greco, T.M., Oberstein, A., Budayeva, H.G., Chakrabarti, R., Rowland, E.A., Kang, Y., Cristea, I.M., Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity (2014) Cell, 1597, pp. 1615-1625; Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Lin, H., SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine (2013) Nature, 496, pp. 110-113; Du, J., Zhou, Y., Su, X., Yu, J.J., Khan, S., Jiang, H., Kim, J., Lin, H., Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase (2011) Science, 334, pp. 806-809; Martínez-Redondo, P., Vaquero, A., The diversity of histone versus nonhistone sirtuin substrates (2013) Genes Cancer, 4, pp. 148-163; Sanchez-Fidalgo, S., Villegas, I., Sanchez-Hidalgo, M., de la Lastra, C.A., Sirtuin modulators: mechanisms and potential clinical implications (2012) Curr. Med. Chem., 19, pp. 2414-2441; Camins, A., Sureda, F.X., Junyent, F., Verdaguer, E., Folch, J., Pelegri, C., Vilaplana, J., Pallas, M., Sirtuin activators: designing molecules to extend life span (2010) Biochim. Biophys. Acta, 1799, pp. 740-749; Hubbard, B.P., Sinclair, D.A., Small molecule SIRT1 activators for the treatment of aging and age-related diseases (2014) Trends Pharmacol. Sci., 35, pp. 146-154; Baur, J.A., Ungvari, Z., Minor, R.K., Le Couteur, D.G., de Cabo, R., Are sirtuins viable targets for improving healthspan and lifespan? (2012) Nat. Rev. Drug Discov., 11, pp. 443-461; Borradaile, N.M., Pickering, J.G., NAD(+), sirtuins, and cardiovascular disease (2009) Curr. Pharm. Des., 15, pp. 110-117; Potente, M., Ghaeni, L., Baldessari, D., Mostoslavsky, R., Rossig, L., Dequiedt, F., Haendeler, J., Dimmeler, S., SIRT1 controls endothelial angiogenic functions during vascular growth (2007) Genes Dev., 21, pp. 2644-2658; Hirschey, M.D., Shimazu, T., Jing, E., Grueter, C.A., Collins, A.M., Aouizerat, B., Stancakova, A., Verdin, E., SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome (2011) Mol. Cell, 44, pp. 177-190; Hou, J., Chong, Z.Z., Shang, Y.C., Maiese, K., Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation (2010) Curr. Neurovasc. Res., 7, pp. 95-112; Zhou, S., Chen, H.Z., Wan, Y.Z., Zhang, Q.J., Wei, Y.S., Huang, S., Liu, J.J., Liang, C.C., Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction (2011) Circ. Res., 109, pp. 639-648; Orimo, M., Minamino, T., Miyauchi, H., Tateno, K., Okada, S., Moriya, J., Komuro, I., Protective role of SIRT1 in diabetic vascular dysfunction (2009) Arterioscler. Thromb. Vasc. Biol., 29, pp. 889-894; Togliatto, G., Trombetta, A., Dentelli, P., Gallo, S., Rosso, A., Cotogni, P., Granata, R., Brizzi, M.F., Unacylated ghrelin (UnAG) induces oxidative stress resistance in a glucose intolerance mouse model and peripheral artery disease by restoring endothelial cell miR-126 expression (2015) Diabetes, 64, pp. 1370-1382; Song, Z., Liu, Y., Hao, B., Yu, S., Zhang, H., Liu, D., Zhou, B., Qian, X., Ginsenoside Rb1 prevents H2O2-induced HUVEC senescence by stimulating sirtuin-1 pathway (2014) PLoS One, 9, p. e112699; Jamal, J., Mustafa, M.R., Wong, P.F., Paeonol protects against premature senescence in endothelial cells by modulating Sirtuin 1 pathway (2014) J. Ethnopharmacol., 154, pp. 428-436; Ota, H., Akishita, M., Eto, M., Iijima, K., Kaneki, M., Ouchi, Y., Sirt1 modulates premature senescence-like phenotype in human endothelial cells (2007) J. Mol. Cell. Cardiol., 43, pp. 571-579; Ota, H., Eto, M., Ogawa, S., Iijima, K., Akishita, M., Ouchi, Y., SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis (2010) J. Atheroscler. Thromb., 17, pp. 431-435; Ota, H., Akishita, M., Tani, H., Tatefuji, T., Ogawa, S., Iijima, K., Eto, M., Ouchi, Y., Trans-Resveratrol in Gnetum gnemon protects against oxidative-stress-induced endothelial senescence (2013) J. Nat. Prod., 76, pp. 1242-1247; Kao, C.L., Chen, L.K., Chang, Y.L., Yung, M.C., Hsu, C.C., Chen, Y.C., Lo, W.L., Hwang, S.J., Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation (2010) J. Atheroscler. Thromb., 17, pp. 970-979; Zu, Y., Liu, L., Lee, M.Y., Xu, C., Liang, Y., Man, R.Y., Vanhoutte, P.M., Wang, Y., SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells (2010) Circ. Res., 106, pp. 1384-1393; Mattagajasingh, I., Kim, C.S., Naqvi, A., Yamamori, T., Hoffman, T.A., Jung, S.B., DeRicco, J., Irani, K., SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 14855-14860; Storz, P., Forkhead homeobox type O transcription factors in the responses to oxidative stress (2011) Antioxid. Redox Signal., 14, pp. 593-605; Voghel, G., Thorin-Trescases, N., Farhat, N., Nguyen, A., Villeneuve, L., Mamarbachi, A.M., Fortier, A., Thorin, E., Cellular senescence in endothelial cells from atherosclerotic patients is accelerated by oxidative stress associated with cardiovascular risk factors (2007) Mech. Ageing Dev., 128, pp. 662-671; Vasko, R., Xavier, S., Chen, J., Lin, C.H., Ratliff, B., Rabadi, M., Maizel, J., Goligorsky, M.S., Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence (2014) J. Am. Soc. Nephrol., 25, pp. 276-291; Napoli, C., Balestrieri, M.L., Sica, V., Lerman, L.O., Crimi, E., De Rosa, G., Schiano, C., D'Armiento, F.P., Beneficial effects of low doses of red wine consumption on perturbed shear stress-induced atherogenesis (2008) Heart Vessels, 23, pp. 124-133; Chen, Z., Peng, I.C., Cui, X., Li, Y.S., Chien, S., Shyy, J.Y., Shear stress, SIRT1, and vascular homeostasis (2010) Proc. Natl. Acad. Sci. U. S. A., 107, pp. 10268-10273; Wen, L., Chen, Z., Zhang, F., Cui, X., Sun, W., Geary, G.G., Wang, Y., Shyy, J.Y., Ca2+/calmodulin-dependent protein kinase kinase beta phosphorylation of Sirtuin 1 in endothelium is atheroprotective (2013) Proc. Natl. Acad. Sci. U. S. A., 110, pp. E2420-E2427; Zhang, Q.J., Wang, Z., Chen, H.Z., Zhou, S., Zheng, W., Liu, G., Wei, Y.S., Liang, C.C., Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice (2008) Cardiovasc. Res., 80, pp. 191-199; Cardellini, M., Menghini, R., Martelli, E., Casagrande, V., Marino, A., Rizza, S., Porzio, O., Federici, M., TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1 (2009) Diabetes, 58, pp. 2396-2401; Stein, S., Schafer, N., Breitenstein, A., Besler, C., Winnik, S., Lohmann, C., Heinrich, K., Matter, C.M., SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice (2010) Aging (Albany NY), 2, pp. 353-360; Wan, Y.Z., Gao, P., Zhou, S., Zhang, Z.Q., Hao, D.L., Lian, L.S., Li, Y.J., Liu, D.P., SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence (2014) Aging Cell, 13, pp. 890-899; Stein, S., Matter, C.M., Protective roles of SIRT1 in atherosclerosis (2011) Cell Cycle, 10, pp. 640-647; Xie, J., Zhang, X., Zhang, L., Negative regulation of inflammation by SIRT1 (2013) Pharmacol. Res., 67, pp. 60-67; Yang, L., Zhang, J., Yan, C., Zhou, J., Lin, R., Lin, Q., Wang, W., Zeng, A., SIRT1 regulates CD40 expression induced by TNF-alpha via NF-kB pathway in endothelial cells (2012) Cell. Physiol. Biochem., 30, pp. 1287-1298; Ceolotto, G., De Kreutzenberg, S.V., Cattelan, A., Fabricio, A.S., Squarcina, E., Gion, M., Semplicini, A., Avogaro, A., Sirtuin 1 stabilization by HuR represses TNF-alpha- and glucose-induced E-selectin release and endothelial cell adhesiveness in vitro: relevance to human metabolic syndrome (2014) Clin. Sci. (Lond.), 127, pp. 449-461; Marampon, F., Gravina, G.L., Scarsella, L., Festuccia, C., Lovat, F., Ciccarelli, C., Zani, B.M., Ferri, C., Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis (2013) J. Hypertens., 31, pp. 1972-1983; Clarke, N.E., Belyaev, N.D., Lambert, D.W., Turner, A.J., Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress (2014) Clin. Sci. (Lond.), 126, pp. 507-516; Chen, J., Michan, S., Juan, A.M., Hurst, C.G., Hatton, C.J., Pei, D.T., Joyal, J.S., Smith, L.E., Neuronal sirtuin1 mediates retinal vascular regeneration in oxygen-induced ischemic retinopathy (2013) Angiogenesis, 16, pp. 985-992; Michan, S., Juan, A.M., Hurst, C.G., Cui, Z., Evans, L.P., Hatton, C.J., Pei, D.T., Chen, J., Sirtuin1 over-expression does not impact retinal vascular and neuronal degeneration in a mouse model of oxygen-induced retinopathy (2014) PLoS One, 9, p. e85031; Loomans, C.J., de Koning, E.J., Staal, F.J., Rookmaaker, M.B., Verseyden, C., de Boer, H.C., Verhaar, M.C., van Zonneveld, A.J., Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes (2004) Diabetes, 53, pp. 195-199; Fadini, G.P., Miorin, M., Facco, M., Bonamico, S., Baesso, I., Grego, F., Menegolo, M., Avogaro, A., Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus (2005) J. Am. Coll. Cardiol., 45, pp. 1449-1457; Hirschi, K.K., Ingram, D.A., Yoder, M.C., Assessing identity, phenotype, and fate of endothelial progenitor cells (2008) Arterioscler. Thromb. Vasc. Biol., 28, pp. 1584-1595; Fadini, G.P., Boscaro, E., de Kreutzenberg, S., Agostini, C., Seeger, F., Dimmeler, S., Zeiher, A., Avogaro, A., Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes (2010) Diabetes Care, 33, pp. 1097-1102; Balestrieri, M.L., Fiorito, C., Crimi, E., Felice, F., Schiano, C., Milone, L., Casamassimi, A., Napoli, C., Effect of red wine antioxidants and minor polyphenolic constituents on endothelial progenitor cells after physical training in mice (2008) Int. J. Cardiol., 126, pp. 295-729; Kumar, A.H., Caplice, N.M., Clinical potential of adult vascular progenitor cells (2010) Arterioscler. Thromb. Vasc. Biol., 30, pp. 1080-1087; Balestrieri, M.L., Rienzo, M., Felice, F., Rossiello, R., Grimaldi, V., Milone, L., Casamassimi, A., Napoli, C., High glucose downregulates endothelial progenitor cell number via SIRT1 (2008) Biochim. Biophys. Acta, 1784, pp. 936-945; Zhao, L.R., Du, Y.J., Chen, L., Liu, Z.G., Pan, Y.H., Liu, J.F., Liu, B., Quercetin protects against high glucose-induced damage in bone marrow-derived endothelial progenitor cells (2014) Int. J. Mol. Med., 34, pp. 1025-1031; Balestrieri, M.L., Schiano, C., Felice, F., Casamassimi, A., Balestrieri, A., Milone, L., Servillo, L., Napoli, C., Effect of low doses of red wine and pure resveratrol on circulating endothelial progenitor cells (2008) J. Biochem., 143, pp. 179-186; Marfella, R., Rizzo, M.R., Siniscalchi, M., Paolisso, P., Barbieri, M., Sardu, C., Savinelli, A., Balestrieri, M.L., Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage (2013) Int. J. Cardiol., 168, pp. 3954-3962; Lemarie, C.A., Shbat, L., Marchesi, C., Angulo, O.J., Deschenes, M.E., Blostein, M.D., Paradis, P., Schiffrin, E.L., Mthfr deficiency induces endothelial progenitor cell senescence via uncoupling of eNOS and downregulation of SIRT1 (2011) Am. J. Physiol. Heart Circ. Physiol., 300, pp. H745-H753; Paschalaki, K.E., Starke, R.D., Hu, Y., Mercado, N., Margariti, A., Gorgoulis, V.G., Randi, A.M., Barnes, P.J., Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence (2013) Stem Cells, 31, pp. 2813-2826; Yuan, Q., Bai, Y.P., Shi, R.Z., Liu, S.Y., Chen, X.M., Chen, L., Li, Y.J., Hu, C.P., Regulation of endothelial progenitor cell differentiation and function by dimethylarginine dimethylaminohydrolase 2 in an asymmetric dimethylarginine-independent manner (2014) Cell Biol. Int., 38, pp. 1013-1022; Zhao, T., Li, J., Chen, A.F., MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1 (2010) Am. J. Physiol. Endocrinol. Metab., 299, pp. E110-E116; Cheng, B.B., Yan, Z.Q., Yao, Q.P., Shen, B.R., Wang, J.Y., Gao, L.Z., Li, Y.Q., Jiang, Z.L., Association of SIRT1 expression with shear stress induced endothelial progenitor cell differentiation (2012) J. Cell. Biochem., 113, pp. 3663-3671; Wang, P., Du, H., Zhou, C.C., Song, J., Liu, X., Cao, X., Mehta, J.L., Miao, C.Y., Intracellular NAMPT-NAD+-SIRT1 cascade improves post-ischaemic vascular repair by modulating Notch signalling in endothelial progenitors (2014) Cardiovasc. Res., 104, pp. 477-488; Thompson, A.M., Wagner, R., Rzucidlo, E.M., Age-related loss of SirT1 expression results in dysregulated human vascular smooth muscle cell function (2014) Am. J. Physiol. Heart Circ. Physiol., 307, pp. H533-H541; Li, L., Zhang, H.N., Chen, H.Z., Gao, P., Zhu, L.H., Li, H.L., Lv, X., Liang, C.C., SIRT1 acts as a modulator of neointima formation following vascular injury in mice (2011) Circ. Res., 108, pp. 1180-1189; Gorenne, I., Kumar, S., Gray, K., Figg, N., Yu, H., Mercer, J., Bennett, M., Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis (2013) Circulation, 127, pp. 386-396; Gao, P., Xu, T.T., Lu, J., Li, L., Xu, J., Hao, D.L., Chen, H.Z., Liu, D.P., Overexpression of SIRT1 in vascular smooth muscle cells attenuates angiotensin II-induced vascular remodeling and hypertension in mice (2014) J. Mol. Med., 92, pp. 347-357; Xia, J., Wu, X., Yang, Y., Zhao, Y., Fang, M., Xie, W., Wang, H., Xu, Y., SIRT1 deacetylates RFX5 and antagonizes repression of collagen type I (COL1A2) transcription in smooth muscle cells (2012) Biochem. Biophys. Res. Commun., 428, pp. 264-270; Takemura, A., Iijima, K., Ota, H., Son, B.K., Ito, Y., Ogawa, S., Eto, M., Ouchi, Y., Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular smooth muscle cells (2011) Arterioscler. Thromb. Vasc. Biol., 31, pp. 2054-2062; van der Veer, E., Ho, C., O'Neil, C., Barbosa, N., Scott, R., Cregan, S.P., Pickering, J.G., Extension of human cell lifespan by nicotinamide phosphoribosyltransferase (2007) J. Biol. Chem., 282, pp. 10841-10845; Yu, X., Zhang, L., Wen, G., Zhao, H., Luong, L.A., Chen, Q., Huang, Y., Xiao, Q., Upregulated sirtuin 1 by miRNA-34a is required for smooth muscle cell differentiation from pluripotent stem cells (2014) Cell Death Differ., , ([Epub ahead of print]); Zeng, H.T., Fu, Y.C., Yu, W., Lin, J.M., Zhou, L., Liu, L., Wang, W., SIRT1 prevents atherosclerosis via liver-X-receptor and NF-κB signaling in a U937 cell model (2013) Mol. Med. Rep., 8, pp. 23-28; Fan, W., Fang, R., Wu, X., Liu, J., Feng, M., Dai, G., Chen, G., Wu, G., Shear-sensitive microRNA-34a modulates flow-dependent regulation of endothelial inflammation (2015) J. Cell Sci., 128, pp. 70-80; Guo, R., Liu, B., Wang, K., Zhou, S., Li, W., Xu, Y., Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-κB pathway (2014) Diab. Vasc. Dis. Res., 11, pp. 92-102; Liu, J., Wu, X., Wang, X., Zhang, Y., Bu, P., Zhang, Q., Jiang, F., Global gene expression profiling reveals functional importance of Sirt2 in endothelial cells under oxidative stress (2013) Int. J. Mol. Sci., 14, pp. 5633-5649; Hashimoto-Komatsu, A., Hirase, T., Asaka, M., Node, K., Angiotensin II induces microtubule reorganization mediated by a deacetylase SIRT2 in endothelial cells (2011) Hypertens. Res., 34, pp. 949-956; Lee, A.S., Jung, Y.J., Kim, D., Nguyen-Thanh, T., Kang, K.P., Lee, S., Park, S.K., Kim, W., SIRT2 ameliorates lipopolysaccharide-induced inflammation in macrophages (2014) Biochem. Biophys. Res. Commun., 450, pp. 1363-1369; Tseng, A.H., Wu, L.H., Shieh, S.S., Wang, D.L., SIRT3 interactions with FOXO3 acetylation, phosphorylation and ubiquitinylation mediate endothelial cell responses to hypoxia (2014) Biochem. J., 464, pp. 157-168; Luo, X., Yang, Z., Zheng, S., Cao, Y., Wu, Y., Sirt3 activation attenuated oxidized low-density lipoprotein-induced human umbilical vein endothelial cells' apoptosis by sustaining autophagy (2014) Cell Biol. Int., , (May 5); Zeng, H., He, X., Hou, X., Li, L., Chen, J.X., Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3 (2014) Am. J. Physiol. Heart Circ. Physiol., 306, pp. H585-H597; Winnik, S., Gaul, D.S., Preitner, F., Lohmann, C., Weber, J., Miranda, M.X., Liu, Y., Matter, C.M., Deletion of Sirt3 does not affect atherosclerosis but accelerates weight gain and impairs rapid metabolic adaptation in LDL receptor knockout mice: implications for cardiovascular risk factor development (2014) Basic Res. Cardiol., 109, p. 399; Paulin, R., Dromparis, P., Sutendra, G., Gurtu, V., Zervopoulos, S., Bowers, L., Haromy, A., Michelaki, E.D., Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans (2014) Cell Metab., 20, pp. 827-839; Chen, Y., Wang, H., Luo, G., Dai, X., SIRT4 inhibits cigarette smoke extracts-induced mononuclear cell adhesion to human pulmonary microvascular endothelial cells via regulating NF-kappaB activity (2014) Toxicol. Lett., 226, pp. 320-327; Dong, C., Della-Morte, D., Wang, L., Cabral, D., Beecham, A., McClendon, M.S., Luca, C.C., Rundek, T., Association of the sirtuin and mitochondrial uncoupling protein genes with carotid plaque (2011) PLoS One, 6, p. e27157; Mostoslavsky, R., Chua, K.F., Lombard, D.B., Pang, W.W., Fischer, M.R., Gellon, L., Liu, P., Alt, F.W., Genomic instability and aging-like phenotype in the absence of mammalian SIRT6 (2006) Cell, 124, pp. 315-329; Zhong, L., Mostoslavsky, R., SIRT6: a master epigenetic gatekeeper of glucose metabolism (2010) Transcription, 1, pp. 17-21; Yao, Q.P., Zhang, P., Qi, Y.X., Chen, S.G., Shen, B.R., Han, Y., Yan, Z.Q., Jiang, Z.L., The role of SIRT6 in the differentiation of vascular smooth muscle cells in response to cyclic strain (2014) Int. J. Biochem. Cell Biol., 49, pp. 98-104; Cardus, A., Uryga, A.K., Walters, G., Erusalimsky, J.D., SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence (2013) Cardiovasc. Res., 97, pp. 571-579; Liu, R., Liu, H., Ha, Y., Tilton, R.G., Zhang, W., Oxidative stress induces endothelial cell senescence via downregulation of Sirt6 (2014) Biomed. Res. Int., 2014, p. 902842; Balestrieri, M.L., Rizzo, M.R., Barbieri, M., Paolisso, P., D'Onofrio, N., Giovane, A., Siniscalchi, M., Marfella, R., Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment (2014) Diabetes; Hu, S., Liu, H., Ha, Y., Luo, X., Motamedi, M., Gupta, M.P., Ma, J.X., Zhang, W., Posttranslational modification of Sirt6 activity by peroxynitrite (2014) Free Radic. Biol. Med., , (Dec 1. pii: S0891-5849(14)01374-4); Vakhrusheva, O., Smolka, C., Gajawada, P., Kostin, S., Boettger, T., Kubin, T., Braun, T., Bober, E., Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice (2008) Circ. Res., 102, pp. 703-710; Borradaile, N.M., Pickering, J.G., Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment (2009) Aging Cell, 8, pp. 100-112; Hubbi, M.E., Hu, H., Kshitiz, D.M.G., Semenza, G.L., Sirtuin-7 inhibits the activity of hypoxia-inducible factors (2013) J. Biol. Chem., 288, pp. 20768-20775; Mortuza, R., Chen, S., Feng, B., Sen, S., Chakrabarti, S., High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway (2013) PLoS One, 8, p. e54514; Patel, K.R., Scott, E., Brown, V.A., Gescher, A.J., Steward, W.P., Brown, K., Clinical trials of resveratrol (2011) Ann. NY Acad. Sci., 1215, pp. 161-169; Gano, L.B., Donato, A.J., Pasha, H.M., Jr Hearon, C.M., Sindler, A.L., Seals, D.R., The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production and inflammation with aging in mice (2014) Am. J. Physiol. Heart Circ. Physiol., 307, pp. H1754-H1763; Mellini, P., Valente, S., Mai, A., Sirtuin modulators: an updated patent review (2012-2014) (2015) Expert Opin. Ther. Pat., 25, pp. 5-15; Chung, S., Yao, H., Caito, S., Hwang, J.W., Arunachalam, G., Rahman, I., Regulation of SIRT1 in cellular functions: role of polyphenols (2010) Arch. Biochem. Biophys., 501, pp. 79-90; Scalera, F., Fulge, B., Martens-Lobenhoffer, J., Heimburg, A., Bode-Boger, S.M., Red wine decreases asymmetric dimethylarginine via SIRT1 induction in human endothelial cells (2009) Biochem. Biophys. Res. Commun., 390, pp. 703-709; Guo, H., Chen, Y., Liao, L., Wu, W., Resveratrol protects HUVECs from oxidized-LDL induced oxidative damage by autophagy upregulation via the AMPK/SIRT1 pathway (2013) Cardiovasc. Drugs Ther., 27, pp. 189-198; Yuan, Q., Chen, L., Xiang, D.X., Li, Y.J., Hu, C.P., Effect of resveratrol derivative BTM-0512 on high glucose-induced dysfunction of endothelial cells: role of SIRT1 (2011) Can. J. Physiol. Pharmacol., 89, pp. 713-722; Smith, J.J., Kenney, R.D., Gagne, D.J., Frushour, B.P., Ladd, W., Galonek, H.L., Israelian, K., Boss, O., Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo (2009) BMC Syst. Biol., 3, p. 31; Funk, J.A., Odejinmi, S., Schnellmann, R.G., SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells (2010) J. Pharmacol. Exp. Ther., 333, pp. 593-601; Yamazaki, Y., Usui, I., Kanatani, Y., Matsuya, Y., Tsuneyama, K., Fujisaka, S., Bukhari, A., Tobe, K., Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice (2009) Am. J. Physiol. Endocrinol. Metab., 297, pp. E1179-E1186; Mitchell, S.J., Martin-Montalvo, A., Mercken, E.M., Palacios, H.H., Ward, T.M., Abulwerdi, G., Minor, R.K., de Cabo, R., The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet (2014) Cell. Rep., 6, pp. 836-843; Grozinger, C.M., Chao, E.D., Blackwell, H.E., Moazed, D., Schreiber, S.L., Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening (2001) J. Biol. Chem., 276, pp. 38837-38843; Mai, A., Massa, S., Lavu, S., Pezzi, R., Simeoni, S., Ragno, R., Mariotti, F.R., Sinclair, D.A., Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors (2005) J. Med. Chem., 48, pp. 7789-7795; Orecchia, A., Scarponi, C., Di Felice, F., Cesarini, E., Avitabile, S., Mai, A., Mauro, M.L., Failla, C.M., Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells (2011) PLoS One, 6, p. e24307; Miranda, M.X., van Tits, L.J., Lohmann, C., Arsiwala, T., Winnik, S., Tailleux, A., Stein, S., Matter, C.M., The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression (2015) Eur. Heart J., 36, pp. 51-59; Servillo, L., D'Onofrio, N., Longobardi, L., Sirangelo, I., Giovane, A., Cautela, D., Castaldo, D., Balestrieri, M.L., Stachydrine ameliorates high-glucose induced endothelial cell senescence and SIRT1 downregulation (2013) J. Cell. Biochem., 114, pp. 2522-2530; Revollo, J.R., Li, X., The ways and means that fine tune Sirt1 activity (2013) Trends Biochem. Sci., 38, pp. 160-167; Venkatasubramanian, S., Noh, R.M., Daga, S., Langrish, J.P., Joshi, N.V., Mills, N.L., Hoffmann, E., Newby, D.E., Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers (2013) J. Am. Heart Assoc., 2, p. e000042",Review,Scopus,2-s2.0-84929060305
"Zhong P., Wu L., Qian Y., Fang Q., Liang D., Wang J., Zeng C., Wang Y., Liang G.","Blockage of ROS and NF-κB-mediated inflammation by a new chalcone L6H9 protects cardiomyocytes from hyperglycemia-induced injuries",2015,"Biochimica et Biophysica Acta - Molecular Basis of Disease","1852","7",,"1230","1241",,,10.1016/j.bbadis.2015.02.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925808679&partnerID=40&md5=04458f980f1ca066030d890442f9f7a2","Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical UniversityWenzhou, Zhejiang, China; Department of Cardiology,, The 5th Affiliated Hospital of Wenzhou Medical UniversityLishui, Zhejiang, China; Department of Cardiology, The 2nd Affiliated Hospital of Wenzhou Medical UniversityWenzhou, Zhejiang, China","Zhong, P., Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical UniversityWenzhou, Zhejiang, China, Department of Cardiology,, The 5th Affiliated Hospital of Wenzhou Medical UniversityLishui, Zhejiang, China; Wu, L., Department of Cardiology, The 2nd Affiliated Hospital of Wenzhou Medical UniversityWenzhou, Zhejiang, China; Qian, Y., Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical UniversityWenzhou, Zhejiang, China; Fang, Q., Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical UniversityWenzhou, Zhejiang, China; Liang, D., Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical UniversityWenzhou, Zhejiang, China; Wang, J., Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical UniversityWenzhou, Zhejiang, China; Zeng, C., Department of Cardiology,, The 5th Affiliated Hospital of Wenzhou Medical UniversityLishui, Zhejiang, China; Wang, Y., Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical UniversityWenzhou, Zhejiang, China; Liang, G., Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical UniversityWenzhou, Zhejiang, China","Increased oxidative stress and cardiac inflammation have been implicated in the pathogenesis of diabetic cardiomyopathy (DCM). We previously found that a novel chalcone derivative, L6H9, was able to reduce LPS-induced inflammatory response in macrophages. This study was designed to investigate its protective effects on DCM and the underlying mechanisms. H9C2 cells were cultured with DMEM containing 33. mmol/L of glucose in the presence or absence of L6H9. Pretreatment with L6H9 significantly reduced high glucose-induced inflammatory cytokine expression, ROS level increase, mitochondrial dysfunction, cell apoptosis, fibrosis, and hypertrophy in H9c2 cells, which may be mediated by NF-κB inhibition and Nrf2 activation. In mice with STZ-induced diabetes, oral administration of L6H9 at 20. mg/kg/day for 8. weeks significantly decreased the cardiac cytokine and ROS level, accompanied by decreasing cardiac apoptosis and hypertrophy, and, finally, improved histological abnormalities and fibrosis, without affecting the hyperglycemia. L6H9 also attenuated the diabetes-induced NF-κB activation and Nrf2 decrease in diabetic hearts. These results strongly suggest that L6H9 may have great therapeutic potential in the treatment of DCM via blockage of inflammation and oxidative stress. This study also provides a deeper understanding of the regulatory role of Nrf2 and NF-κB in DCM, indicating that they may be important therapeutic targets for diabetic complications. © 2015 Elsevier B.V.","Chalcone derivative; Diabetic cardiomyopathy; Inflammation; NF-κB; Nrf2; Oxidative stress","Falcão-Pires, I., Leite-Moreira, A.F., Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment (2012) Heart Fail. Rev., 17, pp. 325-344; Zhang, Y., Sowers, J.R., Ren, J., Pathophysiological insights into cardiovascular health in metabolic syndrome (2012) Exp. Diabetes Res., 2012, p. 320534; Boudina, S., Abel, E.D., Diabetic cardiomyopathy, causes and effects (2010) Rev. Endocr. Metab. Disord., 11, pp. 31-39; Zhou, X., Ma, L., Habibi, J., Whaley-Connell, A., Hayden, M.R., Tilmon, R.D., Brown, A.N., Sowers, J.R., Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat (2010) Hypertension, 55, pp. 880-888; Booz, G.W., Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (2011) Free Radic. Biol. Med., 51, pp. 1054-1061; Pan, Y., Wang, Y., Zhao, Y., Peng, K., Li, W., Wang, Y., Zhang, J., Liang, G., Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy (2014) Diabetes, 63, pp. 3497-3511; Batovska, D.I., Todorova, I.T., Trends in utilization of the pharmacological potential of chalcones (2010) Curr. Clin. Pharmacol., 5, pp. 1-29; Opletalova, V., Jahodar, L., Jun, D., Opletal, L., Chalcones (1,3-diarylpropen-1-ones) and their analogs as potential therapeutic agents in cardiovascular system diseases (2003) Ceska a Slovenska farmacie: casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 52, pp. 12-19; Kontogiorgis, C., Mantzanidou, M., Hadjipavlou-Litina, D., Chalcones and their potential role in inflammation (2008) Mini-Rev. Med. Chem., 8, pp. 1224-1242; Sivakumar, P., Prabhakar, P., Doble, M., Synthesis, antioxidant evaluation, and quantitative structure-activity relationship studies of chalcones (2011) Med. Chem. Res., 20, pp. 482-492; Wu, J., Li, J., Cai, Y., Pan, Y., Ye, F., Zhang, Y., Zhao, Y., Liang, G., Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents (2011) J. Med. Chem., 54, pp. 8110-8123; Yu, W., Wu, J., Cai, F., Xiang, J., Zha, W., Fan, D., Guo, S., Liu, C., Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats (2012) PLoS One, 7, p. e52013; Kumar, S., Kain, V., Sitasawad, S.L., Cardiotoxicity of calmidazolium chloride is attributed to calcium aggravation, oxidative and nitrosative stress, and apoptosis (2009) Free Radic. Biol. Med., 47, pp. 699-709; Singh, M., Murthy, V., Ramassamy, C., Neuroprotective mechanisms of the standardized extract of Bacopa monniera in a paraquat/diquat-mediated acute toxicity (2013) Neurochem. Int., 62, pp. 530-539; Obana, M.M.K., Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart (2012) Am. J. Physiol. Heart Circ. Physiol., 303, pp. H569-H577; Cai, L., Kang, Y.J., Oxidative stress and diabetic cardiomyopathy: a brief review (2001) Cardiovasc. Toxicol., 1, pp. 181-193; Ma, Q., Role of Nrf2 in oxidative stress and toxicity (2013) Annu. Rev. Pharmacol. Toxicol., 53, pp. 401-426; Kumar, S., Kain, V., Sitasawad, S.L., High glucose-induced Ca2+ overload and oxidative stress contribute to apoptosis of cardiac cells through mitochondrial dependent and independent pathways (2012) Biochim. Biophys. Acta, 1820, pp. 907-920; Baines, C.P., The cardiac mitochondrion: nexus of stress (2010) Annu. Rev. Physiol., 72, pp. 61-80; Zeng, C., Zhong, P., Zhao, Y., Kanchana, K., Zhang, Y., Khan, Z.A., Chakrabarti, S., Liang, G., Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-kappaB both in vitro and in vivo (2015) J. Mol. Cell. Cardiol., 79, pp. 1-12; Rajesh, M., Mukhopadhyay, P., Batkai, S., Patel, V., Saito, K., Matsumoto, S., Kashiwaya, Y., Pacher, P., Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy (2010) J. Am. Coll. Cardiol., 56, pp. 2115-2125; Snell-Bergeon, J.K., West, N.A., Mayer-Davis, E.J., Liese, A.D., Marcovina, S.M., Agostino, R.B., Hamman, R.F., Dabelea, D., (2010) Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH case-control study; Nian, M., Lee, P., Khaper, N., Liu, P., Inflammatory cytokines and postmyocardial infarction remodeling (2004) Circ. Res., 94, pp. 1543-1553; Wen, H.L., Liang, Z.S., Zhang, R., Yang, K., Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy (2013) Cardiovasc. Diabetol., 12, p. 50; Lorenzo, O., Picatoste, B., Ares-Carrasco, S., Ramirez, E., Egido, J., Tunon, J., Potential role of nuclear factor kappaB in diabetic cardiomyopathy (2011) Mediat. Inflamm., 2011, p. 652097; Seddon, M., Looi, Y.H., Shah, A.M., Oxidative stress and redox signalling in cardiac hypertrophy and heart failure (2007) Heart, 93, pp. 903-907; Lorenzo, O., Ramirez, E., Picatoste, B., Eqido, J., Tunon, J., Alteration of energy substrates and ROS production in diabetic cardiomyopathy (2013) Mediat. Inflamm., 2013, p. 461967; Bugger, H., Abel, E.D., Molecular mechanism of diabetic cardiomyopathy (2014) Diabetologia, 57, pp. 660-671; Huynh, K., Bernardo, B.C., McMullen, J.R., Ritchie, R.H., Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways (2014) Pharmacol. Ther., 142, pp. 375-415; Li, B., Liu, S., Miao, L., Cai, L., Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy (2012) Exp. Diabetes Res., 2012, p. 216512; Leonard, M.O., Kieran, N.E., Howell, K., Burne, M.J., Varadarajan, R., Dhakshinamoorthy, S., Porter, A.G., Taylor, C.T., Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury (2006) FASEB J., 20, pp. 2624-2626; Tan, Y., Ichikawa, T., Li, J., Si, Q., Yang, H., Chen, X., Goldblatt, C.S., Cai, L., Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo (2011) Diabetes, 60, pp. 625-633; Shi, Y., Liang, X.C., Zhang, H., Wu, Q.L., Qu, L., Sun, Q., Quercetin protects rat dorsal root ganglion neurons against high glucose-induced injury in vitro through Nrf-2/HO-1 activation and NF-kappaB inhibition (2013) Acta Pharmacol. Sin., 34, pp. 1140-1148; Wang, Y., Sun, W., Du, B., Miao, X., Bai, Y., Xin, Y., Tan, Y., Cai, L., Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB (2013) Am. J. Physiol. Heart Circ. Physiol., 304, pp. H567-H578; Kumar, V., Kumar, S., Hassan, M., Wu, H., Thimmulappa, R.K., Kumar, A., Sharma, S.K., Malhotra, S.V., Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells (2011) J. Med. Chem., 54, pp. 4147-4159; Maier, H.J., Schips, T.G., Wietelmann, A., Kruger, M., Brunner, C., Sauter, M., Klingel, K., Wirth, T., Cardiomyocyte-specific IkappaB kinase (IKK)/NF-kappaB activation induces reversible inflammatory cardiomyopathy and heart failure (2012) Proc. Natl. Acad. Sci. U. S. A., 109, pp. 11794-11799; Liu, Z.W., Zhu, H.T., Chen, K.L., Dong, X., Wei, J., Qiu, C., Xue, J.H., Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy (2013) Cardiovasc. Diabetol., 12, p. 158; Cai, L., Kang, Y.J., Cell death and diabetic cardiomyopathy (2003) Cardiovasc. Toxicol., 3, pp. 219-228; Zhang, Y., Babcock, S.A., Hu, N., Maris, J.R., Wang, H., Ren, J., Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3beta and mitochondrial function (2012) BMC Med., 10, p. 40; El-Seweidy, M.M., Sadik, N.A., Shaker, O.G., Role of sulfurous mineral water and sodium hydrosulfide as potent inhibitors of fibrosis in the heart of diabetic rats (2011) Arch. Biochem. Biophys., 506, pp. 48-57; Dai, Q.M., Lu, J., Liu, N.F., Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor (2011) Chin. Med. J., 124, pp. 89-94; Li, W., Cui, M., Wei, Y., Kong, X., Tang, L., Xu, D., Inhibition of the expression of TGF-beta1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist (2012) Cell. Physiol. Biochem., 30, pp. 749-757; Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises (2007) Mol. Pharm., 4, pp. 807-818; Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., Sleight, P., Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators (2000) N. Engl. J. Med., 342, pp. 154-160; Khaper, N., Bryan, S., Dhingra, S., Singal, R., Bajaj, A., Pathak, C.M., Singal, P.K., Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure (2010) Antioxid. Redox Signal., 13, pp. 1033-1049",Article,Scopus,2-s2.0-84925808679
"Moore M.N.","Do airborne biogenic chemicals interact with the PI3K/Akt/mTOR cell signalling pathway to benefit human health and wellbeing in rural and coastal environments?",2015,"Environmental Research","140",,,"65","75",,,10.1016/j.envres.2015.03.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925597864&partnerID=40&md5=d518a6b60c7472a92e17773cd42c4bd2","European Centre for Environment and oHuman Health (ECEHH), University of Exeter Medical School, Knowledge Spa, Royal Cornwall HospitalTruro, Cornwall, United Kingdom; Department of Science and Innovative Technology (DSIT), University of Eastern PiedmontAlessandria, Italy; Plymouth Marine Laboratory (PML), Prospect PlaceThe Hoe, Plymouth, United Kingdom; School of Biological Sciences, University of Plymouth, Drake's CircusPlymouth, United Kingdom","Moore, M.N., European Centre for Environment and oHuman Health (ECEHH), University of Exeter Medical School, Knowledge Spa, Royal Cornwall HospitalTruro, Cornwall, United Kingdom, Department of Science and Innovative Technology (DSIT), University of Eastern PiedmontAlessandria, Italy, Plymouth Marine Laboratory (PML), Prospect PlaceThe Hoe, Plymouth, United Kingdom, School of Biological Sciences, University of Plymouth, Drake's CircusPlymouth, United Kingdom","Living and taking recreation in rural and coastal environments promote health and wellbeing, although the causal factors involved are unclear. It has been proposed that such environments provide a counter to the stresses of everyday living, leading to enhanced mental and physical health. Living in natural environments will result in airborne exposure to a wide range of biogenic chemicals through inhalation and ingestion of airborne microbiota and particles. The ""biogenics"" hypothesis formulated here is that regular exposure to low concentrations of mixtures of natural compounds and toxins in natural environments confers pleiotropic health benefits by inhibiting the activities of interconnected cell signalling systems, particularly PI3K/Akt/mTORC1. When overactive, Akt and mTOR (mTORC1) can lead to many pathological processes including cancers, diabetes, inflammation, immunosuppression, and neurodegenerative diseases. There is a substantial body of evidence that many natural products (i.e., from bacteria, algae, fungi and higher plants) inhibit the activities of these protein kinases. Other mTOR-related interconnected metabolic control ""switches"" (e.g., PTEN & NF-κB), autophagy and other cytoprotective processes are also affected by natural products.The ""biogenics"" hypothesis formulated here is that regular intermittent exposure to a mixture of airborne biogenic compounds in natural environments confers pleiotropic health benefits by inhibiting activities of the highly interconnected PI3K/Akt/mTORC1 system. It is proposed that future experimental exposures to biogenic aerosols in animal models coupled with epidemiology, should target the activities of the various kinases in the PI3K/Akt/mTORC1 systems and related physiological processes for selected urban, rural and coastal populations in order to test this hypothesis. © 2015 Elsevier Inc.","Autophagy; Cell-signalling; Green-blue space; MTOR; Phytochemicals","Abrahams, P.W., Soils: their implications to human health (2002) Sci. Total Environ., 291, pp. 1-32; Afanas'ev, I., Signaling and damaging functions of free radicals in aging - free radical theory, hormesis, and TOR (2010) Aging Dis., 1, pp. 75-88; Al-awar, R.S., Corbett, T.H., Ray, J.E., Polin, L., Kennedy, J.H., Wagner, M.M., Williams, D.C., Biological evaluation of cryptophycin 52 fragment A analogues: effect of multidrug resistance ATP binding cassette transporters on antitumor activity (2004) Mol. Cancer Ther., 3, pp. 1061-1067; Allen, K.J., Koplin, J.J., Ponsonby, A.L., Gurrin, L.C., Wake, M., Vuillermin, P., Martin, P., Dharmage, S.C., Vitamin D insufficiency is associated with challenge-proven food allergy in infants (2013) J. Allergy Clin. Immunol., 131, pp. 1109-1116; Arafa El-S, Z.Q., Shah, Z.I., Wani, G., Barakat, B.M., Racoma, I., El-Mahdy, M.A., Wani, A.A., Thymoquinione up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells (2011) Mutat. Res., 706, pp. 28-35; Artaxo, P., Hansson, H.-C., Size distribution of biogenic aerosol particles from the Amazon Basin (1995) Atmos. Environ., 29, pp. 393-402; Asnaghi, L., Bruno, P., Pruiulla, M., Nicolin, A., MTOR: a protein kinase switching between life and death (2004) Pharmacol. Res., 50, pp. 545-549; Aspinall, P., Mavros, P., Coyne, R., Roe, J., The urban brain: analysing outdoor physical activity with mobile EEG (2015) Br. J. Sports Med., 49, pp. 272-276; Badadani, M., Autophagy mechanism, regulation, functions and disorders (2012) ISRN Cell Biol., 2012, p. 11. , Article ID 927064; Bahadur, R., Uplinger, T., Russell, L.M., Sive, B.C., Cliff, S.S., Millet, D.B., Goldstein, A., Bates, T.S., Phenol groups in northeastern US submicrometer aerosol particles produced from seawater sources (2010) Environ. Sci. Technol., 44, pp. 2542-2548; Balistreri, C.R., Candore, G., Accardi, G., Colonna-Romano, G., Lio, D., NF-κB pathway activators as potential ageing biomarkers: targets for new therapeutic strategies (2013) Immun. Ageing, 10, p. 24; Ballou, L.M., Lin, R.Z., Rapamycin and mTOR kinase inhibitors (2008) J. Chem. Biol., 1, pp. 27-36; Banerjee, J., Biswas, S., Madhu, N.R., Karmakar, S.R., Biswas, S.J., A better understanding of pharmacological activities and uses of phytochemicals of Lycopodium clavatum: a review (2014) J. Pharmacogn. Phytochem., 3, pp. 207-210; Bassères, D.S., Baldwin, A.S., Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression (2006) Oncogene, 25, pp. 6817-6830; Beckman, C.H., Phenolic-storing cells: keys to programmed cell death and periderm formation in wilt disease resistance and in general defence responses in plants? (2000) Physiol. Mol. Plant Pathol., 57, pp. 101-110; Beevers, C.S., Zhou, H., Huang, S., Hitting the golden TORget: curcumins's effects on mTOR signaling (2013) Anticancer Agents Med. Chem., 13, pp. 988-994; Bennick, A., Interaction of plant polyphenols with salivary proteins (2002) Crit. Rev. Oral Biol. Med., 13, pp. 184-196; Bennett, J.W., Klich, M.A., Mycotoxins (2003) Clin. Microbiol. Rev., 16, pp. 497-516; Berman, M.G., Jonides, J., Kaplan, S., The cognitive benefits of interacting with nature (2008) Psychol. Sci., 19, pp. 1207-1212; Bharate, S.B., Sawant, S.D., Pal Singh, P., Vishwakarma, R.A., Kinase inhibitors of marine origin (2013) Chem. Rev., 113, pp. 6761-6815; Bharate, S.B., Yadav, R.R., Battula, S., Vishwakarma, R.A., Meridianins: marine-derived potent kinase inhibitors (2012) Mini Rev. Med. Chem., 12, pp. 618-631; Blagosklonny, M.V., Hormesis does not make sense except in the light of TOR-driven aging (2011) Aging, 3, pp. 1051-1062; Bode, A.M., Dong, Z., Signal transduction and molecular targets of selected flavonoids (2013) Antioxid. Redox Signal., 19, pp. 163-180; Boopathy, N.S., Kathiresan, K., Anticancer drugs from marine flora: an overview (2010) J. Oncol., 2010, p. 18. , Article ID 214186; Brunekreef, B., Forsberg, B., Epidemiological evidence of effects of coarse airborne particles on health (2005) Eur. Respir. J., 26, pp. 309-318; Buchkovich, N.J., Yu, Y., Zampieri, C.A., Alwine, J.C., The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway (2008) Nat. Rev. Microbiol., 6, pp. 266-275; Campos, M.G.R., Bogdanov, S., de Almeida-Muradian, L.B., Szczesna, T., Mancebo, Y., Frigerio, C., Ferreira, F., Pollen composition and standardisation of analytical methods (2008) J. Apicult. Res. Bee World, 47, pp. 156-163; Carluccio, M.A., Siculella, L., Ancora, M.A., Massaro, M., Scoditti, E., Storelli, C., Visioli, F., De Caterina, R., Olive oil and red wine antioxidant polyphenols inhibit endothelial activation antiatherogenic properties of mediterranean diet phytochemicals (2003) Arterioscler. Thromb. Vasc. Biol., 23, pp. 622-629; Chai, T.-T., Panirchellvum, E., Ong, H.-C., Wong, F.-C., Phenolic contents and antioxidant properties of Stenochlaena palustris, an edible medicinal fern (2012) Bot. Stud., 53, pp. 439-446; Chatterjee, S., Sarkar, S., Bhattacharya, S., Toxic metals and autophagy (2014) Chem. Res. Toxicol., 27, pp. 1887-1900; Chen, W.Q., Xu, B., Mao, J.W., Wei, F.X., Li, M., Liu, T., Xiao-Bao, J., Zhang, L.R., Inhibitory effects of α-pinene on hepatoma carcinoma cell proliferation (2014) Asian Pacific J. Cancer Prev., 15, pp. 3293-3297; Cheng, Y.S., McDonald, J.D., Kracko, D., Irvin, C.M., Zhou, Y., Pierce, R.H., Henry, M.S., Baden, D.G., Concentration and particle size of airborne toxic algae (Brevetoxin) derived from ocean red tide events (2005) Environ. Sci. Technol., 39, pp. 3443-3449; Cheng, Y.S., Zhou, Y., Irvin, C.M., Pierce, R.H., Naar, J., Backer, L.C., Fleming, L.E.K.B., Baden, D.G., Characterization of marine aerosol for assessment of human exposure to brevetoxins (2005) Environ. Health Perspect., 113, pp. 638-643; Cheng, Y.S., Zhou, Y., Irvin, C.M., Kirkpatrick, B., Backer, L.C., Characterization of aerosols containing microcystin (2007) Mar. Drugs, 5, pp. 136-150; Christensen, L.P., Jakobsen, H.B., Paulsen, E., Hodal, L., Andersen, K.E., Airborne Compositae dermatitis: monoterpenes and no parthenolide are released from flowering Tanacetum parthenium (feverfew) plants (1999) Arch. Dermatol. Res., 291, pp. 425-431; Clark, C.D., Zika, R.G., (2000) Marine organic photochemistry: from the sea surface to marine aerosols. In Marine Chemistry - The Handbook of Environmental Chemistry, 5, pp. 1-33. , Springer Berlin, Heidelberg; Cock, I.E., The phytochemistry and chemotherapeutic potential of Tasmannia lanceolata (Tasmanian pepper): a review (2013) Pharmacog. Commun., 3, pp. 1-13; Corradetti, M.N., Guan, K.-L., Upstream of the mammalian target of rapamycin: do all roads pass through mTOR (2006) Oncogene, 25, pp. 6347-6360; Cox, L.M., Yamanishi, S., Sohn, J., Alekseyenko, A.V., Leung, J.M., Cho, I., Kim, S.G., Blaser, M.J., Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences (2014) Cell, 158, pp. 705-721; Cuervo, A.M., Autophagy: in sickness and health (2004) Trends Cell Biol., 14, pp. 70-77; Cunliffe, M., Engel, A., Frka, S., Gašparović, B., Guitart, C., Murrell, J.C., Salter, M., Wurl, O., Sea surface microlayers: a unified physicochemical and biological perspective of the air-ocean interface (2013) Prog. Oceanogr., 109, pp. 104-116; Dadvand, P., de Nazelle, A., Figueras, F., Basagaña, X., Su, J., Amoly, E., Jerrett, M., Nieuwenhuijsen, M.J., Green space, health inequality and pregnancy (2012) Environ. Int., 40, pp. 110-115; D'amato, Urban air pollution and plant-derived respiratory allergy (2000) Clin. Exp. Allergy, 30, pp. 628-636; Dan, H.C., Cooper, M.J., Cogswell, P.C., JP-Y, T., Baldwin, A.S., Akt-dependant regulation of NF-κB is controlled by mTOR and Raptor in association with IKK (2008) Genes Dev., 22, pp. 1490-1500; Davinelli, S., Willcox, D.C., Scapagnini, G., Extending healthy ageing: nutrient sensitive pathway and centenarian population (2012) Immun. Ageing, 9, p. 9; de las Heras, B., Hortelano, S., Molecular basis of the anti-inflammatory effects of terpenoids (2009) Inflamm. Allergy Drug Targets, 8, pp. 28-39; de Magalhães, J.P., Wuttke, D., Wood, S.H., Plank, M., Vora, C., Genome-environment interactions that modulate aging: powerful targets for drug discovery (2011) Pharmacol. Rev., 64, pp. 88-101; De Martino, M.C., van Koetsveld, P.M., Feelders, R.A., Sprij-Mooij, D., Waaijers, M., Lamberts, S.W., de Herder, W.W., Hofland, L.J., The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells (2012) Endocr.-Relat. Cancer, 19, pp. 351-364; de Oliveira, C.B., Comunello, L.N., Maciel, E.S., Giubel, S.R., Bruno, A.N., Chiela, E.C.F., Lenz, G., Gosmann, G., The inhibitory effects of phenolic and terpenoid compounds from Baccharis trimera in Siha cells: differences in their activity and mechanism of action (2013) Molecules, 18, pp. 11022-11032; de Souza, E.C.L., Padrón, A.S., Braga, W.M.O., de Andrde, B.M., Vasiman, M., Nasciutti, L.E., Ferreira, A.C.F., de Carvalho, D.P., MTOR down-regulates iodide uptake in thyrocytes (2010) J. Endocrinol., 206, pp. 113-120; Deeb, D., Gao, X., Dulchavsky, S.A., Gautam, S., CDDO-Me induces apoptosis and inhibits Akt, mTOR and NF-κB signaling proteins in prostate cancer cells (2007) Anticancer Res., 27, pp. 3035-3044; Delmas, D., Solary, E., Latruffe, N., Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe (2011) Curr. Med. Chem., 18, pp. 1100-1121; Del Rio, D., Rodriguez-Mateos, A., Spencer, J.P., Tognolini, M., Borges, G., Crozier, A., Dietary (poly) phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases (2013) Antiox. Redox Signal., 18, pp. 1818-1892; Depledge, M.H., Harvey, A.J., Brownlee, C., Frost, M., Moore, M.N., Fleming, L.E., Changing views of the interconnections between the oceans and human health in Europe (2013) Microbial. Ecol., 65, pp. 852-859; Després, V.R., Huffman, J.A., Burrows, S.M., Hoose, C., Safatov, A.S., Buryak, G., Fröhlich-Nowoisky, J., Jaenicke, R., Primary biological aerosol particles in the atmosphere: a review (2012) Tellus B, 64, p. 015598; Dreyer, H.C., Fujita, S., Cadenas, J.G., Chinkes, D.L., Volpi, E., Rasmussen, B.B., Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle (2006) J. Physiol., 576, pp. 613-624; Duke, S.O., Phytochemical phytotoxins and hormesis - a commentary (2011) Dose-Response, 9, pp. 76-78; Dungan, R.S., Airborne endotoxin from indoor and outdoor environments: effect of sample dilution on the kinetic Limulus amebocyte lysate (LAL) assay (2011) J. Occup. Environ. Hyg., 8, pp. 147-153; Eskelinen, E.-L., Saftig, P., Autophagy: a lysosomal degradation pathway with a central role in health and disease (2009) Biochim. Biophys. Acta - Mol. Cell Res., 1793, pp. 4664-4673; Farmer, E.A., Ryan, C.A., Interplant communication: airborne methyl jasmonate induces synthesis of proteinase inhibitors in plant leaves (1990) Proc. Natl. Acad. Sci. USA, 87, pp. 7713-7716; Farrand, L., Oh, S.-W., Song, Y.S., Tsang, B.K., Phytochemicals: a multitargeted approach to gynecologic cancer therapy (2014) BioMed. Res. Int., , 2014, 10 pages, 10.1155/2014/890141, Article ID 890141; Ferrari, N., Tosetti, F., De Flora, S., Donatelli, F., Sogno, I., Noonan, D.M., Albini, A., Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention (2011) Curr. Drug Targets, 12, pp. 1909-1924; Fischer, G., Dott, W., Relevance of airborne fungi and their secondary metabolites for environmental occupational and indoor hygiene (2003) Arch. Microbiol., 179, pp. 75-82; Fleming, L.E., Backer, L.C., Baden, D.G., Overview of aerolosized Florida red tide toxins: exposures and effects (2005) Environ. Health Perspect., 113, pp. 618-620; Fleming, L.E., Kirkpatrick, B., Backer, L.C., Bean, J.A., Wanner, A., Reich, A., Zaias, J., Baden, D.G., Aerosolized red tide toxins (brevetoxins) and asthma (2007) Chest, 131, pp. 187-194; Fleming, L.E., McDonough, N., Austen, M., Mee, L., Moore, M., Hess, P., Depledge, M.H., Smalley, A., Oceans and Human Health: a rising tide of challenges and opportunities for Europe (2014) Mar. Environ. Res., 99, pp. 16-19; Fontana, L., Partridge, L., Longo, V.D., Extending healthy life span - from yeast to humans (2010) Science, 328, pp. 321-326; Frohlich-Nowoisky, J., Pickersgill, D.A., Després, V.R., Poschl, U., High diversity of fungi in air particulate matter (2009) Proc. Natl. Acad. Sci., 106, pp. 12814-12819; Frumkin, H., Beyond toxicity: human health and the natural environment (2001) Am. J. Prev. Med., 20, pp. 234-240; Gantar, M., Dhandaayuthapani, S., Rathinavelu, A., Phycocyanin induces apoptosis and enhances the effect of topecan on prostate cell line LNCaP (2012) J. Med. Food, 15, pp. 1091-1095; Gerriets, V.A., Rathmell, J.C., Metabolic pathways in T cell fate and function (2012) Trends Immunol., 33, pp. 168-173; Gerssen, A., van Olst, E.H., Mulder, P.P., de Boer, J., In-house validation of a liquid chromatography tandem mass spectrometry method for the analysis of lipophilic marine toxins in shellfish using matrix-matched calibration (2010) Anal. Bioanal. Chem., 397, pp. 3079-3088; Ghoshal, K.P., Saoji, A.A., Phytochemical screening of the pollen of some selected plants with antidiabetic properties (2013) Aust. J. Basic Appl. Sci., 7, pp. 105-109; Goufo, P., Trindade, H., Rice antioxidants: phenolic acids, flavonoids, anthocyanins, proanthocyanidins, tocopherols, tocotrienols, c-oryzanol, and phytic acid (2014) Food Sci. Nutr., 2, pp. 75-104; Graham, B., Guyon, P., Maenhaut, W., Taylor, P.E., Ebert, M., Matthias-Maser, S., Mayol-Bracero, O.L., Andreae, M.O., Composition and diurnal variability of the natural Amazonian aerosol (2003) J. Geophys. Res., 108 (D24), p. 4765; Griffin, D.W., Donaldson, K.A., Paul, J.H., Rose, J.B., Pathogenic human viruses in coastal waters (2003) Clin. Microbiol. Rev., 16, pp. 129-143; Halliwell, B., The wanderings of a free radical (2009) Free Radic. Biol. Med., 46, pp. 531-542; Harries, L.W., Fellows, A.D., Pilling, L.C., Hernandez, D., Singleton, A., Bandinelli, S., Guralnik, J., Melzer, D., Advancing age is associated with gene expression changes resembling mTOR inhibition: evidence from two human populations (2012) Mech. Ageing Dev., 133, pp. 556-562; Hau, A.M., Greenwood, J.A., Lohr, C.V., Serrill, J.D., Proteau, P.J., Ganley, I.G., McPhail, K.L., Ishmael, J.E., Coibamide A induces mTOR-independent autophagy and cell death in human glioblastoma cells (2013) PLoS One, 8 (6), p. e65250; Hippert, M.M., O'Toole, P.S., Thorburn, A., Autophagy in cancer: good, bad, or both? (2006) Cancer Res., 66, pp. 9349-9351; Hooper, P.L., Hooper, P.L., Tytell, M., Vigh, L., Xenohormesis: health benefits from an eon of plant stress response evolution (2010) Cell Stress Chaperones, 15, pp. 761-770; Huang, H.-C., Syu, K.-Y., Lin, J.-K., Chemical composition of Solanum nigrum Linn extract and induction of autophagy by leaf water extract and its major flavonoids in AU565 breast cancer cells (2010) J. Agric. Food Chem., 58, pp. 8699-8708; Huang, R.-J., Thorenz, U.R., Kundel, M., Venables, D.S., Ceburnis, D., Ho, F.F., Chen, J., Hoffmann, T., The seaweeds Fucus vesiculosis and Ascophyllum nodosum are significant contributors to coastal iodine emissions (2013) Atmos. Chem. Phys., 13, pp. 5255-5264; Hurd, L., Bee pollen: top rank antioxidant (2003) Total Health, 24, pp. 40-42; Ibañez, E., Herrero, M., Mendiola, J.A., Castro-Puyana, M., Extraction and characterization of bioactive compounds with health benefits from marine resources: macro and micro algae, cyanobacteria, and invertebrates (2012) Marine bioactive compounds: sources, characterization and applications, p. 2012. , © Springer Science+Business Media, LLC, M. Hayes (Ed.); Inglés, M., Gambini, J., Miguel, M.G., Bonet-Costa, V., Abdelaziz, K.M., El Alami, M., Viña, J., Borrás, C., PTEN mediates the antioxidant effect of resveratrol at nutritionally relevant concentrations (2014), http://dx.doi.org/10.1155/2014/580852, BioMed. Res. Int., 2014, 6 pages, Article ID 580852Jeong, Y.-T., Kim, Y.D., Jung, Y.-M., Park, D.-C., Lee, D.-S., Ku, S.-K., Li, X., Chang, H.W., Low molecular weight fucoidan (LMWF) improves ER stress-reduced insulin sensitivity through AMPK activation in L6 myotubes and restores lipid homeostasis in a mouse model of type 2 diabetes (2013) Mol. Pharmacol., 84, pp. 147-157; Johnson, S.M., Gulhati, P., Arrieta, I., Wang, X., Uchida, T., Gao, T., Evers, B.M., Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signalling (2009) Anticancer Res., 29, pp. 3185-3190; Jones, A.M., Harrison, R.M., The effects of meteorological factors on atmospheric bioaerosol concentrations - a review (2004) Sci. Total Environ., 326, pp. 151-180; Kaur, R., Kumar, N.R., Harjai, K., Phytochemical analysis of different extracts of bee pollen (2013) Int. J. Pharm. Biol. Res., 4, pp. 65-68; Kelsey, R.G., Stevenson, T.T., Scholl, J.P., Watson, T.J., Shafizadeh, F., The Chemical Composition of the Litter and Soil in a Community of Artemisia tridentata sspVaseyana (1978) Biochem. Syst. Ecol., 6, pp. 193-200; Kennedy, D.O., Wightman, E.L., Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function (2011) Adv. Nutr., 2, pp. 32-50; Khan, N., Afaq, F., Saleem, M., Ahmad, N., Mukhtar, H., Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate (2006) Cancer Res., 66, pp. 2500-2505; Kim, M.K., Suh, D.H., Seoung, J., Kim, H.S., Chung, H.H., Song, Y.S., Autophagy as a target for anticancer therapy and its modulation by phytochemicals (2012) J. Food Drug Anal., 20, pp. S241-S245; Kim, S.J., Cho, A.R., Han, J., Antioxidant and antimicrobial activities of leafy green vegetable extracts and their applications to meat product preservation (2013) Food Control, 29, pp. 112-120; Klionsky, D.J., Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes (2007) Autophagy, 4, pp. 1-25; Kong, D., Zhang, Y., Yamori, T., Duan, H., Jin, M., Inhibitory activity of flavonoids against Class I phosphatidylinositol 3-kinase isoforms (2011) Molecules, 16, pp. 5159-5167; Korsnes, M.S., Yessotoxin as a tool to study induction of multiple cell death pathways (2012) Toxins, 4, pp. 568-579; Kourtchev, I., Fuller, S., Aalto, J., Ruuskanen, T.M., McLeod, M.W., Maenhaut, W., Jones, R., Kalberer, M., Molecular composition of boreal forest aerosol from Hyytiälä, Finland, using ultrahigh resolution mass spectrometry (2013) Environ. Sci. Technol., 47, pp. 4069-4079; Kraft, C., Peter, M., Hofmann, K., Selective autophagy: ubiquitin-mediated recognition and beyond (2010) Nature Cell Biol., 12, pp. 836-841; Krajcsi, P., Wold, W.S.M., Viral proteins that regulate cell signalling (1998) J. Gen. Virol., 79, pp. 1323-1335; Krivácsy, Z., Kiss, G., Ceburnis, D., Jennings, G., Maenhaut, W., Salma, I., Shooter, D., Study of water-soluble atmospheric humic matter in urban and marine environments (2008) Atmos. Res., 87, pp. 1-12; Kroll, J.H., Seinfeld, J.H., Chemistry of secondary organic aerosol: Formation and evolution of low-volatility organics in the atmosphere (2008) Atmos. Environ., 42, pp. 3593-3624; Kuiter, A.T., Denneman, C.A.J., Water-soluble phenolic substances in soils under several coniferous and deciduous tree species (1987) Soil Biol. Biochem., 19, pp. 765-776; Kulmala, M., Hämeri, K., Aalto, P.P., Mäkelä, J.M., Pirjola, L., Nilsson, E.D., Buzorius, G., O'Do, C.D., Overview of the international project on biogenic aerosol formation in the boreal forest (BIOFOR) (2001) Tellus B, 53, pp. 324-343; Kusuhara, M., Urakami, K., Masuda, Y., Zangiacomi, V., Ishii, H., Tai, S., Maruyama, K., Yamaguchi, K., Fragrant environment with α-pinene decreases tumor growth in mice (2012) Biomed. Res., 33, pp. 57-61; Lamb, C.A., Yoshimori, T., Tooze, S.A., The autophagosome: origins unknown, biogenesis complex (2013) Nat. Rev. Mol. Cell Biol., 14, pp. 759-774; Lamming, D.W., Ye, L., Sabatini, D.M., Baur, J.A., Rapalogs and mTOR inhibitors as anti-aging therapeutics (2013) J. Clin. Invest., 123, pp. 980-989; Laplante, M., Sabatini, D.M., MTOR signaling at a glance (2009) J. Cell Sci., 122, pp. 3589-3594; Laplante, M., Sabatini, D.M., MTOR signaling in growth control and disease (2012) Cell, 149, pp. 274-293; Lee, H., Kim, J.-S., Kim, E., Fucoidan and seaweed Fucus vesiculosis inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways (2012) PLoS One, 7 (11), p. e50624; Lee, P.-S., Wilhelmson, A.S.K., Hubner, A.P., Reynolds, S.B., Gallachi, D.A., Chiou, T.T., Kwiatkowski, D.J., MTORC1-S6K activation by endotoxin contributes to cytokine up-regulation and early lethality in animals (2010) PloS One, 5 (12), p. e14399; Levine, B., Kroemer, G., Autophagy in the pathogenesis of disease (2008) Cell, 132, pp. 27-42; Lippmann, M., Yeates, D.B., Albert, R.E., Deposition, retention, and clearance of inhaled particles (1980) Br. J. Ind. Med., 37, pp. 337-362; Lisse, T.S., Hewison, M., Vitamin d-a new player in the world of mTOR signalling (2011) Cell Cycle, 10, pp. 1888-11889; Maas, J., Verheij, R.A., Groenewegen, P.P., de Vries, S., Spreeuwenberg, P., Green space, urbanity, and health: how strong is the relation? (2006) J. Epidemiol. Commun. Health, 60, pp. 587-592; Madrid, L.V., Mayo, M.W., Renther, J.Y., Baldwin, A.S., Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappaB through utilization of the I kappa B kinase and activation of the mitogen activated protein kinase p38 (2001) J. Biol. Chem., 276, pp. 18934-18940; Malloy, C.D., Marr, J.S., Mycotoxins and public health: a review (1997) J. Public Health Manag. Pract., 3, pp. 61-69; Markman, B., Dienstmann, R., Tabernero, J., Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs (2010) Oncotarget, 1, pp. 530-543; Martin, S., Saha, B., Riley, J.L., The battle over mTOR: an emerging theatre in host-pathogen immunity (2012) PLoS Pathog., 8 (9), p. e1002894; Martins, I., Galluzzi, L., Kroemer, G., Hormesis, cell death and aging (2011) Aging, 3, pp. 821-828; Matricardi, P.M., Rosmini, F., Riondino, S., Fortini, M., Ferrigno, L., Rapicetta, M., Bonini, S., Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study (2000) Br. Med. J., 320, pp. 412-417; Matsunaga, S.N., Chatani, S., Nakatsuka, S., Kusumoto, D., Kubota, K., Utsumi, Y., Enoki, T., Hiura, T., Volatile diterpene emission from dominant conifers in Japan (2011) Biogeosci. Disc., 8, pp. 6681-6700; Matthias-Maser, S., Obolkin, V., Khodzer, T., Jaenicke, R., Seasonal variation of primary biological aerosol particles in the remote continental region of Lake Baikal/Siberia (2000) Atmos. Environ., 34, pp. 3805-3811; Mattson, M.P., Hormesis defined (2008) Ageing Res. Rev., 7, pp. 1-7; Mattson, M.P., Wan, R., Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems (2005) J. Nutr. Biochem., 16, pp. 129-137; Menendez, J.A., Joven, J., Aragonès, G., Barrajón-Catalán, E., Beltrán-Debón, R., Borrás-Linares, I., Campos, J., Segura-Carretero, A., Xenohormetic and anti-ageing activity of secoiridoid polyphenols present in extra virgin olive oil (2013) Cell Cycle, 12, pp. 555-578; Mestre, M.B., Colombo, M.I., Autophagy and toxins: a matter of life or death (2013) Curr. Mol. Med., 13, pp. 241-251; Mizushima, N., Levine, B., Cuervo, A.M., Klionsky, D.J., Autophagy fights disease through cellular self-digestion (2008) Nature, 451, pp. 1069-1075; Mitchell, R., Popham, F., Effect of exposure to natural environment on health inequalities: an observational population study (2008) Lancet, 372, pp. 1655-1660; Møller, M.T.N., Samari, H.R., Seglen, P.O., Toxin-induced tail phosphorylation of hepatocellular S6 kinase: evidence for a dual involvement of the AMP-activated protein kinase in S6 kinase regulation (2004) Toxicol. Sci., 82, pp. 628-637; Moore, M.N., Autophagy as a second level protective process in conferring resistance to environmentally-induced oxidative stress (2008) Autophagy, 4, pp. 254-256; Moore, M.N., Stebbing, A.R.D., The quantitative cytochemical effects of three metal ions on a lysosomal hydrolase of a hydroid (1976) J. Mar. Biol. Assoc. UK, 56, pp. 995-1005; Moore, M.N., Depledge, M.H., Fleming, L., Hess, P., Lees, D., Leonard, P., Madsen, L., Viarengo, A., Oceans and human health (OHH): a European perspective from the Marine Board of the European Science Foundation (Marine Board-ESF) (2013) Microbial. Ecol., 65, pp. 889-900; Moore, M.N., Depledge, M.H., Fleming, L., Hess, P., Lees, D., Leonard, P., Madsen, L., Viarengo, A., (2014) Linking oceans & human health: a strategic research priority for Europe. Position Paper 19, p. 111. , European Marine Board, Ostend, Belgium; Moore, M.N., Koehler, A., Lowe, D., Viarengo, A., Lysosomes and autophagy in aquatic animals (2008) Methods in Enzymology, 451, pp. 582-620. , Academic Press/Elsevier, Burlington; Moore, M.N., Viarengo, A., Donkin, P., Hawkins, A.J.S., Autophagic and lysosomal reactions to stress in the hepatopancreas of blue mussels (2007) Aquat. Toxicol., 84, pp. 80-91; Munday, R., Is protein phosphatase inhibition responsible for the toxic effects of okadaic acid in animals (2013) Toxins, 5, pp. 267-285; Murakami, A., Modulation of protein quality control systems by food phytochemicals (2013) J. Clin. Biochem. Nutr., 52, pp. 215-227; Nacarelli, T., Azar, A., Sell, C., Inhibition of mTOR prevents ROS production initiated by ethidium bromide-induced mitochondrial DNA depletion (2014) Front. Endocrinol., 5, pp. 122-130; Nagle, D.G., Zhou, Y.-D., Marine natural products as inhibitors of hypoxic signalling in tumors (2009) Phytochem. Rev., 8, pp. 415-429; Nam, N.H., Naturally occurring NF-kappaB inhibitors (2006) Mini Rev. Med. Chem., 6, pp. 945-951; O'Dowd, C.D., de Leeuw, G., Marine aerosol production: a review of the current knowledge (2007) Phil. Trans. R. Soc. A, 365, pp. 1753-1774; Okuda, M., Ohkubo, K., Gotoh, M., Hiroshima, K., Ishida, Y., Hori, K., Dynamics of airborne pollen particles from inhalation to allergic reaction in the nose (2005) Rhinology, 43, pp. 29-33; Ong, T., Wong, W.-Z., Stewart, J.D., Brockman, H.E., Chlorophyllin: a potent antimutagen against environmental and dietary complex mixture (1986) Mutat. Res., 173, pp. 111-115; Ong, T., Brockman, H.E., Whong, W.-Z., Chlorophyllin: an antigenotoxic agent (1994), 546, pp. 272-281. , Food Phytochemicals for Cancer Prevention, ACS Symposium Series(Chapter 22)Ozkan, A., Sen, H.M., Sehitoglu, I., Alacam, H., Guven, M., Aras, A.B., Akman, T., Karaman, H.I., Neuroprotective effect of humic acid on focal cerebral ischemia injury: an experimental study in rats (2015) Inflamm, 38, pp. 32-39; Pandey, K.B., Rizvi, S.I., Plant polyphenols as dietary antioxidants in human health and disease (2009) Oxid. Med. Cell. Longev., 2, pp. 270-278; Paré, P.W., Tumlinson, J.H., Plant volatiles as a defense against insect herbivores (1999) Plant Physiol., 121, pp. 325-332; Park, B.-J., Tsunetsugu, Y., Kasetani, T., Hirano, H., Kagawa, T., Sato, M., Miyazaki, Y., Physiological effects of Shinrin-yoku (taking in the atmosphere of the forest) - using salivary cortisol and cerebral activity as indicators (2007) J. Physiol. Anthropol., 26, pp. 123-128; Park, B.-J., Tsunetsugu, Y., Kasetani, T., Hirano, H., Kagawa, T., Sato, M., Miyazaki, Y., The physiological effects of Shinrin-yoku (taking in the forest atmosphere or forest bathing): evidence from field experiments in 24 forests across Japan (2010) Environ. Health Prev. Med., 15, pp. 18-26; Park, H.S., Kim, S.R., Kim, J.O., Lee, Y.C., The roles of phytochemicals in bronchial asthma (2010) Molecules, 1510, pp. 6810-6834; SHS, P., Cheetham, T.D., Diagnosis and management of vitamin D deficiency (2010) Br. Med. J., 340, pp. 142-147; Pierce, R.H., Red tide (Ptychodiscus brevis) toxin aerosols: a review (1986) Toxicon, 24, pp. 955-965; Pierce, R.H., Henry, M.S., Higham, C.J., Blum, P., Sengco, M.R., Anderson, D.M., Removal of harmful algal cells (Karenia brevis) and toxins from seawater culture by clay flocculation (2004) Harmful Algae, 3, pp. 141-148; Postolache, T.T., Lapidus, M., Sander, E.R., Langenberg, P., Hamilton, R.G., Soriano, J.J., McDonald, N.F., Tonelli, L.H., Changes in allergy symptoms and depression scores are positively correlated in patients with recurrent mood disorders exposed to seasonal peaks in aeroallergens (2007) Sci. World J., 7, pp. 1968-1977; Pott, F., Stobert, W., Carcinogenicity of airborne combustion products observed in subcutaneous tissue and lungs of laboratory rodents (1983) Environ. Health Perspect., 47, pp. 293-303; Rahman, I., Biswas, S.K., Kirkham, P.A., Regulation of inflammation and redox signaling by dietary polyphenols (2006) Biochem. Pharmacol., 72, pp. 1439-1452; Ramos, S., Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways (2008) Mol. Nutr. Food Res., 52, pp. 507-526; Reemtsma, T., Quintana, J.B., Rodil, R., García-López, M., Rodríguez, I., Organophosphorus flame retardants and plasticizers in water and air I. Occurrence and fate (2008) TrAC, 27, pp. 727-737; Rogge, W.F., Hildemann, L.M., Mazurek, M.A., Cass, G.R., Quantification of urban organic aerosols at a molecular level"" identification, abundance and seasonal variation (1993) Atmos. Environ., 27 A, pp. 1309-1330; Rogge, W.F., Hildemann, L.M., Mazurek, M.A., Cass, G.R., Simoneit, B.R.T., Sources of fine organic aerosol. 3. Road dust, tire debris, and organometallic brake lining dust: roads as sources and sinks (1993) Environ. Sci. Technol., 27, pp. 1892-1904; Rogge, W.F., Hildemann, L.M., Mazurek, M.A., Cass, G.R., Simoneit, B.R.T., Sources of fine organic aerosol. 4. Particulate abrasion products from leaf surfaces of urban plants (1993) Environ. Sci. Technol., 27, pp. 2700-2711; Rook, G.A., Regulation of the immune system by biodiversity from the natural environment: an ecosystem service essential to health (2013) Proc. Natl. Acad. Sci., 110, pp. 18360-18367; Rubinsztein, D.C., Mariño, G., Guido Kroemer, G., Autophagy and aging (2011) Cell, 146, pp. 682-695; Russell, P.B., Bergstrom, R.W., Shinozuka, Y., Clarke, A.D., DeCarlo, P.F., Jimenez, J.L., Livingston, J.M., Strawa, A., Absorption Angstrom Exponent in AERONET and related data as an indicator of aerosol composition (2010) Atmos. Chem. Phys., 10, pp. 1155-1169; Russo, R., Cassiano, M.G.V., Ciociaro, A., Adornetto, A., Varano, G.P., Chiappini, C., Berliocchi, L., Corasaniti, M.T., Role of d-limonene in autophagy induced by bergamot essential oil in SH-SY5Y neuroblastoma cells (2014) PloS One, 9, p. e113682; Sabatini, D.M., MTOR and cancer: insights into a complex relationship (2006) Nat. Rev. Cancer, 6, pp. 729-734; Salminen, A., Kaarniranta, K., SIRT1: regulation of longevity via autophagy (2009) Cell. Signal., 21, pp. 1356-1360; Salminen, A., Kaarniranta, K., NF-κB signalling in the aging process (2009) J. Clin. Immunol., 29, pp. 397-405; Salminen, A., Kaarniranta, K., Genetics vs. entropy: longevity factors suppress the NF-κB-driven entropic aging process (2010) Ageing Res. Rev., 9, pp. 298-314; Salminen, A., Lehtonen, M., Suuronen, T., Kaarniranta, K., Huuskonen, J., Terpenoids: natural inhibitors of NF-κB signaling with anti-inflammatory and anti-cancer potential (2008) Cell. Mol. Life Sci., 65, pp. 2979-2999; Salminen, A., Hyttinen, J.M.T., Kauppinen, A., Kaarniranta, K., Context-dependent regulation of autophagy by IKK - NF-κB signaling: impact on the aging process (2012) Int. J. Cell Biol., 2012, p. 15. , Article ID 849541; Sandifer, P.A., Sutton-Grier, A.E., Ward, B.P., Exploring connections among nature, biodiversity, ecosystem services, and human health and well-being: Opportunities to enhance health and biodiversity conservation (2015) Ecosyst. Serv., 12, pp. 1-15; Sarojini, Y., Laksshminarayana, K., Rao, P.S., Variations in distribution of flavonoids in some seaweed of Visakhapatnam coast of India (2012) Der. Pharma Chem., 4, pp. 1481-1484; SarrafZadegan, N., AminiNik, S., Blood pressure pattern in urban and rural areas in Isfahan, Iran (1997) J. Human Hypertens., 11, pp. 425-428; Seedorf, H., Griffin, N.W., Ridaura, V.K., Ridaura, V.K., Reyes, A., Cheng, J., Rey, F.E., Gordon, J.I., Bacteria from diverse habitats colonise and compete in the mouse gut (2014) Cell, 159, pp. 253-266; Selvakumaran, M., Amaravadi, R.K., Vasilevskaya, I.A., O'Dwyer, P.J., Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy (2013) Cancer Res., 19, pp. 2995-3007; Scherz-Shouval, R., Elazar, Z., Regulation of autophagy by ROS: physiology and pathology (2011) Trends Biochem. Sci., 36, pp. 30-38; Shapiro, K., Krusor, C., Mazzillo, F.F., Conrad, P.A., Largier, J.L., Mazet, J.A., Silver, M.W., Aquatic polymers can drive pathogen transmission in coastal ecosystems (2014) Proc. R. Soc. B: Biol. Sci., 281 (1795), p. 20141287; Shelton, B.G., Kirkland, K.H., Flanders, W.D., Morris, G.K., Profiles of airborne fungi in buildings and outdoor environments in the United States (2002) Appl. Environ. Microbiol, 68, pp. 1743-1753; Skaug, M.A., Helland, I., Solvoll, K., Saugstad, O.D., Presence of ochratoxin A in human milk in relation to dietary intake. (2001) Food Addit. Contam., 18, pp. 321-327; Smillie, C.S., Smith, M.B., Friedman, J., Cordero, O.X., David, L.A., Alm, E.J., Ecology drives a global network of gene exchange connecting the human microbiome (2011) Nature, 480, pp. 241-244; Son, Y.S., Lim, B.A., Park, H.J., Kim, J.C., Characteristics of volatile organic compounds (VOCs) emitted from building materials to improve indoor air quality: focused on natural VOCs (2013) Air Qual. Atmos. Health, 6, pp. 737-746; Stanley, R.G., Linskins, H.F., (1974) Pollen: Biology, Chemistry and Management, , Springer-Verlag, Berlin; Steelman, L.S., Chappell, W.H., Abrams, S.L., Kempf, R.C., Long, J., Laidler, P., Mijatovic, S., McCubrey, J.A., Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging (2011) Aging, 3, pp. 192-222; Stegelmeier, B.L., Edgar, J.A., Colegate, S.M., Gardner, D.R., Schoch, T.K., Coulombe, R.A., Molyneux, R.J., Pyrrolizidine alkaloid plants, metabolism and toxicity (1999) J. Nat. Toxins, 8, pp. 95-116; Steward, G.F., Culley, A.I., Mueller, J.A., Wood-Charlson, E.M., Belcaid, M., Poisson, G., Are we missing half of the viruses in the ocean? (2013) ISME J., 7, pp. 672-679; Sundin, T., Hentosh, P., InTERTesting association between telomerase, mTOR and phytochemicals (2012) Exp. Rev. Mol. Med., 14, p. e8; Syed, D.N., Adhami, V.M., Khan, M.I., Mukhtar, H., Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin (2013) Anti-Cancer Agents Med. Chem., 13, pp. 995-1001; Tan, H.K., Moad, A.I.H., Tan, M.L., The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals (2014) Asian Pac.ific J. Cancer Prev., 15, pp. 6463-6475; Thoppil, R.J., Bishayee, A., Terpenoids as potential chemopreventive and therapeutic agents in liver cancer (2011) World J. Hepatol., 27, pp. 228-249; Trocoli, A., Djavaheri-Mergny, M., The complex interplay between autophagy and NF-κB signalling pathways in cancer cells (2011) Am. J. Cancer Res., 1, pp. 629-649; Tsunetsugu, Y., Park, B.J., Miyazaki, Y., Trends in research related to ""Shinrin-yoku"" (taking in the forest atmosphere or forest bathing) in Japan (2010) Environ. Health Prev. Med., 15, pp. 27-37; Van Aller, G.S., Carson, J.D., Tang, W., Peng, H., Zhao, L., Copeland, R.A., Tummino, P.J., Luo, L., Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor (2011) Biochem. Biophys. Res. Commun., 406, pp. 194-199; van Strien, R.T., Engel, R., Holst, O., Bufe, A., Eder, W., Waser, M., Braun-Fahrländer, C., von Mutius, E., Microbial exposure of rural school children, as assessed by levels of N-acetyl-muramic acid in mattress dust, and its association with respiratory health (2004) J. Allergy Clin. Immunol., 113, pp. 860-867. , ALEX Study Team; Verrault, D., Moineau, S., Duchaine, C., Methods for sampling airborne viruses (2008) Microbiol. Mol. Biol. Rev., 72, pp. 413-444; von Roemeling, C.A., Marlow, L.A., Kennedy, W.P., Kennedy, G.T., Copland, J.A., Menefee, M.E., Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma (2013) Am. J. Cancer Res., 3, pp. 390-401; Wang, D.Z., Neurotoxins from marine dinoflagellates: a brief review (2008) Mar. Drugs, 6, pp. 349-371; Wang, P., Liu, Z., Liu, X., Teng, H., Zhang, C., Hou, L., Zou, X., Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells (2014) PLoS One, 9 (8), p. e106071; Wang, S., Liu, Z., Wang, L., Zhang, X., NF-κB signalling pathway, inflammation and colorectal cancer (2009) Cell. Mol. Immunol., 6, pp. 327-334; Weijenberg, M.P., Hughes, L.A., Bours, M.J., Simons, C.C., van Engeland, M., van den Brandt, P.A., The mTOR pathway and the role of energy balance throughout life in colorectal cancer etiology and prognosis: unravelling mechanisms through a multidimensional molecular epidemiologic approach (2013) Curr. Nutr. Rep., 2, pp. 19-26; Wheeler, B.W., White, M., Stahl-Timmins, W., Depledge, M.H., Does living by the coast improve health and wellbeing (2012) Health Place, 18, pp. 1198-1201; White, M., Smith, A., Humphryes, K., Pahl, S., Snelling, D., Depledge, M., Blue space: the importance of water for preference, affect, and restorativeness ratings of natural and built scenes (2010) J. Environ. Psychol., 30, pp. 482-493; White, M., Alcock, I., Wheeler, B.W., Depledge, M., Coastal proximity, health and well-being: results from a longitudinal panel survey (2013) Health Place, 23, pp. 97-103; White, M.P., Wheeler, B.W., Herbert, S., Alcock, I., Depledge, M.H., Coastal proximity and physical activity: is the coast an under-appreciated public health resource? (2014) Prev. Med., 69, pp. 135-140; Whon, T.W., Kim, M.-S., Roh, S.W., Shin, N.-R., Lee, H.-W., Bae, J.-W., Metagenomic characterization of airborne viral DNA diversity in the near-surface atmosphere (2012) J. Virol., 86, pp. 8211-8231; Wilhelm, S.W., Suttle, C.A., Viruses and nutrient cycles in the Sea: viruses play critical roles in the structure and function of aquatic food webs (1999) BioScience, 49, pp. 781-788; Williams, J.V., Inhalation and skin tests with extracts of hay and fungi in patients with farmer's lung (1963) Thorax, 18, pp. 182-196; Williamson, S.J., Rusch, D.B., Yooseph, S., Halpern, A.L., Heidelberg, K.B., Glass, J.I., Andrews-Pfannkoch, C., Venter, J.C., The Sorcerer II global ocean sampling expedition: metagenomic characterization of viruses within aquatic microbial samples (2008) PLoS One, 23 (1), p. e1456. , 3; Wilson, E.O., (1984) Biophilia, , Harvard University Press, Cambridge, Mass; Womiloju, T.O., Miller, J.D., Mayer, P.M., Brook, J.R., Methods to determine the biological composition of particulate matter collected from outdoor air (2003) Atmos. Environ., 37, pp. 4335-4344; Wu, S., Sun, J., Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection (2011) Discov. Med., 11, pp. 325-335; Xie, H., Lee, M.H., Zhu, F., Reddy, K., Huang, Z., Kim, D.J., Li, Y., Dong, Z., Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo (2013) Mol. Cancer Ther., 12, pp. 958-959; Zhang, X., Chen, L.X., Ouyang, L., Cheng, Y., Liu, B., Plant natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents (2012) Cell Prolif., 45, pp. 466-476; Zhang, Y.-J., Duan, Y., Zheng, X.F.S., Targeting the mTOR kinase domain: the second generation of mTOR inhibitors (2011) Drug Discov. Today, 16, pp. 325-331; Zhou, H., Luo, Y., Huang, S., Updates on mTOR inhibitors (2010) Anticancer Agents Med. Chem., 10, pp. 571-581",Review,Scopus,2-s2.0-84925597864
"Forino M., Tenore G.C., Tartaglione L., Carmela D., Novellino E., Ciminiello P.","(1S,3R,4S,5R)5-O-Caffeoylquinic acid: Isolation, stereo-structure characterization and biological activity",2015,"Food Chemistry","178",,,"306","310",,,10.1016/j.foodchem.2015.01.109,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922272913&partnerID=40&md5=eb6e5e9c7b5b87f30b6f938be11e68ae","Department of Pharmacy, University of Napoli Federico II, via D. Montesano 49Napoli, Italy","Forino, M., Department of Pharmacy, University of Napoli Federico II, via D. Montesano 49Napoli, Italy; Tenore, G.C., Department of Pharmacy, University of Napoli Federico II, via D. Montesano 49Napoli, Italy; Tartaglione, L., Department of Pharmacy, University of Napoli Federico II, via D. Montesano 49Napoli, Italy; Carmela, D., Department of Pharmacy, University of Napoli Federico II, via D. Montesano 49Napoli, Italy; Novellino, E., Department of Pharmacy, University of Napoli Federico II, via D. Montesano 49Napoli, Italy; Ciminiello, P., Department of Pharmacy, University of Napoli Federico II, via D. Montesano 49Napoli, Italy","Sorbus domestica fruits (sorbs) are commonly harvested and consumed for their nutritious qualities and have long been used as natural remedy against diabetes in the popular medicine. Recently, sorbs have been described as sources of antioxidant compounds including polyphenols. Chemical analyses carried out on sorbs collected in Southern Italy have led to the isolation of a chlorogenic acid isomer as the main antioxidant compound contained in the fruit butanol extract. NMR studies have identified the isolated compound as (1S,3R,4S,5R)5-O-Caffeoylquinic acid. In comparison to chlorogenic acid, the isolated isomer features an inverted configuration at C4. Such configurational inversion causes the chlorogenic acid stereoisomer acid to assume a preferential conformation remarkably different from that of chlorogenic acid. This seems to account for the enhanced potency of (1S,3R,4S,5R)5-O-Caffeoylquinic acid to reduce both the glucose and cholesterol uptakes by the cell line HepG2 when compared to chlorogenic acid. © 2015 Elsevier Ltd. All rights reserved.","Antioxidant activity; Chlorogenic acid (1S 3R 4S 5R)5-O-Caffeoylquinic acid; NMR; Sorbus domestica","Brand-Williams, W., Cuvelier, M.E., Berset, C., Use of a free radical method to evaluate antioxidant activity (1995) Lebensmittel-Wissenschaft und Technologie, 28, pp. 25-30; Freudenberg, K., Tannins. III. Chlorogenic acid, the tannin-like constituent of coffee berries (1920) Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen, 53 B, pp. 232-239; Gil-Izquierdo, A., Mellenthin, A., Identification and quantitation of flavonols in rowanberry (2001) European Food Research Technology, 213, pp. 12-17; Joost, H.G., Bell, G.I., Best, J.D., Birnbaum, M.J., Charron, M.J., Chen, Y.T., Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators (2002) American Journal of Physiology, Endocrinology and Metabolism, 282, pp. 974-976; Kahkonen, M.P., Hopia, A.I., Heinonen, M., Berry phenolics and their antioxidant activity (2001) Journal of Agricultural and Food Chemistry, 49, pp. 4076-4082; Kultur, S., Medicinal plants used in KIrklareli Province (Turkey) (2007) Journal of Ethnopharmacology, 111, pp. 341-364; Matsumori, N., Kaneno, D., Murata, M., Nakamura, H., Tachibana, K., Stereochemical determination of acyclic structures based on carbon-proton spin-coupling constants. A method of configuration analysis for natural products (1999) The Journal of Organic Chemistry, 64, pp. 866-876; Tenore, G., Stiuso, P., Campiglia, P., Novellino, E., In vitro hypoglycaemic and hypolipidemic potential of white tea (2013) Food Chemistry, 141, pp. 2379-2384; Termentzi, A., Alexiou, P., Demopoulos, V.J., Kokkalou, E., Sorbus domestica fruit extracts depends on their phenolic content and may be useful for the control of diabetic complications (2008) Pharmazie, 63, pp. 693-696; Termentzi, A., Kefalas, P., Kokkalou, E., LC-DAD-MS (ESI+) analysis of the phenolic content of Sorbus domestica fruits in relation to their maturity stage (2008) Food Chemistry, 106, pp. 1234-1245; Vinson, J.A., (2013) Coffee Bioactives: More Than Just Caffeine, , Abstracts of papers, 245th ACS National Meeting & exposition, New Orleans, LA, USA, April 7-11",Article,Scopus,2-s2.0-84922272913
"Koopman J.J.E., Wensink M.J., Rozing M.P., van Bodegom D., Westendorp R.G.J.","Intrinsic and extrinsic mortality reunited",2015,"Experimental Gerontology","67",,,"48","53",,,10.1016/j.exger.2015.04.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928810100&partnerID=40&md5=214348312b0336f49d1779ef64b07143","Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600Leiden, Netherlands; Leyden Academy on Vitality and Ageing, Rijnsburgerweg 10Leiden, Netherlands; Max Planck Institute for Demographic Research, Konrad-Zuse-Straße 1Rostock, Germany; Max Planck Odense Center on the Biodemography of Aging, Department of Epidemiology Biostatistics and Biodemography, Institute of Public Health University of Southern Denmark, J.B. Winsløws Vej 9Odense, Denmark; Department of Old Age Psychiatry and Neuropsychiatry, GGZ inGeest PO Box 74077Amsterdam, Netherlands; Department of Public Health, University of Copenhagen, Gothersgade 160Copenhagen, Denmark","Koopman, J.J.E., Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600Leiden, Netherlands, Leyden Academy on Vitality and Ageing, Rijnsburgerweg 10Leiden, Netherlands; Wensink, M.J., Leyden Academy on Vitality and Ageing, Rijnsburgerweg 10Leiden, Netherlands, Max Planck Institute for Demographic Research, Konrad-Zuse-Straße 1Rostock, Germany, Max Planck Odense Center on the Biodemography of Aging, Department of Epidemiology Biostatistics and Biodemography, Institute of Public Health University of Southern Denmark, J.B. Winsløws Vej 9Odense, Denmark; Rozing, M.P., Department of Old Age Psychiatry and Neuropsychiatry, GGZ inGeest PO Box 74077Amsterdam, Netherlands; van Bodegom, D., Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600Leiden, Netherlands, Leyden Academy on Vitality and Ageing, Rijnsburgerweg 10Leiden, Netherlands; Westendorp, R.G.J., Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600Leiden, Netherlands, Department of Public Health, University of Copenhagen, Gothersgade 160Copenhagen, Denmark","Intrinsic and extrinsic mortality are often separated in order to understand and measure aging. Intrinsic mortality is assumed to be a result of aging and to increase over age, whereas extrinsic mortality is assumed to be a result of environmental hazards and be constant over age. However, allegedly intrinsic and extrinsic mortality have an exponentially increasing age pattern in common. Theories of aging assert that a combination of intrinsic and extrinsic stressors underlies the increasing risk of death. Epidemiological and biological data support that the control of intrinsic as well as extrinsic stressors can alleviate the aging process. We argue that aging and death can be better explained by the interaction of intrinsic and extrinsic stressors than by classifying mortality itself as being either intrinsic or extrinsic. Recognition of the tight interaction between intrinsic and extrinsic stressors in the causation of aging leads to the recognition that aging is not inevitable, but malleable through the environment. © 2015 Elsevier Inc.","Aging; Extrinsic mortality; Gene-environment interaction; Intrinsic mortality; Partitioning of mortality","Arking, R., (2006) Biology of Aging: Observations and Principles, pp. 9-13. , Oxford University Press, New York; Blagosklonny, M.V., Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition (2006) Cell Cycle, 5, pp. 2087-2102; Carnes, B.A., Olshansky, S.J., A biologically motivated partitioning of mortality (1997) Exp. Gerontol., 32, pp. 615-631; Carnes, B.A., Holden, L.R., Olshansky, S.J., Witten, M.T., Siegel, J.S., Mortality partitions and their relevance to research on senescence (2006) Biogerontology, 7, pp. 183-198; Casadevall, A., Pirofski, L.A., Ditch the term pathogen (2014) Nature, 516, pp. 165-166; Caswell, H., Extrinsic mortality and the evolution of senescence (2007) Trends Ecol. Evol., 22, pp. 173-174; Damián, J., Pastor-Barriuso, R., Valderrama-Gama, E., de Pedro-Cuesta, J., Factors associated with falls among older adults living in institutions (2013) BMC Geriatr., 13, p. 6; DiCarlo, A.L., Kaminski, J., Kovacs, E.J., Sempowski, G.D., Palmer, D.B., Immune senescence (2009) Trends Immunol., 30, pp. 293-382; Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.I., Corella, D., Arós, F., Gómez-Gracia, E., Martínez-González, M.A., Primary prevention of cardiovascular disease with a Mediterranean diet (2013) N. Engl. J. Med., 368, pp. 1279-1290; World Health Organization Regional Office for Europe, , http://data.euro.who.int/dmdb/, Available at:, (Accessed: July and August 2013); World Health Organization Regional Office for Europe, , http://data.euro.who.int/hmdb/, Available at:, (Accessed: July 2013); Freitas, A.A., de Magalhães, J.P., A review and appraisal of the DNA damage theory of ageing (2011) Mutat. Res., 728, pp. 12-22; Gluckman, P.D., Hanson, M.A., Living with the past: evolution, development, and patterns of disease (2004) Science, 305, pp. 1733-1736; Grigorenko, E.L., The inherent complexities of gene-environment interactions (2005) J. Gerontol. Ser. B Psychol. Sci. Soc. Sci., 60, pp. 53-64; Gurven, M., Fenelon, A., Has actuarial aging ""slowed"" over the past 250years? A comparison of small-scale subsistence populations and European cohorts (2009) Evolution, 63, pp. 1017-1035; Hunter, D.J., Gene-environment interactions in human diseases (2005) Nat. Rev. Genet., 6, pp. 287-298; Izaks, G.J., Westendorp, R.G.J., Ill or just old? Towards a conceptual framework of the relation between ageing and disease (2003) BMC Geriatr., 3, p. 7; Jackson, R., Elderly and sun-affected skin: distinguishing between changes caused by aging and changes caused by habitual exposure to sun (2001) Can. Fam. Phys., 47, pp. 1236-1243; Jansen, M., van Alfen, N., Geurts, A.C.H., de Groot, I.J.M., Assisted bicycle training delays functional deterioration in boys with Duchenne muscular dystrophy: the randomized controlled trial ""No Use Is Disuse"" (2013) Neurorehabil. Neural Repair, 27, pp. 816-827; Khoury, M.J., Davis, R., Gwinn, M., Lindegren, M.L., Yoon, P., Do we need genomic research for the prevention of common diseases with environmental causes? (2005) Am. J. Epidemiol., 161, pp. 799-805; Kirkwood, T.B.L., Austad, S.N., Why do we age? (2000) Nature, 408, pp. 233-238; Koopman, J.J.E., Rozing, M.P., Kramer, A., de Jager, D.J., Ansell, D., De Meester, J.M.J., Prütz, K.G., Westendorp, R.G.J., Senescence rates in patients with end-stage renal disease: a critical appraisal of the Gompertz model (2011) Aging Cell, 10, pp. 233-238; Koopman, J.J.E., van Bodegom, D., Jukema, J.W., Westendorp, R.G.J., Risk of cardiovascular disease in a traditional African population with a high infectious load: a population-based study (2012) PLoS One, 7, p. e46855; Koopman, J.J.E., van Bodegom, D., Westendorp, R.G.J., Jukema, J.W., Scarcity of atrial fibrillation in a traditional African population: a community-based study (2014) BMC Cardiovasc. Disord., 14, p. 87; Koopman, J.J.E., van Bodegom, D., Maan, A.C., Li, Z., Ziem, J.B., Westendorp, R.G.J., Jukema, J.W., Heart rate variability, but not heart rate, is associated with handgrip strength and mortality in older Africans at very low cardiovascular risk: a population-based study (2015) Int. J. Cardiol., 187, pp. 559-561; Koopman, J.J.E., van Bodegom, D., van Heemst, D., Westendorp, R.G.J., Handgrip strength, ageing and mortality in rural Africa (2014) Age Ageing, , (in press); Lakatta, E.G., Levy, D., Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: aging arteries: a ""set up"" for vascular disease (2003) Circulation, 107, pp. 139-146; Lavallière, M., Handrigan, G.A., Teasdale, N., Corbeil, P., Obesity, where is it driving us? (2012) J. Transp. Saf. Secur., 4, pp. 83-93; Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., Amann, M., Kok, C., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) Lancet, 380, pp. 2224-2260; Lindström, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J.G., Hemiö, K., Hämäläinen, H., Tuomilehto, J., Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study (2006) Lancet, 368, pp. 1673-1679; López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging (2013) Cell, 153, pp. 1194-1217; Mair, W., Goymer, P., Pletcher, S.D., Partridge, L., Demography of dietary restriction and death in Drosophila (2003) Science, 301, pp. 1731-1733; Partridge, L., Pletcher, S.D., Mair, W., Dietary restriction, mortality trajectories, risk and damage (2005) Mech. Ageing Dev., 126, pp. 35-41; Peck, M.D., Epidemiology of burns throughout the world. Part I: distribution and risk factors (2011) Burns, 37, pp. 1087-1100; Rasmussen-Torvik, L.J., Shay, C.M., Abramson, J.G., Friedrich, C.A., Nettleton, J.A., Prizment, A.E., Folsom, A.R., Ideal cardiovascular health is inversely associated with incident cancer: the Atherosclerosis Risk in Communities Study (2013) Circulation, 127, pp. 1270-1275; Ricklefs, R.E., Scheuerlein, A., Biological implications of the Weibull and Gompertz models of aging (2002) J. Gerontol. Ser. A Biol. Sci. Med. Sci., 57, pp. B69-B76; Rothman, K.J., Greenland, S., Causation and causal inference in epidemiology (2005) Am. J. Public Health, 95 (1 SUPPL), pp. S144-S150; Rozing, M.P., Westendorp, R.G.J., Parallel lines: nothing has changed? (2008) Aging Cell, 7, pp. 924-927; Tomasetti, C., Vogelstein, B., Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions (2015) Science, 347, pp. 78-81; Wahren-Herlenius, M., Kuchroo, V., Gene-environment interaction in induction of autoimmunity (2011) Semin. Immunol., 23, pp. 65-154; Wensink, M.J., Wrycza, T.F., Baudisch, A., Interaction mortality: senescence may have evolved because it increases lifespan (2014) PLoS One, 9, p. e109638; Wexler, N.S., Lorimer, J., Porter, J., Gomez, F., Moskowitz, C., Shackell, E., Marder, K., Landwehrmeyer, B., Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset (2004) Proc. Natl. Acad. Sci. U. S. A., 101, pp. 3498-3503; Willett, W.C., Balancing life-style and genomics research for disease prevention (2002) Science, 296, pp. 695-698; Williams, P.D., Day, T., Fletcher, Q., Rowe, L., The shaping of senescence in the wild (2006) Trends Ecol. Evol., 21, pp. 458-463",Note,Scopus,2-s2.0-84928810100
"Leske S., Strodl E., Harper C., Clemens S., Hou X.-Y.","Psychological distress may affect nutrition indicators in Australian adults",2015,"Appetite","90",,,"144","153",,,10.1016/j.appet.2015.02.003,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925739729&partnerID=40&md5=6ca19b4e6174fe0ba69aae13a23f81ab","School of Psychology and Counselling, Queensland University of Technology, Victoria Park Road. Kelvin GroveBrisbane, QLD, Australia; School of Public Health, University of QueenslandBrisbane, Australia; Policy and Evaluation Group, Queensland Centre for Mental Health ResearchBrisbane, Australia; Preventive Health Unit, Chief Health Officer Branch, Queensland Government Department of Health, Floor 1, 15 Butterfield StreetHerston, QLD, Australia; School of Public Health and Social Work, Queensland University of Technology, Victoria Park Road. Kelvin GroveBrisbane, QLD, Australia","Leske, S., School of Psychology and Counselling, Queensland University of Technology, Victoria Park Road. Kelvin GroveBrisbane, QLD, Australia, School of Public Health, University of QueenslandBrisbane, Australia, Policy and Evaluation Group, Queensland Centre for Mental Health ResearchBrisbane, Australia; Strodl, E., School of Psychology and Counselling, Queensland University of Technology, Victoria Park Road. Kelvin GroveBrisbane, QLD, Australia; Harper, C., Preventive Health Unit, Chief Health Officer Branch, Queensland Government Department of Health, Floor 1, 15 Butterfield StreetHerston, QLD, Australia; Clemens, S., Preventive Health Unit, Chief Health Officer Branch, Queensland Government Department of Health, Floor 1, 15 Butterfield StreetHerston, QLD, Australia; Hou, X.-Y., School of Public Health and Social Work, Queensland University of Technology, Victoria Park Road. Kelvin GroveBrisbane, QLD, Australia","Objective: The purpose of this research was to explore which demographic and health status variables moderated the relationship between psychological distress and three nutrition indicators: the consumption of fruits, vegetables and takeaway. Method: We analysed data from the 2009 Self-Reported Health Status Survey Report collected in the state of Queensland, Australia. Adults (N = 6881) reported several demographic and health status variables. Moderated logistic regression models were estimated separately for the three nutrition indicators, testing as moderators demographic (age, gender, educational attainment, household income, remoteness, and area-level socioeconomic status) and health status indicators (body mass index, high cholesterol, high blood pressure, and diabetes status). Results: Several significant interactions emerged between psychological distress, demographic (age, area-level socio-economic status, and income level), and health status variables (body mass index, diabetes status) in predicting the nutrition indicators. Relationships between distress and the nutrition indicators were not significantly different by gender, remoteness, educational attainment, high cholesterol status, and high blood pressure status. Conclusions: The associations between psychological distress and several nutrition indicators differ amongst population subgroups. These findings suggest that in distressed adults, age, area-level socio-economic status, income level, body mass index, and diabetes status may serve as protective or risk factors through increasing or decreasing the likelihood of meeting nutritional guidelines. Public health interventions for improving dietary behaviours and nutrition may be more effective if they take into account the moderators identified in this study rather than using global interventions. © 2015 Elsevier Ltd.","Fruit; Milk; Moderator; Psychological distress; Takeaway; Vegetable","Alonso, A., de la Fuente, C., Martín-Arnau, A.M., de Irala, J., Martínez, J.A., Martínez-González, M.A., Fruit and vegetable consumption is inversely associated with blood pressure in a Mediterranean population with a high vegetable-fat intake. The Seguimiento Universidad de Navarra (SUN) Study (2004) The British Journal of Nutrition, 92, pp. 311-319; Anderson, A.S., Marshall, D., Lean, M., Five a day? Factors affecting fruit and vegetable consumption in Scotland (1994) Nutrition & Food Science, 94 (5), pp. 14-16; Atlantis, E., Barnes, E.H., Ball, K., Weight status and perception barriers to healthy physical activity and diet behavior (2008) International Journal of Obesity (2005), 32, pp. 343-352; (2001) Information paper. ABS views on remoteness, 2001 (1244.0), , Australian Bureau of Statistics, Canberra; (2001) Australian outcomes of ABS views on remoteness consultation, Australia, Jun 2001 (1244.0.00.001), , Australian Bureau of Statistics, Canberra; (2001) Information paper. Census of population and housing. Socio-economic indexes for areas, Australia, 2001(2039.0), , Australian Bureau of Statistics, Canberra; (2012) Australian health survey. First results, 2011-12. (4364.0.55.001), , Australian Bureau of Statistics, Canberra; Information paper. Use of the Kessler psychological distress scale in ABS health surveys, Australia, 2007-08, , http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/B7EEC52AF6D8147ACA257A380016CF5D?opendocument, Cat. no. 4817.0.55.001. ABS: Canberra; 2012. Available from; Azagba, S., Sharaf, M.F., Disparities in the frequency of fruit and vegetable consumption by socio-demographic and lifestyle characteristics in Canada (2011) Nutrition Journal, 10, p. 118; Backman, D., Gonzaga, G., Sugerman, S., Effect of fresh fruit availability at worksites on the fruit and vegetable consumption of low-wage employees (2011) Journal of Nutrition Education and Behavior, 43 (4), pp. S113-S121; Baer, D., Nietert, P.J., Patterns of fruit, vegetable, and milk consumption among smoking and nonsmoking female teens (2002) American Journal of Preventive Medicine, 22 (4), pp. 240-246; Bisset, S., Gauvin, L., Potvin, L., Paradis, G., Association of body mass index and dietary restraint with changes in eating behaviour throughout late childhood and early adolescence. A 5-year study (2007) Public Health Nutrition, 10, pp. 780-789; Bodor, J.N., Rose, D., Farley, T.A., Neighborhood fruit and vegetable availability and consumption. The role of small food stores in an urban environment (2008) Public Health Nutrition, 11 (4), pp. 413-420; Bradshaw, E., (2011) Extra food intake and depressive symptoms in adolescents. Is there a relationship? (Masters's thesis). University of Notre Dame Australia, Fremantle, WA; Casagrande, S.S., Wang, Y., Anderson, C., Have Americans increased their fruit and vegetable intake? The trends between 1988 and 2002 (2007) American Journal of Preventive Medicine, 32 (4), pp. 257-263; Cohen, J.H., Kristal, A.R., Neumark-Sztainaer, D., Rock, C.L., Neuhouser, M.L., Psychological distress is associated with unhealthful dietary practices (2002) Journal of the American Dietetic Association, 102, pp. 699-703. , http://www.sciencedirect.com/science/journal/00028223, Available from; Conceição de Oliveira, M., Sichieri, R., Sanchez Moura, A., Weight loss associated with a daily intake of three apples or three pears among overweight women (2003) Nutrition (Burbank, Los Angeles County, Calif.), 19, pp. 253-256; Cox, D.N., Anderson, A.S., Lean, M.E.J., UK consumer attitudes, beliefs and barriers to increasing fruit and vegetable consumption (1998) Public Health Nutrition, 1 (1), pp. 61-68; Dickson, B.K., Blackledge, J., Hajjar, I.M., The impact of lifestyle behavior on hypertension awareness, treatment, and control in a southeastern population (2006) The American Journal of the Medical Sciences, 332 (4), pp. 211-215; Drapeau, V., Després, J.P., Bouchard, C., Allard, L., Fournier, G., Leblanc, C., Modifications in food-group consumption are related to long-term body-weight changes (2004) The American Journal of Clinical Nutrition, 80 (1), pp. 29-37. , http://ajcn.nutrition.org/, Available from; Drewnowski, A., Darmon, N., The economics of obesity. Dietary energy density and energy cost (2005) The American Journal of Clinical Nutrition, 82 (1), pp. 265S-273S; Drewnowski, A., Specter, S., Poverty and obesity. The role of energy density and energy costs (2004) The American Journal of Clinical Nutrition, 79 (1), pp. 6-16; Dubowitz, T., Heron, M., Bird, C.E., Neighborhood socioeconomic status and fruit and vegetable intake among whites, blacks, and Mexican Americans in the United States (2008) The American Journal of Clinical Nutrition, 87 (6), pp. 1883-1891; Eisenberg, M.E., Neumark-Sztainer, D., Story, M., The role of social norms and friends' influences on unhealthy weight-control behaviors among adolescent girls (2005) Social Science and Medicine, 60 (6), pp. 1165-1173; Fang, J., Keenan, N.L., Dai, S., Fruit/vegetable intake and physical activity among adults with high cholesterol (2011) American Journal of Health Behavior, 35 (6), pp. 689-698; Fleischhacker, S.E., Evenson, K.R., Rodriguez, D.A., Ammerman, A.S., A systematic review of fast food access studies (2011) Obesity Reviews, pp. e460-e471; French, S.A., Pricing effects on food choices (2003) Journal of Nutrition, 133 (3), pp. 841S-843S; Gibson, E.L., Emotional influences on food choice. Sensory, physiological and psychological pathways (2006) Physiology and Behavior, 89, pp. 53-61; Glanz, K., Basil, M., Maibach, E., Goldberg, J., Snyder, D., Why Americans eat what they do. Taste, nutrition, cost, convenience, and weight control concerns as influences on food consumption (1998) Journal of the American Dietetic Association, 98 (10), pp. 118-1126. , http://www.sciencedirect.com/science/journal/00028223, Available from; Guenther, P.M., Dodd, K.W., Reedy, J., Most Americans eat much less than recommended amounts of fruits and vegetables (2006) Journal of the American Dietetic Association, 106 (9), pp. 1371-1379; He, K., Hu, F.B., Colditz, G.A., Manson, J.E., Willett, W.C., Liu, S., Changes in intake of fruits and vegetables in relation to risk of obesity and weight gain among middle-aged women (2004) International Journal of Obesity, 28 (12), pp. 1569-1574; Heitmann, B.L., Lissner, L., Dietary underreporting by obese individuals. Is it specific or non-specific? (1995) British Medical Journal, 311 (7011), pp. 986-989; (2012) IBM SPSS statistics for windows, version 21.0.0.0, , IBM Corp, Armonk, NY; Johansson, L., Andersen, L.F., Who eats 5 a day? Intake of fruits and vegetables among Norwegians in relation to gender and lifestyle (1998) Journal of the American Dietetic Association, 98 (6), pp. 689-691; Kamphuis, C.B.M., Giskes, K., de Bruijn, G.-J., Wendel-Vos, W., Brug, J., van Lenthe, F.J., Environmental determinants of fruit and vegetable consumption among adults. A systematic review (2006) British Journal of Nutrition, 96 (4), pp. 620-635; Kant, A.K., Graubard, B.I., Kumanyika, S.K., Trends in black-white differentials in dietary intakes of US adults, 1971-2002 (2007) American Journal of Preventive Medicine, 32 (4), pp. 264-272; Kessler, R., Mroczek, D., (1992) An Update of the Development of Mental Health Screening Scales for the US National Health Interview Study, , [memo dated 12/22/92], Ann Arbor (MI): Survey Research Center of the Institute for Social Research, University of Michigan; Kiviniemi, M.T., Orom, H., Giovino, G.A., Race/ethnicity, psychological distress, and fruit/vegetable consumption. The nature of the distress-behavior relation differs by race/ethnicity (2011) Appetite, 56, pp. 737-740; Knott, C., Health Survey for England (HSE). 2012. Chapter 4, General mental and physical health, , http://www.hscic.gov.uk/catalogue/PUB13218/HSE2012-Ch4-Gen-health.pdf, Available from; Konttinen, H., Mannisto, S., Sarlio-Lahteenkorva, S., Silventoinen, K., Haukkala, A., Emotional eating, depressive symptoms and self-reported food consumption. A population-based study (2010) Appetite, 54, pp. 473-479; Leather, S., Fruit and vegetables. Consumption patterns and health consequences (1995) British Food Journal, 97 (7), pp. 10-17; Lennernäs, M., Fjellström, C., Becker, W., Influences on food choice perceived to be important by nationally-representative samples of adults in the European Union (1997) European Journal of Clinical Nutrition, 51, pp. S8-S15; Lim, S.S., Norman, R.J., Clifton, P.M., Noakes, M., Hyperandrogenemia, psychological distress, and food cravings in young women (2009) Physiology & Behavior, 98, pp. 276-280; Lindström, M., Hanson, B.S., Wirfält, E., Socioeconomic differences in the consumption of vegetables, fruit and fruit juices (2001) European Journal of Public Health, 11 (1), pp. 51-59; Litt, J.S., Soobader, M.J., Turbin, M.S., The influence of social involvement, neighborhood aesthetics, and community garden participation on fruit and vegetable consumption (2011) American Journal of Public Health, 101 (8), pp. 1466-1473; Macht, M., How emotions affect eating. A five-way model (2008) Appetite, 50, pp. 1-11; McClelland, J.W., Demark-Wahnefried, W., Mustian, R.D., Fruit and vegetable consumption of rural African Americans. Baseline survey results of the black churches united for better health 5-A-Day project (1998) Nutrition Cancer, 30 (2), pp. 148-157; Mishra, G., McNaughton, S., Ball, K., Brown, W., Giles, G., Dobson, A., Major dietary patterns of young and middle aged women. Results from a prospective Australian cohort study (2010) European Journal of Clinical Nutrition, 64 (10), pp. 1125-1133; Miura, K., Giskes, K.M., Turrell, G., Socio-economic differences in takeaway food consumption among adults (2012) Public Health Nutrition, 15 (2), pp. 218-226; Morland, K., Wing, S., Roux, A.D., The contextual effect of the local food environment on residents' diets. The atherosclerosis risk in communities study (2002) American Journal of Public Health, 92 (11), pp. 1761-1767; (2003) Dietary guidelines for all Australians, , National Health and Medical Research Council, Canberra; O'Connor, T.M., Hughes, S.O., Watson, K.B., Parenting practices are associated with fruit and vegetable consumption in pre-school children (2010) Public Health Nutrition, 13 (1), pp. 91-101; Peduzzi, P., Concato, J., Kemper, E., Holford, T.R., Feinstein, A.R., A simulation study of the number of events per variable in logistic regression analysis (1996) Journal of Clinical Epidemiology, 49 (12), pp. 1373-1379. , http://www.jclinepi.com/, Available from; Pollard, G., White, D., Harper, C., (2009) Self-Reported Health Status: Queensland. 2009 Survey Report, , Queensland Health, Brisbane; Powell, L.M., Zhao, Z., Wang, Y., Food prices and fruit and vegetable consumption among young American adults (2009) Health and Place, 15 (4), pp. 1064-1070; Putnam, J.J., Allshouse, J.E., (1999) Food consumption, prices, and expenditure, 1970-97, , USDA, Economic Research Service, Food and Rural and Economic Division, Washington, DC; Quadir, T., Akhtar-Danesh, N., Fruit and vegetable intake In Canadian ethnic populations (2010) Canadian Journal of Dietetic Practice and Research: A Publication of Dietitians of Canada, 71 (1), pp. 11-16; (2009) SRHS 2009_CR2011_008_1_dta. Brisbane, Queensland. Preventive Health Unit, SRHS 2009_CR2011_008_1_dta. 6th March, 2014; (2011) Self-Reported Health Status 2011. Fruit and vegetable consumption and factors associated with intentions to increase consumption, Queensland. Queensland Health: Brisbane, 2011; (2012) Self-reported health status 2012. Health indicators. Chronic disease and behavioural risk factors, Queensland. Queensland Health: Brisbane 2012; Rutishauser, I.H.E., Webb, K., Abraham, B., Allsopp, R., (2001) Evaluation of short dietary questions from the 1995 National Nutrition Survey. Australian Food and Nutrition Monitoring Unit: Brisbane 2001; Sartorelli, D.S., Franco, L.J., Cardoso, M.A., High intake of fruits and vegetables predicts weight loss in Brazilian overweight adults (2008) Nutrition Research, 28 (4), pp. 233-238; Scarborough, P., Nnoaham, K.E., Clarke, D., Capewell, S., Rayner, M., Modelling the impact of a healthy diet on cardiovascular disease and cancer mortality (2010) Journal of Epidemiology and Community Health, 66, pp. 420-426; Schiller, J.S., Ward, B.W., Freeman, G., Early release of selected estimates based on data from the January-June 2013 National Health Interview Survey (2013) Serious psychological distress National Center for Health Statistics, pp. 93-97. , http://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease201312_13.pdf, Available from; Schmidt, M., Affenito, S.G., Striegel-Moore, R., Khoury, P.R., Barton, B., Crawford, P., Fast-food intake and diet quality in black and white girls. The National Heart, Lung, and Blood Institute Growth and Health Study (2005) Archives of Pediatrics and Adolescent Medicine, 159 (7), pp. 626-631. , http://archpedi.jamanetwork.com/journal.aspx, Available from; Slade, T., Grove, R., Burgess, P., Kessler psychological distress scale. Normative data from the 2007 Australian National Survey of Mental Health and Wellbeing (2011) Australian and New Zealand Journal of Psychiatry, 45 (4); Sorensen, G., Stoddard, A.M., Dubowitz, T., The influence of social context on changes in fruit and vegetable consumption. Results of the healthy directions studies (2007) American Journal of Public Health, 97 (7), pp. 1216-1227; Stewart, H., Harris, J.M., Guthrie, J., (2004) What determines the variety of a household's vegetable purchases?, , Agriculture Information Bulletin Number 792-793, Economic Research Service, U.S. Department of Agriculture, Washington, DC; te Velde, S.J., Twisk, J.W., Brug, J., Tracking of fruit and vegetable consumption from adolescence into adulthood and its longitudinal association with overweight (2007) British Journal of Nutrition, 98 (2), pp. 431-438; Taveras, E.M., Berkey, C.S., Rifas-Shiman, S.L., Ludwig, D.S., Rockett, H.R., Field, A.E., Association of consumption of fried food away from home with body mass index and diet quality in older children and adolescents (2005) Pediatrics, 116 (4), pp. e518-e524; Thornton, L.E., Bentley, R.J., Kavanagh, A., Individual and area-level socioeconomic associations with fast food purchasing (2011) Journal of Epidemiology and Community Health, 65, pp. 873-e880; Thornton, L.E., Crawford, D.A., Ball, K., Who is eating where? Findings from the SocioEconomic Status and Activity in Women (SESAW) study (2010) Public Health Nutrition, 14 (3), pp. 523-531; (2010) Dietary guidelines for Americans, , U.S. Government Printing Office, Washington, DC; Van der Horst, K., Brunner, T.A., Siegrist, M., Fast food and take-away food consumption are associated with different lifestyle characteristics (2011) Journal of Human Nutrition and Dietetics, 24, pp. 596-602; Viner, R.M., Cole, T.J., Who changes body mass between adolescence and adulthood? Factors predicting change in BMI between 16 year and 30 years in the 1970 British Birth Cohort (2006) International Journal of Obesity, 30 (9), pp. 1368-1374; Vioque, J., Weinbrenner, T., Castello, A., Asensio, L., de la Hera, M.G., Intake of fruits and vegetables in relation to 10-year weight gain among Spanish adults (2008) Obesity, 16 (3), pp. 664-670; Wolf, R.L., Lepore, S.J., Vandergrift, J.L., Knowledge, barriers, and stage of change as correlates of fruit and vegetable consumption among urban and mostly immigrant black men (2008) Journal of the American Dietetic Association, 108 (8), pp. 1315-1322; WMA Declaration of Helsinki. Ethical principles for medical research involving human subjects, , http://www.wma.net/en/30publications/10policies/b3/index.html, Available from; Zenk, S.N., Schulz, A.J., Hollis-Neely, T., Fruit and vegetable intake in African Americans. Income and store characteristics (2005) American Journal of Preventive Medicine, 29 (1), pp. 1-9; Zhang, Q., Fu, L., Review of the multi-level factors contributing to fruit and vegetable consumption in the US (2011) North American Journal of Medicine and Science, 4 (4), pp. 232-237. , http://najms.net/, Available from",Article,Scopus,2-s2.0-84925739729
"Xu Z., Cai L.","Diabetic cardiomyopathy: Role of epidermal growth factor receptor tyrosine kinase",2015,"Journal of Molecular and Cellular Cardiology","84",,,"10","12",,,10.1016/j.yjmcc.2015.04.002,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927511772&partnerID=40&md5=b1e17b9fac959776a2f5124a0fe13835","Cardiovascular Center at the First Hospital of Jilin UniversityChangchun, China","Xu, Z., Cardiovascular Center at the First Hospital of Jilin UniversityChangchun, China; Cai, L., Cardiovascular Center at the First Hospital of Jilin UniversityChangchun, China",[No abstract available],,"Bugger, H., Abel, E.D., Molecular mechanisms of diabetic cardiomyopathy (2014) Diabetologia, 57, pp. 660-671; Huynh, K., Bernardo, B.C., McMullen, J.R., Ritchie, R.H., Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways (2014) Pharmacol Ther, 142, pp. 375-415; Dhomen, N.S., Mariadason, J., Tebbutt, N., Scott, A.M., Therapeutic targeting of the epidermal growth factor receptor in human cancer (2012) Crit Rev Oncog, 17, pp. 31-50; Sanchez-Guerrero, E., Jo, S.R., Chong, B.H., Khachigian, L.M., EGFR and the complexity of receptor crosstalk in the cardiovascular system (2013) Curr Mol Med, 13, pp. 3-12; Zhai, P., Galeotti, J., Liu, J., Holle, E., Yu, X., Wagner, T., An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy (2006) Circ Res, 99, pp. 528-536; Kawanabe, Y., Masaki, T., Hashimoto, N., Involvement of epidermal growth factor receptor-protein tyrosine kinase transactivation in endothelin-1-induced vascular contraction (2004) J Neurosurg, 100, pp. 1066-1071; Han, L., Ma, Q., Li, J., Liu, H., Li, W., Ma, G., High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR (2011) PLoS One, 6, p. e27074; Matrougui, K., Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase (2010) Diabetes Metab Res Rev, 26, pp. 13-16; Lucchini, E., Pilotto, S., Spada, E., Melisi, D., Bria, E., Tortora, G., Targeting the epidermal growth factor receptor in solid tumors: focus on safety (2014) Expert Opin Drug Saf, 13, pp. 535-549; Chen, J., Chen, J.K., Nagai, K., Plieth, D., Tan, M., Lee, T.C., EGFR signaling promotes TGFbeta-dependent renal fibrosis (2012) J Am Soc Nephrol, 23, pp. 215-224; Zhang, M.Z., Wang, Y., Paueksakon, P., Harris, R.C., Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy (2014) Diabetes, 63, pp. 2063-2072; Akhtar, S., Almubrad, T., Bron, A.J., Yousif, M.H., Benter, I.F., Akhtar, S., Role of epidermal growth factor receptor (EGFR) in corneal remodelling in diabetes (2009) Acta Ophthalmol, 87, pp. 881-889; Belmadani, S., Palen, D.I., Gonzalez-Villalobos, R.A., Boulares, H.A., Matrougui, K., Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice (2008) Diabetes, 57, pp. 1629-1637; Kasayama, S., Yoshimura, M., Oka, T., Decreased expression of hepatic epidermal growth factor receptor gene in diabetic mice (1989) J Mol Endocrinol, 3, pp. 49-56; Sayed-Ahmed, N., Besbas, N., Mundy, J., Muchaneta-Kubara, E., Cope, G., Pearson, C., Upregulation of epidermal growth factor and its receptor in the kidneys of rats with streptozotocin-induced diabetes (1996) Exp Nephrol, 4, pp. 330-339; Khan, A.J., Fligiel, S.E., Liu, L., Jaszewski, R., Chandok, A., Majumdar, A.P., Induction of EGFR tyrosine kinase in the gastric mucosa of diabetic rats (1999) Proc Soc Exp Biol Med, 221, pp. 105-110; Benter, I.F., Yousif, M.H., Hollins, A.J., Griffiths, S.M., Akhtar, S., Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase (2005) J Vasc Res, 42, pp. 284-291; Akhtar, S., Yousif, M.H., Dhaunsi, G.S., Sarkhouh, F., Chandrasekhar, B., Attur, S., Activation of ErbB2 and downstream signalling via rho kinases and ERK1/2 contributes to diabetes-induced vascular dysfunction (2013) PLoS One, 8, p. e67813; Pareja, M., Sanchez, O., Lorita, J., Soley, M., Ramirez, I., Activated epidermal growth factor receptor (ErbB1) protects the heart against stress-induced injury in mice (2003) Am J Physiol Regul Integr Comp Physiol, 285, pp. R455-R462; Williams-Pritchard, G., Knight, M., Hoe, L.S., Headrick, J.P., Peart, J.N., Essential role of EGFR in cardioprotection and signaling responses to A1 adenosine receptors and ischemic preconditioning (2011) Am J Physiol Heart Circ Physiol, 300, pp. H2161-H2168; Akhtar, S., Yousif, M.H., Chandrasekhar, B., Benter, I.F., Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury (2012) PLoS One, 7, p. e39066; Benter, I.F., Juggi, J.S., Khan, I., Yousif, M.H., Canatan, H., Akhtar, S., Signal transduction mechanisms involved in cardiac preconditioning: role of Ras-GTPase, Ca2+/calmodulin-dependent protein kinase II and epidermal growth factor receptor (2005) Mol Cell Biochem, 268, pp. 175-183; Galan, M., Kassan, M., Choi, S.K., Partyka, M., Trebak, M., Henrion, D., A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus (2012) Hypertension, 60, pp. 71-80; Liang, D., Zhong, P., Hu, J., Lin, F., Qian, Y., Xu, Z., EGFR inhibition protects cardiac damage and remodeling through attenuating oxidative stress in STZ-induced diabetic mouse model (2015) J Mol Cell Cardiol, 82, pp. 63-74; Barrick, C.J., Yu, M., Chao, H.H., Threadgill, D.W., Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice (2008) Toxicol Appl Pharmacol, 228, pp. 315-325",Editorial,Scopus,2-s2.0-84927511772
"Song J.L., Nigam P., Tektas S.S., Selva E.","MicroRNA regulation of Wnt signaling pathways in development and disease",2015,"Cellular Signalling","27","7",,"1380","1391",,,10.1016/j.cellsig.2015.03.018,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927613389&partnerID=40&md5=ab914979e6044c8e34792abbb06fc89a","Department of Biological Sciences, University of DelawareNewark, DE, United States","Song, J.L., Department of Biological Sciences, University of DelawareNewark, DE, United States; Nigam, P., Department of Biological Sciences, University of DelawareNewark, DE, United States; Tektas, S.S., Department of Biological Sciences, University of DelawareNewark, DE, United States; Selva, E., Department of Biological Sciences, University of DelawareNewark, DE, United States","Wnt signaling pathways and microRNAs (miRNAs) are critical regulators of development. Aberrant Wnt signaling pathways and miRNA levels lead to developmental defects and diverse human pathologies including but not limited to cancer. Wnt signaling pathways regulate a plethora of cellular processes during embryonic development and maintain homeostasis of adult tissues. A majority of Wnt signaling components are regulated by miRNAs which are small noncoding RNAs that are expressed in both animals and plants. In animal cells, miRNAs fine tune gene expression by pairing primarily to the 3'untranslated region of protein coding mRNAs to repress target mRNA translation and/or induce target degradation. miRNA-mediated regulation of signaling transduction pathways is important in modulating dose-sensitive response of cells to signaling molecules. This review discusses components of the Wnt signaling pathways that are regulated by miRNAs in the context of development and diseases. A fundamental understanding of miRNA functions in Wnt signaling transduction pathways may yield new insight into crosstalks of regulatory mechanisms essential for development and disease pathophysiology leading to novel therapeutics. © 2015 Elsevier Inc.","Cancer; Non-canonical Wnt signaling; Post-transcriptional regulation; Regulatory network; β-catenin","Clevers, H., (2006) Cell, 127 (3), pp. 469-480; Moon, R.T., Kohn, A.D., De Ferrari, G.V., Kaykas, A., (2004) Nat. Rev. Genet., 5 (9), pp. 691-701; Clevers, H., Nusse, R., (2012) Cell, 149 (6), pp. 1192-1205; MacDonald, B.T., Tamai, K., He, X., (2009) Dev. Cell, 17 (1), pp. 9-26. , (PMCID: 2861485); Kim, W., Kim, M., Jho, E.H., (2013) Biochem. J., 450 (1), pp. 9-21; Anastas, J.N., Moon, R.T., (2013) Nat. Rev. Cancer, 13 (1), pp. 11-26; Inui, M., Martello, G., Piccolo, S., (2010) Nat. Rev. Mol. Cell Biol., 11 (4), pp. 252-263; Schepeler, T., (2013) Crit. Rev. Oncog., 18 (4), pp. 357-371; Nusse, R., Varmus, H.E., (1982) Cell, 31 (1), pp. 99-109; Rijsewijk, F., van Deemter, L., Wagenaar, E., Sonnenberg, A., Nusse, R., (1987) EMBO J., 6 (1), pp. 127-131. , (PMCID: 553367); Tsukamoto, A.S., Grosschedl, R., Guzman, R.C., Parslow, T., Varmus, H.E., (1988) Cell, 55 (4), pp. 619-625; Sokol, S., Christian, J.L., Moon, R.T., Melton, D.A., (1991) Cell, 67 (4), pp. 741-752; Slusarski, D.C., Yang-Snyder, J., Busa, W.B., Moon, R.T., (1997) Dev. Biol., 182 (1), pp. 114-120; Teo, J.L., Kahn, M., (2010) Adv. Drug Deliv. Rev., 62 (12), pp. 1149-1155; Lin, C.L., Wang, J.Y., Huang, Y.T., Kuo, Y.H., Surendran, K., Wang, F.S., (2006) J. Am. Soc. Nephrol., 17 (10), pp. 2812-2820; Martin, B.L., Kimelman, D., (2012) Dev. Cell, 22 (1), pp. 223-232. , (PMCID: 3465166); Miki, T., Yasuda, S.Y., Kahn, M., (2011) Stem Cell Rev., 7 (4), pp. 836-846; Hikasa, H., Sokol, S.Y., (2013) Cold Spring Harb. Perspect. Biol., 5 (1), p. a007955. , (PMCID: 3579404); Lee, J.Y., Marston, D.J., Walston, T., Hardin, J., Halberstadt, A., Goldstein, B., (2006) Curr. Biol., 16 (20), pp. 1986-1997. , (PMCID: 2989422); Boras-Granic, K., Wysolmerski, J.J., (2008) Organogenesis, 4 (2), pp. 116-122. , (PMCID: 2634257); Gao, B., Yang, Y., (2013) Curr. Opin. Genet. Dev., 23 (4), pp. 438-444. , (PMCID: 3759593); Gessert, S., Kuhl, M., (2010) Circ. Res., 107 (2), pp. 186-199; Mulligan, K.A., Cheyette, B.N., (2012) J. Neuroimmune Pharmacol., 7 (4), pp. 774-787. , (PMCID: 3518582); Day, T.F., Yang, Y., (2008) J. Bone Joint Surg. Am., 90, pp. 19-24; Yost, C., Torres, M., Miller, J.R., Huang, E., Kimelman, D., Moon, R.T., (1996) Genes Dev., 10 (12), pp. 1443-1454; Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G.H., Tan, Y., (2002) Cell, 108 (6), pp. 837-847; Hart, M., Concordet, J.P., Lassot, I., Albert, I., del los Santos, R., Durand, H., (1999) Curr. Biol., 9 (4), pp. 207-210; Cadigan, K.M., Liu, Y.I., (2006) J. Cell Sci., 119, pp. 395-402; Gao, C., Chen, Y.G., (2010) Cell. Signal., 22 (5), pp. 717-727; Schwarz-Romond, T., Metcalfe, C., Bienz, M., (2007) J. Cell Sci., 120, pp. 2402-2412; Wong, H.C., Bourdelas, A., Krauss, A., Lee, H.J., Shao, Y., Wu, D., (2003) Mol. Cell, 12 (5), pp. 1251-1260; Logan, C.Y., Miller, J.R., Ferkowicz, M.J., McClay, D.R., (1999) Development, 126 (2), pp. 345-357; Weitzel, H.E., Illies, M.R., Byrum, C.A., Xu, R., Wikramanayake, A.H., Ettensohn, C.A., (2004) Development, 131 (12), pp. 2947-2956; Miyawaki, K., Yamamoto, M., Saito, K., Saito, S., Kobayashi, N., Matsuda, S., (2003) Dev. Growth Differ., 45 (2), pp. 121-128; Kawai, N., Iida, Y., Kumano, G., Nishida, H., (2007) Dev. Dyn., 236 (6), pp. 1570-1582; Larabell, C.A., Torres, M., Rowning, B.A., Yost, C., Miller, J.R., Wu, M., (1997) J. Cell Biol., 136 (5), pp. 1123-1136. , (PMCID: 2132470); Orsulic, S., Huber, O., Aberle, H., Arnold, S., Kemler, R., (1999) J. Cell Sci., 112, pp. 1237-1245; Heuberger, J., Birchmeier, W., (2010) Cold Spring Harb. Perspect. Biol., 2 (2), p. a002915. , (PMCID: 2828280); Heasman, J., Crawford, A., Goldstone, K., Garner-Hamrick, P., Gumbiner, B., McCrea, P., (1994) Cell, 79 (5), pp. 791-803; Fagotto, F., Funayama, N., Gluck, U., Gumbiner, B.M., (1996) J. Cell Biol., 132 (6), pp. 1105-1114. , (PMCID: 2120760); Wikramanayake, A.H., Huang, L., Klein, W.H., (1998) Proc. Natl. Acad. Sci. U. S. A., 95 (16), pp. 9343-9348. , (PMCID: 21340); Bovolenta, P., Esteve, P., Ruiz, J.M., Cisneros, E., Lopez-Rios, J., (2008) J. Cell Sci., 121, pp. 737-746; Glinka, A., Wu, W., Delius, H., Monaghan, A.P., Blumenstock, C., Niehrs, C., (1998) Nature, 391 (6665), pp. 357-362; Semenov, M., Tamia, K., He, X., (2005) J. Biol. Chem., 280, pp. 26770-26775; Wylie, C., Kofron, M., Payne, C., Anderson, R., Hosobuchi, M., Joseph, E., (1996) Development, 122 (10), pp. 2987-2996; Kelly, G.M., Erezyilmaz, D.F., Moon, R.T., (1995) Mech. Dev., 53 (2), pp. 261-273; Pelegri, F., Maischein, H.M., (1998) Mech. Dev., 77 (1), pp. 63-74; Imai, K., Takada, N., Satoh, N., Satou, Y., (2000) Development, 127 (14), pp. 3009-3020; Tada, M., Smith, J.C., (2000) Development, 127 (10), pp. 2227-2238; Wallingford, J.B., Rowning, B.A., Vogeli, K.M., Rothbacher, U., Fraser, S.E., Harland, R.M., (2000) Nature, 405 (6782), pp. 81-85; Heisenberg, C.P., Tada, M., Rauch, G.J., Saude, L., Concha, M.L., Geisler, R., (2000) Nature, 405 (6782), pp. 76-81; Kibar, Z., Vogan, K.J., Groulx, N., Justice, M.J., Underhill, D.A., Gros, P., (2001) Nat. Genet., 28 (3), pp. 251-255; Wang, J., Hamblet, N.S., Mark, S., Dickinson, M.E., Brinkman, B.C., Segil, N., (2006) Development, 133 (9), pp. 1767-1778. , (PMCID: 4158842); Merkel, C.E., Karner, C.M., Carroll, T.J., (2007) Pediatr. Nephrol., 22 (11), pp. 1825-1838; Matthews, H.K., Marchant, L., Carmona-Fontaine, C., Kuriyama, S., Larrain, J., Holt, M.R., (2008) Development, 135 (10), pp. 1771-1780; Wang, Y., Thekdi, N., Smallwood, P.M., Macke, J.P., Nathans, J., (2002) J. Neurosci., 22 (19), pp. 8563-8573; Lyuksyutova, A.I., Lu, C.C., Milanesio, N., King, L.A., Guo, N., Wang, Y., (2003) Science, 302 (5652), pp. 1984-1988; Range, R.C., Angerer, R.C., Angerer, L.M., (2013) PLoS Biol., 11 (1), p. e1001467. , (PMCID: 3545869); Jordan, B.K., Shen, J.H., Olaso, R., Ingraham, H.A., Vilain, E., (2003) Proc. Natl. Acad. Sci. U. S. A., 100 (19), pp. 10866-10871. , (PMCID: 196894); Byrum, C.A., Xu, R., Bince, J.M., McClay, D.R., Wikramanayake, A.H., (2009) Dev. Dyn., 238 (7), pp. 1649-1665. , (PMCID: 3057072); Kang, S., Bennett, C.N., Gerin, I., Rapp, L.A., Hankenson, K.D., Macdougald, O.A., (2007) J. Biol. Chem., 282 (19), pp. 14515-14524; Komiya, Y., Habas, R., (2008) Organogenesis, 4 (2), pp. 68-75. , (PMCID: 2634250); Sugimura, R., Li, L., (2010) Birth Defects Res. C Embryo Today, 90 (4), pp. 243-256; Habas, R., Kato, Y., He, X., (2001) Cell, 107 (7), pp. 843-854; Heng, Y.W., Koh, C.G., (2010) Int. J. Biochem. Cell Biol., 42 (10), pp. 1622-1633; Beane, W.S., Gross, J.M., McClay, D.R., (2006) Dev. Biol., 292 (1), pp. 213-225; Croce, J., Duloquin, L., Lhomond, G., McClay, D.R., Gache, C., (2006) Development, 133 (3), pp. 547-557; Tada, M., Concha, M.L., Heisenberg, C.P., (2002) Semin. Cell Dev. Biol., 13 (3), pp. 251-260; Kim, G.H., Han, J.K., (2005) Dev. Dyn., 232 (4), pp. 958-968; Mierke, C.T., (2013) Phys. Biol., 10 (6), p. 065005; Ahumada, A., Slusarski, D.C., Liu, X., Moon, R.T., Malbon, C.C., Wang, H.Y., (2002) Science, 298 (5600), pp. 2006-2010; Kohn, A.D., Moon, R.T., (2005) Cell Calcium, 38 (3-4), pp. 439-446; Ma, L., Wang, H.Y., (2007) J. Biol. Chem., 282 (39), pp. 28980-28990; Sheldahl, L.C., Slusarski, D.C., Pandur, P., Miller, J.R., Kuhl, M., Moon, R.T., (2003) J. Cell Biol., 161 (4), pp. 769-777. , (PMCID: 2199364); Rao, T.P., Kuhl, M., (2010) Circ. Res., 106 (12), pp. 1798-1806; De, A., (2011) Acta Biochim. Biophys. Sin. (Shanghai), 43 (10), pp. 745-756; Habas, R., Dawid, I.B., He, X., (2003) Genes Dev., 17 (2), pp. 295-309. , (PMCID: 195976); Schlessinger, K., McManus, E.J., Hall, A., (2007) J. Cell Biol., 178 (3), pp. 355-361. , (PMCID: 2064837); Schlessinger, K., Hall, A., Tolwinski, N., (2009) Genes Dev., 23 (3), pp. 265-277; Rao, A., Luo, C., Hogan, P.G., (1997) Annu. Rev. Immunol., 15, pp. 707-747; Minami, Y., Oishi, I., Endo, M., Nishita, M., (2010) Dev. Dyn., 239 (1), pp. 1-15; Green, J., Nusse, R., van Amerongen, R., (2014) Cold Spring Harb. Perspect. Biol., 6 (2); Yoshikawa, S., McKinnon, R.D., Kokel, M., Thomas, J.B., (2003) Nature, 422 (6932), pp. 583-588; Kim, G.H., Her, J.H., Han, J.K., (2008) J. Cell Biol., 182 (6), pp. 1073-1082. , (PMCID: 2542470); Lin, S., Baye, L.M., Westfall, T.A., Slusarski, D.C., (2010) J. Cell Biol., 190 (2), pp. 263-278. , (PMCID: 2930277); Liu, Y., Shi, J., Lu, C.C., Wang, Z.B., Lyuksyutova, A.I., Song, X.J., (2005) Nat. Neurosci., 8 (9), pp. 1151-1159; Keeble, T.R., Cooper, H.M., (2006) Int. J. Biochem. Cell Biol., 38 (12), pp. 2011-2017; Lu, W., Yamamoto, V., Ortega, B., Baltimore, D., (2004) Cell, 119 (1), pp. 97-108; Keeble, T.R., Halford, M.M., Seaman, C., Kee, N., Macheda, M., Anderson, R.B., (2006) J. Neurosci., 26 (21), pp. 5840-5848; Li, L., Hutchins, B.I., Kalil, K., (2009) J. Neurosci., 29 (18), pp. 5873-5883. , (PMCID: 2697037); Macheda, M.L., Sun, W.W., Kugathasan, K., Hogan, B.M., Bower, N.I., Halford, M.M., (2012) J. Biol. Chem., 287 (35), pp. 29312-29323. , (PMCID: 3436188); Habu, M., Koyama, H., Kishida, M., Kamino, M., Iijima, M., Fuchigami, T., (2014) J. Biochem., 156 (1), pp. 29-38; Nomi, M., Oishi, I., Kani, S., Suzuki, H., Matsuda, T., Yoda, A., (2001) Mol. Cell. Biol., 21 (24), pp. 8329-8335. , (PMCID: 99997); DeChiara, T.M., Kimble, R.B., Poueymirou, W.T., Rojas, J., Masiakowski, P., Valenzuela, D.M., (2000) Nat. Genet., 24 (3), pp. 271-274; Oldridge, M., Fortuna, A.M., Maringa, M., Propping, P., Mansour, S., Pollitt, C., (2000) Nat. Genet., 24 (3), pp. 275-278; Schwabe, G.C., Trepczik, B., Suring, K., Brieske, N., Tucker, A.S., Sharpe, P.T., (2004) Dev. Dyn., 229 (2), pp. 400-410; Baskar, S., Kwong, K.Y., Hofer, T., Levy, J.M., Kennedy, M.G., Lee, E., (2008) Clin. Cancer Res., 14 (2), pp. 396-404; Shabani, M., Asgarian-Omran, H., Vossough, P., Sharifian, R.A., Faranoush, M., Ghragozlou, S., (2008) Leuk. Lymphoma, 49 (7), pp. 1360-1367; Zhang, S., Chen, L., Cui, B., Chuang, H.Y., Yu, J., Wang-Rodriguez, J., (2012) PLoS ONE, 7 (3), p. e31127. , (PMCID: 3293865); Rabbani, H., Ostadkarampour, M., Danesh Manesh, A.H., Basiri, A., Jeddi-Tehrani, M., Forouzesh, F., (2010) Iran. Biomed. J., 14 (3), pp. 77-82. , (PMCID: 3904057); Wright, T.M., Brannon, A.R., Gordan, J.D., Mikels, A.J., Mitchell, C., Chen, S., (2009) Oncogene, 28 (27), pp. 2513-2523. , (PMCID: 2771692); Edris, B., Espinosa, I., Muhlenberg, T., Mikels, A., Lee, C.H., Steigen, S.E., (2012) J. Pathol., 227 (2), pp. 223-233. , (PMCID: 3992120); Kobayashi, M., Shibuya, Y., Takeuchi, J., Murata, M., Suzuki, H., Yokoo, S., (2009) Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 107 (3), pp. 398-406; Bicocca, V.T., Chang, B.H., Masouleh, B.K., Muschen, M., Loriaux, M.M., Druker, B.J., (2012) Cancer Cell, 22 (5), pp. 656-667. , (PMCID: 3500515); Rebagay, G., Yan, S., Liu, C., Cheung, N.K., (2012) Front Oncol., 2, p. 34. , (PMCID: 3356025); Axelrod, J.D., (2009) Semin. Cell Dev. Biol., 20 (8), pp. 964-971; Simons, M., Mlodzik, M., (2008) Annu. Rev. Genet., 42, pp. 517-540. , (PMCID: 2814158); Kikuchi, A., Yamamoto, H., Sato, A., Matsumoto, S., (2011) Int. Rev. Cell Mol. Biol., 291, pp. 21-71; Tanaka, K., Kitagawa, Y., Kadowaki, T., (2002) J. Biol. Chem., 277 (15), pp. 12816-12823; Burrus, L.W., McMahon, A.P., (1995) Exp. Cell Res., 220 (2), pp. 363-373; Janda, C.Y., Waghray, D., Levin, A.M., Thomas, C., Garcia, K.C., (2012) Science, 337 (6090), pp. 59-64. , (PMCID: 3577348); MacDonald, B.T., Hien, A., Zhang, X., Iranloye, O., Virshup, D.M., Waterman, M.L., (2014) J. Biol. Chem., 289 (26), pp. 18122-18136. , (PMCID: 4140276); Verras, M., Papandreou, I., Lim, A.L., Denko, N.C., (2008) Mol. Cell. Biol., 28 (23), pp. 7212-7224. , (PMCID: 2593368); Takada, R., Satomi, Y., Kurata, T., Ueno, N., Norioka, S., Kondoh, H., (2006) Dev. Cell, 11 (6), pp. 791-801; Zhai, L., Chaturvedi, D., Cumberledge, S., (2004) J. Biol. Chem., 279 (32), pp. 33220-33227; Ching, W., Hang, H.C., Nusse, R., (2008) J. Biol. Chem., 283 (25), pp. 17092-17098. , (PMCID: 2427328); Komekado, H., Yamamoto, H., Chiba, T., Kikuchi, A., (2007) Genes Cells, 12 (4), pp. 521-534; Willert, K., Brown, J.D., Danenberg, E., Duncan, A.W., Weissman, I.L., Reya, T., (2003) Nature, 423 (6938), pp. 448-452; Herr, P., Basler, K., (2012) Dev. Biol., 361 (2), pp. 392-402; Banziger, C., Soldini, D., Schutt, C., Zipperlen, P., Hausmann, G., Basler, K., (2006) Cell, 125 (3), pp. 509-522; Bartscherer, K., Pelte, N., Ingelfinger, D., Boutros, M., (2006) Cell, 125 (3), pp. 523-533; Goodman, R.M., Thombre, S., Firtina, Z., Gray, D., Betts, D., Roebuck, J., (2006) Development, 133 (24), pp. 4901-4911; Najdi, R., Proffitt, K., Sprowl, S., Kaur, S., Yu, J., Covey, T.M., (2012) Differentiation, 84 (2), pp. 203-213. , (PMCID: 4015730); Gross, J.C., Chaudhary, V., Bartscherer, K., Boutros, M., (2012) Nat. Cell Biol., 14 (10), pp. 1036-1045; Koles, K., Nunnari, J., Korkut, C., Barria, R., Brewer, C., Li, Y., (2012) J. Biol. Chem., 287 (20), pp. 16820-16834. , (PMCID: 3351299); Mulligan, K.A., Fuerer, C., Ching, W., Fish, M., Willert, K., Nusse, R., (2012) Proc. Natl. Acad. Sci. U. S. A., 109 (2), pp. 370-377. , (PMCID: 3258625); Neumann, S., Coudreuse, D.Y., van der Westhuyzen, D.R., Eckhardt, E.R., Korswagen, H.C., Schmitz, G., (2009) Traffic, 10 (3), pp. 334-343; Greco, V., Hannus, M., Eaton, S., (2001) Cell, 106 (5), pp. 633-645; Hsiung, F., Ramirez-Weber, F.A., Iwaki, D.D., Kornberg, T.B., (2005) Nature, 437 (7058), pp. 560-563; Korkut, C., Ataman, B., Ramachandran, P., Ashley, J., Barria, R., Gherbesi, N., (2009) Cell, 139 (2), pp. 393-404. , (PMCID: 2785045); Panakova, D., Sprong, H., Marois, E., Thiele, C., Eaton, S., (2005) Nature, 435 (7038), pp. 58-65; Grzeschik, K.H., Bornholdt, D., Oeffner, F., Konig, A., del Carmen, B.M., Enders, H., (2007) Nat. Genet., 39 (7), pp. 833-835; Wang, X., Reid Sutton, V., Omar Peraza-Llanes, J., Yu, Z., Rosetta, R., Kou, Y.C., (2007) Nat. Genet., 39 (7), pp. 836-838; Barrott, J.J., Cash, G.M., Smith, A.P., Barrow, J.R., Murtaugh, L.C., (2011) Proc. Natl. Acad. Sci. U. S. A., 108 (31), pp. 12752-12757. , (PMCID: 3150921); Biechele, S., Cox, B.J., Rossant, J., (2011) Dev. Biol., 355 (2), pp. 275-285; Cui, M., Siriwon, N., Li, E., Davidson, E.H., Peter, I.S., (2014) Proc. Natl. Acad. Sci. U. S. A., 111 (47), pp. E5029-E5038. , (PMCID: 4250154); Fu, J., Jiang, M., Mirando, A.J., Yu, H.M., Hsu, W., (2009) Proc. Natl. Acad. Sci. U. S. A., 106 (44), pp. 18598-18603. , (PMCID: 2773984); Carpenter, A.C., Rao, S., Wells, J.M., Campbell, K., Lang, R.A., (2010) Genesis, 48 (9), pp. 554-558. , (PMCID: 3689319); Voloshanenko, O., Erdmann, G., Dubash, T.D., Augustin, I., Metzig, M., Moffa, G., (2013) Nat. Commun., 4, p. 2610. , (PMCID: 3826636); Giraldez, A.J., Copley, R.R., Cohen, S.M., (2002) Dev. Cell, 2 (5), pp. 667-676; Zhang, X., Abreu, J.G., Yokota, C., MacDonald, B.T., Singh, S., Coburn, K.L., (2012) Cell, 149 (7), pp. 1565-1577. , (PMCID: 3383638); Zhang, X., Cheong, S.M., Amado, N.G., Reis, A.H., MacDonald, B.T., Zebisch, M., (2015) Dev. Cell, 32 (6), pp. 719-730; Kakugawa, S., Langton, P.F., Zebisch, M., Howell, S.A., Chang, T.H., Liu, Y., (2015) Nature, 519 (7542), pp. 187-192; Gerlitz, O., Nellen, D., Ottiger, M., Basler, K., (2002) Int. J. Dev. Biol., 46 (1), pp. 173-176; Flowers, G.P., Topczewska, J.M., Topczewski, J., (2012) Development, 139 (13), pp. 2416-2425. , (PMCID: 3367448); Petersen, C.P., Reddien, P.W., (2011) Science, 332 (6031), pp. 852-855. , (PMCID: 3320723); Nusse, R., (2015) Nature, 519 (7542), pp. 163-164; Teh, M.T., Blaydon, D., Ghali, L.R., Briggs, V., Edmunds, S., Pantazi, E., (2007) J. Cell Sci., 120, pp. 330-339; Onizuka, T., Yuasa, S., Kusumoto, D., Shimoji, K., Egashira, T., Ohno, Y., (2012) J. Mol. Cell. Cardiol., 52 (3), pp. 650-659; Karasawa, T., Yokokura, H., Kitajewski, J., Lombroso, P.J., (2002) J. Biol. Chem., 277 (40), pp. 37479-37486; Endo, Y., Beauchamp, E., Woods, D., Taylor, W.G., Toretsky, J.A., Uren, A., (2008) Mol. Cell. Biol., 28 (7), pp. 2368-2379. , (PMCID: 2268413); Galli, L.M., Munji, R.N., Chapman, S.C., Easton, A., Li, L., Onguka, O., (2014) Dev. Dyn., 243 (6), pp. 833-843. , (PMCID: 4031291); Varela-Nallar, L., Grabowski, C.P., Alfaro, I.E., Alvarez, A.R., Inestrosa, N.C., (2009) Neural Dev., 4, p. 41. , (PMCID: 2779803); Lyons, J.P., Mueller, U.W., Ji, H., Everett, C., Fang, X., Hsieh, J.C., (2004) Exp. Cell Res., 298 (2), pp. 369-387; Heinonen, K.M., Vanegas, J.R., Lew, D., Krosl, J., Perreault, C., (2011) PLoS ONE, 6 (4), p. e19279. , (PMCID: 3082562); Umbhauer, M., Djiane, A., Goisset, C., Penzo-Mendez, A., Riou, J.F., Boucaut, J.C., (2000) EMBO J., 19 (18), pp. 4944-4954. , (PMCID: 314225); Chen, W., ten Berge, D., Brown, J., Ahn, S., Hu, L.A., Miller, W.E., (2003) Science, 301 (5638), pp. 1391-1394; Robitaille, J., MacDonald, M.L., Kaykas, A., Sheldahl, L.C., Zeisler, J., Dube, M.P., (2002) Nat. Genet., 32 (2), pp. 326-330; Hering, H., Sheng, M., (2002) FEBS Lett., 521 (1-3), pp. 185-189; Medina, A., Reintsch, W., Steinbeisser, H., (2000) Mech. Dev., 92 (2), pp. 227-237; Le Grand, F., Jones, A.E., Seale, V., Scime, A., Rudnicki, M.A., (2009) Cell Stem Cell, 4 (6), pp. 535-547. , (PMCID: 2743383); De Calisto, J., Araya, C., Marchant, L., Riaz, C.F., Mayor, R., (2005) Development, 132 (11), pp. 2587-2597; Nalesso, G., Sherwood, J., Bertrand, J., Pap, T., Ramachandran, M., De Bari, C., (2011) J. Cell Biol., 193 (3), pp. 551-564. , (PMCID: 3087013); Schroeder, K.E., Condic, M.L., Eisenberg, L.M., Yost, H.J., (1999) Dev. Biol., 214 (2), pp. 288-297; Kuhl, M., Sheldahl, L.C., Malbon, C.C., Moon, R.T., (2000) J. Biol. Chem., 275 (17), pp. 12701-12711; Tao, Q., Yokota, C., Puck, H., Kofron, M., Birsoy, B., Yan, D., (2005) Cell, 120 (6), pp. 857-871; Slusarski, D.C., Corces, V.G., Moon, R.T., (1997) Nature, 390 (6658), pp. 410-413; Kestler, H.A., Kuhl, M., (2011) J. Cell Biol., 193 (3), pp. 431-433. , (PMCID: 3087014); Ishitani, T., Kishida, S., Hyodo-Miura, J., Ueno, N., Yasuda, J., Waterman, M., (2003) Mol. Cell. Biol., 23 (1), pp. 131-139. , (PMCID: 140665); Bartel, D.P., (2004) Cell, 116 (2), pp. 281-297; Lee, R.C., Feinbaum, R.L., Ambros, V., (1993) Cell, 75 (5), pp. 843-854; Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, J.C., Rougvie, A.E., (2000) Nature, 403 (6772), pp. 901-906; Bartel, D.P., (2009) Cell, 136 (2), pp. 215-233; Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., (2005) Nature, 433 (7027), pp. 769-773; Giraldez, A.J., Mishima, Y., Rihel, J., Grocock, R.J., Van Dongen, S., Inoue, K., (2006) Science, 312 (5770), pp. 75-79; Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., Rajewsky, N., (2008) Nature, 455 (7209), pp. 58-63; He, L., Hannon, G.J., (2004) Nat. Rev. Genet., 5 (7), pp. 522-531; Iorio, M.V., Croce, C.M., (2012) EMBO Mol. Med., 4 (3), pp. 143-159. , (PMCID: 3376845); Zhu, S., Pan, W., Qian, Y., (2013) J. Mol. Med. (Berl.), 91 (9), pp. 1039-1050; Bian, S., Sun, T., (2011) Mol. Neurobiol., 44 (3), pp. 359-373. , (PMCID: 3246283); Kim, V.N., Nam, J.W., (2006) Trends Genet., 22 (3), pp. 165-173; Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., (2005) Cancer Res., 65 (21), pp. 9628-9632; Han, J., Lee, Y., Yeom, K.H., Nam, J.W., Heo, I., Rhee, J.K., (2006) Cell, 125 (5), pp. 887-901; Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., (2003) Nature, 425 (6956), pp. 415-419; Lund, E., Dahlberg, J.E., (2006) Cold Spring Harb. Symp. Quant. Biol., 71, pp. 59-66; Zhang, H., Kolb, F.A., Brondani, V., Billy, E., Filipowicz, W., (2002) EMBO J., 21 (21), pp. 5875-5885; Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., Zamore, P.D., (2003) Cell, 115 (2), pp. 199-208; Khvorova, A., Reynolds, A., Jayasena, S.D., (2003) Cell, 115 (2), pp. 209-216; Okamura, K., Phillips, M.D., Tyler, D.M., Duan, H., Chou, Y.T., Lai, E.C., (2008) Nat. Struct. Mol. Biol., 15 (4), pp. 354-363. , (PMCID: 2698667); Ruby, J.G., Jan, C.H., Bartel, D.P., (2007) Nature, 448 (7149), pp. 83-86; Okamura, K., Hagen, J.W., Duan, H., Tyler, D.M., Lai, E.C., (2007) Cell, 130 (1), pp. 89-100; Berezikov, E., Chung, W.J., Willis, J., Cuppen, E., Lai, E.C., (2007) Mol. Cell, 28 (2), pp. 328-336. , (PMCID: 2763384); Kim, Y.K., Kim, V.N., (2007) EMBO J., 26 (3), pp. 775-783. , (PMCID: 1794378); Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P., Burge, C.B., (2003) Cell, 115 (7), pp. 787-798; Lewis, B.P., Burge, C.B., Bartel, D.P., (2005) Cell, 120 (1), pp. 15-20; Brennecke, J., Stark, A., Russell, R.B., Cohen, S.M., (2005) PLoS Biol., 3 (3), p. e85. , (PMCID: 1043860); Krek, A., Grun, D., Poy, M.N., Wolf, R., Rosenberg, L., Epstein, E.J., (2005) Nat. Genet., 37 (5), pp. 495-500; Lim, L.P., Lau, N.C., Weinstein, E.G., Abdelhakim, A., Yekta, S., Rhoades, M.W., (2003) Genes Dev., 17 (8), pp. 991-1008. , (PMCID: 196042); Lai, E.C., (2002) Nat. Genet., 30 (4), pp. 363-364; Grimson, A., Farh, K.K., Johnston, W.K., Garrett-Engele, P., Lim, L.P., Bartel, D.P., (2007) Mol. Cell, 27 (1), pp. 91-105; Xie, X., Lu, J., Kulbokas, E.J., Golub, T.R., Mootha, V., Lindblad-Toh, K., (2005) Nature, 434 (7031), pp. 338-345; Friedman, R.C., Farh, K.K., Burge, C.B., Bartel, D.P., (2009) Genome Res., 19 (1), pp. 92-105; Tay, Y., Zhang, J., Thomson, A.M., Lim, B., Rigoutsos, I., (2008) Nature, 455 (7216), pp. 1124-1128; Chekulaeva, M., Filipowicz, W., (2009) Curr. Opin. Cell Biol., 21 (3), pp. 452-460; Place, R.F., Li, L.C., Pookot, D., Noonan, E.J., Dahiya, R., (2008) Proc. Natl. Acad. Sci. U. S. A., 105 (5), pp. 1608-1613. , (PMCID: 2234192); Alvarez-Garcia, I., Miska, E.A., (2005) Development, 132 (21), pp. 4653-4662; Bushati, N., Cohen, S.M., (2007) Annu. Rev. Cell Dev. Biol., 23, pp. 175-205; Ambros, V., (2004) Nature, 431 (7006), pp. 350-355; Wienholds, E., Plasterk, R.H., (2005) FEBS Lett., 579 (26), pp. 5911-5922; Bernstein, E., Kim, S.Y., Carmell, M.A., Murchison, E.P., Alcorn, H., Li, M.Z., (2003) Nat. Genet., 35 (3), pp. 215-217; Giraldez, A.J., Cinalli, R.M., Glasner, M.E., Enright, A.J., Thomson, J.M., Baskerville, S., (2005) Science, 308 (5723), pp. 833-838; Song, J.L., Stoeckius, M., Maaskola, J., Friedlander, M., Stepicheva, N., Juliano, C., (2012) Dev. Biol., 362 (1), pp. 104-113. , (PMCID: 3254792); Ivey, K.N., Srivastava, D., (2010) Cell Stem Cell, 7 (1), pp. 36-41; Mukherji, S., Ebert, M.S., Zheng, G.X., Tsang, J.S., Sharp, P.A., van Oudenaarden, A., (2011) Nat. Genet., 43 (9), pp. 854-859. , (PMCID: 3163764); Jovanovic, M., Hengartner, M.O., (2006) Oncogene, 25 (46), pp. 6176-6187; Stark, A., Brennecke, J., Russell, R.B., Cohen, S.M., (2003) PLoS Biol., 1 (3), p. E60; Martello, G., Zacchigna, L., Inui, M., Montagner, M., Adorno, M., Mamidi, A., (2007) Nature, 449 (7159), pp. 183-188; Niehrs, C., (2004) Nat. Rev. Genet., 5 (6), pp. 425-434; Meng, F., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T., Patel, T., (2007) Gastroenterology, 133 (2), pp. 647-658. , (PMCID: 4285346); Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., (2008) Nature, 456 (7224), pp. 980-984; Fish, J.E., Santoro, M.M., Morton, S.U., Yu, S., Yeh, R.F., Wythe, J.D., (2008) Dev. Cell, 15 (2), pp. 272-284. , (PMCID: 2604134); Kuhnert, F., Mancuso, M.R., Hampton, J., Stankunas, K., Asano, T., Chen, C.Z., (2008) Development, 135 (24), pp. 3989-3993; Kim, N.H., Kim, H.S., Kim, N.G., Lee, I., Choi, H.S., Li, X.Y., (2011) Sci. Signal., 4 (197), p. ra71. , (PMCID: 3447368); Stepicheva, N., Nigam, P.A., Siddam, A., Peng, C.F., Song, J.L., (2015) Dev. Biol., (15). , http://dx.doi.org/10.106/j.ydbio.2015.01.008, 00016-0, (PMID: 261438), S0012-1606; Anton, R., Chatterjee, S.S., Simundza, J., Cowin, P., Dasgupta, R., (2011) PLoS ONE, 6 (10), p. e26257. , (PMCID: 3197157); Bianco, P., Riminucci, M., Gronthos, S., Robey, P.G., (2001) Stem Cells, 19 (3), pp. 180-192; Inose, H., Ochi, H., Kimura, A., Fujita, K., Xu, R., Sato, S., (2009) Proc. Natl. Acad. Sci. U. S. A., 106 (49), pp. 20794-20799. , (PMCID: 2791638); Kang, H., Hata, A., (2014) BMB Rep., , (PMID: 25341923); Lin, G.L., Hankenson, K.D., (2011) J. Cell. Biochem., 112 (12), pp. 3491-3501. , (PMCID: 3202082); Vimalraj, S., Selvamurugan, N., (2012) Curr. Issues Mol. Biol., 15 (1), pp. 7-18; Wang, T., Xu, Z., (2010) Biochem. Biophys. Res. Commun., 402 (2), pp. 186-189; Hu, W., Ye, Y., Zhang, W., Wang, J., Chen, A., Guo, F., (2013) Mol. Med. Rep., 7 (2), pp. 689-693; Chen, C., Peng, Y., Peng, J., Jiang, S., (2014) J. Mol. Endocrinol., 52 (3), pp. 311-320; Kapinas, K., Kessler, C., Ricks, T., Gronowicz, G., Delany, A.M., (2010) J. Biol. Chem., 285 (33), pp. 25221-25231. , (PMCID: 2919085); Zhang, J., Tu, Q., Bonewald, L.F., He, X., Stein, G., Lian, J., (2011) J. Bone Miner. Res., 26 (8), pp. 1953-1963. , (PMCID: 3810406); Zhang, W.B., Zhong, W.J., Wang, L., (2014) Bone, 58, pp. 59-66; Chen, H., Mo, D., Li, M., Zhang, Y., Chen, L., Zhang, X., (2014) Cell. Signal., 26 (11), pp. 2583-2589; Chen, H., Wang, S., Chen, L., Chen, Y., Wu, M., Zhang, Y., (2014) FEBS Lett., 588 (3), pp. 429-435; Wang, Q., Cai, J., Cai, X.H., Chen, L., (2013) PLoS ONE, 8 (9), p. e72266. , (PMCID: 3762871); Wu, T., Zhou, H., Hong, Y., Li, J., Jiang, X., Huang, H., (2012) J. Biol. Chem., 287 (10), pp. 7503-7511. , (PMCID: 3293535); Qin, L., Chen, Y., Niu, Y., Chen, W., Wang, Q., Xiao, S., (2010) BMC Genomics, 11, p. 320. , (PMCID: 2895628); Kennell, J.A., Gerin, I., MacDougald, O.A., Cadigan, K.M., (2008) Proc. Natl. Acad. Sci. U. S. A., 105 (40), pp. 15417-15422. , (PMCID: 2563117); Arfat, Y., Xiao, W.Z., Ahmad, M., Zhao, F., Li, D.J., Sun, Y.L., (2014) Curr. Med. Chem., 22 (6), pp. 748-758; Olson, E.N., (2006) Science, 313 (5795), pp. 1922-1927; Chen, J., Wang, D.Z., (2012) J. Mol. Cell. Cardiol., 52 (5), pp. 949-957. , (PMCID: 3721071); Zhao, Y., Ransom, J.F., Li, A., Vedantham, V., von Drehle, M., Muth, A.N., (2007) Cell, 129 (2), pp. 303-317; Rao, P.K., Toyama, Y., Chiang, H.R., Gupta, S., Bauer, M., Medvid, R., (2009) Circ. Res., 105 (6), pp. 585-594. , (PMCID: 2828903); Li, M., Hu, X., Zhu, J., Zhu, C., Zhu, S., Liu, X., (2014) Cell. Physiol. Biochem., 33 (6), pp. 1988-2002; Qin, D.N., Qian, L., Hu, D.L., Yu, Z.B., Han, S.P., Zhu, C., (2013) Cell Biochem. Biophys., 66 (3), pp. 709-722; Zhang, L.L., Liu, J.J., Liu, F., Liu, W.H., Wang, Y.S., Zhu, B., (2012) Biochem. Biophys. Res. Commun., 420 (4), pp. 875-881; Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond, S.M., (2006) Nat. Genet., 38 (2), pp. 228-233. , (PMCID: 2538576); Kwon, C., Han, Z., Olson, E.N., Srivastava, D., (2005) Proc. Natl. Acad. Sci. U. S. A., 102 (52), pp. 18986-18991; Lu, T.Y., Lin, B., Li, Y., Arora, A., Han, L., Cui, C., (2013) J. Mol. Cell. Cardiol., 63 C, pp. 146-154; Sun, E., Shi, Y., (2014) Exp. Neurol.; Follert, P., Cremer, H., Beclin, C., (2014) Front. Mol. Neurosci., 7, p. 5. , (PMCID: 3916726); Petri, R., Malmevik, J., Fasching, L., Akerblom, M., Jakobsson, J., (2014) Exp. Cell Res., 321 (1), pp. 84-89; Liu, Y., Huang, T., Zhao, X., Cheng, L., (2011) Biochem. Biophys. Res. Commun., 408 (2), pp. 259-264; Anderegg, A., Lin, H.P., Chen, J.A., Caronia-Brown, G., Cherepanova, N., Yun, B., (2013) PLoS Genet., 9 (12), p. e1003973. , (PMCID: 3861205); Wu, D., Raafat, A., Pak, E., Clemens, S., Murashov, A.K., (2012) Exp. Neurol., 233 (1), pp. 555-565. , (PMCID: 3268911); Wu, D., Murashov, A.K., (2013) Front. Mol. Neurosci., 6, p. 35. , (PMCID: 3807041); Kim, Y., Capel, B., (2006) Dev. Dyn., 235 (9), pp. 2292-2300; Bernard, P., Harley, V.R., (2007) Int. J. Biochem. Cell Biol., 39 (1), pp. 31-43; Pancratov, R., Peng, F., Smibert, P., Yang, S., Olson, E.R., Guha-Gilford, C., (2013) Development, 140 (14), pp. 2904-2916. , (PMCID: 3699279); Wang, Y., Huang, C., Reddy Chintagari, N., Bhaskaran, M., Weng, T., Guo, Y., (2013) Nucleic Acids Res., 41 (6), pp. 3833-3844. , (PMCID: 3616718); Ye, X., Hemida, M.G., Qiu, Y., Hanson, P.J., Zhang, H.M., Yang, D., (2013) Cell. Mol. Life Sci., 70 (23), pp. 4631-4644; Alexander, M.S., Kawahara, G., Motohashi, N., Casar, J.C., Eisenberg, I., Myers, J.A., (2013) Cell Death Differ., 20 (9), pp. 1194-1208. , (PMCID: 3741500); Slobodov, G., Feloney, M., Gran, C., Kyker, K.D., Hurst, R.E., Culkin, D.J., (2004) J. Urol., 171 (4), pp. 1554-1558; Sanchez Freire, V., Burkhard, F.C., Kessler, T.M., Kuhn, A., Draeger, A., Monastyrskaya, K., (2010) Am. J. Pathol., 176 (1), pp. 288-303. , (PMCID: 2797891); Monastyrskaya, K., Sanchez-Freire, V., Hashemi Gheinani, A., Klumpp, D.J., Babiychuk, E.B., Draeger, A., (2013) Am. J. Pathol., 182 (2), pp. 431-448; Hashemi Gheinani, A., Burkhard, F.C., Rehrauer, H., Aquino Fournier, C., Monastyrskaya, K., (2015) J. Biol. Chem., 290 (11), pp. 7067-7086; Simonson, M.S., (2007) Kidney Int., 71 (9), pp. 846-854; Mishra, R., Cool, B.L., Laderoute, K.R., Foretz, M., Viollet, B., Simonson, M.S., (2008) J. Biol. Chem., 283 (16), pp. 10461-10469; Mishra, R., Simonson, M.S., (2008) Arterioscler. Thromb. Vasc. Biol., 28 (3), pp. 541-547; Mu, J., Pang, Q., Guo, Y.H., Chen, J.G., Zeng, W., Huang, Y.J., (2013) PLoS ONE, 8 (3), p. e58622. , (PMCID: 3595285); Sun, X., He, Y., Huang, C., Ma, T.T., Li, J., (2013) Cell. Signal., 25 (12), pp. 2805-2811; Saydam, O., Shen, Y., Wurdinger, T., Senol, O., Boke, E., James, M.F., (2009) Mol. Cell. Biol., 29 (21), pp. 5923-5940. , (PMCID: 2772747); Goodenberger, M.L., Jenkins, R.B., (2012) Cancer Genet., 205 (12), pp. 613-621; Delic, S., Lottmann, N., Stelzl, A., Liesenberg, F., Wolter, M., Gotze, S., (2014) Neuro Oncol., 16 (2), pp. 179-190. , (PMCID: 3895379); Guo, M., Zhang, X., Wang, G., Sun, J., Jiang, Z., Khadarian, K., (2015) Cancer Lett., 360 (1), pp. 76-86; Yan, Z., Wang, J., Wang, C., Jiao, Y., Qi, W., Che, S., (2014) FEBS Lett., 588 (17), pp. 3038-3046; Chen, L., Zhang, A., Li, Y., Zhang, K., Han, L., Du, W., (2013) Cancer Lett., 329 (2), pp. 174-180; Li, Q., Shen, K., Zhao, Y., He, X., Ma, C., Wang, L., (2013) FEBS Lett., 587 (12), pp. 1742-1748; Li, Q., Shen, K., Zhao, Y., Ma, C., Liu, J., Ma, J., (2013) J. Transl. Med., 11, p. 302. , (PMCID: 4028874); Wang, X., Wang, K., Han, L., Zhang, A., Shi, Z., Zhang, K., (2013) Cancer Lett., 331 (2), pp. 211-219; Gokhale, A., Kunder, R., Goel, A., Sarin, R., Moiyadi, A., Shenoy, A., (2010) J. Cancer Res. Ther., 6 (4), pp. 521-529; http://www.cancer.org/acs/groups/content/documents/document/acspc-042280.pdf, Available from:Kim, N.H., Cha, Y.H., Kang, S.E., Lee, Y., Lee, I., Cha, S.Y., (2013) Cell Cycle, 12 (10), pp. 1578-1587. , (PMCID: 3680537); Zhang, H., Hao, Y., Yang, J., Zhou, Y., Li, J., Yin, S., (2011) Nat. Commun., 2, p. 554; Subramanian, M., Rao, S.R., Thacker, P., Chatterjee, S., Karunagaran, D., (2014) J. Cell. Biochem., 115 (11), pp. 1974-1984; Ke, T.W., Hsu, H.L., Wu, Y.H., Chen, W.T., Cheng, Y.W., Cheng, C.W., (2014) Dis. Markers, 2014, p. 617150. , (PMCID: 4004168); Strillacci, A., Valerii, M.C., Sansone, P., Caggiano, C., Sgromo, A., Vittori, L., (2013) J. Pathol., 229 (3), pp. 379-389; Tang, Q., Zou, Z., Zou, C., Zhang, Q., Huang, R., Guan, X., (2015) Tumour Biol., 36 (3), pp. 1701-1710; Yamada, N., Noguchi, S., Mori, T., Naoe, T., Maruo, K., Akao, Y., (2013) Cancer Lett., 335 (2), pp. 332-342; Nagel, R., le Sage, C., Diosdado, B., van der Waal, M., Oude Vrielink, J.A., Bolijn, A., (2008) Cancer Res., 68 (14), pp. 5795-5802; Ji, S., Ye, G., Zhang, J., Wang, L., Wang, T., Wang, Z., (2013) Gut, 62 (5), pp. 716-726. , (PMCID: 3618686); Yu, Y., Kanwar, S.S., Patel, B.B., Oh, P.S., Nautiyal, J., Sarkar, F.H., (2012) Carcinogenesis, 33 (1), pp. 68-76. , (PMCID: 3276336); Zhang, N., Li, X., Wu, C.W., Dong, Y., Cai, M., Mok, M.T., (2013) Oncogene, 32 (42), pp. 5078-5088; Xia, H., Ooi, L.L., Hui, K.M., (2012) PLoS ONE, 7 (9), p. e44206. , (PMCID: 3433464); Wang, X., Chen, J., Li, F., Lin, Y., Zhang, X., Lv, Z., (2012) Biochem. Biophys. Res. Commun., 428 (4), pp. 525-531; Gu, W., Li, X., Wang, J., (2014) Oncol. Rep., 31 (1), pp. 397-404; Xu, J., Zhu, X., Wu, L., Yang, R., Yang, Z., Wang, Q., (2012) Liver Int., 32 (5), pp. 752-760; Zhang, J.G., Shi, Y., Hong, D.F., Song, M., Huang, D., Wang, C.Y., (2015) Sci. Rep., 5, p. 8087; Wu, L., Cai, C., Wang, X., Liu, M., Li, X., Tang, H., (2011) FEBS Lett., 585 (9), pp. 1322-1330; Tang, J., Tao, Z.H., Wen, D., Wan, J.L., Liu, D.L., Zhang, S., (2014) Biochem. Biophys. Res. Commun., 447 (1), pp. 210-215; Tao, Z.H., Wan, J.L., Zeng, L.Y., Xie, L., Sun, H.C., Qin, L.X., (2013) J. Exp. Med., 210 (4), pp. 789-803. , (PMCID: 3620363); Law, P.T., Ching, A.K., Chan, A.W., Wong, Q.W., Wong, C.K., To, K.F., (2012) Carcinogenesis, 33 (6), pp. 1134-1141; Dearth, R.K., Cui, X., Kim, H.J., Kuiatse, I., Lawrence, N.A., Zhang, X., (2006) Mol. Cell. Biol., 26 (24), pp. 9302-9314. , (PMCID: 1698542); Longato, L., de la Monte, S., Kuzushita, N., Horimoto, M., Rogers, A.B., Slagle, B.L., (2009) Hepatology, 49 (6), pp. 1935-1943. , (PMCID: 2754284); Shen, G., Jia, H., Tai, Q., Li, Y., Chen, D., (2013) Carcinogenesis, 34 (1), pp. 211-219; Zhang, Y., Wei, W., Cheng, N., Wang, K., Li, B., Jiang, X., (2012) Hepatology, 56 (5), pp. 1631-1640; Xu, N., Shen, C., Luo, Y., Xia, L., Xue, F., Xia, Q., (2012) Biochem. Biophys. Res. Commun., 425 (2), pp. 468-472; Hua, H.W., Jiang, F., Huang, Q., Liao, Z., Ding, G., (2015) Oncotarget, 6 (6), pp. 3840-3847; Sachdeva, M., Mo, Y.Y., (2010) Cancer Res., 70 (1), pp. 378-387. , (PMCID: 2805032); Kim, S.J., Oh, J.S., Shin, J.Y., Lee, K.D., Sung, K.W., Nam, S.J., (2011) J. Control. Release, 155 (3), pp. 427-434; Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szasz, A.M., Wang, Z.C., (2009) Cell, 137 (6), pp. 1032-1046; Valastyan, S., Weinberg, R.A., (2010) Cell Cycle, 9 (11); Xi, S., Yang, M., Tao, Y., Xu, H., Shan, J., Inchauste, S., (2010) PLoS ONE, 5 (10), p. e13764. , (PMCID: 2966442); De Menna, M., D'Amato, V., Ferraro, A., Fusco, A., Di Lauro, R., Garbi, C., (2013) Oncogene, 32 (35), pp. 4110-4119; Cai, J., Guan, H., Fang, L., Yang, Y., Zhu, X., Yuan, J., (2013) J. Clin. Invest., 123 (2), pp. 566-579. , (PMCID: 3561816); Isobe, T., Hisamori, S., Hogan, D.J., Zabala, M., Hendrickson, D.G., Dalerba, P., (2014) Elife, 3. , (PMCID: 4235011); Weilbaecher, K.N., Guise, T.A., McCauley, L.K., (2011) Nat. Rev. Cancer, 11 (6), pp. 411-425. , (PMCID: 3666847); Hassan, M.Q., Gordon, J.A., Beloti, M.M., Croce, C.M., van Wijnen, A.J., Stein, J.L., (2010) Proc. Natl. Acad. Sci. U. S. A., 107 (46), pp. 19879-19884. , (PMCID: 2993380); Lian, J.B., Stein, G.S., van Wijnen, A.J., Stein, J.L., Hassan, M.Q., Gaur, T., (2012) Nat. Rev. Endocrinol., 8 (4), pp. 212-227. , (PMCID: 3589914); Li, Z., Hassan, M.Q., Volinia, S., van Wijnen, A.J., Stein, J.L., Croce, C.M., (2008) Proc. Natl. Acad. Sci. U. S. A., 105 (37), pp. 13906-13911. , (PMCID: 2544552); Hassan, M.Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J.A., (2012) J. Biol. Chem., 287 (50), pp. 42084-42092. , (PMCID: 3516754); Iliopoulos, D., Bimpaki, E.I., Nesterova, M., Stratakis, C.A., (2009) Cancer Res., 69 (8), pp. 3278-3282. , (PMCID: 3124768); Guo, Y., Ying, L., Tian, Y., Yang, P., Zhu, Y., Wang, Z., (2013) FEBS J., 280 (18), pp. 4531-4538; Hirata, H., Ueno, K., Shahryari, V., Tanaka, Y., Tabatabai, Z.L., Hinoda, Y., (2012) PLoS ONE, 7 (11), p. e51056. , (PMCID: 3511415); Ueno, K., Hirata, H., Majid, S., Yamamura, S., Shahryari, V., Tabatabai, Z.L., (2012) Mol. Cancer Ther., 11 (1), pp. 244-253. , (PMCID: 3940358); Hirata, H., Hinoda, Y., Ueno, K., Nakajima, K., Ishii, N., Dahiya, R., (2012) Carcinogenesis, 33 (3), pp. 501-508. , (PMCID: 3291860); Hirata, H., Hinoda, Y., Ueno, K., Shahryari, V., Tabatabai, Z.L., Dahiya, R., (2012) Carcinogenesis, 33 (1), pp. 41-48. , (PMCID: 3276333); Wang, Z., Humphries, B., Xiao, H., Jiang, Y., Yang, C., (2014) J. Biol. Chem., 289 (26), pp. 18373-18386. , (PMCID: 4140296); Zhang, J., Han, C., Wu, T., (2012) Gastroenterology, 143 (1). , 246-56.e8. (PMCID: 3668336); Aprelikova, O., Palla, J., Hibler, B., Yu, X., Greer, Y.E., Yi, M., (2013) Oncogene, 32 (27), pp. 3246-3253. , (PMCID: 3711253); Jia, Y., Yang, Y., Zhan, Q., Brock, M.V., Zheng, X., Yu, Y., (2012) J. Mol. Diagn., 14 (6), pp. 577-585; Zhang, Z., Liu, S., Shi, R., Zhao, G., (2011) Cancer Genet., 204 (9), pp. 486-491; Liu, Y., Yan, W., Zhang, W., Chen, L., You, G., Bao, Z., (2012) Oncol. Rep., 28 (3), pp. 1013-1021; Zhang, W., Shen, C., Li, C., Yang, G., Liu, H., Chen, X., (2015) Mol. Carcinog.; Zhang, P., Bill, K., Liu, J., Young, E., Peng, T., Bolshakov, S., (2012) Cancer Res., 72 (7), pp. 1751-1762. , (PMCID: 3319789); Jang, J.S., Jeon, H.S., Sun, Z., Aubry, M.C., Tang, H., Park, C.H., (2012) Clin. Cancer Res., 18 (13), pp. 3658-3667. , (PMCID: 3616503); Xia, H., Ng, S.S., Jiang, S., Cheung, W.K., Sze, J., Bian, X.W., (2010) Biochem. Biophys. Res. Commun., 39 (1), pp. 535-541; Cong, N., Du, P., Zhang, A., Shen, F., Su, J., Pu, P., (2013) Oncol. Rep., 29 (4), pp. 1579-1587; Zhang, X., Li, M., Zuo, K., Li, D., Ye, M., Ding, L., (2013) J. Clin. Endocrinol. Metab., 98 (8), pp. E1305-E1313; Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., (2008) Nat. Med., 14 (11), pp. 1271-1277; Liang, J., Li, Y., Daniels, G., Sfanos, K., De Marzo, A., Wei, J., (2015) Mol. Cancer Res.; Liu, H., Yin, J., Wang, H., Jiang, G., Deng, M., Zhang, G., (2015) Cell. Signal., 27 (3), pp. 510-518. , http://dx.doi.org/101016j.cellsig.2015.01.001; Zheng, C., Yinghao, S., Li, J., (2012) Med. Oncol., 29 (2), pp. 815-822; Hsieh, I.S., Chang, K.C., Tsai, Y.T., Ke, J.Y., Lu, P.J., Lee, K.H., (2013) Carcinogenesis, 34 (3), pp. 530-538; Xu, X., Gnatenko, D.V., Ju, J., Hitchcock, I.S., Martin, D.W., Zhu, W., (2012) Blood, 120 (17), pp. 3575-3585. , (PMCID: 3482865); Veronese, A., Visone, R., Consiglio, J., Acunzo, M., Lupini, L., Kim, T., (2011) Proc. Natl. Acad. Sci. U. S. A., 108 (12), pp. 4840-4845. , (PMCID: 3064338); Buechling, T., Chaudhary, V., Spirohn, K., Weiss, M., Boutros, M., (2011) EMBO Rep., 12 (12), pp. 1265-1272. , (PMCID: 3245698); Port, F., Hausmann, G., Basler, K., (2011) EMBO Rep., 12 (11), pp. 1144-1152. , (PMCID: 3207098); Fuerer, C., Habib, S.J., Nusse, R., (2010) Dev. Dyn., 239 (1), pp. 184-190. , (PMCID: 2846786); Belenkaya, T.Y., Wu, Y., Tang, X., Zhou, B., Cheng, L., Sharma, Y.V., (2008) Dev. Cell, 14 (1), pp. 120-131; Franch-Marro, X., Wendler, F., Guidato, S., Griffith, J., Baena-Lopez, A., Itasaki, N., (2008) Nat. Cell Biol., 10 (2), pp. 170-177; Port, F., Kuster, M., Herr, P., Furger, E., Banziger, C., Hausmann, G., (2008) Nat. Cell Biol., 10 (2), pp. 178-185; Yu, J., Chia, J., Canning, C.A., Jones, C.M., Bard, F.A., Virshup, D.M., (2014) Dev. Cell, 29 (3), pp. 277-291; Delling, U., Tureckova, J., Lim, H.W., De Windt, L.J., Rotwein, P., Molkentin, J.D., A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression (2000) Mol Cell Biol., 20 (17), pp. 6600-6611. , (PMCID: 86143)",Review,Scopus,2-s2.0-84927613389
"Bagdas D., Etoz B.C., Gul Z., Ziyanok S., Inan S., Turacozen O., Gul N.Y., Topal A., Cinkilic N., Tas S., Ozyigit M.O., Gurun M.S.","In vivo systemic chlorogenic acid therapy under diabetic conditions: Wound healing effects and cytotoxicity/genotoxicity profile",2015,"Food and Chemical Toxicology","81",,,"54","61",,,10.1016/j.fct.2015.04.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928128269&partnerID=40&md5=bfd02e98f833362fa926a3cafcc2c063","Experimental Animals Breeding and Research Center, Faculty of Medicine, Uludag UniversityBursa, Turkey; Department of Physiology, Faculty of Medicine, Uludag UniversityBursa, Turkey; Department of Pharmacology, Faculty of Medicine, Uludag UniversityBursa, Turkey; Department of Biology, Faculty of Science and Arts, Uludag UniversityBursa, Turkey; Department of Pathology, Faculty of Veterinary Medicine, Uludag UniversityBursa, Turkey; Department of Surgery, Faculty of Veterinary Medicine, Uludag UniversityBursa, Turkey","Bagdas, D., Experimental Animals Breeding and Research Center, Faculty of Medicine, Uludag UniversityBursa, Turkey; Etoz, B.C., Department of Physiology, Faculty of Medicine, Uludag UniversityBursa, Turkey; Gul, Z., Department of Pharmacology, Faculty of Medicine, Uludag UniversityBursa, Turkey; Ziyanok, S., Department of Biology, Faculty of Science and Arts, Uludag UniversityBursa, Turkey; Inan, S., Department of Pathology, Faculty of Veterinary Medicine, Uludag UniversityBursa, Turkey; Turacozen, O., Department of Biology, Faculty of Science and Arts, Uludag UniversityBursa, Turkey; Gul, N.Y., Department of Surgery, Faculty of Veterinary Medicine, Uludag UniversityBursa, Turkey; Topal, A., Department of Surgery, Faculty of Veterinary Medicine, Uludag UniversityBursa, Turkey; Cinkilic, N., Department of Biology, Faculty of Science and Arts, Uludag UniversityBursa, Turkey; Tas, S., Department of Biology, Faculty of Science and Arts, Uludag UniversityBursa, Turkey; Ozyigit, M.O., Department of Pathology, Faculty of Veterinary Medicine, Uludag UniversityBursa, Turkey; Gurun, M.S., Department of Pharmacology, Faculty of Medicine, Uludag UniversityBursa, Turkey","Oxidative stress occurs following the impairment of pro-oxidant/antioxidant balance in chronic wounds and leads to harmful delays in healing progress. A fine balance between oxidative stress and endogenous antioxidant defense system may be beneficial for wound healing under redox control. This study tested the hypothesis that oxidative stress in wound area can be controlled with systemic antioxidant therapy and therefore wound healing can be accelerated. We used chlorogenic acid (CGA), a dietary antioxidant, in experimental diabetic wounds that are characterized by delayed healing. Additionally, we aimed to understand possible side effects of CGA on pivotal organs and bone marrow during therapy. Wounds were created on backs of streptozotocin-induced diabetic rats. CGA (50 mg/kg/day) was injected intraperitoneally. Animals were sacrificed on different days. Biochemical and histopathological examinations were performed. Side effects of chronic antioxidant treatment were tested. CGA accelerated wound healing, enhanced hydroxyproline content, decreased malondialdehyde/nitric oxide levels, elevated reduced-glutathione, and did not affect superoxide dismutase/catalase levels in wound bed. While CGA induced side effects such as cyto/genotoxicity, 15 days of treatment attenuated blood glucose levels. CGA decreased lipid peroxidation levels of main organs. This study provides a better understanding for antioxidant intake on diabetic wound repair and possible pro-oxidative effects. © 2015 Elsevier Ltd.","Antioxidant; Chlorogenic acid; Cytotoxicity; Diabetic wound healing; Genotoxicity; Oxidative stress","Ahmed, N., Advanced glycation endproducts - role in pathology of diabetic complications (2005) Diabetes Res. Clin. Pract, 67, pp. 3-21; Albina, J.E., Mills, C.D., Henry, W.L., Caldwell, M.D., Temporal expression of different pathways of L-arginine metabolism in healing wound (1990) J. Immunol, 144, pp. 3877-3880. , http://www.jimmunol.org/content/144/10/3877.long; Azam, S., Hadi, N., Khan, N.U., Hadi, S.M., Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: implications for anticancer properties (2004) Toxicol. In Vitro, 18, pp. 555-561. , http://dx.doi.org/10.1016/j.tiv.2003.12.012; Azuma, K., Ippoushi, K., Nakayama, M., Ito, H., Higashio, H., Terao, J., Absorption of chlorogenic acid and caffeic acid in rats after oral administration (2000) J. Agric. Food Chem, 48, pp. 5496-5500; Bagdas, D., Cinkilic, N., Ozboluk, H.Y., Ozyigit, M.O., Gurun, M.S., Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain (2013) J. Nat. Med, 67, pp. 698-704; Bagdas, D., Cam Etoz, B., Inan Ozturkoglu, S., Cinkilic, N., Ozyigit, M.O., Gul, Z., Effects of systemic chlorogenic acid on random-pattern dorsal skin flap survival in diabetic rats (2014) Biol. Pharm. Bull, 37, pp. 361-370. , http://dx.doi.org/10.1248/bpb.b13-00635; Bagdas, D., Ozboluk, H.Y., Cinkilic, N., Gurun, M.S., Antinociceptive effect of chlorogenic acid in rats with painful diabetic neuropathy (2014) J. Med. Food, 17, pp. 730-732; Bagdas, D., Etoz, B.C., Gul, Z., Ozyigit, M.O., Cinkilic, N., Inan, S., Chlorogenic acid enhances abdominal skin flap survival based on epigastric artery in nondiabetic and diabetic rats (2014) Ann. Plast. Surg, , (in press); Bagdas, D., Gul, N.Y., Topal, A., Tas, S., Ozyigit, M.O., Cinkilic, N., Pharmacologic overview of systemic chlorogenic acid therapy on experimental wound healing (2014) Naunyn Schmiedebergs Arch. Pharmacol, 387, pp. 1101-1116; Baynes, J.W., Role of oxidative stress in development of complications in diabetes (1991) Diabetes, 40, pp. 405-412; Bouayed, J., Bohn, T., Exogenous antioxidants - double-edged swords in cellular redox state: health beneficial effects at physiologic doses versus deleterious effects at high doses (2010) Oxid. Med. Cell. Longev, 3, pp. 228-237; Cals-Grierson, M., Ormerod, A., Nitric oxide function on the skin (2004) Nitric Oxide, 10, pp. 179-193. , http://www.sciencedirect.com/science/article/pii/S1089860304000734; Chen, W.C., Liou, S.S., Tzeng, T.F., Lee, S.L., Liu, I.M., Effect of topical application of chlorogenic acid on excision wound healing in rats (2013) Planta Med, 79, pp. 616-621; Cinkilic, N., Cetintas, S.K., Zorlu, T., Vatan, O., Yilmaz, D., Cavas, T., Radioprotection by two phenolic compounds: chlorogenic and quinic acid, on X-ray induced DNA damage in human blood lymphocytes in vitro (2013) Food Chem. Toxicol, 53, pp. 359-363; Clark, R.A., Cutaneous tissue repair: basic biologic considerations. I (1985) J. Am. Acad. Dermatol, 13 (5), pp. 701-725; Clifford, M.N., Chlorogenic acids and other cinnamates - nature, occurrence and dietary burden (1999) J. Sci. Food Agric, 79, pp. 362-372; Dadpay, M., Sharifian, Z., Bayat, M., Dabbagh, A., Effects of pulsed infra-red low level-laser irradiation on open skin wound healing of healthy and streptozotocin-induced diabetic rats by biomechanical evaluation (2012) J. Photochem. Photobiol. B., 111, pp. 1-8; Deodhar, A.K., Rana, R.E., Surgical physiology of wound healing: a review (1997) J. Postgrad. Med, 43 (2), pp. 52-56; Dos Santos, J.S., Monte-Alto-Costa, A., Caffeic acid phenethyl ester improves burn healing in rats through anti-inflammatory and antioxidant effects (2013) J. Burn Care Res, 34, pp. 682-688; Dos Santos, M.D., Almeida, M.C., Lopes, N.P., de Souza, G.E., Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid (2006) Biol. Pharm. Bull, 29, pp. 2236-2240. , http://dx.doi.org/10.1248/bpb.29.2236; Duarte, M.P., Laires, A., Gaspar, J., Leão, D., Oliveira, J.S., Rueff, J., Genotoxicity of instant coffee: possible involvement of phenolic compounds (1999) Mutat. Res, 442, pp. 43-51. , http://dx.doi.org/10.1016/S1383-5718(99)00057-1; Duarte, M.P., Laires, A., Gaspar, J., Oliveira, J.S., Rueff, J., Genotoxicity of instant coffee and of some phenolic compounds present in coffee upon nitrosation (2000) Teratog. Carcinog. Mutagen, 20, pp. 241-249; Edwards, C.A., O'Brien, W.D., Modified assay for determination of hydroxyproline in a tissue hydrolyzate (1980) Clin. Chim. Acta, 104, pp. 161-167. , http://dx.doi.org/10.1016/0009-8981(80)90192-8; Ellman, G.L., Tissue sulfhydryl groups (1959) Arch. Biochem. Biophys, 82, pp. 70-77; Fitzmaurice, S.D., Sivamani, R.K., Isseroff, R.R., Antioxidant therapies for wound healing: a clinical guide to currently commercially available products (2011) Skin Pharmacol. Physiol, 24 (3), pp. 113-126. , Epub 2011 Jan 15; Fukumoto, L.R., Mazza, G., Assessing antioxidant and prooxidant activities of phenolic compounds (2000) J. Agric. Food Chem, 48, pp. 3597-3604; Giner, E., Andújar, I., Recio, M.C., Ríos, J.L., Cerdá-Nicolás, J.M., Giner, R.M.T., Oleuropein ameliorates acute colitis in mice (2011) J. Agric. Food Chem, 59, pp. 12882-12892; Greenhalgh, D.G., Wound healing and diabetes mellitus (2003) Clin. Plast. Surg, 30, pp. 37-45; Griess, P., Bemerkungen zu der Abhandlung der HH. Weselsky und Benedikt ""Ueber einige Azoverbindungen"" (1879) Ber. Dtsch. Chem. Ges, 12, pp. 426-428; Guo, S., Dipietro, L.A., Factors affecting wound healing (2010) J. Dent. Res, 89 (3), pp. 219-229; Hunyadi, A., Martins, A., Hsieh, T.J., Seres, A., Zupkó, I., Chlorogenic acid and rutin play a major role in the in vivo anti-diabetic activity of Morus alba leaf extract on type II diabetic rats (2012) PLoS ONE, 7, p. e50619; Jefferies, H., Coster, J., Khalil, A., Bot, J., McCauley, R.D., Hall, J.C., Glutathione (2003) ANZ J. Surg, 73, pp. 517-522; Junod, A., Lambert, A.E., Stauffacher, W., Renold, A.E., Diabetogenic action of streptozotocin: relationship of dose to metabolic response (1969) J. Clin. Invest, 48, pp. 2129-2139; Kalani, M., Ostergren, J., Brismar, K., Jörneskog, G., Fagrell, B., Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers (1999) Diabetes Care, 22 (1), pp. 147-151; Karthikesan, K., Pari, L., Menon, V.P., Antihyperlipidemic effect of chlorogenic acid and tetrahydrocurcumin in rats subjected to diabetogenic agents (2010) Chem. Biol. Interact, 188, pp. 643-650; Karthikesan, K., Pari, L., Menon, V.P., Combined treatment of tetrahydrocurcumin and chlorogenic acid exerts potential antihyperglycemic effect on streptozotocin-nicotinamide-induced diabetic rats (2010) Gen. Physiol. Biophys, 29, pp. 23-30; Karthikesan, K., Pari, L., Menon, V.P., Protective effect of tetrahydrocurcumin and chlorogenic acid against streptozotocin-nicotinamide generated oxidative stress induced diabetes (2010) J. Funct. Foods, 2, pp. 134-142; Khalil, A.A., Aziz, F.A., Hall, J.C., Reperfusion injury (2006) Plast. Reconstr. Surg, 117, pp. 1024-1033; King, L., Impaired wound healing in patients with diabetes (2001) Nurs. Stand, 15, pp. 39-45; Komesu, M.C., Tanga, M.B., Buttros, K.R., Nakao, C., Effects of acute diabetes on rat cutaneous wound healing (2004) Pathophysiology, 11, pp. 63-67; Korhonen, R., Lahti, A., Kankaanranta, H., Moilanen, E., Nitric oxide production and signaling in inflammation (2005) Curr. Drug Targets Inflamm. Allergy, 4, pp. 471-479; Kupeli Akkol, E., Acikara, O.B., Suntar, I., Citoglu, G.S., Keles, H., Ergene, B., Enhancement of wound healing by topical application of Scorzonera species: determination of the constituents by HPLC with new validated reverse phase method (2011) J. Ethnopharmacol, 137, pp. 1018-1027; Lee, K., Lee, J.S., Jang, H.J., Kim, S.M., Chang, M.S., Park, S.H., Chlorogenic acid ameliorates brain damage and edema by inhibiting matrix metalloproteinase-2 and 9 in a rat model of focal cerebral ischemia (2012) Eur. J. Pharmacol, 689, pp. 89-95; Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., Protein measurement with the Folin phenol reagent (1951) J. Biol. Chem, 193, pp. 265-275. , http://www.jbc.org/content/193/1/265.short#ref-list-1; MacGregor, J.T., Heddle, J.A., Hite, M., Margolin, B.H., Ramel, C., Salamone, M.F., Guidelines for the conduct of micronucleus assays in mammalian bone marrow erythrocytes (1987) Mutat. Res, 189, pp. 103-112. , http://dx.doi.org/10.1016/0165-1218(87)90016-4; Martin, A., Komada, M.R., Sane, D.C., Abnormal angiogenesis in diabetes mellitus (2003) Med. Res. Rev, 23 (2), pp. 117-145; Oboh, G., Agunloye, O.M., Akinyemi, A.J., Ademiluyi, A.O., Adefegha, S.A., Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer's disease and some pro-oxidant induced oxidative stress in rats' brain-in vitro (2013) Neurochem. Res, 38, pp. 413-419; Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction (1979) Anal. Biochem, 95, pp. 351-358; Oršolić, N., Gajski, G., Garaj-Vrhovac, V., Dikić, D., Prskalo, Z.Š., Sirovina, D., DNA-protective effects of quercetin or naringenin in alloxan-induced diabetic mice (2011) Eur. J. Pharmacol, 656, pp. 110-118; Pari, L., Karthikesan, K., Menon, V.P., Comparative and combined effect of chlorogenic acid and tetrahydrocurcumin on antioxidant disparities in chemical induced experimental diabetes (2010) Mol. Cell. Biochem, 341, pp. 109-117; Rasik, A.M., Shukla, A., Antioxidant status in delayed healing type of wounds (2000) Int. J. Exp. Pathol, 81, pp. 257-263; Raza, H., John, A., Green tea polyphenol epigallocatechin-3-gallate differentially modulates oxidative stress in PC12 cell compartments (2005) Toxicol. Appl. Pharmacol, 207, pp. 212-220. , http://dx.doi.org/10.1016/j.taap.2005.01.004; Robson, M.C., Steed, D.L., Franz, M.G., Wound healing: biologic features and approaches to maximize healing trajectories (2001) Curr. Probl. Surg, 38, pp. 72-140. , http://www.currprobsurg.com/article/S0011-3840(01)00036-3/abstract; Sakihama, Y., Cohen, M.F., Grace, S.C., Yamasaki, H., Plant phenolic antioxidant and prooxidant activities: phenolics-induced oxidative damage mediated by metals in plants (2002) Toxicology, 177, pp. 67-80. , http://dx.doi.org/10.1016/S0300-483X(02)00196-8; Sato, Y., Itagaki, S., Kurokawa, T., Ogura, J., Kobayash, M., Hirano, T., In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid (2011) Int. J. Pharm, 403, pp. 136-138; Schwentker, A., Vodovotz, Y., Weller, R., Billiar, T.R., Nitric oxide and wound repair: role of cytokines? (2002) Nitric Oxide, 7, pp. 1-10. , http://dx.doi.org/10.1016/S1089-8603(02)00002-2; Serarslan, G., Altug, E., Kontas, T., Atik, E., Avci, G., Caffeic acid phenethyl ester accelerates cutaneous wound healing in a rat model and decreases oxidative stress (2007) Clin. Exp. Dermatol, 32, pp. 709-715; Shimoyama, A.T., Santin, J.R., Machado, I.D., de Oliveira e Silva, A.M., de Melo, I.L., Mancini-Filho, J., Antiulcerogenic activity of chlorogenic acid in different models of gastric ulcer (2013) Naunyn Schmiedebergs Arch. Pharmacol, 386, pp. 5-14; Sinha, A.K., Colorimetric assay of catalase (1972) Anal. Biochem, 47, pp. 389-394; Song, H.S., Park, T.W., Sohn, U.D., Shin, Y.K., Choi, B.C., Kim, C.J., The effect of caffeic acid on wound healing in skin-incised mice (2008) Korean. J. Physiol. Pharmacol, 12, pp. 343-347; Stadelmann, W.K., Digenis, A.G., Tobin, G.R., Physiology and healing dynamics of chronic cutaneous wounds (1998) Am. J. Surg, 176, pp. 26-38. , http://www.americanjournalofsurgery.com/article/S0002-9610(98)00183-4/abstract; Sun, Y., Oberley, L.W., Li, Y., A simple method for clinical assay of superoxide dismutase (1988) Clin. Chem, 34, pp. 497-500. , http://www.clinchem.org/content/34/3/497.long; Suntar, I., Acikara, O.B., Citoglu, G.S., Keles, H., Ergene, B., Akkol, E.K., In vivo and in vitro evaluation of the therapeutic potential of some Turkish Scorzonera species as wound healing agent (2012) Curr. Pharm. Des, 18, pp. 1421-1433; Suzuki, S., Miyachi, Y., Niwa, Y., Isshiki, N., Significance of reactive oxygen species in distal flap necrosis and its salvage with liposomal SOD (1989) Br. J. Plast. Surg, 42, pp. 559-564; Swaim, S.F., Bradley, D.M., Spano, J.S., McGuire, J.A., Hoffman, C.E., Trachy, R.E., Evaluation of multipeptide copper complex medications on open wound healing in dogs (1993) J. Am. Anim. Hosp. Assoc, 29, pp. 519-527; Teke, Z., Bostanci, E.B., Yenisey, C., Kelten, E.C., Sacar, S., Simsek, N.G., Effects of caffeic acid phenethyl ester on anastomotic healing in secondary peritonitis (2012) J. Invest. Surg, 25, pp. 301-310; Thomé, R.G., dos Santos, H.B., dos Santos, F.V., da Silva Oliveira, R.J., de Camargos, L.F., Pereira, M.N., Evaluation of healing wound and genotoxicity potentials from extracts hydroalcoholic of Plantago major and Siparuna guianensis (2012) Exp. Biol. Med, 237, pp. 1379-1386; Velnar, T., Bailey, T., Smrkolj, V., The wound healing process: an overview of the cellular and molecular mechanisms (2009) J. Int. Med. Res, 37, pp. 1528-1542; Wätjen, W., Michels, G., Steffan, B., Niering, P., Chovolou, Y., Kampkötter, A., Low concentrations of flavonoids are protective in rat H4IIE cells whereas high concentrations cause DNA damage and apoptosis (2005) J. Nutr, 135, pp. 525-531. , http://jn.nutrition.org/content/135/3/525.long; Witte, M.B., Barbul, A., Role of nitric oxide in wound repair (2002) Am. J. Surg, 183, pp. 406-412. , http://www.americanjournalofsurgery.com/article/S0002-9610(02)00815-2/fulltext; Yordi, E.G., Pérez, E.M., Matos, M.J., Villares, E.U., Antioxidant and pro-oxidant effects of polyphenolic compounds and structure-activity relationship evidence (2012) Nutrition Well-Being and Health, , InTech, J. Bouayed (Ed.); Yun, N., Kang, J.W., Lee, S.M., Protective effects of chlorogenic acid against ischemia/reperfusion injury in rat liver: molecular evidence of its antioxidant and anti-inflammatory properties (2012) J. Nutr. Biochem, 23, pp. 1249-1255",Article,Scopus,2-s2.0-84928128269
"Mukherjee K., Chio T.I., Sackett D.L., Bane S.L.","Detection of oxidative stress-induced carbonylation in live mammalian cells",2015,"Free Radical Biology and Medicine","84",,,"11","21",,,10.1016/j.freeradbiomed.2015.03.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928411683&partnerID=40&md5=5f1c4b098219f933b30d138c981a6734","Department of Chemistry, Binghamton University, State University of New YorkBinghamton, NY, United States; Program in Physical Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthBethesda, MD, United States","Mukherjee, K., Department of Chemistry, Binghamton University, State University of New YorkBinghamton, NY, United States; Chio, T.I., Department of Chemistry, Binghamton University, State University of New YorkBinghamton, NY, United States; Sackett, D.L., Program in Physical Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthBethesda, MD, United States; Bane, S.L., Department of Chemistry, Binghamton University, State University of New YorkBinghamton, NY, United States","Oxidative stress is often associated with etiology and/or progression of disease conditions, such as cancer, neurodegenerative diseases, and diabetes. At the cellular level, oxidative stress induces carbonylation of biomolecules such as lipids, proteins, and DNA. The presence of carbonyl-containing biomolecules as a hallmark of these diseases provides a suitable target for diagnostic detection. Here, a simple, robust method for detecting cellular aldehydes and ketones in live cells using a fluorophore is presented. A hydrazine-functionalized synthetic fluorophore serves as an efficient nucleophile that rapidly reacts with reactive carbonyls in the cellular milieu. The product thus formed exhibits a wavelength shift in the emission maximum accompanied by an increase in emission intensity. The photochemical characteristics of the fluorophore enable the identification of the fluorophore-conjugated cellular biomolecules in the presence of unreacted dye, eliminating the need for removal of excess fluorophore. Moreover, this fluorophore is found to be nontoxic and is thus appropriate for live cell analysis. Utility of the probe is demonstrated in two cell lines, PC3 and A549. Carbonylation resulting from serum starvation and hydrogen peroxide-induced stress is detected in both cell lines using fluorescence microscopy and a fluorescence plate reader. The fluorescent signal originates from carbonylated proteins and lipids but not from oxidized DNA, and the majority of the fluorescence signal (>60%) is attributed to fluorophore-conjugated lipid oxidation products. This method should be useful for detecting cellular carbonylation in a high-content assay or high-throughput assay format. © 2015 Elsevier Inc. All rights reserved.","Biomolecule carbonylation; Fluorophore; Hydrazine; Live cells; Microscopy; Oxidative stress; Plate reader","Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B., Oxidative stress, inflammation, and cancer: How are they linked? (2010) Free Radic. Biol. Med., 49, pp. 1603-1616; Schulz, J.B., Lindenau, J., Seyfried, J., Dichgans, J., Glutathione, oxidative stress and neurodegeneration (2000) FEBS J., 267, pp. 4904-4911; Rains, J.L., Jain, S.K., Oxidative stress, insulin signaling, and diabetes (2011) Free Radic. Biol. Med., 50, pp. 567-575; Kirkham, P.A., Caramori, G., Casolari, P., Papi, A.A., Edwards, M., Shamji, B., Triantaphyllopoulos, K., Adcock, I.M., Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease (2011) Am. J. Respir. Crit. Care Med., 184, pp. 796-802; Badran, M., Ayas, N., Laher, I., Cardiovascular complications of sleep apnea: Role of oxidative stress (2014) Oxid. Med. Cell. Longev, 2014, p. 985258; Dalle-Donne, I., Giustarini, D., Colombo, R., Rossi, R., Milzani, A., Protein carbonylation in human diseases (2003) Trends Mol. Med., 9, pp. 169-176; Baraibar, M.A., Ladouce, R., Friguet, B., Proteomic quantification and identification of carbonylated proteins upon oxidative stress and during cellular aging (2013) J. Proteomics, 92, pp. 63-70; Levine, R.L., Carbonyl modified proteins in cellular regulation, aging, and disease (2002) Free Radic. Biol. Med., 32, pp. 790-796; Suzuki, Y.J., Carini, M., Butterfield, D.A., Protein carbonylation (2010) Antioxid. Redox Signal., 12, pp. 323-325; Abuja, P.M., Albertini, R., Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins (2001) Clin. Chim. Acta, 306, pp. 1-17; Spickett, C.M., The lipid peroxidation product 4-hydroxy-2-nonenal: Advances in chemistry and analysis (2013) Redox Biol, 1, pp. 145-152; De Bont, R., Van Larebeke, N., Endogenous DNA damage in humans: A review of quantitative data (2004) Mutagenesis, 19, pp. 169-185; Dalle-Donne, I., Rossi, R., Giustarini, D., Milzani, A., Colombo, R., Protein carbonyl groups as biomarkers of oxidative stress (2003) Clin. Chim. Acta, 329, pp. 23-38; Berlett, B.S., Stadtman, E.R., Protein oxidation in aging, disease, and oxidative stress (1997) J. Biol. Chem., 272, pp. 20313-20316; Moller, I.M., Rogowska-Wrzesinska, A., Rao, R.S., Protein carbonylation and metal-catalyzed protein oxidation in a cellular perspective (2011) J. Proteomics, 74, pp. 2228-2242; Tamarit, J., De Hoogh, A., Obis, E., Alsina, D., Cabiscol, E., Ros, J., Analysis of oxidative stress-induced protein carbonylation using fluorescent hydrazides (2012) J. Proteomics, 75, pp. 3778-3788; Halliwell, B., Chirico, S., Lipid peroxidation: Its mechanism, measurement, and significance (1993) Am J. Clin. Nutr., 57, pp. 715S-724S. , discussion 724S-725S; Gueraud, F., Atalay, M., Bresgen, N., Cipak, A., Eckl, P.M., Huc, L., Jouanin, I., Uchida, K., Chemistry and biochemistry of lipid peroxidation products (2010) Free Radic. Res., 44, pp. 1098-1124; Del Rio, D., Stewart, A.J., Pellegrini, N., A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress (2005) Nutr. Metab. Cardiovasc. Dis., 15, pp. 316-328; Levine, R.L., Garland, D., Oliver, C.N., Amici, A., Climent, I., Lenz, A.G., Ahn, B.W., Stadtman, E.R., Determination of carbonyl content in oxidatively modified proteins (1990) Methods Enzymol., 186, pp. 464-478; Yan, L.J., Sohal, R.S., Gel electrophoretic quantitation of protein carbonyls derivatized with tritiated sodium borohydride (1998) Anal. Biochem., 265, pp. 176-182; Gladstone, Jr.I.M., Levine, R.L., Oxidation of proteins in neonatal lungs (1994) Pediatrics, 93, pp. 764-768; Paromov, V., Qui, M., Yang, H., Smith, M., Stone, W.L., The influence of N-acetyl-L-cysteine on oxidative stress and nitric oxide synthesis in stimulated macrophages treated with a mustard gas analogue (2008) BMC Cell Biol, 9, p. 33; Jia, L., Liu, Z., Sun, L., Miller, S.S., Ames, B.N., Cotman, C.W., Liu, J., Acrolein, a toxicant in cigarette smoke, causes oxidative damage and mitochondrial dysfunction in RPE cells: Protection by (R)-alpha-lipoic acid (2007) Investig. Ophthalmol. Vis. Sci, 48, pp. 339-348; Zheng, J., Bizzozero, O.A., Accumulation of protein carbonyls within cerebellar astrocytes in murine experimental autoimmune encephalomyelitis (2010) J. Neurosci. Res., 88, pp. 3376-3385; Wehr, N.B., Levine, R.L., Quantification of protein carbonylation (2013) Methods Mol. Biol., 965, pp. 265-281; Yan, L.J., Forster, M.J., Chemical probes for analysis of carbonylated proteins: A review, J. Chromatogr. B Analyt. Technol. Biomed (2011) Life Sci., 879, pp. 1308-1315; Ahn, B., Rhee, S.G., Stadtman, E.R., Use of fluorescein hydrazide and fluorescein thiosemicarbazide reagents for the fluorometric determination of protein carbonyl groups and for the detection of oxidized protein on polyacrylamide gels (1987) Anal. Biochem., 161, pp. 245-257; Buss, H., Chan, T.P., Sluis, K.B., Domigan, N.M., Winterbourn, C.C., Protein carbonyl measurement by a sensitive ELISA method (1997) Free Radic. Biol. Med., 23, pp. 361-366; Key, J.A., Li, C., Cairo, C.W., Detection of cellular sialic acid content using nitrobenzoxadiazole carbonyl-reactive chromophores (2012) Bioconjugate Chem, 23, pp. 363-371; Shi, X., Jung, Y., Lin, L.J., Liu, C., Wu, C., Cann, I.K., Ha, T., Quantitative fluorescence labeling of aldehyde-tagged proteins for single-molecule imaging (2012) Nat. Methods, 9, pp. 499-503; Banerjee, A., Panosian, T.D., Mukherjee, K., Ravindra, R., Gal, S., Sackett, D.L., Bane, S., Site-specific orthogonal labeling of the carboxy terminus of alpha-tubulin (2010) ACS Chem. Biol., 5, pp. 777-785; Zanella, F., Lorens, J.B., Link, W., High content screening: Seeing is believing (2010) Trends Biotechnol., 28, pp. 237-245; Buss, I.H., Winterbourn, C.C., Protein carbonyl measurement by ELISA (2002) Methods Mol. Biol., 186, pp. 123-128; Folch, J., Lees, M., Stanley, G.H.S., A simple method for the isolation and purification of total lipides from animal tissues (1957) J. Biol. Chem., 226, pp. 497-509; Walzl, A., Unger, C., Kramer, N., Unterleuthner, D., Scherzer, M., Hengstschlager, M., Schwanzer-Pfeiffer, D., Dolznig, H., The resazurin reduction assay can distinguish cytotoxic from cytostatic compounds in spheroid screening assays (2014) J. Biomol. Screen.; Anoopkumar-Dukie, S., Carey, J.B., Conere, T., O'Sullivan, E., Van Pelt, F.N., Allshire, A., Resazurin assay of radiation response in cultured cells (2005) Br. J. Radiol., 78, pp. 945-947; Vichai, V., Kirtikara, K., Sulforhodamine B colorimetric assay for cytotoxicity screening (2006) Nat. Protoc., 1, pp. 1112-1116; Dilek Ö., Bane, S.L., Synthesis of boron dipyrromethene fluorescent probes for bioorthogonal labeling (2008) Tetrahedron Lett., 49, pp. 1413-1416; Banerjee, A., Harnessing the flexibility of tubulin tyrosine ligase to site-specifically label C-terminus of alpha-tubulin (2010) ProQuest UMI; Finkel, T., Holbrook, N.J., Oxidants, oxidative stress and the biology of ageing (2000) Nature, 408, pp. 239-247; Atamna, H., Cheung, I., Ames, B.N., A method for detecting abasic sites in living cells: Age-dependent changes in base excision repair (2000) Proc. Natl. Acad. Sci. USA, 97, pp. 686-691; Melton, D., Lewis, C.D., Price, N.E., Gates, K.S., Covalent adduct formation between the antihypertensive drug hydralazine and abasic sites in double- and single-stranded DNA (2014) Chem. Res. Toxicol., 27, pp. 2113-2118; Cooke, M.S., Evans, M.D., Dizdaroglu, M., Lunec, J., Oxidative DNA damage: Mechanisms, mutation, and disease (2003) FASEB J, 17, pp. 1195-1214; Giorgio, M., Trinei, M., Migliaccio, E., Pelicci, P.G., Hydrogen peroxide: A metabolic by-product or a common mediator of ageing signals? (2007) Nat. Rev. Mol. Cell Biol, 8, pp. 722-728; Wijeratne, S.S., Cuppett, S.L., Schlegel, V., Hydrogen peroxide induced oxidative stress damage and antioxidant enzyme response in Caco-2 human colon cells (2005) J. Agric. Food Chem., 53, pp. 8768-8774; Lash, L.H., Hagen, T.M., Jones, D.P., Exogenous glutathione protects intestinal epithelial cells from oxidative injury (1986) Proc. Natl. Acad. Sci. USA, 83, pp. 4641-4645; Ghelli, A., Porcelli, A.M., Zanna, C., Martinuzzi, A., Carelli, V., Rugolo, M., Protection against oxidant-induced apoptosis by exogenous glutathione in Leber hereditary optic neuropathy cybrids (2008) Invest. Ophthalmol. Vis. Sci., 49, pp. 671-676; Kang, Y.J., Feng, Y., Hatcher, E.L., Glutathione stimulates A549 cell proliferation in glutamine-deficient culture: The effect of glutamate supplementation (1994) J. Cell. Physiol., 161, pp. 589-596; Kuznetsov, A.V., Kehrer, I., Kozlov, A.V., Haller, M., Redl, H., Hermann, M., Grimm, M., Mitochondrial, R.O.S., Production under cellular stress: Comparison of different detection methods (2011) Anal. Bioanal. Chem., 400, pp. 2383-2390; Wang, H., Joseph, J.A., Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader (1999) Free Radic. Biol. Med., 27, pp. 612-616",Article,Scopus,2-s2.0-84928411683
"Jiang X., Huang L., Xing D.","Photoactivation of Dok1/ERK/PPARγ signaling axis inhibits excessive lipolysis in insulin-resistant adipocytes",2015,"Cellular Signalling","27","7",,"1265","1275",,,10.1016/j.cellsig.2015.03.010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925954455&partnerID=40&md5=02faa1f80e5000cd57a669ed31be7842","MOE Key Laboratory of Laser Life Science and Institute of Laser Life Science, College of Biophotonics, South China Normal UniversityGuangzhou, China","Jiang, X., MOE Key Laboratory of Laser Life Science and Institute of Laser Life Science, College of Biophotonics, South China Normal UniversityGuangzhou, China; Huang, L., MOE Key Laboratory of Laser Life Science and Institute of Laser Life Science, College of Biophotonics, South China Normal UniversityGuangzhou, China; Xing, D., MOE Key Laboratory of Laser Life Science and Institute of Laser Life Science, College of Biophotonics, South China Normal UniversityGuangzhou, China","Insulin resistance is a hallmark of the metabolic syndrome and type 2 diabetes. Increased plasma FFA level is an important cause of obesity-associated insulin resistance. Over-activated ERK is closely related with FFA release from adipose tissues in patients with type 2 diabetes. Nevertheless, there are no effective strategies to lower plasma FFA level. Low-power laser irradiation (LPLI) has been reported to regulate multiple biological processes. However, whether LPLI could ameliorate metabolic disorders and the molecular mechanisms involved remain unknown. In this study, we first demonstrated that LPLI suppresses excessive lipolysis of insulin-resistant adipocytes by activating tyrosine kinases-1(Dok1)/ERK/PPARγ pathway. Our data showed that LPLI inhibits ERK phosphorylation through the activation of Dok1, resulting in decreased phospho-PPARγ level. Non-phosphorylated PPARγ maintains in nucleus to promote the expression of adipogenic genes, reversing excessive lipolysis in insulin-resistant adipocytes. In summary, the present research highlights the important roles of Dok1/ERK/PPARγ pathway in lowering FFA release from adipocytes, and our research extends the knowledge of the biological effects induced by LPLI. © 2015 Published by Elsevier Inc.","Dok1; ERK; Excessive lipolysis; Insulin resistance; LPLI","Kahn, B.B., Flier, J.S., (2000) J. Clin. Invest., 106 (4), pp. 473-481; Stumvoll, M., Goldstein, B.J., van Haeften, T.W., (2005) Lancet, 365 (9467), pp. 333-1346; Laakso, M., Kuusisto, J., (2014) Nat. Rev. Endocrinol., 1 (5), pp. 293-302; Kahn, S.E., Hull, R.L., Utzschneider, K.M., (2006) Nature, 444 (7121), pp. 840-846; Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin, M., Hotamisligil, G.S., (2002) Nature, 420 (6913), pp. 333-336; Yu, C., Chen, Y., Cline, G.W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Shulman, G.I., (2002) J. Biol. Chem., 277 (52), pp. 50230-50236; Itani, S.I., Ruderman, N.B., Schmieder, F., Boden, G., (2002) Diabetes, 51 (7), pp. 2005-2011; Wymann, M.P., Schneiter, R., (2008) Nat. Rev. Mol. Cell Biol., 9 (2), pp. 162-176; Samuel, V.T., Shulman, G.I., (2012) Cell, 148 (5), pp. 852-871; Kersten, S., Desvergne, B., Wahli, W., (2000) Nature, 405 (6785), pp. 421-424; Carlson, C.J., Koterski, S., Sciotti, R.J., Poccard, G.B., Rondinone, C.M., (2003) Diabetes, 52 (3), pp. 634-641; Hu, E., Kim, J.B., Sarraf, P., Spiegelman, B.M., (1996) Science, 274 (5295), pp. 2100-2103; van Beekum, O., Fleskens, V., Kalkhoven, E., (2009) Obesity (Silver Spring), 17 (2), pp. 213-219; Burgermeister, E., Seger, R., (2008) PPAR Res., 2008, p. 309469; Carpino, N., Wisniewski, D., Strife, A., Marshak, D., Kobayashi, R., Stillman, B., Clarkson, B., (1997) Cell, 88 (2), pp. 197-204; Hosooka, T., Noguchi, T., Kotani, K., Nakamura, T., Sakaue, H., Inoue, H., Ogawa, W., Kasuga, M., (2008) Nat. Med., 14 (2), pp. 188-193; Yamanashi, Y., Tamura, T., Kanamori, T., Yamane, H., Nariuchi, H., Yamamoto, T., Baltimore, D., (2000) Genes Dev., 14 (1), pp. 11-16; Siouda, M., Yue, J., Shukla, R., Guillermier, S., Herceg, Z., Creveaux, M., Accardi, R., Sylla, B.S., (2012) Mol. Cell. Biol., 32 (23), pp. 4877-4890; Wu, S., Xing, D., (2014) Laser Photonics Rev., 1, pp. 115-130; Byrnes, K.R., Barna, L., Chenault, V.M., Waynant, R.W., Ilev, I.K., Longo, L., Miracco, C., Anders, J.J., (2004) Photomed. Laser Surg., 22 (4), pp. 281-290; Antunes, H.S., De Azevedo, A.M., Da Silva Bouzas, L.F., Adao, C.A., Pinheiro, C.T., Mayhe, R., Pinheiro, L.H., Ferreira, C.G., (2007) Blood, 109 (5), pp. 2250-2255; Meng, C., He, Z., Xing, D., (2013) J. Neurosci., 33 (33), pp. 13505-13517; Feng, J., Zhang, Y., Xing, D., (2012) Cell. Signal., 24 (6), pp. 1116-1125; Huang, L., Gong, L., Jiang, X., Xing, D., (2014) J. Innov. Opt. Health Sci., 7, p. 1350067; Lee, S., Roy, F., Galmarini, C.M., Accardi, R., Michelon, J., Viller, A., Cros, E., Sylla, B.S., (2004) Oncogene, 23 (13), pp. 2287-2297; Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., Guarente, L., (2004) Nature, 429 (6993), pp. 771-776; Houstis, N., Rosen, E.D., Lander, E.S., (2006) Nature, 440 (4086), pp. 944-948; Huang, L., Wu, S., Xing, D., (2011) J. Cell. Physiol., 226 (3), pp. 588-601; Xu, C., He, J., Jiang, H., Zu, L., Zhai, W., Pu, S., Xu, G., (2009) Mol. Endocrinol., 23 (8), pp. 1161-1170; Ding, Y., Yang, L., Zhang, S., Wang, Y., Du, Y., Pu, J., Peng, G., Liu, P., (2012) J. Lipid Res., 53 (3), pp. 399-411; Zhao, M., Schmitz, A.A., Qin, Y., Di Cristofano, A., Pandolfi, P.P., Van Aelst, L., (2001) J. Exp. Med., 194 (3), pp. 265-274; Boden, G., (2011) Curr. Opin. Endocrinol. Diabetes Obes., 18 (2), pp. 139-143; Jager, J., Corcelle, V., Gremeaux, T., Laurent, K., Waget, A., Pages, G., Binetruy, B., Tanti, J.F., (2011) Diabetologia, 54 (1), pp. 180-189; Burgermeister, E., Chuderland, D., Hanoch, T., Meyer, M., Liscovitch, M., Seger, R., (2007) Mol. Cell. Biol., 27 (3), pp. 803-817; Burgermeister, E., Seger, R., (2007) Cell Cycle, 6 (13), pp. 1539-1548; Roden, M., Price, T.B., Perseghin, G., Petersen, K.F., Rothman, D.L., Cline, G.W., Shulman, G.I., (1996) J. Clin. Invest., 97 (12), pp. 2859-2865; Jucker, B.M., Rennings, A.J., Cline, G.W., Shulman, G.I., (1997) J. Biol. Chem., 272 (16), pp. 10464-10473; Peplow, P.V., Baxter, G.D., (2013) Lasers Surg. Med., 45 (4), pp. 240-245; Ryotokuji, K., Ishimaru, K., Kihara, K., Namiki, Y., Hozumi, N., (2013) Laser Ther., 22 (3), pp. 209-214; Kim, J., Han, D.C., Kim, J.M., Lee, S.Y., Kim, S.J., Woo, J.R., Lee, J.W., Kwon, B.M., (2009) Cell. Mol. Life Sci., 66 (10), pp. 1766-1781; Puri, V., Virbasius, J.V., Guilherme, A., Czech, M.P., (2008) Acta Physiol. (Oxf.), 192 (1), pp. 103-115; Duncan, R.E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E., Sul, H.S., (2007) Annu. Rev. Nutr., 27, pp. 79-101; Fernandez-Galilea, M., Perez-Matute, P., Prieto-Hontoria, P.L., Martinez, J.A., Moreno-Aliaga, M.J., (2012) J. Lipid Res., 53 (12), pp. 2296-2306",Article,Scopus,2-s2.0-84925954455
"Buckley M.L., Ramji D.P.","The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis",2015,"Biochimica et Biophysica Acta - Molecular Basis of Disease","1852","7",,"1498","1510",,,10.1016/j.bbadis.2015.04.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928555600&partnerID=40&md5=9351ef12d18aa0bb65a27773c449bcf7","Cardiff School of Biosciences, Cardiff University, Sir Martin Evans Building, Museum AvenueCardiff, United Kingdom","Buckley, M.L., Cardiff School of Biosciences, Cardiff University, Sir Martin Evans Building, Museum AvenueCardiff, United Kingdom; Ramji, D.P., Cardiff School of Biosciences, Cardiff University, Sir Martin Evans Building, Museum AvenueCardiff, United Kingdom","Atherosclerosis, the underlying cause of myocardial infarction and thrombotic cerebrovascular events, is responsible for the majority of deaths in westernized societies. Mortality from this disease is also increasing at a marked rate in developing countries due to the acquisition of a westernized lifestyle accompanied with elevated rates of obesity and diabetes. Atherosclerosis is recognized as a chronic inflammatory disorder associated with lipid accumulation and the development of fibrotic plaques within the walls of medium and large arteries. A range of immune cells, such as macrophages and T-lymphocytes, through the action of various cytokines, such as interleukins-1 and -33, transforming growth factor-β and interferon-γ, orchestrates the inflammatory response in this disease. The disease is also characterized by marked dysfunction in lipid homeostasis and signaling pathways that control the inflammatory response. This review will discuss the molecular basis of atherosclerosis with particular emphasis on the roles of the immune cells and cytokines along with the dysfunctional lipid homeostasis and cell signaling associated with this disease. © 2015.","Atherosclerosis; Cytokines; Immune cells; Inflammation; Lipoproteins; Signaling","Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Heart disease and stroke statistics-2014 update: A report from the American Heart Association (2014) Circulation, 129, pp. 399-410; McLaren, J.E., Michael, D.R., Ashlin, T.G., Ramji, D.P., Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy (2011) Prog. Lipid Res., 50, pp. 331-347; Tomkin, G.H., Owens, D., The chylomicron: relationship to atherosclerosis (2012) Int. J. Vasc. Med., 2012, p. 784536; Kovacic, S., Bakran, M., Genetic susceptibility to atherosclerosis (2012) Stroke Res. Treat., 2012, p. 362941; Lagace, T.A., PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells (2014) Curr. Opin. Lipidol., 25, pp. 387-393; Zhang, L., Reue, K., Fong, L.G., Young, S.G., Tontonoz, P., Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis (2012) Arterioscler. Thromb. Vasc. Biol., 32, pp. 2541-2546; Golstein, J.L., Brown, M.S., The LDL receptor (2009) Arterioscler. Thromb. Vasc. Biol., 29, pp. 431-438; Ono, K., Current concept of reverse cholesterol transport and novel strategy for atheroprotection (2012) J. Cardiol., 60, pp. 339-343; Phillips, M.C., Molecular mechanism of cellular cholesterol efflux (2014) J. Biol. Chem., 29, pp. 24020-24029; Michael, D.R., Ashlin, T.G., Buckley, M.L., Ramji, D.P., Macrophages, lipid metabolism and gene expression in atherogenesis: A therapeutic target of the future? (2012) J. Clin. Lipidol., 7, pp. 37-48; Michael, D.R., Ashlin, T.G., Buckley, M.L., Ramji, D.P., Liver X receptors, atherosclerosis and inflammation (2012) Curr. Atheroscler. Rep., 14, pp. 284-293; Spann, N.J., Garmire, L.X., McDonald, J.G., Myers, D.S., Milne, S.B., Shibata, N., Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses (2012) Cell, 15, pp. 138-152; Ouimet, M., Franklin, V., Mak, E., Liao, X., Tabas, I., Marcel, Y.L., Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase (2011) Cell Metab., 13, pp. 655-667; Plutzky, J., The PPAR-RXR transcriptional complex in the vasculature: energy in the balance (2011) Circ. Res., 108, pp. 1002-1016; Cheang, W.S., Fang, X., Tian, X.Y., Pleiotropic effects of peroxisome proliferator-activated receptor γ and δ in vascular diseases (2013) Circ. J., 77, pp. 2664-2671; Rader, D.J., Hovingh, G.K., HDL and cardiovascular disease (2014) Lancet, 384, pp. 618-625; Kingwell, B.A., Chapman, M.J., Konhish, A., Miller, N.E., HDL-targeted therapies: progress, failures and future (2014) Nat. Rev. Drug Discov., 13, pp. 445-464; Van Eck, M., ATP-binding cassette transporter A1: key player in cardiovascular and metabolic disease at local and systemic level (2014) Curr. Opin. Lipidol., 25, pp. 297-303; Calabresi, L., Gomaraschi, M., Simonelli, S., Bernini, F., Franceschini, G., HDL and atherosclerosis: Insights from inherited HDL disorders (2015) Biochim. Biophys. Acta, 185, pp. 13-18; Getz, G.S., Reardon, C.A., Animal models of atherosclerosis (2012) Arterioscler. Thromb. Vasc. Biol., 32, pp. 1104-1115; Zadelaar, S., Kleemann, R., Verschuren, L., de Vries-Van der Weij, J., van der Hoorn, J., Princen, H.M., Kooistra, T., Mouse models for atherosclerosis and pharmaceutical modifiers (2007) Arterioscler. Thromb. Vasc. Biol., 27, pp. 1706-1721; Greenow, K., Pearce, N.J., Ramji, D.P., The key role of apolipoprotein E in atherosclerosis (2005) J. Mol. Med., 83, pp. 329-342; Lin, S., Lin, Y., Nery, J.R., Urich, M.A., Breschi, A., Davis, C.A., Comparison of the transcriptional landscapes between human and mouse tissues (2014) Proc. Natl. Acad. Sci. U. S. A., 111, pp. 17224-17229; Seok, J., Warren, H.S., Cuenca, A.G., Mindrinos, M.N., Baker, H.V., Xu, W., Genomic responses in mouse models poorly mimic human inflammatory diseases (2013) Proc. Natl. Acad. Sci. U. S. A., 110, pp. 3507-3512; Bryan, M.T., Duckles, H., Feng, S., Hsiao, S.T., Kim, H.R., Serbanovic-Canic, J., Evans, P.C., Mechanoresponsive networks controlling vascular inflammation (2014) Arterioscler. Thromb. Vasc. Biol., 34, pp. 2199-2205; Tousoulis, D., Simpoulou, C., Papageorgiou, N., Oikonomou, E., Hatzis, G., Siasos, G., Tsiamis, E., Stefanadis, C., Endothelial dysfunction in conduit arteries and in microcirculation, Novel therapeutic approaches (2014) Pharmacol. Ther., 144, pp. 253-267; Wen, Y., Leake, D.S., Low density lipoprotein undergoes oxidation within lysosomes in cells (2007) Circ. Res., 100, pp. 1337-1343; Frostegård, J., Immunity, atherosclerosis and cardiovascular disease (2013) BMC Med., 11, p. 117; Wraith, K.S., Magwenzi, S., Aburima, A., Wen, Y., Leake, D.S., Naseem, K.M., Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways (2013) Blood, 122, pp. 580-589; Libby, P., Lichtman, A.H., Hansson, G.K., Immune effector mechanisms implicated in atherosclerosis: From mice to humans (2013) Immunity, 38, pp. 1092-1104; Bae, Y.S., Lee, J.H., Choi, S.H., Kim, S., Almazan, F., Witztum, J.L., Miller, Y.I., Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2 (2009) Circ. Res., 104, pp. 201-218; Choi, S.H., Harkewicz, R., Lee, J.H., Boullier, A., Almazan, F., Li, A.C., Witztum, J.L., Miller, Y.I., Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake (2009) Circ. Res., 104, pp. 1355-1363; Koenen, R.R., Weber, C., Therapeutic trageting of chemokine interactions in atherosclerosis (2010) Nat. Rev. Drug Discov., 141, pp. 141-153; Weber, C., Noels, H., Atherosclerosis: current pathogenesis and therapeutic options (2011) Nat. Med., 17, pp. 1410-1422; Moore, K.J., Sheedy, F.J., Fisher, E.A., Macrophages in atherosclerosis: a dynamic balance (2013) Nat. Rev. Immunol., 13, pp. 709-721; Zernecke, A., Weber, C., Chemokines in atherosclerosis: proceedings resumed (2014) Arterioscler. Thromb. Vasc. Biol., 34, pp. 742-750; Cole, J.E., Kassiteridi, C., Monaco, C., Toll-like receptors in atherosclerosis: a ""Pandora's box"" of advances and controversies (2013) Trends Pharmacol. Sci., 34, pp. 629-636; Michelsen, K.S., Wong, M.H., Shah, P.K., Zhang, W., Yano, J., Doherty, T.M., Akira, S., Ardity, M., Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E (2004) Proc. Natl. Acad. Sci. U. S. A., 101, pp. 10679-10684; Mullick, A.E., Tobias, P.S., Curtiss, L.K., Modulation of atherosclerosis in mice by Toll-like receptor 2 (2005) J. Clin. Invest., 115, pp. 3149-3156; Kim, T.W., Febbraio, M., Robinet, P., Dugar, B., Greene, D., Cerny, A., The critical role of IL-1 receptor-associated kinase 4-mediated NF-κB activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis (2011) J. Immunol, 186, pp. 2871-2880; Lutgens, E., Lievens, D., Beckers, L., Wijnands, E., Soehnlein, O., Zernecke, A., Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile (2010) J. Exp. Med., 207, pp. 391-404; Richards, M.R., Black, A.S., Bonnet, D.J., Barish, G.D., Woo, C.W., Tabas, I., Curtiss, L.K., Tobias, P.S., The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice (2013) Innate Immun., 19, pp. 20-29; Björkbacka, H., Kunjathoor, V.V., Moore, K.J., Koehn, S., Ordija, C.M., Lee, M.A., Means, T., Freeman, M.W., Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways (2004) Nat. Med., 10, pp. 416-421; Duewell, P., Kono, H., Rayner, K.J., Sirois, C.M., Vladimer, G., Bauernfeind, F.G., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals (2010) Nature, 464, pp. 1357-1361; Menu, P., Pellegrin, M., Aubert, J.F., Bouzourene, K., Tardivel, A., Mazzolai, L., Tschopp, J., Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome (2011) Cell Death Dis., 2; Canton, J., Neculai, D., Grinstein, S., Scavenger receptors in homeostasis and immunity (2013) Nat. Rev. Immunol., 13, pp. 621-636; Kzhyshkowska, J., Neyen, C., Gordon, S., Role of macrophage scavenger receptors in atherosclerosis (2012) Immunobiology, 217, pp. 492-502; Febbraio, M., Podrez, E.A., Smith, J.D., Hajjar, D.P., Hazen, S.L., Hoff, H.F., Sharma, K., Silverstein, R.L., Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice (2000) J. Clin. Invest., 105, pp. 1049-1056; Makinen, P.I., Lappalainen, J.P., Heinonen, S.E., Leppanen, P., Lahteenvuo, M.T., Aarnio, J.V., Heikkila, J., Ylä-Herttuala, S., Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors (2010) Cardiovasc. Res., 88, pp. 530-538; Manning-Tobin, J.J., Moore, K.J., Seimon, T.A., Bell, S.A., Sharuk, M., Alvarez-Leite, J.I., de Winther, M.P., Freeman, M.W., Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice (2009) Arterioscler. Thromb. Vasc. Biol., 29, pp. 19-26; Moore, K.J., Kunjathoor, V., Koehn, S.L., Manning, J.J., Tseng, A.A., Silver, J.M., McKee, M., Freeman, M.W., Loss of receptor-mediated uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice (2005) J. Clin. Invest., 115, pp. 2192-2201; Michael, D.R., Ashlin, T.G., Davies, C.S., Gallagher, H., Stoneman, T.W., Buckley, M.L., Ramji, D.P., Differential regulation of macropinocytosis in macrophages by cytokines: Implications for foam cell formation and atherosclerosis (2013) Cytokine, 64, pp. 357-361; Bentzon, J.F., Otsuka, F., Virmani, R., Falk, E., Mechanisms of plaque formation and rupture (2014) Circ. Res., 114, pp. 1852-1866; Zhu, X., Owen, J.S., Wilson, M.D., Li, H., Griffiths, G.L., Thomas, M.J., Hiltbold, E.M., Parks, J.S., Macrophage ABCA1 reduces Myd88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol (2010) J. Lipid Res., 51, pp. 3196-3206; Yvan-Charvet, L., Welch, C., Pagler, T.A., Ranalletta, M., Lamkanfi, M., Han, S., Ishibashi, M., Tall, A.R., Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions (2008) Circulation, 118, pp. 1837-1847. , (118); Tabas, I., Macrophage death and defective inflammation resolution in atherosclerosis (2010) Nat. Rev. Immunol., 10, pp. 36-46; Feng, B., Yao, P.M., Li, Y.K., Devlin, C.M., Zhang, D.J., Harding, H.P., Sweeney, M., The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages (2003) Nat. Cell Biol., 5, pp. 781-792; Van Vré, E.A., Ait-Oufella, H., Tedgui, A., Mallat, Z., Apoptotic cell death and efferocytosis in atherosclerosis (2012) Arterioscler. Thromb. Vasc. Biol., 32, pp. 887-893; Szondy, Z., Garabuczi, E., Joós, G., Tsay, G.J., Sarang, Z., Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implications (2014) Front. Immunol., 5, p. 354; Witztum, J.L., Lichman, A.H., The influence of innate and adaptive immune responses on atherosclerosis (2014) Annu. Rev. Pathol., 9, pp. 73-102; Newby, A., Proteinases and plaque rupture: unblocking the road to translation (2014) Curr. Opin. Lipidol., 25, pp. 358-366; Newby, A., Matrix metalloproteinase inhibition therapy for vascular diseases (2012) Vasc. Pharmacol., 56, pp. 232-244; Silvestre-Roig, C., de Winther, M.P., Weber, C., Daemen, M.J., Lutgens, E., Soehnlein, O., Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies (2014) Circ. Res., 114, pp. 214-226; McLaren, J.E., Ramji, D.P., Interferon gamma: A master regulator of atherosclerosis (2009) Cytokine Growth Factor Rev., 20, pp. 125-135; Muslin, A.J., MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets (2008) Clin. Sci., 115, pp. 203-218; Kyriakis, J.M., Avruch, J., Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update (2012) Physiol. Rev., 92, pp. 689-737; Pamukcu, B., Lip, G.Y., Shantsila, E., The nuclear factor-kappaB pathway in atherosclerosis: a potential therapeutic target for atherothrobotic vascular disaese (2011) Thromb. Res., 128, pp. 117-123; Ghigo, A., Morello, F., Perino, A., Hirsch, E., Therapeutic applications of PI3K inhibitors in cardiovascular diseases (2013) Future Med. Chem., 5, pp. 479-492; Zhou, X., Yin, Z., Guo, X., Hajjar, D.P., Han, J., Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux (2010) J. Biol. Chem., 285, pp. 6316-6326; Li, N., McLaren, J.E., Michael, D.R., Clement, M., Fielding, C.A., Ramji, D.P., ERK is integral to the IFN-gamma-mediated activation of STAT1, the expression of key genes implicated in atherosclerosis, and the uptake of modified lipoproteins by human macrophages (2010) J. Immunol., 185, pp. 3041-3048; Salter, R.C., Ashlin, T.G., Kwan, A.P.L., Ramji, D.P., ADAMTS proteases: key roles in atherosclerosis? (2010) J. Mol. Med., 88, pp. 1203-1211; Ashlin, T.G., Buckley, M.L., Salter, R.C., Johnson, J.L., Kwan, A.P.L., Ramji, D.P., The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1, -4 and -5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphoinositide 3-kinase signaling pathways (2014) Int. J. Biochem. Cell Biol., 46, pp. 113-123; Heo, K.S., Cushman, H.J., Akaike, M., Woo, C.H., Wang, X., Qiu, X., Fujiwara, K., Abe, J., ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis (2014) Circulation, 130, pp. 180-191; Le, N.T., Heo, K.S., Takei, Y., Lee, H., Woo, C.H., Chang, E., A crucial role for p90RSK-mediated reduction of ERK5 transcriptional activity in endothelial dysfunction and atherosclerosis (2013) Circulation, 127, pp. 486-499; Komaravolu, R.K., Adam, C., Moonen, J.R., Harmsen, M.C., Goebeler, M., Schmidt, M., Erk5 inhibits endothelial migration via KLF2-dependent down-regulation of PAK1 (2015) Cardiovasc. Res., 105, pp. 86-95; Mei, S., Gu, H., Ward, A., Yang, X., Guo, H., He, K., Liu, Z., Cao, W., P38 mitogen-activated protein kinase (MAPK) promotes cholesterol ester accumulation in macrophages through inhibition of macroautophagy (2012) J. Biol. Chem., 287, pp. 11761-11768; DeVries-Seimon, T., Li, Y.K., Yao, P.M., Stone, E., Wang, Y.B., Davis, R.J., Flavell, R., Tabas, I., Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor (2005) J. Cell Biol., 171, pp. 61-73; Seimon, T.A., Wang, Y., Han, S., Senokuchi, T., Schrijvers, D.M., Kuriakose, G., Tall, A.R., Tabas, I.A., Macrophage deficiency of p38 alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice (2009) J. Clin. Invest., 119, pp. 886-898; Kardakaris, R., Gareus, R., Xanthoulea, S., Pasparakis, M., Endothelial and macrophage-specific deficiency of p38α MAPK does not affect the pathogenesis of atherosclerosis in ApoE-/- Mice (2011) PLoS ONE, 6; Ricci, R., Sumara, G., Sumara, I., Rozenberg, I., Kurrer, M., Akhmedov, A., Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis (2004) Science, 306, pp. 1558-1561; Amini, N., Boyle, J.J., Moers, B., Warboys, C.M., Malik, T.H., Zakkar, M., Francis, S.E., Evans, P.C., Requirement of JNK1 for endothelial cell injury in atherogenesis (2014) Atherosclerosis, 235, pp. 613-618; Yoshimura, K., Aoki, H., Ikeda, Y., Fujii, K., Akiyama, N., Furutani, A., Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase (2005) Nat. Med., 11, pp. 1330-1338; Wang, J., An, F.S., Zhang, W., Gong, L., Wie, S.J., Qin, W.D., Wang, X.P., Zhang, M.X., Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice (2011) Mol. Med., 17, pp. 990-991; Mallavia, B., Recio, C., Oguiza, A., Ortiz-Muñoz, G., Lazaro, I., Lopez-Parra, V., Lopez-Franco, O., Gomez-Guerrero, C., Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis (2013) Am. J. Pathol., 182, pp. 1910-1921; Cuaz-Pérolin, C., Billiet, L., Baugé, E., Copin, C., Scott-Algara, D., Genze, F., Büchele, B., Rouis, M., Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice (2008) Arterioscler. Thromb. Vasc. Biol., 28, pp. 272-277; Wolfrum, S., Teupser, D., Tan, M., Chen, K.Y., Breslow, J.L., The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-kappaB target genes (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 18601-18606; Sun, X., He, S., Wara, A.K., Icli, B., Shvartz, E., Tesmenitsky, Y., Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice (2014) Circ. Res., 114, pp. 32-40; Wang, Y., Wang, G.Z., Rabinovitch, P.S., Tabas, I., Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages (2014) Circ. Res., 114, pp. 421-433; Gareus, R., Kotsaki, E., Xanthoulea, S., van der Made, I., Gijbels, M.J.J., Kardakaris, R., Polykratis, A., Pasparakis, M., Endothelial cell-specific NF-kappa B inhibition protects mice from atherosclerosis (2008) Cell Metab., 8, pp. 372-383; Goossens, P., Vergouwe, M.N., Gijbels, M.J., Curfs, D.M., van Woezik, J.H., Hoeksema, M.A., Xanthoulea, S., de Winther, M.P., Myeloid IκBα deficiency promotes atherogenesis by enhancing leukocyte recruitment to the plaques (2011) PLoS ONE, 6; Tilstam, P.V., Gijbels, M.J., Habbeddine, M., Cudejko, C., Asare, Y., Theelen, W., Zhou, B., Bone marrow-specific knock-in of a non-activatable Ikkα kinase mutant influences haematopoiesis but not atherosclerosis in Apoe-deficient mice (2014) PLoS ONE, 9; Cao, C., Zhu, Y., Chen, W., Li, L., Qi, Y., Wang, X., Zhao, Y., Chen, X., IKKε knockout prevents high fat diet induced arterial atherosclerosis and NF-κB signaling in mice (2013) PLoS ONE, 8; Kanters, E., Pasparakis, M., Gijbels, M.J., Vergouwe, M.N., Partouns-Hedriks, I., Fijneman, R.J., Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice (2003) J. Clin. Invest., 112, pp. 1176-1185; Park, S.H., Sui, Y., Gizard, F., Xu, J., Rios-Pilier, J., Helsley, R.N., Han, S.S., Zhou, C., Myeloid-specific IκB kinase β deficiency decreases atherosclerosis in low-density lipoprotein receptor-deficient mice (2012) Arterioscler. Thromb. Vasc. Biol., 32, pp. 2869-2876; Sui, Y., Park, S.H., Xu, J., Monette, S., Helsley, R.N., Han, S.S., Zhou, C., IKKβ links vascular inflammation to obesity and atherosclerosis (2014) J. Exp. Med., 211, pp. 869-886; Wong, M.C., van Diepen, J.A., Hu, L., Guigas, B., de Boer, H.C., van Puijvelde, G.H., Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden mice (2012) Atherosclerosis, 220, pp. 362-368; Kanters, E., Gijbels, M.J.J., van der Made, I., Vergouwe, M.N., Heeringa, P., Kraal, G., Hofker, M.H., de Winther, M.P., Hematopoietic NF-kappa B1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype (2004) Blood, 103, pp. 934-940; Ye, X., Jiang, X., Guo, W., Clark, K., Gao, Z., Overexpression of NF-kappa B p65 in macrophages ameliorates atherosclerosis in apoE-knockout mice (2013) Am. J. Physiol. Endocrinol. Metab., 305, pp. E1375-E1383; Lawrence, T., Gilroy, D.W., Colville-Nash, P.R., Willoughby, D.A., Possible new role for NF-kappaB in the resolution of inflammation (2001) Nat. Med., 7, pp. 1291-1297; Lawrence, T., Fong, C., The resolution of inflammation: Anti-inflammatory roles for NF-κB (2010) Int. J. Biochem. Cell Biol., 42, pp. 519-523; Chang, J.D., Sukhova, G.K., Libby, P., Schvartz, E., Lichtenstein, A.H., Field, S.J., Kennedy, C., Cantley, L.C., Deletion of the phosphoinositide 3-kinase p110 gamma gene attenuates murine atherosclerosis (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 8077-8082; Zotes, T.M., Arias, C.F., Fuster, J.J., Spada, R., Perez-Yaguee, S., Hirsch, E., Wymann, M., Barber, D.F., PI3K p110 gamma deletion attenuates murine atherosclerosis by reducing macrophage proliferation but not polarization or apoptosis in lesions (2013) PLoS ONE, 8; Fougerat, A., Gayral, S., Gourdy, P., Schambourg, A., Rueckle, T., Schwarz, M.K., Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes (2008) Circulation, 117, pp. 1310-1317; Siragusa, M., Katare, R., Meloni, M., Damilano, F., Hirsch, E., Emanueli, C., Madeddu, P., Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice (2010) Circ. Res., 106, pp. 757-768; Fernández-Hernando, C., Ackah, E., Yu, J., Suárez, Y., Murata, T., Iwakiri, Y., Prendergast, J., Sessa, W.C., Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease (2007) Cell Metab., 6, pp. 446-457; Fernández-Hernando, C., József, L., Jenkins, D., Di Lorenzo, A., Sessa, W.C., Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis (2009) Arterioscler. Thromb. Vasc. Biol., 29, pp. 2033-2040; Babaev, V.R., Hebron, K.E., Wiese, C.B., Toth, C.L., Ding, L., Zhang, Y., May, J.M., Linton, M.F., Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice (2014) J. Lipid Res., 55, pp. 2296-2308; Rensing, K.L., de Jager, S.C., Stroes, E.S., Vos, M., Twickler, M.T., Dallinga-Thie, G.M., de Vries, C.J., von der Thüsen, J.H., Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice (2014) Cardiovasc. Res., 101, pp. 277-287; Ding, L., Biswas, S., Morton, R.E., Smith, J.D., Hay, N., Byzova, T.V., Febbraio, M., Podrez, E.A., Akt3 deficiency in macrophages promotes foam cell formation and atherosclerosis in mice (2012) Cell Metab., 15, pp. 861-872; Randolph, G.J., Mechanisms that regulate macrophage burden in atherosclerosis (2014) Circ. Res., 114, pp. 1757-1771; Swirski, F.K., Libby, P., Aikawa, E., Alcaide, P., Luscinskas, F.W., Weissleder, R., Pittet, M.J., Ly-6C(hi) monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata (2007) J. Clin. Invest., 117, pp. 195-205; Gui, T., Shimokado, A., Sun, Y., Akasaka, T., Muragaki, Y., Diverse roles of macrophages in atherosclerosis: From inflammatory biology to biomarker discovery (2012) Mediat. Inflamm., 2012, p. 693083; Robbins, C.S., Hilgendorf, I., Weber, G.F., Theurl, I., Iwamoto, Y., Figueiredo, J.L., Local proliferation dominates lesional macrophage accumulation in atherosclerosis (2013) Nat. Med., 19, pp. 1166-1172; Letinger, N., Schulman, I.G., Phenotypic polarization of macrophages in atherosclerosis (2013) Arterioscler. Thromb. Vasc. Biol., 33, pp. 1120-1126; Wolfs, I.M.J., Donners, M.M.P.C., de Winther, M.P.J., Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation (2011) Thromb. Haemost., 106, pp. 763-771; Colin, S., Chinett-Gbaguidi, G., Staels, B., Macrophage phenotypes in atherosclerosis (2014) Immunol. Rev., 262, pp. 153-166; Gleissner, C.A., Shaked, I., Little, K., Ley, K., CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages (2010) J. Immunol, 184, pp. 4810-4818; Sachais, B.S., Turrentine, T., McKenna, J.M.D., Rux, A.H., Rader, D., Kowalska, M.A., Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57BI/6 and apoE(-/-) mice (2007) Thromb. Haemost., 98, pp. 1108-1113; Niessner, A., Weyand, C.M., Dendritic cells in atherosclerotic disease (2010) Clin. Immunol., 134, pp. 25-32; Shaposhnik, Z., Wang, X., Weinstein, M., Bennett, B.J., Lusis, A.J., Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions (2007) Arterioscler. Thromb. Vasc. Biol., 27, pp. 621-627; Chistiakov, D.A., Sobenin, I.A., Orekhov, A.N., Bobryshev, Y.V., Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects (2014) Front. Physiol., 5, p. 196; Ait-Oufella, H., Sage, A.P., Mallat, Z., Tedgui, A., Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis (2014) Circ. Res., 114, pp. 1640-1660; Macritchie, N., Grassia, G., Sabir, S.R., Maddaluno, M., Welsh, P., Sattar, N., Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein E-deficient mice (2012) Arterioscler. Thromb. Vasc. Biol., 32, pp. 2569-2579; Sage, A., Murphy, D.M., Maffia, P., Masters, L.M., Sabir, S.R., Baker, L.L., MHC class II-restricted antigen presentation by plasmacytoid dendritic cells drives pro-atherogenic T cell immunity (2014) Circulation, 130, pp. 1363-1373; Daissormont, I.T., Christ, A., Temmerman, L., Sampedro Millares, S., Seijkens, T., Manca, M., Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity (2011) Circ. Res., 109, pp. 1387-1395; Paulson, K.E., Zhu, S.N., Chen, M., Nurmohamed, S., Jongstra-Bilen, J., Cybulsky, M.L., Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis (2010) Circ. Res., 106, pp. 383-390; Habets, K.L., van Puijvelde, G.H., van Duivenvoorde, L.M., van Wanrooij, E.J., de Vos, P., Tervaert, J.W., van Berkel, T.J., Kuiper, J., Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice (2010) Cardiovasc. Res., 85, pp. 622-630; Hermansson, A., Johansson, D.K., Ketelhuth, D.F., Andersson, J., Zhou, X., Hansson, G.K., Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesteromic mice (2011) Circulation, 123, pp. 1083-1091; Agrawal, S., Febbraio, M., Podrez, E., Cathcart, M.K., Stark, G.R., Chisolm, G.M., Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development (2007) Circulation, 115, pp. 2939-2947; Lim, W.S., Timmins, J.M., Seimon, T.A., Sadler, A., Kolodgie, F.D., Virmani, R., Tabas, I., Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo (2008) Circulation, 117, pp. 940-951; Taleb, S., Tedgui, A., Mallat, Z., IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles (2015) Arterioscler. Thromb. Vasc. Biol., 35, pp. 258-264; Singh, N.N., Ramji, D.P., The role of transforming growth factor-beta in atherosclerosis (2006) Cytokine Growth Factor Rev., 17, pp. 487-499; Shah, P.K., Chyu, K., Dimayuga, P.C., Nilsson, J., Vaccine for atherosclerosis (2014) J. Am. Coll. Cardiol., 64, pp. 2779-2791; To, K., Agotis, A., Besra, G., Bobik, A., Toh, B.H., NKT cell subsets mediate differential proatherogenic effects in ApoE-/- mice (2009) Arterioscler. Thromb. Vasc. Biol., 29, pp. 671-677; Selathurai, A., Deswaerte, V., Kanellakis, P., Tipping, P., Toh, B.H., Bobik, A., Kyaw, T., Natural killer (NK) cells augment atherosclerosis by cytotoxic-dependent mechanisms (2014) Cardiovasc. Res., 102, pp. 128-137; Döring, Y., Drechsler, M., Soehnlein, O., Weber, C., Neutrophils in atherosclerosis: From mice to man (2015) Arterioscler. Thromb. Vasc. Biol., 35, pp. 288-295; Tsiantoulas, D., Diehl, C.J., Witztum, J.L., Binder, C.J., B cells and humoral immunity in atherosclerosis (2014) Circ. Res., 114, pp. 1743-1756; Kyaw, T., Tipping, P., Bobik, A., Toh, B.H., Protective role of natural IgM-producing B1a cells in atherosclerosis (2012) Trends Cardiovasc. Med., 22, pp. 48-53; Hilgendorf, I., Theurl, I., Gerhardt, L.M., Robbins, C.S., Weber, G.F., Gonen, A., Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity (2014) Circulation, 129, pp. 1677-1687; Bot, I., de Jager, S.C.A., Zernecke, A., Lindstedt, K.A., van Berkel, T.J.C., Weber, C., Biessen, E.A.L., Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice (2007) Circulation, 115, pp. 2516-2525; Sun, J., Sukhova, G.K., Wolters, P.J., Yang, M., Kitamoto, S., Libby, P., MacFarlane, L.A., Mast cells promote atherosclerosis by releasing proinflammatory cytokines (2007) Nat. Med., 13, pp. 719-724; Ait-Oufella, H., Taleb, S., Mallat, Z., Tedgui, A., Recent advances on the role of cytokines in atherosclerosis (2011) Arterioscler. Thromb. Vasc. Biol., 31, pp. 969-979; Kleemann, R., Zadelaar, S., Kooistra, T., Cytokines and atherosclerosis: a comprehensive review of studies in mice (2008) Cardiovasc. Res., 79, pp. 360-376; Tedgui, A., Mallat, Z., Cytokines in atherosclerosis: Pathogenic and regulatory pathways (2006) Physiol. Rev., 86, pp. 515-581; Bond, M., Chase, A.J., Baker, A.H., Newby, A.C., Inhibition of transcription factor NF-kappa B reduces matrix metalloproteinase-1,-3 and-9 production by vascular smooth muscle cells (2001) Cardiovasc. Res., 50, pp. 556-565; Gupta, S., Pablo, A.M., Jiang, X.C., Wang, N., Tall, A.R., Schindler, C., IFN-gamma potentiates atherosclerosis in apoE knock-out mice (1997) J. Clin. Invest., 99, pp. 2752-2761; Buono, C., Come, C.E., Stavrakis, G., Maguire, G.G., Connelly, P.W., Lichtman, A.H., Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse (2003) Arterioscler. Thromb. Vasc. Biol., 23, pp. 454-460; Whitman, S.C., Ravisankar, P., Elam, H., Daugherty, A., Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice (2000) Am. J. Pathol., 157, pp. 1819-1824; Koga, M., Kai, H., Yasukawa, H., Yamamoto, T., Kawai, Y., Kato, S., Kusaba, K., Imaizumi, T., Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice (2007) Circ. Res., 101, pp. 348-356; Xanthoulea, S., Thelen, M., Pöttgens, C., Gijbels, M.J., Lutgens, E., de Winther, M.P., Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice (2009) PLoS ONE, 7; Xiao, N., Yin, M., Zhang, L., Qu, X., Du, H., Sun, X., Tumor necrosis factor-alpha deficiency retards early fatty-streak lesion by influencing the expression of inflammatory factors in apoE-null mice (2009) Mol. Genet. Metab., 96, pp. 239-244; Ohta, H., Wada, H., Niwa, T., Kirii, H., Iwamoto, N., Fujii, H., Saito, K., Seishima, M., Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice (2005) Atherosclerosis, 180, pp. 11-17; Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Seishima, M., Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice (2003) Arterioscler. Thromb. Vasc. Biol., 23, pp. 656-660; Chamberlain, J., Francis, S., Brookes, Z., Shaw, G., Graham, D., Alp, N.J., Dower, S., Crossman, D.C., Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding (2009) PLoS ONE, 4; Devlin, C.M., Kuriakose, G., Hirsch, E., Tabas, I., Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size (2002) Proc. Natl. Acad. Sci. U. S. A., 99, pp. 6280-6285; Merhi-Soussi, F., Kwak, B.R., Magne, D., Chadjichristos, C., Berti, M., Pelli, G., James, R.W., Gabay, C., Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice (2005) Cardiovasc. Res., 66, pp. 583-593; Elhage, R., Jawien, J., Rudling, M., Ljunggren, H.G., Takeda, K., Akira, S., Bayard, F., Hansson, G.K., Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice (2003) Cardiovasc. Res., 59, pp. 234-240; Tenger, C., Sundborger, A., Jawien, J., Zhou, X., IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells (2005) Arterioscler. Thromb. Vasc. Biol., 25, pp. 791-796; Whitman, S.C., Ravisankar, P., Daugherty, A., Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma (2002) Circ. Res., 90, pp. E34-E38; Mallat, Z., Corbaz, A., Scoazec, A., Graber, P., Alouani, S., Esposito, B., Humbert, Y., Tedgui, A., Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability (2001) Circ. Res., 89, pp. E41-E45; Caligiuri, C., Rudling, M., Ollivier, V., Jacob, M.P., Michel, J.B., Hansson, G.K., Nicoletti, A., Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice (2003) Mol. Med., 9, pp. 10-17; Liu, Y., Li, D., Chen, J., Xie, J., Bandyopadhyay, S., Zhang, D., Nemarkommula, A.R., Hermonat, P.L., Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10 (2006) Atherosclerosis, 188, pp. 19-27; Yoshioka, T., Okada, T., Maeda, Y., Ikeda, U., Shimpo, M., Nomoto, T., Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice (2004) Gene Ther., 11, pp. 1772-1779; Namiki, M., Kawashima, S., Yamashita, T., Ozaki, M., Sakoda, T., Inoue, N., Hirata, K., Yokoyama, M., Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice (2004) Atherosclerosis, 172, pp. 21-29; Mallat, Z., Gojova, A., Marchiol-Fournigault, C., Esposito, B., Kamate, C., Merval, R., Fradelizi, D., Tedgui, A., Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice (2001) Circ. Res., 89, pp. 930-934; Robertson, A.K., Rudling, M., Zhou, X., Gorelik, L., Flavell, R.A., Hansson, G.K., Disruption of TGF-beta signaling in T cells accelerates atherosclerosis (2003) J. Clin. Invest., 112, pp. 1342-1350; Gisterá, A., Robertson, A.K., Andersson, J., Ketelhuth, D.F., Ovchinnikova, O., Nilsson, S.K., Lundberg, A.M., Hansson, G.K., Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway (2013) Sci. Transl. Med., 5; Reifenberg, K., Cheng, F., Orning, C., Crain, J., Küpper, I., Wiese, E., Protschka, M., Torzewski, M., Overexpression of TGF-β1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice (2012) PLoS ONE, 7; Frutkin, A.D., Otsuka, G., Stempien-Otero, A., Sesti, C., Du, L., Jaffe, M., TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice (2009) Arterioscler. Thromb. Vasc. Biol., 29, pp. 1251-1257; Miller, A.M., Xu, D., Asquith, D.L., Denby, L., Li, Y., Sattar, N., IL-33 reduces the development of atherosclerosis (2008) J. Exp. Med., 205, pp. 339-346; McLaren, J.E., Michael, D.R., Salter, R.C., Ashlin, T.G., Calder, C.J., Miller, A.M., Liew, F.Y., Ramji, D.P., IL-33 reduces macrophage foam cell formation (2010) J. Immunol., 185, pp. 1222-1229; Michael, D.R., Salter, R.C., Ramji, D.P., TGF-β inhibits the uptake of modified low density lipoprotein by human macrophages through a Smad-dependent pathway: a dominant role for Smad-2 (2012) Biochim. Biophys. Acta, 1822, pp. 1608-1616; Miller, A.M., Role of IL-33 in inflammation and disease (2011) J. Inflamm., 8, p. 22; Miller, A.M., Liew, F.Y., The IL-33/ST2 pathway - A new therapeutic target in cardiovascular disease (2011) Pharmacol. Ther., 131, pp. 179-186; Schmitz, J., Owyang, A., Oldham, E., Song, Y.L., Murphy, E., McClanahan, T.K., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines (2005) Immunity, 23, pp. 479-490; Dinarello, C.A., An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor (2005) Immunity, 23, pp. 461-462; Lefrançais, E., Cayrol, C., Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members (2012) Eur. Cytokine Netw., 23, pp. 120-127; Lüthi, A.U., Cullen, S.P., McNeela, E.A., Duriez, P.J., Afonina, I.S., Sheridan, C., Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases (2009) Immunity, 31, pp. 84-98; Ali, S., Mohs, A., Thomas, M., Klare, J., Ross, R., Schmitz, M.L., Martin, M.U., The dual function cytokine IL-33 interacts with the transcription factor NF-kappa B to dampen NF-kappa B-stimulated gene transcription (2011) J. Immunol., 187, pp. 1609-1616; Carriere, V., Roussel, L., Ortega, N., Lacorre, D.A., Americh, L., Aguilar, L., Bouche, G., Girard, J.P., IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 282-287; Wasserman, A., Ben-Shoshan, J., Entin-Meer, M., Maysel-Auslender, S., Guzner-Gur, H., Keren, G., Interleukin-33 augments Treg cell levels: a flaw mechanism in atherosclerosis (2012) Isr. Med. Assoc. J., 14, pp. 620-623; Seki, K., Sanada, S., Kudinova, A.Y., Steinhauser, M.L., Handa, V., Gannon, J., Lee, R.T., Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling (2009) Circ. Heart Fail., 2, pp. 684-691; Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N.J., Lee, R.T., IL-33 and ST2 comprise a critical biomechanically induced and card ioprotective signaling system (2007) J. Clin. Invest., 117, pp. 1538-1549; Liu, C.-L., Shen, D.-L., Kui, Z., Tang, J.-N., Hai, Q.-M., Zhang, J.-Y., Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina (2013) Clin. Invest. Med., 36, pp. E234-E241; Zhang, H.-F., Xie, S.-L., Chen, Y.-X., Mai, J.-T., Wang, J.-F., Zhu, W.-L., Zhu, L.-G., Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress (2012) J. Transl. Med., 10, p. 120; Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., MacGillivray, C., Tominaga, S., Solomon, S.D., Rouleau, J.L., Lee, R.T., Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction (2002) Circulation, 106, pp. 2961-2966; Chen, L.Q., de Lemos, J.A., Das, S.R., Ayers, C.R., Rohatgi, A., Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: The Dallas Heart Study (2013) Clin. Chem., 59, pp. 536-546; Weir, R.A.P., Miller, A.M., Murphy, G.E.J., Clements, S., Steedman, T., Connell, J.M.C., McInnes, I.B., McMurray, J.J., Serum soluble ST2 a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction (2010) J. Am. Coll. Cardiol., 55, pp. 243-250; Januzzi, J.L., Peacock, W.F., Maisel, A.S., Chae, C.U., Jesse, R.L., Baggish, A.L., Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study (2007) J. Am. Coll. Cardiol., 50, pp. 607-613; Libby, P., Ridker, P.M., Hansson, G.K., Progress and challenges in translating the biology of atherosclerosis (2011) Nature, 473, pp. 317-325; Do, R.Q., Nicholls, S.J., Schwartz, G.G., Evolving targets for lipid-modifying therapy (2014) EMBO Mol. Med., 6, pp. 1215-1230; Aryal, B., Rotllan, N., Fernández-Hernando, C., Noncoding RNAs and atherosclerosis (2014) Curr. Atheroscler. Rep., 16, p. 407",Review,Scopus,2-s2.0-84928555600
"Kim T.-M., Baek J.-H., Kim J.H., Oh M.S., Kim J.","Development of in vitro PIK3C3/VPS34 complex protein assay for autophagy-specific inhibitor screening",2015,"Analytical Biochemistry","480",, 12033,"21","27",,,10.1016/j.ab.2015.04.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928751588&partnerID=40&md5=cdaa8b03c01b23b62893216ceb104df5","Department of Life and Nanopharmaceutical Science, Kyung Hee UniversitySeoul, South Korea; Department of Oral Biochemistry and Molecular Biology, School of Dentistry, Kyung Hee UniversitySeoul, South Korea; Department of Oriental Pharmaceutical Science, College of Pharmacy, Kyung Hee UniversitySeoul, South Korea","Kim, T.-M., Department of Life and Nanopharmaceutical Science, Kyung Hee UniversitySeoul, South Korea; Baek, J.-H., Department of Life and Nanopharmaceutical Science, Kyung Hee UniversitySeoul, South Korea; Kim, J.H., Department of Life and Nanopharmaceutical Science, Kyung Hee UniversitySeoul, South Korea, Department of Oral Biochemistry and Molecular Biology, School of Dentistry, Kyung Hee UniversitySeoul, South Korea; Oh, M.S., Department of Life and Nanopharmaceutical Science, Kyung Hee UniversitySeoul, South Korea, Department of Oriental Pharmaceutical Science, College of Pharmacy, Kyung Hee UniversitySeoul, South Korea; Kim, J., Department of Oral Biochemistry and Molecular Biology, School of Dentistry, Kyung Hee UniversitySeoul, South Korea","Abstract Autophagy is an important catabolic program to respond to a variety of cellular stresses by forming a double membrane vesicle, autophagosome. Autophagy plays key roles in various cellular functions. Accordingly, dysregulation of autophagy is closely associated with diseases such as diabetes, neurodegenerative diseases, cardiomyopathy, and cancer. In this sense, autophagy is emerging as an important therapeutic target for disease control. Among the autophagy machineries, PIK3C3/VPS34 complex functions as an autophagy-triggering kinase to recruit the subsequent autophagy protein machineries on the phagophore membrane. Accumulating evidence showing that inhibition of PIK3C3/VPS34 complex successfully inhibits autophagy makes the complex an attractive target for developing autophagy inhibitors. However, one concern about PIK3C3/VPS34 complex is that many different PIK3C3/VPS34 complexes have distinct cellular functions. In this study, we have developed an in vitro PIK3C3/VPS34 complex monitoring assay for autophagy inhibitor screening in a high-throughput assay format instead of targeting the catalytic activity of the PIK3C3/VPS34 complex, which shuts down all PIK3C3/VPS34 complexes. We performed in vitro reconstitution of an essential autophagy-promoting PIK3C3/VPS34 complex, Vps34-Beclin1-ATG14L complex, in a microwell plate (96-well format) and successfully monitored the complex formation in many different conditions. This PIK3C3/VPS34 complex protein assay would provide a reliable tool for the screening of autophagy-specific inhibitors. © 2015 Elsevier Inc. All rights reserved.","ATG14L; Autophagy-specific inhibitor screening method; In vitro PIK3C3/VPS34 complex protein assay","Feng, Y., He, D., Yao, Z., Klionsky, D.J., The machinery of macroautophagy (2014) Cell Res., 24, pp. 24-41; Mizushima, N., Autophagy in protein and organelle turnover (2011) Cold Spring Harb. Symp. Quant. Biol., 76, pp. 397-402; Jiang, P., Mizushima, N., Autophagy and human diseases (2014) Cell Res., 24, pp. 69-79; Choi, A.M., Ryter, S.W., Levine, B., Autophagy in human health and disease (2013) N. Engl. J. Med., 368, pp. 651-662; Rubinsztein, D.C., Codogno, P., Levine, B., Autophagy modulation as a potential therapeutic target for diverse diseases (2012) Nat. Rev. Drug Discov., 11, pp. 709-730; Mizushima, N., Levine, B., Cuervo, A.M., Klionsky, D.J., Autophagy fights disease through cellular self-digestion (2008) Nature, 451, pp. 1069-1075; Wu, L., Yan, B., Discovery of small molecules that target autophagy for cancer treatment (2011) Curr. Med. Chem., 18, pp. 1866-1873; Baek, K.H., Park, J., Shin, I., Autophagy-regulating small molecules and their therapeutic applications (2012) Chem. Soc. Rev., 41, pp. 3245-3263; Shen, H.M., Mizushima, N., At the end of the autophagic road: an emerging understanding of lysosomal functions in autophagy (2014) Trends Biochem. Sci., 39, pp. 61-71; Steinman, R.M., Mellman, I.S., Muller, W.A., Cohn, Z.A., Endocytosis and the recycling of plasma membrane (1983) J. Cell Biol., 96, pp. 1-27; Caro, L.H., Plomp, P.J., Wolvetang, E.J., Kerkhof, C., Meijer, A.J., 3-Methyladenine, an inhibitor of autophagy, has multiple effects on metabolism (1988) Eur. J. Biochem., 175, pp. 325-329; Blommaart, E.F., Krause, U., Schellens, J.P., Vreeling-Sindelarova, H., Meijer, A.J., The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes (1997) Eur. J. Biochem., 243, pp. 240-246; Yan, Y., Backer, J.M., Regulation of class III (Vps34) PI3Ks (2007) Biochem. Soc. Trans., 35, pp. 239-241; Ktistakis, N.T., Manifava, M., Schoenfelder, P., Rotondo, S., How phosphoinositide 3-phosphate controls growth downstream of amino acids and autophagy downstream of amino acid withdrawal (2012) Biochem. Soc. Trans., 40, pp. 37-43; Noda, T., Matsunaga, K., Taguchi-Atarashi, N., Yoshimori, T., Regulation of membrane biogenesis in autophagy via PI3P dynamics (2010) Semin. Cell Dev. Biol., 21, pp. 671-676; Fruman, D.A., Rommel, C., PI3K and cancer: lessons, challenges, and opportunities (2014) Nat. Rev. Drug Discov., 13, pp. 140-156; Funderburk, S.F., Wang, Q.J., Yue, Z., The Beclin1-VPS34 complex - at the crossroads of autophagy and beyond (2010) Trends Cell Biol., 20, pp. 355-362; Sun, Q., Fan, W., Chen, K., Ding, X., Chen, S., Zhong, Q., Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase (2008) Proc. Natl. Acad. Sci. U.S.A., 105, pp. 19211-19216; Liang, C., Feng, P., Ku, B., Dotan, I., Canaani, D., Oh, B.H., Jung, J.U., Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG (2006) Nat. Cell Biol., 8, pp. 688-699; Molejon, M.I., Ropolo, A., Re, A.L., Boggio, V., Vaccaro, M.I., The VMP1-Beclin1 interaction regulates autophagy induction (2013) Sci. Rep., 3, p. 1055; Fimia, G.M., Stoykova, A., Romagnoli, A., Giunta, L., Di Bartolomeo, S., Nardacci, R., Corazzari, M., Cecconi, F., Ambra1 regulates autophagy and development of the nervous system (2007) Nature, 447, pp. 1121-1125; Takahashi, Y., Coppola, D., Matsushita, N., Cualing, H.D., Sun, M., Sato, Y., Liang, C., Wang, H.G., Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis (2007) Nat. Cell Biol., 9, pp. 1142-1151; Zhong, Y., Wang, Q.J., Li, X., Yan, Y., Backer, J.M., Chait, B.T., Heintz, N., Yue, Z., Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin1-phosphatidylinositol-3-kinase complex (2009) Nat. Cell Biol., 11, pp. 468-476; McKnight, N.C., Zhenyu, Y., Beclin 1, an essential component and master regulator of PI3K-III in health and disease (2013) Curr. Pathobiol. Rep., 1, pp. 231-238; Kang, R., Zeh, H.J., Lotze, M.T., Tang, D., The Beclin 1 network regulates autophagy and apoptosis (2011) Cell Death Differ., 18, pp. 571-580; Yuan, H.X., Russell, R.C., Guan, K.L., Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy (2013) Autophagy, 9, pp. 1983-1995; Russell, R.C., Tian, Y., Yuan, H., Park, H.W., Chang, Y.Y., Kim, J., Kim, H., Guan, K.L., ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase (2013) Nat. Cell Biol., 15, pp. 741-750; Kim, J., Kim, Y.C., Fang, C., Russell, R.C., Kim, J.H., Fan, W., Liu, R., Guan, K.L., Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy (2013) Cell, 152, pp. 290-303; Horbinski, C., Stachowiak, M.K., Higgins, D., Finnegan, S.G., Polyethyleneimine-mediated transfection of cultured postmitotic neurons from rat sympathetic ganglia and adult human retina (2001) BMC Neurosci., 2, p. 2; Kim, J., Choi, M.K., Koo, B.S., Yoon, M.Y., Development of high-throughput assay of lethal factor using native substrate (2005) Anal. Biochem., 341, pp. 33-39; Xie, Z., Klionsky, D.J., Autophagosome formation: core machinery and adaptations (2007) Nat. Cell Biol., 9, pp. 1102-1109; Wirth, M., Joachim, J., Tooze, S.A., Autophagosome formation - the role of ULK1 and Beclin1-PI3KC3 complexes in setting the stage (2013) Semin. Cancer Biol., 23, pp. 301-309; Tanida, I., Autophagosome formation and molecular mechanism of autophagy (2011) Antioxid. Redox Signal., 14, pp. 2201-2214; Yang, Z., Klionsky, D.J., An overview of the molecular mechanism of autophagy (2009) Curr. Top. Microbiol. Immunol., 335, pp. 1-32; Matsunaga, K., Saitoh, T., Tabata, K., Omori, H., Satoh, T., Kurotori, N., Maejima, I., Yoshimori, T., Two Beclin1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages (2009) Nat. Cell Biol., 11, pp. 385-396; Itakura, E., Kishi, C., Inoue, K., Mizushima, N., Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG (2008) Mol. Biol. Cell, 19, pp. 5360-5372",Article,Scopus,2-s2.0-84928751588
"Dalboge L.S., Pedersen So.L., Secher T., Holst B., Vrang N., Jelsing J.","Neuromedin U inhibits food intake partly by inhibiting gastric emptying",2015,"Peptides","69",,,"56","65",,,10.1016/j.peptides.2015.04.010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928387659&partnerID=40&md5=86e3daa7fb6cec83e4ef22c1be57b7c7","Gubra ApS, Agern Alle 1Hørsholm, Denmark; University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research, Blegdamsvej 3BCopenhagen N, Denmark","Dalbøge, L.S., Gubra ApS, Agern Alle 1Hørsholm, Denmark, University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research, Blegdamsvej 3BCopenhagen N, Denmark; Pedersen, Sø.L., Gubra ApS, Agern Alle 1Hørsholm, Denmark; Secher, T., Gubra ApS, Agern Alle 1Hørsholm, Denmark; Holst, B., University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research, Blegdamsvej 3BCopenhagen N, Denmark; Vrang, N., Gubra ApS, Agern Alle 1Hørsholm, Denmark; Jelsing, J., Gubra ApS, Agern Alle 1Hørsholm, Denmark","Neuromedin U (NMU) is a gut-brain peptide, implicated in energy and glucose homeostasis via the peripherally expressed NMU receptor 1 (NMUR1) and the central NMUR2. We investigated the effects of a lipidated NMU analog on gastric emptying (GE), glucose homeostasis and food intake to evaluate the use of a NMU analog as drug candidate for treatment of obesity and diabetes. Finally mRNA expression of NMU and NMUR1 in the gut and NMUR2 in the hypothalamus was investigated using a novel chromogen-based in situ hybridization (ISH) assay. Effects on food intake (6 and 18 h post dosing) were addressed in both mice and rats. The effects on GE and glycaemic control were assessed in mice, immediately after the first dose and after seven days of bidaily (BID) dosing. The lipidated NMU analog exerted robust reductions in GE and food intake in mice and improved glycaemic control when measured immediately after the first dose. No effects were observed after seven days BID. In rats, the analog induced only a minor effect on food intake. NMU mRNA was detected in the enteric nervous system throughout the gut, whereas NMUR1 was confined to the lamina propria. NMUR2 was detected in the paraventricular (PVN) and arcuate nuclei (ARC) in mice, with a reduced expression in ARC in rats. In summary, the anorectic effect of the lipidated NMU is partly mediated by a decrease in gastric emptying which is subject to tachyphylaxis after continuous dosing. Susceptibility to NMU appears to be species specific. © 2015 Elsevier Inc.","Gastric emptying; In situ hybridization; Lipidation; Neuromedin U; NMUR1; NMUR2; Tachyphylaxis","Domin, J., Ghatei, M.A., Chohan, P., Bloom, S.R., Neuromedin U - A study of its distribution in the rat (1987) Peptides, 8, pp. 779-784; Fujii, R., Hosoya, M., Fukusumi, S., Kawamata, Y., Habata, Y., Hinuma, S., Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3 (2000) J Biol Chem, 275, pp. 21068-21074; Howard, A.D., Wang, R., Pong, S.S., Mellin, T.N., Strack, A., Guan, X.M., Identification of receptors for neuromedin U and its role in feeding (2000) Nature, 406, pp. 70-74; Raddatz, R., Wilson, A.E., Artymyshyn, R., Bonini, J.A., Borowsky, B., Boteju, L.W., Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system (2000) J Biol Chem, 275, pp. 32452-32459; Szekeres, P.G., Muir, A.I., Spinage, L.D., Miller, J.E., Butler, S.I., Smith, A., Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3 (2000) J Biol Chem, 275, pp. 20247-20250; Brighton, P.J., Szekeres, P.G., Willars, G.B., Neuromedin U and its receptors: Structure, function, and physiological roles (2004) Pharmacol Rev, 56, pp. 231-248; Graham, E.S., Turnbull, Y., Fotheringham, P., Nilaweera, K., Mercer, J.G., Morgan, P.J., Neuromedin U and Neuromedin U receptor-2 expression in the mouse and rat hypothalamus: Effects of nutritional status (2003) J Neurochem, 87, pp. 1165-1173; Hedrick, J.A., Morse, K., Shan, L., Qiao, X., Pang, L., Wang, S., Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U (2000) Mol Pharmacol, 58, pp. 870-875; Hainerova, I., Torekov, S.S., Ek, J., Finkova, M., Borch-Johnsen, K., Jorgensen, T., Association between neuromedin U gene variants and overweight and obesity (2006) J Clin Endocrinol Metab, 91, pp. 5057-5063; Hanada, R., Teranishi, H., Pearson, J.T., Kurokawa, M., Hosoda, H., Fukushima, N., Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway (2004) Nat Med, 10, pp. 1067-1073; Novak, C.M., Zhang, M., Levine, J.A., Neuromedin U in the paraventricular and arcuate hypothalamic nuclei increases non-exercise activity thermogenesis (2006) J Neuroendocrinol, 18, pp. 594-601; Nakazato, M., Hanada, R., Murakami, N., Date, Y., Mondal, M.S., Kojima, M., Central effects of neuromedin U in the regulation of energy homeostasis (2000) Biochem Biophys Res Commun, 277, pp. 191-194; Peier, A., Kosinski, J., Cox-York, K., Qian, Y., Desai, K., Feng, Y., The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2) (2009) Endocrinology, 150, pp. 3101-3109; Kojima, M., Haruno, R., Nakazato, M., Date, Y., Murakami, N., Hanada, R., Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3) (2000) Biochem Biophys Res Commun, 276, pp. 435-438; Peier, A.M., Desai, K., Hubert, J., Du, X., Yang, L., Qian, Y., Effects of peripherally administered neuromedin U on energy and glucose homeostasis (2011) Endocrinology, 152, pp. 2644-2654; Hussain, S.S., Bloom, S.R., The regulation of food intake by the gut-brain axis: Implications for obesity (2013) Int J Obes (Lond), 37, pp. 625-633; Suzuki, K., Jayasena, C.N., Bloom, S.R., Obesity and appetite control (2012) Exp Diab Res, 2012, p. 824305; Dalboge, L.S., Pedersen, S.L., Van Witteloostuijn, S.B., Rasmussen, J.E., Rigbolt, K.T., Jensen, K.J., Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake (2015) J Pept Sci, 21 (FEBRUARY 2), pp. 85-94; Wang, F., Flanagan, J., Su, N., Wang, L.C., Bui, S., Nielson, A., RNAscope: A novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues (2012) J Mol Diagn, 14, pp. 22-29; Bolborea, M., Dale, N., Hypothalamic tanycytes: Potential roles in the control of feeding and energy balance (2013) Trends Neurosci, 36, pp. 91-100; Ingallinella, P., Peier, A.M., Pocai, A., Marco, A.D., Desai, K., Zytko, K., PEGylation of neuromedin U yields a promising candidate for the treatment of obesity and diabetes (2012) Bioorg Med Chem, 20, pp. 4751-4759; Guan, X.M., Yu, H., Jiang, Q., Van Der Ploeg, L.H., Liu, Q., Distribution of neuromedin U receptor subtype 2 mRNA in the rat brain (2001) Brain Res Gene Expr Patterns, 1, pp. 1-4; Secher, A., Jelsing, J., Baquero, A.F., Hecksher-Sorensen, J., Cowley, M.A., Dalboge, L.S., The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss (2014) J Clin Invest, 124, pp. 4473-4488; Schaeffer, M., Langlet, F., Lafont, C., Molino, F., Hodson, D.J., Roux, T., Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying neurons (2013) Proc Natl Acad Sci U S A, 110, pp. 1512-1517; Balland, E., Dam, J., Langlet, F., Caron, E., Steculorum, S., Messina, A., Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain (2014) Cell Metab, 19, pp. 293-301; Drucker, D.J., Shi, Q., Crivici, A., Sumner-Smith, M., Tavares, W., Hill, M., Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV (1997) Nat Biotechnol, 15, pp. 673-677; Kaczmarek, P., Malendowicz, L.K., Pruszynska-Oszmalek, E., Wojciechowicz, T., Szczepankiewicz, D., Szkudelski, T., Neuromedin U receptor 1 expression in the rat endocrine pancreas and evidence suggesting neuromedin U suppressive effect on insulin secretion from isolated rat pancreatic islets (2006) Int J Mol Med, 18, pp. 951-955; Janssen, P., Vanden Berghe, P., Verschueren, S., Lehmann, A., Depoortere, I., Tack, J., Review article: The role of gastric motility in the control of food intake (2011) Aliment Pharmacol Ther, 33, pp. 880-894; Nauck, M.A., Kemmeries, G., Holst, J.J., Meier, J.J., Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans (2011) Diabetes, 60, pp. 1561-1565; Nakagawa, A., Satake, H., Nakabayashi, H., Nishizawa, M., Furuya, K., Nakano, S., Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells (2004) Auton Neurosci: Basic Clin, 110, pp. 36-43; Raybould, H.E., Tache, Y., Cholecystokinin inhibits gastric motility and emptying via a capsaicin-sensitive vagal pathway in rats (1988) Am J Physiol, 255, pp. G242-G246; Mondal, M.S., Date, Y., Murakami, N., Toshinai, K., Shimbara, T., Kangawa, K., Neuromedin U acts in the central nervous system to inhibit gastric acid secretion via CRH system (2003) Am J Physiol Gastrointest Liver Physiol, 284, pp. G963-G969; Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang-Christensen, M., Knudsen, L.B., Liraglutide: Short-lived effect on gastric emptying - Long lasting effects on body weight (2012) Diab Obes Metab, 14, pp. 531-538; Cooke, J.H., Patterson, M., Patel, S.R., Smith, K.L., Ghatei, M.A., Bloom, S.R., Peripheral and central administration of xenin and neurotensin suppress food intake in rodents (2009) Obesity, 17 (SILVER SPRING), pp. 1135-1143; Crawley, J.N., Beinfeld, M.C., Rapid development of tolerance to the behavioural actions of cholecystokinin (1983) Nature, 302, pp. 703-706; Brown, D.R., Quito, F.L., Neuromedin U octapeptide alters ion transport in porcine jejunum (1988) Eur J Pharmacol, 155, pp. 159-162; Maggi, C.A., Patacchini, R., Giuliani, S., Turini, D., Barbanti, G., Rovero, P., Motor response of the human isolated small intestine and urinary bladder to porcine neuromedin U-8 (1990) Br J Pharmacol, 99, pp. 186-188; Neuner, P., Peier, A.M., Talamo, F., Ingallinella, P., Lahm, A., Barbato, G., Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide (2014) J Pept Sci, 20, pp. 7-19; Verbaeys, I., Leon-Tamariz, F., Buyse, J., Decuypere, E., Pottel, H., Cokelaere, M., Lack of tolerance development with long-term administration of PEGylated cholecystokinin (2009) Peptides, 30, pp. 699-704; Ballesta, J., Carlei, F., Bishop, A.E., Steel, J.H., Gibson, S.J., Fahey, M., Occurrence and developmental pattern of neuromedin U-immunoreactive nerves in the gastrointestinal tract and brain of the rat (1988) Neuroscience, 25, pp. 797-816; Nakashima, Y., Ida, T., Sato, T., Nakamura, Y., Takahashi, T., Mori, K., Neuromedin U is necessary for normal gastrointestinal motility and is regulated by serotonin (2010) Ann N y Acad Sci, 1200, pp. 104-111; Timmermans, J.P., Scheuermann, D.W., Stach, W., Adriaensen, D., De Groodt-Lasseel, M.H., Polak, J.M., Neuromedin U-immunoreactivity in the nervous system of the small intestine of the pig and its coexistence with substance P and CGRP (1989) Cell Tissue Res, 258, pp. 331-337; Austin, C., Oka, M., Nandha, K.A., Legon, S., Khandan-Nia, N., Lo, G., Distribution and developmental pattern of neuromedin U expression in the rat gastrointestinal tract (1994) J Mol Endocrinol, 12, pp. 257-263; Dass, N.B., Bassil, A.K., North-Laidler, V.J., Morrow, R., Aziz, E., Tuladhar, B.R., Neuromedin U can exert colon-specific, enteric nerve-mediated prokinetic activity, via a pathway involving NMU1 receptor activation (2007) Br J Pharmacol, 150, pp. 502-508",Article,Scopus,2-s2.0-84928387659
"To T., Zhu J., Villeneuve P.J., Simatovic J., Feldman L., Gao C., Williams D., Chen H., Weichenthal S., Wall C., Miller A.B.","Chronic disease prevalence in women and air pollution - A 30-year longitudinal cohort study",2015,"Environment International","80",,,"26","32",,,10.1016/j.envint.2015.03.017,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926381489&partnerID=40&md5=9eb21b1c39e6fc1953d10b2934073a89","Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada; Institute for Clinical Evaluative SciencesToronto, ON, Canada; Dalla Lana School of Public HealthToronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of TorontoToronto, ON, Canada; Department of Health Sciences, Carleton UniversityOttawa, ON, Canada; Public Health OntarioToronto, ON, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill UniversityMontreal, ON, Canada","To, T., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada, Institute for Clinical Evaluative SciencesToronto, ON, Canada, Dalla Lana School of Public HealthToronto, ON, Canada, Institute of Health Policy, Management and Evaluation, University of TorontoToronto, ON, Canada; Zhu, J., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada, Institute for Clinical Evaluative SciencesToronto, ON, Canada; Villeneuve, P.J., Department of Health Sciences, Carleton UniversityOttawa, ON, Canada; Simatovic, J., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada; Feldman, L., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada, Dalla Lana School of Public HealthToronto, ON, Canada; Gao, C., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada, Institute for Clinical Evaluative SciencesToronto, ON, Canada; Williams, D., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada; Chen, H., Institute for Clinical Evaluative SciencesToronto, ON, Canada, Dalla Lana School of Public HealthToronto, ON, Canada, Public Health OntarioToronto, ON, Canada; Weichenthal, S., Department of Epidemiology, Biostatistics and Occupational Health, McGill UniversityMontreal, ON, Canada; Wall, C., Dalla Lana School of Public HealthToronto, ON, Canada; Miller, A.B., Dalla Lana School of Public HealthToronto, ON, Canada","Background: Air pollution, such as fine particulate matter (PM<inf>2.5</inf>), can increase risk of adverse health events among people with heart disease, diabetes, asthma and chronic obstructive pulmonary disease (COPD) by aggravating these conditions. Identifying the influence of PM<inf>2.5</inf> on prevalence of these conditions may help target interventions to reduce disease morbidity among high-risk populations. Objectives: The objective of this study is to measure the association of exposure of PM<inf>2.5</inf> with prevalence risk of various chronic diseases among a longitudinal cohort of women. Methods: Women from Ontario who enrolled in the Canadian National Breast Screening Study (CNBSS) from 1980 to 1985 (n=29,549) were linked to provincial health administrative data from April 1, 1992 to March 31, 2013 to determine the prevalence of major chronic disease and conditions (heart disease, diabetes, asthma, COPD, acute myocardial infarction, angina, stroke and cancers). Exposure to PM<inf>2.5</inf> was measured using satellite data collected from January 1, 1998 to December 31, 2006 and assigned to resident postal-code at time of entry into study. Poisson regression models were used to describe the relationship between exposure to ambient PM<inf>2.5</inf> and chronic disease prevalence. Prevalence rate ratios (PRs) were estimated while adjusting for potential confounders: baseline age, smoking, BMI, marital status, education and occupation. Separate models were run for each chronic disease and condition. Results: Congestive heart failure (PR=1.31, 95% CI: 1.13, 1.51), diabetes (PR=1.28, 95% CI: 1.16, 1.41), ischemic heart disease (PR=1.22, 95% CI: 1.14, 1.30), and stroke (PR=1.21, 95% CI: 1.09, 1.35) showed over a 20% increase in PRs per 10μg/m3 increase in PM<inf>2.5</inf> after adjusting for risk factors. Risks were elevated in smokers and those with BMI greater than 30. Conclusions: This study estimated significant elevated prevalent rate ratios per unit increase in PM<inf>2.5</inf> in nine of the ten chronic diseases studied. © 2015 Elsevier Ltd.","Air pollution; Chronic disease prevalence; Environmental exposures","Brook, R., Franklin, B., Cascio, W., Hong, Y., Howard, G., Lipsett, M., Luepker, R., Tager, I., Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association (2004) Circulation, 109, pp. 2655-2671. , Association E.P.O.P.A.P.S.O.T.A.H; Brook, R., Cakmak, S., Turner, M., Brook, J., Crouse, D., Peters, P., van Donkelaar, A., Burnett, R., Long-term fine particulate matter exposure and mortality from diabetes in Canada (2013) Diabetes Care, 36, pp. 3313-3320; Chen, H., Burnett, R., Kwong, J., Villeneuve, P., Goldberg, M., Brook, R., van Donkelaar, A., Copes, R., Risk of incident diabetes in relation to long-term exposure to fine particulate matter in Ontario, Canada (2013) Environ. Health Perspect., 121, pp. 46-52. , (121:804-810); Chen, H., Burnett, R., Kwong, J., Villeneuve, P., Goldberg, M., Brook, R., van Donkelaar, A., Copes, R., Spatial association between ambient fine particulate matter and incident hypertension (2014) Circulation, 129, pp. 562-569; Coogan, P., White, L., Jerrett, M., Brook, R., Su, J., Seto, E., Burnett, R., Rosenberg, L., Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles (2012) Circ. Res., 125, pp. 767-772; Crouse, D., Peters, P., van Donkelaar, A., Goldberg, M., Villeneuve, P., Brion, O., Khan, S., Burnett, R., Risk of nonaccidental and cardiovascular mortality in relation to long-term exposure to low concentrations of fine particulate matter: a Canadian national-level cohort study (2012) Environ. Health Perspect., 121, pp. 46-52. , (120:708-714); EPA, U.S., (2008) Integrated Science Assessment for Oxides of Nitrogen - Health Criteria (Final Report), , U.S. Environmental Protection Agency, Washington, DC; EPA, U.S., (2009) Integrated Science Assessment for Particulate Matter (Final Report), , U.S. Environmental Protection Agency, Washington, DC; EPA, U.S., (2013) Integrated Science Assessment of Ozone and Related Photochemical Oxidants (Final Report), , U.S. Environmental Protection Agency, Washington, DC; Eze, I., Schaffner, E., Fischer, E., Schikowski, T., Adam, M., Imboden, M., Tsai, M., Probst-Hensch, N., Long-term air pollution exposure and diabetes in a population-based Swiss cohort (2014) Environ. Int., 70, pp. 95-105; Heinävaara, S., Sarkeala, T., Anttila, A., Overdiagnosis due to breast cancer screening: updated estimates of the Helsinki Service Study in Finland (2014) Br. J. Cancer, , (ahead of print); Hopman, W., Leroux, C., Berger, C., Joseph, L., Barr, S., Prior, J., Harrison, M.S.P., Group, C.R., Changes in body mass index in Canadians over a five-year period: results of a prospective, population based study (2007) BMC Public Health, p. 7; Johnson, D., Parker, J., Air pollution exposure and self-reported cardiovascular disease (2009) Environ. Res., 109, pp. 582-589; Koton, S., Molshatzki, N., Yuval Myers, V., Broday, D., Drory, Y., Steinberg, D., Gerber, Y., Cumulative exposure to particulate matter air pollution and long-term post-myocardial infarction outcomes (2013) Prev. Med., 57, pp. 339-344; Kramer, U., Herder, C., Sugiri, D., Strassburger, K., Schikowski, T., Ranft, U., Rathmann, W., Traffic-related air pollution and incident type 2 diabetes: results from the SALIA cohort study (2010) Environ. Health Perspect., 118, pp. 1273-1279; Miller, A.B., Baines, C.J., To, T., Wall, C., Canadian National Breast Screening Study 1. Breast cancer detection and death rates among women aged 40 to 49years (1992) CMAJ, 147, pp. 1458-1476; Miller, A.B., Baines, C.J., To, T., Wall, C., Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 50years (1996) CMAJ, 147, pp. 1477-1488; Njor, S., Olsen, A., Blichert-Toft, M., Schwartz, W., Vejborg, I., Lynge, E., Overdiagnosis in screening mammography in Denmark: population based cohort study (2013) BMJ, 346, p. f1064; Pearson, J., Bachireddy, C., Shyamprasad, S., Goldfine, A., Brownstein, J., Association between fine particulate matter and diabetes prevalence in the U.S. (2010) Diabetes Care, 33, pp. 2196-2201; Puett, R., Hart, J., Schwartz, J., Hu, F., Liese, A., Laden, F., Are particulate matter exposures associated with risk of type 2 diabetes? (2011) Environ. Health Perspect., 121, pp. 46-52. , (119:384-389); Royall, R., Model robust confidence intervals using maximum likelihood estimators (1986) Int. Stat. Rev., p. 54; Schikowski, T., Adam, M., Marcon, A., Cai, Y., Vierkötter, A., Carsin, A., Jacquemin, B., Künzli, N., Association of ambient air pollution with the prevalence and incidence of COPD (2014) Eur. Respir. J., 44, pp. 614-626; To, T., Feldman, L., Foty, R., Dell, S., Gershon, A., Zhu, J., Su, J., Licskai, C., Using the air quality health index to measure the impact of poor air quality on chronic diseases in Ontario: a population-based study. American Thoracic Society. Philadelphia (2013) Am. J. Respir. Crit. Care Med.; To, T., Shen, S., Atenafu, E.G., Guan, J., McLimont, S., Stocks, B., Licskai, C., The Air Quality Health Index and asthma morbidity: a population-based study (2013) Environ. Health Perspect., 121, pp. 46-52; van Donkelaar, A., Martin, R.V., Brauer, M., Kahn, R., Levy, R., Verduzco, C., Villeneuve, P.J., Global estimates of ambient fine particulate matter concentrations from satellite-based aerosol optical depth: development and application (2010) Environ. Health Perspect., 118, pp. 847-855; Zocchetti, C., Consonni, D., Bertazzi, P., Estimation of prevalence rate ratios from cross-sectional data (1995) Int. J. Epidemiol., 24, pp. 1064-1065; Zou, G., A modified Poisson regression approach to prospective studies with binary data (2004) Am. J. Epidemiol., 159, pp. 702-706",Article,Scopus,2-s2.0-84926381489
"Koob S., Barrera M., Anand R., Reichert A.S.","The non-glycosylated isoform of MIC26 is a constituent of the mammalian MICOS complex and promotes formation of crista junctions",2015,"Biochimica et Biophysica Acta - Molecular Cell Research","1853","7",,"1551","1563",,,10.1016/j.bbamcr.2015.03.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926386874&partnerID=40&md5=53d6e2ba15f92ab195e8015ff73b4ce6","Mitochondrial Biology, Buchmann Institute of Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue-Str. 15Frankfurt am Main, Germany; Institute of Biochemistry and Molecular Biology I, Heinrich Heine University, Medical Faculty, Universitätsstr. 1Düsseldorf, Germany","Koob, S., Mitochondrial Biology, Buchmann Institute of Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue-Str. 15Frankfurt am Main, Germany; Barrera, M., Mitochondrial Biology, Buchmann Institute of Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue-Str. 15Frankfurt am Main, Germany; Anand, R., Institute of Biochemistry and Molecular Biology I, Heinrich Heine University, Medical Faculty, Universitätsstr. 1Düsseldorf, Germany; Reichert, A.S., Mitochondrial Biology, Buchmann Institute of Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue-Str. 15Frankfurt am Main, Germany, Institute of Biochemistry and Molecular Biology I, Heinrich Heine University, Medical Faculty, Universitätsstr. 1Düsseldorf, Germany","Mitochondrial membrane architecture is important for organelle function. Alterations thereof are linked to a number of human disorders including diabetes and cardiomyopathy. The MICOS complex was recently reported to be a central player determining cristae structure and formation of crista junctions. Here we investigated the functional role of MIC26, a lipoprotein formerly termed APOO. Its levels are increased in diabetic heart tissue and in blood plasma of patients suffering from acute coronary syndrome. We demonstrate that human MIC26 exists in three distinct forms: (1) a glycosylated and secreted 55. kDa protein, (2) an ER/Golgi-resident form thereof, and (3) a non-glycosylated 22. kDa mitochondrial protein. The latter isoform spans the mitochondrial inner membrane and physically interacts with several MICOS complex subunits such as MIC60, MIC27, and MIC10. We further demonstrate that MIC26 and MIC27, a homologous protein formerly termed APOOL, regulate their levels in an antagonistic manner. Both proteins are positively correlated with the levels of MIC10 as well as tafazzin, an enzyme required for cardiolipin remodeling. Overexpression of MIC26 induced fragmentation of mitochondria, promoted ROS formation and resulted in impaired mitochondrial respiration. Downregulation of MIC26 induced a decrease in mitochondrial oxygen consumption, whereas mitochondrial network morphology and ROS levels remained unaffected. MIC26 depletion led to alterations in mitochondrial ultrastructure and caused a significant reduction in the number of crista junctions. In summary, we show that the human apolipoprotein MIC26 is a bona fide subunit of the MICOS complex and that MIC26 is linked to cardiolipin metabolism and promotes crista junction formation. © 2015 Elsevier B.V.","Apolipoproteins; Arteriosclerosis; Cardiolipin metabolism; Crista junctions; MICOS complex; Mitochondria","Zick, M., Rabl, R., Reichert, A.S., Cristae formation-linking ultrastructure and function of mitochondria (2009) Biochim. Biophys. Acta, 1793, pp. 5-19; Shen, X., Zheng, S., Thongboonkerd, V., Xu, M., Pierce, W.M., Klein, J.B., Epstein, P.N., Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes (2004) Am. J. Physiol. Endocrinol. Metab., 287, pp. E896-E905; Duncan, J.G., Mitochondrial dysfunction in diabetic cardiomyopathy (2011) Biochim. Biophys. Acta, 1813, pp. 1351-1359; Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., Anversa, P., Myocardial cell death in human diabetes (2000) Circ. Res., 87, pp. 1123-1132; Sasaki, S., Determination of altered mitochondria ultrastructure by electron microscopy (2010) Methods Mol. Biol., 648, pp. 279-290; Winklhofer, K.F., Haass, C., Mitochondrial dysfunction in Parkinson's disease (2010) Biochim. Biophys. Acta, 1802, pp. 29-44; Chou, S.M., ""Megaconial"" mitochondria observed in a case of chronic polymyositis (1968) Acta Neuropathol., 12, pp. 68-89; Zerbes, R.M., van der Klei, I.J., Veenhuis, M., Pfanner, N., van der Laan, M., Bohnert, M., Mitofilin complexes: conserved organizers of mitochondrial membrane architecture (2012) Biol. Chem., 393, pp. 1247-1261; Kleschevnikov, A.M., Belichenko, P.V., Salehi, A., Wu, C., Discoveries in Down syndrome: moving basic science to clinical care (2012) Prog. Brain Res., 197, pp. 199-221; Mannella, C.A., Marko, M., Buttle, K., Reconsidering mitochondrial structure: new views of an old organelle (1997) Trends Biochem. Sci., 22, pp. 37-38; Frey, T.G., Mannella, C.A., The internal structure of mitochondria (2000) Trends Biochem. Sci., 25, pp. 319-324; Sukhorukov, V.M., Bereiter-Hahn, J., Anomalous diffusion induced by cristae geometry in the inner mitochondrial membrane (2009) PLoS One, 4, p. e4604; Monian, P., Jiang, X., Clearing the final hurdles to mitochondrial apoptosis: regulation post cytochrome C release (2012) Exp. Oncol., 34, pp. 185-191; Dibrova, D.V., Cherepanov, D.A., Galperin, M.Y., Skulachev, V.P., Mulkidjanian, A.Y., Evolution of cytochrome bc complexes: from membrane-anchored dehydrogenases of ancient bacteria to triggers of apoptosis in vertebrates (2013) Biochim. Biophys. Acta, 1827, pp. 1407-1427; Gilkerson, R.W., Selker, J.M., Capaldi, R.A., The cristal membrane of mitochondria is the principal site of oxidative phosphorylation (2003) FEBS Lett., 546, pp. 355-358; Vogel, F., Bornhovd, C., Neupert, W., Reichert, A.S., Dynamic subcompartmentalization of the mitochondrial inner membrane (2006) J. Cell Biol., 175, pp. 237-247; Wurm, C.A., Jakobs, S., Differential protein distributions define two sub-compartments of the mitochondrial inner membrane in yeast (2006) FEBS Lett., 580, pp. 5628-5634; Hoppins, S., The regulation of mitochondrial dynamics (2014) Curr. Opin. Cell Biol., 29 C, pp. 46-52; Belenguer, P., Pellegrini, L., The dynamin GTPase OPA1: more than mitochondria? (1833) Biochim. Biophys. Acta, 2013, pp. 176-183; Wagner, K., Mick, D.U., Rehling, P., Protein transport machineries for precursor translocation across the inner mitochondrial membrane (2009) Biochim. Biophys. Acta, 1793, pp. 52-59; Osman, C., Voelker, D.R., Langer, T., Making heads or tails of phospholipids in mitochondria (2011) J. Cell Biol., 192, pp. 7-16; Schägger, H., Respiratory chain supercomplexes of mitochondria and bacteria (2002) Biochim. Biophys. Acta, 1555, pp. 154-159; Schägger, H., de Coo, R., Bauer, M.F., Hofmann, S., Godinot, C., Brandt, U., Significance of respirasomes for the assembly/stability of human respiratory chain complex I (2004) J. Biol. Chem., 279, pp. 36349-36353; Walker, J.E., The ATP synthase: the understood, the uncertain and the unknown (2013) Biochem. Soc. Trans., 41, pp. 1-16; Tatsuta, T., Scharwey, M., Langer, T., Mitochondrial lipid trafficking (2006) Trends Cell Biol., 24, pp. 44-52; Gebert, N., Joshi, A.S., Kutik, S., Becker, T., McKenzie, M., Guan, X.L., Mooga, V.P., Pfanner, N., Mitochondrial cardiolipin involved in outer-membrane protein biogenesis: implications for Barth syndrome (2009) Curr. Biol., 19, pp. 2133-2139; Bazan, S., Mileykovskaya, E., Mallampalli, V.K., Heacock, P., Sparagna, G.C., Dowhan, W., Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV (2013) J. Biol. Chem., 288, pp. 401-411; Bottinger, L., Horvath, S.E., Kleinschroth, T., Hunte, C., Daum, G., Pfanner, N., Becker, T., Phosphatidylethanolamine and cardiolipin differentially affect the stability of mitochondrial respiratory chain supercomplexes (2012) J. Mol. Biol., 423, pp. 677-686; Acehan, D., Malhotra, A., Xu, Y., Ren, M., Stokes, D.L., Schlame, M., Cardiolipin affects the supramolecular organization of ATP synthase in mitochondria (2011) Biophys. J., 100, pp. 2184-2192; Schlame, M., Cardiolipin remodeling and the function of tafazzin (2013) Biochim. Biophys. Acta, 1831, pp. 582-588; Bione, S., D'Adamo, P., Maestrini, E., Gedeon, A.K., Bolhuis, P.A., Toniolo, D., A novel X-linked gene, G4.5. is responsible for Barth syndrome (1996) Nat. Genet., 12, pp. 385-389; Acehan, D., Xu, Y., Stokes, D.L., Schlame, M., Comparison of lymphoblast mitochondria from normal subjects and patients with Barth syndrome using electron microscopic tomography (2007) Lab. Invest., 87, pp. 40-48; Dudek, J., Cheng, I.F., Balleininger, M., Vaz, F.M., Streckfuss-Bomeke, K., Hubscher, D., Vukotic, M., Guan, K., Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome (2013) Stem Cell Res., 11, pp. 806-819; Weber, T.A., Koob, S., Heide, H., Wittig, I., Head, B., van der Bliek, A., Brandt, U., Reichert, A.S., APOOL is a cardiolipin-binding constituent of the Mitofilin/MINOS protein complex determining cristae morphology in mammalian mitochondria (2013) PLoS One, 8, p. e63683; Rabl, R., Soubannier, V., Scholz, R., Vogel, F., Mendl, N., Vasiljev-Neumeyer, A., Korner, C., Reichert, A.S., Formation of cristae and crista junctions in mitochondria depends on antagonism between Fcj1 and Su e/g (2009) J. Cell Biol., 185, pp. 1047-1063; von der Malsburg, K., Muller, J.M., Bohnert, M., Oeljeklaus, S., Kwiatkowska, P., Becker, T., Loniewska-Lwowska, A., van der Laan, M., Dual role of mitofilin in mitochondrial membrane organization and protein biogenesis (2011) Dev. Cell, 21, pp. 694-707; Harner, M., Korner, C., Walther, D., Mokranjac, D., Kaesmacher, J., Welsch, U., Griffith, J., Neupert, W., The mitochondrial contact site complex, a determinant of mitochondrial architecture (2011) EMBO J., 30, pp. 4356-4370; Hoppins, S., Collins, S.R., Cassidy-Stone, A., Hummel, E., Devay, R.M., Lackner, L.L., Westermann, B., Nunnari, J., A mitochondrial-focused genetic interaction map reveals a scaffold-like complex required for inner membrane organization in mitochondria (2011) J. Cell Biol., 195, pp. 323-340; Pfanner, N., van der Laan, M., Amati, P., Capaldi, R.A., Caudy, A.A., Chacinska, A., Darshi, M., Nunnari, J., Uniform nomenclature for the mitochondrial contact site and cristae organizing system (2014) J. Cell Biol., 204, pp. 1083-1086; John, G.B., Shang, Y., Li, L., Renken, C., Mannella, C.A., Selker, J.M., Rangell, L., Zha, J., The mitochondrial inner membrane protein mitofilin controls cristae morphology (2005) Mol. Biol. Cell, 16, pp. 1543-1554; Darshi, M., Mendiola, V.L., Mackey, M.R., Murphy, A.N., Koller, A., Perkins, G.A., Ellisman, M.H., Taylor, S.S., ChChd3, an inner mitochondrial membrane protein, is essential for maintaining crista integrity and mitochondrial function (2011) J. Biol. Chem., 286, pp. 2918-2932; Alkhaja, A.K., Jans, D.C., Nikolov, M., Vukotic, M., Lytovchenko, O., Ludewig, F., Schliebs, W., Deckers, M., MINOS1 is a conserved component of mitofilin complexes and required for mitochondrial function and cristae organization (2012) Mol. Biol. Cell, 23, pp. 247-257; Koob, S., Reichert, A.S., Novel intracellular functions of apolipoproteins: the ApoO protein family as constituents of the Mitofilin/MINOS complex determines cristae morphology in mitochondria (2014) Biol. Chem., 395, pp. 285-296; Lamant, M., Smih, F., Harmancey, R., Philip-Couderc, P., Pathak, A., Roncalli, J., Galinier, M., Rouet, P., ApoO, a novel apolipoprotein, is an original glycoprotein up-regulated by diabetes in human heart (2006) J. Biol. Chem., 281, pp. 36289-36302; Yu, B.L., Wu, C.L., Zhao, S.P., Plasma apolipoprotein O level increased in the patients with acute coronary syndrome (2012) J. Lipid Res., 53, pp. 1952-1957; Nijstad, N., de Boer, J.F., Lagor, W.R., Toelle, M., Usher, D., Annema, W., der Giet, M., Tietge, U.J., Overexpression of apolipoprotein O does not impact on plasma HDL levels or functionality in human apolipoprotein A-I transgenic mice (2011) Biochim. Biophys. Acta, 1811, pp. 294-299; Philip-Couderc, P., Smih, F., Pelat, M., Vidal, C., Verwaerde, P., Pathak, A., Buys, S., Rouet, P., Cardiac transcriptome analysis in obesity-related hypertension (2003) Hypertension, 41, pp. 414-421; Wu, C.L., Zhao, S.P., Yu, B.L., Microarray analysis provides new insights into the function of apolipoprotein O in HepG2 cell line (2013) Lipids Health Dis., 12, p. 186; Turkieh, A., Caubere, C., Barutaut, M., Desmoulin, F., Harmancey, R., Galinier, M., Berry, M., Smih, F., Apolipoprotein O is mitochondrial and promotes lipotoxicity in heart (2014) J. Clin. Invest., 124, pp. 2277-2286; Koob, S., Barrera, M., Anand, R., Reichert, A.S., (2015) Data supporting the role of the non-glycosylated isoform of MIC26 in determining cristae morphology, , (Data in brief, in press); Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4 (1970) Nature, 227, pp. 680-685; Schagger, H., Tricine-SDS-PAGE (2006) Nat. Protoc., 1, pp. 16-22; Schagger, H., von Jagow, G., Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100kDa (1987) Anal. Biochem., 166, pp. 368-379; Yu, B.L., Wu, C.L., Zhao, S.P., Plasma apolipoprotein O level increased in the patients with acute coronary syndrome (2013) J. Lipid Res., 53, pp. 1952-1957; Morris, R.L., Hollenbeck, P.J., Axonal transport of mitochondria along microtubules and F-actin in living vertebrate neurons (1995) J. Cell Biol., 131, pp. 1315-1326; Scherz-Shouval, R., Elazar, Z., Monitoring starvation-induced reactive oxygen species formation (2009) Methods Enzymol., 452, pp. 119-130; Borggreve, S.E., De Vries, R., Dullaart, R.P., Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins (2003) Eur. J. Clin. Invest., 33, pp. 1051-1069; Raz, I., Eldor, R., Cernea, S., Shafrir, E., Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage (2005) Diabetes Metab. Res. Rev., 21, pp. 3-14; Despres, J.P., Moorjani, S., Lupien, P.J., Tremblay, A., Nadeau, A., Bouchard, C., Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease (1990) Arteriosclerosis, 10, pp. 497-511; Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I., Despres, J.P., Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease (2009) Hypertension, 53, pp. 577-584; Harner, M.E., Unger, A.K., Izawa, T., Walther, D.M., Ozbalci, C., Geimer, S., Reggiori, F., Neupert, W., Aim24 and MICOS modulate respiratory function, tafazzin-related cardiolipin modification and mitochondrial architecture (2014) Elife, 3, p. e01684; Lowell, B.B., Shulman, G.I., Mitochondrial dysfunction and type 2 diabetes (2005) Science, 307, pp. 384-387; Mantena, S.K., King, A.L., Andringa, K.K., Eccleston, H.B., Bailey, S.M., Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases (2008) Free Radic. Biol. Med., 44, pp. 1259-1272",Article,Scopus,2-s2.0-84926386874
"Lacroix I.M.E., Li-Chan E.C.Y.","Comparison of the susceptibility of porcine and human dipeptidyl-peptidase IV to inhibition by protein-derived peptides",2015,"Peptides","69",,,"19","25",,,10.1016/j.peptides.2015.03.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927662509&partnerID=40&md5=6ded088c801cea7e95f39b04cf1449a7","University of British Columbia, Faculty of Land and Food Systems, Food Nutrition and Health ProgramVancouver, BC, Canada","Lacroix, I.M.E., University of British Columbia, Faculty of Land and Food Systems, Food Nutrition and Health ProgramVancouver, BC, Canada; Li-Chan, E.C.Y., University of British Columbia, Faculty of Land and Food Systems, Food Nutrition and Health ProgramVancouver, BC, Canada","The enzyme dipeptidyl-peptidase IV (DPP-IV) is recognized to be a promising target for the management of type 2 diabetes. Over the last decade, numerous synthetic molecules and more recently, peptides from dietary proteins, have been reported to be able to inhibit DPP-IV activity. Most studies that have investigated the in vitro effect of these inhibitors have used porcine or human DPP-IV. Although structurally alike, it is unclear whether these two species display similar inhibition patterns. Therefore, the objective of this study was to compare the effects of protein-derived peptides on the activity of porcine and recombinant human DPP-IV. The two species showed different inhibition susceptibility to 43 of the 62 peptide sequences investigated. While 37 protein-derived peptides were more effective at inhibiting the porcine DPP-IV, only six caused a stronger inhibition of the activity of the human enzyme. Although the peptides WR, IPIQY and WCKDDQNPHS were found to be among the most potent inhibitors of both species, the inhibitory effect was greater on the porcine enzyme than on human DPP-IV (αK<inf>i</inf> or K<inf>i</inf> = 11.5, 13.4, 13.3 μM and 31.4, 28.2, 75.0 μM for porcine and human DPP-IV, respectively). Investigation into the mode of action of the most effective inhibitory peptides revealed that both species were inhibited in a similar manner by short fragments (≤5 amino acid residues), but that some of the longer peptides acted differently on the enzymes. This study shows that porcine DPP-IV is generally inhibited with greater potency by protein-derived peptides than is the human enzyme. © 2015 Elsevier Inc.","Inhibitory peptides; Porcine dipeptidyl-peptidase IV (pDPP-IV); Recombinant human dipeptidyl-peptidaseIV (rhDPP-IV)","Bär, J., Weber, A., Hoffmann, T., Stork, J., Wermann, M., Wagner, L., Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structure and mechanistic comparison between the recombinant human and the purified porcine enzyme (2003) Biol Chem, 384, pp. 1553-1563; Bella, Jr.A.M., Erickson, R.H., Kim, Y.S., Rat intestinal brush border membrane dipeptidyl-aminopeptidase IV: Kinetic properties and substrate specificities of the purified enzyme (1982) Arch Biochem Biophys, 218, pp. 156-162; Chen, X., Biochemical properties of recombinant prolyl dipeptidases DPP-IV and DPP8 (2006) Adv Exp Med Biol, 575, pp. 27-32; Engel, M., Hoffmann, T., Wagner, L., Heiser, U., Kiefersauer, R., Huber, R., The crystal structure of dipeptidyl peptidase IV (CD26) revels its functional regulation and enzymatic mechanism (2003) Proc Natl Acad Sci USA, 100, pp. 5063-5068; Filippatos, T.D., Athyros, V.G., Elisaf, M.S., The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors (2014) Expert Opin Drug Metab Toxicol, 10, pp. 787-812; Gallego, M., Aristory, M.-C., Toldrá, F., Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham (2014) Meat Sci, 96, pp. 757-761; Hatanaka, T., Inoue, Y., Arima, J., Kumagai, Y., Usuki, H., Kawakami, K., Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran (2012) Food Chem, 134, pp. 797-802; Hsu, K.-C., Tung, Y.-S., Huang, S.-L., Jao, C.-L., Dipeptidyl peptidase-IV inhibitory activity of peptides in porcine skin gelatin hydrolysate (2013) Bioactive Food Peptides in Health and Disease, pp. 205-218. , http://www.intechopen.com/books/bioactive-food-peptides-in-health-and-disease/dipeptidyl-peptidase-iv-inhibitory-activity-of-peptides-in-porcine-skin-gelatin-hydrolysates, InTech; Huang, S.-L., Jao, C.-L., Ho, K.-P., Hsu, K.-C., Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates (2012) Peptides, 35, pp. 114-121; Hunziker, D., Hennig, M., Peters, J.-U., Inhibitors of dipeptidyl peptidase IV - Recent advances and structural views (2005) Curr Top Med Chem, 5, pp. 1623-1637; Kühn-Wache, K., Secondary Binding Site of Dipeptidyl Peptidase IV (DP IV), , US patent US 2005/0176622 A1; Lacroix, I.M.E., Li-Chan, E.C.Y., Dipeptidyl peptidase-IV inhibitory activity of dairy protein hydrolysates (2012) Int Dairy J, 25, pp. 97-102; Lacroix, I.M.E., Li-Chan, E.C.Y., Inhibition of dipeptidyl peptidase (DPP)-IV and α-glucosidase activities by pepsin-treated whey proteins (2013) J Agric Food Chem, 61, pp. 7500-7506; Lacroix, I.M.E., Li-Chan, E.C.Y., Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins (2014) Peptides, 54, pp. 39-48; Lacroix, I.M.E., Li-Chan, E.C.Y., Peptide array on cellulose support-A screening tool to identify peptides with dipeptidyl-peptidase IV inhibitory activity within the sequence of α-lactalbumin (2014) Int J Mol Sci, 15, pp. 20846-20858; Lambeir, A.-M., Durinx, C., Scharpé, S., De Meester, I., Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV (2003) Crit Rev Clin Lab Sci, 40, pp. 209-294; Lan, V.T.T., Ito, K., Ito, S., Kawarasaki, Y., Trp-Arg-Xaa tripeptides act as uncompetitive-type inhibitors of human dipeptidyl peptidase IV (2014) Peptides, 54, pp. 166-170; Li-Chan, E.C.Y., Hunag, S.-L., Jao, C.-L., Ho, K.-P., Hsu, K.-C., Peptides derived from Atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors (2012) J Agric Food Chem, 60, pp. 973-978; Mochida, T., Hira, T., Hara, H., The corn protein, zein hydrolysate, administered into the ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 secretion and dipeptidyl peptidase-IV activity in rats (2010) Endocrinology, 151, pp. 3095-3104; Nongonierma, A.B., Fitzgerald, R.J., Dipeptidyl peptidase IV inhibitory and antioxidative properties of milk protein-derived peptides and hydrolysates (2013) Peptides, 39, pp. 157-163; Nongonierma, A.B., Fitzgerald, R.J., Inhibition of dipeptidyl peptidase IV (DPP-IV) by proline containing casein-derived peptides (2013) J Funct Foods, 5, pp. 1909-1917; Nongonierma, A.B., Fitzgerald, R.J., Inhibition of dipeptidyl peptidase IV (DPP-IV) by tryptophan containing dipeptides (2013) Food Funct, 4, pp. 1843-1849; Nongonierma, A.B., Fitzgerald, R.J., Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis (2014) Food Chem, 145, pp. 845-852; Rahfeld, J., Schierhorn, M., Hartrodt, B., Neubert, K., Heins, J., Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? (1991) Biochim Biophys Acta, 1076, pp. 314-316; Silveira, S.T., Martínez-Maqueda, D., Recio, I., Hernández-Ledesma, B., Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin (2013) Food Chem, 141, pp. 1072-1077; Stöckel-Maschek, A., Stiebitz, B., Faust, J., Born, I., Kähne, T., Gorrell, M.D., Different inhibition mechanisms of dipeptidyl peptidase IV by tryptophan containing peptides and amides (2003) Adv Exp Med Biol, 524, pp. 69-72; Stulc, T., Sedo, A., Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects? (2010) Diabetes Res Clin Pract, 88, pp. 125-131; Thoma, R., Löffler, B., Stihle, M., Huber, W., Ruf, A., Hennig, M., Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV (2003) Structure, 11, pp. 947-959; Tominaga, Y., Yokota, S., Tanaka, H., Kishida, H., Kitagawa, M., Tachi, H., Dipeptidyl peptidase-4 Inhibitor, , United States Patent US 2012/0189611 A1; Uchida, M., Ohshiba, Y., Mogami, O., Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin (2011) J Pharmacol Sci, 117, pp. 63-66; Uenishi, H., Kabuki, T., Seto, Y., Serizawa, A., Nakajima, H., Isolation and identification of casein-derived dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-type cheese and its effects on plasma glucose in rats (2012) Int Dairy J, 22, pp. 24-30; Van Amerongen, A., Mjc, B., Van Zeeland-Wolbers Lma, Van Gilst, W.H., Buikema, J.H., Nelissen, J.W.P.M., Egg Protein Hydrolysates, , International Patent WO 2009/128713 A1; Velarde-Salcedo, A.J., Barrera-Pacheco, A., Lara-González, S., Montero-Morán, G.M., Díaz-Gois, A., González De Mejia, E., In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins (2013) Food Chem, 136, pp. 758-764; Yan, T.-R., Ho, S.-C., Hou, C.-L., Catalytic properties of X-prolyl dipeptidyl aminopeptidase from Lactococcus lactis subsp. Cremoris nTR (1992) Biosci Biotech Biochem, 56, pp. 704-707; Zhong, J., Rao, X., Rajagopalan, S., An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease (2013) Atherosclerosis, 226, pp. 305-314",Article,Scopus,2-s2.0-84927662509
"Brocklebank L.A., Falconer C.L., Page A.S., Perry R., Cooper A.R.","Accelerometer-measured sedentary time and cardiometabolic biomarkers: A systematic review",2015,"Preventive Medicine","76",,,"92","102",,,10.1016/j.ypmed.2015.04.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928910775&partnerID=40&md5=41c1f85250d4ee1aaade8fcd8b461aa6","Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, 12 Woodland RoadBristol, United Kingdom; National Inst. for Health Research (NIHR), Bristol Nutrition Biomedical Research Unit in Nutrition, Diet and Lifestyle, University of Bristol, Education and Research Centre, Upper Maudlin StreetBristol, United Kingdom","Brocklebank, L.A., Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, 12 Woodland RoadBristol, United Kingdom, National Inst. for Health Research (NIHR), Bristol Nutrition Biomedical Research Unit in Nutrition, Diet and Lifestyle, University of Bristol, Education and Research Centre, Upper Maudlin StreetBristol, United Kingdom; Falconer, C.L., Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, 12 Woodland RoadBristol, United Kingdom, National Inst. for Health Research (NIHR), Bristol Nutrition Biomedical Research Unit in Nutrition, Diet and Lifestyle, University of Bristol, Education and Research Centre, Upper Maudlin StreetBristol, United Kingdom; Page, A.S., Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, 12 Woodland RoadBristol, United Kingdom, National Inst. for Health Research (NIHR), Bristol Nutrition Biomedical Research Unit in Nutrition, Diet and Lifestyle, University of Bristol, Education and Research Centre, Upper Maudlin StreetBristol, United Kingdom; Perry, R., National Inst. for Health Research (NIHR), Bristol Nutrition Biomedical Research Unit in Nutrition, Diet and Lifestyle, University of Bristol, Education and Research Centre, Upper Maudlin StreetBristol, United Kingdom; Cooper, A.R., Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, 12 Woodland RoadBristol, United Kingdom, National Inst. for Health Research (NIHR), Bristol Nutrition Biomedical Research Unit in Nutrition, Diet and Lifestyle, University of Bristol, Education and Research Centre, Upper Maudlin StreetBristol, United Kingdom","Objective: We conducted a systematic review to investigate the cross-sectional and prospective associations of accelerometer-measured total sedentary time and breaks in sedentary time with individual cardiometabolic biomarkers in adults ≥. 18. years of age. Methods: Ovid Medline, Embase, Web of Science and the Cochrane Library were searched for studies meeting the inclusion criteria. Due to inconsistencies in the measurement and analysis of sedentary time, data was synthesised and presented narratively rather than as a meta-analysis. Results: Twenty-nine studies were included in the review; twenty-eight reported on total sedentary time and six on breaks in sedentary time. There was consistent evidence from cross-sectional data of an unfavourable association between total sedentary time and insulin sensitivity. There was also some evidence that total sedentary time was unfavourably associated with fasting insulin, insulin resistance and triglycerides. Furthermore, there was some evidence from cross-sectional data of a favourable association between breaks in sedentary time and triglycerides. Conclusion: Total sedentary time was consistently shown to be associated with poorer insulin sensitivity, even after adjusting for time spent in physical activity. This finding supports the proposed association between sedentary time and the development of Type 2 diabetes and reinforces the need to identify interventions to reduce time spent sedentary. © 2015.","Accelerometer; Breaks in sedentary time; Cardiometabolic risk factors; Sedentary time; Systematic review","Aadland, E., Andersen, J.R., Anderssen, S.A., Kvalheim, O.M., Physical activity versus sedentary behavior: associations with lipoprotein particle subclass concentrations in healthy adults (2013) PLoS One, 8, p. e85223; Andrews, R.C., Cooper, A.R., Montgomery, A.A., Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the early ACTID randomised controlled trial (2011) Lancet, 378, pp. 129-139; Atkin, A.J., Gorely, T., Clemes, S.A., Methods of measurement in epidemiology: sedentary behaviour (2012) Int. J. Epidemiol., 41, pp. 1460-1471; Balkau, B., Mhamdi, L., Oppert, J.M., Physical activity and insulin sensitivity: the RISC study (2008) Diabetes, 57, pp. 2613-2618; Bey, L., Hamilton, M.T., Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low-intensity activity (2003) J. Physiol., 551, pp. 673-682; Buman, M.P., Winkler, E.A., Kurka, J.M., Reallocating time to sleep, sedentary behaviors, or active behaviors: associations with cardiovascular disease risk biomarkers, NHANES 2005-2006 (2014) Am. J. Epidemiol., 179, pp. 323-334; Carson, V., Wong, S.L., Winkler, E., Healy, G.N., Colley, R.C., Tremblay, M.S., Patterns of sedentary time and cardiometabolic risk among Canadian adults (2014) Prev. Med., 65, pp. 23-27; Celis-Morales, C.A., Perez-Bravo, F., Ibanes, L., Insulin resistance in Chileans of European and indigenous descent: evidence for an ethnicity×environment interaction (2011) PLoS One, 6, p. e24690; Celis-Morales, C.A., Perez-Bravo, F., Ibanez, L., Salas, C., Bailey, M.E., Gill, J.M., Objective vs. self-reported physical activity and sedentary time: effects of measurement method on relationships with risk biomarkers (2012) PLoS One, 7, p. e36345; Chase, J.M., Lockhart, C.K., Ashe, M.C., Madden, K.M., Accelerometer-based measures of sedentary behavior and cardio-metabolic risk in active older adults (2014) Clin. Invest. Med., 37, pp. E108-E116; Clark, B.K., Sugiyama, T., Healy, G.N., Salmon, J., Dunstan, D.W., Owen, N., Validity and reliability of measures of television viewing time and other non-occupational sedentary behaviour of adults: a review (2009) Obes. Rev., 10, pp. 7-16; Clemes, S.A., David, B.M., Zhao, Y., Han, X., Brown, W., Validity of two self-report measures of sitting time (2012) J. Phys. Act. Health, 9, pp. 533-539; Colberg, S.R., Sigal, R.J., Fernhall, B., Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement (2010) Diabetes Care, 33, pp. e147-e167; Cooper, A.R., Sebire, S., Montgomery, A.A., Sedentary time, breaks in sedentary time and metabolic variables in people with newly diagnosed type 2 diabetes (2012) Diabetologia, 55, pp. 589-599; Cooper, A.J., Brage, S., Ekelund, U., Wareham, N.J., Griffin, S.J., Simmons, R.K., Association between objectively assessed sedentary time and physical activity with metabolic risk factors among people with recently diagnosed type 2 diabetes (2014) Diabetologia, 57, pp. 73-82; Corder, K., Ekelund, U., Steele, R.M., Wareham, N.J., Brage, S., Assessment of physical activity in youth (2008) J. Appl. Physiol., 105, pp. 977-987; Corder, K., Brage, S., Ekelund, U., Accelerometers and pedometers: methodology and clinical application (2007) Curr. Opin. Clin. Nutr. Metab. Care, 10, pp. 597-603; De Rezende, L.F., Rey-Lopez, J.P., Matsudo, V.K., Do Carmo Luiz, O., Sedentary behavior and health outcomes among older adults: a systematic review (2014) BMC Public Health, 14, p. 333; Edwardson, C.L., Gorely, T., Davies, M.J., Association of sedentary behaviour with metabolic syndrome: a meta-analysis (2012) PLoS One, 7, p. e34916; Ekelund, U., Griffin, S.J., Wareham, N.J., Physical activity and metabolic risk in individuals with a family history of type 2 diabetes (2007) Diabetes Care, 30, pp. 337-342; Ekelund, U., Brage, S., Griffin, S.J., Wareham, N.J., Objectively measured moderate- and vigorous-intensity physical activity but not sedentary time predicts insulin resistance in high-risk individuals (2009) Diabetes Care, 32, pp. 1081-1086; Gennuso, K.P., Gangnon, R.E., Matthews, C.E., Thraen-Borowski, K.M., Colbert, L.H., Sedentary behavior, physical activity, and markers of health in older adults (2013) Med. Sci. Sports Exerc., 45, pp. 1493-1500; Green, A.N., Mcgrath, R., Martinez, V., Taylor, K., Paul, D.R., Vella, C.A., Associations of objectively measured sedentary behavior, light activity, and markers of cardiometabolic health in young women (2014) Eur. J. Appl. Physiol., 114, pp. 907-919; Hamburg, N.M., Mcmackin, C.J., Huang, A.L., Physical inactivity rapidly induces insulin resistance and microvascular dysfunction in healthy volunteers (2007) Arterioscler. Thromb. Vasc. Biol., 27, pp. 2650-2656; Healy, G.N., Dunstan, D.W., Salmon, J., Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose (2007) Diabetes Care, 30, pp. 1384-1389; Healy, G.N., Dunstan, D.W., Salmon, J., Breaks in sedentary time: beneficial associations with metabolic risk (2008) Diabetes Care, 31, pp. 661-666; Healy, G.N., Wijndaele, K., Dunstan, D.W., Objectively measured sedentary time, physical activity, and metabolic risk: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) (2008) Diabetes Care, 31, pp. 369-371; Healy, G.N., Matthews, C.E., Dunstan, D.W., Winkler, E.A., Owen, N., Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06 (2011) Eur. Heart J., 32, pp. 590-597; Henson, J., Yates, T., Biddle, S.J., Associations of objectively measured sedentary behaviour and physical activity with markers of cardiometabolic health (2013) Diabetologia, 56, pp. 1012-1020; Kim, J., Tanabe, K., Yokoyama, N., Zempo, H., Kuno, S., Objectively measured light-intensity lifestyle activity and sedentary time are independently associated with metabolic syndrome: a cross-sectional study of Japanese adults (2013) Int. J. Behav. Nutr. Phys. Act., 10, p. 30; Kozey-Keadle, S., Libertine, A., Lyden, K., Staudenmayer, J., Freedson, P.S., Validation of wearable monitors for assessing sedentary behavior (2011) Med. Sci. Sports Exerc., 43, pp. 1561-1567; Lahjibi, E., Heude, B., Dekker, J.M., Impact of objectively measured sedentary behaviour on changes in insulin resistance and secretion over 3years in the RISC study: interaction with weight gain (2013) Diabetes Metab., 39, pp. 217-225; Lecheminant, J.D., Tucker, L.A., Recommended levels of physical activity and insulin resistance in middle-aged women (2011) Diabetes Educ., 37, pp. 573-580; Loprinzi, P.D., Fitzgerald, E.M., Woekel, E., Cardinal, B.J., Association of physical activity and sedentary behavior with biological markers among U.S. pregnant women (2013) J Womens Health (Larchmt), 22, pp. 953-958; Lund, S., Holman, G.D., Schmitz, O., Pedersen, O., Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin (1995) Proc. Natl. Acad. Sci. U. S. A., 92, pp. 5817-5821; Lynch, B.M., Dunstan, D.W., Healy, G.N., Winkler, E., Eakin, E., Owen, N., Objectively measured physical activity and sedentary time of breast cancer survivors, and associations with adiposity: findings from NHANES (2003-2006) (2010) Cancer Causes Control, 21, pp. 283-288; Lynch, B.M., Friedenreich, C.M., Winkler, E.A., Associations of objectively assessed physical activity and sedentary time with biomarkers of breast cancer risk in postmenopausal women: findings from NHANES (2003-2006) (2011) Breast Cancer Res. Treat., 130, pp. 183-194; Maher, C., Olds, T., Mire, E., Katzmarzyk, P.T., Reconsidering the sedentary behaviour paradigm (2014) PLoS One, 9, p. e86403; Matthews, C.E., Ainsworth, B.E., Thompson, R.W., Bassett, D.R., (2002) Med. Sci. Sports Exerc., 34, pp. 1376-1381; Mcguire, K.A., Ross, R., Sedentary behavior is not associated with cardiometabolic risk in adults with abdominal obesity (2011) PLoS One, 6, p. e20503; Morrato, E.H., Hill, J.O., Wyatt, H.R., Ghushchyan, V., Sullivan, P.W., Physical activity in U.S. adults with diabetes and at risk for developing diabetes, 2003 (2007) Diabetes Care, 30, pp. 203-209; Nybo, H., Petersen, H.C., Gaist, D., Predictors of mortality in 2,249 nonagenarians-the Danish 1905-cohort survey (2003) J. Am. Geriatr. Soc., 51, pp. 1365-1373; Ryan, C.G., Grant, P.M., Tigbe, W.W., Granat, M.H., The validity and reliability of a novel activity monitor as a measure of walking (2006) Br. J. Sports Med., 40, pp. 779-784; Scheers, T., Philippaerts, R., Lefevre, J., SenseWear-determined physical activity and sedentary behavior and metabolic syndrome (2013) Med. Sci. Sports Exerc., 45, pp. 481-489; Letter to the editor: standardized use of the terms ""sedentary"" and ""sedentary behaviours"" (2012) Appl. Physiol. Nutr. Metab., 37, pp. 540-542; Stamatakis, E., Hamer, M., Tilling, K., Lawlor, D.A., Sedentary time in relation to cardio-metabolic risk factors: differential associations for self-report vs accelerometry in working age adults (2012) Int. J. Epidemiol., 41, pp. 1328-1337; Von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies (2008) J. Clin. Epidemiol., 61, pp. 344-349; Wells, G.A., Shea, B., O'Connell, D., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [online], , http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, Available, (Accessed 21 January 2015); Wijndaele, K., Orrow, G., Ekelund, U., Increasing objectively measured sedentary time increases clustered cardiometabolic risk: a 6year analysis of the ProActive study (2014) Diabetologia, 57, pp. 305-312; Wilmot, E.G., Edwardson, C.L., Achana, F.A., Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis (2012) Diabetologia, 55, pp. 2895-2905",Review,Scopus,2-s2.0-84928910775
"Tachikawa R., Koyasu S., Matsumoto T., Hamada S., Azuma M., Murase K., Tanizawa K., Inouchi M., Oga T., Mishima M., Togashi K., Chin K.","Obstructive sleep apnea and abdominal aortic calcification: Is there anassociation independent of comorbid risk factors?",2015,"Atherosclerosis","241","1",,"6","11",,,10.1016/j.atherosclerosis.2015.04.801,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928689716&partnerID=40&md5=fffacda9f861e3fdbfc0a42d447cd341","Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan","Tachikawa, R., Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Koyasu, S., Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Matsumoto, T., Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Hamada, S., Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Azuma, M., Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Murase, K., Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Tanizawa, K., Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Inouchi, M., Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Oga, T., Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Mishima, M., Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Togashi, K., Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan; Chin, K., Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto UniversityKyoto, Japan","Background: No studies have addressed the relationship between obstructive sleep apnea (OSA) and abdominal aortic calcification (AAC), a marker for subclinical atherosclerosis and future cardiovascular events. Objectives: To investigate 1) the association between OSA severity and AAC, and 2) whether OSA can impact the extent of AAC independent of comorbid atherogenic risk factors. Methods: 390 participants aged 40-70 years underwent polysomnography and abdominal computed tomography. AAC was separately quantified in the upper and lower abdominal aorta using the modified Agatston scoring method, and the total AAC score was calculated as a sum of the two scores. OSA was defined as none/mild (apnea-hypopnea index [AHI] <15, n=87), moderate (AHI 15-30, n=129), and severe (AHI ≥30, n=174). Results: Log-transformed total AAC score adjusted for age and body mass index (BMI) was greater in participants with an elevated AHI (3.4 for none/mild OSA, 3.7 for moderate OSA, and 4.2 for severe OSA, p=0.04). Multivariate linear regression analysis including age and BMI as covariates showed that severe OSA was associated with higher scores for the lower and total AAC (β=0.15 and 0.14, p=0.01 and 0.01, respectively). The association did not persist after additionally adjusting for traditional atherogenic risk factors including visceral fat, smoking, hypertension, dyslipidemia, and diabetes. Conclusions: Severe OSA was associated with a greater extent of AAC, which was dependent on coexisting atherogenic risk factors. Comorbid cardiometabolic disorders may largely mediate the association of OSA with subclinical atherosclerosis. © 2015 Elsevier Ireland Ltd.","Abdominal aorta; Arterial calcification; Atherosclerosis; Cardiovascular risk factors; Obstructive sleep apnea","Drager, L.F., Bortolotto, L.A., Maki-Nunes, C., The incremental role of obstructive sleep apnoea on markers of atherosclerosis in patients with metabolic syndrome (2010) Atherosclerosis, 208, pp. 490-495; Drager, L.F., Polotsky, V.Y., Lorenzi-Filho, G., Obstructive sleep apnea: an emerging risk factor for atherosclerosis (2011) Chest, 140, pp. 534-542; Ali, S.S., Oni, E.T., Warraich, H.J., Systematic review on noninvasive assessment of subclinical cardiovascular disease in obstructive sleep apnea: new kid on the block! (2014) Sleep. Med. Rev., 18, pp. 379-391; Sangiorgi, G., Rumberger, J.A., Severson, A., Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology (1998) J.Am. Coll. Cardiol., 31, pp. 126-133; Detrano, R., Guerci, A.D., Carr, J.J., Coronary calcium as a predictor of coronary events in four racial or ethnic groups (2008) N.Engl. J. Med., 358, pp. 1336-1345; Bastos Goncalves, F., Voute, M.T., Hoeks, S.E., Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis (2012) Heart, 98, pp. 988-994; Sorajja, D., Gami, A.S., Somers, V.K., Behrenbeck, T.R., Garcia-Touchard, A., Lopez-Jimenez, F., Independent association between obstructive sleep apnea and subclinical coronary artery disease (2008) Chest, 133, pp. 927-933; Kim, S.H., Cho, G.Y., Baik, I., Association of coronary artery calcification with obstructive sleep apnea and obesity in middle-aged men (2010) Nutr. Metab. Cardiovasc. Dis., 20, pp. 575-582; Weinreich, G., Wessendorf, T.E., Erdmann, T., Association of obstructive sleep apnoea with subclinical coronary atherosclerosis (2013) Atherosclerosis, 231, pp. 191-197; Kwon, Y., Duprez, D.A., Jacobs, D.R., Obstructive sleep apnea and progression of coronary artery calcium: the multi-ethnic study of atherosclerosis study (2014) J.Am. Heart Assoc., 3, p. e001241; Agatston, A.S., Janowitz, W.R., Hildner, F.J., Zusmer, N.R., Viamonte, M., Detrano, R., Quantification of coronary artery calcium using ultrafast computed tomography (1990) J.Am. Coll. Cardiol., 15, pp. 827-832; Murase, K., Mori, K., Yoshimura, C., Association between plasma neutrophil gelatinase associated lipocalin level and obstructive sleep apnea or nocturnal intermittent hypoxia (2013) PLoS One, 8, p. e54184; Iber, C., Ancoli-Israel, S., Chesson, A., Quan, S., (2007) The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, , American Academy of Sleep Medicine, Westchester, IL, USA; Harada, Y., Oga, T., Chihara, Y., Azuma, M., Murase, K., Toyama, Y., Differences in associations between visceral fat accumulation and obstructive sleep apnea by sex (2014) Ann. Am. Thorac. Soc., 11, pp. 383-391; Teramoto, T., Sasaki, J., Ueshima, H., Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese (2007) J.Atheroscler. Thromb., 14, pp. 45-50; Jayalath, R.W., Mangan, S.H., Golledge, J., Aortic calcification (2005) Eur. J. Vasc. Endovasc. Surg., 30, pp. 476-488; New, S.E., Aikawa, E., Cardiovascular calcification: an inflammatory disease (2011) Circ. J., 75, pp. 1305-1313; Findings from the PDAY study. Pathobiological determinants of atherosclerosis in youth (PDAY) research group (1993) Arterioscler. Thromb., 13, pp. 1291-1298; Jensky, N.E., Criqui, M.H., Wright, M.C., Wassel, C.L., Brody, S.A., Allison, M.A., Blood pressure and vascular calcification (2010) Hypertension, 55, pp. 990-997; Wong, N.D., Lopez, V.A., Allison, M., Abdominal aortic calcium and multi-site atherosclerosis: the multiethnic study of atherosclerosis (2011) Atherosclerosis, 214, pp. 436-441; Fox, C.S., Hwang, S.J., Massaro, J.M., Relation of subcutaneous and visceral adipose tissue to coronary and abdominal aortic calcium (from the Framingham Heart Study) (2009) Am. J. Cardiol., 104, pp. 543-547; Shaaban, A.M., Duerinckx, A.J., Wall shear stress and early atherosclerosis: a review (2000) AJR Am. J. Roentgenol., 174, pp. 1657-1665; Kauppila, L.I., Polak, J.F., Cupples, L.A., Hannan, M.T., Kiel, D.P., Wilson, P.W., New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study (1997) Atherosclerosis, 132, pp. 245-250",Article,Scopus,2-s2.0-84928689716
"Michos E.D., Misialek J.R., Selvin E., Folsom A.R., Pankow J.S., Post W.S., Lutsey P.L.","25-hydroxyvitamin D levels, vitamin D binding protein gene polymorphisms and incident coronary heart disease among whites and blacks: The ARIC study",2015,"Atherosclerosis","241","1",,"12","17",,,10.1016/j.atherosclerosis.2015.04.803,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928798984&partnerID=40&md5=c18659e035f46d645187ede4f9f323d8","Division of Cardiology, Johns Hopkins University School of Medicine, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States; Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States","Michos, E.D., Division of Cardiology, Johns Hopkins University School of Medicine, United States, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States; Misialek, J.R., Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States; Selvin, E., Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States; Folsom, A.R., Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States; Pankow, J.S., Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States; Post, W.S., Division of Cardiology, Johns Hopkins University School of Medicine, United States, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States; Lutsey, P.L., Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States","Background: In observational studies, low 25-hydroxyvitamin D (25(OH)D) has been associated with increased risk of coronary heart disease (CHD), and this association may vary by race. Racial differences in the frequency of vitamin D binding protein (DBP) single nucleotide polymorphisms (SNPs) might account for similar bioavailable vitamin D in blacks despite lower mean 25(OH)D. We hypothesized that the associations of low 25(OH)D with CHD risk would be stronger among whites and among persons with genotypes associated with higher DBP levels. Methods: We measured 25(OH)D by mass spectroscopy in 11,945 participants in the ARIC Study (baseline 1990-1992, mean age 57 years, 59% women, 24% black). Two DBP SNPs (rs7041; rs4588) were genotyped. We used adjusted Cox proportional hazards models to examine the association of 25(OH)D with adjudicated CHD events through December 2011. Results: Over a median of 20 years, there were 1230 incident CHD events. Whites in the lowest quintile of 25(OH)D (<17ng/ml) compared to the upper 4 quintiles had an increased risk of incident CHD (HR 1.28, 95% CI 1.05-1.56), but blacks did not (1.03, 0.82-1.28), after adjustment for demographics and behavioral/socioeconomic factors (p-interaction with race=0.22). Results among whites were no longer significant after further adjustment for potential mediators of this association (i.e. diabetes, hypertension). There was no statistically significant interaction of 25(OH)D with the DBP SNPs rs4588 (p=0.92) or rs7041 (p=0.87) in relation to CHD risk. Conclusions: Low 25(OH)D was associated with incident CHD in whites, but no interactions of 25(OH)D with key DBP genotypes was found. © 2015 Elsevier Ireland Ltd.","Coronary heart disease; Epidemiology; Race; Vitamin D; Vitamin D binding protein","Holick, M.F., Vitamin D deficiency (2007) N.Engl. J. Med., 357, pp. 266-281; Wang, L., Song, Y., Manson, J.E., Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies (2012) Circ. Cardiovasc Qual. Outcomes, 5, pp. 819-829; Wang, T.J., Pencina, M.J., Booth, S.L., Vitamin D deficiency and risk of cardiovascular disease (2008) Circulation, 117, pp. 503-511; Anderson, J.L., May, H.T., Horne, B.D., Relationship of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general health care population (2010) Am. J. Cardiol., 106, pp. 963-968; Fiscella, K., Franks, P., Vitamin D, race, and cardiovascular mortality: findings from a National US Sample (2010) Ann. Fam. Med., 8, pp. 11-18; Giovannucci, E., Liu, Y., Hollis, B.W., Rimm, E.B., 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study (2008) Arch. Intern. Med., 168, pp. 1174-1180; Robinson-Cohen, C., Hoofnagle, A.N., Ix, J.H., Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events (2013) JAMA, 310 (2), pp. 179-188; Lutsey, P.L., Michos, E.D., Vitamin D, calcium, and atherosclerotic risk - evidence from serum levels and supplementation studies (2013) Curr. Atheroscler. Rep., 15 (1), p. 293; Manson, J.E., Bassuk, S.S., Lee, I.M., The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease (2012) Contemp. Clin. Trials, 33 (1), pp. 159-171; Michos, E.D., Reis, J.P., Post, W.S., 25-hydroxyvitamin D deficiency is associated with fatal stroke among whites but not blacks: the nhanes-iii linked mortality files (2012) Nutrition, 28, pp. 367-371; Powe, C.E., Evans, M.K., Wenger, J., Vitamin D-binding protein and vitamin D status of black Americans and white Americans (2013) N.Engl. J. Med., 369, pp. 1991-2000; Bikle, D.D., Gee, E., Halloran, B., Kowalski, M.A., Ryzen, E., Haddad, J.G., Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein (1986) J.Clin. Endocrinol. Metab., 63, pp. 954-959; The, A.R.I.C., Investigators. The atherosclerosis risk in communities (aric) study: design and objectives. The aric investigators (1989) Am. J. Epidemiol., 129, pp. 687-702; Inker, L.A., Schmid, C.H., Tighiouart, H., Estimating glomerular filtration rate from serum creatinine and cystatin C (2012) N.Engl. J. Med., 367, pp. 20-29; White, A.D., Folsom, A.R., Chambless, L.E., Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience (1996) J.Clin. Epidemiol., 49, pp. 223-233; Musunuru, K., Lettre, G., Young, T., Candidate gene association resource (care): design, methods, and proof of concept (2010) Circ. Cardiovasc. Genet., 3, pp. 267-275; Keating, B.J., Tischfield, S., Murray, S.S., Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies (2008) PLoS One, 3 (10); Baecke, J.A., Burema, J., Frijters, J.E., Ashort questionnaire for the measurement of habitual physical activity in epidemiological studies (1982) Am. J. Clin. Nutr., 36, pp. 936-942; Shoben, A.B., Kestenbaum, B., Levin, G., Seasonal variation in 25-hydroxyvitamin D concentrations in the Cardiovascular Health Study (2011) Am. J. Epidemiol., 174 (12), pp. 1363-1372; Lutsey, P.L., Michos, E.D., Misialek, J.R., Race and vitamin D binding protein gene polymorphisms modify the association of 25-hydroxyvitamin D and incident heart failure: the Atherosclerosis Risk in Communities Study (ARIC) (2015) JACC Heart Fail, , Published online April 08, 2015; Go, A.S., Mozaffarian, D., Roger, V.L., Heart disease and stroke statistics-2014 update: a report from the American Heart Association (2014) Circulation, 129, pp. e28-292; Kunutsor, S., Apekey, T., Steur, M., Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants (2013) Eur. J. Epidemiol., 28, pp. 205-221; Li, Y.C., Kong, J., Wei, M., 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system (2002) J.Clin. Invest, 110 (2), pp. 229-238; Mitri, J., Pittas, A.G., Vitamin D and diabetes (2014) Endocrinol. Metab. Clin. North Am., 43 (1), pp. 205-232; Reis, J.P., Michos, E.D., Pankow, J.S., Selvin, E., Lutsey, P.L., Race, vitamin D binding protein gene polymorphisms, 25-hydroxyvitamin D, and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study (2015) Am. J. Clin. Nutr., , (in press); Schleithoff, S.S., Zittermann, A., Tenderich, G., Berthold, H.K., Stehle, P., Koerfer, R., Vitamin D supplementation improves cytopkine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial (2006) Am. J. Clin. Nutr., 83 (4), pp. 754-759; Oh, J., Weng, S., Felton, S.K., 1,25(OH)<inf>2</inf> vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus (2009) Circulation, 120, pp. 687-698; Schnatz, P.F., Manson, J.E., Vitamin D and cardiovascular disease: an appraisal of the evidence (2014) Clin. Chem., 60 (4), pp. 600-609; Harris, S.S., Vitamin D and African Americans (2006) J.Nutr., 136, pp. 1126-1129; Gutierrez, O.M., Farwell, W.R., Kermah, D., Taylor, E.N., Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey (2011) Osteoporos. Int., 22, pp. 1745-1753; Strawbridge, R.J., Deleskog, A., McLeod, O., Aserum 25-hydroxyvitamin D concentration-associated genetic variant in DHCR7 interacts with type 2 diabetes status to influence subclinical atherosclerosis (measured by carotid intima-media thickness) (2014) Diabetologia, 57 (6), pp. 1159-1172",Article,Scopus,2-s2.0-84928798984
"Ashwini S., Bobby Z., Joseph M.","Mild hypothyroidism improves glucose tolerance in experimental type 2 diabetes",2015,"Chemico-Biological Interactions","235",,,"47","55",,,10.1016/j.cbi.2015.04.007,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928128964&partnerID=40&md5=abb81ae8d42cb65ea1e5f9f30f0ffd3d","Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and ResearchPondicherry, India","Ashwini, S., Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and ResearchPondicherry, India; Bobby, Z., Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and ResearchPondicherry, India; Joseph, M., Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and ResearchPondicherry, India","Background: Co-existence of type 2 diabetes and hypothyroidism is an emerging trend observed in clinical practice. Although the effects of isolated type 2 diabetes and hypothyroidism are well known, there are limited studies addressing the metabolic complications when these two conditions co-exist. The aim of the present study was to assess the interaction between type 2 diabetes and hypothyroidism with respect to glucose tolerance, dyslipidemia and redox balance in a state were these two diseases coexist. Methods: Sixty male Wistar Albino rats were randomised into six groups. Group 1: control, Group 2: overt hypothyroidism, Group 3: mild hypothyroidism, Group 4: type 2 diabetes, Group 5: mild hypothyroidism + type 2 diabetes, Group 6: overt hypothyroidism + type 2 diabetes. Experimental hypothyroidism was created by the administration of propyl-2-thiouracil and type 2 diabetes by feeding rats with 60% fructose (w/w). The duration of the study was 6 weeks. All the parameters were estimated at the start (basal) and the end of the study. Intraperitoneal glucose tolerance test was carried out and area under curve (AUC) calculated to assess the glucose tolerance. Thyroid profile, lipid profile and oxidative stress parameters were also measured. Results: Plasma TSH level was elevated 3-fold in the mild hypothyroid group and 15.2-fold in the overt hypothyroid group in comparison to the control group. Thyroid profile was found to be normal in type 2 diabetic group. There was no significant difference between hypothyroidism and hypothyroidism + diabetes groups with respect to thyroid profile. Among the six groups the degree of glucose intolerance was found to be maximum for overt hypothyroidism + diabetes group, followed by diabetes group and overt hypothyroidism group. An interesting finding was that glucose intolerance was significantly reduced in mild hypothyroidism + diabetes group (increase in AUC: 48.04%) in comparison with isolated diabetes group (increase in AUC: 71.63%). Similar results were obtained with parameters of oxidative stress. Oxidative stress was observed in overt hypothyroidism + diabetes, diabetes, overt hypothyroidism groups with severity decreasing in that order. Coexistence of mild hypothyroidism with diabetes decreased oxidative stress in comparison with isolated diabetes group. There was no statistical difference in lipid profile between mild hypothyroidism + diabetes and isolated diabetes group. Conclusion: Presence of mild hypothyroidism in type 2 diabetes confers a protective effect with respect to glucose tolerance and redox balance whereas presence of overt hypothyroidism in type 2 diabetes has a deleterious effect. The increased incidence of hypothyroidism in diabetes, especially subclinical hypothyroidism, could be a reflection of a physiological attempt by the body to mitigate damage wrought by diabetes. © 2015 Elsevier Ireland Ltd. All rights reserved.","Glucose tolerance; Mild hypothyroidism; Overt hypothyroidism; Oxidative stress; Type 2 diabetes","(2013) IDF Diabetes Atlas, , http://www.idf.org/diabetesatlas, [Internet]. 6th ed. Brussels, Belgium: International Diabetes Federation; . Available from: < >; Unnikrishnan, A., Bantwal, G., John, M., Kalra, S., Sahay, R., Tewari, N., Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India (2013) Indian J. Endocrinol. Metab., 17, pp. 647-652; Tamez-Pérez, H.-E., Martínez, E., Quintanilla-Flores, D.L., Tamez-Peña, A.L., Gutiérrez-Hermosillo, H., Díaz De León-González, E., The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population. An observational study (2012) Med. Clín., 138, pp. 475-477; Díez, J.J., Iglesias, P., An analysis of the relative risk for hypothyroidism in patients with Type 2 diabetes (2012) Diabetes Med., 29, pp. 1510-1514; Vondra, K., Vrbikova, J., Dvorakova, K., Thyroid gland diseases in adult patients with diabetes mellitus (2005) Minerva Endocrinol., 30, pp. 217-236; Chubb, S.A.P., Davis, W.A., Inman, Z., Davis, T.M.E., Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: The Fremantle Diabetes Study (2005) Clin. Endocrinol. (Oxf.), 62, pp. 480-486; Witting, V., Bergis, D., Sadet, D., Badenhoop, K., Thyroid disease in insulin-treated patients with type 2 diabetes: A retrospective study (2014) Thyroid Res, 7, p. 2; Bartalena, L., Cossu, E., Grasso, L., Velluzzi, F., Loviselli, A., Cirillo, R., Relationship between nocturnal serum thyrotropin peak and metabolic control in diabetic patients (1993) J. Clin. Endocrinol. Metab., 76, pp. 983-987; Sarandöl, E., Taş, S., Dirican, M., Serdar, Z., Oxidative stress and serum paraoxonase activity in experimental hypothyroidism: Effect of vitamin e supplementation (2005) Cell Biochem. Funct., 23, pp. 1-8; Shimoni, Y., Ewart, H.S., Severson, D., Type i and II models of diabetes produce different modifications of K+ currents in rat heart: Role of insulin (1998) J. Physiol., 507, pp. 485-496; Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.W., Karin, M., Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta (2001) Science, 293, pp. 1673-1677; Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge (1972) Clin. Chem., 18, pp. 499-502; Beutler, E., Duron, O., Kelly, B.M., Improved method for the determination of blood glutathione (1963) J. Lab. Clin. Med., 61, pp. 882-888; Aebi, H., Catalase in vitro (1984) Methods Enzymol, 105, pp. 121-126; Wendel, A., Glutathione peroxidase (1981) Methods Enzymol, pp. 325-333; Yagi, K., Assay for blood, plasma or serum lipid peroxides (1984) Methods Enzymol, pp. 28-31; Benzie, I.F., Strain, J.J., The ferric reducing ability of plasma (FRAP) as a measure of ""antioxidant power"": The FRAP assay (1996) Anal. Biochem., 239, pp. 70-76; Bishayee, S., Balasubramanian, A.S., Lipid peroxide formation in rat brain (1971) J. Neurochem., 18, pp. 909-920; Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction (1979) Anal. Biochem., 95, pp. 351-358; Cettour-Rose, P., Theander-Carrillo, C., Asensio, C., Klein, M., Visser, T.J., Burger, A.G., Hypothyroidism in rats decreases peripheral glucose utilisation, a defect partially corrected by central leptin infusion (2005) Diabetologia, 48, pp. 624-633; Cortés, C., Eugenin, E., Aliaga, E., Carreño, L.J., Bueno, S.M., Gonzalez, P.A., Hypothyroidism in the adult rat causes incremental changes in brain-derived neurotrophic factor, neuronal and astrocyte apoptosis, gliosis, and deterioration of postsynaptic density (2012) Thyroid, 22, pp. 951-963; Feng, X., Jiang, Y., Meltzer, P., Yen, P.M., Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray (2000) Mol. Endocrinol., 14, pp. 947-955; Park, E.A., Jerden, D.C., Bahouth, S.W., Regulation of phosphoenolpyruvate carboxykinase gene transcription by thyroid hormone involves two distinct binding sites in the promoter (1995) Biochem. J., 309, pp. 913-919. , PT 3; Weinberg, M.B., Utter, M.F., Effect of thyroid hormone on the turnover of rat liver pyruvate carboxylase and pyruvate dehydrogenase (1979) J. Biol. Chem., 254, pp. 9492-9499; Weinstein, S.P., O'Boyle, E., Fisher, M., Haber, R.S., Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: Evidence for hormonal regulation of the hepatic glucose transport system (1994) Endocrinology, 135, pp. 649-654; Weinstein, S.P., O'Boyle, E., Haber, R.S., Thyroid hormone increases basal and insulin-stimulated glucose transport in skeletal muscle. The role of GLUT4 glucose transporter expression (1994) Diabetes, 43, pp. 1185-1189; Moeller, L.C., Dumitrescu, A.M., Walker, R.L., Meltzer, P.S., Refetoff, S., Thyroid hormone responsive genes in cultured human fibroblasts (2005) J. Clin. Endocrinol. Metab., 90, pp. 936-943; Brunetto, E.L., Teixeira Sda, S., Giannocco, G., Machado, U.F., Nunes, M.T., T3 rapidly increases SLC2A4 gene expression and GLUT4 trafficking to the plasma membrane in skeletal muscle of rat and improves glucose homeostasis (2012) Thyroid, 22, pp. 70-79; Shimizu, Y., Shimazu, T., Thyroid hormone augments GLUT4 expression and insulin-sensitive glucose transport system in differentiating rat brown adipocytes in culture (2002) J. Vet. Med. Sci., 64, pp. 677-681; Goglia, F., Moreno, M., Lanni, A., Action of thyroid hormones at the cellular level: The mitochondrial target (1999) FEBS Lett, 452, pp. 115-120; Althausen, T.L.S.M., The influence of the thyroid gland on absorption in the digestive tract (1938) Am. J. Physiol., 123, pp. 577-588; McCulloch, A.J., Nosadini, R., Pernet, A., Piniewska, M., Cook, D.B., Clark, F., Glucose turnover and indices of recycling in thyrotoxicosis and primary thyroid failure (1979) Clin. Sci. (Lond.), 1983 (64), pp. 41-47; Okajima, F., Ui, M., Metabolism of glucose in hyper- and hypo-thyroid rats in vivo. Glucose-turnover values and futile-cycle activities obtained with 14C- and 3H-labelled glucose (1979) Biochem J, 182, pp. 565-575; Stanická, S., Vondra, K., Pelikánová, T., Vlcek, P., Hill, M., Zamrazil, V., Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy (2005) Clin. Chem. Lab. Med., 43, pp. 715-720; Comte, B., Vidal, H., Laville, M., Riou, J.P., Influence of thyroid hormones on gluconeogenesis from glycerol in rat hepatocytes: A dose-response study (1990) Metabolism, 39, pp. 259-263; Quagliaro, L., Piconi, L., Assaloni, R., Martinelli, L., Motz, E., Ceriello, A., Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: The role of protein kinase C and NAD(P)H-oxidase activation (2003) Diabetes, 52, pp. 2795-2804; Nanda, N., Bobby, Z., Hamide, A., Koner, B.C., Sridhar, M.G., Association between oxidative stress and coronary lipid risk factors in hypothyroid women is independent of body mass index (2007) Metabolism, 56, pp. 1350-1355; Nanda, N., Bobby, Z., Hamide, A., Oxidative stress and protein glycation in primary hypothyroidism Male/female difference (2008) Clin. Exp. Med., 8, pp. 101-108; Rains, J.L., Jain, S.K., Oxidative stress, insulin signaling, and diabetes (2011) Free Radical Biol. Med., 50, pp. 567-575; Reddy, S.S., Ramatholisamma, P., Karuna, R., Saralakumari, D., Preventive effect of Tinospora cordifolia against high-fructose diet-induced insulin resistance and oxidative stress in male Wistar rats (2009) Food Chem. Toxicol., 47, pp. 2224-2229; Suzuki, K., Islam, K.N., Kaneto, H., Ookawara, T., Taniguchi, N., The contribution of fructose and nitric oxide to oxidative stress in hamster islet tumor (HIT) cells through the inactivation of glutathione peroxidase (2000) Electrophoresis, 21, pp. 285-288; Wright, E., Scism-Bacon, J., Glass, L., Oxidative stress in type 2 diabetes: The role of fasting and postprandial glycaemia (2006) Int. J. Clin. Pract., 60, pp. 308-314; Mooradian, A.D., Dyslipidemia in type 2 diabetes mellitus (2009) Nat. Clin. Pract. Endocrinol. Metab., 5, pp. 150-159; Lopez, D., Abisambra Socarrás, J.F., Bedi, M., Ness, G.C., Activation of the hepatic LDL receptor promoter by thyroid hormone (2007) Biochim. Biophys. Acta, 1771, pp. 1216-1225; Shin, D.-J., Osborne, T.F., Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2) (2003) J. Biol. Chem., 278, pp. 34114-34118; Afzal, M., Kazmi, I., Semwal, S., Al-Abbasi, F.A., Anwar, F., Therapeutic exploration of betulinic acid in chemically induced hypothyroidism (2014) Mol. Cell. Biochem., 386, pp. 27-34; Ahmed, O.M., Gabar, M.A., Ali, T.M., Impacts of the coexistence of diabetes and hypothyroidism on body weight gain, leptin and various metabolic aspects in albino rats (2012) J. Diabetes Complications, 26, pp. 491-500",Article,Scopus,2-s2.0-84928128964
"Gao J., Han Y.-L., Jin Z.-Y., Xu X.-M., Zha X.-Q., Chen H.-Q., Yin Y.-Y.","Protective effect of polysaccharides from Opuntia dillenii Haw. fruits on streptozotocin-induced diabetic rats",2015,"Carbohydrate Polymers","124",,,"25","34",,,10.1016/j.carbpol.2015.01.068,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923562212&partnerID=40&md5=0ef52c8a97cbb3ee9f64a253789bd060","School of Biotechnology and Food Engineering, Hefei University of Technology, 193 Tunxi RoadHefei, Anhui, China; State Key Laboratory of Food Science and Technology, School of Food Science and Technology, Jiangnan University, 1800 Lihu RoadWuxi, Jiangsu, China; Dapartment of Pharmacology, Anhui Medical University, 81 Meishan RoadHefei, Anhui, China","Gao, J., School of Biotechnology and Food Engineering, Hefei University of Technology, 193 Tunxi RoadHefei, Anhui, China; Han, Y.-L., School of Biotechnology and Food Engineering, Hefei University of Technology, 193 Tunxi RoadHefei, Anhui, China; Jin, Z.-Y., State Key Laboratory of Food Science and Technology, School of Food Science and Technology, Jiangnan University, 1800 Lihu RoadWuxi, Jiangsu, China; Xu, X.-M., State Key Laboratory of Food Science and Technology, School of Food Science and Technology, Jiangnan University, 1800 Lihu RoadWuxi, Jiangsu, China; Zha, X.-Q., School of Biotechnology and Food Engineering, Hefei University of Technology, 193 Tunxi RoadHefei, Anhui, China; Chen, H.-Q., School of Biotechnology and Food Engineering, Hefei University of Technology, 193 Tunxi RoadHefei, Anhui, China; Yin, Y.-Y., Dapartment of Pharmacology, Anhui Medical University, 81 Meishan RoadHefei, Anhui, China","In this study, a novel water-soluble polysaccharide fraction with molecular weight of 6479.1 kDa was isolated from the fruits of Opuntia dillenii Haw.; which consisted of rhamnose, xylose, mannose and glucose in the molar ratio of 14.99:1.14:1.00:6.47. The protective effect of O. dillenii Haw. fruits polysaccharide (ODFP) against oxidative damage in streptozotocin (STZ)-induced diabetic rats was investigated. The results showed that oral administration of ODFP significantly decreased food intake, water intake, urine production, organ weights and blood glucose level, and increased body weight in STZ-induced diabetic rats. ODFP also significantly increased the activities of SOD, GPx and CAT, and decreased malondialdehyde level in serum, liver, kidney, and pancreas in STZ-induced diabetic rats. Moreover, histopathological examination showed that ODFP could markedly improve the structure integrity of pancreatic islet tissue in STZ-induced diabetic rats. These results suggest that ODFP have hypoglycemic and antioxidant properties and can protect rats from STZ-induced oxidative damage. © 2015 Elsevier Ltd.","Antioxidant; Diabetes mellitus; Opuntia dillenii Haw. Fruit; Oxidative stress; Polysaccharide","Alarcon-Aguilar, F.J., Jimenez-Estrada, M., Reyes-Chilpa, R., Roman-Ramos, R., Hypoglycemic effect of extracts and fractions from Psacalium decompositum in healthy and alloxan-diabetic mice (2000) Journal of Ethnopharmacology, 72, pp. 21-27; Al-Amin, Z.M., Thomson, M., Al-Qattan, K.K., Peltonen-Shalaby, R., Ali, M., Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats (2006) British Journal of Nutrition, 96, pp. 660-666; Albersheim, P., Nevins, D.J., English, P.D., Karr, A., A method for the analysis of sugars in plant cell-wall polysaccharide by gas liquid chromatography (1967) Carbohydrate Research, 5, pp. 340-345; Arulselvan, P., Subramanian, S.P., Beneficial effects of Murraya koenigii leaves on antioxidant defense system and ultrastructural changes of pancreatic β-cells in experimental diabetes in rats (2007) Chemico-Biological Interactions, 165, pp. 155-164; Baynes, J.W., Role of oxidative stress in development of complications in diabetes (1991) Diabetes, 40, pp. 405-412; Beers, R.F., Sizer, I.W., A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase (1952) Journal of Biological Chemistry, 195 (1), pp. 133-140; Blumenkrantz, N., Asboe-Hansen, G., New method for quantitative determination of uronic acids (1973) Analytical Biochemistry, 54 (2), pp. 484-489; Chen, X.M., Tang, J., Xie, W.Y., Wang, J.J., Jin, J., Ren, J., Protective effect of the polysaccharide from Ophiopogon japonicus on streptozotocin-induced diabetic rats (2013) Carbohydrate Polymers, 94, pp. 378-385; Chen, H.X., Zhang, M., Xie, B.J., Components and antioxidant activity of polysaccharide conjugate from green tea (2005) Food Chemistry, 90, pp. 17-21; Dubois, M., Gilles, K.A., Hamilton, J.K., Rebers, P.A., Smith, F., Colorimetric method for determination of sugars and related substances (1956) Analytical Chemistry, 28 (3), pp. 350-356; Fu, J.F., Fu, J.F., Liu, Y., Li, R.Y., Gao, B., Zhang, N.Y., Modulatory effects of one polysaccharide from Acanthopanax senticosus in alloxan-induced diabetic mice (2012) Carbohydrate Polymers, 87, pp. 2327-2331; Gao, J., Zhang, T., Jin, Z.-Y., Xu, X.-M., Wang, J.-H., Zha, X.-Q., Structural characterisation, physicochemical properties and antioxidant activity of polysaccharide from Lilium lancifolium Thunb (2015) Food Chemistry, 169, pp. 430-438; Giacco, F., Brownlee, M., Oxidative stress and diabetic complications (2010) Circulation Research, 107 (9), pp. 1058-1070; Ishurd, O., Zgheel, F., Elghazoun, M., Elmabruk, M., Kermagi, A., Kennedy, J., A novel (1 → 4)-α-d-glucan isolated from the fruits of Opuntia ficus indica (L.) Miller (2010) Carbohydrate Polymers, 82, pp. 848-853; Jia, J., Zhang, X., Hu, Y.-S., Wu, Y., Wang, Q.-Z., Li, N.-N., Evaluation of in vivo antioxidant activities of Ganoderma lucidum polysaccharides in STZ-diabetic rats (2009) Food Chemistry, 115, pp. 32-36; Kaneto, H., Katakami, N., Kawamori, D., Miyatsuka, T., Sakamoto, K., Matsuoka, T., Involvement of oxidative stress in the pathogenesis of diabetes (2007) Antioxidants & Redox Signaling, 9, pp. 355-366; Kinalski, M., Sledziewski, A., Telejko, B., Zarzycki, W., Kinalska, I., Lipid peroxidation and scavenging enzyme activity in streptozotocin-induced diabetes (2000) Acta Diabetology, 37, pp. 179-183; Kono, Y., Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase (1978) Archives of Biochemistry and Biophysics, 186 (1), pp. 189-195; Li, X.M., Protective effect of Lycium barbarum polysaccharides on streptozotocin-induced oxidative stress in rats (2007) International Journal of Biological Macromolecules, 40, pp. 461-465; Luo, Q., Cai, Y., Yan, J., Sun, M., Corke, H., Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum (2004) Life Sciences, 76, pp. 137-149; Mao, X.Q., Yu, F., Wang, N., Wu, Y., Zou, F., Wu, K., Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism (2009) Phytomedicine, 16, pp. 416-425; Maritim, A.C., Sanders, R.A., Watkins, J.B., Diabetes, oxidative stress, and antioxidants: A review (2003) Journal of Biochemical and Molecular Toxicology, 17, pp. 24-38; Matsuhiro, B., Lillo, L.E., Saenz, C., Urzua, C.C., Zarate, O., Chemical characterization of the mucilage from fruits of Opuntia ficus indica (2006) Carbohydrate Polymers, 63, pp. 263-267; Meng, H.L., (2008) Hypoglycemic Effects and Its Mechanism of Cactus Pear in Diabetic Mice [D], , Guangxi Medical University Nanning, Guangxi, China (In Chinese); Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction (1979) Analytical Biochemistry, 95 (2), pp. 351-358; Paglia, D.E., Valentine, W.N., Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase (1967) Journal of Laboratory and Clinical Medicine, 70 (1), pp. 158-169; Rains, J.L., Jain, S.K., Oxidative stress, insulin signaling, and diabetes (2011) Free Radical Biology and Medicine, 50 (5), pp. 567-575; Roberts, C.K., Sindhu, K.K., Oxidative stress and metabolic syndrome (2009) Life Sciences, 84 (21), pp. 705-712; Robertson, R.P., Oxidative stress and impaired insulin secretion in type 2 diabetes (2006) Current Opinion in Pharmacology, 6 (6), pp. 615-619; Simmons, R.A., Developmental origins of diabetes: The role of oxidative stress (2006) Free Radical Biology and Medicine, 40 (6), pp. 917-922; Staub, A.M., Removal of proteins from polysaccharides (1965) Methods in Carbohydrate Chemistry, 5, pp. 5-7; Stevens, M.J., Redox-based mechanisms in diabetes (2005) Antioxidants & Redox Signaling, 7, pp. 1483-1485; Szkudelski, T., The mechanism of alloxan and streptozotocin action of β-cells of the rat pancreas (2001) Physiological Research, 50, pp. 537-546; Trinder, P., Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen (1969) Journal of Clinical Pathology, 22 (2), pp. 158-161; Xu, J., Wang, Y., Xu, D.-S., Ruan, K.-F., Feng, Y., Wang, S., Hypoglycemic effects of MDG-1, a polysaccharide derived from Ophiopogon japonicas, in the ob/ob mouse model of type 2 diabetes mellitus (2011) International Journal of Biological Macromolecules, 49, pp. 657-662; Xue, S.X., Chen, X.M., Lu, J.X., Jin, L.Q., Protective effect of sulfated Achyranthes bidentata polysaccharides on streptozotocin-induced oxidative stress in rats (2009) Carbohydrate Polymers, 75, pp. 415-419; Yang, N., Zhao, M., Zhu, B., Yang, B., Chen, C., Cui, C., Anti-diabetic effects of polysaccharides from Opuntia monacantha cladode in normal and streptozotocin-induced diabetic rats (2008) Innovative Food Science & Emerging Technologies, 9 (4), pp. 570-574; Zhao, L.-Y., Huang, W., Yuan, Q.-X., Cheng, J., Huang, Z.-C., Ouyang, L.-J., Hypolipidaemic effects and mechanisms of the main component of Opuntia dillenii Haw. Polysaccharides in high-fat emulsion-induced hyperlipidaemic rats (2012) Food Chemistry, 134, pp. 964-971; Zhao, L.Y., Lan, Q.J., Huang, Z.C., Ouyang, L.J., Zeng, F.H., Antidiabetic effect of a newly identified component of Opuntia dillenii polysaccharides (2011) Phytomedicine, 18 (8), pp. 661-668; Zou, S., Zhang, X., Yao, W.B., Niu, Y.G., Gao, X.D., Structure characterization and hypoglycemic activity of polysaccharide isolated from the fruits of Lycium barbarum L. (2010) Carbohydrate Polymers, 80, pp. 1161-1167",Article,Scopus,2-s2.0-84923562212
"Lahrita L., Kato E., Kawabata J.","Uncovering potential of Indonesian medicinal plants on glucose uptake enhancement and lipid suppression in 3T3-L1 adipocytes",2015,"Journal of Ethnopharmacology","168",,,"229","236",,,10.1016/j.jep.2015.03.082,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928236711&partnerID=40&md5=e209e2ccd603cb7566ca721f4aa39b4f","Laboratory of Food Biochemistry, Division of Applied Bioscience, Hokkaido UniversityKita-ku Sapporo, Japan","Lahrita, L., Laboratory of Food Biochemistry, Division of Applied Bioscience, Hokkaido UniversityKita-ku Sapporo, Japan; Kato, E., Laboratory of Food Biochemistry, Division of Applied Bioscience, Hokkaido UniversityKita-ku Sapporo, Japan; Kawabata, J., Laboratory of Food Biochemistry, Division of Applied Bioscience, Hokkaido UniversityKita-ku Sapporo, Japan","Ethnopharmacological relevance As obesity is a key factor in the development of type 2 diabetes, lowering lipid accumulation in adipose tissues is as important as increasing insulin sensitivity in diabetic patients. The selected plant extracts used in this screen have been traditionally used in Indonesian medicine for the treatment of diabetes and its complications. Aim of the study To investigate the ability of the selected plants to both increase insulin sensitivity through the enhancement of glucose uptake after insulin induction in adipocytes and suppress lipid production in the same target cells. Materials and methods Dried Indonesian medicinal plants were extracted with 50% (v/v) aq. methanol. The extracts were dissolved in 50% DMSO when tested in 3T3-L1 adipocytes. The screening platform consists of insulin-induced glucose uptake, lipid accumulation, and cell viability. Initially, an enzymatic fluorescence assay was designed to demonstrate the enhancement of 2-deoxyglucose (2-DG) uptake after insulin induction. Different concentrations of the extracts that enhanced glucose uptake were subjected to lipid accumulation assay using Oil Red O staining. Potential extracts based on lipid suppression were subsequently assessed by CCK-8 cell viability assay to distinguish lipid reduction activity from cytotoxicity. Results Out of 59 plants, 13 plants demonstrated their ability to increase glucose uptake in 3T3-L1 adipocytes after insulin induction, and 4 of these plants' extracts suppressed lipid production of the cells. The CCK-8 assay results of those 4 plant extracts suggest that the lipid inhibition activity of Eurycoma longifolia Jack (root) and Piper nigrum L. (fruits) extracts is not attributed to their cytotoxicity in the adipose cells. Both of the plant extracts increased glucose uptake by more than 200% at 50 μg/mL and suppressed lipid accumulation in a concentration-dependent manner. Conclusions Screening of selected Indonesian medicinal plants has uncovered the potentials of E. longifolia Jack (root) and P. nigrum L. (fruits) with dual active functions, increasing insulin sensitivity through the enhancement of glucose uptake and reducing lipid accumulation in adipose cells. These findings suggest that the ability of both plants to suppress lipid production would provide additional benefits in the treatment of diabetes. © 2015 Elsevier Ireland Ltd.","Diabetes Obesity; Eurycoma longifolia; Jack Piper nigrum L.; Tropicalplants","Ang, H.H., Ngai, T.H., Tan, T.H., Effects of Eurycoma longifolia Jack on sexual qualities in middle aged male rats (2003) Phytomedicine, 10, pp. 590-593; Arambewela, L.S.R., Arawwawala, L.D.A.M., Ratnasooriya, W.D., Antidiabetic activities of aqueous and ethanolic extracts of Piper betle leaves in rats (2005) J. Ethnopharmacol., 102, pp. 239-245; Atangwho, I.J., Ebonga, P.E., Eyonga, E.U., Asmawib, M.Z., Ahmad, M., Synergistic antidiabetic activity of Vernonia amygdalina and Azadirachta indica: Biochemical effects and possible mechanism (2012) J. Ethnopharmacol., 141, pp. 878-887; Chen, L., Li, Q.Y., Shi, X.J., Mao, S.L., Du, Y.L., 6-Hydroxydaidzein enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells (2013) J. Agric. Food Chem., 61, pp. 10714-10719; Choi, S., Choi, Y., Choi, Y., Kim, S., Jang, J., Park, T., Piperine reverses high fat diet-induced hepatic steatosis and insulin resistance in mice (2013) Food Chem., 141, pp. 3627-3635; Choi, S.S., Cha, B.Y., Lee, Y.S., Yonezawa, T., Teruya, T., Nagai, K., Woo, J.T., Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells (2009) Life Sci., 84, pp. 908-914; Dalimartha, S., (2000) Atlas Tumbuhan Obat Indonesia, , second ed. Trubus Agriwidya Jakarta (in Indonesian); Elfahmi, Woerdenbag, H.J., Kayser, O., Jamu: Indonesian traditional herbal medicine towards rational phytopharmacological use (2014) J. Herb. Med., 4, pp. 51-73; Erasmus, N., Solomon, M.C., Fortuin, K.A., Henkel, R.R., Effect of Eurycoma longifolia Jack (tongkat ali) extract on human spermatozoa in vitro (2012) Andrologia, 44, pp. 308-314; Febrinda, A.E., Yuliana, N.D., Ridwan, E., Wresdiyati, T., Astawan, M., Hyperglycemic control and diabetes complication preventive activities of bawang dayak (Eleutherine palmifolia L. Merr.) bulbs extracts in alloxan-diabetic rats (2014) Int. Food Res. J., 21 (4), pp. 1405-1411; Ghate, R., Patil, V.P., Hugar, S., Matha, N.H., Kalyane, N.V., Antihyperglycemic activity of Areca catechu flowers (2014) Asian Pac. J. Trop. Dis., 4 (SUPPL. 1), pp. S148-S152; Han, K.L., Ung, H.J., Ohn, H.S., Wang, J.H., Ginsenoside 20(S)-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor γ (PPARγ) in 3T3-L1 Adipocytes (2006) Biol. Pharm. Bull., 29 (1), pp. 110-113; Hariana, A., (2006) Tumbuhan Obat Dan Khasiatnya, , second ed. Penebar Swadaya Jakarta (in Indonesian); Husen, R., Pihie, A.H.L., Nallappan, M., Screening for antihyperglycaemic activity in several local herbs of Malaysia (2004) J. Ethnopharmacol., 95, pp. 205-208; Diabetes Federation, I., (2014) IDF Diabetes Atlas, , sixth edition International Diabetes Federation Brussels, Belgium 2014 update; Ieyama, T., Gunawan-Puteri, M.D., Kawabata, J., α-glucosidase inhibitors from the bulb of Eleutherine americana (2011) Food Biochem., 128, pp. 308-311; Ishiyama, M., Miyazono, Y., Sasamoto, K., Ohkura, Y., Ueno, K., A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability (1997) Talanta, 44, pp. 1299-1305; Jiwajinda, S., Santisopasri, V., Murakami, A., Kawanaka, M., Sugiyama, H., Gasquet, M., Elias, R., Ohigashi, H., In vitro anti-tumor promoting and anti-parasitic activities of the quassinoids from Eurycoma longifolia, a medicinal plant in Southeast Asia (2002) J. Ethnopharmacol., 82, pp. 55-58; Juárez-Rojop, I.E., Díaz-Zagoya, J.C., Ble-Castillo, J.L., Miranda-Osorio, P.H., Castell-Rodríguez, A.E., Tovilla-Zárate, C.A., Rodríguez-Hernández, A., Bermúdez-Ocaña, D.Y., Hypoglycemic effect of Carica papaya leaves in streptozotocin-induced diabetic rats (2012) BMC Complement. Altern. Med., 12, p. 236; Jwa, H., Choi, Y., Park, U.H., Um, S.J., Yoon, S.K., Piperine, an LXRα antagonist, protects against hepatic steatosis and improves insulin signaling in mice fed a high-fat diet (2012) Biochem. Pharmacol, 84 (11), pp. 1501-1510; Kardono, L.B., Angerhofer, C.K., Tsauri, S., Padmawinata, K., Pezzuto, J.M., Kinghorn, A.D., Cytotoxic and antimalarial constituents of the roots of Eurycoma longifolia (1991) J. Nat. Prod., 54 (5), pp. 1360-1367; Kasabri, V., Flatt, P.R., Abdel-Wahab, Y.H.A., Terminalia bellirica stimulates the secretion and action of insulin and inhibits starch digestion and protein glycation in vitro (2010) Br. J. Nutr., 103, pp. 212-217; Kato, E., Kawabata, J., Glucose uptake enhancing activity of puerarin and the role of C-glucoside suggested from activity of related compounds (2010) Bioorg. Med. Chem. Lett., 20, pp. 4333-4336; Kim, S.O., Sakchaisri, K., Asami, Y., Ryoo, I.J., Choo, S.J., Yoo, I.D., Nak-Kyun Soung, N.K., Ahn, J.S., Illudins C2 and C3 stimulate lipolysis in 3T3-L1 adipocytes and suppress adipogenesis in 3T3-L1 preadipocytes (2014) J. Nat. Prod., 77, pp. 744-750; Kuo, P.C., Damu, A.G., Lee, K.H., Wu, T.S., Cytotoxic and antimalarial constituents from the roots of Eurycoma longifolia (2004) Bioorg. Med. Chem., 12, pp. 537-544; Kuri-Harcuch, W., Green, H., Adipose conversion of 3T3 cells depends on a serum factor (1978) Proc. Natl. Acad. Sci. USA, 75 (12), pp. 6107-6109; Mayerson, A.B., Hundal, R.S., Dufour, S., Lebon, V., Befroy, D., Cline, G.W., Enocksson, S., Petersen, K.F., The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes (2002) Diabetes, 51, pp. 797-802; Noorshahida, A., Wong, T.W., Choo, C.Y., Hypoglycemic effect of quassinoids from Brucea javanica (L.) Merr (Simaroubaceae) seeds (2009) J. Ethnopharmacol., 124, pp. 586-591; Nurhanan, M.Y., Azimahtol Hawariah, L.P., Mohd Ilham, A., Mohd Shukri, M.A., Cytotoxic effects of the root extracts of Eurycoma longifolia Jack (2005) Phytother. Res., 19, pp. 994-996; Onyesife, C.O., Victor, N.O., Emeka, G.A., Hypoglycemic potentials of ethanol leaves extract of black pepper (Piper nigrum) on alloxan-induced diabetic rats (2014) Ann. Biol. Res., 5 (6), pp. 26-31; Onyesife, C.O., Victor, N.O., Emeka, G.A., Toxicological assessments of Piper nigrum on alloxan induced diabetic rats (2014) Am.-Eurasian J. Toxicol. Sci., 6 (2), pp. 30-34; Oppi-Williams, C., Suagee, J.K., Corl, B.A., Regulation of lipid synthesis by liver X receptor α and sterol regulatory element-binding protein 1 in mammary epithelial cells (2013) J. Dairy Sci., 96, pp. 112-121; Pushparaj, P., Tan, C.H., Tan, B.K.H., Effects of Averrhoa bilimbi leaf extract on blood glucose and lipids in streptozotocin-diabetic rats (2000) J. Ethnopharmacol., 72, pp. 69-76; Rajeshwari, U., Shobha, I., Andallu, B., Comparison of aniseeds and coriander seeds for antidiabetic, hypolipidemic and antioxidant activities (2011) Spatula DD, 1 (1), pp. 9-16; Richard, A.J., Burris, T.P., Sanchez-Infantes, D., Wang, Y.J., Ribnicky, D.M., Stephens, J.M., Artemisia extracts activate PPARγ, promote adipogenesis, and enhance insulin sensitivity in adipose tissue of obese mice (2014) Nutrition, 30, pp. S31-S36; Sabu, M.C., Kuttan, R., Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property (2002) J. Ethnopharmacol., 81, pp. 155-160; Safithri, M., Fahma, F., Potency of Piper crocatum decoction as an antihiperglycemia in rat strain Sprague dawley (2008) Hayati J. Biosci., 15 (1), pp. 45-48; Solomon, M.C., Erasmus, N., Henkel, R.R., In vivo effects of Eurycoma longifolia Jack (tongkat ali) extract on reproductive functions in the rat (2014) Andrologia, 46, pp. 339-348; Thorve, V.S., Kshirsagara, A.D., Vyawaharea, N.S., Joshib, V.S., Ingalea, K.G., Mohitea, R.J., Diabetes-induced erectile dysfunction: Epidemiology, pathophysiology and management (2011) J. Diabetes Complicat., 25, pp. 129-136; Tong, X.Z., Zhu, H., Shi, Y., Xu, H.T., Wang, B., Zhao, J.H., An LC/MS/MS method for simultaneous quantitation of two homoisoflavones: Protosappanin B and brazilin with hypoglycemic activity in rat plasma and its application to a comparative pharmacokinetic study in normal and streptozotocin-treated rats (2013) J. Ethnopharmacol., 148, pp. 682-690; Vijayakumar, R.S., Nalini, N., Piperine, an active principle from Piper nigrum, modulates hormonal and apo lipoprotein profiles in hyperlipidemic rats (2006) J. Basic Clin. Physiol. Pharmacol., 17 (2), pp. 71-86; Virtanen, K.A., Hallsten, K., Parkkola, R., Janatuinen, T., Lonnqvist, F., Viljanen, T., Ronnemaa, T., Nuutila, P., Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose Uptake in type 2 diabetic subjects (2003) Diabetes, 52, pp. 283-290; Wijayakusuma, H., (2006) Bebas Diabetes Mellitus Ala Hembing, , third ed. Puspa Swara Jakarta (in Indonesian); Yamamoto, N., Sato, T., Kawasaki, K., Murosaki, S., Yamamoto, Y., A nonradioisotope, enzymatic assay for 2-deoxyglucose uptake in L6 skeletal muscle cells cultured in a 96-well microplate (2006) Anal. Biochem., 351, pp. 139-145; Yang, Y., Shang, W., Zhou, L., Jiang, B., Jin, H., Chen, M., Emodin with PPARγ ligand-binding activity promotes adipocyte differentiation and increases glucose uptake in 3T3-Ll cells (2007) Biochem. Biophys. Res. Commun., 353, pp. 225-230; Yassa, H.D., Tohamy, A.F., Extract of Moringa oleifera leaves ameliorates streptozotocin-induced Diabetes mellitus in adult rats (2014) Acta Histochem., 116, pp. 844-854",Article,Scopus,2-s2.0-84928236711
"Onivogui G., Diaby M., Chen X., Zhang H., Kargbo M.R., Song Y.","Antibacterial and antifungal activities of various solvent extracts from the leaves and stem bark of Anisophyllea laurina R. Br ex Sabine used as traditional medicine in Guinea",2015,"Journal of Ethnopharmacology","168",,,"287","290",,,10.1016/j.jep.2015.03.055,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928471577&partnerID=40&md5=5acac9319d7310f10a6a5a8ee568a06e","Center of Excellence for Functional Food and Health, School of Food Science and Technology, China Jiangnan University, No. 1800 Lihu RoadWuxi Jiangsu, China; State Key Laboratory of Food Science and Technology, Jiangnan University, China","Onivogui, G., Center of Excellence for Functional Food and Health, School of Food Science and Technology, China Jiangnan University, No. 1800 Lihu RoadWuxi Jiangsu, China; Diaby, M., State Key Laboratory of Food Science and Technology, Jiangnan University, China; Chen, X., Center of Excellence for Functional Food and Health, School of Food Science and Technology, China Jiangnan University, No. 1800 Lihu RoadWuxi Jiangsu, China, State Key Laboratory of Food Science and Technology, Jiangnan University, China; Zhang, H., Center of Excellence for Functional Food and Health, School of Food Science and Technology, China Jiangnan University, No. 1800 Lihu RoadWuxi Jiangsu, China; Kargbo, M.R., State Key Laboratory of Food Science and Technology, Jiangnan University, China; Song, Y., Center of Excellence for Functional Food and Health, School of Food Science and Technology, China Jiangnan University, No. 1800 Lihu RoadWuxi Jiangsu, China, State Key Laboratory of Food Science and Technology, Jiangnan University, China","Ethnopharmacological relevance Anisophyllea laurina R. Br ex Sabine is a plant that has been used in the folk medicine to treat malaria, dysentery, diabetes and toothache against bacterial infection. Through this study, most likely we are reporting for the first time, its effectiveness as an antibacterial and antifungal agent. Aim of the study To evaluate antibacterial and antifungal activities of various solvent extracts from the leaves and stem bark of A. laurina R. Br ex Sabine. Materials and methods The various solvent extracts of leaves and stem bark were tested for antibacterial and antifungal activities against eight bacteria strains and three fungal strains using the well diffusion and micro-dilution methods. Results Antibacterial and antifungal activities of methanol and ethanol extracts were higher than the ethyl acetate and water extract. Leaves extracts had the highest potential activity against bacteria than stem bark extracts, but showed low antifungal activity compared to stem bark extracts. They also exhibited potent growth inhibitory activity against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli ATCC 8739 and Bacillus subtilis with MIC value of 125 μg/mL. Conclusions The current study confirmed that the leaves and stem bark extracts of A. laurina R. Br ex Sabine proved to be most effective as antibacterial and antifungal activities. © 2015 Elsevier Ireland Ltd.","Anisophyllea laurina R. Br ex Sabine; Antibacterial activity; Antifungal activity; Leaves; Stem bark","Duraipandiyan, V., Ignacimuthu, S., Antibacterial and antifungal activity of Cassia fistula L.: An ethnomedicinal plant (2007) J. Ethnopharmacol., 112, pp. 590-594; Duraipandiyan, V., Ignacimuthu, S., Antifungal activity of traditional medicinal plants from Tamil Nadu, India (2011) Asian Pac. J. Trop. Biomed., 1, pp. S204-S215; Fabricant, D., Farnsworth, N., The value of plants used in traditional medicine for drug discovery (2001) Environ. Health Perspect., 109, p. 69; Juncosa, A.M., A historical and taxonomic synopsis of Rhizophoraceae and Anisophylleaceae (1988) Ann. Mo. Bot. Gard., 75, pp. 1278-1295; Khan, A.V., Ahmed, Q.U., Shukla, I., Khan, A.A., Antibacterial activity of leaves extracts of Trifolium alexandrinum Linn. Against pathogenic bacteria causing tropical diseases (2012) Asian Pac. J. Trop. Biomed., 2, pp. 189-194; Lebbie, A.R., Raymond, G.P., Ethnobotanical value and conservation of sacred groves of the kpaa mende in sierra leone (1995) Econ. Bot., 49 (3), pp. 297-308; Malekinejad, H., Tukmechi, A., Ebrahimi, H., Bazargani-Gilani, B., One step forward to improve the latest method of antibacterial susceptibility testing of vitro-cultured bacteria: An implication for antibacterial efficacy of Enrofloxacine on Aeromonas hydrophila (2010) World J. Microbio. Biotech., 27, pp. 147-151; Neuwinger, H.D., (2000) African Traditional Medicine: A Dictionary of Plant Use and Applications, p. 589. , Medpharm Scientific, Stuttgart Germany; Rubilar, M., Pinelo, M., Ihl, M., Scheuermann, E., Sineiro, J., Nuñez, M., Murta leaves (Ugni molinae Turcz) as a source of antioxidant polyphenols (2006) J. Agric. Food Chem., 54 (1), pp. 59-64; Traore, M.S., Balde, M.A., Diallo, M.S., Balde, E.S., Diane, S., Camara, A., Diallo, A., Balde, A.M., Ethnobotanical survey on medicinal plants used by Guinean traditional healers in the treatment of malaria (2013) J. Ethnopharmacol., 150, pp. 1145-1153; Zhang, L.B., Simmons, M.P., Renner, S.S., A phylogeny of Anisophylleaceae based on six nuclear and plastid loci: Ancient disjunctions and recent dispersal between South America, Africa, and Asia (2007) Mol. Phylogenet. Evol., 44, pp. 1057-1067",Article,Scopus,2-s2.0-84928471577
"Schlamadinger D.E., Miranker A.D.","Fiber-dependent and -independent toxicity of islet amyloid polypeptide",2015,"Biophysical Journal","107","11",,"2559","2566",,,10.1016/j.bpj.2014.09.047,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84914125240&partnerID=40&md5=ef3111753169809fa568c3ffcdcd3dba","Department of Molecular Biophysics and Biochemistry, Yale UniversityNew Haven, CT, United States","Schlamadinger, D.E., Department of Molecular Biophysics and Biochemistry, Yale UniversityNew Haven, CT, United States; Miranker, A.D., Department of Molecular Biophysics and Biochemistry, Yale UniversityNew Haven, CT, United States","The 37-residue peptide hormone islet amyloid polypeptide (IAPP) plays a central role in diabetes pathology. Although its amyloid fiber aggregation kinetics and cytotoxicity to β-cells are well documented, few reports have directly assessed the role of fibers in cell-based toxicity experiments. Here, we report that amyloid formation of IAPP can be strongly inhibited by the extracellular environment of live cells. For example, fiber formation is more strongly suppressed in cell culture medium than in aqueous buffer. The serum component of the medium is responsible for this inhibition. Although amyloid formation was previously shown to be catalyzed by both synthetic and chloroform-extracted phospholipid surfaces, it is instead inhibited by membrane surfaces prepared directly from the plasma membranes of an immortal β-cell line. This disparity is reconciled by direct assessment of fibers in cell-culture-based toxicity experiments. We discovered that fibers are nontoxic if they are washed free of adsorbed nonfibrillar components. Moreover, toxicity is not only rescued when monomers are added back to fibers but is greater than what is observed from the precursor alone. Our results are interpreted in light of the capacity of the fiber surface to template amyloid nucleation. © 2014 Biophysical Society.",,"Höppener, J.W.M., Ahrén, B., Lips, C.J.M., Islet amyloid and type 2 diabetes mellitus (2000) N. Engl. J. Med., 343, pp. 411-419; Kahn, S.E., Andrikopoulos, S., Verchere, C.B., Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes (1999) Diabetes, 48, pp. 241-253; Matveyenko, A.V., Butler, P.C., β-Cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes (2006) Diabetes, 55, pp. 2106-2114; Potter, K.J., Abedini, A., Verchere, C.B., Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts (2010) Proc. Natl. Acad. Sci. USA, 107, pp. 4305-4310; Farese, R.V., Dimarco, P.E., Morrison, A.D., Rapid glucose-dependent increases in phosphatidic acid and phosphoinositides in rat pancreatic islets (1986) Endocrinology, 118, pp. 1498-1503; Rustenbeck, I., Matthies, A., Lenzen, S., Lipid composition of glucose-stimulated pancreatic islets and insulin-secreting tumor cells (1994) Lipids, 29, pp. 685-692; Knight, J.D., Williamson, J.A., Miranker, A.D., Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin (2008) Protein Sci., 17, pp. 1850-1856; Caillon, L., Lequin, O., Khemtémourian, L., Evaluation of membrane models and their composition for islet amyloid polypeptide-membrane aggregation (2013) Biochim. Biophys. Acta, 1828, pp. 2091-2098; Jha, S., Snell, J.M., Alexandrescu, A.T., PH dependence of amylin fibrillization (2014) Biochemistry, 53, pp. 300-310; Abedini, A., Raleigh, D.P., The role of His-18 in amyloid formation by human islet amyloid polypeptide (2005) Biochemistry, 44, pp. 16284-16291; Marek, P.J., Patsalo, V., Raleigh, D.P., Ionic strength effects on amyloid formation by amylin are a complicated interplay among Debye screening, ion selectivity, and Hofmeister effects (2012) Biochemistry, 51, pp. 8478-8490; Williamson, J.A., Loria, J.P., Miranker, A.D., Helix stabilization precedes aqueous and bilayer-catalyzed fiber formation in islet amyloid polypeptide (2009) J. Mol. Biol., 393, pp. 383-396; Apostolidou, M., Jayasinghe, S.A., Langen, R., Structure of α-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding (2008) J. Biol. Chem., 283, pp. 17205-17210; Nanga, R.P.R., Brender, J.R., Ramamoorthy, A., Structures of rat and human islet amyloid polypeptide IAPP(1-19) in micelles by NMR spectroscopy (2008) Biochemistry, 47, pp. 12689-12697; Knight, J.D., Hebda, J.A., Miranker, A.D., Conserved and cooperative assembly of membrane-bound α-helical states of islet amyloid polypeptide (2006) Biochemistry, 45, pp. 9496-9508; Last, N.B., Rhoades, E., Miranker, A.D., Islet amyloid polypeptide demonstrates a persistent capacity to disrupt membrane integrity (2011) Proc. Natl. Acad. Sci. USA, 108, pp. 9460-9465; Engel, M.F.M., Khemtémourian, L., Höppener, J.W., Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane (2008) Proc. Natl. Acad. Sci. USA, 105, pp. 6033-6038; Magzoub, M., Miranker, A.D., Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide (2012) FASEB J., 26, pp. 1228-1238; Janson, J., Ashley, R.H., Butler, P.C., The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles (1999) Diabetes, 48, pp. 491-498; Lin, C.Y., Gurlo, T., Butler, P.C., Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced β-cell apoptosis in h-IAPP transgenic mice (2007) Diabetes, 56, pp. 1324-1332; Bram, Y., Frydman-Marom, A., Gazit, E., Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies (2014) Sci. Rep., 4, p. 4267; Cao, P., Abedini, A., Raleigh, D.P., Islet amyloid polypeptide toxicity and membrane interactions (2013) Proc. Natl. Acad. Sci. USA, 110, pp. 19279-19284; Hebda, J.A., Saraogi, I., Miranker, A.D., A peptidomimetic approach to targeting pre-amyloidogenic states in type II diabetes (2009) Chem. Biol., 16, pp. 943-950; Knight, J.D., Miranker, A.D., Phospholipid catalysis of diabetic amyloid assembly (2004) J. Mol. Biol., 341, pp. 1175-1187; Sezgin, E., Kaiser, H.-J., Levental, I., Elucidating membrane structure and protein behavior using giant plasma membrane vesicles (2012) Nat. Protoc., 7, pp. 1042-1051; Elbaum-Garfinkle, S., Ramlall, T., Rhoades, E., The role of the lipid bilayer in tau aggregation (2010) Biophys. J., 98, pp. 2722-2730; Choi, S., Choi, E.Y., Oh, S.W., A rapid, simple measurement of human albumin in whole blood using a fluorescence immunoassay (I) (2004) Clin. Chim. Acta, 339, pp. 147-156; Cao, P., Meng, F., Raleigh, D.P., The ability of rodent islet amyloid polypeptide to inhibit amyloid formation by human islet amyloid polypeptide has important implications for the mechanism of amyloid formation and the design of inhibitors (2010) Biochemistry, 49, pp. 872-881; Seeliger, J., Weise, K., Winter, R., The effect of Aβ on IAPP aggregation in the presence of an isolated β-cell membrane (2012) J. Mol. Biol., 421, pp. 348-363; Cohen, S.I., Linse, S., Knowles, T.P., Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism (2013) Proc. Natl. Acad. Sci. USA, 110, pp. 9758-9763; Ruschak, A.M., Miranker, A.D., Fiber-dependent amyloid formation as catalysis of an existing reaction pathway (2007) Proc. Natl. Acad. Sci. USA, 104, pp. 12341-12346; Weise, K., Radovan, D., Winter, R., Interaction of hIAPP with model raft membranes and pancreatic β-cells: Cytotoxicity of hIAPP oligomers (2010) ChemBioChem, 11, pp. 1280-1290; O'Nuallain, B., Williams, A.D., Wetzel, R., Seeding specificity in amyloid growth induced by heterologous fibrils (2004) J. Biol. Chem., 279, pp. 17490-17499; Yan, L.-M., Velkova, A., Kapurniotu, A., IAPP mimic blocks Aβ cytotoxic self-assembly: Cross-suppression of amyloid toxicity of Aβ and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes (2007) Angew. Chem. Int. Ed. Engl., 46, pp. 1246-1252; Shen, Y., Joachimiak, A., Tang, W.-J., Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism (2006) Nature, 443, pp. 870-874; Jayasinghe, S.A., Langen, R., Lipid membranes modulate the structure of islet amyloid polypeptide (2005) Biochemistry, 44, pp. 12113-12119; Nath, A., Miranker, A.D., Rhoades, E., A membrane-bound antiparallel dimer of rat islet amyloid polypeptide (2011) Angew. Chem. Int. Ed. Engl., 50, pp. 10859-10862",Article,Scopus,2-s2.0-84914125240
"Milane L., Trivedi M., Singh A., Talekar M., Amiji M.","Mitochondrial biology, targets, and drug delivery",2015,"Journal of Controlled Release","207",,,"40","58",,,10.1016/j.jconrel.2015.03.036,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927145438&partnerID=40&md5=162652e84169d4ef04eccdd6e7f60006","Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern UniversityBoston, MA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, Nova Southeastern UniversityDavie, FL, United States","Milane, L., Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern UniversityBoston, MA, United States; Trivedi, M., Department of Pharmaceutical Sciences, School of Pharmacy, Nova Southeastern UniversityDavie, FL, United States; Singh, A., Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern UniversityBoston, MA, United States; Talekar, M., Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern UniversityBoston, MA, United States; Amiji, M., Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern UniversityBoston, MA, United States","In recent years, mitochondrial medicine has emerged as a new discipline resting at the intersection of mitochondrial biology, pathology, and pharmaceutics. The central role of mitochondria in critical cellular processes such as metabolism and apoptosis has placed mitochondria at the forefront of cell science. Advances in mitochondrial biology have revealed that these organelles continually undergo fusion and fission while functioning independently and in complex cellular networks, establishing direct membrane contacts with each other and with other organelles. Understanding the diverse cellular functions of mitochondria has contributed to understanding mitochondrial dysfunction in disease states. Polyplasmy and heteroplasmy contribute to mitochondrial phenotypes and associated dysfunction. Residing at the center of cell biology, cellular functions, and disease pathology and being laden with receptors and targets, mitochondria are beacons for pharmaceutical modification. This review presents the current state of mitochondrial medicine with a focus on mitochondrial function, dysfunction, and common disease; mitochondrial receptors, targets, and substrates; and mitochondrial drug design and drug delivery with a focus on the application of nanotechnology to mitochondrial medicine. Mitochondrial medicine is at the precipice of clinical translation; the objective of this review is to aid in the advancement of mitochondrial medicine from infancy to application. © 2015 Elsevier B.V. All rights reserved.","Drug delivery; Mitochondria; Mitochondriotropics; Nanomedicine; Nanoparticles","Siekevitz, P., (1957) Powerhouse of the Cell; Glater, E.E., Megeath, L.J., Stowers, R.S., Schwarz, T.L., Axonal transport of mitochondria requires milton to recruit kinesin heavy chain and is light chain independent (2006) J. Cell Biol., 173, pp. 545-557; Braschi, E., McBride, H.M., Mitochondria and the culture of the Borg: Understanding the integration of mitochondrial function within the reticulum, the cell, and the organism (2010) BioEssays, 32, pp. 958-966; Youle, R.J., Van Der Bliek, A.M., Mitochondrial fission, fusion, and stress (2012) Science, 337, pp. 1062-1065; Rambold, A.S., Lippincott-Schwartz, J., SevERing mitochondria (2011) Science, 334, pp. 186-187; Daniele, T., Schiaffino, M.V., Organelle biogenesis and interorganellar connections: Better in contact than in isolation (2014) Commun. Integr. Biol., 7, p. e29587; Kornmann, B., Currie, E., Collins, S.R., Schuldiner, M., Nunnari, J., Weissman, J.S., An ER-mitochondria tethering complex revealed by a synthetic biology screen (2009) Science, 325, pp. 477-481; Daniele, T., Hurbain, I., Vago, R., Casari, G., Raposo, G., Tacchetti, C., Mitochondria and melanosomes establish physical contacts modulated by Mfn2 and involved in organelle biogenesis (2014) Curr. Biol., 24, pp. 393-403; Wilkins, H.M., Carl, S.M., Swerdlow, R.H., Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies (2014) Redox Biol., 2, pp. 619-631; Johnstone, R.W., Ruefli, A.A., Lowe, S.W., Apoptosis: A link between cancer genetics and chemotherapy (2002) Cell, 108, pp. 153-164; Tafani, M., Karpinich, N.O., Serroni, A., Russo, M.A., Farber, J.L., Re-evaluation of the distinction between type i and type II cells: The necessary role of the mitochondria in both the extrinsic and intrinsic signaling pathways upon Fas receptor activation (2006) J. Cell. Physiol., 208, pp. 556-565; Gulbins, E., Dreschers, S., Bock, J., Role of mitochondria in apoptosis (2003) Exp. Physiol., 88, pp. 85-90; Wang, X., The expanding role of mitochondria in apoptosis (2001) Genes Dev., 15, pp. 2922-2933; Benn, S.C., Woolf, C.J., Adult neuron survival strategies - Slamming on the brakes (2004) Nat. Rev. Neurosci., 5, pp. 686-700; Fadeel, B., Ottosson, A., Pervaiz, S., Big wheel keeps on turning: Apoptosome regulation and its role in chemoresistance (2007) Cell Death Differ., 15, pp. 443-452; Armstrong, J.S., Mitochondria: A target for cancer therapy (2006) Br. J. Pharmacol., 147, pp. 239-248; Green, D.R., Kroemer, G., The pathophysiology of mitochondrial cell death (2004) Science, 305, pp. 626-629; Vieira, H.L., Haouzi, D., El Hamel, C., Jacotot, E., Belzacq, A.S., Brenner, C., Permeabilization of the mitochondrial inner membrane during apoptosis: Impact of the adenine nucleotide translocator (2000) Cell Death Differ., 7, pp. 1146-1154; Costantini, P., Jacotot, E., Decaudin, D., Kroemer, G., Mitochondrion as a novel target of anticancer chemotherapy (2000) J. Natl. Cancer Inst., 92, pp. 1042-1053; Eaton, S., Control of mitochondrial β-oxidation flux (2002) Prog. Lipid Res., 41, pp. 197-239; Kim, J.-J.P., Battaile, K.P., Burning fat: The structural basis of fatty acid β-oxidation (2002) Curr. Opin. Struct. Biol., 12, pp. 721-728; Kerner, J., Hoppel, C., Fatty acid import into mitochondria (2000) Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1486, pp. 1-17; Naviaux, R.K., Metabolic features of the cell danger response (2014) Mitochondrion, 16, pp. 7-17; Hanahan, D., Weinberg, R.A., Hallmarks of cancer: The next generation (2011) Cell, 144, pp. 646-674; Fulda, S., Debatin, K.-M., Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy (2006) Oncogene, 25, pp. 4798-4811; Ryan, K.M., Phillips, A.C., Vousden, K.H., Regulation and function of the p53 tumor suppressor protein (2001) Curr. Opin. Cell Biol., 13, pp. 332-337; Schneider-Jakob, S., Corazza, N., Badmann, A., Sidler, D., Stuber-Roos, R., Keogh, A., Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid (2010) Cell Death Dis., 1, p. e86; Soares, F., Tattoli, I., Rahman, M.A., Robertson, S.J., Belcheva, A., Liu, D., The mitochondrial protein NLRX1 controls the balance between extrinsic and intrinsic apoptosis (2014) J. Biol. Chem., 289, pp. 19317-19330; Verschoor, M.L., Ungard, R., Harbottle, A., Jakupciak, J.P., Parr, R.L., Singh, G., Mitochondria and cancer: Past, present, and future (2013) BioMed Res. Int., 2013, pp. 1-10; López-Lázaro, M., The Warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen? (2008) Anti Cancer Agents Med. Chem., 8, pp. 305-312; Altenberg, B., Greulich, K.O., Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes (2004) Genomics, 84, pp. 1014-1020; Hsu, P.P., Sabatini, D.M., Cancer cell metabolism: Warburg and beyond (2008) Cell, 134, pp. 703-707; Warburg, O., On respiratory impairment in cancer cells (1956) Science, 124, pp. 269-270; Young, C.D., Anderson, S.M., Sugar and fat - That's where it's at: Metabolic changes in tumors (2008) Breast Cancer Res., 10, p. 202; Pedersen, P.L., Warburg, me and hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the ""warburg Effect"", i.e., elevated glycolysis in the presence of oxygen (2007) J. Bioenerg. Biomembr., 39, pp. 211-222; Akakura, S., Ostrakhovitch, E., Sanokawa-Akakura, R., Tabibzadeh, S., Cancer cells recovering from damage exhibit mitochondrial restructuring and increased aerobic glycolysis (2014) Biochem. Biophys. Res. Commun., 448, pp. 461-466; Milane, L., Duan, Z., Amiji, M., Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells (2011) Mol. Pharm., 8, pp. 185-203; Milane, L., Ganesh, S., Shah, S., Duan, Z.-F., Amiji, M., Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology (2011) J. Control. Release, 155, pp. 237-247; Milane, L., Duan, Z., Amiji, M., Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer (2011) Nanomed. Nanotechnol. Biol. Med., 7, pp. 435-444; Milane, L., Duan, Z., Amiji, M., Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning (2011) Cancer Cell Int., 11, p. 3; Milane, L., Duan, Z., Amiji, M., Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer (2011) PLoS One, 6, p. e24075; Maldonado, E.N., Lemasters, J.J., ATP/ADP ratio, the missed connection between mitochondria and the Warburg effect (2014) Mitochondrion, 19, pp. 78-84; Newsholme, P., Gaudel, C., Krause, M., Mitochondria and diabetes. An intriguing pathogenetic role (2012) Adv. Exp. Med. Biol., 942, pp. 235-247; Sivitz, W.I., Yorek, M.A., Mitochondrial dysfunction in diabetes: From molecular mechanisms to functional significance and therapeutic opportunities (2010) Antioxid. Redox Signal., 12, pp. 537-577; Szendroedi, J., Phielix, E., Roden, M., The role of mitochondria in insulin resistance and type 2 diabetes mellitus (2012) Nat. Rev. Endocrinol., 8, pp. 92-103; Jelenik, T., Roden, M., Mitochondrial plasticity in obesity and diabetes mellitus (2013) Antioxid. Redox Signal., 19, pp. 258-268; Simpkins, J.W., Wang, J., Wang, X., Perez, E., Prokai, L., Dykens, J.A., Mitochondria play a central role in estrogen-induced neuroprotection (2005) Curr. Drug Targets CNS Neurol. Disord., 4, pp. 69-83; Esposito, L., Raber, J., Kekonius, L., Yan, F., Yu, G.-Q., Bien-Ly, N., Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice (2006) J. Neurosci. Off. J. Soc. Neurosci., 26, pp. 5167-5179; Rosales-Corral, S., Acuna-Castroviejo, D., Tan, D.X., López-Armas, G., Cruz-Ramos, J., Munoz, R., Accumulation of exogenous amyloid-beta peptide in hippocampal mitochondria causes their dysfunction: A protective role for melatonin (2012) Oxidative Med. Cell. Longev., 2012, p. 843649; Devi, L., Prabhu, B.M., Galati, D.F., Avadhani, N.G., Anandatheerthavarada, H.K., Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction (2006) J. Neurosci. Off. J. Soc. Neurosci., 26, pp. 9057-9068; Singh, P., Suman, S., Chandna, S., Das, T.K., Possible role of amyloid-beta, adenine nucleotide translocase and cyclophilin-D interaction in mitochondrial dysfunction of Alzheimer's disease (2009) Bioinformation, 3, pp. 440-445; Mandelkow, E.-M., Stamer, K., Vogel, R., Thies, E., Mandelkow, E., Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses (2003) Neurobiol. Aging, 24, pp. 1079-1085; Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H., Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome (2002) Neuron, 33, pp. 677-688; Pienaar, I.S., Chinnery, P.F., Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression (2013) Pharmacol. Ther., 137, pp. 1-21; Gosal, D., Ross, O.A., Toft, M., Parkinson's disease: The genetics of a heterogeneous disorder (2006) Eur. J. Neurol., 13, pp. 616-627; Pienaar, I.S., Elson, J.L., Racca, C., Nelson, G., Turnbull, D.M., Morris, C.M., Mitochondrial Abnormality Associates with Type-Specific Neuronal Loss and Cell Morphology Changes in the Pedunculopontine Nucleus in Parkinson Disease (2013) Am. J. Pathol., 183, pp. 1826-1840; Pilsl, A., Winklhofer, K.F., Parkin, PINK1 and mitochondrial integrity: Emerging concepts of mitochondrial dysfunction in Parkinson's disease (2012) Acta Neuropathol. (Berl.), 123, pp. 173-188; Mattson, M.P., Apoptosis in neurodegenerative disorders (2000) Nat. Rev. Mol. Cell Biol., 1, pp. 120-129; Choi, W.S., Yoon, S.Y., Oh, T.H., Choi, E.J., O'Malley, K.L., Oh, Y.J., Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP +-induced dopaminergic neuronal cell death: Role of caspases, ROS, and JNK (1999) J. Neurosci. Res., 57, pp. 86-94; Thakar, J.H., Hassan, M.N., Grimes, J.D., 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), its metabolite cyperquat (MPP +) and energy transduction in mitochondria from rat striatum and liver (1988) Prog. Neuropsychopharmacol. Biol. Psychiatry, 12, pp. 355-362; Thakar, J.H., Hassan, M.N., Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), cyperquat (MPP +) and paraquat on isolated mitochondria from rat striatum, cortex and liver (1988) Life Sci., 43, pp. 143-149; Wang, S., He, H., Chen, L., Zhang, W., Zhang, X., Chen, J., Protective effects of salidroside in the MPTP/MPP(+)-induced model of Parkinson's disease through ROS-NO-related mitochondrion pathway (2014) Mol. Neurobiol.; Saporito, M.S., Thomas, B.A., Scott, R.W., MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo (2000) J. Neurochem., 75, pp. 1200-1208; Nicklas, W.J., Youngster, S.K., Kindt, M.V., Heikkila, R.E., MPTP, MPP + and mitochondrial function (1987) Life Sci., 40, pp. 721-729; Dutta, R., McDonough, J., Yin, X., Peterson, J., Chang, A., Torres, T., Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients (2006) Ann. Neurol., 59, pp. 478-489; Weissig, V., Torchilin, V., Mitochondriotropic cationic vesicles a strategy towards mitochondrial gene therapy (2000) Curr. Pharm. Biotechnol., 1, pp. 325-346; Horobin, R.W., Trapp, S., Weissig, V., Mitochondriotropics: A review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria (2007) J. Control. Release, 121, pp. 125-136; Neuzil, J., Dong, L.-F., Rohlena, J., Truksa, J., Ralph, S.J., Classification of mitocans, anti-cancer drugs acting on mitochondria (2013) Mitochondrion, 13, pp. 199-208; Fröhlich, C., Grabiger, S., Schwefel, D., Faelber, K., Rosenbaum, E., Mears, J., Structural insights into oligomerization and mitochondrial remodelling of dynamin 1-like protein (2013) EMBO J., 32, pp. 1280-1292; Suzuki, M., Jeong, S.Y., Karbowski, M., Youle, R.J., Tjandra, N., The solution structure of human mitochondria fission protein Fis1 reveals a novel TPR-like helix bundle (2003) J. Mol. Biol., 334, pp. 445-458; Koshiba, T., Detmer, S.A., Kaiser, J.T., Chen, H., McCaffery, J.M., Chan, D.C., Structural basis of mitochondrial tethering by mitofusin complexes (2004) Science, 305, pp. 858-862; Klosowiak, J.L., Focia, P.J., Chakravarthy, S., Landahl, E.C., Freymann, D.M., Rice, S.E., Structural coupling of the EF hand and C-terminal GTPase domains in the mitochondrial protein Miro (2013) EMBO Rep., 14, pp. 968-974; Trempe, J.-F., Sauvé, V., Grenier, K., Seirafi, M., Tang, M.Y., Ménade, M., Structure of parkin reveals mechanisms for ubiquitin ligase activation (2013) Science, 340, pp. 1451-1455; Trempe, J.-F., Fon, E.A., Structure and function of Parkin, PINK1, and DJ-1, the three musketeers of neuroprotection (2013) Neurodegeneration, 4, p. 38; Jin, M.S., Oldham, M.L., Zhang, Q., Chen, J., Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans (2012) Nature, 490, pp. 566-569; Petros, A.M., Medek, A., Nettesheim, D.G., Kim, D.H., Yoon, H.S., Swift, K., Solution structure of the antiapoptotic protein bcl-2 (2001) Proc. Natl. Acad. Sci., 98, pp. 3012-3017; Hiller, S., Garces, R.G., Malia, T.J., Orekhov, V.Y., Colombini, M., Wagner, G., Solution structure of the integral human membrane protein VDAC-1 in detergent micelles (2008) Science, 321, pp. 1206-1210; Rabeh, W.M., Zhu, H., Nedyalkova, L., Tempel, W., Wasney, G., Landry, R., (2006) Crystal Structure of Human Hexokinase II, , BE Publ. (null-null); Jaremko, L., Jaremko, M., Giller, K., Becker, S., Zweckstetter, M., Structure of the mitochondrial translocator protein in complex with a diagnostic ligand (2014) Science, 343, pp. 1363-1366; Wu, Y., Sha, B., Crystal structure of yeast mitochondrial outer membrane translocon member Tom70p (2006) Nat. Struct. Mol. Biol., 13, pp. 589-593; Emamzadah, S., Tropia, L., Vincenti, I., Falquet, B., Halazonetis, T.D., Reversal of the DNA-binding-induced loop L1 conformational switch in an engineered human p53 protein (2014) J. Mol. Biol., 426, pp. 936-944; Perspicace, S., Rufer, A.C., Thoma, R., Mueller, F., Hennig, M., Ceccarelli, S., Isothermal titration calorimetry with micelles: Thermodynamics of inhibitor binding to carnitine palmitoyltransferase 2 membrane protein (2013) FEBS Open Bio, 3, pp. 204-211; Vinothkumar, K.R., Zhu, J., Hirst, J., Architecture of mammalian respiratory complex i (2014) Nature, 515, pp. 80-84; Sun, F., Huo, X., Zhai, Y., Wang, A., Xu, J., Su, D., Crystal structure of mitochondrial respiratory membrane protein complex II (2005) Cell, 121, pp. 1043-1057; Solmaz, S.R.N., Hunte, C., Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer (2008) J. Biol. Chem., 283, pp. 17542-17549; Shinzawa-Itoh, K., Aoyama, H., Muramoto, K., Terada, H., Kurauchi, T., Tadehara, Y., Structures and physiological roles of 13 integral lipids of bovine heart cytochrome c oxidase (2007) EMBO J., 26, pp. 1713-1725; Braig, K., Menz, R.I., Montgomery, M.G., Leslie, A.G., Walker, J.E., Structure of bovine mitochondrial F(1)-ATPase inhibited by Mg(2 +) ADP and aluminium fluoride (2000) Structure, 8, pp. 567-573; Bushnell, G.W., Louie, G.V., Brayer, G.D., High-resolution three-dimensional structure of horse heart cytochrome c (1990) J. Mol. Biol., 214, pp. 585-595; Berardi, M.J., Shih, W.M., Harrison, S.C., Chou, J.J., Mitochondrial uncoupling protein 2 structure determined by NMR molecular fragment searching (2011) Nature, 476, pp. 109-113; Nury, H., Dahout-Gonzalez, C., Trézéguet, V., Lauquin, G., Brandolin, G., Pebay-Peyroula, E., Structural basis for lipid-mediated interactions between mitochondrial ADP/ATP carrier monomers (2005) FEBS Lett., 579, pp. 6031-6036; Handa, N., Kishishita, S., Morita, S., Akasaka, R., Jin, Z., Chrzas, J., Structure of the human Tim44 C-terminal domain in complex with pentaethylene glycol: Ligand-bound form (2007) Acta Crystallogr. D Biol. Crystallogr., 63, pp. 1225-1234; Gertz, M., Fischer, F., Nguyen, G.T.T., Lakshminarasimhan, M., Schutkowski, M., Weyand, M., Ex-527 inhibits Sirtuins by exploiting their unique NAD +-dependent deacetylation mechanism (2013) Proc. Natl. Acad. Sci. U. S. A., 110, pp. E2772-E2781; Shiau, A.K., Barstad, D., Radek, J.T., Meyers, M.J., Nettles, K.W., Katzenellenbogen, B.S., Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism (2002) Nat. Struct. Biol., 9, pp. 359-364; Goodsell, D.S., (2012) Citric Acid Cycle, , RCSB Protein Data Bank 10.2210/rcsb-pdb/mom-2012-10; Schlatter, D., Thoma, R., Küng, E., Stihle, M., Müller, F., Borroni, E., Crystal engineering yields crystals of cyclophilin D diffracting to 1.7 A resolution (2005) Acta Crystallogr. D Biol. Crystallogr., 61, pp. 513-519; Arakawa, A., Handa, N., Shirouzu, M., Yokoyama, S., Biochemical and structural studies on the high affinity of Hsp70 for ADP (2011) Protein Sci., 20, pp. 1367-1379; Sharma, M.R., Booth, T.M., Simpson, L., Maslov, D.A., Agrawal, R.K., Structure of A Mitochondrial Ribosome with Minimal RNA, , http://www.pnas.org, (n.d., accessed December 16, 2014); http://cytochemistry.net/cell-biology/mitochondria_lifecycle.htmhttp://www.rcsb.org/pdbBloom, W., Fawcett, D.W., (1994) A Textbook of Histology, , Chapman & Hall New York; London; Xie, Q., Wondergem, R., Shen, Y., Cavey, G., Ke, J., Thompson, R., Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion (2011) Proc. Natl. Acad. Sci. U. S. A., 108, pp. 4105-4110; Lai, K.-C., Huang, A.-C., Hsu, S.-C., Kuo, C.-L., Yang, J.-S., Wu, S.-H., Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway (2010) J. Agric. Food Chem., 58, pp. 2935-2942; Homes, T.P., Mattner, F., Keller, P.A., Katsifis, A., Synthesis and in vitro binding of N, N-dialkyl-2-phenylindol-3-yl-glyoxylamides for the peripheral benzodiazepine binding sites (2006) Bioorg. Med. Chem., 14, pp. 3938-3946; Halestrap, A.P., Regulation of mitochondrial metabolism through changes in matrix volume (1994) Biochem. Soc. Trans., 22, pp. 522-529; Lacapère, J.J., Papadopoulos, V., Peripheral-type benzodiazepine receptor: Structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis (2003) Steroids, 68, pp. 569-585; Pinho, C.M., Teixeira, P.F., Glaser, E., Mitochondrial import and degradation of amyloid-β peptide (2014) Biochim. Biophys. Acta, 1837, pp. 1069-1074; Heller, A., Brockhoff, G., Goepferich, A., Targeting drugs to mitochondria (2012) Eur. J. Pharm. Biopharm., 82, pp. 1-18; Toogood, P.L., Mitochondrial drugs (2008) Curr. Opin. Chem. Biol., 12, pp. 457-463; Palmieri, F., The mitochondrial transporter family (SLC25): Physiological and pathological implications (2004) Pflugers Arch. Eur. J. Physiol., 447, pp. 689-709; Facundo, H.T.F., Fornazari, M., Kowaltowski, A.J., Tissue protection mediated by mitochondrial K + channels (2006) Biochim. Biophys. Acta, 1762, pp. 202-212; Szewczyk, A., Skalska, J., Głab, M., Kulawiak, B., Malińska, D., Koszela-Piotrowska, I., Mitochondrial potassium channels: From pharmacology to function (2006) Biochim. Biophys. Acta, 1757, pp. 715-720; Szewczyk, A., Wojtczak, L., Mitochondria as a pharmacological target (2002) Pharmacol. Rev., 54, pp. 101-127; O'Rourke, B., Evidence for mitochondrial K + channels and their role in cardioprotection (2004) Circ. Res., 94, pp. 420-432; Nübel, T., Ricquier, D., Respiration under control of uncoupling proteins: Clinical perspective (2006) Horm. Res., 65, pp. 300-310; Ishigaki, Y., Katagiri, H., Yamada, T., Ogihara, T., Imai, J., Uno, K., Dissipating excess energy stored in the liver is a potential treatment strategy for diabetes associated with obesity (2005) Diabetes, 54, pp. 322-332; Pereira, C.V., Lebiedzinska, M., Wieckowski, M.R., Oliveira, P.J., Regulation and protection of mitochondrial physiology by sirtuins (2012) Mitochondrion, 12, pp. 66-76; He, W., Newman, J.C., Wang, M.Z., Ho, L., Verdin, E., Mitochondrial sirtuins: Regulators of protein acylation and metabolism (2012) Trends Endocrinol. Metab., 23, pp. 467-476; Pedram, A., Razandi, M., Wallace, D.C., Levin, E.R., Functional estrogen receptors in the mitochondria of breast cancer cells (2006) Mol. Biol. Cell, 17, pp. 2125-2137; Kallio, A., Zheng, A., Dahllund, J., Heiskanen, K.M., Härkönen, P., Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells (2005) Apoptosis, 10, pp. 1395-1410; Stirone, C., Duckles, S.P., Krause, D.N., Procaccio, V., Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels (2005) Mol. Pharmacol., 68, pp. 959-965; Wang, X., Dykens, J.A., Perez, E., Liu, R., Yang, S., Covey, D.F., Neuroprotective effects of 17beta-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells (2006) Mol. Pharmacol., 70, pp. 395-404; Sheridan, C., Martin, S.J., Mitochondrial fission/fusion dynamics and apoptosis (2010) Mitochondrion, 10, pp. 640-648; Su, B., Wang, X., Zheng, L., Perry, G., Smith, M.A., Zhu, X., Abnormal mitochondrial dynamics and neurodegenerative diseases (2010) Biochim. Biophys. Acta, 1802, pp. 135-142; Hoppins, S., Nunnari, J., Mitochondrial dynamics and apoptosis - The ER connection (2012) Science, 337, pp. 1052-1054; Rojas-Charry, L., Cookson, M.R., Niño, A., Arboleda, H., Arboleda, G., Downregulation of Pink1 influences mitochondrial fusion-fission machinery and sensitizes to neurotoxins in dopaminergic cells (2014) NeuroToxicology, 44, pp. 140-148; Mathupala, S., Ko, Y., Pedersen, P., Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria (2006) Oncogene, 25, pp. 4777-4786; Cavaliere, V., Lombardo, T., Costantino, S.N., Kornblihtt, L., Alvarez, E.M., Blanco, G.A., Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine (2014) Eur. J. Cancer, 50, pp. 3243-3261; Belzacq, A.S., El Hamel, C., Vieira, H.L., Cohen, I., Haouzi, D., Métivier, D., Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437 (2001) Oncogene, 20, pp. 7579-7587; Papadopoulos, V., Lecanu, L., Brown, R.C., Han, Z., Yao, Z.-X., Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders (2006) Neuroscience, 138, pp. 749-756; Azarashvili, T., Krestinina, O., Yurkov, I., Evtodienko, Y., Reiser, G., High-affinity peripheral benzodiazepine receptor ligand, PK11195, regulates protein phosphorylation in rat brain mitochondria under control of Ca(2 +) (2005) J. Neurochem., 94, pp. 1054-1062; Castedo, M., Perfettini, J.-L., Kroemer, G., Mitochondrial apoptosis and the peripheral benzodiazepine receptor: A novel target for viral and pharmacological manipulation (2002) J. Exp. Med., 196, pp. 1121-1125; Kunduzova, O.R., Escourrou, G., De La Farge, F., Salvayre, R., Séguélas, M.-H., Leducq, N., Involvement of peripheral benzodiazepine receptor in the oxidative stress, death-signaling pathways, and renal injury induced by ischemia-reperfusion (2004) J. Am. Soc. Nephrol., 15, pp. 2152-2160; Solazzo, M., Fantappiè, O., Lasagna, N., Sassoli, C., Nosi, D., Mazzanti, R., P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines (2006) Exp. Cell Res., 312, pp. 4070-4078; Wickramasekera, N.T., Das, G.M., Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication (2014) Mitochondrion, 16, pp. 26-37; Marchenko, N.D., Zaika, A., Moll, U.M., Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling (2000) J. Biol. Chem., 275, pp. 16202-16212; De, S., Kumari, J., Mudgal, R., Modi, P., Gupta, S., Futami, K., RECQL4 is essential for the transport of p53 to mitochondria in normal human cells in the absence of exogenous stress (2012) J. Cell Sci., 125, pp. 2509-2522; Yousif, L.F., Stewart, K.M., Horton, K.L., Kelley, S.O., Mitochondria-penetrating peptides: Sequence effects and model cargo transport (2009) Chembiochem, 10, pp. 2081-2088; Van Vlerken, L.E., Duan, Z., Little, S.R., Seiden, M.V., Amiji, M.M., Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems (2010) AAPS J., 12, pp. 171-180; Van Vlerken, L.E., Duan, Z., Little, S.R., Seiden, M.V., Amiji, M.M., Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model (2008) Mol. Pharm., 5, pp. 516-526; Desai, A., Vyas, T., Amiji, M., Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations (2008) J. Pharm. Sci., 97, pp. 2745-2756; Deshpande, D., Janero, D.R., Amiji, M., Engineering of an ω-3 polyunsaturated fatty acid-containing nanoemulsion system for combination C6-ceramide and 17β-estradiol delivery and bioactivity in human vascular endothelial and smooth muscle cells (2013) Nanomed. Nanotechnol. Biol. Med., 9, pp. 885-894; Deshpande, D., Devalapally, H., Amiji, M., Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles (2008) Pharm. Res., 25, pp. 1936-1947; Devalapally, H., Duan, Z., Seiden, M.V., Amiji, M.M., Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles (2008) Clin. Cancer Res., 14, pp. 3193-3203; Van Vlerken, L.E., Duan, Z., Seiden, M.V., Amiji, M.M., Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer (2007) Cancer Res., 67, pp. 4843-4850; Devalapally, H., Duan, Z., Seiden, M.V., Amiji, M.M., Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer (2007) Int. J. Cancer, 121, pp. 1830-1838; Anders, M.W., Exploiting endobiotic metabolic pathways to target xenobiotic antioxidants to mitochondria (2013) Mitochondrion, 13, pp. 454-463; Jabůrek, M., Yarov-Yarovoy, V., Paucek, P., Garlid, K.D., State-dependent inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate (1998) J. Biol. Chem., 273, pp. 13578-13582; Busija, D.W., Lacza, Z., Rajapakse, N., Shimizu, K., Kis, B., Bari, F., Targeting mitochondrial ATP-sensitive potassium channels - A novel approach to neuroprotection (2004) Brain Res. Brain Res. Rev., 46, pp. 282-294; Kopustinskiene, D.M., Toleikis, A., Saris, N.-E.L., Adenine nucleotide translocase mediates the K(ATP)-channel-openers-induced proton and potassium flux to the mitochondrial matrix (2003) J. Bioenerg. Biomembr., 35, pp. 141-148; Pirinen, E., Lo Sasso, G., Auwerx, J., Mitochondrial sirtuins and metabolic homeostasis (2012) Best Pract. Res. Clin. Endocrinol. Metab., 26, pp. 759-770; Zhong, L., Mostoslavsky, R., Fine tuning our cellular factories: Sirtuins in mitochondrial biology (2011) Cell Metab., 13, pp. 621-626; Psarra, A.-M.G., Solakidi, S., Sekeris, C.E., The mitochondrion as a primary site of action of steroid and thyroid hormones: Presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells (2006) Mol. Cell. Endocrinol., 246, pp. 21-33; Solakidi, S., Psarra, A.-M.G., Nikolaropoulos, S., Sekeris, C.E., Estrogen receptors alpha and beta (ERalpha and ERbeta) and androgen receptor (AR) in human sperm: Localization of ERbeta and AR in mitochondria of the midpiece (2005) Hum. Reprod., 20, pp. 3481-3487; Solakidi, S., Psarra, A.-M.G., Sekeris, C.E., Differential subcellular distribution of estrogen receptor isoforms: Localization of ERalpha in the nucleoli and ERbeta in the mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2 cell lines (2005) Biochim. Biophys. Acta, 1745, pp. 382-392; Yang, S.-H., Liu, R., Perez, E.J., Wen, Y., Stevens, S.M., Valencia, T., Mitochondrial localization of estrogen receptor beta (2004) Proc. Natl. Acad. Sci. U. S. A., 101, pp. 4130-4135; Li, Y., Johnson, N., Capano, M., Edwards, M., Crompton, M., Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis (2004) Biochem. J., 383, pp. 101-109; Zhao, K., Zhao, G.-M., Wu, D., Soong, Y., Birk, A.V., Schiller, P.W., Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury (2004) J. Biol. Chem., 279, pp. 34682-34690; Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., Kanthasamy, A.G., Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes (2014) Biochim. Biophys. Acta, 1842, pp. 1282-1294; Hoye, A.T., Davoren, J.E., Wipf, P., Fink, M.P., Kagan, V.E., Targeting mitochondria (2008) Acc. Chem. Res., 41, pp. 87-97; Chamberlain, G.R., Tulumello, D.V., Kelley, S.O., Targeted delivery of doxorubicin to mitochondria (2013) ACS Chem. Biol., 8, pp. 1389-1395; Jean, S.R., Pereira, M.P., Kelley, S.O., Structural modifications of mitochondria-targeted chlorambucil alter cell death mechanism but preserve MDR evasion (2014) Mol. Pharm., 11, pp. 2675-2682; Seibel, P., Trappe, J., Villani, G., Klopstock, T., Papa, S., Reichmann, H., Transfection of mitochondria: Strategy towards a gene therapy of mitochondrial DNA diseases (1995) Nucleic Acids Res., 23, pp. 10-17; Murphy, M.P., Targeting lipophilic cations to mitochondria (2008) Biochim. Biophys. Acta, 1777, pp. 1028-1031; Boddapati, S.V., D'Souza, G.G.M., Erdogan, S., Torchilin, V.P., Weissig, V., Organelle-targeted nanocarriers: Specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo (2008) Nano Lett., 8, pp. 2559-2563; Biswas, S., Dodwadkar, N.S., Sawant, R.R., Koshkaryev, A., Torchilin, V.P., Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting (2011) J. Drug Target., 19, pp. 552-561; Weissig, V., Lizano, C., Torchilin, V.P., Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes (2000) Drug Deliv., 7, pp. 1-5; Paunesku, T., Rajh, T., Wiederrecht, G., Maser, J., Vogt, S., Stojićević, N., Biology of TiO2-oligonucleotide nanocomposites (2003) Nat. Mater., 2, pp. 343-346; Suzuki, H., Toyooka, T., Ibuki, Y., Simple and easy method to evaluate uptake potential of nanoparticles in mammalian cells using a flow cytometric light scatter analysis (2007) Environ. Sci. Technol., 41, pp. 3018-3024; Yoong, S.L., Wong, B.S., Zhou, Q.L., Chin, C.F., Li, J., Venkatesan, T., Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin (2014) Biomaterials, 35, pp. 748-759; Marrache, S., Dhar, S., Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics (2012) Proc. Natl. Acad. Sci. U. S. A., 109, pp. 16288-16293; Salnikov, V., Lukyánenko, Y.O., Frederick, C.A., Lederer, W.J., Lukyánenko, V., Probing the outer mitochondrial membrane in cardiac mitochondria with nanoparticles (2007) Biophys. J., 92, pp. 1058-1071; Boddapati, S.V., D'Souza, G.G.M., Weissig, V., Liposomes for drug delivery to mitochondria (2010) Methods Mol. Biol., 605, pp. 295-303; Boddapati, S.V., Tongcharoensirikul, P., Hanson, R.N., D'Souza, G.G.M., Torchilin, V.P., Weissig, V., Mitochondriotropic liposomes (2005) J. Liposome Res., 15, pp. 49-58; Malhi, S.S., Budhiraja, A., Arora, S., Chaudhari, K.R., Nepali, K., Kumar, R., Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes (2012) Int. J. Pharm., 432, pp. 63-74; Yasuzaki, Y., Yamada, Y., Harashima, H., Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes (2010) Biochem. Biophys. Res. Commun., 397, pp. 181-186; Yamada, Y., Harashima, H., Targeting the mitochondrial genome via a dual function MITO-Porter: Evaluation of mtDNA levels and mitochondrial function (2015) Methods Mol. Biol., 1265, pp. 123-133; Yamada, Y., Furukawa, R., Yasuzaki, Y., Harashima, H., Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery (2011) Mol. Ther., 19, pp. 1449-1456; Kawamura, E., Yamada, Y., Harashima, H., Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter (2013) Mitochondrion, 13, pp. 610-614; Yamada, Y., Harashima, H., A method for screening mitochondrial fusogenic envelopes for use in mitochondrial drug delivery (2014) Methods Mol. Biol., 1141, pp. 57-66; Luo, G.-F., Chen, W.-H., Liu, Y., Lei, Q., Zhuo, R.-X., Zhang, X.-Z., Multifunctional enveloped mesoporous silica nanoparticles for subcellular co-delivery of drug and therapeutic peptide (2014) Sci. Rep., 4, p. 6064; Yu, Y., Wang, Z.-H., Zhang, L., Yao, H.-J., Zhang, Y., Li, R.-J., Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma (2012) Biomaterials, 33, pp. 1808-1820",Review,Scopus,2-s2.0-84927145438
"Wang J., Cao H., Wang H., Yin G., Du J., Xia F., Lu J., Xiang M.","Multiple mechanisms involved in diabetes protection by lipopolysaccharide in non-obese diabetic mice",2015,"Toxicology and Applied Pharmacology","285","3",,"149","158",,,10.1016/j.taap.2015.04.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928815160&partnerID=40&md5=ca541833498c07d1d0585b0710d7f679","Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Department of Pharmacology, College of Medicine, Wuhan University of Science and TechnologyWuhan, China; Section of Neurobiology, Torrey Pines Institute for Molecular StudiesPort Saint Lucie, FL, United States","Wang, J., Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China, Department of Pharmacology, College of Medicine, Wuhan University of Science and TechnologyWuhan, China; Cao, H., Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Wang, H., Section of Neurobiology, Torrey Pines Institute for Molecular StudiesPort Saint Lucie, FL, United States; Yin, G., Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Du, J., Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Xia, F., Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Lu, J., Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Xiang, M., Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China","Toll-like receptor 4 (TLR4) activation has been proposed to be important for islet cell inflammation and eventually β cell loss in the course of type 1 diabetes (T1D) development. However, according to the ""hygiene hypothesis"", bacterial endotoxin lipopolysaccharide (LPS), an agonist on TLR4, inhibits T1D progression. Here we investigated possible mechanisms for the protective effect of LPS on T1D development in non-obese diabetic (NOD) mice. We found that LPS administration to NOD mice during the prediabetic state neither prevented nor reversed insulitis, but delayed the onset and decreased the incidence of diabetes, and that a multiple-injection protocol is more effective than a single LPS intervention. Further, LPS administration suppressed spleen T lymphocyte proliferation, increased the generation of CD4+CD25+Foxp3+ regulatory T cells (Tregs), reduced the synthesis of strong Th1 proinflammatory cytokines, and downregulated TLR4 and its downstream MyD88-dependent signaling pathway. Most importantly, multiple injections of LPS induced a potential tolerogenic dendritic cell (DC) subset with low TLR4 expression without influencing the DC phenotype. Explanting DCs from repeated LPS-treated NOD mice into NOD/SCID diabetic mice conferred sustained protective effects against the progression of diabetes in the recipients. Overall, these results suggest that multiple mechanisms are involved in the protective effects of LPS against the development of diabetes in NOD diabetic mice. These include Treg induction, down-regulation of TLR4 and its downstream MyD88-dependent signaling pathway, and the emergence of a potential tolerogenic DC subset. © 2015 Elsevier Inc.","Dendritic cells; Non-obese diabetic mice; Regulatory T cells; Toll-like receptor 4; Type 1 diabetes","Ardeshna, K.M., Pizzey, A.R., Devereaux, S., Khwaja, A., The PI3 kinase, p38 SAP kinase, and NF-kappa B signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells (2000) Blood, 96, pp. 1039-1046; Aumeunier, A., Grela, F., Ramadan, A., Van, L.P., Bardel, E., Alcala, A.G., Jeannin, P., Thieblemont, N., Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice (2010) PLoS One, 5; Balasa, B., Van Gunst, K., Sarvetnick, N., The microbial product lipopolysaccharide confers diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: implications for the etiology of autoimmune diabetes (2000) Clin. Immunol., 95, pp. 93-98; Baumann, B., Salem, H.H., Boehm, B.O., Anti-inflammatory therapy in type 1 diabetes (2012) Curr. Diab. Rep., 12, pp. 499-509; Bell, C.M., Guo, K., Wendel, H.P., Endotoxin removal from albumin and saline solutions (2007) Int. J. Artif. Organs, 30, pp. 589-593; Beutler, B., Tlr4: central component of the sole mammalian LPS sensor (2000) Curr. Opin. Immunol., 12, pp. 20-26; Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S., Kazzaz, Z., Douek, D.C., Microbial translocation is a cause of systemic immune activation in chronic HIV infection (2006) Nat. Med., 12, pp. 1365-1371; Caramalho, I., Rodrigues-Duarte, L., Perez, A., Zelenay, S., Penha-Goncalves, C., Demengeot, J., Regulatory T cells contribute to diabetes protection in lipopolysaccharide-treated non-obese diabetic mice (2011) Scand. J. Immunol., 74, pp. 585-595; Chung, C.Y., Ysebaert, D., Berneman, Z.N., Cools, N., Dendritic cells: cellular mediators for immunological tolerance (2013) Clin. Dev. Immunol., 2013, p. 972865; Clanchy, F.I.L., Sacre, S.M., Modulation of toll-like receptor function has therapeutic potential in autoimmune disease (2010) Expert. Opin. Biol. Ther., 10, pp. 1703-1716; Csorba, T.R., Lyon, A.W., Hollenberg, M.D., Autoimmunity and the pathogenesis of type 1 diabetes (2010) Crit. Rev. Clin. Lab. Sci., 47, pp. 51-71; Devaraj, S., Dasu, M.R., Rockwood, J., Winter, W., Griffen, S.C., Jialal, I., Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state (2008) J. Clin. Endocrinol. Metab., 93, pp. 578-583; Devaraj, S., Dasu, M.R., Park, S.H., Jialal, I., Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes (2009) Diabetologia, 52, pp. 1665-1668; Devaraj, S., Jialal, I., Yun, J.M., Bremer, A., Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications (2011) Metab. Clin. Exp., 60, pp. 256-259; Devaraj, S., Tobias, P., Jialal, I., Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes (2011) Cytokine, 55, pp. 441-445; Dobrovolskaia, M.A., Medvedev, A.E., Thomas, K.E., Cuesta, N., Toshchakov, V., Ren, T., Cody, M.J., Vogel, S.N., Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR ""homotolerance"" versus ""heterotolerance"" on NF-B signaling pathway components (2003) J. Immunol., 170, pp. 508-519; Ehlers, M.R., Nepom, G.T., Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience (2012) Rev. Diabet. Stud., 9, pp. 359-371; Eizirik, D.L., Colli, M.L., Ortis, F., The role of inflammation in insulitis and beta-cell loss in type 1 diabetes (2009) Nat. Rev. Endocrinol., 5, pp. 219-226; Fischer, E.S., Bohm, K., Lydeard, J.R., Yang, H.D., Stadler, M.B., Cavadini, S., Nagel, J., Thoma, N.H., Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide (2014) Nature, 512, pp. 49-53; Garay-Malpartida, H.M., Mourao, R.F., Mantovani, M., Santos, I.A., Sogayar, M.C., Goldberg, A.C., Toll-like receptor 4 (TLR4) expression in human and murine pancreatic beta-cells affects cell viability and insulin homeostasis (2011) BMC Immunol., 12, p. 18; Giannoukakis, N., Tolerogenic dendritic cells for type 1 diabetes (2013) Immunotherapy, 5, pp. 569-571; Giannoukakis, N., Phillips, B., Finegold, D., Harnaha, J., Trucco, M., Phase 1 (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients (2011) Diabetes Care, 34, pp. 2026-2032; Hong, S., Li, H., Qian, J., Yang, J., Lu, Y., Yi, Q., Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity (2012) Clin. Exp. Immunol., 170, pp. 167-177; Hubert, P., Jacobs, N., Caberg, J.H., Boniver, J., Delvenne, P., The cross-talk between dendritic and regulatory T cells: good or evil? (2007) J. Leukoc. Biol., 82, pp. 781-794; In't Veld, P., Insulitis in human type 1 diabetes: the quest for an elusive lesion (2011) Islets, 3, pp. 131-138; In't Veld, P., Insulitis in human type 1 diabetes: a comparison between patients and animal models (2014) Semin. Immunopathol., 36, pp. 569-579; Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors (2010) Nat. Immunol., 11, pp. 373-384; Kondrashova, A., Hyoty, H., Role of viruses and other microbes in the pathogenesis of type 1 diabetes (2014) Int. Rev. Immunol., 33, pp. 284-295; Li, M., Song, L., Gao, X., Chang, W., Qin, X., Toll-like receptor 4 on islet beta cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes (2012) Exp. Mol. Med., 44, pp. 260-267; Lucas, K., Maes, M., Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway (2013) Mol. Neurobiol., 48, pp. 190-204; Mohammad, M.K., Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse (2006) Int. Immunol., 18, pp. 1101-1113; Morel, P.A., Dendritic cell subsets in type 1 diabetes: friend or foe? (2013) Front. Immunol., 4, p. 415; Pasquali, L., Giannoukakis, N., Trucco, M., Induction of immune tolerance to facilitate beta cell regeneration in type 1 diabetes (2008) Adv. Drug Deliv. Rev., 60, pp. 106-113; Sousa, C.R., Essay - dendritic cells in a mature age (2006) Nat. Rev. Immunol., 6, pp. 476-483; Tan, J.K., O'Neill, H.C., Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity (2005) J. Leukoc. Biol., 78, pp. 319-324; Verdijk, R.M., Mutis, T., Esendam, B., Kamp, J., Melief, C.J.M., Brand, A., Goulmy, E., Polyriboinosinic polyribocytidylic acid (poly(I: C)) induces stable maturation of functionally active human dendritic cells (1999) J. Immunol., 163, pp. 57-61; Vives-Pi, M., Somoza, N., Fernandez-Alvarez, J., Vargas, F., Caro, P., Alba, A., Gomis, R., Pujol-Borrell, R., Evidence of expression of endotoxin receptors CD14, Toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells (2003) Clin. Exp. Immunol., 133, pp. 208-218; Wang, X., Zhang, A.X., Liu, Y., Chen, S., Feng, Z.Q., Shang, W.B., Maziarz, M., Hampe, C.S., Anti-idiotypic antibody specific to GAD65 autoantibody prevents type 1 diabetes in the NOD mouse (2012) PLoS One, 7, p. e32515; Wang, J., Lu, J., Lan, Y., Zhou, H., Li, W., Xiang, M., Total coumarins from Urtica dentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways (2013) J. Ethnopharmacol., 146, pp. 379-392; Watanabe, S., Kumazawa, Y., Inoue, J., Liposomal lipopolysaccharide initiates TRIF-dependent signaling pathway independent of CD14 (2013) PLoS One, 8, p. e60078; Xiang, M., Hou, W.R., Xie, S.N., Zhang, W.D., Wang, X., Immunosuppressive effects of an ethyl acetate extract from Urtica dentata Hand on skin allograft rejection (2009) J. Ethnopharmacol., 126, pp. 57-63; Xue, M., Dervish, S., Harrison, L.C., Fulcher, G., Jackson, C.J., Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) mice (2012) J. Biol. Chem., 287, pp. 16356-16364; Zoka, A., Muzes, G., Somogyi, A., Varga, T., Szeman, B., Al-Aissa, Z., Hadarits, O., Firneisz, G., Altered immune regulation in type 1 diabetes (2013) Clin. Dev. Immunol., 2013, p. 254874",Article,Scopus,2-s2.0-84928815160
"Chang K.-W., Li J., Yang C.-H., Shiesh S.-C., Lee G.-B.","An integrated microfluidic system for measurement of glycated hemoglobin Levels by using an aptamer-antibody assay on magnetic beads",2015,"Biosensors and Bioelectronics","68",,,"397","403",,,10.1016/j.bios.2015.01.027,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921459521&partnerID=40&md5=73cabed4674710a82ea14495f78aaeaf","Department of Power Mechanical Engineering, National Tsing Hua UniversityHsinchu, Taiwan; Institute of Biomedical Engineering, National Tsing Hua UniversityHsinchu, Taiwan; Institute of NanoEngineering and Microsystems, National Tsing Hua UniversityHsinchu, Taiwan; Department of Medical Laboratory Science and Biotechnology, National Cheng Kung UniversityTainan, Taiwan","Chang, K.-W., Department of Power Mechanical Engineering, National Tsing Hua UniversityHsinchu, Taiwan; Li, J., Department of Power Mechanical Engineering, National Tsing Hua UniversityHsinchu, Taiwan; Yang, C.-H., Department of Medical Laboratory Science and Biotechnology, National Cheng Kung UniversityTainan, Taiwan; Shiesh, S.-C., Department of Medical Laboratory Science and Biotechnology, National Cheng Kung UniversityTainan, Taiwan; Lee, G.-B., Department of Power Mechanical Engineering, National Tsing Hua UniversityHsinchu, Taiwan, Institute of Biomedical Engineering, National Tsing Hua UniversityHsinchu, Taiwan, Institute of NanoEngineering and Microsystems, National Tsing Hua UniversityHsinchu, Taiwan","Blood glycated hemoglobin (HbA1c), reflecting the average blood glucose level in the proceeding 2-3 months, is recommended for screening/diagnosing and patient management of diabetes. However, accurate measurement of the HbA1c level at the point of care is hampered by costly, large-scale instruments (such as high-performance liquid chromatography) or reagent instability of classical immunologic methods, which involve antibody-based immunoturbidimetry. In this work, an integrated microfluidic system using aptamer-based testing to measure HbA1c in blood samples is therefore presented. This measuring system used nucleic-acid aptamers that exhibited high sensitivity and high specificity for hemoglobin and HbA1c to perform a stable and robust testing. The compact microfluidic system consumed less samples and reagents and significantly shortened the detection time. Combining the advantages of microfluidics and aptamers, this integrated microsystem presents a promising tool for accurate and point-of-case HbA1c detection. To demonstrate its clinical utility, whole blood samples with clinically-relevant concentrations of HbA1c and Hb were automatically measured on the integrated microfluidic system. Experimental data showed that the developed aptamer-based microfluidic system is capable of detecting HbA1c and Hb with a good linear response. The entire process was completed within 25. min. The aptamer-antibody on-chip sandwich immunoassay may be further refined to allow diabetes screening and diagnosis at lower cost and earlier phase to minimize the risk of diabetic complications. © 2015 Elsevier B.V.","Aptamer; Diabetes mellitus; HbA1c; MEMS; Microfluidic","(1993) N. Engl. J. Med., 329 (14), pp. 977-986; Ahn, C.H., Choi, J.W., Beaucage, G., Nevin, J.H., Lee, J.B., Puntambekar, A., Lee, J.Y., (2004) Proc. IEEE, 92 (1), pp. 154-173; Al-Ghamdi, A.A., (2004) Saudi Med. J., 25 (3), pp. 342-345; Bigdeli, M.G., Ebrahimi, S., Darabi, M., Sanei, S., (2008) Clin. Chem., 54 (6), p. A105; Chien, L.J., Wang, J.H., Hsieh, T.M., Chen, P.H., Chen, P.J., Lee, D.S., Luo, C.H., Lee, G.B., (2009) Biomed. Microdevices, 11 (2), pp. 359-367; Farmer, A., (2012) Br. Med. J., 345, p. e7293; Folch, A., Ayon, A., Hurtado, O., Schmidt, M.A., Toner, M., (1999) J. Biomech. Eng.-Trans. ASME, 121 (1), pp. 28-34; Goodall, I., (2005) Clin. Biochem. Rev., 26 (1), pp. 5-19; Hua, M., Tao, M.L., Wang, P., Zhang, Y.F., Wu, Z.S., Chang, Y.B., Yang, Y.H., (2010) Anal. Sci., 26 (12), pp. 1265-1270; Huang, C.J., Chien, H.C., Chou, T.C., Lee, G.B., (2011) Microfluidics Nanofluidics, 10 (1), pp. 37-45; Huang, C.W., Huang, S.B., Lee, G.B., (2008) J. Micromech. Microeng., 18, p. 3; Huang, Y., Mather, E.L., Bell, J.L., Madou, M., (2002) Anal. Bioanal. Chem., 372 (1), pp. 49-65; Kilpatrick, E.S., (2008) J. Clin. Pathol., 61 (9), pp. 977-982; Kobold, U., (2005) FEBS J., 272, pp. 490-491; Lee, W.B., Chen, Y.H., Lin, H.I., Shiesh, S.C., Lee, G.B., (2011) Sens. Actuators B-Chem., 157 (2), pp. 710-721; Li, M., Zhou, X.J., Ding, W.Q., Guo, S.W., Wu, N.Q., (2013) Biosens. Bioelectron., 41, pp. 889-893; Liu, G., Khor, S.M., Iyengar, S.G., Gooding, J.J., (2012) Analyst, 137 (4), pp. 829-832; Molitch, M.E., Steffes, M.W., Cleary, P.A., Nathan, D.M., (1993) Kidney Int., 43 (3), pp. 668-674; Nisar, A., AftuIpurkar, N., Mahaisavariya, B., Tuantranont, A., (2008) Sens. Actuators B-Chem., 130 (2), pp. 917-942; Reaver, N.G.F., Zheng, R., Kim, D.S., Cameron, B.D., (2013) Plasmon. Biol. Med., 10, p. 8597; Rogers, L.C., Frykberg, R.G., Armstrong, D.G., Boulton, A.J., Edmonds, M., Van, G.H., Hartemann, A., Uccioli, L., (2011) Diabetes Care, 34 (9), pp. 2123-2129; Roubicek, M., Vines, G., Gonzalez Sanguineti, A., (1998) Diabetes Care, 21 (9), pp. 1578-1579. , (1577-1578; author reply); Spitz, A.F., Kanani, H., (2006) Diabetes Care, 29 (5), pp. 1184-1185. , (1183-1184, discussion); Swensen, J.S., Xiao, Y., Ferguson, B.S., Lubin, A.A., Lai, R.Y., Heeger, A.J., Plaxco, K.W., Soh, H.T., (2009) J. Am. Chem. Soc., 131 (12), pp. 4262-4266; Tanaka, T., Tsukube, S., Izawa, K., Okochi, M., Lim, T.K., Watanabe, S., Harada, M., Matsunaga, T., (2007) Biosens. Bioelectron., 22 (9-10), pp. 2051-2056; Tankova, T., Chakarova, N., Dakovska, L., Atanassova, I., (2012) Acta Diabetol, 49 (5), pp. 371-378; Weng, C.H., Lien, K.Y., Yang, S.Y., Lee, G.B., (2011) Microfluidics Nanofluidics, 10 (2), pp. 301-310; Wu, H.W., Hsu, R.C., Lin, C.C., Hwang, S.M., Lee, G.B., (2010) Biomicrofluidics, 4 (2), p. 024112; Xiang, Y., Tong, A.J., Lu, Y., (2009) J. Am. Chem. Soc., 131 (42), pp. 15352-15357; Yoo, J.C., La, G.S., Kang, C.J., Kim, Y.S., (2008) Curr. Appl. Phys., 8 (6), pp. 692-695; Wu, C.C., Lin, H.I., Chang, K.W., Mai, D.J., Shiesh, S.C., Lee, G.B., (2015) Microfluidics Nanofluidics; Wu, C.C., Lin, H.I., Weng, C.H., Shiesh, S.C., Lee, G.B., (2012) Proceedings of MicroTAS, pp. 353-355. , Okinawa, Japan",Article,Scopus,2-s2.0-84921459521
"Ucel U.I., Can O.D., Demir Ozkay U., Ozturk Y.","Antihyperalgesic and antiallodynic effects of mianserin on diabetic neuropathic pain: A study on mechanism of action",2015,"European Journal of Pharmacology","756",,,"92","106",,,10.1016/j.ejphar.2015.02.048,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926182224&partnerID=40&md5=c7e52b633ed7ef320381c98e740996bc","Anadolu University, Faculty of Pharmacy, Department of PharmacologyEskişehir, Turkey","Üçel, U.I., Anadolu University, Faculty of Pharmacy, Department of PharmacologyEskişehir, Turkey; Can, Ö.D., Anadolu University, Faculty of Pharmacy, Department of PharmacologyEskişehir, Turkey; Demir Özkay, Ü., Anadolu University, Faculty of Pharmacy, Department of PharmacologyEskişehir, Turkey; Öztürk, Y., Anadolu University, Faculty of Pharmacy, Department of PharmacologyEskişehir, Turkey","This study used various experimental pain methods to investigate the effects of subacute mianserin administration on diabetes-induced neuropathic pain in rats. The effect of mianserin on hyperalgesia occurring in connection with peripheral diabetic neuropathy was examined using the Randall-Selitto (mechanical nociceptive stimulus), Hargreaves (thermal nociceptive stimulus), and cold-plate (4 °C, thermal nociceptive stimulus) tests. The dynamic plantar aesthesiometer, which measures the threshold values for mechanical stimuli, was used for allodynia studies. Thermal allodynia was evaluated with the warm-plate (38 °C) test. At 30 and 45 mg/kg, mianserin effectively improved mechanical and thermal hyperalgesia occurring in connection with diabetic neuropathy. Subacute administration of mianserin also reduced diabetes-associated mechanical and thermal allodynia. The ability of mianserin to reduce diabetic neuropathic pain was comparable to that of pregabalin (10 mg/kg). The antihyperalgesic and antiallodynic effects of mianserin were reversed with α-methyl-para-tyrosine methyl ester (AMPT, an inhibitor of catecholamine synthesis), phentolamine (a non-selective α-adrenoceptor antagonist), propranolol (a non-selective β-adrenoceptor antagonist), and naloxone (a non-selective opioid receptor antagonist) administrations. The same effects were not reversed, however, by para-chlorophenylalanine methyl ester (PCPA; an inhibitor of serotonin synthesis). These results suggest that the beneficial effect of mianserin on diabetic neuropathic pain is mediated through an increase in catecholamine levels in the synaptic cleft as well as through interactions with both subtypes of adrenoceptors and opioid receptors. Considering that mianserin exhibits simultaneous antidepressant and antinociceptive effects, this drug could provide a good alternative for treating the pain associated with diabetic neuropathy and the mood disorders caused directly by diabetes. © 2015 Elsevier B.V.",,"Aslam, A., Singh, J., Rajbhandari, S., Pathogenesis of painful diabetic neuropathy (2014) Pain Res. Treat., 2014, p. 412041; Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T.S., Nurmikko, T., EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision (2010) Eur. J. Neurol., 17, pp. 1113-e88. , Federation Of Neurological Societies E; Banafshe, H.R., Hamidi, G.A., Noureddini, M., Mirhashemi, S.M., Mokhtari, R., Shoferpour, M., Effect of curcumin on diabetic peripheral neuropathic pain: Possible involvement of opioid system (2014) Eur. J. Pharmacol., 723, pp. 202-206; Beyreuther, B., Callizot, N., Stöhr, T., Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy (2006) Eur. J. Pharmacol., 539, pp. 64-70; Bordet, T., Buisson, B., Michaud, M., Abitbol, J.L., Marchand, F., Grist, J., Andriambeloson, E., Pruss, R.M., Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy (2008) J. Pharmacol. Exp. Ther., 326, pp. 623-632; Boulton, A.J., Vinik, A.I., Arezzo, J.C., Bril, V., Feldman, E.L., Freeman, R., Malik, R.A., Ziegler, D., Diabetic neuropathies: A statement by the American Diabetes Association (2005) Diabetes Care, 28, pp. 956-962; Can, O.D., Oztürk, Y., Ozkay, U.D., Effects of insulin and St. Johns Wort treatments on anxiety, locomotory activity, depression, and active learning parameters of streptozotocin-diabetic rats (2011) Planta Med., 77, pp. 1970-1976; Can Ö., D., Öztürk, Y., Öztürk, N., Sagratini, G., Ricciutelli, M., Vittori, S., Maggi, F., Effects of treatment with St. Johns Wort on blood glucose levels and pain perceptions of streptozotocin-diabetic rats (2011) Fitoterapia, 82, pp. 576-584; Cannon, K.E., Hough, L.B., Inhibition of chemical and low-intensity mechanical nociception by activation of histamine H3 receptors (2005) J. Pain, 6, pp. 193-200; Chattopadhyay, M., Zhou, Z., Hao, S., Mata, M., Fink, D.J., Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy (2012) Mol. Pain, 8, p. 17; Chauhan, N., Taliyan, R., Sharma, P.L., Effect of dipyrone and thalidomide alone and in combination on STZ-induced diabetic neuropathic pain (2012) Naunyn Schm. Arch., 385, pp. 527-538; Chen, S.R., Chen, H., Yuan, W.X., Pan, H.L., Increased presynaptic and postsynaptic α<inf>2</inf>-adrenoceptor activity in the spinal dorsal horn in painful diabetic neuropathy (2011) J. Pharmacol. Exp. Ther., 337, pp. 285-292; Choucair-Jaafar, N., Salvat, E., Freund-Mercier, M.J., Barrot, M., The antiallodynic action of nortriptyline and terbutaline is mediated by β(2) adrenoceptors and δ opioid receptors in the ob/ob model of diabetic polyneuropathy (2014) Brain Res., 1546, pp. 18-26; Corrodi, H., Hanson, L.C., Central effects of an inhibitor of tyrosine hydroxylation (1966) Psychopharmacologia, 10, pp. 116-125; Cotter, M.A., Cameron, N.E., Correction of neurovascular deficits in diabetic rats by beta2-adrenoceptor agonist and alpha1-adrenoceptor antagonist treatment: Interactions with the nitric oxide system (1998) Eur. J. Pharmacol., 343, pp. 217-223; Drenska, D., Varadinova, M., Boyadjieva, N., Bozhilova-Pastirova, A., Effect of anthocyanins and mianserin on neuronal density in rat hippocampus in a model of oxidative stres (2008) Pharmacologyonline, 2, pp. 133-138; Gabra, B.H., Sirois, P., Beneficial effect of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice (2003) Peptides, 24, pp. 1131-1139; Gray, A.M., Spencer, P.S., Sewell, R.D., The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds (1998) Br. J. Pharmacol., 124, pp. 669-674; Hargreaves, K., Dubner, R., Brown, F., Flores, C., Joris, J., A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia (1988) Pain, 32, pp. 77-88; Lee, Y.H., Ryu, T.G., Park, S.J., Yang, E.J., Jeon, B.H., Hur, G.M., Kim, K.J., Alpha1-adrenoceptors involvement in painful diabetic neuropathy: A role in allodynia (2000) Neuroreport, 11, pp. 1417-1420; Malcangio, M., Tomlinson, D.R., A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats (1998) Pain, 76, pp. 151-157; Marshall, R.J., The pharmacology of mianserin - An update (1983) Br. J. Clin. Pharmacol., 15, pp. 263S-268S; Micó, J.A., Ardid, D., Berrocoso, E., Eschalier, A., Antidepressants and pain (2006) Trends Pharmacol. Sci., 27, pp. 348-354; Ohsawa, M., Aasato, M., Hayashi, S.S., Kamei, J., RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice (2011) Pain, 152, pp. 114-122; Olianas, M.C., Dedoni, S., Onali, P., The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors (2012) Br. J. Pharmacol., 167, pp. 1329-1341; Omiya, Y., Yuzurihara, M., Suzuki, Y., Kase, Y., Kono, T., Role of alpha2-adrenoceptors in enhancement of antinociceptive effect in diabetic mice (2008) Eur. J. Pharmacol., 592, pp. 62-66; Onal, A., Parlar, A., Ulker, S., Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain (2007) Pharmacol. Biochem. Behav., 88, pp. 171-178; Ortega-Álvaro, A., Berrocoso, E., Rey-Brea, R., Leza, J.C., Mico, J.A., Comparison of the antinociceptive effects of ibuprofen arginate and ibuprofen in rat models of inflammatory and neuropathic pain (2012) Life Sci., 90, pp. 13-20; Pakulska, W., Czarnecka, E., Influence of mianserin on the antinociceptive effect of morphine, metamizol and indomethacin in mice (2002) Pharmacol. Res., 46, pp. 415-423; Peroutka, S., Snyder, S.H., [3H]Mianserin: Differential labeling of serotonin and histamine receptors in rat brain (1981) J. Pharmacol. Exp. Ther., 216, pp. 142-148; Pertovaara, A., The noradrenergic pain regulation system: A potential target for pain therapy (2013) Eur. J. Pharmacol., 716, pp. 2-7; Petrak, F., Hardt, J., Wittchen, H.U., Kulzer, B., Hirsch, A., Hentzelt, F., Borck, K., Hoffmann, S.O., Prevalence of psychiatric disorders in an onset cohort of adults with type 1 diabetes (2003) Diabetes Metab. Res. Rev., 19, pp. 216-222; Peyrot, M., Rubin, R.R., Levels and risks of depression and anxiety symptomatology among diabetic adults (1997) Diabetes Care, 20, pp. 585-590; Pinder, R.M., Adrenoreceptor interactions of the enantiomers and metabolites of mianserin: Are they responsible for the antidepressant effect? (1985) Acta Psychiatr. Scand., 320, pp. 1-9; Pospisilik, J.A., Martin, J., Doty, T., Ehses, J.A., Pamir, N., Lynn, F.C., Piteau, S., Pederson, R.A., Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats (2003) Diabetes, 52, pp. 741-750; Richelson, E., Nelson, A., Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro (1984) J. Pharmacol. Exp. Ther., 230, pp. 94-102; Ringkamp, M., Grethel, E.J., Choi, Y., Meyer, R.A., Raja, S.N., Mechanical hyperalgesia after spinal nerve ligation in rat is not reversed by intraplantar or systemic administration of adrenergic antagonists (1999) Pain, 79, pp. 135-141; Rosellini, W., Casavant, R., Engineer, N., Beall, P., Pierce, D., Jain, R., Dougherty, P.M., Wireless peripheral nerve stimulation increases pain threshold in two neuropathic rat models (2012) Exp. Neurol., 235, pp. 621-626; Sawynok, J., Esser, M.J., Reid, A.R., Antidepressants as analgesics: An overview of central and peripheral mechanisms of action (2001) J. Psychiatry Neurosci., 26, pp. 21-29; Schreiber, S., Backer, M.M., Kaufman, J.P., Pick, C.G., Interaction between the tetracyclic antidepressant mianserin HCl and opioid receptors (1998) Eur. Neuropsycopharmacol., 8, pp. 297-302; Shi, L., Zhang, H.H., Hu, J., Jiang, X.H., Xu, G.Y., Purinergic P2X receptors and diabetic neuropathic pain (2012) Sheng Li Xue Bao, 64, pp. 531-542; Silva, J., Abebe, W., Sousa, S.M., Duarte, V.G., Machado, M.I., Matos, F.J., Analgesic and anti-inflammatory effects of essential oils of Eucalyptus (2003) J. Ethnopharmacol., 89, pp. 277-283; Skalska, S., Kyselova, Z., Gajdosikova, A., Karasu, C., Stefek, M., Stolc, S., Protective effect of stobadine on NCV in streptozotocin-diabetic rats: Augmentation by vitamin e (2008) Gen. Physiol. Biophys., 27, pp. 106-114; Suzuki, Y., Sato, J., Kawanishi, M., Mizumura, K., Lowered response threshold and increased responsiveness to mechanical stimulation of cutaneous nociceptive fibers in streptoxotocin-diabetic rat skin in vitro - Correlates of mechanical allodynia and hyperalgesia observed in the early stage of diabetes (2002) Neurosci. Res., 43, pp. 171-178; Taylor, B.K., Spinal inhibitory neurotransmission in neuropathic pain (2009) Curr. Pain Headache Rep., 13, pp. 208-214; The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus (1993) N. Engl. J. Med., 329, pp. 977-986. , Diabetes Control And Complications Trial Research Group T; Torres, I., Suárez, E., Rodríguez-Sasiaín, J.M., Gomez, E., Calvo, R., Changes in the analgesic effects of mianserin associated with altered plasma protein binding in experimental cancer (1995) Res. Commun. Mol. Pathol. Pharmacol, 89, pp. 341-350; Valverde, O., Mico, J.A., Maldonado, R., Mellado, M., Gibert-Rahola, J., Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants in two behavioural pain tests in mice (1994) Prog. Neuropsychopharmacol. Biol. Psychiatry, 18, pp. 1073-1092; Villetti, G., Bergamaschi, M., Bassani, F., Bolzoni, P.T., Maiorino, M., Pietra, C., Rondelli, I., Barbieri, M., Antinociceptive activity of the N-methyl-d-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain (2003) J. Pharmacol. Exp. Ther., 306, pp. 804-814; Widerlöv, E., Lewander, T., Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine; Time- and dose-response relationships (1978) Naunyn Schm. Arch. Pharmacol., 304, pp. 111-123; Wong, M.C., Chung, J.W., Wong, T.K., Effects of treatments for symptoms of painful diabetic neuropathy: Systematic review (2007) BMJ, 335, p. 87; Woolfe, G., Macdonald, A.D., The evaluation of the analgesic action of pethidine hydrochloride (Demerol) (1944) J. Pharmacol. Exp. Ther., 80, pp. 300-307; Yalcin, I., Aksu, F., Belzung, C., Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol (2005) Eur. J. Pharmacol., 514, pp. 165-174; Yalcin, I., Aksu, F., Bodard, S., Chalon, S., Belzung, C., Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: Possible involvement of the noradrenergic system (2007) Behav. Pharmacol., 18, pp. 623-631; Yalcin, I., Choucair-Jaafar, N., Benbouzid, M., Tessier, L.H., Muller, A., Hein, L., Freund-Mercier, M.J., Barrot, M., Beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain (2009) Ann. Neurol., 65, pp. 218-225; Yalcin, I., Tessier, L.H., Petit-Demoulière, N., Doridot, S., Hein, L., Freund-Mercier, M.J., Barrot, M., β<inf>2</inf>-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain (2009) Neurobiol. Dis., 33, pp. 386-394; Yalcin, I., Tessier, L.H., Petit-Demoulière, N., Waltisperger, E., Hein, L., Freund-Mercier, M.J., Barrot, M., Chronic treatment with agonists of beta (2)-adrenergic receptors in neuropathic pain (2010) Exp. Neurol., 221, pp. 115-121; Yamamoto, H., Shimoshige, Y., Yamaji, T., Murai, N., Aoki, T., Matsuoka, N., Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats (2009) Neuropharmacology, 57, pp. 403-408; Yamazaki, S., Yamaji, T., Murai, N., Yamamoto, H., Price, R.D., Matsuoka, N., Mutoh, S., FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy (2008) Neuropharmacology, 55, pp. 1226-1230; Yan, J.E., Yuan, W., Lou, X., Zhu, T., Streptozotocin-induced diabetic hyperalgesia in rats is associated with upregulation of toll-like receptor 4 expression (2012) Neurosci. Lett., 526, pp. 54-58; Zhu, J.X., Xu, F.Y., Xu, W.J., Zhao, Y., Qu, C.L., Tang, J.S., Barry, D.M., Huo, F.Q., The role of α<inf>2</inf> adrenoceptor in mediating noradrenaline action in the ventrolateral orbital cortex on allodynia following spared nerve injury (2013) Exp. Neurol., 248, pp. 381-386",Article,Scopus,2-s2.0-84926182224
"Vezouviou E., Lowe C.R.","A near infrared holographic glucose sensor",2015,"Biosensors and Bioelectronics","68",,,"371","381",,,10.1016/j.bios.2015.01.014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921358048&partnerID=40&md5=dd25b18c7056db262ce248ae68f5e295","Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court RoadCambridge, United Kingdom; Philips Research, 101 Science Park, United Kingdom","Vezouviou, E., Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court RoadCambridge, United Kingdom, Philips Research, 101 Science Park, United Kingdom; Lowe, C.R., Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court RoadCambridge, United Kingdom","Real-time glucose monitoring has been beneficial in reducing health complications associated with diabetes as well as a decrease in mortality. This report describes a novel holographic platform, fabricated via laser ablation on chitosan hydrogel with gold nanoparticles with a replaying in visible and near IR. The sensor responded with a 12. nm and 7. nm shift in wavelength at glucose concentrations in the 0-70. mM range and in the visible and near IR, respectively, at pH 7.4 and an ionic strength of 154. mM. The sensor did not respond to potential interferences found in the interstitial fluid, such as fructose, vitamin C and lactate, at their respective normal concentrations and was stable to fluctuations in temperature, pH and ionic strength. The characteristics of this sensor suggests that it may be applicable for use as an implanted device for the real time monitoring of glucose concentrations in the interstitial fluid using near IR as the interrogating medium. © 2015 Elsevier B.V.","Biosensor; Chitosan; Diabetes; Glucose; Holography; Near Infrared","Azevedo, E., (2011) Aldehyde-Functionalized Chitosan and Cellulose:Chitosan Composites: Application as Drug Carriers and Vascular Bypass Grafts, , University of Iowa, (Pharmacy.); Bendana, X.M., Auguié, B., Barnes, W.L., García de Abajo, F.J., Diffractive arrays of gold nanoparticles near an interface: critical role of the substrate (2010) Phys. Rev. B, 82, p. 155447; Zanchet, D., Hall, B.D., Ugarte, D., Estimating nanoparticle size from diffraction measurements (2000) Appl. Crystallogr., 33, pp. 1335-1341; Gierczyk, M.K., Schroedera, G., Sporzyńskib, A., NMR studies of boronic acids and their derivatives (2013) N. J. Chem., 37, pp. 1056-1072; Garza, J.T., Cummins, B.M., Coté, G.L., Limitations of current fluorescent glucose sensing assays based on competitive binding,Optical diagnostics and sensing XIII: Toward Point-of-Care diagnostics.8591. (2013)Bjelkhagen, H.I, (1998) New recording materials for holography.; Brimelow, A., (2013) Diabetes: Excess Deaths Well Down, Study Indicates, , BBC News: Health, BBC online; Ley, C., Calderara, I., Lougnot, D.J., Holographic grating recorded in polymer hydrogels- an optical application as a sensor in aqueous environment (1997) Measurement Sci. Technol., 8 (9), pp. 997-1000; Chia, C.W., Saudek, C.D., Glucose sensors: toward closed loop insulin delivery (2004) Endocrinol. Metab., 33 (1), pp. 175-195; Cho, A., Century-Long debate over momentum of light resolved? (2010) Science, 327, p. 1067; Cowan, J.J., The surface plasmon resonance effect in holography (1972) Opt. Commun., 5 (2), pp. 69-72; Cowan, J.J., Holography with standing surface plasma waves (1974) Opt. Commun., 12 (4), pp. 373-378; Kumosa, L.S., Gough, D.A., Routh, T.L., Lin, J.T., Lucisano, J.Y., Function of an implanted tissue glucose sensor for more than 1 year in animals (2010) Sci. Transl. Med. Home, 2 (42), pp. 42-53; Cunningham, J.A.S., (2010) In Vivo Glucose Sensing (Chemical Analysis: A Series of Monographs on Analytical Chemistry and Its Applications), , Wiley-Blackwell, New Jersey; Denisyuk, G., The theory of deep holograms (1968) Proceedings-Royal Society A, 304 (1478), pp. 275-289; Denisyuk, G., Holography, 1948-971 (1972) Science, 177 (4046), pp. 299-313; Dimitrov, D.V., Remote control in diabetes (2013) Adv. Predict. Prev. Pers. Med., 3, pp. 389-398; Dyer, A.M.H.M., Watts, P., Castile, J., Jabbal-Gill, I., Nankervis, R., Smith, A., Illum, L., Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles (2002) Pharm. Res., 19 (7), pp. 998-1008; Mecher, F.G.-G., Tillmann, H., Horhold, H.H., Hummelens, J.C., Meerholz, K., Near-Infrared sensitivity engancement of photorefractive polymer composites by pre-illumination (2002) Nature, 418, pp. 959-964; Escott, D.J.A., Chitinase activity in human serum and leukocytes (1995) Infect. Immun., 65 (12), pp. 4770-4773; Sparacino, A.F., Cobelli, C., ""Smart"" continuous glucose monitoring sensors: on-line signal processing issues (2010) Sensors, 10 (7). , (7651-6772); Gaponenko, S.V., (2010) Introduction to Nanophotonics, , Cambridge University Press; Gifford, R., Continuous glucose monitoring: 40 years, what we've learned and what's next (2013) Phys. Chem.; Graham, S., (2004) Pract. Hologr., , (3rd Edition); Honarkan, M.B., Applications of biopolymers I: chitosan (2009) Monatshefte für Chemie, 140 (12), pp. 1403-1420; Huang, X.Y., Synthesis of polysaccharide-stabilized gold and silver nanoparticles: a green method (2004) Carb. Res., 339 (15), pp. 2627-2631; Naydenova, S.S.M., Martin, S., Toal, V., Holographic recording in nanoparticle-doped photopolymer (2005) Mater. Syst. Opt. Data Storage Processing, p. 6252; Huttunen, J.K., Fructose in medicine: a review with particular reference to diabetes mellitus (1971) Postgrad. Med. J., 47 (552), pp. 654-659; Hisamitsu, K.K., Okano, T., Sakurai, Y., Glucose-responsive gel from phenylboronate polymer and poly(vinyl alcohol): prompt response at physiological pH through the interaction of boronate with amino group in the gel (1997) Pharm. Res., 14 (3), pp. 289-293; Vigoureux, F.D., Girard, C., Supperresolution of near-field optical microscopy defined from properties of confined electromagnetic waves (1992) Appl. Opt., 31 (6), pp. 3036-3045; Cambre, B.S.S., Biomedical applications of boronic acid polymers (2011) Polymer, 52, pp. 4631-4643; Adleman, H.A.E., Buse, K., Psaltis, D., Holographic grating formation in a colloidal suspension of silver nanoparticles (2006) Opt. Lett., 31 (4), p. 447; Yan, G.S., Deeter, S., Wang, B., The relationship among pKa, pH, and binding constants in the interactions between boronic acids and diols-it is not as simple as it appears (2004) Tetrahedron, 60 (49), pp. 11205-11209; Aslan, J.R.L., Geddes, C.D., Nanogold-plasmon-resonance-based glucose sensing (2004) Anal. Biochem., 330, pp. 145-155; Ino, T.F., Anzai, K., Iwase, M., Kogawa, K., Ogimoto, M., Ono, J., Takashi, A., Tamura, K., Serum Vitamin C levels in Type 2 diabetic nephropathy (2005) Diabetes Care, 28 (11), pp. 2808-2809; Kogelnik, H., Coupled-wave theory for thick hologram gratings (1969) Bell Syst. Tech. J., 48 (9), pp. 2909-2947; Kumar, C., (2005) Clinical Medicine, , Saunders Ltd; Rodrigueza, M.S.M., Butlerb, J.J., Transmission properties of refractive index-shifted Bragg gratings (2000) Opt. Commun., 117 (1-6), pp. 251-257; Ellmerer, L.S., Sendlhofer, G., Wutte, A., Brunner, G.A., Trajanoski, Z., Skrabal, F., Wach, P., Pieber, T.R., Lactate metabolism of subcutaneous adipose tissue studied by open flow microperfusion (1998) J. Endocrinol. Metab., 83 (12), pp. 4394-4401; Matsumoto, T.S., Kondo, K., Selective adsorption of glucose on novel chitosan gel modified by phenylboronate (2002) Sep. Purif. Technol., 29 (3), pp. 229-233; Ozaki, J.K., Kawata, S., Surface-plasmon holography with white light illumination (2011) Plasmon. Metamater. I, 8455. , (84550K-84551-84550K-84556); Rinaudo, G.P., Desbrieres, J., Influence of acetic acid concentration on the solubilization of chitosan (1999) Polymer, 40, pp. 7029-7032; Tarkka, M.E.T., Brady, D.J., Schuster, G.B., Holgoraphic storage in a near-IR sensitive photochromic dye (1994) Opt. Commun., 109 (1-2), pp. 54-58; Uchida, A.T., Generation of electron beams carrying orbital angular momentum (2010) Nat. Lett., 464, pp. 737-739; Steiner, A.D., Wolfbeis, O.S., Optical methods for sensing glucose (2011) Chem. Soc. Rev., 40 (11), pp. 4805-4839; McGarraugh, G., The chemistry of commercial continuous glucose monitors (2009) Diabetes Technol. Ther., 11 (1), pp. 17-24; Michael S.Boyne, D.M.S., Kaplan, J., Saudek, C.D., Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor (2003) Am. Diabetes Assoc., 52 (11); Monis, C., (2010) Hydrogel contact lenses. Chemical and Materials engineering, , San Jose State University; Mou, X., Long-term calibration considerations during subcutaneous microdialysis sampling in mobile rats (2010) Biomaterials, 31 (16), p. 4530; Hajdukova, P., Stepanek, J., Spirkova, M., Chemically reduced and laser-ablated gold nanoparticles immobilized to silanized glass plates: Preparation, characterization and SERS spectral testing (2007) Colloids Surf. A, Physicochem. Eng. Asp., 301 (1-3), p. 264; Panyala, E.-M., Havel, J., Silver or silver nanoparticles: a hazardous threat to the environment and human health? (2008) J. Appl. Biomed., 6, pp. 117-129; Oliver, N.S., Glucose sensors: a review of current and emerging technology (2009) Diabetic Med., 26 (3), p. 197; (2013) Diabetes.; Rossetti, J.B., Vehi, J., Fanelli, C.G., Estimating plasma glucose from interstitial glucose: the issue of calibration algorithms in commercial continuous glucose monitoring devices (2010) Sensors, 10 (12), pp. 10936-10952; Šmíd, H.H., Keprt, J., Dichromated gelatin and its importance for optical hologram recording (2004) Czechoslov. J. Phys., 54 (12), pp. 1461-1472; Shervedani, M.B., Electrochemical characterization of in situ functionalized gold cysteamine self-assembled monolayer with 4-formylphenylboronic acid for detection of dopamine (2008) Electroanalytics, 20, p. 5; Reem Smoum, A.R., Srebnik, M., Chitosan-pentaglycine-phenylboronic acid conjugate: a potential colon-specific platform for calcitonin (2006) Bioconjugate Chem., 17 (4), pp. 1000-1007; Regittnig, W., Assessment of transcapillary glucose exchange in human skeletal muscle and adipose tissue (2003) Am. J. Physiol.: Endocrinol. Metab., 285 (2), p. E241; Jin, Y.C., Reid, S., Li, M., Wang, B., Carbohydrate recognition by boronolectins, small molecules, and lectins (2009) Pharma. Med. Chem., 30 (2), pp. 171-257; Kabilan, A.J.M., Sartain, F.K., Lee, M.C., Hussain, A., Yang, X., Blyth, J., Karangu, N., Lowe, C.R., Holographic glucose sensors (2005) Biosens. Bioelectronics, 20 (8), pp. 1602-1610; Kabilan, J.B., Lee, M.C., Marshall, A.J., Hussain, A., Yang, X.P., Lowe, C.R., Glucose-sensitive holographic sensors (2004) Mol. Recognit., 17, p. 3; Nichols, A.K., Storm, W.L., Shin, J.H., Schoenfish, M.H., Biocompatible materials for continuous glucose monitoring devices (2013) Chem. Rev., 113 (4), pp. 2528-2549; Vaddiraju, D.J.B., Tomazos, I., Jain, F.C., Papadimitrakopoulos, F., Technologies for continuous glucose monitoring: current problems and future promises (2010) J. Diabetes Sci. Technol., 4 (6), pp. 1540-1562; Sartain, F.K., Complexation of l-lactate with boronic acids: a solution and holographic analysis (2008) Chem.-A Eur. J., 14 (13), p. 4060; Saxby, G., (1994) Practical holography.; Saxby, G., (2004) Practical Holography, , Taylor & Francis; Springsteen, G., A detailed examination of boronic acid-diol complexation (2002) Tetrahedron, 58 (26), p. 5291; Kawasaki, H.A., Yamanouchi, T., Increased fructose concentrations in blood and urine in patients with diabetes (2002) Diabetes Care, 25 (2), pp. 353-357; Konno, K.I., Temporal and spatially controllable cell encapsulation using a water-soluble phospholipid polymer with phenylboronic acid moiety (2007) Biomaterials, 28 (10), pp. 1770-1777; Smirnova, L.M.K., Kutsenko, A.S., Sakhno, O.V., Stumpe, J., The fabrication of periodic polymer/silver nanoparticle structures: in situ reduction of silver nanoparticles from precursor spatially distributed in polymer using holographic exposure (2009) Nanotechnology, 20 (40), pp. 1-10; Takumi Sannomiya, T.E.B., Hafner, C., Heuberger, M., Vörös, J., Optical sensing and determination of complex reflection coefficients of plasmonic structures using transmission interferometric plasmonic sensor (2010) Rev. Sci. Instrum., 81 (5), pp. 53102-53109; Vezouviou, E., (2013) A near Infrared holographic glucose sensor for diabetes management. Chemical Engineering and Biotechnology, , University of Cambridge; Wu, Z.Z.S., Zhang, X., Shu, S., Chu, T., Yu, D., Phenylboronic acid grafted chitosan as a glucose-sensitive vehicle for controlled insulin release (2011) J. Pharmaceutical Sci., 100 (6), pp. 2278-2286; Hong, E.A.H.H., Contribution of gold nanoparticles to the signal amplification in surface plasmon resonance (2012) Analyst, 137, pp. 4712-4719; Yang, X.P., Blyth, J., Lowe, C.R., Towards the real-time monitoring of glucose in tear fluid: holographic glucose sensors with reduced interference from lactate and pH (2007) Biosens. Bioelectron., 23 (6), pp. 899-905; Xiaoping Yang, M.-C.L., Sartain, F., Pan, X., Lowe, C.R., Designed boronate ligands for glucose-selective holographic sensors (2006) Chem.- A Eur. J., 12 (33); Asantewaa, J.A., Burley, J.C., Billa, N., Roberts, C.J., Correlating physicochemical properties of boronic acid-chitosan conjugates to glucose adsorption sensitivity (2013) Pharmaceutics, 5, pp. 69-80; Pan, S.N., Leifert, A., Fischler, M., Wen, F., Simon, U., Schmid, G., Brandau, W., Jahnen-Dechent, W., Size-dependent cytotoxicity of gold nanoparticles (2007) Small Nano Micro, 3 (11), pp. 1941-1949",Article,Scopus,2-s2.0-84921358048
"Ren K., Tang Z.-L., Jiang Y., Tan Y.-M., Yi G.-H.","Apolipoprotein M",2015,"Clinica Chimica Acta","446",,,"21","29",,,10.1016/j.cca.2015.03.038,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927653732&partnerID=40&md5=a05cf10147c721e239a7a6975334e392","Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South ChinaHengyang City, Hunan Province, China","Ren, K., Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South ChinaHengyang City, Hunan Province, China; Tang, Z.-L., Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South ChinaHengyang City, Hunan Province, China; Jiang, Y., Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South ChinaHengyang City, Hunan Province, China; Tan, Y.-M., Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South ChinaHengyang City, Hunan Province, China; Yi, G.-H., Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South ChinaHengyang City, Hunan Province, China","Apolipoprotein M (ApoM) is a novel apolipoprotein that was discovered in 1999 and is bound primarily to high-density lipoproteins (HDLs) in the plasma. Multiple factors may influence its expression at both the post-transcriptional and the transcriptional levels both in vivo and ex vivo as follows: hepatocyte nuclear factor-1α, 4α (HNF-1α, 4α), liver receptor homolog-1 (LRH-1), forkhead box A2 (Foxa2) and platelet activating factor (PAF) upregulate its expression; liver X receptor (LXR), retinoid X receptor (RXR), farnesoid X receptor (FXR), small heterodimer partner (SHP) and the majority of cytokines downregulate its expression. However, mechanisms underlying these processes remain unknown. Structurally, there exists a characterized hydrophobic binding pocket within the apoM protein, which enables it to bind functional lipids such as Sphingosine-1-Phosphate (S1P). Functionally, it facilitates the formation of preβ-HDL and enhances an avalanche of atheroprotective effects exerted by HDL. Moreover, in patients with diabetes, the levels of plasma apoM may decrease, whereas the augmentation of apoM decreases plasma glucose levels and magnifies the secretion of insulin. This article offers a panorama of the progress made in the research regarding the characteristics of apoM, particularly the regulation of its expression and its functions. © 2015 Elsevier B.V.","Apolipoprotein M; Function; Regulation","Fisher, E.A., Feig, J.E., Hewing, B., Hazen, S.L., Smith, J.D., High-density lipoprotein function, dysfunction, and reverse cholesterol transport (2012) Arterioscler Thromb Vasc Biol, 32, pp. 2813-2820; Investigators, A.-H., Boden, W.E., Probstfield, J.L., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy (2011) N Engl J Med, 365, pp. 2255-2267; Voight, B.F., Peloso, G.M., Orho-Melander, M., Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study (2012) Lancet, 380, pp. 572-580; Murphy, A.J., Chin-Dusting, J.P., Sviridov, D., Woollard, K.J., The anti inflammatory effects of high density lipoproteins (2009) Curr Med Chem, 16, pp. 667-675; Barter, P.J., Brewer, H.J., Chapman, M.J., Hennekens, C.H., Rader, D.J., Tall, A.R., Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis (2003) Arterioscler Thromb Vasc Biol, 23, pp. 160-167; Xu, N., Dahlback, B., A novel human apolipoprotein (apoM) (1999) J Biol Chem, 274, pp. 31286-31290; Pan, G., Fu, Y., Zuo, B., Molecular characterization, expression profile and association analysis with fat deposition traits of the porcine APOM gene (2010) Mol Biol Rep, 37, pp. 1363-1371; Flower, D.R., The lipocalin protein family: structure and function (1996) Biochem J, 318, pp. 1-14; Schlehuber, S., Skerra, A., Lipocalins in drug discovery: from natural ligand-binding proteins to ""anticalins"" (2005) Drug Discov Today, 10, pp. 23-33; Duan, J., Dahlback, B., Villoutreix, B.O., Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis (2001) FEBS Lett, 499, pp. 127-132; Ahnstrom, J., Faber, K., Axler, O., Dahlback, B., Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M (2007) J Lipid Res, 48, pp. 1754-1762; Rosen, H., Stevens, R.C., Hanson, M., Roberts, E., Oldstone, M.B., Sphingosine-1-phosphate and its receptors: structure, signaling, and influence (2013) Annu Rev Biochem, 82, pp. 637-662; Raper, J., Fung, R., Ghiso, J., Nussenzweig, V., Tomlinson, S., Characterization of a novel trypanosome lytic factor from human serum (1999) Infect Immun, 67, pp. 1910-1916; Smith, A.B., Esko, J.D., Hajduk, S.L., Killing of trypanosomes by the human haptoglobin-related protein (1995) Science, 268, pp. 284-286; Dalbey, R.E., Lively, M.O., Bron, S., van Dijl, J.M., The chemistry and enzymology of the type I signal peptidases (1997) Protein Sci, 6, pp. 1129-1138; Axler, O., Ahnstrom, J., Dahlback, B., Apolipoprotein M associates to lipoproteins through its retained signal peptide (2008) FEBS Lett, 582, pp. 826-828; Christoffersen, C., Ahnstrom, J., Axler, O., Christensen, E.I., Dahlback, B., Nielsen, L.B., The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma (2008) J Biol Chem, 283, pp. 18765-18772; Christoffersen, C., Nielsen, L.B., Axler, O., Andersson, A., Johnsen, A.H., Dahlback, B., Isolation and characterization of human apolipoprotein M-containing lipoproteins (2006) J Lipid Res, 47, pp. 1833-1843; Zhang, X.Y., Jiao, G.Q., Hurtig, M., Expression pattern of apolipoprotein M during mouse and human embryogenesis (2004) Acta Histochem, 106, pp. 123-128; Faber, K., Axler, O., Dahlback, B., Nielsen, L.B., Characterization of apoM in normal and genetically modified mice (2004) J Lipid Res, 45, pp. 1272-1278; Zhang, X.Y., Dong, X., Zheng, L., Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization (2003) Acta Histochem, 105, pp. 67-72; Faber, K., Hvidberg, V., Moestrup, S.K., Dahlback, B., Nielsen, L.B., Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M (2006) Mol Endocrinol, 20, pp. 212-218; Aseem, O., Smith, B.T., Cooley, M.A., Cubilin maintains blood levels of HDL and albumin (2014) J Am Soc Nephrol, 25, pp. 1028-1036; Christensen, E.I., Birn, H., Storm, T., Weyer, K., Nielsen, R., Endocytic receptors in the renal proximal tubule (2012) Physiology, 27, pp. 223-236; Jiao, G.Q., Yuan, Z.X., Xue, Y.S., A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese (2007) Clin Biochem, 40, pp. 1108-1112; Niu, N., Zhu, X., Liu, Y., Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese (2007) Diabetes Metab Res Rev, 23, pp. 21-25; Wu, X., Niu, N., Brismar, K., Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes (2009) Clin Biochem, 42, pp. 17-21; Hu, H.J., Jin, E.H., Yim, S.H., Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis (2011) Exp Mol Med, 43, pp. 613-621; Zhou, J.W., Tsui, S.K., Ng, M.C., Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes (2011) PLoS One, 6, p. e17324; Cao, B., Ye, Y.Z., Rui, J., A single-nucleotide polymorphism in the proximal promoter region of the apolipoprotein M gene is associated with dyslipidaemia but not increased coronary artery diseases in Chinese populations (2013) Lipids Health Dis, 12, p. 184; Zhao, D., He, Z., Qin, X., Li, L., Liu, F., Deng, S., Association of apolipoprotein M gene polymorphisms with ischemic stroke in a Han Chinese population (2011) J Mol Neurosci, 43, pp. 370-375; Zhang, Y., Mangelsdorf, D.J., LuXuRies of lipid homeostasis: the unity of nuclear hormone receptors, transcription regulation, and cholesterol sensing (2002) Mol Interv, 2, pp. 78-87; Zhang, X., Zhu, Z., Luo, G., Zheng, L., Nilsson-Ehle, P., Xu, N., Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro (2008) Biochem Biophys Res Commun, 371, pp. 114-117; Di, D., Wang, Z., Liu, Y., ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells (2012) Biochem Biophys Res Commun, 421, pp. 152-156; Calayir, E., Becker, T.M., Kratzer, A., LXR-agonists regulate ApoM expression differentially in liver and intestine (2008) Curr Pharm Biotechnol, 9, pp. 516-521; Houck, K.A., Borchert, K.M., Hepler, C.D., T0901317 is a dual LXR/FXR agonist (2004) Mol Genet Metab, 83, pp. 184-187; Seol, W., Chung, M., Moore, D.D., Novel receptor interaction and repression domains in the orphan receptor SHP (1997) Mol Cell Biol, 17, pp. 7126-7131; Soodgupta, D., Kaul, D., Kanwar, A.J., Parsad, D., Modulation of LXR-alpha and the effector genes by ascorbic acid and statins in psoriatic keratinocytes (2014) Mol Cell Biochem, 397, pp. 1-6; Luo, G., Feng, Y., Zhang, J., Rosiglitazone enhances apolipoprotein M (Apom) expression in rat's liver (2014) Int J Med Sci, 11, pp. 1015-1021; Venteclef, N., Haroniti, A., Tousaint, J.J., Talianidis, I., Delerive, P., Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1 (2008) J Biol Chem, 283, pp. 3694-3701; Boulias, K., Katrakili, N., Bamberg, K., Underhill, P., Greenfield, A., Talianidis, I., Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP (2005) EMBO J, 24, pp. 2624-2633; Pare, J.F., Malenfant, D., Courtemanche, C., The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis and is regulated by a DR4 element (2004) J Biol Chem, 279, pp. 21206-21216; Clyne, C.D., Speed, C.J., Zhou, J., Simpson, E.R., Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes (2002) J Biol Chem, 277, pp. 20591-20597; Iwaki, M., Matsuda, M., Maeda, N., Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors (2003) Diabetes, 52, pp. 1655-1663; Fayard, E., Auwerx, J., Schoonjans, K., LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis (2004) Trends Cell Biol, 14, pp. 250-260; Richter, S., Shih, D.Q., Pearson, E.R., Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels (2003) Diabetes, 52, pp. 2989-2995; Mosialou, I., Krasagakis, K., Kardassis, D., Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors (2011) J Biol Chem, 286, pp. 17259-17269; Koukos, G., Chroni, A., Duka, A., Kardassis, D., Zannis, V.I., Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT (2007) Biochem J, 406, pp. 167-174; Kuo, C.J., Conley, P.B., Chen, L., Sladek, F.M., Darnell, J.E., Crabtree, G.R., A transcriptional hierarchy involved in mammalian cell-type specification (1992) Nature, 355, pp. 457-461; Kritis, A.A., Ktistaki, E., Barda, D., Zannis, V.I., Talianidis, I., An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression (1993) Nucleic Acids Res, 21, pp. 5882-5889; Ktistaki, E., Talianidis, I., Modulation of hepatic gene expression by hepatocyte nuclear factor 1 (1997) Science, 277, pp. 109-112; Papamichos-Chronakis, M., Petrakis, T., Ktistaki, E., Topalidou, I., Tzamarias, D., Cti6, a PHD domain protein, bridges the Cyc8-Tup1 corepressor and the SAGA coactivator to overcome repression at GAL1 (2002) Mol Cell, 9, pp. 1297-1305; Mosialou, I., Zannis, V.I., Kardassis, D., Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors (2010) J Biol Chem, 285, pp. 30719-30730; Zannis, V.I., Kan, H.Y., Kritis, A., Zanni, E., Kardassis, D., Transcriptional regulation of the human apolipoprotein genes (2001) Front Biosci, 6, pp. D456-D504; Zannis, V.I., Kan, H.Y., Kritis, A., Zanni, E.E., Kardassis, D., Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo (2001) Curr Opin Lipidol, 12, pp. 181-207; Sund, N.J., Vatamaniuk, M.Z., Casey, M., Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia (2001) Genes Dev, 15, pp. 1706-1715; Lee, C.S., Friedman, J.R., Fulmer, J.T., Kaestner, K.H., The initiation of liver development is dependent on Foxa transcription factors (2005) Nature, 435, pp. 944-947; Wolfrum, C., Howell, J.J., Ndungo, E., Stoffel, M., Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M (2008) J Biol Chem, 283, pp. 16940-16949; Zhao, J.Y., Hu, Y.W., Li, S.F., Dihydrocapsaicin down-regulates apoM expression through inhibiting Foxa2 expression and enhancing LXRalpha expression in HepG2 cells (2014) Lipids Health Dis, 13, p. 50; Ahuja, K.D., Ball, M.J., Effects of daily ingestion of chilli on serum lipoprotein oxidation in adult men and women (2006) Br J Nutr, 96, pp. 239-242; Ahuja, K.D., Robertson, I.K., Geraghty, D.P., Ball, M.J., Effects of chili consumption on postprandial glucose, insulin, and energy metabolism (2006) Am J Clin Nutr, 84, pp. 63-69; Vigouroux, C., Gharakhanian, S., Salhi, Y., Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART) (1999) Diabetes Metab, 25, pp. 225-232; de la Brousse, F.C., Shan, B., Chen, J.L., Identification of the promoter of the mouse obese gene (1996) Proc Natl Acad Sci U S A, 93, pp. 4096-4101; Xu, N., Nilsson-Ehle, P., Hurtig, M., Ahren, B., Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo (2004) Biochem Biophys Res Commun, 321, pp. 916-921; Luo, G., Hurtig, M., Zhang, X., Nilsson-Ehle, P., Xu, N., Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells (1734) Biochim Biophys Acta, 2005, pp. 198-202; Tanizawa, Y., Okuya, S., Ishihara, H., Asano, T., Yada, T., Oka, Y., Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic beta cells (1997) Endocrinology, 138, pp. 4513-4516; Zieba, D.A., Amstalden, M., Maciel, M.N., Divergent effects of leptin on luteinizing hormone and insulin secretion are dose dependent (2003) Exp Biol Med, 228, pp. 325-330; Kieffer, T.J., Heller, R.S., Leech, C.A., Holz, G.G., Habener, J.F., Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells (1997) Diabetes, 46, pp. 1087-1093; Xu, N., Zhang, X.Y., Dong, X., Ekstrom, U., Ye, Q., Nilsson-Ehle, P., Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells (2002) Biochem Biophys Res Commun, 292, pp. 944-950; Feingold, K.R., Shigenaga, J.K., Chui, L.G., Moser, A., Khovidhunkit, W., Grunfeld, C., Infection and inflammation decrease apolipoprotein M expression (2008) Atherosclerosis, 199, pp. 19-26; Christoffersen, C., Pedersen, T.X., Gordts, P.L., Roebroek, A.J., Dahlback, B., Nielsen, L.B., Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis (2010) Circ Res, 106, pp. 1624-1634; Christoffersen, C., Benn, M., Christensen, P.M., The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles (2012) J Lipid Res, 53, pp. 2198-2204; Karuna, R., Park, R., Othman, A., Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism (2011) Atherosclerosis, 219, pp. 855-863; Wolfrum, C., Poy, M.N., Stoffel, M., Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis (2005) Nat Med, 11, pp. 418-422; Christoffersen, C., Jauhiainen, M., Moser, M., Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice (2008) J Biol Chem, 283, pp. 1839-1847; Mulya, A., Seo, J., Brown, A.L., Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1 (2010) J Lipid Res, 51, pp. 514-524; Liu, M., Seo, J., Allegood, J., Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein (2014) J Biol Chem, 289, pp. 2801-2814; Dullaart, R.P., Plomgaard, P., de Vries, R., Dahlback, B., Nielsen, L.B., Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness (2009) Clin Chim Acta, 406, pp. 129-133; Axler, O., Ahnstrom, J., Dahlback, B., An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma (2007) J Lipid Res, 48, pp. 1772-1780; Elsoe, S., Christoffersen, C., Luchoomun, J., Turner, S., Nielsen, L.B., Apolipoprotein M promotes mobilization of cellular cholesterol in vivo (1831) Biochim Biophys Acta, 2013, pp. 1287-1292; Stoffel, W., Assmann, G., Metabolism of sphingosine bases. XV. Enzymatic degradation of 4t-sphingenine 1-phosphate (sphingosine 1-phosphate) to 2t-hexadecen-1-al and ethanolamine phosphate (1970) Hoppe Seylers Z Physiol Chem, 351, pp. 1041-1049; Pappu, R., Schwab, S.R., Cornelissen, I., Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate (2007) Science, 316, pp. 295-298; Liu, Y., Wada, R., Yamashita, T., Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation (2000) J Clin Invest, 106, pp. 951-961; English, D., Welch, Z., Kovala, A.T., Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis (2000) FASEB J, 14, pp. 2255-2265; Ishii, I., Fukushima, N., Ye, X., Chun, J., Lysophospholipid receptors: signaling and biology (2004) Annu Rev Biochem, 73, pp. 321-354; Sevvana, M., Ahnstrom, J., Egerer-Sieber, C., Lange, H.A., Dahlback, B., Muller, Y.A., Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M (2009) J Mol Biol, 393, pp. 920-936; Christoffersen, C., Obinata, H., Kumaraswamy, S.B., Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M (2011) Proc Natl Acad Sci U S A, 108, pp. 9613-9618; Elsoe, S., Ahnstrom, J., Christoffersen, C., Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL (2012) Atherosclerosis, 221, pp. 91-97; Sutter, I., Park, R., Othman, A., Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate (2014) J Lipid Res, 55, pp. 1730-1737; Libby, P., Ridker, P.M., Hansson, G.K., Progress and challenges in translating the biology of atherosclerosis (2011) Nature, 473, pp. 317-325; Ahnstrom, J., Axler, O., Jauhiainen, M., Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies (2008) J Lipid Res, 49, pp. 1912-1917; Zhang, X., Jiang, B., Luo, G., Nilsson-Ehle, P., Xu, N., Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro (1771) Biochim Biophys Acta, 2007, pp. 879-882; Xu, N., Nilsson-Ehle, P., Ahren, B., Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: partial reversal by insulin (2006) Biochem Biophys Res Commun, 342, pp. 1174-1177; Cervin, C., Axler, O., Holmkvist, J., An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA (2010) J Intern Med, 267, pp. 316-321; Plomgaard, P., Dullaart, R.P., de Vries, R., Groen, A.K., Dahlback, B., Nielsen, L.B., Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects (2009) J Intern Med, 266, pp. 258-267; Kurano, M., Hara, M., Tsuneyama, K., Induction of insulin secretion by apolipoprotein M, a carrier for sphingosine 1-phosphate (1841) Biochim Biophys Acta, 2014, pp. 1217-1226; Park, Y.J., Yoo, S.A., Lee, J.H., Chung, Y.J., Cho, C.S., Kim, W., The APOM polymorphism as a novel risk factor for dyslipidaemia in rheumatoid arthritis: a possible shared link between disease susceptibility and dyslipidaemia (2013) Clin Exp Rheumatol, 31, pp. 180-188; Burger, D., Dayer, J.M., High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? (2002) Autoimmun Rev, 1, pp. 111-117; Singal, D.P., Li, J., Zhu, Y., HLA class III region and susceptibility to rheumatoid arthritis (2000) Clin Exp Rheumatol, 18, pp. 485-491; Santos, M.J., Fernandes, D., Caetano-Lopes, J., Lymphotoxin-alpha 252 A>G polymorphism: a link between disease susceptibility and dyslipidemia in rheumatoid arthritis? (2011) J Rheumatol, 38, pp. 1244-1249",Review,Scopus,2-s2.0-84927653732
"Morita T., Nakano D., Kitada K., Morimoto S., Ichihara A., Hitomi H., Kobori H., Shiojima I., Nishiyama A.","Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type i diabetic kidney",2015,"European Journal of Pharmacology","756",,,"85","91",,,10.1016/j.ejphar.2015.03.053,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926218025&partnerID=40&md5=854196f984dd5f656d71e632392c9738","Department of Pharmacology, Kagawa UniversityMiki, Kita, Kagawa, Japan; Second Department of Internal Medicine, Kansai Medical University, Japan; Department of Endocrinology and Hypertension, Tokyo Women's Medical UniversityTokyo, Japan","Morita, T., Department of Pharmacology, Kagawa UniversityMiki, Kita, Kagawa, Japan, Second Department of Internal Medicine, Kansai Medical University, Japan; Nakano, D., Department of Pharmacology, Kagawa UniversityMiki, Kita, Kagawa, Japan; Kitada, K., Department of Pharmacology, Kagawa UniversityMiki, Kita, Kagawa, Japan; Morimoto, S., Department of Endocrinology and Hypertension, Tokyo Women's Medical UniversityTokyo, Japan; Ichihara, A., Department of Endocrinology and Hypertension, Tokyo Women's Medical UniversityTokyo, Japan; Hitomi, H., Department of Pharmacology, Kagawa UniversityMiki, Kita, Kagawa, Japan; Kobori, H., Department of Pharmacology, Kagawa UniversityMiki, Kita, Kagawa, Japan; Shiojima, I., Department of Endocrinology and Hypertension, Tokyo Women's Medical UniversityTokyo, Japan; Nishiyama, A., Department of Pharmacology, Kagawa UniversityMiki, Kita, Kagawa, Japan","We previously reported that the functional deletion of p21, a cyclin-dependent kinase inhibitor, in mice attenuated renal cell senescence in streptozotocin (STZ)-induced type 1 diabetic mice. In the present study, we investigated the effect of iron chelation on renal cell senescence and inflammation in the type 1 diabetic kidney. STZ-treated mice showed increase in iron accumulation, tubular cell senescence and macrophage infiltration at week 28 in the kidney. Administering deferasirox, which removes only dietary iron, significantly attenuated iron accumulation in proximal tubules and the number of infiltrating F4/80-positive cells without effecting blood glucose, hematocrit or hemoglobin levels. In contrast however, deferasirox did not influence renal cell senescence. The lack of p21 decreased the renal tubular iron accumulation and did not change tubular cell senescence. Interestingly, the STZ-treated animals showed an increase in p16, another cyclin-dependent kinase inhibitor. The results suggest that type 1 diabetes increases renal tubular iron accumulation and macrophage infiltration through a p21-dependent mechanism, and that the chelation of dietary iron attenuates these responses. © 2015 Elsevier B.V. All rights reserved.","Cellular senescence; Diabetic nephropathy; Iron; P21; Proximal tubular cells","Agrawal, S., Guess, A.J., Chanley, M.A., Smoyer, W.E., Albumin-induced podocyte injury and protection are associated with regulation of COX-2 (2014) Kidney Int., 86, pp. 1150-1160; Alcantara, O., Boldt, D.H., Iron deprivation blocks multilineage haematopoietic differentiation by inhibiting induction of p21(WAF1/CIP1) (2007) Br. J. Haematol., 137, pp. 252-261; Anderson, E.R., Taylor, M., Xue, X., Ramakrishnan, S.K., Martin, A., Xie, L., Bredell, B.X., Shah, Y.M., Intestinal HIF2alpha promotes tissue-iron accumulation in disorders of iron overload with anemia (2013) Proceedings of the National Academy of Sciences of the United States of America, 110, pp. E4922-E4930; Diaz-Garcia, J.D., Gallegos-Villalobos, A., Gonzalez-Espinoza, L., Sanchez-Nino, M.D., Villarrubia, J., Ortiz, A., Deferasirox nephrotoxicity-the knowns and unknowns (2014) Nat. Rev. Nephrol., 10, pp. 574-586; Fan, Y.Y., Kohno, M., Hitomi, H., Kitada, K., Fujisawa, Y., Yatabe, J., Yatabe, M., Nakano, D., Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney (2011) Endocrinology, 152, pp. 680-688; Farrehi, P.M., Ozaki, C.K., Carmeliet, P., Fay, W.P., Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice (1998) Circulation, 97, pp. 1002-1008; Fernandez-Real, J.M., Lopez-Bermejo, A., Ricart, W., Cross-talk between iron metabolism and diabetes (2002) Diabetes, 51, pp. 2348-2354; Fernandez-Real, J.M., Penarroja, G., Castro, A., Garcia-Bragado, F., Lopez-Bermejo, A., Ricart, W., Blood letting in high-ferritin type 2 diabetes: Effects on vascular reactivity (2002) Diabetes Care, 25, pp. 2249-2255; Fowlkes, J.L., Bunn, R.C., Cockrell, G.E., Clark, L.M., Wahl, E.C., Lumpkin, C.K., Thrailkill, K.M., Dysregulation of the intrarenal vitamin D endocytic pathway in a nephropathy-prone mouse model of type 1 diabetes (2011) Exp. Diabetes Res., 2011, p. 269378; Gabrielsen, J.S., Gao, Y., Simcox, J.A., Huang, J., Thorup, D., Jones, D., Cooksey, R.C., McClain, D.A., Adipocyte iron regulates adiponectin and insulin sensitivity (2012) J. Clin. Investig., 122, pp. 3529-3540; Green, A., Basile, R., Rumberger, J.M., Transferrin and iron induce insulin resistance of glucose transport in adipocytes (2006) Metab.: Clin. Exp., 55, pp. 1042-1045; Hayflick, L., Moorhead, P.S., The serial cultivation of human diploid cell strains (1961) Exp. Cell Res., 25, pp. 585-621; Hentze, M.W., Muckenthaler, M.U., Andrews, N.C., Balancing acts: Molecular control of mammalian iron metabolism (2004) Cell, 117, pp. 285-297; Ikeda, Y., Enomoto, H., Tajima, S., Izawa-Ishizawa, Y., Kihira, Y., Ishizawa, K., Tomita, S., Tamaki, T., Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice (2013) Am. J. Physiol. Ren. Physiol., 304, pp. F1028-F1036; Ikeda, Y., Tajima, S., Izawa-Ishizawa, Y., Kihira, Y., Ishizawa, K., Tomita, S., Tsuchiya, K., Tamaki, T., Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes (2012) PloS One, 7, p. e40465; Keith, B., Johnson, R.S., Simon, M.C., HIF1alpha and HIF2alpha: Sibling rivalry in hypoxic tumour growth and progression (2012) Nat. Rev. Cancer, 12, pp. 9-22; Kitada, K., Nakano, D., Hitomi, H., Kobori, H., Deguchi, K., Mori, H., Masaki, T., Nishiyama, A., Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor-alpha in human proximal tubular cells (2012) Clin. Exp. Pharmacol. Physiol., 39, pp. 858-863; Kitada, K., Nakano, D., Ohsaki, H., Hitomi, H., Minamino, T., Yatabe, J., Felder, R.A., Nishiyama, A., Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy (2014) J. Diabetes Complicat., 28, pp. 604-611; Lee, S.C., Han, S.H., Li, J.J., Lee, S.H., Jung, D.S., Kwak, S.J., Kim, S.H., Kang, S.W., Induction of heme oxygenase-1 protects against podocyte apoptosis under diabetic conditions (2009) Kidney Int., 76, pp. 838-848; Matsumoto, M., Sasaki, N., Tsujino, T., Akahori, H., Naito, Y., Masuyama, T., Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat (2013) Renal Fail., 35, pp. 1156-1162; Mussoni, L., Sironi, L., Tedeschi, L., Calvio, A.M., Colli, S., Tremoli, E., Magnesium inhibits arterial thrombi after vascular injury in rat: In vivo impairment of coagulation (2001) Thromb. Haemost., 86, pp. 1292-1295; Nandal, A., Ruiz, J.C., Subramanian, P., Ghimire-Rijal, S., Sinnamon, R.A., Stemmler, T.L., Bruick, R.K., Philpott, C.C., Activation of the HIF prolyl hydroxylase by the iron chaperones PCBP1 and PCBP2 (2011) Cell Metab., 14, pp. 647-657; Nankivell, B.J., Tay, Y.C., Boadle, R.A., Harris, D.C., Lysosomal iron accumulation in diabetic nephropathy (1994) Renal Fail., 16, pp. 367-381; Nishioka, S., Nakano, D., Kitada, K., Sofue, T., Ohsaki, H., Moriwaki, K., Hara, T., Nishiyama, A., The cyclin-dependent kinase inhibitor p21 is essential for the beneficial effects of renal ischemic preconditioning on renal ischemia/reperfusion injury in mice (2014) Kidney Int., 85, pp. 871-879; Ogasawara, S., Hosojima, M., Kaseda, R., Kabasawa, H., Yamamoto-Kabasawa, K., Kurosawa, H., Sato, H., Saito, A., Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes (2012) Diabetes Care, 35, pp. 1112-1118; Perlstein, T.S., Pande, R., Berliner, N., Vanasse, G.J., Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: Association with anemia of inflammation (2011) Blood, 117, pp. 2800-2806; Persson, H.L., Vainikka, L.K., Eriksson, I., Wennerstrom, U., TNF-alpha-stimulated macrophages protect A549 lung cells against iron and oxidation (2013) Exp. Toxicol. Pathol., 65, pp. 81-89; Sindrilaru, A., Peters, T., Wieschalka, S., Baican, C., Baican, A., Peter, H., Hainzl, A., Scharffetter-Kochanek, K., An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice (2011) J. Clin. Investig., 121, pp. 985-997; Souma, T., Abe, M., Moriguchi, T., Takai, J., Yanagisawa-Miyazawa, N., Shibata, E., Akiyama, Y., Ito, S., Luminal alkalinization attenuates proteinuria-induced oxidative damage in proximal tubular cells (2011) J. Am. Soc. Nephrol.: JASN, 22, pp. 635-648; Tajima, S., Ikeda, Y., Enomoto, H., Imao, M., Horinouchi, Y., Izawa-Ishizawa, Y., Kihira, Y., Tsuchiya Tamaki, K.T., Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice (2014) Eur. J. Nutr., , http://dx.doi.org/10.1007/s00394-014-0749-1; Uchino, E., Tsuzuki, T., Inoue, K., The effects of age and sex on seven elements of Sprague-Dawley rat organs (1990) Lab. Anim., 24, pp. 253-264; Valenti, L., Dongiovanni, P., Motta, B.M., Swinkels, D.W., Bonara, P., Rametta, R., Burdick, L., Fargion, S., Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations (2011) Arterioscler. Thromb. Vasc. Biol., 31, pp. 683-690; Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K.A., Koepsell, H., Cunard, R., Rieg, T., Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus (2013) Am. J. Physiol. Ren. Physiol., 304, pp. F156-F167; Vervloet, M.G., Massy, Z.A., Brandenburg, V.M., Mazzaferro, S., Cozzolino, M., Urena-Torres, P., Bover, J., Goldsmith, D., Bone: A new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders (2014) Lancet Diabetes Endocrinol., 2, pp. 427-436; Wolf, M., Update on fibroblast growth factor 23 in chronic kidney disease (2012) Kidney Int., 82, pp. 737-747; Yamahara, K., Kume, S., Koya, D., Tanaka, Y., Morita, Y., Chin-Kanasaki, M., Araki, H., Uzu, T., Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions (2013) J. Am. Soc. Nephrol.: JASN, 24, pp. 1769-1781",Article,Scopus,2-s2.0-84926218025
"Zhao Z., Basilio J., Hanson S., Little R.R., Sumner A.E., Sacks D.B.","Evaluation of hemoglobin A<inf>1c</inf> measurement by Capillarys 2 electrophoresis for detection of abnormal glucose tolerance in African immigrants to the United States",2015,"Clinica Chimica Acta","446",,,"54","60",,,10.1016/j.cca.2015.03.025,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928111961&partnerID=40&md5=8cd5c82966ede680079c2040491ebeca","Department of Laboratory Medicine, Clinical Center, National Institutes of HealthBethesda, MD, United States; Department of Pathology and Anatomical Sciences, University of MissouriColumbia, MO, United States; Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of HealthBethesda, MD, United States","Zhao, Z., Department of Laboratory Medicine, Clinical Center, National Institutes of HealthBethesda, MD, United States; Basilio, J., Department of Laboratory Medicine, Clinical Center, National Institutes of HealthBethesda, MD, United States; Hanson, S., Department of Pathology and Anatomical Sciences, University of MissouriColumbia, MO, United States; Little, R.R., Department of Pathology and Anatomical Sciences, University of MissouriColumbia, MO, United States; Sumner, A.E., Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of HealthBethesda, MD, United States; Sacks, D.B., Department of Laboratory Medicine, Clinical Center, National Institutes of HealthBethesda, MD, United States","Background: Hemoglobin A<inf>1c</inf> (HbA<inf>1c</inf>) is used to monitor long-term glycemic control in individuals with diabetes, guide therapy, predict the risk of microvascular complications, and more recently to diagnose diabetes. An automated liquid-flow capillary electrophoresis method was recently developed to measure HbA<inf>1c</inf> using the Capillarys 2 Flex Piercing instrument. Methods: Analytical evaluation was performed at 2 clinical centers. A clinical analysis was conducted in 109 African-born individuals, 24% of whom have variant hemoglobin (HbAS or HbAC). Abnormal glucose tolerance (which includes both diabetes and prediabetes) was defined as 2. h glucose of ≥. 140. mg/dl (7.8. mmol/l) during an oral glucose tolerance test. Results: Interlaboratory CVs were ≤2.1%. The method showed satisfactory correlation with 2 other analyzers that measure HbA<inf>1c</inf> by high-performance liquid chromatography. Neither labile HbA<inf>1c</inf>, carbamylated hemoglobin, uremia, bilirubin nor common hemoglobin variants (HbC/HbS/HbE) interfered. Forty-five individuals (41%) had abnormal glucose tolerance. The sensitivity of HbA<inf>1c</inf> for diagnosing abnormal glucose tolerance was 38%, 36% and 42% for total, normal and variant hemoglobin groups, respectively. Conclusions: The analytical performance of HbA<inf>1c</inf> on the Capillarys 2 is suitable for clinical application. Variant hemoglobin in Africans did not interfere with the detection of abnormal glucose tolerance by HbA<inf>1c</inf> measured on the Capillarys 2. © 2015.","Abnormal glucose tolerance; Africans; Capillarys 2; Diabetes; Hemoglobin a1c; Sickle cell","Standards of medical care in diabetes-2014 (2014) Diabetes Care, 37, pp. S14-S80; Mbanya, J.C., Henry, R.R., Smith, U., Presidents' statement on WHO recommendation on HbA1c for diabetes diagnosis (2011) Diabetes Res Clin Pract, 93, pp. 310-311; Sacks, D.B., Measurement of hemoglobin A(1c): a new twist on the path to harmony (2012) Diabetes Care, 35, pp. 2674-2680; Little, R.R., Rohlfing, C.L., Sacks, D.B., Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care (2011) Clin Chem, 57, pp. 205-214; Sebia, CAPILLARYS Hb A1c using the CAPILLARYS 2 Flex Piercing instrument (2013) Package insert; Michlitsch, J., Azimi, M., Hoppe, C., Newborn screening for hemoglobinopathies in California (2009) Pediatr Blood Cancer, 52, pp. 486-490; Motulsky, A.G., Frequency of sickling disorders in U.S. blacks (1973) N Engl J Med, 288, pp. 31-33; Allison, A.C., The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria (1954) Trans R Soc Trop Med Hyg, 48, pp. 312-318; Piel, F.B., Howes, R.E., Patil, A.P., The distribution of haemoglobin C and its prevalence in newborns in Africa (2013) Sci Rep, 3, p. 1671; Cowie, C.C., Rust, K.F., Byrd-Holt, D.D., Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006 (2010) Diabetes Care, 33, pp. 562-568; Mongia, S.K., Little, R.R., Rohlfing, C.L., Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays (2008) Am J Clin Pathol, 130, pp. 136-140; Roberts, W.L., Safar-Pour, S., De, B.K., Rohlfing, C.L., Weykamp, C.W., Little, R.R., Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods (2005) Clin Chem, 51, pp. 776-778; Goodall, I., Colman, P.G., Schneider, H.G., McLean, M., Barker, G., Desirable performance standards for HbA(1c) analysis - precision, accuracy and standardisation: consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA) (2007) Clin Chem Lab Med, 45, pp. 1083-1097; Little, R.R., Vesper, H., Rohlfing, C.L., Ospina, M., Safar-Pour, S., Roberts, W.L., Validation by a mass spectrometric reference method of use of boronate affinity chromatography to measure glycohemoglobin in the presence of hemoglobin S and C traits (2005) Clin Chem, 51, pp. 264-265; Sumner, A.E., Thoreson, C.K., O'Connor, M.Y., Detection of abnormal glucose tolerance in Africans is improved by combining A1C with fasting glucose: the Africans in America Study (2015) Diabetes Care, 38, pp. 213-219; O'Connor, M.Y., Thoreson, C.K., Ricks, M., Worse cardiometabolic health in African immigrant men than African American men: reconsideration of the healthy immigrant effect (2014) Metab Syndr Relat Disord, 12, pp. 347-353; Ukegbu, U.J., Castillo, D.C., Knight, M.G., Metabolic syndrome does not detect metabolic risk in African men living in the U.S. (2011) Diabetes Care, 34, pp. 2297-2299; Sumner, A.E., Luercio, M.F., Frempong, B.A., Validity of the reduced-sample insulin modified frequently-sampled intravenous glucose tolerance test using the nonlinear regression approach (2009) Metabolism, 58, pp. 220-225; Boston, R.C., Stefanovski, D., Moate, P.J., Sumner, A.E., Watanabe, R.M., Bergman, R.N., MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test (2003) Diabetes Technol Ther, 5, pp. 1003-1015; Rohlfing, C.L., Parvin, C.A., Sacks, D.B., Little, R.R., Comparing analytic performance criteria: evaluation of HbA1c certification criteria as an example (2014) Clin Chim Acta, 433, pp. 259-263; http://www.ngsp.org/, [Accessed March 2015]Sacks, D.B., A1C versus glucose testing: a comparison (2011) Diabetes Care, 34, pp. 518-523; Marinova, M., Altinier, S., Caldini, A., Multicenter evaluation of hemoglobin A1c assay on capillary electrophoresis (2013) Clin Chim Acta, 424, pp. 207-211; Urrechaga, E., High-resolution HbA(1c) separation and hemoglobinopathy detection with capillary electrophoresis (2012) Am J Clin Pathol, 138, pp. 448-456; Jaisson, S., Leroy, N., Meurice, J., Guillard, E., Gillery, P., First evaluation of Capillarys 2 Flex Piercing(R) (Sebia) as a new analyzer for HbA1c assay by capillary electrophoresis (2012) Clin Chem Lab Med, 50, pp. 1769-1775; Weykamp, C., Waenink-Wieggers, H., Kemna, E., Siebelder, C., HbA1c: performance of the Sebia Capillarys 2 Flex Piercing (2013) Clin Chem Lab Med, 51, pp. e129-e131; Heylen, O., Van Neyghem, S., Exterbille, S., Wehlou, C., Gorus, F., Weets, I., Evaluation of the Sebia CAPILLARYS 2 flex piercing for the measurement of HbA(1c) on venous and capillary blood samples (2014) Am J Clin Pathol, 141, pp. 867-877; Petersen, J.R., Okorodudu, A.O., Mohammad, A., Payne, D.A., Capillary electrophoresis and its application in the clinical laboratory (2003) Clin Chim Acta, 330, pp. 1-30; Greene, D.N., Pyle, A.L., Chang, J.S., Hoke, C., Lorey, T., Comparison of Sebia Capillarys Flex capillary electrophoresis with the BioRad Variant II high pressure liquid chromatography in the evaluation of hemoglobinopathies (2012) Clin Chim Acta, 413, pp. 1232-1238; Doelman, C.J., Siebelder, C.W., Nijhof, W.A., Weykamp, C.W., Janssens, J., Penders, T.J., Capillary electrophoresis system for hemoglobin A1c determinations evaluated (1997) Clin Chem, 43, pp. 644-648; The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus (1993) N Engl J Med, 329, pp. 977-986; Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 Diabetes (UKPDS 33) (1998) Lancet, 352, pp. 837-853; Type 2 Diabetes: newer agents for blood glucose control in type 2 diabetes (2009) National Institute for Health and Clinical Excellence; Sacks, D.B., Arnold, M., Bakris, G.L., Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) Clin Chem, 57, pp. e1-e47; Bry, L., Chen, P.C., Sacks, D.B., Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin (2001) Clin Chem, 47, pp. 153-163; Lin, C.N., Emery, T.J., Little, R.R., Effects of hemoglobin C, D, E, and S traits on measurements of HbA1c by six methods (2012) Clin Chim Acta, 413, pp. 819-821; Balkau, B., Soulimane, S., Lange, C., Gautier, A., Tichet, J., Vol, S., Are the same clinical risk factors relevant for incident diabetes defined by treatment, fasting plasma glucose, and HbA1c? (2011) Diabetes Care, 34, pp. 957-959; Lorenzo, C., Haffner, S.M., Performance characteristics of the new definition of diabetes: the insulin resistance atherosclerosis study (2010) Diabetes Care, 33, pp. 335-337; Lorenzo, C., Wagenknecht, L.E., Hanley, A.J., Rewers, M.J., Karter, A.J., Haffner, S.M., A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS) (2010) Diabetes Care, 33, pp. 2104-2109; Kramer, C.K., Araneta, M.R., Barrett-Connor, E., A1C and diabetes diagnosis: the Rancho Bernardo Study (2010) Diabetes Care, 33, pp. 101-103; Olson, D.E., Rhee, M.K., Herrick, K., Ziemer, D.C., Twombly, J.G., Phillips, L.S., Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria (2010) Diabetes Care, 33, pp. 2184-2189",Article,Scopus,2-s2.0-84928111961
"Molitch M.E.","Current approaches to the pharmacological management of Cushing's disease",2015,"Molecular and Cellular Endocrinology","408",,,"185","189",,,10.1016/j.mce.2014.09.021,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928810591&partnerID=40&md5=4b8e3f10320b1790115d6429cecef9df","Martha Leland Sherwin Professor of Endocrinology, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of MedicineChicago, IL, United States","Molitch, M.E., Martha Leland Sherwin Professor of Endocrinology, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of MedicineChicago, IL, United States","If treatment of Cushing's disease (CD) by surgery is not successful, medical therapy is often required. Long-term use of metyrapone is limited by hirsutism and hypertension and escape because of increased ACTH levels. Although ketoconazole can normalize cortisol levels in 50%, liver toxicity limits its use. Mitotane, an adrenolytic agent, has had minimal use for benign disease. Etomidate is useful when rapid reduction in cortisol levels is needed. Cabergoline can normalize cortisol levels in CD in about one-third of patients and is well tolerated. Pasireotide can normalize cortisol levels in CD in about 25% but causes worsening of glucose tolerance in most patients. Mifepristone, a blocker of cortisol receptors, improves clinical aspects of CD in most patients but cortisol and ACTH measurements do not reflect clinical activity and adrenal insufficiency, hypokalemia, and endometrial hyperplasia can occur. Combinations of drugs can be tried in patients resistant to monotherapy. © 2014 Elsevier Ireland Ltd.","Adrenal; Cabergoline; Cushing's; Mifepristone; Pasireotide; Pituitary adenoma","Baudry, C., Coste, J., Khalil, R.B., Silvera, S., Guignat, L., Guibourdenche, J., Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center (2012) Eur. J. Endocrinol, 167, pp. 473-481; Bertagna, X., Guignat, L., Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery (2013) J. Clin. Endocrinol. Metab, 98, pp. 1307-1318; Bertagna, X., Pivonello, R., Fleseriu, M., Zhang, Y., Robinson, P., Taylor, A., LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study (2014) J. Clin. Endocrinol. Metab, 99, pp. 1375-1383; Biller, B.M., Grossman, A.B., Stewart, P.M., Melmed, S., Bertagna, X., Bertherat, J., Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement (2008) J. Clin. Endocrinol. Metab, 93, pp. 2454-2462; Breitschaft, A., Hu, K., Reséndiz, K.H., Darstein, C., Golor, G., Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study (2014) Diabetes Res. Clin. Pract, 103, pp. 458-465; Castinetti, F., Conte-Devoix, B., Brue, T., Medical treatment of Cushing's syndrome; glucocorticoid receptor antagonists and mifepristone (2010) Neuroendocrinology, 92, pp. 125-130; Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Ketoconazole in Cushing's disease: is it worth a try? (2014) J. Clin. Endocrinol. Metab, 99, pp. 1623-1630; Clayton, R.N., Raskasuskiene, D., Reulen, R.C., Jones, P.W., Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature (2011) J. Clin. Endocrinol. Metab, 96, pp. 632-642; Colao, A., Petersenn, S., Newell-Price, J., Findling, J.W., Gu, F., Maldonado, M., A 12-month phase 3 study of pasireotide in Cushing's disease (2012) N. Engl. J. Med, 366, pp. 914-924. , for the Pasireotide B2305 Study Group; Dekkers, O.M., Horváth-Puhó, E., Jøgensen, J.O.L., Cannegieter, S.C., Ehrenstein, V., Vandenbroucke, J.P., Multisystem morbidity and mortality in Cushing's syndrome: a cohort study (2013) J. Clin. Endocrinol. Metab, 98, pp. 2277-2284; European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole (2013), EMA/458028/2013Feelders, R.A., Hofland, L.J., Medical management of Cushing's disease (2013) J. Clin. Endocrinol. Metab, 98, pp. 425-438; Feelders, R.A., de Bruin, C., Pereira, A.M., Romijn, J.A., Netea-Maier, R.T., Hermus, A.R., Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease (2010) N. Engl. J. Med, 362, pp. 1846-1848; Feelders, R.A., Pulgar, S.J., Kempel, A., Pereira, A.M., The burden of Cushing's disease: clinical and health-related quality of life aspects (2012) Eur. J. Endocrinol, 167, pp. 311-326; Fleseriu, M., Biller, B.M.K., Findling, J.W., Molitch, M.E., Schteingart, D.E., Gross, C., Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome (2012) J. Clin. Endocrinol. Metab, 97, pp. 2039-2049. , on behalf of the SEISMIC Study investigators; Fleseriu, M., Molitch, M.E., Gross, C., Schteingart, D.E., Vaughan, T.B., Biller, B.M.K., A new therapeutic approach in the medical treatment of Cushing 's syndrome: glucocorticoid receptor blockade with mifepristone (2013) Endocr. Pract, 19, pp. 313-326. , on behalf of the SEISMIC Study investigators; Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O.D., Lacroix, A., Cabergoline monotherapy in the long-term treatment of Cushing's disease (2010) Eur. J. Endocrinol, 163, pp. 709-716; Henry, R.R., Ciaraldi, T.P., Armstrong, D., Burke, P., Ligueros-Sayfari, M., Mudaliar, S., Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers (2013) J. Clin. Endocrinol. Metab, 98, pp. 3446-3453; Hofland, L.J., Lamberts, S.W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocr. Rev, 24, pp. 28-47; Illouz, F., Dubois-Ginouves, S., Laboureau, S., Rohmer, V., Rodien, P., Use of cabergoline in persisting Cushing's disease (2006) Ann. Endocrinol, 67, pp. 353-356; Kamenicky, P., Droumaguet, C., Salenave, S., Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome (2011) J. Clin. Endocrinol. Metab, 96, pp. 2796-2804; Krieger, D.T., Amorosa, L., Linick, F., Cyproheptadine-induced remission of Cushing's disease (1975) N. Engl. J. Med, 293, pp. 893-896; Lambert, J.K., Goldberg, L., Fayngold, S., Kostadinov, J., Post, K.D., Geer, E.B., Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients (2013) J. Clin. Endocrinol. Metab, 98, pp. 1022-1030; Lila, A.R., Gopal, R.A., Acharya, S.V., George, J., Sarathi, V., Bandgar, T., Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy (2010) Endocr. Pract, 16, pp. 968-976; Luton, J.P., Mahoudeau, J.A., Bouchad, P., Thieblot, P., Hatucourverture, M., Simon, D., Treatment of Cushing's disease by o,p' DDD. Survey of 62 cases (1979) N. Engl. J. Med, 300, pp. 459-464; Monaghan, P.J., Owen, L.J., Trainer, P.J., Brabant, G., Keevil, B.G., Darby, D., Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone (2011) Ann. Clin. Biochem, 48, pp. 441-446; Patil, C.G., Prevedello, D.M., Lad, S.P., Vance, M.L., Thorner, M.O., Katznelson, L., Late recurrences of Cushing's disease after initial successful transsphenoidal surgery (2008) J. Clin. Endocrinol. Metab, 98, pp. 358-372; Pivonello, R., Ferone, D., de Herder, W.W., Kros, J.M., de Caro, M.L.D.B., Arvigo, M., Dopamine receptor expression and function in corticotroph pituitary tumors (2004) J. Clin. Endocrinol. Metab, 89, pp. 2452-2462; Pivonello, R., De Martino, M.C., Cappabianca, P., De Leo, M., Faggiano, A., Lombardi, G., The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery (2009) J. Clin. Endocrinol. Metab, 94, pp. 223-230; Preda, V.A., Sen, J., Karavitaki, N., Grossman, A.B., Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review (2012) Eur. J. Endocrinol, 167, pp. 137-143; Ram, Z., Nieman, L.K., Cutler, G.B., Chrousos, G.P., Doppman, J.L., Oldfield, E.H., Early repeat surgery for persistent Cushing's disease (1994) J. Neurosurg, 80, pp. 37-45; Sonino, N., Boscaro, M., Paoletta, A., Mantero, F., Ziliotto, D., Ketoconazole treatment in Cushing's syndrome; experience in 34 patients (1991) Clin. Endocrinol, 35, pp. 347-352; Starke, R.M., Williams, B.J., Vance, M.L., Sheehan, J.P., Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review (2010) Curr. Opin. Endocrinol. Diabetes Obes, 17, pp. 356-364; Tabarin, A., Navarranne, A., Guérin, J., Corcuff, J.B., Parneix, M., Roger, P., Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome (1991) Clin. Endocrinol, 34, pp. 63-69; Trainer, P.J., Next generation medical therapy for Cushing's syndrome - can we measure a benefit? (2014) J. Clin. Endocrinol. Metab, 99, pp. 1157-1160; FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal livery injury and risk of drug interactions and adrenal gland problems (2013) FDA Drug Safety Communications, pp. 1-6. , 7-27-13; van Erp, N.P., Guchelaar, H.J., Ploeger, B.A., Romijn, J.A., Hartigh, J.D., Gelderblom, H., Mitotanehas a strong and a durable inducing effect on CYP3A4 activity (2011) Eur. J. Endocrinol, 164, pp. 621-626; Valassi, E., Crespo, I., Gich, I., Rodriguez, J., Webb, S.M., A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome (2012) Clin. Endocrinol, 77, pp. 735-742; Verhelst, J.A., Trainer, P.J., Howlett, T.A., Perry, L., Rees, L.H., Grossman, A.B., Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome (1991) Clin. Endocrinol. (Oxf), 35, pp. 169-178; Vilar, L., Naves, L.A., Azevedo, M.F., Arrua, M.J., Arahata, C.M., Moura e Silva, L., Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease (2010) Pituitary, 13, pp. 123-129",Review,Scopus,2-s2.0-84928810591
"Penning T.M.","Editorial",2015,"Chemico-Biological Interactions","234",,,"1","3",,,10.1016/j.cbi.2015.04.014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928408086&partnerID=40&md5=d2fc8a811745e297a277279abc2848c1","University of Pennsylvania, Dept. of Pharmacol, Sch of Med, 3620 Hamilton WalkPhiladelphia, PA, United States","Penning, T.M., University of Pennsylvania, Dept. of Pharmacol, Sch of Med, 3620 Hamilton WalkPhiladelphia, PA, United States",[No abstract available],,,Editorial,Scopus,2-s2.0-84928408086
"Franekova J., Blaha M., Belohoubek J., Kotrbata M., Secnik P., Kubicek Z., Kettner J., Jabor A.","A clinical and laboratory approach used to elucidate discordant results of high-sensitivity troponin T and troponin I",2015,"Clinica Chimica Acta","446",,,"128","131",,,10.1016/j.cca.2015.03.046,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928716760&partnerID=40&md5=7a50133952de7a66ed0ad2f32b871114","Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Charles University, 3rd Faculty of Medicine, Ruská 87Prague 10, Czech Republic","Franeková, J., Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic, Charles University, 3rd Faculty of Medicine, Ruská 87Prague 10, Czech Republic; Bláha, M., Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Bělohoubek, J., Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Kotrbatá, M., Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Sečník, P., Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Kubíček, Z., Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Kettner, J., Department of Cardiology, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic; Jabor, A., Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9Prague 4, Czech Republic, Charles University, 3rd Faculty of Medicine, Ruská 87Prague 10, Czech Republic","Background: Careful interpretation of discordant results in high-sensitivity troponin measurements is necessary in cases of suspect immunoassay interferences. We describe several procedures taken in a case of a polymorbid patient with chest pain, without clear evidence of myocardial necrosis and with increased high-sensitivity cardiac troponin T (hs-cTnT). We checked the Vafaie's algorithm for the evaluation of suspect interference in troponin measurements. Methods: We conducted a case report analysis, additional measurements, a dilution test and pretreatment of plasma with blocking agents. Results: Concentration of hs-cTnT (99th percentile of ""healthy"" population 14. ng/L) increased from 120.1. ng/L to 280.4. ng/L during an 8-month period and decreased to 216.3. ng/L during the following month with repeatedly negative troponin I (TnI), hs-cTnI, myoglobin and creatine kinase MB (CK-MB). Suspected false positivity of hs-cTnT was further confirmed by treatment of plasma with an antiheterophile blocking agent (hs-cTnT before treatment 280.4. ng/L, after 16.53/16.23. ng/L). This outcome was further confirmed by the manufacturer's experiments. Conclusions: The false-positive results of hs-cTnT were caused by the presence of extremely rare high molecular weight protein, presumably IgM, most likely HAMA (human anti-mouse antibody). Only the pre-treatment of plasma with a blocking agent provided a reliable indication of the interference. Cooperation among clinicians, laboratory personnel and the manufacturer is essential. © 2015 Elsevier B.V.","Heterophile antibodies; Immunoassay interference; Troponin","Vafaie, M., Biener, M., Mueller, M., Analytically false or true positive elevations of high sensitivity cardiac troponin: a systematic approach (2014) Heart, 100, pp. 508-514; Lum, G., Solarz, D.E., Farney, L., False positive cardiac troponin results in patients without acute myocardial infarction (2006) Lab Med, 37, pp. 546-550; Dupont, J., Fromonot, J., Franceschi, F., A case of false positive troponin elevation: role of the biological laboratory (2013) Int J Cardiol, 162, pp. e66-e67; Ntelios, D., Mpei, E., Gousi, E., Potolidis, E., Fanourgiakis, P., Mandros, C., Are troponin assays occasionally deceiving us? (2013) Am J Emerg Med, 31 (997), pp. 1-2; Pernet, P., Bénéteau-Burnat, B., Hermand, C., Vaubourdolle, M., Point-of-care testing: false elevation of cardiac troponin I assayed in the emergency department (2008) Am J Emerg Med, 26 (969), pp. e1-e2; Lippi, G., Aloe, R., Meschi, T., Borghi, L., Cervellin, G., Interference from heterophilic antibodies in troponin testing. Case report and systematic review of the literature (2013) Clin Chim Acta, 426, pp. 79-84; Bolstad, N., Warren, D.J., Nustad, K., Heterophilic antibody interference in immunometric assays (2013) Best Pract Res Clin Endocrinol Metab, 27, pp. 647-661; Emerson, J.F., Lai, K.K.Y., Endogenous antibody interferences in immunoassays (2013) Lab Med, 44, pp. 69-73; Sturgeon, C.M., Viljoen, A., Analytical error and interference in immunoassay: minimizing risk (2011) Ann Clin Biochem, 48, pp. 418-432; Emerson, J.F., Ngo, G., Emerson, S.S., Screening for interference in immunoassays (2003) Clin Chem, 49, pp. 1163-1169; Tate, J., Ward, G., Interferences in immunoassay (2004) Clin Biochem Rev, 25, pp. 105-120; Apple, F.S., Collinson, P.O., Analytical characteristics of high-sensitivity cardiac troponin assays (2012) Clin Chem, 58, pp. 54-61; Ghali, S., Lewis, K., Kazan, V., Fluctuation of spuriously elevated troponin I: a case report (2012) Case Rep Crit Care, 2012, p. 585879; Ungerer, J.P., Marquart, L., O'Rourke, P.K., Wilgen, U., Pretorius, C.J., Concordance, variance, and outliers in 4 contemporary cardiac troponin assays: implications for harmonization (2012) Clin Chem, 58, pp. 274-283",Article,Scopus,2-s2.0-84928716760
"Xu R.-X., Zhang Y., Li X.-L., Li S., Guo Y.-L., Dong Q., Liu G., Li J.-J.","Relationship between plasma phospholipase A<inf>2</inf> concentrations and lipoprotein subfractions in patients with stable coronary artery disease",2015,"Clinica Chimica Acta","446",,,"195","200",,,10.1016/j.cca.2015.04.032,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928804760&partnerID=40&md5=1defb3b0184d237b3da156b7b038371e","Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China","Xu, R.-X., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Zhang, Y., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Li, X.-L., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Li, S., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Guo, Y.-L., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Dong, Q., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Liu, G., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Li, J.-J., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China","Background: Both increased lipoprotein-associated phospholipase A<inf>2</inf> (Lp-PLA<inf>2</inf>) concentrations and atherogenic lipoprotein subfractions have been shown to reflect unfavourable cardiovascular risk. However, the correlation between Lp-PLA<inf>2</inf> and lipoprotein subfractions in patients with coronary artery disease (CAD) has not been assessed yet. Methods: A total of 324 consecutive subjects who were not treated with lipid-lowering drugs were enrolled (angiographically proven CAD: n=253; non-CAD: n=71). Plasma Lp-PLA<inf>2</inf> concentrations were measured using ELISA. The low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions were determined by Lipoprint System. Results: Plasma Lp-PLA<inf>2</inf> concentrations were higher in patients with CAD compared with those without CAD (153.61±78.73 vs. 131.41±65.49ng/ml, p=0.028). The univariable correlation analysis revealed that Lp-PLA<inf>2</inf> concentrations were positively correlated with the cholesterol concentrations of each LDL subfractions and the intermediate as well as small HDL subfractions, while negatively linked with the LDL particle size and large HDL-cholesterol (HDL-C) concentrations in CAD group. However, no similar results were observed in the non-CAD group. Furthermore, multivariable regression analysis was performed in patients with CAD and showed that plasma Lp-PLA<inf>2</inf> concentrations were independently correlated with the cholesterol concentrations of each LDL subfractions [large LDL-cholesterol (LDL-C): β=0.263, p<0.001; intermediate LDL-C: β=0.327, p<0.001; small LDL-C: β=0.135, p=0.033] and small HDL-C (β=0.133, p=0.034). Conclusion: Lp-PLA<inf>2</inf> concentrations were positively associated with all LDL subfractions and small HDL subfraction, suggesting an interaction between Lp-PLA<inf>2</inf> and lipoprotein subfraction phenotypes in the status of CAD. © 2015 Elsevier B.V.","Coronary artery disease; High-density lipoprotein subfraction; Lipoprotein associated phospholipase A<inf>2</inf>; Low-density lipoprotein subfraction","Cai, A., Zheng, D., Qiu, R., Mai, W., Zhou, Y., Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment (2013) Dis Markers, 34, pp. 323-331; Rosenson, R.S., Stafforini, D.M., Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2 (2012) J Lipid Res, 53, pp. 1767-1782; Tselepis, A.D., Dentan, C., Karabina, S.A., Chapman, M.J., Ninio, E., PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme (1995) Arterioscler Thromb Vasc Biol, 15, pp. 1764-1773; Stafforini, D.M., Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2) (2009) Cardiovasc Drugs Ther, 23, pp. 73-83; MacPhee, C.H., Moores, K.E., Boyd, H.F., Dhanak, D., Ife, R.J., Leach, C.A., Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor (1999) Biochem J, 338, pp. 479-487; Goncalves, I., Edsfeldt, A., Ko, N.Y., Grufman, H., Berg, K., Björkbacka, H., Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation (2012) Arterioscler Thromb Vasc Biol, 32, pp. 1505-1512; Mangili, A., Ahmad, R., Wolfert, R.L., Kuvin, J., Polak, J.F., Karas, R.H., Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients (2014) Clin Infect Dis, 58, pp. 893-900; Stafforini, D.M., McIntyre, T.M., Carter, M.E., Prescott, S.M., Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor (1987) J Biol Chem, 262, pp. 4215-4222; Noto, H., Chitkara, P., Raskin, P., The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes (2006) J Diabetes Complicat, 20, pp. 343-348; Feng, L.M., Feng, G.F., Chen, Y., Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adult serum (2014) Lipids Health Dis, 13, p. 6; Gregson, J., Stirnadel-Farrant, H.A., Doobaree, I.U., Koro, C., Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature (2012) Atherosclerosis, 225, pp. 11-21; Irving, B.A., Nair, K.S., Srinivasan, M., Effects of insulin sensitivity, body composition, and fitness on lipoprotein particle sizes and concentrations determined by nuclear magnetic resonance (2011) J Clin Endocrinol Metab, 96, pp. E713-E718; Superko, H.R., Pendyala, L., Williams, P.T., Momary, K.M., King, S.B., Garrett, B.C., High-density lipoprotein subclasses and their relationship to cardiovascular disease (2012) J Clin Lipidol, 6, pp. 496-523; Goliasch, G., Oravec, S., Blessberger, H., Dostal, E., Hoke, M., Wojta, J., Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (</=40years of age) (2012) Eur J Clin Invest, 42, pp. 631-636; Gazi, I., Lourida, E.S., Filippatos, T., Tsimihodimos, V., Elisaf, M., Tselepis, A.D., Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma (2005) Clin Chem, 51, pp. 2264-2273; Sanchez-Quesada, J.L., Vinagre, I., De Juan-Franco, E., Vinagre, I., De Juan-Franco, E., Sánchez-Hernández, J., Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes (2013) Cardiovasc Diabetol, 12, p. 112; Christogiannis, L.G., Kostapanos, M.S., Tellis, C.C., Milionis, H.J., Tselepis, A.D., Elisaf, M.S., Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension (2013) J Hum Hypertens, 27, pp. 44-50; Banuls, C., Bellod, L., Jove, A., Martínez-Triguero, M.L., Víctor, V.M., Rocha, M.M., Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type (2012) Clin Chim Acta Int J Clin Chem, 413, pp. 251-257; Kolodgie, F.D., Burke, A.P., Skorija, K.S., Ladich, E., Kutys, R., Makuria, A.T., Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis (2006) Arterioscler Thromb Vasc Biol, 26, pp. 2523-2529; Khuseyinova, N., Imhof, A., Rothenbacher, D., Trischler, G., Kuelb, S., Scharnagl, H., Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis (2005) Atherosclerosis, 182, pp. 181-188; Lp, P.L.A.S.C., Thompson, A., Gao, P., Orfei, L., Watson, S., Di Angelantonio, E., Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies (2010) Lancet, 375, pp. 1536-1544; Constantinides, A., van Pelt, L.J., van Leeuwen, J.J., de Vries, R., Tio, R.A., van der Horst, I.C., Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes (2011) Eur J Clin Investig, 41, pp. 820-827; Dohi, T., Miyauchi, K., Ohkawa, R., Nakamura, K., Thuboi, S., Ogita, M., Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography (2012) Ann Clin Biochem, 49, pp. 527-533; Robins, S.J., Collins, D., Nelson, J.J., Bloomfield, H.E., Asztalos, B.F., Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial (2008) Arterioscler Thromb Vasc Biol, 28, pp. 1172-1178; Jabor, B., Choi, H., Ruel, I., Hafiane, A., Mourad, W., Genest, J., Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol (2013) Can J Cardiol, 29, pp. 1679-1686; Miklishanskaia, S.V., Vlasik, T.N., Kheimets, G.I., Kaznacheeva, E.I., Liakishev, A.A., Kukharchuk, V.V., Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease (2013) Kardiologiia, 53, pp. 4-11; Chae, J.S., Kim, O.Y., Paik, J.K., Kang, R., Seo, W.J., Jeong, T.S., Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome (2011) Atherosclerosis, 218, pp. 499-506; Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (2002) Circulation, 106, pp. 3143-3421; El Harchaoui, K., van der Steeg, W.A., Stroes, E.S., Kuivenhoven, J.A., Otvos, J.D., Wareham, N.J., Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study (2007) J Am Coll Cardiol, 49, pp. 547-553; Lepedda, A.J., Nieddu, G., Zinellu, E., De Muro, P., Piredda, F., Guarino, A., Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker (2013) Oxid Med Cell Longev, 2013, p. 385214; Barylski, M., Toth, P.P., Nikolic, D., Banach, M., Rizzo, M., Montalto, G., Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality (2014) Best Pract Res Clin Endocrinol Metab, 28, pp. 453-461; Kypreos, K.E., Gkizas, S., Rallidis, L.S., Karagiannides, I., HDL particle functionality as a primary pharmacological target for HDL-based therapies (2013) Biochem Pharmacol, 85, pp. 1575-1578; Tian, L., Long, S., Li, C., Liu, Y., Chen, Y., Zeng, Z., High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes (2012) Lipids Health Dis, 11, p. 54",Article,Scopus,2-s2.0-84928804760
"Maruf A.A., Lip H., Wong H., O'Brien P.J.","Protective effects of ferulic acid and related polyphenols against glyoxal- or methylglyoxal-induced cytotoxicity and oxidative stress in isolated rat hepatocytes",2015,"Chemico-Biological Interactions","234",,,"96","104",,,10.1016/j.cbi.2014.11.007,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928390457&partnerID=40&md5=fdbde638086cdcdd46671961518b47e4","Graduate Department of Pharmaceutical Sciences, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Canada","Maruf, A.A., Graduate Department of Pharmaceutical Sciences, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Canada; Lip, H., Graduate Department of Pharmaceutical Sciences, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Canada; Wong, H., Graduate Department of Pharmaceutical Sciences, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Canada; O'Brien, P.J., Graduate Department of Pharmaceutical Sciences, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Canada","Glyoxal (GO) and methylglyoxal (MGO) cause protein and nucleic acid carbonylation and oxidative stress by forming reactive oxygen and carbonyl species which have been associated with toxic effects that may contribute to cardiovascular disease, complications associated with diabetes mellitus, Alzheimer's and Parkinson's disease. GO and MGO can be formed through oxidation of commonly used reducing sugars e.g., fructose under chronic hyperglycemic conditions. GO and MGO form advanced glycation end products which lead to an increased potential for developing inflammatory diseases. In the current study, we have investigated the protective effects of ferulic acid and related polyphenols e.g., caffeic acid, p-coumaric acid, methyl ferulate, ethyl ferulate, and ferulaldehyde on GO- or MGO-induced cytotoxicity and oxidative stress (ROS formation, protein carbonylation and mitochondrial membrane potential maintenance) in freshly isolated rat hepatocytes. To investigate and compare the protective effects of ferulic acid and related polyphenols against GO- or MGO-induced toxicity, five hepatocyte models were used: (a) control hepatocytes, (b) GSH-depleted hepatocytes, (c) catalase-inhibited hepatocytes, (d) aldehyde dehydrogenase (ALDH2)-inhibited hepatocytes, and (e) hepatocyte inflammation system (a non-toxic H<inf>2</inf>O<inf>2</inf>-generating system). All of the polyphenols tested significantly decreased GO- or MGO-induced cytotoxicity, ROS formation and improved mitochondrial membrane potential in these models. The rank order of their effectiveness was caffeic acid ∼ ferulaldehyde > ferulic acid > ethyl ferulate > methyl ferulate > p-coumaric acid. Ferulic acid was found to decrease protein carbonylation in GSH-depleted hepatocytes. This study suggests that ferulic acid and related polyphenols can be used therapeutically to inhibit or decrease GO- or MGO-induced hepatotoxicity. © 2014 Elsevier Ireland Ltd. All rights reserved.","Ferulic acid; Glyoxal; Isolated rat hepatocytes; Methylglyoxal; Oxidative stress; Polyphenols","Shangari, N., Chan, T.S., Popovic, M., O'Brien, P.J., Glyoxal markedly compromises hepatocyte resistance to hydrogen peroxide (2006) Biochem. Pharmacol., 71, pp. 1610-1618; Thornalley, P.J., Jahan, I., Ng, R., Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro (2001) J. Biochem., 129, pp. 543-549; Yang, K., Qiang, D., Delaney, S., Mehta, R., Bruce, W.R., O'Brien, P.J., Differences in glyoxal and methylglyoxal metabolism determine cellular susceptibility to protein carbonylation and cytotoxicity (2011) Chem. Biol. Interact., 191, pp. 322-329; Shangari, N., Bruce, W.R., Poon, R., O'Brien, P.J., Toxicity of glyoxals - Role of oxidative stress, metabolic detoxification and thiamine deficiency (2003) Biochem. Soc. Trans., 31, pp. 1390-1393; Anderson, G.H., Much ado about high-fructose corn syrup in beverages: The meat of the matter (2007) Am. J. Clin. Nutr., 86, pp. 1577-1578; Negre-Salvayre, A., Coatrieux, C., Inqueneau, C., Salvayre, R., Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors (2008) Br. J. Pharmacol., 153, pp. 6-20; O'Brien, P.J., Siraki, A.G., Shangari, N., Aldehyde sources, metabolism, molecular toxicity mechanisms and possible effects on human health (2005) Crit. Rev. Toxicol., 35, pp. 609-662; Mehta, R., Wong, L., O'Brien, P.J., Cytoprotective mechanisms of carbonyl scavenging drugs in isolated rat hepatocytes (2009) Chem. Biol. Interact., 178, pp. 317-323; Peyroux, J., Sternberg, M., Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes (2006) Pathol. Biol. (Paris), 54, pp. 405-419; Kiho, T., Kato, M., Usui, S., Hirano, K., Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal (2005) Clin. Chim. Acta, 358, pp. 139-145; Sullivan, K.A., Feldman, E.L., New developments in diabetic neuropathy (2005) Curr. Opin. Neurol., 18, pp. 586-590; Thornalley, J., The glyoxalase system: New developments towards functional characterization of a metabolic pathway fundamental to biological life (1990) Biochem. J., 269, pp. 1-11; Baba, S.P., Barski, O.A., Ahmed, Y., O'Toole, T.E., Conklin, D.J., Bhatnagar, A., Srivastava, S., Reductive metabolism of AGE precursors: A metabolic route for preventing AGE accumulation in cardiovascular tissue (2009) Diabetes, 58, pp. 2486-2497; Kraemer, R.J., Dietrich, R.A., Isolation and characterization of human liver aldehyde dehydrogenase (1968) Biochem. J., 243, pp. 6402-6408; Feng, C.Y., Wong, S., Dong, Q., Bruce, J., Mehta, R., Bruce, W.R., O'Brien, P.J., Hepatocyte inflammation model for cytotoxicity research: Fructose or glycolaldehyde as a source of endogenous toxins (2009) Arch. Physiol. Biochem., 115, pp. 105-111; Lee, O., Bruce, W.R., Dong, Q., Bruce, J., Mehta, R., O'Brien, P.J., Fructose and carbonyl metabolites as endogenous toxins (2009) Chem. Biol. Interact., 178, pp. 332-339; Towell, J.F., Wang, R.I.H., Hydrogen peroxide-induced glutathione depletion and aldehyde dehydrogenase inhibition in erythrocytes (1987) Biochem. Pharmacol., 36, pp. 2087-2093; Van Duynhoven, J., Vaughan, E.E., Jacobs, D.M., Kemperman, R.A., Van Velzen, E.J., Gross, G., Roger, L.C., Van De Wiele, T., Metabolic fate of polyphenols in the human superorganism (2001) Proc. Natl. Acad. Sci. U.S.A., 108, pp. 4531-4538; Scalbert, A., Morand, C., Manach, C., Rémésy, C., Absorption and metabolism of polyphenols in the gut and impact on health (2002) Biomed. Pharmacother., 56, pp. 276-282; Gonthier, M.P., Chevnier, V., Donovan, J.L., Manach, C., Morand, C., Mila, I., Lapierre, C., Scalbert, A., Microbial aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols (2003) J. Nutr., 133, pp. 461-467; Mamiya, T., Kise, M., Morikawa, K., Ferulic acid attenuated cognitive deficits and increase in carbonyl proteins induced by buthionine-sulfoximine in mice (2008) Neurosci. Lett., 430, pp. 115-118; Soobrattee, M.A., Neergheen, V.S., Luximon-Ramma, A., Aruoma, O.I., Bahorun, T., Phenolics as potential antioxidant therapeutic agents: Mechanisms and actions (2005) Mutat. Res., 579, pp. 200-213; Beecher, G.R., Nutrient content of tomatoes and tomato products (1998) Proc. Soc. Exp. Biol. Med., 218, pp. 98-100; Graf, E., Antioxidant potential of ferulic acid (1992) Free Radic. Biol. Med., 13, pp. 435-448; Rechner, A.R., Spencer, J.P., Kuhnle, G., Hahn, U., Rice-Evans, C.A., Novel biomarkers of the metabolism of caffeic acid derivatives in vivo (2001) Free Radic. Biol. Med., 30, pp. 1213-1222; Kikugawa, K., Hakamada, T., Hasunuma, M., Kurechi, T., Reaction of p-hydroxycinnamic acid derivatives with nitrite and its relevance to nitrosamine formation (1983) J. Agric. Food Chem., 31, pp. 780-785; Chen, J.H., Ho, C., Antioxidant activities of caffeic acid and its related hydroxycinnamic acid compounds (1997) J. Agric. Food Chem., 45, pp. 2374-2378; Kikuzaki, H., Hisamoto, M., Hirose, K., Akiyama, K., Taniguchi, H., Antioxidant properties of ferulic acid and its related compounds (2002) J. Agric. Food Chem., 50, pp. 2161-2168; Rios, L.Y., Gonthier, M.P., Remesy, C., Mila, I., Lapierre, C., Lazarus, S.A., Williamson, G., Scalbert, A., Chocolate intake increases urinary excretion of polyphenol-derived phenolic acids in healthy human subjects (2003) Am. J. Clin. Nutr., 77, pp. 912-918; Radnai, B., Tucsek, Z., Bognar, Z., Antus, C., Mark, L., Berent, Z., Gallyas, Jr.F., Veres, B., Ferulaldehyde, a water-soluble degradation product of polyphenols, inhibits the lipopolysaccharide-induced inflammatory response in mice (2009) J. Nutr., 130, pp. 291-297; Nenadis, N., Zhang, H.Y., Tsimidou, M.Z., Structure-antioxidant activity relationship of ferulic acid derivatives: Effect of carbon side chain characteristic groups (2003) J. Agric. Food Chem., 51, pp. 1874-1879; Mehta, R., Shangari, N., O'Brien, P.J., Preventing cell death induced by carbonyl stress, oxidative stress or mitochondrial toxins with vitamin B anti-AGE agents (2008) Mol. Nutr. Food Res., 52, pp. 379-385; Banach, M.S., Dong, Q., O'Brien, P.J., Hepatocyte cytotoxicity induced by hydroperoxide (oxidative stress model) or glyoxal (carbonylation model): Prevention by bioactive nut extracts or catechins (2009) Chem. Biol. Interact., 178, pp. 324-331; Dong, Q., Banach, M.S., O'Brien, P.J., Cytoprotection by almond skin extracts or catechins of hepatocyte cytotoxicity induced by hydroperoxide (oxidative stress model) versus glyoxal or methylglyoxal (carbonylation model) (2010) Chem. Biol. Interact., 185, pp. 101-109; Lip, H., Yang, K., Macallister, S.L., O'Brien, P.J., Glyoxal and methylglyoxal: Autoxidation from dihydroxyacetone and polyphenol cytoprotective antioxidant mechanisms (2013) Chem. Biol. Interact., 202, pp. 267-274; (1993) Guide to the Care and Use of Experimental Animals, , (canadian Council On Animal Care) Bradda Printing Services ON, Canada, Ottawa; Moldeus, P., Hogberg, J., Orrenius, S., Isolation and use of liver cells (1978) Methods Enzymol., 52, pp. 60-71; Khan, S., O'Brien, P.J., 1-Bromoalkanes as new potent nontoxic glutathione depletors in isolated rat hepatocytes (1991) Biochem. Biophys. Res. Commun., 179, pp. 436-441; Boutin, J.A., Kass, G.E., Moldeus, P., Drug-induced hydrogen peroxide production in isolated rat hepatocytes (1989) Toxicology, 54, pp. 129-137; Vander Jagt, D.L., Hunsaker, L.A., Methylglyoxal metabolism and diabetic complications: Roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase (2003) Chem. Biol. Interact., 143-144, pp. 341-351; Possel, H., Noack, H., Augustin, W., Keilhoff, G., Wolf, G., 2,7-Dihydrodichlorofluorescein diacetate as a fluorescent marker for peroxynitrite formation (1997) FEBS Lett., 416, pp. 175-178; Andersson, B.S., Aw, T.Y., Jones, D.P., Mitochondrial transmembrane potential and pH gradient during anoxia (1987) Am. J. Physiol., 252, pp. C349-C355; Maruf, A.A., Wan, L., O'Brien, P.J., Evaluation of azathioprine-induced cytotoxicity in an in vitro rat hepatocyte system (2014) Biomed. Res. Int., 2014, p. 7. , Article ID 379748; Hartley, D.P., Jroll, D.J., Petersen, D.R., Prooxidant-initiated lipid peroxi-dation in isolated rat hepatocytes: Detection of 4-hydroxynonenal- and malondialdehyde-protein adducts (1997) Chem. Res. Toxicol., 10, pp. 895-905; O'Brien, P.J., Siraki, A.G., Accelerated cytotoxicity mechanism screening using drug metabolizing enzyme modulators (2005) Curr. Drug Metab., 6, pp. 101-109; Chan, K., Jensen, N.S., Silber, P.M., O'Brien, P.J., Structure-activity relationships for halobenzene induced cytotoxicity in rat and human hepatoctyes (2007) Chem. Biol. Interact., 165, pp. 165-174; Sompong, W., Meeprom, A., Cheng, H., Adisakwattana, S., A comparative study of ferulic acid on different monosaccharide-mediated protein glycation and oxidative damage in bovine serum albumin (2013) Molecules, 18, pp. 13886-13903; Macallister, S.L., Maruf, A.A., Wan, L., Chung, E., O'Brien, P.J., Modeling xenobiotic susceptibility to hepatotoxicity using an in vitro oxidative stress inflammation model (2013) Can. J. Physiol. Pharmacol., 91, pp. 236-240",Article,Scopus,2-s2.0-84928390457
"Bjerggaard M., Philipsen A., Jorgensen M.E., Charles M., Witte D.R., Sandbaek A., Lauritzen T., Faerch K.","Association of self-perceived body image with body mass index and type 2 diabetes-The ADDITION-PRO study",2015,"Preventive Medicine","75",,,"64","69",,,10.1016/j.ypmed.2015.03.018,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927661144&partnerID=40&md5=210c19548261fae05709853fd7581b69","Steno Diabetes Center A/SGentofte, Denmark; Department of Public Health, Section of General Practices, University of AarhusAarhus, Denmark","Bjerggaard, M., Steno Diabetes Center A/SGentofte, Denmark, Department of Public Health, Section of General Practices, University of AarhusAarhus, Denmark; Philipsen, A., Steno Diabetes Center A/SGentofte, Denmark; Jørgensen, M.E., Steno Diabetes Center A/SGentofte, Denmark; Charles, M., Department of Public Health, Section of General Practices, University of AarhusAarhus, Denmark; Witte, D.R., Department of Public Health, Section of General Practices, University of AarhusAarhus, Denmark; Sandbæk, A., Department of Public Health, Section of General Practices, University of AarhusAarhus, Denmark; Lauritzen, T., Department of Public Health, Section of General Practices, University of AarhusAarhus, Denmark; Færch, K., Steno Diabetes Center A/SGentofte, Denmark","Objective: Weight loss is important for prevention of type 2 diabetes and an accurate self-perceived body image can promote weight reduction. We evaluated the association of self-perceived body image with body mass index (BMI) and type 2 diabetes. Methods: Data from the Danish ADDITION-PRO cohort study (2009-2011) were used. A total of 2082 men and women attended a health examination including assessment of BMI, waist circumference, the Stunkard scale of self-perceived obesity and an oral glucose tolerance test for assessment of diabetes risk. Results: Mean (SD) age was 66.2 (6.9) years and 24% were obese (BMI ≥30kg/m2). However, only 7% of obese men and 11% of obese women perceived themselves as obese. Among obese women, for a given level of BMI and waist circumference, one unit higher self-perceived body image was associated with 52% (95% CI: 14-73) lower risk of having type 2 diabetes and 45% (95% CI: 12-65) lower risk of having pre-diabetes. Overweight, but not obese, men had a 35% (95% CI: 36-56) lower risk of type 2 diabetes per unit increase in body image. Conclusions: Obese individuals seem to underestimate their body shape. However, having a realistic body image (higher self-perceived obesity) is independently associated with lower diabetes risk. Self-perceived body image might serve as a valuable tool for type 2 diabetes risk assessment. © 2015 Elsevier Inc.","Body image; Body mass index; Type 2 diabetes","Algars, M., Santtila, P., Varjonen, M., The adult body: how age, gender, and body mass index are related to body image (2009) J. Aging Health, 21, pp. 1112-1132; Ard, J.D., Greene, L.E., Malpede, C.Z., Jefferson, W.K., Association between body image disparity and culturally specific factors that affect weight in Black and White women (2007) Ethn. Dis., 17 (2 S), pp. 34-39; Bays, H.E., Bazata, D.D., Fox, K.M., Grandy, S., Gavin, J.R., Perceived body image in men and women with type 2 diabetes mellitus: correlation of body mass index with the figure rating scale (2009) Nutr. J., 8, p. 57; Bhuiyan, A.R., Gustat, J., Srinivasan, S.R., Berenson, G.S., Differences in body shape representations among young adults from a biracial (Black-White), semirural community: the Bogalusa Heart Study (2003) Am. J. Epidemiol., 158, pp. 792-797; Christakis, N.A., Fowler, J.H., The spread of obesity in a large social network over 32years (2007) N. Engl. J. Med., 357, pp. 370-379; Eikenberg, J.D., Davy, B.M., Prediabetes: a prevalent and treatable, but often unrecognized, clinical condition (2013) J. Acad. Nutr. Diet., 113, pp. 213-218; Fallon, A.E., Rozin, P., Sex differences in perceptions of desirable body shape (1985) J. Abnorm. Psychol., 94, pp. 102-105; Field, A.E., Coakley, E.H., Musk, A., Impact of overweight on the risk of developing common chronic diseases during a 10year period (2001) Arch. Intern. Med., 161, pp. 1581-1586; Johansen, N.B., Hansen, A.L., Jensen, T.M., Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care (2012) BMC Public Health, 12, p. 1078; Kabir, Y., Zafar, T.A., Waslien, C., Relationship between perceived body image and recorded body mass index among Kuwaiti female university students (2013) Women Health, 53, pp. 693-705; Kamel, E.G., McNeill, G., Men are less aware of being overweight than women (2000) Obes. Res., 8, p. 604; Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (2002) N. Engl. J. Med., 346, pp. 393-403; Kuchler, F., Variyam, J.N., Mistakes were made: misperception as a barrier to reducing overweight (2003) Int. J. Obes. Relat. Metab. Disord., 27, pp. 856-861; Logue, J., Walker, J.J., Colhoun, H.M., Do men develop type 2 diabetes at lower body mass indices than women? (2011) Diabetologia, 54, pp. 3003-3006; Lynch, E., Liu, K., Spring, B., Hankinson, A., Wei, G.S., Greenland, P., Association of ethnicity and socioeconomic status with judgments of body size: the Coronary Artery Risk Development in Young Adults (CARDIA) Study (2007) Am. J. Epidemiol., 165, pp. 1055-1062; Lynch, E., Liu, K., Wei, G.S., Spring, B., Kiefe, C., Greenland, P., The relation between body size perception and change in body mass index over 13 years. The Coronary Artery Risk Development in Young Adults (CARDIA) Study (2008) Am. J. Epidemiol., 169; Paeratakul, S., White, M.A., Williamson, D.A., Ryan, D.H., Bray, G.A., Sex, race/ethnicity, socioeconomic status, and BMI in relation to self-perception of overweight (2002) Obes. Res., 10, pp. 345-350; Rumsfeld, J.S., MaWhinney, S.M., McCarthy, M., Impact of overweight on the risk of developing common chronic diseases during a 10year period (1999) JAMA, 281, pp. 1298-1303; Stunkard, A.J., Sorensen, T., Schulsinger, F., Use of the Danish Adoption Register for the study of obesity and thinness (1983) Res. Publ. Assoc. Res. Nerv. Ment. Dis., 60, pp. 115-120; Thompson, J.K., Altabe, M.N., Psychometric qualities of the figure rating scale (1991) Int. J. Eat. Disord., 10, pp. 615-619; (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, , Organisation WH, Geneva",Article,Scopus,2-s2.0-84927661144
"Lepard M.G., Joseph A.L., Agne A.A., Cherrington A.L.","Diabetes Self-Management Interventions for Adults with Type 2 Diabetes Living in Rural Areas: A Systematic Literature Review",2015,"Current Diabetes Reports","15","6",,"","",12,,10.1007/s11892-015-0608-3,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928975623&partnerID=40&md5=7531ee0e59070b2d2fa366929d8dd6a0","University of Tennessee Health Science Center School of Medicine, 910 Madison, Suite 1002Memphis, TN, United States; Department of Cognitive, Linguistic and Psychological Sciences, Brown University, 190 Thayer Street, Box 1821Providence, RI, United States; Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, MT 415, 1720 2nd Avenue SouthBirmingham, AL, United States; Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, MT 612, 1720 2nd Avenue SouthBirmingham, AL, United States","Lepard, M.G., University of Tennessee Health Science Center School of Medicine, 910 Madison, Suite 1002Memphis, TN, United States; Joseph, A.L., Department of Cognitive, Linguistic and Psychological Sciences, Brown University, 190 Thayer Street, Box 1821Providence, RI, United States; Agne, A.A., Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, MT 415, 1720 2nd Avenue SouthBirmingham, AL, United States; Cherrington, A.L., Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, MT 612, 1720 2nd Avenue SouthBirmingham, AL, United States","In rural communities, high rates of diabetes and its complications are compounded by limited access to health care and scarce community resources. We systematically reviewed the evidence for the impact of diabetes self-management education interventions designed for patients living in rural areas on glycemic control and other diabetes outcomes. Fifteen studies met inclusion criteria. Ten were randomized controlled trials. Intervention strategies included in-person diabetes (n = 9) and telehealth (n = 6) interventions. Four studies demonstrated between group differences for biologic outcomes, four studies demonstrated changes in behavior, and three studies demonstrated changes in knowledge. Intervention dose was associated with improved A1c or weight loss in two studies and session attendance in one study. Interventions that included collaborative goal-setting were associated with improved metabolic outcomes and self-efficacy. Telehealth and face-to-face diabetes interventions are both promising strategies for rural communities. Effective interventions included collaborative goal-setting. Intervention dose was linked to better outcomes and higher attendance. © 2015, Springer Science+Business Media New York.","Diabetes self-management; Rural; Systematic review; Telehealth","(2014) estimates of diabetes and its burden in the United States, 2014. In: Prevention. CfDCa, , GA: U.S. Department of Health and Human Service; Hoyert, D.L.X.J., National vital statistics reports (2012) Deaths: preliminary data for, 2011. , Hyattsville: MD National Center for Health Statistic; Seaquist, E.R., Addressing the burden of diabetes (2014) JAMA, 311 (22), pp. 2267-2268. , COI: 1:CAS:528:DC%2BC2cXhvVWqsbbP, PID: 2491525; Zhuo, X., Zhang, P., Hoerger, T.J., Lifetime direct medical costs of treating type 2 diabetes and diabetic complications (2013) Am J Prev Med, 45 (3), pp. 253-261. , PID: 2395335; Jessee, B.T., Rutledge, C.M., Effectiveness of nurse practitioner coordinated team group visits for type 2 diabetes in medically underserved Appalachia (2012) J Am Acad Nurse Pract, 24 (12), pp. 735-743. , PID: 2319013; In: Report MaMW, editor: Centers for Disease Control and Prevention; January 14th (2011) 2011; Maez, L., Erickson, L., Naumuk, L., Diabetic education in rural areas (2014) Rural Remote Health, 14 (2), p. 2742. , COI: 1:STN:280:DC%2BC2cfislGlug%3D%3D, PID: 2493047; Siminerio, L.M.P.G., Zgibor, J.C., Implementing the chronic care model for improvements in diabetes care and education in a rural primary care practice (2005) Diabetes Educ, 31 (2), pp. 225-234. , PID: 1579785; Andrus, M.R., Kelley, K.W., Murphey, L.M., Herndon, K.C., A comparison of diabetes care in rural and urban medical clinics in Alabama (2004) J Community Health, 29 (1), pp. 29-44. , PID: 1476893; Skillman, S.M., Andrilla, C.H., Patterson, D.G., Fenton, S.H., Ostergard, S.J., Health information technology workforce needs of rural primary care practices (2014) J Rural Health Off J Am Rural Health Assoc Natl Rural Health Care Assoc; (2014) poverty overview. In: Service ER, , DC: United States Department of Agricultur; Hale NL, Bennett KJ, Probst JC. Diabetes care and outcomes: disparities across rural America. J Community Health. 2010;35(4):365–74. This manuscript describes geographic disparities in diabetes-related complications (rural versus urban) using a nationally representative sample in the United StatesBodenheimer, T., Wagner, E.H., Grumbach, K., Improving primary care for patients with chronic illness: the chronic care model, Part 2 (2002) JAMA, 288 (15), pp. 1909-1914. , PID: 1237709; Norris, S.L., Lau, J., Smith, S.J., Schmid, C.H., Engelgau, M.M., Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control (2002) Diabetes Care, 25 (7), pp. 1159-1171. , PID: 12087014, This classic manuscript provides the evidence supporting the beneficial impact of diabetes self-management education on glycemic control and diabetes car; Strine, T.W., Okoro, C.A., Chapman, D.P., Beckles, G.L., Balluz, L., Mokdad, A.H., The impact of formal diabetes education on the preventive health practices and behaviors of persons with type 2 diabetes (2005) Prev Med, 41 (1), pp. 79-84. , PID: 1591699; Balamurugan, A., Rivera, M., Jack, L., Jr., Allen, K., Morris, S., Barriers to diabetes self-management education programs in underserved rural Arkansas: implications for program evaluation (2006) Prev Chronic Dis, 3 (1), p. 15. , PID: 1635636; Cherrington, A., Martin, M.Y., Hayes, M., Halanych, J.H., Wright, M.A., Appel, S.J., Intervention mapping as a guide for the development of a diabetes peer support intervention in rural Alabama (2012) Prev Chronic Dis, 9. , PID: 2223975; Massey, C.N., Appel, S.J., Buchanan, K.L., Cherrington, A.L., Improving diabetes care in rural communities: an overview of current initiatives and a call for renewed efforts (2010) Clin Diabetes, 28 (1), pp. 20-27; Vassilev, I.R.A., Kennedy, A., Koetsenruijter, J., The influence of social networks on self-management support: a metasynthesis (2014) BMC Public Health, 14 (719), pp. 1-12; Shea, S., Weinstock, R.S., Starren, J., Teresi, J., Palmas, W., Field, L., A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus (2006) J Am Med Inform Assoc, 13 (1), pp. 40-51. , PID: 1622193; Izquierdo, R.L.C., Meyer, S., Telemedicine intervention effects on waist circumference and body mass index in the IDEATel project (2010) Diabetes Technol Ther, 12 (3), pp. 213-220. , PID: 2015177; Ciemins, E., Coon, P., Peck, R., Holloway, B., Min, S.J., Using telehealth to provide diabetes care to patients in rural Montana: findings from the promoting realistic individual self-management program (2011) Telemed J e-health Off J Am Telemed Assoc, 17 (8), pp. 596-602; Davis, R.M., Hitch, A.D., Salaam, M.M., Herman, W.H., Zimmer-Galler, I.E., Mayer-Davis, E.J., TeleHealth improves diabetes self-management in an underserved community: diabetes TeleCare (2010) Diabetes Care, 33 (8), pp. 1712-1717. , PID: 2048412; Hawkins, S.Y., Improving glycemic control in older adults using a videophone motivational diabetes self-management intervention (2010) Res Theory Nurs Pract, 24 (4), pp. 217-232. , PID: 2119791; McIlhenny, C.V.G.B., Knee, D.R., Demuth, B.R., Roberts, J.B., Using technology to deliver healthcare education to rural patients (2011) Rural Remote Health, 11 (4), p. 1798. , PID: 2199585; Anderson-Loftin, W., Barnett, S., Bunn, P., Sullivan, P., Hussey, J., Tavakoli, A., Soul food light: culturally competent diabetes education (2005) Diabetes Educ, 31 (4), pp. 555-563. , PID: 1610033; Bray, P.T.D., Wynn, J.D., Cummings, D.M., Whetstone, L., Confronting disparities in diabetes care: the clinical effectiveness of redesigning care management for minority patients in rural primary care practices (2005) J Rural Health, 21 (3), pp. 317-321. , PID: 1629465; Brown, S.A., Blozis, S.A., Kouzekanani, K., Garcia, A.A., Winchell, M., Hanis, C.L., Dosage effects of diabetes self-management education for Mexican Americans: the Starr County Border Health Initiative (2005) Diabetes Care, 28 (3), pp. 527-532. , PID: 1573518; Brown SA, G.A., Winter, M., Silva, L., Brown, A., Hanis, C.L., Integrating education group support and case management for diabetic Hispanics (2011) Ethn Dis, 2 (1), pp. 20-26; Kattelmann, K.K., Conti, K., Ren, C., The Medicine Wheel nutrition intervention: a diabetes education study with the Cheyenne River Sioux Tribe (2010) J Am Diet Assoc, 110, pp. 44-51. , PID: 2039929; Mayer-Davis, E.J., D'Antonio, A.M., Smith, S.M., Kirkner, G., Martin, S.L., Parra-Medina, D., Pounds off with empowerment (POWER) a clinical trial of weight management strategies for black and white adults with diabetes who live in medically underserved rural communities (2004) Res Pract, 94 (10), pp. 1736-1742; Samuel-Hodge, C.D., Keyserling, T.C., Park, S., Johnston, L.F., Gizlice, Z., Bangdiwala, S.I., A randomized trial of a church-based diabetes self-management program for African Americans with type 2 diabetes (2009) Diabetes Educ, 35 (3), pp. 439-454. , PID: 1938388; Sixta, C.S., Ostwald, S., Texas-Mexico border intervention by promotores for patients with type 2 diabetes (2008) Diabetes Educ, 34 (2), pp. 299-309. , PID: 1837577; Skelly, A.H.C.J., Leeman, J., Soward, A., Burns, D., Controlled trial of nursing interventions to improve health outcomes of Older African American women with type 2 diabetes (2009) Nurs Res, 58 (6), pp. 410-418. , PID: 1985112; Stoodt, G., Lengerich, E.J., Reducing the burden of chronic disease in rural North Carolina (1993) N C Med J, 54 (10), pp. 532-535. , COI: 1:STN:280:DyaK2c%2FnslWquw%3D%3D, PID: 825531; Glanz, K., Rimer, B., Lewis, F., (2002) Health behavior and health education: theory, research, and practise, , (eds), Jossey-Bass, San Francisco; Fisher EB, Brownson CA, O'Toole ML, Shetty G, Anwuri VV, Fazzone P et al. The Robert Wood Johnson Foundation Diabetes Initiative: demonstration projects emphasizing self-management. Diabetes Educ. 2007;33(1):83-4, 6-8, 91-2, passimRicci-Cabello, I., Ruiz-Perez, I., Nevot-Cordero, A., Rodriguez-Barranco, M., Sordo, L., Goncalves, D.C., Health care interventions to improve the quality of diabetes care in African Americans: a systematic review and meta-analysis (2013) Diabetes Care, 36 (3), pp. 760-768. , PID: 2343109",Review,Scopus,2-s2.0-84928975623
"Laffin L.J., Bakris G.L.","Update on Blood Pressure Goals in Diabetes Mellitus",2015,"Current Cardiology Reports","17","6",,"","",7,,10.1007/s11886-015-0591-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928341358&partnerID=40&md5=3315c1e13a8cc18ccfd4cf7f46d4a985","Department of Medicine, ASH Comprehensive Hypertension Center, University of Chicago MedicineChicago, IL, United States; The University of Chicago Medicine, 5841 S. Maryland Ave, MC 1027Chicago, IL, United States","Laffin, L.J., Department of Medicine, ASH Comprehensive Hypertension Center, University of Chicago MedicineChicago, IL, United States; Bakris, G.L., The University of Chicago Medicine, 5841 S. Maryland Ave, MC 1027Chicago, IL, United States","The most recent guideline statements by the 2014 Expert Panel of the National Institutes of Health as well as the American and International Societies of Hypertension recommend a blood pressure goal of <140/90 mmHg in patients with diabetes mellitus. This follows prior guidelines that recommended lower BP treatment goals of <130/80 mmHg in patients with diabetes. Reducing cardiovascular morbidity and mortality by trying to achieve recommended goals of risk factors like blood pressure, glucose, and cholesterol in patients with diabetes is paramount. Data from multiple trials demonstrates that early treatment of hypertension in people with diabetes clearly prevents both macrovascular and microvascular complications, but the goal blood pressure that should be achieved is now modified to a higher level. We address the evidence and evolution of how and why this blood pressure goal has changed in recent years. © 2015, Springer Science+Business Media New York.","Diabetes mellitus; Guidelines; Hypertension","Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jr., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report (2003) Jama, 289 (19), pp. 2560-2572. , COI: 1:CAS:528:DC%2BD3sXjvFCqtrk%3D, PID: 12748199; Standards of medical care in diabetes–2014 (2014) Diabetes Care, 37, pp. 14-80; Bakris, G., Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better (2013) Nat Rev Nephrol, 9 (11), pp. 634-635. , PID: 24080799, Paper reviews all the studies and provides a perspective on renal outcomes and BP goal; Barzilay, J.I., Howard, A.G., Evans, G.W., Fleg, J.L., Cohen, R.M., Booth, G.L., Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial (2012) Diabetes Care, 35 (7), pp. 1401-1405. , PID: 22723577; James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) (2014) JAMA, 311 (5), pp. 507-520. , COI: 1:CAS:528:DC%2BC2cXis1aktr8%3D, PID: 24352797, Expert panel report with strong evidence provided for guidance made; Weber, M.A., Schiffrin, E.L., White, W.B., Mann, S., Lindholm, L.H., Kenerson, J.G., Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension (2014) J Clin Hypertens, 16 (1), pp. 14-26. , A unified American and International guidance paper on BP guidelines; Navar-Boggan, A.M., Pencina, M.J., Williams, K., Sniderman, A.D., Peterson, E.D., Proportion of US adults potentially affected by the 2014 hypertension guideline (2014) Jama, 311 (14), pp. 1424-1429. , COI: 1:CAS:528:DC%2BC2cXhsVGktrnM, PID: 24682242; I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications (1993) J Hypertens, 11 (3), pp. 309-317; Parving, H.H., Hommel, E., Mathiesen, E., Skott, P., Edsberg, B., Bahnsen, M., Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes (1988) Br Med J, 296 (6616), pp. 156-160. , COI: 1:STN:280:DyaL1c7gvVOiuw%3D%3D; Levin, A., Stevens, P.E., Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward (2014) Kidney Int, 85 (1), pp. 49-61; Bakris, G.L., Molitch, M., Microalbuminuria as a risk predictor in diabetes: the continuing saga (2014) Diabetes Care, 37 (3), pp. 867-875. , PID: 24558077, Provides an evidence based look at microalbuminuria in diabetes and evaluation of outcome predictor; Epstein, M., Sowers, J.R., Diabetes mellitus and hypertension (1992) Hypertension, 19 (5), pp. 403-418. , COI: 1:STN:280:DyaK383jsVGgsA%3D%3D, PID: 1568757; Nosadini, R., Sambataro, M., Thomaseth, K., Pacini, G., Cipollina, M.R., Brocco, E., Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes (1993) Kidney Int, 44 (1), pp. 139-146. , COI: 1:STN:280:DyaK3szmtVCrsA%3D%3D, PID: 8355455; Randeree, H.A., Omar, M.A., Motala, A.A., Seedat, M.A., Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure (1992) Diabetes Care, 15 (10), pp. 1258-1263. , COI: 1:STN:280:DyaK3s%2FkvVGjsA%3D%3D, PID: 1425085; Cruickshank, K., Riste, L., Anderson, S.G., Wright, J.S., Dunn, G., Gosling, R.G., Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? (2002) Circulation, 106 (16), pp. 2085-2090. , PID: 12379578; Hemmingsen, B., Lund, S.S., Gluud, C., Vaag, A., Almdal, T.P., Hemmingsen, C., Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus (2013) Cochrane Database Syst Rev, 11. , PID: 24214280; Gaede, P., Vedel, P., Parving, H.H., Pedersen, O., Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study (1999) Lancet, 353 (9153), pp. 617-622. , COI: 1:STN:280:DyaK1M7ltleqtQ%3D%3D, PID: 10030326; UKPDS 38. UK Prospective Diabetes Study Group (1998) BMJ, 317, pp. 703-713; Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S., Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group (1998) Lancet, 351 (9118), pp. 1755-1762. , COI: 1:CAS:528:DyaK1cXksV2qtrY%3D, PID: 9635947; Patel, A., Group, A.C., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial (2007) Lancet, 370 (9590), pp. 829-840. , COI: 1:CAS:528:DC%2BD2sXhtVWjs7zO, PID: 17765963; Group, A.S., Cushman, W.C., Evans, G.W., Byington, R.P., Goff, D.C., Jr., Grimm, R.H., Jr., Effects of intensive blood-pressure control in type 2 diabetes mellitus (2010) N Engl J Med, 362 (17), pp. 1575-1585; Schrier, R.W., Estacio, R.O., Esler, A., Mehler, P., Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes (2002) Kidney Int, 61 (3), pp. 1086-1097. , PID: 11849464; Howard, B.V., Roman, M.J., Devereux, R.B., Fleg, J.L., Galloway, J.M., Henderson, J.A., Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial (2008) Jama, 299 (14), pp. 1678-1689. , COI: 1:CAS:528:DC%2BD1cXks1Wmtbs%3D, PID: 18398080; Cooper-DeHoff, R.M., Gong, Y., Handberg, E.M., Bavry, A.A., Denardo, S.J., Bakris, G.L., Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease (2010) Jama, 304 (1), pp. 61-68. , COI: 1:CAS:528:DC%2BC3cXovVSjurY%3D, PID: 20606150; Weber, M.A., Bakris, G.L., Jamerson, K., Weir, M., Kjeldsen, S.E., Devereux, R.B., Cardiovascular events during differing hypertension therapies in patients with diabetes (2010) J Am Coll Cardiol, 56 (1), pp. 77-85. , COI: 1:CAS:528:DC%2BC3cXhtVSltbbN, PID: 20620720; Investigators, O., Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Telmisartan, ramipril, or both in patients at high risk for vascular events (2008) N Engl J Med, 358 (15), pp. 1547-1559; Berl, T., Hunsicker, L.G., Lewis, J.B., Pfeffer, M.A., Porush, J.G., Rouleau, J.L., Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial (2005) J Am Soc Nephrol: JASN, 16 (7), pp. 2170-2179. , COI: 1:CAS:528:DC%2BD2MXms1egsLw%3D, PID: 15930097; Bakris, G.L., Weir, M.R., Shanifar, S., Zhang, Z., Douglas, J., van Dijk, D.J., Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study (2003) Arch Intern Med, 163 (13), pp. 1555-1565. , PID: 12860578; Wheeler, D.C., Becker, G.J., Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? (2013) Kidney Int, 83 (3), pp. 377-383. , COI: 1:CAS:528:DC%2BC3sXjsFGrtrs%3D, PID: 23325075; Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Bohm, M., 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) J Hypertens, 31 (7), pp. 1281-1357. , COI: 1:CAS:528:DC%2BC3sXhtVyksb%2FJ, PID: 23817082; Messerli, F.H., Bangalore, S., Julius, S., Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension (2008) Circulation, 117 (20), pp. 2706-2715. , PID: 18490538, discussion 15; Bakris, G.L., Fonseca, V., Katholi, R.E., McGill, J.B., Messerli, F.H., Phillips, R.A., Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial (2004) Jaxma, 292 (18), pp. 2227-2236. , COI: 1:CAS:528:DC%2BD2cXpslyqtL8%3D",Review,Scopus,2-s2.0-84928341358
"Nygren M., Carstensen J., Koch F., Ludvigsson J., Frostell A.","Experience of a serious life event increases the risk for childhood type 1 diabetes: the ABIS population-based prospective cohort study",2015,"Diabetologia","58","6",,"1188","1197",,,10.1007/s00125-015-3555-2,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928724702&partnerID=40&md5=02c13b5f77b17222e74329dbee8510e2","Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping UniversityLinköping, Sweden; Division of Health and Society, Department of Medical and Health Sciences, Linköping UniversityLinköping, Sweden; Division of Psychology, Department of Behavioural Sciences and Learning, Linköping UniversityLinköping, Sweden","Nygren, M., Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping UniversityLinköping, Sweden, Division of Health and Society, Department of Medical and Health Sciences, Linköping UniversityLinköping, Sweden, Division of Psychology, Department of Behavioural Sciences and Learning, Linköping UniversityLinköping, Sweden; Carstensen, J., Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping UniversityLinköping, Sweden, Division of Health and Society, Department of Medical and Health Sciences, Linköping UniversityLinköping, Sweden, Division of Psychology, Department of Behavioural Sciences and Learning, Linköping UniversityLinköping, Sweden; Koch, F., Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping UniversityLinköping, Sweden, Division of Health and Society, Department of Medical and Health Sciences, Linköping UniversityLinköping, Sweden, Division of Psychology, Department of Behavioural Sciences and Learning, Linköping UniversityLinköping, Sweden; Ludvigsson, J., Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping UniversityLinköping, Sweden, Division of Health and Society, Department of Medical and Health Sciences, Linköping UniversityLinköping, Sweden, Division of Psychology, Department of Behavioural Sciences and Learning, Linköping UniversityLinköping, Sweden; Frostell, A., Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping UniversityLinköping, Sweden, Division of Health and Society, Department of Medical and Health Sciences, Linköping UniversityLinköping, Sweden, Division of Psychology, Department of Behavioural Sciences and Learning, Linköping UniversityLinköping, Sweden","Aims/hypothesis: The aim of this study was to prospectively investigate whether psychological stress during childhood may be a risk factor for manifest type 1 diabetes. Methods: The All Babies In Southeast Sweden (ABIS) study invited all families with babies born between 1 October 1997 and 30 September 1999 in southeast Sweden to participate. Our study subsample includes 10,495 participants in at least one of the data collections at 2–3, 5–6, 8 and 10–13 years of age not yet diagnosed with type 1 diabetes at inclusion; 58 children were subsequently diagnosed. Age at diagnosis was obtained from the national register SweDiabKids in 2012. Family psychological stress was measured via questionnaires given to the parents assessing serious life events, parenting stress, parental worries and the parent’s social support. Results: Childhood experience of a serious life event was associated with a higher risk of future diagnosis of type 1 diabetes (HR 3.0 [95% CI 1.6, 5.6], p = 0.001) after adjusting for heredity of type 1 diabetes and age at entry into the study. The result was still valid when controlling for heredity of type 2 diabetes, size for gestational age, the parents’ education level and whether the mother worked at least 50% of full time before the child’s birth (HR 2.8 [95% CI 1.5, 5.4], p = 0.002), and also when childhood BMI was added to the model (HR 5.0 [95% CI 2.3, 10.7], p < 0.001). Conclusions/interpretation: This first prospective study concluded that experience of a serious life event in childhood may be a risk factor for manifest type 1 diabetes. © 2015, Springer-Verlag Berlin Heidelberg.","Longitudinal studies; Prospective studies; Psychological stress; Risk factors; Stressful events; Type 1 diabetes mellitus","Atkinson, M.A., Bluestone, J.A., Eisenbarth, G.S., How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited (2011) Diabetes, 60, pp. 1370-1379. , COI: 1:CAS:528:DC%2BC3MXmsVKltb4%3D, PID: 21525508; Tauriainen, S., Oikarinen, S., Oikarinen, M., Hyöty, H., Enteroviruses in the pathogenesis of type 1 diabetes (2011) Semin Immunopathol, 33, pp. 45-55. , COI: 1:CAS:528:DC%2BC3MXntVGmtQ%3D%3D, PID: 20424841; Knip, M., Virtanen, S.M., Åkerblom, H.K., Infant feeding and the risk of type 1 diabetes (2010) Am J Clin Nutr, 91, pp. 1506-1513. , PID: 20335552; Cardwell, C., Stene, L., Joner, G., Birthweight and the risk of childhood-onset type 1 diabetes: a meta-analysis of observational studies using individual patient data (2010) Diabetologia, 53, pp. 641-651. , COI: 1:STN:280:DC%2BC3c7nsF2mtw%3D%3D, PID: 20063147; Ludvigsson, J., Why diabetes incidence increases—a unifying theory (2006) Ann N Y Acad Sci, 1079, pp. 374-382. , PID: 17130582; Patterson, C., Guariguata, L., Dahlquist, G., Soltész, G., Ogle, G., Silink, M., Diabetes in the young—a global view and worldwide estimates of numbers of children with type 1 diabetes (2014) Diabetes Res Clin Pract, 103, pp. 161-175. , PID: 24331235; Stein, S.P., Charles, E., Emotional factors in juvenile diabetes mellitus: a study of early life experience of adolescent diabetics (1971) Am J Psychiatry, 128, pp. 700-704. , COI: 1:STN:280:DyaE387ns1Wnuw%3D%3D, PID: 5147725; Leaverton, D.R., White, C.A., McCormick, C.R., Smith, P., Sheikholislam, B., Parental loss antecedent to childhood diabetes mellitus (1980) J Am Acad Child Psychiatry, 19, pp. 678-689. , COI: 1:STN:280:DyaL3M7ktlWmsQ%3D%3D, PID: 7204798; Siemiatycki, J., Colle, E., Campbell, S., Dewar, R.A., Belmonte, M.M., Case-control study of IDDM (1989) Diabetes Care, 12, pp. 209-216. , COI: 1:STN:280:DyaL1M7ps1WktQ%3D%3D, PID: 2702913; Vialettes, B., Ozanon, J., Kaplansky, S., Stress antecedents and immune status in recently diagnosed type 1 (insulindependent) diabetes mellitus (1989) Diabete Metab, 15, pp. 45-50. , COI: 1:STN:280:DyaL1M3lt1ektA%3D%3D, PID: 2656329; Hägglöf, B., Blom, L., Dahlquist, G., Lönnberg, G., Sahlin, B., The Swedish childhood diabetes study: indications of severe psychological stress as a risk factor for type 1 (insulin-dependent) diabetes mellitus in childhood (1991) Diabetologia, 34, pp. 579-583. , PID: 1936661; Thernlund, G.M., Dahlquist, G., Hansson, K., Psychological stress and the onset of IDDM in children (1995) Diabetes Care, 18, pp. 1323-1329. , COI: 1:STN:280:DyaK28zlt1ChtA%3D%3D, PID: 8721932; Littorin, B., Sundkvist, G., Nyström, L., Family characteristics and life events before the onset of autoimmune type 1 diabetes in young adults: a nationwide study (2001) Diabetes Care, 24, pp. 1033-1037. , COI: 1:STN:280:DC%2BD3Mzktlygsg%3D%3D, PID: 11375366; Vlajinac, H., Sipetić, S., Marinković, J., Bjekić, M., Kocev, N., Sajić, S., The Belgrade childhood diabetes study—comparison of children with type 1 diabetes with their siblings (2006) Paediatr Perinat Epidemiol, 20, pp. 238-243. , PID: 16629698; Sipetić, S., Vlajinac, H., Marinkovi, J., Stressful life events and psychological dysfunctions before the onset of type 1 diabetes mellitus (2007) J Pediatr Endocrinol Metab, 20, pp. 527-534. , PID: 17550217; Karavanaki, K., Tsoka, E., Liacopoulou, M., Psychological stress as a factor potentially contributing to the pathogenesis of type 1 diabetes mellitus (2008) J Endocrinol Investig, 31, pp. 406-415. , COI: 1:STN:280:DC%2BD1czptlWksg%3D%3D; Zung, A., Blumenfeld, O., Shehadeh, N., Increase in the incidence of type 1 diabetes in Israeli children following the Second Lebanon War (2012) Pediatr Diabetes, 13, pp. 326-333. , PID: 22151880; Nygren, M., Ludvigsson, J., Carstensen, J., Sepa Frostell, A., Family psychological stress early in life and development of type 1 diabetes: the ABIS prospective study (2013) Diabetes Res Clin Pract, 100, pp. 257-264. , PID: 23549245; Carlsson, E., Frostell, A., Ludvigsson, J., Faresjö, M., Psychological stress in children may alter the immune response (2014) J Immunol, 192, pp. 2071-2081. , COI: 1:CAS:528:DC%2BC2cXivFOru74%3D, PID: 24501202; Holmes, T.H., Rahe, R.H., The Social Readjustment Rating Scale (1967) J Psychosom Res, 11, pp. 213-218. , COI: 1:STN:280:DyaF1c%2FltVeisw%3D%3D, PID: 6059863; Coddington, R.D., The significance of life events as etiologic factors in the diseases of children. II. A study of a normal population (1972) J Psychosom Res, 16, pp. 205-213. , COI: 1:STN:280:DyaE3s%2FgvVartw%3D%3D, PID: 5072914; Östberg, M., Hagekull, B., Wettergren, S., A measure of parental stress in mothers with small children: dimensionality, stability and validity (1997) Scand J Psychol, 38, pp. 199-208. , PID: 9309950; Abidin, R.R., (1990) Parenting Stress Index (PSI) manual, , Psychological Assessment Resources, Inc, Odessa; Koch, F.S., Ludvigsson, J., Sepa, A., Parents’ psychological stress over time may affect children’s cortisol at age 8 (2010) J Pediatr Psychol, 35, pp. 950-959. , PID: 20081219; Crnic, K.A., Greenberg, M.T., Ragozin, A.S., Robinson, N.M., Basham, R.B., Effects of stress and social support on mothers and premature and full-term infants (1983) Child Dev, 54, pp. 209-217. , COI: 1:STN:280:DyaL3s7ls12muw%3D%3D, PID: 6831987; Östberg, M., Hagekull, B., A structural modeling approach to the understanding of parenting stress (2000) J Clin Child Psychol, 29, pp. 615-625. , PID: 11126638; Koch, F.S., Sepa, A., Ludvigsson, J., Psychological stress and obesity (2008) J Pediatr, 153, pp. 839-844. , PID: 18657829; Gustafsson, P.E., Gustafsson, P.A., Nelson, N., Cortisol levels and psychosocial factors in preadolescent children (2006) Stress Health, 22, pp. 3-9; Dhabhar, F.S., Enhancing vs suppressive effects of stress on immune function: implications for immunoprotection and immunopathology (2009) Neuroimmunomodulation, 16, pp. 300-317. , COI: 1:CAS:528:DC%2BD1MXnvFKjtb0%3D, PID: 19571591; Sepa, A., Frodi, A., Ludvigsson, J., Psychosocial correlates of parenting stress, lack of support and lack of confidence/security (2004) Scand J Psychol, 45, pp. 169-179. , PID: 15016271; Koch, F.S., (2009) Stress and obesity in childhood, , Linköping University Linköping, Sweden; Monroe, S.M., Modern approaches to conceptualizing and measuring human life stress (2008) Annu Rev Clin Psychol, 4, pp. 33-52. , PID: 17716038; Lewinsohn, P.M., Rohde, P., Gau, J.M., Comparability of self-report checklist and interview data in the assessment of stressful life events in young adults (2003) Psychol Rep, 93, pp. 459-471. , PID: 14650673; Brown, G.W., Harris, T.O., (1978) Social origins of depression: a study of psychiatric disorder in women, , Tavistock Publications, London; Dohrenwend, B.P., Inventorying stressful life events as risk factors for psychopathology: toward resolution of the problem of intracategory variability (2006) Psychol Bull, 132, pp. 477-495. , PID: 16719570; Duggal, S., Malkoff-Schwartz, S., Birmaher, B., Assessment of life stress in adolescents: self-report vs interview methods (2000) J Am Acad Child Adolesc Psychiatry, 39, pp. 445-452. , COI: 1:STN:280:DC%2BD3c3isVCisA%3D%3D, PID: 10761346; Schemper, M., Cox analysis of survival data with non-proportional hazard functions (1992) Statistician, 41, pp. 455-465; Sepa, A., Frodi, A., Ludvigsson, J., Mothers’ experiences of serious life events increase the risk of diabetes-related autoimmunity in their children (2005) Diabetes Care, 28, pp. 2394-2399. , PID: 16186269; Sepa, A., Wahlberg, J., Vaarala, O., Frodi, A., Ludvigsson, J., Psychological stress may induce diabetes-related autoimmunity in infancy (2005) Diabetes Care, 28, pp. 290-295. , PID: 15677781; Nygren, M., Carstensen, J., Koch, F., Frostell, A., Ludvigsson, J., ISPAD 2013 oral sessions: O42 experiences of a stressful life event increases the risk for childhood type 1 diabetes: the ABIS population-based prospective cohort study (2013) Pediatr Diabetes, 14, p. 36",Article,Scopus,2-s2.0-84928724702
"Stoekenbroek R.M., Rensing K.L., Bernelot Moens S.J., Nieuwdorp M., DeVries J.H., Zwinderman A.H., Stroes E.S., Currie C.J., Hutten B.A.","High daily insulin exposure in patients with type 2 diabetes isassociated with increased risk of cardiovascular events",2015,"Atherosclerosis","240","2",,"318","323",,1,10.1016/j.atherosclerosis.2015.03.040,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926512788&partnerID=40&md5=0df1a4afb74819a8e90db5d583f783a8","Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Academic Medical Centre, Department of Internal MedicineAmsterdam, Netherlands; Academic Medical Centre, Department of Clinical Epidemiology, Biostatistics and BioinformaticsAmsterdam, Netherlands; School of Medicine, Cardiff University, Department of MedicineCardiff, United Kingdom","Stoekenbroek, R.M., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Rensing, K.L., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Bernelot Moens, S.J., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Nieuwdorp, M., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; DeVries, J.H., Academic Medical Centre, Department of Internal MedicineAmsterdam, Netherlands; Zwinderman, A.H., Academic Medical Centre, Department of Clinical Epidemiology, Biostatistics and BioinformaticsAmsterdam, Netherlands; Stroes, E.S., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Currie, C.J., School of Medicine, Cardiff University, Department of MedicineCardiff, United Kingdom; Hutten, B.A., Academic Medical Centre, Department of Clinical Epidemiology, Biostatistics and BioinformaticsAmsterdam, Netherlands","Aims: Intensive glucose control, often involving insulin treatment, failed to improve cardiovascular outcomes in several clinical trials. Observational studies reported an association between insulin use and cardiovascular disease (CVD) risk. It has therefore been suggested that insulin adversely affects CVD risk. To investigate the feasibility of this hypothesis, we studied the association between insulin dose and CVD risk in type 2 diabetes. Methods: A case-control study was conducted of new users of oral antidiabetics who were prescribed insulin, using the Dutch Pharmo database. Cases were hospitalized for a cardiovascular event (CVE) and matched 1:2 to patients who were not hospitalized for a CVE, by sex, age, duration of diabetes and type of oral antidiabetic. Patients were divided into tertiles according to mean daily insulin dose. Conditional logistic regression analyses were used to explore the association between insulin exposure and CVE risk. Results: We included 836 patients (517 (62%) male, mean age 66 years). After adjusting for available potential confounders, including HbA1c and triglycerides, insulin exposure was positively related to CVE risk (odds ratios for high (≥53.0 U/day) and intermediate (24.3-52.9 U/day) vs. low exposure (≤24.2 U/day): 3.00 [95% confidence interval (CI) 1.70 to 5.28] and 2.03 [95% CI 1.17 to 3.52]. Conclusion: Our findings are in line with the suggestion that high-dose insulin therapy adversely affects CVD risk, but need to be interpreted with caution due to the observational nature of the study. The role of particularly high-dose insulin in the progression of CVD warrants further investigation. © 2015 Elsevier Ireland Ltd.","Cardiovascular disease; Diabetes; Insulin therapy","Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction (1998) N.Engl. J. Med., 339, pp. 229-234; Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F.L., Powe, N.R., Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus (2004) Ann. Intern. Med., 141, pp. 421-431; Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C., Bigger, J.T., Buse, J.B., Effects of intensive glucose lowering in type 2 diabetes (2008) N.Engl. J. Med., 358, pp. 2545-2559; Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes (2008) N.Engl. J. Med., 358, pp. 2560-2572; Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., Glucose control and vascular complications in veterans with type 2 diabetes (2009) N.Engl. J. Med., 360, pp. 129-139; Gerstein, H.C., Bosch, J., Dagenais, G.R., Diaz, R., Jung, H., Maggioni, A.P., Basal insulin and cardiovascular and other outcomes in dysglycemia (2012) N.Engl. J. Med., 367, pp. 319-328; Riddle, M.C., Ambrosius, W.T., Brillon, D.J., Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial (2010) Diabetes Care, 33, pp. 983-990; Bonds, D.E., Miller, M.E., Bergenstal, R.M., The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study (2010) BMJ, 340. , b4909-b4909; Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes (2008) N.Engl. J. Med., 359, pp. 1577-1589; Hoebers, L.P., Claessen, B.E., Woudstra, P., DeVries, J.H., Wykrzykowska, J.J., Vis, M.M., Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus (2014) Eurointervention, 10, pp. 90-96; Anselmino, M., Ohrvik, J., Malmberg, K., Standl, E., Ryden, L., Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the euro heart survey on diabetes and the Heart (2008) Eur. Heart J., 29, pp. 177-184; Smooke, S., Horwich, T.B., Fonarow, G.C., Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (2005) Am. Heart J., 149, pp. 168-174; Margolis, D.J., Hoffstad, O., Strom, B.L., Association between serious ischemic cardiac outcomes and medications used to treat diabetes (2008) Pharmacoepidemiol. Drug Saf., 17, pp. 753-759; Colayco, D.C., Niu, F., McCombs, J.S., Cheetham, T.C., A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study (2011) Diabetes Care, 34, pp. 77-83; Gamble, J.M., Simpson, S.H., Eurich, D.T., Majumdar, S.R., Johnson, J.A., Insulin use and increased risk of mortality in type 2 diabetes: a cohort study (2010) Diabetes Obes. Metab., 12, pp. 47-53; Currie, C.J., Peters, J.R., Tynan, A., Evans, M., Heine, R.J., Bracco, O.L., Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study (2010) Lancet, 375, pp. 481-489; Rensing, K.L., Reuwer, A.Q., Arsenault, B.J., von der Thusen, J.H., Hoekstra, J.B., Kastelein, J.J., Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? (2011) Diabetes Obes. Metab., 13, pp. 1073-1087; Park, Y.M., Kashyap, R., Major, A., Silverstein, R.L., Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis (2012) Lab. Invest., 92, pp. 1171-1180; Muntoni, S., Muntoni, S., Draznin, B., Effects of chronic hyperinsulinemia in insulin-resistant patients (2008) Curr. Diabetes Rep., 8, pp. 233-238; Chaudhuri, A., Dandona, P., Fonseca, V., Cardiovascular benefits of exogenous insulin (2012) J.Clin. Endocrinol. Metab., 97, pp. 3079-3091; Paneni, F., Beckman, J.A., Creager, M.A., Cosentino, F., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I (2013) Eur. Heart J., 34, pp. 2436-2443; El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P.L., Roeder, R.G., Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia (2008) J.Exp. Med., 205, pp. 2409-2417; Eeg-Olofsson, K., Cederholm, J., Nilsson, P.M., New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR) (2010) J.Intern. Med., 268, pp. 471-482; Zoungas, S., Chalmers, J., Ninomiya, T., Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds (2012) Diabetologia, 55, pp. 636-643; Turnbull, F.M., Abraira, C., Anderson, R.J., Byington, R.P., Chalmers, J.P., Duckworth, W.C., Intensive glucose control and macrovascular outcomes in type 2 diabetes (2009) Diabetologia, 52, pp. 2288-2298; Kramer, C.K., Zinman, B., Retnakaran, R., Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis (2013) Lancet Diabetes Endocrinol., 1, pp. 28-34; Hemmingsen, B., Christensen, L.L., Wetterslev, J., Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses (2012) BMJ, 344; Goudswaard, A.N., Furlong, N.J., Valk, G.D., Stolk, R.P., Rutten, G.E.H.M., Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus (2004) Cochrane Database Syst. Rev., (4); Kooy, A., De Jager, J., Lehert, P., Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus (2009) Arch. Intern. Med., 169, pp. 616-625; Executive summary: standards of medical care in diabetes-2014 (2014) Diabetes Care, 37 (SUPPL.1), pp. S5-S13",Article,Scopus,2-s2.0-84926512788
"Zaccardi F., Pitocco D., Willeit P., Laukkanen J.A.","Efficacy and safety of P2Y<inf>12</inf> inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials",2015,"Atherosclerosis","240","2",,"439","445",,,10.1016/j.atherosclerosis.2015.04.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928015933&partnerID=40&md5=bf82a9ac4667757ff8b55314b7e3a37f","Institute of Internal Medicine and Diabetes Care Unit, Catholic University School of MedicineRome, Italy; Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Institute of Public Health and Clinical Nutrition, University of Eastern FinlandKuopio, Finland","Zaccardi, F., Institute of Internal Medicine and Diabetes Care Unit, Catholic University School of MedicineRome, Italy, Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Pitocco, D., Institute of Internal Medicine and Diabetes Care Unit, Catholic University School of MedicineRome, Italy; Willeit, P., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Laukkanen, J.A., Institute of Public Health and Clinical Nutrition, University of Eastern FinlandKuopio, Finland","Objective: The efficacy of antiplatelet drugs may differ in specific patient subgroups. We aimed to assess the efficacy and safety of the P2Y<inf>12</inf> inhibitors clopidogrel, ticlopidine, prasugrel, ticagrelor, and cangrelor according to diabetes status, age, gender, body mass index, and body weight. Methods: Randomized clinical trials (RCTs) of P2Y<inf>12</inf> inhibitors reporting information on cardiovascular disease (defined as myocardial infarction, stroke, or cardiovascular death) and bleeding (defined as any bleeding) events among the subgroups diabetes and non-diabetes, age ≥65 and <65 year-old, men and women, body mass index ≥30 and <30kg/m2, and body weight ≥60 and <60kg, were identified in Medline, Embase, Web of Science, and Cochrane Library on August 31st, 2014. For each inhibitor, random-effects meta-analyses were used to estimate the ratio of relative risks (rRR) for cardiovascular and bleeding events among patient subgroups. Results: Twenty distinct RCTs (233285 participants, 21323 cardiovascular and 5183 bleeding events) were identified. Cardiovascular risk reduction with clopidogrel did not significantly differ according to diabetes (rRR: 1.04; 95% CI: 0.95 to 1.13; p=0.395), age (0.98; 0.88 to 1.09; p=0.347), gender (0.97; 0.90 to 1.04; p=0.382), or body mass index (1.11, 0.95 to 1.31; p=0.191). Results for other inhibitors were comparable, although available data were sparse. Limited data on bleeding events were available. Conclusion: Data from RCTs did not show a different cardiovascular efficacy of clopidogrel in diabetes mellitus and other clinically relevant subgroups. Limited information was available on the efficacy and safety of other P2Y<inf>12</inf> inhibitors in specific subgroups. © 2015 Elsevier Ireland Ltd.","Antiplatelet resistance; Clopidogrel; Diabetes; Meta-analysis; P2Y<inf>12</inf> inhibitors; Thienopyridines","Patrono, C., Rocca, B., Drug insight: aspirin resistance-fact or fashion? (2007) Nat. Clin. Pract. Cardiovasc. Med., 4, pp. 42-50; Pulcinelli, F.M., Biasucci, L.M., Riondino, S., COX-1 sensitivity and TXA2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment (2009) Eur. Heart J., 30, pp. 1279-1286; Evangelista, V., De Berardis, G., Totani, L., Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin (2007) J.Thromb. Haemost., 5, pp. 2197-2203; Belch, J., MacCuish, A., Campbell, I., Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease (2008) BMJ, 337, pp. 1030-1036; Ogawa, H., Nakayama, M., Morimoto, T., Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A randomized controlled trial (2008) JAMA, 300, pp. 2134-2141; De Berardis, G., Sacco, M., Strippoli, G.F.M., Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials (2009) BMJ, 339. , b4531; Pignone, M.J., Alberts, M.J., Colwell, J.A., Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation (2010) Circulation, 121, pp. 2694-2701; Wang, T.H., Bhatt, D.L., Topol, E.J., Aspirin and clopidogrel resistance: an emerging clinical entity (2006) Eur. Heart J., 27, pp. 647-654; Angiolillo, D.J., Suryadevara, S., Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus (2009) Best Pract. Res. Clin. Endocrinol. Metab., 23, pp. 375-388; Siller-Matula, J.M., Trenk, D., Schrör, K., Response variability to P2Y<inf>12</inf> receptor inhibitors: expectations and reality (2013) JACC Cardiovasc. Interv., 6, pp. 1111-1128; Gagne, J.J., Bykov, K., Choudhry, N.K., Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison (2013) BMJ, 347. , f5307; Siller-Matula, J.M., Jilma, B., Why have studies of tailored anti-platelet therapy failed so far? (2013) Thromb. Haemost., 110, pp. 628-631; Calvin, A.D., Aggarwal, N.R., Murad, M.H., Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes (2009) Diabetes Care, 32, pp. 2300-2306; Moher, D., Liberati, A., Tetzlaff, J., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009) PLoS Med., 6. , PRISMA Group, e1000097; Higgins, J.P.T., Altman, D.G., Sterne, J.A.C., Assessing risk of bias in included studies (2011) Cochrane Handbook for Systematic Reviews of Interventions, , Cochrane Collaboration, J.P.T. Higgins, S. Green (Eds.); Altman, D.G., Bland, J.M., Interaction revisited: the difference between two estimates (2003) BMJ, 326, p. 219; Egger, M., Davey Smith, G., Schneider, M., Bias in meta-analysis detected by a simple, graphical test (1997) BMJ, 315, pp. 629-634; Connolly, S.J., Pogue, J., Hart, R.G., Effect of clopidogrel added to aspirin in patients with atrial fibrillation (2009) N.Engl. J. Med., 360, pp. 2066-2078. , ACTIVE Investigators; Arandomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) (1996) Lancet, 348, pp. 1329-1339; Bhatt, D.L., Marso, S.P., Hirsch, A.T., Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus (2002) Am. J. Cardiol., 90, pp. 625-628; Wang, Y., Wang, Y., Zhao, X., Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (2013) N.Engl. J. Med., 369, pp. 11-19. , CHANCE Investigators; Bhatt, D.L., Fox, K.A., Hacke, W., Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events (2006) N.Engl. J. Med., 354, pp. 1706-1717. , CHARISMA Investigators; Dasgupta, A., Steinhubl, S.R., Bhatt, D.L., Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial) (2009) Am. J. Cardiol., 103, pp. 1359-1363. , CHARISMA Investigators; Berger, J.S., Bhatt, D.L., Cannon, C.P., The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis (2009) J.Am. Coll. Cardiol., 54, pp. 1935-1945; Sabatine, M.S., Cannon, C.P., Gibson, C.M., Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation (2005) N.Engl. J. Med., 352, pp. 1179-1189. , CLARITY-TIMI 28 Investigators; Chen, Z.M., Jiang, L.X., Chen, Y.P., COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial (2005) Lancet, 366, pp. 1607-1621; Steinhubl, S.R., Berger, P.B., Mann, J.T., Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (2002) JAMA, 288, pp. 2411-2420. , CREDO Investigators; Yusuf, S., Zhao, F., Mehta, S.R., Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (2001) N.Engl. J. Med., 345, pp. 494-502; Mehta, S.R., Bassand, J.P., Chrolavicius, S., Dose comparisons of clopidogrel and aspirin in acute coronary syndromes (2010) N.Engl. J. Med., 363, pp. 930-942. , CURRENT-OASIS 7 Investigators; Sacco, R.L., Diener, H.C., Yusuf, S., Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke (2008) N.Engl. J. Med., 359, pp. 1238-1251. , PRoFESS Study Group; Benavente, O.R., Hart, R.G., McClure, L.A., Effects of clopidogrel added to aspirin in patients with recent lacunar stroke (2012) N.Engl. J. Med., 367, pp. 817-825. , SPS3 Investigators; Gent, M., Blakely, J.A., Easton, J.D., The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke (1989) Lancet, 1, pp. 1215-1220; Valentine, N., Van de Laar, F.A., van Driel, M.L., Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus (2012) Cochrane Database Syst. Rev., 11. , CD005449; Hass, W.K., Easton, J.D., Adams, H.P., Arandomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group (1989) N.Engl. J. Med., 321, pp. 501-507; Montalescot, G., Bolognese, L., Dudek, D., Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes (2013) N.Engl. J. Med., 369, pp. 999-1010. , ACCOAST Investigators; Roe, M.T., Armstrong, P.W., Fox, K.A., Prasugrel versus clopidogrel for acute coronary syndromes without revascularization (2012) N.Engl. J. Med., 367, pp. 1297-1309. , TRILOGY ACS Investigators; Wiviott, S.D., Braunwald, E., McCabe, C.H., Prasugrel versus clopidogrel in patients with acute coronary syndromes (2007) N.Engl. J. Med., 357, pp. 2001-2015. , TRITON-TIMI 38 Investigators; Wiviott, S.D., Braunwald, E., Angiolillo, D.J., Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 (2008) Circulation, 118, pp. 1626-1636. , TRITON-TIMI 38 Investigators; Wallentin, L., Becker, R.C., Budaj, A., Ticagrelor versus clopidogrel in patients with acute coronary syndromes (2009) N.Engl. J. Med., 361, pp. 1045-1057. , PLATO Investigators; James, S., Angiolillo, D.J., Cornel, J.H., Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial (2010) Eur. Heart J., 31, pp. 3006-3016; Husted, S., James, S., Becker, R.C., Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial (2012) Circ. Cardiovasc. Qual. Outcomes, 5, pp. 680-688. , PLATO Study Group; Harrington, R.A., Stone, G.W., McNulty, S., Platelet inhibition with cangrelor in patients undergoing PCI (2009) N.Engl. J. Med., 361, pp. 2318-2329; Bhatt, D.L., Stone, G.W., Mahaffey, K.W., Effect of platelet inhibition with cangrelor during PCI on ischemic events (2013) N.Engl. J. Med., 368, pp. 1303-1313. , CHAMPION PHOENIX Investigators; Bhatt, D.L., Lincoff, A.M., Gibson, C.M., Intravenous platelet blockade with cangrelor during PCI (2009) N.Engl. J. Med., 361, pp. 2330-2341. , CHAMPION PLATFORM Investigators; Andersson, C., Lyngbæk, S., Nguyen, C.D., Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes (2012) JAMA, 308, pp. 882-889; Jochmann, N., Stangl, K., Garbe, E., Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases (2005) Eur. Heart J., 26, pp. 1585-1595; Breet, N.J., van Donkersgoed, H.E., van Werkum, J.W., Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? (2011) Neth. Heart J., 19, pp. 279-284; Hochholzer, W., Trenk, D., Fromm, M.F., Impact of cytochrome P450 2C19 loss of function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement (2010) J.Am. Coll. Cardiol., 55, pp. 2427-2434; Rydén, L., Grant, P.J., Anker, S.D., ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) (2013) Eur. Heart J., 34, pp. 3035-3087",Article,Scopus,2-s2.0-84928015933
"Rao X., Montresor-Lopez J., Puett R., Rajagopalan S., Brook R.D.","Ambient air pollution: An emerging risk factor for diabetes mellitus",2015,"Current Diabetes Reports","15","6",,"1","11",,,10.1007/s11892-015-0603-8,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928320426&partnerID=40&md5=68c6e621d93bfed012292aa80dff24a5","Division of Cardiovascular Medicine, University of MarylandBaltimore, MD, United States; Maryland Institute for Applied Environmental Health, Department of Epidemiology and Biostatistics, School of Public Health, University of MarylandCollege Park, MD, United States; Department of Internal Medicine, University of MichiganAnn Arbor, MI, United States; Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Dr, PO Box 322Ann Arbor, MI, United States","Rao, X., Division of Cardiovascular Medicine, University of MarylandBaltimore, MD, United States; Montresor-Lopez, J., Maryland Institute for Applied Environmental Health, Department of Epidemiology and Biostatistics, School of Public Health, University of MarylandCollege Park, MD, United States; Puett, R., Maryland Institute for Applied Environmental Health, Department of Epidemiology and Biostatistics, School of Public Health, University of MarylandCollege Park, MD, United States; Rajagopalan, S., Division of Cardiovascular Medicine, University of MarylandBaltimore, MD, United States; Brook, R.D., Department of Internal Medicine, University of MichiganAnn Arbor, MI, United States, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Dr, PO Box 322Ann Arbor, MI, United States","Growing evidence supports that air pollution has become an important risk factor for developing diabetes mellitus. Understanding the contributing effect of air pollution in population studies, elucidating the potential mechanisms involved, and identifying the most responsible pollutants are all required in order to promulgate successful changes in policy and to help formulate preventive measures in an effort to reduce the risk for diabetes. This review summarizes recent findings from epidemiologic studies and mechanistic insights that provide links between exposure to air pollution and a heightened risk for diabetes. © 2015, Springer Science+Business Media New York.","Insulin resistance; Metabolic syndrome; Obesity; Particulate matter","Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) Lancet, 380 (9859), pp. 2224-2260. , PID: 23245609; Brook, R.D., Rajagopalan, S., Pope, C.A., III, Brook, J.R., Bhatnagar, A., Diez-Roux, A.V., Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association (2010) Circulation, 121 (21), pp. 2331-2378. , COI: 1:CAS:528:DC%2BC3cXmslGmu78%3D, PID: 20458016; Mustafic, H., Jabre, P., Caussin, C., Murad, M.H., Escolano, S., Tafflet, M., Main air pollutants and myocardial infarction: a systematic review and meta-analysis (2012) Jama, 307 (7), pp. 713-721. , COI: 1:CAS:528:DC%2BC38XisVCntLk%3D, PID: 22337682; Cesaroni, G., Forastiere, F., Stafoggia, M., Andersen, Z.J., Badaloni, C., Beelen, R., Long term exposure to ambient air pollution and incidence of acute coronary events: Prospective cohort study and meta-analysis in 11 European cohorts from the ESCAPE Project (2014) BMJ, 348, p. f7412. , PID: 24452269; Rajagopalan, S., Brook, R.D., Air pollution and type 2 diabetes: Mechanistic insights (2012) Diabetes, 61 (12), pp. 3037-3045. , COI: 1:CAS:528:DC%2BC38XhvVahtrnM, PID: 23172950; Zhao, X., Sun, Z., Ruan, Y., Yan, J., Mukherjee, B., Yang, F., Personal black carbon exposure influences ambulatory blood pressure: Air pollution and cardiometabolic disease (AIRCMD-China) study (2014) Hypertension, 63 (4), pp. 871-877. , COI: 1:CAS:528:DC%2BC2cXktFeksrs%3D, PID: 24420543; Brook, R.D., Jerrett, M., Brook, J.R., Bard, R.L., Finkelstein, M.M., The relationship between diabetes mellitus and traffic-related air pollution (2008) J Occup Environ Med, 50 (1), pp. 32-38. , COI: 1:CAS:528:DC%2BD1cXhsFyitQ%3D%3D, PID: 18188079; Pearson, J.F., Bachireddy, C., Shyamprasad, S., Goldfine, A.B., Brownstein, J.S., Association between fine particulate matter and diabetes prevalence in the USA (2010) Diabetes Care, 33 (10), pp. 2196-2201. , PID: 20628090; Eze, I.C., Schaffner, E., Fischer, E., Schikowski, T., Adam, M., Imboden, M., Long-term air pollution exposure and diabetes in a population-based Swiss cohort (2014) Environ Int, 70, pp. 95-105. , COI: 1:CAS:528:DC%2BC2cXhtFCitrvI, PID: 24912113, This work add further evidence showing an association between air pollution and diabetes. More importantly, the association could be observed even at low levels exposure which are below air quality guidelines; Kramer, U., Herder, C., Sugiri, D., Strassburger, K., Schikowski, T., Ranft, U., Traffic-related air pollution and incident type 2 diabetes: Results from the SALIA cohort study (2010) Environ Health Perspect, 118 (9), pp. 1273-1279. , PID: 20504758; Andersen, Z.J., Raaschou-Nielsen, O., Ketzel, M., Jensen, S.S., Hvidberg, M., Loft, S., Diabetes incidence and long-term exposure to air pollution: a cohort study (2012) Diabetes Care, 35 (1), pp. 92-98. , COI: 1:CAS:528:DC%2BC38XitFWis7w%3D, PID: 22074722; Coogan, P.F., White, L.F., Jerrett, M., Brook, R.D., Su, J.G., Seto, E., Air Pollution and Incidence of Hypertension and Diabetes in African American Women Living in Los Angeles (2012) Circulation, , PID: 22219348; Dijkema, M.B., Mallant, S.F., Gehring, U., van den Hurk, K., Alssema, M., van Strien, R.T., Long-term exposure to traffic-related air pollution and type 2 diabetes prevalence in a cross-sectional screening-study in the Netherlands (2011) Environ Health, 10, p. 76. , COI: 1:CAS:528:DC%2BC3MXht1yqsLjI, PID: 21888674; Puett, R.C., Hart, J.E., Schwartz, J., Hu, F.B., Liese, A.D., Laden, F., Are particulate matter exposures associated with risk of type 2 diabetes? (2011) Environ Health Perspect, 119 (3), pp. 384-389. , PID: 21118784; McConnell, R., Shen, E., Gilliland, F.D., Jerrett, M., Wolch, J., Chang, C.C., A longitudinal cohort study of body mass index and childhood exposure to secondhand tobacco smoke and air pollution: the southern California children’s health study (2014) Environ Health Perspect; Jerrett, M., McConnell, R., Wolch, J., Chang, R., Lam, C., Dunton, G., Traffic-related air pollution and obesity formation in children: a longitudinal, multilevel analysis (2014) Environ Health, 13, p. 49. , PID: 24913018; Wang, Y., Eliot, M.N., Kuchel, G.A., Schwartz, J., Coull, B.A., Mittleman, M.A., Long-term exposure to ambient air pollution and serum leptin in older adults: Results from the MOBILIZE Boston study (2014) J Occup Environ Med, 56 (9), pp. e73-e77. , COI: 1:CAS:528:DC%2BC2cXhsFejt7vI, PID: 25192230; Xu, X., Yavar, Z., Verdin, M., Ying, Z., Mihai, G., Kampfrath, T., Effect of early particulate air pollution exposure on obesity in mice: Role of p47phox (2010) Arterioscler Thromb Vasc Biol, 30 (12), pp. 2518-2527. , COI: 1:CAS:528:DC%2BC3cXhsVCksb3N, PID: 20864666; Sun, Q., Yue, P., Deiuliis, J.A., Lumeng, C.N., Kampfrath, T., Mikolaj, M.B., Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity (2009) Circulation, 119 (4), pp. 538-546. , COI: 1:CAS:528:DC%2BD1MXpt1ektg%3D%3D, PID: 19153269; Muoio, D.M., Newgard, C.B., Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes (2008) Nat Rev Mol Cell Biol, 9 (3), pp. 193-205. , COI: 1:CAS:528:DC%2BD1cXitlGnurg%3D, PID: 18200017; Marx, J., Unraveling the causes of diabetes (2002) Science, 296 (5568), pp. 686-689. , COI: 1:CAS:528:DC%2BD38XjtlOhtbw%3D, PID: 11976439; Kelishadi, R., Mirghaffari, N., Poursafa, P., Gidding, S.S., Lifestyle and environmental factors associated with inflammation, oxidative stress and insulin resistance in children (2009) Atherosclerosis, 203 (1), pp. 311-319. , COI: 1:CAS:528:DC%2BD1MXis1equrg%3D, PID: 18692848; Kim, J.H., Hong, Y.C., GSTM1, GSTT1, and GSTP1 polymorphisms and associations between air pollutants and markers of insulin resistance in elderly Koreans (2012) Environ Health Perspect, 120 (10), pp. 1378-1384. , COI: 1:CAS:528:DC%2BC38Xhs12isr3L, PID: 22732554; Thiering, E., Cyrys, J., Kratzsch, J., Meisinger, C., Hoffmann, B., Berdel, D., Long-term exposure to traffic-related air pollution and insulin resistance in children: Results from the GINIplus and LISAplus birth cohorts (2013) Diabetologia, 56 (8), pp. 1696-1704. , COI: 1:CAS:528:DC%2BC3sXhtVyrurrM, PID: 23666166; Brook, R.D., Xu, X., Bard, R.L., Dvonch, J.T., Morishita, M., Kaciroti, N., Reduced metabolic insulin sensitivity following sub-acute exposures to low levels of ambient fine particulate matter air pollution (2013) Sci Total Environ, 448, pp. 66-71. , COI: 1:CAS:528:DC%2BC3sXjt1WqsLg%3D, PID: 22901427; Zanobetti, A., Dominici, F., Wang, Y., Schwartz, J.D., A national case-crossover analysis of the short-term effect of PM2.5 on hospitalizations and mortality in subjects with diabetes and neurological disorders (2014) Environ Health, 13 (1), p. 38. , PID: 24886318; Dales, R.E., Cakmak, S., Vidal, C.B., Rubio, M.A., Air pollution and hospitalization for acute complications of diabetes in Chile (2012) Environ Int, 46, pp. 1-5. , COI: 1:CAS:528:DC%2BC38XptlWmtbs%3D, PID: 22647388; Tamayo, T., Rathmann, W., Kramer, U., Sugiri, D., Grabert, M., Holl, R.W., Is particle pollution in outdoor air associated with metabolic control in type 2 diabetes? (2014) PLoS One, 9 (3), p. e91639. , PID: 24619127; Zanobetti, A., Luttmann-Gibson, H., Horton, E.S., Cohen, A., Coull, B.A., Hoffmann, B., Brachial artery responses to ambient pollution, temperature, and humidity in people with type 2 diabetes: a repeated-measures study (2014) Environ Health Perspect, 122 (3), pp. 242-248. , PID: 24398072; O'Neill, M.S., Veves, A., Zanobetti, A., Sarnat, J.A., Gold, D.R., Economides, P.A., Diabetes enhances vulnerability to particulate air pollution-associated impairment in vascular reactivity and endothelial function (2005) Circulation, 111 (22), pp. 2913-2920. , PID: 15927967; Vora, R., Zareba, W., Utell, M.J., Pietropaoli, A.P., Chalupa, D., Little, E.L., Inhalation of ultrafine carbon particles alters heart rate and heart rate variability in people with type 2 diabetes (2014) Part Fibre Toxicol, 11 (1), p. 31. , PID: 25028096; Brook, R.D., Cakmak, S., Turner, M.C., Brook, J.R., Crouse, D.L., Peters, P.A., Long-term fine particulate matter exposure and mortality from diabetes mellitus in Canada (2013) Diabetes Care, , PID: 23780947, This is a study demonstrating long-term air pollution exposure, even at low levels, is associated with an increased risk of diabetes mortality; Raaschou-Nielsen, O., Sorensen, M., Ketzel, M., Hertel, O., Loft, S., Tjonneland, A., Long-term exposure to traffic-related air pollution and diabetes-associated mortality: a cohort study (2013) Diabetologia, 56 (1), pp. 36-46. , COI: 1:CAS:528:DC%2BC38XhvVKgs77P, PID: 22918192; Goldberg, S.L., Chen, L., Guerin, A., Macalalad, A.R., Liu, N., Kaminsky, M., Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib (2013) Curr Med Res Opin, 29 (9), pp. 1075-1082. , COI: 1:CAS:528:DC%2BC3sXhtlWltb3O, PID: 23738923; Janghorbani, M., Momeni, F., Mansourian, M., Systematic review and meta analysis of air pollution exposure and risk of diabetes (2014) Eur J Epidemiol, 29 (4), pp. 231-242. , COI: 1:CAS:528:DC%2BC2cXnslejsL8%3D, PID: 24791705; Rioux, C.L., Tucker, K.L., Brugge, D., Gute, D.M., Mwamburi, M., Traffic exposure in a population with high prevalence type 2 diabetes—do medications influence concentrations of C-reactive protein? (2011) Environ Pollut, 159 (8-9), pp. 2051-2060. , COI: 1:CAS:528:DC%2BC3MXnsVylu7s%3D, PID: 21292365; Khafaie, M.A., Salvi, S.S., Ojha, A., Khafaie, B., Gore, S.S., Yajnik, C.S., Systemic inflammation (C-reactive protein) in type 2 diabetic patients is associated with ambient air pollution in Pune City (2013) India Diabetes Care, 36 (3), pp. 625-630. , COI: 1:CAS:528:DC%2BC3sXktFOhurc%3D; Teichert, T., Vossoughi, M., Vierkotter, A., Sugiri, D., Schikowski, T., Schulte, T., Association between traffic-related air pollution, subclinical inflammation and impaired glucose metabolism: Results from the SALIA study (2013) PLoS One, 8 (12), p. e83042. , PID: 24340078; Xu, X., Liu, C., Xu, Z., Tzan, K., Zhong, M., Wang, A., Long-term exposure to ambient fine particulate pollution induces insulin resistance and mitochondrial alteration in adipose tissue (2011) Toxicol Sci, 124 (1), pp. 88-98. , COI: 1:CAS:528:DC%2BC3MXhtlGku7fL, PID: 21873646; Liu, C., Xu, X., Bai, Y., Wang, T.Y., Rao, X., Wang, A., Air pollution-mediated susceptibility to inflammation and insulin resistance: Influence of CCR2 pathways in mice (2014) Environ Health Perspect, 122 (1), pp. 17-26. , PID: 24149114; Zheng, Z., Xu, X., Zhang, X., Wang, A., Zhang, C., Huttemann, M., Exposure to ambient particulate matter induces a NASH-like phenotype and impairs hepatic glucose metabolism in an animal model (2013) J Hepatol, 58 (1), pp. 148-154. , COI: 1:CAS:528:DC%2BC3sXhvVyiug%3D%3D, PID: 22902548; Liu, C., Bai, Y., Xu, X., Sun, L., Wang, A., Wang, T.Y., Exaggerated effects of particulate matter air pollution in genetic type II diabetes mellitus (2014) Part Fibre Toxicol, 11, p. 27. , PID: 24886175; Bass, V., Gordon, C.J., Jarema, K.A., MacPhail, R.C., Cascio, W.E., Phillips, P.M., Ozone induces glucose intolerance and systemic metabolic effects in young and aged Brown Norway rats (2013) Toxicol Appl Pharmacol, 273 (3), pp. 551-560. , COI: 1:CAS:528:DC%2BC3sXhslOlt77O, PID: 24103449; Hotamisligil, G.S., Inflammation and metabolic disorders (2006) Nature, 444 (7121), pp. 860-867. , COI: 1:CAS:528:DC%2BD28XhtlShtrzK, PID: 17167474; Despres, J.P., Lemieux, I., Abdominal obesity and metabolic syndrome (2006) Nature, 444 (7121), pp. 881-887. , COI: 1:CAS:528:DC%2BD28XhtlShtrzF, PID: 17167477; Horng, T., Hotamisligil, G.S., Linking the inflammasome to obesity-related disease (2011) Nat Med, 17 (2), pp. 164-165. , COI: 1:CAS:528:DC%2BC3MXhsFyqs74%3D, PID: 21297609; Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B.T., Tschopp, J., Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica (2008) Science, 320 (5876), pp. 674-677. , COI: 1:CAS:528:DC%2BD1cXltFyis7c%3D, PID: 18403674; Bauer, R.N., Diaz-Sanchez, D., Jaspers, I., Effects of air pollutants on innate immunity: the role of Toll-like receptors and nucleotide-binding oligomerization domain-like receptors (2012) J Allergy Clin Immunol, 129 (1), pp. 14-24. , COI: 1:CAS:528:DC%2BC3MXhs1yrsLbN, PID: 22196521, quiz 5–6; Kampfrath, T., Maiseyeu, A., Ying, Z., Shah, Z., Deiuliis, J.A., Xu, X., Chronic fine particulate matter exposure induces systemic vascular dysfunction via NADPH oxidase and TLR4 pathways (2011) Circ Res, 108 (6), pp. 716-726. , COI: 1:CAS:528:DC%2BC3MXjsV2jtr8%3D, PID: 21273555; Goto, Y., Ishii, H., Hogg, J.C., Shih, C.H., Yatera, K., Vincent, R., Particulate matter air pollution stimulates monocyte release from the bone marrow (2004) Am J Respir Crit Care Med, 170 (8), pp. 891-897. , PID: 15256391; Deiuliis, J.A., Kampfrath, T., Zhong, J., Oghumu, S., Maiseyeu, A., Chen, L.C., Pulmonary T cell activation in response to chronic particulate air pollution (2011) Am J Physiol Lung Cell Mol Physiol, , PID: 22160305; Dominici, F., Peng, R.D., Ebisu, K., Zeger, S.L., Samet, J.M., Bell, M.L., Does the effect of PM10 on mortality depend on PM nickel and vanadium content? A reanalysis of the NMMAPS data (2007) Environ Health Perspect, 115 (12), pp. 1701-1703. , PID: 18087586; Liberda, E.N., Cuevas, A.K., Gillespie, P.A., Grunig, G., Qu, Q., Chen, L.C., Exposure to inhaled nickel nanoparticles causes a reduction in number and function of bone marrow endothelial progenitor cells (2010) Inhal Toxicol, 22, pp. 95-99. , COI: 1:CAS:528:DC%2BC3cXhsFCktLrJ, PID: 20936915; Liu, C., Ying, Z., Harkema, J., Sun, Q., Rajagopalan, S., Epidemiological and experimental links between air pollution and type 2 diabetes (2013) Toxicol Pathol, 41 (2), pp. 361-373. , COI: 1:CAS:528:DC%2BC2cXovVyrsbw%3D, PID: 23104765; Watterson, T.L., Hamilton, B., Martin, R., Coulombe, R.A., Jr., Urban particulate matter causes ER stress and the unfolded protein response in human lung cells (2009) Toxicol Sci, 112 (1), pp. 111-122. , COI: 1:CAS:528:DC%2BD1MXhtlGitLzF, PID: 19675143; Laing, S., Wang, G., Briazova, T., Zhang, C., Wang, A., Zheng, Z., Airborne particulate matter selectively activates endoplasmic reticulum stress response in the lung and liver tissues (2010) Am J Physiol Cell Physiol, 299 (4), pp. C736-C749. , COI: 1:CAS:528:DC%2BC3cXhtlKlurjL, PID: 20554909; Mendez, R., Zheng, Z., Fan, Z., Rajagopalan, S., Sun, Q., Zhang, K., Exposure to fine airborne particulate matter induces macrophage infiltration, unfolded protein response, and lipid deposition in white adipose tissue (2013) Am J Transl Res, 5 (2), pp. 224-234. , COI: 1:CAS:528:DC%2BC3sXhtFSlur7N, PID: 23573366; Xu, Z., Xu, X., Zhong, M., Hotchkiss, I.P., Lewandowski, R.P., Wagner, J.G., Ambient particulate air pollution induces oxidative stress and alterations of mitochondria and gene expression in brown and white adipose tissues (2011) Part Fibre Toxicol, 8, p. 20. , COI: 1:CAS:528:DC%2BC3MXhtFCkurrK, PID: 21745393; Thaler, J.P., Yi, C.X., Schur, E.A., Guyenet, S.J., Hwang, B.H., Dietrich, M.O., Obesity is associated with hypothalamic injury in rodents and humans (2012) J Clin Invest, 122 (1), pp. 153-162. , COI: 1:CAS:528:DC%2BC38XkvFCltw%3D%3D, PID: 22201683; Nakane, H., Translocation of particles deposited in the respiratory system: a systematic review and statistical analysis (2012) Environ Health Prev Med, 17 (4), pp. 263-274. , PID: 22101916; Block, M.L., Elder, A., Auten, R.L., Bilbo, S.D., Chen, H., Chen, J.C., The outdoor air pollution and brain health workshop (2012) Neurotoxicology, 33 (5), pp. 972-984. , PID: 22981845; Fonken LK, Xu X, Weil ZM, Chen G, Sun Q, Rajagopalan S et al. Air pollution impairs cognition, provokes depressive-like behaivors and alters hippocampal cytokine expression and morphology. Mol Psychiatry. 2011;16(10):987–95, 73Ying, Z., Xu, X., Bai, Y., Zhong, J., Chen, M., Liang, Y., Long-term exposure to concentrated ambient PM2.5 increases mouse blood pressure through abnormal activation of the sympathetic nervous system: a role for hypothalamic inflammation (2014) Environ Health Perspect, 122 (1), pp. 79-86. , PID: 24240275, This study demonstrated sympathetic activation in CNS mediates hypertensive action of chronic PM2.5 exposure",Review,Scopus,2-s2.0-84928320426
"Taylor S.L., Trudeau D., Arnold B., Wang J., Gerrow K., Summerfeldt K., Holmes A., Zamani A., Brocardo P.S., Brown C.E.","VEGF can protect against blood brain barrier dysfunction, dendritic spine loss and spatial memory impairment in an experimental model of diabetes",2015,"Neurobiology of Disease","78",,,"1","11",,,10.1016/j.nbd.2015.03.022,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926374530&partnerID=40&md5=d3f251e9d0e00cece7fa5afed6a8e697","Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Department of Biology, University of VictoriaVictoria, BC, Canada; Department of Psychiatry, University of British ColumbiaVancouver, BC, Canada","Taylor, S.L., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Trudeau, D., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Arnold, B., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Wang, J., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Gerrow, K., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Summerfeldt, K., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Holmes, A., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Zamani, A., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Brocardo, P.S., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada; Brown, C.E., Division of Medical Sciences, University of VictoriaVictoria, BC, Canada, Department of Biology, University of VictoriaVictoria, BC, Canada, Department of Psychiatry, University of British ColumbiaVancouver, BC, Canada","Clinical and experimental studies have shown a clear link between diabetes, vascular dysfunction and cognitive impairment. However, the molecular underpinnings of this association remain unclear. Since vascular endothelial growth factor (VEGF) signaling is important for maintaining vascular integrity and function, we hypothesized that vascular and cognitive impairment in the diabetic brain could be related to a deficiency in VEGF signaling. Here we show that chronic hyperglycemia (~. 8. weeks) in a mouse model of type 1 diabetes leads to a selective reduction in the expression of VEGF and its cognate receptor (VEGF-R2) in the hippocampus. Correlating with this, diabetic mice showed selective deficits in spatial memory in the Morris water maze, increased vessel area, width and permeability in the dentate gyrus/CA1 region of the hippocampus and reduced spine densities in CA1 neurons. Chronic low dose infusion of VEGF in diabetic mice was sufficient to restore VEGF signaling, protect them from memory deficits, as well as vascular and synaptic abnormalities in the hippocampus. These findings suggest that a hippocampal specific reduction in VEGF signaling and resultant vascular/neuronal defects may underlie early manifestations of cognitive impairment commonly associated with diabetes. Furthermore, restoring VEGF signaling may be a useful strategy for preserving hippocampal-related brain circuitry in degenerative vascular diseases. © 2015.","Blood brain barrier; Dendritic spines; Diabetes; Hippocampus; Learning and memory; Vascular endothelial growth factor","Antenor-Dorsey, J.A., White matter microstructural integrity in youth with type 1 diabetes (2013) Diabetes, 62, pp. 581-589; Argandona, E.G., Effect of intracortical vascular endothelial growth factor infusion and blockade during the critical period in the rat visual cortex (2012) Brain Res., 1473, pp. 141-154; Bardal, S., Chronic treatment with vascular endothelial growth factor preserves agonist-evoked vascular responses in the streptozotocin-induced diabetic rat (2006) Diabetologia, 49, pp. 811-818; Biessels, G.J., Gispen, W.H., The impact of diabetes on cognition: what can be learned from rodent models? (2005) Neurobiol. Aging, 26, pp. 36-41; Biessels, G.J., Cerebral function in diabetes mellitus (1994) Diabetologia, 37, pp. 643-650; Biessels, G.J., Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats (1996) Diabetes, 45, pp. 1259-1266; Biessels, G.J., Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment (1998) Brain Res., 800, pp. 125-135; Biessels, G.J., Neurophysiological changes in the central and peripheral nervous system of streptozotocin-diabetic rats. Course of development and effects of insulin treatment (1999) Brain, 122, pp. 757-768; Biessels, G.J., Cognition and diabetes: a lifespan perspective (2008) Lancet Neurol., 7, pp. 184-190; Brands, A.M., The effects of type 1 diabetes on cognitive performance: a meta-analysis (2005) Diabetes Care, 28, pp. 726-735; Brismar, T., Predictors of cognitive impairment in type 1 diabetes (2007) Psychoneuroendocrinology, 32, pp. 1041-1051; Caldwell, R.B., Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress (2005) Curr. Drug Targets, 6, pp. 511-524; Cao, L., VEGF links hippocampal activity with neurogenesis, learning and memory (2004) Nat. Genet., 36, pp. 827-835; Carmeliet, P., Storkebaum, E., Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders (2002) Semin. Cell Dev. Biol., 13, pp. 39-53; Clark, R.E., Intact performance on feature-ambiguous discriminations in rats with lesions of the perirhinal cortex (2011) Neuron, 70, pp. 132-140; den Heijer, T., Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI (2003) Diabetologia, 46, pp. 1604-1610; Dietrich, W.D., Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats (1993) Stroke, 24, pp. 111-116; Feng, G., Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP (2000) Neuron, 28, pp. 41-51; Franc, D.T., High connectivity between reduced cortical thickness and disrupted white matter tracts in long-standing type 1 diabetes (2011) Diabetes, 60, pp. 315-319; Francis, G.J., Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy (2008) Brain, 131, pp. 3311-3334; Gagne, J., Binding properties of glutamate receptors in streptozotocin-induced diabetes in rats (1997) Diabetes, 46, pp. 841-846; Gaudieri, P.A., Cognitive function in children with type 1 diabetes: a meta-analysis (2008) Diabetes Care, 31, pp. 1892-1897; Gold, S.M., Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes (2007) Diabetologia, 50, pp. 711-719; Haigh, J.J., Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling (2003) Dev. Biol., 262, pp. 225-241; Harik, S.I., LaManna, J.C., Vascular perfusion and blood-brain glucose transport in acute and chronic hyperglycemia (1988) J. Neurochem., 51, pp. 1924-1929; Hawkins, B.T., Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases (2007) Diabetologia, 50, pp. 202-211; Huber, J.D., Diabetes, cognitive function, and the blood-brain barrier (2008) Curr. Pharm. Des., 14, pp. 1594-1600; Iadecola, C., The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia (2010) Acta Neuropathol., 120, pp. 287-296; Jakobsen, J., Regional brain glucose metabolism and blood flow in streptozocin-induced diabetic rats (1990) Diabetes, 39, pp. 437-440; Jin, K.L., Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia (2000) Proc. Natl. Acad. Sci. U. S. A., 97, pp. 10242-10247; Kelly-Cobbs, A., Pressure-independent cerebrovascular remodelling and changes in myogenic reactivity in diabetic Goto-Kakizaki rat in response to glycaemic control (2011) Acta Physiol (Oxf.), 203, pp. 245-251; Kennedy, J.M., Zochodne, D.W., Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? (2005) Diabetes, 54, pp. 830-837; Kerti, L., Higher glucose levels associated with lower memory and reduced hippocampal microstructure (2013) Neurology, 81, pp. 1746-1752; King, G.L., Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta (1985) J. Clin. Invest., 75, pp. 1028-1036; Knudsen, G.M., Regional density of perfused capillaries and cerebral blood flow in untreated short-term and long-term streptozotocin diabetes (1991) J. Cereb. Blood Flow Metab., 11, pp. 361-365; Lee, S., Autocrine VEGF signaling is required for vascular homeostasis (2007) Cell, 130, pp. 691-703; Lee, C.C., Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways (2011) Neuropharmacology, 61, pp. 867-879; Li, W., Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia (2010) Diabetes, 59, pp. 228-235; Liu, J., Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1 (1999) J. Biol. Chem., 274, pp. 15781-15785; Ma, Y., Effects of vascular endothelial growth factor in ischemic stroke (2012) J. Neurosci. Res., 90 (10), pp. 1873-1882; Manschot, S.M., Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats (2003) Brain Res., 966, pp. 274-282; Manschot, S.M., Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes (2006) Diabetes, 55, pp. 1106-1113; Martinez-Tellez, R., Alteration in dendritic morphology of cortical neurons in rats with diabetes mellitus induced by streptozotocin (2005) Brain Res., 1048, pp. 108-115; Mendonca, M.C., Expression of VEGF and Flk-1 and Flt-1 receptors during blood-brain barrier (BBB) impairment following Phoneutria nigriventer spider venom exposure (2013) Toxins (Basel), 5, pp. 2572-2588; Morris, R.G., Place navigation impaired in rats with hippocampal lesions (1982) Nature, 297, pp. 681-683; Mumby, D.G., Pinel, J.P., Rhinal cortex lesions and object recognition in rats (1994) Behav. Neurosci., 108, pp. 11-18; Newton, S.S., Vascular growth factors in neuropsychiatry (2013) Cell. Mol. Life Sci., 70, pp. 1739-1752; Ortuzar, N., VEGF reverts the cognitive impairment induced by a focal traumatic brain injury during the development of rats raised under environmental enrichment (2013) Behav. Brain Res., 246, pp. 36-46; Poe, G.R., Partial hippocampal inactivation: effects on spatial memory performance in aged and young rats (2000) Behav. Neurosci., 114, pp. 940-949; Popovic, M., Learning and memory in streptozotocin-induced diabetic rats in a novel spatial/object discrimination task (2001) Behav. Brain Res., 122, pp. 201-207; Prakash, R., Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling (2012) Diabetes, 61, pp. 1533-1542; Prakash, R., Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes (2013) PLoS ONE, 8, p. e56264; Quaegebeur, A., The neurovascular link in health and disease: molecular mechanisms and therapeutic implications (2011) Neuron, 71, pp. 406-424; Reeson, P., Delayed inhibition of VEGF signaling after stroke attenuates blood brain barrier breakdown and improves functional recovery in a co-morbidity dependent manner (2015) J. Neurosci., 35, pp. 5128-5143; Ruiz de Almodovar, C., Role and therapeutic potential of VEGF in the nervous system (2009) Physiol. Rev., 89, pp. 607-648; Seaquist, E.R., The final frontier: how does diabetes affect the brain? (2010) Diabetes, 59, pp. 4-5; Shehata, G., Eltayeb, A., Cognitive function and event-related potentials in children with type 1 diabetes mellitus (2010) J. Child Neurol., 25, pp. 469-474; Storkebaum, E., Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS (2005) Nat. Neurosci., 8, pp. 85-92; Stranahan, A.M., Mattson, M.P., Impact of energy intake and expenditure on neuronal plasticity (2008) Neuromol. Med., 10, pp. 209-218; Stranahan, A.M., Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons (2008) Nat. Neurosci., 11, pp. 309-317; Stranahan, A.M., Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats (2008) Hippocampus, 18, pp. 1085-1088; Su, E.N., An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent (2012) BMC Ophthalmol., 12, p. 10; Sun, Y., VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia (2003) J. Clin. Invest., 111, pp. 1843-1851; Sutherland, R.J., A behavioural analysis of spatial localization following electrolytic, kainate- or colchicine-induced damage to the hippocampal formation in the rat (1983) Behav. Brain Res., 7, pp. 133-153; Sweetnam, D., Diabetes impairs cortical plasticity and functional recovery following ischemic stroke (2012) J. Neurosci., 32, pp. 5132-5143; Tennant, K.A., Brown, C.E., Diabetes augments in vivo microvascular blood flow dynamics after stroke (2013) J. Neurosci., 33, pp. 19194-19204; Tennant, K.A., Jones, T.A., Sensorimotor behavioral effects of endothelin-1 induced small cortical infarcts in C57BL/6 mice (2009) J. Neurosci. Methods, 181, pp. 18-26; Toth, C., Diabetes, leukoencephalopathy and rage (2006) Neurobiol. Dis., 23, pp. 445-461; Vinik, A., Flemmer, M., Diabetes and macrovascular disease (2002) J. Diabet. Complications, 16, pp. 235-245; Warner-Schmidt, J.L., Duman, R.S., VEGF as a potential target for therapeutic intervention in depression (2008) Curr. Opin. Pharmacol., 8, pp. 14-19; Warren, C.M., A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes (2014) Sci. Signal., 7, p. ra1; Winters, B.D., Bussey, T.J., Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory (2005) J. Neurosci., 25, pp. 52-61; Won, S.J., Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by increasing superoxide production (2011) Ann. Neurol., 70, pp. 583-590; Wu, W., The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life (2008) Ann. Neurol., 64, pp. 698-706; Ye, X., Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats (2011) Exp. Neurol., 232, pp. 299-308; Zhang, Z.G., Chopp, M., Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic (2009) Lancet Neurol., 8, pp. 491-500; Zhang, Z.G., VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain (2000) J. Clin. Invest., 106, pp. 829-838; Zhao, Q., Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain (2012) BMC Complement. Altern. Med., 12, p. 188; Zlokovic, B.V., The blood-brain barrier in health and chronic neurodegenerative disorders (2008) Neuron, 57, pp. 178-201",Article,Scopus,2-s2.0-84926374530
"Sikand G., Kris-Etherton P., Boulos N.M.","Impact of Functional Foods on Prevention of Cardiovascular Disease and Diabetes",2015,"Current Cardiology Reports","17","6",,"","",16,,10.1007/s11886-015-0593-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928321636&partnerID=40&md5=7e986e41cf0810f49dc7408455bbb3b5","Department of Medicine/Cardiology Division, University of California Irvine School of Medicine, 101 City Drive South, City Tower, Suite 400Orange, CA, United States; Department of Nutritional Sciences, Penn State University, 319 Chandlee LabUniversity Park, PA, United States; Heart Disease Prevention Program, Division of Cardiology, C240 Medical Sciences, University of CaliforniaIrvine, CA, United States","Sikand, G., Department of Medicine/Cardiology Division, University of California Irvine School of Medicine, 101 City Drive South, City Tower, Suite 400Orange, CA, United States; Kris-Etherton, P., Department of Nutritional Sciences, Penn State University, 319 Chandlee LabUniversity Park, PA, United States; Boulos, N.M., Heart Disease Prevention Program, Division of Cardiology, C240 Medical Sciences, University of CaliforniaIrvine, CA, United States","A healthy dietary pattern is a cornerstone for the prevention and treatment of cardiovascular disease (CVD) and type 2 diabetes (T2DM). Compelling scientific evidence has shown many health effects of individual foods (including herbs and spices), beverages, and their constituent nutrients and bioactive components on risk of chronic disease and associated risk factors. The focus of functional foods research that is reviewed herein has been on assessing the health effects and underlying mechanisms of action of fruits and vegetables, whole grains, dairy products including fermented products, legumes, nuts, green tea, spices, olive oil, seafood, red wine, herbs, and spices. The unique health benefits of these functional foods have been the basis for recommending their inclusion in a healthy dietary pattern. A better understanding of strategies for optimally including functional foods in a healthy dietary pattern will confer greater benefits on the prevention and treatment of CVD and T2DM. © 2015, Springer Science+Business Media New York.","Cardiovascular disease prevention; Functional foods; Type 2 diabetes prevention","http://www.who.int/mediacentre/factsheets/fs312/en/, World Health Organization Media Center Website. Access date November 21 2014Chen, G., Wang, H., Zhang, X., Yang, S., Nutraceuticals and functional foods in the management of hyperlipidemia (2014) Crit Rev Food Sci Nutr, 54, pp. 1180-1201. , COI: 1:CAS:528:DC%2BC3sXot1CgtLw%3D, PID: 24499150; Oh, Y.S., Jun, H.S., Role of bioactive food components in diabetes prevention: effects on beta-cell function and preservation (2014) Nutrit Metabol Insights, 7, pp. 51-59; Position of the Academy of Nutrition and Dietetics: Functional Foods J Acad Nutr Diet 2013;113:1096–1103. This position paper provides a definition of functional foods and the regulatory overview that requires significant substantiation of functional foodsMirmiran, P., Bahadoran, Z., Azizi, F., Functional foods-based diets a novel dietary approach for management of type 2 diabetes and its complications: a review (2014) World J Diab, 5 (3), pp. 267-281. , This review article provides a comprehensive review of the prevention of diabetes with functional foods based diets; Functional Foods. http;//www.foodinsight.org/Content/3842/Final%20Functional%20Foods%20Backgrounder.pdf (2015) Accessed February, p. 2. , www.foodinsight.org/Content/3842/Final%20Functional%20Foods%20Backgrounder.pdf; Ross, S., Functional foods: the food and drug administration perspective (2000) Am J Clin Nutr, 71 (6), pp. 1735-1738. , COI: 1:CAS:528:DC%2BD3cXjvFGnt7g%3D, PID: 10837331; http://www.gao.gov/new.items/rc00156.pdf, US General Accounting Office. Food safety: Improvements needed in over-seeing the safety of dietary supplements and “functional foods”. Published July 2000. Accessed February 2 2015http://www.fda.gov/Food/LabelingNutrition/LabelClaims/ucm111447.htm.Published, US Food and Drug Administration Claims that can be made for conventional foods and dietary supplements. September 2003. Accessed February 2 2015http://www.registrarcorp.com/contact/regulatory_updates.jsp?lang, Food and Drug Administration. Guidance for industry: A food labeling guide. = en&func = 1 Access date February 2 2015Borneo, R., Leon, A.E., Whole grain cereals: functional components and health benefits (2012) Food Funct, 3, pp. 110-119. , COI: 1:CAS:528:DC%2BC38XhslaltLc%3D, PID: 22134555; Ye, E.Q., Chacko, S.A., Chou, E.L., Kugizaski, M., Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease and weight gain (2012) J Nutr, 142, pp. 1304-1313. , COI: 1:CAS:528:DC%2BC38XpsFWmur0%3D, PID: 22649266; Okarter, N., Liu, R.H., Health benefits of whole grain phytochemicals (2010) Crit Rev Good Sci Nutr, 50, pp. 120-193. , COI: 1:CAS:528:DC%2BC3cXjsFeitbs%3D; Anderson, A., Tengblad, S., Karlstrom, B., Kamal-Eldin, A., Whole grain foods do not affect insulin sensitivity or markers of lipid peroxidations and inflammation in healthy, moderately overweight subjects (2007) J Nutr, 137, pp. 1401-1407; Martinez, I.M., Lattimer, J.M., Hubach, K.L., Case, J.A., Gut microbiome composition is linked to whole grain induced immunological improvements (2013) ISME J, 7, pp. 269-280. , COI: 1:CAS:528:DC%2BC3sXhsVansL0%3D, PID: 23038174; Cho, S., Lu, Q., Fahey, G.C., Klurfeld, D.M., Consumption of cereal fiber, mixtures of whole grains and bran, and whole grains and risk reduction in type 2 diabetes, obesity, and cardiovascular disease (2013) Am J Clin Nutr, 98, pp. 594-619. , COI: 1:CAS:528:DC%2BC3sXhtFyntrzN, PID: 23803885; http://www.cnpp.usda.gov/Publications/DietaryGuidelines/2010/DGAC/Report/D-3-FattyAcidsCholesterol.pdf, Accessed February 2 2015He, M., Van Dam, R.N., Rimm, E., Hu, F.B., Whole-grain, cereal fiber, bran, and germ intake and the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus (2010) Circulation, 121, pp. 2162-2168. , PID: 20458012; Toh, J.Y., Tan, V.M., Lim, P.C., Lim, S.T., Chong, M.F., Flavonoids from fruit and vegetables: a focus on cardiovascular risk factors (2013) Curr Atheroscler Rep, 15 (12), p. 368. , COI: 1:STN:280:DC%2BC2c%2FlvFCktg%3D%3D, PID: 24091782; Chawla, R., Patil, G.R., Soluble dietary fiber (2010) Compr Rev Food Sci Food Saf, 9 (2), pp. 178-196. , COI: 1:CAS:528:DC%2BC3cXnt1KitL4%3D; Raninen, K., Lappi, J., Mykkanen, H., Poutanen, K., Dietary fiber type reflects physiological functionality: comparison of grain fiber, inulin and polydextrose (2011) Nutr Rev, 60 (1), pp. 9-21; Viuda-martos, M., Sanchez-zapata, E., Sayas-barberá, E., Sendra, E., Pérez-Álvarez, J.A., Fernández-lópez, J., Tomato and tomato byproducts. Human health benefits of lycopene and its application to meat products: a review (2014) Crit Rev Food Sci Nutr, 54 (8), pp. 1032-1049. , COI: 1:CAS:528:DC%2BC3sXltVGjs7g%3D, PID: 24499120; Muller, F.O., Re: The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives (2011) Cardiovasc J Afr, 22 (1), p. 37. , COI: 1:STN:280:DC%2BC3M7nt1Cjsw%3D%3D, PID: 21298205; Takahashi, K., Kamada, C., Yoshimura, C., Okumura, R., Effects of total and green vegetable intakes on glycated hemoglobin A1c and triglycerides in elderly patients with type 2 diabetes mellitus: the Japanese Elderly Intervention Trial (2012) Geriatr Gerontol Int, 12, pp. 50-58. , PID: 22435940; Hegde, S.V., Adhikari, P.M.N., D’Souza, V., Effect of daily supplementation of fruits on oxidative stress indices and glycemic status in type 2 diabetes mellitus (2013) Complem Ther Clin Pract, 19, pp. 97-100; Tanaka, S., Yoshimura, Y., Kawasaki, R., Kamada, C., Fruit intake and incident diabetic retinopathy with type 2 diabetes (2013) Epidemiology, 24, pp. 204-211. , PID: 23348071; Chan, H.T., Yiu, K.H., Wong, C.Y., Li, S.W., Increased dietary fruit intake was associated with lower burden of carotid atherosclerosis in Chinese patients with type 2 diabetes mellitus (2013) Diabet Med, 30, pp. 100-108. , COI: 1:CAS:528:DC%2BC3sXjt1Sru78%3D, PID: 22913415; Yang, J., Xiao, Y.Y., Grape phytochemicals and associated health benefits (2013) Crit Rev Food Sci Nutr, 53 (11), pp. 1202-1225. , COI: 1:CAS:528:DC%2BC3sXhsVCitrbI, PID: 24007424; Stowe, C.B., The effects of pomegranate juice consumption on blood pressure and cardiovascular health (2011) Complement Ther Clin Pract, 17 (2), pp. 113-115. , PID: 21457902; Ismail, T., Sestilli, P., Akhtar, S., Pomogranate peel and fruit extracts: a review of potential anti-inflammatory and anti-infective effects (2012) J Ethnopharmacol, 143 (2), pp. 397-405. , COI: 1:CAS:528:DC%2BC38XhtFeitbnP, PID: 22820239; Bondonno, C.P., Yang, X., Croft, K.D., Flavonoid rich apples and nitrate-rich spinach augment nitric oxide status and improve endothelial function in healthy men and women: a randomized controlled trial (2012) Free Radic Ciol Med, 52 (1), pp. 95-102. , COI: 1:CAS:528:DC%2BC38XitlylsQ%3D%3D; Sirtori, C.R., Galli, C., Anderson, J.W., Arnoldi, A., Nutritional and neutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins (2009) Atherosclerosis, 203 (1), pp. 8-17. , COI: 1:CAS:528:DC%2BD1MXis1Cjs7g%3D, PID: 18687434; Flight, I., Clifton, P., Cereal grains and legumes in the prevention of coronary heart dz & stroke: a review of the literature (2006) Eur J Clin Nutr, 60, pp. 1145-1159. , COI: 1:CAS:528:DC%2BD28XhtVWqsLfL, PID: 16670693; Duranti, M., Grain legume proteins and nutraceutical properties (2006) Fitoterapia, 77, pp. 67-82. , COI: 1:CAS:528:DC%2BD28XhtlKmur0%3D, PID: 16406359; Barrett, M.I., Udani, J.K., A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clincal studies on weight loss and glycemic control (2011) Nutr J, 10, p. 24. , PID: 21414227; Yao, Y., Cheng, X.Z., Wang, L.X., Wang, S.H., Major phenolic compounds, antioxidant capacity and antidiabetic potential of rice bean (Vigna umbellata L.) in China (2012) In J Mol Sci, 13, pp. 2707-2716. , COI: 1:CAS:528:DC%2BC38Xjs12qsrs%3D; Helmstadter, A., Beans and diabetes: Phenolus vulgaris preparation as antihypertensive agents (2010) J Med Food, 13, pp. 251-254. , PID: 20132042; Preuss, H.G., Bean amylase inhibitor and other carbohydrate absorption blockers effects on diabesity and general health (2009) J Am Coll Nutr, 28, pp. 266-276. , COI: 1:CAS:528:DC%2BC3cXhtVWmt7o%3D, PID: 20150600; Thompson, S.V., Winham, D.M., Hutchins, A.M., Bean and rice meals reduce postprandial glycemic responses in adults with type 2 diabetes: a crossover study (2012) Nutr J, 11, p. 23. , PID: 22494488; Weisse, K., Brandsch, C., Zernsdorf, B., Nembongwe, G., Lupin protein compared to casein lowers the LDL-Cholesterol:HDL-Cholesterol ratio of hypercholesterolemic adults (2010) Eur J Nutr, 49 (2), pp. 65-71. , COI: 1:CAS:528:DC%2BC3cXhslOnsL4%3D, PID: 19680704; Gilbert, E.R., Liu, D., Anti-diabetic functions of soy isoflavone genistein: mechanism underlying its effects on pancreatic beta-cell function (2013) Food Fnct, 4, pp. 200-212. , COI: 1:CAS:528:DC%2BC3sXhvVCitb4%3D; Anderson, J.W., Bush, H.M., Soy protein effects on serum lipoproteins: a quality assessment and meta analysis of randomized, controlled studies (2011) J Am Coll Nutr, 30, pp. 79-91. , COI: 1:CAS:528:DC%2BC3MXhtVaksLvF, PID: 21730216; Azadbakht, L., Shakerhosseini, R., Atabak, S., Jamshidian, M., Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type 2 diabetes with nephropathy (2003) Eur J Clin Nutr, 57, pp. 1292-1294. , COI: 1:CAS:528:DC%2BD3sXnsVOqu7g%3D, PID: 14506491; Bhathena, S.J., Velasquez, M.T., Beneficial role of dietary phytoestrogens in obesity and diabetes (2002) Am J Clin Nutr, 76, pp. 1191-1201. , COI: 1:CAS:528:DC%2BD38Xpt1emtrs%3D, PID: 12450882; Yang, B., Chen, Y., Xu, T., Yu, Y., Systematic review and meta-analysis of soy products consumption in patients with type 2 diabetes mellitus (2011) Asia Pac J Clin Nutr, 20, pp. 593-602. , COI: 1:CAS:528:DC%2BC38XhtVyrt74%3D, PID: 22094845; Ronis, M.J., Chen, Y., Badeaus, J., Badger, T.M., Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR and SREBP signaling (2009) J Nutr, 139, pp. 1431-1438. , COI: 1:CAS:528:DC%2BD1MXhtlWrt7rN, PID: 19515742; Liu, C.F., Pan, T.M., Beneficial Effects of Bioactive Peptides derived from Soybean on Human Health and Their Production by Genetic Engineering (2011) Soybean and health, pp. 311-329; Anderson, J.W., Bush, H.M., Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies (2011) J Am Coll Nutr, 30, pp. 79-291; Harland, J.I., Haffner, T.A., Systematic review, meta-analysis and regression of randomized controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol (2008) Atherosclerosis, 200, pp. 13-27. , COI: 1:CAS:528:DC%2BD1cXhtVensb7I, PID: 18534601; Afshin, A., Micha, R., Khatibzadeh, S., Mozaffarian, D., Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis (2014) Am J Clin Nutr, 100, pp. 278-288. , COI: 1:CAS:528:DC%2BC2cXhtFWht7bP, PID: 24898241; Kendall, C.W., Esfahani, A., Truan, J., Srichaikul, K., Health benefits of nuts in prevention and management of diabetes (2010) Asia Pac J Clin Nutr, 19, pp. 110-116. , COI: 1:CAS:528:DC%2BC3cXkvVCntbw%3D, PID: 20199995; Ross, E., Nuts and novel biomarkers of cardiovascular disease (2009) Am J Clin Nutr, 89, pp. 1649-1656; Jenkins, D.J., Hu, F.B., Tapsell, L.C., Josse, A.R., Possible benefits of nuts in type 2 diabetes (2008) J Nutr, 138, pp. 1752-1756. , COI: 1:CAS:528:DC%2BD1cXhtVyksrvL, PID: 18716181; Li, T.Y., Brennan, A.M., Wedick, N.M., Mantzoros, C., Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes (2009) J Nutr, 139, pp. 1333-1338. , COI: 1:CAS:528:DC%2BD1MXhtlWrt7zI, PID: 19420347; Tey, S.L., Brown, R., Gray, A., Chisholm, A., Nuts improve diet quality compared to other energy dense snacks while maintaining body weight (2011) J Nutr Metab, 2011, p. 357350. , PID: 21845219; Mattes, R.D., Dreher, M.L., Nuts and healthy body weight maintenance mechanisms (2010) Asia Pac J Clin Nutr, 19, pp. 137-141. , PID: 20199999; Mantzoros, C.S., Williams, C.J., Manson, J.E., Meigs, J.B., Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women (2006) Am J Clin Nutr, 84, pp. 328-335. , COI: 1:CAS:528:DC%2BD28XosVehs7s%3D, PID: 16895879; Jiang, R., Jacobs, D.R., Mayer-Davis, E., Szklo, M., Nut and seed consumption and inflammatory markers in the multi-ethnic study of atherosclerosis (2006) Am J Epidemiol, 163, pp. 222-231. , PID: 16357111; Ross, E., Nuts and novel biomarkers of cardiovascular disease (2009) Am J Clin Nutr, 89, pp. 1649-1656; Bao, U., Han, J., Hu, F.G., Stampfer, M., Willett, W., Fuchs, C.S., Association of nut consumption with total and cause specific mortality (2013) N Engl J Med, 369, pp. 2001-2011. , COI: 1:CAS:528:DC%2BC3sXhvVCjtb%2FP, PID: 24256379, In two major cohort studies (Nurses’ Health Study and the Health Professionals Follow-up Study), the frequency of nut consumption was inversely associated with total and cause-specific mortality in a dose-dependent manner. Nut consumption (seven or more times per week) resulted in a 20 % lower death rate; Wang ZM, Zhou B, Wang YS, Gong Q et al. Black and green tea consumption and the risk of coronary artery disease: a meta-analysis. Am J Clin Nutr. 93 (3):506–515Jiao, H., Hu, G., Gu, D., Ni, X., (2014) Having a Promising Efficacy on Type II diabetes, , It’s definitely a green tea time, Curr Med Chem:; Takahashi, M., Miyashita, M., Suzuki, K., Acute ingestion of catechin-rich green tea improves postprandial glucose status and increases serum thioredoxin concentrations in postmenopausal women (2014) Br J Nutr, pp. 1-9; Zuo, X., Tian, C., Zhao, N., Ren, W., Tea polyphenols alleviate high fat and high glucose-induced endothelial hyper permeability by attenuating ROS production via NADPH oxidase pathway (2014) BMC Res Notes, 7, p. 120. , PID: 24580748; Grassi, D., Desideri, G., Ferri, C., Protective effects of dark chocolate on endothelial function and diabetes (2013) Curr Opin Clin Nutr Metab Care, 16 (6), pp. 662-668. , COI: 1:CAS:528:DC%2BC3sXhs1WlsbnP, PID: 24100673; Katz, D.L., Doughty, K., Ali, A., Cocoa and chocolate in human health and disease (2011) Antioxid Redox Signal, 15 (10), pp. 2779-2811. , COI: 1:CAS:528:DC%2BC3MXht12qsrnE, PID: 21470061; Buitrago-Lopez, A., Sanderson, J., Johnson, L., Warnakula, S., Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis (2011) BMJ, 343, p. 4488. , PID: 21875885; Messerli, F.H., Chocolate consumption, cognitive function, and nobel laureates (2012) N Engl J Med, 367, pp. 1562-1564. , COI: 1:CAS:528:DC%2BC38XhsFGqsrjL, PID: 23050509; Fernández-Murga, L., Tarín, J.J., García-Perez, M.A., Cano, A., The impact of chocolate on cardiovascular health (2011) Maturitas, 69, pp. 312-321. , PID: 21665390; Eilat-adar, S., Sinai, T., Yosefy, C., Henkin, Y., Nutritional recommendations for cardiovascular disease prevention (2013) Nutrients, 5 (9), pp. 3646-3683. , PID: 24067391; Kwon MJ, Song YS, Choi MS, Park S et al. Cholesteryl ester transfer protein activity and atherogenic parametes in rabbits supplemented with cholesterol and garlic powder. Life Sci. 72(26):2953–2964Khoo, Y.S., Aziz, Z., Garlic supplementation and serum cholesterol: a meta-analysis (2009) J Clin Pharm Ther, 34, pp. 133-145. , COI: 1:STN:280:DC%2BD1M7nsF2ktQ%3D%3D, PID: 19250134; Ackermann, R.T., Mulrow, C.D., Ramirez, G., Gardner, C.D., Garlic shows promise for improving some cardiovascular risk factors (2001) Arch Intern Med, 161, pp. 813-824. , COI: 1:STN:280:DC%2BD3M3mtVeltw%3D%3D, PID: 11268223; Zeb, I., Ahmadi, N., Nasir, K., Kadakia, J., Larijani, V.N., Flores, F., Aged garlic extract and coenzyme Q10 have favorable effect on inflammatory markers and coronary atherosclerosis progression: a randomized clinical trial (2012) J Cardiovasc Dis Res, 3 (3), pp. 185-190. , PID: 22923934; Qin, B., Panickar, K.S., Anderson, R.A., Cinnamon: potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes (2010) J Diabetes Sci Technol, 4 (3), pp. 685-693. , PID: 20513336; Crawford, P., Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial (2009) J Am Board Fam Med, 22 (5), pp. 507-512. , PID: 19734396; https://naturalmedicines.therapeuticresearch.com, Natural Standard. Accessed September 29, 2014Smith, J.D., Clinard, V.B., Natural products for the management of type 2 diabetes mellitus and comorbid conditions (2014) J Am Pharm Assoc, 54 (5), pp. 304-320; Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis (2014) Phytother Res, 28 (5), pp. 633-642. , COI: 1:CAS:528:DC%2BC2cXmvVyqs74%3D, PID: 23922235; Neelakantan, N., Narayanan, M., de Souza, R.J., Effect of fenugreek (Trigonella foenum-graecum L) intake on glycemia: a meta-analysis of clinical trials (2014) Nutr J, 13, p. 7. , PID: 24438170; Liu, Y., Kakani, R., Nair, M.G., Compounds in functional food fenugreek spice exhibit anti-inflammatory and antioxidant activities (2012) Food Chem, 3, pp. 1187-1192; Mandegary, A., Pournamdari, M., Sharififar, F., Pournourmohammadi, S., Fardiar, R., Shooli, S., Alkaloid and flavonoid rich fractions of fenugreek seeds (Trigonella foenum-graecum L.) with antinociceptive and anti-inflammatory effects (2012) Food Chem Toxicol, 50 (7), pp. 2503-2507. , COI: 1:CAS:528:DC%2BC38XosVehsbs%3D, PID: 22542922; Elwood, P., Pickering, J., Givens, D.I., Gallacher, J., The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence (2010) Lipids, 45 (10), pp. 925-939. , COI: 1:CAS:528:DC%2BC3cXht1GjtLrM, PID: 20397059; Soedamah-Muthu, S.S., Ding, E.L., Al-Delaimy, W.K., Hu, F.B., Engberink, M.F., Willett, W.C., Milk and dairy consumption and incidence of cardiovascular diseases and all-cause mortality: dose–response meta-analysis of prospective cohort studies (2011) Am J Clin Nutri, 93 (1), pp. 158-171. , COI: 1:CAS:528:DC%2BC3MXls1CrsA%3D%3D; Sonestedt, E., Wirfält, E., Wallström, P., Gullberg, B., Orho-Melander, M., Hedblad, B., Dairy products and its association with incidence of cardiovascular disease: the Malmö diet and cancer cohort (2011) Eur J Epidemiol, 26 (8), pp. 609-618. , COI: 1:CAS:528:DC%2BC3MXhtFGit7bI, PID: 21660519; Patterson, E., Larsson, S.C., Wolk, A., Åkesson, A., Association between dairy food consumption and risk of myocardial infarction in women differs by type of dairy food (2013) J Nutri, 143 (1), pp. 74-79. , COI: 1:CAS:528:DC%2BC3sXhs1Ghug%3D%3D; de Oliveira Otto, M.C., Nettleton, J.A., Lemaitre, R.N., Steffen, L.M., Kromhout, D., Rich, S.S., Biomarkers of dairy fatty acids and risk of cardiovascular disease in the multi-ethnic study of atherosclerosis (2013) J Am Heart Assoc, 2 (4), p. 000092. , PID: 23868191; Mann, G.V., Spoerry, A., Studies of a surfactant and cholesteremia in the Maasai (1974) Am J Clin Nutri, 27 (5), pp. 464-469. , COI: 1:CAS:528:DyaE2cXhsVCmurY%3D; de Roos, N.M., Schouten, G., Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels (1999) Eur J Clin Nutr, 53 (4), pp. 277-280. , PID: 10334653; Lewis, S.J., Burmeister, S., A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids (2005) Eur J Clin Nutr, 59 (6), pp. 776-780. , COI: 1:CAS:528:DC%2BD2MXks12ktb4%3D, PID: 15841092; Simons, L.A., Amansec, S.G., Conway, P., Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol (2006) Nutr Metab Cardiovasc Dis, 16 (8), pp. 531-535. , PID: 17126768; Ataie-Jafari, A., Larijani, B., Alavi Majd, H., Tahbaz, F., Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects (2009) Ann Nutr Metab, 54 (1), pp. 22-27. , COI: 1:CAS:528:DC%2BD1MXltVekuro%3D, PID: 19229114; Xiao, J.Z., Kondo, S., Takahashi, N., Miyaji, K., Oshida, K., Hiramatsu, A., Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers (2003) J Dairy Sci, 86 (7), pp. 2452-2461. , COI: 1:CAS:528:DC%2BD3sXltlSrtbg%3D, PID: 12906063; Anderson, J.W., Effect of fermented milk (yogurt) containing lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans (1999) J Am Coll Nutr, 18 (1), pp. 43-50. , COI: 1:STN:280:DyaK1M7msV2rsw%3D%3D, PID: 10067658; Guo, Z., Liu, X.M., Zhang, Q.X., Shen, Z., Tian, F.W., Zhang, H., Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials (2011) Nutr Metab Cardiovasc Dis, 21 (11), pp. 844-850. , COI: 1:CAS:528:DC%2BC3MXhtlejsbzM, PID: 21930366; Agerholm, L., Bell, M.L., The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies (2000) Eur J Clin Nutr, 54 (11), p. 856; DiRienzo, D.B., Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets (2014) Nutr Rev, 72 (1), pp. 18-29. , PID: 24330093; Jakobsen, M.U., O’Reilly, E.J., Heitmann, B.L., Pereira, M.A., Bälter, K., Fraser, G.E., Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies (2009) Am J Clin Nutr, 89 (5), pp. 1425-1432. , COI: 1:CAS:528:DC%2BD1MXlt1Ort7o%3D, PID: 19211817, Results from 11 American and European cohort pooled studies (with 344,696 participants) demonstrated that replacing saturated fatty acids with polyunsaturated fatty acids rather than monounsaturated fatty acids or dietary carbohydrate prevents CHD; Mente, A., de Koning, L., Shannon, H.S., Anand, S.S., A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease (2009) Arch Intern Med, 169 (7), pp. 659-669. , COI: 1:CAS:528:DC%2BD1MXltFert70%3D, PID: 19364995; Skeaff, C.M., Miller, J., Dietary fat and coronary heart disease: summary of evidence from prospective cohort and randomised controlled trials (2009) Ann Nutri Metab, 55 (1-3), pp. 173-201. , COI: 1:CAS:528:DC%2BD1MXhtFaksL3P; Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., Ward, H.A., Johnson, L., Association of dietary, circulating, and supplement fatty acids with coronary risk a systematic review and meta-analysis (2014) Ann Intern Med, 160 (6), pp. 398-406. , PID: 24723079; Schwingshackl, L., Hoffmann, G., Monounsaturated fatty acids and risk of cardiovascular disease: synopsis of the evidence available from systematic reviews and meta-analyses (2012) Nutrients, 4 (12), pp. 1989-2007. , COI: 1:CAS:528:DC%2BC3sXjsFSkug%3D%3D, PID: 23363996; Guasch-Ferre, M., Hu, F., Martinez-Gonzalez, M., Fito, M., Bullo, M., Estruch, R., Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED study (2014) BMC Med, 12 (1), p. 78. , PID: 24886626, In this study, for every 10 g/day increase in extra-virgin olive oil consumed, risk of cardiovascular disease and mortality decreased by 10 % and 7 %, respectively; Buckland, G., Mayén, A.L., Agudo, A., Travier, N., Navarro, C., Huerta, J.M., Olive oil intake and mortality within the Spanish population (EPIC-Spain) (2012) Am J Clin Nutr, 96 (1), pp. 142-149. , COI: 1:CAS:528:DC%2BC38XpsVyktrc%3D, PID: 22648725; Samieri, C., Feart, C., Proust-Lima, C., Peuchant, E., Tzourio, C., Stapf, C., Olive oil consumption, plasma oleic acid, and stroke incidence: the Three-City Study (2011) Neurology, 77 (5), pp. 418-425. , COI: 1:CAS:528:DC%2BC3MXpslKgs7c%3D, PID: 21676914; Martínez-González, M.A., Dominguez, L.J., Delgado-Rodríguez, M., Olive oil consumption and risk of CHD and/or stroke: a meta-analysis of case–control, cohort and intervention studies (2014) Br J Nutr, 112 (2), pp. 248-259. , PID: 24775425; Schwingshackl, L., Hoffmann, G., Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies (2014) Lipids Health Dis, 13 (1), p. 154. , PID: 25274026; Di Castelnuovo, A., Rotondo, S., Iacoviello, L., Donati, M.B., de Gaetano, G., Meta-analysis of wine and beer consumption in relation to vascular risk (2002) Circulation, 105 (24), pp. 2836-2844. , PID: 12070110; Li, H., Förstermann, U., Red wine and cardiovascular health (2012) Circ Res, 111 (8), pp. 959-961. , COI: 1:CAS:528:DC%2BC38XhsVWmtrfL, PID: 22955729; Chiva-Blanch, G., Urpi-Sarda, M., Ros, E., Arranz, S., Valderas-Martínez, P., Casas, R., Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication (2012) Circ Res, 111 (8), pp. 1065-1068. , COI: 1:CAS:528:DC%2BC38XhsVWmt77F, PID: 22955728; Krnic, M., Modun, D., Budimir, D., Gunjaca, G., Jajic, I., Vukovic, J., Comparison of acute effects of red wine, beer and vodka against hyperoxia-induced oxidative stress and increase in arterial stiffness in healthy humans (2011) Atherosclerosis, 218 (2), pp. 530-535. , COI: 1:CAS:528:DC%2BC3MXht1GrsbvF, PID: 21803358; Costanzo, S., Di Castelnuovo, A., Donati, M., Iacoviello, L., de Gaetano, G., Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis (2011) Eur J Epidemiol, 26 (11), pp. 833-850. , PID: 22076059; Bang, H.O., Dyerberg, J., Sinclair, H.M., The composition of the Eskimo food in north western Greenland (1980) Am J Clin Nutr, 33 (12), pp. 2657-2661. , COI: 1:CAS:528:DyaL3MXhsValsg%3D%3D, PID: 7435433; Mozaffarian, D., Rimm, E.B., Fish intake, contaminants, and human health: evaluating the risks and the benefits (2006) JAMA, 296 (15), pp. 1885-1899. , COI: 1:CAS:528:DC%2BD28XhtFWmt7%2FF, PID: 17047219; Mozaffarian, D., Lemaitre, R.N., King, I.B., Song, X., Huang, H., Sacks, F.M., Plasma phospholipid long-chain ω-3 fatty acids and total and cause-specific mortality in older adults a cohort study (2013) Ann Intern Med, 158 (7), pp. 515-525. , PID: 23546563; Wu, J.H.Y., Lemaitre, R.N., King, I.B., Song, X., Sacks, F.M., Rimm, E.B., Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study (2012) Circulation, 125 (9), pp. 1084-1093. , COI: 1:CAS:528:DC%2BC38Xjt1Gnu70%3D, PID: 22282329; Djoussé, L., Akinkuolie, A.O., Wu, J.H.Y., Ding, E.L., Gaziano, J.M., Fish consumption, omega-3 fatty acids and risk of heart failure: a meta-analysis (2012) Clin Nutr, 31 (6), pp. 846-853. , PID: 22682084; Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione (2002) Circulation, 105 (16), pp. 1897-1903. , COI: 1:CAS:528:DC%2BD38XktFajtbc%3D, PID: 11997274; Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis (2007) Lancet, 369 (9567), pp. 1090-1098. , COI: 1:CAS:528:DC%2BD2sXjs1Ohtro%3D, PID: 17398308; Harris, W.S., Are n-3 fatty acids still cardioprotective? (2013) Curr Opin Clin Nutr Metab Care, 16 (2), pp. 141-149. , COI: 1:CAS:528:DC%2BC3sXit1egtb8%3D, PID: 23196817; (2010) USDA H. dietary guidelines for Americans 2010, , US Government Printing Office, Washington, DC:; Spencer, J.P.E., Gozier, A., Flavonoids and related compounds (2012) Bioavaialability and function. oxidative stress and disease, vol 30, , Paker L, Cardenas H, (eds), CRG Press, Boca Raton:; Del Rio, D., Rodriguez-Mateos, A., Spencer, J.P., Tognolini M,Borges G, Crozier A. Dietary polyphenolics in Human Health: Atructures Bioavailabity and Evidence of Protective Effects against Chronic Diseases. 2013 Antioxidants and Redox Signaling 18, 14, pp. 1818-1892; Reedy, J., Krebs-Smith, S.M., Miler, P.E., Liese, A., Higher diet quality is associated with decreased risk of all-cause. Cardiovascular disease, and cancer mortality among older adults (2014) J Nutr, 144, pp. 881-889. , COI: 1:CAS:528:DC%2BC2cXovFGmsrw%3D, PID: 24572039; http://www.health.gov/dietaryguidelines/, 2015 Dietary Guidelines for Americans Committee Reportwww.athero.org, Grundy SM, Arai H, Barter P, Bersot TP et al. 2013. An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia (accessed September 20, 2014)http://content.onlinejacc.org/article.aspx?doi, Eckel et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation published online November 12 2013. 201310.1161/01.cir.0000437740.48606.d1. = Accessed February 2 2015Jacobson, T.A., Ito, M.K., Maki, K.C., Orringer, C.E., Bays, H.E., Jones, P.H., National lipid association recommendations for patient-centered management of dyslipidemia: part 1—executive summary (2014) J Clin Lipidol, 8, pp. 473-488. , PID: 25234560; Evert, A.B., Boucher, J.L., Cypress, M., Dunbar, S.A., Franz, M.J., Nutrition therapy recommendations for the management of adults with diabetes (2014) Diab Care, 37, pp. 120-143; Jensen, M.D., Ryan, D.H., Apovian, C.M., Jamy, D., AHA/ACC/TOS Guideline for the management of overweight and obesity in adults. Circulation. 2013: published online before print November 12, 2013 (2013) 10.1161/01.cir.0000437739.71477.ee, , 01.cir.0000437739.71477.ee",Review,Scopus,2-s2.0-84928321636
"Tagore S., De R.K.","Evolutionary growth of certain metabolic pathways involved in the functioning of GAD and INS genes in Type 1 Diabetes Mellitus: Their architecture and stability",2015,"Computers in Biology and Medicine","61",,,"19","35",,,10.1016/j.compbiomed.2015.03.012,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926436133&partnerID=40&md5=8079b4e404ef65917a7a59763fd1c778","Department of Biotechnology and Bioinformatics, Padmashree Dr. D.Y. Patil UniversityNavi Mumbai, India; Machine Intelligence Unit, Indian Statistical InstituteKolkata, India","Tagore, S., Department of Biotechnology and Bioinformatics, Padmashree Dr. D.Y. Patil UniversityNavi Mumbai, India; De, R.K., Machine Intelligence Unit, Indian Statistical InstituteKolkata, India","Background: Studying biochemical pathway evolution for diseases is a flourishing area of Systems Biology. Here, we study Type 1 Diabetes Mellitus (T1D), focusing on growth of glutamate, β-alanine, taurine and hypotaurine, and butanoate metabolisms involved in onset of GAD and INS genes in Homo sapiens with comparative analysis in non-obese diabetic Mus musculus, biobreeding Diabetes-prone Rattus norvegicus, Pan troglodytes, Oryctolagus cuniculus, Danio rerio and Drosophila melanogaster respectively. Methods: We propose an algorithm for growth analysis for four metabolic pathways involved in T1D. It has three modules, pattern finding, interaction identification and growth detection. The first module identifies patterns using Community structures using Hamming distances and the Tanimoto coefficient. We have performed functional analysis by representing patterns using ODEs, and identified Stoichiometric, Gradient and Jacobian matrices. The second module identifies interactions among patterns using cut-sets and network-partitioning by 'Divide-and-conquer'. The third module identifies functions of patterns using interactions, thereby highlighting their nature of growth.Results: We observed that metabolites that are genetically robust and resist alterations against stable state during evolution, account for emergence of a scale-free network.Discussion: New modules get acquired to the fundamental cluster in a preferential manner, an instance of micro-evolution theory. For instance, (S)-3-hydroxy butanoyl-CoA, acetoacetyl-CoA, acetoacetate, acetyl-CoA, (S)-3-hydroxy-3-methyl glutaryl-CoA acts as a fundamental cluster in butanoate metabolism. Moreover, the interactions among metabolites are divergent in nature. Highlights: © 2015 Elsevier Ltd.","Community structure; Evolution; Hamming distance; Hasse diagram; Payoff matrix; Tanimoto coefficient","Risson, S.C.G., Thornton, J.M., Pathway evolution, structurally speaking (2002) Curr. Opin. Struct. Biol., 12, pp. 374-382; Ravasz, E., Somera, A.L., Mongru, D.A., Oltvai, Z.N., Barabási, A.L., Hierarchical organization of modularity in metabolic networks (2002) Science, 297 (5586), pp. 1551-1555; Newman, M.E.J., Detecting community structure in networks (2002) Eur. Phys. J. B, 38 (2), pp. 321-330; Pinter, R.Y., Rokhlenko, O., Yeger-Lotem, E., Ziv-Ukelson, M., Comparison of metabolic pathways (2005) Bioinformatics, 21 (16), pp. 3401-3408; Holmes, G.K., Coeliac disease and Type 1 diabetes mellitus - the case for screening (2001) Diabet. Med., 18 (3), pp. 169-177; Humphrey, A.R.G., McCarty, D.J., Mackay, I.R., Rowley, M.J., Dwyer, T., Zimmet, P., Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus (1998) Diabet. Med., 15 (2), pp. 113-119; Horowitz, N.H., On the evolution of biochemical syntheses (1945) Proc. Natl. Acad. Sci. USA, 31 (6), pp. 153-157; Granick, S., Speculations on the origins and evolution of photosynthesis (1957) Ann. N. Y. Acad. Sci., 69 (2), pp. 292-308; Ycas, M., On earlier states of the biochemical system (1974) J. Theor. Biol., 44 (1), pp. 145-160; Demetrius, L., Directionality theory and the evolution of body size (2000) Proc. Biol. Sci., 267 (1460), pp. 2385-2391; Wegner, P., A technique for counting ones in a binary computer (1960) Commun. ACM, 3 (5), p. 322; Clauset, A., Newman, M.E., Moore, C., Finding community structure in very large networks (2004) Phys. Rev. E. Stat. Nonlin. Soft Matter Phys., 70 (6), p. 066111; Klipp, E., (2005) Systems Biology in Practice: Concepts, Implementation And Application, , John Wiley & Sons Inc., New York; Arora, S., Rao, S., Vazirani, U., Expander flows, geometric embeddings and graph partitioning (2009) J. ACM, 56 (2), pp. 1-37; Quek, L.-E., Nielson, L.K., A depth-first search algorithm to compute elementary flux modes by linear programming (2014) BMC Syst. Biol., 8, p. 94; Behre, J., de Figueiredo, L.F., Schuster, S., Kaleta, C., Detecting structural invariants in biological reaction networks (2012) Methods Mol. Biol., 804, pp. 377-407; Jamshidi, N., Palsson, B.Ø., Flux-concentration duality in dynamic nonequilibrium biological networks (2009) Biophys J., 97 (5), pp. L11-L13; Domijan, M., Pècou, E., The interaction graph structure of mass-action reaction networks (2012) J. Math. Biol., 65 (2), pp. 375-402; Schuster, S., Kreft, J.-U., Schroeter, A., Pfeiffer, T., Use of game-theoretical methods in biochemistry and biophysics (2008) J. Biol. Phys., 34 (1-2), pp. 1-17; Bard, J.B., The next evolutionary synthesis. from Lamarck and Darwin to genomic variation and systems biology (2011) Cell Commun. Signal, 9 (1), p. 30; Toby, I., Biological databases as research tools in the post-genomic era (2012) Aviat. Space Environ. Med., 83 (4), pp. 452-453; Hucka, M., Finney, A., Sauro, H.M., Bolouri, H., Doyle, J.C., The systems biology markup language (SBML). a medium for representation and exchange of biochemical network models (2003) Bioinformatics, 19 (4), pp. 524-531; Hamming, R.W., Error detecting and error correcting codes (1950) Bell Syst. Techn. J., 26 (2), pp. 147-160; Ndifon, W., Plotkin, J.B., Dushoff, J., On the accessibility of adaptive phenotypes of a bacterial metabolic network (2009) PLoS Comput. Biol., 5 (8), p. e1000472; Chen, B.S., Lin, Y.P., On the interplay between the evolvability and network robustness in an evolutionary biological network. a systems biology approach (2011) Evol. Bioinform. Online, 7, pp. 201-233; Gleiss, P.M., Stadler, P.F., Wagner, A., Fell, D.A., Relevant cycles in chemical reaction networks (2010) Adv. Complex Syst., 1, pp. 1-18; Tagore, S., De, R.K., Detecting breakdown points in metabolic networks (2011) Comput. Biol. Chem., 35 (6), pp. 371-380; Davis, M.J., Shin, C.J., Jing, N., Ragan, M.A., Rewiring the dynamic interactome (2012) Mol. Biosyst., 8 (8), pp. 2054-2066; Conway, D.J., Roper, C., Micro-evolution and emergence of pathogens (2000) In. J. Parasitol., 30 (12-13), pp. 1423-1430; Efron, B., Tibshirani, R.J., (1993) An Introduction to the Bootstrap (Monographs on Statistics and Applied Probability), , Springer, Dordrecht; Nesse, R.M., Bergstrom, C.T., Ellison, P.T., Flier, J.S., Gluckman, P., Evolution in health and medicine Sackler colloquium. making evolutionary biology a basic science for medicine (2010) Proc. Natl. Acad. Sci. USA, 107 (1), pp. 1800-1807; Gu, J., Evolutionary systems biology (2011) Curr. Genomics, 12 (6), p. 379; Tagore, S., De, R.K., SAGPAR: structural grammar-based automated pathway reconstruction Interdiscip. Sci, 4 (2), pp. 116-127; Grimbs, S., Selbig, J., Bulik, S., Holzhütter, H.-G., Steuer, R., The stability and robustness of metabolic states. identifying stabilizing sites in metabolic networks (2007) Mol. Syst. Biol., 3, p. 146; Gerschgorin, S., Über die Abgrenzung der Eigenwerte einer Matrix (1931) Izv. Akad. Nauk. USSR Otd. Fiz.-Mat. Nauk., 6, pp. 749-754; Papp, B., Szappanos, B., Notebaart, R.A., Use of genome-scale metabolic models in evolutionary systems biology (2011) Methods Mol. Biol., 759, pp. 483-497; Goldstein, Y., Bockmayr, A., A lattice-theoretic framework for metabolic pathway analysis (2013) Computational Methods in Systems Biology, CMSB 2013, Klosterneuburg, 8130, pp. 178-191. , Springer, LNBI; Loewe, L., A framework for evolutionary systems biology (2009) BMC Syst. Biol., 3, p. 27; Anastasiou, D., Metformin. a case of divide and conquer (2013) Breast Cancer Res., 15 (2), p. 306; Chen, B.S., Hsu, C.Y., Liou, J.J., Robust design of biological circuits. evolutionary systems biology approach (2011) J. Biomed. Biotechnol., 2011, p. 304236; Arnold, B.F., Größl, I., Stahlecker, P., The minimax, the minimin, and the Hurwicz adjustment principle (2002) Theory Decis., 52 (3), pp. 233-260",Article,Scopus,2-s2.0-84926436133
"Yabe D., Seino Y., Fukushima M., Seino S.","β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians",2015,"Current Diabetes Reports","15","6",,"","",9,,10.1007/s11892-015-0602-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928920275&partnerID=40&md5=2768687d6eae7770d2ae1cc5916ff763","Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, 2-1-7 Fukushima-kuOsaka, Japan; Center for Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, 2-1-7 Fukushima-kuOsaka, Japan; Division of Molecular and Metabolic Medicine, Kobe University Graduate School of MedicineKobe, Chuo-ku, Japan; Department of Nutritional Science, Okayama Prefectural University, 111 kuboki, Soujiya-shiOkayama, Japan","Yabe, D., Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, 2-1-7 Fukushima-kuOsaka, Japan, Center for Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, 2-1-7 Fukushima-kuOsaka, Japan, Division of Molecular and Metabolic Medicine, Kobe University Graduate School of MedicineKobe, Chuo-ku, Japan; Seino, Y., Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, 2-1-7 Fukushima-kuOsaka, Japan; Fukushima, M., Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, 2-1-7 Fukushima-kuOsaka, Japan, Division of Molecular and Metabolic Medicine, Kobe University Graduate School of MedicineKobe, Chuo-ku, Japan, Department of Nutritional Science, Okayama Prefectural University, 111 kuboki, Soujiya-shiOkayama, Japan; Seino, S., Division of Molecular and Metabolic Medicine, Kobe University Graduate School of MedicineKobe, Chuo-ku, Japan","Type 2 diabetes (T2DM) is one of the most serious global health problems and is mainly a result of the drastic increase in East Asia, which includes over a fourth of the global diabetes population. Lifestyle factors and ethnicity are two determinants in the etiology of T2DM, and lifestyle changes such as higher fat intake and less physical activity link readily to T2DM in East Asians. It is widely recognized that T2DM in East Asians is characterized primarily by β cell dysfunction, which is evident immediately after ingestion of glucose or meal, and less adiposity compared to the disease in Caucasians. These pathophysiological differences have an important impact on therapeutic approaches. Here, we revisit the pathogenesis of T2DM in light of β cell dysfunction versus insulin resistance in East Asians and discuss ethnic differences in the contributions of insulin secretion and insulin resistance, together with incretin secretin and action, to glucose intolerance. © 2015, The Author(s).","East Asian; Incretin; Insulin resistance; Insulin secretion; Type 2 diabetes","Diabetes Atlas, I.D.F., Update Sixth Edition (2014) Brussels: International Diabetes Federation; 2014; Yoon, K.H., Lee, J.H., Kim, J.W., Cho, J.H., Choi, Y.H., Epidemic obesity and type 2 diabetes in Asia (2006) Lancet, 368, pp. 1681-1688. , PID: 17098087; Chan, J.C., Malik, V., Jia, W., Kadowaki, T., Yajnik, C.S., Diabetes in Asia: epidemiology, risk factors, and pathophysiology (2009) JAMA, 301, pp. 2129-2140. , COI: 1:CAS:528:DC%2BD1MXmsFaks7k%3D, PID: 19470990; Abate, N., Chandalia, M., The impact of ethnicity on type 2 diabetes (2003) J Diabet Complicat, 17, pp. 39-58; Ntuk, U.E., Gill, J.M., Mackay, D.F., Sattar, N., Pell, J.P., Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK Biobank participants (2014) Diabetes Care, 37, pp. 2500-2507. , PID: 24974975, An original article clarifying that East Asians develop type 2 diabetes at lower body mass index compared to Caucasians through a large multi-ethnic cohort in the UK; Nakanishi, S., Okubo, M., Yoneda, M., Jitsuiki, K., Yamane, K., A comparison between Japanese-Americans living in Hawaii and Los Angeles and native Japanese: the impact of lifestyle westernization on diabetes mellitus (2004) Biomed Pharmacother, 58, pp. 571-577. , COI: 1:STN:280:DC%2BD2cnhs1ahsA%3D%3D, PID: 15589065; Fujimoto, W.Y., Boyko, E.J., Hayashi, T., Kahn, S.E., Leonetti, D.L., Risk factors for type 2 diabetes: lessons learned from Japanese Americans in Seattle (2012) J Diabetes Investig, 3, pp. 212-224. , PID: 22798980, An important review describing characteristics of Japanese American’s diabetes which is highly relevant to discuss pathogenesis of type 2 diabetes among East Asians; Moller, J.B., Dalla Man, C., Overgaard, R.V., Ingwersen, S.H., Tornoe, C.W., Ethnic differences in insulin sensitivity, beta-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis (2014) J Clin Endocrinol Metab, 99, pp. 4273-4280. , PID: 25119313, An original article describing direct comparisons of insulin secretion and resistance, during intravenous glucose tolerance test, between Japanese and Caucasians; Moller, J.B., Pedersen, M., Tanaka, H., Ohsugi, M., Overgaard, R.V., Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians (2014) Diabetes Care, 37, pp. 796-804. , PID: 24130359, An original article describing direct comparisons of insulin secretion and resistance, during oral glucose tolerance test, between Japanese and Caucasians; Fukushima, M., Suzuki, H., Seino, Y., Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes (2004) Diabetes Res Clin Pract, 66S, pp. 37-44; Sloan, R., Ethnic distribution of diabetes mellitus in Hawaii (1963) JAMA, 183, pp. 419-424. , COI: 1:STN:280:DyaF387otFSqtQ%3D%3D, PID: 13989245; Kagan, A., Harris, B.R., Winkelstein, W., Jr., Johnson, K.G., Kato, H., Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics (1974) J Chron Dis, 27, pp. 345-364. , COI: 1:STN:280:DyaE2M%2FmtVKntQ%3D%3D, PID: 4436426; West, K.M., Diabetes in American Indians and other native populations of the New World (1974) Diabetes, 23, pp. 841-855. , COI: 1:STN:280:DyaE2M%2FisVOjsg%3D%3D, PID: 4213890; Olefsky, J.M., LIlly lecture 1980. Insulin resistance and insulin action. An in vitro and in vivo perspective (1981) Diabetes, 30, pp. 148-162. , COI: 1:CAS:528:DyaL3MXhsFSlsr4%3D, PID: 7009267; McNeely, M.J., Boyko, E.J., Type 2 diabetes prevalence in Asian Americans: results of a national health survey (2004) Diabetes Care, 27, pp. 66-69. , PID: 14693968; Fujimoto, W.Y., Hershon, K., Kinyoun, J., Stolov, W., Weinberg, C., Type II diabetes mellitus in Seattle and Tokyo (1983) Tohoku J Exp Med, 141, pp. 133-139. , PID: 6680481; Lyssenko, V., Almgren, P., Anevski, D., Perfekt, R., Lahti, K., Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes (2005) Diabetes, 54, pp. 166-174. , COI: 1:CAS:528:DC%2BD2MXhtVWisr4%3D, PID: 15616025; Ogihara, T., Mirmira, R.G., An islet in distress: beta cell failure in type 2 diabetes (2010) J Diabetes Investig, 1, pp. 123-133. , COI: 1:CAS:528:DC%2BC3cXhtFKrtbfL, PID: 24843420; DeFronzo, R.A., Pathogenesis of type 2 diabetes mellitus (2004) Med Clin North Am, 88, pp. 787-835. , COI: 1:CAS:528:DC%2BD2cXot1agurg%3D, PID: 15308380, ix; Fukushima, M., Usami, M., Ikeda, M., Nakai, Y., Taniguchi, A., Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes (2004) Metabolism, 53, pp. 831-835. , COI: 1:CAS:528:DC%2BD2cXlt1elsbw%3D, PID: 15254872; Kadowaki, T., Miyake, Y., Hagura, R., Akanuma, Y., Kajinuma, H., Risk factors for worsening to diabetes in subjects with impaired glucose tolerance (1984) Diabetologia, 26, pp. 44-49. , COI: 1:STN:280:DyaL2c7lvFartA%3D%3D, PID: 6368299; Iwahashi, H., Okauchi, Y., Ryo, M., Noguchi, M., Morita, S., Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients (2012) J Diabetes Investig, 3, pp. 271-275. , COI: 1:CAS:528:DC%2BC38Xht1Sjsb%2FP, PID: 24843576; Yabe, D., Kuroe, A., Watanabe, K., Iwasaki, M., Hamasaki, A., Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients (2015) J Diabet Complicat, 29 (3), pp. 413-421; Seino, Y., Taminato, T., Goto, Y., Ikeda, M., Imura, H., Comparative insulinogenic effect of glucose, arginine and glucagon in patients with diabetes mellitus, endocrine disorders and liver disease (1975) Acta Diabetol, 12 (2), pp. 89-99. , COI: 1:STN:280:DyaE287lslWrsw%3D%3D; Kosaka, K., Kuzuya, T., Akanuma, Y., Hagura, R., Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment (1980) Diabetologia, 18, pp. 23-28. , COI: 1:STN:280:DyaL3c7lslCiug%3D%3D, PID: 6988263; Seino, Y., Goto, Y., Kurahachi, H., Sakurai, H., Ikeda, M., Alteration of plasma glucagon response to arginine after treatment in patients with diabetes mellitus, Cushing’s syndrome and hypothyroidism (1977) Horm Metab Res, 9, pp. 28-32. , COI: 1:CAS:528:DyaE2sXhtFyksbg%3D, PID: 844789; Seino, Y., Ikeda, M., Kurahachi, H., Taminato, T., Sakurai, H., Failure of suppress plasma glucagon concentrations by orally administered glucose in diabetic patients after treatment (1978) Diabetes, 27, pp. 1145-1150. , COI: 1:STN:280:DyaE1M%2FmsFyjtA%3D%3D, PID: 363490; Tripathy, D., Carlsson, M., Almgren, P., Isomaa, B., Taskinen, M.R., Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study (2000) Diabetes, 49, pp. 975-980. , COI: 1:CAS:528:DC%2BD3cXjvFylurc%3D, PID: 10866050; Kim, D.J., Lee, M.S., Kim, K.W., Lee, M.K., Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus (2001) Metabolism, 50, pp. 590-593. , COI: 1:CAS:528:DC%2BD3MXjt1arurc%3D, PID: 11319722; Choi, Y.H., Ahn, Y.B., Yoon, K.H., Kang, M.I., Cha, B.Y., New ADA criteria in the Korean population: fasting blood glucose is not enough for diagnosis of mild diabetes especially in the elderly (2000) Korean J Intern Med, 15, pp. 211-217. , COI: 1:STN:280:DC%2BD3M7lvFKrug%3D%3D, PID: 11242809; Qian, L., Xu, L., Wang, X., Fu, X., Gu, Y., Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation (2009) Diabetes Metab Res Rev, 25, pp. 144-149. , COI: 1:CAS:528:DC%2BD1MXktFCktro%3D, PID: 19116942; Pang, C., Bao, Y.Q., Wang, C., Lu, J.X., Jia, W.P., Relationship between the level of fasting plasma glucose and beta cell functions in Chinese with or without diabetes (2008) Chin Med J (Engl), 121, pp. 2119-2123. , COI: 1:CAS:528:DC%2BD1cXhsVyntb7J; Taniguchi, A., Nakai, Y., Fukushima, M., Kawamura, H., Imura, H., Pathogenic factors responsible for glucose intolerance in patients with NIDDM (1992) Diabetes, 41, pp. 1540-1546. , COI: 1:STN:280:DyaK3s%2FnslSjsg%3D%3D, PID: 1446794; Welch, S., Gebhart, S.S., Bergman, R.N., Phillips, L.S., Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects (1990) J Clin Endocrinol Metab, 71, pp. 1508-1518. , COI: 1:STN:280:DyaK3M%2FjsFyksA%3D%3D, PID: 2229309; Kodama, K., Tojjar, D., Yamada, S., Toda, K., Patel, C.J., Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis (2013) Diabetes Care, 36, pp. 1789-1796. , COI: 1:CAS:528:DC%2BC3sXpslyltb0%3D, PID: 23704681; Tanaka, S., Horimai, C., Katsukawa, F., Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis (2003) Acta Diabetol, 40, pp. 302-304. , PID: 14618500; Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data (1998) BMJ, 317, pp. 371-375; Qiao, Q., Nakagami, T., Tuomilehto, J., Borch-Johnsen, K., Balkau, B., Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts (2000) Diabetologia, 43, pp. 1470-1475. , COI: 1:CAS:528:DC%2BD3cXotFCrtr4%3D, PID: 11151755; Suzuki, H., Fukushima, M., Usami, M., Ikeda, M., Taniguchi, A., Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia (2003) Diabetes Care, 26, pp. 1211-1215. , COI: 1:CAS:528:DC%2BD3sXjtVOis7Y%3D, PID: 12663599; Mitsui, R., Fukushima, M., Taniguchi, A., Nakai, Y., Aoyama, S., Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese (2012) J Diabetes Investig, 3, pp. 377-383. , COI: 1:CAS:528:DC%2BC38XhvVahsb%2FO, PID: 24843593; Nishi, Y., Fukushima, M., Suzuki, H., Mitsui, R., Ueda, N., Insulin secretion and insulin sensitivity in Japanese subjects with impaired fasting glucose and isolated fasting hyperglycemia (2005) Diabetes Res Clin Pract, 70, pp. 46-52. , COI: 1:CAS:528:DC%2BD2MXpsVWisbo%3D, PID: 16126123; Nakagami, T., Qiao, Q., Carstensen, B., Nhr-Hansen, C., Hu, G., Age, body mass index and type 2 diabetes-associations modified by ethnicity (2003) Diabetologia, 46, pp. 1063-1070. , COI: 1:STN:280:DC%2BD3sznt1CntQ%3D%3D, PID: 12827246; Fujimoto, W.Y., Leonetti, D.L., Kinyoun, J.L., Shuman, W.P., Stolov, W.C., Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance, or normal glucose tolerance (1987) Diabetes, 36, pp. 730-739. , COI: 1:STN:280:DyaL2s7ptFCmtw%3D%3D, PID: 3569672; Fujimoto, W.Y., Leonetti, D.L., Kinyoun, J.L., Newell-Morris, L., Shuman, W.P., Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men (1987) Diabetes, 36, pp. 721-729. , COI: 1:STN:280:DyaL2s7ptFCmtg%3D%3D, PID: 3569671; Matsubara, T., Mita, A., Minami, K., Hosooka, T., Kitazawa, S., PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue (2012) Cell Metab, 15, pp. 38-50. , COI: 1:CAS:528:DC%2BC38XkvF2msA%3D%3D, PID: 22225875; Yasuda, K., Miyake, K., Horikawa, Y., Hara, K., Osawa, H., Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus (2008) Nat Genet, 40, pp. 1092-1097. , COI: 1:CAS:528:DC%2BD1cXhtVGgt77M, PID: 18711367; Unoki, H., Takahashi, A., Kawaguchi, T., Hara, K., Horikoshi, M., SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations (2008) Nat Genet, 40, pp. 1098-1102. , COI: 1:CAS:528:DC%2BD1cXhtVGgt77E, PID: 18711366; Ullrich, S., Su, J., Ranta, F., Wittekindt, O.H., Ris, F., Effects of I(Ks) channel inhibitors in insulin-secreting INS-1 cells (2005) Pflugers Arch, 451, pp. 428-436. , COI: 1:CAS:528:DC%2BD2MXht1GlsLfP, PID: 16133261; Yamauchi, T., Hara, K., Maeda, S., Yasuda, K., Takahashi, A., A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B (2010) Nat Genet, 42, pp. 864-868. , COI: 1:CAS:528:DC%2BC3cXhtFWksrfE, PID: 20818381; Kimura, M., Hattori, T., Matsuda, Y., Yoshioka, T., Sumi, N., cDNA cloning, characterization, and chromosome mapping of UBE2E2 encoding a human ubiquitin-conjugating E2 enzyme (1997) Cytogenet Cell Genet, 78, pp. 107-111. , COI: 1:CAS:528:DyaK2sXnslyks78%3D, PID: 9371400; Tsai, F.J., Yang, C.F., Chen, C.C., Chuang, L.M., Lu, C.H., A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese (2010) PLoS Genet, 6, p. 1000847. , PID: 20174558; Shu, X.O., Long, J., Cai, Q., Qi, L., Xiang, Y.B., Identification of new genetic risk variants for type 2 diabetes (2010) PLoS Genet, 6, p. 1001127. , PID: 20862305; Wolosker, H., Blackshaw, S., Snyder, S.H., Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission (1999) Proc Natl Acad Sci U S A, 96, pp. 13409-13414. , COI: 1:CAS:528:DyaK1MXns1Gmtb0%3D, PID: 10557334; Gonoi, T., Mizuno, N., Inagaki, N., Kuromi, H., Seino, Y., Functional neuronal ionotropic glutamate receptors are expressed in the non-neuronal cell line MIN6 (1994) J Biol Chem, 269, pp. 16989-16992. , COI: 1:CAS:528:DyaK2cXksFSlsLs%3D, PID: 8006003; Cho, Y.S., Chen, C.H., Hu, C., Long, J., Ong, R.T., Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in East Asians (2012) Nat Genet, 44, pp. 67-72. , COI: 1:CAS:528:DC%2BC3MXhs1eitr7P; Hwang, J.Y., Sim, X., Wu, Y., Liang, J., Tabara, Y., Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians (2015) Diabetes, 64 (1), pp. 291-298; Neel, J.V., Diabetes mellitus: a ""thrifty"" genotype rendered detrimental by ""progress""? (1962) Am J Hum Genet, 14, pp. 353-362. , COI: 1:STN:280:DyaF387ivFGmtw%3D%3D, PID: 13937884; Southam, L., Soranzo, N., Montgomery, S.B., Frayling, T.M., McCarthy, M.I., Is the thrifty genotype hypothesis supported by evidence based on confirmed type 2 diabetes- and obesity-susceptibility variants? (2009) Diabetologia, 52, pp. 1846-1851. , COI: 1:CAS:528:DC%2BD1MXpsFyrs78%3D, PID: 19526209; Cho, Y.S., Lee, J.Y., Park, K.S., Nho, C.W., Genetics of type 2 diabetes in East Asian populations (2012) Curr Diabetes Rep, 12, pp. 686-696; Nauck, M.A., Homberger, E., Siegel, E.G., Allen, R.C., Eaton, R.P., Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses (1986) J Clin Endocrinol Metab, 63, pp. 492-498. , COI: 1:CAS:528:DyaL28XkvFWkt7g%3D, PID: 3522621; Knop, F.K., Vilsboll, T., Hojberg, P.V., Larsen, S., Madsbad, S., Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? (2007) Diabetes, 56, pp. 1951-1959. , COI: 1:CAS:528:DC%2BD2sXos12qsro%3D, PID: 17513701; Bagger, J.I., Knop, F.K., Lund, A., Vestergaard, H., Holst, J.J., Impaired regulation of the incretin effect in patients with type 2 diabetes (2011) J Clin Endocrinol Metab, 96, pp. 737-745. , COI: 1:CAS:528:DC%2BC3MXjvFahtr8%3D, PID: 21252240; Seino, Y., Fukushima, M., Yabe, D., GIP and GLP-1, the two incretin hormones: similarities and differences (2010) J Diabetes Investig, 1, pp. 9-23; Yabe, D., Seino, Y., Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation (2011) Prog Biophys Mol Biol, 107, pp. 248-256. , COI: 1:CAS:528:DC%2BC3MXhtlOgu7vF, PID: 21820006; Holst, J.J., The physiology of glucagon-like peptide 1 (2007) Physiol Rev, 87, pp. 1409-1439. , COI: 1:CAS:528:DC%2BD2sXhtlaqu7jI, PID: 17928588; Drucker, D.J., Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls (2013) Diabetes, 62, pp. 3316-3323. , COI: 1:CAS:528:DC%2BC3sXhsFOhtL3K, PID: 23818527, A useful review of intra- and extrapancreatic actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1, which is highly relevant to discuss efficacy and safety of incretin-based therapies in the management of type 2 diabetes; Seino, Y., Yabe, D., GIP and GLP-1: incretin actions beyond pancreas (2013) J Diabetes Investig, 4, pp. 108-130. , COI: 1:CAS:528:DC%2BC3sXnsVCmsrg%3D, PID: 24843641; Calanna, S., Christensen, M., Holst, J.J., Laferrere, B., Gluud, L.L., Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies (2013) Diabetologia, 56, pp. 965-972. , COI: 1:CAS:528:DC%2BC3sXmt1Ciurs%3D, PID: 23377698, An important systematic review and meta-analysis comparing secretion of glucagon-like peptide-1 between subjects with type 2 diabetes and normal glucose-tolerance; Calanna, S., Christensen, M., Holst, J.J., Laferrere, B., Gluud, L.L., Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies (2013) Diabetes Care, 36, pp. 3346-3352. , COI: 1:CAS:528:DC%2BC3sXhs1yltLzL, PID: 24065842, An important systematic review and meta-analysis comparing secretion of glucose-dependent insulinotropic polypeptide between subjects with type 2 diabetes and normal glucose-tolerance; Nauck, M.A., Vardarli, I., Deacon, C.F., Holst, J.J., Meier, J.J., Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? (2011) Diabetologia, 54 (1), pp. 10-18; Yabe, D., Kuroe, A., Lee, S., Watanabe, K., Hyo, T., Little enhancement of meal-induced GLP-1 secretion in Japanese: comparison of type 2 diabetes and healthy controls (2010) J Diabetes Investig, 1, pp. 56-59. , COI: 1:CAS:528:DC%2BC3cXosFCnu70%3D, PID: 24843409; Kozawa, J., Okita, K., Imagawa, A., Iwahashi, H., Holst, J.J., Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes (2010) Biochem Biophys Res Commun, 393, pp. 410-413. , COI: 1:CAS:528:DC%2BC3cXjt1Grtrc%3D, PID: 20138827; Lee, S., Yabe, D., Nohtomi, K., Takada, M., Morita, R., Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes (2010) Endocr J, 57, pp. 119-126. , COI: 1:CAS:528:DC%2BC3cXmt1egs7s%3D, PID: 19881250; Oh, T.J., Park, K.S., Cho, Y.M., Correlation of the incretin effect with first- and second-phase insulin secretions in Koreans with various glucose tolerance statuses (2014) Clin Endocrinol (Oxf); Oh, T.J., Kim, M.Y., Shin, J.Y., Lee, J.C., Kim, S., The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes (2014) Clin Endocrinol (Oxf), 80, pp. 221-227. , COI: 1:CAS:528:DC%2BC2cXnt1artg%3D%3D; Yabe, D., Watanabe, K., Sugawara, K., Kuwata, H., Kitamoto, Y., Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes (2012) J Diabetes Investig, 3, pp. 70-79. , COI: 1:CAS:528:DC%2BC38XltV2rt74%3D, PID: 24843548; Vollmer, K., Holst, J.J., Baller, B., Ellrichmann, M., Nauck, M.A., Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance (2008) Diabetes, 57, pp. 678-687. , COI: 1:CAS:528:DC%2BD1cXjt1Chtbk%3D, PID: 18057091; Vilsboll, T., Krarup, T., Madsbad, S., Holst, J.J., Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients (2002) Diabetologia, 45, pp. 1111-1119. , COI: 1:CAS:528:DC%2BD38Xmt1ShsrY%3D, PID: 12189441; Saxena, R., Hivert, M.F., Langenberg, C., Tanaka, T., Pankow, J.S., Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge (2010) Nat Genet, 42, pp. 142-148. , COI: 1:CAS:528:DC%2BC3cXntVCksw%3D%3D, PID: 20081857; Hamasaki, A., Harada, N., Muraoka, A., Yamane, S., Joo, E., Not glucose tolerance but obesity impairs the numerical incretin effect in Japanese subjects (2011) Diabetologia, 54, p. 217; Gheni, G., Ogura, M., Iwasaki, M., Yokoi, N., Minami, K., Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion (2014) Cell Rep, 9, pp. 661-673. , COI: 1:CAS:528:DC%2BC2cXhslOrtLrO, PID: 25373904; Park, H., Park, C., Kim, Y., Rascati, K.L., Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis (2012) Ann Pharmacother, 46, pp. 1453-1469. , PID: 23136353; Kim, Y.G., Hahn, S., Oh, T.J., Kwak, S.H., Park, K.S., Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and Non-Asians: a systematic review and meta-analysis (2013) Diabetologia, 56, pp. 696-708. , COI: 1:CAS:528:DC%2BC3sXjslehs70%3D, PID: 23344728, An important systematic review and meta-analysis comparing glucose-lowering effects of dipeptidyl-peptidase-4 inhibitors between Asians and non-Asians; Kim, Y.G., Hahn, S., Oh, T.J., Park, K.S., Cho, Y.M., (2014) Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab, , 16(10):900–9.An important systematic review and meta-analysis comparing glucose-lowering effects of glucagon-like peptide-1 between Asians and non-Asians; Kubota, A., Matsuba, I., Saito, T., Nabe, K., Seino, Y., Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus (2011) J Diabetes Investig, 2, pp. 377-380. , COI: 1:CAS:528:DC%2BC3MXhtlChu7nP, PID: 24843517; Seino, Y., Rasmussen, M.F., Clauson, P., Kaku, K., The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes (2012) J Diabetes Investig, 3, pp. 388-395. , COI: 1:CAS:528:DC%2BC38XhvVahsb%2FJ, PID: 24843595; Iwasaki, M., Hoshian, F., Tsuji, T., Hirose, N., Matsumoto, T., Predicting efficacy of DPP-4 inhibitors in patients with type 2 diabetes: association of HbA1c reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels (2012) J Diabetes Investig, 3, pp. 464-467. , COI: 1:CAS:528:DC%2BC3sXitVyrtg%3D%3D, PID: 24843607, An original article identifying a novel interaction of dietary habits and HbA1c-lowering of dipeptidyl-peptidase-4 inhibitors; Senmaru, T., Fukui, M., Kobayashi, K., Iwase, H., Inada, S., Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations (2012) J Diabetes Investig, 3, pp. 498-502. , COI: 1:CAS:528:DC%2BC3sXjt1Squ7w%3D, PID: 24843614; Yabe, D., Kuwata, H., Iwasaki, M., Usui, R., Kurose, T., Effects of fish or meat intake before and after rice on postprandial glucose excursions and incretin secretion in type 2 diabetes: meal sequence as a novel target in dietary therapies for diabetes (2014) Diabetes, 64, p. 12; Kubota, A., Yabe, D., Kanamori, A., Kuroe, A., Takahashi, N., Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea (2014) J Diabetes Investig, 5, pp. 445-448. , COI: 1:CAS:528:DC%2BC2cXhtF2lsbrK, PID: 25411605; Kanamori, A., Matsuba, I., Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer (2013) J Clin Med Res, 5, pp. 217-221. , PID: 23671547; Yabe, D., Kuwata, H., Kaneko, M., Ito, C., Nishikino, R., Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs (2015) Diabetes Obes Metab, 17 (4), pp. 430-434; Kohro, T., Yamazaki, T., Sato, H., Harada, K., Ohe, K., Trends in antidiabetic prescription patterns in Japan from 2005 to 2011 (2013) Int Heart J, 54, pp. 93-97. , PID: 23676369; Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012) Diabetologia, 55, pp. 1577-1596. , COI: 1:STN:280:DC%2BC38rnsV2jsA%3D%3D, PID: 22526604; Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012) Diabetes Care, 35, pp. 1364-1379. , COI: 1:CAS:528:DC%2BC38Xps1Kitb4%3D, PID: 22517736; Yabe, D., Seino, Y., Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? (2014) J Diabetes Investig, 5, pp. 475-477. , COI: 1:CAS:528:DC%2BC2cXhsFahtLnL, PID: 25411611, An article comparing incidence of severe hypoglycemia by dipeptidyl peptidase-4 inhibitors in Japan and the USA; Takahashi, H., Shibasaki, T., Park, J.H., Hidaka, S., Takahashi, T., Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion (2015) Diabetes, 64 (4), pp. 1262-1272; Shibasaki, T., Takahashi, T., Takahashi, H., Seino, S., Cooperation between cAMP signalling and sulfonylurea in insulin secretion (2014) Diabetes Obes Metab, 16, pp. 118-125. , COI: 1:CAS:528:DC%2BC2cXhsFarsrzJ, PID: 25200305; Takahashi, T., Shibasaki, T., Takahashi, H., Sugawara, K., Ono, A., Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A (2013) Sci Signal, 6, p. 94. , PID: 24150255; Mukai, E., Fujimoto, S., Sato, H., Oneyama, C., Kominato, R., Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner (2010) Diabetes, 60, pp. 218-226. , PID: 20978090",Review,Scopus,2-s2.0-84928920275
"Saponaro C., Gaggini M., Gastaldelli A.","Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms",2015,"Current Diabetes Reports","15","6",,"1","13",,,10.1007/s11892-015-0607-4,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928383035&partnerID=40&md5=699a13dcccbfc975c6c02f8208808436","Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, via Moruzzi 1Pisa, Italy; Dipartimento di Biotecnologie, Chimica e Farmacia, Università di SienaSiena, Italy; Dipartimento di Patologia Chirurgica, Molecolare Medica e di Area Critica, Università di PisaPisa, Italy","Saponaro, C., Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, via Moruzzi 1Pisa, Italy, Dipartimento di Biotecnologie, Chimica e Farmacia, Università di SienaSiena, Italy; Gaggini, M., Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, via Moruzzi 1Pisa, Italy, Dipartimento di Patologia Chirurgica, Molecolare Medica e di Area Critica, Università di PisaPisa, Italy; Gastaldelli, A., Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, via Moruzzi 1Pisa, Italy","Nonalcoholic fatty liver disease (NAFLD) is an independent risk factor for advanced liver disease, type 2 diabetes (T2DM), and cardiovascular diseases. The prevalence of NAFLD in the general population is around 30 %, but it is up to three times higher in those with T2DM. Among people with obesity and T2DM, the NAFLD epidemic also is worsening. Therefore, it is important to identify early metabolic alterations and to prevent these diseases and their progression. In this review, we analyze the pathophysiologic mechanisms leading to NAFLD, particularly, those common to T2DM, such as liver and muscle insulin resistance. However, it is mainly adipose tissue insulin resistance that results in increased hepatic de novo lipogenesis, inflammation, and lipotoxicity. Although genetics predispose to NAFLD, an unhealthy lifestyle, including high-fat/high-sugar diets and low physical activity, increases the risk. In addition, alterations in gut microbiota and environmental chemical agents, acting as endocrine disruptors, may play a role. © 2015, Springer Science+Business Media New York.","De novo lipogenesis; Endocrine disruptors; Fatty liver; Glucose intolerance; Gut microbiota; Lipotoxicity; NASH","Whiting, D.R., Guariguata, L., Weil, C., Shaw, J., IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 (2011) Diabetes Res Clin Pract, 94, pp. 311-321. , PID: 22079683; Gaggini, M., Morelli, M., Buzzigoli, E., Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease (2013) Nutrients, 5, pp. 1544-1560. , COI: 1:CAS:528:DC%2BC3sXosVSmtbg%3D, PID: 23666091, This review analyzes the mechanisms relating NAFLD to CVD, including the role of ectopic fat accumulation, dyslipidemia, and lipotoxicity; Baffy, G., Brunt, E.M., Caldwell, S.H., Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace (2012) J Hepatol, 56, pp. 1384-1391. , PID: 22326465; Guha, I.N., Parkes, J., Roderick, P., Chattopadhyay, D., Cross, R., Harris, S., Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers (2008) Hepatology, 47, pp. 455-460. , PID: 18038452; Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., Long-term follow-up of patients with NAFLD and elevated liver enzymes (2006) Hepatology, 44, pp. 865-873. , COI: 1:CAS:528:DC%2BD28XhtFyqsrzN, PID: 17006923; Sanyal, A.J., Banas, C., Sargeant, C., Luketic, V.A., Sterling, R.K., Stravitz, R.T., Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C (2006) Hepatology, 43, pp. 682-689. , PID: 16502396; Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (2013) Nat Rev Gastroenterol Hepatol, 10, pp. 330-344. , COI: 1:CAS:528:DC%2BC3sXptVOlsrs%3D, PID: 23507799, This article highlights the evidence that NAFLD is a multisystem disease and T2DM and CVD are factors that might determine interindividual variation in the development and progression of hepatic damage; Zezos, P., Renner, E.L., Liver transplantation and non-alcoholic fatty liver disease (2014) World J Gastroenterol: WJG, 20, pp. 15532-15538. , PID: 25400437; Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S (2014) Hepatology, 59, pp. 2188-2195. , PID: 24375711, By analyzing the United Network for Organ Sharing/Organ Procurement and Transplantation Network database (more than 61,000 patients, 16% of whom received liver transplants), the authors found that NAFLD is the second leading cause of liver transplantation, but more importantly, it is the most rapidly growing indication for transplantation; Chalasani, N., Younossi, Z., Lavine, J.E., The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012) Hepatology, 55, pp. 2005-2023. , PID: 22488764, These are the most recently published guidelines for the diagnosis and management of NAFLD; Yki-Jarvinen, H., Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome (2014) Lancet Diabetes Endocrinol, 2 (11), pp. 901-910. , COI: 1:CAS:528:DC%2BC2MXhtlWgur0%3D, PID: 24731669; Ghouri, N., Preiss, D., Sattar, N., Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data (2010) Hepatology, 52, pp. 1156-1161. , PID: 20658466; Lattuada, G., Ragogna, F., Perseghin, G., Why does NAFLD predict type 2 diabetes? (2011) Curr Diabetes Rep, 11, pp. 167-172. , COI: 1:CAS:528:DC%2BC3MXlsFagsLc%3D; Targher, G., Byrne, C.D., Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications (2013) J Clin Endocrinol Metab, 98, pp. 483-495. , COI: 1:CAS:528:DC%2BC3sXjtlOlu7g%3D, PID: 23293330; Stefan, N., Haring, H.U., The metabolically benign and malignant fatty liver (2011) Diabetes, 60, pp. 2011-2017. , COI: 1:CAS:528:DC%2BC3MXhtValurvL, PID: 21788578; Cusi, K., Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications (2012) Gastroenterology, 142, pp. 711-725. , COI: 1:CAS:528:DC%2BC38XltVyrsLs%3D, PID: 22326434; Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults (2011) Aliment Pharmacol Ther, 34, pp. 274-285. , COI: 1:STN:280:DC%2BC3MnlsVamsg%3D%3D, PID: 21623852; Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects (2007) Gastroenterology, 133, pp. 496-506. , COI: 1:CAS:528:DC%2BD2sXhtVWqsr%2FO, PID: 17681171; Kotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Corner, A., Bergholm, R., Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects (2008) Diabetes Care, 31, pp. 165-169. , COI: 1:CAS:528:DC%2BD1cXhs1ejtL4%3D, PID: 17934148; Portillo Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Cusi, K., High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels (2014) The Journal of Clinical Endocrinology and Metabolism 2014:jc20142739; Fracanzani, A.L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes (2008) Hepatology, 48, pp. 792-798. , COI: 1:CAS:528:DC%2BD1cXhtFKrsLbK, PID: 18752331; Loomba, R., Abraham, M., Unalp, A., Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis (2012) Hepatology, 56, pp. 943-951. , PID: 22505194, This analysis of 1069 NAFLD patients participating in the PIVENS trial and NAFLD Database Study showed that both a personal and a family history of diabetes are associated with the presence of NASH and fibrosis; Zelber-Sagi, S., Lotan, R., Shibolet, O., Webb, M., Buch, A., Nitzan-Kaluski, D., Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up (2013) Liver Int : Off J Int Assoc Study Liver, 33, pp. 1406-1412. , COI: 1:CAS:528:DC%2BC3sXhs1GkurnM; Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity (2004) Hepatology, 40, pp. 1387-1395. , PID: 15565570; Ruhl, C.E., Everhart, J.E., Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey (2015) Aliment Pharmacol Ther, 41, pp. 65-76. , COI: 1:STN:280:DC%2BC2M3mt1KntA%3D%3D, PID: 25376360; Margariti E, Deutsch M, Manolakopoulos S, et al. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol. 2012;25:45–51. This study showed that about one in eight NAFLD patients referred to a tertiary liver center has a normal BMI (<25 kg/m2). These patients have higher levels of ALT/AST than overweight or obese NAFLD patientsYounossi, Z.M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., Nonalcoholic fatty liver disease in lean individuals in the United States (2012) Medicine, 91, pp. 319-327. , PID: 23117851, In this analysis of NHANES III, the authors show that the prevalence of diabetes is higher in people with NAFLD, independent of obesity, although there is a higher prevalence among overweight/obese than lean subjects; Chang, Y., Jung, H.S., Yun, K.E., Cho, J., Cho, Y.K., Ryu, S., Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population (2013) Am J Gastroenterol, 108, pp. 1861-1868. , COI: 1:CAS:528:DC%2BC3sXhvFCqtL3J, PID: 24100261; Neeland, I.J., Turer, A.T., Ayers, C.R., Powell-Wiley, T.M., Vega, G.L., Farzaneh-Far, R., Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults (2012) JAMA, 308, pp. 1150-1159. , COI: 1:CAS:528:DC%2BC38XhsFemurfJ, PID: 22990274; DeFronzo, R.A., Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 (2010) Diabetologia, 53, pp. 1270-1287. , COI: 1:CAS:528:DC%2BC3cXmsFyrs7w%3D, PID: 20361178; Lomonaco, R., Ortiz-Lopez, C., Orsak, B., Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease (2012) Hepatology, 55, pp. 1389-1397. , COI: 1:CAS:528:DC%2BC38XlslyjtL8%3D, PID: 22183689, These authors found that in patients with NAFLD, adipose tissue insulin resistance was associated with liver fibrosis, increased liver enzymes and TGs, and reduced HDL and adiponectin but found no association with NAFLD activity score; Armstrong, M.J., Hazlehurst, J.M., Hull, D., Guo, K., Borrows, S., Yu, J., Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis (2014) Diabetes Obes Metab, 16, pp. 651-660. , COI: 1:CAS:528:DC%2BC2cXhtVKnsb7K, PID: 24962805; Kelsey, M.M., Forster, J.E., Van Pelt, R.E., Reusch, J.E., Nadeau, K.J., Adipose tissue insulin resistance in adolescents with and without type 2 diabetes (2014) Pediatr Obes, 9, pp. 373-380. , COI: 1:STN:280:DC%2BC3sfhslShtA%3D%3D, PID: 23861170; Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms (2005) Diabetologia, 48, pp. 634-642. , COI: 1:CAS:528:DC%2BD2MXjtlGhs7w%3D, PID: 15747110; Stefan, N., Staiger, H., Haring, H.U., Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase (2011) Diabetologia, 54, pp. 7-9. , COI: 1:CAS:528:DC%2BC3cXhsFWqtLbO, PID: 20953581; Lambert, J.E., Ramos-Roman, M.A., Browning, J.D., Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease (2014) Gastroenterology, 146, pp. 726-735. , COI: 1:CAS:528:DC%2BC2cXislKmsbs%3D, PID: 24316260, This study measured DNL in vivo in subjects with NAFLD by using deuterated water and found that DNL increased up to three times compared with controls; Kotronen, A., Seppanen-Laakso, T., Westerbacka, J., Kiviluoto, T., Arola, J., Ruskeepaa, A.L., Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver (2009) Diabetes, 58, pp. 203-208. , COI: 1:CAS:528:DC%2BD1MXptVCnsg%3D%3D, PID: 18952834; Strable, M.S., Ntambi, J.M., Genetic control of de novo lipogenesis: role in diet-induced obesity (2010) Crit Rev Biochem Mol Biol, 45, pp. 199-214. , COI: 1:CAS:528:DC%2BC3cXmtlSjsrc%3D, PID: 20218765; Postic, C., Girard, J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice (2008) J Clin Invest, 118, pp. 829-838. , COI: 1:CAS:528:DC%2BD1cXivFemsr4%3D, PID: 18317565; Itani, S.I., Ruderman, N.B., Schmieder, F., Boden, G., Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha (2002) Diabetes, 51, pp. 2005-2011. , COI: 1:CAS:528:DC%2BD38Xlt1Wls7c%3D, PID: 12086926; Trauner, M., Arrese, M., Wagner, M., Fatty liver and lipotoxicity (1801) Biochim Biophys Acta, 2010, pp. 299-310; Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G., Tiribelli, C., Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis (2008) Trends Mol Med, 14, pp. 72-81. , COI: 1:CAS:528:DC%2BD1cXitVGltL0%3D, PID: 18218340; Gastaldelli, A., Miyazaki, Y., Pettiti, M., Buzzigoli, E., Mahankali, S., Ferrannini, E., Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis (2004) J Clin Endocrinol Metab, 89, pp. 3914-3921. , COI: 1:CAS:528:DC%2BD2cXmslKmur8%3D, PID: 15292327; Gastaldelli, A., Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus (2011) Diabetes Res Clin Pract, 93, pp. 60-65. , COI: 1:CAS:528:DC%2BC3MXhtVKjt73M, PID: 21864753; Boden, G., Obesity, insulin resistance and free fatty acids (2011) Curr Opin Endocrinol Diabetes Obes, 18, pp. 139-143. , COI: 1:CAS:528:DC%2BC3MXis1egurs%3D, PID: 21297467; Fon Tacer, K., Rozman, D., Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation (2011) J Lipids, 2011, p. 783976. , PID: 21773052; Ramos-Arellano, L.E., Munoz-Valle, J.F., De la Cruz-Mosso, U., Salgado-Bernabe, A.B., Castro-Alarcon, N., Parra-Rojas, I., Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects (2014) BMC Cardiovasc Disord, 14, p. 54. , PID: 24766787; Koenig, W., Karakas, M., Zierer, A., Herder, C., Baumert, J., Meisinger, C., Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study (2011) Clin Chem, 57, pp. 1196-1200. , COI: 1:CAS:528:DC%2BC3MXhtVCnu7vO, PID: 21697499; Gastaldelli, A., Miyazaki, Y., Pettiti, M., Santini, E., Ciociaro, D., Defronzo, R.A., The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes (2006) J Clin Endocrinol Metab, 91, pp. 806-812. , COI: 1:CAS:528:DC%2BD28Xis1Cmtr0%3D, PID: 16352689; Musso, G., Gambino, R., Cassader, M., Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD) (2009) Prog Lipid Res, 48, pp. 1-26. , COI: 1:CAS:528:DC%2BD1cXhsFagu7%2FO, PID: 18824034; Brehm, A., Krssak, M., Schmid, A.I., Nowotny, P., Waldhausl, W., Roden, M., Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle (2006) Diabetes, 55, pp. 136-140. , COI: 1:CAS:528:DC%2BD28XlvVSltA%3D%3D, PID: 16380486; Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., Dose–response effect of elevated plasma free fatty acid on insulin signaling (2005) Diabetes, 54, pp. 1640-1648. , COI: 1:CAS:528:DC%2BD2MXltVaitr4%3D, PID: 15919784; Eriksson, J.W., Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance (2007) FEBS Lett, 581, pp. 3734-3742. , COI: 1:CAS:528:DC%2BD2sXotlaisb8%3D, PID: 17628546; Del Prato, S., Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies (2009) Diabet Med, 26, pp. 1185-1192. , PID: 20002468; Dela Pena, A., Leclercq, I., Field, J., George, J., Jones, B., Farrell, G., NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis (2005) Gastroenterology, 129, pp. 1663-1674. , COI: 1:CAS:528:DC%2BD2MXht12gsr%2FE, PID: 16285964; Grasselli, E., Voci, A., Demori, I., De Matteis, R., Compalati, A.D., Gallo, G., Effects of binge ethanol on lipid homeostasis and oxidative stress in a rat model of nonalcoholic fatty liver disease (2014) J Physiol Biochem, 70, pp. 341-353. , COI: 1:CAS:528:DC%2BC2cXnslejsLo%3D, PID: 24481563; Ayala, A., Munoz, M.F., Arguelles, S., Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal (2014) Oxidative Med Cell Longev, 2014, p. 360438; Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease (2011) Nat Rev Immunol, 11, pp. 98-107. , COI: 1:CAS:528:DC%2BC3MXlsFehtQ%3D%3D, PID: 21233852; Makki, K., Froguel, P., Wolowczuk, I., Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines (2013) ISRN Inflamm, 2013, p. 139239. , PID: 24455420; Tilg, H., Moschen, A.R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis (2010) Hepatology, 52, pp. 1836-1846. , COI: 1:CAS:528:DC%2BC3cXhsFOnsrjP, PID: 21038418; Anstee, Q.M., Day, C.P., The genetics of NAFLD (2013) Nat Rev Gastroenterol Hepatol, 10, pp. 645-655. , COI: 1:CAS:528:DC%2BC3sXhsFenu7bK, PID: 24061205, The authors review the genes involved in the pathogenesis of NAFLD; Grarup, N., Sandholt, C.H., Hansen, T., Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond (2014) Diabetologia, 57, pp. 1528-1541. , COI: 1:CAS:528:DC%2BC2cXptVaks74%3D, PID: 24859358, The authors review the genes involved in the development of T2DM; Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes (2006) Nat Genet, 38, pp. 320-323. , COI: 1:CAS:528:DC%2BD28XhslCjtrw%3D, PID: 16415884; Lyssenko, V., Lupi, R., Marchetti, P., Del Guerra, S., Orho-Melander, M., Almgren, P., Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes (2007) J Clin Invest, 117, pp. 2155-2163. , COI: 1:CAS:528:DC%2BD2sXoslOnsrk%3D, PID: 17671651; Musso, G., Gambino, R., Pacini, G., Pagano, G., Durazzo, M., Cassader, M., Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH (2009) Hepatology, 49, pp. 426-435. , COI: 1:CAS:528:DC%2BD1MXivFWhtro%3D, PID: 19105201; Li, H., Xu, R., Peng, X., Wang, Y., Wang, T., Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis (2013) Mol Biol Rep, 40, pp. 3935-3942. , COI: 1:CAS:528:DC%2BC3sXntF2jtbg%3D, PID: 23307301; Vaxillaire, M., Cavalcanti-Proenca, C., Dechaume, A., Tichet, J., Marre, M., Balkau, B., The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population (2008) Diabetes, 57, pp. 2253-2257. , COI: 1:CAS:528:DC%2BD1cXps1Oisbw%3D, PID: 18556336; Liu, Y.L., Reeves, H.L., Burt, A.D., TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) Nat Commun, 5, p. 4309. , COI: 1:CAS:528:DC%2BC2MXksVeqtb8%3D, PID: 24978903, This article shows an association between the gene TM6SF2 and advanced hepatic fibrosis/cirrhosis independent of potential confounding factors (e.g., age, BMI, T2DM, and PNPLA3 rs738409 genotype); Gouda, H.N., Sagoo, G.S., Harding, A.H., Yates, J., Sandhu, M.S., Higgins, J.P., The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis (2010) Am J Epidemiol, 171, pp. 645-655. , PID: 20179158; Naik, A., Kosir, R., Rozman, D., Genomic aspects of NAFLD pathogenesis (2013) Genomics, 102, pp. 84-95. , COI: 1:CAS:528:DC%2BC3sXlvFajs7c%3D, PID: 23545492; Ramya, K., Ayyappa, K.A., Ghosh, S., Mohan, V., Radha, V., Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population (2013) Gene, 532, pp. 253-262. , COI: 1:CAS:528:DC%2BC3sXhsF2gtLrF, PID: 24055485; Dongiovanni, P., Valenti, L., Rametta, R., Daly, A.K., Nobili, V., Mozzi, E., Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease (2010) Gut, 59, pp. 267-273. , COI: 1:CAS:528:DC%2BC3cXjsFeqsb8%3D, PID: 20176643; Bodhini, D., Radha, V., Mohan, V., Association study of IRS1 gene polymorphisms with type 2 diabetes in south Indians (2011) Diabetes Technol Ther, 13, pp. 767-772. , COI: 1:CAS:528:DC%2BC3MXnvFOitb4%3D, PID: 21612394; Wilmot, E.G., Edwardson, C.L., Achana, F.A., Davies, M.J., Gorely, T., Gray, L.J., Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis (2012) Diabetologia, 55, pp. 2895-2905. , COI: 1:STN:280:DC%2BC38fnvVarsg%3D%3D, PID: 22890825; Harrison, S.A., Day, C.P., Benefits of lifestyle modification in NAFLD (2007) Gut, 56, pp. 1760-1769. , COI: 1:CAS:528:DC%2BD1cXmsFKltw%3D%3D, PID: 17911352; Zivkovic, A.M., German, J.B., Sanyal, A.J., Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease (2007) Am J Clin Nutr, 86, pp. 285-300. , COI: 1:CAS:528:DC%2BD2sXpsVGrt7g%3D, PID: 17684197; Johnson, R.J., Nakagawa, T., Sanchez-Lozada, L.G., Shafiu, M., Sundaram, S., Le, M., Sugar, uric acid, and the etiology of diabetes and obesity (2013) Diabetes, 62, pp. 3307-3315. , COI: 1:CAS:528:DC%2BC3sXhsFOhtL3J, PID: 24065788; Liu, W.Y., Luda, J., Du, X.M., Sun, J.Q., Ge, J., Wang, R.W., Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled tria (2014) BMC Public Health, 14, p. 48. , COI: 1:CAS:528:DC%2BC2MXhtlCrtrY%3D, PID: 24438438; Zelber-Sagi, S., Ratziu, V., Oren, R., Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence (2011) World J Gastroenterol : WJG, 17, pp. 3377-3389. , PID: 21876630; Moschen, A.R., Kaser, S., Tilg, H., Non-alcoholic steatohepatitis: a microbiota-driven disease (2013) Trends Endocrinol Metab: TEM, 24, pp. 537-545. , COI: 1:CAS:528:DC%2BC3sXhtVCgtLvE, PID: 23827477, Microbiotal factors and products may be involved in the regulation of insulin sensitivity and metabolic inflammation and are driving forces of hepatic steatosis; Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease (2009) Hepatology, 49, pp. 1877-1887. , COI: 1:CAS:528:DC%2BD1MXotVCmtb4%3D, PID: 19291785; De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice (2014) Hepatology, 59, pp. 1738-1749. , PID: 23959503; Puddu, A., Sanguineti, R., Montecucco, F., Viviani, G.L., Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes (2014) Mediat Inflamm, 2014, p. 162021; Neel, B.A., Sargis, R.M., The paradox of progress: environmental disruption of metabolism and the diabetes epidemic (2011) Diabetes, 60, pp. 1838-1848. , COI: 1:CAS:528:DC%2BC3MXptVChtLY%3D, PID: 21709279, This article discusses the epidemiologic links between chemical exposure and disorders of glucose metabolism, experimental data demonstrating chemical-induced changes in insulin action, and challenges facing the field of metabolic disruption, as well as approaches for addressing those challenges; Newbold, R.R., Padilla-Banks, E., Jefferson, W.N., Heindel, J.J., Effects of endocrine disruptors on obesity (2008) Int J Androl, 31, pp. 201-208. , COI: 1:CAS:528:DC%2BD1cXltFCrsLk%3D, PID: 18315718; Newbold, R.R., Impact of environmental endocrine disrupting chemicals on the development of obesity (2010) Hormones (Athens), 9, pp. 206-217; Lind, P.M., Roos, V., Ronn, M., Johansson, L., Ahlstrom, H., Kullberg, J., Serum concentrations of phthalate metabolites are related to abdominal fat distribution two years later in elderly women (2012) Environ Health, 11, p. 21. , COI: 1:CAS:528:DC%2BC38XpvVWksLs%3D, PID: 22472124; Hatch, E.E., Nelson, J.W., Qureshi, M.M., Weinberg, J., Moore, L.L., Singer, M., Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999–2002 (2008) Environ Health, 7, p. 27. , PID: 18522739; Desvergne, B., Feige, J.N., Casals-Casas, C., PPAR-mediated activity of phthalates: A link to the obesity epidemic? (2009) Mol Cell Endocrinol, 304, pp. 43-48. , COI: 1:CAS:528:DC%2BD1MXls1yls7o%3D, PID: 19433246, EDCs, such as phthalates, might influence major factors controlling glucose and lipid metabolism in humans by activating PPARs; Lehrke, M., Lazar, M.A., The many faces of PPARgamma (2005) Cell, 123, pp. 993-999. , COI: 1:CAS:528:DC%2BD28XptVOj, PID: 16360030; Lee, D.H., Lee, I.K., Song, K., Steffes, M., Toscano, W., Baker, B.A., A strong dose–response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999–2002 (2006) Diabetes Care, 29, pp. 1638-1644. , COI: 1:CAS:528:DC%2BD28XnsVahurk%3D, PID: 16801591; Ruzzin, J., Petersen, R., Meugnier, E., Madsen, L., Lock, E.J., Lillefosse, H., Persistent organic pollutant exposure leads to insulin resistance syndrome (2010) Environ Health Perspect, 118, pp. 465-471. , COI: 1:CAS:528:DC%2BC3cXls1ajtrs%3D, PID: 20064776; Lee, D.H., Lee, I.K., Jin, S.H., Steffes, M., Jacobs, D.R., Jr., Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999–2002 (2007) Diabetes Care, 30, pp. 622-628. , COI: 1:CAS:528:DC%2BD2sXjs1Grtbw%3D, PID: 17327331; Lind, P.M., Zethelius, B., Lind, L., Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly (2012) Diabetes Care, 35, pp. 1519-1524. , COI: 1:CAS:528:DC%2BC38Xht1Sht7vK, PID: 22498808, Plasma concentrations of several phthalate metabolites were found to be related to diabetes prevalence, as well as to markers of insulin secretion and resistance; Bohte, A.E., van Werven, J.R., Bipat, S., Stoker, J., The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis (2011) Eur Radiol, 21, pp. 87-97. , PID: 20680289; Kwok, R., Tse, Y.K., Wong, G.L., Ha, Y., Lee, A.U., Ngu, M.C., Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokeratin-18 fragments (2014) Aliment Pharmacol Ther, 39, pp. 254-269. , COI: 1:STN:280:DC%2BC2c3jslKhtw%3D%3D, PID: 24308774; de Ledinghen, V., Vergniol, J., Capdepont, M., Chermak, F., Hiriart, J.B., Cassinotto, C., Brigitte le B: Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations (2014) J Hepatol, 60, pp. 1026-1031. , PID: 24378529; Singh, S., Venkatesh, S.K., Wang, Z., Miller, F.H., Motosugi, U., Low, R.N., Hassanein, T., Ehman, R.L., (2014) Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis, , A Systematic Review and Meta-analysis of Individual Participant Data, Clin Gastroenterol Hepatol:; Szczepaniak, L.S., Nurenberg, P., Leonard, D., Browning, J.D., Reingold, J.S., Grundy, S., Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population (2005) Am J Physiol Endocrinol Metab, 288, pp. 462-468. , COI: 1:CAS:528:DC%2BD2MXhsVCktLg%3D, PID: 15339742; Fishbein, M.H., Gardner, K.G., Potter, C.J., Schmalbrock, P., Smith, M.A., Introduction of fast MR imaging in the assessment of hepatic steatosis (1997) Magn Reson Imaging, 15, pp. 287-293. , COI: 1:STN:280:DyaK2szksFejug%3D%3D, PID: 9201675; Duman, D.G., Celikel, C., Tuney, D., Imeryuz, N., Avsar, E., Tozun, N., Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment? (2006) Dig Dis Sci, 51, pp. 346-351. , PID: 16534679; Park, S.H., Kim, P.N., Kim, K.W., Lee, S.W., Yoon, S.E., Park, S.W., Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment (2006) Radiology, 239, pp. 105-112. , PID: 16484355; Wong, V.W., Vergniol, J., Wong, G.L., Foucher, J., Chan, A.W., Chermak, F., Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease (2012) Am J Gastroenterol, 107, pp. 1862-1871. , PID: 23032979; Palmentieri, B., de Sio, I., La Mura, V., Masarone, M., Vecchione, R., Bruno, S., The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis (2006) Dig Liver Dis, 38, pp. 485-489. , COI: 1:STN:280:DC%2BD28zlsFWksg%3D%3D, PID: 16716779; Fraquelli, M., Rigamonti, C., Casazza, G., Donato, M.F., Ronchi, G., Conte, D., Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C (2011) J Hepatol, 54, pp. 621-628. , PID: 21146243; Rifai, K., Cornberg, J., Mederacke, I., Bahr, M.J., Wedemeyer, H., Malinski, P., Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI) (2011) Dig Liver Dis, 43, pp. 491-497. , PID: 21439919; Goertz, R.S., Sturm, J., Pfeifer, L., Wildner, D., Wachter, D.L., Neurath, M.F., ARFI cut-off values and significance of standard deviation for liver fibrosis staging in patients with chronic liver disease (2013) Ann Hepatol, 12, pp. 935-941. , PID: 24114824; Baranova, A., Lal, P., Birerdinc, A., Younossi, Z.M., Non-invasive markers for hepatic fibrosis (2011) BMC Gastroenterol, 11, p. 91. , PID: 21849046; Grandison, G.A., Angulo, P., Can NASH be diagnosed, graded, and staged noninvasively? (2012) Clin Liver Dis, 16, pp. 567-585. , PID: 22824481; Bedogni, G., Kahn, H.S., Bellentani, S., Tiribelli, C., A simple index of lipid overaccumulation is a good marker of liver steatosis (2010) BMC Gastroenterol, 10, p. 98. , PID: 20738844; Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population (2006) BMC Gastroenterol, 6, p. 33. , PID: 17081293; Gastaldelli, A., Kozakova, M., Hojlund, K., Flyvbjerg, A., Favuzzi, A., Mitrakou, A., Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population (2009) Hepatology, 49, pp. 1537-1544. , COI: 1:CAS:528:DC%2BD1MXlslKmurs%3D, PID: 19291789; Lee, J.H., Kim, D., Kim, H.J., Lee, C.H., Yang, J.I., Kim, W., Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease (2010) Dig Liver Dis, 42, pp. 503-508. , COI: 1:CAS:528:DC%2BC3cXhtVSltbnL, PID: 19766548; Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L.M., Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors (2009) Gastroenterology, 137, pp. 865-872. , COI: 1:CAS:528:DC%2BD1MXhtF2isrbK, PID: 19524579; Pearce, S.G., Thosani, N.C., Pan, J.J., Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD (2013) Biomark Res, 1, p. 7. , PID: 24252302; Otgonsuren, M., Estep, M.J., Hossain, N., Younossi, E., Frost, S., Henry, L., Hunt, S., Younossi, Z.M., (2014) A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis, , NASH, J Gastroenterol Hepatol:; McPherson, S., Stewart, S.F., Henderson, E., Burt, A.D., Day, C.P., Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (2010) Gut, 59, pp. 1265-1269. , PID: 20801772; Shah, A.G., Lydecker, A., Murray, K., Tetri, B.N., Contos, M.J., Sanyal, A.J., Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease (2009) Clin Gastroenterol Hepatol, 7, pp. 1104-1112. , COI: 1:CAS:528:DC%2BD1MXhsFaqtbnK, PID: 19523535; Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) Hepatology, 45, pp. 846-854. , COI: 1:CAS:528:DC%2BD2sXltlWis7k%3D, PID: 17393509; Harrison, S.A., Oliver, D., Arnold, H.L., Gogia, S., Neuschwander-Tetri, B.A., Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease (2008) Gut, 57, pp. 1441-1447. , COI: 1:STN:280:DC%2BD1crpvF2isA%3D%3D, PID: 18390575; Ratziu, V., Giral, P., Charlotte, F., Bruckert, E., Thibault, V., Theodorou, I., Liver fibrosis in overweight patients (2000) Gastroenterology, 118, pp. 1117-1123. , COI: 1:STN:280:DC%2BD3c3psFSntg%3D%3D, PID: 10833486; Cales, P., Laine, F., Boursier, J., Deugnier, Y., Moal, V., Oberti, F., Comparison of blood tests for liver fibrosis specific or not to NAFLD (2009) J Hepatol, 50, pp. 165-173. , PID: 18977552; Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C., Ratziu, V., Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease (2014) Aliment Pharmacol Ther, 40, pp. 1209-1222. , COI: 1:STN:280:DC%2BC2M7ls1KnsA%3D%3D, PID: 25267215; Kahl, S., Strassburger, K., Nowotny, B., Livingstone, R., Kluppelholz, B., Kessel, K., Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance (2014) PLoS ONE, 9, p. e94059. , PID: 24732091; Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients (2002) J Clin Endocrinol Metab, 87, pp. 2784-2791. , COI: 1:CAS:528:DC%2BD38XkvFaku74%3D, PID: 12050251; Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis (2006) N Engl J Med, 355, pp. 2297-2307. , COI: 1:CAS:528:DC%2BD28Xht1OrtrvI, PID: 17135584; Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., Lenaour, G., Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial (2010) Hepatology, 51, pp. 445-453. , COI: 1:CAS:528:DC%2BC3cXisVGgurg%3D, PID: 19877169; Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (2010) N Engl J Med, 362, pp. 1675-1685. , COI: 1:CAS:528:DC%2BC3cXls1Oltr4%3D, PID: 20427778; Aithal, G.P., Thomas, J.A., Kaye, P.V., Lawson, A., Ryder, S.D., Spendlove, I., Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis (2008) Gastroenterology, 135, pp. 1176-1184. , COI: 1:CAS:528:DC%2BD1cXht12lurrN, PID: 18718471; Armstrong, M.J., Houlihan, D.D., Rowe, I.A., Clausen, W.H., Elbrond, B., Gough, S.C., Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program (2013) Aliment Pharmacol Ther, 37, pp. 234-242. , COI: 1:CAS:528:DC%2BC3sXjvVaku74%3D, PID: 23163663; Bergenstal, R.M., Li, Y., Porter, T.K., Weaver, C., Han, J., Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7 %, without weight gain or hypoglycaemia, over 52 weeks (2013) Diabetes Obes Metab, 15, pp. 264-271. , COI: 1:CAS:528:DC%2BC3sXhs1aqu7k%3D, PID: 23078638; Buse, J.B., Klonoff, D.C., Nielsen, L.L., Guan, X., Bowlus, C.L., Holcombe, J.H., Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials (2007) Clin Ther, 29, pp. 139-153. , COI: 1:CAS:528:DC%2BD2sXjsVOns7w%3D, PID: 17379054",Review,Scopus,2-s2.0-84928383035
"Zyoud S.H., Al-Jabi S.W., Sweileh W.M., Arandi D.A., Dabeek S.A., Esawi H.H., Atyeh R.H., Abu-Ali H.A., Sleet Y.I., Abd-Alfatah B.M., Awang R.","Relationship of treatment satisfaction to health-related quality of life among Palestinian patients with type 2 diabetes mellitus: Findings from a cross-sectional study",2015,"Journal of Clinical and Translational Endocrinology","2","2",,"66","71",,,10.1016/j.jcte.2015.03.002,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928468222&partnerID=40&md5=942cc2f6659ca866a8b9496c3c1bbd33","Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; WHO Collaborating Centre for Drug Information, National Poison Centre, Universiti Sains Malaysia (USM)Penang, Malaysia; Department of Pharmacology and Physiology, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; PharmD Program, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine","Zyoud, S.H., Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine, WHO Collaborating Centre for Drug Information, National Poison Centre, Universiti Sains Malaysia (USM)Penang, Malaysia; Al-Jabi, S.W., Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Sweileh, W.M., Department of Pharmacology and Physiology, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Arandi, D.A., PharmD Program, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Dabeek, S.A., PharmD Program, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Esawi, H.H., PharmD Program, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Atyeh, R.H., PharmD Program, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Abu-Ali, H.A., PharmD Program, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Sleet, Y.I., PharmD Program, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Abd-Alfatah, B.M., PharmD Program, College of Medicine and Health Sciences, An-Najah National UniversityNablus, Palestine; Awang, R., WHO Collaborating Centre for Drug Information, National Poison Centre, Universiti Sains Malaysia (USM)Penang, Malaysia","Objectives The aims of the current study were to assess the association between health-related quality of life (HRQoL) and treatment satisfaction in a sample of diabetic patients from Palestine, and to determine the influence of socio-demographic and clinical factors on HRQoL. Methods It was a cross-sectional study performed during the period June 2013 to October 2013. The Arabic version of Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) was used to assess treatment satisfaction, and the Arabic version of European Quality of Life scale (EQ-5D-5L) was used to assess HRQoL. Multiple linear regression was used to estimate which variables were the most important related to HRQoL. Results A total of 385 diabetic patients were included. There were modest positive correlations between the total score on the Overall Satisfaction domain and EQ-5D-5L (r = 0.14; p = 0.005). After adjusting multiple covariates by multiple linear regression, the association between the Overall Satisfaction and HRQoL was not statistically significant (p = 0.075); (R = 0.495; adjusted R2 = 0.245; F = 10.3; df = 12; p < 0.001). The results showed that elderly patients, being unemployed, and number of comorbid diseases, were significantly associated with HRQoL. Conclusions Overall, these results indicate that elderly patients, being unemployed, and those with comorbid diseases, are independent risk factors for poor HRQoL. Furthermore, it emerges that HRQoL and treatment satisfaction are both probably influenced by socio-demographic and clinical characteristics. In fact, to improve diabetic patients' quality of life, elderly patients were recommended to receive more attention in their health and economic status. © 2015 Elsevier Inc.","Diabetes mellitus; HRQoL; Quality of life; Treatment satisfaction; TSQM","Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030 (2004) Diabetes Care, 27, pp. 1047-1053; Akinci, F., Yildirim, A., Gozu, H., Sargin, H., Orbay, E., Sargin, M., Assessment of health-related quality of life (HRQoL) of patients with type 2 diabetes in Turkey (2008) Diabetes Res Clin Pract, 79, pp. 117-123; Javanbakht, M., Abolhasani, F., Mashayekhi, A., Baradaran, H.R., Jahangiri Noudeh, Y., Health related quality of life in patients with type 2 diabetes mellitus in Iran: A national survey (2012) PLoS One, 7, p. e44526; Redekop, W.K., Koopmanschap, M.A., Stolk, R.P., Rutten, G.E., Wolffenbuttel, B.H., Niessen, L.W., Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes (2002) Diabetes Care, 25, pp. 458-463; Jhita, T., Petrou, S., Gumber, A., Szczepura, A., Raymond, N.T., Bellary, S., Ethnic differences in health related quality of life for patients with type 2 diabetes (2014) Health Qual Life Outcomes, 12, p. 83; Chen, H., Rosenzweig, E.B., Gotzkowsky, S.K., Arneson, C., Nelsen, A.C., Bourge, R.C., Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension (2013) Health Qual Life Outcomes, 11, p. 31; Atkinson, M.J., Kumar, R., Cappelleri, J.C., Hass, S.L., Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers (2005) Value Health, 8, pp. S9-S24; Nicolucci, A., Cucinotta, D., Squatrito, S., Lapolla, A., Musacchio, N., Leotta, S., Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes (2009) Nutr Metab Cardiovasc Dis, 19, pp. 45-53; Bradley, C., De Pablos-Velasco, P., Parhofer, K.G., Eschwege, E., Gonder-Frederick, L., Simon, D., PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus - Study design (2011) Prim Care Diabetes, 5, pp. 231-239; Chen, H., Taichman, D.B., Doyle, R.L., Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension (2008) Proc Am Thorac Soc, 5, pp. 623-630; Williams, S.A., Pollack, M.F., Dibonaventura, M., Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus (2011) Diabetes Res Clin Pract, 91, pp. 363-370; (2012) Health Status in Palestine, , http://www.moh.ps/attach/502.pdf, Ministry of Health, Palestinian Health Information Center (PHIC) 2013 [cited 2013 August 12]; Available from; Al-Jabi, S.W., Zyoud, S.H., Sweileh, W.M., Wildali, A.H., Saleem, H.M., Aysa, H.A., Assessment of health-related quality of life among hypertensive patients: A cross-sectional study from Palestine (2014) J Public Health, 22, pp. 277-286; Al-Jabi, S.W., Zyoud, S.H., Sweileh, W.M., Wildali, A.H., Saleem, H.M., Aysa, H.A., Relationship of treatment satisfaction to health-related quality of life: Findings from a cross-sectional survey among hypertensive patients in Palestine (2014) Health Expect, , Article in Press; Zyoud, S.H., Al-Jabi, S.W., Sweileh, W.M., Wildali, A.H., Saleem, H.M., Aysa, H.A., Health-related quality of life associated with treatment adherence in patients with hypertension: A cross-sectional study (2013) Int J Cardiol, 168, pp. 2981-2983; Belbeisi, A., Zindah, M., Walke, H.T., Jarrar, B., Mokdad, A.H., Health related quality of life measures by demographics and common health risks, Jordan 2004 (2009) Int J Public Health, 54, pp. 106-110; Lee, W.J., Song, K.H., Noh, J.H., Choi, Y.J., Jo, M.W., Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes (2012) J Korean Med Sci, 27, pp. 255-260; Saleem, F., Hassali, M.A., Shafie, A.A., A cross-sectional assessment of health-related quality of life (HRQoL) among hypertensive patients in Pakistan (2014) Health Expect, 17, pp. 388-395; Atkinson, M.J., Sinha, A., Hass, S.L., Colman, S.S., Kumar, R.N., Brod, M., Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease (2004) Health Qual Life Outcomes, 2, p. 12; Bharmal, M., Payne, K., Atkinson, M.J., Desrosiers, M.P., Morisky, D.E., Gemmen, E., Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications (2009) Health Qual Life Outcomes, 7, p. 36; Zyoud, S.H., Al-Jabi, S.W., Sweileh, W.M., Morisky, D.E., Relationship of treatment satisfaction to medication adherence: Findings from a cross-sectional survey among hypertensive patients in Palestine (2013) Health Qual Life Outcomes, 11, p. 191; Depablos-Velasco, P., Salguero-Chaves, E., Mata-Poyo, J., Derivas-Otero, B., Garcia-Sanchez, R., Viguera-Ester, P., Quality of life and satisfaction with treatment in subjects with type 2 diabetes: Results in Spain of the PANORAMA study (2014) Endocrinol Nutr, 61, pp. 18-26; Martinez, Y.V., Prado-Aguilar, C.A., Rascon-Pacheco, R.A., Valdivia-Martinez, J.J., Quality of life associated with treatment adherence in patients with type 2 diabetes: A cross-sectional study (2008) BMC Health Serv Res, 8, p. 164; Tamir, O., Wainstein, J., Raz, I., Shemer, J., Heymann, A., Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes (2012) Rev Diabet Stud, 9, pp. 46-54; Van Den Donk, M., Griffin, S.J., Stellato, R.K., Simmons, R.K., Sandbaek, A., Lauritzen, T., Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): A cluster-randomised trial (2013) Diabetologia, 56, pp. 2367-2377; Rubin, R.R., Peyrot, M., Quality of life and diabetes (1999) Diabetes Metab Res Rev, 15, pp. 205-218; Cheah, W., Lee, P., Lim, P., Aa Fn, L.K., Perception of quality of life among people with diabetes (2012) Malays Fam Physician, 7, pp. 21-30; Papadopoulos, A.A., Kontodimopoulos, N., Frydas, A., Ikonomakis, E., Niakas, D., Predictors of health-related quality of life in type II diabetic patients in Greece (2007) BMC Public Health, 30 (7), p. 186; Maddigan, S.L., Feeny, D.H., Johnson, J.A., Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey (2005) Qual Life Res, 14, pp. 1311-1320; Wexler, D.J., Grant, R.W., Wittenberg, E., Bosch, J.L., Cagliero, E., Delahanty, L., Correlates of health-related quality of life in type 2 diabetes (2006) Diabetologia, 49, pp. 1489-1497; Gurkova, E., Cap, J., Ziakova, K., Quality of life and treatment satisfaction in the context of diabetes self-management education (2009) Int J Nurs Pract, 15, pp. 91-98; Sixma, H.J., Van Campen, C., Kerssens, J.J., Peters, L., Quality of care from the perspective of elderly people: The QUOTE-elderly instrument (2000) Age Ageing, 29, pp. 173-178; Hirsch, A., Bartholomae, C., Volmer, T., Dimensions of quality of life in people with non-insulin-dependent diabetes (2000) Qual Life Res, 9, pp. 207-218; Krousel-Wood, M., Thomas, S., Muntner, P., Morisky, D., Medication adherence: A key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients (2004) Curr Opin Cardiol, 19, pp. 357-362; Nicolucci, A., Kovacs Burns, K., Holt, R.I., Comaschi, M., Hermanns, N., Ishii, H., Diabetes Attitudes, Wishes and Needs second study (DAWN2): Cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes (2013) Diabet Med, 30, pp. 767-777; Holt, R.I., Nicolucci, A., Kovacs Burns, K., Escalante, M., Forbes, A., Hermanns, N., Diabetes Attitudes, Wishes and Needs second study (DAWN2): Cross-national comparisons on barriers and resources for optimal care-healthcare professional perspective (2013) Diabet Med, 30, pp. 789-798; Munro, N., Holt, R.I.G., Davies, M.J., Forbes, A., DAWN2 study findings: Psychosocial support and structured education need to be more widespread (2013) Pract Diabetes, 30, pp. 239-240; Abdul-Rahim, H.F., Husseini, A., Bjertness, E., Giacaman, R., Gordon, N.H., Jervell, J., The metabolic syndrome in the West Bank population: An urban-rural comparison (2001) Diabetes Care, 24, pp. 275-279; Husseini, A., Abdul-Rahim, H., Awartani, F., Giacaman, R., Jervell, J., Bjertness, E., Type 2 diabetes mellitus, impaired glucose tolerance and associated factors in a rural Palestinian village (2000) Diabet Med, 17, pp. 746-748; Jamous, R.M., Sweileh, W.M., Abu-Taha, A.S., Sawalha, A.F., Zyoud, S.H., Morisky, D.E., Adherence and satisfaction with oral hypoglycemic medications: A pilot study in Palestine (2011) Int J Clin Pharm, 33, pp. 942-948; Sweileh, W.M., Contraindications to metformin therapy among patients with type 2 diabetes mellitus (2007) Pharm World Sci, 29, pp. 587-592; Sweileh, W.M., Abu-Hadeed, H.M., Al-Jabi, S.W., Zyoud, S.H., Prevalence of depression among people with type 2 diabetes mellitus: A cross sectional study in Palestine (2014) BMC Public Health, 14, p. 163; Sweileh, W.M., Zyoud, S.H., Abu Nab'A, R.J., Deleq, M.I., Enaia, M.I., Nassar, S.M., Influence of patients' disease knowledge and beliefs about medicines on medication adherence: Findings from a cross-sectional survey among patients with type 2 diabetes mellitus in Palestine (2014) BMC Public Health, 14, p. 94",Article,Scopus,2-s2.0-84928468222
"Patel S.S., Parashar A., Udayabanu M.","Urtica dioica leaves modulates muscarinic cholinergic system in the hippocampus of streptozotocin-induced diabetic mice",2015,"Metabolic Brain Disease","30","3",,"803","811",,,10.1007/s11011-014-9646-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928662606&partnerID=40&md5=76efca0470fad1ed758e2fb15f951cc6","Department of Pharmacy, Jaypee University of Information TechnologyWaknaghat, Himachal Pradesh, India; Department of Pharmacology, Lakshmi Narain College of PharmacyBhopal, Madhya Pradesh, India","Patel, S.S., Department of Pharmacy, Jaypee University of Information TechnologyWaknaghat, Himachal Pradesh, India, Department of Pharmacology, Lakshmi Narain College of PharmacyBhopal, Madhya Pradesh, India; Parashar, A., Department of Pharmacy, Jaypee University of Information TechnologyWaknaghat, Himachal Pradesh, India; Udayabanu, M., Department of Pharmacy, Jaypee University of Information TechnologyWaknaghat, Himachal Pradesh, India","Diabetes mellitus is a chronic metabolic disorder and has been associated with cognitive dysfunction. In our earlier study, chronic Urtica dioica (UD) treatment significantly ameliorated diabetes induced associative and spatial memory deficit in mice. The present study was designed to explore the effect of UD leaves extract on muscarinic cholinergic system, which has long been known to be involved in cognition. Streptozotocin (STZ) (50 mg/kg, i.p., consecutively for 5 days) was used to induce diabetes followed by treatment with UD extract (50 mg/kg, oral) or rosiglitazone (5 mg/kg, oral) for 8 weeks. STZ-induced diabetic mice showed significant reduction in hippocampal muscarinic acetylcholine receptor-1 and choline acetyltransferase expressions. Chronic diabetes significantly up-regulated the protein expression of acetylcholinesterase associated with oxidative stress in hippocampus. Besides, STZ-induced diabetic mice showed hypolocomotion with up-regulation of muscarinic acetylcholine receptor-4 expression in striatum. Chronic UD treatment significantly attenuated the cholinergic dysfunction and oxidative stress in the hippocampus of diabetic mice. UD had no effect on locomotor activity and muscarinic acetylcholine receptor-4 expression in striatum. In conclusion, UD leaves extract has potential to reverse diabetes mediated alteration in muscarinic cholinergic system in hippocampus and thereby improve memory functions. © 2014, Springer Science+Business Media New York.","Choline acetyltransferase; Cognition; Diabetes mellitus; Locomotor activity; Muscarinic receptors; Urtica dioica","Abdalla, F.H., Schmatz, R., Cardoso, A.M., Carvalho, F.B., Baldissarelli, J., de Oliveira, J.S., Rosa, M.M., Mazzanti, C.M., Quercetin protects the impairment of memory and anxiogenic-like behavior in rats exposed to cadmium: possible involvement of the acetylcholinesterase and Na(+), K(+)-ATPase activities (2014) Physiol Behav, 135, pp. 152-167. , COI: 1:CAS:528:DC%2BC2cXht1ens7vK, PID: 24952260; Ahangarpour, A., Mohammadian, M., Dianat, M., Antidiabetic effect of hydroalcholic urtica dioica leaf extract in male rats with fructose-induced insulin resistance (2012) Iran J Med Sci, 37, pp. 181-186. , PID: 23115450; Alipour, M., Salehi, I., Ghadiri Soufi, F., Effect of exercise on diabetes-induced oxidative stress in the rat hippocampus (2012) Iran Red Crescent Med J, 14, pp. 222-228. , COI: 1:STN:280:DC%2BC38jmslOlsA%3D%3D, PID: 22754685; Ambrogi-Lorenzini, C.G., Baldi, E., Bucherelli, C., Sacchetti, B., Tassoni, G., Neural topography and chronology of memory consolidation: a review of functional inactivation findings (1999) Neurobiol Learn Mem, 71, pp. 1-18. , COI: 1:STN:280:DyaK1M7gvVaitg%3D%3D, PID: 9889069; Anisuzzaman, A.S., Uwada, J., Masuoka, T., Yoshiki, H., Nishio, M., Ikegaya, Y., Takahashi, N., Muramatsu, I., Novel contribution of cell surface and intracellular M1-muscarinic acetylcholine receptors to synaptic plasticity in hippocampus (2013) J Neurochem, 126, pp. 360-371. , COI: 1:CAS:528:DC%2BC3sXhtFanu7fK, PID: 23678982; Beckmann, D.V., Carvalho, F.B., Mazzanti, C.M., Dos Santos, R.P., Andrades, A.O., Aiello, G., Rippilinger, A., Mazzanti, A., Neuroprotective role of quercetin in locomotor activities and cholinergic neurotransmission in rats experimentally demyelinated with ethidium bromide (2014) Life Sci, 103, pp. 79-87. , COI: 1:CAS:528:DC%2BC2cXntVCjtrc%3D, PID: 24727240; Bhutada, P., Mundhada, Y., Bansod, K., Bhutada, C., Tawari, S., Dixit, P., Mundhada, D., Ameliorative effect of quercetin on memory dysfunction in streptozotocin-induced diabetic rats (2010) Neurobiol Learn Mem, 94, pp. 293-302. , COI: 1:CAS:528:DC%2BC3cXht1eqsbvN, PID: 20620214; Bubser, M., Byun, N., Wood, M.R., Jones, C.K., (2012) Handbook of experimental pharmacology, , Springer, Berlin:; Claiborne, A., (1985) Handbook of methods for oxygen radical research, , CRC Press, Florida:; Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., Lin, J.K., Ezzati, M., National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants (2011) Lancet, 378, pp. 31-40. , COI: 1:CAS:528:DC%2BC3MXotlyltbo%3D, PID: 21705069; Drever, B.D., Riedel, G., Platt, B., The cholinergic system and hippocampal plasticity (2011) Behav Brain Res, 221, pp. 505-514. , COI: 1:CAS:528:DC%2BC3MXmtFClu7o%3D, PID: 21130117; Ejaz Ahmed, M., Khan, M.M., Javed, H., Vaibhav, K., Khan, A., Tabassum, R., Ashafaq, M., Islam, F., Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type (2013) Neurochem Int, 62, pp. 492-501. , COI: 1:CAS:528:DC%2BC3sXktlKkt7o%3D, PID: 23411413; Exner, M., Hermann, M., Hofbauer, R., Kapiotis, S., Speiser, W., Held, I., Seelos, C., Gmeiner, B.M., The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein (2000) FEBS Lett, 470, pp. 47-50. , COI: 1:CAS:528:DC%2BD3cXhslalt74%3D, PID: 10722843; Fazeli, S.A., Gharravi, A.M., Ghafari, S., Jahanshahi, M., Golalipour, M.J., The granule cell density of the dentate gyrus following administration of Urtica dioica extract to young diabetic rats (2008) Folia Morphol (Warsz), 67, pp. 196-204. , COI: 1:STN:280:DC%2BD1cnjs12rtQ%3D%3D; Gomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., Shannon, H., Wess, J., Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice (1999) Proc Natl Acad Sci U S A, 96, pp. 10483-10488. , COI: 1:CAS:528:DyaK1MXlvFenu7c%3D, PID: 10468635; Hölscher, C., Inhibitors of cyclooxygenases produce amnesia for a passive avoidance task in the chick (1995) Eur J Neurosci, 7, pp. 1360-1365. , PID: 7582110; Hornick, A., Lieb, A., Vo, N.P., Rollinger, J.M., Stuppner, H., Prast, H., The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory (2011) Neuroscience, 197, pp. 280-292. , COI: 1:CAS:528:DC%2BC3MXhsVartb3O, PID: 21945033; Hunter, A., Roberts, F., The effect of pirenzepine on spatial learning in the Morris water maze (1988) Pharmacol Biochem Behav, 30, pp. 519-523. , COI: 1:CAS:528:DyaL1cXks1Krsbs%3D, PID: 3174783; Khandelwal, K.R., (2008) Practical pharmacognosy, , Nirali prakashan, Pune:; Kianbakht, S., Khalighi-Sigaroodi, F., Dabaghian, F.H., Improved glycemic control in patients with advanced type 2 diabetes mellitus taking Urtica dioica leaf extract: a randomized double-blind placebo-controlled clinical trial (2013) Clin Lab, 59, pp. 1071-1076. , PID: 24273930; Kou, Z.Z., Li, C.Y., Hu, J.C., Yin, J.B., Zhang, D.L., Liao, Y.H., Wu, Z.Y., Li, Y.Q., Alterations in the neural circuits from peripheral afferents to the spinal cord: possible implications for diabetic polyneuropathy in streptozotocin-induced type 1 diabetic rats (2014) Front Neural Circ, 8, p. 6; Kumar, A., Rinwa, P., Dhar, H., Possible nitric oxide modulation in the protective effects of rutin against experimental head trauma-induced cognitive deficits: behavioral, biochemical, and molecular correlates (2014) J Surg Res, 188, pp. 268-279. , COI: 1:CAS:528:DC%2BC2cXhsV2iu7k%3D, PID: 24484907; Lee, C.R., Shin, E.J., Kim, H.C., Choi, Y.S., Shin, T., Wie, M.B., Esculetin inhibits N-methyl-D-aspartate neurotoxicity via glutathione preservation in primary cortical cultures (2011) Lab Anim Res, 27, pp. 259-263. , PID: 21998617; Lupien, S.B., Bluhm, E.J., Ishii, D.N., Systemic insulin-like growth factor-I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats (2003) J Neurosci Res, 74, pp. 512-523. , COI: 1:CAS:528:DC%2BD3sXovVyht7w%3D, PID: 14598295; Lustman, P.J., Griffith, L.S., Clouse, R.E., Depression in adults with diabetes: results of 5-year follow-up study (1988) Diabetes Care, 11, pp. 605-612. , COI: 1:STN:280:DyaL1M7itVCqug%3D%3D, PID: 3219966; Mahesh, R., Kumar, B., Jindal, A., Bhatt, S., Devadoss, T., Pandey, D.K., Antidepressant-like activity of (4-phenylpiperazin-1-yl) (quinoxalin-2-yl) methanone (4a), a novel 5-HT(3) receptor antagonist: an investigation in behaviour-based rodent models of depression (2012) Indian J Pharmacol, 44, pp. 560-565. , COI: 1:CAS:528:DC%2BC38Xhs1KmsbzE, PID: 23112413; More, A.S., Kumari, R.R., Gupta, G., Kathirvel, K., Lonare, M.K., Dhayagude, R.S., Kumar, D., Tandan, S.K., Effect of S-methylisothiourea in acetaminophen-induced hepatotoxicity in rat (2012) Naunyn Schmiedeberg’s Arch Pharmacol, 385, pp. 1127-1139. , COI: 1:CAS:528:DC%2BC38XhsVKgsr3O; Namazi, N., Tarighat, A., Bahrami, A., The effect of hydro alcoholic nettle (Urtica dioica) extract on oxidative stress in patients with type 2 diabetes: a randomized double-blind clinical trial (2012) Pak J Biol Sci, 15, pp. 98-102. , COI: 1:STN:280:DC%2BC38rptFyhsA%3D%3D, PID: 22545363; Nouwen, A., Nefs, G., Caramlau, I., Connock, M., Winkley, K., Lloyd, C.E., Peyrot, M., Pouwer, F., Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European Depression in Diabetes (EDID) Research Consortium (2011) Diabetes Care, 34, pp. 752-762. , PID: 21357362; O’Reilly, J.A., Lynch, M., Rosiglitazone improves spatial memory and decreases insoluble Aβ(1–42) in APP/PS1 mice (2012) J Neuroimmune Pharm, 7, pp. 140-144; Oda, Y., Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system (1999) Pathol Int, 49, pp. 921-937. , COI: 1:CAS:528:DC%2BD3cXltlChug%3D%3D, PID: 10594838; Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction (1979) Anal Biochem, 95, pp. 351-358. , COI: 1:CAS:528:DyaE1MXksFaisbk%3D, PID: 36810; Orcic, D., Franciskovic, M., Bekvalac, K., Svircev, E., Beara, I., Lesjak, M., Mimica-Dukic, N., Quantitative determination of plant phenolics in Urtica dioica extracts by high-performance liquid chromatography coupled with tandem mass spectrometric detection (2014) Food Chem, 143, pp. 48-53. , COI: 1:CAS:528:DC%2BC3sXhsVKns77I, PID: 24054211; Panda, S., Kar, A., Evaluation of the antithyroid, antioxidative and antihyperglycemic activity of scopoletin from Aegle marmelos leaves in hyperthyroid rats (2006) Phytother Res, 20, pp. 1103-1105. , COI: 1:CAS:528:DC%2BD2sXotVWltg%3D%3D, PID: 17078113; Patel, S.S., Udayabanu, M., Effect of Urtica dioica on memory dysfunction and hypoalgesia in an experimental model of diabetic neuropathy (2013) Neurosci Lett, 552, pp. 114-119. , COI: 1:CAS:528:DC%2BC3sXhsFens73O, PID: 23916662; Patel, S.S., Udayabanu, M., Urtica dioica extract attenuates depressive like behavior and associative memory dysfunction in dexamethasone induced diabetic mice (2014) Metab Brain Dis, 29, pp. 121-130. , PID: 24435938; Pipatpiboon, N., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., PPARγ agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets (2012) Endocrinology, 153, pp. 329-338. , COI: 1:CAS:528:DC%2BC38XovFWluw%3D%3D, PID: 22109891; Potapenko, E.S., Biancardi, V.C., Zhou, Y., Stern, J.E., Altered astrocyte glutamate transporter regulation of hypothalamic neurosecretory neurons in heart failure rats (2012) Am J Physiol Regul Integr Comp Physiol, 303, pp. 291-300. , COI: 1:CAS:528:DC%2BC38XhtlSlurjL, PID: 22696576; Prabakaran, D., Ashokkumar, N., Protective effect of esculetin on hyperglycemia-mediated oxidative damage in the hepatic and renal tissues of experimental diabetic rats (2013) Biochimie, 95, pp. 366-373. , COI: 1:CAS:528:DC%2BC38XhsF2ms7zP, PID: 23079336; Prickaerts, J., Blokland, A., Honig, W., Meng, F., Jolles, J., Spatial discrimination learning and choline acetyltransferase activity in streptozotocin-treated rats: effects of chronic treatment with acetyl-L-carnitine (1995) Brain Res, 674, pp. 142-146. , COI: 1:CAS:528:DyaK2MXktFeksLk%3D, PID: 7773683; Qujeq, D., Tatar, M., Feizi, F., Parsian, H., Sohan Faraji, A., Halalkhor, S., Effect of Urtica dioica leaf alcoholic and aqueous extracts on the number and the diameter of the islets in diabetic rats (2013) Int J Mol Cell Med, 2, pp. 21-26. , PID: 24551786; Rinwa, P., Kumar, A., Modulation of nitrergic signaling pathway by American ginseng attenuates chronic unpredictable stress-induced cognitive impairment, neuroinflammation, and biochemical alterations (2014) Naunyn Schmiedeberg’s Arch Pharmacol, 387, pp. 129-141. , COI: 1:CAS:528:DC%2BC3sXhs1eqtb7P; Santi, A., Baldissareli, J., Murussi, C.R., Dias, G.R., de Menezes, C.C., Zanini, D., Abdalla, F.H., Loro, V.L., Effects of quercetin on oxidative stress biomarkers in methimazole - induced hypothyroid rats (2014) Exp Clin Endocrinol Diabetes, 122, pp. 533-539. , COI: 1:CAS:528:DC%2BC2cXhsl2nsr3O, PID: 24918533; Saravanan, G., Ponmurugan, P., Antidiabetic effect of S-allylcysteine: effect on thyroid hormone and circulatory antioxidant system in experimental diabetic rats (2012) J Diabetes Complicat, 26, pp. 280-285. , PID: 22541895; Sherin, A., Anu, J., Peeyush, K.T., Smijin, S., Anitha, M., Roshni, B.T., Paulose, C.S., Cholinergic and GABAergic receptor functional deficit in the hippocampus of insulin-induced hypoglycemic and streptozotocin-induced diabetic rats (2012) Neuroscience, 202, pp. 69-76. , COI: 1:CAS:528:DC%2BC38XhsFGgtr0%3D, PID: 22155651; Stanley Mainzen Prince, P., Kamalakkannan, N., Rutin improves glucose homeostasis in streptozotocin diabetic tissues by altering glycolytic and gluconeogenic enzymes (2006) J Biochem Mol Toxicol, 20, pp. 96-102. , COI: 1:STN:280:DC%2BD283hsFakuw%3D%3D, PID: 16615078; Toldy, A., Stadler, K., Sasvari, M., Jakus, J., Jung, K.J., Chung, H.Y., Berkes, I., Radak, Z., The effect of exercise and nettle supplementation on oxidative stress markers in the rat brain (2005) Brain Res Bull, 65, pp. 487-493. , COI: 1:CAS:528:DC%2BD2MXjvVKlsLs%3D, PID: 15862920; Udayabanu, M., Kumaran, D., Katyal, A., Free chelatable zinc modulates the cholinergic function during hypobaric hypoxia-induced neuronal damage: an in vivo study (2012) Neuroscience, 202, pp. 434-445. , COI: 1:CAS:528:DC%2BC38XhsFGgsLo%3D, PID: 22138153; Vessal, M., Hemmati, M., Vasei, M., Antidiabetic effects of quercetin in streptozocin-induced diabetic rats (2003) Comp Biochem Physiol C Toxicol Pharmacol, 135C, pp. 357-364. , COI: 1:CAS:528:DC%2BD3sXmsVCiur4%3D, PID: 12927910; Volpicelli-Daley, L.A., Hrabovska, A., Duysen, E.G., Ferguson, S.M., Blakely, R.D., Lockridge, O., Levey, A.I., Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice (2003) Mol Pharmacol, 64, pp. 1309-1316. , COI: 1:CAS:528:DC%2BD3sXps1Oitb4%3D, PID: 14645660; Wang, S.B., Jia, J.P., Oxymatrine attenuates diabetes-associated cognitive deficits in rats (2014) Acta Pharmacol Sin, 35, pp. 331-338. , COI: 1:CAS:528:DC%2BC2cXjtlyisbk%3D, PID: 24442148; Wolff, S.P., Dean, R.T., Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes (1987) Biochem J, 245, pp. 243-250. , COI: 1:CAS:528:DyaL2sXktlOms7c%3D, PID: 3117042; Yuede, C.M., Dong, H., Csernansky, J.G., Anti-dementia drugs and hippocampal-dependent memory in rodents (2007) Behav Pharmacol, 18, pp. 347-363. , COI: 1:CAS:528:DC%2BD2sXpvVems74%3D, PID: 17762506; Zhang, W.Y., Lee, J.J., Kim, Y., Kim, I.S., Park, J.S., Myung, C.S., Amelioration of insulin resistance by scopoletin in high-glucose-induced, insulin-resistant HepG2 cells (2010) Horm Metab Res, 42, pp. 930-935. , COI: 1:CAS:528:DC%2BC3cXhs1art7fL, PID: 20886413",Article,Scopus,2-s2.0-84928662606
"Pachori R.B., Avinash P., Shashank K., Sharma R., Acharya U.R.","Application of empirical mode decomposition for analysis of normal and diabetic RR-interval signals",2015,"Expert Systems with Applications","42","9",,"4567","4581",,1,10.1016/j.eswa.2015.01.051,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923337303&partnerID=40&md5=6750be3afdaf550a2b21cdb1fad65f46","Discipline of Electrical Engineering, Indian Institute of Technology IndoreIndore, India; Department of Electronics and Communication Engineering, Ngee Ann PolytechnicSingapore, Singapore","Pachori, R.B., Discipline of Electrical Engineering, Indian Institute of Technology IndoreIndore, India; Avinash, P., Discipline of Electrical Engineering, Indian Institute of Technology IndoreIndore, India; Shashank, K., Discipline of Electrical Engineering, Indian Institute of Technology IndoreIndore, India; Sharma, R., Discipline of Electrical Engineering, Indian Institute of Technology IndoreIndore, India; Acharya, U.R., Department of Electronics and Communication Engineering, Ngee Ann PolytechnicSingapore, Singapore","Large number of people are affected by Diabetes Mellitus (DM) which is difficult to cure due to its chronic nature and genetic link. The uncontrolled diabetes may lead to heart related problems. Therefore, the diagnosis and monitoring of diabetes is of great importance. The automatic detection of diabetes can be performed using RR-interval signals. The RR-interval signals are nonlinear and non-stationary in nature. Hence linear methods may not be able to capture the hidden information present in the signal. In this paper, a new nonlinear method based on empirical mode decomposition (EMD) is proposed to discriminate between diabetic and normal RR-interval signals. The mean frequency parameter using Fourier-Bessel series expansion (MFFB) and the two bandwidth parameters namely, amplitude modulation bandwidth (BAM) and frequency modulation bandwidth (BFM) extracted from the intrinsic mode functions (IMFs) obtained from the EMD of RR-interval signals are used to discriminate the two groups. Unique representations such as analytic signal representation (ASR) and second order difference plot (SODP) for IMFs of RR-interval signals are also proposed to differentiate the two groups. The area parameters are computed from ASR and SODP of IMFs of RR-interval signals. Area computed from these representation as area corresponding to the 95% central tendency measure (CTM) of ASR of IMFs (AASR) and 95% confidence ellipse area of SODP of IMF (ASODP) are also proposed to discriminate diabetic and normal RR-interval signals. Overall, five features are extracted from IMFs of RR-interval signals namely MFFB,BAM,BFM,AASR and ASODP. Kruskal-Wallis statistical test is used to measure the discrimination ability of the proposed features for detection of diabetic RR-interval signals. Results obtained from proposed methodology indicate that these features provide the statistically significant difference between diabetic and normal classes. © 2015 Elsevier Ltd. All rights reserved.","Diabetes; EMD; IMF; Nonlinear; RR signal","Abubaker, H.B., Alsafar, H.S., Jelinek, H.F., Khalaf, K.A., Khandoker, A.H., Poincaré plot analysis of heart rate variability in the diabetic patients in the UAE (2014) Middle East Conference on Biomedical Engineering, pp. 368-370; Acharya, U.R., An integrated diabetic index using heart rate variability signal features for diagnosis of diabetes (2013) Computer Methods in Biomechanics and Biomedical Engineering, 16 (2), pp. 222-234; Acharya, U.R., Faust, O., Kadri, N.A., Suri, J.S., Yu, W., Automated identification of normal and diabetes heart rate signals using nonlinear measures (2013) Computers in Biology and Medicine, 43 (10), pp. 1523-1529; Acharya, U.R., Kannathal, N., Krishnan, S.M., Comprehensive analysis of cardiac health using heart rate signals (2004) Physiological Measurement, 25 (5), pp. 1139-1151; Ahamed Seyd, P., Paul, J.K., Jeevamma, J., Automated diagnosis of diabetes using heart rate variability signals (2012) Journal of Medical Systems, 36 (3), pp. 1935-1941; Al-Hazimi, A., Al-Ama, N., Syiamic, A., Qosti, R., Abdel-Galil, K., Time domain analysis of heart rate variability in diabetic patients with and without autonomic neuropathy (2002) Annals of Saudi Medicine, 22 (56), pp. 400-403; Amoud, H., Hilbert-Huang transformation: Application to postural stability analysis (2007) IEEE International Conference on Engineering in Medicine and Biology Society, pp. 1562-1565; Amoud, H., Snoussi, H., Hewson, D., Duchêne, J., Univariate and bivariate empirical mode decomposition for postural stability analysis (2008) EURASIP Journal on Advances in Signal Processing, 2008, pp. 1-11; Bajaj, V., Pachori, R.B., Classification of seizure and nonseizure EEG signals using empirical mode decomposition (2012) IEEE Transactions on Information Technology in Biomedicine, 16 (6), pp. 1135-1142; Baumert, M., Sacre, J., Heart rate complexity and cardiac sympathetic dysinnervation in patients with type 2 diabetes mellitus (2013) IEEE International Conference on Engineering in Medicine and Biology Society, pp. 5570-5573; (2010) Acqknowledge 4.1, , http://www.biopac.ca/Acqknowledge_40.htm, BIOPAC Systems Canada, Inc. BIOPAC Systems, Inc; Cavalheiro, G., Almeida, M.F.S., Pereira, A.A., Andrade, O.A., Study of age-related changes in postural control during quiet standing through linear discriminant analysis (2009) BioMedical Engineering OnLine, 8 (35), pp. 1-13; Chemla, D., Young, J., Badilini, F., Maison-Blanche, P., Affres, H., Lecarpentier, Y., Comparison of fast fourier transform and autoregressive spectral analysis for the study of heart rate variability in diabetic patients (2005) International Journal of Cardiology, 104 (3), pp. 307-313; Cohen, L., Lee, C., Instantaneous bandwidth for signals and spectrogram (1990) IEEE International Conference on Acoustics, Speech, and Signal Processing, pp. 2451-2454; Cohen, M.E., Hudson, D.L., Deedwania, P.C., Applying continuous chaotic modeling to cardiac signal analysis (1996) IEEE Engineering in Medicine and Biology Magazine, 15 (5), pp. 97-102; Cooke, D.W., Plotnick, L., Type 1 diabetes mellitus in pediatrics (2008) Pediatrics in Review, 29 (11), pp. 374-385; Di Carli, M.F., Janisse, J., Grunberger, G., Ager, J., Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes (2003) Journal of the American College of Cardiology, 41 (8), pp. 1387-1393; Faust, O., Acharya, U.R., Molinari, F., Chattopadhyay, S., Tamura, T., Linear and non-linear analysis of cardiac health in diabetic subjects (2012) Biomedical Signal Processing and Control, 7 (3), pp. 295-302; Flynn, A.C., Jelinek, H.F., Smith, M., Heart rate variability analysis: A useful assessment tool for diabetes associated cardiac dysfunction in rural and remote areas (2005) Australian Journal of Rural Health, 13 (2), pp. 77-82; Furuya, M., Masuda, Y., Sato, K., Nishibe, T., Yana, K., Ono, T., Long and short term QT-RR interval co-variability in type 2 diabetes (2014) IEEE International Conference Engineering in Medicine and Biology Society, pp. 38-41; Gamero, L.G., Vila, J., Palacios, F., Wavelet transform analysis of heart rate variability during myocardial ischaemia (2002) Medical and Biological Engineering and Computing, 40 (1), pp. 72-78; Gardner, D.G., Shoback, D.M., (2011) Greenspan's Basic and Clinical Endocrinology, , McGraw Hill; Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E., Global estimates of diabetes prevalence for 2013 and projections for 2035 (2014) Diabetes Research and Clinical Practice, 103 (2), pp. 137-149; Guariguata, L., Whiting, D., Weil, C., Unwin, N., The international diabetes federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults (2011) Diabetes Research and Clinical Practice, 94 (3), pp. 322-332; Huang, N.E., Shen, Z., Long, S.R., Wu, M.C., Shih, H.H., Zheng, Q., The empirical mode decomposition and the Hilbert spectrum for nonlinear and non-stationary time series analysis (1998) Proceedings of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences, 454 (1971), pp. 903-995; (2013) IDF Diabetes Atlas, , http://www.idf.org/diabetesatlas, International Diabetes Federation 6th ed., Brussels, Belgium, International Diabetes Federation; Jain, P., Pachori, R.B., Time-order representation based method for epoch detection from speech signals (2012) Journal of Intelligent Systems, 21 (1), pp. 79-95; Jain, P., Pachori, R.B., Event-based method for instantaneous fundamental frequency estimation from voiced speech based on eigenvalue decomposition of the Hankel matrix (2014) IEEE/ACM Transactions on Audio, Speech, and Language Processing, 22 (10), pp. 1467-1482; Jelinek, H., Flynn, A., Warner, P., Automated assessment of cardiovascular disease associated with diabetes in rural and remote health care practice (2004) The National SARRAH Conference, pp. 1-7; Jelinek, H., Tarvainen, M., Cornforth, D., Renyi entropy in identification of cardiac autonomic neuropathy in diabetes (2012) Computing in Cardiology, pp. 909-912; Jian, L.W., Lim, T.-C., Automated detection of diabetes by means of higher order spectral features obtained from heart rate signals (2013) Journal of Medical Imaging and Health Informatics, 3, pp. 440-447; Kirvela, M., Salmela, K., Toivonen, L., Koivusalo, A.-M., Lindgren, L., Heart rate variability in diabetic and non-diabetic renal transplant patients (1996) Acta Anaesthesiologica Scandinavica, 40 (7), pp. 804-808; Kleiger, R.E., Stability over time of variables measuring heart rate variability in normal subjects (1991) The American Journal of Cardiology, 68 (6), pp. 626-630; Lai, Y.-C., Ye, N., Recent developments in chaotic time series analysis (2003) International Journal of Bifurcation and Chaos, 13 (6), pp. 1383-1422; Lombardi, F., Chaos theory, heart rate variability, and arrhythmic mortality (2000) Circulation, 101 (1), pp. 8-10; Martis, R.J., Application of empirical mode decomposition (EMD) for automated detection of epilepsy using EEG signals (2012) International Journal of Neural Systems, 22 (6), pp. 1-16; McKnight, P.E., Najab, J., Kruskal-Wallis test (2010) The Corsini Encyclopedia of Psychology; Nolan, R.P., Barry-Bianchi, S.M., Mechetiuc, A.E., Chen, M.H., Sex-based differences in the association between duration of type 2 diabetes and heart rate variability (2009) Diabetes and Vascular Disease Research, 6 (4), pp. 276-282; Omar, M.O.A., Mohamed, A.S.A., Application of the empirical mode decomposition to ECG and HRV signals for congestive heart failure classification (2011) First Middle East Conference on Biomedical Engineering, pp. 392-395; Pachori, R.B., Discrimination between ictal and seizure-free EEG signals using empirical mode decomposition (2008) Research Letters in Signal Processing, 2008, pp. 1-5; Pachori, R.B., Bajaj, V., Analysis of normal and epileptic seizure EEG signals using empirical mode decomposition (2011) Computer Methods and Programs in Biomedicine, 104 (3), pp. 373-381; Pachori, R.B., Postural time-series analysis using empirical mode decomposition and second-order difference plots (2009) IEEE International Conference on Acoustics, Speech and Signal Processing, pp. 537-540; Pachori, R.B., Gangashetty, S.V., AM-FM model based approach for detection of glottal closure instants (2010) 10th International Conference on Information Sciences Signal Processing and Their Applications, pp. 266-269. , IEEE Kuala Lumpur; Pachori, R.B., Gangashetty, S.V., Detection of voice onset time using FB expansion and AM-FM model (2010) 10th International Conference on Information Sciences Signal Processing and Their Applications, pp. 149-152. , IEEE Kuala Lumpur; Pachori, R.B., Hewson, D., Assessment of the effects of sensory perturbations using Fourier-Bessel expansion method for postural stability analysis (2011) Journal of Intelligent Systems, 20 (2), pp. 167-186; Pachori, R.B., Hewson, D.J., Snoussi, H., Duchêne, J., Analysis of center of pressure signals using empirical mode decomposition and Fourier-Bessel expansion (2008) IEEE Region 10 Conference TENCON, pp. 1-6. , IEEE; Pachori, R.B., Patidar, S., Epileptic seizure classification in EEG signals using second-order difference plot of intrinsic mode functions (2014) Computer Methods and Programs in Biomedicine, 113 (2), pp. 494-502; Pachori, R.B., Sharma, R., Patidar, S., Classification of normal and epileptic seizure EEG signals based on empirical mode decomposition (2015) Complex System Modelling and Control Through Intelligent Soft Computations Studies in Fuzziness and Soft Computing, pp. 367-388. , Q. Zhu, A.T. Azar, Springer International Publishing; Pachori, R.B., Sircar, P., A new technique to reduce cross terms in the Wigner distribution (2007) Digital Signal Processing, 17 (2), pp. 466-474; Pachori, R.B., Sircar, P., EEG signal analysis using FB expansion and second-order linear TVAR process (2008) Signal Processing, 88 (2), pp. 415-420; Pachori, R.B., Sircar, P., Analysis of multicomponent AM-FM signals using FB-DESA method (2010) Digital Signal Processing, 20 (1), pp. 42-62; Pachori, R.B., Sircar, P., (2010) Non-stationary Signal Analysis: Methods Based on Fourier-Bessel Representation, , LAP LAMBERT Academic Publishing Germany; Pal, S., Mitra, M., Empirical mode decomposition based ECG enhancement and QRS detection (2012) Computers in Biology and Medicine, 42 (1), pp. 83-92; Pan, J., Tompkins, W.J., A real-time QRS detection algorithm (1985) IEEE Transactions on Biomedical Engineering, 32 (3), pp. 230-236; Patidar, S., Pachori, R.B., Classification of cardiac sound signals using constrained tunable-Q wavelet transform (2014) Expert Systems with Applications, 41 (16), pp. 7161-7170; Prieto, T.E., Myklebust, J.B., Hoffmann, R.G., Lovett, E.G., Myklebust, B.M., Measures of postural steadiness: Differences between healthy young and elderly adults (1996) IEEE Transactions on Biomedical Engineering, 43 (9), pp. 956-966; Roy, B., Ghatak, S., Nonlinear methods to assess changes in heart rate variability in type 2 diabetic patients (2013) Arquivos Brasileiros de Cardiologia, 101 (4), pp. 317-327; Sacre, J.W., Jellis, C.L., Marwick, T.H., Coombes, J.S., Reliability of heart rate variability in patients with type 2 diabetes mellitus (2012) Diabetic Medicine, 29, pp. e33-e40; Sarwar, N., Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies (2010) The Lancet, 375 (9733), pp. 2215-2222; Schroeder, J., Signal processing via Fourier-Bessel series expansion (1993) Digital Signal Processing, 3 (2), pp. 112-124; Schroeder, E.B., Chambless, L.E., Liao, D., Prineas, R.J., Evans, G.W., Rosamond, W.D., Diabetes, glucose, insulin, and heart rate variability (2005) Diabetes Care, 28 (3), pp. 668-674; Seyd, P.T.A., Ahamed, V.T., Jacob, J., Joseph, P., Time and frequency domain analysis of heart rate variability and their correlations in diabetes mellitus (2008) World Academy of Science, Engineering and Technology, 2 (3); Sharma, R., Pachori, R.B., Classification of epileptic seizures in EEG signals based on phase space representation of intrinsic mode functions (2015) Expert Systems with Applications, 42 (3), pp. 1106-1117; Sharma, R., Pachori, R.B., Gautam, S., Empirical mode decomposition based classification of focal and non-focal EEG signals (2014) International Conference on Medical Biometrics, pp. 135-140. , IEEE; Shi, Y., Hu, F.B., The global implications of diabetes and cancer (2014) The Lancet, 383 (9933), pp. 1947-1948; Swapna, G., Acharya, U.R., Vinithasree, S., Suri, J.S., Automated detection of diabetes using higher order spectral features extracted from heart rate signals (2013) Intelligent Data Analysis, 17 (2), pp. 309-326; Thuraisingham, R.A., Tran, Y., Boord, P., Craig, A., Analysis of eyes open, eye closed EEG signals using second-order difference plot (2007) Medical and Biological Engineering and Computing, 45 (12), pp. 1243-1249; Warlar, R., Eswaran, C., Integer coefficient bandpass filter for the simultaneous removal of baseline wander, 50 and 100 Hz interference from the ECG (1991) Medical and Biological Engineering and Computing, 29 (3), pp. 333-336; (2011), http://www.who.int/mediacentre/factsheets/fs312/en/, World Health Organization: Diabetes accessed 2014-09-03",Article,Scopus,2-s2.0-84923337303
"Recarti C., Sep S.J.S., Stehouwer C.D.A., Unger T.","Excess Cardiovascular Risk in Diabetic Women: A Case for Intensive Treatment",2015,"Current Hypertension Reports","17","6",,"","",6,,10.1007/s11906-015-0554-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928473692&partnerID=40&md5=01956872fc5040b53ac65499dbcb2318","CARIM—School for Cardiovascular Diseases, Maastricht UniversityMaastricht, Netherlands","Recarti, C., CARIM—School for Cardiovascular Diseases, Maastricht UniversityMaastricht, Netherlands; Sep, S.J.S., CARIM—School for Cardiovascular Diseases, Maastricht UniversityMaastricht, Netherlands; Stehouwer, C.D.A., CARIM—School for Cardiovascular Diseases, Maastricht UniversityMaastricht, Netherlands; Unger, T., CARIM—School for Cardiovascular Diseases, Maastricht UniversityMaastricht, Netherlands","Diabetes is a common and rapidly growing disease that affects more than 380 million people worldwide and is an established risk factor for cardiovascular disease with differential effects on women compared to men. While the general population of women, particularly young women, has more favourable cardiovascular risk profiles than men, this protective effect has been shown to be lost or even reversed in diabetic women. Several studies have demonstrated a significant diabetes-associated excess risk of cardiovascular disease in women. Sex-specific differences in risk factors associated with diabetes and their management may be responsible for the relative excess cardiovascular risk in women with diabetes. Diabetic women need intensive treatment in order to optimize management of cardiovascular risk factors. Further studies are needed to elucidate the mechanisms underlying the excess cardiovascular risk in diabetic women in order to tailor prevention and treatment strategies. © 2015, The Author(s).","Cardiovascular risk; Diabetes; Sex differences; Women","Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2 · 7 million participants (2011) Lancet, 378 (9785), pp. 31-40. , COI: 1:CAS:528:DC%2BC3MXotlyltbo%3D, PID: 2170506; (2014) IDF Diabetes Atlas update poster, , http://www.idf.org/diabetesatlas, Brussels Belgium: International Diabetes Federatio; http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html, WHO Estimates for 2000–201http://www.idf.org/diabetesatlas, International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels Belgium: International Diabetes Federation, 2013. The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. The 6th Edition of the IDF Diabetes Atlas reports diabetes epidemiology using new studies that became available in 2013, and updated population estimateIncidence and trends of childhood type 1 diabetes worldwide 1990–1999 (2006) Diabet Med J Br Diabet Assoc, 23 (8), pp. 857-866; Soltesz, G., Patterson, C.C., Dahlquist, G., Worldwide childhood type 1 diabetes incidence—what can we learn from epidemiology? (2007) Pediatr Diabetes, 8, pp. 6-14. , PID: 1772738; Pundziute-Lyckå, A., Dahlquist, G., Nyström, L., Arnqvist, H., Björk, E., Blohmé, G., The incidence of Type I diabetes has not increased but shifted to a younger age at diagnosis in the 0–34 years group in Sweden 1983–1998 (2002) Diabetologia, 45 (6), pp. 783-791. , PID: 1210772; Gale, E.A., Gillespie, K.M., Diabetes and gender (2001) Diabetologia, 44 (1), pp. 3-15. , COI: 1:STN:280:DC%2BD3M7kvVChsg%3D%3D, PID: 1120640; Weets, I., De Leeuw, I.H., Du Caju, M.V.L., Rooman, R., Keymeulen, B., Mathieu, C., The incidence of type 1 diabetes in the age group 0–39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation (2002) Diabetes Care, 25 (5), pp. 840-846. , PID: 1197867; Kyvik, K.O., Nystrom, L., Gorus, F., Songini, M., Oestman, J., Castell, C., The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children (2004) Diabetologia, 47 (3), pp. 377-384. , COI: 1:STN:280:DC%2BD2c7mtVChtQ%3D%3D, PID: 1476265; Zimmet, P., Alberti, K.G., Shaw, J., Global and societal implications of the diabetes epidemic (2001) Nature, 414 (6865), pp. 782-787. , COI: 1:CAS:528:DC%2BD38Xhtlymtg%3D%3D, PID: 1174240; Roche, M.M., Wang, P.P., Sex differences in all-cause and cardiovascular mortality, hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late (2013) Diabetes Care, 36 (9), pp. 2582-2590. , PID: 2356492; Roglic, G., Unwin, N., Mortality attributable to diabetes: estimates for the year 2010 (2010) Diabetes Res Clin Pract, 87 (1), pp. 15-19. , PID: 1991472; Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H., Keen, H., Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes (2001) Diabetologia, 44, pp. S14-S21. , PID: 1158704; Taylor, K.S., Heneghan, C.J., Farmer, A.J., Fuller, A.M., Adler, A.I., Aronson, J.K., All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database (2013) Diabetes Care, 36 (8), pp. 2366-2371. , COI: 1:CAS:528:DC%2BC3sXhtlOrs7vI, PID: 2343515; Van Dieren, S., Beulens, J.W.J., van der Schouw, Y.T., Grobbee, D.E., Neal, B., The global burden of diabetes and its complications: an emerging pandemic (2010) Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol, 17, pp. S3-S8; Booth, G.L., Kapral, M.K., Fung, K., Tu, J.V., Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study (2006) Lancet, 368 (9529), pp. 29-36. , PID: 1681537; Kappert, K., Böhm, M., Schmieder, R., Schumacher, H., Teo, K., Yusuf, S., Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET) (2012) Circulation, 126 (8), pp. 934-941. , PID: 22829023, This study demonstrated that, in a cohorts of individuals at high cardiovascular risk, female have a lower risk for combined cardiovascular end points compared to male non-diabetic patients. However, diabetic women were shown to be at significantly greater risk of developing MI compared to diabetic me; Anand, S.S., Islam, S., Rosengren, A., Franzosi, M.G., Steyn, K., Yusufali, A.H., Risk factors for myocardial infarction in women and men: insights from the INTERHEART study (2008) Eur Heart J, 29 (7), pp. 932-940. , PID: 1833447; Huxley RR, Peters SAE, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015. This is a meta-analysis of data from 26 studies, including 214,114 individuals and 15,273 events (14,682 deaths). This study showed that the excess fatal cardiovascular risk in women with type 1 diabetes is twice as high compared with men with type 1 diabeteLee, W.L., Cheung, A.M., Cape, D., Zinman, B., Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies (2000) Diabetes Care, 23 (7), pp. 962-968. , COI: 1:STN:280:DC%2BD3M%2FhtlGnsg%3D%3D, PID: 1089584; Kanaya, A.M., Grady, D., Barrett-Connor, E., Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis (2002) Arch Intern Med, 162 (15), pp. 1737-1745. , PID: 1215337; Huxley, R., Barzi, F., Woodward, M., Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies (2006) BMJ, 332 (7533), pp. 73-78. , PID: 1637140; Peters, S.A.E., Huxley, R.R., Woodward, M., Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events (2014) Diabetologia, 57 (8), pp. 1542-1551. , PID: 24859435, This is a meta-analysis of data from 64 studies, including 858,507 individuals and 28,203 incident events of coronary heart disease. This study showed that the relative risk of incident coronary heart disease was 44% greater in diabetic women than in me; Banerjee, C., Moon, Y.P., Paik, M.C., Rundek, T., Mora-McLaughlin, C., Vieira, J.R., Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study (2012) Stroke J Cereb Circ, 43 (5), pp. 1212-1217; Hyvärinen, M., Tuomilehto, J., Laatikainen, T., Söderberg, S., Eliasson, M., Nilsson, P., The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender (2009) Cardiovasc Diabetol, 8, p. 17. , PID: 1931790; Doi, Y., Ninomiya, T., Hata, J., Fukuhara, M., Yonemoto, K., Iwase, M., Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study (2010) Stroke J Cereb Circ, 41 (2), pp. 203-209. , COI: 1:CAS:528:DC%2BC3cXps1Snsw%3D%3; Tanizaki, Y., Kiyohara, Y., Kato, I., Iwamoto, H., Nakayama, K., Shinohara, N., Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study (2000) Stroke J Cereb Circ, 31 (11), pp. 2616-2622. , COI: 1:STN:280:DC%2BD3crhtFGhsw%3D%3; Hu, G., Jousilahti, P., Qiao, Q., Katoh, S., Tuomilehto, J., Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction (2005) Diabetologia, 48 (5), pp. 856-861. , COI: 1:STN:280:DC%2BD2M3ltFaktw%3D%3D, PID: 1582774; Cui, R., Iso, H., Yamagishi, K., Saito, I., Kokubo, Y., Inoue, M., Diabetes mellitus and risk of stroke and its subtypes among Japanese: the Japan public health center study (2011) Stroke J Cereb Circ, 42 (9), pp. 2611-2614; Peters, S.A.E., Huxley, R.R., Woodward, M., Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes (2014) Lancet, 383 (9933), pp. 1973-1980. , PID: 2461302; Rautio, A., Eliasson, M., Stegmayr, B., Favorable trends in the incidence and outcome in stroke in nondiabetic and diabetic subjects: findings from the Northern Sweden MONICA Stroke Registry in 1985 to 2003 (2008) Stroke J Cereb Circ, 39 (12), pp. 3137-3144; Winell, K., Pääkkönen, R., Pietilä, A., Reunanen, A., Niemi, M., Salomaa, V., Prognosis of ischaemic stroke is improving similarly in patients with type 2 diabetes as in nondiabetic patients in Finland (2011) Int J Stroke Off J Int Stroke Soc, 6 (4), pp. 295-301; Venketasubramanian, N., Röther, J., Bhatt, D.L., Pasquet, B., Mas, J.-L., Alberts, M.J., Two-year vascular event rates in patients with symptomatic cerebrovascular disease: the REACH registry (2011) Cerebrovasc Dis Basel Switz, 32 (3), pp. 254-260; Eriksson, M., Carlberg, B., Eliasson, M., The disparity in long-term survival after a first stroke in patients with and without diabetes persists: the Northern Sweden MONICA study (2012) Cerebrovasc Dis Basel Switz, 34 (2), pp. 153-160; Mansfield, M.W., Heywood, D.M., Grant, P.J., Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus (1996) Arterioscler Thromb Vasc Biol, 16 (1), pp. 160-164. , COI: 1:STN:280:DyaK287ktVajtg%3D%3D, PID: 854841; Howard, B.V., Cowan, L.D., Go, O., Welty, T.K., Robbins, D.C., Lee, E.T., Adverse effects of diabetes on multiple cardiovascular disease risk factors in women (1998) The Strong Heart Study Diabetes Care, 21 (8), pp. 1258-1265. , COI: 1:STN:280:DyaK1czmslyjtQ%3D%3; Juutilainen, A., Kortelainen, S., Lehto, S., Rönnemaa, T., Pyörälä, K., Laakso, M., Gender difference in the impact of type 2 diabetes on coronary heart disease risk (2004) Diabetes Care, 27 (12), pp. 2898-2904. , PID: 1556220; Wannamethee, S.G., Papacosta, O., Lawlor, D.A., Whincup, P.H., Lowe, G.D., Ebrahim, S., Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study (2012) Diabetologia, 55 (1), pp. 80-87. , COI: 1:STN:280:DC%2BC38%2FktVOksg%3D%3D, PID: 2186117; Steinberg, H.O., Paradisi, G., Cronin, J., Crowde, K., Hempfling, A., Hook, G., Type II diabetes abrogates sex differences in endothelial function in premenopausal women (2000) Circulation, 101 (17), pp. 2040-2046. , COI: 1:STN:280:DC%2BD3c3ltlOrsw%3D%3D, PID: 1079034; Han, T.S., Sattar, N., Williams, K., Gonzalez-Villalpando, C., Lean, M.E.J., Haffner, S.M., Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study (2002) Diabetes Care, 25 (11), pp. 2016-2021. , COI: 1:CAS:528:DC%2BD38XovFKnsLc%3D, PID: 1240174; Kautzky-Willer, A., Kamyar, M.R., Gerhat, D., Handisurya, A., Stemer, G., Hudson, S., Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus (2010) Gend Med, 7 (6), pp. 571-583. , PID: 2119535; Gouni-Berthold, I., Berthold, H.K., Mantzoros, C.S., Böhm, M., Krone, W., Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes (2008) Diabetes Care, 31 (7), pp. 1389-1391. , PID: 1837541; Franch-Nadal, J., Mata-Cases, M., Vinagre, I., Patitucci, F., Hermosilla, E., Casellas, A., Differences in the cardiometabolic control in type 2 diabetes according to gender and the presence of cardiovascular disease: results from the eControl study (2014) Int J Endocrinol, 2014, p. 131709. , PID: 2532852; Franzini, L., Ardigò, D., Cavalot, F., Miccoli, R., Rivellese, A.A., Trovati, M., Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND.IT Study Group of the Italian Society of Diabetology (2013) Nutr Metab Cardiovasc Dis NMCD, 23 (3), pp. 235-241. , COI: 1:STN:280:DC%2BC38vlslKqsQ%3D%3; Penno, G., Solini, A., Bonora, E., Fondelli, C., Orsi, E., Zerbini, G., Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study (2013) J Intern Med, 274 (2), pp. 176-191. , COI: 1:CAS:528:DC%2BC3sXhtFWlu7nI, PID: 23565931, In the RIACE cohort, consisting of 15,773 consecutive Caucasian individuals with type 2 diabetes (2007–2008), the higher likelihood of failing treatment targets in women was not associated with treatment differences between the sexe; Ding, E.L., Song, Y., Malik, V.S., Liu, S., Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis (2006) JAMA, 295 (11), pp. 1288-1299. , COI: 1:CAS:528:DC%2BD28Xis1ShsLs%3D, PID: 1653773; Ding, E.L., Song, Y., Manson, J.E., Rifai, N., Buring, J.E., Liu, S., Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study (2007) Diabetologia, 50 (10), pp. 2076-2084. , COI: 1:CAS:528:DC%2BD2sXpvF2ls70%3D, PID: 1770115; Ding, E.L., Song, Y., Manson, J.E., Hunter, D.J., Lee, C.C., Rifai, N., Sex hormone-binding globulin and risk of type 2 diabetes in women and men (2009) N Engl J Med, 361 (12), pp. 1152-1163. , COI: 1:CAS:528:DC%2BD1MXhtFOjsLnO, PID: 1965711; Kalyani, R.R., Franco, M., Dobs, A.S., Ouyang, P., Vaidya, D., Bertoni, A., The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women (2009) J Clin Endocrinol Metab, 94 (11), pp. 4127-4135. , COI: 1:CAS:528:DC%2BD1MXhsVejtLjJ, PID: 1978920; Jayasena, C.N., Franks, S., The management of patients with polycystic ovary syndrome (2014) Nat Rev Endocrinol, 10 (10), pp. 624-636. , PID: 2502281; Gubbels Bupp, M.R., Sex, the aging immune system, and chronic disease (2015) Cell Immunol; Boukhris, M., Tomasello, S.D., Marzà, F., Bregante, S., Pluchinotta, F.R., Galassi, A.R., Coronary heart disease in postmenopausal women with type II diabetes mellitus and the impact of estrogen replacement therapy: a narrative review (2014) Int J Endocrinol, 2014, p. 413920. , PID: 2513636; Hu, F.B., Stampfer, M.J., Haffner, S.M., Solomon, C.G., Willett, W.C., Manson, J.E., Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes (2002) Diabetes Care, 25 (7), pp. 1129-1134. , PID: 1208700; Schram, M.T., Sep, S.J.S., van der Kallen, C.J., Dagnelie, P.C., Koster, A., Schaper, N., The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities (2014) Eur J Epidemiol, 29 (6), pp. 439-451. , PID: 2475637",Review,Scopus,2-s2.0-84928473692
"Kang S., Kang P., Ko T., Cho S., Rhee S.-J., Yu K.-S.","An efficient and effective ensemble of support vector machines for anti-diabetic drug failure prediction",2015,"Expert Systems with Applications","42","9",,"4265","4273",,,10.1016/j.eswa.2015.01.042,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923233733&partnerID=40&md5=4941a498dcd7737bb2f569198ddb6cf5","Department of Industrial Engineering, Seoul National University, 1 Gwanak-roGwanak-gu, Seoul, South Korea; School of Industrial Management Engineering, Korea University, 145 Anam-roSeongbuk-gu, Seoul, South Korea; Department of Clinical Pharmacology and Therapeutics, Seoul National University, College of Medicine and Hospital, 101 Daehak-roJongno-gu, Seoul, South Korea","Kang, S., Department of Industrial Engineering, Seoul National University, 1 Gwanak-roGwanak-gu, Seoul, South Korea; Kang, P., School of Industrial Management Engineering, Korea University, 145 Anam-roSeongbuk-gu, Seoul, South Korea; Ko, T., Department of Industrial Engineering, Seoul National University, 1 Gwanak-roGwanak-gu, Seoul, South Korea; Cho, S., Department of Industrial Engineering, Seoul National University, 1 Gwanak-roGwanak-gu, Seoul, South Korea; Rhee, S.-J., Department of Clinical Pharmacology and Therapeutics, Seoul National University, College of Medicine and Hospital, 101 Daehak-roJongno-gu, Seoul, South Korea; Yu, K.-S., Department of Clinical Pharmacology and Therapeutics, Seoul National University, College of Medicine and Hospital, 101 Daehak-roJongno-gu, Seoul, South Korea","The treatment of patients with type 2 diabetes is mostly based on drug therapies, aiming at managing glucose levels appropriately. As the number of patients with type 2 diabetes continually increases worldwide, predicting drug treatment failure becomes an important issue. Support vector machine (SVM) can be a good method for the anti-diabetic drug failure prediction problem; however, it is difficult to train SVM on large-scale medical datasets directly because of its high training time complexity O(N3). To address the limitation, we propose an efficient and effective ensemble of SVMs, called E3-SVM. The proposed method excludes superfluous data points when constructing an SVM ensemble, thereby yielding a better classification performance. The proposed method consists of two phases. The first phase is to select the data points that are likely to be the support vectors by applying data selection methods. The second phase is to construct an SVM ensemble using the selected data points. We demonstrated the efficiency and effectiveness of the proposed method using the real-world dataset of the anti-diabetic drug failure prediction problem for type 2 diabetes. Experimental results show that the proposed method requires less training time to achieve comparable success, compared to the conventional SVM ensembles. Moreover, the proposed method obtains more reliable prediction results for each independent run of constructing an ensemble. In conclusion, firstly, the proposed method provides an efficient and effective way to use SVM for large-scale datasets. Secondly, we confirmed the suitability of SVM for the anti-diabetic drug failure prediction problem with an accuracy of about 80%. © 2015 Elsevier Ltd. All rights reserved.","Data selection; Drug failure prediction; Ensemble; Support vector machines; Type 2 diabetes","Standards of medical care in diabetes-2014 (2014) Diabetes Care, 37, pp. S14-S80. , http://dx.doi.org/, American Diabetes Association; Barakat, N., Bradley, A.P., Barakat, M.N.H., Intelligible support vector machines for diagnosis of diabetes mellitus (2010) IEEE Transactions on Information Technology in Biomedicine, 14, pp. 1114-1120; Bennett, C.M., Guo, M., Dharmage, S.C., HbA1c as a screening tool for detection of type 2 diabetes: A systematic review (2007) Diabetic Medicine, 24, pp. 333-343; Breiman, L., Bagging predictors (1996) Machine Learning, 24, pp. 123-140; Brown, J.B., Nichols, G.A., Perry, A., The burden of treatment failure in type 2 diabetes (2004) Diabetes Care, 27, pp. 1535-1540; Burges, C.J.C., A tutorial on support vector machines for pattern recognition (1998) Data Mining and Knowledge Discovery, 2, pp. 121-167; Chang, C.-C., Lin, C.-J., LIBSVM: A library for support vector machines (2011) ACM Transactions on Intelligent Systems and Technology, 2, pp. 271-2727. , http://www.csie.ntu.edu.tw/cjlin/libsvm, Software available at; Fan, R.-E., Chen, P.-H., Lin, C.-J., Working set selection using second order information for training support vector machines (2005) The Journal of Machine Learning Research, 6, pp. 1889-1918; Freund, Y., Schapire, R.E., A decision-theoretic generalization of on-line learning and an application to boosting (1997) Journal of Computer and System Sciences, 55, pp. 119-139; Hu, Y.-H., Wu, F., Lo, C.-L., Tai, C.-T., Predicting warfarin dosage from clinical data: A supervised learning approach (2012) Artificial Intelligence in Medicine, 56, pp. 27-34; Huang, Y., McCullagh, P., Black, N., Harper, R., Feature selection and classification model construction on type 2 diabetic patients data (2007) Artificial Intelligence in Medicine, 41, pp. 251-262; Joachims, T., Making large-scale support vector machine learning practical (1999) Advances in Kernel Methods: Support Vector Learning, pp. 169-184. , B. Schölkopf, C.J.C. Burges, A.J. Smola, MIT Press Cambridge, MA, USA; Kang, S., Cho, S., Approximating support vector machine with artificial neural network for fast prediction (2014) Expert Systems with Applications, 41, pp. 4989-4995; Kim, H.-C., Pang, S., Je, H.-M., Kim, D., Bang, S.Y., Constructing support vector machine ensemble (2003) Pattern Recognition, 36, pp. 2757-2767; Li, Y., Maguire, L., Selecting critical patterns based on local geometrical and statistical information (2011) IEEE Transactions on Pattern Analysis and Machine Intelligence, 33, pp. 1189-1201; Lu, Z.X., Walker, K.Z., O'Dea, K., Sikaris, K.A., Shaw, J.E., A1C for screening and diagnosis of type 2 diabetes in routine clinical practice (2010) Diabetes Care, 33, pp. 817-819; Marinov, M., Mosa, A.S.M., Yoo, I., Boren, S.A., Data-mining technologies for diabetes: A systematic review (2011) Journal of Diabetes Science and Technology, 5, pp. 1549-1556; Platt, J.C., Fast training of support vector machines using sequential minimal optimization (1999) Advances in Kernel Methods: Support Vector Learning, pp. 185-208. , B. Schölkopf, C.J.C. Burges, A.J. Smola, MIT Press Cambridge, MA, USA; Rokach, L., Ensemble-based classifiers (2010) Artificial Intelligence Review, 33, pp. 1-39; Sajda, P., Machine learning for detection and diagnosis of disease (2006) Annual Review of Biomedical Engineering, 8, pp. 537-565; Schapire, R.E., Singer, Y., Improved boosting algorithms using confidence-rated predictions (1999) Machine Learning, 37, pp. 297-336; Shin, H., Cho, S., Neighborhood property-based pattern selection for support vector machines (2007) Neural Computation, 19, pp. 816-855; Vapnik, V.N., (1995) The Nature of Statistical Learning Theory, , Springer New York; Wang, S.-J., Mathew, A., Chen, Y., Feng Xi, L., Ma, L., Lee, J., Empirical analysis of support vector machine ensemble classifiers (2009) Expert Systems with Applications, 36, pp. 6466-6476; Yki-Järvinen, H., Combination therapies with insulin in type 2 diabetes (2001) Diabetes Care, 24, pp. 758-767; Yu, W., Liu, T., Valdez, R., Gwinn, M., Khoury, M., Application of support vector machine modeling for prediction of common diseases: The case of diabetes and pre-diabetes (2010) BMC Medical Informatics and Decision Making, 10, p. 16; Zeng, T., Liu, J., Mixture classification model based on clinical markers for breast cancer prognosis (2010) Artificial Intelligence in Medicine, 48, pp. 129-137",Article,Scopus,2-s2.0-84923233733
"Khurana M., Vaidyanathan J., Marathe A., Mehrotra N., Sahajwalla C.G., Zineh I., Jain L.","Canagliflozin use in patients with renal impairment - Utility of quantitative clinical pharmacology analyses in dose optimization",2015,"Journal of Clinical Pharmacology","55","6",,"647","656",,,10.1002/jcph.466,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928891886&partnerID=40&md5=a37a181c275c10ea59cdc949de36f467","Office of Clinical Pharmacology, Off. of Translational Sci., Ctr. for Drug Eval. and Research, US Food and Drug Administration MDSilver Spring, United States","Khurana, M., Office of Clinical Pharmacology, Off. of Translational Sci., Ctr. for Drug Eval. and Research, US Food and Drug Administration MDSilver Spring, United States; Vaidyanathan, J., Office of Clinical Pharmacology, Off. of Translational Sci., Ctr. for Drug Eval. and Research, US Food and Drug Administration MDSilver Spring, United States; Marathe, A., Office of Clinical Pharmacology, Off. of Translational Sci., Ctr. for Drug Eval. and Research, US Food and Drug Administration MDSilver Spring, United States; Mehrotra, N., Office of Clinical Pharmacology, Off. of Translational Sci., Ctr. for Drug Eval. and Research, US Food and Drug Administration MDSilver Spring, United States; Sahajwalla, C.G., Office of Clinical Pharmacology, Off. of Translational Sci., Ctr. for Drug Eval. and Research, US Food and Drug Administration MDSilver Spring, United States; Zineh, I., Office of Clinical Pharmacology, Off. of Translational Sci., Ctr. for Drug Eval. and Research, US Food and Drug Administration MDSilver Spring, United States; Jain, L., Office of Clinical Pharmacology, Off. of Translational Sci., Ctr. for Drug Eval. and Research, US Food and Drug Administration MDSilver Spring, United States","Canagliflozin (INVOKANA™) is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). Canagliflozin inhibits renal sodium-glucose co-transporter 2 (SGLT2), thereby, reducing reabsorption of filtered glucose and increasing urinary glucose excretion. Given the mechanism of action of SGLT2 inhibitors, we assessed the interplay between renal function, efficacy (HbA1c reduction), and safety (renal adverse reactions). The focus of this article is to highlight the FDA's quantitative clinical pharmacology analyses that were conducted to support the regulatory decision on dosing in patients with renal impairment (RI). The metrics for assessment of efficacy for T2DM drugs is standard; however, there is no standard method for evaluation of renal effects for diabetes drugs. Therefore, several analyses were conducted to assess the impact of canagliflozin on renal function (as measured by eGFR) based on available data. These analyses provided support for approval of canagliflozin in T2DM patients with baseline eGFR ≥ 45 mL/min/1.73 m2, highlighting a data-driven approach to dose optimization. The availability of a relatively rich safety dataset (ie, frequent and early measurements of laboratory markers) in the canagliflozin clinical development program enabled adequate assessment of benefit-risk balance in various patient subgroups based on renal function. © 2015, The American College of Clinical Pharmacology.","canagliflozin; diabetes; regulatory; renal impairment; SGLT2","http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdf, Invokana® (NDA 204042)http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000SumR.pdf, Invokana® (NDA 204042)Neumiller, J.J., White, Jr.J.R., Campbell, R.K., Sodium-glucose co-transport inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus (2010) Drugs, 70 (4), pp. 377-385; (2010) Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing and Labeling March; http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf, Invokana® (NDA 204042)http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000TOC.cfm, Invokana® (NDA 204042)K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification (2002) Am J Kidney Dis, 39 (2), pp. S1-S266. , National Kidney Foundation.:",Article,Scopus,2-s2.0-84928891886
"Rodriguez A.R., Plascencia-Villa G., Witt C.M., Yu J.-J., Jose-Yacaman M., Chambers J.P., Perry G., Guentzel M.N., Arulanandam B.P.","Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells",2015,"Cellular Immunology","295","2",,"83","91",,,10.1016/j.cellimm.2015.03.010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926473483&partnerID=40&md5=5b39dab567bf0860ca944a067c9c164f","RCMI Biophotonics Core, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; RCMI Nanotechnology and Human Health Core, Department of Physics, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; South Texas Center for Emerging Infectious Diseases, Department of Biology, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; Department of Physics, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; UTSA Neurosciences Institute, Department of Biology, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States","Rodriguez, A.R., RCMI Biophotonics Core, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; Plascencia-Villa, G., RCMI Nanotechnology and Human Health Core, Department of Physics, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; Witt, C.M., RCMI Biophotonics Core, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; Yu, J.-J., South Texas Center for Emerging Infectious Diseases, Department of Biology, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; José-Yacamán, M., Department of Physics, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; Chambers, J.P., South Texas Center for Emerging Infectious Diseases, Department of Biology, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; Perry, G., UTSA Neurosciences Institute, Department of Biology, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; Guentzel, M.N., South Texas Center for Emerging Infectious Diseases, Department of Biology, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States; Arulanandam, B.P., South Texas Center for Emerging Infectious Diseases, Department of Biology, University of Texas at San Antonio, One UTSA CircleSan Antonio, TX, United States","The human pathogen Chlamydia pneumoniae has been implicated in chronic inflammatory diseases including type 2 diabetes. Therefore, we designed a study to evaluate pancreatic beta cells and mast cells during chlamydial infection. Our study revealed that C. pneumoniae infected mast cells significantly (p < 0.005) decreased beta cell ATP and insulin production, in contrast to uninfected mast cells co-cultured with beta cells. Infected mast cells exhibited pyknotic nuclei and active caspase-3 and caspase-1 expression. Additionally, ex vivo analyses of tissues collected from C. pneumoniae infected mice showed increased interleukin-1β production in splenocytes and pancreatic tissues as was observed with in vitro mast cell-beta cell co-cultures during C. pneumoniae infection. Notably, infected mast cells promoted beta cell destruction. Our findings reveal the negative effect of C. pneumoniae on mast cells, and the consequential impact on pancreatic beta cell function and viability. © 2015 Elsevier Inc.","Beta cells; Insulin; Mast cells; Obesity; Type 2 diabetes","Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 (2012) JAMA, 307, pp. 491-497; Hasson, R.E., Adam, T.C., Pearson, J., Davis, J.N., Spruijt-Metz, D., Goran, M.I., Sociocultural and socioeconomic influences on type 2 diabetes risk in overweight/obese African-American and Latino-American children and adolescents (2013) J. Obesity, 2013, p. 512914; Palaniappan, L.P., Carnethon, M.R., Fortmann, S.P., Heterogeneity in the relationship between ethnicity, BMI, and fasting insulin (2002) Diabetes Care, 25, pp. 1351-1357; Zhang, Q., Wang, Y., Huang, E.S., Changes in racial/ethnic disparities in the prevalence of type 2 diabetes by obesity level among US adults (2009) Ethn. Health, 14, pp. 439-457; Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease (2011) Nat. Rev. Immunol., 11, pp. 98-107; Gross, O., Thomas, C.J., Guarda, G., Tschopp, J., The inflammasome: an integrated view (2011) Immunol. Rev., 243, pp. 136-151; Dufort, F.J., Bleiman, B.F., Gumina, M.R., Blair, D., Wagner, D.J., Roberts, M.F., Abu-Amer, Y., Chiles, T.C., Cutting edge: IL-4-mediated protection of primary B lymphocytes from apoptosis via Stat6-dependent regulation of glycolytic metabolism (2007) J. Immunol., 179, pp. 4953-4957; Lawrence, J.C., Piper, R.C., Robinson, L.J., James, D.E., GLUT4 facilitates insulin stimulation and cAMP-mediated inhibition of glucose transport (1992) Proc. Natl. Acad. Sci. U.S.A., 89, pp. 3493-3497; Rodriguez, A.R., Yu, J.J., Murthy, A.K., Guentzel, M.N., Klose, K.E., Forsthuber, T.G., Chambers, J.P., Arulanandam, B.P., Mast cell/IL-4 control of Francisella tularensis replication and host cell death is associated with increased ATP production and phagosomal acidification (2011) Mucosal Immunol., 4, pp. 217-226; Ashcroft, F.M., Harrison, D.E., Ashcroft, S.J., Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells (1984) Nature, 312, pp. 446-448; Cook, D.L., Hales, C.N., Intracellular ATP directly blocks K+ channels in pancreatic B-cells (1984) Nature, 311, pp. 271-273; Reynolds, D.S., Stevens, R.L., Lane, W.S., Carr, M.H., Austen, K.F., Serafin, W.E., Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases (1990) Proc. Natl. Acad. Sci. U.S.A., 87, pp. 3230-3234; Ishizuka, T., Terada, N., Gerwins, P., Hamelmann, E., Oshiba, A., Fanger, G.R., Johnson, G.L., Gelfand, E.W., Mast cell tumor necrosis factor alpha production is regulated by MEK kinases (1997) Proc. Natl. Acad. Sci. U.S.A., 94, pp. 6358-6363; Malaviya, R., Jakschik, B.A., Control of mast-cell 5-lipoxygenase (1997) Am. J. Ther., 4, pp. 225-228; Galli, S.J., Kalesnikoff, J., Grimbaldeston, M.A., Piliponsky, A.M., Williams, C.M., Tsai, M., Mast cells as ""tunable"" effector and immunoregulatory cells: recent advances (2005) Annu. Rev. Immunol., 23, pp. 749-786; Ketavarapu, J.M., Rodriguez, A.R., Yu, J.J., Cong, Y., Murthy, A.K., Forsthuber, T.G., Guentzel, M.N., Arulanandam, B.P., Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4 (2008) Proc. Natl. Acad. Sci. U.S.A., 105, pp. 9313-9318; Rodriguez, A.R., Yu, J.J., Guentzel, M.N., Navara, C.S., Klose, K.E., Forsthuber, T.G., Chambers, J.P., Arulanandam, B.P., Mast cell TLR2 signaling is crucial for effective killing of Francisella tularensis (2012) J. Immunol., 188, pp. 5604-5611; Malaviya, R., Ross, E.A., MacGregor, J.I., Ikeda, T., Little, J.R., Jakschik, B.A., Abraham, S.N., Mast cell phagocytosis of FimH-expressing enterobacteria (1994) J. Immunol., 152, pp. 1907-1914; Sher, A., Hein, A., Moser, G., Caulfield, J.P., Complement receptors promote the phagocytosis of bacteria by rat peritoneal mast cells (1979) Lab. Invest., 41, pp. 490-499; Ehses, J.A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J.A., Maor-Cahn, R., Gueripel, X., Donath, M.Y., Increased number of islet-associated macrophages in type 2 diabetes (2007) Diabetes, 56, pp. 2356-2370; Kaartinen, M., Penttila, A., Kovanen, P.T., Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas (1994) Arterioscler. Thromb., 14, pp. 966-972; Grayston, J.T., Kuo, C.C., Coulson, A.S., Campbell, L.A., Lawrence, R.D., Lee, M.J., Strandness, E.D., Wang, S.P., Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery (1995) Circulation, 92, pp. 3397-3400; Kuo, C.C., Grayston, J.T., Campbell, L.A., Goo, Y.A., Wissler, R.W., Benditt, E.P., Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34years old) (1995) Proc. Natl. Acad. Sci. U.S.A., 92, pp. 6911-6914; Knaack, D., Fiore, D.M., Surana, M., Leiser, M., Laurance, M., Fusco-DeMane, D., Hegre, O.D., Efrat, S., Clonal insulinoma cell line that stably maintains correct glucose responsiveness (1994) Diabetes, 43, pp. 1413-1417; Chen, Y.L., Wolin, M.S., Messina, E.J., Evidence for cGMP mediation of skeletal muscle arteriolar dilation to lactate (1985) J. Appl. Physiol., 81 (1996), pp. 349-354; Hummel, K.P., Dickie, M.M., Coleman, D.L., Diabetes, a new mutation in the mouse (1966) Science, 153, pp. 1127-1128; Clement, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., Gourmelen, M., Guy-Grand, B., A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction (1998) Nature, 392, pp. 398-401; Li, W., Guentzel, M.N., Seshu, J., Zhong, G., Murthy, A.K., Arulanandam, B.P., Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach (2007) Clin. Vaccine Immunol., 14, pp. 1537-1544; Bobryshev, Y.V., Cao, W., Phoon, M.C., Tran, D., Chow, V.T., Lord, R.S., Lu, J., Detection of Chlamydophila pneumoniae in dendritic cells in atherosclerotic lesions (2004) Atherosclerosis, 173, pp. 185-195; Cirino, F., Webley, W.C., West, C., Croteau, N.L., Andrzejewski, C., Stuart, E.S., Detection of Chlamydia in the peripheral blood cells of normal donors using in vitro culture, immunofluorescence microscopy and flow cytometry techniques (2006) BMC Infect. Dis., 6, p. 23; Kintscher, U., Hartge, M., Hess, K., Foryst-Ludwig, A., Clemenz, M., Wabitsch, M., Fischer-Posovszky, P., Marx, N., T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance (2008) Arterioscler. Thromb. Vasc. Biol., 28, pp. 1304-1310; Banaee, T., Daneshvar Kakhki, R., Abrishami, M., Mahmoudi, M., Farzadnia, M., Higher titers of anti-Chlamydia pneumoniae IgG in diabetic retinopathy: a cross-sectional study (2014) Diabetes Metab. Res. Rev., , (n/a-n/a); Miklossy, J., Martins, R., Darbinian, N., Khalili, K., McGee, P.L., Type 2 diabetes: local inflammation and direct effect of bacterial toxic components (2008) Open Pathol. J., 2, pp. 86-95; Arkhammar, P., Nilsson, T., Rorsman, P., Berggren, P.O., Inhibition of ATP-regulated K+ channels precedes depolarization-induced increase in cytoplasmic free Ca2+ concentration in pancreatic beta-cells (1987) J. Biol. Chem., 262, pp. 5448-5454; Khan, F.A., Goforth, P.B., Zhang, M., Satin, L.S., Insulin activates ATP-sensitive K(+) channels in pancreatic beta-cells through a phosphatidylinositol 3-kinase-dependent pathway (2001) Diabetes, 50, pp. 2192-2198; Petit, P., Manteghetti, M., Puech, R., Loubatieres-Mariani, M.M., ATP and phosphate-modified adenine nucleotide analogues. Effects on insulin secretion and calcium uptake (1987) Biochem. Pharmacol., 36, pp. 377-380; Smith, P.A., Ashcroft, F.M., Rorsman, P., Simultaneous recordings of glucose dependent electrical activity and ATP-regulated K(+)-currents in isolated mouse pancreatic beta-cells (1990) FEBS Lett., 261, pp. 187-190; Wang, C., Chen, Z., Li, S., Zhang, Y., Jia, S., Li, J., Chi, Y., Yang, J., Hepatic overexpression of ATP synthase beta subunit activates PI3K/Akt pathway to ameliorate hyperglycemia of diabetic mice (2014) Diabetes, 63, pp. 947-959; Shimada, K., Crother, T.R., Karlin, J., Chen, S., Chiba, N., Ramanujan, V.K., Vergnes, L., Arditi, M., Caspase-1 dependent IL-1beta secretion is critical for host defense in a mouse model of Chlamydia pneumoniae lung infection (2011) PLoS ONE, 6, p. e21477; Cnop, M., Welsh, N., Jonas, J.C., Jorns, A., Lenzen, S., Eizirik, D.L., Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities (2005) Diabetes, 54, pp. S97-S107; Schroder, K., Tschopp, J., The inflammasomes (2010) Cell, 140, pp. 821-832; Ojcius, D.M., Degani, H., Mispelter, J., Dautry-Varsat, A., Enhancement of ATP levels and glucose metabolism during an infection by Chlamydia. NMR studies of living cells (1998) J. Biol. Chem., 273, pp. 7052-7058; Yaraei, K., Campbell, L.A., Zhu, X., Liles, W.C., Kuo, C.C., Rosenfeld, M.E., Effect of Chlamydia pneumoniae on cellular ATP content in mouse macrophages: role of Toll-like receptor 2 (2005) Infect. Immun., 73, pp. 4323-4326; Orme, M.H., Alrubaie, S., Bradley, G.L., Walker, C.D., Leevers, S.J., Input from Ras is required for maximal PI(3)K signalling in Drosophila (2006) Nat. Cell Biol., 8, pp. 1298-1302; Ribatti, D., Crivellato, E., Mast cells, angiogenesis, and tumour growth (1822) Biochim. Biophys. Acta, 2012, pp. 2-8; Park, Y., Park, S., Yoo, E., Kim, D., Shin, H., Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility (2004) Ann. N. Y. Acad. Sci., 1037, pp. 170-174; Ururahy, M.A., Loureiro, M.B., Freire-Neto, F.P., de Souza, K.S., Zuhl, I., Brandao-Neto, J., Hirata, R.D., de Rezende, A.A., Increased TLR2 expression in patients with type 1 diabetes: evidenced risk of microalbuminuria (2012) Pediatr. Diabetes, 13, pp. 147-154; Chen, C., Chai, H., Wang, X., Lin, P.H., Yao, Q., Chlamydia heat shock protein 60 decreases expression of endothelial nitric oxide synthase in human and porcine coronary artery endothelial cells (2009) Cardiovasc. Res., 83, pp. 768-777; Costa, C.P., Kirschning, C.J., Busch, D., Durr, S., Jennen, L., Heinzmann, U., Prebeck, S., Miethke, T., Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae (2002) Eur. J. Immunol., 32, pp. 2460-2470; Cohen, T.S., Prince, A.S., Activation of inflammasome signaling mediates pathology of acute P. aeruginosa pneumonia (2013) J. Clin. Invest., 123, pp. 1630-1637; Okusawa, S., Yancey, K.B., van der Meer, J.W., Endres, S., Lonnemann, G., Hefter, K., Frank, M.M., Gelfand, J.A., C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha (1988) J. Exp. Med., 168, pp. 443-448",Article,Scopus,2-s2.0-84926473483
"Harada N., Katsuki T., Takahashi Y., Masuda T., Yoshinaga M., Adachi T., Izawa T., Kuwamura M., Nakano Y., Yamaji R., Inui H.","Androgen receptor silences thioredoxin-interacting protein and competitively inhibits glucocorticoid receptor-mediated apoptosis in pancreatic β-cells",2015,"Journal of Cellular Biochemistry","116","6",,"998","1006",,,10.1002/jcb.25054,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926658128&partnerID=40&md5=1a56ed3a87299f479f40eb6272c58cba","Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-choNaka-ku, Sakai, Osaka, Japan; Department of Nutrition, Shigakkan UniversityAichi, Ohbu, Japan; Laboratory of Food and Health Sciences, Minatogawa CollegeHyogo, Sanda, Japan; Division of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture UniversityOsaka, Izumisano, Japan; Osaka Women's Junior CollegeFujiidera, Osaka, Japan","Harada, N., Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-choNaka-ku, Sakai, Osaka, Japan; Katsuki, T., Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-choNaka-ku, Sakai, Osaka, Japan; Takahashi, Y., Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-choNaka-ku, Sakai, Osaka, Japan; Masuda, T., Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-choNaka-ku, Sakai, Osaka, Japan; Yoshinaga, M., Department of Nutrition, Shigakkan UniversityAichi, Ohbu, Japan; Adachi, T., Laboratory of Food and Health Sciences, Minatogawa CollegeHyogo, Sanda, Japan; Izawa, T., Division of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture UniversityOsaka, Izumisano, Japan; Kuwamura, M., Division of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture UniversityOsaka, Izumisano, Japan; Nakano, Y., Osaka Women's Junior CollegeFujiidera, Osaka, Japan; Yamaji, R., Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-choNaka-ku, Sakai, Osaka, Japan; Inui, H., Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-choNaka-ku, Sakai, Osaka, Japan","Androgen receptor (AR) is known to bind to the same cis-element that glucocorticoid receptor (GR) binds to. However, the effects of androgen signaling on glucocorticoid signaling have not yet been elucidated. Here, we investigated the effects of testosterone on dexamethasone (DEX, a synthetic glucocorticoid)-induced apoptosis of pancreatic β-cells, which might be involved in the pathogenesis of type 2 diabetes mellitus in males. We used INS-1 #6 cells, which were isolated from the INS-1 pancreatic β-cell line and which express high levels of AR. Testosterone and dihydrotestosterone inhibited apoptosis induced by DEX in INS-1 #6 cells. AR knockdown and the AR antagonist hydroxyflutamide each diminished the anti-apoptotic effects of testosterone. AR was localized in the nucleus of both INS-1 #6 cells and pancreatic β-cells of male rats. Induction of thioredoxin-interacting protein (TXNIP) is known to cause pro-apoptotic effects in β-cells. Testosterone suppressed the DEX-induced increase of TXNIP at the transcriptional level. A Chromatin immunoprecipitation assays showed that both AR and GR competitively bound to the TXNIP promoter in ligand-dependent manners. Recombinant DNA-binding domain of AR bound to the same cis-element of the TXNIP promoter that GR binds to. Our results show that AR and GR competitively bind to the same cis-element of TXNIP promoter as a silencer and enhancer, respectively. These results indicate that androgen signaling functionally competes with glucocorticoid signaling in pancreatic β-cell apoptosis. J. Cell. Biochem. 116: 998-1006, 2015. © 2015 Wiley Periodicals, Inc.","ANDROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; PANCREATIC β-CELLS; SILENCER; THIOREDOXIN-INTERACTING PROTEIN; TYPE 2 DIABETES MELLITUS","Ackermann, A.M., Gannon, M., Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion (2007) J Mol Endocrinol, 38, pp. 193-206; Arora, V.K., Schenkein, E., Murali, R., Subudhi, S.K., Wongvipat, J., Balbas, M.D., Shah, N., Sawyers, C.L., Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade (2013) Cell, 155, pp. 1309-1322; Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P.A., Wollheim, C.B., Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines (1992) Endocrinology, 130, pp. 167-178; Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A., Butler, P.C., Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes (2003) Diabetes, 52, pp. 102-110; Chang, C., Yeh, S., Lee, S.O., Chang, T.-M., Androgen receptor (AR) pathophysiological roles in androgen related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: Lessons learned from mice lacking AR in specific cells (2013) Nucl Recept Signal, 11, p. e001; Chen, S., Wang, J., Yu, G., Liu, W., Pearce, D., Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity (1997) J Biol Chem, 272, pp. 14087-14092; Chen, J., Hui, S.T., Couto, F.M., Mungrue, I.N., Davis, D.B., Attie, A.D., Lusis, A.J., Shalev, A., Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes (2008) FASEB J, 22, pp. 3581-3594; Cheng, S., Brzostek, S., Lee, S.R., Hollenberg, A.N., Balk, S.P., Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor (2002) Mol Endocrinol, 16, pp. 1492-1501; Claessens, F., Verrijdt, G., Schoenmakers, E., Haelens, A., Peeters, B., Verhoeven, G., Rombauts, W., Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation (2001) J Steroid Biochem Mol Biol, 76, pp. 23-30; De Gendt, K., Verhoeven, G., Tissue- and cell-specific functions of the androgen receptor revealed through conditional knockout models in mice (2012) Mol Cell Endocrinol, 352, pp. 13-25; Ding, E.L., Song, Y., Malik, V.S., Liu, S., Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis (2006) JAMA, 295, pp. 1288-1299; Hanchang, W., Semprasert, N., Limjindaporn, T., Yenchitsomanus, P.T., Kooptiwut, S., Testosterone protects against glucotoxicity-induced apoptosis of pancreatic beta-cells (INS-1) and male mouse pancreatic islets (2013) Endocrinology, 154, pp. 4058-4067; Harada, N., Yasunaga, R., Higashimura, Y., Yamaji, R., Fujimoto, K., Moss, J., Inui, H., Nakano, Y., Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells (2007) J Biol Chem, 282, pp. 22651-22661; Harada, N., Atarashi, K., Murata, Y., Yamaji, R., Nakano, Y., Inui, H., Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: Implication of DNA binding and acetylation of the receptor (2011) J Steroid Biochem Mol Biol, 123, pp. 65-70; Harada, N., Inoue, K., Yamaji, R., Nakano, Y., Inui, H., Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells (2012) Cancer Sci, 103, pp. 1022-1027; Heemers, H.V., Tindall, D.J., Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex (2007) Endocr Rev, 28, pp. 778-808; Hohmeier, H.E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., Newgard, C.B., Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion (2000) Diabetes, 49, pp. 424-430; Horiuchi, H., Harada, N., Adachi, T., Nakano, Y., Inui, H., Yamaji, R., S-Equol enantioselectively activates cAMP-protein kinase A signaling and reduces alloxan-induced cell death in INS-1 pancreatic beta-cells (2014) J Nutr Sci Vitaminol (Tokyo), 60, pp. 291-296; Keating, N.L., O'malley, A.J., Smith, M.R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer (2006) J Clin Oncol, 24, pp. 4448-4456; Kibbe, C., Chen, J., Xu, G., Jing, G., Shalev, A., FOXO1 competes with carbohydrate response element-binding protein (ChREBP) and inhibits thioredoxin-interacting protein (TXNIP) transcription in pancreatic beta cells (2013) J Biol Chem, 288, pp. 23194-23202; Lamb, D.J., Weigel, N.L., Marcelli, M., Androgen receptors and their biology (2001) Vitam Horm, 62, pp. 199-230; Merglen, A., Theander, S., Rubi, B., Chaffard, G., Wollheim, C.B., Maechler, P., Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells (2004) Endocrinology, 145, pp. 667-678; Mitani, T., Harada, N., Nakano, Y., Inui, H., Yamaji, R., Coordinated action of hypoxia-inducible factor-1alpha and beta-catenin in androgen receptor signaling (2012) J Biol Chem, 287, pp. 33594-33606; Morimoto, S., Fernandez-Mejia, C., Romero-Navarro, G., Morales-Peza, N., Diaz-Sanchez, V., Testosterone effect on insulin content, messenger ribonucleic acid levels, promoter activity, and secretion in the rat (2001) Endocrinology, 142, pp. 1442-1447; Morimoto, S., Mendoza-Rodriguez, C.A., Hiriart, M., Larrieta, M.E., Vital, P., Cerbon, M.A., Protective effect of testosterone on early apoptotic damage induced by streptozotocin in rat pancreas (2005) J Endocrinol, 187, pp. 217-224; Nazareth, L.V., Stenoien, D.L., Bingman, W.E., III, James, A.J., Wu, C., Zhang, Y., Edwards, D.P., Weigel, N.L., A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) (1999) Mol Endocrinol, 13, pp. 2065-2075; Olsen, N.J., Kovacs, W.J., Effects of androgens on T and B lymphocyte development (2001) Immunol Res, 23, pp. 281-288; Park, S.Y., Kwack, M.H., Chung, E.J., Im, S.U., Han, I.S., Kim, M.K., Kim, J.C., Sung, Y.K., Establishment of SV40T-transformed human dermal papilla cells and identification of dihydrotestosterone-regulated genes by cDNA microarray (2007) J Dermatol Sci, 47, pp. 201-208; Prescott, J., Jariwala, U., Jia, L., Cogan, J.P., Barski, A., Pregizer, S., Shen, H.C., Coetzee, G.A., Androgen receptor-mediated repression of novel target genes (2007) Prostate, 67, pp. 1371-1383; Qin, W., Pan, J., Wu, Y., Bauman, W.A., Cardozo, C., Protection against dexamethasone-induced muscle atrophy is related to modulation by testosterone of FOXO1 and PGC-1alpha (2010) Biochem Biophys Res Commun, 403, pp. 473-478; Reich, E., Tamary, A., Sionov, R.V., Melloul, D., Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death (2012) Diabetologia, 55, pp. 1048-1057; Saltiel, A.R., Kahn, C.R., Insulin signalling and the regulation of glucose and lipid metabolism (2001) Nature, 414, pp. 799-806; Shaked, M., Ketzinel-Gilad, M., Ariav, Y., Cerasi, E., Kaiser, N., Leibowitz, G., Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets (2009) Diabetologia, 52, pp. 636-644; Shalev, A., Lack of TXNIP protects beta-cells against glucotoxicity (2008) Biochem Soc Trans, 36, pp. 963-965; Velasco, A.M., Gillis, K.A., Li, Y., Brown, E.L., Sadler, T.M., Achilleos, M., Greenberger, L.M., Zhang, Y., Identification and validation of novel androgen-regulated genes in prostate cancer (2004) Endocrinology, 145, pp. 3913-3924; Wang, Z., Rong, Y.P., Malone, M.H., Davis, M.C., Zhong, F., Distelhorst, C.W., Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis (2006) Oncogene, 25, pp. 1903-1913; Xia, F., Xu, X., Zhai, H., Meng, Y., Zhang, H., Du, S., Xu, H., Lu, Y., Castration-induced testosterone deficiency increases fasting glucose associated with hepatic and extra-hepatic insulin resistance in adult male rats (2013) Reprod Biol Endocrinol, 11, p. 106; Yamaji, R., Fujita, K., Takahashi, S., Yoneda, H., Nagao, K., Masuda, W., Naito, M., Nakano, Y., Hypoxia up-regulates glyceraldehyde-3-phosphate dehydrogenase in mouse brain capillary endothelial cells: Involvement of Na + /Ca2+ exchanger (2003) Biochim Biophys Acta, 1593, pp. 269-276; Yen, P.M., Liu, Y., Palvimo, J.J., Trifiro, M., Whang, J., Pinsky, L., Janne, O.A., Chin, W.W., Mutant and wild-type androgen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription (1997) Mol Endocrinol, 11, pp. 162-171; Zhao, J., Bauman, W.A., Huang, R., Caplan, A.J., Cardozo, C., Oxandrolone blocks glucocorticoid signaling in an androgen receptor-dependent manner (2004) Steroids, 69, pp. 357-366; Zhou, X., Roles of androgen receptor in male and female reproduction: Lessons from global and cell-specific androgen receptor knockout (ARKO) mice (2010) J Androl, 31, pp. 235-243",Article,Scopus,2-s2.0-84926658128
"Mackey R.H., McTigue K.M., Chang Y.F., Barinas-Mitchell E., Evans R.W., Tinker L.F., Lewis C.E., Manson J.E., Stefanick M.L., Howard B.V., Phillips L.S., Liu S., Kulick D., Kuller L.H.","Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study",2015,"BBA Clinical","3",,,"243","250",,,10.1016/j.bbacli.2015.03.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925066477&partnerID=40&md5=71597769fbfee024ec0e6307a992edc2","Department of Epidemiology, University of PittsburghPittsburgh, PA, United States; Department of Medicine, University of PittsburghPittsburgh, PA, United States; Department of Neurological Surgery, University of PittsburghPittsburgh, PA, United States; Department of Public Health Sciences, Fred Hutchinson Cancer Research CenterSeattle, WA, United States; Department of Medicine, University of Alabama at Birmingham, United States; Brigham and Women's Hospital, Harvard Medical SchoolBoston, MA, United States; Stanford Prevention Research Center, Department of Medicine, Stanford UniversityStanford, CA, United States; Medstar Health Research InstituteHyattsville, MD, United States; Clinical Studies Center, Atlanta VA Medical CenterDecatur, GA, United States; Division of Endocrinology, Emory University School of MedicineAtlanta, GA, United States; Department of Epidemiology, Brown UniversityProvidence, RI, United States; Mayo Clinic ArizonaPhoenix, AZ, United States","Mackey, R.H., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States; McTigue, K.M., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States, Department of Medicine, University of PittsburghPittsburgh, PA, United States; Chang, Y.F., Department of Neurological Surgery, University of PittsburghPittsburgh, PA, United States; Barinas-Mitchell, E., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States; Evans, R.W., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States; Tinker, L.F., Department of Public Health Sciences, Fred Hutchinson Cancer Research CenterSeattle, WA, United States; Lewis, C.E., Department of Medicine, University of Alabama at Birmingham, United States; Manson, J.E., Brigham and Women's Hospital, Harvard Medical SchoolBoston, MA, United States; Stefanick, M.L., Stanford Prevention Research Center, Department of Medicine, Stanford UniversityStanford, CA, United States; Howard, B.V., Medstar Health Research InstituteHyattsville, MD, United States; Phillips, L.S., Clinical Studies Center, Atlanta VA Medical CenterDecatur, GA, United States, Mayo Clinic ArizonaPhoenix, AZ, United States; Liu, S., Division of Endocrinology, Emory University School of MedicineAtlanta, GA, United States; Kulick, D., Department of Epidemiology, Brown UniversityProvidence, RI, United States; Kuller, L.H., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States","Background: We hypothesized that higher concentrations of LDL particles (LDL-P) and leptin, and lower concentrations of HDL particles (HDL-P), and total and high molecular weight (HMW) adiponectin, would predict incident coronary heart disease (CHD) among severely obese postmenopausal women. Methods: In a case-cohort study nested in the Women's Health Initiative Observational Study, we sampled 677 of the 1852 white or black women with body mass index (BMI) ≥40kg/m2 and no prevalent cardiovascular disease (CVD), including all 124 cases of incident CHD over mean 5.0year follow-up. Biomarkers were assayed on stored blood samples. Results: In multivariable-adjusted weighted Cox models, higher baseline levels of total and small LDL-P, and lower levels of total and medium HDL-P, and smaller mean HDL-P size were significantly associated with incident CHD. In contrast, large HDL-P levels were inversely associated with CHD only for women without diabetes, and higher total and HMW adiponectin levels and lower leptin levels were associated with CHD only for women with diabetes. Higher total LDL-P and lower HDL-P were associated with CHD risk independently of confounders including CV risk factors and other lipoprotein measures, with adjusted HR (95% CIs) of 1.55 (1.28, 1.88) and 0.70 (0.57, 0.85), respectively, and similar results for medium HDL-P. Conclusions: Higher CHD risk among severely obese postmenopausal women is strongly associated with modifiable concentrations of LDL-P and HDL-P, independent of diabetes, smoking, hypertension, physical activity, BMI and waist circumference. General significance: Severely obese postmenopausal women should be considered high risk candidates for lipid lowering therapy. © 2015 The Authors.","Adiponectin; Coronary heart disease; Extreme obesity; Lipoproteins; Postmenopausal women; Severe obesity","Poirier, P., Alpert, M.A., Fleisher, L.A., Thompson, P.D., Sugerman, H.J., Burke, L.E., Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association (2009) Circulation, 120 (1), pp. 86-95; Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 (2012) JAMA, 307 (5), pp. 491-497; McTigue, K.M., Chang, Y.F., Eaton, C., Garcia, L., Johnson, K.C., Lewis, C.E., Severe obesity, heart disease, and death among white, African American, and Hispanic postmenopausal women (2014) Obesity (Silver Spring), 22 (3), pp. 801-810; Sjostrom, L., Peltonen, M., Jacobson, P., Sjostrom, C.D., Karason, K., Wedel, H., Bariatric surgery and long-term cardiovascular events (2012) JAMA, 307 (1), pp. 56-65; McTigue, K.M., Mackey, R.H., Kuller, L.H., Cardiovascular complications of extreme obesity in women (2011) Curr. Cardiovasc. Risk Rep., 5, pp. 246-252; Sattar, N., Wannamethee, G., Sarwar, N., Chernova, J., Lawlor, D.A., Kelly, A., Leptin and coronary heart disease: prospective study and systematic review (2009) J. Am. Coll. Cardiol., 53 (2), pp. 167-175; Sook Lee, E., Park, S.S., Kim, E., Sook Yoon, Y., Ahn, H.Y., Park, C.Y., Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis (2013) Int. J. Epidemiol., 42 (4), pp. 1029-1039; Lawlor, D.A., Davey, S.G., Ebrahim, S., Thompson, C., Sattar, N., Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women (2005) J. Clin. Endocrinol. Metab., 90 (10), pp. 5677-5683; Sattar, N., Watt, P., Cherry, L., Ebrahim, S., Davey, S.G., Lawlor, D.A., High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study (2008) J. Clin. Endocrinol. Metab., 93 (5), pp. 1846-1849; Herder, C., Peltonen, M., Svensson, P.A., Carstensen, M., Jacobson, P., Roden, M., Adiponectin and bariatric surgery: associations with diabetes and cardiovascular disease in the Swedish Obese Subjects Study (2014) Diabetes Care, 37 (5), pp. 1401-1409; Mackey, R.H., Greenland, P., Goff, D.C., Lloyd-Jones, D., Sibley, C.T., Mora, S., High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-ethnic Study of Atherosclerosis) (2012) J. Am. Coll. Cardiol., 60 (6), pp. 508-516; Parish, S., Offer, A., Clarke, R., Hopewell, J.C., Hill, M.R., Otvos, J.D., Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study (2012) Circulation, 125 (20), pp. 2469-2478; Kuller, L.H., Grandits, G., Cohen, J.D., Neaton, J.D., Prineas, R., Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome (2007) Atherosclerosis, 195 (1), pp. 122-128; Mora, S., Glynn, R.J., Ridker, P.M., High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy (2013) Circulation, 128 (11), pp. 1189-1197; Otvos, J.D., Mora, S., Shalaurova, I., Greenland, P., Mackey, R.H., Goff, D.C., Clinical implications of discordance between low-density lipoprotein cholesterol and particle number (2011) J. Clin. Lipidol., 5 (2), pp. 105-113; Mora, S., Buring, J.E., Ridker, P.M., Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events (2014) Circulation, 129 (5), pp. 553-561; Mackey, R.H., Kuller, L.H., Sutton-Tyrrell, K., Evans, R.W., Holubkov, R., Matthews, K.A., Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study (2005) Arch. Intern. Med., 165 (5), pp. 510-515; Chandra, A., Neeland, I.J., Das, S.R., Khera, A., Turer, A.T., Ayers, C.R., Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study) (2015) Am. J. Cardiol., 115 (7), pp. 890-894; El Harchaoui, K., van der Steeg, W.A., Stroes, E.S., Kuivenhoven, J.A., Otvos, J.D., Wareham, N.J., Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study (2007) J. Am. Coll. Cardiol., 49 (5), pp. 547-553; Mora, S., Szklo, M., Otvos, J.D., Greenland, P., Psaty, B.M., Goff, D.C., LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-ethnic Study of Atherosclerosis (MESA) (2007) Atherosclerosis, 192 (1), pp. 211-217; El Harchaoui, K., Arsenault, B.J., Franssen, R., Despres, J.P., Hovingh, G.K., Stroes, E.S., High-density lipoprotein particle size and concentration and coronary risk (2009) Ann. Intern. Med., 150 (2), pp. 84-93; van der Steeg, W.A., Holme, I., Boekholdt, S.M., Larsen, M.L., Lindahl, C., Stroes, E.S., High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies (2008) J. Am. Coll. Cardiol., 51 (6), pp. 634-642; Anderson, G.L., Manson, J., Wallace, R., Lund, B., Hall, D., Davis, S., Implementation of the Women's Health Initiative study design (2003) Ann. Epidemiol., 13 (9), pp. S5-S17; Barlow, W.E., Ichikawa, L., Rosner, D., Izumi, S., Analysis of case-cohort designs (1999) J. Clin. Epidemiol., 52 (12), pp. 1165-1172; Curb, J.D., McTiernan, A., Heckbert, S.R., Kooperberg, C., Stanford, J., Nevitt, M., Outcomes ascertainment and adjudication methods in the Women's Health Initiative (2003) Ann. Epidemiol., 13 (9), pp. S122-S128; Go, A.S., Bauman, M.A., Coleman King, S.M., Fonarow, G.C., Lawrence, W., Williams, K.A., An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention (2014) J. Am. Coll. Cardiol., 63 (12), pp. 1230-1238; (2) Classification and diagnosis of diabetes (2015) Diabetes Care, 38, pp. S8-S16; Jeyarajah, E.J., Cromwell, W.C., Otvos, J.D., Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy (2006) Clin. Lab. Med., 26 (4), pp. 847-870; Mackey, R.H., Mora, S., Bertoni, A.G., Wassel, C.L., Carnethon, M.R., Sibley, C.T., Lipoprotein particles and incident type 2 diabetes in the Multi-ethnic Study of Atherosclerosis (2015) Diabetes Care, , [Epub ahead of print]; Mora, S., Otvos, J.D., Rifai, N., Rosenson, R.S., Buring, J.E., Ridker, P.M., Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women (2009) Circulation, 119 (7), pp. 931-939; Kontush, A., Chapman, M.J., Why is HDL functionally deficient in type 2 diabetes? (2008) Curr. Diab. Rep., 8 (1), pp. 51-59; Camont, L., Chapman, M.J., Kontush, A., Biological activities of HDL subpopulations and their relevance to cardiovascular disease (2011) Trends Mol. Med., 17 (10), pp. 594-603; von Eynatten, M., Hamann, A., Twardella, D., Nawroth, P.P., Brenner, H., Rothenbacher, D., Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease (2008) Eur. Heart J., 29 (10), pp. 1307-1315; Wannamethee, S.G., Welsh, P., Whincup, P.H., Sawar, N., Thomas, M.C., Gudnarsson, V., High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? (2011) Eur. J. Cardiovasc. Prev. Rehabil., 18 (1), pp. 65-71; Kizer, J.R., Benkeser, D., Arnold, A.M., Mukamal, K.J., Ix, J.H., Zieman, S.J., Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study (2012) Circulation, 126 (25), pp. 2951-2961; Kizer, J.R., Benkeser, D., Arnold, A.M., Djousse, L., Zieman, S.J., Mukamal, K.J., Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults (2013) J. Clin. Endocrinol. Metab., 98 (1), pp. 255-263; Tsukamoto, O., Fujita, M., Kato, M., Yamazaki, S., Asano, Y., Ogai, A., Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure (2009) J. Am. Coll. Cardiol., 53 (22), pp. 2070-2077; Piemonti, L., Calori, G., Mercalli, A., Lattuada, G., Monti, P., Garancini, M.P., Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality (2003) Diabetes Care, 26 (10), pp. 2883-2889; Allison, M.A., Bluemke, D.A., McClelland, R., Cushman, M., Criqui, M.H., Polak, J.F., Relation of leptin to left ventricular hypertrophy (from the Multi-ethnic Study of Atherosclerosis) (2013) Am. J. Cardiol., 112 (5), pp. 726-730; Mackey, R.H., Belle, S.H., Courcoulas, A.P., Dakin, G.F., Deveney, C.W., Flum, D.R., Distribution of 10-year and lifetime predicted risk for cardiovascular disease prior to surgery in the longitudinal assessment of bariatric surgery-2 study (2012) Am. J. Cardiol., 60 (6), pp. 508-516; Davidson, M.H., Ballantyne, C.M., Jacobson, T.A., Bittner, V.A., Braun, L.T., Brown, A.S., Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists (2011) J. Clin. Lipidol., 5 (5), pp. 338-367; McTigue, K., Larson, J.C., Valoski, A., Burke, G., Kotchen, J., Lewis, C.E., Mortality and cardiac and vascular outcomes in extremely obese women (2006) JAMA, 296 (1), pp. 79-86; Livingston, E.H., Chandalia, M., Abate, N., Do current body mass index criteria for obesity surgery reflect cardiovascular risk? (2007) Surg. Obes. Relat. Dis., 3 (6), pp. 577-585; Matthews, K.A., Crawford, S.L., Chae, C.U., Everson-Rose, S.A., Sowers, M.F., Sternfeld, B., Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? (2009) J. Am. Coll. Cardiol., 54 (25), pp. 2366-2373; Kuller, L.H., Pettee Gabriel, K.K., Kinzel, L.S., Underwood, D.A., Conroy, M.B., Chang, Y., The Women on the Move Through Activity and Nutrition (WOMAN) study: final 48-month results (2012) Obesity (Silver Spring), 20 (3), pp. 636-643; Rosenson, R.S., Otvos, J.D., Hsia, J., Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study (2009) Diabetes Care, 32 (6), pp. 1087-1091; Mora, S., Glynn, R.J., Hsia, J., MacFadyen, J.G., Genest, J., Ridker, P.M., Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials (2010) Circulation, 121 (9), pp. 1069-1077",Article,Scopus,2-s2.0-84925066477
"Tavares M.R., Pavan I.C.B., Amaral C.L., Meneguello L., Luchessi A.D., Simabuco F.M.","The S6K protein family in health and disease",2015,"Life Sciences","131",,,"1","10",,,10.1016/j.lfs.2015.03.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928478164&partnerID=40&md5=fe8cea5bef3336b20efe4bf9ac19df61","Laboratory of Disorders of Metabolism, School of Applied Sciences, University of CampinasLimeira, São Paulo, Brazil; Laboratory of Biotechnology, School of Applied Sciences, University of CampinasLimeira, São Paulo, Brazil","Tavares, M.R., Laboratory of Disorders of Metabolism, School of Applied Sciences, University of CampinasLimeira, São Paulo, Brazil; Pavan, I.C.B., Laboratory of Disorders of Metabolism, School of Applied Sciences, University of CampinasLimeira, São Paulo, Brazil; Amaral, C.L., Laboratory of Disorders of Metabolism, School of Applied Sciences, University of CampinasLimeira, São Paulo, Brazil; Meneguello, L., Laboratory of Biotechnology, School of Applied Sciences, University of CampinasLimeira, São Paulo, Brazil; Luchessi, A.D., Laboratory of Biotechnology, School of Applied Sciences, University of CampinasLimeira, São Paulo, Brazil; Simabuco, F.M., Laboratory of Disorders of Metabolism, School of Applied Sciences, University of CampinasLimeira, São Paulo, Brazil","The S6K proteins are mTOR pathway effectors and accumulative evidence suggest that mTOR/S6K signaling contributes to several pathological conditions, such as diabetes, cancer and obesity. The activation of the mTOR/S6K axis stimulates protein synthesis and cell growth. S6K1 has two well-known isoforms, p70-S6K1 and p85-S6K1, generated by alternative translation initiation sites. A third isoform, named p31-S6K1, has been characterized as a truncated type of the protein due to alternative splicing, and reports have shown its important role in cancer. Studies involving S6K2 are scarce. This article aims to review what is new in the literature about these kinases and establish differences regarding their interacting proteins, activation and function, connecting their roles in the homeostasis of the cell and in pathological conditions. © 2015 Elsevier Inc. All rights reserved.","Cancer; Diabetes; Metabolism; mTOR; Obesity; S6K1; S6K2","Abe, Y., Yoon, S.O., Kubota, K., Mendoza, M.C., Gygi, S.P., Blenis, J., P90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling (2009) J. Biol. Chem., 284, pp. 14939-14948; Antion, M.D., Merhav, M., Hoeffer, C.A., Reis, G., Kozma, S.C., Thomas, G., Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity (2008) Learn. Mem., 1, pp. 29-38; Banerjee, P., Ahmad, M.F., Grove, J.R., Kozlosky, C., Price, D.J., Avruch, J., Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase (1990) Proc. Natl. Acad. Sci. U. S. A., 21, pp. 8550-8554; Bartley, C.M., O'Keefe, R.A., Bordey, A., FMRP S499 is phosphorylated independent of mTORC1-S6K1 activity (2014) PLoS One; Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B., Karni, R., S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1 (2013) Cell Rep., 3, pp. 103-115; Ben-Sahra, I., Howell, J.J., Asara, J.M., Manning, B.D., Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1 (2013) Science, 339, pp. 1323-1328; Bielinski, V.A., Mumby, M.C., Functional analysis of the PP2A subfamily of protein phosphatases in regulating Drosophila S6 kinase (2007) Exp. Cell Res., 313, pp. 3117-3126; Blouet, C., Ono, H., Schwartz, G.J., Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis (2008) Cell Metab., 6, pp. 459-467; Burnett, P.E., Barrow, R.K., Cohen, N.A., Snyder, S.H., Sabatini, D.M., RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 (1998) Proc. Natl. Acad. Sci. U. S. A., 95, pp. 1432-1437; Burnett, P.E., Blackshaw, S., Lai, M.M., Qureshi, I.A., Burnett, A.F., Sabatini, D.M., Snyder, S.H., Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton (1998) Proc. Natl. Acad. Sci. U. S. A., 95, pp. 8351-8356; Carnevalli, L.S., Masuda, K., Frigerio, F., Le Bacquer, O., Um, S.H., Gandin, V., S6K1 plays a critical role in early adipocyte differentiation (2010) Dev. Cell, 18, pp. 763-774; Catalán, V., Gómez-Ambrosi, J., Rodríguez, A., Ramírez, B., Andrada, P., Rotellar, F., Expression of S6K1 in human visceral adipose tissue is upregulated in obesity and related to insulin resistance and inflammation (2014) Acta Diabetol.; Chauhan, A., More, R.S., Mullins, P.A., Taylor, G., Petch, C., Schofield, P.M., Aging-associated endothelial dysfunction in humans is reversed by L-arginine (1996) J. Am. Coll. Cardiol., 28, pp. 1796-1804; Chauvin, C., Koka, V., Nouschi, A., Mieulet, V., Hoareau-Aveilla, C., Dreazen, A., Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program (2014) Oncogene, 33, pp. 474-483; Chou, M.M., Blenis, J., The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1 (1996) Cell, 85, pp. 573-583; Cruz, R., Hedden, L., Boyer, D., Kharas, M.G., Fruman, D.A., Lee-Fruman, K.K., S6 kinase 2 potentiates interleukin-3-driven cell proliferation (2005) J. Leukoc. Biol., 78, pp. 1378-1385; Csibi, A., Lee, G., Yoon, S.O., Tong, H., Ilter, D., Elia, I., The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation (2014) Curr. Biol., 24, pp. 2274-2280; Dagon, Y., Hur, E., Zheng, B., Wellenstein, K., Cantley, L.C., Kahn, B.B., P70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake (2012) Cell Metab., 16, pp. 104-112; Dauer, W., Przedborski, S., Parkinson's disease: Mechanisms and models (2003) Neuron, 39, pp. 889-909; Dennis, M.D., Jefferson, L.S., Kimball, S.R., Role of p70S6K1-mediated phosphorylation of eIF4B and PDCD4 proteins in the regulation of protein synthesis (2012) J. Biol. Chem., 51, pp. 42890-42899; Deprez, J., Vertommen, D., Alessi, D.R., Hue, L., Rider, M.H., Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades (1997) J. Biol. Chem., 272, pp. 17269-17275; Di, R., Wu, X., Chang, Z., Zhao, X., Feng, Q., Lu, S., S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt (2012) Biochem. J., 441, pp. 199-207; Efeyan, A., Zoncu, R., Sabatini, D.M., Amino acids and mTORC1: From lysosomes to disease (2012) Trends Mol. Med., 18, pp. 524-533; Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., Chen, J., Phosphatidic acid-mediated mitogenic activation of mTOR signaling (2001) Science, 294, pp. 1942-1945; Filonenko, V.V., Tytarenko, R., Azatjan, S.K., Savinska, L.O., Gaydar, Y.A., Gout, I.T., Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors (2004) Exp. Oncol., 26, pp. 294-299; Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L., Prevalence of obesity and trends in the distribution of body mass index among US adults 1999-2010 (2012) JAMA, 39, pp. 491-497; Georgescu, M.M., PTEN tumor suppressor network in PI3K-Akt pathway control (2010) Genes Cancer, 1, pp. 1170-1177; Goh, E.T., Pardo, O.E., Michael, N., Niewiarowski, A., Totty, N., Volkova, D., Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway (2010) J. Biol. Chem., 285, pp. 17065-17076; Goldberg, E.L., Romero-Aleshire, M.J., Renkema, K.R., Ventevogel, M.S., Chew, W.M., Uhrlaub, J.L., Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms (2015) Aging Cell, 14, pp. 130-138; Groot, R.P., Ballou, L.M., Sassone-Corsi, P., Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: An alternative route to mitogen-induced gene expression (1994) Cell, 79, pp. 81-91; Grove, J.R., Banerjee, P., Balasubramanyam, A., Coffer, P.J., Price, D.J., Avruch, J., Woodgett, J.R., Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini (1991) Mol. Cell. Biol., 11, pp. 5541-5550; Hall, M.N., MTOR-what does it do? (2008) Transplant. Proc., 40, pp. 5-8; Harada, H., Andersen, J.S., Mann, M., Terada, N., Korsmeyer, S.J., P70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD (2001) Proc. Natl. Acad. Sci. U. S. A., 98, pp. 9666-9670; Harries, L.W., Fellows, A.D., Pilling, L.C., Hernandez, D., Singleton, A., Bandinelli, S., Advancing age is associated with gene expression changes resembling mTOR inhibition: Evidence from two human populations (2012) Mech. Ageing Dev., 133, pp. 556-562; Harrison, D.E., Strong, R., Sharp, Z.D., Nelson, J.F., Astle, C.M., Flurkey, K., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice (2009) Nature, 460, pp. 392-395; Heikamp, E.B., Patel, C.H., Collins, S., Waickman, A., Oh, M.H., Sun, I.H., Illei, P., The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex (2014) Nat. Immunol., 15, pp. 457-564; Hong, S., Zhao, B., Lombard, D.B., Fingar, D.C., Inoki, K., Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1(S6K1) phosphorylation (2014) J. Biol. Chem., 289, pp. 13132-13141; Hue, L., Rider, M.H., Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues (1987) Biochem. J., 245, pp. 313-324; Huffman, T.A., Mothe-Satney, I., Lawrence, Jr.J.C., Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin (2002) Proc. Natl. Acad. Sci. U. S. A., 99, pp. 1047-1052; Ip, C.K., Cheung, A.N., Ngan, H.Y., Wong, A.S., P70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells (2011) Oncogene, 30, pp. 2420-2432; Ip, C.K., Wong, A.S., P70 S6 kinase and actin dynamics: A perspective (2012) Spermatogenesis, 2, pp. 44-52; Ismail, H.M., Khalil, M., Dawoud, M., S6 kinase 2 is bound to chromatin-nuclear matrix cellular fractions and is able to phosphorylate histone H3 at threonine 45 in vitro and in vivo (2014) J. Cell. Biochem., 105, pp. 1048-1062; Ismail, H.M., Myronova, O., Tsuchiya, Y., Niewiarowski, A., Tsaneva, I., Gout, I., Identification of the general transcription factor Yin Yang 1 as a novel and specific binding partner for S6 kinase 2 (2013) Cell. Signal., 5, pp. 1054-1063; James, W.P., Rigby, N., Leach, R., Obesity and the metabolic syndrome: The stress on society (2006) Ann. N. Y. Acad. Sci., 1083, pp. 1-10; Jastrzebski, K., Hannan, K.M., Tchoubrieva, E.B., Hannan, R.D., Pearson, R.B., Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function (2007) Growth Factors, 25, pp. 209-226; Jung, C.H., Jun, C.B., Ro, S.H., Kim, Y.M., Otto, N.M., Cao, J., ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery (2009) Mol. Biol. Cell, 20, pp. 1992-2003; Karni, R., Stanchina, E., Lowe, S.W., Sinha, R., Mu, D., Krainer, A.R., The gene encoding the splicing factor SF2/ASF is a proto-oncogene (2007) Nat. Struct. Mol. Biol., 3, pp. 185-193; Khotskaya, Y.B., Goverdhan, A., Shen, J., Ponz-Sarvise, M., Chang, S.S., Hsu, M.C., S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer (2014) Am. J. Transl. Res., 6, pp. 361-376; Kim, K., Pyo, S., Um, S.H., S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver (2012) Hepatology, 55, pp. 1727-1737; Kim, S.Y., Baik, K.H., Baek, K.H., Chah, K.H., Kim, K.A., Moon, G., S6K1 negatively regulates TAK1 activity in the toll-like receptor signaling pathway (2014) Mol. Cell. Biol., 34, pp. 510-521; Koh, P.O., Ferulic acid attenuates focal cerebral ischemia-induced decreases in p70S6 kinase and S6 phosphorylation (2013) Neurosci. Lett., 555, pp. 7-11; Kurebayashi, Y., Nagai, S., Ikejiri, A., Ohtani, M., Ichiyama, K., Baba, Y., PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ (2012) Cell Rep., 4, pp. 360-373; Lai, K.P., Leong, W.F., Chau, J.F., Jia, D., Zeng, L., Liu, H., S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response (2010) EMBO J., 29, pp. 2994-3006; Lim, H.K., Choi, Y.A., Park, W., Lee, T., Ryu, S.H., Kim, S.Y., Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway (2003) J. Biol. Chem., 278, pp. 45117-45127; Liu, J., Stevens, P.D., Li, X., Schmidt, M.D., Gao, T., PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth (2011) Mol. Cell. Biol., 31, pp. 4917-4927; Liwak, U., Thakor, N., Jordan, L.E., Roy, R., Lewis, S.M., Pardo, O.E., Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2 (2012) Mol. Cell. Biol., 32, pp. 1818-1829; Low, S., Chin, M.C., Deurenberg-Yap, M., Review on epidemic of obesity (2009) Ann. Acad. Med. Singap., 38, pp. 57-59; Lyzogubov, V., Khozhaenko, Y., Usenko, V., Antonjuk, S., Ovcharenko, G., Tikhonkova, I., Filonenko, V., Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer (2005) Exp. Oncol., 27, pp. 141-144; Magnuson, B., Ekim, B., Fingar, D.C., Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks (2012) Biochem. J., 441, pp. 1-21; Malagelada, C., Jin, Z.H., Jackson-Lewis, V., Przedborski, S., Greene, L.A., Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease (2010) J. Neurosci., 30, pp. 1166-1175; Mannick, J.B., Del Giudice, G., Lattanzi, M., Valiante, N.M., Praestgaard, J., Huang, B., MTOR inhibition improves immune function in the elderly (2014) Sci. Transl. Med.; Martin, I., Nguyen, T.D., Krell, V., Greiner, J.F., Müller, J., Hauser, S., Generation of Schwann cell-derived multipotent neurospheres isolated from intact sciatic nerve (2012) Stem Cell Rev., 8, pp. 1178-1187; Ming, X.F., Montani, J.P., Yang, Z., Perspectives of targeting mTORC1-S6K1 in cardiovascular aging (2012) Front. Physiol.; Nahhas, M., Bhopal, R., Anandan, C., Elton, R., Sheikh, A., Investigating the association between obesity and asthma in 6- to 8-year-old Saudi children: A matched case-control study (2014) NPJ Prim. Care Respir. Med., 24, p. 14004; Narayanan, U., Nalavadi, V., Nakamoto, M., Thomas, G., Ceman, S., Bassell, G.J., Warren, S.T., S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade (2008) J. Biol. Chem., 283, pp. 18478-18482; Oh, C.H., Park, S.Y., Han, J.S., Phospholipase D1 is required for lipopolysaccharide-induced tumor necrosis factor-α expression and production through S6K1/JNK/c-Jun pathway in raw 264.7 cells (2014) Cytokine, 66, pp. 69-77; Palmer, R.M., Ashton, D.S., Moncada, S., Vascular endothelial cells synthesize nitric oxide from L-arginine (1988) Nature, 333, pp. 664-666; Pardo, O.E., Arcaro, A., Salerno, G., Tetley, T.D., Valovka, T., Gout, I., Seckl, M.J., Novel cross talk between MEK and S6K2 in FGF- 2 induced proliferation of SCLC cells (2001) Oncogene, 20, pp. 7658-7667; Pardo, O.E., Seckl, M.J., S6K2: The neglected S6 kinase family member (2013) Front. Oncol., 3, p. 191; Pardo, O.E., Wellbrock, C., Khanzada, U.K., Aubert, M., Arozarena, I., Davidson, S., FGF- 2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2 (2006) EMBO J., 25, pp. 3078-3088; Park, S.Y., Cho, J.H., Ma, W., Choi, H.J., Han, J.S., Phospholipase D2 acts as an important regulator in LPS-induced nitric oxide synthesis in Raw 264.7 cells (2010) Cell. Signal., 22, pp. 619-628; Pearce, L.R., Alton, G.R., Richter, D.T., Kath, J.C., Lingardo, L., Chapman, J., Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1) (2010) Biochem. J., 431, pp. 245-255; Pende, M., Um, S.H., Mieulet, V., Sticker, M., Goss, V.L., Mestan, J., S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway (2004) Mol. Cell. Biol., 8, pp. 3112-3124; Pérez-Tenorio, G., Karlsson, E., Waltersson, M.A., Olsson, B., Holmlund, B., Nordenskjöld, B., Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer (2011) Breast Cancer Res. Treat., 128, pp. 713-723; Peterson, R.T., Desai, B.N., Hardwick, J.S., Schreiber, S.L., Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein (1999) Proc. Natl. Acad. Sci. U. S. A., 96, pp. 4438-4442; Petritsch, C., Beug, H., Balmain, A., Oft, M., TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest (2000) Genes Dev., 14, pp. 3093-3101; Phin, S., Kupferwasser, D., Lam, J., Lee-Fruman, K.K., Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1 (2003) Biochem. J., 373, pp. 583-591; Porstmann, T., Santos, C.R., Griffiths, B., Cully, M., Wu, M., Leevers, S., SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth (2008) Cell Metab., 8, pp. 224-236; Preitschopf, A., Li, K., Schörghofer, D., Kinslechner, K., Schütz, B., Thi Thanh Pham, H., MTORC1 is essential for early steps during Schwann cell differentiation of amniotic fluid stem cells and regulates lipogenic gene expression (2014) PLoS One; Price, D.J., Mukhopadhyay, N.K., Avruch, J., Insulin-activated protein kinases phosphorylate a pseudosubstrate synthetic peptide inhibitor of the p70 S6 kinase (1991) J. Biol. Chem., 25, pp. 16281-16284; Pullen, N., Dennis, P.B., Andjelkovic, M., Dufner, A., Kozma, S.C., Hemmings, B.A., Thomas, G., Phosphorylation and activation of p70s6k by PDK1 (1998) Science, 279, pp. 707-710; Rajapakse, A.G., Yepuri, G., Carvas, J.M., Stein, S., Matter, C.M., Scerri, I., Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: Inhibition by resveratrol (2011) PLoS One; Richardson, C.J., Bröenstrup, M., Fingar, D.C., Jülich, K., Ballif, B.A., Gygi, S., Blenis, J., SKAR is a specific target of S6 kinase 1 in cell growth control (2004) Curr. Biol., 14, pp. 1540-1549; Rosner, M., Hengstschläger, M., Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR (2011) Oncogene, 30, pp. 4509-4522; Rossi, R., Pester, J.M., McDowell, M., Soza, S., Montecucco, A., Lee-Fruman, K.K., Identification of S6K2 as a centrosome-located kinase (2007) FEBS Lett., 581, pp. 4058-4064; Savinska, L.O., Lyzogubov, V.V., Usenko, V.S., Ovcharenko, G.V., Gorbenko, O.N., Rodnin, M.V., Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors (2004) Eksp. Onkol., 26, pp. 24-30; Scalera, F., Closs, E.I., Flick, E., Martens-Lobenhoffer, J., Boissel, J.P., Lendeckel, U., Paradoxical effect of L-arginine: Acceleration of endothelial cell senescence (2009) Biochem. Biophys. Res. Commun., 386, pp. 650-655; Selman, C., Tullet, J.M., Wieser, D., Irvine, E., Lingard, S.J., Choudhury, A.I., Ribosomal protein S6 kinase 1 signaling regulates mammalian life span (2009) Science, 326, pp. 140-144; Sengupta, S., Peterson, T.R., Sabatini, D.M., Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress (2010) Mol. Cell, 40, pp. 310-322; Sherman, D.L., Krols, M., Wu, L.M., Grove, M., Nave, K.A., Gangloff, Y.G., Brophy, P.J., Arrest of myelination and reduced axon growth when Schwann cells lack mTOR (2012) J. Neurosci., 32, pp. 1817-1825; Simon, G.E., Ludman, E.J., Linde, J.A., Operskalski, B.H., Ichikawa, L., Rohde, P., Association between obesity and depression in middle-aged women (2008) Gen. Hosp. Psychiatry, 30, pp. 32-39; Song, X., Dilly, A.K., Kim, S.Y., Choudry, H.A., Lee, Y.J., Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1-Bad-Bak pathway in peritoneal carcinomatosis (2014) Cell Death Dis.; Sridharan, S., Basu, A., S6 kinase 2 promotes breast cancer cell survival via Akt (2011) Cancer Res., 71, pp. 2590-2599; Stanfel, M.N., Shamieh, L.S., Kaeberlein, M., Kennedy, B.K., The TOR pathway comes of age (2009) Biochim. Biophys. Acta, 1790, pp. 1067-1074; Stevanovic, D., Trajkovic, V., Müller-Lühlhoff, S., Brandt, E., Abplanalp, W., Bumke-Vogt, C., Ghrelin induced food intake and adiposity depend on central mTORC1/S6K1 signaling (2013) Mol. Cell. Endocrinol., 381, pp. 280-290; Surani, S.R., Diabetes, sleep apnea, obesity and cardiovascular disease: Why not address them together? (2014) World J. Diabetes, 3, pp. 381-384; Tremblay, F., Brûlé, S., Um, S.H., Li, Y., Masuda, K., Roden, M., Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 14056-14061; Um, S.H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity (2004) Nature, 431, pp. 200-205; Valovka, T., Verdier, F., Cramer, R., Zhyvoloup, A., Fenton, T., Rebholz, H., Protein kinase C phosphorylates ribosomal protein S6 kinase betaII and regulates its subcellular localization (2003) Mol. Cell. Biol., 23, pp. 852-863; Vasa, M., Breitschopf, K., Zeiher, A.M., Dimmeler, S., Nitric oxide activates telomerase and delays endothelial cell senescence (2000) Circ. Res., 87, pp. 540-542; Wang, X., Li, W., Williams, M., Terada, N., Alessi, D.R., Proud, C.G., Regulation of elongation factor 2 kinase by p90 (RSK1) and p70 S6 kinase (2001) EMBO J., 20, pp. 4370-4379; Wilson, K.F., Wu, W.J., Cerione, R.A., Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex (2000) J. Biol. Chem., 275, pp. 37307-37310; Xiong, Y., Fru, M.F., Yu, Y., Montani, J.P., Ming, X.F., Yang, Z., Long term exposure to L-arginine accelerates endothelial cell senescence through arginase-II and S6K1 signaling (2014) Aging (Albany NY), 6, pp. 369-379; Xu, Y., Liu, C., Chen, S., Ye, Y., Guo, M., Ren, Q., Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading toneuronal cell death in in vitro models of Parkinson's disease (2014) Cell. Signal., 26, pp. 1680-1689; Yamnik, R.L., Digilova, A., Davis, D.C., Brodt, Z.N., Murphy, C.J., Holz, M.K., S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation (2009) J. Biol. Chem., 284, pp. 6361-6369; Yepuri, G., Velagapudi, S., Xiong, Y., Rajapakse, A.G., Montani, J.P., Ming, X.F., Yang, Z., Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging (2012) Aging Cell, 11, pp. 1005-1016; Zhang, H.H., Lipovsky, A.I., Dibble, C.C., Sahin, M., Manning, B.D., S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt (2006) Mol. Cell, 24, pp. 185-197; Zhang, J., Gao, Z., Yin, J., Quon, M.J., Ye, J., S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2 (2008) J. Biol. Chem., 283, pp. 35375-35382",Review,Scopus,2-s2.0-84928478164
"Owen J.G., Reisin E.","Anti-hypertensive Drug Treatment of Patients with and the Metabolic Syndrome and Obesity: a Review of Evidence, Meta-Analysis, Post hoc and Guidelines Publications",2015,"Current Hypertension Reports","17","6",,"","",10,,10.1007/s11906-015-0558-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928822229&partnerID=40&md5=dc3d8398f8e2284b450de5d23d7a6250","Section of Nephrology and Hypertension, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, Room 330, Box T4M-2New Orleans, LA, United States","Owen, J.G., Section of Nephrology and Hypertension, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, Room 330, Box T4M-2New Orleans, LA, United States; Reisin, E., Section of Nephrology and Hypertension, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, Room 330, Box T4M-2New Orleans, LA, United States","Epidemiological studies have shown an increasing prevalence of obesity and the metabolic syndrome worldwide. Lifestyle modifications that include dietary changes, weight reduction, and exercise are the cornerstones in the treatment of this pathology. However, adherence to this approach often meets with failure in clinical practice; therefore, drug therapy should not be delayed. The ideal pharmacological antihypertensive regimen should target the underlying mechanisms involved in this syndrome, including sympathetic activation, increased renal tubular sodium reabsorption, and overexpression of the renin-angiotensin-aldosterone system by the adipocyte. Few prospective trials have been conducted in the search of the ideal antihypertensive regimen in patients with obesity and the metabolic syndrome. We summarize previously published ad hoc studies, prospective studies, and guideline publications regarding the treatment of hypertension in patients with obesity and the metabolic syndrome. We conclude that the optimal antihypertensive drug therapy in these patients has not been defined. Though caution exists regarding the use of thiazide diuretics due to potential metabolic derangements, there is insufficient data to show worsened cardiovascular or renal outcomes in patients treated with these drugs. In regard to beta blockers, the risk of accelerating conversion to diabetes and worsening of inflammatory mediators described in patients treated with traditional beta blockers appears much less pronounced or absent when using the vasodilating beta blockers. Renin-angiotensin-aldosterone system (RAAS) inhibition with an ACE or an ARB and treatment with calcium channel blockers appears safe and well tolerated in obesity-related hypertension and in patients with metabolic syndrome. Future prospective pharmacological studies in this population are needed. © 2015, Springer Science+Business Media New York.","Adipokines; Beta-blockers; Calcium channel blockers; Cardiometabolic syndrome; Diabetes; Hypertension; Leptin; Metabolic-syndrome; Obesity; Overweight; Pre-diabetes; Renin angiotensin aldosterone system; Thiazide diuretics","Reaven, G.M., Banting lecture 1988. Role of insulin resistance in human disease (1988) Diabetes, 37, pp. 1595-1607. , COI: 1:STN:280:DyaL1M%2Flt12msQ%3D%3D, PID: 3056758; Gill, H., Mugo, M., Whaley-Connell, A., Stump, C., Sowers, J.R., The key role of insulin resistance in the cardiometabolic-syndrome (2005) Am J Med Sci, 330, pp. 290-294. , PID: 16355013; Roberts, C.K., Hevener, A.L., Barnard, R.J., Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training (2013) Compr Physiol, 3 (1), pp. 1-58. , PID: 23720280, An excellent review that discusses the effect of exercise on blood pressure reduction; Ferrannini, E., Haffner, S.M., Mitchell, B.D., Stern, M.P., Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome (1991) Diabetologia, 34, pp. 416-422. , COI: 1:STN:280:DyaK3MzlslaktQ%3D%3D, PID: 1884900, PubMed: 1884900; Haffner, S.M., Valdez, R.A., Hazuda, H.P., Mitchell, B.D., Morales, P.A., Stern, M.P., Prospective analysis of the insulin-resistance syndrome (syndrome X) (1992) Diabetes, 41, pp. 715-722. , COI: 1:STN:280:DyaK383mslamug%3D%3D, PID: 1587398; Despres, J.P., Lemieux, I., Abdominal obesity and metabolic syndrome (2006) Nature, 444, pp. 881-887. , COI: 1:CAS:528:DC%2BD28XhtlShtrzF, PID: 17167477; Despres, J.P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk (2008) Arterioscler Thrombrosis Vasc Biol, 28, pp. 1039-1049. , COI: 1:CAS:528:DC%2BD1cXlsFOjur8%3D; Ogden, C.L., Carroll MD. Prevalence of overweight, obesity, and extreme obesity among adults: United States, Trends 1960–1962 Through 2007–2008 (2010) National Center for Health Statistics; Ogden, C.L., Carroll, M.D., Kit, B.K., Flegal, K.M., Prevalence of childhood and adult obesity in the United States, 2011–2012 (2014) JAMA, 311 (8), pp. 806-814. , COI: 1:CAS:528:DC%2BC2cXjvVOhs74%3D, PID: 24570244; http://www.who.int/gho/publications/world_health_statistics/EN_WHS2012_Full.pdf, WHO. World Health Statistics 2012Finucane, M.M., Stevens, G.A., National, regional, and global trends in body mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants (2011) Lancet, 377 (9765), pp. 557-567. , PID: 21295846; Danaei, G., Finucane, M.M., National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants (2011) Lancet, 378 (9785), pp. 31-40. , COI: 1:CAS:528:DC%2BC3MXotlyltbo%3D, PID: 21705069; Chan, J.C., Malik, V., Jia, W., Kadowaki, T., Yajnik, C.S., Yoon, K.H., Diabetes in Asia: epidemiology, risk factors, and pathophysiology (2009) JAMA, 301 (20), p. 2129. , COI: 1:CAS:528:DC%2BD1MXmsFaks7k%3D, PID: 19470990; Nora, M., Guimarães, M., Almeida, R., Martins, P., Gonçalves, G., Santos, M., Excess body mass index loss predicts metabolic syndrome remission after gastric bypass (2014) Diabetol Metab Syndr, 6 (1), pp. 1-7. , PID: 24383616; Ilanne-Parikka, P., Eriksson, J.G., Lindstrom, J., Peltonen, M., Aunola, S., Hamalainen, H., Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish diabetes prevention study (2008) Diabetes Care, 31, pp. 805-807. , PID: 18184907; Orchard, T.J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial (2005) Ann Intern Med, 142, pp. 611-619. , COI: 1:CAS:528:DC%2BD2MXktFahtrY%3D, PID: 15838067; Weston, K.S., Wisløff, U., Coombes, J.S., High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis (2014) Br J Sports Med, 48, pp. 1227-1234. , PID: 24144531; Babio, N., Bullo, M., Salas-Salvado, J., Mediterranean diet and metabolic syndrome: the evidence (2009) Public Health Nutr, 12 (9A), pp. 1607-1617. , PID: 19689829; Appel, L.J., Moore, T.J., Obarzanek, E., A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group (1997) N Engl J Med, 336, pp. 1117-1124. , COI: 1:STN:280:DyaK2s3jvVOmsA%3D%3D, PID: 9099655, A large collaborative study that address ther effect of diet on blood pressure; Williams, D.E., Prevost, A.T., Whichelow, M.J., Cox, B.D., Day, N.J., Wareham, N.J., A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome (2000) Br J Nutr, 83, pp. 257-266. , COI: 1:CAS:528:DC%2BD3cXhslKlu7g%3D, PID: 10884714; Chen, L., Caballero, B., Mitchell, D.C., Loria, C., Lin, P.H., Champagne, C.M., Reducing consumption of sugar sweetened beverages is associated with reduced blood pressure (2010) Circulation, 121, pp. 2398-2406. , COI: 1:CAS:528:DC%2BC3cXntF2isbk%3D, PID: 20497980; Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (2002) N Engl J Med, 346 (6), pp. 393-403. , COI: 1:CAS:528:DC%2BD38XhtVWqurc%3D, PID: 11832527; Diabetes Prevention Program Research Group, Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study (2012) Diabetes Care, 35 (4), pp. 731-737; Heymsfield, S.B., Segal, K.R., Hauptman, J., Lucas, C.P., Boldrin, M.N., Rissanen, A., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults (2000) Arch Intern Med, 160 (9), p. 1321. , COI: 1:CAS:528:DC%2BD3cXjslKnsLc%3D, PID: 10809036; Reaven, G., Segal, K., Hauptman, J., Boldrin, M., Lucas, C., Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X (2001) Am J Cardiol, 87 (7), p. 827. , COI: 1:CAS:528:DC%2BD3MXitF2qtbs%3D, PID: 11274935; Torgerson, J.S., Hauptman, J., Boldrin, M.N., Sjöström, L., XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients (2004) Diabetes Care, 27 (1), p. 155. , COI: 1:CAS:528:DC%2BD2cXmvV2jug%3D%3D, PID: 14693982; Bray, G.A., Ryan, D.H., Medical therapy for the patient with obesity (2012) Circulation, 125 (13), pp. 1695-1703. , PID: 22474312; Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L.R., Meta-analysis: pharmacologic treatment of obesity (2005) Ann Intern Med, 142 (7), p. 532. , COI: 1:CAS:528:DC%2BD2MXjslCqsL8%3D, PID: 15809465; Kelley, D.E., Bray, G.A., Pi-Sunyer, F.X., Klein, S., Hill, J., Miles, J., Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial (2002) Diabetes Care, 25 (6), p. 1033. , COI: 1:CAS:528:DC%2BD38XkslSksLg%3D, PID: 12032111; Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Siering, U., Semlitsch, Long-term effects of weight-reducing drugs in hypertensive patients (2013) Cochrane Database Syst Rev, 3, p. 007654. , PID: 23543553; O’Neil, P.M., Smith, S.R., Weissman, N.J., Fidler, M.C., Sanchez, M., Zhang, J., Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study (2012) Obesity, 20 (7), p. 1426. , PID: 22421927; Gadde, K.M., Allison, D.B., Ryan, D.H., Peterson, C.A., Troupin, B., Schwiers, M.L., Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial (2011) Lancet, 377 (9774), p. 1341. , COI: 1:CAS:528:DC%2BC3MXkvVSqtL4%3D, PID: 21481449; Garvey, W.T., Ryan, D.H., Look, M., Gadde, K.M., Allison, D.B., Peterson, C.A., Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study (2012) Am J Clin Nutr, 95 (2), pp. 297-308. , COI: 1:CAS:528:DC%2BC38XhsFyht70%3D, PID: 22158731; Greenway, F.L., Fujioka, K., Plodkowski, R.A., Mudaliar, S., Guttadauria, M., Erickson, J., Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2010) Lancet, 376 (9741), p. 595. , COI: 1:CAS:528:DC%2BC3cXhtVGmtbbK, PID: 20673995; Apovian, C.M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) (2013) Obesity, 21 (5), pp. 935-943. , COI: 1:CAS:528:DC%2BC3sXpvFaksL0%3D, PID: 23408728; Landsberg, L., Aronne, L.J., Beilin, L.J., Burke, V., Igel, L.I., Loyd-Jones, D., Obesity related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of the obesity society and the American society of hypertension (2013) Obesity, 21 (1), pp. 8-24. , PID: 23401272, A position paper on obesity-related hypertension; Kirk, E.P., Klein, S., Pathogenesis and pathophysiology of the cardiometabolic syndrome (2011) J Clin Hypertens, 11 (12), pp. 761-765; de Faria, A.P., Modolo, R., Fontana, V., Moreno, H., Adipokines: novel players in resistant hypertension (2014) J Clin Hypertens, 16 (10), pp. 754-759; Rahmouni, K., Obesity associated hypertension: recent progress in deciphering the pathogenesis (2014) Hypertension, 64, pp. 215-221. , COI: 1:CAS:528:DC%2BC2cXhtFeitr3I, PID: 24821943, An excellent review that examine the pathogenesis of obesity hypertension; Yvan-Charvet, L., Quignard-Boulange, A., Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity (2011) Kidney Int, 79, pp. 162-168. , COI: 1:CAS:528:DC%2BC3cXhs1ejtbbP, PID: 20944545; Engeli, S., Schling, P., Gorzelniak, K., Boschmann, M., Janke, J., Ailhaud, G., The adipose tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? (2003) Int J Biochem Cell Biol, 35, pp. 807-825. , COI: 1:CAS:528:DC%2BD3sXisFShurk%3D, PID: 12676168; Vykoukal, D., Davies, M.G., Vascular biology of the metabolic syndrome (2011) J Vasc Surg, 54 (3), pp. 819-831. , PID: 21439758; Frigolet, M.E., Torres, N., Tovar, A.R., The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity (2013) J Nutr Biochem, 24, pp. 2003-2015. , COI: 1:CAS:528:DC%2BC3sXhs1SrsrfF, PID: 24120291; Cassis, I.A., Police, S.B., Yiannikouris, F., Thatcher, S.E., Local adipose tissue renin-angiotensin system (2008) Curr Hypertens Rep, 10, pp. 93-98. , COI: 1:CAS:528:DC%2BD1cXnslGrsrc%3D, PID: 18474174; Faloia, E., Gatti, C., Camilloni, M.A., Marinello, B., Sardu, C., Garrapa, G.G., Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects (2002) J Endocrinol Investig, 25, pp. 309-314. , COI: 1:CAS:528:DC%2BD38XktlWiurc%3D; Massiera, F., Bloch-Faure, M., Ceiler, D., Murakami, K., Fukamizu, A., Gasc, J.M., Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation (2001) FASEB J, 15, pp. 2727-2729. , COI: 1:CAS:528:DC%2BD3MXptFags7k%3D, PID: 11606482; Yasue, S., Masuzaki, H., Okada, S., Ishii, T., Kozuka, C., Tanaka, T., Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy (2010) Am J Hypertens, 23, pp. 425-431. , COI: 1:CAS:528:DC%2BC3cXjsFCktbo%3D, PID: 20057360; Van Harmelen, V., Ariapart, P., Hoffstedt, J., Increased adipose tissue angiotensinogen gene expression in human obesity (2000) Obes Res, 8, pp. 337-341. , PID: 10933310; Massiera, F., Seydoux, J., Geloen, A., Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity (2001) Endocrinology, 142, pp. 5220-5225. , COI: 1:CAS:528:DC%2BD3MXovVSnu70%3D, PID: 11713218; Yvan-Charvet, L., Even, P., Bloch-Faure, M., Deletion of the angiotensin type 2 receptor reduces adipose cell size and protects from diet-induced obesity and insulin resistance (2005) Diabetes, 54, pp. 991-999. , COI: 1:CAS:528:DC%2BD2MXjtFWnt7k%3D, PID: 15793237; Kouyama, R., Suganami, T., Nishida, J., Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor (2005) Endocrinology, 146, pp. 3481-3489. , COI: 1:CAS:528:DC%2BD2MXntVaiurg%3D, PID: 15878965; Yiannikouris, F., Gupte, M., Putnam, K., Thatcher, S., Charnigo, R., Rateri, D.L., Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice (2012) Hypertension, 60, pp. 1524-1530. , COI: 1:CAS:528:DC%2BC38Xhs1GqsrbF, PID: 23108647; Briones, A.M., Nguyen Dinh Cat, A., Callera, G.E., Yogi, A., Burger, D., He, Y., Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction (2012) Hypertension, 59, pp. 1069-1078. , COI: 1:CAS:528:DC%2BC38Xls12ksLs%3D, PID: 22493070; De Souza, F., Muxfeldt, E., Fiszman, R., Salles, G., Efficacy of spironolactone therapy in patients with true resistant hypertension (2010) Hypertension, 55, pp. 147-152. , PID: 19858405; Hirata, A., Maeda, N., Hiuge, A., Hibuse, T., Fujita, K., Okada, T., Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice (2009) Cardiovasc Res, 84 (1), pp. 164-172. , COI: 1:CAS:528:DC%2BD1MXhtFarsbnP, PID: 19505930; Schafer, N., Lohmann, C., Winnik, S., van Tits, L.J., Miranda, M.X., Vergopoulos, A., Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity (2013) Eur Heart J, 34 (45), pp. 3515-3524. , PID: 23594590; Bender, S.B., McGraw, A.P., Jaffe, I.Z., Sowers, J.R., Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? (2013) Diabetes, 62 (2), pp. 313-319. , COI: 1:CAS:528:DC%2BC3sXhvFOgurk%3D, PID: 23349535; Caprio, M., Antelmi, A., Chetrite, G., Muscat, A., Mammi, C., Marzolla, V., Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome (2011) Endocrinology, 152 (1), pp. 113-125. , COI: 1:CAS:528:DC%2BC3MXitVCis74%3D, PID: 21084448; Armani, A., Cinti, F., Marzolla, V., Morgan, J., Cranston, G.A., Antelmi, A., Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice (2014) FASEB J, 28 (8), pp. 3745-3757. , COI: 1:CAS:528:DC%2BC2cXht1Krt7zE, PID: 24806198; Nagase, M., Fujita, T., Mineralocorticoid receptor activation in obesity hypertension (2009) Hypertens Res, 32 (8), pp. 649-657. , COI: 1:CAS:528:DC%2BD1MXps1Wks7o%3D, PID: 19521418; Troisi, R.J., Weiss, S.T., Parker, D.R., Sparrow, D., Young, J.B., Landsberg, L., Relation of obesity and diet to sympathetic nervous system activity (1991) Hypertension, 17, pp. 669-677. , COI: 1:STN:280:DyaK3M3hs1KjsA%3D%3D, PID: 2022410; Grassi, G., Seravalle, G., Cattaneo, B.M., Bolla, G.B., Lanfranchi, A., Colombo, M., Sympathetic activation in obese normotensive subjects (1995) Hypertension, 25, pp. 560-563. , COI: 1:STN:280:DyaK2M3jsl2ntA%3D%3D, PID: 7721398; Konno, S., Hirooka, Y., Kishi, T., Sunagawa, K., Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced rats (2012) J Hypertens, 30 (10), pp. 1992-1999. , COI: 1:CAS:528:DC%2BC38Xhtlemtr%2FO, PID: 22902874; Huggett, R.J., Burns, J., Mackintosh, A.F., Mary, D.A.S.G., Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension (2004) Hypertension, 44, pp. 847-852. , COI: 1:CAS:528:DC%2BD2cXpvVGlsrg%3D, PID: 15520303; Grassi, G., Sympathetic overdrive and cardiovascular risk in the metabolic syndrome (2006) Hypertens Res, 29, pp. 839-847. , COI: 1:CAS:528:DC%2BD2sXhsFantL4%3D, PID: 17345783; Grassi, G., Adrenergic overdrive as the link among hypertension, obesity and impaired thermogenesis: lights and shadows (2007) Hypertension, 49, pp. 5-6. , COI: 1:CAS:528:DC%2BD2sXpslKjuw%3D%3D, PID: 17116757; Raumouni, K., Correla, M.I., Haynes, W.G., Mark, A.L., Obesity associated hypertension: new insights into mechanisms (2005) Hypertension, 25, pp. 9-14; Simonds, S.E., Cowley, M.A., Enriori, P.J., Leptin increasing sympathetic nerve outflow in obesity: a cure for obesity or a potential contributor to metabolic syndrome? (2012) Adipocyte, 1 (3), pp. 177-181. , PID: 23700530; Hamnvik, O.R., Liu, X., Petrou, M., Gong, H., Chamberland, J.P., Kim, E.H., Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome and glucose levels at 2 year follow up: the Cyprus Metabolism Prospective Cohort Study (2011) Metab Clin Exp, 60, pp. 987-993. , COI: 1:CAS:528:DC%2BC3MXnslKmtLo%3D, PID: 21056886; Smith, M.M., Minson, C.T., Obesity and adipokines: effects on sympathetic overactivity (2012) J Physiol, 590 (8), pp. 1787-1801. , COI: 1:CAS:528:DC%2BC38XntFyksrk%3D, PID: 22351630; Shek, E.W., Brands, M.W., Hall, J.E., Chronic leptin infusion increases arterial pressure (1998) Hypertension, 31, pp. 409-414. , COI: 1:CAS:528:DyaK1cXptF2mtA%3D%3D, PID: 9453337; Haynes, W.G., Morgan, D.A., Walsh, S.A., Mark, A.L., Sivitz, W.I., Receptor mediated regional sympathetic nerve activation by leptin (1997) J Clin Investig, 100, pp. 270-278. , COI: 1:CAS:528:DyaK2sXkslKgur4%3D, PID: 9218503; Kazumi, T., Kawaguchi, A., Katoh, J., Iwahashi, M., Yoshino, G., Fasting insulin and leptin levels are associated with systolic blood pressure independent of percentage body fat and body fat mass index (1999) J Hypertens, 17, pp. 1451-1455. , COI: 1:CAS:528:DyaK1MXnsVSjuro%3D, PID: 10526906; Agata, J., Masuda, A., Takada, M., Higashiura, K., Murakami, H., Miyazaki, Y., High plasma immunoreactive leptin level in essential hypertension (1997) Am J Hypertens, 10, pp. 1171-1174. , COI: 1:STN:280:DyaK1c%2Fjs1WmtQ%3D%3D, PID: 9370390; Bravo, P.E., Morse, S., Borne, D.M., Aguilar, E.A., Reisin, E., Leptin and hypertension in obesity (2006) Vasc Health Risk Manag, 2 (2), pp. 163-169. , COI: 1:CAS:528:DC%2BD28Xhtlars7zF, PID: 17319461; Dudenbostel, T., Calhoun, D.A., Resistant hypertension, obstructive sleep apnoea and aldosterone (2012) J Hum Hypertens, 26 (5), pp. 281-287. , COI: 1:CAS:528:DC%2BC38XlsFSktLc%3D, PID: 21654850; Somers, V.K., Dyken, M.E., Clary, M.P., Abboud, F.M., Sympathetic neural mechanisms in obstructive sleep apnea (1995) J Clin Investig, 96, pp. 1897-1904. , COI: 1:CAS:528:DyaK2MXosFyhtrc%3D, PID: 7560081; Abdel-Kader, K., Dohar, S., Shah, N., Jhamb, M., Reis, S.E., Strollo, P., Resistant hypertension and obstructive sleep apnea in the setting of kidney disease (2012) J Hypertens, 30 (5), pp. 960-966. , COI: 1:CAS:528:DC%2BC38XlsFShsL8%3D, PID: 22388231; Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jr., National heart, lung, and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; national high blood pressure education program coordinating committee. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report (2003) JAMA, 289 (19), pp. 2560-2572. , COI: 1:CAS:528:DC%2BD3sXjvFCqtrk%3D, PID: 12748199; Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2002) JAMA, 288 (23), p. 2981; Rapoport, M.I., Hurd, H.F., Thiazide-induced glucose intolerance treated with potassium (1964) Arch Intern Med, 113, pp. 405-408. , COI: 1:CAS:528:DyaF2cXktVOjsL4%3D, PID: 14096393; Amery, A., Berthaux, P., Bulpitt, C., Deruyttere, M., de Schaepdryver, A., Dollery, C., Glucose intolerance during diuretic therapy: results of trial by the European working party on hypertension in the elderly (1978) Lancet, 1 (8066), pp. 681-683. , COI: 1:STN:280:DyaE1c7jsVKisw%3D%3D, PID: 76223; Hoskins, B., Jackson, C.M., The mechanism of chlorothiazide-induced carbohydrate intolerance (1978) J Pharmacol Exp Ther, 206 (2), pp. 423-430. , COI: 1:CAS:528:DyaE1cXlsleltLc%3D, PID: 210275; Helderman, J.H., Elahi, D., Andersen, D.K., Raizes, G.S., Tobin, J.D., Shocken, D., Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium (1983) Diabetes, 32 (2), pp. 106-111. , COI: 1:CAS:528:DyaL3sXhtlOntbg%3D, PID: 6337892; Plavinik, F.L., Rodrigues, C., Zanella, M.T., Ribeiro, A.B., Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy (1992) Hypertension, 19, pp. 26-29; Carlsen, J.E., Kober, L., Torp-Pedersen, C., Johansen, P., Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects (1990) Br Med J, 300 (6730), pp. 975-978. , COI: 1:STN:280:DyaK3c3mt1yquw%3D%3D; Harper, R., Ennis, C.N., Sheridan, B., Atkinson, A.B., Johnston, G.D., Bell, P.M., Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension (1994) Br Med J, 309 (6949), pp. 226-230. , COI: 1:STN:280:DyaK2czkvVeiuw%3D%3D; Harper, R., Ennis, C.N., Heaney, A.P., Sheridan, B., Gormley, M., Atkinson, A.B., A comparison of the effects of low and conventional dose thiazide diuretic on insulin action in hypertensive patients with NIDDM (1995) Diabetologia, 38 (7), pp. 853-859. , COI: 1:STN:280:DyaK28%2FksVyrsA%3D%3D, PID: 7556989; Punzi, H.A., Punzi, C.F., Antihypertensive and lipid-lowering heart attack trial study; trinity hypertension research institute. Metabolic issues in the antihypertensive and lipid-lowering heart attack trial study (2004) Curr Hyperten Rep, 6 (2), pp. 106-110; Messerli, F.H., ALLHAT, or the soft science of the secondary end point (2003) Ann Intern Med, 139 (9), pp. 777-780. , PID: 14597462; Barzilay, J.I., Davis, B.R., Cutler, J.A., Pressel, S.L., Whelton, P.K., Basile, J., ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2006) Arch Intern Med, 166 (2), pp. 2191-2201. , COI: 1:CAS:528:DC%2BD28Xhtlajsb7P, PID: 17101936; Black, H.R., Davis, B., Barzilay, J., Nwachuku, C., Baimbridge, C., Marginean, H., Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or Lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) (2008) Diabetes Care, 31 (2), pp. 353-360. , COI: 1:CAS:528:DC%2BD1cXis1ajs70%3D, PID: 18000186; Reisin, E., Graves, J.W., Yamal, J.M., Barzilay, J.I., Pressel, S.L., Einhorn, P.T., Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT (2014) J Hypertens, 32 (7), pp. 1503-1513. , COI: 1:CAS:528:DC%2BC2cXhtFOlurzE, PID: 24842697, A post hoc study in a large population that sought to determine the effect of clorthalidone versus lisinopril or amlodipine in normal weight,overweight and obese patients; Barzilay, J.I., Davis, B.R., Pressel, S.L., Cutler, J.A., Einhorn, P.T., Black, H.R., Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT diabetes extension study (2012) Circ Cardiovasc Qual Outcomes, 5 (2), pp. 153-162. , PID: 22396585; Kostis, J.B., Wilson, A.C., Freudenberger, R.S., Cosgrove, N.M., Pressel, S.L., Davis, B.R., Long-term effect of diuretic based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes (2005) Am J Cardiol, 95, pp. 29-35. , COI: 1:CAS:528:DC%2BD2cXhtFahs7nK, PID: 15619390; Reisin, E., Weir, M.R., Falkner, B., Hutchinson, H.G., Anzalone, D.A., Tuck, M.L., For the Treatment in Obese Patients with Hypertension (TROPHY) study group (1997) Hypertension, 30 (1), pp. 140-145. , COI: 1:CAS:528:DyaK2sXlt1CrsrY%3D, PID: 9231834, One of the first prospective,multicenter study that examine the effect of hydrochlorothiazide versus lisinopril in obese hypertensive patients; Reisin, E., Jack, A.V., Obesity and hypertension: mechanisms, cardio-renal consequences and therapeutic approaches (2009) Med Clin North Am, 93 (3), pp. 733-751. , COI: 1:CAS:528:DC%2BD1MXotFSqu7Y%3D, PID: 19427502; Kintscher, U., Bramlage, P., Paar, W.D., Thoenes, M., Unger, T., Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post authorization survey. Prospective, observational two armed study in 14,200 patients (2007) Cardiovasc Diabetol, 6, p. 12. , PID: 17407587; Benson, S.C., Pershadsingh, H.A., Ho, C.I., Chittiboyina, A., Desai, P., Prevenec, M., Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activities (2004) Hypertension, 43 (5), pp. 993-1002. , COI: 1:CAS:528:DC%2BD2cXjt1GmtrY%3D, PID: 15007034; Schupp, M., Janke, J., Clasen, R., Unger, T., Kintsher, U., Angiotensin type I receptor blockers induce peroxisome proliferator-activated receptor-gamma activity (2004) Circulation, 109 (17), pp. 2054-2057. , COI: 1:CAS:528:DC%2BD2cXjsVWqsrs%3D, PID: 15117841; Zappe, D.H., Sowers, J.R., Hsueh, W.A., Haffner, S.M., Deedwania, P.C., Fonseca, V.A., Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in Prediabetic hypertensive patients with the cardiometabolic syndrome (2008) J Clin Hypertens, 10 (12), pp. 894-903. , COI: 1:CAS:528:DC%2BD1MXhtVGltbs%3D; Yao, Y., Zou, R., Liu, X., Jiang, J., Huang, Q., He, Y., Telmisartan but not valsartan inhibits TGF-beta mediated accumulation of extracellular matrix via activation of PPARgamma (2008) J Huazhong Univ Sci Technolog Med Sci, 28 (5), pp. 543-548. , COI: 1:CAS:528:DC%2BD1cXhtlyrsLvO, PID: 18846335; Julius, S., Weber, M.A., Kjeldsen, S.E., McInnes, G.T., Zanchetti, A., Brunner, H.R., The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: outcomes in patients receiving monotherapy (2006) Hypertension, 48, pp. 385-391. , COI: 1:CAS:528:DC%2BD28XnvFKqu7o%3D, PID: 16864741; Aksnes, T.A., Kjeldsen, S.E., Rostrup, M., Omvik, P., Hua, T.A., Julius, S., New onset diabetes and cardiac outcome: impact of new-onset diabetes mellitus on cardiac outcomes in the valsartan antihypertensive long-term use evaluation (VALUE) trial population (2007) Hypertension, 50, pp. 467-473. , COI: 1:CAS:528:DC%2BD2sXptlyksbk%3D, PID: 17679652; Niskanen, L., Hedner, T., Hanson, L., Lanke, J., Niklason, A., CAPPP study group, Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based Treatment Regimen: a subanalysis of the captopril prevention project (2001) Diabetes Care, 24, pp. 2091-2096. , COI: 1:CAS:528:DC%2BD3MXpt1Kis7c%3D, PID: 11723089; Parving, H.H., Brenner, B.M., McMurray, J.J., de Zeeuw, D., Haffner, S.M., Solomon, S.D., Cardiorenal end points in a trial of aliskiren for type 2 diabetes (2012) N Engl J Med, 367 (23), pp. 2204-2213. , COI: 1:CAS:528:DC%2BC38XhvVakt73F, PID: 23121378; Friedrich, S., Schmieder, R.E., Review of direct renin inhibition by aliskiren (2013) J Renin-Angiotensin-Aldosterone Syst, 14 (3), pp. 193-196. , COI: 1:CAS:528:DC%2BC2cXhs1OisL7P, PID: 23873285; Jamerson, K., Weber, M.A., Bakris, G.L., Dahlof, B., Pitt, B., Shi, V., Benazapril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients (2008) New England Journal, 359 (23), pp. 2417-2428. , COI: 1:CAS:528:DC%2BD1cXhsVCrurjJ; Bakris, G.L., Sarafi dis, P.A., Weir, M.R., Dahlof, B., Pitt, B., Jamerson, K., Renal outcomes with different fixed dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial (2010) Lancet, 375, pp. 1173-1181. , COI: 1:CAS:528:DC%2BC3cXktlGitr8%3D, PID: 20170948; Bakris, G., Briasoulis, A., Dahlof, B., Jamerson, K., Weber, M.A., Kelly, R.Y., Comparison of benazepril plus amlodipine or hydrochlorothiazide in high risk patients with hypertension and coronary artery disease (2013) Am J Cardiol, 112, pp. 255-259. , COI: 1:CAS:528:DC%2BC3sXlvFSitb8%3D, PID: 23582626; Weber, M.A., Jamerson, K., Bakris, G.L., Weir, M.R., Zappe, D., Zhang, Y., Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomized controlled trial (2013) Lancet, 381, pp. 537-545. , PID: 23219284; Ripley, T.L., Saseen, J.J., Beta-blockers: a review of their pharmacological and physiological diversity in hypertension (2014) Ann Pharmacother, 48 (6), pp. 723-733. , COI: 1:CAS:528:DC%2BC2cXhslWgsL3M, PID: 24687542; Messerli, F.H., Grossman, E., Beta-blockers in hypertension: is carvedilol different (2004) Am J Cardiol, 93 (9A), pp. 7-12. , COI: 1:CAS:528:DC%2BD2cXltFyhsL0%3D, PID: 15144930; Deedwania, P., Hypertension, dyslipidemia and insulin resistance in patients with diabetes or the cardiometabolic syndrome: benefits of vasodilating beta blockers (2011) J Clin Hypertens, 13, pp. 52-59. , COI: 1:CAS:528:DC%2BC3MXislensrc%3D; Reisin, E., Owen, J., Treatment—special conditions: metabolic syndrome: obesity and the hypertension connection (2015) J Am Soc Hypertens, 9 (2), pp. 156-159. , PID: 25748147; Pepine, C.J., Handberg, E.M., Cooper-DeHoff, R.M., A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial (2003) JAMA, 290, pp. 2805-2816. , COI: 1:CAS:528:DC%2BD3sXps1Crurk%3D, PID: 14657064; Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol (2002) Lancet, 359, pp. 995-1003. , COI: 1:CAS:528:DC%2BD38XisV2htrw%3D, PID: 11937178; Gress, T.W., Nieto, F.J., Shahar, E., Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study (2000) N Engl J Med, 342, pp. 905-912. , COI: 1:CAS:528:DC%2BD3cXisFWmt7o%3D, PID: 10738048; 2013 ESH/ESC guidelines for the management of arterial hypertension (2013) J Hypertens, 31, pp. 1281-1357; James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., 2014 Evidence based guideline for the management of high blood pressure in adults: report from the panel members appointment to the eighth Joint National Committee (JNC 8) (2014) JAMA, 311 (5), pp. 507-520. , COI: 1:CAS:528:DC%2BC2cXis1aktr8%3D, PID: 24352797; Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 to 34 (2011) Royal College of Physicians (UK); Dasqupta, K., Quinn, R.R., Zarnke, K.B., Rabi, D.M., Ravani, P., Daskalopoulou, S.S., The 2014 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension (2014) Can J Cardiol, 30 (5), pp. 485-501",Review,Scopus,2-s2.0-84928822229
"Dlamini Z., Ntlabati P., Mbita Z., Shoba-Zikhali L.","Pyruvate dehydrogenase kinase 4 (PDK4) could be involved in a regulatory role in apoptosis and a link between apoptosis and insulin resistance",2015,"Experimental and Molecular Pathology","98","3",,"574","584",,,10.1016/j.yexmp.2015.03.022,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928552592&partnerID=40&md5=d773ab383b208e2a71fa641f986097c4","Innovation and Engagements Portfolio, Mangosuthu University of Technology ResearchDurban, South Africa; Merck Chemicals (Pty) LtdWadeville, Germiston, South Africa; Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, South Africa; Technology Innovation AgencyDurban, Umbogintwini, South Africa","Dlamini, Z., Innovation and Engagements Portfolio, Mangosuthu University of Technology ResearchDurban, South Africa; Ntlabati, P., Merck Chemicals (Pty) LtdWadeville, Germiston, South Africa; Mbita, Z., Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, South Africa; Shoba-Zikhali, L., Technology Innovation AgencyDurban, Umbogintwini, South Africa","Pyruvate dehydrogenase kinase 4 (PDK4), a mammalian mitochondrial serine kinase has emerged as an interesting candidate for diabetes therapy. Due to the high prevalence of this disease especially type 2 diabetes (T2D) and the health complications associated with it, there is extensive effort to find the appropriate treatment. Understanding the regulation of PDK4 activity would therefore contribute significantly to the development of therapeutic agents. This research outlines the utilization of bioinformatics tools such as Interweaver, ClustalW and Protein Structure Visualizer, in order to predict proteins that potentially interact with PDK4 and possibly regulate its activity. Interweaver database identified 96 proteins that have possible interaction sites for PDK4. Protein p100/p49, containing a death domain that is known to have a role in suppressing apoptosis, was identified as a potential partner for PDK4. The alignment between p100/p49 primary sequence and that of PDK4 using ClustalW demonstrated sequence similarity between the two proteins. Swiss PDB Viewer then located the positions of the amino acids that are in the hypothetical protein binding motif of p100/p49 within the 3D structure of hPDK4. These amino acids were found to be located in the region of PDK4 which is known to bind protein substrates of PDK4 and may be accessible to other proteins as well. These findings were very interesting as PDK4 has not previously been associated with apoptosis and this could be the link between apoptosis and insulin resistance. Cell biology studies were then performed to verify the relationship between PDK4 and apoptosis. In this regard, HeLa and HepG2 cells were treated with apoptosis-inducing agents such as TNFα, C2-ceramide, and linoleic acid. These cells were then monitored for apoptosis and PDK4 mRNA expression using a DNA laddering assay as well as Real Time PCR. The results showed that these factors induced apoptosis in a concentration dependent manner and suppressed PDK4 mRNA levels. These findings suggested a relationship between PDK4 and apoptosis. © 2015.","ClustalW; Interweaver; Protein p100/p49; Protein structure visualizer; Swiss PDB viewer; Type 2 diabetes (T2D)","Accili, D., New perspectives in diabetes research (2000) Trends Endocrinol. Metab., 11, pp. 349-350; Alves, M., Calegari, V.C., Cunha, D.A., Saad, M.J., Velloso, L.A., Rocha, E.M., Increased expression of advanced glycation end products and their receptor and activation of NFκB in lacrimal glands of diabetic rats (2005) Diabetologia, 12, pp. 2675-2681; Anuranda, R., Prefontaine, K.E., Physical association and functional antagonism between the p65 subunit of transcriptional factor NF-κB and the glucocorticoid receptor (1994) Proc. Natl. Acad. Sci. U. S. A., 91, pp. 752-756; Bailey, C.J., Potential new treatments for type 2 diabetes (2000) Trends Pharmacol. Sci., 21, pp. 259-265; Baumann, C.A., Saltiel, A.R., Spatial compartmentalization of signal transduction in insulin action (2001) Bioessays, 23, pp. 215-222; Behrooz, A.Z., Bobby, P.C.K., Genetic polymorphisms in susceptibility in type 1 diabetes (2007) Clin. Chim. Acta, 387, pp. 9-17; Blank, V., Kourilsky, P., Israel, A., Cytoplasmic retention, DNA binding and processing of the NF-κB p50 precursor is controlled by a small region in its C-terminus (1991) EMBO J., 10, pp. 4159-4167; Bonizzi, G., Bebien, M., Otero, D.C., Johnson-Vroom, K.E., Cao, Y., Vu, D., Jegga, A.G., Karin, M., Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB: p52 dimers (2004) EMBO J., 23, pp. 4202-4210; Bours, V., Villalobos, J., Burd, P.R., Kelly, K., Siebenlist, U., Cloning of a mitogen-inducible gene encoding a κB DNA binding protein with homology to the rel oncogene and to cell-cycle motifs (1990) Nature, 348, pp. 76-80; Bower-Kinley, M.M., Davis, W.I., Wu, P., Harris, R.A., Popov, K.M., Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex (1998) Biochem. J., 329, pp. 191-196; Chen, F., Is NFκB a culprit in type 2 diabetes? (2005) Biochem. Biophys. Res. Commun., 332, pp. 1-3; Cheng, A., Dube, N., Gu, F., Tremblay, M.L., Coordinated action of protein tyrosine phosphatases in insulin transduction (2002) Eur. J. Biochem., 269, pp. 1050-1059; Chiang, J.L., Kirkman, M.S., Laffel, L.M.B., Peters, A.N., Type 1diabetes through the life span: a position statement of the American diabetes association (2014) Diabetes Care, 37, pp. 2034-2054; Clark, S.F., Martin, S., Carrozzi, A.J., Hill, M.M., James, D.E., Intracellular localization of phosphatidylinositol 3-kinase and insulin receptor substrate-1 in adipocytes: potential involvement of a membrane skeleton (1998) J. Cell Biol., 140, pp. 1211-1225; Coba, M.P., Muñoz, M.C., Dominici, F.P., Toblli, J.E., Peña, C., Bartke, A., Turyn, D., Increased in vivo phosphorylation of insulin receptor at serine 994 in the liver of obese insulin-resistant Zucker rats (2004) J. Endocrinol., 182, pp. 433-444; Desaghner, S., Martinou, J.C., Mitochondria as the central point of apoptosis (2000) Trends Cell Biol., 10, pp. 369-377; Dichtl, W., Mikko, P.S., Jonson, A.N., Jovinge, S., Pachinger, O., Giachelli, C.M., Hamsten, A., Nilsson, J., Linoleic acid-stimulated vascular adhesion molecule-1 expression in endothelial cells depends on nuclear factor κB activation (2002) Metabolism, 3, pp. 327-333; Dlamini, Z., Mbita, Z., Zungu, M., Genealogy, expression, and molecular mechanisms in apoptosis (2004) Pharmacol. Ther., 101, pp. 1-15; Duan, C., Li, M., Rui, L., SH2-B promotes insulin receptor substrate 1 (IRS1) -and IRS2-mediated activation of the Phosphatidylinositol 3-kinase pathway in response to leptin (2004) J. Biol. Chem., 279, pp. 43684-43691; Duckett, C.S., Perkins, N.D., Kowalik, T.F., Schmid, R.M., Huang, E., Baldwin, A., Nabel, G.J., Dimerization of NF-κB2 with rel A (p65) regulates DNA, transcriptional activation, and inhibition by an IκB-α (MAD-3) (1993) Mol. Cell. Biol., 13, pp. 1315-1322; Egawa, K., Sharma, P.M., Nakashima, N., Huang, Y., Huver, E., Boss, G.R., Olefsky, J.M., Membrane-targeted phosphatidylinositol 3-kinase mimics insulin actions and induces a state of cellular insulin resistance (1999) J. Biol. Chem., 274, pp. 14306-14314; Fatehi-Hassanabad, Z., Chan, C.B., Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic β-cell function (2005) Nutr. Metab. (Lond.), 2, pp. 1-12; Feng, F., Wang, L., Albanese, N., Holmes, A., Xia, P., TWEAK attenuates the action of insulin in hepatocytes (2008) Endocrinology, 149, pp. 1505-1513; Formisano, P., Beguinot, F., The role of protein kinase C isoforms in insulin action (2001) J. Endocrinol. Invest., 24, pp. 460-467; Furuyama, T., Kitayama, K., Yamashita, H., Mori, N., Forkhead transcription FOXO1 (FKHR) dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation (2003) Biochem. J., 375, pp. 365-371; Ganchi, P.A., Sun, S., Greene, W.C., Ballard, D.W., A novel NF-κB complex containing p65 homodimers: implications for transcriptional control at the level of subunit dimerisation (1993) Mol. Cell. Biol., 13, pp. 7826-7835; Ghavami, S., Shojaei, S., Yaganeh, B., Ande, S.R., Jangamreddy, J.R., Mehrpour, M., Christffesson, J., Los, M.J., Autophagy and apoptosis dysfunction in neurodegenerative disoders (2014) Prog. Neurol., 112, pp. 24-49; Ghosh, S., Karin, M., Missing pieces in the NFκB puzzle (2002) Cell, 109, pp. S81-S96; Ghosh, S., May, M.J., Kopp, E.B., NFκB and Rel proteins: evolutionary conserved mediators of immune responses (1998) Annu. Rev. Immunol., 16, pp. 225-260; Grimm, S., Baeuerle, P.A., The inducible transcription factor NF-κB: structure-function relationship of its protein subunits (1993) Biochem. J., 290, pp. 297-308; Gudi, R., Bower-Kinley, M.M., Kedishvili, N.Y., Zhao, Y., Popov, K.M., Diversity of the pyruvate dehydrogenase kinase gene family in humans (1995) J. Biol. Chem., 270, pp. 28989-28994; Guex, N., Swiss-Pdb Viewer: a new fast and easy to use PDB viewer for the Macintosh (1996) Experientia, 52, p. A26; Harper, N., Hughes, M., MacFarlane, M., Cohen, G.M., Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signalling complex during tumor necrosis factor-induced apoptosis (2003) J. Biol. Chem., 278, pp. 25534-25541; Hovorka, R., Allen, J.M., Elleri, D., Chassin, L.J., Harris, J., Xing, D., Hovorka, T., Dunger, D.B., Manual closed-loop insulin delivery in children and adolescents with type1 diabetes: a phase 2 randomised crossover trial (2010) Lancet, 375, pp. 743-751; Huang, D., Huxford, T., Chen, Y., Ghosh, G., The role of DNA in the mechanism of NFκB dimer formation: crystal structures of the dimerization domains of the p50 and p65 units (1997) Structure, 15, pp. 1427-1435; Huang, B., Wu, P., Bowker-Kinley, M.M., Harris, R.A., Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferation-activated receptor-α ligands, glucocorticoids and insulin (2002) Diabetes, 51, pp. 276-282; Iwai, K., Lee, B.R., Hashiguchi, M., Fukushima, A., Iwashima, M., IκB-α-specific transcript regulation by the C-terminal end of c-Rel (2005) FEBS Lett., 579, pp. 141-144; Jing, M., Cheruvu, V.K., Ismail-Beigi, F., Stimulation of glucose transport in response to activation of distinct AMPK signalling pathway (2008) Am. J. Physiol., 295, pp. C1071-C1082; Kannan, K., Jain, S.K., Oxidative stress and apoptosis (2000) Pathophysiology, 7, pp. 153-163; Karin, M., Lin, A., NFκB at the crossroads of life and death (2002) Nat. Immunol., 3, pp. 221-227; Kim, E., Kwon, K., Shi, B., Seo, E., Lee, Y., Kim, J., Park, J., Ryu, D., Scopoletin induces apoptosis in human promyeloleukemic cells, accompanied by activations of nuclear factor κB and caspase-3 (2005) Life Sci., 77, pp. 824-836; Kim, J.W., Tchrnyshyov, I., Semenza, G.L., Dang, C.V., HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia (2006) Cell Metab., 3, pp. 177-185; Kolobova, E., Tuganova, A., Boulatnikov, I., Popov, K.M., Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites (2001) Biochem. J., 358, pp. 69-77; Korotchkina, L.G., Patel, M.S., Mutagenesis studies of the phosphorylation sites of recombinant human pyruvate dehydrogenase. Site-specific regulation (1995) J. Biol. Chem., 270, pp. 14297-14304; Korotchkina, L.G., Patel, M.S., Site-specific of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase (2001) J. Biol. Chem., 276, pp. 37223-37229; Kwon, H.S., Huang, B., Unterman, T.G., Harris, R.A., Protein kinase B-alpha inhibits human pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation of FOXO transcription factors (2004) Diabetes, 53, pp. 899-910; Lee, H.S., Chang, J.S., Baek, J.A., Chung, M.Y., Lee, H.C., Rhim, B.Y., Sok, D.E., Kim, K., TNF-α activates death pathway in human aorta smooth muscle cell in the presence of 7-ketocholesterol (2005) Biochem. Biophys. Res. Commun., 333, pp. 1093-1099; Liang, C., Zhang, M., Sun, S., β-TrCP binding and processing of NF-κB2/p100 involve its phosphorylation at serine 866 and 870 (2006) Cell. Signal., 18, pp. 1309-1317; Lihui, O., Clement, L., Lisafeld, B., Margot, M.I., Conjugated Linoleic acid induces apoptosis of murine mammary tumour cells via Bcl-2 loss (2007) Biochem. Biophys. Res. Commun., 356, pp. 1044-1049; Liou, H.C., Regulation of the immune system by NFκB and IκB (2002) J. Biochem. Mol. Biol., 35, pp. 537-547; Lui, Z.G., Hsu, H., Goeddel, D.V., Karin, M., Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF kappa-B activation prevents cell death (1996) Cell, 87, pp. 565-576; Majer, M., Popov, K.M., Harris, R.A., Bogardus, C., Prochazka, M., Insulin down regulates pyruvate dehydrogenase (PDK4) mRNA: potential mechanism contributing to increased lipid oxidation in insulin-resistance subjects (1998) Mol. Genet. Metab., 65, pp. 181-186; Malecki, M.T., Genetics of type 2 diabetes mellitus (2005) Diabetes Res. Clin. Pract., 68, pp. S10-S21; Mandrup-Poulsen, T., Apoptotic signal transduction pathways in diabetes (2003) Biochem. Pharmacol., 66, pp. 1433-1440; Marcotte, E., Pellegrini, M., Ng, N.L., Rice, D.W., Yeates, T.O., Isenberg, D., Detecting protein function and protein-protein interactions from genome sequences (1999) Science, 285, pp. 751-753; Matsuda, I., Matsuo, K., Matsushita, Y., Haruna, Y., Niwa, M., Kataoka, T., The c-terminal domain of the long form of cellular FLICE-inhibitory protein (c-FLIP<inf>L</inf>) inhibits the interaction of the caspase 8 prodomain with the receptor-interacting protein1 (RIP) death domain and regulates caspase 8-dependent nuclear factor <inf>k</inf>B (NF-<inf>K</inf>B) activation (2014) J. Biol. Chem., 289 (7), pp. 3876-3887; McKay, L.I., Cidlowski, J.A., Molecular control of immune/inflammatory responses: Interactions between nuclear factor-κB and steroid receptor-signalling pathway (1999) Endocr. Rev., 20, pp. 435-459; Moon, S., Lee, Y., Kim, S., Jeoung, N.H., Lee, I., Kim, J., Association of pyruvate dehydrogenase kinase 4 gene polymorphisms with type 2 diabetes and metabolic syndrome (2012) Diabetes Clin. Prac., 95, pp. 230-236; Mu, Y., Yanase, T., Nishi, Y., Tanaka, A., Saito, M., Jin, C., Mukasa, C., Nawata, H., Saturated FFAs, palmitic acid and stearic acid, induce apoptosis in human granulosa cells (2001) Endocrinology, 142, pp. 3590-3597; Ng, S.K., Zhang, Z., Tan, S.H., Integrative approach for computationally inferring protein domain interactions (2003) Bioinformatics, 19, pp. 923-929; Nir, T., Dor, Y., How to make pancreatic β cells - prospects for cell therapy in diabetes (2005) Curr. Opin. Biotechnol., 16, pp. 524-529; Nunn, A.V., Bell, J., Barter, P., The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance (2007) Nucl. Recept., 5, p. 1; Nur-E-Kamal, A., Gross, S.R., Pan, Z., Balklava, Z., Ma, J., Lui, L.F., Nuclear translocation of cytochrome c during apoptosis (2004) J. Biol. Chem., 279, pp. 24911-24914; Orange, J.S., Geha, R.S., Finding NEMO: genetic disorders of NFκB activation (2003) J. Clin. Invest., 112, pp. 983-985; Owen, K., Hattersley, A.T., Maturity-onset diabetes of the young: from clinical description to molecular genetic characterisation (2001) Baillieres Best Pract. Res. Clin. Endocrinol. Metab., 15, pp. 309-323; Patel, M.S., Roche, T.E., Molecular biology and biochemistry of pyruvate dehydrogenase complexes (1990) FASEB J., 4, pp. 3224-3233; Pawson, T., Nash, P., Modular protein interaction domains in cellular communication (2003) Handb. Cell Signal.; Pearson, W.R., Rapid and sensitive sequence comparison with FASTP and FASTA (1990) Meth. Enzymol., 183, pp. 63-98; Pessin, J.E., Thurmond, D.C., Elmendorf, J.S., Coker, K.J., Okada, S., Molecular basis of insulin stimulated GLUT4 vesicle trafficking (1999) J. Biol. Chem., 5, pp. 2593-2596; Popov, K.M., Kedishvili, N.Y., Zhao, Y., Shimomura, Y., Crabb, D.W., Harris, R.A., Primary structure of pyruvate dehydrogenase kinase establishes a new family of eukaryotic protein kinases (1993) J. Biol. Chem., 268, pp. 26602-26606; Randle, P.J., Fuel sensing in animals (1986) Biochem. Soc. Trans., 14, pp. 799-806; Ray, A., Prefontaine, K.E., Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor (1994) Proc. Natl. Acad. Sci. U. S. A., 91, pp. 752-756; Roche, T.E., Hiromasa, Y., Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia and cancer (2007) Cell. Mol. Life Sci., 64, pp. 830-849; Roche, T.E., Baker, J.C., Yan, X., Hiromasa, Y., Gong, X., Peng, T., Dong, J., Kasten, S.A., Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms (2001) Prog. Nucleic Acid Res. Mol. Biol., 70, pp. 33-75; Rowles, J., Scherer, S.W., Xi, T., Majer, M., Nickle, D.C., Rommens, J.M., Popov, K.M., Prochazka, M., Cloning and characterization of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human (1996) J. Biol. Chem., 271, pp. 22376-22382; Scheinman, R.I., Baldwin, A.S., NF-κB p100 (Lyt-10) is a component of H2TF1 and can function as an IκB-like molecule (1993) Mol. Cell. Biol., 13, pp. 6089-6101; Schlessinger, J., Ullrich, A., Growth factor signalling by receptor tyrosine kinases (1992) Neuron, 9, pp. 383-391; Schmid, R.M., Perkins, N.D., Duckett, C.S., Andrews, P.C., Nabel, G.J., Cloning of an NF-κB subunit which stimulates HIV transcription in synergy with p65 (1991) Nature, 352, pp. 733-736; Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Elchinger, F., Nitsche, A., Kretzler, M., Molecular activation of NFκB transcriptional programs in human diabetic nephropathy (2006) Diabetes, 11, pp. 2993-3003; Shumate, M.L., Yumet, G., Ahmed, T.A., Cooney, R.N., Interleukin-1 inhibits the induction of insulin-like growth factor-I by growth hormone in CWSV-1 hepatocytes (2005) Am. J. Physiol. Gastrointest. Liver Physiol., 289, pp. G227-G239; Steussy, C.N., Popov, K.M., Bowker-Kinley, M.M., Sloan, R.B., Harris, R.A., Hamilton, J.A., Structure of pyruvate dehydrogenase kinase: novel folding pattern for a serine protein kinase (2001) J. Biol. Chem., 276, pp. 37443-37450; Sugden, M.C., Holness, M.J., Therapeutic potential of the mammalian pyruvate dehydrogenase in the prevention of hyperglycaemia (2002) Curr. Drug Targets Immune Endocr. Metab. Disord., 2, pp. 151-165; Sugden, M.C., Holness, M.J., Recent advances in mechanisms regulating glucose oxidation at the level of pyruvate dehydrogenase complex by PDKs (2003) Am. J. Physiol. Endocrinol. Metab., 284, pp. 855-862; Tremblay, F., Brûlé, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X.J., Marette, A., Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient and obesity induced insulin resistance (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 14056-14061; Uchida, T., Myers, M.G., White, M.F., IRS-4 mediates Protein Kinase B signalling during insulin stimulation without promoting anti-apoptosis (2000) Mol. Cell. Biol., 20, pp. 126-138; Vestergaard, C., Johansen, C., Otkjaer, K., Deleuran, M., Iversen, L., Tumour necrosis factor-α-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor κB (2005) Cytokine, 29, pp. 49-55; Vriend, G., A molecular modelling and drug design program (1990) J. Mol. Graph., 8, pp. 52-55; Waraich, R.S., Weigert, C., Kalbacher, H., Hennige, A.M., Lutz, S., Haring, H.U., Schleicher, E.D., Lehmann, R., Phosphorylation of Ser357 of rat insulin receptor substrate -1 mediates adverse effects of protein kinase C-delta on insulin action in skeletal muscle cells (2008) J. Biol. Chem., 25, pp. 11226-11233; White, N.H., Cleary, P.A., Dahms, W., Goldstein, D., Malone, J., Tamborlane, W.V., Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the diabetes control and complications trial (DCCT) (2001) J. Pediatr., 139, pp. 804-812; Whitehead, J.P., Clark, S.F., Urso, B., James, D.E., Signalling through the insulin receptor (2000) Curr. Opin. Cell Biol., 12, pp. 222-228; Whiting, D.R., Guariguata, L., Weil, C., Shaw, J., IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 (2011) Diabetes Res. Clin. Prac., 94, pp. 311-321; Xu, J., Kim, H.T., Ma, Y., Zhao, L., Zhai, L., Kokorina, N., Wang, P., Messina, J.L., Trauma and hemorrhage-induced acute hepatic insulin resistance: dominant role of tumour necrosis factor alpha (TNFα) (2008) Endocrinology, 149, pp. 2369-2382; Yeaman, S.J., Hutcheson, E.T., Roche, T.E., Pettit, F.G., Brown, J.R., Reed, L.J., Watson, D.C., Dixon, G.H., Sites of phosphorylation on pyruvate dehydrogenase from bovine kidney and heart (1978) Biochemistry, 17, pp. 2364-2370; Zhang, Z., Ng, S.K., InterWeaver: interaction reports for discovering potential protein interaction partners with online evidence (2004) Nucleic Acids Res., 32, pp. 73-75",Article,Scopus,2-s2.0-84928552592
"Burke S.J., Karlstad M.D., Regal K.M., Sparer T.E., Lu D., Elks C.M., Grant R.W., Stephens J.M., Burk D.H., Collier J.J.","CCL20 is elevated during obesity and differentially regulated by NF-κB subunits in pancreatic β-cells",2015,"Biochimica et Biophysica Acta - Gene Regulatory Mechanisms","1849","6",,"637","652",,,10.1016/j.bbagrm.2015.03.007,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928136157&partnerID=40&md5=f7cc4da04948cf8c3ed3bed4aef868ac","Laboratory of Islet Biology and Inflammation, Pennington Biomedical Research CenterBaton Rouge, LA, United States; Department of Nutrition, University of Tennessee KnoxvilleKnoxville, TN, United States; Department of Surgery, Graduate School of Medicine, University of Tennessee Medical CenterKnoxville, TN, United States; Department of Microbiology, University of Tennessee KnoxvilleKnoxville, TN, United States; Sarah W. Stedman Nutrition and Metabolism Center, Duke Molecular Physiology Institute, Duke University Medical CenterDurham, NC, United States; Adipocyte Biology Laboratory, Pennington Biomedical Research CenterBaton Rouge, LA, United States; Cell Biology and Bioimaging Core Facility, Pennington Biomedical Research CenterBaton Rouge, LA, United States","Burke, S.J., Laboratory of Islet Biology and Inflammation, Pennington Biomedical Research CenterBaton Rouge, LA, United States, Department of Nutrition, University of Tennessee KnoxvilleKnoxville, TN, United States; Karlstad, M.D., Department of Surgery, Graduate School of Medicine, University of Tennessee Medical CenterKnoxville, TN, United States; Regal, K.M., Department of Surgery, Graduate School of Medicine, University of Tennessee Medical CenterKnoxville, TN, United States; Sparer, T.E., Department of Microbiology, University of Tennessee KnoxvilleKnoxville, TN, United States; Lu, D., Sarah W. Stedman Nutrition and Metabolism Center, Duke Molecular Physiology Institute, Duke University Medical CenterDurham, NC, United States; Elks, C.M., Adipocyte Biology Laboratory, Pennington Biomedical Research CenterBaton Rouge, LA, United States; Grant, R.W., Adipocyte Biology Laboratory, Pennington Biomedical Research CenterBaton Rouge, LA, United States; Stephens, J.M., Adipocyte Biology Laboratory, Pennington Biomedical Research CenterBaton Rouge, LA, United States; Burk, D.H., Cell Biology and Bioimaging Core Facility, Pennington Biomedical Research CenterBaton Rouge, LA, United States; Collier, J.J., Laboratory of Islet Biology and Inflammation, Pennington Biomedical Research CenterBaton Rouge, LA, United States, Department of Nutrition, University of Tennessee KnoxvilleKnoxville, TN, United States, Department of Surgery, Graduate School of Medicine, University of Tennessee Medical CenterKnoxville, TN, United States","Enhanced leukocytic infiltration into pancreatic islets contributes to inflammation-based diminutions in functional β-cell mass. Insulitis (aka islet inflammation), which can be present in both T1DM and T2DM, is one factor influencing pancreatic β-cell death and dysfunction. IL-1β, an inflammatory mediator in both T1DM and T2DM, acutely (within 1. h) induced expression of the CCL20 gene in rat and human islets and clonal β-cell lines. Transcriptional induction of CCL20 required the p65 subunit of NF-κB to replace the p50 subunit at two functional κB sites within the CCL20 proximal gene promoter. The NF-κB p50 subunit prevents CCL20 gene expression during unstimulated conditions and overexpression of p50 reduces CCL20, but enhances cyclooxygenase-2 (COX-2), transcript accumulation after exposure to IL-1β. We also identified differential recruitment of specific co-activator molecules to the CCL20 gene promoter, when compared with the CCL2 and COX2 genes, revealing distinct transcriptional requirements for individual NF-κB responsive genes. Moreover, IL-1β, TNF-α and IFN-γ individually increased the expression of CCR6, the receptor for CCL20, on the surface of human neutrophils. We further found that the chemokine CCL20 is elevated in serum from both genetically obese db/. db mice and in C57BL6/J mice fed a high-fat diet. Taken together, these results are consistent with a possible activation of the CCL20-CCR6 axis in diseases with inflammatory components. Thus, interfering with this signaling pathway, either at the level of NF-κB-mediated chemokine production, or downstream receptor activation, could be a potential therapeutic target to offset inflammation-associated tissue dysfunction in obesity and diabetes. © 2015 Elsevier B.V.","Chemokine; Cytokine; Diabetes; Inflammation; Innate immunity; Transcription","Baker, R.G., Hayden, M.S., Ghosh, S., NF-kappaB, inflammation, and metabolic disease (2011) Cell Metab., 13, pp. 11-22; Burke, S.J., Collier, J.J., Insulitis and diabetes: A perspective on islet inflammation (2014) Immunome Res., 10. , (in Press); Donath, M.Y., Schumann, D.M., Faulenbach, M., Ellingsgaard, H., Perren, A., Ehses, J.A., Islet inflammation in type 2 diabetes: from metabolic stress to therapy (2008) Diabetes Care, 31, pp. S161-S164; Corbett, J.A., Wang, J.L., Sweetland, M.A., Lancaster, J.R., McDaniel, M.L., Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide (1992) J. Clin. Invest., 90, pp. 2384-2391; Collier, J.J., Burke, S.J., Eisenhauer, M.E., Lu, D., Sapp, R.C., Frydman, C.J., Campagna, S.R., Pancreatic beta-cell death in response to Pro-inflammatory cytokines is distinct from genuine apoptosis (2011) PLoS One, 6, p. e22485; Corbett, J.A., Sweetland, M.A., Wang, J.L., Lancaster, J.R., McDaniel, M.L., Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans (1993) Proc. Natl. Acad. Sci. U. S. A., 90, pp. 1731-1735; Boni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D.T., Prazak, R., Kerr-Conte, J., Donath, M.Y., Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I (2009) Endocrinology, 150, pp. 5218-5229; Burke, S.J., Updegraff, B.L., Bellich, R.M., Goff, M.R., Lu, D., Minkin, S.C., Karlstad, M.D., Collier, J.J., Regulation of iNOS gene transcription by IL-1beta and IFN-gamma requires a coactivator exchange mechanism (2013) Mol. Endocrinol., 27, pp. 1724-1742; Burke, S.J., Collier, J.J., The gene encoding cyclooxygenase-2 is regulated by IL-1beta and prostaglandins in 832/13 rat insulinoma cells (2011) Cell. Immunol., 271, pp. 379-384; Heitmeier, M.R., Scarim, A.L., Corbett, J.A., Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1 (1997) J. Biol. Chem., 272, pp. 13697-13704; Sarkar, S.A., Lee, C.E., Victorino, F., Nguyen, T.T., Walters, J.A., Burrack, A., Eberlein, J., Homann, D., Expression and regulation of chemokines in murine and human type 1 diabetes (2012) Diabetes, 61, pp. 436-446; Burke, S.J., Lu, D., Sparer, T.E., Masi, T., Goff, M.R., Karlstad, M.D., Collier, J.J., NF-kappaB and STAT1 control CXCL1 and CXCL2 gene transcription (2014) Am. J. Physiol. Endocrinol. Metab., 306, pp. E131-E149; Burke, S.J., Goff, M.R., Lu, D., Proud, D., Karlstad, M.D., Collier, J.J., Synergistic expression of the CXCL10 gene in response to IL-1beta and IFN-gamma involves NF-kappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4 (2013) J. Immunol., 191, pp. 323-336; Burke, S.J., Goff, M.R., Updegraff, B.L., Lu, D., Brown, P.L., Minkin, S.C., Biggerstaff, J.P., Collier, J.J., Regulation of the CCL2 gene in pancreatic beta-cells by IL-1beta and glucocorticoids: Role of MKP-1 (2012) PLoS One, 7, p. e46986; Tilstra, J.S., Clauson, C.L., Niedernhofer, L.J., Robbins, P.D., NF-kappaB in aging and disease (2011) Aging Dis., 2, pp. 449-465; Brown, K.D., Claudio, E., Siebenlist, U., The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis (2008) Arthritis Res. Ther., 10, p. 212; Ben-Neriah, Y., Karin, M., Inflammation meets cancer, with NF-kappaB as the matchmaker (2011) Nat. Immunol., 12, pp. 715-723; Ellrichmann, G., Thone, J., Lee, D.H., Rupec, R.A., Gold, R., Linker, R.A., Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation (2012) J. Neuroinflammation, 9, p. 15; Cai, D., Neuroinflammation and neurodegeneration in overnutrition-induced diseases (2013) Trends Endocrinol. Metab., 24, pp. 40-47; Oeckinghaus, A., Hayden, M.S., Ghosh, S., Crosstalk in NF-kappaB signaling pathways (2011) Nat. Immunol., 12, pp. 695-708; Beg, A.A., Baldwin, A.S., The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors (1993) Genes Dev., 7, pp. 2064-2070; Moser, B., Wolf, M., Walz, A., Loetscher, P., Chemokines: multiple levels of leukocyte migration control (2004) Trends Immunol., 25, pp. 75-84; Gerard, C., Rollins, B.J., Chemokines and disease (2001) Nat. Immunol., 2, pp. 108-115; Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Ferrante, A.W., CCR2 modulates inflammatory and metabolic effects of high-fat feeding (2006) J. Clin. Invest., 116, pp. 115-124; Kim, C.S., Park, H.S., Kawada, T., Kim, J.H., Lim, D., Hubbard, N.E., Kwon, B.S., Yu, R., Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters (2006) Int. J. Obes., 30, pp. 1347-1355; Martin, A.P., Rankin, S., Pitchford, S., Charo, I.F., Furtado, G.C., Lira, S.A., Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes (2008) Diabetes, 57, pp. 3025-3033; Cowley, M.J., Weinberg, A., Zammit, N.W., Walters, S.N., Hawthorne, W.J., Loudovaris, T., Thomas, H., Grey, S.T., Human islets express a marked proinflammatory molecular signature prior to transplantation (2012) Cell Transplant., 21, pp. 2063-2078; Merani, S., Truong, W.W., Hancock, W., Anderson, C.C., Shapiro, A.M., Chemokines and their receptors in islet allograft rejection and as targets for tolerance induction (2006) Cell Transplant., 15, pp. 295-309; Citro, A., Cantarelli, E., Maffi, P., Nano, R., Melzi, R., Mercalli, A., Dugnani, E., Piemonti, L., CXCR1/2 inhibition enhances pancreatic islet survival after transplantation (2012) J. Clin. Invest., 122, pp. 3647-3651; Hromas, R., Gray, P.W., Chantry, D., Godiska, R., Krathwohl, M., Fife, K., Bell, G.I., Klemsz, M.J., Cloning and characterization of exodus, a novel beta-chemokine (1997) Blood, 89, pp. 3315-3322; Matsui, T., Akahoshi, T., Namai, R., Hashimoto, A., Kurihara, Y., Rana, M., Nishimura, A., Kondo, H., Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis (2001) Clin. Exp. Immunol., 125, pp. 155-161; Jafarzadeh, A., Bagherzadeh, S., Ebrahimi, H.A., Hajghani, H., Bazrafshani, M.R., Khosravimashizi, A., Nemati, M., Daneshvar, H., Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: Evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern (2014) J. Mol. Neurosci., 53, pp. 500-505; Ylipaasto, P., Smura, T., Gopalacharyulu, P., Paananen, A., Seppanen-Laakso, T., Kaijalainen, S., Ahlfors, H., Roivainen, M., Enterovirus-induced gene expression profile is critical for human pancreatic islet destruction (2012) Diabetologia, 55, pp. 3273-3283; Sato, K., Kawasaki, H., Nagayama, H., Enomoto, M., Morimoto, C., Tadokoro, K., Juji, T., Takahashi, T., Chemokine receptor expressions and responsiveness of cord blood T cells (2001) J. Immunol., 166, pp. 1659-1666; Christopherson, K., Brahmi, Z., Hromas, R., Regulation of naive fetal T-cell migration by the chemokines Exodus-2 and Exodus-3 (1999) Immunol. Lett., 69, pp. 269-273; Kucharzik, T., Hudson, J.T., Waikel, R.L., Martin, W.D., Williams, I.R., CCR6 expression distinguishes mouse myeloid and lymphoid dendritic cell subsets: demonstration using a CCR6 EGFP knock-in mouse (2002) Eur. J. Immunol., 32, pp. 104-112; Brandes, M., Legler, D.F., Spoerri, B., Schaerli, P., Moser, B., Activation-dependent modulation of B lymphocyte migration to chemokines (2000) Int. Immunol., 12, pp. 1285-1292; Krzysiek, R., Lefevre, E.A., Bernard, J., Foussat, A., Galanaud, P., Louache, F., Richard, Y., Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3alpha/CCL20 in human B cells (2000) Blood, 96, pp. 2338-2345; Robertson, M.J., Williams, B.T., Christopherson, K., Brahmi, Z., Hromas, R., Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines (2000) Cell. Immunol., 199, pp. 8-14; Schutyser, E., Struyf, S., Van Damme, J., The CC chemokine CCL20 and its receptor CCR6 (2003) Cytokine Growth Factor Rev., 14, pp. 409-426; Diana, J., Simoni, Y., Furio, L., Beaudoin, L., Agerberth, B., Barrat, F., Lehuen, A., Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes (2013) Nat. Med., 19, pp. 65-73; Battaglia, M., Neutrophils and type 1 autoimmune diabetes (2014) Curr. Opin. Hematol., 21, pp. 8-15; Valle, A., Giamporcaro, G.M., Scavini, M., Stabilini, A., Grogan, P., Bianconi, E., Sebastiani, G., Battaglia, M., Reduction of circulating neutrophils precedes and accompanies type 1 diabetes (2013) Diabetes, 62, pp. 2072-2077; Hohmeier, H.E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., Newgard, C.B., Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion (2000) Diabetes, 49, pp. 424-430; Janjic, D., Maechler, P., Sekine, N., Bartley, C., Annen, A.S., Wolheim, C.B., Free radical modulation of insulin release in INS-1 cells exposed to alloxan (1999) Biochem. Pharmacol., 57, pp. 639-648; Collier, J.J., Fueger, P.T., Hohmeier, H.E., Newgard, C.B., Pro- and antiapoptotic proteins regulate apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and beta-cell lines (2006) Diabetes, 55, pp. 1398-1406; Markert, M., Andrews, P.C., Babior, B.M., Measurement of O2- production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils (1984) Methods Enzymol., 105, pp. 358-365; Donath, M.Y., Boni-Schnetzler, M., Ellingsgaard, H., Halban, P.A., Ehses, J.A., Cytokine production by islets in health and diabetes: cellular origin, regulation and function (2010) Trends Endocrinol. Metab., 21, pp. 261-267; McGillicuddy, F.C., Harford, K.A., Reynolds, C.M., Oliver, E., Claessens, M., Mills, K.H., Roche, H.M., Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis (2011) Diabetes, 60, pp. 1688-1698; Hayden, M.S., Ghosh, S., Shared principles in NF-kappaB signaling (2008) Cell, 132, pp. 344-362; Jobin, C., Panja, A., Hellerbrand, C., Iimuro, Y., Didonato, J., Brenner, D.A., Sartor, R.B., Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells (1998) J. Immunol., 160, pp. 410-418; Ueda, A., Okuda, K., Ohno, S., Shirai, A., Igarashi, T., Matsunaga, K., Fukushima, J., Okubo, T., NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene (1994) J. Immunol., 153, pp. 2052-2063; Newton, R., Kuitert, L.M., Bergmann, M., Adcock, I.M., Barnes, P.J., Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta (1997) Biochem. Biophys. Res. Commun., 237, pp. 28-32; Moorthy, A.K., Savinova, O.V., Ho, J.Q., Wang, V.Y., Vu, D., Ghosh, G., The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner (2006) EMBO J., 25, pp. 1945-1956; Medzhitov, R., Horng, T., Transcriptional control of the inflammatory response (2009) Nat. Rev. Immunol., 9, pp. 692-703; Covic, M., Hassa, P.O., Saccani, S., Buerki, C., Meier, N.I., Lombardi, C., Imhof, R., Hottiger, M.O., Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression (2005) EMBO J., 24, pp. 85-96; Vo, N., Goodman, R.H., CREB-binding protein and p300 in transcriptional regulation (2001) J. Biol. Chem., 276, pp. 13505-13508; Olza, J., Aguilera, C.M., Gil-Campos, M., Leis, R., Bueno, G., Martinez-Jimenez, M.D., Valle, M., Gil, A., Myeloperoxidase is an early biomarker of inflammation and cardiovascular risk in prepubertal obese children (2012) Diabetes Care, 35, pp. 2373-2376; Guo, S., Dai, C., Guo, M., Taylor, B., Harmon, J.S., Sander, M., Robertson, R.P., Stein, R., Inactivation of specific beta cell transcription factors in type 2 diabetes (2013) J. Clin. Invest., 123, pp. 3305-3316; Li, C.R., Mueller, E.E., Bradley, L.M., Islet antigen-specific Th17 cells can induce TNF-alpha-dependent autoimmune diabetes (2014) J. Immunol., 192, pp. 1425-1432; Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance (1993) Science, 259, pp. 87-91; Dinarello, C.A., Donath, M.Y., Mandrup-Poulsen, T., Role of IL-1beta in type 2 diabetes (2010) Curr. Opin. Endocrinol. Diabetes Obes., 17, pp. 314-321; Rabinovitch, A., Suarez-Pinzon, W.L., Sorensen, O., Bleackley, R.C., Power, R.F., IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice (1995) J. Immunol., 154, pp. 4874-4882; Boni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J.A., Kerr-Conte, J., Pattou, F., Donath, M.Y., Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation (2008) J. Clin. Endocrinol. Metab., 93, pp. 4065-4074; Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H.I., Spinas, G.A., Kaiser, N., Donath, M.Y., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets (2002) J. Clin. Invest., 110, pp. 851-860; Grant, R.W., Dixit, V.D., Adipose tissue as an immunological organ (2015) Obesity (Silver Spring), 23, pp. 512-518; Grant, R.W., Dixit, V.D., Mechanisms of disease: inflammasome activation and the development of type 2 diabetes (2013) Front. Immunol., 4, p. 50; Cnop, M., Abdulkarim, B., Bottu, G., Cunha, D.A., Igoillo-Esteve, M., Masini, M., Turatsinze, J.V., Eizirik, D.L., RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate (2014) Diabetes, 63, pp. 1978-1993; Nepom, G.T., Ehlers, M., Mandrup-Poulsen, T., Anti-cytokine therapies in T1D: Concepts and strategies (2013) Clin. Immunol., 149, pp. 279-285; Atkinson, M.A., Eisenbarth, G.S., Michels, A.W., Type 1 diabetes (2014) Lancet, 383, pp. 69-82; Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease (2011) Nat. Rev. Immunol., 11, pp. 98-107; Yeung, W.C., Al-Shabeeb, A., Pang, C.N., Wilkins, M.R., Catteau, J., Howard, N.J., Rawlinson, W.D., Craig, M.E., Children with islet autoimmunity and enterovirus infection demonstrate a distinct cytokine profile (2012) Diabetes, 61, pp. 1500-1508; Perez, F., Oyarzun, A., Carrasco, E., Angel, B., Albala, C., Santos, J.L., Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies (2004) Rev. Med. Chil., 132, pp. 413-420; van Poppel, P.C., van Asseldonk, E.J., Holst, J.J., Vilsboll, T., Netea, M.G., Tack, C.J., The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance (2014) Diabetes Obes. Metab., 16, pp. 1269-1273; van Asseldonk, E.J., Stienstra, R., Koenen, T.B., Joosten, L.A., Netea, M.G., Tack, C.J., Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study (2011) J. Clin. Endocrinol. Metab., 96, pp. 2119-2126; Larsen, C.M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J.A., Seifert, B., Mandrup-Poulsen, T., Donath, M.Y., Interleukin-1-receptor antagonist in type 2 diabetes mellitus (2007) N. Engl. J. Med., 356, pp. 1517-1526; Coppieters, K.T., Dotta, F., Amirian, N., Campbell, P.D., Kay, T.W., Atkinson, M.A., Roep, B.O., von Herrath, M.G., Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients (2012) J. Exp. Med., 209, pp. 51-60; Sarikonda, G., Pettus, J., Phatak, S., Sachithanantham, S., Miller, J.F., Wesley, J.D., Cadag, E., von Herrath, M., CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes (2014) J. Autoimmun., 50, pp. 77-82; Kershaw, E.E., Flier, J.S., Adipose tissue as an endocrine organ (2004) J. Clin. Endocrinol. Metab., 89, pp. 2548-2556; Duffaut, C., Zakaroff-Girard, A., Bourlier, V., Decaunes, P., Maumus, M., Chiotasso, P., Sengenes, C., Bouloumie, A., Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators (2009) Arterioscler. Thromb. Vasc. Biol., 29, pp. 1608-1614; Mackay, C.R., Moving targets: cell migration inhibitors as new anti-inflammatory therapies (2008) Nat. Immunol., 9, pp. 988-998; Liston, A., Kohler, R.E., Townley, S., Haylock-Jacobs, S., Comerford, I., Caon, A.C., Webster, J., McColl, S.R., Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response (2009) J. Immunol., 182, pp. 3121-3130; Honkanen, J., Nieminen, J.K., Gao, R., Luopajarvi, K., Salo, H.M., Ilonen, J., Knip, M., Vaarala, O., IL-17 immunity in human type 1 diabetes (2010) J. Immunol., 185, pp. 1959-1967; Schulthess, F.T., Paroni, F., Sauter, N.S., Shu, L., Ribaux, P., Haataja, L., Strieter, R.M., Maedler, K., CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling (2009) Cell Metab., 9, pp. 125-139; Oshima, H., Taketo, M.M., Oshima, M., Destruction of pancreatic beta-cells by transgenic induction of prostaglandin E2 in the islets (2006) J. Biol. Chem., 281, pp. 29330-29336",Article,Scopus,2-s2.0-84928136157
"Schweitzer D., Deutsch L., Klemm M., Jentsch S., Hammer M., Peters S., Haueisen J., Muller U.A., Dawczynski J.","Fluorescence lifetime imaging ophthalmoscopy in type 2 diabetic patients who have no signs of diabetic retinopathy",2015,"Journal of Biomedical Optics","20","6", 061106,"","",,,10.1117/1.JBO.20.6.061106,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924812965&partnerID=40&md5=176bd563e86887cb924c8173e374827d","University Hospital Jena, Dept. of Experimental Ophthalmology, Bachstrasse 18Jena, Germany; Ilmenau University of Technology, Institute of Biomedical Engineering and Informatics, P.O. Box 100565Ilmenau, Germany; University Hospital Jena, Clinic of Internal Medicine III, Erlanger Allee 101Jena, Germany; University Hospital Leipzig, Department of Ophthalmology, Liebigstr.10-14Leipzig, Germany","Schweitzer, D., University Hospital Jena, Dept. of Experimental Ophthalmology, Bachstrasse 18Jena, Germany; Deutsch, L., University Hospital Jena, Dept. of Experimental Ophthalmology, Bachstrasse 18Jena, Germany; Klemm, M., Ilmenau University of Technology, Institute of Biomedical Engineering and Informatics, P.O. Box 100565Ilmenau, Germany; Jentsch, S., University Hospital Jena, Dept. of Experimental Ophthalmology, Bachstrasse 18Jena, Germany; Hammer, M., University Hospital Jena, Dept. of Experimental Ophthalmology, Bachstrasse 18Jena, Germany; Peters, S., University Hospital Jena, Dept. of Experimental Ophthalmology, Bachstrasse 18Jena, Germany; Haueisen, J., Ilmenau University of Technology, Institute of Biomedical Engineering and Informatics, P.O. Box 100565Ilmenau, Germany; Müller, U.A., University Hospital Jena, Clinic of Internal Medicine III, Erlanger Allee 101Jena, Germany; Dawczynski, J., University Hospital Leipzig, Department of Ophthalmology, Liebigstr.10-14Leipzig, Germany","The time-resolved autofluorescence of the eye is used for the detection of metabolic alteration in diabetic patients who have no signs of diabetic retinopathy. One eye from 37 phakic and 11 pseudophakic patients with type 2 diabetes, and one eye from 25 phakic and 23 pseudophakic healthy subjects were included in the study. After a three-exponential fit of the decay of autofluorescence, histograms of lifetimes Τi, amplitudes αi, and relative contributions Qi were statistically compared between corresponding groups in two spectral channels (490 &lt; ch1 &lt; 560 nm, 560 &lt; ch2 &lt; 700 nm). The change in single fluorophores was estimated by applying the Holm Bonferroni method and by calculating differences in the sum histograms of lifetimes. Median and mean of the histograms of Τ2, Τ3, and α3 in ch1 show the greatest differences between phakic diabetic patients and age-matched controls (p 0.000004). The lack of pixels with a Τ2 of 360 ps, the increased number of pixels with Τ2 &gt; 450 ps, and the shift of Τ3 from 3000 to 3700 ps in ch1 of diabetic patients when compared with healthy subjects indicate an increased production of free flavin adenine dinucleotide, accumulation of advanced glycation end products (AGE), and, probably, a change from free to protein-bound reduced nicotinamide adenine dinucleotide at the fundus. AGE also accumulated in the crystalline lens. © The Authors.","advanced glycation end products.; diabetes; flavin adenine dinucleotide; fluorescence lifetime imaging ophthalmoscopy; metabolism; reduced nicotinamide adenine dinucleotide","Ohkubo, Y., Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin dependent diabetes mellitus: A randomized prospective 5-year study (1995) Diab. Res. Clin. Pract., 28, pp. 103-117; Intensive blood-glucose control with sulfonyl ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (1998) Lancet, 352, pp. 837-853. , UK Prospektive Diabetes Study (UKPDS) Group; Barber, A.J., Gardner, T.W., Abcouwer, S.F., The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy (2011) Invest. Ophthalmol. Vis. Sci., 52, pp. 1156-1162; Barber, A.J., Neural apoptosis in the retina during experimental and human diabetes: Early onset and effect of insulin (1998) J. Clin. Invest., 102, pp. 783-791; El-Remessy, A.B., Neuroprotective and blood-retinal barrierpreserving effect of cannabitol in experimental diabetes (2006) Am. J. Pathol., 168, pp. 235-244; Diederen, R.M.H., Reexamining the hyperglycemic pseudohypoxia hypothesis of diabetic oculopathy (2006) Invest. Ophthalmol. Vis. Sci., 47, pp. 2726-2731; Ola, M.S., Analysis of glucose metabolism in diabetic rat retinas (2006) Am. J. Physiol. Endocrinol. Metab., 290, pp. E1057-E1067; Ido, Y., Early neural and vascular dysfunction in diabetic rats are largely sequelae of increased sorbitol oxidation (2010) Antioxid. Redox Signal., 12, pp. 39-51; Lieth, E., Retinal neurodegeneration: Early pathology in diabetes (2000) Clin. Exp. Ophthalmol., 28, pp. 3-8; Yang, J.H., Retinal neurodegeneration in type II diabetic Otsuka Long-Evans Tokusshima fatty rats (2013) Invest. Ophthalmol. Vis. Sci., 54, pp. 3844-3851; Kowluru, R.U., Abbas, S.N., Diabetes-induced mitochondrial dysfunction in the retina (2003) Invest. Ophthalmol. Vis. Sci., 44, pp. 5327-5334; Field, M.G., Rapid, noninvasive detection of diabetes-induced retinal metabolic stress (2008) Arch. Ophthalmol., 126 (7), pp. 934-938; Delori, F.C., In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics (1995) Invest. Ophthalmol. Vis. Sci., 36 (3), pp. 718-729; Schweitzer, D., Ophthalmic applications of FLIM (2014) Chapter 20 in Fluorescence Lifetime Spectroscopy and Imaging, pp. 423-447. , L. Marcu, P. M. W. French, and D. S. Elson, Eds. CRC Press, Boca Raton, FL; Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification (1991) ETDRS Report Number 10 Ophthalmology, 98, pp. 786-806. , Early Treatment Diabetic Retinopathy Study Research Group; Van Dijk, H.W., Early neurodegeneration in the retina of type 2 diabetic patients (2012) Invest. Ophthalmol. Vis. Sci., 53, pp. 2715-2719; Schweitzer, D., Towards metabolic mapping of the human retina (2007) Microsc. Res. Tech., 70, pp. 410-419; Schweitzer, D., Quantifying fundus autofluorescence (2009) Chapter 8 in Fundus Autofluorescence, pp. 78-95. , N. Lois and J.,V. Forrester, Eds. Wolters Kluwer LippincottWilliams &Wilkins, Philadelphia, PA; Chew, E.Y., Evaluation of the age-related eye disease study clinical lens grading system AREDS report no. 31 (2010) Ophthalmology, 117, pp. 2112-2119; Deutsch, L., (2012) Evaluierung des Fluorescence Lifetime Imaging Vom Augenhintergrund Bei Patienten Mit Diabetes Mellitus, , MD Dissertation, FSU Jena, Germany; Dysli, C., Quantitative analysis of fluorescence lifetime measurements of the macula using the fluorescence lifetime imaging ophthalmoscope in healthy subjects (2014) Invest. Ophthalmol. Vis. Sci., 55, pp. 2106-2113; Kloos, C., Unnoticed shift in the normal range of glycated HbA1c with TOSOH high performance liquid chromatography (2011) Diabetologia, 54, p. 401; The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus (1993) N. Engl. J. Med., 329, pp. 977-986. , Diabetes Control and Complication Trial Research Group; Holm, S., A simple sequentially rejective multiple test procedure (1979) Scand. J. Stat., 6, pp. 65-70; Klemm, M., (2010) Private Communication, , University of Technology, Institute of Biomedical Engineering and Informatics, Ilmenau, Germany; Klemm, M., Repeatability of autofluorescence lifetime imaging at the human fundus in healthy volunteers (2013) Curr. Eye Res., 38, pp. 793-801; Schweitzer, D., Spectral and time-resolved studies on ocular structures (2007) Proc. SPIE, 6628, p. 662807; Peters, S., Hammer, M., Schweitzer, D., Two-photon excited fluorescence microscopy application for ex vivo investigation of ocular fundus samples (2011) Proc. SPIE, 8086, p. 808605; Schweitzer, D., Time-resolved autofluorescence imaging of human donor retina tissue from donors with significant extramacular drusen (2012) Invest. Ophthalmol. Vis. Sci., 53, pp. 3376-3386; Schweitzer, D., Detection of early metabolic alterations in the ocular fundus of diabetic patients by time-resolved autofluorescence of endogenous fluorophores (2011) Proc. SPIE, 8087, p. 80871G; Inzucchi, S.E., Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012) Diabetes Care, 35, pp. 1364-1379; Abholz, H.H., Nationale Versorgungs Leitlinie Therapie des Typ-2 diabetes (2013) Dtsch. Arztebl., 110 (40). , 1875-1655-1623; Vishwasrao, H.D., Conformational dependence of intracellular NADH on metabolic state revealed by associated fluorescence anisotrophy (2005) J. Biol. Chem., 280, pp. 25119-25126; Schweitzer, D., Metabolic mapping (2010) Chapter 10 in Medical Retina, pp. 107-123. , F. G. Holz and R. F. Spaide, Eds. Springer, Berlin Heidelberg; Jyothikumar, V., Sun, Y., Periasamy, A., Investigation of tryptophan-NADH interactions in live human cells using three-photon fluorescence lifetime imaging and Förster resonance energy transfer microscopy (2013) J. Biomed. Opt., 18, p. 060501; Skala, M.C., In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia (2007) PNAS, 104 (49), pp. 19494-19499; Schweitzer, D., Hammer, M., Schweitzer, F., Limitations of the confocal laser scanning technique in measurements of time-resolved autofluorescence of the ocular fundus (2005) Biomed. Tech. (Berl.), 50, pp. 263-267",Article,Scopus,2-s2.0-84924812965
"Tamir S., Paddock M.L., Darash-Yahana-Baram M., Holt S.H., Sohn Y.S., Agranat L., Michaeli D., Stofleth J.T., Lipper C.H., Morcos F., Cabantchik I.Z., Onuchic J.N., Jennings P.A., Mittler R., Nechushtai R.","Structure-function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease",2015,"Biochimica et Biophysica Acta - Molecular Cell Research","1853","6",,"1294","1315",,,10.1016/j.bbamcr.2014.10.014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926372228&partnerID=40&md5=25e9e63e08c235eb5554e9c8f0afb175","The Alexander Silberman Life Science Institute and the Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat RamJerusalem, Israel; Department of Chemistry and Biochemistry, University of California at San DiegoLa Jolla, CA, United States; Department of Biology, University of North TexasDenton, TX, United States; Center for Theoretical Biological Physics, Rice UniversityHouston, TX, United States; Department of Physics and Astronomy, Rice UniversityHouston, TX, United States; Department of Chemistry, Rice UniversityHouston, TX, United States; Department of Biochemistry and Cell Biology, Rice UniversityHouston, TX, United States","Tamir, S., The Alexander Silberman Life Science Institute and the Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat RamJerusalem, Israel; Paddock, M.L., Department of Chemistry and Biochemistry, University of California at San DiegoLa Jolla, CA, United States; Darash-Yahana-Baram, M., The Alexander Silberman Life Science Institute and the Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat RamJerusalem, Israel; Holt, S.H., Department of Biology, University of North TexasDenton, TX, United States; Sohn, Y.S., The Alexander Silberman Life Science Institute and the Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat RamJerusalem, Israel; Agranat, L., The Alexander Silberman Life Science Institute and the Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat RamJerusalem, Israel; Michaeli, D., The Alexander Silberman Life Science Institute and the Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat RamJerusalem, Israel; Stofleth, J.T., Department of Chemistry and Biochemistry, University of California at San DiegoLa Jolla, CA, United States; Lipper, C.H., Department of Chemistry and Biochemistry, University of California at San DiegoLa Jolla, CA, United States; Morcos, F., Center for Theoretical Biological Physics, Rice UniversityHouston, TX, United States, Department of Physics and Astronomy, Rice UniversityHouston, TX, United States, Department of Chemistry, Rice UniversityHouston, TX, United States, Department of Biochemistry and Cell Biology, Rice UniversityHouston, TX, United States; Cabantchik, I.Z., The Alexander Silberman Life Science Institute and the Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat RamJerusalem, Israel; Onuchic, J.N., Center for Theoretical Biological Physics, Rice UniversityHouston, TX, United States, Department of Physics and Astronomy, Rice UniversityHouston, TX, United States, Department of Chemistry, Rice UniversityHouston, TX, United States, Department of Biochemistry and Cell Biology, Rice UniversityHouston, TX, United States; Jennings, P.A., Department of Chemistry and Biochemistry, University of California at San DiegoLa Jolla, CA, United States; Mittler, R., Department of Biology, University of North TexasDenton, TX, United States; Nechushtai, R., The Alexander Silberman Life Science Institute and the Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat RamJerusalem, Israel","A novel family of 2Fe-2S proteins, the NEET family, was discovered during the last decade in numerous organisms, including archea, bacteria, algae, plant and human; suggesting an evolutionary-conserved function, potentially mediated by their CDGSH Iron-Sulfur Domain. In human, three NEET members encoded by the CISD1-3 genes were identified. The structures of CISD1 (mitoNEET, mNT), CISD2 (NAF-1), and the plant At-NEET uncovered a homodimer with a unique ""NEET fold"", as well as two distinct domains: a beta-cap and a 2Fe-2S cluster-binding domain. The 2Fe-2S clusters of NEET proteins were found to be coordinated by a novel 3Cys:1His structure that is relatively labile compared to other 2Fe-2S proteins and is the reason of the NEETs' clusters could be transferred to apo-acceptor protein(s) or mitochondria. Positioned at the protein surface, the NEET's 2Fe-2S's coordinating His is exposed to protonation upon changes in its environment, potentially suggesting a sensing function for this residue. Studies in different model systems demonstrated a role for NAF-1 and mNT in the regulation of cellular iron, calcium and ROS homeostasis, and uncovered a key role for NEET proteins in critical processes, such as cancer cell proliferation and tumor growth, lipid and glucose homeostasis in obesity and diabetes, control of autophagy, longevity in mice, and senescence in plants. Abnormal regulation of NEET proteins was consequently found to result in multiple health conditions, and aberrant splicing of NAF-1 was found to be a causative of the neurological genetic disorder Wolfram Syndrome 2. Here we review the discovery of NEET proteins, their structural, biochemical and biophysical characterization, and their most recent structure-function analyses. We additionally highlight future avenues of research focused on NEET proteins and propose an essential role for NEETs in health and disease. This article is part of a Special Issue entitled: Fe/S proteins: Analysis, structure, function, biogenesis and diseases. © 2013 Elsevier B.V.","2Fe-2S cluster; Cancer; Cluster donor/acceptor protein; Homeostasis; Mitochondria; Obesity and diabetes; Wolfram Syndrome 2","Beinert, H., Iron-sulfur proteins: ancient structures, still full of surprises (2000) J. Biol. Inorg. Chem., 5, pp. 2-15; Beinert, H., Holm, R.H., Münck, E., Iron-sulfur clusters: nature's modular, multipurpose structures (1997) Science, 277, pp. 653-659; Lill, R., Function and biogenesis of iron-sulphur proteins (2009) Nature, 460, pp. 831-838; Lill, R., Mühlenhoff, U., Maturation of iron-sulfur proteins in eukaryotes: mechanisms, connected processes, and diseases (2008) Annu. Rev. Biochem., 77, pp. 669-700; Lill, R., Mühlenhoff, U., Iron-sulfur protein biogenesis in eukaryotes: components and mechanisms (2006) Annu. Rev. Cell Dev. Biol., 22, pp. 457-486; Bandyopadhyay, S., Chandramouli, K., Johnson, M.K., Iron-sulfur cluster biosynthesis (2008) Biochem. Soc. Trans., 36, pp. 1112-1119; Stehling, O., Wilbrecht, C., Lill, R., Mitochondrial iron-sulfur protein biogenesis and human disease (2014) Biochimie, 100, pp. 61-77; Xu, X.M., Møller, S.G., Iron-sulfur cluster biogenesis systems and their crosstalk (2008) Chembiochem, 9, pp. 2355-2362; Beilschmidt, L.K., Puccio, H.M., Mammalian Fe-S cluster biogenesis and its implication in disease (2014) Biochimie, 100, pp. 48-60; Ye, H., Rouault, T.A., Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease (2010) Biochemistry, 49, pp. 4945-4956; Rouault, T.A., Tong, W.H., Iron-sulfur cluster biogenesis and human disease (2008) Trends Genet., 24, pp. 398-407; Mochel, F., Knight, M.A., Tong, W.H., Hernandez, D., Ayyad, K., Taivassalo, T., Andersen, P.M., Haller, R.G., Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance (2008) Am. J. Hum. Genet., 82, pp. 652-660; Camaschella, C., Campanella, A., De Falco, L., Boschetto, L., Merlini, R., Silvestri, L., Levi, S., Iolascon, A., The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload (2007) Blood, 110, pp. 1353-1358; Amr, S., Heisey, C., Zhang, M., Xia, X.J., Shows, K.H., Ajlouni, K., Pandya, A., Shiang, R., A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2 (2007) Am. J. Hum. Genet., 81, pp. 673-683; Rigoli, L., Di Bella, C., Wolfram syndrome 1 and Wolfram syndrome 2 (2012) Curr. Opin. Pediatr., 24, pp. 512-517; Wiley, S.E., Andreyev, A.Y., Divakaruni, A.S., Karisch, R., Perkins, G., Wall, E.A., van der Geer, P., Murphy, A.N., Wolfram syndrome protein, Miner1, regulates sulphydryl redox status, the unfolded protein response, and Ca2+ homeostasis (2013) EMBO Mol. Med., 5, pp. 904-918; Colca, J.R., McDonald, W.G., Waldon, D.J., Leone, J.W., Lull, J.M., Bannow, C.A., Lund, E.T., Mathews, W.R., Identification of a novel mitochondrial protein (""mitoNEET"") cross-linked specifically by a thiazolidinedione photoprobe (2004) Am. J. Physiol. Endocrinol. Metab., 286, pp. E252-E260; Wiley, S.E., Murphy, A.N., Ross, S.A., van der Geer, P., Dixon, J.E., MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 5318-5323; Boucquey, M., De Plaen, E., Locker, M., Poliard, A., Mouillet-Richard, S., Boon, T., Kellermann, O., Noxp20 and Noxp70, two new markers of early neuronal differentiation, detected in teratocarcinoma-derived neuroectodermic precursor cells (2006) J. Neurochem., 99, pp. 657-669; Wiley, S.E., Paddock, M.L., Abresch, E.C., Gross, L., van der Geer, P., Nechushtai, R., Murphy, A.N., Dixon, J.E., The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster (2007) J. Biol. Chem., 282, pp. 23745-23749; Conlan, A.R., Axelrod, H.L., Cohen, A.E., Abresch, E.C., Zuris, J., Yee, D., Nechushtai, R., Paddock, M.L., Crystal structure of Miner1: the redox-active 2Fe-2S protein causative in Wolfram syndrome 2 (2009) J. Mol. Biol., 392, pp. 143-153; Chen, Y.F., Kao, C.H., Chen, Y.T., Wang, C.H., Wu, C.Y., Tsai, C.Y., Liu, F.C., Tsai, T.F., Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice (2009) Genes Dev., 23, pp. 1183-1194; Tamir, S., Zuris, J.A., Agranat, L., Lipper, C.H., Conlan, A.R., Michaeli, D., Harir, Y., Nechushtai, R., Nutrient-deprivation autophagy factor-1 (NAF-1): biochemical properties of a novel cellular target for anti-diabetic drugs (2013) PLoS ONE, 8, p. e61202; Paddock, M.L., Wiley, S.E., Axelrod, H.L., Cohen, A.E., Roy, M., Abresch, E.C., Capraro, D., Jennings, P.A., MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 14342-14347; Lin, J., Zhou, T., Ye, K., Wang, J., Crystal structure of human mitoNEET reveals distinct groups of iron sulfur proteins (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 14640-14645; Hou, X., Liu, R., Ross, S., Smart, E.J., Zhu, H., Gong, W., Crystallographic studies of human mitoNEET (2007) J. Biol. Chem., 282, pp. 33242-33246; Ferraro, D.J., Gakhar, L., Ramaswamy, S., Rieske business: structure-function of Rieske non-heme oxygenases (2005) Biochem. Biophys. Res. Commun., 338, pp. 175-190; Conlan, A.R., Paddock, M.L., Axelrod, H.L., Cohen, A.E., Abresch, E.C., Wiley, S., Roy, M., Jennings, P.A., The novel 2Fe-2S outer mitochondrial protein mitoNEET displays conformational flexibility in its N-terminal cytoplasmic tethering domain (2009) Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun., 65, pp. 654-659; Tamir, S., Eisenberg-Domovich, Y., Conlan, A.R., Stofleth, J.T., Lipper, C.H., Paddock, M.L., Mittler, R., Nechushtai, R., A point mutation in the [2Fe-2S] cluster binding region of the NAF-1 protein (H114C) dramatically hinders the cluster donor properties (2014) Acta Crystallogr. D Biol. Crystallogr., 70, pp. 1572-1578; Lin, J., Zhang, L., Lai, S., Ye, K., Structure and molecular evolution of CDGSH iron-sulfur domains (2011) PLoS ONE, 6, p. e24790; Nechushtai, R., Conlan, A.R., Harir, Y., Song, L., Yogev, O., Eisenberg-Domovich, Y., Livnah, O., Mittler, R., Characterization of Arabidopsis NEET reveals an ancient role for NEET proteins in iron metabolism (2012) Plant Cell, 24, pp. 2139-2154; Dicus, M.M., Conlan, A., Nechushtai, R., Jennings, P.A., Paddock, M.L., Britt, R.D., Stoll, S., Binding of histidine in the (Cys)3(His)1-coordinated [2Fe-2S] cluster of human mitoNEET (2010) J. Am. Chem. Soc., 132, pp. 2037-2049; Iwasaki, T., Samoilova, R.I., Kounosu, A., Ohmori, D., Dikanov, S.A., Continuous-wave and pulsed EPR characterization of the [2Fe-2S](Cys)3(His)1 cluster in rat mitoNEET (2009) J. Am. Chem. Soc., 131, pp. 13659-13667; Bäckström, D., Lorusso, M., Anderson, K., Ehrenberg, A., Characterization of the iron-sulfur protein of the mitochondrial outer membrane partially purified from beef kidney cortex (1978) Biochim. Biophys. Acta, 502, pp. 276-288; Heidrich, H.G., Albracht, S.P., Bäckström, D., Two iron-sulfur centers in mitochondrial outer membranes from beef heart as prepared by free-flow electrophoresis (1978) FEBS Lett., 95, pp. 314-318; Tirrell, T.F., Paddock, M.L., Conlan, A.R., Smoll, E.J., Nechushtai, R., Jennings, P.A., Kim, J.E., Resonance Raman studies of the (His)(Cys)3 2Fe-2S cluster of mitoNEET: comparison to the (Cys)4 mutant and implications of the effects of pH on the labile metal center (2009) Biochemistry, 48, pp. 4747-4752; Homer, C., Yee, D., Axelrod, H.L., Cohen, A.E., Abresch, E.C., Chang, C., Nechushtai, R., Paddock, M.L., Structural basis for phosphate stabilization of the uniquely coordinated 2Fe-2S cluster of the outer mitochondrial membrane protein mitoNEET (2009) Biophys. J., 96, pp. 442a-443a; Bak, D.W., Zuris, J.A., Paddock, M.L., Jennings, P.A., Elliott, S.J., Redox characterization of the FeS protein mitoNEET and impact of thiazolidinedione drug binding (2009) Biochemistry, 48, pp. 10193-10195; Bak, D.W., Elliott, S.J., Alternative FeS cluster ligands: tuning redox potentials and chemistry (2014) Curr. Opin. Chem. Biol., 19 C, pp. 50-58; Bak, D.W., Elliott, S.J., Conserved hydrogen bonding networks of mitoNEET tune Fe-S cluster binding and structural stability (2013) Biochemistry, 52, pp. 4687-4696; Zuris, J.A., Halim, D.A., Conlan, A.R., Abresch, E.C., Nechushtai, R., Paddock, M.L., Jennings, P.A., Engineering the redox potential over a wide range within a new class of FeS proteins (2010) J. Am. Chem. Soc., 132, pp. 13120-13122; Baxter, E.L., Zuris, J.A., Wang, C., Vo, P.L., Axelrod, H.L., Cohen, A.E., Paddock, M.L., Jennings, P.A., Allosteric control in a metalloprotein dramatically alters function (2013) Proc. Natl. Acad. Sci. U. S. A., 110, pp. 948-953; Baxter, E.L., Jennings, P.A., Onuchic, J.N., Interdomain communication revealed in the diabetes drug target mitoNEET (2011) Proc. Natl. Acad. Sci. U. S. A., 108, pp. 5266-5271; Nechushtai, R., Lammert, H., Michaeli, D., Eisenberg-Domovich, Y., Zuris, J.A., Luca, M.A., Capraro, D.T., Jennings, P.A., Allostery in the ferredoxin protein motif does not involve a conformational switch (2011) Proc. Natl. Acad. Sci. U. S. A., 108, pp. 2240-2245; Shimomura, Y., Wada, K., Fukuyama, K., Takahashi, Y., The asymmetric trimeric architecture of [2Fe-2S] IscU: implications for its scaffolding during iron-sulfur cluster biosynthesis (2008) J. Mol. Biol., 383, pp. 133-143; Bonomi, F., Iametti, S., Ta, D., Vickery, L.E., Multiple turnover transfer of [2Fe2S] clusters by the iron-sulfur cluster assembly scaffold proteins IscU and IscA (2005) J. Biol. Chem., 280, pp. 29513-29518; Zuris, J.A., Harir, Y., Conlan, A.R., Shvartsman, M., Michaeli, D., Tamir, S., Paddock, M.L., Nechushtai, R., Facile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor protein (2011) Proc. Natl. Acad. Sci. U. S. A., 108, pp. 13047-13052; Petrat, F., de Groot, H., Sustmann, R., Rauen, U., The chelatable iron pool in living cells: a methodically defined quantity (2002) Biol. Chem., 383, pp. 489-502; Shvartsman, M., Ioav Cabantchik, Z., Intracellular iron trafficking: role of cytosolic ligands (2012) Biometals, 25, pp. 711-723; Cabantchik, Z.I., Labile iron in cells and body fluids: physiology, pathology, and pharmacology (2014) Front. Pharmacol., 5, p. 45; Sohn, Y.S., Tamir, S., Song, L., Michaeli, D., Matouk, I., Conlan, A.R., Harir, Y., Mittler, R., NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth (2013) Proc. Natl. Acad. Sci. U. S. A., 110, pp. 14676-14681; Levine, B., Klionsky, D.J., Development by self-digestion: molecular mechanisms and biological functions of autophagy (2004) Dev. Cell, 6, pp. 463-477; Su, M., Mei, Y., Sinha, S., Role of the crosstalk between autophagy and apoptosis in cancer (2013) J. Oncol., 2013, p. 102735; Chang, N.C., Nguyen, M., Bourdon, J., Risse, P.A., Martin, J., Danialou, G., Rizzuto, R., Shore, G.C., Bcl-2-associated autophagy regulator Naf-1 required for maintenance of skeletal muscle (2012) Hum. Mol. Genet., 21, pp. 2277-2287; Chang, N.C., Nguyen, M., Germain, M., Shore, G.C., Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1 (2010) EMBO J., 29, pp. 606-618; Chang, N.C., Nguyen, M., Shore, G.C., BCL2-CISD2: an ER complex at the nexus of autophagy and calcium homeostasis? (2012) Autophagy, 8, pp. 856-857; Maiuri, M.C., Criollo, A., Kroemer, G., Crosstalk between apoptosis and autophagy within the Beclin 1 interactome (2010) EMBO J., 29, pp. 515-516; Tamir, S., Rotem-Bamberger, S., Katz, C., Morcos, F., Hailey, K.L., Zuris, J.A., Wang, C., Nechushtai, R., Integrated strategy reveals the protein interface between cancer targets Bcl-2 and NAF-1 (2014) Proc. Natl. Acad. Sci. U. S. A., 111, pp. 5177-5182; Su, L.W., Chang, S.H., Li, M.Y., Huang, H.Y., Jane, W.N., Yang, J.Y., Purification and biochemical characterization of Arabidopsis At-NEET, an ancient iron-sulfur protein, reveals a conserved cleavage motif for subcellular localization (2013) Plant Sci., 213, pp. 46-54; Landry, A.P., Ding, H., Redox control of human mitochondrial outer membrane protein mitoNEET [2Fe-2S] clusters by biological thiols and hydrogen peroxide (2014) J. Biol. Chem., 289, pp. 4307-4315; Roberts, M.E., Crail, J.P., Laffoon, M.M., Fernandez, W.G., Menze, M.A., Konkle, M.E., Identification of disulfide bond formation between mitoNEET and glutamate dehydrogenase 1 (2013) Biochemistry, 52, pp. 8969-8971; Colca, J.R., Kletzien, R.F., What has prevented the expansion of insulin sensitisers? (2006) Expert Opin. Investig. Drugs, 15, pp. 205-210; Bolten, C.W., Blanner, P.M., McDonald, W.G., Staten, N.R., Mazzarella, R.A., Arhancet, G.B., Meier, M.F., Colca, J.R., Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma (2007) Gene Regul. Syst. Bio., 1, pp. 73-82; Hunter, R.L., Choi, D.Y., Ross, S.A., Bing, G., Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats (2008) Neurosci. Lett., 432, pp. 198-201; Geldenhuys, W.J., Funk, M.O., Barnes, K.F., Carroll, R.T., Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET (2010) Bioorg. Med. Chem. Lett., 20, pp. 819-823; Bieganski, R.M., Yarmush, M.L., Novel ligands that target the mitochondrial membrane protein mitoNEET (2011) J. Mol. Graph. Model., 29, pp. 965-973; Arif, W., Xu, S., Isailovic, D., Geldenhuys, W.J., Carroll, R.T., Funk, M.O., Complexes of the outer mitochondrial membrane protein mitoNEET with resveratrol-3-sulfate (2011) Biochemistry, 50, pp. 5806-5811; Geldenhuys, W.J., Funk, M.O., Awale, P.S., Lin, L., Carroll, R.T., A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET (2011) Bioorg. Med. Chem. Lett., 21, pp. 5498-5501; Zuris, J.A., Ali, S.S., Yeh, H., Nguyen, T.A., Nechushtai, R., Paddock, M.L., Jennings, P.A., NADPH inhibits [2Fe-2S] cluster protein transfer from diabetes drug target mitoNEET to an apo-acceptor protein (2012) J. Biol. Chem., 287, pp. 11649-11655; Tan, G., Landry, A.P., Dai, R., Wang, L., Lu, J., Ding, H., Competition of zinc ion for the [2Fe-2S] cluster binding site in the diabetes drug target protein mitoNEET (2012) Biometals, 25, pp. 1177-1184; Chen, Z., Vigueira, P.A., Chambers, K.T., Hall, A.M., Mitra, M.S., Qi, N., McDonald, W.G., Finck, B.N., Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione (2012) J. Biol. Chem., 287, pp. 23537-23548; Feinstein, D.L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., Dello Russo, C., Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? (2005) Biochem. Pharmacol., 70, pp. 177-188; Kusminski, C.M., Holland, W.L., Sun, K., Park, J., Spurgin, S.B., Lin, Y., Askew, G.R., Scherer, P.E., MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity (2012) Nat. Med., 18, pp. 1539-1549; Shulga, N., Pastorino, J.G., Mitoneet mediates TNFα induced necroptosis promoted by fructose and ethanol exposure (2014) J. Cell Sci., 127, pp. 896-907; Colca, J.R., Insulin sensitizers may prevent metabolic inflammation (2006) Biochem. Pharmacol., 72, pp. 125-131; Stark, R., Roden, M., Award, E.S.C.I., Mitochondrial function and endocrine diseases (2006) Eur. J. Clin. Invest., 37 (2007), pp. 236-248; Bandyopadhyay, P., Novel therapies in diabetes mellitus (2006) Drug News Perspect., 19, pp. 499-507; Bogacka, I., Xie, H., Bray, G.A., Smith, S.R., Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo (2005) Diabetes, 54, pp. 1392-1399; Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Furnsinn, C., Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? (2004) Diabetes, 53, pp. 1052-1059; Geldenhuys, W.J., Leeper, T.C., Carroll, R.T., MitoNEET as novel drug target for mitochondrial dysfunction (2014) Drug Discov. Today, 19, pp. 1601-1606; Geldenhuys, W.J., Van der Schyf, C.J., Rationally designed multi-targeted agents against neurodegenerative diseases (2013) Curr. Med. Chem., 20, pp. 1662-1672; Zhou, T., Lin, J., Feng, Y., Wang, J., Binding of reduced nicotinamide adenine dinucleotide phosphate destabilizes the iron-sulfur clusters of human mitoNEET (2010) Biochemistry, 49, pp. 9604-9612; Taminelli, G.L., Sotomayor, V., Valdivieso, A.G., Teiber, M.L., Marin, M.C., Santa-Coloma, T.A., CISD1 codifies a mitochondrial protein upregulated by the CFTR channel (2008) Biochem. Biophys. Res. Commun., 365, pp. 856-862; Okatsu, K., Iemura, S., Koyano, F., Go, E., Kimura, M., Natsume, T., Tanaka, K., Matsuda, N., Mitochondrial hexokinase HKI is a novel substrate of the Parkin ubiquitin ligase (2012) Biochem. Biophys. Res. Commun., 428, pp. 197-202; Kaundal, R.K., Sharma, S.S., Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents (2010) Drug News Perspect., 23, pp. 241-256; Yonutas, H.M., Sullivan, P.G., Targeting PPAR isoforms following CNS injury (2013) Curr. Drug Targets, 14, pp. 733-742; Chen, Y.F., Wu, C.Y., Kirby, R., Kao, C.H., Tsai, T.F., A role for the CISD2 gene in lifespan control and human disease (2010) Ann. N. Y. Acad. Sci., 1201, pp. 58-64; Jones, M.A., Amr, S., Ferebee, A., Huynh, P., Rosenfeld, J.A., Miles, M.F., Davies, A.G., Grotewiel, M., Genetic studies in Drosophila and humans support a model for the concerted function of CISD2, PPT1 and CLN3 in disease (2014) Biol. Open, 3, pp. 342-352; Wu, C.Y., Chen, Y.F., Wang, C.H., Kao, C.H., Zhuang, H.W., Chen, C.C., Chen, L.K., Tsai, T.F., A persistent level of Cisd2 extends healthy lifespan and delays aging in mice (2012) Hum. Mol. Genet., 21, pp. 3956-3968; Stelzer, G., Dalah, I., Stein, T.I., Satanower, Y., Rosen, N., Nativ, N., Oz-Levi, D., Lancet, D., In-silico human genomics with GeneCards (2011) Hum. Genom., 5, pp. 709-717; http://www.genecards.org/cgi-bin/carddisp.pl?gene=CISD1Cortes, D.F., Sha, W., Hower, V., Blekherman, G., Laubenbacher, R., Akman, S., Torti, S.V., Shulaev, V., Differential gene expression in normal and transformed human mammary epithelial cells in response to oxidative stress (2011) Free Radic. Biol. Med., 50, pp. 1565-1574; Salem, A.F., Whitaker-Menezes, D., Howell, A., Sotgia, F., Lisanti, M.P., Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance (2012) Cell Cycle, 11, pp. 4174-4180; Katz, C., Benyamini, H., Rotem, S., Lebendiker, M., Danieli, T., Iosub, A., Refaely, H., Friedler, A., Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2 (2008) Proc. Natl. Acad. Sci. U. S. A., 105, pp. 12277-12282; Katz, C., Levy-Beladev, L., Rotem-Bamberger, S., Rito, T., Rüdiger, S.G., Friedler, A., Studying protein-protein interactions using peptide arrays (2011) Chem. Soc. Rev., 40, pp. 2131-2145; Wang, Z., Gerstein, M., Snyder, M., RNA-Seq: a revolutionary tool for transcriptomics (2009) Nat. Rev. Genet., 10, pp. 57-63; McGettigan, P.A., Transcriptomics in the RNA-seq era (2013) Curr. Opin. Chem. Biol., 17, pp. 4-11; Bhattacharya, S., Mariani, T.J., Systems biology approaches to identify developmental bases for lung diseases (2013) Pediatr. Res., 73, pp. 514-522; Costa, V., Aprile, M., Esposito, R., Ciccodicola, A., RNA-Seq and human complex diseases: recent accomplishments and future perspectives (2013) Eur. J. Hum. Genet., 21, pp. 134-142; Kavanagh, T., Mills, J.D., Kim, W.S., Halliday, G.M., Janitz, M., Pathway analysis of the human brain transcriptome in disease (2013) J. Mol. Neurosci., 51, pp. 28-36; Babady, N.E., Carelle, N., Wells, R.D., Rouault, T.A., Hirano, M., Lynch, D.R., Delatycki, M.B., Puccio, H., Advancements in the pathophysiology of Friedreich's ataxia and new prospects for treatments (2007) Mol. Genet. Metab., 92, pp. 23-35; Blekherman, G., Laubenbacher, R., Cortes, D.F., Mendes, P., Torti, F.M., Akman, S., Torti, S.V., Shulaev, V., Bioinformatics tools for cancer metabolomics (2011) Metabolomics, 7, pp. 329-343; Denoroy, L., Zimmer, L., Renaud, B., Parrot, S., Ultra high performance liquid chromatography as a tool for the discovery and the analysis of biomarkers of diseases: a review (2013) J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 927, pp. 37-53; Lv, H., Mass spectrometry-based metabolomics towards understanding of gene functions with a diversity of biological contexts (2013) Mass Spectrom. Rev., 32, pp. 118-128; Nagrath, D., Caneba, C., Karedath, T., Bellance, N., Metabolomics for mitochondrial and cancer studies (2011) Biochim. Biophys. Acta, 1807, pp. 650-663; Wishart, D.S., Tzur, D., Knox, C., Eisner, R., Guo, A.C., Young, N., Cheng, D., Querengesser, L., HMDB: the Human Metabolome Database (2007) Nucleic Acids Res., 35, pp. D521-D526; Morcos, F., Pagnani, A., Lunt, B., Bertolino, A., Marks, D.S., Sander, C., Zecchina, R., Weigt, M., Direct-coupling analysis of residue coevolution captures native contacts across many protein families (2011) Proc. Natl. Acad. Sci. U. S. A., 108, pp. E1293-E1301; Sulkowska, J.I., Morcos, F., Weigt, M., Hwa, T., Onuchic, J.N., Genomics-aided structure prediction (2012) Proc. Natl. Acad. Sci. U. S. A., 109, pp. 10340-10345; Marks, D.S., Colwell, L.J., Sheridan, R., Hopf, T.A., Pagnani, A., Zecchina, R., Sander, C., Protein 3D structure computed from evolutionary sequence variation (2011) PLoS ONE, 6, p. e28766; Jana, B., Morcos, F., Onuchic, J.N., From structure to function: the convergence of structure based models and co-evolutionary information (2014) Phys. chem. chem. phys.: PCCP, 16, pp. 6496-6507; Morcos, F., Jana, B., Hwa, T., Onuchic, J.N., Coevolutionary signals across protein lineages help capture multiple protein conformations (2013) Proc. Natl. Acad. Sci. U. S. A., 110, pp. 20533-20538; Schug, A., Weigt, M., Onuchic, J.N., Hwa, T., Szurmant, H., High-resolution protein complexes from integrating genomic information with molecular simulation (2009) Proc. Natl. Acad. Sci. U. S. A., 106, pp. 22124-22129; Cheng, R.R., Morcos, F., Levine, H., Onuchic, J.N., Toward rationally redesigning bacterial two-component signaling systems using coevolutionary information (2014) Proc. Natl. Acad. Sci. U. S. A., 111, pp. E563-E571; Noel, J.K., Whitford, P.C., Sanbonmatsu, K.Y., Onuchic, J.N., SMOG@ctbp: simplified deployment of structure-based models in GROMACS (2010) Nucleic Acids Res., 38, pp. W657-W661; Clementi, C., Plotkin, S.S., The effects of nonnative interactions on protein folding rates: theory and simulation (2004) Protein Sci., 13, pp. 1750-1766; Ferecatu, I., Gons'alves, S., Golinelli-Cohen, M.P., Clémancey, M., Martelli, A., Riquier, S., Guittet, E., Bouton, C., The diabetes drug target mitoNEET governs a novel trafficking pathway to rebuild an Fe-S cluster into cytosolic aconitase/iron regulatory protein 1 (2014) J. Biol. Chem., 289, pp. 28070-28086; http://cluspro.bu.edu/queue.php",Review,Scopus,2-s2.0-84926372228
"Ma S., Venkatesh A., Langellotto F., Le Y.Z., Hall M.N., Ruegg M.A., Punzo C.","Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival",2015,"Experimental Eye Research","135",,,"1","13",,,10.1016/j.exer.2015.04.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927751042&partnerID=40&md5=e92fe223e987c0f9961155412d2d3be7","Tianjin Medical University Eye Hospital, No. 251 Fu Kang RoadNankai District, Tianjin, China; Department of Ophthalmology, University of Massachusetts Medical School, 368 Plantation StreetWorcester, MA, United States; Department of Medicine Endocrinology, University of Oklahoma Health Sciences Center, BSEB 302G, 941 S L Young Blvd.Oklahoma City, United States; Biozentrum, University of Basel, Klingelbergstrasse 70Basel, Switzerland; Department of Pathology, Children's Hospital, Harvard Medical School, Enders 1126, 300 Longwood AveBoston, MA, United States","Ma, S., Tianjin Medical University Eye Hospital, No. 251 Fu Kang RoadNankai District, Tianjin, China, Department of Ophthalmology, University of Massachusetts Medical School, 368 Plantation StreetWorcester, MA, United States; Venkatesh, A., Department of Ophthalmology, University of Massachusetts Medical School, 368 Plantation StreetWorcester, MA, United States; Langellotto, F., Department of Ophthalmology, University of Massachusetts Medical School, 368 Plantation StreetWorcester, MA, United States, Department of Pathology, Children's Hospital, Harvard Medical School, Enders 1126, 300 Longwood AveBoston, MA, United States; Le, Y.Z., Department of Medicine Endocrinology, University of Oklahoma Health Sciences Center, BSEB 302G, 941 S L Young Blvd.Oklahoma City, United States; Hall, M.N., Biozentrum, University of Basel, Klingelbergstrasse 70Basel, Switzerland; Rüegg, M.A., Biozentrum, University of Basel, Klingelbergstrasse 70Basel, Switzerland; Punzo, C., Department of Ophthalmology, University of Massachusetts Medical School, 368 Plantation StreetWorcester, MA, United States","Cones are the primary photoreceptor (PR) cells responsible for vision in humans. They are metabolically highly active requiring phosphoinositide 3-kinase (PI3K) activity for long-term survival. One of the downstream targets of PI3K is the kinase mammalian target of rapamycin (mTOR), which is a key regulator of cell metabolism and growth, integrating nutrient availability and growth factor signals. Both PI3K and mTOR are part of the insulin/mTOR signaling pathway, however if mTOR is required for long-term PR survival remains unknown. This is of particular interest since deregulation of this pathway in diabetes results in reduced PR function before the onset of any clinical signs of diabetic retinopathy. mTOR is found in two distinct complexes (mTORC1 & mTORC2) that are characterized by their unique accessory proteins RAPTOR and RICTOR respectively. mTORC1 regulates mainly cell metabolism in response to nutrient availability and growth factor signals, while mTORC2 regulates pro-survival mechanisms in response to growth factors. Here we analyze the effect on cones of loss of mTORC1, mTORC2 and simultaneous loss of mTORC1 & mTORC2. Interestingly, neither loss of mTORC1 nor mTORC2 affects cone function or survival at one year of age. However, outer and inner segment morphology is affected upon loss of either complex. In contrast, concurrent loss of mTORC1 and mTORC2 leads to a reduction in cone function without affecting cone viability. The data indicates that PI3K mediated pro-survival signals diverge upstream of both mTOR complexes in cones, suggesting that they are independent of mTOR activity. Furthermore, the data may help explain why PR function is reduced in diabetes, which can lead to deregulation of both mTOR complexes simultaneously. Finally, although mTOR is a key regulator of cell metabolism, and PRs are metabolically highly active, the data suggests that the role of mTOR in regulating the metabolic transcriptome in healthy cones is minimal. © 2015 The Authors.","Cone survival; Diabetic retinopathy; MTOR; Neuroprotective; Photoreceptors; PI3K; Retinitis pigmentosa; Visual function","Ames, A., CNS energy metabolism as related to function (2000) Brain Res. Brain Res. Rev., 34, pp. 42-68; Bentzinger, C.F., Romanino, K., Cloetta, D., Lin, S., Mascarenhas, J.B., Oliveri, F., Xia, J., Ruegg, M.A., Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy (2008) Cell. Metab., 8, pp. 411-424; Bill, A., Sperber, G., Ujiie, K., Physiology of the choroidal vascular bed (1983) Int. Ophthalmol., 6, pp. 101-107; Bownds, D., Gordon-Walker, A., Gaide-Huguenin, A.C., Robinson, W., Characterization and analysis of frog photoreceptor membranes (1971) J.Gen. Physiol., 58, pp. 225-237; Busskamp, V., Krol, J., Nelidova, D., Daum, J., Szikra, T., Tsuda, B., Juttner, J., Roska, B., MiRNAs 182 and 183 are necessary to maintain adult cone photoreceptor outer segments and visual function (2014) Neuron, 83, pp. 586-600; Carter-Dawson, L.D., LaVail, M.M., Sidman, R.L., Differential effect of the rd mutation on rods and cones in the mouse retina (1978) Invest. Ophthalmol. Vis. Sci., 17, pp. 489-498; Cepko, C.L., Austin, C.P., Yang, X., Alexiades, M., Ezzeddine, D., Cell fate determination in the vertebrate retina (1996) Proc. Natl. Acad. Sci. U. S. A., 93, pp. 589-595; Chertov, A.O., Holzhausen, L., Kuok, I.T., Couron, D., Parker, E., Linton, J.D., Sadilek, M., Hurley, J.B., Roles of glucose in photoreceptor survival (2011) J.Biol. Chem., 286, pp. 34700-34711; Cloetta, D., Thomanetz, V., Baranek, C., Lustenberger, R.M., Lin, S., Oliveri, F., Atanasoski, S., Ruegg, M.A., Inactivation of mTORC1 in the developing brain causes microcephaly and affects gliogenesis (2013) J.Neurosci., 33, pp. 7799-7810; Crouse, J.A., Lopes, V.S., Sanagustin, J.T., Keady, B.T., Williams, D.S., Pazour, G.J., Distinct functions for IFT140 and IFT20 in opsin transport (2014) Cytoskeleton, 71, pp. 302-310; Cybulski, N., Polak, P., Auwerx, J., Ruegg, M.A., Hall, M.N., MTOR complex 2 in adipose tissue negatively controls whole-body growth (2009) Proc. Natl. Acad. Sci. U. S. A., 106, pp. 9902-9907; DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., Thompson, C.B., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation (2008) Cell. Metab., 7, pp. 11-20; Dibble, C.C., Asara, J.M., Manning, B.D., Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1 (2009) Mol. Cell. Biol., 29, pp. 5657-5670; Duvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., Triantafellow, E., Manning, B.D., Activation of a metabolic gene regulatory network downstream of mTOR complex 1 (2010) Mol. Cell., 39, pp. 171-183; Garcia-Martinez, J.M., Alessi, D.R., MTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) (2008) Biochem. J., 416, pp. 375-385; Gu, H., Marth, J.D., Orban, P.C., Mossmann, H., Rajewsky, K., Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting (1994) Science, 265, pp. 103-106; Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Sabatini, D.M., Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1 (2006) Dev. Cell., 11, pp. 859-871; Huang, W., Zhu, P.J., Zhang, S., Zhou, H., Stoica, L., Galiano, M., Krnjevic, K., Costa-Mattioli, M., MTORC2 controls actin polymerization required for consolidation of long-term memory (2013) Nat. Neurosci., 16, pp. 441-448; Ivanovic, I., Anderson, R.E., Le, Y.Z., Fliesler, S.J., Sherry, D.M., Rajala, R.V., Deletion of the p85alpha regulatory subunit of phosphoinositide 3-kinase in cone photoreceptor cells results in cone photoreceptor degeneration (2011) Invest. Ophthalmol. Vis. Sci., 52, pp. 3775-3783; Jackson, G.R., Barber, A.J., Visual dysfunction associated with diabetic retinopathy (2010) Curr. Diab. Rep., 10, pp. 380-384; Jeon, C.J., Strettoi, E., Masland, R.H., The major cell populations of the mouse retina (1998) J.Neurosci., 18, pp. 8936-8946; Julien, L.A., Carriere, A., Moreau, J., Roux, P.P., MTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling (2010) Mol. Cell. Biol., 30, pp. 908-921; Kellersch, B., Brocker, T., Langerhans cell homeostasis in mice is dependent on mTORC1 but not mTORC2 function (2013) Blood, 121, pp. 298-307; Kunchithapautham, K., Coughlin, B., Lemasters, J.J., Rohrer, B., Differential effects of rapamycin on rods and cones during light-induced stress in albino mice (2011) Invest. Ophthalmol. Vis. Sci., 52, pp. 2967-2975; Lamming, D.W., Ye, L., Katajisto, P., Goncalves, M.D., Saitoh, M., Stevens, D.M., Davis, J.G., Baur, J.A., Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity (2012) Science, 335, pp. 1638-1643; LaVail, M.M., Yasumura, D., Matthes, M.T., Lau-Villacorta, C., Unoki, K., Sung, C.H., Steinberg, R.H., Protection of mouse photoreceptors by survival factors in retinal degenerations (1998) Invest. Ophthalmol. Vis. Sci., 39, pp. 592-602; Le, Y.Z., Ash, J.D., Al-Ubaidi, M.R., Chen, Y., Ma, J.X., Anderson, R.E., Targeted expression of Cre recombinase to cone photoreceptors in transgenic mice (2004) Mol. Vis., 10, pp. 1011-1018; Leveillard, T., Mohand-Said, S., Lorentz, O., Hicks, D., Fintz, A.C., Clerin, E., Simonutti, M., Sahel, J.A., Identification and characterization of rod-derived cone viability factor (2004) Nat. Genet., 36, pp. 755-759; Li, L., Khan, N., Hurd, T., Ghosh, A.K., Cheng, C., Molday, R., Heckenlively, J.R., Khanna, H., Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin mislocalization and photoreceptor degeneration (2013) Invest. Ophthalmol. Vis. Sci., 54, pp. 4503-4511; Li, Y., Tao, W., Luo, L., Huang, D., Kauper, K., Stabila, P., Lavail, M.M., Wen, R., CNTF induces regeneration of cone outer segments in a rat model of retinal degeneration (2010) PLoS One, 5, p. e9495; Lisman, J.E., Bering, H., Electrophysiological measurement of the number of rhodopsin molecules in single Limulus photoreceptors (1977) J.Gen. Physiol., 70, pp. 621-633; Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., Protein measurement with the Folin phenol reagent (1951) J.Biol. Chem., 193, pp. 265-275; Madisen, L., Zwingman, T.A., Sunkin, S.M., Oh, S.W., Zariwala, H.A., Gu, H., Ng, L.L., Zeng, H., Arobust and high-throughput Cre reporting and characterization system for the whole mouse brain (2010) Nat. Neurosci., 13, pp. 133-140; Mattapallil, M.J., Wawrousek, E.F., Chan, C.C., Zhao, H., Roychoudhury, J., Ferguson, T.A., Caspi, R.R., The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes (2012) Invest. Ophthalmol. Vis. Sci., 53, pp. 2921-2927; Mohand-Said, S., Deudon-Combe, A., Hicks, D., Simonutti, M., Forster, V., Fintz, A.C., Leveillard, T., Sahel, J.A., Normal retina releases a diffusible factor stimulating cone survival in the retinal degeneration mouse (1998) Proc. Natl. Acad. Sci. U. S. A., 95, pp. 8357-8362; Mohand-Said, S., Hicks, D., Dreyfus, H., Sahel, J.A., Selective transplantation of rods delays cone loss in a retinitis pigmentosa model (2000) Arch. Ophthalmol., 118, pp. 807-811; Mohand-Said, S., Hicks, D., Simonutti, M., Tran-Minh, D., Deudon-Combe, A., Dreyfus, H., Silverman, M.S., Sahel, J., Photoreceptor transplants increase host cone survival in the retinal degeneration (rd) mouse (1997) Ophthalmic Res., 29, pp. 290-297; Murray, J.T., Campbell, D.G., Morrice, N., Auld, G.C., Shpiro, N., Marquez, R., Peggie, M., Cohen, P., Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3 (2004) Biochem. J., 384, pp. 477-488; Polak, P., Cybulski, N., Feige, J.N., Auwerx, J., Ruegg, M.A., Hall, M.N., Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration (2008) Cell. Metab., 8, pp. 399-410; Punzo, C., Kornacker, K., Cepko, C.L., Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa (2009) Nat. Neurosci., 12, pp. 44-52; Rajala, A., Dighe, R., Agbaga, M.P., Anderson, R.E., Rajala, R.V., Insulin receptor signaling in cones (2013) J.Biol. Chem., 288, pp. 19503-19515; Rajala, A., Tanito, M., Le, Y.Z., Kahn, C.R., Rajala, R.V., Loss of neuroprotective survival signal in mice lacking insulin receptor gene in rod photoreceptor cells (2008) J.Biol. Chem., 283, pp. 19781-19792; Rajala, R.V., Tanito, M., Neel, B.G., Rajala, A., Enhanced retinal insulin receptor-activated neuroprotective survival signal in mice lacking the protein-tyrosine phosphatase-1B gene (2010) J.Biol. Chem., 285, pp. 8894-8904; Rajala, R.V., Wiskur, B., Tanito, M., Callegan, M., Rajala, A., Diabetes reduces autophosphorylation of retinal insulin receptor and increases protein-tyrosine phosphatase-1B activity (2009) Invest. Ophthalmol. Vis. Sci., 50, pp. 1033-1040; Reiter, C.E., Wu, X., Sandirasegarane, L., Nakamura, M., Gilbert, K.A., Singh, R.S., Fort, P.E., Gardner, T.W., Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin (2006) Diabetes, 55, pp. 1148-1156; Robida-Stubbs, S., Glover-Cutter, K., Lamming, D.W., Mizunuma, M., Narasimhan, S.D., Neumann-Haefelin, E., Sabatini, D.M., Blackwell, T.K., TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO (2012) Cell. Metab., 15, pp. 713-724; Romanino, K., Mazelin, L., Albert, V., Conjard-Duplany, A., Lin, S., Bentzinger, C.F., Handschin, C., Ruegg, M.A., Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function (2011) Proc. Natl. Acad. Sci. U. S. A., 108, pp. 20808-20813; Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L., Sabatini, D.M., Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB (2006) Mol. Cell., 22, pp. 159-168; Scott, B.L., Racz, E., Lolley, R.N., Bazan, N.G., Developing rod photoreceptors from normal and mutant Rd mouse retinas: altered fatty acid composition early in development of the mutant (1988) J.Neurosci. Res., 20, pp. 202-211; Shende, P., Plaisance, I., Morandi, C., Pellieux, C., Berthonneche, C., Zorzato, F., Krishnan, J., Brink, M., Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice (2011) Circulation, 123, pp. 1073-1082; Steinberg, R.H., Survival factors in retinal degenerations (1994) Curr. Opin. Neurobiol., 4, pp. 515-524; Streichert, L.C., Birnbach, C.D., Reh, T.A., Adiffusible factor from normal retinal cells promotes rod photoreceptor survival in an invitro model of retinitis pigmentosa (1999) J.Neurobiol., 39, pp. 475-490; Thomanetz, V., Angliker, N., Cloetta, D., Lustenberger, R.M., Schweighauser, M., Oliveri, F., Suzuki, N., Ruegg, M.A., Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology (2013) J.Cell. Biol., 201, pp. 293-308; Treins, C., Warne, P.H., Magnuson, M.A., Pende, M., Downward, J., Rictor is a novel target of p70 S6 kinase-1 (2010) Oncogene, 29, pp. 1003-1016; Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation (2009) Science, 324, pp. 1029-1033; Venkatesh, A., Ma, S., Langellotto, F., Gao, G., Punzo, C., Retinal gene delivery by rAAV and DNA electroporation (2013) Curr. Protoc. Microbiol. Chapter, 14. , Unit14D 14; Venkatesh, A., Ma, S., Le, Y.Z., Hall, M.N., Ruegg, M.A., Punzo, C., Activated mTORC1 promotes long-term cone survival in retinitis pigmentosa mice (2015) J.Clin. Invest., 125, pp. 1446-1458; Whikehart, D.R., (2003) Biochemistry of the Eye; Winkler, B.S., Pourcho, R.G., Starnes, C., Slocum, J., Slocum, N., Metabolic mapping in mammalian retina: a biochemical and 3H-2-deoxyglucose autoradiographic study (2003) Exp. Eye Res., 77, pp. 327-337; Winkler, B.S., Starnes, C.A., Sauer, M.W., Firouzgan, Z., Chen, S.C., Cultured retinal neuronal cells and Muller cells both show net production of lactate (2004) Neurochem. Int., 45, pp. 311-320; Ye, L., Varamini, B., Lamming, D.W., Sabatini, D.M., Baur, J.A., Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2 (2012) Front. Genet., 3, p. 177; Young, R.W., The renewal of rod and cone outer segments in the rhesus monkey (1971) J.Cell. Biol., 49, pp. 303-318; Zoncu, R., Efeyan, A., Sabatini, D.M., MTOR: from growth signal integration to cancer, diabetes and ageing (2011) Nat. Rev. Mol. Cell. Biol., 12, pp. 21-35",Article,Scopus,2-s2.0-84927751042
"Berezin A.E., Kremzer A.A., Martovitskaya Y.V., Samura T.A., Berezina T.A.","The predictive role of circulating microparticles in patients with chronic heart failure",2015,"BBA Clinical","3",,,"18","24",,,10.1016/j.bbacli.2014.11.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84916882856&partnerID=40&md5=6241dee0bdb796815e19ce68b68e4110","Internal Medicine Department, State Medical University, 26, Mayakovsky Av.Zaporozhye, Ukraine; Clinical Pharmacology Department, State Medical UniversityZaporozhye, Ukraine; Pathology Department, State Medical UniversityZaporozhye, Ukraine; Private Medical Center Vita-CenterZaporozhye, Ukraine","Berezin, A.E., Internal Medicine Department, State Medical University, 26, Mayakovsky Av.Zaporozhye, Ukraine; Kremzer, A.A., Clinical Pharmacology Department, State Medical UniversityZaporozhye, Ukraine; Martovitskaya, Y.V., Pathology Department, State Medical UniversityZaporozhye, Ukraine; Samura, T.A., Clinical Pharmacology Department, State Medical UniversityZaporozhye, Ukraine; Berezina, T.A., Private Medical Center Vita-CenterZaporozhye, Ukraine","Aim: The study aim was to evaluate whether circulating microparticles with apoptotic or non-apoptotic phenotypes are useful for risk assessment of 3-year cumulative fatal and non-fatal cardiovascular events in CHF patients. Methods: The incidence of fatal and non-fatal cardiovascular events, as well as the frequency of occurrence of death from any cause in a cohort of 388 patients with CHF during 3. years of observation was studied prospectively. Circulating levels of NT-pro brain natriuretic peptide (NT-pro-BNP), high-sensitivity C-reactive protein (hs-CRP), and endothelial apoptotic microparticles (EMPs) were measured at baseline. Results: Median follow-up was 2.32. years (IQR = 1.8-3.1). During follow-up, 110 cardiovascular events (including 43 fatal cases) were determined. Additionally, 74 subjects were hospitalized repetitively due to worsening CHF and also 16 subjects were readmitted in the hospital due to other cardiovascular reasons. In the univariate logistic regression analysis, the main factors independently related with cumulative endpoints were creatinine, fasting glucose, HbA1c, total cholesterol, uric acid, various types of EPMs, NT-pro-BNP, hs-CRP, NYHA class, decreased left ventricular ejection fraction (LVEF) less 45%, and type 2 diabetes mellitus. In multivariate model NYHA class, decreased LVEF (less 45%), NT-pro-BNP, hs-CRP, CD144. +/CD31. +/annexin V. + EMPs, and CD31. +/annexin V. + EMPs remained statistically significant for cumulative endpoint. Adding of CD144. +/CD31. +/annexin V. + EMCs and CD31. +/annexin V. + EMCs to the standard ABC model may improve the relative IDI for cumulative endpoint by 11.4% and 10.5% respectively. Conclusion: Apoptotic phenotype of circulating microparticles may relate 3-year combined clinical outcomes in CHF patients. © 2014.","Cardiovascular outcomes; Chronic heart failure; Microparticles; Predictive value","Lloyd-Jones, D., Adams, R.J., Brown, T.M., Carnethon, M., Ferguson, T.B., Ford, E., Heart disease and stroke statistics-2010 update: a report from the American Heart Association (2010) Circulation, 121 (7), pp. e46-e215; Santulli, G., Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts (2013) JCvD, 1 (1), pp. 1-2; Ehrlich, J.R., Kaluzny, M., Baumann, S., Lehmann, R., Hohnloser, S.H., Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation (2011) Clin. Res. Cardiol., 100 (11), pp. 1029-1036; Tschöpe, C., Van Linthout, S., New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction (2014) Curr. Heart Fail. Rep., 11 (4), pp. 436-444; Maisel, A., Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research (2011) J. Am. Coll. Cardiol., 58 (18), pp. 1890-1892; Alba, A.C., Agoritsas, T., Jankowski, M., Courvoisier, D., Walter, S.D., Guyatt, G.H., Ross, H.J., Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review (2013) Circ. Heart Fail., 6 (5), pp. 881-889; Oremus, M., Don-Wauchope, A., McKelvie, R., Santaguida, P.L., Hill, S., Balion, C., BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure (2014) Heart Fail. Rev., 19 (4), pp. 471-505; Carrasco-Sánchez, F.J., Páez-Rubio, M.I., Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing (2014) Mol. Diagn. Ther., 18 (6), pp. 599-604; Rajendiran, K.S., Ananthanarayanan, R.H., Satheesh, S., Rajappa, M., Elevated levels of serum sialic acid and high-sensitivity C-reactive protein: markers of systemic inflammation in patients with chronic heart failure (2014) Br. J. Biomed. Sci., 71 (1), pp. 29-32; De Beradinis, B., Januzzi, J.L., Use of biomarkers to guide outpatient therapy of heart failure (2012) Curr. Opin. Cardiol., 27 (6), pp. 661-668; Mause, S.F., Weber, C., Microparticles: protagonists of a novel communication network for intercellular information exchange (2010) Circ. Res., 107, pp. 1047-1057; Arraud, N., Linares, R., Tan, S., Gounou, C., Pasquet, J.M., Mornet, S., Brisson, A.R., Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration (2014) J. Thromb. Haemost., 12 (5), pp. 614-627; Berezin, A.E., Kremzer, A.A., Samura, T.A., Martovitskaya, Y., Circulating endothelial-derived apoptotic microparticles in the patients with ischemic symptomatic chronic heart failure: relevance of pro-inflammatory activation and outcomes (2014) Int. Cardiovasc. Res. J., 8 (3), pp. 116-123; Pirro, M., Schillaci, G., Bagaglia, F., Menecali, C., Paltriccia, R., Mannarino, M.R., Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk (2008) Atherosclerosis, 197 (2), pp. 757-767; Jimenez, J.J., Jy, W., Mauro, L.M., Soderland, C., Horstman, L.L., Ahn, Y.S., Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis (2003) Thromb. Res., 109, pp. 175-180; Charan Reddy, K.V., Regulatory noncoding RNAs in cardiovascular disease: shedding light on 'dark matter' (2014) JCvD, , http://researchpub.org/journal/jcvd/number/early/47.pdf, ([press]); Wronska, A., Kurkowska-Jastrzebska, I., Santulli, G., Application of microRNAs in diagnosis and treatment of cardiovascular disease (2014) Acta Physiol., , (press); Santulli, G., Campanile, A., Spinelli, L., Assante di Panzillo, E., Ciccarelli, M., G protein-coupled receptor kinase 2 in patients with acute myocardial infarction (2011) Am. J. Cardiol., 107, pp. 1125-1130; Santulli, G., Adrenal signaling in heart failure: something more than a distant ship's smoke on the horizon (2014) Hypertension, 63 (2), pp. 215-216; Bluemke, D.A., Achenbach, S., Budoff, M., Gerber, T.C., Gersh, B., Hillis, L.D., Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention, and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young (2008) Circulation, 118, pp. 586-606; Schiller, N.B., Shah, P.M., Crawford, M., De Maria, A., Devereux, R., Feigenbaum, H., Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms (1989) J. Am. Soc. Echocardiogr., 2, pp. 358-367; Pellerin, D., Sharma, R., Elliott, P., Veyrat, C., Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function (2003) Heart, 89. , 90003, iii9-iii17; Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F., Feldman, H.I., A new equation to estimate glomerular filtration rate (2009) Ann. Intern. Med., 150 (9), pp. 604-612. , for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration); Lacroix, R., Judicone, C., Mooberry, M., Boucekine, M., Key, N.S., Dignat-George, F., The ISTH SSC Workshop. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop (2013) J. Thromb. Haemost., , (Epub ahead of print); Orozco, A.F., Lewis, D.E., Flow cytometric analysis of circulating microparticles in plasma (2010) Cytometry A, 77 (6), pp. 502-514; Nomura, S., Ozaki, Y., Ikeda, Y., Function and role of microparticles in various clinical settings (2008) Thromb. Res., 123, pp. 8-23; Leroyer, A.S., Anfosso, F., Lacroix, R., Sabatier, F., Simoncini, S., Njock, S.M., Endothelial-derived microparticles: biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis (2010) Thromb. Haemost., 104, pp. 456-463; Boulanger, C.M., Leroyer, A.S., Amabile, N., Tedgui, A., Circulating endothelial microparticles: a new marker of vascular injury (2008) Ann. Cardiol. Angeiol. (Paris), 57, pp. 149-154; Pérez-Casal, M., Downey, C., Cutillas-Moreno, B., Zuzel, M., Fukudome, K., Toh, C.H., Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects (2009) Haematologica, 94, pp. 387-394; Mezentsev, A., Merks, R.M., O'Riordan, E., Chen, J., Mendelev, N., Goligorsky, M.S., Brodsky, S.V., Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress (2005) Am. J. Physiol. Heart Circ. Physiol., 289 (3), pp. H1106-H1114; Sabatier, F., Roux, V., Anfosso, F., Camoin, L., Sampol, J., Dignat-George, F., Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity (2002) Blood, 99, pp. 3962-3970; Morel, O., Toti, F., Freyssinet, J.M., Markers of thrombotic disease: procoagulant microparticles (2007) Ann. Pharm. Fr., 65 (2), pp. 75-84; Loyer, X., Vion, A.C., Tedgui, A., Boulanger, C.M., Microvesicles as cell-cell messengers in cardiovascular diseases (2014) Circ. Res., 114 (2), pp. 345-353; VanWijk, M.J., Van Bavel, E., Sturk, A., Nieuwland, R., Microparticles in cardiovascular diseases (2003) Cardiovasc. Res., 59 (2), pp. 277-287; Markiewicz, M., Richard, E., Marks, N., Ludwicka-Bradley, A., Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases (2013) J. Aging Res., 2013, p. 734509; Chironi, G.N., Boulanger, C.M., Simon, A., Dignat-George, F., Freyssinet, J.M., Tedgui, A., Endothelial microparticles in diseases (2009) Cell Tissue Res., 335, pp. 143-151; Montoro-García, S., Shantsila, E., Tapp, L.D., López-Cuenca, A., Romero, A.I., Hernández-Romero, D., Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes (2013) Atherosclerosis, 227 (2), pp. 313-322; Matsuzawa, Y., Sugiyama, S., Sumida, H., Sugamura, K., Nozaki, T., Ohba, K., Peripheral endothelial function and cardiovascular events in high-risk patients (2013) J. Am. Heart Assoc., 2 (6), p. e000426; Berezin, A.E., Kremzer, A.A., Samura, T.A., Martovitskaya, Y.V., Apoptotic microparticles to progenitor mononuclear cells ratio in heart failure: relevance of clinical status and outcomes (2014) JCvD, 2 (2), pp. 50-57",Article,Scopus,2-s2.0-84916882856
"Bittencourt M.S., Hajjar L.A.","Insulin therapy in insulin resistance: Could it be part of a lethal pathway?",2015,"Atherosclerosis","240","2",,"400","401",,,10.1016/j.atherosclerosis.2015.04.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927758941&partnerID=40&md5=743209b9f3b72bc1526193ddc2d84162","Division of Internal Medicine, University Hospital and State of São Paulo Cancer Institute (ICESP), University of São PauloSão Paulo, Brazil; Department of Cardiopneumology, Heart Institute and State of São Paulo Cancer Institute (ICESP), University of São PauloSão Paulo, Brazil","Bittencourt, M.S., Division of Internal Medicine, University Hospital and State of São Paulo Cancer Institute (ICESP), University of São PauloSão Paulo, Brazil, Department of Cardiopneumology, Heart Institute and State of São Paulo Cancer Institute (ICESP), University of São PauloSão Paulo, Brazil; Hajjar, L.A., Department of Cardiopneumology, Heart Institute and State of São Paulo Cancer Institute (ICESP), University of São PauloSão Paulo, Brazil",[No abstract available],"Cardiovascular disease; Diabetes; Insulin resistance; Insulin therapy; Mortality","Harrison, L.B., Adams-Huet, B., Raskin, P., Beta-cell function preservation after 3.5 years of intensive diabetes therapy (2012) Diabetes care, 35, pp. 1406-1412; Alvarsson, M., Sundkvist, G., Lager, I., Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients (2003) Diabetes care, 26, pp. 2231-2237; Gerstein, H.C., Bosch, J., Dagenais, G.R., Basal insulin and cardiovascular and other outcomes in dysglycemia (2012) N.Engl. J. Med., 367, pp. 319-328; Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) Group (1998) Lancet, 352, pp. 837-853; Holman, R.R., Paul, S.K., Bethel, M.A., 10-year follow-up of intensive glucose control in type 2 diabetes (2008) N.Engl. J. Med., 359, pp. 1577-1589; Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials (2011) BMJ Clin. Res. ed., 343, p. d4169; Engel-Nitz, N.M., Martin, S., Sun, P., Cardiovascular events and insulin therapy: a retrospective cohort analysis (2008) Diabetes Res. Clin. Pract., 81, pp. 97-104; Gerstein, H.C., Miller, M.E., Effects of intensive glucose lowering in type 2 diabetes (2008) N.Engl. J. Med., 358, pp. 2545-2559. , Action to Control Cardiovascular Risk in Diabetes Study, G; Roumie, C.L., Greevy, R.A., Grijalva, C.G., Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes (2014) JAMA J. Am. Med. Assoc., 311, pp. 2288-2296; Saenz, A., Fernandez-Esteban, I., Mataix, A., Metformin monotherapy for type 2 diabetes mellitus (2005) Cochrane Database Syst. Rev., 20 (3). , CD002966; Muis, M.J., Bots, M.L., Grobbee, D.E., Insulin treatment and cardiovascular disease; friend or foe? A point of view (2005) Diabet. Med. J. Br. Diabet. Assoc., 22, pp. 118-126; Rensing, K.L., Reuwer, A.Q., Arsenault, B.J., Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? (2011) Diabetes Obes. Metabol., 13, pp. 1073-1087; Smooke, S., Horwich, T.B., Fonarow, G.C., Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (2005) Am. Heart J., 149, pp. 168-174; Gamble, J.M., Simpson, S.H., Eurich, D.T., Insulin use and increased risk of mortality in type 2 diabetes: a cohort study (2010) Diabetes Obes. Metabol., 12, pp. 47-53; Turnbull, F.M., Abraira, C., Anderson, R.J., Intensive glucose control and macrovascular outcomes in type 2 diabetes (2009) Diabetologia, 52, pp. 2288-2298; Stoekenbroek, R.M., Rensing, K.L., Bernelot Moens, S.J., High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovsacular disease (2015) Atherosclerosis, 240, pp. 318-323; Holden, S.E., Jenkins-Jones, S., Morgan, C.L., Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer (2015) Diabetes Obes. Metabol., 17, pp. 350-362",Note,Scopus,2-s2.0-84927758941
"Braatz E.M., Coleman R.A.","A mathematical model of insulin resistance in Parkinson's disease",2015,"Computational Biology and Chemistry","56",,,"84","97",,,10.1016/j.compbiolchem.2015.04.003,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927942044&partnerID=40&md5=1045c2c268e8806431bba14362e2e21a","Department of Chemistry, Integrated Science Center, College of William and Mary, 540 Landrum DriveWilliamsburg, VA, United States","Braatz, E.M., Department of Chemistry, Integrated Science Center, College of William and Mary, 540 Landrum DriveWilliamsburg, VA, United States; Coleman, R.A., Department of Chemistry, Integrated Science Center, College of William and Mary, 540 Landrum DriveWilliamsburg, VA, United States","This paper introduces a mathematical model representing the biochemical interactions between insulin signaling and Parkinson's disease. The model can be used to examine the changes that occur over the course of the disease as well as identify which processes would be the most effective targets for treatment. The model is mathematized using biochemical systems theory (BST). It incorporates a treatment strategy that includes several experimental drugs along with current treatments. In the past, BST models of neurodegeneration have used power law analysis and simulation (PLAS) to model the system. This paper recommends the use of MATLAB instead. MATLAB allows for more flexibility in both the model itself and in data analysis. Previous BST analyses of neurodegeneration began treatment at disease onset. As shown in this model, the outcomes of delayed, realistic treatment and full treatment at disease onset are significantly different. The delayed treatment strategy is an important development in BST modeling of neurodegeneration. It emphasizes the importance of early diagnosis, and allows for a more accurate representation of disease and treatment interactions. © 2015 Elsevier Ltd. All rights reserved.","Computational biology; Delayed treatment; Insulin resistance; Neurodegenerative disease; Parkinsons disease; Type-II diabetes mellitus","Ambhore, N.S., Prasanna, M., Antony, A.S., Kumar, M.N.S., Elango, K., Pharmacological and anti-oxidant evaluation of Aspirin, nimodipine and its combination for anti-Parkinson's activity in MPTP induced rat model (2014) Int. J. Health Allied Sci., 3 (1), pp. 14-22; Arima, K., Hirai, S., Sunohara, N., Aoto, K., Izumiyama, Y., Ueda, K., Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies (1999) Brain Res., 843 (12), pp. 53-61; Bancher, C., Braak, H., Fischer, P., Jellinger, K.A., Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients (1993) Neurosci. Lett., 162, pp. 179-182; Beckman, J.S., Crow, J.P., Pathological implications of nitric oxide, superoxide, and peroxynitrite formation (1993) Biochem. Soc. Trans., 21, pp. 330-334; Bosco, D., Plastino, M., Cristiano, D., Colica, C., Ermio, C., De Bartolo, M., Dementia is associated with insulin resistance in patients with Parkinson's disease (2012) J. Neurol. Sci., 315 (12), pp. 39-43; Broome, T.M., Coleman, R.A., A mathematical model of cell death in multiple sclerosis (2011) J. Neurosci. Methods, 201 (2), pp. 420-425; Chang, J.M., Kuo, M.C., Kuo, H.T., Hwang, S.J., Tsai, J.C., Chen, H.C., 1-α,25-Dihydroxyvitamin D<inf>3</inf> regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells (2004) J. Lab. Clin. Med., 143 (1), pp. 14-22; Cheng, B., Guo, Y., Li, C., Ji, B., Pan, Y., Chen, J., Bai, B., Edaravone protected PC12 cells against MPP(+)-cytotoxicity via inhibiting oxidative stress and up-regulating heme oxygenase-1 expression (2014) J. Neurol. Sci., 343 (12), pp. 115-119; Choi, J.-S., Oh, J.-I., Na, M., Lee, S.-K., Joo, S.H., PKCδ promotes etoposide-induced cell death by phosphorylating Hsp27 in HeLa cells (2012) Biochem. Biophys. Res. Commun., 426 (4), pp. 590-595; Choi, W.-S., Eom, D.-S., Han, B.S., Kim, W.K., Han, B.H., Choi, E.-J., Phosphorylation of p38 MAPK Induced by oxidative stress is linked to activation of both caspase-8 and -9-mediated apoptotic pathways in dopaminergic neurons (2004) J. Biol. Chem., 279 (19), pp. 20451-20460; Dean, O., Giorlando, F., Berk, M., N-Acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action (2011) J. Psychiatry Neurosci., 36 (2), pp. 78-86; Evans, J.L., Goldfine, I.D., Maddux, B.A., Grodsky, G.M., Oxidative stress and stress-actived signaling pathways: A unifying hypothesis of type 2 diabetes (2002) Endocr. Rev., 23 (5), pp. 599-622; Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death (2009) Mol. Cell, 33 (5), pp. 627-638; Gao, Z., Yin, J., Zhang, J., Ward, R.E., Martin, R.J., Lefevre, M., Butyrate improves insulin sensitivity and increases energy expenditure in mice (2009) Diabetes, 58 (7), pp. 1509-1517; Ghosh, A., Roy, A., Liu, X., Kordower, J.H., Mufson, E.J., Hartley, D.M., Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease (2007) Proc. Natl. Acad. Sci., 104 (47), pp. 18754-18759; Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration (2010) Cell, 140 (6), pp. 918-934; Heidenreich, K.A., Kummer, J.L., Inhibition of p38 mitogen-activated protein kinase by insulin in cultured fetal neurons (1996) J. Biol. Chem., 271 (17), pp. 9891-9894; Hunot, S., Boissiere, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., Hirsch, E.C., Nitric oxide synthase and neuronal vulnerability in Parkinson's disease (1996) Neuroscience, 72 (2), pp. 355-363; Hu, S.H., Jiang, S.-S., Yang, Y., Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes (2013) Exp. Clin. Endocrinol. Diabetes, 121, pp. 220-224; Ko, H.S., Von Coelln, R., Sriram, S.R., Kim, S.W., Chung, K.K.K., Pletnikova, O., Accumulation of the authentic parkin substrate aminoacyl-trna synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death (2005) J. Neurosci., 25 (35), pp. 7968-7978; Lamarche, F., Carcenac, C., Gonthier, B., Cottet-Rousselle, C., Chauvin, C., Barret, L., Mitochondrial permeability transition pore inhibitors prevent ethanol-induced neuronal death in mice (2013) Chem. Res. Toxicol., 26, pp. 78-88; Lei, P., Ayton, S., Finkelstein, D.I., Adlard, P.A., Masters, C.L., Bush, A.I., Tau protein: Relevance to Parkinson's disease (2010) Int. J. Biochem. Cell Biol., 42, pp. 1775-1778; Lucas, J.J., Hernandez, F., Gomez-Ramos, P., Moran, M.A., Hen, R., Avila, J., Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice (2001) EMBO J., 20 (12), pp. 27-39; Marchitti, S.A., Deitrich, R.A., Vasiliou, V., Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: The role of aldehyde dehydrogenase (2007) Pharmacol. Rev., 59 (2), pp. 125-150; Mehlen, P., Schulz-Osthoff, K., Arrigo, A.P., Small stress proteins as novel regulators of apoptosis: Heat shock protein 27 blocks Fas/APO-1 and staurosporine-induced cell death (1996) J. Biol. Chem., 271, pp. 16510-16514; Mehlen, P., Kretz-Remy, C., Preville, X., Arrigo, A.P., Human Hsp27, drosophila Hsp27 and human alphaB-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNF-alpha-induced cell death (1996) EMBO J., 15, pp. 2695-2706; Miranda, S., Foncea, R., Guerrero, J., Leighton, F., Oxidative stress and upregulation of mitochondrial biogenesis genes in mitochondrial DNA-depleted HeLa cells (1999) Biochem. Biophys. Res. Commun., 258 (1), pp. 44-49; Moon, Y., Lee, K.H., Park, J.-H., Geum, D., Kim, K., Mitochondrial membrane depolarization and selective death of dopaminergic neurons by rotenone: Protective effect of coenzyme Q<inf>10</inf> (2005) J. Neurochem., 93 (5), pp. 1199-1208; Morris, J.K., Bomhoff, G.L., Gorres, B.K., Davis, V.A., Kim, J., Lee, P.-P., Insulin resistance impairs nigrostriatal dopamine function (2011) Exp. Neurol., 231 (1), pp. 171-180; Morris, J.K., Zhang, H., Gupte, A.A., Bomhoff, G.L., Stanford, J.A., Geiger, P.C., Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease (2008) Brain Res., 1240, pp. 185-195; Mudo, G., Makela, J., Di Liberto, V., Tselykh, T.V., Olivieri, M., Piepponen, P., Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease (2012) Cell. Mol. Life Sci., 69 (7), pp. 1153-1165; Oka, S., Kamata, H., Kamata, K., Yagisawa, H., Hirata, H., N-Acetylcysteine suppresses TNF-induced NF-kappa B activation through inhibition of i kappa B kinases (2000) FEBS Lett., 472, pp. 196-202; Petit-Paitel, A., Brai, F., Cazareth, J., Chabry, J., Involvement of cytosolic and mitochondrial GSK-3β in mitochondrial dysfunction and neuronal cell death of MPTP/MPP+-treated neurons (2009) PLoS One, 4 (5), pp. 1-12; Piao, Y., Kim, H.G., Oh, M.S., Pak, Y.K., Overexpression of TFAM, NRF-1, and myr-AKT protects the MPP+-induced mitochondrial dysfunctions in neuronal cells (2012) Biochim. Biophys. Acta, 1820 (5), pp. 577-585; Puchacz, E., Stumpf, W.E., Stachowiak, E.K., Stachowiak, M.K., Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells (1996) Mol. Brain Res., 36 (1), pp. 193-196; Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., Glass, C.K., The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation (1998) Nature, 391, pp. 79-82; Samuni, Y., Goldstein, S., Dean, O.M., Berk, M., The chemistry and biological activities of N-acetycysteine (2013) Biochim. Biophys. Acta, 1830, pp. 4117-4129; Sass, M.B., Lorenz, A.N., Green, R.L., Coleman, R.A., A pragmatic approach to biochemical systems theory applied to an α-synuclein-based model of Parkinson's disease (2009) J. Neurosci. Methods, 178 (2), pp. 366-377; Shimura, H., Miura-Shimura, Y., Kosik, K.S., Binding of tau to heat shock protein 27 leads to decerased concentration of hyperphosphorylated tau and enhanced cell survival (2004) J. Biol. Chem., 279 (17), pp. 17957-17962; Snyder, C.M., Shroff, E.H., Liu, J., Chandel, N.S., Nitric oxide induces cell death by regulating anti-apoptotic BCL-2 family members (2009) PLoS One, 4 (9); Susin, S.A., Lorenzo, H.K., Zamzami, N., Marzo, I., Snow, B.E., Brothers, G.M., Molecular characterization of mitochondrial apoptosis-inducing factor (1999) Nature, 397 (6718), pp. 441-446; Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimura, H., Yamamoto, T., Okada, H., Insulin receptor mRNA in the substantia nigra in Parkinson's disease (1996) Neurosci. Lett., 204 (3), pp. 201-204; Taylor, D.M., Moser, R., Regulier, E., Breuillaud, L., Dixon, M., Beesen, A.A., MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in huntington's disease via additive effects of JNK and p38 inhibition (2013) J. Neurosci., 33 (6), pp. 2313-2325; Winklhofer, K.F., Henn, I.H., Kay-Jackson, P.C., Heller, U., Tatzelt, J., Inactivation of parkin by oxidative stress and C-terminal truncations: A protective role of molecular chaperones (2003) J. Biol. Chem., 278 (47), pp. 199-208; Xing, B., Liu, M., Bing, G., Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity (2007) J. Neuroimmunol., 192 (12), pp. 89-98; Xiong, N., Xiong, J., Khare, G., Chen, C., Huang, J., Zhao, Y., Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease (2011) PLoS One, 6 (6); Yeager, M.P., Coleman, R.A., In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease (2010) J. Neurosci. Methods, 188 (1), pp. 151-164; Yu, S., Ueda, K., Chan, P., α-Synuclein and dopamine metabolism (2005) Mol. Neurobiol., 31 (13), pp. 243-254; Zarubin, T., Han, J., Activation and signaling of the p38 MAP kinase pathway (2005) Cell Res., 15 (1), pp. 11-18; Zheng, B., Zhixiang, L., Locascio, J.J., Lesniak, K.A., Roderick, S.S., Watt, M.L., PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease (2010) Sci. Transl. Med., 2 (52), pp. 57-73; Zhou, S., Yu, G., Chi, L., Zhu, J., Zhang, W., Zhang, Y., Zhang, L., Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau phosphorylation induced by intracerebroventricular streptozotocin in rats (2013) Neurotoxicology, 38, pp. 136-145; Zourlidou, A., Payne Smith, M.D., Latchman, D.S., HSP27 but not HSP70 has a potent protective effect against α-synuclein-induced cell death in mammalian neuronal cells (2004) J. Neurochem., 88 (6), pp. 1439-1448",Article,Scopus,2-s2.0-84927942044
"Zhang W., Du Y., Wang M.L.","Noninvasive glucose monitoring using saliva nano-biosensor",2015,"Sensing and Bio-Sensing Research","4",,,"23","29",,,10.1016/j.sbsr.2015.02.002,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924812338&partnerID=40&md5=7bd975e8fae65e747612e526e0c10ec2","Department of Civil and Environmental Engineering, 400 SN, Northeastern University, 360 Huntington AveBoston, MA, United States","Zhang, W., Department of Civil and Environmental Engineering, 400 SN, Northeastern University, 360 Huntington AveBoston, MA, United States; Du, Y., Department of Civil and Environmental Engineering, 400 SN, Northeastern University, 360 Huntington AveBoston, MA, United States; Wang, M.L., Department of Civil and Environmental Engineering, 400 SN, Northeastern University, 360 Huntington AveBoston, MA, United States","Millions of people worldwide live with diabetes and several millions die from it each year. A noninvasive, painless method of glucose testing would highly improve compliance and glucose control while reducing complications and overall disease management costs. To provide accurate, low cost, and continuous glucose monitoring, we have developed a unique, disposable saliva nano-biosensor. More than eight clinical trials on real-time noninvasive salivary glucose monitoring were carried out on two healthy individuals (a 2-3. h-period for each trial, including both regular food and standard glucose beverage intake with more than 35 saliva samples obtained). Excellent clinical accuracy was revealed as compared to the UV Spectrophotometer. By measuring subjects' salivary glucose and blood glucose in parallel, we found the two generated profiles share the same fluctuation trend but the correlation between them is individual dependent. There is a time lag between the peak glucose values from blood and from saliva. However, the correlation between the two glucose values at fasting is constant for each person enabling noninvasive diagnosis of diabetes through saliva instead of blood. Furthermore, a good correlation of glucose levels in saliva and in blood before and 2. h after glucose intake was observed. Glucose monitoring before and 2. h after meals is usually prescribed by doctors for diabetic patients. Thus, this disposable biosensor will be an alternative for real-time salivary glucose tracking at any time. © 2015 The Authors.","Disposable; Glucose monitoring; Nano-biosensor; Noninvasive; Saliva","Guariguata, L., (2013) IDF Diabetes Atlas, , International Diabetes Federation; Grp, I.D.A., Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011 (2013) Diabetes Res. Clin. Pract., 100, pp. 277-279; Klonoff, D.C., Perz, J.F., Assisted monitoring of blood glucose: special safety needs for a new paradigm in testing glucose (2010) J. Diabetes Sci. Technol., 4, pp. 1027-1031; Thompson, N.D., Perz, J.F., Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies (2009) J. Diabetes Sci. Technol., 3, pp. 283-288; Hayford, J.T., Weydert, J.A., Thompson, R.G., Validity of urine glucose measurements for estimating plasma-glucose concentration (1983) Diabetes Care, 6, pp. 40-44; Tierney, M.J., Electroanalysis of glucose in transcutaneously extracted samples (2000) Electroanalysis, 12, pp. 666-671; http://www.orsense.com/product.php?ID=44Amir, O., Continuous noninvasive glucose monitoring technology based on ""occlusion (2007) J. Diabetes Sci. Technol., 1, pp. 463-469; Zhang, L., Xiao, H., Wong, D.T., Salivary biomarkers for clinical applications (2009) Mol. Diagn. & Ther., 13, pp. 245-259; Lamy, E., Mau, M., Saliva proteomics as an emerging, non-invasive tool to study livestock physiology, nutrition and diseases (2012) J. Proteomics, 75, pp. 4251-4258; Wong, D.T., Salivary diagnostics powered by nanotechnologies, proteomics and genomics (2006) J. Am. Dent. Assoc., 137, pp. 313-321; Yamaguchi, M., Mitsumori, M., Kano, Y., Development of noninvasive procedure for monitoring blood glucose levels using saliva (1998) Proceedings of the 20th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 20, pp. 1763-1766; Panchbhai, A.S., Degwekar, S.S., Bhowte, R.R., Estimation of salivary glucose, salivary amylase, salivary total protein and salivary flow rate in diabetics in India (2010) J. Oral Sci., 52, pp. 359-368; Forde, M.D., Systemic assessments utilizing saliva: Part 1. General considerations and current assessments (2006) Int. J. Prosthodont., 19, pp. 43-52; Reynolds, S.J., Muwonga, J., OraQuick ADVANCE Rapid HIV-1/2 antibody test (2004) Exp. Rev. Mol. Diagn., 4, pp. 587-591; Maliszewski, T.F., Bass, D.E., True and apparent thiocyanate in body fluids of smokers and nonsmokers (1955) J. Appl. Physiol., 8, pp. 289-291; Li, Y., Salivary transcriptome diagnostics for oral cancer detection (2004) Clin. Cancer Res., 10, pp. 8442-8450; Li, Y., Serum circulating human mRNA profiling and its utility for oral cancer detection (2006) J. Clin. Oncol., 24, pp. 1754-1760; Degier, J.J., Comparison of plasma and saliva levels of diazepam (1980) Br. J. Clin. Pharmacol., 10, pp. 151-155; Knott, C., Hamshawthomas, A., Reynolds, F., Phenytoin-valproate interaction - importance of saliva monitoring in epilepsy (1982) Br. Med. J., 284, pp. 13-16; Jurysta, C., Salivary glucose concentration and excretion in normal and diabetic subjects (2009) J. Biomed. Biotechnol., 2009, p. 6; Enejder, A.M.K., Raman spectroscopy for noninvasive glucose measurements (2005) J. Biomed. Opt., 10, p. 031114; Christodoulides, N., Lab-on-a-chip methods for point-of-care measurements of salivary biomarkers of periodontitis (2007) Oral-Based Diagn., 1098, pp. 411-428; Amer, S., Salivary glucose concentrations in patients with diabetes mellitus - a minimally invasive technique for monitoring blood glucose levels (2001) Pak. J. Pharm. Sci., 14, pp. 33-37; Yamaguchi, M., Mitsumori, M., Kano, Y., Noninvasively measuring blood glucose using saliva (1998) IEEE Eng. Med. Biol., 17, pp. 59-63; Aydin, S., A comparison of ghrelin, glucose, alpha-amylase and protein levels in saliva from diabetics (2007) J. Biochem. Mol. Biol., 40, pp. 29-35; Abikshyeet, P., Ramesh, V., Oza, N., Glucose estimation in the salivary secretion of diabetes mellitus patients (2012) Diabetes Metab. Syndr. Obes., 5, pp. 149-154; Zhang, W., Wang, M.L., (2014) Saliva Glucose Monitoring System, , US20140197042 A1; Huang, H., Yang, X., Chitosan mediated assembly of gold nanoparticles multilayer (2003) Colloids Surf. A, 226, pp. 77-86; Shleev, S., Direct electron transfer between copper-containing proteins and electrodes (2005) Biosens. Bioelectron., 20, pp. 2517-2554; Zhang, W., Du, Y., Wang, M., On-chip ultra-sensitive glucose sensing using multilayer films composed of single-walled carbon nanotubes-gold nanoparticles-and glucose oxidase (2015) Sens. Actuators B, , (under review); Ricci, F., Prussian blue based screen printed biosensors with improved characteristics of long-term lifetime and pH stability (2003) Biosens. Bioelectron., 18, pp. 165-174; Zhu, J.H., Planar amperometric glucose sensor based on glucose oxidase immobilized by chitosan film on Prussian blue layer (2002) Sensors, 2, pp. 127-136; Montereali, M.R., A disposable laccase-tyrosinase based biosensor for amperometric detection of phenolic compounds in must and wine (2010) J. Mol. Catal. B, 64, pp. 189-194; Marder, M.Z., Abelson, D.C., Mandel, I.D., Salivary alterations in diabetes-mellitus (1975) J. Dent. Res., 54, p. 143; Campbell, M.J., Glucose in the saliva of the non-diabetic and the diabetic patient (1965) Arch. Oral Biol., 10, pp. 197-205; Inoue, H., Rheological properties of human saliva and salivary mucins (2008) J. Oral Biosci., 50, pp. 134-141; Ericsson, Y., Stjernstrom, L., Saliva viscosity measurements (1951) Oral Surg. Oral Med. Oral Pathol., 4, pp. 1465-1474; Mitsumori, M., Yamaguchi, M., Kano, Y., A new approach to noninvasive measurement of blood glucose using saliva analyzing system (1998) Proceedings of the 20th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 20, pp. 1767-1770; Andersson, A.B., Glucose concentration in parotid saliva after glucose/food intake in individuals with glucose intolerance and diabetes mellitus (1998) Eur. J. Oral Sci., 106, pp. 931-937; Borg, A., Birkhed, D., Secretion of glucose in human-parotid saliva after carbohydrate intake (1988) Scand. J. Dent. Res., 96, pp. 551-556; Sariri, R., Varasteh, A., Erfani, A., Alternations in salivary glucose during Ramadan fasting (2010) Health, 2, pp. 769-772; Agrawal, R., Noninvasive method for glucose level estimation by saliva (2013) Diabetes Metab., 4, p. 1000266; Mirzaii-Dizgah, I., Mirzaii-Dizgah, M.R., Mirzaii-Dizgah, M.H., Stimulated saliva glucose as a diagnostic specimen for detection of diabetes mellitus (2013) J. Arch. Mil. Med., 1, pp. 24-27",Article,Scopus,2-s2.0-84924812338
"Camuset G., Picot S., Jaubert J., Borgherini G., Ferdynus C., Foucher A., Maiza J.-C., Fels O., Poyart C., Poubeau P., Gerardin P.","Invasive Group B Streptococcal Disease in Non-pregnant Adults, Réunion Island, 2011",2015,"International Journal of Infectious Diseases","35",,,"e46","e50",,,10.1016/j.ijid.2015.04.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928911483&partnerID=40&md5=0f14b921a324d9f4b2c56cc2d2131ae2","Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Centre National de Référence des Streptocoques, Groupe Hospitalier Cochin-Saint Vincent de Paul, Assistance Publique-HÔpitaux de ParisParis, France; Institut Cochin-Inserm; U567-UMR CNRS 10, Université Paris DescartesParis, France; Unité Biologie des Bactéries Pathogènes à Gram-Positif-URA CNRS 2172, Institut PasteurParis, France; Centre d'Investigation Clinique 1410 (Inserm/CHU/Université de La Réunion), Union Régionale des Médecins Libéraux de l'Océan IndienSaint Pierre, La Réunion, France; UMR PIMIT Processus Infectieux en Milieu Insulaire Tropical (Inserm 1187), CNRS 9192, IRD 249, Université de La Réunion, Plateforme technologique CYROISainte Clotilde, La Réunion, France","Camuset, G., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Picot, S., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Jaubert, J., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Borgherini, G., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Ferdynus, C., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Foucher, A., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Maïza, J.-C., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Fels, O., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Poyart, C., Centre National de Référence des Streptocoques, Groupe Hospitalier Cochin-Saint Vincent de Paul, Assistance Publique-HÔpitaux de ParisParis, France, Institut Cochin-Inserm; U567-UMR CNRS 10, Université Paris DescartesParis, France, Unité Biologie des Bactéries Pathogènes à Gram-Positif-URA CNRS 2172, Institut PasteurParis, France; Poubeau, P., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France; Gérardin, P., Centre Hospitalier Universitaire (CHU)SaintPierre/Saint-Denis, La Réunion, France, Centre d'Investigation Clinique 1410 (Inserm/CHU/Université de La Réunion), Union Régionale des Médecins Libéraux de l'Océan IndienSaint Pierre, La Réunion, France, UMR PIMIT Processus Infectieux en Milieu Insulaire Tropical (Inserm 1187), CNRS 9192, IRD 249, Université de La Réunion, Plateforme technologique CYROISainte Clotilde, La Réunion, France","Objectives: While the prevalence of Group B streptococcus (GBS) colonization is important, little is known about invasive GBS (iGBS) disease in tropical areas. Our objective was to assess the burden of iGBS disease among non-pregnant adults. Methods: A prospective hospital-based study of all non-pregnant adult patients with iGBS disease was conducted between January and December 2011 in Saint Pierre, Réunion Island, to assess its cumulative incidence rate (CIR). Capsular serotyping and multilocus sequence typing were performed to characterize GBS isolates. Case-control study was done to identify risk factors. Results: The overall CIR of iGBS disease was 10.1 per 100,000. The CIR in elderly patients (≥ 65 yrs) was estimated at 40.6 per 100.000, and that of adults (15-64 years) at 6.7 per 100.000. Aboriginal origin in the Indian Ocean and overweight were both associated with iGBS disease. The most prominent clinical forms were osteo-articular and skin/soft tissue infections, as a consequence of diabetic foot. The serotypes were classic, type-Ia being the most prevalent. The hyper virulent ST-17 (CC17) was associated with type-III. Conclusions: The incidence of iGBS disease found in Réunion island is twofold that usually reported. This burden is linked to overweight in aboriginal people from the Indian Ocean. © 2015 The Authors.","Diabetes mellitus; Group B streptococcus; Incidence; Invasive disease; Tropical area","Fairley, M.M., Group, B., Streptococcal disease in nonpregnant adults (2001) Clin Infect Dis, 33, pp. 556-561; Schwartz, B., Schuchat, A., Oxtoby, M.J., Cochi, S.L., Hightower, A., Broome, C.V., Invasive group B streptococcal disease in adults: a population-based study in metropolitan Atlanta (1991) JAMA, 266, pp. 1112-1114; Farley, M.M., Harvey, C., Stull, T., Smith, J.D., Schuchat, A., Wenger, J.D., A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults (1993) N Engl J Med, 328, pp. 1807-1811; Favier, F., Jaussent, I., Moullec, N.L., Debussche, X., Boyer, M.C., Schwager, J.C., Prevalence of Type 2 diabetes and central adiposity in La Reunion Island, the REDIA Study (2005) Diabetes Res Clin Pract., 67, pp. 234-242; Gérardin, P., Fianu, A., Choker, G., Carbonnier, M., Jamal-Bey, K., Heisert, M., Infection bactérienne néonatale précoce dans le sud de la Réunion: incidence et application des critères de risque Anaes (2008) Med Mal Infect, 38, pp. 192-199; Dahan-Saal, J., Gérardin, P., Robillard, P.Y., Bouveret, A., Barau, G., Picot, S., Déterminants de la colonisation maternelle à Streptocoque B et facteurs associés à sa transmission verticale périnatale: études cas - témoins (2011) Gynecol Obstet Fertil, 39, pp. 281-288; Stapelton, R.D., Kahn, J.M., Evans, L.E., Critchlow, C.W., Gardella, C.M., Risk factors for group B streptococcal genitourinary tract colonization in pregnant women (2005) Obstet Gynecol, 106, pp. 1246-1252; Valkenburg-van den Berg, A.W., Spri, A.J., Oostvogel, P.M., Mutsaers, J.A., Renes, W.B., Rosendaal, F.R., Prevalence of colonisation with group B streptococcus in pregnant women of multi-ethnic population in the Netherlands (2006) Eur J Clin Microbiol Infect Dis, 124, pp. 178-183; Poyart, C., Tazi, A., Reglier-Poupet, H., Billoet, A., Tavares, N., Raymond, J., Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci (2007) J Clin Microbiol, 45, pp. 1985-1988; Zou, G., A modified poisson regression approach to prospective studies with binary data (2004) Am J Epidemiol, 159, pp. 702-706; Skoff, T.H., Farley, M.M., Petit, S., Craig, A.S., Schaffner, W., Gershman, K., Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007 (2009) Clin Infect Dis, 49, pp. 85-92; Manning, S.D., Tallman, P., Baker, C.J., Gillepsie, B., Marrs, C.F., Foxman, B., Determinants of co-colonization with group B streptococcus among heterosexual college couples (2002) Epidemiology, 13, pp. 533-539; Iacobelli, S., Robillard, P.Y., Gouyon, J.B., Nichols, M., Boukerrou, M., Barau, G., Longitudinal health outcome and well-being of mother-infant pairs after adolescent pregnancy in Reunion island, Indian Ocean (2014) Int J Gynecol Obstet, 125, pp. 144-148; Tazi, A., Morand, P.C., Réglier-Poupet, H., Dmytruk, N., Billoet, A., Antona, D., Invasive group B streptococcal infections in adults, France (2007-2010) (2011) Clin Microbiol Infect, 17, pp. 1587-1592; Kothari, N.J., Morin, C.A., Glennen, A., Jackson, D., Harper, J., Schrag, S.J., Invasive group B streptococcal disease in the elderly, Minnesota, USA, 2003-2007 (2009) Emerg Infect Dis, 15, pp. 1279-1281; Louthrenoo, W., Kasitanon, N., Wangkaew, S., Hongsongkiat, S., Sukitawut, W., Wichainun, R., Streptococcus agalactiae: an emerging cause of septic arthritis (2014) J Clin Rheumatol., 20, pp. 74-78; Zhao, Z., Kong, F., Zeng, X., Gidding, H.F., Morgan, J., Gilbert, G.L., Distribution of gentypes and antibiotic resistance genes among invasive Streptococcus agalactiae (group B streptococcus) isolates from Australasian patients belonging to different age groups (2008) Clin Microbiol Infect, 14, pp. 260-267; Martins, E.R., Melo-Cristino, J., Ramirez, M., Portuguese Group for the Study of Streptococcal Infections (2012) J Clin Microbiol, 50, pp. 1219-1227; Domelier, A.S., van der Mee-Marquet, N., Arnault, L., Meregheti, L., Lanotte, P., Rosenau, A., Molecular characterization of erythromycin-resistant Streptococcus agalactiae strains (2008) J Antimicrob Chemother, 62, pp. 1227-1233; Huber, C.A., Odimba, F., Pflueger, V., Dauenberger, C.A., Revathi, G., Characterization of invasive and colonizing isolates of Streptococcus agalactiae in East African adults (2011) J Clin Microbiol, 49, pp. 3652-3655",Article,Scopus,2-s2.0-84928911483
"Lovshin J.A., Gilbert R.E.","Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?",2015,"Current Hypertension Reports","17","6",,"1","9",,,10.1007/s11906-015-0551-3,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928382328&partnerID=40&md5=640de5b0d387006ad33907f24477e8fd","Mt. Sinai Hospital, Division of Endocrinology and Metabolism, University of TorontoToronto, ON, Canada; Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s HospitalToronto, ON, Canada","Lovshin, J.A., Mt. Sinai Hospital, Division of Endocrinology and Metabolism, University of TorontoToronto, ON, Canada; Gilbert, R.E., Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s HospitalToronto, ON, Canada","By eliminating glucose in the urine, the sodium-glucose-linked cotransporter-2 (SGLT2) inhibitors act as osmotic diuretics to lower blood pressure in addition to reducing plasma glucose and assisting with weight loss. While not approved as antihypertensive agents, the ability of this new class of antihyperglycemic agents to lower blood pressure is not insubstantial, and while not used primarily for this indication, they may assist diabetic individuals in attaining currently recommended blood pressure targets. In addition to lowering systemic pressure, preclinical and exploratory human studies suggest that SGLT2 inhibitors may also lower intraglomerular pressure, potentially reducing the rate of GFR decline in patients with diabetic nephropathy. However, given the lack of clinically meaningful endpoint data, the use of SGLT2 inhibitors, primarily, as either antihypertensive or renoprotective agents would, at present, be premature. Fortunately, further insight will be garnered from large, randomized controlled trials that will assess the effects of various SGLT2 inhibitors on cardiovascular and renal outcomes. © 2015, Springer Science+Business Media New York.","Blood pressure; Diabetes mellitus; Diabetic nephropathy; Sodium-glucose-linked cotransporter-2; Tubuloglomerular Feedback","Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015) Diabetes Care, 38 (1), pp. 140-149; Nigro, S.C., Riche, D.M., Pheng, M., Baker, W.L., Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes (2013) Ann Pharmacother, 47 (10), pp. 1301-1311. , COI: 1:CAS:528:DC%2BC2cXhs1OjsbbE; Anderson, S.L., Marrs, J.C., Dapagliflozin for the treatment of type 2 diabetes (2012) Ann Pharmacother, 46 (4), pp. 590-598; White, J.R., Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence (2015) Ann Pharmacother; Stamler, J., Vaccaro, O., Neaton, J.D., Wentworth, D., Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial (1993) Diabetes Care, 16 (2), pp. 434-444. , COI: 1:STN:280:DyaK3s7mtFyrtQ%3D%3D; Dolan, E., Stanton, A., Thijs, L., Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study (2005) Hypertension, 46 (1), pp. 156-161. , COI: 1:CAS:528:DC%2BD2MXlt1WltLo%3D; American Diabetes, A., Standards of medical care in diabetes—2014 (2014) Diabetes Care, 37, pp. 14-80; Williams, B., Treating hypertension in patients with diabetes: when to start and how low to go? (2015) JAMA, 313 (6), pp. 573-574. , COI: 1:CAS:528:DC%2BC2MXjtVChtr4%3D; James, P.A., Oparil, S., Carter, B.L., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) (2014) JAMA, 311 (5), pp. 507-520. , COI: 1:CAS:528:DC%2BC2cXis1aktr8%3D; Mancia, G., Fagard, R., Narkiewicz, K., 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) Eur Heart J, 34 (28), pp. 2159-2219; Dasgupta, K., Quinn, R.R., Zarnke, K.B., The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension (2014) Can J Cardiol, 30 (5), pp. 485-501; Group, A.S., Cushman, W.C., Evans, G.W., Effects of intensive blood-pressure control in type 2 diabetes mellitus (2010) N Engl J Med, 362 (17), pp. 1575-1585; Bangalore, S., Kumar, S., Lobach, I., Messerli, F.H., Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials (2011) Circulation, 123 (24), pp. 2799-2810. , COI: 1:CAS:528:DC%2BC3MXnsleisLk%3D, 9 p following 810; Emdin, C.A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., Patel, A., Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis (2015) JAMA, 313 (6), pp. 603-615. , COI: 1:CAS:528:DC%2BC2MXjtVChsbo%3D; Leiter, L.A., Berard, L., Bowering, C.K., Type 2 diabetes mellitus management in Canada: is it improving? (2013) Can J Diabetes, 37, pp. 82-89; Oliva, R.V., Bakris, G.L., Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors (2014) J Am Soc Hypertens: JASH, 8 (5), pp. 330-339. , COI: 1:CAS:528:DC%2BC2cXktlWrsLY%3D; Musso, G., Gambino, R., Cassader, M., Pagano, G., A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials (2012) Ann Med, 44 (4), pp. 375-393. , COI: 1:CAS:528:DC%2BC38Xmt1Shsrc%3D; Vasilakou, D., Karagiannis, T., Athanasiadou, E., Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis (2013) Ann Intern Med, 159 (4), pp. 262-274; Baker, W.L., Smyth, L.R., Riche, D.M., Bourret, E.M., Chamberlin, K.W., White, W.B., Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis (2014) J Am Soc Hypertens: JASH, 8 (4), pp. 260-262. , COI: 1:CAS:528:DC%2BC2cXjsVKrur8%3D; Gilbert, R.E., SGLT-2 inhibition in patients with kidney disease (2014) Diabetes Metab, 40 (6 Suppl 1), pp. 23-27. , COI: 1:CAS:528:DC%2BC2MXovVSjug%3D%3D; Weir, M.R., Januszewicz, A., Gilbert, R.E., Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus (2014) J Clin Hypertens (Greenwich), 16 (12), pp. 875-882. , COI: 1:CAS:528:DC%2BC2cXitFSqtrvL; Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016–27. This RCT demonstrated that 52-week administration of canagliflozin to patients with type 2 diabetes in different stages of chronic kidney disease reduced glycemia and improved blood pressure despite impaired renal function. Consistent with other reports it also demonstrated an early modest decline in eGFR (with stabilization chronically) and reduction in albuminuria for SGLT2 inhibitor therapy with canagliflozinBarnett, A.H., Mithal, A., Manassie, J., Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (2014) Lancet Diabetes Endocrinol, 2 (5), pp. 369-384. , COI: 1:CAS:528:DC%2BC2cXnslaqsbw%3D; Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control (2014) Kidney Int, 85 (4), pp. 962-971. , COI: 1:CAS:528:DC%2BC3sXhsFequr3L; Gilbert, R.E., The perils of clinical trials (2014) Kidney Int, 85 (4), pp. 745-747. , COI: 1:CAS:528:DC%2BC2cXls1KgtL0%3D; O’Brien, E., Parati, G., Stergiou, G., Ambulatory blood pressure measurement: what is the international consensus? (2013) Hypertension, 62 (6), pp. 988-994; Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes (2013) Diabetes Obes Metab, 15 (9), pp. 853-862. , COI: 1:CAS:528:DC%2BC3sXhtFygsr%2FE, This study compared the effects of dapagliflozin to HCTZ and to placebo on ambulatory blood pressure over 12 weeks. Dapagliflozin achieved reductions in daytime blood pressure similar to that of HCTZ and was superior to placebo; however, no significant effect was observed on nighttime blood pressure for dapagliflozin; Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420–8. This study is the largest RCT reporting the effects of an SGLT2 inhibitor (empagliflozin) on 24-h ambulatory blood pressure profiles in patients with type 2 diabetes and hypertension. The study demonstrated that empagliflozin significantly reduced daytime systolic and diastolic blood pressure and had modest effects on reducing nighttime blood pressure as well, although to a lesser effect, when this drug was administered in the morning. These effects were independent of an effect on heart rateMajewski, C., Bakris, G.L., Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes (2015) Diabetes Care, 38 (3), pp. 429-430; Rieg, T., Masuda, T., Gerasimova, M., Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia (2014) Am J Physiol Renal Physiol, 306 (2), pp. F188-F193. , COI: 1:CAS:528:DC%2BC2cXitleit7k%3D; DeFronzo, R.A., Hompesch, M., Kasichayanula, S., Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes (2013) Diabetes Care, 36 (10), pp. 3169-3176. , COI: 1:CAS:528:DC%2BC3sXhs1ylt7fP; Bolinder, J., Ljunggren, O., Kullberg, J., Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin (2012) J Clin Endocrinol Metab, 97 (3), pp. 1020-1031. , COI: 1:CAS:528:DC%2BC38Xkt1yms78%3D; Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030 (2010) Diabetes Res Clin Pract, 87 (1), pp. 4-14. , COI: 1:STN:280:DC%2BC3c%2Fot1Witg%3D%3D; Afkarian, M., Sachs, M.C., Kestenbaum, B., Kidney disease and increased mortality risk in type 2 diabetes (2013) J Am Soc Nephrol, 24 (2), pp. 302-308. , COI: 1:CAS:528:DC%2BC3sXivFejtr4%3D; Gilbert, R.E., Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? (2014) Kidney Int, 86 (4), pp. 693-700. , COI: 1:CAS:528:DC%2BC3sXhvVaksr3I, In depth description of the pathophysiological basis for potential renoprotection with SGLT2 inhibitors; Thomas, M.C., Renal effects of dapagliflozin in patients with type 2 diabetes (2014) Ther Adv Endocrinol Metab, 5 (3), pp. 53-61. , COI: 1:CAS:528:DC%2BC2cXhvFahtL3F; De Nicola, L., Gabbai, F.B., Liberti, M.E., Sagliocca, A., Conte, G., Minutolo, R., Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes (2014) Am J Kidney Dis, 64 (1), pp. 16-24. , COI: 1:CAS:528:DC%2BC2cXkvVGks70%3D; Cherney, D.Z., Perkins, B.A., Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? (2014) Can J Diabetes, 38 (5), pp. 356-363; Cefalu, W.T., Leiter, L.A., Yoon, K.H., Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial (2013) Lancet, 382 (9896), pp. 941-950. , COI: 1:CAS:528:DC%2BC3sXhtFSls7fO; Cherney, D.Z., Perkins, B.A., Soleymanlou, N., The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus (2014) Cardiovasc Diabetol, 13, p. 28; Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–97. This was the first study in patients with type 1 diabetes with early signs of impaired renal function (hyperfiltration) to demonstrate a potential renoprotective role for SGLT2 inhibitor (empagliflozin) therapy. Short-term therapy with empagliflozin significantly reduced GFR independent of glycemia in hyperfiltering subjects. These effects were thought to be mediated by the increased distal sodium delivery to the macula densa achieved by SGLT2 inhibition. In turn, resulting in improved tubuloglomerular feedback  to the juxaglomerular apparatus to control afferent tone, and reduce intraglomerular pressurePohl, M.A., Blumenthal, S., Cordonnier, D.J., Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations (2005) J Am Soc Nephrol, 16 (10), pp. 3027-3037. , COI: 1:CAS:528:DC%2BD2MXhtFegtLnE; Thomas, M.C., Moran, J.L., Harjutsalo, V., Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy? (2012) Diabetologia, 55 (5), pp. 1505-1513. , COI: 1:CAS:528:DC%2BC38XlvFGmtLo%3D; Ficociello, L.H., Perkins, B.A., Roshan, B., Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes (2009) Diabetes Care, 32 (5), pp. 889-893. , COI: 1:CAS:528:DC%2BD1MXmt1Wnur0%3D; Premaratne, E., Verma, S., Ekinci, E.I., Theverkalam, G., Jerums, G., MacIsaac, R.J., The impact of hyperfiltration on the diabetic kidney (2015) Diabetes Metab, 41 (1), pp. 5-17. , COI: 1:STN:280:DC%2BC2MzjtFGjsg%3D%3D; Munger, K.A., Kost, C.K., Brenner, B.M., Maddox, D.A., The renal circulations and glomerular ultrafiltration (2012) Brenner and Rector’s the kidney, pp. 94-137. , Taal MW, (ed), Elsevier, Philadelphia:; Vallon, V., Rose, M., Gerasimova, M., Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus (2013) Am J Physiol Renal Physiol, 304 (2), pp. F156-F167. , COI: 1:CAS:528:DC%2BC3sXit1ygu70%3D; Thomson, S.C., Rieg, T., Miracle, C., Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat (2012) Am J Physiol Regul Integr Comp Physiol, 302 (1), pp. R75-R83. , COI: 1:CAS:528:DC%2BC38XitVemsL4%3D; Gilbert, R.E., Game, D.S., Advani, A., Vasoactive molecules and the kidney (2012) Brenner and Rector’s the kidney, pp. 384-420. , Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu SL, Brener BM, (eds), Elsevier, Philadelphia:; Terami, N., Ogawa, D., Tachibana, H., Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice (2014) PLoS One, 9 (6), p. e100777; Gembardt, F., Bartaun, C., Jarzebska, N., The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension (2014) Am J Physiol Renal Physiol, 307 (3), pp. 317-325. , COI: 1:CAS:528:DC%2BC2cXhsFanu77O; Vallon, V., Gerasimova, M., Rose, M.A., SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice (2014) Am J Physiol Renal Physiol, 306 (2), pp. 194-204. , COI: 1:CAS:528:DC%2BC2cXitleit7Y%3D; Gangadharan Komala, M., Gross, S., Mudaliar, H., Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice (2014) PLoS One, 9 (11), p. 108994; Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus (2015) Drugs, 75 (1), pp. 33-59; Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes (2014) Drug Des Dev Ther, 8, pp. 1335-1380. , COI: 1:CAS:528:DC%2BC2cXhvFOntrnP; Halimi, S., Verges, B., Adverse effects and safety of SGLT-2 inhibitors (2014) Diabetes Metab, 40, pp. 28-34. , COI: 1:CAS:528:DC%2BC2MXovVSjtw%3D%3D; Bode, B., Stenlof, K., Harris, S., Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes (2015) Diabetes Obes Metab, 17 (3), pp. 294-303. , COI: 1:CAS:528:DC%2BC2MXitlKrt7c%3D, This study examined efficacy and safety of SGLT2 inhibitor therapy (canagliflozin) in a longitudinal 104-week study in patients with type 2 diabetes at higher risk for adverse events due to increased age (55–80 years). Small increases were observed with canagliflozin compared to placebo for adverse events related to osmotic diuresis and volume depletion; however, overall, the rates of these events were low. Specifically, orthostatic hypotension was an uncommonly observed event; Taylor, S.I., Blau, J.E., Rother, K.I., Possible adverse effects of SGLT2 inhibitors on bone (2015) Lancet Diabetes Endocrinol, 3 (1), pp. 8-10. , COI: 1:CAS:528:DC%2BC2MXksF2ltLo%3D",Review,Scopus,2-s2.0-84928382328
"Lai S.-W., Lai H.-C., Lin C.-L., Liao K.-F.","Finasteride use and acute pancreatitis in Taiwan",2015,"Journal of Clinical Pharmacology","55","6",,"657","660",,,10.1002/jcph.462,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928880535&partnerID=40&md5=c601e147af3fd4e1459da6d798142864","College of Medicine, China Medical UniversityTaichung, Taiwan; Department of Family Medicine, China Medical University HospitalTaichung, Taiwan; College of Chinese Medicine, China Medical UniversityTaichung, Taiwan; Division of Hepato-Gastroenterology, Department of Internal Medicine, China Medical University HospitalTaichung, Taiwan; Management Office for Health Data, China Medical University HospitalTaichung, Taiwan; Graduate Institute of Integrated Medicine, China Medical UniversityTaichung, Taiwan; Department of Internal Medicine, Taichung Tzu Chi General Hospital, No. 66, Fongsing RoadTanzi District, Taichung City, Taiwan","Lai, S.-W., College of Medicine, China Medical UniversityTaichung, Taiwan, Department of Family Medicine, China Medical University HospitalTaichung, Taiwan; Lai, H.-C., College of Chinese Medicine, China Medical UniversityTaichung, Taiwan, Division of Hepato-Gastroenterology, Department of Internal Medicine, China Medical University HospitalTaichung, Taiwan; Lin, C.-L., College of Medicine, China Medical UniversityTaichung, Taiwan, Management Office for Health Data, China Medical University HospitalTaichung, Taiwan; Liao, K.-F., Graduate Institute of Integrated Medicine, China Medical UniversityTaichung, Taiwan, Department of Internal Medicine, Taichung Tzu Chi General Hospital, No. 66, Fongsing RoadTanzi District, Taichung City, Taiwan","The aim of this study was to examine whether there is an association between finasteride use and the risk of acute pancreatitis. This population-based case-control study used the database of the Taiwan National Health Insurance Program. There were 2,530 male subjects aged 40-84 years with a first-attack of acute pancreatitis during the period of 1998-2011 as the case group and 10,119 randomly selected subjects without acute pancreatitis as the control group. Both groups were matched by age and index year of diagnosing acute pancreatitis. Subjects who never had finasteride prescription were defined as ""never use."" Subjects who at least received 1 prescription for finasteride before the date of diagnosing acute pancreatitis were defined as ""ever use."" The association of acute pancreatitis with finasteride use was examined by the odds ratio (OR) and 95% confidence interval (CI) using the multivariable unconditional logistic regression model. The crude OR of acute pancreatitis was 1.78 (95%CI 1.33, 2.39) for subjects with ever use of finasteride, when compared with subjects with never use of finasteride. After adjusting for potential confounders, the adjusted OR of acute pancreatitis decreased to 1.25 (95%CI 0.90, 1.73) for subjects with ever use of finasteride, but no statistical significance was seen. No association can be detected between finasteride use and the risk of acute pancreatitis. © 2015, The American College of Clinical Pharmacology.","acute pancreatitis; alcoholism; biliary stone; diabetes mellitus; finasteride","Tacklind, J., Fink, H.A., Macdonald, R., Rutks, I., Wilt, T.J., Finasteride for benign prostatic hyperplasia (2010) Cochrane Database Syst Rev, 10. , CD006015; Mella, J.M., Perret, M.C., Manzotti, M., Catalano, H.N., Guyatt, G., Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review (2010) Arch Dermatol, 146 (10), pp. 1141-1150; Lin, W.L., Hsieh, Y.W., Lin, C.L., Sung, F.C., Wu, C.H., Kao, C.H., A population-based nested case-control study: The use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia [published online ahead of print 2014] Clin Endocrinol (Oxf), , doi: 10.1111/cen.12599; Chang, M.C., Su, C.H., Sun, M.S., Etiology of acute pancreatitis - A multi-center study in Taiwan (2003) Hepatogastroenterology, 50 (53), pp. 1655-1657; Lowenfels, A.B., Maisonneuve, P., Sullivan, T., The changing character of acute pancreatitis: Epidemiology, etiology, and prognosis (2009) Curr Gastroenterol Rep, 11 (2), pp. 97-103; Lai, S.W., Muo, C.H., Liao, K.F., Sung, F.C., Chen, P.C., Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: A population-based cohort study in Taiwan (2011) Am J Gastroenterol, 106 (9), pp. 1697-1704; Ksiadzyna, D., Drug-induced acute pancreatitis related to medications commonly used in gastroenterology (2011) Eur J Intern Med, 22 (1), pp. 20-25; Lin, Y.H., Perng, C.L., Lin, H.J., Chang, F.Y., Acute pancreatitis possibly related to finasteride (2001) J Clin Gastroenterol, 32 (3), p. 276; National Health Insurance Research Database, , http://nhird.nhri.org.tw/en/Backgroundhtml, Taiwan 2014 September; Lai, S.W., Liao, K.F., Liao, C.C., Muo, C.H., Liu, C.S., Sung, F.C., Polypharmacy correlates with increased risk for hip fracture in the elderly: A population-based study (2010) Medicine (Baltimore), 89 (5), pp. 295-299; Lai, S.W., Su, L.T., Lin, C.H., Tsai, C.H., Sung, F.C., Hsieh, D.P., Polypharmacy increases the risk of Parkinson's disease in older people in Taiwan: A population-based study (2011) Psychogeriatrics, 11 (3), pp. 150-156; Floyd, A., Pedersen, L., Nielsen, G.L., Thorlacius-Ussing, O., Sorensen, H.T., Risk of acute pancreatitis in users of finasteride: A population-based case-control study (2004) J Clin Gastroenterol, 38 (3), pp. 276-278; Iqbal, M.J., Greenway, B., Wilkinson, M.L., Johnson, P.J., Williams, R., Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: A comparison of normal adult, foetal and malignant tissue (1983) Clin Sci (Lond), 65 (1), pp. 71-75; Livingstone, D.E., Barat, P., Di Rollo, E.M., 5alpha-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis and liver fibrosis in rodents [published online ahead of print 2014] Diabetes, , doi: 10.2337/db14-0249",Article,Scopus,2-s2.0-84928880535
"Dube S., Errazuriz-Cruzat I., Basu A., Basu R.","The Forgotten Role of Glucose Effectiveness in the Regulation of Glucose Tolerance",2015,"Current Diabetes Reports","15","6",,"","",6,,10.1007/s11892-015-0605-6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928150416&partnerID=40&md5=6e00415900c7fdb8812925b406a0d863","Endocrine Research Unit, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo College of Medicine, Joseph 5-194Rochester, MN, United States; Gandhi Medical CollegeBhopal, MP, India; Clinica Alemana de Santiago, Facultad de Medicina Clinica Alemana, Universidad del DesarrolloSantiago, Chile","Dube, S., Gandhi Medical CollegeBhopal, MP, India; Errazuriz-Cruzat, I., Clinica Alemana de Santiago, Facultad de Medicina Clinica Alemana, Universidad del DesarrolloSantiago, Chile; Basu, A., Endocrine Research Unit, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo College of Medicine, Joseph 5-194Rochester, MN, United States; Basu, R., Endocrine Research Unit, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo College of Medicine, Joseph 5-194Rochester, MN, United States","Glucose effectiveness (S<inf>G</inf>) is the ability of glucose per se to stimulate its own uptake and to suppress its own production under basal/constant insulin concentrations. In an individual, glucose tolerance is a function of insulin secretion, insulin action and S<inf>G</inf>. Under conditions of declining insulin secretion and action (e.g. type 2 diabetes), the degree of S<inf>G</inf> assumes increasing significance in determining the level of glucose tolerance both in fasted and postprandial states. Although the importance of S<inf>G</inf> has been recognized for years, mechanisms that contribute to S<inf>G</inf> are poorly understood. Research data on modulation of S<inf>G</inf> and its impact in glucose intolerance is limited. In this review, we will focus on the role of S<inf>G</inf> in the regulation of glucose tolerance, its evaluation, and potential advantages of therapies that can enhance glucose-induced stimulation of glucose uptake and suppression of its own production in conditions of impaired insulin secretion and action. © 2015, Springer Science+Business Media New York.","Diabetes; Glucose effectiveness; Glucose tolerance","Hoffman, R.P., Armstrong, P.T., Glucose effectiveness, peripheral and hepatic insulin sensitivity, in obese and lean prepuberal children (1996) Int J Obes Relat Metab Disord, 20, pp. 521-525. , COI: 1:STN:280:DyaK28zns1ykug%3D%3D, PID: 8782727; Firth, R.G., Bell, P.M., Marsh, H.M., Postprandial hyperglycemia in patients with non-insulin-dependent diabetes mellitus (1986) J Clin Invest, 77, pp. 1525-1532. , COI: 1:STN:280:DyaL287ps1Ojuw%3D%3D, PID: 3517067; Mitrakou, A., Kelley, D., Veneman, T., Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM (1990) Diabetes, 39, pp. 1381-1390. , COI: 1:CAS:528:DyaK3MXhs1WrtLk%3D, PID: 2121568; Ferrannini, E., Simonson, D.C., Katz, L.D., The disposal of an oral glucose load in patients with non-insulin-dependent diabetes (1988) Metabolism, 37, pp. 79-85. , COI: 1:STN:280:DyaL1c%2FptlOlsQ%3D%3D, PID: 3275860; DeFronzo, R.A., Ferrannini, E., Hendler, R., Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man (1983) Diabetes, 32, pp. 35-45. , COI: 1:CAS:528:DyaL3sXmsFyrsQ%3D%3D, PID: 6336701; Ader, M., Ni, T., Bergman, R.N., Glucose effectiveness assessed under dynamic and steady-state conditions (1997) J Clin Invest, 99, pp. 1187-1199. , COI: 1:CAS:528:DyaK2sXhvFyitr4%3D, PID: 9077526; Yki-Jarvinen, H., Young, A.A., Lamkin, C., Kinetics of glucose disposal in whole body and across the forearm in man (1987) J Clin Invest, 79, pp. 1713-1719. , COI: 1:CAS:528:DyaL2sXksFKgtLo%3D, PID: 3294899; Rossetti, L., Giaccari, A., Barzilai, N., Mechanism by which hyperglycemia inhibits hepatic glucose production in conscious rats (1993) J Clin Invest, 92, pp. 1126-1134. , COI: 1:CAS:528:DyaK3sXms1Oqt7Y%3D, PID: 8397219; Rizza, R.A., Mandarino, L.J., Gerich, J.E., Dose-response characteristics for effects of insulin on production and utilization of glucose in man (1981) Am J Physiol, 240, pp. E630-E639. , COI: 1:CAS:528:DyaL3MXktVSruro%3D, PID: 7018254; Kolterman, O.G., Gray, R.S., Griffin, J., Receptor and postreceptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus (1981) J Clin Invest, 68, pp. 957-969. , COI: 1:CAS:528:DyaL3MXlvVGju70%3D, PID: 7287908; Liljenquist, J., Meuller, G., Cherrington, A., Hyperglycemia per se can inhibit glucose production in man (1979) J Clin Endocrinol Metab, 48, pp. 171-175. , COI: 1:CAS:528:DyaE1MXosVOnuw%3D%3D, PID: 422700; Bergman, R.N., Bucolo, R.J., Interaction of insulin and glucose in the control of hepatic glucose balance (1974) Am J Physiol, 227, pp. 1314-1322. , COI: 1:CAS:528:DyaE2MXltF2jtQ%3D%3D, PID: 4440776; Shulman, G., Liljenquist, J., Williams, P., Glucose disposal during insulinopenia in somatostatin-treated dogs: the roles of glucose and glucagon (1978) J Clin Invest, 62, pp. 487-491. , COI: 1:CAS:528:DyaE1cXlt1elsL8%3D, PID: 670404; Sacca, L., Cicala, M., Trimarco, B., Differential effects of insulin on splanchnic and peripheral glucose disposal after an intravenous glucose load in man (1982) J Clin Invest, 70, pp. 117-126. , COI: 1:CAS:528:DyaL38Xks1Kkt7k%3D, PID: 6123524; Cherrington, A., Williams, P., Harris, M., Relationship between the plasma glucose level and glucose uptake in the conscious dog (1978) Metabolism, 27, pp. 787-791. , COI: 1:CAS:528:DyaE1cXktl2qtbw%3D, PID: 661564; Verdonk, C., Rizza, R., Gerich, J., Effects of plasma glucose concentration on glucose utilization and glucose clearance in normal man (1981) Diabetes, 30, pp. 535-537. , COI: 1:CAS:528:DyaL38XkvV2kt7k%3D, PID: 7227662; Best, J., Taborsky, G., Halter, J., Glucose disposal is not proportional to plasma glucose level in man (1981) Diabetes, 30, pp. 847-850. , COI: 1:CAS:528:DyaL38Xlt1SrtLo%3D, PID: 6115785; Lewis, S., Schultz, T., Westbie, D., Insulin glucose dynamics during flow through perfusion of the isolated rat hind limb (1977) Horm Metab Res, 9, pp. 190-195. , COI: 1:CAS:528:DyaE2sXkslyks7g%3D, PID: 885470; Bell, P.M., Firth, R.G., Rizza, R.A., Assessment of insulin action in insulin-dependent diabetes mellitus using [61 4C]glucose, [33H]glucose, and [23H]glucose (1986) J Clin Invest, 78, pp. 1479-1486. , COI: 1:CAS:528:DyaL2sXot1GhsA%3D%3D, PID: 3537009; Vranic, M., Fono, P., Kovacevic, N., Glucose kinetics and fatty acids in dogs on matched insulin infusion after glucose load (1971) Metabolism, 20, pp. 954-967. , COI: 1:CAS:528:DyaE38Xht1eruw%3D%3D, PID: 5097683; Ishiwata, K., Hetenyi, G., Jr., Vranic, M., Effect of D-glucose or D-ribose on the turnover of glucose in pancreatectomized dogs maintained on a matched intraportal infusion of insulin (1969) Diabetes, 18 (12), pp. 820-827. , COI: 1:STN:280:DyaE3c%2Fms1Oksw%3D%3D, PID: 5361445; Sacca, L., Hendler, R., Sherwin, R.S., Hyperglycemia inhibits glucose production in man independent of changes in glucoregulatory hormones (1978) J Clin Endocrinol Metab, 47, pp. 1160-1163. , COI: 1:STN:280:DyaL3s7os1KitQ%3D%3D, PID: 400737; Del Prato, S., Matsuda, M., Simonson, D.C., Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance (1997) Diabetologia, 40, pp. 687-697. , PID: 9222649; Petersen, K.F., Laurent, D., Rothman, D.L., Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans (1998) J Clin Invest, 101, pp. 1203-1209. , COI: 1:CAS:528:DyaK1cXitVWjtrY%3D, PID: 9502760; Bucolo, R.J., Bergman, R.N., Marsh, D.J., Dynamics of glucose auto-regulation in the isolated, blood-perfused canine liver (1974) Am J Physiol, 221, pp. 209-217; Best, J., Kahn, S.E., Ader, M., Role of glucose effectiveness in the determination of glucose tolerance (1996) Diabetes Care, 19, pp. 1018-1030. , COI: 1:STN:280:DyaK2s%2FivFSqsA%3D%3D, PID: 8875104; Galante, P., Mosthaf, L., Kellerer, M., Acute hyperglycemia provides an insulin-independent inducer for GLUT4 translocation in C<inf>2</inf>C<inf>12</inf> myotubes and rat skeletal muscle (1995) Diabetes, 44, pp. 646-651. , COI: 1:CAS:528:DyaK2MXmt1antb4%3D, PID: 7789629; Nolte, L.A., Rincon, J., Wahlstrom, E.O., Hyperglycemia activates glucose transport in rat skeletal muscle via a Ca2+-dependent mechanism (1995) Diabetes, 44, pp. 1345-1348. , COI: 1:CAS:528:DyaK2MXovVOjs7s%3D, PID: 7589835; Schwartz, M.W., Seeley, R.J., Tschöp, M.H., Cooperation between brain and islet in glucose homeostasis and diabetes (2013) Nature, 503 (7474), pp. 59-66. , COI: 1:CAS:528:DC%2BC3sXhslelur7O, PID: 24201279, This review article discusses the role of brain-centric glucoregulatory systems in lowering blood glucose levels via insulin-independent and -dependent mechanisms; Vicini, P., Caumo, A., Cobelli, C., Glucose effectiveness and insulin sensitivity from the minimal models: consequences of undermodeling assessed by Monte Carlo simulation (1999) IEEE Trans Biomed Eng, 46 (2), pp. 130-137. , COI: 1:STN:280:DyaK1M7jtFWhtA%3D%3D, PID: 9932334; Pacini, G., Tonolo, G., Sambataro, M., Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT (1998) Am J Physiol, 274, pp. E592-E599. , COI: 1:CAS:528:DyaK1cXislyit7s%3D, PID: 9575818; Bordenave, S., Brandou, F., Manetta, J., Effects of acute exercise on insulin sensitivity, glucose effectiveness and disposition index in type 2 diabetic patients (2008) Diabetes Metab, 34 (3), pp. 250-257. , COI: 1:CAS:528:DC%2BD1cXhtVGgsr7J, PID: 18448376; Ni, T.C., Ader, M., Bergman, R.N., Reassessment of glucose effectiveness and insulin sensitivity from minimal model analysis: a theoretical evaluation of the single-compartment glucose distribution assumption (1997) Diabetes, 46 (11), pp. 1813-1821. , COI: 1:CAS:528:DyaK2sXntVKitrk%3D, PID: 9356031; Caumo, A., Vicini, P., Zachwieja, J.J., Undermodeling affects minimal model indexes: insights from a two-compartment model (1999) Am J Physiol, 276, pp. E1171-E1193. , COI: 1:CAS:528:DyaK1MXktlSqur4%3D, PID: 10362630; Martin, B.C., Warram, J.H., Krolewski, A.S., Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study (1992) Lancet, 340, pp. 925-929. , COI: 1:STN:280:DyaK3s%2FitlaltA%3D%3D, PID: 1357346; Lorenzo, C., Wagenknecht, L.E., Rewers, M.J., Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) (2010) Diabetes Care, 33 (9), pp. 2098-2103. , COI: 1:CAS:528:DC%2BC3cXht1OmurbF, PID: 20805282; Henriksen, J.E., Alford, F., Handberg, A., Increased glucose effectiveness in normoglycemic but insulin-resistant relatives of patients with non-insulin-dependent diabetes mellitus (1994) J Clin Invest, 94, pp. 1196-1204. , COI: 1:STN:280:DyaK2czmsFWrug%3D%3D, PID: 8083360; Bergman, R.N., Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach (1989) Diabetes, 38, pp. 1512-1527. , COI: 1:CAS:528:DyaK3cXjtVKqtg%3D%3D, PID: 2684710; Doi, K., Taniguchi, A., Nakai, Y., Decreased glucose effectiveness but not insulin resistance in glucose-tolerant offspring of Japanese non-insulin-dependent diabetic patients: a minimal-model analysis (1997) Metabolism, 46 (8), pp. 880-883. , COI: 1:CAS:528:DyaK2sXltlSktbs%3D, PID: 9258268; Osei, K., Cottrell, D.A., Orabella, M.M., Insulin sensitivity, glucose effectiveness, and body fat distribution pattern in nondiabetic offspring of patients with NIDDM (1991) Diabetes Care, 14, pp. 890-896. , COI: 1:STN:280:DyaK387ivVahsg%3D%3D, PID: 1773687; Nielsen, M.F., Nyholm, B., Caumo, A., Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes (2000) Diabetes, 49 (12), pp. 2135-2141. , COI: 1:CAS:528:DC%2BD3cXos1ejsL0%3D, PID: 11118017; Alzaid, A.A., Dinneen, S.F., Turk, D.J., Assessment of insulin action and glucose effectiveness in diabetic and nondiabetic humans (1994) J Clin Invest, 94, pp. 2341-2348. , COI: 1:CAS:528:DyaK2MXisFWhurg%3D, PID: 7989590; Basu, A., Caumo, A., Bettini, F., Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol (1997) Diabetes, 46, pp. 421-432. , COI: 1:CAS:528:DyaK2sXhsVGlurw%3D, PID: 9032098; Nielsen, M.F., Basu, R., Wise, S., Normal glucose induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake (1998) Diabetes, 47, pp. 1735-1747. , COI: 1:CAS:528:DyaK1cXntVSjsrc%3D, PID: 9792543; Basu, A., Dalla Man, C., Basu, R., Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism (2009) Diabetes Care, 32 (5), pp. 866-872. , COI: 1:CAS:528:DC%2BD1MXmt1Wnur8%3D, PID: 19196896; Taniguchi, A., Nakai, Y., Fukushima, M., Pathogenic factors responsible for glucose intolerance in patients with NIDDM (1992) Diabetes, 41, pp. 1540-1546. , COI: 1:STN:280:DyaK3s%2FnslSjsg%3D%3D, PID: 1446794; Wajchenberg, B.L., Santomauro, A.T.M.G., Porrelli, R.N., Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM) (1993) Diabetes Res Clin Pract, 20, pp. 147-154. , COI: 1:STN:280:DyaK3szoslWisw%3D%3D, PID: 8375268; Welch, S., Gebhart, S.S.P., Bergman, R.N., Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects (1990) J Clin Endocrinol Metab, 71, pp. 1508-1518. , COI: 1:STN:280:DyaK3M%2FjsFyksA%3D%3D, PID: 2229309; Avogaro, A., Vicini, P., Valerio, A., The hot but not the cold minimal model allows precise assessment of insulin sensitivity in NIDDM subjects (1996) Am J Physiol, 270, pp. E532-E540. , COI: 1:CAS:528:DyaK28XitVajur4%3D, PID: 8638702; Quon, M.J., Cochran, C., Taylor, S.I., Non-insulin-mediated glucose disappearance in subjects with IDDM (1994) Diabetes, 43, pp. 890-896. , COI: 1:STN:280:DyaK2c3otlOhuw%3D%3D, PID: 8013753; Finegood, D.T., Tzur, D., Reduced glucose effectiveness associated with reduced insulin release: an artifact of the minimal-model method (1996) Am J Physiol, 271, pp. E485-E495. , COI: 1:CAS:528:DyaK28XmtFajt78%3D, PID: 8843742; Cobelli, C., Vicini, P., Caumo, A., If the minimal model is too minimal, who suffers more: SG or SI ? (1997) Diabetologia, 40, pp. 362-363. , COI: 1:STN:280:DyaK2s3jvFeitQ%3D%3D, PID: 9084979; Schwartz, M.W., Porte, D., Jr., Diabetes, obesity, and the brain (2005) Science, 307, pp. 375-379. , COI: 1:CAS:528:DC%2BD2MXksFyhsQ%3D%3D, PID: 15662002; Sandoval, D., Cota, D., Seeley, R.J., The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation (2008) Annu Rev Physiol, 70, pp. 513-535. , COI: 1:CAS:528:DC%2BD1cXkt1eqt7g%3D, PID: 17988209; Elmquist, J.K., Coppari, R., Balthasar, N., Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis (2005) J Comp Neurol, 493, pp. 63-71. , COI: 1:CAS:528:DC%2BD2MXhtlSjsLnO, PID: 16254991; Obici, S., Zhang, B.B., Karkanias, G., Hypothalamic insulin signaling is required for inhibition of glucose production (2008) Nat Med, 8, pp. 1376-1382; Lam, T.K., Gutierrez-Juarez, R., Pocai, A., Regulation of blood glucose by hypothalamic pyruvate metabolism (2005) Science, 309, pp. 943-947. , COI: 1:CAS:528:DC%2BD2MXmvFSksr4%3D, PID: 16081739; Coppari, R., Ichinose, M., Lee, C.E., The hypothalamic arcuate nucleus: a key site for mediating leptin’s effects on glucose homeostasis and locomotor activity (2005) Cell Metab, 1, pp. 63-72. , COI: 1:CAS:528:DC%2BD2MXhtlaqs7o%3D, PID: 16054045; Morton, G.J., Gelling, R.W., Niswender, K.D., Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons (2005) Cell Metab, 2, pp. 411-420. , COI: 1:CAS:528:DC%2BD2MXhtlequrnN, PID: 16330326; D’Alessio, D.A., Kahn, S.E., Leusner, C.R., Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal (1994) J Clin Invest, 93, pp. 2263-2266. , PID: 8182159; Sandoval, D.A., Bagnol, D., Woods, S.C., Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake (2008) Diabetes, 57, pp. 2046-2054. , COI: 1:CAS:528:DC%2BD1cXps1OisrY%3D, PID: 18487451; Hardie, D.G., Carling, D., Carlson, M., The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? (1998) Annu Rev Biochem, 67, pp. 821-855. , COI: 1:CAS:528:DyaK1cXlsFOmtr4%3D, PID: 9759505; Musi, N., Hirshman, M.F., Nygren, J., Metformin increases AMPactivated protein kinase activity in skeletal muscle of subjects with type 2 diabetes (2002) Diabetes, 51, pp. 2074-2081. , COI: 1:CAS:528:DC%2BD38Xlt1WltrY%3D, PID: 12086935; Kahn, B.B., Alquier, T., Carling, D., AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism (2005) Cell Metab, 1, pp. 15-25. , COI: 1:CAS:528:DC%2BD2MXhtlaqs74%3D, PID: 16054041; Pau, C.T., Keefe, C., Duran, J., Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study (2014) J Clin Endocrinol Metab, 99 (5), pp. 1870-1878. , COI: 1:CAS:528:DC%2BC2cXoslOmt7o%3D, PID: 24606093, This study provides evidence that a possible mechanism of action of metformin is via improvement of glucose effectiveness; Brun, J.F., Guintrand-Hugret, R., Boegner, C., Influence of short-term submaximal exercise on parameters of glucose assimilation analyzed with the minimal model (1995) Metabolism, 44, pp. 833-840. , COI: 1:CAS:528:DyaK2MXmvVGgt7s%3D, PID: 7616840; Hayashi, Y., Nagasaka, S., Takahashi, N., A single bout of exercise at higher intensity enhances glucose effectiveness in sedentary men (2005) J Clin Endocrinol Metab, 90, pp. 4035-4040. , COI: 1:CAS:528:DC%2BD2MXmtlCit7g%3D, PID: 15840752; Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (2002) N Engl J Med, 346, pp. 393-403. , COI: 1:CAS:528:DC%2BD38XhtVWqurc%3D, PID: 11832527; Tuomilehto, J., Lindstrom, J., Eriksson, J.G., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance (2001) N Engl J Med, 344, pp. 1343-1350. , COI: 1:STN:280:DC%2BD3M3kvFejsA%3D%3D, PID: 11333990; Zierath, J.R., Invited review: exercise training-induced changes in insulin signaling in skeletal muscle (2002) J Appl Physiol, 93, pp. 773-781. , COI: 1:CAS:528:DC%2BD38XmsFWmu7g%3D, PID: 12133891; Manetta, J., Brun, J.F., Mercier, J., The effects of exercise training intensification on glucose disposal in elite cyclists (2000) Int J Sports Med, 21, pp. 338-343. , COI: 1:CAS:528:DC%2BD3cXlsVKqtbk%3D, PID: 10950442; Manetta, J., Brun, J.F., Callis, A., Insulin and non-insulin-dependent glucose disposal in middle-aged and young athletes versus sedentary men (2001) Metabolism, 50, pp. 349-354. , COI: 1:CAS:528:DC%2BD3MXhvVertr8%3D, PID: 11230790; Higaki, Y., Kagawa, T., Fujitani, Y., Effects of a single bout of exercise on glucose effectiveness (1996) J Appl Physiol, 80, pp. 754-759. , COI: 1:CAS:528:DyaK28Xitlaqsrg%3D, PID: 8964733; Araujo-Vilar, D., Osifo, E., Kirk, M., Influence of moderate physical exercise on insulin-mediated and non-insulin-mediated glucose uptake in healthy subjects (1997) Metabolism, 46, pp. 203-209. , COI: 1:CAS:528:DyaK2sXht1emt74%3D, PID: 9030830; Boule, N.G., Weisnagel, S.J., Lakka, T.A., Effects of exercise training on glucose homeostasis: the HERITAGE Family Study (2005) Diabetes Care, 28, pp. 108-114. , PID: 15616242; Fujitani, J., Higaki, Y., Kagawa, T., Intravenous glucose tolerance test-derived glucose effectiveness in strength-trained humans (1998) Metabolism, 47, pp. 874-877. , COI: 1:CAS:528:DyaK1cXksFCgurg%3D, PID: 9667238; Nishida, Y., Higaki, Y., Tokuyama, K., Effect of mild exercise training on glucose effectiveness in healthy men (2001) Diabetes Care, 24, pp. 1008-1013. , COI: 1:CAS:528:DC%2BD3MXks1agur0%3D, PID: 11375361; Kennedy, J.W., Hirshman, M.F., Gervino, E.V., Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes (1999) Diabetes, 48, pp. 1192-1197. , COI: 1:CAS:528:DyaK1MXjtFSgtL8%3D, PID: 10331428; Hayashi, T., Hirshman, M.F., Kuth, E.J., Evidence for 5′-AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport (1998) Diabetes, 47, pp. 1369-1373. , COI: 1:CAS:528:DyaK1cXltFyrtb4%3D, PID: 9703344",Review,Scopus,2-s2.0-84928150416
"de Ligt M., Timmers S., Schrauwen P.","Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?",2015,"Biochimica et Biophysica Acta - Molecular Basis of Disease","1852","6",,"","",,,10.1016/j.bbadis.2014.11.012,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925424159&partnerID=40&md5=4767d6bbfc90fc4224f8216adee648f5","Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical CenterMaastricht, Netherlands","de Ligt, M., Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical CenterMaastricht, Netherlands; Timmers, S., Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical CenterMaastricht, Netherlands; Schrauwen, P., Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical CenterMaastricht, Netherlands","There is an increasing need for novel preventive and therapeutic strategies to combat obesity and related metabolic disorders. In this respect, the natural polyphenol resveratrol has attracted significant interest. Animal studies indicate that resveratrol mimics the effects of calorie restriction via activation of sirtuin 1 (SIRT1). SIRT1 is an important player in the regulation of cellular energy homeostasis and mitochondrial biogenesis. Rodent studies have shown beneficial effects of resveratrol supplementation on mitochondrial function, glucose metabolism, body composition and liver fat accumulation. However, confirmation of these beneficial effects in humans by placebo-controlled clinical trials remains relatively limited. This review will give an overview of pre-clinical and clinical studies examining the effects of resveratrol on obesity-induced negative health outcomes. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes. © 2014 Elsevier B.V.","Mitochondria; Obesity; Resveratrol; Sirtuin; Type 2 diabetes","Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E.C., Abera, S.F., Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 (2014) Lancet, 384, pp. 766-781; Deivanayagam, S., Mohammed, B.S., Vitola, B.E., Naguib, G.H., Keshen, T.H., Kirk, E.P., Klein, S., Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents (2008) Am. J. Clin. Nutr., 88, pp. 257-262; Korenblat, K.M., Fabbrini, E., Mohammed, B.S., Klein, S., Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects (2008) Gastroenterology, 134, pp. 1369-1375; Fabbrini, E., Mohammed, B.S., Magkos, F., Korenblat, K.M., Patterson, B.W., Klein, S., Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease (2008) Gastroenterology, 134, pp. 424-431; Bournat, J.C., Brown, C.W., Mitochondrial dysfunction in obesity (2010) Curr. Endocrinol. Diabetes. Obes., 17, pp. 446-452; Larson-Meyer, D.E., Newcomer, B.R., Heilbronn, L.K., Volaufova, J., Smith, S.R., Alfonso, A.J., Lefevre, M., Ravussin, E., Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function (2008) Obesity (Silver Spring), 16, pp. 1355-1362; Civitarese, A.E., Carling, S., Heilbronn, L.K., Hulver, M.H., Ukropcova, B., Deutsch, W.A., Smith, S.R., Team, C.P., Calorie restriction increases muscle mitochondrial biogenesis in healthy humans (2007) PLoS Med., 4, p. e76; Nonomura, S., Kanagawa, H., Makimoto, A., Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-J O-Kon. (Polygonum cuspidatum Sieb. Et Zucc.) (1963) Yakugaku Zasshi, 83, pp. 988-990; Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., Zipkin, R.E., Zhang, L.L., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan (2003) Nature, 425, pp. 191-196; Sauve, A.A., Wolberger, C., Schramm, V.L., Boeke, J.D., The biochemistry of sirtuins (2006) Annu. Rev. Biochem., 75, pp. 435-465; Ruderman, N.B., Xu, X.J., Nelson, L., Cacicedo, J.M., Saha, A.K., Lan, F., Ido, Y., AMPK and SIRT1: a long-standing partnership? (2010) Am. J. Physiol. Endocrinol. Metab., 298, pp. E751-E760; Yu, J., Auwerx, J., The role of sirtuins in the control of metabolic homeostasis (2009) Ann. N. Y. Acad. Sci., 1173, pp. E10-E19; Timmers, S., Konings, E., Bilet, L., Houtkooper, R.H., van de Weijer, T., Goossens, G.H., Hoeks, J., Kersten, S., Calorie restriction-like effects of 30days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans (2011) Cell Metab., 14, pp. 612-622; Dube, J.J., Amati, F., Stefanovic-Racic, M., Toledo, F.G., Sauers, S.E., Goodpaster, B.H., Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited (2008) Am. J. Physiol. Endocrinol. Metab., 294, pp. E882-E888; Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K.B., Gu, C., Patterson, B.W., Resveratrol supplementation does not improve metabolic function in nonobese postmenopausal women with normal glucose tolerance (2012) Cell Metab., 16, pp. 658-664; Canto, C., Auwerx, J., Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? (2012) Pharmacol. Rev., 64, pp. 166-187; Price, N.L., Gomes, A.P., Ling, A.J., Duarte, F.V., Martin-Montalvo, A., North, B.J., Agarwal, B., Teodoro, J.S., SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function (2012) Cell Metab., 15, pp. 675-690; Pacholec, M., Bleasdale, J.E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R.S., Griffith, D., Pabst, B., SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1 (2010) J. Biol. Chem., 285, pp. 8340-8351; Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Lewis, K., Resveratrol improves health and survival of mice on a high-calorie diet (2006) Nature, 444, pp. 337-342; Um, J.H., Park, S.J., Kang, H., Yang, S., Foretz, M., McBurney, M.W., Kim, M.K., Chung, J.H., AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol (2010) Diabetes, 59, pp. 554-563; Park, S.J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Brown, A.L., Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases (2012) Cell, 148, pp. 421-433; Bachmann, O.P., Dahl, D.B., Brechtel, K., Machann, J., Haap, M., Maier, T., Loviscach, M., Schick, F., Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans (2001) Diabetes, 50, pp. 2579-2584; Schrauwen-Hinderling, V.B., Kooi, M.E., Hesselink, M.K., Moonen-Kornips, E., Schaart, G., Mustard, K.J., Hardie, D.G., Schrauwen, P., Intramyocellular lipid content and molecular adaptations in response to a 1-week high-fat diet (2005) Obes. Res., 13, pp. 2088-2094; Krssak, M., Falk Petersen, K., Dresner, A., DiPietro, L., Vogel, S.M., Rothman, D.L., Roden, M., Shulman, G.I., Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study (1999) Diabetologia, 42, pp. 113-116; Blaak, E.E., van Aggel-Leijssen, D.P., Wagenmakers, A.J., Saris, W.H., van Baak, M.A., Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise (2000) Diabetes, 49, pp. 2102-2107; Mensink, M., Blaak, E.E., van Baak, M.A., Wagenmakers, A.J., Saris, W.H., Plasma free fatty acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes (2001) Diabetes, 50, pp. 2548-2554; Mihaylova, M.M., Shaw, R.J., The AMPK signalling pathway coordinates cell growth, autophagy and metabolism (2011) Nat. Cell Biol., 13, pp. 1016-1023; Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Laurila, E., PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes (2003) Nat. Genet., 34, pp. 267-273; Patti, M.E., Butte, A.J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Saccone, R., Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1 (2003) Proc. Natl. Acad. Sci. U. S. A., 100, pp. 8466-8471; Meex, R.C., Schrauwen-Hinderling, V.B., Moonen-Kornips, E., Schaart, G., Mensink, M., Phielix, E., van de Weijer, T., Hesselink, M.K., Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity (2010) Diabetes, 59, pp. 572-579; Menshikova, E.V., Ritov, V.B., Toledo, F.G., Ferrell, R.E., Goodpaster, B.H., Kelley, D.E., Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity (2005) Am. J. Physiol. Endocrinol. Metab., 288, pp. E818-E825; Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Elliott, P., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha (2006) Cell, 127, pp. 1109-1122; Chen, L.L., Zhang, H.H., Zheng, J., Hu, X., Kong, W., Hu, D., Wang, S.X., Zhang, P., Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial beta-oxidation (2011) Metabolism, 60, pp. 1598-1609; Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N., Swindell, W.R., Perez, E., Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span (2008) Cell Metab., 8, pp. 157-168; Kim, S., Jin, Y., Choi, Y., Park, T., Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice (2011) Biochem. Pharmacol., 81, pp. 1343-1351; Dal-Pan, A., Blanc, S., Aujard, F., Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity (2010) BMC Physiol., 10, p. 11; Dal-Pan, A., Terrien, J., Pifferi, F., Botalla, R., Hardy, I., Marchal, J., Zahariev, A., Perret, M., Caloric restriction or resveratrol supplementation and ageing in a non-human primate: first-year outcome of the RESTRIKAL study in Microcebus murinus (2011) Age (Dordr), 33, pp. 15-31; Cannon, B., Nedergaard, J., Brown adipose tissue: function and physiological significance (2004) Physiol. Rev., 84, pp. 277-359; Andrade, J.M., Frade, A.C., Guimaraes, J.B., Freitas, K.M., Lopes, M.T., Guimaraes, A.L., de Paula, A.M., Santos, S.H., Resveratrol increases brown adipose tissue thermogenesis markers by increasing SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue of mice fed a standard diet (2014) Eur. J. Nutr., 53, pp. 1503-1510; Alberdi, G., Rodriguez, V.M., Miranda, J., Macarulla, M.T., Churruca, I., Portillo, M.P., Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats (2013) Food Chem., 141, pp. 1530-1535; Tseng, Y.H., Kokkotou, E., Schulz, T.J., Huang, T.L., Winnay, J.N., Taniguchi, C.M., Tran, T.T., Yamamoto, Y., New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure (2008) Nature, 454, pp. 1000-1004; Virtanen, K.A., Lidell, M.E., Orava, J., Heglind, M., Westergren, R., Niemi, T., Taittonen, M., Enerback, S., Functional brown adipose tissue in healthy adults (2009) N. Engl. J. Med., 360, pp. 1518-1525; Bhatt, J.K., Thomas, S., Nanjan, M.J., Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus (2012) Nutr. Res., 32, pp. 537-541; Crandall, J.P., Oram, V., Trandafirescu, G., Reid, M., Kishore, P., Hawkins, M., Cohen, H.W., Barzilai, N., Pilot study of resveratrol in older adults with impaired glucose tolerance (2012) J. Gerontol. A Biol. Sci. Med. Sci., 67, pp. 1307-1312; Poulsen, M.M., Vestergaard, P.F., Clasen, B.F., Radko, Y., Christensen, L.P., Stodkilde-Jorgensen, H., Moller, N., Jorgensen, J.O., High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition (2013) Diabetes, 62, pp. 1186-1195; Movahed, A., Nabipour, I., Lieben Louis, X., Thandapilly, S.J., Yu, L., Kalantarhormozi, M., Rekabpour, S.J., Netticadan, T., Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients (2013) Evid. Based Complement. Alternat. Med., 2013, p. 851267; Rivera, L., Moron, R., Zarzuelo, A., Galisteo, M., Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats (2009) Biochem. Pharmacol., 77, pp. 1053-1063; Shang, J., Chen, L.L., Xiao, F.X., Sun, H., Ding, H.C., Xiao, H., Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase (2008) Acta Pharmacol. Sin., 29, pp. 698-706; Kang, W., Hong, H.J., Guan, J., Kim, D.G., Yang, E.J., Koh, G., Park, D., Lee, D.H., Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents (2012) Metabolism, 61, pp. 424-433; Jeon, B.T., Jeong, E.A., Shin, H.J., Lee, Y., Lee, D.H., Kim, H.J., Kang, S.S., Roh, G.S., Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet (2012) Diabetes, 61, pp. 1444-1454; Barger, J.L., Kayo, T., Vann, J.M., Arias, E.B., Wang, J., Hacker, T.A., Wang, Y., Leeuwenburgh, C., A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice (2008) PLoS One, 3, p. e2264; Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., Zhai, Q., SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B (2007) Cell Metab., 6, pp. 307-319; Marchal, J., Blanc, S., Epelbaum, J., Aujard, F., Pifferi, F., Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, Microcebus murinus (2012) PLoS One, 7, p. e34289; Jimenez-Gomez, Y., Mattison, J.A., Pearson, K.J., Martin-Montalvo, A., Palacios, H.H., Sossong, A.M., Ward, T.M., Allard, J.S., Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet (2013) Cell Metab., 18, pp. 533-545; Chachay, V.S., Macdonald, G.A., Martin, J.H., Whitehead, J.P., O'Moore-Sulliva, T.M., Lee, P., Franklin, M., Ferguson, M., Resveratrol does not benefit patients with nonalcoholic fatty liver disease (2014) Clin. Gastroenterol. Hepatol., 12, pp. 2092-2103; Dash, S., Xiao, C., Morgantini, C., Szeto, L., Lewis, G.F., High-dose resveratrol treatment for 2weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men (2013) Arterioscler. Thromb. Vasc. Biol., 33, pp. 2895-2901; Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., Battyany, I., Szabados, E., Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease (2012) Clin. Hemorheol. Microcirc., 50, pp. 179-187; Elliott, P.J., Walpole, S., Morelli, L., Lambert, P.D., Lunsmann, W., Westphal, C.H., Lavu, S., Resveratrol/SRT-501 (2009) Drugs Future, 34; Brasnyo, P., Molnar, G.A., Mohas, M., Marko, L., Laczy, B., Cseh, J., Mikolas, E., Halmai, R., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients (2011) Br. J. Nutr., 106, pp. 383-389; van Herpen, N.A., Schrauwen-Hinderling, V.B., Schaart, G., Mensink, R.P., Schrauwen, P., Three weeks on a high-fat diet increases intrahepatic lipid accumulation and decreases metabolic flexibility in healthy overweight men (2011) J. Clin. Endocrinol. Metab., 96, pp. E691-E695; WGO, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, global guideline (2012) WGO Global Guidelines, pp. 1-29; Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X., Li, X., Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation (2009) Cell Metab., 9, pp. 327-338; Rodgers, J.T., Puigserver, P., Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1 (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 12861-12866; Ponugoti, B., Kim, D.H., Xiao, Z., Smith, Z., Miao, J., Zang, M., Wu, S.Y., Kemper, J.K., SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism (2010) J. Biol. Chem., 285, pp. 33959-33970; Walker, A.K., Yang, F., Jiang, K., Ji, J.Y., Watts, J.L., Purushotham, A., Boss, O., Smith, J.J., Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) Genes Dev., 24, pp. 1403-1417; Alberdi, G., Rodriguez, V.M., Macarulla, M.T., Miranda, J., Churruca, I., Portillo, M.P., Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet (2013) Nutrition, 29, pp. 562-567; Poulsen, M.M., Larsen, J.O., Hamilton-Dutoit, S., Clasen, B.F., Jessen, N., Paulsen, S.K., Kjaer, T.N., Pedersen, S.B., Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet (2012) Nutr. Res., 32, pp. 701-708; Heeboll, S., Thomsen, K.L., Pedersen, S.B., Vilstrup, H., George, J., Gronbaek, H., Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease (2014) World J. Hepatol., 6, pp. 188-198; Xin, P., Han, H., Gao, D., Cui, W., Yang, X., Ying, C., Sun, X., Hao, L., Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats (2013) Food Chem. Toxicol., 52, pp. 12-18; Cho, I.J., Ahn, J.Y., Kim, S., Choi, M.S., Ha, T.Y., Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters (2008) Biochem. Biophys. Res. Commun., 367, pp. 190-194; Zhou, M., Wang, S., Zhao, A., Wang, K., Fan, Z., Yang, H., Liao, W., Zhang, Y., Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice (2012) J. Proteome Res., 11, pp. 4961-4971; Cho, S.J., Jung, U.J., Choi, M.S., Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice (2012) Br. J. Nutr., 108, pp. 2166-2175; Chen, Q., Wang, E., Ma, L., Zhai, P., Dietary resveratrol increases the expression of hepatic 7alpha-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice (2012) Lipids Health Dis., 11, p. 56; Bai, Y., Mao, Q.Q., Qin, J., Zheng, X.Y., Wang, Y.B., Yang, K., Shen, H.F., Xie, L.P., Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo (2010) Cancer Sci., 101, pp. 488-493; Do, G.M., Jung, U.J., Park, H.J., Kwon, E.Y., Jeon, S.M., McGregor, R.A., Choi, M.S., Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice (2012) Mol. Nutr. Food Res., 56, pp. 1282-1291; Ahn, J., Cho, I., Kim, S., Kwon, D., Ha, T., Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet (2008) J. Hepatol., 49, pp. 1019-1028; Gomez-Zorita, S., Fernandez-Quintela, A., Macarulla, M.T., Aguirre, L., Hijona, E., Bujanda, L., Milagro, F., Portillo, M.P., Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress (2012) Br. J. Nutr., 107, pp. 202-210; Franco, J.G., Lisboa, P.C., Lima, N.S., Amaral, T.A., Peixoto-Silva, N., Resende, A.C., Oliveira, E., Moura, E.G., Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning (2013) J. Nutr. Biochem., 24, pp. 960-966; Gao, M., Liu, D., Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice (2013) AAPS J., 15, pp. 744-752; Bujanda, L., Hijona, E., Larzabal, M., Beraza, M., Aldazabal, P., Garcia-Urkia, N., Sarasqueta, C., Gonzalez, A., Resveratrol inhibits nonalcoholic fatty liver disease in rats (2008) BMC Gastroenterol., 8, p. 40; Li, L., Hai, J., Li, Z., Zhang, Y., Peng, H., Li, K., Weng, X., Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease (2014) Food Chem. Toxicol., 63, pp. 166-173; Tauriainen, E., Luostarinen, M., Martonen, E., Finckenberg, P., Kovalainen, M., Huotari, A., Herzig, K.H., Mervaala, E., Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation (2011) J. Nutr. Metab., 2011, p. 525094; Farmer, S.R., Obesity: be cool, lose weight (2009) Nature, 458, pp. 839-840",Review,Scopus,2-s2.0-84925424159
"Sharps M., Higgs S., Blissett J., Nouwen A., Chechlacz M., Allen H.A., Robinson E.","Examining evidence for behavioural mimicry of parental eating by adolescent females. An observational study",2015,"Appetite","89",,,"56","61",,,10.1016/j.appet.2015.01.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922361059&partnerID=40&md5=263d4f7f06540cb628b5115e95367ae1","Institute of Psychology, Health and Society, University of LiverpoolLiverpool, United Kingdom; School of Psychology, University of BirminghamEdgbaston,Birmingham, United Kingdom; Department of Psychology, School of Science and Technology, Middlesex University, The Town hallThe Burroughs,Hendon,London, United Kingdom; Department of Experimental Psychology, University of Oxford, Tinbergen building, 9 South Parks roadOxford, United Kingdom; Faculty of Science, University of Nottingham, University ParkNottingham, United Kingdom","Sharps, M., Institute of Psychology, Health and Society, University of LiverpoolLiverpool, United Kingdom; Higgs, S., School of Psychology, University of BirminghamEdgbaston,Birmingham, United Kingdom; Blissett, J., School of Psychology, University of BirminghamEdgbaston,Birmingham, United Kingdom; Nouwen, A., Department of Psychology, School of Science and Technology, Middlesex University, The Town hallThe Burroughs,Hendon,London, United Kingdom; Chechlacz, M., Department of Experimental Psychology, University of Oxford, Tinbergen building, 9 South Parks roadOxford, United Kingdom; Allen, H.A., Faculty of Science, University of Nottingham, University ParkNottingham, United Kingdom; Robinson, E., Institute of Psychology, Health and Society, University of LiverpoolLiverpool, United Kingdom","Behavioural mimicry is a potential mechanism explaining why adolescents appear to be influenced by their parents' eating behaviour. In the current study we examined whether there is evidence that adolescent females mimic their parents when eating. Videos of thirty-eight parent and female adolescent dyads eating a lunchtime meal together were examined. We tested whether a parent placing a food item into their mouth was associated with an increased likelihood that their adolescent child would place any food item (non-specific mimicry) or the same item (specific mimicry) in their mouth at three different time frames, namely, during the same second or within the next fifteen seconds (+15), five seconds (+5) or two second (+2) period. Parents and adolescents' overall food intake was positively correlated, whereby a parent eating a larger amount of food was associated with the adolescent eating a larger meal. Across all of the three time frames adolescents were more likely to place a food item in their mouth if their parent had recently placed that same food item in their mouth (specific food item mimicry); however, there was no evidence of non-specific mimicry. This observational study suggests that when eating in a social context there is evidence that adolescent females may mimic their parental eating behaviour, selecting and eating more of a food item if their parent has just started to eat that food. © 2015 Elsevier Ltd.","Mimicry; Social eating; Social modelling","Bernieri, F.J., Coordinated movement and rapport in teacher-student interactions (1988) Journal of Nonverbal Behaviour, 12, pp. 120-138; Bevelander, K.E., Anschutz, D.J., Engels, R.C.M.E., Social norms in food intake among normal weight and overweight children (2012) Appetite, 58, pp. 864-872; Bevelander, K.E., Lichtwarck-Aschoff, A., Anschutz, D.J., Hermans, R.C.J., Engels, R.C.M.E., Imitation of snack food intake among normal-weight and overweight children (2013) Frontiers in Psychology, 4, p. 949; Chartrand, T.L., Bargh, J.A., The chameleon effect. The perception-behaviour link and social interaction (1999) Journal of Personality and Social Psychology, 76, pp. 893-910; Chartrand, T.L., Maddux, W.W., Lakin, J.L., Beyond the perception-behavior link. The ubiquitous utility and motivational moderators of nonconscious mimicry 2005 (2009) The new unconscious. Oxford series in social cognition and social neuroscience, pp. 334-361. , Oxford University Press, New York, R.R. Hassin, J.S. Uleman, J.A. Bargh (Eds.); Cole, T.J., Bellizzi, M.C., Flegal, K.M., Dietz, W.H., Establishing a standard definition for child overweight and obesity worldwide. International survey (2000) BMJ (Clinical Research Ed.), 320 (7244), pp. 1240-1243; Cole, T.J., Flegal, K.M., Nicholls, D., Jackson, A.A., Body mass index cut offs to define thinness in children and adolescents. International survey (2007) BMJ (Clinical Research Ed.), 335 (7612), p. 194; Conger, J.C., Conger, A.J., Costanzo, P.R., Wright, K.L., Matter, J.A., The effect of social cues on the eating behaviour of obese and normal subjects (1980) Journal of Personality, 48, pp. 258-271; Goldman, S.J., Herman, C.P., Polivy, J., Is the effect of a social model attenuated by hunger? (1991) Appetite, 17, pp. 129-140; Hardman, C.A., Scott, J., Field, M., Jones, A., To eat or not to eat; the effects of expectancy on reactivity to food cues (2014) Appetite, 76, pp. 153-160; Harper, L.V., Sanders, K.M., The effect of adults' eating on young children's acceptance of unfamiliar foods (1975) Journal of Experimental Child Psychology, 20, pp. 206-2014; Herman, C.P., Roth, D.A., Polivy, J., Effects of the presence of others on food intake. A normative interpretation (2003) Psychological Bulletin, 129, pp. 873-886; Hermans, R.C.J., Larsen, J.K., Herman, C.P., Engels, R.C.M.E., Effects of social modelling on young women's nutrient dense food intake (2009) Appetite, 53, pp. 135-138; Hermans, R.C.J., Lichtwarck-Aschoff, A., Bevelander, K.E., Herman, C.P., Larsen, J.K., Engels, R.C.M.E., Mimicry of food intake. The dynamic interplay between eating companions (2012) PLoS ONE, 7, p. e31027; Iacoboni, M., Woods, R.P., Brass, M., Bekkering, H., Mazzoitta, J.C., Cortical mechanisms of human imitation (1999) Science, 286, pp. 2526-2528; Laibson, D., A cue-theory of consumption (2001) The Quarterly Journal of Economics, 116, pp. 81-119; Lakin, J.L., Chartrand, T.L., Using nonconscious behavioural mimicry to create affiliation and rapport (2003) Psychological Science, 14, pp. 334-339; Larsen, H., Engels, R.C.M.E., Souren, P.M., Overbeek, G.J., Granic, I., Peer influence in the micro-perspective. Imitation of alcoholic and non-alcoholic beverages (2010) Addictive Behaviours, 35, pp. 49-52; Lau, R.R., Quadrel, M.J., Hartman, K.A., Development and change of young adults' preventive health beliefs and behaviour. Influence from parents and peers (1990) Journal of Health and Social Behaviour, 31, pp. 240-259; McGowan, L., Croker, H., Wardle, J., Cooke, L.J., Environmental and individual determinants of core and non-core food and drink intake in preschool-aged children in the United Kingdom (2012) European Journal of Clinical Nutrition, 66, pp. 322-328; Neumann, R., Strack, F., ""Mood contagion"". The automatic transfer of mood between persons (2000) Journal of Personality and Social Psychology, 79, pp. 211-223; Oliveria, S., Ellison, R., Moore, L., Gillman, M., Garrahie, E., Singer, M., Parent-child relationships in nutrient intake. The Framingham children's study (1992) American Journal of Clinical Nutrition, 56, pp. 593-598; Pliner, P., Mann, N., Influence of social norms and palatability on amount consumed and food choice (2004) Appetite, 42, pp. 227-237; Robinson, E., Benwell, H., Higgs, S., Food intake norms increase and decrease snack food intake in a remote confederate study (2013) Appetite, 65, pp. 20-24; Robinson, E., Blissett, J., Higgs, S., Social influences on eating. Implications for nutritional interventions (2013) Nutritional Research Reviews, 26, pp. 166-176; Robinson, E., Sharps, M., Price, N., Dallas, R., Eating like you are overweight. The effect of overweight models on food intake in a remote confederate study (2014) Appetite, 82, pp. 119-123; Roth, D.A., Herman, C.P., Polivy, J., Pliner, P., Self-presentational conflict in social eating situations. A normative perspective (2001) Appetite, 36, pp. 165-171; Salvy, S.J., Elmo, A., Nitecki, L.A., Kluczynski, A., Roemmich, J.N., Influence of parents and friends on children's and adolescents' food intake and food selection (2011) American Journal of Clinical Nutrition, 93, pp. 87-92; Story, M., Neumark-Sztainer, D., French, S., Individual and environmental influences on adolescent eating behaviours (2002) Journal of the American Dietetic Association, 102, pp. 40-51; Sweetman, C., McGowan, L., Croker, H., Cooke, L., Characteristics of family mealtimes affecting children's vegetable consumption and liking (2011) Journal of the American Dietetic Association, 111, pp. 269-273; Vartanian, L.R., Sokol, N., Herman, C.P., Polivy, J., Social models provide a norm of appropriate food intake for young women (2013) PLoS ONE, 8 (11), p. e79268; Wroten, K.C., O'Neil, C.E., Stuff, J.E., Liu, Y., Nicklas, T.A., Resemblance of dietary intakes of snacks, sweets, fruit and vegetables among mother-child dyads from low income families (2012) Appetite, 59, pp. 316-323",Article,Scopus,2-s2.0-84922361059
"Petito Boyce C., Goodman J.E., Sax S.N., Loftus C.T.","Providing perspective for interpreting cardiovascular mortality risks associated with ozone exposures",2015,"Regulatory Toxicology and Pharmacology","72","1",,"107","116",,,10.1016/j.yrtph.2015.03.009,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927135122&partnerID=40&md5=cddbd111064ff56a8713db32711c5870","Gradient, 600 Stewart Street, Ste 1900Seattle, WA, United States; Gradient, 20 University Road, Ste 5Cambridge, MA, United States","Petito Boyce, C., Gradient, 600 Stewart Street, Ste 1900Seattle, WA, United States; Goodman, J.E., Gradient, 20 University Road, Ste 5Cambridge, MA, United States; Sax, S.N., Gradient, 20 University Road, Ste 5Cambridge, MA, United States; Loftus, C.T., Gradient, 600 Stewart Street, Ste 1900Seattle, WA, United States","When identifying standards for air pollutants based on uncertain evidence, both science and policy judgments play critical roles. Consequently, critical contextual factors are important for understanding the strengths, limitations, and appropriate interpretation of available science, and potential benefits of risk mitigation alternatives. These factors include the relative magnitude and certainty of the risks posed by various factors and the impacts of other risk factors on air pollutant epidemiology study findings. This commentary explores ozone's status as a risk factor for cardiovascular mortality in contrast with decades of strong and consistent evidence for other established risk factors. By comparison, the ozone evidence is less conclusive, more heterogeneous, and subject to substantial uncertainty; ozone's potential effects, if any, are small and challenging to discern. Moreover, the absence of a demonstrated causal relationship calls into question efforts to quantify cardiovascular mortality risks attributed to ozone exposures on a population level and highlights the need to explicitly acknowledge this uncertainty if such calculations are performed. These concerns are relevant for other similar policy contexts - where multiple established risk factors contribute to the health impact of interest; exposure-effect associations are relatively small, weak, and uncertain; and a causal relationship has not been clearly established. © 2015 The Authors.","Air pollution; Cardiovascular mortality; Environmental health policy; NAAQS (National Ambient Air Quality Standards); Ozone exposure","Barr, E.L., Zimmet, P.Z., Welborn, T.A., Jolley, D., Magliano, D.J., Dunstan, D.W., Cameron, A.J., Shaw, J.E., Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study (AusDiab) (2007) Circulation, 116 (2), pp. 151-157; Beebe-Dimmer, J., Lynch, J.W., Turrell, G., Lustgarten, S., Raghunathan, T., Kaplan, G.A., Childhood and adult socioeconomic conditions and 31-year mortality risk in women (2004) Am. J. Epidemiol., 159 (5), pp. 481-490; Bell, M.L., Dominici, F., Samet, J.M., A meta-analysis of time-series studies of ozone and mortality with comparison to the national morbidity, mortality, and air pollution study (2005) Epidemiology, 16 (4), pp. 436-445; Berry, J.D., Dyer, A., Cai, X., Garside, D.B., Ning, H., Thomas, A., Greenland, P., Lloyd-Jones, D.M., Lifetime risks of cardiovascular disease (2012) N. Engl. J. Med., 366 (4), pp. 321-329; Bukowski, J., Do pollution time-series studies contain uncontrolled or residual confounding by risk factors for acute health events? (2008) Regul. Toxicol. Pharmacol., 51, pp. 135-140; Cox, L.A., Miscommunicating risk, uncertainty, and causation: fine particulate air pollution and mortality risk as an example (Letter) (2012) Risk Anal., 32 (5), pp. 765-767; Crippa, A., Discacciati, A., Larsson, S.C., Wolk, A., Orsini, N., Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis (2014) Am. J. Epidemiol., 180 (8), pp. 763-775; D'Agostino, R.B., Vasan, R.S., Pencina, M.J., Wolf, P.A., Cobain, M., Massaro, J.M., Kannel, W.B., General cardiovascular risk profile for use in primary care: the Framingham heart study (2008) Circulation, 117 (6), pp. 743-753; Dahabreh, I.J., Paulus, J.K., Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis (2011) JAMA, 305 (12), pp. 1225-1233; Danaei, G., Ding, E.L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C.J., Ezzati, M., The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors (2009) PLoS Med., 6 (4), p. e1000058; Dominici, F., Wang, C., Crainiceanu, C., Parmigiani, G., Model selection and health effect estimation in environmental epidemiology (2008) Epidemiology, 19 (4), pp. 558-560; Edmondson, D., Newman, J.D., Whang, W., Davidson, K.W., Emotional triggers in myocardial infarction: do they matter? (2013) Eur. Heart J., 34 (4), pp. 300-306; Fann, N., Lamson, A.D., Anenberg, S.C., Wesson, K., Risley, D., Hubbell, B.J., Estimating the national public health burden associated with exposure to ambient PM(2.5) and ozone (2012) Risk Anal., 32 (1), pp. 81-95; Fann, N., Lamson, A.D., Anenberg, S.C., Wesson, K., Risley, D., Hubbell, B.J., Response to Cox Letter: miscommunicating risk, uncertainty, and causation: fine particulate air pollution and mortality risk as an example (Letter) (2012) Risk Anal., 32 (5), pp. 768-770; Fewell, Z., Smith, G.D., Sterne, J.A., The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study (2007) Am. J. Epidemiol., 166 (6), pp. 646-655; Gallicchio, L., Kalesan, B., Sleep duration and mortality: a systematic review and meta-analysis (2009) J. Sleep Res., 18 (2), pp. 148-158; Goldberg, M.S., Burnett, R.T., Brook, J.R., Counterpoint: time-series studies of acute health events and environmental conditions are not confounded by personal risk factors (2008) Regul. Toxicol. Pharmacol., 51, pp. 141-147; Goodman, J.E., Prueitt, R.L., Sax, S.N., Lynch, H.N., Zu, K., Lemay, J.C., King, J.M., Venditti, F.J., Weight-of-evidence evaluation of short-term ozone exposure and cardiovascular effects (2014) Crit. Rev. Toxicol., 44 (9), pp. 725-790; Harvard, T.H., Chan School of Public Health, 2014 https://healthyheartscore.sph.harvard.edu/, Healthy Heart Score Cardiovascular Health Calculator Survey. Available at (accessed 15.01.15)Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., Brindle, P., Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study (2008) Heart, 94 (1), pp. 34-39; Huang, Y., Su, L., Cai, X., Mai, W., Wang, S., Hu, Y., Wu, Y., Xu, D., Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis (2014) Am. Heart J., 167 (2), pp. 160-168; Committee on evaluation of the presumptive disability decision-making process for veterans, Board on military and veterans health (2008) Improving the Presumptive Disability Decision-Making Process for Veterans, p. 781. , http://books.nap.edu/openbook.php?record_id=11908&, National Academies Press, Washington, DC, Available at: (accessed 15.01.15); Janke, K., Propper, C., Henderson, J., Do current levels of air pollution kill? The impact of air pollution on population mortality in England (2009) Health Econ., 18 (9), pp. 1031-1055; Jerrett, M., Burnett, R.T., Willis, A., Krewski, D., Goldberg, M.S., DeLuca, P., Finkelstein, N., Spatial analysis of the air pollution-mortality relationship in the context of ecologic confounders (2003) J. Toxicol. Environ. Health, 66 (16-19), pp. 1735-1777; Jerrett, M., Burnett, R.T., Pope, C.A., Ito, K., Thurston, G., Krewski, D., Shi, Y., Thun, M., Long-term ozone exposure and mortality (2009) N. Engl. J. Med., 360 (11), pp. 1085-1095; Lipsett, M.J., Ostro, B.D., Reynolds, P., Goldberg, D., Hertz, A., Jerrett, M., Smith, D.F., Bernstein, L., Long-term exposure to air pollution and cardiorespiratory disease in the California teachers study cohort (2011) Am. J. Respir. Crit. Care Med., 184 (7), pp. 828-835; Lloyd-Jones, D.M., Hong, Y., Labarthe, D., Mozaffarian, D., Appel, L.J., Van Horn, L., Greenlund, K., Rosamond, W.D., Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond (2010) Circulation, 121 (4), pp. 586-613; Lumley, T., Sheppard, L., Assessing seasonal confounding and model selection bias in air pollution epidemiology using positive and negative control analyses (2000) Environmetrics, 11, pp. 705-717; Lumley, T., Sheppard, L., Time series analyses of air pollution and health: straining at gnats and swallowing camels? (2003) Epidemiology, 14 (1), pp. 13-14; McClellan, R.O., Role of science and judgment in setting national ambient air quality standards: how low is low enough? (2012) Air Qual. Atmos. Health, 5 (2), pp. 243-258; Meyers, D.G., Neuberger, J.S., He, J., Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis (2009) J. Am. Coll. Cardiol., 54 (14), pp. 1249-1255; Mittleman, M.A., Mostofsky, E., Physical, psychological and chemical triggers of acute cardiovascular events: preventive strategies (2011) Circulation, 124 (3), pp. 346-354; Mittleman, M.A., Mintzer, D., Maclure, M., Tofler, G.H., Sherwood, J.B., Muller, J.E., Triggering of myocardial infarction by cocaine (1999) Circulation, 99 (21), pp. 2737-2741; Moller, J., Theorell, T., de Faire, U., Ahlbom, A., Hallqvist, J., Work related stressful life events and the risk of myocardial infarction. Case-control and case-crossover analyses within the Stockholm Heart Epidemiology Programme (SHEEP) (2005) J. Epidemiol. Community Health, 59, pp. 23-30; Mustafic, H., Jabre, P., Caussin, C., Murad, M.H., Escolano, S., Tafflet, M., Perier, M.C., Jouven, X., Main air pollutants and myocardial infarction: a systematic review and meta-analysis (2012) JAMA, 307 (7), pp. 713-721; Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases (2012), http://www.nhlbi.nih.gov/research/reports/2012-mortality-chart-book, Available at: (accessed on January 15)Nocon, M., Hiemann, T., Muller-Riemenschneider, F., Thalau, F., Roll, S., Willich, S.N., Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis (2008) Eur. J. Cardiovasc. Prev. Rehabil., 15 (3), pp. 239-246; Whitlock, G., Lewington, S., Sherliker, P., Clarke, R., Emberson, J., Halsey, J., Qizilbash, N., Peto, R., Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies (2009) Lancet, 373 (9669), pp. 1083-1096; Prueitt, R.L., Lynch, H.N., Zu, K., Sax, S.N., Venditti, F.J., Goodman, J.E., Weight-of-evidence evaluation of long-term ozone exposure and cardiovascular effects (2014) Crit. Rev. Toxicol., 44 (9), pp. 791-822; Ranthe, M.F., Carstensen, L., Oyen, N., Tfelt-Hansen, J., Christiansen, M., McKenna, W.J., Wohlfahrt, J., Boyd, H.A., Family history of premature death and risk of early onset cardiovascular disease (2012) J. Am. Coll. Cardiol., 60 (9), pp. 814-821; Ronksley, P.E., Brien, S.E., Turner, B.J., Mukamal, K.J., Ghali, W.A., Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis (2011) BMJ, 342, p. d671; Rothman, K.J., Greenland, S., Lash, T.L., (2008) Modern Epidemiology, 3rd ed., p. 758. , Lippincott Williams & Wilkins, Philadelphia, PA; Russ, T.C., Stamatakis, E., Hamer, M., Starr, J.M., Kivimaki, M., Batty, G.D., Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies (2012) BMJ, 345, p. e4933; Sacks, J.D., Ito, K., Wilson, W.E., Neas, L.M., Impact of covariate models on the assessment of the air pollution-mortality association in a single- and multipollutant context (2012) Am. J. Epidemiol., 176 (7), pp. 622-634; Smith, R.L., Xu, B., Switzer, P., Reassessing the relationship between ozone and short-term mortality in U.S. urban communities (2009) Inhal. Toxicol., 21, pp. 37-61; Sofi, F., Cesari, F., Abbate, R., Gensini, G.F., Casini, A., Adherence to Mediterranean diet and health status: meta-analysis (2008) BMJ, 337, p. a1344; Steenland, K., Armstrong, B., An overview of methods for calculating the burden of disease due to specific risk factors (2006) Epidemiology, 17 (5), pp. 512-519; Thun, M.J., Carter, B.D., Feskanich, D., Freedman, N.D., Prentice, R., Lopez, A.D., Hartge, P., Gapstur, S.M., 50-year trends in smoking-related mortality in the United States (2013) N. Engl. J. Med., 368 (4), pp. 351-364; Integrated Science Assessment for Ozone and Related Photochemical Oxidants (Final) (2013), p. 1251. , EPA/600/R-10/076FHealth Risk and Exposure Assessment for Ozone (Final Report) (2014), EPA-452/R-14-004a, EPA-452/R-14-004b, EPA-452/R-14-004c, EPA-452/R-14-004d, EPA-452/R-14-004eNational Ambient Air Quality Standards for Ozone (Proposed rule) (2014) Fed. Reg, 79, pp. 75234-75411. , 40 CFR Parts 50, 51, 52, 53 and 58; van der Maas, P.J., How summary measures of population health are affecting health agenda (Editorial) (2003) Bull. World Health Org., 81 (5), p. 314; Wang, X.Y., Hu, W., Tong, S., Long-term exposure to gaseous air pollutants and cardio-respiratory mortality in Brisbane, Australia (2009) Geospat. Health, 3 (2), pp. 257-263; Wang, X., Ouyang, Y., Liu, J., Zhu, M., Zhao, G., Bao, W., Hu, F.B., Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies (2014) BMJ, 349, p. g4490; Wicks, A.F., Lumley, T., Lemaitre, R.N., Sotoodehnia, N., Rea, T.D., McKnight, B., Strogatz, D.S., Siscovick, D.S., Major life events as potential triggers of sudden cardiac arrest (2012) Epidemiology, 23 (3), pp. 482-485; Wilmot, E.G., Edwardson, C.L., Achana, F.A., Davies, M.J., Gorely, T., Gray, L.J., Khunti, K., Biddle, S.J., Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis (2012) Diabetologia, 55 (11), pp. 2895-2905",Article,Scopus,2-s2.0-84927135122
"Chen T., Gao J., Xiang P., Chen Y., Ji J., Xie P., Wu H., Xiao W., Wei Y., Wang S., Lan L., Ji H., Yan T.","Protective effect of platycodin D on liver injury in alloxan-induced diabetic mice via regulation of Treg/Th17 balance",2015,"International Immunopharmacology","26","2",,"338","348",,,10.1016/j.intimp.2015.04.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928471785&partnerID=40&md5=db7e7b2666aaa17d8dd9d17a3db1d9a3","State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China; Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; School of Pharmacy, China Pharmaceutical UniversityNanjing, China; Changchun University of Chinese MedicineChangchun, China","Chen, T., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Gao, J., School of Pharmacy, China Pharmaceutical UniversityNanjing, China; Xiang, P., School of Pharmacy, China Pharmaceutical UniversityNanjing, China; Chen, Y., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Ji, J., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Xie, P., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Wu, H., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Xiao, W., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Wei, Y., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Wang, S., Changchun University of Chinese MedicineChangchun, China; Lan, L., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Ji, H., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China, Department of Pharmacology, China Pharmaceutical UniversityNanjing, China; Yan, T., State Key Laboratory of Natural Medicines, China Pharmaceutical UniversityNanjing, China","Platycodin D is a major pharmacological constituent of Platycodi Radix with immunomodulatory activity. The present study was designed to investigate how platycodin D (PLD) reveals liver injury in diabetic mice and its mechanism. Fifty mice were divided into five groups randomly: control group, model group, rosiglitazone (ROG, 10 mg/kg) group, PLD (50 mg/kg) group, and PLD (100 mg/kg) group. Diabetes was induced with the injection of alloxan monohydrate (150 mg/kg) subcutaneously, and animals with blood glucose level of ≥250 mg/dl were considered as diabetic mice. After the first day of diabetes induction, the treatments were performed for 8 weeks. Then the animals were anaesthetized, and blood and liver samples were also collected for further assay. PLD significantly decreased the serum levels of glucose, insulin, interleukin-6 (IL-6), interleukin-1β, tumor necrosis factor-α (TNF-α), and interleukin (IL)-17A and increased IL-10 level in serum. PLD effectively downregulated aspartate transaminase (AST), alanine aminotransferase (ALT), total cholesterol (TC), and triglycerides (TG) in liver. PLD also attenuated liver histological change. In addition, PLD significantly attenuated IL-17A and IL-10 levels in vitro, flow cytometry (FCM) studies also showed that PLD remarkably inhibited Th17 cells and significantly increased Treg cells in liver tissues and spleen cells. Western blot demonstrated PLD inhibited the phosphorylation of JAK and STAT-3 and the expression of RORγt and increased the expression of Foxp3. The findings showed that PLD exerts beneficial effects on alloxan-induced liver injury in mice. © 2015 Elsevier B.V. All rights reserved.","Diabetic; Liver injury; Platycodin D; Treg/Th17 balance","Rathmann, W., Giani, G., Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030 (2004) Diabetes Care, 27, pp. 2568-2569. , (author reply 2569); Feng, M., Wang, Q., Wang, H., Wang, M., Guan, W., Lu, L., Adoptive transfer of hepatic stellate cells ameliorates liver ischemia reperfusion injury through enriching regulatory T cells (2014) Int. Immunopharmacol., 19, pp. 267-274; McVicker, B.L., Thiele, G.M., Casey, C.A., Osna, N.A., Tuma, D.J., Susceptibility to T cell-mediated liver injury is enhanced in asialoglycoprotein receptor-deficient mice (2013) Int. Immunopharmacol., 16, pp. 17-26; Li, J., Qiu, S.J., She, W.M., Wang, F.P., Gao, H., Li, L., Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis (2012) PLoS One, 7, p. e39307; Li, J., Wang, F.P., She, W.M., Yang, C.Q., Li, L., Tu, C.T., Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B (2014) J. Viral Hepat., 21, pp. 129-140; Que, Z., Zou, F., Zhang, A., Zheng, Y., Bi, L., Zhong, J., Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse Lewis lung cancer cells (2014) Int. Immunopharmacol., 23, pp. 192-204; Li, G., Ren, J., Wang, G., Gu, G., Hu, D., Ren, H., T2 enhances in situ level of Foxp3+ regulatory cells and modulates inflammatory cytokines in Crohn's disease (2014) Int. Immunopharmacol., 18, pp. 244-248; Tianzhu, Z., Shihai, Y., Juan, D., The Effects of Cordycepin on Ovalbumin-Induced Allergic Inflammation by Strengthening Treg Response and Suppressing Th17 responses in ovalbumin-sensitized mice (2014) Inflammation., 37, pp. 1976-1983; Pang, N., Zhang, F., Ma, X., Zhu, Y., Zhao, H., Xin, Y., TGF-beta/Smad signaling pathway regulates Th17/Treg balance during Echinococcus multilocularis infection (2014) Int. Immunopharmacol., 20, pp. 248-257; Han, L.K., Xu, B.J., Kimura, Y., Zheng, Y., Okuda, H., Platycodi radix affects lipid metabolism in mice with high fat diet-induced obesity (2000) J. Nutr., 130, pp. 2760-2764; Han, L.K., Zheng, Y.N., Xu, B.J., Okuda, H., Kimura, Y., Saponins from platycodi radix ameliorate high fat diet-induced obesity in mice (2002) J. Nutr., 132, pp. 2241-2245; Zhang, T., Yang, S., Du, J., Jinfu, Y., Shumin, W., (2015) Platycodin D Attenuates Airway Inflammation in A Mouse Model of Allergic Asthma by Regulation NF-kappaB Pathway, Inflammation; Chun, J., Kim, Y.S., Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways (2013) Chem. Biol. Interact., 205, pp. 212-221; Choi, S.S., Han, E.J., Lee, T.H., Lee, J.K., Han, K.J., Lee, H.K., Antinociceptive mechanisms of platycodin D administered intracerebroventricularly in the mouse (2002) Planta Med., 68, pp. 794-798; Xie, Y., Sun, H.X., Li, D., Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen (2009) Vaccine, 27, pp. 757-764; Szkudelski, T., The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas (2001) Physiol. Res., 50, pp. 537-546; Shi, Y., Liang, X.C., Zhang, H., Wu, Q.L., Qu, L., Sun, Q., Quercetin protects rat dorsal root ganglion neurons against high glucose-induced injury in vitro through Nrf-2/HO-1 activation and NF-kappaB inhibition (2013) Acta Pharmacol. Sin., 34, pp. 1140-1148; Chaudhry, J., Ghosh, N.N., Roy, K., Chandra, R., Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats (2007) Life Sci., 80, pp. 1135-1142; Wang, X.T., Li, J., Liu, L., Hu, N., Jin, S., Liu, C., Tissue cholesterol content alterations in streptozotocin-induced diabetic rats (2012) Acta Pharmacol. Sin., 33, pp. 909-917; Mahendran, G., Thamotharan, G., Sengottuvelu, S., Bai, V.N., Anti-diabetic activity of Swertia corymbosa (Griseb.) Wight ex C.B. Clarke aerial parts extract in streptozotocin induced diabetic rats (2014) J. Ethnopharmacol., 151, pp. 1175-1183; Dai, J., Liu, M., Ai, Q., Lin, L., Wu, K., Deng, X., Involvement of catalase in the protective benefits of metformin in mice with oxidative liver injury (2014) Chem. Biol. Interact., 216, pp. 34-42; Tan, S.M., Sharma, A., Stefanovic, N., Yuen, D.Y., Karagiannis, T.C., Meyer, C., Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease (2014) Diabetes, 63, pp. 3091-3103; Lee, D.S., Jeong, G.S., Cudratricusxanthone A protect pancreatic beta cells from cytokines-mediated toxicity through the inhibition of NF-kappaB and STAT pathways (2014) Int. Immunopharmacol., 21, pp. 26-33; Yao, R., Ma, Y.L., Liang, W., Li, H.H., Ma, Z.J., Yu, X., MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1 (2012) PLoS One, 7, p. e46082; Wang, X., Huang, X.J., Ihsan, A., Liu, Z.Y., Huang, L.L., Zhang, H.H., Metabolites and JAK/STAT pathway were involved in the liver and spleen damage in male Wistar rats fed with mequindox (2011) Toxicology, 280, pp. 126-134; Song, L., Zhuo, M., Tang, Y., Chen, X., Tang, Z., Zang, G., Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo (2014) Int. Immunopharmacol., 23, pp. 1-7; Chen, J., Wu, H., Wang, Q., Chang, Y., Liu, K., Song, S., Ginsenoside metabolite compound k alleviates adjuvant-induced arthritis by suppressing T cell activation (2014) Inflammation, 37, pp. 1608-1615; Wang, S., Ni, B., Chen, K., Shi, S., Influences of cerebral stent implantation on CD4 + CD25 + FOXP3 + Treg, Th1 and Th17 cells (2013) Int. Immunopharmacol., 17, pp. 519-525; Baek, S.Y., Lee, J., Lee, D.G., Park, M.K., Lee, J., Kwok, S.K., Ursolic acid ameliorates autoimmune arthritis via suppression of Th17 and B cell differentiation (2014) Acta Pharmacol. Sin., 35, pp. 1177-1187; Oukka, M., Interplay between pathogenic Th17 and regulatory T cells (2007) Ann. Rheum. Dis., 66, pp. iii87-iii90; Liu, Y., She, W., Wang, F., Li, J., Wang, J., Jiang, W., 3,3′-Diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance (2014) Int. Immunopharmacol., 23, pp. 489-498; Zhao, S., Guo, D., Bi, H., Cui, Y., Xie, X., Wang, X., Li, J., Diverse roles of natural killer T lymphocytes in liver and spleen in mice with experimental autoimmune uveitis (2014) Inflammation., 37, pp. 581-592; Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells (2006) Nature, 441, pp. 235-238; Xiao, S., Jin, H., Korn, T., Liu, S.M., Oukka, M., Lim, B., Retinoic acid increases Foxp3 + regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression (2008) J. Immunol., 181, pp. 2277-2284; Wang, J., Kong, L., Luo, Q., Li, B., Wu, J., Liu, B., Dual effects of respiratory syncytial virus infections on airway inflammation by regulation of Th17/Treg responses in ovalbumin-challenged mice (2014) Inflammation, 37, pp. 1984-2005; Liu, Y.M., Chen, Y., Li, J.Z., Gong, J.P., Up-regulation of Galectin-9 in vivo results in immunosuppressive effects and prolongs survival of liver allograft in rats (2014) Immunol. Lett., 162, pp. 217-222; Ji, N.F., Xie, Y.C., Zhang, M.S., Zhao, X., Cheng, H., Wang, H., Ligustrazine corrects Th1/Th2 and Treg/Th17 imbalance in a mouse asthma model (2014) Int. Immunopharmacol., 21, pp. 76-81",Article,Scopus,2-s2.0-84928471785
"Yadav S., Agarwal R., Singh S., Goel S.","Pyrenochaeta romeroi causing subcutaneous phaeohyphomycotic cyst in a diabetic female",2015,"Medical Mycology Case Reports","8",, 148,"47","49",,,10.1016/j.mmcr.2015.04.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928717116&partnerID=40&md5=ab658bc84a0c6b8614849a22eee3890e","Department of Microbiology, Bhagat Phool Singh Goverment Medical CollegeKhanpur Kalan, Sonepat, Haryana, India; Department of Pathology, Bhagat Phool Singh Goverment Medical CollegeKhanpur Kalan, Sonepat, Haryana, India","Yadav, S., Department of Microbiology, Bhagat Phool Singh Goverment Medical CollegeKhanpur Kalan, Sonepat, Haryana, India; Agarwal, R., Department of Pathology, Bhagat Phool Singh Goverment Medical CollegeKhanpur Kalan, Sonepat, Haryana, India; Singh, S., Department of Microbiology, Bhagat Phool Singh Goverment Medical CollegeKhanpur Kalan, Sonepat, Haryana, India; Goel, S., Department of Microbiology, Bhagat Phool Singh Goverment Medical CollegeKhanpur Kalan, Sonepat, Haryana, India","Abstract Opportunistic subcutaneous fungal infections are increasing in present times due to increasing incidence of many medical conditions causing immunosupression like diabetes, AIDS, organ transplant recipients and anticancer therapy. Pyrenochaeta romeroi, a fungus from the dematiaceae group, first described by Borelli in 1959, is saprophyte to soil and plants.We present a rare case of subcutaneous phaeohyphomycotic cyst in a diabetic female caused by P. romeroi. © 2015 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.","Cyst; Phaeohypomycosis; Pyrenochaeta; Subcutaneous","Ajello, L., (1975) Proceedings of the Third International Conference on Mycosis, pp. 126-133. , Scientific publication no. 304, Pan American Health Organization Washington DC; Rinaldi, M.G., Phaeohyphomycosis (1996) Dermatol. Clin., 14, pp. 147-153; Borelli, D., Opportunistic fungi as producers of gray colonies and mycetomata (1979) Dermatologica, 159, pp. 168-174; Andre, M., Brumpt, V., Destombes, P., Segretain, G., Fungal mycetoma with black grains due to Pyrenochaeta romeroi in Cambodia (1968) Bull. Soc. Pathol. Exot. Fil., 61, pp. 108-112; Thammayya, A., Sanyal, M., Basu, N., Pyrenochaeta romeroi causing mycetoma pedis in India (1979) J. Indian Med. Assoc., 73, pp. 66-67; Thiyagarajan, U.M., Bagul, A., Nicholson, M.L., A nodulo-cystic eumycetoma caused by Pyrenochaeta romeroi in a renal transplant recipient: a case report (2011) J. Med. Case Rep., 5, pp. 460-461; Badali, H., Chander, J., Gulati, N., Attri, A., Chopra, R., Najafzadeh, M.J., Subcutaneous phaeohyphomycotic cyst caused by Pyrenochaeta romeroi (2010) Med. Mycol., 48, pp. 763-768; Girard, C., Dereure, O., Rispail, P., Duran, L., Guilhou, J.J., Subcutaneous phaeohyphomycosis due to Pyrenochaeta romeroi in a patient with leprosy (2004) Acta Derm. Venereol., 84, pp. 154-155; Khan, Z., Ahmad, S., Kapila, K., Ramaswamy, N.V., Alath, P., Joseph, L., Chandy, R., Pyrenochaeta romeroi: a causative agent of phaeohyphomycotic cyst (2011) J. Med. Microbiol., 60, pp. 842-846; De Hoog, G.S., Guarro, J., Gene, J., Figueras, M.J., (2000) Atlas of Clinical Fungi, , second ed. Utrech/Reus: Centraalbureau voor Schimmelcultures/Universtat Rovira i Virgili Netherlands; Ferrer, C., Perez-Santonja, J.J., Rodriguez, A.E., Colom, M.F., Gene, J., Alio, J.L., New Pyrenochaeta species causing keratitis (2009) J. Clin. Microbiol., 47, pp. 1596-1598; Verkley, G.J., Gene, J., Guarro, J., Perez-Santonja, J.J., Rodriguez, A.E., Colom, M.F., Pyrenochaeta keratinophila sp. nov., isolated from an ocular infection in spain (2010) Rev. Iberoam. Micol., 27, pp. 22-24; Badali, H., Najafzadeh, M.J., Van Esbroeck, M., Van Den Enden, E., Tarazooie, B., Meis, J.F., The clinical spectrum of Exophiala jeanselmei, with a case report and antifungal susceptibility of the species (2009) Med. Mycol., 47, pp. 1-10",Article,Scopus,2-s2.0-84928717116
"Rohini K., Kalyani C., Shankar G., Sougata G., Piyush A., Parag K., Balu A.C., Kale S.N.","ZnO nanoparticles-red sandalwood conjugate: A promising anti-diabetic agent",2015,"Journal of Nanoscience and Nanotechnology","15","6",,"4046","4051",,,10.1166/jnn.2015.10323,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920693100&partnerID=40&md5=608ace58855184289290c260abbf094b","Department of Applied Physics, Defence Institute of Advanced TechnologyGirinagar, Pune, India; Institute of Bioinformatics and Biotechnology, University of PunePune, India; Department of Microbiology, University of PunePune, India","Rohini, K., Department of Applied Physics, Defence Institute of Advanced TechnologyGirinagar, Pune, India; Kalyani, C., Department of Applied Physics, Defence Institute of Advanced TechnologyGirinagar, Pune, India; Shankar, G., Department of Applied Physics, Defence Institute of Advanced TechnologyGirinagar, Pune, India; Sougata, G., Institute of Bioinformatics and Biotechnology, University of PunePune, India; Piyush, A., Institute of Bioinformatics and Biotechnology, University of PunePune, India; Parag, K., Department of Applied Physics, Defence Institute of Advanced TechnologyGirinagar, Pune, India; Balu, A.C., Department of Microbiology, University of PunePune, India; Kale, S.N., Department of Applied Physics, Defence Institute of Advanced TechnologyGirinagar, Pune, India","With the advances in nanoscience and nanotechnology the interest of researchers has expanded to interdisciplinary domain like bio-medical applications. Among such domains, one of the most important areas explored meticulously is the development of promising solutions in diabetes therapeutics. The disease associated with metabolic disorder, is one of the major challenges, due to its ever-increasing number of patients. The adverse effects of the synthetic enzymes like - amylase and - glucosidase inhibitors have invited many scientists to develop promising contender with minimal side-effects. On the other hand, Zinc has strong role in insulin synthesis, storage and secretion and thus its deficiency can be related to diabetes. In this context we have explored natural extract of Red Sandalwood (RSW) as a potent anti-diabetic agent, in conjugation with ZnO nanoparticles. ZnO nanoparticles have been synthesized via soft chemistry routes and duly characterized for their phase formation with the help of X-ray diffraction technique and Field-Emission Scanning Electron Microscopy. These monodispersed nanoparticles, ∼20 nm in size, were further conjugated to RSW extract. The conjugation chemistry was studied via Fourier transform infrared spectroscopy, UVvisible spectroscopy. Extract loading percentage was found from thermo-gravimetric analysis. 65% of the RSW extract was found conjugated to the ZnO nanoparticles. The anti-diabetic activity was assessed with the help of like-α-amylase and α-glucosidase inhibition assay with murine pancreatic and small intestinal extracts. It was observed that the conjugated ZnO-RSW nanoparticles showed excellent activity against the crude murine pancreatic glucosidase as compared to the individual ZnO nanoparticles and the RSW extract. The ZnO-RSWconjugate showed 61.93% of inhibition while the bare ZnO nanoparticles and RSW showed 21.48% and 5.90% respectively. © 2015 American Scientific Publishers All rights reserved.","Anti-Diabetic; Nanoparticle conjugation; ZnO","Katekhaye, S.D., Nagmoti, D.M., (2013) Phytopharmacology, 4, p. 123; Mohamed, E.A., Siddiqui, M.J., Ang, L.F., Sadikun, A., Chan, S.H., Tan, S.C., Asmawi, M.Z., Yam, M.F., (2012) BMC Complementary and Alternative Medicine, 12, p. 176; Ghosh, S., Ahire, M., Patil, S., Jabgunde, A., Bhat Dusane, M., Joshi, B.N., Pardesi, K., Chopade, B.A., (2012) Evidence-Based Complementary and Alternative Medicine: ECAM, 2012, p. 929051; Sanap, S.P., Ghosh, S., Jabgunde, A.M., Pinjari, R.V., Gejji, S.P., Singh, S., Chopade, B.A., Dhavale, D.D., (2010) Organic and Biomolecular Chemistry, 8, p. 3307; Nair, S.S., Kavrekar, V., Mishra, A., (2013) European Journal of Experimental Biology, 3, p. 128; Halim, M.E., Misra, A., (2011) Journal of Medicinal Plants Research, 5, p. 398; (2005) WHO Traditional Medicine Strategy 2002-2005, , World Health Organization, Geneva; Kankanange, K., Upali, I., Walpola, B.C., Subasinghe, S., Yoon, M., (2011) J. Korean Soc. Appl. Biol. Chem., 54, p. 495; Nagaraju, N., Prasad, M., Gopalakrishna, G., Rao, K.N., (2008) Blood Sugar Lowering Effect of Pterocarpus Santalinus (Red Sanders) Wood Extract in Different Rat Models, , http://informahealthcare.com/doi/abs/10.3109/13880209109082866journalCode=phb; Kondeti, V.K., Badri, K.R., Maddirala, D.R., Thur, S.K., Fatima, S.S., Kasetti, R.B., Rao, C.A., (2010) Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 48, p. 1281; Chausmer, A.B., (1998) Journal of the American College of Nutrition, 17, p. 109; Umrani, R.D., Paknikar, K.M., (2013) Nanomedicine (London, England); Kitture, R., Koppikar, S.J., K-ghanekar, R., Kale, S.N.N., (2011) Journal of Physics and Chemistry Of Solids, 72, p. 60; Yadav, B.C., Srivastava, R., Dwivedi, C.D., Pramanik, P., (2008) Sensors and Actuators B: Chemical, 131, p. 216; Oh, E., Choi, H.Y., Jung, S.H., Cho, S., Kim, J.C., Lee, K.H., Kang, S.W., Jeong, S.H., (2009) Sensors and Actuators B: Chemical, 141, p. 239; Shinde, V.R., Gujar, T.P., Lokhande, C.D., Mane, R.S., Han, S.-H., (2007) Materials Science and Engineering: B, 137, p. 119; Bie, L.-J., Yan, X.-N., Yin, J., Duan, Y.-Q., Yuan, Z.-H., (2007) Sensors and Actuators B: Chemical, 126, p. 604; Wang, S.Q., Tooley, I.R., (2011) Seminars in Cutaneous Medicine and Surgery, 30, p. 210; Schilling, K., Bradford, B., Castelli, D., Dufour, E., Nash, J.F., Pape, W., Schulte, S., Schellauf, F., (2010) Photochemical Photobiological Sciences Official Journal of the European Photochemistry Association and The European Society For Photobiology, 9, p. 495; Farouk, A., Moussa, S., Ulbricht, M., Textor, T., (2012) International Journal of Carbohydrate Chemistry, 2012, p. 1; Dhobale, S., Thite, T., Laware, S.L., Rode, C.V., Koppikar, S.J., Kaul Ghanekar, R., Kale, S.N., (2008) Journal of Applied Physics, 104, p. 094907; Hsieh, C., (2007) J. Chin. Chem. Soc., 54, p. 31; Sun, D., Wong, M., Sun, L., Li, Y., Miyatake, N., Sue, H.J., (2007) Journal of Solgel Science and Technology, 43, p. 237; Sakohara, S., Ishida, M., Anderson, M.A., (1998) The Journal of Physical Chemistry B, 102, p. 10169; Mane, R.S., Ghosh, S., Singh, S., Chopade, B.A., Dhavale, D.D., (2011) Bioorg. Med. Chem., 19, p. 6720; Viswanatha, R., Venkatesh, T.G., Vidyasagar, C.C., Nayaka, Y.A., (2012) Arch. Appl. Sci. Res., 4, p. 480; Sree Latha Devi, R.K., Basha, S.K.M., (2012) International Journal of Basic and Applied Chemical Sciences, 2, p. 102; Sahoo, N.G., Bao, H., Pan, Y., Pal, M., Kakran, M., Cheng, H.K.F., Li, L., Tan, L.P., (2011) Chemical Communications (Cambridge, England), 47, p. 5235; Kanchana, G., Sundaramoorthi, P., Jeyanthi, G.P., (2009) Bio-chemical Analysis and FTIR-Spectral Studies of Artificially Removed Renal Stone Mineral Constituents, 8, p. 161",Article,Scopus,2-s2.0-84920693100
"Fergus I.V., Connell K.L., Ferdinand K.C.","A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk",2015,"Current Cardiology Reports","17","6",,"","",6,,10.1007/s11886-015-0592-x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928346266&partnerID=40&md5=e606cba02ec6487a779c9a28dd07687e","Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030New York, NY, United States; The University of the West Indies, Cave Hill CampusSt. Michael, Barbados; Tulane University School of Medicine, 1430 Tulane Avenue, #8548New Orleans, LA, United States","Fergus, I.V., Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030New York, NY, United States; Connell, K.L., The University of the West Indies, Cave Hill CampusSt. Michael, Barbados; Ferdinand, K.C., Tulane University School of Medicine, 1430 Tulane Avenue, #8548New Orleans, LA, United States","Cardiometabolic risk describes a collection of risk factors, with a likely underlying pathophysiology, resulting in accelerated atherosclerosis and the terminal cardiovascular events of myocardial infarction and stroke. Beta-blockers, which are divided as vasodilators or non-vasodilators, are used in the treatment of hypertension and other cardiovascular diseases. Vasodilators have been shown to be of particular benefit in both blood pressure control and other cardiometabolic components with limited disturbance in metabolic parameters. Nebivolol, a third-generation beta-blocker (BB), acts by increasing nitric oxide (NO) bioavailability. This property may be especially important in NO-deficient population, such as black people, in regulating both blood pressure control and glucose homeostasis. © 2015, Springer Science+Business Media New York.","Beta-blockers; Cardiometabolic risk; Nitric oxide; Vasodilators","Brunzell, J.D., Davidson, M., Furberg, C.D., Lipoprotein management in patients with cardiometabolic risk: Consensus Conference report from the American Diabetes Association and the American College of Cardiology Foundation (2008) J Am Coll Cardiol, 51 (15), pp. 1512-1524. , PID: 18402913; Lichtenstein, H., Loria, C.M., Millen, B.E., Houston Miller, N., Nonas, C.A., Eckel, R.H., AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report (2013) Circulation, 2013, pp. 2-40; Ayers, K., Byrne, L.M., DeMatteo, A., (2012), This study describes the differences in metabolic and anti-inflammatory of a vasodilating (nebivolol) and non- vasodilating (metoprolol) drugs, It highlights the unique property of nebivolol as a vasodilating BB via NO mediated mechanisms:Taylor, A.A., Bakris, G.L., The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome (2010) Am J Med, 123 (7), pp. 21-26. , COI: 1:CAS:528:DC%2BC3cXhtVKksr%2FM, PID: 20609696; Fares H, Lavie C, Ventura, HO. Vasodilating versus first generation beta blockade for the treatment of cardiovascular conditions. Postgrad Med. 2012; 124(2)Merchant, N., Searles, C.D., Pandian, A., Rahman, S.T., Ferdinand, K.C., Umpierrez, G.E., Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance and endothelial function (2009) J Clin Hypertens, 11 (12), pp. 721-725; Frishman, W.H., Saunders, E.B., Adrenergic blockers (2011) J Clin Hypertens, 13, pp. 649-653. , COI: 1:CAS:528:DC%2BC3MXhsVWjsL3J; Prichard, B.N.C., Gillam, P.M.S., Use of propranolol (Inderal) in the treatment of hypertension (1964) Br Med J, 2, pp. 725-727; Murray, D.R., Prabhu, S.D., Chandrasekar, B., Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression (2000) Circulation, 101, p. 2338. , COI: 1:CAS:528:DC%2BD3cXktVGgtrs%3D, PID: 10821806; Toblli, J.E., Digenarro, F., Giani, J.F., Dominici, F.P., Nebivolol: impact on cardiac and endothelial and clinical utility (2012) Vasc Health and Risk Manag, pp. 151-160; DeNicolantonio, J.J., Lavie, C.J., Fares, H., Menezes, A., O’Keefe, J.H., Meta analysis of carvedilol vs B 1 selective beta blockers (atenolol, bisoprolol, metoprolol and nebivolol) (2013) Am J Cardiol, 111, pp. 765-769. , This analysis is a major comparison of the traditional non- vasodilating BB (bisoprolol and metoprolol) with the vasodilating BB nebivolol; Van Veldhuisen, D.J., Cohen-Solal, A., Böhm, M., Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure) (2009) J Am Coll Cardiol, 53, p. 2150. , PID: 19497441; Hjalmarson, A., Goldstein, S., Fagerberg, B., Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group (2000) JAMA, 283, p. 1295. , COI: 1:CAS:528:DC%2BD3cXitVCktbk%3D, PID: 10714728; Bakris, G.L., Fonseca, V., Katholi, R.E., McGill, J.B., Messerli, F.H., Phillips, R.A., Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial (2004) JAMA, 292, pp. 2227-2236. , COI: 1:CAS:528:DC%2BD2cXpslyqtL8%3D, PID: 15536109; Remme, W.J., Torp-Pedersen, C., Cleland, J.G., Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET (2007) J Am Coll Cardiol, 49, p. 963. , COI: 1:CAS:528:DC%2BD2sXisVCgtb8%3D, PID: 17336720; Yancy, C.W., ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) JACC, 62 (16), pp. 147-239. , PID: 23747642; Gilbert, E.M., Anderson, J.L., Deitchman, D., Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo (1990) Am J Med, 88, p. 223. , COI: 1:STN:280:DyaK3c7nvVWgtA%3D%3D, PID: 1968710; Eichhorn, E.J., McGhie, A.L., Bedotto, J.B., Effects of bucindolol on neurohormonal activation in congestive heart failure (1991) Am J Cardiol, 67, p. 67. , COI: 1:STN:280:DyaK3M%2Fps1OhtA%3D%3D, PID: 1670902; A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure (2001) N Engl J Med, 344, pp. 1659-1667; Lechat, P., Escolano, S., Golmard, J.L., Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS) (1997) Circulation, 96, p. 2197. , COI: 1:CAS:528:DyaK2sXmvVKrsrg%3D, PID: 9337190; Fonseca, V., Sharma, P.P., Shah, M., Deedwania, P., Risk of new-onset diabetes mellitus associated with -blocker treatment for hypertension (2011) Curr Med Res Opin, 27, pp. 799-807. , PID: 21306286; Peter, P., Martin, U., Sharma, A., Dunne, F., Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension (2006) J Clin Pharm Ther, 31, pp. 153-159. , COI: 1:CAS:528:DC%2BD2sXitVCqtbo%3D, PID: 16635049; Probstfield, J.L., Applegate, W.B., Borhani, N.O., Curb, J.D., Cutler, J.A., Davis, B.R., The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group (1989) Clin Exp Hypertens A, 11 (5-6), pp. 973-989. , COI: 1:STN:280:DyaK3c%2FgtlyntQ%3D%3D, PID: 2676266; Giles, T.D., Sander, G.E., Nossaman, B.D., Kadowitz, P.J., Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelium-derived hyperpolarizing factors and prostaglandins (2012) J Clin Hypertens, 14 (4), pp. 198-205. , COI: 1:CAS:528:DC%2BC38XotlCns7g%3D; Kandavar, R., Higashi, W.C., Blackstock, C., Vaughn, C., Sukhanov, S., The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension (2011) Am Soc Hypertens, 5 (3), pp. 161-165. , COI: 1:CAS:528:DC%2BC3MXnvVegsrw%3D; Rizos, C.V., Elisaf, M.S., Antihypertensive drugs and glucose metabolism (2014) World J Cardiol, 6 (7), pp. 517-530. , PID: 25068013; Gilbert, E.M., Abraham, W.T., Olsen, S., Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart (1996) Circulation, 94, p. 2817. , COI: 1:CAS:528:DyaK2sXlsVShug%3D%3D, PID: 8941107; Ladage, D., Reidenbach, C., Rieckeheer, E., Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age (2010) J Cardiovasc Pharmacol, 56, pp. 275-281. , COI: 1:CAS:528:DC%2BC3cXhtFKmurzK, PID: 20571428; Martsevich, S.Y., Kutishenko, N.P., Deev, A.D., Oganov, R.G., Shalnova, S.A., Comparison of antihypertensive and metabolic effects of carvedilol and metoprolol in hypertensive patients with overweight and obesity (2010) Camellia Trial J Hyper, 28, p. 560; Deedwania P, Shea J, Chen W, Brener L. Effects of nebivolol on blood pressure and glucose parameters on hypertensive patients with prediabetes. J Clin Hypertens. 2013;15(4):270–8. This seminal paper highlights the positive effects of the unique NO mediated vasodilating beta blocker nebivolol on insulin resistance and blood pressureMerchant, N., Rahman, S.T., Ferdinand, K.C., Haque, T., Umpierrez, G.E., Khan, B.V., Effects of nebivolol in obese African American patients with hypertension NOAAH: markers of inflammation and obesity in response to exercise induced stress (2011) J Human Hypertens, 25, pp. 196-202. , COI: 1:CAS:528:DC%2BC3MXhs1yls7s%3D; Mancia, G., ESH/ESC guidelines for the management of arterial hypertension—the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) J Hypertens, 31 (7), pp. 1281-1357. , COI: 1:CAS:528:DC%2BC3sXhtVyksb%2FJ, PID: 23817082; Frishman, W.H., Sica, D.A., b-Adrenergic blockers (2008) Hypertension primer, 4th ed.: the essentials of high blood pressure, pp. 446-450. , Izzo JL, Sica D, Black HR, (eds), Wolters Kluwer ⁄ Lippincott Williams & Wilkins, Philadelphia:; Saunders, E., Smith, W.B., DeSalvo, K.B., The efficacy and tolerability of nebivolol in hypertensive African American patients (2007) J Clin Hypertens (Greenwich), 9, pp. 866-875. , COI: 1:CAS:528:DC%2BD2sXhsVSkurjO; Hall, W.D., Clark, L.T., Wenger, N.K., The metabolic syndrome in African Americans: a review (2003) Ethn Dis, 13 (4), pp. 414-428. , PID: 14632261; Torre, JJ and AACE Hypertension Task Force Members. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of Hypertension. AACE Hypertension Guidelines. Endocr Pract. 2006;12(2)James, P., Oparil, S., 2014 evidence-based guideline for the management of high blood pressure in adults—report from the panel members appointed to JNC8 (2014) JAMA, 311, pp. 507-520. , COI: 1:CAS:528:DC%2BC2cXis1aktr8%3D, PID: 24352797; Krakoff, L.R., Gillespie, R.L., Ferdinand, K.C., Fergus, I.V., Recommendations from the JNC 8 panel members raise concerns for elderly black and female populations (2014) J Am Coll Cardiol, 64, pp. 394-402; Williams, B., Lacy, P.S., Thom, S.M., Cruickshank, K., Stanton, A., Collier, D., Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outomes; principal results of the Conduit Artery Function Evaluation (CAFÉ) study (2006) Circulation, 113 (9), pp. 1213-1225. , COI: 1:CAS:528:DC%2BD28XhvVektrg%3D, PID: 16476843; Landsberg L, Aronne LJ, Beilin LJ, Igel LI, Lloyd-Jones D, Sowers J. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. J Clin Hypertens. 2013;15(1):14–33. This report highlights the unifying pathophysiology of traditional markers of the MetS in obesity and gives guidelines on the management of hypertension in obesityWright, J.T., Jr., Harris-Haywood, S., Pressel, S., Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2008) Arch Intern Med, 168 (2), pp. 207-217. , COI: 1:CAS:528:DC%2BD1cXitFKgtrc%3D, PID: 18227370",Review,Scopus,2-s2.0-84928346266
"Prasad M.P.R., Rao B.D., Kalpana K., Rao M.V., Patil J.V.","Glycaemic index and glycaemic load of sorghum products",2015,"Journal of the Science of Food and Agriculture","95","8",,"1626","1630",,,10.1002/jsfa.6861,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928543286&partnerID=40&md5=910ec0dbe2653d9769103eceb8f9cc72","National Institute of NutritionHyderabad, India; Directorate of Sorghum ResearchRajendra Nagar, Hyderabad, India","Prasad, M.P.R., National Institute of NutritionHyderabad, India; Rao, B.D., National Institute of NutritionHyderabad, India, Directorate of Sorghum ResearchRajendra Nagar, Hyderabad, India; Kalpana, K., Directorate of Sorghum ResearchRajendra Nagar, Hyderabad, India; Rao, M.V., National Institute of NutritionHyderabad, India; Patil, J.V., Directorate of Sorghum ResearchRajendra Nagar, Hyderabad, India","BACKGROUND: Sorghum, a small-seeded grass, is an important food crop and chief energy source for the people of semi-arid regions of the world. In India, sorghum production/consumption decreased after the 'green revolution', but it is now regaining momentum owing to numerous health and nutritional benefits. An understanding of the glycaemic index (GI) and glycaemic load (GL) of staples can help in choosing suitable foods for the prevention and control of diabetes. In view of this, the present study was undertaken to evaluate the GI and GL of different sorghum foods and compare them with those of wheat/rice based foods. RESULTS: The GI of sorghum-based foods such as coarse semolina upma (P<0.05), fine semolina upma (P<0.01), flakes poha (P<0.01) and pasta (P<0.01) was significantly lower than that of their respective control (wheat/rice-based) foods. All sorghum-based foods showed significantly lower GL (P<0.01) than their respective control (wheat/rice-based) foods. CONCLUSION: A few sorghum-based products have low GI (<55; coarse semolina upma, fine semolina upma, flakes poha and pasta) and all sorghum-based products (with the exception of sorghum roti) tested in the present study have lower GL than their respective wheat/rice-based foods. Consumption of low-GI and low-GL sorghum-based foods may help in decreasing postprandial blood glucose levels. © 2014 Society of Chemical Industry.","Blood glucose; Glycaemic index; Glycaemic load; Serving size; Sorghum","(2006) World Health Statistics, , World Health Organization, Geneva; (2003) Diet, Nutrition and the Prevention of Chronic Diseases (WHO Technical Report Series No. 916), , World Health Organization, Geneva; Zhang, C., Liu, S., Solomom, C.G., Hu, F.B., Dietary fibre intake, dietary glycemic load and the risk of gestational diabetes mellitus (2006) Diabetes Care, 29, pp. 2223-2230; Du, H., van Bakel, M.M.E., van der Kallen, C.J.H., Blaak, E.E., van Greevenbroek, M.M.J., Glycemic index and glycemic load in relation to food and nutrient intake and metabolic risk factors in a Dutch population (2008) Am J Clin Nutr, 87, pp. 655-661. , van der A DL; Nilsson, A., Ostman, E.M., Granfeldt, Y., Bjrock, I.M.E., Effect of cereal breakfast differing in glycemic index and content of indigestible carbohydrates on daylong glucose tolerance in healthy subjects (2008) Am J Clin Nutr, 87, pp. 645-654; Liu, S., Willett, W.C., Stampfre, M.J., Hu, F.B., Franz, M., Sampson, L., A prospective study of dietary glycemic load, carbohydrate intake and risk of coronary heart disease in US women (2000) Am J Clin Nutr, 71, pp. 1455-1461; Sieri, S., Pala, V., Brighenti, F., Pellegrini, N., Muti, P., Micheli, A., Dietary glycemic index, glycemic load and the risk of breast cancer in an Italian prospective cohort study (2007) Am J Clin Nutr, 86, pp. 1160-1166; Jenkins, D.J., Wolever, T.M., Taylor, R.H., Barker, H., Fielden, H., Baldwin, J.M., Glycemic index of foods: a physiological basis for carbohydrate exchange (1981) Am J Clin Nutr, 34, pp. 362-366; Salmeron, J., Ascherio, A., Rimm, E.B., Colditz, G.A., Spiegelman, D., Jenkins, D.J., Dietary fibre, glycemic load and risk of NIDDM in men (1997) Diabetes Care, 20, pp. 545-550; Abate, N., Chandalia, M., The impact of ethnicity on type 2 diabetes (2003) J Diabetes Complicat, 17, pp. 39-58; Radhika, G., Sumathi, C., Ganesan, A., Sudha, V., Jeyakumar, C.H., Mohan, V., Glycaemic index of Indian flatbreads (rotis) prepared using whole wheat flour and 'atta mix'-added whole wheat flour (2010) Br J Nutr, 103, pp. 1642-1647; Sharp, P.S., Mohan, V., Levy, J.C., Mather, H.M., Kohner, E.M., Insulin resistance in patients of Asian Indian and European origin with non-insulin diabetic dependent diabetes (1986) Horm Metab Res, 29, pp. 235-237; Chatterjee, S., Rae, A., Ray, R., Food consumption and calories intake in contemporary India (2007), https://editorialexpress.com/cgi-in/conference/download.cgi, Online]. . [17 August 2013]Mani, U.V., Prabhu, B.M., Damle, S.S., Mani, I., Glycaemic index of some commonly consumed foods in western India (1993) Asian J Clin Nutr, 2, pp. 111-114; Henry, C.J.K., Lightowler, H.J., Newens, K., Sudha, V., Radhika, G., Sathya, R.M., Glycaemic index of common foods tested in the UK and India (2008) Br J Nutr, 99, pp. 840-845; Vijayan, L., Sumathi, S., Glycaemic response to selected Kerala breakfast items in people with diabetes (1997) Asia Pac J Clin Nutr, 6, pp. 80-83; Dayakarrao, B., Kachui, N., Patil, J.V., A relook into competitiveness of sorghum cultivation vis-à-vis other competing crops (2013) Compendium of Papers and Abstracts. Global Consultation on Millets Promotion for Health and Nutritional Security, pp. 78-84. , Rakshit S, Das IK, Shyamprasad G, Mishra JS, Ratnavathi CV, Chapke RR, Directorate of Sorghum Research, Hyderabad - (); Gopalan, C., Rama Sastry, B.V., Bala Subramanian, S.C., (2004) Nutritive Value of Indian Foods, , National Institute of Nutrition/ICMR, Hyderabad (); Gibson, R.S., Perlas, L., Hotz, C., Improving bioavailability of nutrients in plant foods at the household level (2006) Proc Nutr Soc, 65, pp. 160-168; Ciacci, C., Maiuri, L., Caporaso, N., Bucci, C., Del Giudice, L., Massardo, D.R., Celiac disease: in vitro and in vivo safety and palatability of wheat-free sorghum food products (2007) Clin Nutr, 26, pp. 799-805; Awika, J.M., Rooney, L.W., Sorghum phytochemicals and potential impact on human health (2004) Phytochemistry, 65, pp. 1199-1221; Wolever, T.M., Jenkins, D.J.A., Jenkins, A.L., Josse, R.G., The glycemic index methodology and clinical implications (1991) Am J Clin Nutr, 54, pp. 846-854; (1998) Carbohydrates in Human Nutrition (FAO Food and Nutrition Paper No. 66), , Food and Agriculture Organization of the United Nations, Rome; Ratnavathi, C.V., Sailaja, V., Kiranmayi, E., Gopala Krishna, D., (2008) Delicious Sorghum Foods, pp. 20-26. , Directorate of Sorghum Research/ICAR, Hyderabad; (1990) Official Methods of Analysis, , 15th edn). Association of Official Analytical Chemists, Arlington, VA (); Brouns, F., Bjorck, I., Frayn, K.N., Gibbs, A.L., Lang, V., Slama, G., Glycemic index methodology (2005) Nutr Res Rev, 18, pp. 145-171; Lakshmi, B.K., Vimala, V., Hypoglycemic effect of selected sorghum recipes (1996) Nutr Res, 16, pp. 1651-1658; Asp, N.G., Definition and analysis of dietary fibre (1987) Scand J Gastroenterol Suppl, 129, pp. 16-20; Thompson, L.U., Yoon, J.H., Jenkins, D.J., Wolever, T.M., Jenkins, A.L., Relationship between polyphenol intake and blood glucose response of normal and diabetic individuals (1984) Am J Clin Nutr, 39, pp. 745-751; Leeman, M., Östman, E., Björck, I., Glycaemic and satiating properties of potato products (2008) Eur J Clin Nutr, 62, pp. 87-95; Holm, J., Bjorck, I., Ostrowska, S., Eliasson, A.-C., Asp, N.-G., Larsson, K., Digestibility of amylose-lipid complexes in vitro and in vivo (1983) Stärke, 35, pp. 294-297; Foster-Powell, K., Holt, S.H.A., Brand-Miller, J.C., International table of glycemic index and glycemic load values (2002) Am J Clin Nutr, 76, pp. 5-56",Article,Scopus,2-s2.0-84928543286
"Boucher J., Simard E., Froehlich U., D'Orleans-Juste P., Grandbois M.","Using carboxyfluorescein diacetate succinimidyl ester to monitor intracellular protein glycation",2015,"Analytical Biochemistry","478",,,"73","81",,,10.1016/j.ab.2015.03.017,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926512119&partnerID=40&md5=dc11ffbb31dd1dbdeecd01abceaaa2b6","Department of Pharmacology, Université de SherbrookeSherbrooke, QC, Canada","Boucher, J., Department of Pharmacology, Université de SherbrookeSherbrooke, QC, Canada; Simard, É., Department of Pharmacology, Université de SherbrookeSherbrooke, QC, Canada; Froehlich, U., Department of Pharmacology, Université de SherbrookeSherbrooke, QC, Canada; D'Orléans-Juste, P., Department of Pharmacology, Université de SherbrookeSherbrooke, QC, Canada; Grandbois, M., Department of Pharmacology, Université de SherbrookeSherbrooke, QC, Canada","Protein glycation is a ubiquitous process involved in vascular complications observed in diabetes. Glyoxal (GO), an intracellular reactive oxoaldehyde that is one of the most potent glycation agents, readily reacts with amines present on proteins to produce the lysine-derived adduct carboxymethyllysine, which is a prevalent advanced glycation end-product (AGE). Our group previously showed that cell exposure to GO leads to an alteration in the cell contractile activity that could occur as a result of the glycation of various proteins regulating the cell contractile machinery. Here, we measured the extent of glycation on three functionally distinct proteins known to participate in cell contraction and cytoskeletal organization - Rho-kinase (ROCK), actin, and gelsolin (GSN) - using an assay based on the reaction of the cell membrane-permeable fluorescent probe carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), which reacts with primary amine groups of proteins. By combining CFDA-SE fluorescence and Western blot detection, we observed (following GO incubation) increased glycation of actin and ROCK as well as an increased interaction between actin and GSN as observed by co-immunoprecipitation. Thus, we conclude that the use of the fluorescent probe CFDA-SE offers an interesting alternative to perform a comparative analysis of the extent of intracellular protein glycation in live cells. © 2015 Published by Elsevier Inc. All rights reserved.","Actin; Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE); Cellular protein glycation; Gelsolin; Glyoxal; Rho-kinase","Aronson, D., Pharmacological prevention of cardiovascular aging - Targeting the Maillard reaction (2004) Br. J. Pharmacol., 142, pp. 1055-1058; Hammes, H.P., Brownlee, M., Edelstein, D., Saleck, M., Martin, S., Federlin, K., Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat (1994) Diabetologia, 37, pp. 32-35; Maillard, L., Action des acides aminés sur les sucres: Formation des mélanoidines par voie méthodique (1912) C. R. Acad. Sci. (Paris), 154, pp. 66-68; Soulis, T., Cooper, M.E., Vranes, D., Bucala, R., Jerums, G., Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment (1996) Kidney Int., 50, pp. 627-634; Hamelin, M., Mary, J., Vostry, M., Friguet, B., Bakala, H., Glycation damage targets glutamate dehydrogenase in the rat liver mitochondrial matrix during aging (2007) FEBS J., 274, pp. 5949-5961; Nass, N., Vogel, K., Hofmann, B., Presek, P., Silber, R.-E., Simm, A., Glycation of PDGF results in decreased biological activity (2010) Int. J. Biochem. Cell Biol., 42, pp. 749-754; Thornalley, P.J., Battah, S., Ahmed, N., Karachalias, N., Agalou, S., Babaei-Jadidi, R., Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry (2003) Biochem. J., 375, pp. 581-592; Tan, J.L., Ravid, S., Spudich, J.A., Control of nonmuscle myosins by phosphorylation (1992) Annu. Rev. Biochem., 61, pp. 721-759; Totsukawa, G., Yamakita, Y., Yamashiro, S., Hartshorne, D.J., Sasaki, Y., Matsumura, F., Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts (2000) J. Cell Biol., 150, pp. 797-806; Cazzola, M., Calzetta, L., Rogliani, P., Lauro, D., Novelli, L., Page, C.P., High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway (2012) Am. J. Respir. Cell Mol. Biol., 47, pp. 509-516; Guo, Z., Su, W., Allen, S., Pang, H., Daugherty, A., Smart, E., COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice (2005) Cardiovasc. Res., 67, pp. 723-735; Nobe, K., High-glucose-altered endothelial cell function involves both disruption of cell-to-cell connection and enhancement of force development (2006) J. Pharmacol. Exp. Ther., 318, pp. 530-539; Dvorsky, R., Blumenstein, L., Vetter, I.R., Ahmadian, M.R., Structural insights into the interaction of ROCKI with the switch regions of RhoA (2004) J. Biol. Chem., 279, pp. 7098-7104; Levayer, R., Lecuit, T., Biomechanical regulation of contractility: Spatial control and dynamics (2012) Trends Cell Biol., 22, pp. 61-81; Tojkander, S., Gateva, G., Lappalainen, P., Actin stress fibers - Assembly, dynamics, and biological roles (2012) J. Cell Sci., 125, pp. 1855-1864; Carvalho, K., Lemiere, J., Faqir, F., Manzi, J., Blanchoin, L., Plastino, J., Actin polymerization or myosin contraction: Two ways to build up cortical tension for symmetry breaking (2013) Philos. Trans. R. Soc. B, 368; McGough, A., Chiu, W., Way, M., Determination of the gelsolin binding site on F-actin: Implications for severing and capping (1998) Biophys. J., 74, pp. 764-772; Prochniewicz, E., Zhang, Q., Janmey, P.A., Thomas, D.D., Cooperativity in F-actin: Binding of gelsolin at the barbed end affects structure and dynamics of the whole filament (1996) J. Mol. Biol., 260, pp. 756-766; Brown, M.R., Knull, H.R., Effects of nonenzymatic glycation of subfragment-1 of myosin on interactions with actin (1992) Biochem. Cell Biol., 70, pp. 617-622; McLean, W.G., The role of axonal cytoskeleton in diabetic neuropathy (1997) Neurochem. Res., 22, pp. 951-956; Suzuki, K., Nakagawa, K., Miyazawa, T., Augmentation of blood lipid glycation and lipid oxidation in diabetic patients (2014) Clin. Chem. Lab. Med., 52, pp. 47-52; Weykamp, C., John, W.G., Mosca, A., A review of the challenge in measuring hemoglobin A1c (2009) J. Diabetes Sci. Technol., 3, pp. 439-445; Gonzalez-Dosal, R., Sørensen, M.D., Clark, B.F.C., Rattan, S.I.S., Kristensen, P., Phage-displayed antibodies for the detection of glycated proteasome in aging cells (2006) Ann. NY Acad. Sci., 1067, pp. 474-478; De La Maza, M.P., Garrido, F., Escalante, N., Leiva, L., Fluorescent advanced glycation end-products (ages) detected by spectro-photofluorimetry, as a screening tool to detect diabetic microvascular complications (2012) J. Diabetes Mellitus, 2, pp. 221-226; Wang, X.-Q., Duan, X.-M., Liu, L.-H., Fang, Y.-Q., Tan, Y., Carboxyfluorescein diacetate succinimidyl ester fluorescent dye for cell labeling (2005) Acta Biochim. Biophys. Sin., 37, pp. 379-385; Banks, H.T., Sutton, K.L., Thompson, W.C., Bocharov, G., Roose, D., Schenkel, T., Estimation of cell proliferation dynamics using CFSE data (2011) Bull. Math. Biol., 73, pp. 116-150; Lyons, A.B., Blake, S.J., Doherty, K.V., Flow cytometric analysis of cell division by dilution of CFSE and related dyes (2013) Curr. Protoc. Cytometry, , unit 9.11; Lyons, A.B., Doherty, K.V., Flow cytometric analysis of cell division by dye dilution (2004) Curr. Protoc. Cytometry, , unit 9.11; Parish, C.R., Glidden, M.H., Quah, B.J., Warren, H.S., Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation (2002) Curr. Protoc. Immunol., , unit 4.9; Auger-Messier, M., Clement, M., Lanctot, P.M., Leclerc, P.C., Leduc, R., Escher, E., The constitutively active N111G-AT1 receptor for angiotensin II maintains a high affinity conformation despite being uncoupled from its cognate G protein Gq/11α (2003) Endocrinology, 144, pp. 5277-5284; Sen, S., Bose, T., Roy, A., Chakraborti, A.S., Effect of non-enzymatic glycation on esterase activities of hemoglobin and myoglobin (2007) Mol. Cell. Biochem., 301, pp. 251-257; Kato, Y., Matsuda, T., Nakamura, R., Improvement of physicochemical and enzymatic properties of bovine trypsin by nonenzymatic glycation (1993) Biosci. Biotechnol. Biochem., 57, pp. 1-5; Bagi, Z., Feher, A., Cassuto, J., Akula, K., Labinskyy, N., Kaley, G., Increased availability of angiotensin AT1 receptors leads to sustained arterial constriction to angiotensin II in diabetes - Role for Rho-kinase activation (2011) Br. J. Pharmacol., 163, pp. 1059-1068; Didion, S.P., Lynch, C.M., Faraci, F.M., Cerebral vascular dysfunction in TallyHo mice: A new model of type II diabetes (2007) Am. J. Physiol. Heart Circ. Physiol., 292, pp. H1579-H1583; Beck, M., Schmidt, A., Malmstroem, J., Claassen, M., Ori, A., Szymborska, A., The quantitative proteome of a human cell line (2011) Mol. Syst. Biol., 7, p. 549; Stossel, T.P., Cell surface actin remodeling (2006) J. Cell Sci., 119, pp. 3261-3264; Dumitriu, I.E., Mohr, W., Kolowos, W., Kern, P., Kalden, J.R., Herrmann, M., 5,6-Carboxyfluorescein diacetate succinimidyl ester-labeled apoptotic and necrotic as well as detergent-treated cells can be traced in composite cell samples (2001) Anal. Biochem., 299, pp. 247-252; Graziano, M., St-Pierre, Y., Beauchemin, C., Desrosiers, M., Potworowski, E.F., The fate of thymocytes labeled in vivo with CFSE (1998) Exp. Cell Res., 240, pp. 75-85; Labenski, M.T., Fisher, A.A., Lo, H.-H., Monks, T.J., Lau, S.S., Protein electrophile-binding motifs: Lysine-rich proteins are preferential targets of quinones (2009) Drug Metab. Dispos., 37, pp. 1211-1218; Bouma, B., Kroon-Batenburg, L.M.J., Wu, Y.-P., Brünjes, B., Posthuma, G., Kranenburg, O., Glycation induces formation of amyloid cross-beta structure in albumin (2003) J. Biol. Chem., 278, pp. 41810-41819; Thornalley, P.J., Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - Role in ageing and disease (2008) Drug Metabol. Drug Interact., 23, pp. 125-150; McRobert, E.A., Gallicchio, M., Jerums, G., Cooper, M.E., Bach, L.A., The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications (2003) J. Biol. Chem., 278, pp. 25783-25789; Akhtar, S., Yousif, M.H.M., Dhaunsi, G.S., Sarkhouh, F., Chandrasekhar, B., Attur, S., Activation of ErbB2 and downstream signalling via Rho kinases and ERK1/2 contributes to diabetes-induced vascular dysfunction (2013) PLoS One, 8, p. e67813; Lee, H.-H., Tien, S.-C., Jou, T.-S., Chang, Y.-C., Jhong, J.-G., Chang, Z.-F., Src-dependent phosphorylation of ROCK participates in regulation of focal adhesion dynamics (2010) J. Cell Sci., 123, pp. 3368-3377; Boucher, J., Simard É., Froehlich, U., Grandbois, M., Amplification of AngII-dependent cell contraction by glyoxal: Implication of cell mechanical properties and actomyosin activity (2014) Integr. Biol. (Camb.), 4, pp. 411-421; Zhou, H., Li, Y., Long-term diabetic complications may be ameliorated by targeting Rho kinase (2011) Diabetes Metab. Res. Rev., 27, pp. 318-330; Pekiner, C., Cullum, N.A., Hughes, J.N., Hargreaves, A.J., Mahon, J., Casson, I.F., Glycation of brain actin in experimental diabetes (2006) J. Neurochem., 61, pp. 436-442; Sampietro, T., Lenzi, S., Cecchetti, P., Giampietro, O., Cruschelli, L., Navalesi, R., Nonenzymatic glycation of human platelet membrane proteins in vitro and in vivo (1986) Clin. Chem., 32, pp. 1328-1331; Sulochana, K.N., Indra, C., Rajesh, M., Srinivasan, V., Ramakrishnan, S., Beneficial role of amino acids in mitigating cytoskeletal actin glycation and improving F-actin content in vitro (2001) Glycoconj. J., 18, pp. 277-282; Terman, J.R., Kashina, A., Post-translational modification and regulation of actin (2013) Curr. Opin. Cell Biol., 25, pp. 30-38; Kinosian, H.J., Newman, J., Lincoln, B., Selden, L.A., Gershman, L.C., Estes, J.E., Ca2+ regulation of gelsolin activity: Binding and severing of F-actin (1998) Biophys. J., 75, pp. 3101-3109; Pottiez, G., Haverland, N., Ciborowski, P., Mass spectrometric characterization of gelsolin isoforms (2010) Rapid Commun. Mass Spectrom., 24, pp. 2620-2624",Article,Scopus,2-s2.0-84926512119
"Yang T., Peleli M., Zollbrecht C., Giulietti A., Terrando N., Lundberg J.O., Weitzberg E., Carlstrom M.","Inorganic nitrite attenuates NADPH oxidase-derived superoxide generation in activated macrophages via a nitric oxide-dependent mechanism",2015,"Free Radical Biology and Medicine","83",,,"159","166",,,10.1016/j.freeradbiomed.2015.02.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926679440&partnerID=40&md5=bcae49fce80ac4721e7dc28791eb0bfc","Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden; Department of Clinical Science, Faculty of Medicine, Marche Polytechnic UniversityAncona, Italy","Yang, T., Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden; Peleli, M., Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden; Zollbrecht, C., Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden; Giulietti, A., Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden, Department of Clinical Science, Faculty of Medicine, Marche Polytechnic UniversityAncona, Italy; Terrando, N., Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden; Lundberg, J.O., Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden; Weitzberg, E., Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden; Carlström, M., Department of Physiology and Pharmacology, Karolinska InstitutetStockholm, Sweden","Oxidative stress contributes to the pathogenesis of many disorders, including diabetes and cardiovascular disease. Immune cells are major sources of superoxide (O<inf>2</inf>·-) as part of the innate host defense system, but exaggerated and sustained O<inf>2</inf>·- generation may lead to progressive inflammation and organ injuries. Previous studies have proven organ-protective effects of inorganic nitrite, a precursor of nitric oxide (NO), in conditions manifested by oxidative stress and inflammation. However, the mechanisms are still not clear. This study aimed at investigating the potential role of nitrite in modulating NADPH oxidase (NOX) activity in immune cells. Mice peritoneal macrophages or human monocytes were activated by lipopolysaccharide (LPS), with or without coincubation with nitrite. O<inf>2</inf>·- and peroxynitrite (ONOO-) formation were detected by lucigenin-based chemiluminescence and fluorescence techniques, respectively. The intracellular NO production was measured by DAF-FM DA fluorescence. NOX isoforms and inducible NO synthase (iNOS) expression were detected by qPCR. LPS increased both O<inf>2</inf>·- and ONOO- production in macrophages, which was significantly reduced by nitrite (10 μmol/L). Mechanistically, the effects of nitrite are (1) linked to increased NO generation, (2) similar to that observed with the NO donor DETA-NONOate, and (3) can be abolished by the NO scavenger carboxy-PTIO or by the xanthine oxidase (XO) inhibitor febuxostat. Nox2 expression was increased in activated macrophages, but was not influenced by nitrite. However, nitrite attenuated LPS-induced upregulation of iNOS expression. Similar to that observed in mice macrophages, nitrite also reduced O<inf>2</inf>·- generation in LPS-activated human monocytes. In conclusion, XO-mediated reduction of nitrite attenuates NOX activity in activated macrophages, which may modulate the inflammatory response. © 2015 Elsevier Inc. All rights reserved.","iNOS; Lipopolysaccharide; Macrophage; NADPH oxidase; Nitrate; Nitric; Nitrite; Oxidative stress; oxide; oxygen species; Reactive","Circu, M.L., Aw, T.Y., Reactive oxygen species, cellular redox systems, and apoptosis (2010) Free Radic. Biol. Med., 48, pp. 749-762; Varga, Z.V., Giricz, Z., Liaudet, L., Hasko, G., Ferdinandy, P., Pacher, P., Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy (2014) Biochim. Biophys. Acta; Cat, N.D., Montezano, A., Burger, A.C., Touyz, D., Angiotensin, I.I.R.M., NADPH oxidase, and redox signaling in the vasculature (2013) Antioxid. Redox Signal., 19, pp. 1110-1120; Paravicini, T.M., Touyz, R.M., NADPH oxidases, reactive oxygen species, and hypertension: Clinical implications and therapeutic possibilities (2008) Diabetes Care, 31, pp. S170-S180; Vaziri, N.D., Rodriguez-Iturbe, B., Mechanisms of disease: Oxidative stress and inflammation in the pathogenesis of hypertension (2006) Nat. Clin. Pract. Nephrol., 2, pp. 582-593; Araujo, M., Wilcox, C.S., Oxidative stress in hypertension: Role of the kidney (2014) Antioxid. Redox Signal., 20, pp. 74-101; Ghosh, S.M., Kapil, V., Fuentes-Calvo, I., Bubb, K.J., Pearl, V., Milsom, A.B., Khambata, R., Ahluwalia, A., Enhanced vasodilator activity of nitrite in hypertension: Critical role for erythrocytic xanthine oxidoreductase and translational potential (2013) Hypertension, 61, pp. 1091-1102; Lundberg, J.O., Gladwin, M.T., Ahluwalia, A., Benjamin, N., Bryan, N.S., Butler, A., Cabrales, P., Weitzberg, E., Nitrate and nitrite in biology, nutrition and therapeutics (2009) Nat. Chem. Biol., 5, pp. 865-869; Castiglione, N., Rinaldo, S., Giardina, G., Stelitano, V., Cutruzzola, F., Nitrite and nitrite reductases: From molecular mechanisms to significance in human health and disease (2012) Antioxid. Redox Signal., 17, pp. 684-716; Lundberg, J.O., Carlstrom, M., Larsen, F.J., Weitzberg, E., Roles of dietary inorganic nitrate in cardiovascular health and disease (2011) Cardiovasc. Res., 89, pp. 525-532; Huang, L., Borniquel, S., Lundberg, J.O., Enhanced xanthine oxidoreductase expression and tissue nitrate reduction in germ free mice (2010) Nitric Oxide, 22, pp. 191-195; Gao, X., Yang, T., Liu, M., Peleli, M., Zollbrecht, C., Weitzberg, E., Lundberg, J.O., Carlstrom, M., NADPH oxidase in the renal microvasculature is a primary target for blood pressure-lowering effects by inorganic nitrate and nitrite (2015) Hypertension, 65, pp. 161-170; Lundberg, J.O., Weitzberg, E., Gladwin, M.T., The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics (2008) Nat. Rev. Drug Discov., 7, pp. 156-167; Liese, A.D., Nichols, M., Sun, X., Dagostino, R.B., Jr., Haffner, S.M., Adherence to the DASH diet is inversely associated with incidence of type 2 diabetes: The insulin resistance atherosclerosis study (2009) Diabetes Care, 32, pp. 1434-1436; Sacks, F.M., Svetkey, L.P., Vollmer, W.M., Appel, L.J., Bray, G.A., Harsha, D., Obarzanek, E., Lin, P.H., Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group (2001) N. Engl. J. Med., 344, pp. 3-10; Carlstrom, M., Persson, A.E., Larsson, E., Hezel, M., Scheffer, P.G., Teerlink, T., Weitzberg, E., Lundberg, J.O., Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension (2011) Cardiovasc. Res., 89, pp. 574-585; Carlstrom, M., Larsen, F.J., Nystrom, T., Hezel, M., Borniquel, S., Weitzberg, E., Lundberg, J.O., Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice (2010) Proc. Natl. Acad. Sci. USA, 107, pp. 17716-17720; Carlstrom, M., Brown, R.D., Yang, T., Hezel, M., Larsson, E., Scheffer, P.G., Teerlink, T., Persson, A.E., L-Arginine or tempol supplementation improves renal and cardiovascular function in rats with reduced renal mass and chronic high salt intake (2013) Acta Physiol. (Oxf.), 207, pp. 732-741; Yun, B.W., Feechan, A., Yin, M., Saidi, N.B., Le Bihan, T., Yu, M., Moore, J.W., Loake, G.J., S-Nitrosylation of NADPH oxidase regulates cell death in plant immunity (2011) Nature, 478, pp. 264-268; Cauwels, A., Buys, E.S., Thoonen, R., Geary, L., Delanghe, J., Shiva, S., Brouckaert, P., Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase-dependent manner (2009) J. Exp. Med., 206, pp. 2915-2924; Hamburger, T., Broecker-Preuss, M., Hartmann, M., Schade, F.U., De Groot, H., Petrat, F., Effects of glycine, pyruvate, resveratrol, and nitrite on tissue injury and cytokine response in endotoxemic rats (2013) J. Surg. Res., 183, pp. e7-e21; Verreck, F.A., De Boer, T., Langenberg, D.M., Hoeve, M.A., Kramer, M., Vaisberg, E., Kastelein, R., Ottenhoff, T.H., Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria (2004) Proc. Natl. Acad. Sci. USA, 101, pp. 4560-4565; Terrando, N., Gomez-Galan, M., Yang, T., Carlstrom, M., Gustavsson, D., Harding, R.E., Lindskog, M., Eriksson, L.I., Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline (2013) FASEB J., 27, pp. 3564-3571; Setsukinai, K., Urano, Y., Kakinuma, K., Majima, H.J., Nagano, T., Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species (2003) J. Biol. Chem., 278, pp. 3170-3175; Bedard, K., Krause, K.H., The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology (2007) Physiol. Rev., 87, pp. 245-313; Ruiz, S., Pergola, P.E., Zager, R.A., Vaziri, N.D., Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease (2013) Kidney Int., 83, pp. 1029-1041; Weismann, D., Hartvigsen, K., Lauer, N., Bennett, K.L., Scholl, H.P., Charbel Issa, P., Cano, M., Binder, C.J., Complement factor H binds malondialdehyde epitopes and protects from oxidative stress (2011) Nature, 478, pp. 76-81; Cachofeiro, V., Goicochea, M., De Vinuesa, S.G., Oubina, P., Lahera, V., Luno, J., Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease (2008) Kidney Int. Suppl., pp. S4-S9; Jadert, C., Petersson, J., Massena, S., Ahl, D., Grapensparr, L., Holm, L., Lundberg, J.O., Phillipson, M., Decreased leukocyte recruitment by inorganic nitrate and nitrite in microvascular inflammation and NSAID-induced intestinal injury (2012) Free Radic. Biol. Med., 52, pp. 683-692; Petersson, J., Carlstrom, M., Schreiber, O., Phillipson, M., Christoffersson, G., Jagare, A., Roos, S., Holm, L., Gastroprotective and blood pressure lowering effects of dietary nitrate are abolished by an antiseptic mouthwash (2009) Free Radic. Biol. Med., 46, pp. 1068-1075; Jung, K.H., Chu, K., Ko, S.Y., Lee, S.T., Sinn, D.I., Park, D.K., Kim, J.M., Roh, J.K., Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury (2006) Stroke, 37, pp. 2744-2750; Montenegro, M.F., Amaral, J.H., Pinheiro, L.C., Sakamoto, E.K., Ferreira, G.C., Reis, R.I., Marcal, D.M., Tanus-Santos, J.E., Sodium nitrite downregulates vascular NADPH oxidase and exerts antihypertensive effects in hypertension (2011) Free Radic. Biol. Med., 51, pp. 144-152; Cathcart, M.K., Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: Contributions to atherosclerosis (2004) Arterioscler. Thromb. Vasc. Biol., 24, pp. 23-28; Droge, W., Free radicals in the physiological control of cell function (2002) Physiol. Rev., 82, pp. 47-95; Goldstein, S., Russo, A., Samuni, A., Reactions of PTIO and carboxy-PTIO with NO, NO2, and O2 (2003) J. Biol. Chem., 278, pp. 50949-50955; Clancy, R.M., Leszczynska-Piziak, J., Abramson, S.B., Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase (1992) J. Clin. Invest., 90, pp. 1116-1121; Qian, J., Chen, F., Kovalenkov, Y., Pandey, D., Moseley, M.A., Foster, M.W., Black, S.M., Fulton, D.J., Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S-nitrosylation (2012) Free Radic. Biol. Med., 52, pp. 1806-1819; Selemidis, S., Dusting, G.J., Peshavariya, H., Kemp-Harper, B.K., Drummond, G.R., Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells (2007) Cardiovasc. Res., 75, pp. 349-358; Kong, X., Thimmulappa, R., Kombairaju, P., Biswal, S., NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice (2010) J. Immunol., 185, pp. 569-577; Lassegue, B., San Martin, A., Griendling, K.K., Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system (2012) Circ. Res., 110, pp. 1364-1390; Datla, S.R., Griendling, K.K., Reactive oxygen species, NADPH oxidases, and hypertension (2010) Hypertension, 56, pp. 325-330; Bosca, L., Zeini, M., Traves, P.G., Hortelano, S., Nitric oxide and cell viability in inflammatory cells: A role for NO in macrophage function and fate (2005) Toxicology, 208, pp. 249-258; Macmicking, J., Xie, Q.W., Nathan, C., Nitric oxide and macrophage function (1997) Annu. Rev. Immunol., 15, pp. 323-350; Xia, Y., Zweier, J.L., Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages (1997) Proc. Natl. Acad. Sci. USA, 94, pp. 6954-6958; Doumas, M., Faselis, C., Papademetriou, V., Renal sympathetic denervation and systemic hypertension (2010) Am. J. Cardiol., 105, pp. 570-576; Barajas, L., Wang, P., Localization of tritiated norepinephrine in the renal arteriolar nerves (1979) Anat. Rec., 195, pp. 525-534",Article,Scopus,2-s2.0-84926679440
"Moreno Velasquez I., Golabkesh Z., Kallberg H., Leander K., de Faire U., Gigante B.","Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction",2015,"Atherosclerosis","240","2",,"477","481",,,10.1016/j.atherosclerosis.2015.04.014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928667962&partnerID=40&md5=10c3d424a8d50428f255258349bdf5c3","Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden; Dept of Cardiology, Karolinska University Hospital, Sweden; Division of Cardiovascular Medicine, Dept of Clinical Sciences, Danderyd University Hospital Stockholm, Sweden","Moreno Velásquez, I., Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden; Golabkesh, Z., Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden; Källberg, H., Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden; Leander, K., Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden; de Faire, U., Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden, Dept of Cardiology, Karolinska University Hospital, Sweden; Gigante, B., Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden, Division of Cardiovascular Medicine, Dept of Clinical Sciences, Danderyd University Hospital Stockholm, Sweden","Objective: To investigate the association between circulating levels of the soluble interleukin 6 receptor (sIL6R) and the soluble gp130 (sgp130) with myocardial infarction (MI) and to explore the potential interaction between sIL6R and sgp130 in this association. Methods: Study population is the Stockholm Heart Epidemiology Program (SHEEP), a population-based case-control study. SIL6R (ng/mL) and sgp130 (ng/mL) levels were measured in serum samples from 682 and 664 MI cases and 1103 and 1062 controls, respectively. Odds ratios (with 95% CIs) for MI were calculated using unconditional logistic regression. We adjusted for age, sex, hospital catchment area (crude) and for hypertension, diabetes, hypercholesterolemia, body mass index and smoking (adjusted model). Synergy index (S) and attributable proportion (AP) were estimated as measures of biological interaction. Results: Elevated concentrations of sIL6R (>75th percentile value) were associated with an increased occurrence of MI (compared to ≤75th percentile), with an adjusted OR of 1.4 (95% CI, 1.1-1.8). Very high (>90th percentile value) levels of sgp130 were associated with a reduced occurrence of MI [OR 0.7 (95% CI, 0.5-0.9)] (adjusted). There was an indication of a possible interaction between high sIL6R and low sgp130 (adjusted S score 1.7, 95% CI=0.5-6.1; AP 0.19, 95% CI=-0.2-0.5), suggesting that low sgp130 levels may synergize with high sIL6R levels to increase risk of MI. Conclusions: sIL6R and sgp130 had opposing associations with MI. Indeed, circulating sgp130 levels may modify the association of elevated sIL6R levels with MI. © 2015 Elsevier Ireland Ltd.","Biomarkers; Interleukin 6 receptor; Myocardial infarction; SIL6R; Soluble gp130","Jones, S.A., Horiuchi, S., Topley, N., Yamamoto, N., Fuller, G.M., The soluble interleukin 6 receptor: mechanisms of production and implications in disease (2001) FASEB J., 15 (1), pp. 43-58; Hartman, J., Frishman, W.H., Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy (2014) Cardiol. Rev., 22 (3), pp. 147-151; Boekholdt, S.M., Stroes, E.S., The interleukin-6 pathway and atherosclerosis (2012) Lancet, 379 (9822), pp. 1176-1178; Rose-John, S., IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6 (2012) Int. J. Biol. Sci., 8 (9), pp. 1237-1247; Schuett, H., Oestreich, R., Waetzig, G.H., Annema, W., Luchtefeld, M., Hillmer, A., Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice (2012) Arterioscler. Thromb. Vasc. Biol., 32 (2), pp. 281-290; Bennet, A.M., Prince, J.A., Fei, G.Z., Lyrenas, L., Huang, Y., Wiman, B., Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction (2003) Atherosclerosis, 171 (2), pp. 359-367; Ridker, P.M., Rifai, N., Stampfer, M.J., Hennekens, C.H., Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men (2000) Circulation, 101 (15), pp. 1767-1772; Kanda, T., Inoue, M., Kotajima, N., Fujimaki, S., Hoshino, Y., Kurabayashi, M., Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent myocardial infarction (2000) Cardiology, 93 (3), pp. 191-196; Anderson, D.R., Poterucha, J.T., Mikuls, T.R., Duryee, M.J., Garvin, R.P., Klassen, L.W., IL-6 and its receptors in coronary artery disease and acute myocardial infarction (2013) Cytokine, 62 (3), pp. 395-400; Askevold, E.T., Nymo, S., Ueland, T., Gravning, J., Wergeland, R., Kjekshus, J., Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) (2013) Circ. Heart Fail., 6 (1), pp. 91-98; Gigante, B., Vikstrom, M., Meuzelaar, L.S., Chernogubova, E., Silveira, A., Hooft, F.V., Variants in the coagulation factor 2 receptor (F2R) gene influence the risk of myocardial infarction in men through an interaction with interleukin 6 serum levels (2009) Thromb. Haemost., 101 (5), pp. 943-953; Reuterwall, C., Hallqvist, J., Ahlbom, A., De Faire, U., Diderichsen, F., Hogstedt, C., Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group (1999) J.Intern. Med., 246 (2), pp. 161-174; Leander, K., Gigante, B., Silveira, A., Vikstrom, M., Hamsten, A., Hogberg, J.N.A.M.P.T., (visfatin) and AKT1 genetic variants associate with myocardial infarction (2012) Clin. Chim. Acta, 413 (7-8), pp. 727-732; Bennet, A.M., Brismar, K., Hallqvist, J., Reuterwall, C., De Faire, U., The risk of myocardial infarction is enhanced by a synergistic interaction between serum insulin and smoking (2002) Eur. J. Endocrinol., 147 (5), pp. 641-647; Rothman, K., (2012) Epidemiology: An Introduction; Knol, M.J., VanderWeele, T.J., Groenwold, R.H., Klungel, O.H., Rovers, M.M., Grobbee, D.E., Estimating measures of interaction on an additive scale for preventive exposures (2011) Eur. J. Epidemiol., 26 (6), pp. 433-438; Andersson, T., Alfredsson, L., Kallberg, H., Zdravkovic, S., Ahlbom, A., Calculating measures of biological interaction (2005) Eur. J. Epidemiol., 20 (7), pp. 575-579; Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment (1997) Immunity, 6 (3), pp. 315-325; Taleb, S., Tedgui, A., Mallat, Z., Regulatory T-cell immunity and its relevance to atherosclerosis (2008) J.Intern. Med., 263 (5), pp. 489-499; Protogerou, A.D., Zampeli, E., Fragiadaki, K., Stamatelopoulos, K., Papamichael, C., Sfikakis, P.P., Apilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis (2011) Atherosclerosis, 219 (2), pp. 734-736; Ritschel, V.N., Seljeflot, I., Arnesen, H., Halvorsen, S., Weiss, T., Eritsland, J., IL-6 signalling in patients with acute ST-elevation myocardial infarction (2014) Res. Immunol., 4, pp. 8-13; Fiskesund, R., Su, J., Bulatovic, I., Vikstrom, M., de Faire, U., Frostegard, J., IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL (2012) Res. Immunol., 2, pp. 13-18; Gigante, B., Leander, K., Vikstrom, M., Baldassarre, D., Veglia, F., Strawbridge, R.J., Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men (2014) Atherosclerosis, 236 (2), pp. 394-399; Rose-John, S., Scheller, J., Elson, G., Jones, S.A., Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer (2006) J.Leukoc. Biol., 80 (2), pp. 227-236; Yamamoto, K., Rose-John, S., Therapeutic blockade of interleukin-6 in chronic inflammatory disease (2012) Clin. Pharmacol. Ther., 91 (4), pp. 574-576; Scheller, J., Rose-John, S., The interleukin 6 pathway and atherosclerosis (2012) Lancet, 380 (9839), p. 338; Schuett, H., Luchtefeld, M., Grothusen, C., Grote, K., Schieffer, B., How much is too much? Interleukin-6 and its signalling in atherosclerosis (2009) Thromb. Haemost., 102 (2), pp. 215-222; Doran, A.C., Meller, N., McNamara, C.A., Role of smooth muscle cells in the initiation and early progression of atherosclerosis (2008) Arterioscler. Thromb. Vasc. Biol., 28 (5), pp. 812-819; Scheller, J., Garbers, C., Rose-John, S., Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities (2013) Semin. Immunol.; Kallberg, H., Ding, B., Padyukov, L., Bengtsson, C., Ronnelid, J., Klareskog, L., Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke (2011) Ann. Rheum. Dis., 70 (3), pp. 508-511; Leander, K., Wiman, B., Hallqvist, J., Falk, G., De Faire, U., The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women (2002) J.Intern. Med., 252 (4), pp. 332-341; Gigante, B., Leander, K., Vikstrom, M., Ye, S., de Faire, U., Chromosome 1p13 genetic variants antagonize the risk of myocardial infarction associated with high ApoB serum levels (2012) BMC Cardiovasc. Disord., 12, p. 90; Gigante, B., Bennet, A.M., Leander, K., Vikstrom, M., de Faire, U., The interaction between coagulation factor 2 receptor and interleukin 6 haplotypes increases the risk of myocardial infarction in men (2010) PLoS One, 5 (6), p. e11300; Mahdi, H., Fisher, B.A., Kallberg, H., Plant, D., Malmstrom, V., Ronnelid, J., Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis (2009) Nat. Genet., 41 (12), pp. 1319-1324; Knol, M.J., VanderWeele, T.J., Recommendations for presenting analyses of effect modification and interaction (2012) Int. J. Epidemiol., 41 (2), pp. 514-520; Zuliani, G., Galvani, M., Maggio, M., Volpato, S., Bandinelli, S., Corsi, A.M., Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance (2010) Atherosclerosis, 213 (1), pp. 319-324; Hamsten, A., Wiman, B., de Faire, U., Blomback, M., Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction (1985) N.Engl. J. Med., 313 (25), pp. 1557-1563; Hamsten, A., Walldius, G., Dahlen, G., Johansson, B., De Faire, U., Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction (1986) Atherosclerosis, 59 (2), pp. 223-235; Ueda, K., Takahashi, M., Ozawa, K., Kinoshita, M., Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction (1999) Am. Heart J., 138 (5), pp. 908-915; Morris, T., Stables, M., Hobbs, A., de Souza, P., Colville-Nash, P., Warner, T., Effects of low-dose aspirin on acute inflammatory responses in humans (2009) J.Immunol., 183 (3), pp. 2089-2096",Article,Scopus,2-s2.0-84928667962
"Hagen I., Schulte D.M., Muller N., Martinsen J., Turk K., Hedderich J., Schreiber S., Laudes M.","Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects",2015,"Cytokine","73","2",,"265","269",,,10.1016/j.cyto.2015.02.022,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925302301&partnerID=40&md5=e7b5ee678842c069f149f8267e5b9e12","Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3Kiel, Germany; Institute of Medical Informatics and Statistics, University of Kiel, Brunswiker Straße 10Kiel, Germany","Hagen, I., Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3Kiel, Germany; Schulte, D.M., Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3Kiel, Germany; Müller, N., Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3Kiel, Germany; Martinsen, J., Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3Kiel, Germany; Türk, K., Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3Kiel, Germany; Hedderich, J., Institute of Medical Informatics and Statistics, University of Kiel, Brunswiker Straße 10Kiel, Germany; Schreiber, S., Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3Kiel, Germany; Laudes, M., Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3Kiel, Germany","Introduction: Obesity is associated with low-grade systemic inflammation which is thought to trigger the development of comorbidities such as type 2 diabetes. The soluble receptor for advanced glycation end products (sRAGE) belongs to the innate immune system and has been linked to obesity, recently. The aim of the present study was to examine whether serum sRAGE concentrations are related to the grade of weight loss and improvement of insulin resistance due to a very low calorie diet (VLCD). Methods: 22 severe obese subjects (Median Body Mass Index (BMI): 44.5kg/m2) were included in a dietary intervention study of 6month, consisting of a very low calorie formula diet phase (VLCD: 800kcal/d) for 12weeks and a following 12week weight maintenance phase. Fasting glucose, fasting insulin, adiponectin, leptin and sRAGE were determined from sera. Insulin sensitivity was estimated by Homeostasis Model Assessment (HOMA) index and leptin-to-adiponectin-ratio (LAR). Results: Mean body weight reduction by VLCD accounted to 21.7. kg with a significant improvement of insulin resistance. At baseline, sRAGE serum levels were significantly inversely related to BMI (. rS=. -0.642, p=. 0.001) and HOMA (. rS=. -0.419, p=. 0.041). Of interest, sRAGE serum levels at baseline were significantly lower in study subjects with greater reduction of BMI (. p=. 0.017). In addition, a significantly greater HOMA reduction was observed in subjects with lower sRAGE serum levels at baseline (. p=. 0.006). Finally, correlation analysis revealed, that changes of sRAGE serum levels were significantly correlated to changes of BMI (. rS=. -0.650, p=. 0.022) during intervention. Conclusion: Anti-inflammatory sRAGE might be a potential future biomarker to predict weight loss and improvement of insulin resistance by a VLCD whereby lower baseline sRAGE serum levels indicate a better outcome of the dietary intervention. © 2015 Elsevier Ltd.","Biomarker; Dietary intervention; Soluble receptor for advanced glycation end products; Very low calorie diet","Eckel, R.H., Grundy, S.M., Zimmet, P.Z., The metabolic syndrome (2005) Lancet, 365, pp. 1415-1428; Tilg, H., Moschen, A.R., Adipocytokines: mediators linking adipose tissue, inflammation and immunity (2006) Nat Rev Immunol, 6, pp. 772-783; Chuah, Y.K., Basir, R., Talib, H., Tie, T.H., Nordin, N., Receptor for advanced glycation end products and its involvement in inflammatory diseases (2013) Int J Inflammat, 2013, p. 403460; Schmidt, A.M., Yan, S.D., Brett, J., Mora, R., Nowygrod, R., Stern, D., Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products (1993) J Clin Investig, 91, pp. 2155-2168; Brett, J., Schmidt, A.M., Yan, S.D., Zou, Y.S., Weidman, E., Pinsky, D., Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues (1993) The Am J Path, 143, pp. 1699-1712; Chen, Y., Akirav, E.M., Chen, W., Henegariu, O., Moser, B., Desai, D., RAGE ligation affects T cell activation and controls T cell differentiation (2008) J Immunol, 181, pp. 4272-4278; Li, J., Schmidt, A.M., Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products (1997) The J Biol Chem, 272, pp. 16498-16506; Mahajan, N., Dhawan, V., Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases (2013) Int J Cardiol, 168, pp. 1788-1794; Raucci, A., Cugusi, S., Antonelli, A., Barabino, S.M., Monti, L., Bierhaus, A., A soluble form of the receptor for advanced glycation end products (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) (2008) FASEB J: Off Pub Fed Am Soc Exp Biol, 22, pp. 3716-3727; Hudson, B.I., Carter, A.M., Harja, E., Kalea, A.Z., Arriero, M., Yang, H., Identification, classification, and expression of RAGE gene splice variants (2008) FASEB J: Off Pub Fed Am Soc Exp Biol, 22, pp. 1572-1580; Davis, K.E., Prasad, C., Vijayagopal, P., Juma, S., Imrhan, V., Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults (2014) Nutr Res, 34, pp. 478-485; Norata, G.D., Garlaschelli, K., Grigore, L., Tibolla, G., Raselli, S., Redaelli, L., Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population (2009) Nutr, Metab, Cardiovasc Dis: NMCD, 19, pp. 129-134; Yamagishi, S., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects (2006) Metab, Clin Exp, 55, pp. 1227-1231; Colhoun, H.M., Betteridge, D.J., Durrington, P., Hitman, G., Neil, A., Livingstone, S., Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial (2011) Diabetes, 60, pp. 2379-2385; Basta, G., Sironi, A.M., Lazzerini, G., Del Turco, S., Buzzigoli, E., Casolaro, A., Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein (2006) J Clin Endo Metab, 91, pp. 4628-4634; Falcone, C., Bozzini, S., D'Angelo, A., Matrone, B., Colonna, A., Benzi, A., Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation (2013) Dis Markers, 35, pp. 135-140; Geroldi, D., Falcone, C., Emanuele, E., D'Angelo, A., Calcagnino, M., Buzzi, M.P., Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension (2005) J Hypertens, 23, pp. 1725-1729; Mahajan, N., Malik, N., Bahl, A., Dhawan, V., Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease (2009) Atherosclerosis, 207, pp. 597-602; Yang, S.J., Kim, S., Hwang, S.Y., Kim, T.N., Choi, H.Y., Yoo, H.J., Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography (2012) Atherosclerosis, 220, pp. 402-406; Fujisawa, K., Katakami, N., Kaneto, H., Naka, T., Takahara, M., Sakamoto, F., Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes (2013) Atherosclerosis, 227, pp. 425-428; Nakamura, K., Yamagishi, S., Adachi, H., Matsui, T., Kurita-Nakamura, Y., Takeuchi, M., Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes (2008) Microvasc Res, 76, pp. 52-56; Choi, K.M., Han, K.A., Ahn, H.J., Hwang, S.Y., Hong, H.C., Choi, H.Y., Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial (2012) J Clin Endocrin Metab, 97, pp. 3751-3758; Brix, J.M., Hollerl, F., Kopp, H.P., Schernthaner, G.H., Schernthaner, G., The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity (2012) Int J obes, 36, pp. 1412-1417; Parikh, M., Chung, M., Sheth, S., McMacken, M., Zahra, T., Saunders, J.K., Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do not meet nih criteria for surgery and the role of soluble rage as a novel biomarker of success (2014) Ann Surg, 260, pp. 617-624; Lorenzi, R., Pattou, F., Beuscart, J.B., Grossin, N., Lambert, M., Fontaine, P., Anti-sRAGE autoimmunity in obesity: downturn after bariatric surgery is independent of previous diabetic status (2014) Diabetes Metab; Bischoff, S.C., Damms-Machado, A., Betz, C., Herpertz, S., Legenbauer, T., Low, T., Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life-a prospective study (2012) Int J Obes, 36, pp. 614-624; Finucane, F.M., Luan, J., Wareham, N.J., Sharp, S.J., O'Rahilly, S., Balkau, B., Correlation of the leptin: adiponectin ratio with measures of insulin resistance in non-diabetic individuals (2009) Diabetologia, 52, pp. 2345-2349; Catalan, V., Gomez-Ambrosi, J., Rodriguez, A., Ramirez, B., Rotellar, F., Valenti, V., Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss (2011) Mol Med, 17, pp. 1157-1167; Herder, C., Carstensen, M., Ouwens, D.M., Anti-inflammatory cytokines and risk of type 2 diabetes (2013) Diabetes Obes Metab, 15, pp. 39-50",Article,Scopus,2-s2.0-84925302301
"Hlila M.B., Mosbah H., Majouli K., Mssada K., Jannet H.B., Aouni M., Selmi B.","α-Glucosidase inhibition by Tunisian Scabiosa arenaria Forssk. extracts",2015,"International Journal of Biological Macromolecules","77",,,"383","389",,,10.1016/j.ijbiomac.2015.03.035,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928751762&partnerID=40&md5=1ed91daea7bd08fe8ab321e01bf5f129","Laboratory of Transmissible Diseases and Biological Active Substances, Faculty of Pharmacy, University of Monastir, Avenue AvicenneMonastir, Tunisia; Higher Institute of Biotechnology of Monastir, Avenue Taher Hadded, BP 74Monastir, Tunisia; Research Laboratory in Biochemistry, Faculty of Medicine, University of Monastir, Avenue Avicenne, Tunisia; Laboratory of Bioactive Substances, Biotechnology Center in the Technopole of Borj-Cédria (CBBS)Hammam-lif, Tunisia; Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Team: Medicinal Chemistry and Natural Products, Faculty of Sciences of Monastir, University of Monastir, Avenue de l' EnvironnementMonastir, Tunisia","Hlila, M.B., Laboratory of Transmissible Diseases and Biological Active Substances, Faculty of Pharmacy, University of Monastir, Avenue AvicenneMonastir, Tunisia; Mosbah, H., Higher Institute of Biotechnology of Monastir, Avenue Taher Hadded, BP 74Monastir, Tunisia; Majouli, K., Research Laboratory in Biochemistry, Faculty of Medicine, University of Monastir, Avenue Avicenne, Tunisia; Mssada, K., Laboratory of Bioactive Substances, Biotechnology Center in the Technopole of Borj-Cédria (CBBS)Hammam-lif, Tunisia; Jannet, H.B., Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Team: Medicinal Chemistry and Natural Products, Faculty of Sciences of Monastir, University of Monastir, Avenue de l' EnvironnementMonastir, Tunisia; Aouni, M., Laboratory of Transmissible Diseases and Biological Active Substances, Faculty of Pharmacy, University of Monastir, Avenue AvicenneMonastir, Tunisia; Selmi, B., Laboratory of Transmissible Diseases and Biological Active Substances, Faculty of Pharmacy, University of Monastir, Avenue AvicenneMonastir, Tunisia","Recent decades have witnessed a sharp increase in the incidence and prevalence of type 2 diabetes mellitus. One antidiabetic therapeutic approach is to reduce gastrointestinal glucose production and absorption through the inhibition of carbohydrate-digesting enzymes such as α-amylase and α-glucosidase. In this study, crude extracts and their corresponding fractions of flowers, fruits, (stems and leaves) and roots of the endemic North African plant Scabiosa arenaria Forssk. were screened for their ability of α-glucosidase inhibition. It was found that the fruits ethyl acetate (EtOAc), the fruits butanolic (n-BuOH) and the flowers ethyl acetate (EtOAc) fractions inhibited α-glucosidase in a non competitive manner with IC<inf>50</inf> values of 0.11±0.09, 0.28±0.04 and 0.221±0.01mg/ml, respectively. RP-HPLC analysis indicated that the major components of these active fractions are flavonoid aglycone, cinnamic acid and its derivatives. This result supports the conclusion that the three studied fractions could be a useful natural source for the development of a novel α-glucosidase inhibitory agent against diabetic complications. © 2015 Elsevier B.V.","Non-competitive inhibition; RP-HPLC; Scabiosa arenaria Forssk.; α-Glucosidase","Rea, G., Antonacci, A., Lambreva, M., Margonelli, A., Ambrosi, C., Giardi, M.T., The NUTRASNACKS Project: Basic research and biotechnological programs on nutraceutical (2010) Bio-Farms for Nutraceuticals: Functional Food and Safety Control by Biosensors, 698, pp. 1-16. , Springer, US, Chapter 1; Cameron, S.I., Smith, R.F., Kierstead, K.E., (2005) Pharm. Biol., 43, pp. 425-433; Evangelista, Z.M., Moreno, A.E., (2007) Biotecnologia, 11, pp. 37-50; Colvine, K., Kerr, A.J., McLachlan, A., Gow, P., Kumar, S., Ly, J., Wiltshire, C., Dalbeth, N., (2008) N. N. Z. Med. J., 121, pp. 73-81; Corrado, A., D'Onofrio, F., Santoro, N., Melillo, N., Cantatore, F.P., (2006) Minerva Med., 97, pp. 495-509; Gorelick, J., Kitron, A., Pen, S., Rosenzweig, T., Madar, Z., (2011) J. Ethnopharmacol., 137, pp. 1245-1249; Yu, Z.P., Yin, Y.G., Zhao, W.Z., Yu, Y.D., Liu, B.Q., Chen, F., (2013) Food Chem., 129, pp. 1376-1382; Amessis-Ouchemoukh, N., Madani, K., Falé, M.P., Serralheiro, L., Araújo, M.E., (2014) Ind. Crops Prod., 53, pp. 6-15; Yan, J., Zhang, G., Pan, J., Wang, Y., (2014) Int. J. Biol. Macromol., 64, pp. 213-223; Kim, S.D., (2013) Food Chem., 136, pp. 297-300; Heacock, P.M., Hertzler, S.R., Williams, J.A., Wolf, B.W., (2005) J. Am. Diet. Assoc., 105, pp. 65-71; Baron, A.D., (1998) Diabetes Res. Clin. Pract., 40, pp. 51-55; Lebovitz, H.E., (1997) Endocrinol. Metab. Clin. North Am., 26, pp. 539-551; Fujisawa, T., Ikegami, H., Inoue, K., Kawabata, Y., Ogihara, T., (2005) Metabolism, 54, pp. 387-390; Le floc'h, E., Boulos, L., Vela, E., (2010) Catalogue synonymique commenté de la Flore de Tunisie, pp. 195-196. , République Tunisienne, Ministère de L'environnement et du Développement Durable, banque nationale de gènes; Bonet, M.A., Parada, M., Selga, A., Vallès, J., (1999) J. Ethnopharmacol., 68, pp. 145-168; Bussmann, R.W., Malca-García, G., Glenn, A., Sharon, D., Chaitc, G., Díaz, D., Pourmand, K., Benito, M., (2010) Ethnopharmacology, 132, pp. 101-108; Bussman, R., Glen, A.J., (2010) Ethnobiol. Ethnomed., 6, p. 30; Bonet, A., Vallès, J., (2007) J. Ethnopharmacol., 110, pp. 130-147; Marhuenda-Requena, E., Saenz-Rodriguez, M.T., Garcia-Gimenez, M.D., (1987) Plantes-Medicinale-et-Phytotherapie, 21, pp. 47-55; Girre, L., (1980) Connaitre et Reconnaitre les plantes Médicinales, , Rennes, Ouest, France; Elhawary, S.S., Eltantawy, M.E., Sleem, A.A., Abdallah, H.M., Mohamed, N.M., (2011) World Appl. Sci. J., 15, pp. 311-317; Polat, E., Alankus-Caliskan, O., Karayildirim, T., Bedir, E., (2010) Biochem. Syst. Ecol., 38, pp. 253-255; Horn, M.M., Drewes, S.E., Brown, N.J., Munro, O.Q., Meyer, J.J.M., Mathekga, A.D.M., (2001) Phytochemistry, 57, p. 51; Papalexandrou, A., Magiatis, P., Perdetzoglou, D., Skaltsounis, A.L., Chinou, I.B., Harvala, C., (2003) Biochem. Syst. Ecol., 31, pp. 91-93; Baykal, T., Panayir, T., Tasdemir, D., Sticher, O., Calis, I., (1998) Phytochemistry, 48, pp. 867-873; Zheng, Q., Koike, K., Han, L., Okoda, H., Nikaido, T.J., (2004) Nat. Prod., 67, pp. 604-613; Garaev, E.A., Movsumov, I.S., Isaev, M.I., (2008) Chem. Nat. Compd., 44, p. 520; Christopoulou, C., Graikou, K., Chinou, I., (2008) Chem. Biodivers., 5, pp. 318-323; Besbes-Hlila, M., Omri, A., Ben Jannet, H., Lamari, A., Aouni, M., Selmi, B., (2012) Pharma boíl., 51, pp. 525-532; Besbes, M., Omri, A., Cheraif, I., Daami Remadi, M., Ben Jannet, H., Mastouri, M., (2013) Chem. Biodivers., 9, pp. 829-839; Tao, T., Zhang, Y., Cheng, Y., Wang, Y., (2013) Biomed. Chromatogr., 27, pp. 148-155; Rengasamy, R.R.K., Aderogba, M., Amoo, S.O., Stirk, W.A., Van Staden, J., (2013) J. Food Chem., 141, pp. 1412-1415; Proestos, C., Chorianopoulos, N., Nychas, G.J., Komaitis, M., (2005) J. Agric. Food Chem., 53, pp. 1190-1195; Shai, L.J., Masoko, P., Mokgotho, M.P., Magano, S.R., Mogale, A.M., Boaduo, N., Eloff, J.N., (2010) S. Afr. J. Bot., 76, pp. 465-470; Rubilar, M., Jara, C., Poo, Y., Acevedo, F., Gutierrez, C., Sineiro, J., Shene, C., (2011) J. Agric. Food Chem., 59, pp. 1630-1637; Li, D.Q., Zhao, J., Xie, J., Li, S.P., (2014) J. Pharm. Biomed. Anal., 88, pp. 130-135; Aderogba, A.M., Ndhlala, A.R., Rengasamy, K.R.R., Staden, J.V., (2013) Molecules, 18, pp. 12633-12644; Djeridanea, A., Hamdi, A., Bensania, W., Cheifa, K., Lakhdari, I., Yousfi, M., (2013) Diabetes Metab. Syndr.: Clin. Res. Rev.; Nardini, M., Ghiselli, A., (2004) Food Chem., 84, pp. 137-143; Deans, S.G., Svoboda, K.P., (1990) Flavour Fragr. J., 5, pp. 187-190; Burt, S., (2004) Int. J. Food Microbiol., 94, pp. 223-253; Kenjiro, T., Yuii, M., Kouta, T., Tomoko, M., (2006) J. Nutr. Sci. Vitaminol., 52, pp. 149-153; Ren, S., Xu, D.D., Gao, Y., Ma, Y.T., Gao, Q.P., (2013) Chem. Res. Chin. Univ., 29, pp. 682-685; Islam, M.N., Jung, H.A., Sohn, H.S., Kim, H.M., Choi, J.S., (2013) Arch. Pharm. Res., 36, pp. 542-552; Yilmazer-Musa, M., Griffith, A.M., Michels, A.J., Balz-Frei, E.S., (2012) J. Agric. Food Chem., 60, pp. 8924-8929; Sirichai, A., Kasem, S., Sophon, R., Amorn, P., Nattaya, N., Warinthorn, C., Sujitra, D., Sirintorn, Y., (2004) Bioorg. Med. Chem. Lett., 14, pp. 2893-2896; Jung, E.H., Kim, S.R., Hwang, I.K., Ha, T.Y., (2007) J. Agric. Food Chem., 55, pp. 9800-9804; Moradi-Afrapoli, F., Asghari, B., Saeidnia, S., Ajani, Y., Mirjani, M., Malmir, M., Bazaz, R.D., Yassa, N., (2012) DARU J. Pharm. Sci., 20, p. 37; Escandon-Rivera, S., Gonzalez-Andrade, M., Bye, R., Linares, E., Navarrete, A., Mata, R., (2012) J. Nat. Prod., 25, pp. 968-974",Article,Scopus,2-s2.0-84928751762
"Redon J., Lurbe E.","The Kidney in Obesity",2015,"Current Hypertension Reports","17","6",,"1","9",,,10.1007/s11906-015-0555-z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928402298&partnerID=40&md5=b00ed4d02fdc4038305c9ae5b63fc8c3","Hypertension Clinic, Hospital Clinico of Valencia, University of Valencia and INCLIVA Research InstituteValencia, Spain; CIBERObn, Instituto de Salud Carlos IIIMadrid, Spain; Obesity and Cardiovascular Risk Unit for Children and Adolescents, Hospital General of Valencia, University of ValenciaValencia, Spain; Instituto de Investigación Biomédica, INCLIVA, Avda Blasco Ibañez, 17Valencia, Spain","Redon, J., Hypertension Clinic, Hospital Clinico of Valencia, University of Valencia and INCLIVA Research InstituteValencia, Spain, CIBERObn, Instituto de Salud Carlos IIIMadrid, Spain, Instituto de Investigación Biomédica, INCLIVA, Avda Blasco Ibañez, 17Valencia, Spain, Instituto de Investigación Biomédica, INCLIVA, Avda Blasco Ibañez, 17Valencia, Spain; Lurbe, E., CIBERObn, Instituto de Salud Carlos IIIMadrid, Spain, Obesity and Cardiovascular Risk Unit for Children and Adolescents, Hospital General of Valencia, University of ValenciaValencia, Spain","Body mass index has been found to be the second most important contributor to relative risk for developing end state renal disease (ESRD), after proteinuria. The impact of obesity on the kidney includes a wide spectrum, from characteristic pathologic lesions to increment in urinary albumin excretion (UAE) and proteinuria/or decrease in glomerular filtration rate (GFR). The cause of renal disease associated to obesity is not well understood, but two relevant elements emerge. The first is the presence of obesity-related glomerulopathy, and the second is the fat deposit in the kidney with impact on renal haemodynamics and intrarenal regulation. The mechanisms linking obesity and renal damage are complex and include haemodynamic changes, inflammation, oxidative stress, apoptosis, and finally renal scarring. The protection of kidney damage needs to combine weight reduction with the proper control of the cardiometabolic risk factors associated, hypertension, metabolic syndrome, diabetes and dyslipidaemia. The search for specific treatments merits future research. © 2015, Springer Science+Business Media New York.","Chronic kidney disease; Obesity; Obesity glomerulopathy; Perivascular fat; Proteinuria","Prospective Studies Collaboration, Body-mass index and cause specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies (2009) Lancet, 373, pp. 1083-1096. , The relevance of BMI in mortality is collected based in a large number of prospective studies; Finucane, M.M., Stevens, G.A., Cowan, M.J., Danaei, G., Lin, J.K., Paciorek, C.J., National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9 · 1 million participants (2011) Lancet, 377, pp. 557-567. , PID: 21295846; Lapidus, L., Bengtsson, C., Larsson, B., Pennert, K., Rybo, E., Sjöström, L., Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg Sweden (1984) BMJ, 289, pp. 1257-1261. , COI: 1:STN:280:DyaL2M%2FkslyqtQ%3D%3D, PID: 6437507; Ducimetière, P., Richard, J., Cambien, F., The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris prospective study (1986) Int J Obes, 10, pp. 229-240. , PID: 3759330; Rimm, E.B., Stampfer, M.J., Giovannucci, E., Ascherio, A., Spiegelman, D., Colditz, G.A., Body size and fat distribution as predictors of coronary heart disease among middle-aged and older men (1995) Am J Epidemiol, 141, pp. 1117-1127. , COI: 1:STN:280:DyaK2M3ovFeltg%3D%3D, PID: 7771450; Rexrode, K.M., Hennekens, C.H., Willet, W.C., A prospective study of body mass index, weight change, and risk of stroke in women (1997) JAMA, 277, pp. 1539-1545. , COI: 1:STN:280:DyaK2s3pslOgtA%3D%3D, PID: 9153368; Folsom, A.R., Stevens, J., Schreiner, P.J., McGovern, P.G., Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites (1998) Am J Epidemiol, 148, pp. 1187-1194. , COI: 1:STN:280:DyaK1M%2FotlWmtg%3D%3D, PID: 9867265; Molarius, A., Seidell, J.C., Sans, S., Tuomilehto, J., Kuulasmaa, K., Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA project (1999) Int J Obes, 23, pp. 116-122. , COI: 1:STN:280:DyaK1M7ns1Ogsg%3D%3D; Folsom, A.R., Kushi, L.H., Anderson, K.E., Mink, P.J., Olson, J.E., Hong, C.P., Associations of general and abdominal obesity with multiple health outcomes in older women. The Iowa women’s health study (2000) Arch Intern Med, 60, pp. 2117-2128; Lakka, H.M., Lakka, T.A., Tuomilehto, J., Salonen, J.T., Abdominal obesity is associated with increased risk of acute coronary events in men (2002) Eur Heart J, 23, pp. 705-713; Kurth, T., Gaziano, J.M., Berger, K., Kase, C.S., Rexrode, K.M., Cook, N.R., Body mass index and the risk of stroke in men (2002) Arch Intern Med, 162, pp. 2557-2562. , PID: 12456227; Yusuf, S., Hawken, S., Ounpuu, S., Bautista, L., Franzosi, M.G., Commerford, P., Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case control study (2005) Lancet, 366, pp. 1640-1649. , PID: 16271645; Gelber, R.P., Gaziano, J.M., Orav, E.J., Manson, J.E., Buring, J.E., Kurth, T., Measures of obesity and cardiovascular risk among men and women (2008) J Am Coll Cardiol, 52, pp. 605-615. , PID: 18702962; Redon, J., Cifkova, R., Laurent, S., Nilsson, P., Narkiewicz, K., Erdine, S., The metabolic syndrome in hypertension: European society of hypertension position statement (2008) J Hypertens, 26, pp. 1891-1900. , COI: 1:CAS:528:DC%2BD1cXhtFCju7%2FN, PID: 18806611; Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E., Hsu, C., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation (2004) N Engl J Med, 351, pp. 1296-1306. , COI: 1:CAS:528:DC%2BD2cXnvFSgtr8%3D, PID: 15385656; Chronic Kidney Disease Prognosis Consortium, Matsushita, K., van der Velde, M., Astor, B.C., Woodward, M., Levey, A.S., Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis (2010) Lancet, 375, pp. 2073-2081; Coresh, J., Selvin, E., Stevens, L.A., Manzi, J., Kusek, J.W., Eggers, P., Prevalence of chronic kidney disease in the United States (2007) JAMA, 298, pp. 2038-2047. , COI: 1:CAS:528:DC%2BD2sXht1yjsLnM, PID: 17986697; Aitken, G.R., Roderick, P.J., Fraser, S., Mindell, J.S., O'Donoghue, D., Day, J., Change in prevalence of chronic kidney disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010 (2014) BMJ Open, 4. , PID: 25270853; Komura, H., Nomura, I., Kitamura, K., Kuwasako, K., Kato, J., Gender difference in relationship between body mass index and development of chronic kidney disease (2013) BMC Res Notes, 6, p. 463. , PID: 24225117; Iseki, K., Ikemiya, Y., Kinjo, K., Inoue, T., Iseki, C., Takishita, S., Body mass index and the risk of development of end-stage renal disease in a screened cohort (2004) Kidney Int, 65, pp. 1870-1876. , PID: 15086929; Stengel, B., Tarver-Carr, M.E., Powe, N.R., Eberhardt, M.S., Brancati, F.L., Lifestyle factors, obesity and the risk of chronic kidney disease (2003) Epidemiology, 14, pp. 479-487. , PID: 12843775; Mohsen, A., Brown, R., Hoefield, R., Kalra, P.A., O'Donoghue, D., Middleton, R., Body mass index has no effect on rate of progression of chronic kidney disease in subjects with type 2 diabetes mellitus (2012) J Nephrol, 25, pp. 384-393. , PID: 22241634; Brown, R.N., Mohsen, A., Green, D., Hoefield, R.A., Summers, L.K., Middleton, R.J., Body mass index has no effect on rate of progression of chronic kidney disease in non-diabetic subjects (2012) Nephrol Dial Transplant, 27, pp. 2776-2780. , PID: 22442391; França, A.K., Dos Santos, A.M., Salgado, J.V., Hortegal, E.V., da Silva, A.A., Salgado, F.N., Estimated visceral adipose tissue, but not body mass index, is associated with reductions in glomerular filtration rate based on cystatin C in the early stages of chronic kidney disease (2014) Int J Nephrol, 2014, p. 574267. , PID: 24876964; Odagiri, K., Mizuta, I., Yamamoto, M., Miyazaki, Y., Watanabe, H., Uehara, A., Waist to height ratio is an independent predictor for the incidence of chronic kidney disease (2014) PLoS One, 9, p. 88873. , PID: 24533159; Kurella, M., Lo, J.C., Chertow, G.M., Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults (2005) J Am Soc Nephrol, 16, pp. 2134-2140. , PID: 15901764; Thomas, G., Sehgal, A.R., Kashyap, S.R., Srinivas, T.R., Kirwan, J.P., Navaneethan, S.D., Metabolic syndrome and kidney disease: a systematic review and meta-analysis (2011) Clin J Am Soc Nephrol, 6, pp. 2364-2373. , PID: 21852664, Systematic review of the association between MetS, its components, and development of microalbuminuria or proteinuria and CKD in 30146 subjects. The study demonstrated the impact of metabolic síndrome in the development of microalbuminuria, proteinuria and CKD; Song, H., Wang, X., Cai, Q., Ding, W., Huang, S., Zhuo, L., Association of metabolic syndrome with decreased glomerular filtration rate among 75,468 Chinese adults: a cross-sectional study (2014) PLoS One, 9. , PID: 25415451; Nashar, K., Egan, B.M., Relationship between chronic kidney disease and metabolic syndrome: current perspectives (2014) Diabetes Metab Syndr Obes, 7, pp. 421-435. , PID: 25258547; Hsu, C.Y., Iribarren, C., McCulloch, C.E., Darbinian, J., Go, A.S., Risk factors for end-stage renal disease: 25-year follow-up (2009) Arch Intern Med, 169, pp. 342-350. , PID: 19237717; Vupputuri, S., Fox, C.S., Coresh, J., Woodward, M., Muntner, P., Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index (2009) Am J Kidney Dis, 53, pp. 993-1001. , COI: 1:CAS:528:DC%2BD1MXnslKrsr4%3D, PID: 19394726; Kambham, N., Markowitz, G.S., Valeri, A.M., Lin, J., D'Agati, V.D., Obesity-related glomerulopathy: an emerging epidemic (2001) Kidney Int, 59, pp. 1498-1509. , COI: 1:STN:280:DC%2BD3M3js1aqsQ%3D%3D, PID: 11260414; Serra, A., Romero, R., Lopez, D., Navarro, M., Esteve, A., Perez, N., Renal injury in the extremely obese patients with normal renal function (2008) Kidney Int, 73, pp. 947-955. , COI: 1:STN:280:DC%2BD1c3hslyhtw%3D%3D, PID: 18216780; de Vries, A.P., Ruggenenti, P., Ruan, X.Z., Praga, M., Cruzado, J.M., Bajema, I.M., Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease (2014) Lancet Diabetes Endocrinol, 2, pp. 417-426. , PID: 24795255, The study collects the evidence of the ectopic lipid accumulation in the kidney and its relationship with obesity related renal disease, including hemodynamic and structural changes; Tang, J., Yan, H., Zhuang, S., Inflammation and oxidative stress in obesity-related glomerulopathy (2012) Int J Nephrol, 2012, p. 608397. , PID: 22567283; Alexander, M.P., Patel, T.V., Farag, Y.M., Florez, A., Rennke, H.G., Singh, A.K., Kidney pathological changes in metabolic syndrome: a cross-sectional study (2009) Am J Kidney Dis, 53, pp. 751-759. , COI: 1:CAS:528:DC%2BD1MXlvFOjsr4%3D, PID: 19339092; Liu, Y., New insights into epithelial-mesenchymal transition in kidney fibrosis (2010) J Am Soc Nephrol, 21, pp. 212-222. , COI: 1:CAS:528:DC%2BC3cXislSqtL8%3D, PID: 20019167; Matsusaka, T., Sandgren, E., Shintani, A., Kon, V., Pastan, I., Fogo, A.B., Podocyte injury damages other podocytes (2011) J Am Soc Nephrol, 22, pp. 1275-1285. , PID: 21719786; Wagner, R., Machann, J., Lehmann, R., Rittig, K., Schick, F., Lenhart, J., Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes (2012) Diabetologia, 55, pp. 2054-2058. , COI: 1:CAS:528:DC%2BC38Xotlelt7g%3D, PID: 22526613; Foster, M.C., Hwang, S.J., Porter, S.A., Massaro, J.M., Hoffmann, U., Fox, C.S., Fatty kidney, hypertension, and chronic kidney disease: the Framingham heart study (2011) Hypertension, 58, pp. 784-790. , COI: 1:CAS:528:DC%2BC3MXhtlChsb%2FP, PID: 21931075, In participants from the Framingham Heart Study underwent quantification of renal sinus fat area using computed tomography. With a prevalence of fatty kidney of 30 %, it was a risk for having hypertension independent of potential counfounding factors. Renal sinus fat may play a role in blood pressure regulation and chronic kidney disease; Stefan N, Artunc F, Heyne N, Machann J, Schleicher ED, Häring HU. Obesity and renal disease: not all fat is created equal and not all obesity is harmful to the kidneys. Nephrol Dial Transplant. 2014. Apr 20Felizardo, R.J., da Silva, M.B., Aguiar, C.F., Câmara, N.O., Obesity in kidney disease: a heavyweight opponent (2014) World J Nephrol, 3, pp. 50-63. , PID: 25332896, The review discussed the consequences of obesity in the context of renal injury; Ribstein, J., du Cailar, G., Mimran, A., Combined renal effects of overweight and hypertension (1995) Hypertension, 26, pp. 610-615. , COI: 1:STN:280:DyaK28%2FjsF2guw%3D%3D, PID: 7558220; Krikken, J.A., Lely, A.T., Bakker, S.J., Navis, G., The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men (2007) Kidney Int, 71, pp. 260-265. , COI: 1:CAS:528:DC%2BD2sXos12rsg%3D%3D, PID: 17091123; Chagnac, A., Weinstein, T., Herman, M., Hirsh, J., Gafter, U., Ori, Y., The effects of weight loss on renal function in patients with severe obesity (2003) J Am Soc Nephrol, 14, pp. 1480-1486. , PID: 12761248; Ahmed, S.B., Fisher, N.D., Stevanovic, R., Hollenberg, N.K., Body mass index and angiotensin-dependent control of the renal circulation in healthy humans (2005) Hypertension, 46, pp. 1316-1320. , COI: 1:CAS:528:DC%2BD2MXht1arsrvE, PID: 16286575; De Cosmo, S., Menzaghi, C., Prudente, S., Trischitta, V., Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence (2013) Nephrol Dial Transplant, 28, pp. 29-36. , PID: 23048172; Chen, S., Chen, Y., Liu, X., Li, M., Wu, B., Li, Y., Association of insulin resistance with chronic kidney disease in non-diabetic subjects with normal weight (2013) PLoS One, 8, p. 74058. , COI: 1:CAS:528:DC%2BC3sXhsFSqs7vJ, PID: 24058515; Manabe, I., Chronic inflammation links cardiovascular, metabolic and renal diseases (2011) Circ J, 75, pp. 2739-2748. , COI: 1:CAS:528:DC%2BC38Xps1Cg, PID: 22067929; Nolan, E., O'Meara, Y.M., Godson, C., Lipid mediators of inflammation in obesity-related glomerulopathy (2013) Nephrol Dial Transplant, 28 (4), pp. iv22-iv29. , COI: 1:CAS:528:DC%2BC3sXhslakt7fN, PID: 24081855; Wolf, G., Chen, S., Han, D.C., Ziyadeh, F.N., Leptin and renal disease (2002) Am J Kidney Dis, 39, pp. 1-11. , COI: 1:CAS:528:DC%2BD38XlslKjtA%3D%3D, PID: 11774095; Nasrallah, M.P., Ziyadeh, F.N., Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney (2013) Semin Nephrol, 33, pp. 54-65. , COI: 1:CAS:528:DC%2BC3sXit1KqtLw%3D, PID: 23374894; Rutkowski, J.M., Wang, Z.V., Park, A.S., Zhang, J., Zhang, D., Hu, M.C., Adiponectin promotes functional recovery after podocyte ablation (2013) J Am Soc Nephrol, 24, pp. 268-282. , COI: 1:CAS:528:DC%2BC3sXivFejsbk%3D, PID: 23334396; Axelsson, J., Bergsten, A., Qureshi, A.R., Heimbürger, O., Bárány, P., Lönnqvist, F., Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance (2006) Kidney Int, 69, pp. 596-604. , COI: 1:CAS:528:DC%2BD28XnsV2ksw%3D%3D, PID: 16395259; Kang, Y.S., Song, H.K., Lee, M.H., Ko, G.J., Han, J.Y., Han, S.Y., Visfatin is upregulated in type-2 dia- betic rats and targets renal cells (2010) Kidney Int, 78, pp. 170-181. , COI: 1:CAS:528:DC%2BC3cXotFejurg%3D, PID: 20375985; Ix, J.H., Sharma, K., Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK (2010) J Am Soc Nephrol, 21, pp. 406-412. , COI: 1:CAS:528:DC%2BC3cXjvFCltbo%3D, PID: 20150538; Nishiyama, A., Abe, Y., Molecular mechanisms and therapeu- tic strategies of chronic renal injury: renoprotective effects of aldosterone blockade (2006) J Pharmacol Sci, 100, pp. 9-16. , COI: 1:CAS:528:DC%2BD28Xht1SrtL4%3D, PID: 16397374; Sharma, K., Obesity, oxidative stress, and fibrosis in chronic kidney disease (2014) Kidney Int Suppl, 4 (4), pp. 113-117. , COI: 1:CAS:528:DC%2BC2cXhvVKmtbzP; Declèves, A.E., Zolkipli, Z., Satriano, J., Wang, L., Nakayama, T., Rogac, M., Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury (2014) Kidney Int, 85, pp. 611-623. , PID: 24304883, The role of AMP-activated protein kinase, a critical pathway in regulating renal lipid accumulation is reviewed; Dugan, L.L., You, Y.H., Ali, S.S., Diamond-Stanic, M., Miyamoto, S., DeCleves, A.E., AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function (2013) J Clin Invest, 123, pp. 4888-4899. , COI: 1:CAS:528:DC%2BC3sXhslKksb3O, PID: 24135141; Chen, B., Yang, D., Chen, Y., Xu, W., Ye, B., Ni, Z., The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China (2010) Clin Chim Acta, 411, pp. 705-709. , COI: 1:CAS:528:DC%2BC3cXktVSht7w%3D, PID: 20138167; Thoenes, M., Reil, J.C., Khan, B.V., Bramlage, P., Volpe, M., Kirch, W., Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension (2009) Vasc Health Risk Manag, 55, pp. 577-585; Chandie Shaw, P.K., Berger, S.P., Mallat, M., Frölich, M., Dekker, F.W., Rabelink, T.J., Central obesity is an independent risk factor for albuminuria in nondiabetic south Asian subjects (2007) Diabetes Care, 30, pp. 1840-1844. , PID: 17456841; Du, N., Peng, H., Chao, X., Zhang, Q., Tian, H., Li, H., Interaction of obesity and central obesity on elevated urinary albumin-to-creatinine ratio (2014) PLoS One, 9, p. 98926. , PID: 24892930; Goknar, N., Oktem, F., Ozgen, I.T., Torun, E., Kuçukkoc, M., Demir, A.D., Determination of early urinary renal injury markers in obese children (2015) Pediatr Nephrol, 30, pp. 139-144. , PID: 24801174; Xiao, N., Jenkins, T.M., Nehus, E., Inge, T.H., Michalsky, M.P., Harmon, C.M., Kidney function in severely obese adolescents undergoing bariatric surgery (2014) Obesity, 22, pp. 2319-2325. , COI: 1:CAS:528:DC%2BC2cXhvVylsb%2FL, PID: 25376399; Lurbe, E., Torro, M.I., Alvarez, J., Aguilar, F., Fernandez-Formoso, J.A., Redon, J., Prevalence and factors related to urinary albumin excretion in obese youths (2013) J Hypertens, 31, pp. 2230-2236. , COI: 1:CAS:528:DC%2BC3sXhsFKksrzO, PID: 24096259; Adelman, R.D., Restaino, I.G., Alon, U.S., Blowey, D.L., Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents (2001) J Pediatr, 138, pp. 481-485. , COI: 1:STN:280:DC%2BD3MzktVWktQ%3D%3D, PID: 11295709; Fox, C.S., Larson, M.G., Leip, E.P., Culleton, B., Wilson, P.W., Levy, D., Predictors of new-onset kidney disease in a community- based population (2004) JAMA, 291, pp. 844-850. , COI: 1:CAS:528:DC%2BD2cXhsVyhu7k%3D, PID: 14970063; Ejerblad, E., Fored, C.M., Lindblad, P., Fryzek, J., McLaughlin, J.K., Nyrén, O., Obesity and risk for chronic renal failure (2006) J Am Soc Nephrol, 17, pp. 1695-1702. , COI: 1:CAS:528:DC%2BD28XlvVemu7s%3D, PID: 16641153; Tozawa, M., Iseki, K., Iseki, C., Oshiro, S., Ikemiya, Y., Takishita, S., Influence of smoking and obesity on the development of proteinuria (2002) Kidney Int, 62, pp. 956-962. , PID: 12164878; Franceschini N, Gouskova NA, Reiner AP, Bostom A, Howard BV, Pettinger M, Umans JG, Brookhart MA, Winkelmayer WC, Eaton CB, Heiss G, Fine JP. Adiposity patterns and the risk for ESRD in postmenopausal women. Clin J Am Soc Nephrol. 2014; Dec 1Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, Yamazaki M, Oda Y, Hasegawa G, Toda H, Nakamura N, Fukui M. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 2015; Jan 29Song YM, Sung J, Lee K. Longitudinal relationships of metabolic syndrome and obesity with kidney function: healthy twin study. Clin Exp Nephrol. 2015; Jan 30Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM, Warnock DG, Judd SE, Gutiérrez OM. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int. 2014; Dec 17Chen, S., Zhou, S., Wu, B., Zhao, Y., Liu, X., Liang, Y., Association between metabolically unhealthy overweight/obesity and chronic kidney disease: the role of inflammation (2014) Diabetes Metab, 40, pp. 423-430. , COI: 1:CAS:528:DC%2BC2cXhs1KmsbnM, PID: 25451190; Hoogeveen, E.K., Halbesma, N., Rothman, K.J., Stijnen, T., van Dijk, S., Dekker, F.W., Obesity and mortality risk among younger dialysis patients (2012) Clin J Am Soc Nephrol, 7, pp. 280-288. , PID: 22223612; Hoogeveen, E.K., Aalten, J., Rothman, K.J., Roodnat, J.I., Mallat, M.J., Borm, G., Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up (2011) Transplantation, 91, pp. 869-874. , PID: 21326138; Meier-Kriesche, H.U., Arndorfer, J.A., Kaplan, B., The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death (2002) Transplantation, 73, pp. 70-74. , PID: 11792981; Sharma, D., Hawkins, M., Abramowitz, M.K., Association of sarcopenia with eGFR and misclassification of obesity in adults with CKD in the United States (2014) Clin J Am Soc Nephrol, 9, pp. 2079-2088. , COI: 1:CAS:528:DC%2BC2MXosFSqtg%3D%3D, PID: 25392147; Hanly, P.J., Ahmed, S.B., Sleep apnea and the kidney: is sleep apnea a risk factor for chronic kidney disease? (2014) Chest, 146, pp. 1114-1122. , PID: 25288001; Musso, G., Gambino, R., Tabibian, J.H., Ekstedt, M., Kechagias, S., Hamaguchi, M., Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis (2014) PLoS Med, 11, p. 1001680. , PID: 25050550; Praga, M., Hernández, E., Herrero, J.C., Morales, E., Revilla, Y., Díaz-González, R., Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy (2000) Kidney Int, 58, pp. 2111-2118. , COI: 1:CAS:528:DC%2BD3cXotV2isLY%3D, PID: 11044232; Morales, E., Valero, M.A., Leo, N.M., Hernandez, E., Praga, M., Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies (2003) Am J Kidney Dis, 41, pp. 319-327. , PID: 12552492; Saiki, A., Nagayama, D., Ohhira, M., Endoh, K., Ohtsuka, M., Koide, N., Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy (2005) Int J Obes, 29, pp. 1115-1120. , COI: 1:CAS:528:DC%2BD2MXnt1Sht7k%3D; Afshinnia, F., Wilt, T.J., Duval, S., Esmaeili, A., Ibrahim, H.N., Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts (2010) Nephrol Dial Transplant, 25, pp. 1173-1183. , PID: 19945950; Navaneethan, S., Yehnert, H., Moustarah, F., Screiber, M., Schauer, P., Beddhu, S., Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis (2009) Clin J Am Soc Nephrol, 10, pp. 1565-1574; Pohl, M.A., Blumenthal, S., Cordonnier, D.J., De Alvaro, F., Deferrari, G., Eisner, G., Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations (2005) J Am Soc Nephrol, 16, pp. 3027-3037. , COI: 1:CAS:528:DC%2BD2MXhtFegtLnE, PID: 16120823; Pascual, J.M., Rodilla, E., Costa, J.A., Garcia-Escrich, M., Gonzalez, C., Redon, J., Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension (2014) Hypertension, 64, pp. 1228-1234. , COI: 1:CAS:528:DC%2BC2cXhvV2ntLrM, PID: 25245391; Pierine, D.T., Navarro, M.E., Minatel, I.O., Luvizotto, R.A., Nascimento, A.F., Ferreira, A.L., Lycopene supplementation reduces TNF-α via RAGE in the kidney of obese rats (2014) Nutr Diabetes, 4. , COI: 1:CAS:528:DC%2BC2cXhvFCiurzO, PID: 25383746; Stacchiotti, A., Favero, G., Giugno, L., Lavazza, A., Reiter, R.J., Rodella, L.F., Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: protective role of melatonin (2014) PLoS One, 9 (10), p. 111141. , PID: 25347680; Wang, C., Wu, M., Arvapalli, R., Dai, X., Mahmood, M., Driscoll, H., Acetaminophen attenuates obesity-related renal injury through ER-mediated stress mechanisms (2014) Cell Physiol Biochem, 33, pp. 1139-1148. , COI: 1:CAS:528:DC%2BC2cXpsFCnt78%3D, PID: 24731963; Yoshida, S., Ishizawa, K., Ayuzawa, N., Ueda, K., Takeuchi, M., Kawarazaki, W., Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease (2014) Nephron Exp Nephrol, 126, pp. 16-24. , COI: 1:CAS:528:DC%2BC2cXlslSltrg%3D, PID: 24603367; Imig, J.D., Walsh, K.A., Hye Khan, M.A., Nagasawa, T., Cherian-Shaw, M., Shaw, S.M., Soluble epoxide hydrolase inhibition and peroxisome proliferator activate receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats (2012) Exp Biol Med (Maywood), 237, pp. 1402-1412. , COI: 1:CAS:528:DC%2BC3sXjsFagtbk%3D; Abou-Mrad, R.M., Abu-Alfa, A.K., Ziyadeh, F.N., Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients (2013) Am J Physiol Renal Physiol, 305, pp. F613-F617. , COI: 1:CAS:528:DC%2BC3sXhs1Sqtr3K, PID: 23825072",Review,Scopus,2-s2.0-84928402298
"Henriques A., Santos A.C., Guimaraes J.T., Barros H., Azevedo A.","Healthy excessive weight in Portuguese women 4years after delivery of a liveborn",2015,"Preventive Medicine","75",,,"49","55",,,10.1016/j.ypmed.2015.03.009,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926500493&partnerID=40&md5=8284f8dc3b50cd4d9ff9a94889ef39df","EPIUnit - Institute of Public Health, University of PortoPorto, Portugal; Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical SchoolPorto, Portugal; Department of Clinical Pathology, Centro Hospitalar São JoãoPorto, Portugal","Henriques, A., EPIUnit - Institute of Public Health, University of PortoPorto, Portugal; Santos, A.C., EPIUnit - Institute of Public Health, University of PortoPorto, Portugal, Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical SchoolPorto, Portugal; Guimarães, J.T., EPIUnit - Institute of Public Health, University of PortoPorto, Portugal, Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical SchoolPorto, Portugal, Department of Clinical Pathology, Centro Hospitalar São JoãoPorto, Portugal; Barros, H., EPIUnit - Institute of Public Health, University of PortoPorto, Portugal, Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical SchoolPorto, Portugal; Azevedo, A., EPIUnit - Institute of Public Health, University of PortoPorto, Portugal, Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical SchoolPorto, Portugal","Objective: To quantify the prevalence of healthy excessive weight and determinants of metabolic profile, considering women's reproductive life. Methods: We evaluated 1847 mothers of a birth cohort assembled after delivery and reevaluated 4. years later. A healthy profile was defined as the absence of hypertension, diabetes, dyslipidemia, C-reactive protein <. 3. mg/l and being below the second tertile of HOMA-IR. Adjusted odds ratios (OR) and confidence intervals (95% CI) were computed using multinomial logistic regression, taking women with normal BMI as the reference category of the outcome. Results: Four years after delivery, 47% of women had normal BMI, 33% were overweight and 20% obese. In each BMI class, 61%, 33% and 12% presented a healthy metabolic profile, respectively. Family history of CVD/cardiometabolic risk factors was associated with a higher probability of obesity with a not healthy metabolic profile (OR = 1.39 95% CI: 0.98-1.98). Women who breastfed the enrolled child for >. 26. weeks and practiced physical exercise were less likely to be obese and metabolically unhealthy (OR = 0.39 95% CI: 0.23-0.68; OR = 0.48 95% CI: 0.33-0.70, respectively), with no effect on healthy excessive weight. Conclusions: These results support the existence of a healthy excessive weight phenotype in women after motherhood, influenced by anthropometrics, genetic and lifestyles characteristics. © 2015 Elsevier Inc.","Excessive weight; Healthy metabolic profile; Motherhood","Alves, E., Correia, S., Barros, H., Azevedo, A., Prevalence of self-reported cardiovascular risk factors in Portuguese women: a survey after delivery (2012) Int. J. Public Health, 57 (5), pp. 837-847; Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report (2002) Circulation, 106, pp. 3143-3421; Bluher, M., The distinction of metabolically 'healthy' from 'unhealthy' obese individuals (2010) Curr. Opin. Lipidol., 21, pp. 38-43; Bobbioni-Harsch, E., Pataky, Z., Makoundou, V., From metabolic normality to cardiometabolic risk factors in subjects with obesity (2012) Obesity (Silver Spring), 20, pp. 2063-2069; Brochu, M., Tchernof, A., Dionne, I.J., What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? (2001) J. Clin. Endocrinol. Metab., 86, pp. 1020-1025; Caro, J., Navarro, I., Romero, P., Metabolic effects of regular physical exercise in healthy population (2013) Endocrinol. Nutr., 60, pp. 167-172; Carreira, H., Pereira, M., Azevedo, A., Lunet, N., Trends of BMI and prevalence of overweight and obesity in Portugal (1995 - 2005): a systematic review (2012) Public Health Nutr., pp. 1-10; Cox, A.J., Agarwal, S.D.M.H., Carr, J.J., Freedman, B.I., Bowden, D.W., C-reactive protein concentration predicts mortality in type 2 diabetes: the Diabetes Heart Study (2012) Diabet. Med., 29, pp. 767-770; Demerath, E.W., Reed, D., Rogers, N., Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels (2008) Am. J. Clin. Nutr., 88, pp. 1263-1271; Diamant, M., Lamb, H.J., Van De Ree, M.A., The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes (2005) J. Clin. Endocrinol. Metab., 90, pp. 1495-1501; Finucane, M.M., Stevens, G.A., Cowan, M.J., National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants (2011) Lancet, 377, pp. 557-567; Fox, C.S., Heard-Costa, N., Cupples, L.A., Dupuis, J., Vasan, R.S., Atwood, L.D., Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K project (2007) BMC Med. Genet., 8, p. S18; Grundy, S.M., Cleeman, J.I., Daniels, S.R., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) Circulation, 112, pp. 2735-2752; Gunderson, E.P., Sternfeld, B., Wellons, M.F., Childbearing may increase visceral adipose tissue independent of overall increase in body fat (2008) Obesity (Silver Spring), 16, pp. 1078-1084; Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension (2007) Vasc. Health Risk Manag., 3, pp. 783-795; Global guideline for type 2 diabetes (2014) Diabetes Res. Clin. Pract., 104, pp. 1-52; Jensen, M.D., Role of body fat distribution and the metabolic complications of obesity (2008) J. Clin. Endocrinol. Metab., 93, pp. S57-S63; Karelis, A.D., Metabolically healthy but obese individuals (2008) Lancet, 372, pp. 1281-1283; Karelis, A.D., Messier, V., Brochu, M., Rabasa-Lhoret, R., Metabolically healthy but obese women: effect of an energy-restricted diet (2008) Diabetologia, 51, pp. 1752-1754; Kramer, C.K., Zinman, B., Retnakaran, R., Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis (2013) Ann. Intern. Med., 159, pp. 758-769; Kuk, J.L., Ardern, C.I., Are metabolically normal but obese individuals at lower risk for all-cause mortality? (2009) Diabetes Care, 32, pp. 2297-2299; Manu, P., Ionescu-Tirgoviste, C., Tsang, J., Napolitano, B.A., Lesser, M.L., Correll, C.U., Dysmetabolic signals in ""metabolically healthy"" obesity (2012) Obes. Res. Clin. Pract., 6, pp. e9-e20; Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man (1985) Diabetologia, 28, pp. 412-419; Pataky, Z., Makoundou, V., Nilsson, P., Metabolic normality in overweight and obese subjects. Which parameters? Which risks? (2011) Int. J. Obes. (Lond.), 35, pp. 1208-1215; Phillips, C.M., Perry, I.J., Does inflammation determine metabolic health status in obese and nonobese adults? (2013) J. Clin. Endocrinol. Metab., 98, pp. E1610-E1619; Phillips, C.M., Dillon, C., Harrington, J.M., Defining metabolically healthy obesity: role of dietary and lifestyle factors (2013) PLoS One, 8, p. e76188; Primeau, V., Coderre, L., Karelis, A.D., Characterizing the profile of obese patients who are metabolically healthy (2011) Int. J. Obes. (Lond.), 35, pp. 971-981; Shin, M.J., Hyun, Y.J., Kim, O.Y., Kim, J.Y., Jang, Y., Lee, J.H., Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women (2006) Int. J. Obes. (Lond.), 30, pp. 1529-1534; Stefan, N., Kantartzis, K., Machann, J., Identification and characterization of metabolically benign obesity in humans (2008) Arch. Intern. Med., 168, pp. 1609-1616; Thomas, E.L., Parkinson, J.R., Frost, G.S., The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat (2012) Obesity (Silver Spring), 20, pp. 76-87; Turcksin, R., Bel, S., Galjaard, S., Devlieger, R., Maternal obesity and breastfeeding intention, initiation, intensity and duration: a systematic review (2014) Matern. Child Nutr., 10, pp. 166-183; Van Vliet-Ostaptchouk, J.V., Nuotio, M.L., Slagter, S.N., The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies (2014) BMC Endocr. Disord., 14, p. 9; Velho, S., Paccaud, F., Waeber, G., Vollenweider, P., Marques-Vidal, P., Metabolically healthy obesity: different prevalences using different criteria (2010) Eur. J. Clin. Nutr., 64, pp. 1043-1051; Visscher, T.L., Seidell, J.C., The public health impact of obesity (2001) Annu. Rev. Public Health, 22, pp. 355-375; Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults (1998) Am. J. Clin. Nutr., 68, pp. 899-917; Wildman, R.P., Healthy obesity (2009) Curr. Opin. Clin. Nutr. Metab. Care, 12, pp. 438-443; Wildman, R.P., Muntner, P., Reynolds, K., The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004) (2008) Arch. Intern. Med., 168, pp. 1617-1624; Yeh, E.T., Willerson, J.T., Coming of age of C-reactive protein: using inflammation markers in cardiology (2003) Circulation, 107, pp. 370-371; Yoo, H.K., Choi, E.Y., Park, E.W., Cheong, Y.S., Bae, R.A., Comparison of metabolic characteristics of metabolically healthy but obese (MHO) middle-aged men according to different criteria (2013) Korean J. Fam. Med., 34, pp. 19-26",Article,Scopus,2-s2.0-84926500493
"Hamr S.C., Wang B., Swartz T.D., Duca F.A.","Does Nutrient Sensing Determine How We “See” Food?",2015,"Current Diabetes Reports","15","6",,"","",10,,10.1007/s11892-015-0604-7,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929000265&partnerID=40&md5=51c5805a786e1fd8b399308130b98499","Department of Physiology, University of TorontoToronto, Canada; Toronto General Research Institute and Department of Medicine, UHN, MaRS Centre, 101 College Street, Toronto Medical Discovery Tower, 10th floor, Room 701Toronto, ON, Canada; INSERM U1016, Institut CochinParis, France; Danone Nutricia Research, RD 128 Avenue de la VauvePalaiseau, France","Hamr, S.C., Department of Physiology, University of TorontoToronto, Canada, Toronto General Research Institute and Department of Medicine, UHN, MaRS Centre, 101 College Street, Toronto Medical Discovery Tower, 10th floor, Room 701Toronto, ON, Canada; Wang, B., Department of Physiology, University of TorontoToronto, Canada, Toronto General Research Institute and Department of Medicine, UHN, MaRS Centre, 101 College Street, Toronto Medical Discovery Tower, 10th floor, Room 701Toronto, ON, Canada; Swartz, T.D., INSERM U1016, Institut CochinParis, France, Danone Nutricia Research, RD 128 Avenue de la VauvePalaiseau, France, Danone Nutricia Research, RD 128 Avenue de la VauvePalaiseau, France; Duca, F.A., Toronto General Research Institute and Department of Medicine, UHN, MaRS Centre, 101 College Street, Toronto Medical Discovery Tower, 10th floor, Room 701Toronto, ON, Canada","The ability to “see” both incoming and circulating nutrients plays an essential role in the maintenance of energy homeostasis. As such, nutrient-sensing mechanisms in both the gastrointestinal tract and the brain have been implicated in the regulation of energy intake and glucose homeostasis. The intestinal wall is able to differentiate individual nutrients through sensory machinery expressed in the mucosa and provide feedback signals, via local gut peptide action, to maintain energy balance. Furthermore, both the hypothalamus and hindbrain detect circulating nutrients and respond by controlling energy intake and glucose levels. Conversely, nutrient sensing in the intestine plays a role in stimulating food intake and preferences. In this review, we highlight the emerging evidence for the regulation of energy balance through nutrient-sensing mechanisms in the intestine and the brain, and how disruption of these pathways could result in the development of obesity and type 2 diabetes. © 2015, Springer Science+Business Media New York.","Food intake; Glucose homeostasis; Gut peptides; Hypothalamus; Intestine","Ritter, R.C., Gastrointestinal mechanisms of satiation for food (2004) Physiol Behav, 81 (2), pp. 249-273. , COI: 1:CAS:528:DC%2BD2cXkt1Srtro%3D, PID: 15159171; Duca, F.A., Yue, J.T., Fatty acid sensing in the gut and the hypothalamus: in vivo and in vitro perspectives (2014) Mol Cell Endocrinol; Sidhu, S.S., Thompson, D.G., Warhurst, G., Fatty acid-induced cholecystokinin secretion and changes in intracellular Ca2+ in two enteroendocrine cell lines, STC-1 and GLUTag (2000) J Physiol, 528, pp. 165-176. , COI: 1:CAS:528:DC%2BD3cXnslWqt7o%3D, PID: 11018115; Liou, A.P., Lu, X., Sei, Y., The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin (2011) Gastroenterology, 140 (3), pp. 903-912. , COI: 1:CAS:528:DC%2BC3MXjs1WksL0%3D, PID: 20955703; Powley, T.L., Spaulding, R.A., Haglof, S.A., Vagal afferent innervation of the proximal gastrointestinal tract mucosa: chemoreceptor and mechanoreceptor architecture (2011) J Comp Neurol, 519 (4), pp. 644-660. , PID: 21246548; Randich, A., Tyler, W.J., Cox, J.E., Responses of celiac and cervical vagal afferents to infusions of lipids in the jejunum or ileum of the rat (2000) Am J Physiol Regul Integr Comp Physiol, 278 (1), pp. 34-43. , COI: 1:CAS:528:DC%2BD3cXht1Ggs7g%3D, PID: 10644619; Webster, W.A., Beyak, M.J., The long chain fatty acid oleate activates mouse intestinal afferent nerves in vitro (2013) Can J Physiol Pharmacol, 91 (5), pp. 375-379. , COI: 1:CAS:528:DC%2BC3sXntV2ks7k%3D, PID: 23656469; Ritter, R.C., Covasa, M., Matson, C.A., Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight (1999) Neuropeptides, 33 (5), pp. 387-399. , COI: 1:CAS:528:DyaK1MXnsV2qtb8%3D, PID: 10657516; Edfalk, S., Steneberg, P., Edlund, H., Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion (2008) Diabetes, 57 (9), pp. 2280-2287. , COI: 1:CAS:528:DC%2BD1cXhtFSrtrvP, PID: 18519800; Hirasawa, A., Tsumaya, K., Awaji, T., Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 (2005) Nat Med, 11 (1), pp. 90-94. , COI: 1:CAS:528:DC%2BD2MXptVSi, PID: 15619630; Sundaresan S, Shahid R, Riehl TE, et al. CD36-dependent signaling mediates fatty acid-induced gut release of secretin and cholecystokinin. FASEB J. 2013;27(3):1191–202. This study is the first to show that CCK release is partially mediated by CD36 in vivo, elucidating EEC lipid sensing mechanisms upstream of lipid-induced CCK releaseCote, C.D., Zadeh-Tahmasebi, M., Rasmussen, B.A., Hormonal signaling in the gut (2014) J Biol Chem, 289 (17), pp. 11642-11649. , COI: 1:CAS:528:DC%2BC2cXmvVSgsrY%3D, PID: 24577102; Dailey, M.J., Moghadam, A.A., Moran, T.H., Jejunal linoleic acid infusions require GLP-1 receptor signaling to inhibit food intake: implications for the effectiveness of Roux-en-Y gastric bypass (2011) Am J Physiol Endocrinol Metab, 301 (6), pp. 1184-1190. , COI: 1:CAS:528:DC%2BC3MXhs12ntbzN, PID: 21917638; Burton-Freeman, B., Gietzen, D.W., Schneeman, B.O., Meal pattern analysis to investigate the satiating potential of fat, carbohydrate, and protein in rats (1997) Am J Physiol, 273, pp. 1916-1922. , COI: 1:CAS:528:DyaK1cXjsFeiuw%3D%3D, PID: 9435645; Breen DM, Rasmussen BA, Kokorovic A, et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012;18(6):950–5. This study shows for the first time that jejunal glucose and lipid sensing mechanisms lower glucose production and that these jejunal nutrient sensing mechanisms are necessary for DJB surgery to improve glycemia in diabetic rodents, highlighting important therapeutic relevance for intestinal nutrient sensing mechanismsHolst, J.J., The physiology of glucagon-like peptide 1 (2007) Physiol Rev, 87 (4), pp. 1409-1439. , COI: 1:CAS:528:DC%2BD2sXhtlaqu7jI, PID: 17928588; Hayes, M.R., Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects (2012) Physiol Behav, 106 (3), pp. 413-416. , COI: 1:CAS:528:DC%2BC38Xjs1Ggs7c%3D, PID: 22366059; Williams, D.L., Baskin, D.G., Schwartz, M.W., Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety (2009) Endocrinology, 150 (4), pp. 1680-1687. , COI: 1:CAS:528:DC%2BD1MXktVWlsr4%3D, PID: 19074583; Theodorakis, M.J., Carlson, O., Michopoulos, S., Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP (2006) Am J Physiol Endocrinol Metab, 290 (3), pp. 550-559. , COI: 1:CAS:528:DC%2BD28Xjt1SksL4%3D, PID: 16219666; Jang, H.J., Kokrashvili, Z., Theodorakis, M.J., Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 (2007) Proc Natl Acad Sci U S A, 104 (38), pp. 15069-15074. , COI: 1:CAS:528:DC%2BD2sXhtV2jsr3J, PID: 17724330; Parker, H.E., Habib, A.M., Rogers, G.J., Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells (2009) Diabetologia, 52 (2), pp. 289-298. , COI: 1:CAS:528:DC%2BD1MXjvFGiug%3D%3D, PID: 19082577; Tolhurst, G., Reimann, F., Gribble, F.M., Intestinal sensing of nutrients (2012) Handb Exp Pharmacol, 209, pp. 309-335. , COI: 1:CAS:528:DC%2BC38XhslCgu7zO, PID: 22249821; Reimann, F., Habib, A.M., Tolhurst, G., Glucose sensing in L cells: a primary cell study (2008) Cell Metab, 8 (6), pp. 532-539. , COI: 1:CAS:528:DC%2BD1cXhsV2qtbnK, PID: 19041768; Moriya, R., Shirakura, T., Ito, J., Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice (2009) Am J Physiol Endocrinol Metab, 297 (6), pp. 1358-1365. , COI: 1:CAS:528:DC%2BD1MXhsFOgsbnF, PID: 19808907; Gorboulev V, Schurmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012;61(1):187–96. This study highlights SGLT1 glucose transporter as a potential mediator in glucose-induced incretin secretionPerez, C., Lucas, F., Sclafani, A., Devazepide, a CCK(A) antagonist, attenuates the satiating but not the preference conditioning effects of intestinal carbohydrate infusions in rats (1998) Pharmacol Biochem Behav, 59 (2), pp. 451-457. , COI: 1:CAS:528:DyaK1cXmsVyisw%3D%3D, PID: 9476995; Covasa, M., Ritter, R.C., Attenuated satiation response to intestinal nutrients in rats that do not express CCK-A receptors (2001) Peptides, 22 (8), pp. 1339-1348. , COI: 1:CAS:528:DC%2BD3MXlt1SmtLc%3D, PID: 11457530; Yox, D.P., Ritter, R.C., Capsaicin attenuates suppression of sham feeding induced by intestinal nutrients (1988) Am J Physiol, 255, pp. 569-574. , COI: 1:CAS:528:DyaL1cXmt1Omsbw%3D, PID: 3140678; Meyer, J.H., Hlinka, M., Tabrizi, Y., Chemical specificities and intestinal distributions of nutrient-driven satiety (1998) Am J Physiol, 275, pp. 1293-1307. , COI: 1:CAS:528:DyaK1cXmvV2qsL0%3D, PID: 9756563; Liou, A.P., Chavez, D.I., Espero, E., Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1 (2011) Am J Physiol Gastrointest Liver Physiol, 300 (5), pp. 895-902. , COI: 1:CAS:528:DC%2BC3MXmsFClt7g%3D, PID: 21311026; Darcel, N.P., Liou, A.P., Tome, D., Activation of vagal afferents in the rat duodenum by protein digests requires PepT1 (2005) J Nutr, 135 (6), pp. 1491-1495. , COI: 1:CAS:528:DC%2BD2MXltFahs7s%3D, PID: 15930458; Nemoz-Gaillard, E., Bernard, C., Abello, J., Regulation of cholecystokinin secretion by peptones and peptidomimetic antibiotics in STC-1 cells (1998) Endocrinology, 139 (3), pp. 932-938. , COI: 1:CAS:528:DyaK1cXhtlejtr0%3D, PID: 9492022; Liou, A.P., Sei, Y., Zhao, X., The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to L-phenylalanine in acutely isolated intestinal I cells (2011) Am J Physiol Gastrointest Liver Physiol, 300 (4), pp. 538-546. , COI: 1:CAS:528:DC%2BC3MXlt1Ortrk%3D, PID: 21252045; Blouet, C., Mariotti, F., Azzout-Marniche, D., The reduced energy intake of rats fed a high-protein low-carbohydrate diet explains the lower fat deposition, but macronutrient substitution accounts for the improved glycemic control (2006) J Nutr, 136 (7), pp. 1849-1854. , COI: 1:CAS:528:DC%2BD28Xmtlyiu7g%3D, PID: 16772448; Gannon, M.C., Nuttall, F.Q., Saeed, A., An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes (2003) Am J Clin Nutr, 78 (4), pp. 734-741. , COI: 1:CAS:528:DC%2BD3sXnslGjsLY%3D, PID: 14522731; Akhavan, T., Luhovyy, B.L., Brown, P.H., Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults (2010) Am J Clin Nutr, 91 (4), pp. 966-975. , COI: 1:CAS:528:DC%2BC3cXjvVCkt7Y%3D, PID: 20164320; Douglas, B.R., Woutersen, R.A., Jansen, J.B., The influence of different nutrients on plasma cholecystokinin levels in the rat (1988) Experientia, 44 (1), pp. 21-23. , COI: 1:CAS:528:DyaL1cXhtlSnsbw%3D, PID: 3350114; van der Klaauw, A.A., Keogh, J.M., Henning, E., High protein intake stimulates postprandial GLP1 and PYY release (2013) Obesity (Silver Spring), 21 (8), pp. 1602-1607; Seimon, R.V., Feltrin, K.L., Meyer, J.H., Effects of varying combinations of intraduodenal lipid and carbohydrate on antropyloroduodenal motility, hormone release, and appetite in healthy males (2009) Am J Physiol Regul Integr Comp Physiol, 296 (4), pp. 912-920. , COI: 1:CAS:528:DC%2BD1MXkvVygtLc%3D, PID: 19211720; Ryan AT, Luscombe-Marsh ND, Saies AA, et al. Effects of intraduodenal lipid and protein on gut motility and hormone release, glycemia, appetite, and energy intake in lean men. Am J Clin Nutr. 2013;98(2):300–11. This study assesses the gut peptide response to intraduodenal nutrient infusion in human subjects, as opposed to the numerous studies of nutrient infusion in rodents. Further, this study shows important differences gut peptide responses to different types of nutrientsBrennan, I.M., Luscombe-Marsh, N.D., Seimon, R.V., Effects of fat, protein, and carbohydrate and protein load on appetite, plasma cholecystokinin, peptide YY, and ghrelin, and energy intake in lean and obese men (2012) Am J Physiol Gastrointest Liver Physiol, 303 (1), pp. 129-140. , COI: 1:CAS:528:DC%2BC38Xht1Oksr%2FI, PID: 22556143; Lam, T.K., Pocai, A., Gutierrez-Juarez, R., Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis (2005) Nat Med, 11 (3), pp. 320-327. , COI: 1:CAS:528:DC%2BD2MXhvVSqsro%3D, PID: 15735652; Obici, S., Feng, Z., Morgan, K., Central administration of oleic acid inhibits glucose production and food intake (2002) Diabetes, 51 (2), pp. 271-275. , COI: 1:CAS:528:DC%2BD38XhtVaqtbg%3D, PID: 11812732; Wang, R., Cruciani-Guglielmacci, C., Migrenne, S., Effects of oleic acid on distinct populations of neurons in the hypothalamic arcuate nucleus are dependent on extracellular glucose levels (2006) J Neurophysiol, 95 (3), pp. 1491-1498. , COI: 1:STN:280:DC%2BD287gs1Cgtg%3D%3D, PID: 16306178; Jo, Y.H., Su, Y., Gutierrez-Juarez, R., Oleic acid directly regulates POMC neuron excitability in the hypothalamus (2009) J Neurophysiol, 101 (5), pp. 2305-2316. , COI: 1:CAS:528:DC%2BD1MXmtVWqtLc%3D, PID: 19261705; Picard A, Rouch C, Kassis N, et al. Hippocampal lipoprotein lipase regulates energy balance in rodents. Mol Metab. 2014;3(2):167–76. This study is the first to identify that the hippocampus can sense lipids via LPL activity to regulate energy homeostasis, supporting a role for extra-hypothalamic regions to sense nutrientsLe Foll, C., Dunn-Meynell, A., Musatov, S., FAT/CD36: a major regulator of neuronal fatty acid sensing and energy homeostasis in rats and mice (2013) Diabetes, 62 (8), pp. 2709-2716. , PID: 23557700; Moulle, V.S., Le Foll, C., Philippe, E., Fatty acid transporter CD36 mediates hypothalamic effect of fatty acids on food intake in rats (2013) PLoS One, 8 (9), p. 74021. , COI: 1:CAS:528:DC%2BC3sXhsVKrtb%2FP, PID: 24040150; Wang, H., Astarita, G., Taussig, M.D., Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity (2011) Cell Metab, 13 (1), pp. 105-113. , COI: 1:CAS:528:DC%2BC3MXhtF2rug%3D%3D, PID: 21195353; Obici, S., Feng, Z., Arduini, A., Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production (2003) Nat Med, 9 (6), pp. 756-761. , COI: 1:CAS:528:DC%2BD3sXktFOnu74%3D, PID: 12754501; Ross, R., Wang, P.Y., Chari, M., Hypothalamic protein kinase C regulates glucose production (2008) Diabetes, 57 (8), pp. 2061-2065. , COI: 1:CAS:528:DC%2BD1cXps1Ois74%3D, PID: 18511848; Guzman, M., Blazquez, C., Is there an astrocyte-neuron ketone body shuttle? (2001) Trends Endocrinol Metab, 12 (4), pp. 169-173. , COI: 1:CAS:528:DC%2BD3MXisF2ks7s%3D, PID: 11295573; Auestad, N., Korsak, R.A., Morrow, J.W., Fatty acid oxidation and ketogenesis by astrocytes in primary culture (1991) J Neurochem, 56 (4), pp. 1376-1386. , COI: 1:CAS:528:DyaK3MXhs1Wnsb0%3D, PID: 2002348; Schonfeld, P., Reiser, G., Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain (2013) J Cereb Blood Flow Metab, 33 (10), pp. 1493-1499. , PID: 23921897; Le Foll, C., Irani, B.G., Magnan, C., Characteristics and mechanisms of hypothalamic neuronal fatty acid sensing (2009) Am J Physiol Regul Integr Comp Physiol, 297 (3), pp. 655-664. , PID: 19535676; Thorens, B., Sensing of glucose in the brain (2012) Handb Exp Pharmacol, 209, pp. 277-294. , COI: 1:CAS:528:DC%2BC38XhslCgu7%2FF, PID: 22249819; Kurata, K., Fujimoto, K., Sakata, T., D-glucose suppression of eating after intra-third ventricle infusion in rat (1986) Physiol Behav, 37 (4), pp. 615-620. , COI: 1:STN:280:DyaL28zhsVaktg%3D%3D, PID: 3749325; Lam, T.K., Gutierrez-Juarez, R., Pocai, A., Regulation of blood glucose by hypothalamic pyruvate metabolism (2005) Science, 309 (5736), pp. 943-947. , COI: 1:CAS:528:DC%2BD2MXmvFSksr4%3D, PID: 16081739; Borg, W.P., Sherwin, R.S., During, M.J., Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release (1995) Diabetes, 44 (2), pp. 180-184. , COI: 1:CAS:528:DyaK2MXjtlCksL4%3D, PID: 7859938; Ritter, S., Dinh, T.T., Zhang, Y., Localization of hindbrain glucoreceptive sites controlling food intake and blood glucose (2000) Brain Res, 856 (1-2), pp. 37-47. , COI: 1:CAS:528:DC%2BD3cXhtFantLg%3D, PID: 10677609; Edmonds, B.K., Edwards, G.L., Dorsomedial hindbrain participation in glucoprivic feeding response to 2DG but not 2DG-induced hyperglycemia or activation of the HPA axis (1998) Brain Res, 801 (1-2), pp. 21-28. , COI: 1:CAS:528:DyaK1cXkslyht7g%3D, PID: 9729250; Ritter, R.C., Slusser, P.G., Stone, S., Glucoreceptors controlling feeding and blood glucose: location in the hindbrain (1981) Science, 213 (4506), pp. 451-452. , COI: 1:CAS:528:DyaL3MXkslOmsrk%3D, PID: 6264602; Ibrahim, N., Bosch, M.A., Smart, J.L., Hypothalamic proopiomelanocortin neurons are glucose responsive and express K(ATP) channels (2003) Endocrinology, 144 (4), pp. 1331-1340. , COI: 1:CAS:528:DC%2BD3sXisVegsLs%3D, PID: 12639916; Muroya, S., Yada, T., Shioda, S., Glucose-sensitive neurons in the rat arcuate nucleus contain neuropeptide Y (1999) Neurosci Lett, 264 (1-3), pp. 113-116. , COI: 1:CAS:528:DyaK1MXisFCrtbg%3D, PID: 10320027; Leloup, C., Arluison, M., Lepetit, N., Glucose transporter 2 (GLUT 2): expression in specific brain nuclei (1994) Brain Res, 638 (1-2), pp. 221-226. , COI: 1:CAS:528:DyaK2cXitFegsr8%3D, PID: 8199863; Bady, I., Marty, N., Dallaporta, M., Evidence from glut2-null mice that glucose is a critical physiological regulator of feeding (2006) Diabetes, 55 (4), pp. 988-995. , COI: 1:CAS:528:DC%2BD28XjsVGmtL8%3D, PID: 16567520; Mounien, L., Marty, N., Tarussio, D., Glut2-dependent glucose-sensing controls thermoregulation by enhancing the leptin sensitivity of NPY and POMC neurons (2010) FASEB J, 24 (6), pp. 1747-1758. , COI: 1:CAS:528:DC%2BC3cXnt1Ojurs%3D, PID: 20097878; Lamy CM, Sanno H, Labouebe G, et al. Hypoglycemia-activated GLUT2 neurons of the nucleus tractus solitarius stimulate vagal activity and glucagon secretion. Cell Metab. 2014;19(3):527–38. This study characterizes a population of glucose-inhibited GLUT2 neurons in the NTS that sense hypoglycemia to trigger glucagon secretion. These results could help elucidate mechanisms underlying a defective counterregulatory response in insulin-treated diabetesDunn-Meynell, A.A., Routh, V.H., Kang, L., Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons (2002) Diabetes, 51 (7), pp. 2056-2065. , COI: 1:CAS:528:DC%2BD38Xlt1Wltr8%3D, PID: 12086933; Stanley, S., Domingos, A.I., Kelly, L., Profiling of glucose-sensing neurons reveals that GHRH neurons are activated by hypoglycemia (2013) Cell Metab, 18 (4), pp. 596-607. , COI: 1:CAS:528:DC%2BC3sXhsFGnsL3N, PID: 24093682; Kang, L., Dunn-Meynell, A.A., Routh, V.H., Glucokinase is a critical regulator of ventromedial hypothalamic neuronal glucosensing (2006) Diabetes, 55 (2), pp. 412-420. , COI: 1:CAS:528:DC%2BD28XhsFajs7g%3D, PID: 16443775; Levin, B.E., Becker, T.C., Eiki, J., Ventromedial hypothalamic glucokinase is an important mediator of the counterregulatory response to insulin-induced hypoglycemia (2008) Diabetes, 57 (5), pp. 1371-1379. , COI: 1:CAS:528:DC%2BD1cXlvVKjtbk%3D, PID: 18292346; Karschin, A., Brockhaus, J., Ballanyi, K., KATP channel formation by the sulphonylurea receptors SUR1 with Kir6.2 subunits in rat dorsal vagal neurons in situ (1998) J Physiol., 509, pp. 339-346. , COI: 1:CAS:528:DyaK1cXktlCjtr0%3D, PID: 9575284; Miki, T., Liss, B., Minami, K., ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis (2001) Nat Neurosci, 4 (5), pp. 507-512. , COI: 1:CAS:528:DC%2BD3MXjt1ersbc%3D, PID: 11319559; Fioramonti, X., Lorsignol, A., Taupignon, A., A new ATP-sensitive K+ channel-independent mechanism is involved in glucose-excited neurons of mouse arcuate nucleus (2004) Diabetes, 53 (11), pp. 2767-2775. , COI: 1:CAS:528:DC%2BD2cXpvV2it74%3D, PID: 15504956; O'Malley, D., Reimann, F., Simpson, A.K., Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing (2006) Diabetes, 55 (12), pp. 3381-3386. , PID: 17130483; Ren, X., Zhou, L., Terwilliger, R., Sweet taste signaling functions as a hypothalamic glucose sensor (2009) Front Integr Neurosci, 3, p. 12. , PID: 19587847; Pellerin, L., Magistretti, P.J., Sweet sixteen for ANLS (2012) J Cereb Blood Flow Metab, 32 (7), pp. 1152-1166. , COI: 1:CAS:528:DC%2BC38XpvVSjt7k%3D, PID: 22027938; Marty, N., Dallaporta, M., Foretz, M., Regulation of glucagon secretion by glucose transporter type 2 (glut2) and astrocyte-dependent glucose sensors (2005) J Clin Invest, 115 (12), pp. 3545-3553. , COI: 1:CAS:528:DC%2BD2MXhtlSqtLvK, PID: 16322792; Cota, D., Proulx, K., Smith, K.A., Hypothalamic mTOR signaling regulates food intake (2006) Science, 312 (5775), pp. 927-930. , COI: 1:CAS:528:DC%2BD28Xktlyhs7Y%3D, PID: 16690869; Blouet, C., Jo, Y.H., Li, X., Mediobasal hypothalamic leucine sensing regulates food intake through activation of a hypothalamus-brainstem circuit (2009) J Neurosci, 29 (26), pp. 8302-8311. , COI: 1:CAS:528:DC%2BD1MXosFeksb0%3D, PID: 19571121; Blouet C, Schwartz GJ. Brainstem nutrient sensing in the nucleus of the solitary tract inhibits feeding. Cell Metab. 2012;16(5):579–87. This study shows that the NTS can sense a postprandial concentration of leucine to lower food intake, and establishes the NTS as an important integrator of diverse fuel-related signals to regulate energy balanceSu Y, Lam TK, He W, et al. Hypothalamic leucine metabolism regulates liver glucose production. Diabetes. 2012;61(1):85–93. This study highlights a novel mechanism of leucine sensing that lowers glucose production, involving the metabolism of leucine rather than activation of the mTOR pathwaySclafani, A., Zukerman, S., Ackroff, K., Fructose and glucose conditioned preferences in FVB mice: strain differences in post-oral sugar appetition (2014) Am J Physiol Regul Integr Comp Physiol. 2014:ajpregu, p. 00312; Sclafani, A., Fanizza, L.J., Azzara, A.V., Conditioned flavor avoidance, preference, and indifference produced by intragastric infusions of galactose, glucose, and fructose in rats (1999) Physiol Behav, 67 (2), pp. 227-234. , COI: 1:CAS:528:DyaK1MXlsVOrtb0%3D, PID: 10477054; Zukerman, S., Ackroff, K., Sclafani, A., Rapid post-oral stimulation of intake and flavor conditioning by glucose and fat in the mouse (2011) Am J Physiol Regul Integr Comp Physiol, 301 (6), pp. 1635-1647. , COI: 1:CAS:528:DC%2BC38XhtFWrsw%3D%3D, PID: 21975648; Myers, K.P., Robust preference for a flavor paired with intragastric glucose acquired in a single trial (2007) Appetite, 48 (1), pp. 123-127. , PID: 16979259; Tellez LA, Medina S, Han W, et al. A gut lipid messenger links excess dietary fat to dopamine deficiency. Science. 2013;341(6147):800–2. This study links intestinal nutrient sensing mechanism with central food reward pathwaysSclafani, A., Ackroff, K., Schwartz, G.J., Selective effects of vagal deafferentation and celiac-superior mesenteric ganglionectomy on the reinforcing and satiating action of intestinal nutrients (2003) Physiol Behav, 78 (2), pp. 285-294. , COI: 1:CAS:528:DC%2BD3sXptFGmsg%3D%3D, PID: 12576127; Tsurugizawa, T., Uematsu, A., Uneyama, H., Blood oxygenation level-dependent response to intragastric load of corn oil emulsion in conscious rats (2009) Neuroreport, 20 (18), pp. 1625-1629. , PID: 19918206; Otsubo, H., Kondoh, T., Shibata, M., Induction of Fos expression in the rat forebrain after intragastric administration of monosodium L-glutamate, glucose and NaCl (2011) Neuroscience, 196, pp. 97-103. , COI: 1:CAS:528:DC%2BC3MXhtlejtbrN, PID: 21930190; Tsurugizawa, T., Uematsu, A., Nakamura, E., Mechanisms of neural response to gastrointestinal nutritive stimuli: the gut-brain axis (2009) Gastroenterology, 137 (1), pp. 262-273. , PID: 19248781; Yiin, Y.M., Ackroff, K., Sclafani, A., Flavor preferences conditioned by intragastric nutrient infusions in food restricted and free-feeding rats (2005) Physiol Behav, 84 (2), pp. 217-231. , COI: 1:CAS:528:DC%2BD2MXhtlCqt7g%3D, PID: 15708774; Sclafani, A., Glass, D.S., Margolskee, R.F., Gut T1R3 sweet taste receptors do not mediate sucrose-conditioned flavor preferences in mice (2010) Am J Physiol Regul Integr Comp Physiol, 299 (6), pp. 1643-1650. , COI: 1:CAS:528:DC%2BC3cXhs1elsLnJ, PID: 20926763; Sclafani, A., Ackroff, K., Abumrad, N.A., CD36 gene deletion reduces fat preference and intake but not post-oral fat conditioning in mice (2007) Am J Physiol Regul Integr Comp Physiol, 293 (5), pp. 1823-1832. , COI: 1:CAS:528:DC%2BD2sXhtlGhsbrN, PID: 17804586; Zukerman, S., Ackroff, K., Sclafani, A., Post-oral appetite stimulation by sugars and nonmetabolizable sugar analogs (2013) Am J Physiol Regul Integr Comp Physiol, 305 (7), pp. 840-853. , COI: 1:CAS:528:DC%2BC3sXhslaisr3F, PID: 23926132; Ackroff, K., Sclafani, A., Post-oral fat stimulation of intake and conditioned flavor preference in C57BL/6 J mice: a concentration-response study (2014) Physiol Behav, 129, pp. 64-72. , COI: 1:CAS:528:DC%2BC2cXmvVWnu7o%3D, PID: 24582671; Ackroff, K., Rozental, D., Sclafani, A., Ethanol-conditioned flavor preferences compared with sugar- and fat-conditioned preferences in rats (2004) Physiol Behav, 81 (4), pp. 699-713. , COI: 1:CAS:528:DC%2BD2cXkslWktbs%3D, PID: 15178165; Kanoski, S.E., Alhadeff, A.L., Fortin, S.M., Leptin signaling in the medial nucleus tractus solitarius reduces food seeking and willingness to work for food (2014) Neuropsychopharmacology, 39 (3), pp. 605-613. , COI: 1:CAS:528:DC%2BC3sXhsFymsLjF, PID: 24002186; Perez, C., Sclafani, A., Cholecystokinin conditions flavor preferences in rats (1991) Am J Physiol, 260, pp. 179-185. , COI: 1:CAS:528:DyaK3MXpsFCksQ%3D%3D, PID: 1992819; Ackroff, K., Touzani, K., Peets, T.K., Flavor preferences conditioned by intragastric fructose and glucose: differences in reinforcement potency (2001) Physiol Behav, 72 (5), pp. 691-703. , COI: 1:CAS:528:DC%2BD3MXjtFGnsbo%3D, PID: 11337001; Ackroff, K., Sclafani, A., Flavor preferences conditioned by intragastric infusion of ethanol in rats (2001) Pharmacol Biochem Behav, 68 (2), pp. 327-338. , COI: 1:CAS:528:DC%2BD3MXitVOmu7c%3D, PID: 11267638; Ackroff, K., Dym, C., Yiin, Y.M., Rapid acquisition of conditioned flavor preferences in rats (2009) Physiol Behav, 97 (3-4), pp. 406-413. , COI: 1:CAS:528:DC%2BD1MXmtFeqs7k%3D, PID: 19303888; Lucas, F., Ackroff, K., Sclafani, A., High-fat diet preference and overeating mediated by postingestive factors in rats (1998) Am J Physiol, 275, pp. 1511-1522. , COI: 1:CAS:528:DyaK1cXnsF2nsr4%3D, PID: 9791068; Sclafani A, Zukerman S, Ackroff K. GPR40 and GPR120 fatty acid sensors are critical for postoral but not oral mediation of fat preferences in the mouse. Am J Physiol Regul Integr Comp Physiol. 2013;305(12):R1490–7. This study demonstrates that mechanisms involved in postoral nutrient conditioning and prefence differ from those involved in nutrient-induced satietyRen, X., Ferreira, J.G., Zhou, L., Nutrient selection in the absence of taste receptor signaling (2010) J Neurosci, 30 (23), pp. 8012-8023. , COI: 1:CAS:528:DC%2BC3cXhtVejtLfF, PID: 20534849; Oliveira-Maia, A.J., Roberts, C.D., Walker, Q.D., Intravascular food reward (2011) PLoS One, 6 (9), p. 24992. , COI: 1:CAS:528:DC%2BC3MXhtlCjsr%2FI, PID: 21980372; Cansell, C., Castel, J., Denis, R.G., Dietary triglycerides act on mesolimbic structures to regulate the rewarding and motivational aspects of feeding (2014) Mol Psychiatry, 19 (10), pp. 1095-1105. , COI: 1:CAS:528:DC%2BC2cXmsVKkt7c%3D, PID: 24732670; Duca, F.A., Sakar, Y., Covasa, M., The modulatory role of high fat feeding on gastrointestinal signals in obesity (2013) J Nutr Biochem, 24 (10), pp. 1663-1677. , COI: 1:CAS:528:DC%2BC3sXhsVCls7vL, PID: 24041374; Parton, L.E., Ye, C.P., Coppari, R., Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity (2007) Nature, 449 (7159), pp. 228-232. , COI: 1:CAS:528:DC%2BD2sXhtVagtb3L, PID: 17728716; Murray, S., Tulloch, A., Gold, M.S., Hormonal and neural mechanisms of food reward, eating behaviour and obesity (2014) Nat Rev Endocrinol, 10 (9), pp. 540-552. , COI: 1:CAS:528:DC%2BC2cXhtVKmtrjK, PID: 24958311; Pothos, E.N., Creese, I., Hoebel, B.G., Restricted eating with weight loss selectively decreases extracellular dopamine in the nucleus accumbens and alters dopamine response to amphetamine, morphine, and food intake (1995) J Neurosci, 15 (10), pp. 6640-6650. , COI: 1:CAS:528:DyaK2MXovFWhurg%3D, PID: 7472425; Geiger, B.M., Haburcak, M., Avena, N.M., Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity (2009) Neuroscience, 159 (4), pp. 1193-1199. , COI: 1:CAS:528:DC%2BD1MXktFeksL4%3D, PID: 19409204; Falken, Y., Hellstrom, P.M., Holst, J.J., Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides (2011) J Clin Endocrinol Metab, 96 (7), pp. 2227-2235. , COI: 1:CAS:528:DC%2BC3MXptlSru7Y%3D, PID: 21543426; Scholtz S, Miras AD, Chhina N, et al. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut. 2014;63(6):891–902. This study demonstrates the impact of gastric bypass surgery on central food reward",Review,Scopus,2-s2.0-84929000265
"Krarup N.T., Borglykke A., Allin K.H., Sandholt C.H., Justesen J.M., Andersson E.A., Grarup N., Jorgensen T., Pedersen O., Hansen T.","A genetic risk score of 45 coronary artery disease risk variants associates with increased risk of myocardial infarction in 6041 danish individuals",2015,"Atherosclerosis","240","2",,"305","310",,,10.1016/j.atherosclerosis.2015.03.022,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926455477&partnerID=40&md5=cb3ff36fa3e0179efbfbafc329567885","The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Research Center for Prevention and Health, Glostrup University HospitalGlostrup, Denmark; Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Faculty of Medicine, University of AalborgAalborg, Denmark; Faculty of Health Sciences, University of Southern DenmarkOdense, Denmark","Krarup, N.T., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Borglykke, A., Research Center for Prevention and Health, Glostrup University HospitalGlostrup, Denmark; Allin, K.H., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Sandholt, C.H., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Justesen, J.M., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Andersson, E.A., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Grarup, N., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Jørgensen, T., Research Center for Prevention and Health, Glostrup University HospitalGlostrup, Denmark, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark, Faculty of Medicine, University of AalborgAalborg, Denmark; Pedersen, O., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Hansen, T., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark, Faculty of Health Sciences, University of Southern DenmarkOdense, Denmark","Background: In Europeans, 45 genetic risk variants for coronary artery disease (CAD) have been identified in genome-wide association studies. We constructed a genetic risk score (GRS) of these variants to estimate the effect on incidence and clinical predictability of myocardial infarction (MI) and CAD. Methods: Genotype was available from 6041 Danes. An unweighted GRS was constructed by making a summated score of the 45 known genetic CAD risk variants. Registries provided information (mean follow-up=11.6 years) on CAD (n=374) and MI (n=124) events. Cox proportional hazard estimates with age as time scale was adjusted for sex, BMI, type 2 diabetes mellitus and smoking status. Analyses were also stratified either by sex or median age (below or above 45 years of age). We estimated GRS contribution to MI prediction by assessing net reclassification index (NRI) and integrated discrimination improvement (IDI) added to the European SCORE for 10-year MI risk prediction. Results: The GRS associated significantly with risk of incident MI (allele-dependent hazard ratio (95%CI): 1.06 (1.02-1.11), p=0.01) but not with CAD (p=0.39). Stratification revealed association of GRS with MI in men (1.06 (1.01-1.12), p=0.02) and in individuals above the median of 45.11 years of age (1.06 (1.00-1.12), p=0.03). There was no interaction between GRS and gender (p=0.90) or age (p=0.83). The GRS improved neither NRI nor IDI. Conclusion: The GRS of 45 GWAS identified risk variants increase the risk of MI in a Danish cohort. The GRS did not improve NRI or IDI beyond the performance of conventional European SCORE risk factors. © 2015 Elsevier Ireland Ltd.","Coronary artery disease; Genetic risk score; Myocardial infarction; Single-nucleotide polymorphism","Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030 (2006) PLoS Med., 3, p. e442; Conroy, R.M., Pyorala, K., Fitzgerald, A.P., Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project (2003) Eur. Heart J., 24, pp. 987-1003; Hawe, E., Talmud, P.J., Miller, G.J., Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study (2003) Ann. Hum. Genet., 67, pp. 97-106; Fischer, M., Broeckel, U., Holmer, S., Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction (2005) Circulation, 111, pp. 855-862; Zdravkovic, S., Wienke, A., Pedersen, N.L., Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins (2002) J.Intern. Med., 252, pp. 247-254; C Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls (2007) Nature, 447, pp. 661-678; McPherson, R., Pertsemlidis, A., Kavaslar, N., Acommon allele on chromosome 9 associated with coronary heart disease (2007) Science, 316, pp. 1488-1491; Helgadottir, A., Thorleifsson, G., Manolescu, A., Acommon variant on chromosome 9p21 affects the risk of myocardial infarction (2007) Science, 316, pp. 1491-1493; Samani, N.J., Erdmann, J., Hall, A.S., Genomewide association analysis of coronary artery disease (2007) N.Engl. J. Med., 357, pp. 443-453; Erdmann, J., Grosshennig, A., Braund, P.S., New susceptibility locus for coronary artery disease on chromosome 3q22.3 (2009) Nat. Genet., 41, pp. 280-282; Myocardial Infarction Genetics, C., Kathiresan, S., Voight, B.F., Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants (2009) Nat. Genet., 41, pp. 334-341; Schunkert, H., Konig, I.R., Kathiresan, S., Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease (2011) Nat. Genet., 43, pp. 333-338; Wild, P.S., Zeller, T., Schillert, A., Agenome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease (2011) Circ. Cardiovasc. Genet., 4, pp. 403-412; Reilly, M.P., Li, M., He, J., Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies (2011) Lancet, 377, pp. 383-392; Davies, R.W., Wells, G.A., Stewart, A.F., Agenome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex (2012) Circ. Cardiovasc. Genet., 5, pp. 217-225; Consortium, C.D., Deloukas, P., Kanoni, S., Large-scale association analysis identifies new risk loci for coronary artery disease (2013) Nat. Genet., 45, pp. 25-33; Vaarhorst, A.A., Lu, Y., Heijmans, B.T., Literature-based genetic risk scores for coronary heart disease: the Cardiovascular Registry Maastricht (CAREMA) prospective cohort study (2012) Circ. Cardiovasc. Genet., 5, pp. 202-209; Hughes, M.F., Saarela, O., Stritzke, J., Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts (2012) PloS One, 7, p. e40922; Tikkanen, E., Havulinna, A.S., Palotie, A., Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease (2013) Arterioscler. Thrombosis Vasc. Biol., 33, pp. 2261-2266; Glumer, C., Jorgensen, T., Borch-Johnsen, K., Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study (2003) Diabetes Care, 26, pp. 2335-2340; Jorgensen, T., Borch-Johnsen, K., Thomsen, T.F., Arandomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (2003) Eur. J. Cardiovasc Prev. Rehabil., 10, pp. 377-386; Andersen, T.F., Madsen, M., Jorgensen, J., The Danish National Hospital Register. A valuable source of data for modern health sciences (1999) Dan. Med. Bull., 46, pp. 263-268; Juel, K., Helweg-Larsen, K., The Danish registers of causes of death (1999) Dan. Med. Bull., 46, pp. 354-357; Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge (1972) Clin. Chem., 18, pp. 499-502; Varbo, A., Benn, M., Tybjaerg-Hansen, A., Remnant cholesterol as a causal risk factor for ischemic heart disease (2013) J.Am. Coll. Cardiol., 61, pp. 427-436; Johnson, A.D., Handsaker, R.E., Pulit, S.L., SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap (2008) Bioinformatics, 24, pp. 2938-2939; Hivert, M.F., Jablonski, K.A., Perreault, L., Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program (2011) Diabetes, 60, pp. 1340-1348; Liu, M., Kapadia, A.S., Etzel, C.J., Evaluating a new risk Marker's predictive contribution in survival models (2010) J.Stat. Theory Pract., 4, pp. 845-855; Pencina, M.J., D'Agostino, R.B., D'Agostino, R.B., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond (2008) Stat. Med., 27, pp. 157-172. , discussion 207-112; Manolio, T.A., Collins, F.S., Cox, N.J., Finding the missing heritability of complex diseases (2009) Nature, 461, pp. 747-753; Kitsios, G.D., Dahabreh, I.J., Trikalinos, T.A., Heterogeneity of the phenotypic definition of coronary artery disease and its impact on genetic association studies (2011) Circ. Cardiovasc. Genet., 4, pp. 58-67; de Miguel-Yanes, J.M., Shrader, P., Pencina, M.J., Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms (2011) Diabetes care, 34, pp. 121-125; Ganna, A., Magnusson, P.K., Pedersen, N.L., (2013) Multilocus Genetic Risk Scores for Coronary Heart Disease Prediction, Arteriosclerosis, Thrombosis, and Vascular Biology; Kilpelainen, T.O., Qi, L., Brage, S., Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children (2011) PLoS Med., 8, p. e1001116; Qi, Q., Chu, A.Y., Kang, J.H., Sugar-sweetened beverages and genetic risk of obesity (2012) N.Engl. J. Med., 367, pp. 1387-1396; Madsen, M., Davidsen, M., Rasmussen, S., The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry (2003) J.Clin. Epidemiol., 56, pp. 124-130; Lidegaard, O., Vestergaard, C.H., Hammerum, M.S., Quality monitoring based on data from the Danish National Patient Registry (2009) Ugeskr. Laeger, 171, pp. 412-415; Dudbridge, F., Power and predictive accuracy of polygenic risk scores (2013) PLoS Genet., 9, p. e1003348; Chatterjee, N., Wheeler, B., Sampson, J., Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies (2013) Nat. Genet., 45, pp. 400-405. , 405e401-403; Soininen, P., Kangas, A.J., Wurtz, P., High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism (2009) Analyst, 134, pp. 1781-1785; Cohen, J.C., Boerwinkle, E., Mosley, T.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease (2006) N.Engl. J. Med., 354, pp. 1264-1272",Article,Scopus,2-s2.0-84926455477
"Wang F., Zhou T., Wei S., Meng X., Zhang J., Hou Y., Sun G.","Endoscopic endonasal transsphenoidal surgery of 1,166 pituitary adenomas",2015,"Surgical Endoscopy and Other Interventional Techniques","29","6",,"1270","1280",,,10.1007/s00464-014-3815-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928895462&partnerID=40&md5=bab25036a1300cf1ca7768d4ecde373d","Department of Neurosurgery, PLA 301 HospitalBeijing, China","Wang, F., Department of Neurosurgery, PLA 301 HospitalBeijing, China; Zhou, T., Department of Neurosurgery, PLA 301 HospitalBeijing, China; Wei, S., Department of Neurosurgery, PLA 301 HospitalBeijing, China; Meng, X., Department of Neurosurgery, PLA 301 HospitalBeijing, China; Zhang, J., Department of Neurosurgery, PLA 301 HospitalBeijing, China; Hou, Y., Department of Neurosurgery, PLA 301 HospitalBeijing, China; Sun, G., Department of Neurosurgery, PLA 301 HospitalBeijing, China","Aim: To report the results of a series of patients undergoing pure endoscopic endonasal pituitary surgery and to evaluate the efficacy and safety of this procedure. Materials and methods: The data of 1,166 patients that underwent endoscopic endonasal transsphenoidal adenoma removal between December 2006 and June 2013 were retrospectively reviewed. Pre- and postoperative hormonal status (3 months after surgery) were analyzed and compared with the clinical parameters originally presented by the patients. The incidences of tumor removal, hormonal control, and tumor removal complications were retrospectively analyzed. Result: Out of 577 nonfunctioning adenomas, 180 were growth hormone (GH) secreting, 308 prolactin (PRL) secreting, 26 mixed GH/PRL adenomas, 68 adrenocorticotropin secreting, and 7 thyroid-stimulating hormone-secreting adenomas. The gross total removal of pituitary adenomas was achieved in 98 % of microadenomas, 92 % of macroadenomas, and 76 % of giant adenomas. Hormonal control was achieved in 47 (69 %) cases of ACTH adenomas, 119 (66 %) GH adenomas, 262 (85 %) PRL adenomas, and 6 (86 %) TSH adenomas. Postoperative complications were observed in 168 (14.4 %) patients. The most frequent complications were diabetes insipidus (7 %), epistaxis (1.7 %), hyposmia (1.5 %), anterior lobe insufficiency (1.3 %) ,and CSF leaks (0.6 %). Conclusion: The pure endoscopic approach is a safe, efficacious, and minimally invasive technique for the removal of pituitary adenomas. A higher gross total resection rate is vital for non-functional and functional adenomas. For patients with functional adenomas, while hormonal remission is unlikely to be achieved by surgery, the use of adjuvant therapy is advocated to obtain long-term hormonal control. © 2014, The Author(s).","Endonasal, transsphenoidal surgery; Endoscopic surgery; Pituitary adenoma","Schloffer, H., Zur frage der Operationen an der Hypophyse (1906) Beitr Klin Chir, 50, pp. 767-817; Cushing, H., (1912) The pituitary body and its disorders: clinical states produced by disorders of the hypophysis cerebri, , JB Lippincott company, Philadelphia:; Jho, H.D., Carrau, R.L., Endoscopic endonasal transsphenoidal surgery: experience with 50 patients (1997) J Neurosurg, 87, pp. 44-51. , COI: 1:STN:280:DyaK2szksFOksA%3D%3D, PID: 9202264; Cappabianca, P., Cavallo, L.M., Colao, A., Del Basso De Caro, M., Esposito, F., Cirillo, S., Lombardi, G., de Divitiis, E., Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures (2002) Minim Invasive Neurosurg, 45, pp. 193-200. , COI: 1:STN:280:DC%2BD38jjtFaitg%3D%3D, PID: 12494353; D’Haens, J., Van Rompaey, K., Stadnik, T., Haentjens, P., Poppe, K., Velkeniers, B., Fully endoscopic transsphenoidal surgery for functioning pituitary adenomas: a retrospective comparison with traditional transsphenoidal microsurgery in the same institution (2009) Surg Neurol, 72, pp. 336-340. , PID: 19604551; Strychowsky, J., Nayan, S., Reddy, K., Farrokhyar, F., Sommer, D., Purely endoscopic transsphenoidal surgery versus traditional microsurgery for resection of pituitary adenomas: systematic review (2011) J Otolaryngol Head Neck Surg, 40, pp. 175-185. , PID: 21453654; Jain, A.K., Gupta, A.K., Pathak, A., Bhansali, A., Bapuraj, J.R., Endonasal transsphenoidal pituitary surgery: is tumor volume a key factor in determining outcome? (2008) Am J Otolaryngol, 29, pp. 48-50. , PID: 18061832; Tabaee, A., Anand, V.K., Barron, Y., Hiltzik, D.H., Brown, S.M., Kacker, A., Mazumdar, M., Schwartz, T.H., Predictors of short-term outcomes following endoscopic pituitary surgery (2009) Clin Neurol Neurosurg, 111, pp. 119-122. , PID: 18986756; Dehdashti, A.R., Ganna, A., Karabatsou, K., Gentili, F., Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series (2008) Neurosurgery, 62, pp. 1006-1015. , PID: 18580798, discussion 1015–1007; Komotar, R.J., Starke, R.M., Raper, D.M., Anand, V.K., Schwartz, T.H., Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas (2012) Pituitary, 15, pp. 150-1599. , PID: 22038033; Anagnostis, P., Adamidou, F., Polyzos, S.A., Efstathiadou, Z., Panagiotou, A., Kita, M., Non-functioning pituitary adenomas: a single center experience (2011) Exp Clin Endocrinol Diabetes, 119, pp. 314-319. , COI: 1:CAS:528:DC%2BC3MXovVyqsL4%3D, PID: 21264809; Ceylan, S., Koc, K., Anik, I., Endoscopic endonasal transsphenoidal approach for pituitary adenomas invading the cavernous sinus (2010) J Neurosurg, 112, pp. 99-107. , PID: 19480546; Campbell, P.G., Kenning, E., Andrews, D.W., Yadla, S., Rosen, M., Evans, J.J., Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas (2010) Neurosurg Focus, 29, p. E5. , PID: 20887130; Choe, J.H., Lee, K.S., Jeun, S.S., Cho, J.H., Hong, Y.K., Endocrine outcome of endoscopic endonasal transsphenoidal surgery in functioning pituitary adenomas (2008) J Korean Neurosurg Soc, 44, pp. 151-155. , PID: 19096666; Hofstetter, C.P., Shin, B.J., Mubita, L., Huang, C., Anand, V.K., Boockvar, J.A., Schwartz, T.H., Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas (2011) Neurosurg Focus, 30, p. E10. , PID: 21456921; Macchia, E., Gasperi, M., Lombardi, M., Morselli, L., Pinchera, A., Acerbi, G., Rossi, G., Martino, E., Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience (2009) J Endocrinol Invest, 32, pp. 773-779. , COI: 1:CAS:528:DC%2BC3cXht1ahsbk%3D, PID: 19636221; Kienitz, T., Quinkler, M., Strasburger, C.J., Ventz, M., Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature (2007) Eur J Endocrinol, 157, pp. 39-46. , COI: 1:CAS:528:DC%2BD2sXosVKrur0%3D, PID: 17609400; Zhao, W., Ye, H., Li, Y., Zhou, L., Lu, B., Zhang, S., Wen, J., Hu, R., Thyrotropin-secreting pituitary adenomas: diagnosis and management of patients from one Chinese center (2012) Wien Klin Wochenschr, 124, pp. 678-684. , COI: 1:CAS:528:DC%2BC38Xhsleksr3L, PID: 23053568; Berker, M., Hazer, D.B., Yucel, T., Gurlek, A., Cila, A., Aldur, M., Onerci, M., Complications of endoscopic surgery of the pituitary adenomas: analysis of 570 patients and review of the literature (2012) Pituitary, 15, pp. 288-300. , PID: 22161543; Cavallo, L.M., Solari, D., Tasiou, A., Esposito, F., de Angelis, M., D’Enza, A.I., Cappabianca, P., Endoscopic endonasal transsphenoidal removal of recurrent and regrowing pituitary adenomas: experience on a 59-patient series (2013) World Neurosurg, 80, pp. 342-350. , PID: 23046913; Gondim, J.A., Almeida, J.P., Albuquerque, L.A., Schops, M., Gomes, E., Ferraz, T., Sobreira, W., Kretzmann, M.T., Endoscopic endonasal approach for pituitary adenoma: surgical complications in 301 patients (2011) Pituitary, 14, pp. 174-183. , PID: 21181278; De Witte, O., Carlot, S., Devuyst, E., Choufani, G., Hassid, S., Minimally invasive endoscopic unilateral transsphenoidal surgery for pituitary adenomas (2011) B-ENT, 7, pp. 27-32. , PID: 22338372; Zada, G., Cavallo, L.M., Esposito, F., Fernandez-Jimenez, J.C., Tasiou, A., De Angelis, M., Cafiero, T., Laws, E.R., Transsphenoidal surgery in patients with acromegaly: operative strategies for overcoming technically challenging anatomical variations (2010) Neurosurg Focus, 29, p. E8. , PID: 20887133; Charalampaki, P., Ayyad, A., Kockro, R.A., Perneczky, A., Surgical complications after endoscopic transsphenoidal pituitary surgery (2009) J Clin Neurosci, 16, pp. 786-789. , PID: 19289287; Frank, G., Pasquini, E., Farneti, G., Mazzatenta, D., Sciarretta, V., Grasso, V., Faustini Fustini, M., The endoscopic versus the traditional approach in pituitary surgery (2006) Neuroendocrinology, 83, pp. 240-248. , COI: 1:CAS:528:DC%2BD28XhtV2hu7vK, PID: 17047389; Netea-Maier, R.T., van Lindert, E.J., den Heijer, M., van der Eerden, A., Pieters, G.F., Sweep, C.G., Grotenhuis, J.A., Hermus, A.R., Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing’s disease (2006) Eur J Endocrinol, 154, pp. 675-684. , COI: 1:CAS:528:DC%2BD28XltV2jsLk%3D, PID: 16645014; Cappabianca, P., Cavallo, L.M., Colao, A., de Divitiis, E., Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas (2002) J Neurosurg, 97, pp. 293-298. , PID: 12186456; Rotenberg, B., Tam, S., Ryu, W.H., Duggal, N., Microscopic versus endoscopic pituitary surgery: a systematic review (2010) Laryngoscope, 120, pp. 1292-1297. , PID: 20578228; Gondim, J.A., Schops, M., de Almeida, J.P., de Albuquerque, L.A., Gomes, E., Ferraz, T., Barroso, F.A., Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center (2010) Pituitary, 13, pp. 68-77. , PID: 19697135; Yano, S., Kawano, T., Kudo, M., Makino, K., Nakamura, H., Kai, Y., Morioka, M., Kuratsu, J., Endoscopic endonasal transsphenoidal approach through the bilateral nostrils for pituitary adenomas (2009) Neurol Med Chir (Tokyo), 49, pp. 1-7",Article,Scopus,2-s2.0-84928895462
"Subramaniam M., Abdin E., Shahwan S., Vaingankar J.A., Picco L., Browning C.J., Thomas S.A., Chong S.A.","Culture and age influences upon gambling and problem gambling",2015,"Addictive Behaviors Reports","1",,,"57","63",,,10.1016/j.abrep.2015.04.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928807550&partnerID=40&md5=9ba9023e846d9f90ba20b65f2bf0ac23","Research Division, Institute of Mental Health, Singapore; Saw Swee Hock School of Public Health, Singapore; School of Primary Health Care, Monash University, Australia; Research Institute, RDNS, Australia; Office of the Pro Vice-Chancellor (International) University of Adelaide, Australia","Subramaniam, M., Research Division, Institute of Mental Health, Singapore, Saw Swee Hock School of Public Health, Singapore; Abdin, E., Research Division, Institute of Mental Health, Singapore; Shahwan, S., Research Division, Institute of Mental Health, Singapore; Vaingankar, J.A., Research Division, Institute of Mental Health, Singapore; Picco, L., Research Division, Institute of Mental Health, Singapore; Browning, C.J., School of Primary Health Care, Monash University, Australia, Research Institute, RDNS, Australia; Thomas, S.A., School of Primary Health Care, Monash University, Australia, Office of the Pro Vice-Chancellor (International) University of Adelaide, Australia; Chong, S.A., Research Division, Institute of Mental Health, Singapore","Objective: This study aimed to (i) examine the prevalence and types of gambling, (ii) establish prevalence of 'pathological' gambling, (iii) explore the correlates of gambling, and (iv) establish psychiatric and physical comorbidity in a sample of older adult gamblers (≥. 60. years) in contrast to younger gamblers in a representative population sample in Singapore. Method: This paper reports the results of a secondary analysis of data from a representative community survey of 6616 participants, of which 2252 had engaged in gambling activities at least once in their lifetime. Results: 48.9% of older adults reported lifetime gambling. Older gamblers were more likely to be males, married or widowed (vs. never married), with pre-primary, primary and secondary education (vs. university), economically inactive (vs. employed) and had personal annual income of SGD $19,999 and below (vs. SGD $50,000 and above). Older gamblers had significantly higher rates of betting on horses, playing numbers or betting on lotteries, and playing Mahjong. After adjusting for demographic variables in multiple logistic regression analyses, gamblers aged 60. years and older had significantly lower odds of having pathological gambling than those in the younger age group (OR. =. 0.4). Older gamblers had significantly higher odds of having diabetes (OR. =. 3.2), hypertension (OR. =. 4.9), and any comorbid chronic physical condition assessed in this study. Conclusions: For the majority of older adults, gambling remains a recreational activity that is entertaining and a way of socialization. However, one must remain cognizant of the possible risks for some to develop disordered gambling. © 2015.","Chronic physical conditions; Composite international diagnostic interview; South oaks gambling screen; Survey","Abbott, M., Volberg, R., Taking the pulse on gambling and problem gambling in New Zealand (2000) A Report on Phase one of the 1999 National Prevalence Survey, , Department of Internal Affairs, Wellington, New Zealand; Abdin, E., Subramaniam, M., Vaingankar, J., Chong, S.A., Reliability and validity of the English version of the South Oaks Gambling Screen in a multiracial Asian community sample in Singapore (2012) Int. Gambl. Stud., 12, pp. 275-293; Abdin, E., Subramaniam, M., Vaingankar, J.A., Luo, N., Chong, S.A., Measuring health-related quality of life among adults in Singapore: population norms for the EQ-5D (2013) Qual. Life Res., 22, pp. 2983-2991; Abdin, E., Subramaniam, M., Vaingankar, J.A., Luo, N., Chong, S.A., Population norms for the EQ-5D index scores using Singapore preference weights (2015) Qual. Life Res., , (in press); (1980) Diagnostic and Statistical Manual of Mental Disorders, , Author, Washington, DC; (2000) Diagnostic and Statistical Manual of Mental Disorders, , Text Revision (Copyright 2000). Washington DC; (2013) Diagnostic and Statistical Manual of Mental Disorders, , American Psychiatric Association, Washington, DC; Boreham, P., Laffan, W., Johnston, J., Southwell, J., Tighe, M., Responsible gambling strategy for older Queenslanders (2006) Final Report (J5003), , http://www.olgr.qld.gov.au/__data/assets/pdf_file/0004/250393/responsibleGamblingStrategyForOlderQldFinalReport.pdf, The University of Queensland Social Research Centre, Queensland; Cheng, S.T., Chan, A.C., Yu, E.C., An exploratory study of the effect of mahjong on the cognitive functioning of persons with dementia (2006) Int. J. Geriatr. Psychiatry, 21, pp. 611-617; Chong, S.A., Abdin, E., Nan, L., Vaingankar, J.A., Subramaniam, M., Prevalence and impact of mental and physical comorbidity in the adult Singapore population (2012) Ann. Acad. Med. Singap., 41, pp. 105-110; Desai, R.A., Maciejewski, P.K., Dausey, D.J., Caldarone, B.J., Potenza, M.N., Health correlates of recreational gambling in older adults (2004) Am. J. Psychiatry, 161, pp. 1672-1679; Desai, R.A., Desai, M.M., Potenza, M.N., Gambling, health and age: data from the National Epidemiologic Survey on Alcohol and Related Conditions (2007) Psychol. Addict. Behav., 21, pp. 431-440; Erickson, L., Molina, C.A., Ladd, G.T., Pietrzak, R.H., Petry, N.M., Problem and pathological gambling are associated with poorer mental and physical health in older adults (2005) Int. J. Geriatr. Psychiatry, 20, pp. 754-759; EuroQol-a new facility for the measurement of health-related quality of life (1990) Health Policy, 16, pp. 199-208; Evans, L., Delfabbro, P., Motivators for change and barriers to help-seeking in Australian problem gamblers (2005) J. Gambl. Stud., 21, pp. 133-155; Ferris, J., Wynne, H., The Canadian Problem Gambling Index (2001) Final Report, , Canadian Centre on Substance Abuse; Grant, J.E., Desai, R.A., Potenza, M.N., Relationship of nicotine dependence, subsyndromal and pathological gambling, and other psychiatric disorders: data from the National Epidemiologic Survey on Alcohol and Related Conditions (2009) J. Clin. Psychiatry, 70, pp. 334-343; Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., Fagerstrom, K.O., The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire (1991) Br. J. Addict., 86, pp. 1119-1127; Jiménez-Murcia, S., Granero, R., Fernández-Aranda, F., Arcelus, J., Aymamí, M.N., Gómez-Peña, M., Predictors of outcome among pathological gamblers receiving cognitive behavioral group therapy (2015) Eur. Addict. Res., 21, pp. 169-178; Kannel, W.B., McGee, D.L., Catelli, W.P., Latest perspective on cigarette smoking and cardiovascular disease: the Framingham experience (2000) Card. Rehabil., 4, pp. 267-277; Kessler, R.C., Ustun, T.B., The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI) (2004) Int. J. Methods Psychiatr. Res., 13, pp. 93-121; Online Gaming - a gamble or a sure bet, , http://www.kpmg.com/EU/en/Documents/Online-Gaming.pdf, KPMG International Cooperative. (last accessed on 18 Oct 2014); Ladd, G.T., Molina, C.A., Kerins, G.J., Petry, N.M., Gambling participation and problems among older adults (2003) J. Geriatr. Psychiatry Neurol., 16, pp. 172-177; Lai, D.W.L., Gambling and the older Chinese in Canada (2006) J. Gambl. Stud., 22, pp. 121-141; Lesieur, H.R., Blume, S.B., The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers (1987) Am. J. Psychiatry, 144, pp. 1184-1188; Levens, S., Dyer, A.M., Zubritsky, C., Knott, K., Oslin, D.W., Gambling among older, primary-care patients: an important public health concern (2005) Am. J. Geriatr. Psychiatr., 13, pp. 69-76; McCready, J., Mann, R.E., Zhao, J., Eves, R., Correlates of gambling-related problems among older adults in Ontario (2008) J. Gambl. Issues, 22, pp. 174-194. , http://jgi.camh.net/doi/pdf/10.4309/jgi.2008.22.3, last accessed on 14th June 2014); McKay, C., Double jeopardy: older women and problem gambling (2005) Int. J. Ment. Heal. Addict., 3, pp. 35-53; Nower, L., Blaszczynski, A., Characteristics of problem gamblers 56years of age or older: a statewide study of casino self-excluders (2008) Psychol. Aging, 23, pp. 577-584; Ohtsuka, K., Chan, C.C., Desperate housewives: an analysis of the characterisations of female gamblers portrayed in gambling movies in Hong Kong (2009) Int. J. Ment. Heal. Addict., 7, pp. 229-238; Ohtsuka, K., Chan, C.C., Senior gambling in Hong Kong: through the lenses of Chinese senior gamblers - an exploratory study (2014) Asian J. Gambl. Issues Public Health, 4, p. 4; Papineau, E., Mahjong, a game with attitude: expression of an alternative culture (2000) China Perspect., 28, pp. 29-42; Petry, N.M., A comparison of young, middle-aged, and older adult treatment-seeking pathological gamblers (2002) Gerontologist, 42, pp. 92-99; Petry, N.M., Stinson, F.S., Grant, B.F., Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (2005) Clin. Psychiatr., 66, pp. 564-574; Pietrzak, R.H., Morasco, B.J., Blanco, C., Grant, B.F., Petry, N.M., Gambling level and psychiatric and medical disorders in older adults: results from the National Epidemiologic Survey on Alcohol and Related Conditions (2007) Am. J. Geriatr. Psychiatr., 15, pp. 301-313; Potenza, M.N., Steinberg, M.A., Wu, R., Rounsaville, B.J., O'malley, S.S., Characteristics of older adult problem gamblers calling a gambling helpline (2006) J. Gambl. Stud., 22, pp. 241-254; Australia's gambling industries (1999) Inquiry Report No. 10, , Ausinfo, Canberra, (November); Raylu, N., Oei, T.P.S., Role of culture in gambling and problem gambling (2004) Clin. Psychol. Rev., 23, pp. 1087-1114; SAS/STATA 9.2 user's guide: introduction to survey sampling and analysis procedures (2008) Book Excerpt, , SAS Institute Inc., Cary, NC; Scull, S., (2003) Problem Gambling in Non-English Speaking Background Communities in Queensland: A Pilot Study, , UQ Community Service & Research Centre; Scull, S., Woolcock, G., Problem gambling in non-English speaking background communities in Queensland, Australia: a qualitative exploration (2005) Int. Gambl. Stud., 5, pp. 29-44; (2013) Population Trends, , http://www.singstat.gov.sg/publications/publications_and_papers/population_and_population_structure/population2013.pdf, Department of Statistics, Ministry of Trade & Industry, Republic of Singapore, Last accessed on 26 May 2014); http://default-document-library/publications/publications%20and%20papers/population%20and%20population%20structure/population.%20pdf, (Accessed on 15 April 2015)Stitt, G.B., Giacopassi, D., Nichols, M., Gambling among older adults: a comparative analysis (2003) Exp. Aging Res., 29, pp. 189-203; Subramaniam, M., Vaingankar, J., Heng, D., Kwok, K.W., Lim, Y.W., Yap, M., The Singapore Mental Health Study: an overview of the methodology (2012) Int. J. Methods Psychiatr. Res., 21, pp. 149-157; Subramaniam, M., Abdin, E., Poon, L.Y., Vaingankar, J.A., Lee, H., Chong, S.A., Verma, S., EQ-5D as a measure of programme outcome: results from the Singapore early psychosis intervention programme (2014) Psychiatry Res., 215, pp. 46-51; Subramaniam, M., Wang, P., Soh, P., Vaingankar, J.A., Chong, S.A., Browning, C.J., Prevalence and determinants of gambling disorder among older adults: a systematic review (2015) Addict. Behav., 41, pp. 199-209; Tang, C.S., Wu, A.M.S., Tang, J.Y.C., Gender differences in characteristics of Chinese treatment-seeking problem gamblers (2007) J. Gambl. Stud., 23, pp. 145-156; Tse, S., Hong, S.I., Wang, C.W., Cunningham-Williams, R.M., Gambling behavior and problems among older adults: a systematic review of empirical studies (2012) J. Gerontol. B Psychol. Sci. Soc. Sci., 67, pp. 639-652; Tse, S., Hong, S.I., Ng, K.L., Estimating the prevalence of problem gambling among older adults in Singapore (2013) Psychiatry Res., 210, pp. 607-611; Global Issues - Ageing, , http://www.un.org/en/globalissues/ageing/, (accessed online on 18 Oct 2014); Volberg, R., McNeilly, D., (2003) Gambling and Problem Gambling Among Seniors in Florida, , Florida Council on Compulsive Gambling, Maitland, FL; Volberg, R.A., Nysse-Carris, K.L., Gerstein, D.R., California problem gambling prevalence survey, , http://134.186.34.197/OPG/pdf/CA_Problem_Gambling_Prevalence:Survey-Final_Report.pdf, (Last accessed on 23 Oct 2014); Wang, P., Tai, E.S., Thumboo, J., Vrijhoef, H.J., Luo, N., Does diabetes have an impact on health-state utility? A study of Asians in Singapore (2014) Patient, 7, pp. 329-337; Welte, J.W., Barnes, G.M., Tidwell, M.C., Hoffman, J.H., Gambling and problem gambling across the lifespan (2011) J. Gambl. Stud., 27, pp. 49-61; Wiebe, J.M., Cox, B.J., Problem and probable pathological gambling among older adults assessed by the SOGS-R (2005) J. Gambl. Stud., 21, pp. 205-221; Wiebe, J., Single, E., Falkowski-Ham, A., Mun, P., (2004) Gambling and problem gambling among older adults in Ontario, , http://www.responsiblegambling.org/docs/research-reports/gambling-and-problem-gambling-among-older-adults-in-ontario.pdf?sfvrsn=10.Last, November, Responsible Gambling Council and Canadian Centre on Substance Abuse, accessed on 15 April 2015); Global Population Ageing: Peril or Promise?, , http://www3.weforum.org/docs/WEF_GAC_GlobalPopulationAgeing_Report_2012.pdf, Global Agenda Council on Ageing Society, World Economic Forum. (Last accessed on 29 May 2014); Zheng, W.Y., Walker, M., Blaszczynski, A., Mahjong gambling in the Chinese-Australian community in Sydney: a prevalence study (2010) J. Gambl. Stud., 26, pp. 441-454",Article,Scopus,2-s2.0-84928807550
"Sei Y., Mizuno M., Suzuki Y., Imai M., Higashide K., Harris C.L., Sakata F., Iguchi D., Fujiwara M., Kodera Y., Maruyama S., Matsuo S., Ito Y.","Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy",2015,"Molecular Immunology","65","2",,"302","309",,,10.1016/j.molimm.2015.02.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925587513&partnerID=40&md5=c187b5e8bafc28b7175be06828f20728","Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan; Renal Replacement Therapy, Nagoya University Graduate School of MedicineNagoya, Japan; Immunology, Nagoya City University Graduate School of MedicineNagoya, Japan; Complement Biology Group, Institute of Infection and Immunity, School of Medicine, Cardiff UniversityCardiff, United Kingdom; Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of MedicineNagoya, Japan","Sei, Y., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan; Mizuno, M., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan, Renal Replacement Therapy, Nagoya University Graduate School of MedicineNagoya, Japan; Suzuki, Y., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan, Renal Replacement Therapy, Nagoya University Graduate School of MedicineNagoya, Japan; Imai, M., Immunology, Nagoya City University Graduate School of MedicineNagoya, Japan; Higashide, K., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan; Harris, C.L., Complement Biology Group, Institute of Infection and Immunity, School of Medicine, Cardiff UniversityCardiff, United Kingdom; Sakata, F., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan, Renal Replacement Therapy, Nagoya University Graduate School of MedicineNagoya, Japan; Iguchi, D., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan; Fujiwara, M., Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of MedicineNagoya, Japan; Kodera, Y., Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of MedicineNagoya, Japan; Maruyama, S., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan; Matsuo, S., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan; Ito, Y., Division of Nephrology, Nagoya University Graduate School of MedicineNagoya, Japan, Renal Replacement Therapy, Nagoya University Graduate School of MedicineNagoya, Japan","We investigated the expression of membrane complement regulators (CRegs), CD46, CD55 and CD59 in human mesothelial cells, and correlated with clinical background and level of complement (C) activation products in peritoneal dialysis (PD) fluids (PDF) to clarify influence of the C activation system in PD patients. Expression of CRegs was assessed on primary cultures of mesothelial cells (HPMC) harvested from PD fluid of 31 PD patients. Because expression of CD55 but not CD46 and CD59 in mesothelial cells was significantly correlated to value of dialysate-to-plasma creatinine concentration ratio (D/P Cre) (p<. 0.005) as an indicator of peritoneal function, we focused on analysis of CD55 expression of HPMCs in comparison with levels of C activation products in the PDF of the PD patients, and their background factors. When comparing expression of the CRegs between systemic neutrophils and HPMC, no correlation was observed, supporting that change of CRegs' expression in HPMC was independently occurring in the peritoneum. Expression of CD55 protein in HPMC was closely correlated with expression at the mRNA level (p<. 0.0001) and was inversely correlated with levels of sC5b-9 (p<. 0.05), but not C3, C4, IL6 and CA125 in the PDF. Complications of diabetes, usage of icodextrin and residual renal function were not correlated with change of CD55 expression in HPMCs. Our data show that the process of PD therapy modifies expression of CD55 on peritoneal mesothelium and triggers local C activation. These findings support efforts to modify PD therapy to limit effects on activation and regulation of the C system. © 2015 Elsevier Ltd.","CD55; Complement; D/P creatinine; Membrane complement regulators; Peritoneal dialysis","Japanese classification of gastric carcinoma: 3rd English edition (2011) Gastric Cancer, 14, pp. 101-112; Barbano, G., Cappa, F., Prigione, I., Tedesco, F., Pausa, M., Gugliemino, R., Pistoia, V., Perfumo, F., Peritoneal mesothelial cells produce complement factors and express CD59 that inhibits C5b-9 mediated cell lysis (1999) Adv. Perit. Dial., 15, pp. 253-257; Bot, J., Whitaker, D., Vivian, J., Lake, R., Yao, V., McCauley, R., Culturing mouse peritoneal mesothelial cells (2003) Pathol. Res. Pract., 199, pp. 341-344; Celik, I., Stover, C., Botto, M., Thiel, S., Tzima, S., Künkel, D., Walport, M., Schwaeble, W., Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis (2001) Infect. Immun., 69, pp. 7304-7309; Connel, N.D., Rheinwald, J.G., Regulation of the cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture (1983) Cell, 34, pp. 245-253; Drevets, D.A., Campbell, P.A., Roles of complement and complement recepotor type 3 in phagocytosis of Listeria monocytogenes by inflammatory mouse peritoneal macrophages (1991) Infect. Immun., 59, pp. 2645-2652; Dulaney, J.T., Hetch, F.E., Periotoneal dialysis and loss of peroteins: a review (1984) Kidney Int., 26, pp. 253-262; Gopinath, R., Nutman, T.B., Identification of eosinophils in lysed whole blood using side scatter and CD16 negativity (1997) Cytometry, 30, pp. 313-316; Greenstein, J.D., Peake, P.W., Charlesworth, J.A., The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activation (1995) Clin. Exp. Immunol., 100, pp. 40-46; Hideshima, T., Okada, N., Okada, H., Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells (1990) Immunology, 69, pp. 396-401; Hurst, S.M., Wilkinson, T.S., McLoughlin, R.M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Jones, S.A., IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation (2001) Immunity, 14, pp. 705-714; Ikeda, J., Morii, E., Liu, Y., Qiu, Y., Nakamichi, N., Jokoji, R., Miyoshi, Y., Aozasa, K., Prognositic significance of CD55 expression in breast cancer (2008) Clin. Cancer Res., 14, pp. 4780-4786; Ito, T., Yorioka, N., Yamamoto, M., Kataoka, K., Yamakido, M., Effect of glocose on intercellular junctions of cultured human peritoneal mesothelial cells (2000) J. Am. Soc. Nephrol., 11, pp. 1969-1979; Kazancioglu, R., Periotneal defense mechanisms-the effects of new peritoneal dialysis solutions (2009) Perit. Dial. Int., 29, pp. S198-S201; Leendertse, M., Willems, R.J.L., Flierman, R., de Vos, A.F., Bonten, M.J.M., The complement system facilitates clearance of Enterococcus faecium during murine peritonitis (2010) J. Infect. Dis., 201, pp. 544-552; Li, L., Spendlove, I., Morgan, J., Durrant, L.G., CD55 is over-expressed in the tumour environment (2001) Br. J. Cancer, 84, pp. 80-86; Mizuno, M., Harris, C.L., Johnson, P.M., Morgan, B.P., Rat membrane cofactor protein (MCP; CD46) is expressed only in the acrosome of developing and mature spermatozoa and mediates binding to immobilized activated C3 (2004) Biol. Reprod., 71, pp. 1374-1383; Mizuno, M., Ito, Y., Mizuno, T., Harris, C.L., Morgan, B.P., Hepburn, N., Yuzawa, Y., Matsuo, S., Zymosan, but not LPS, developed severe and progressive peritoneal injuries accompanied with complement activation in peritoneal dialysate fluid in a rat peritonitis model with mechanical scraping (2009) J. Immunol., 183, pp. 1403-1412; Mizuno, M., Ito, Y., Mizuno, T., Suzuki, Y., Harris, C.L., Okada, N., Matsuo, S., Morgan, B.P., Membrane complement regulators protect against fibrin exudation in a severe peritoneal inflammation model in rats (2012) Am. J. Physiol. Renal. Physiol., 302, pp. F1245-F1251; Mizuno, M., Morgan, B.P., The possibilities and pitfalls for anti-complement therapies in inflammatory diseases (2004) Curr. Drug Targets Inflamm. Allergy, 3, pp. 85-94; Mizuno, M., Nozaki, M., Morine, N., Suzuki, N., Nishikawa, K., Morgan, B.P., Matsuo, S., A protein toxin from the sea anemone Phyllodiscus semoni targets the kidney and causes a renal injury resembling haemolytic uremic syndrome (2007) Am. J. Pathol., 171, pp. 402-414; Mizuno, T., Mizuno, M., Imai, M., Suzuki, Y., Kushida, M., Noda, Y., Maruyama, S., Ito, Y., Anti-C5a complementary peptide ameliorates acute peritoneal injuries induced by neutralization of Crry and CD59 (2013) Am. J. Physiol. Renal. Physiol., 305, pp. F1603-F1616; Mizuno, T., Mizuno, M., Morgan, B.P., Noda, Y., Yamada, K., Okada, N., Yuzawa, Y., Ito, Y., Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation in peritoneal dialysate fluid (2011) Nephrol. Dial. Transplant., 26, pp. 1821-1830; Mizutani, M., Ito, Y., Mizuno, M., Nishimura, H., Suzuki, Y., Hattori, R., Matsukawa, Y., Matsuo, S., Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate (2010) Am. J. Physiol. Renal Physiol., 298, pp. F721-F733; Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis (2010) Nat. Immunol., 11, pp. 785-797; Schmitt, C.A., Schwaeble, W., Wittig, B.M., Meyer zum Buschenfelde, K.H., Dippold, W.G., Expression and regulation by interferon-gamma of the membrane -bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumors (1999) Eur. J. Cancer, 35, pp. 117-124; Shibuya, K., Abe, T., Fujita, T., Decay-accelerating factor functions as a signal transducing molecule for human monocytes (1992) J. Immunol., 149, pp. 1758-1762; Stylianou, E., Jenner, L.A., Davies, M., Coles, G.A., Williams, J.D., Isolation, culture and characterization of human peritoneal mesothelial cells (1990) Kidney Int., 37, pp. 1563-1570; Szeto, C.C., Chow, K.M., Lam, C.W., Leung, C.B., Kwan, B.C., Chung, K.Y., Law, M.C., Li, P.K., Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial (2007) Nephrol. Dial. Transplant., 22, pp. 552-559; Tang, S., Leung, J.C., Chan, L.Y., Tsang, A.W., Chen, C.X., Zhou, W., Lai, K.N., Sacks, S.H., Regulation of complement C3 and C4 synthesis in human peritoneal mesothelial cells by peritoneal dialysis fluid (2004) Clin. Exp. Immunol., 136, pp. 85-94; Twardowski, Z.J., PET-a simpler approach for determining prescriptions for adequate dialysis therapy (1990) Adv. Perit. Dial., 6, pp. 186-191; Young, G.A., Kendall, S., Brownjohn, A.M., Complement activation during CAPD (1993) Nephrol. Dial. Transplant., 8, pp. 1372-1375",Article,Scopus,2-s2.0-84925587513
"Chen A.-Z., Tang N., Wang S.-B., Kang Y.-Q., Song H.-F.","Insulin-loaded poly-l-lactide porous microspheres prepared in supercritical CO2 for pulmonary drug delivery",2015,"Journal of Supercritical Fluids","101",,,"117","123",,,10.1016/j.supflu.2015.03.010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926647644&partnerID=40&md5=c6525259193e03b3669f85f829d6cd87","College of Chemical Engineering, Huaqiao UniversityXiamen, China; Institute of Biomaterials and Tissue Engineering, Huaqiao UniversityXiamen, China","Chen, A.-Z., College of Chemical Engineering, Huaqiao UniversityXiamen, China, Institute of Biomaterials and Tissue Engineering, Huaqiao UniversityXiamen, China; Tang, N., College of Chemical Engineering, Huaqiao UniversityXiamen, China; Wang, S.-B., College of Chemical Engineering, Huaqiao UniversityXiamen, China, Institute of Biomaterials and Tissue Engineering, Huaqiao UniversityXiamen, China; Kang, Y.-Q., College of Chemical Engineering, Huaqiao UniversityXiamen, China; Song, H.-F., College of Chemical Engineering, Huaqiao UniversityXiamen, China","The insulin-loaded poly-l-lactide porous microspheres (INS-PLLA PMs) were successfully developed in an emulsion-combined precipitation of compressed CO2 antisolvent (PCA) using ammonium bicarbonate (AB) as a porogen. The resulting INS-PLLA PMs exhibited a rough and porous structure with a geometric mean diameter (Dg) of 15.62 μm, an aerodynamic diameter (Da) of 4.31 μm, a fine particle fraction (FPF) of 65.57% and good aerosolization characteristics. The physicochemical characterization reveals that no chemical changes occurred on INS-PLLA PMs, while minor structural changes existed in insulin. The result of circular dichroism (CD) spectroscopy demonstrates a slight change happened in the secondary structure of insulin, however, the bioactivity verification test shows that the hypoglycemic activity of insulin from INS-PLLA PMs was well maintained, which shows no significant difference from the raw insulin. The fluorescent image of INS-PLLA PMs demonstrates that the insulin was homogeneously distributed in the matrix, and INS-PLLA PMs displayed a sustained-release effect. Furthermore, INS-PLLA PMs with almost no organic residue could promote the safety and suitability for pulmonary delivery of protein drugs. This study indicates that emulsion-combined PCA process is an effective and benign technology to produce INS-PLLA PMs, which have potential in the application of pulmonary drug delivery for treatment of diabetes. ©2015 Elsevier B.V. All rights reserved.","CO2; Insulin; Porous microspheres; Pulmonary drug delivery; Supercritical","Johnson, K.A., Preparation of peptide and protein powders for inhalation (1997) Advanced Drug Delivery Reviews, 26, pp. 3-15; Lam, J.K., Liang, W., Chan, H.K., Pulmonary delivery of therapeutic siRNA (2012) Advanced Drug Delivery Reviews, 64, pp. 1-15; Sou, T., Meeusen, E.N., De Veer, M., Morton, D.A., Kaminskas, L.M., McIntosh, M.P., New developments in dry powder pulmonary vaccine delivery (2011) Trends in Biotechnology, 29, pp. 191-198; Yang, M.Y., Chan, J.G.Y., Chan, H.K., Pulmonary drug delivery by powder aerosols (2014) Journal of Controlled Release, 193, pp. 228-240; Liang, Z., Ni, R., Zhou, J., Mao, S., Recent advances in controlled pulmonary drug delivery (2014) Drug Discovery Today; Loira-Pastoriza, C., Todoroff, J., Vanbever, R., Delivery strategies for sustained drug release in the lungs (2014) Advanced Drug Delivery Reviews, 75, pp. 81-91; Courrier, H.M., Butz, N., Vandamme, T.F., Pulmonary drug delivery systems: Recent developments and prospects (2002) Critical Reviews in Therapeutic Drug Carrier Systems, 19, pp. 425-498; Kim, H., Park, H., Lee, J., Kim, T.H., Lee, E.S., Oh, K.T., Lee, K.C., Youn, Y.S., Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes (2011) Biomaterials, 32, pp. 1685-1693; Klingler, C., Müller, B.W., Steckel, H., Insulin-micro- and nanoparticles for pulmonary delivery (2009) International Journal of Pharmaceutics, 377, pp. 173-179; Ungaro, F., De Rosa, G., Miro, A., Quaglia, F., La Rotonda, M.I., Cyclodextrins in the production of large porous particles: Development of dry powders for the sustained release of insulin to the lungs (2006) European Journal of Pharmaceutical Sciences, 28, pp. 423-432; Shi, K., Liu, Y., Ke, L., Fang, Y., Yang, R., Cui, F., Epsilon-poly-l-lysine guided improving pulmonary delivery of supramolecular self-assembled insulin nanospheres (2015) International Journal of Biological Macromolecules, 72, pp. 1441-1450; Edwards, D.A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M.L., Mintzes, J., Langer, R., Large porous particles for pulmonary drug delivery (1997) Science, 276, pp. 1868-1871; Oh, Y.J., Lee, J., Seo, J.Y., Rhim, T., Kim, S.H., Yoon, H.J., Lee, K.Y., Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model (2011) Journal of Controlled Release, 150, pp. 56-62; Nahar, K., Gupta, N., Gauvin, R., Absar, S., Patel, B., Gupta, V., Khademhosseini, A., Ahsan, F., In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals (2013) European Journal of Pharmaceutical Sciences, 49, pp. 805-818; Ungaro, F., D'Emmanuele Di Villa Bianca, R., Giovino, C., Miro, A., Sorrentino, R., Quaglia, F., La Rotonda, M.I., Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: In vivo deposition and hypoglycaemic activity after delivery to rat lungs (2009) Journal of Controlled Release, 135, pp. 25-34; Cryan, S.A., Carrier-based strategies for targeting protein and peptide drugs to the lungs (2005) AAPS Journal, 7, pp. E20-E41; Yang, Y., Bajaj, N., Xu, P., Ohn, K., Tsifansky, M.D., Yeo, Y., Development of highly porous large PLGA microparticles for pulmonary drug delivery (2009) Biomaterials, 30, pp. 1947-1953; Iskandar, F., Nandiyanto, A.B.D., Widiyastuti, W., Young, L.S., Okuyama, K., Gradon, L., Production of morphology-controllable porous hyaluronic acid particles using a spray-drying method (2009) Acta Biomaterialia, 5, pp. 1027-1034; Parsian, A.R., Vatanara, A., Rahmati, M.R., Gilani, K., Khosravi, K.M., Najafabadi, A.R., Inhalable budesonide porous microparticles tailored by spray freeze drying technique (2014) Powder Technology, 260, pp. 36-41; Beck-Broichsitter, M., Schweiger, C., Schmehl, T., Gessler, T., Seeger, W., Kissel, T., Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery (2012) Journal of Controlled Release, 158, pp. 329-335; Lee, J., Oh, Y.J., Lee, S.K., Lee, K.Y., Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery (2010) Journal of Controlled Release, 146, pp. 61-67; Kim, I., Byeon, H.J., Kim, T.H., Lee, E.S., Oh, K.T., Shin, B.S., Lee, K.C., Youn, Y.S., Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer (2012) Biomaterials, 33, pp. 5574-5583; Kim, H., Lee, J., Kim, T.H., Lee, E.S., Oh, K.T., Lee, D.H., Park, E.S., Youn, Y.S., Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment ofdiabetes (2011) Pharmaceutical Research, 28, pp. 2008-2019; Chen, A.Z., Yang, Y.M., Wang, S.B., Wang, G.Y., Liu, Y.G., Sun, Q.Q., Preparation of methotrexate-loaded, large, highly-porous PLLA microspheres by a high-voltage electrostatic antisolvent process (2013) Journal of Materials Science - Materials in Medicine, 24, pp. 1917-1925; Chen, A.Z., Li, L., Wang, S.B., Lin, X.F., Liu, Y.G., Zhao, C., Wang, G.Y., Zhao, Z., Study of Fe3O4-PLLA-PEG-PLLA magnetic microspheres based on supercritical CO2: Preparation, physicochemical characterization, and drug loading investigation (2012) The Journal of Supercritical Fluids, 67, pp. 139-148; Deng, A., Chen, A., Wang, S., Li, Y., Liu, Y., Cheng, X., Zhao, Z., Lin, D., Porous nanostructured poly-l-lactide scaffolds prepared by phase inversion using supercritical CO2 as a nonsolvent in the presence of ammonium bicarbonate particles (2013) The Journal of Supercritical Fluids, 77, pp. 110-116; Melgosa, R., Sanz, M.T., García-Solaesa Á., Bucio, S.L., Beltrán, S., Enzymatic activity and conformational and morphological studies of four commercial lipases treated with supercritical carbon dioxide (2014) The Journal of Supercritical Fluids; Prosapio, V., Reverchon, E., De Marco, I., Antisolvent micronization of BSA using supercritical mixtures carbon dioxide + organic solvent (2014) The Journal of Supercritical Fluids, 94, pp. 189-197; Falco, N., Reverchon, E., Della Porta, G., Continuous supercritical emulsions extraction: Packed tower characterization and application to poly(lactic-co-glycolic acid) plus insulin microspheres production (2012) Industrial & Engineering Chemistry Research, 51, pp. 8616-8623; Ratanajiajaroen, P., Ohshima, M., Preparation of highly porous β-chitin structure through nonsolvent-solvent exchange-induced phase separation and supercritical CO2 drying (2012) The Journal of Supercritical Fluids, 68, pp. 31-38; Brown, Z.K., Fryer, P.J., Norton, I.T., Bridson, R.H., Drying of agar gels using supercritical carbon dioxide (2010) The Journal of Supercritical Fluids, 54, pp. 89-95; Varona, S., Rodríguez-Rojo, S., Martín Á., Cocero, M.J., Duarte, C.M.M., Supercritical impregnation of lavandin (Lavandula hybrida) essential oil in modified starch (2011) The Journal of Supercritical Fluids, 58, pp. 313-319; Dhanda, D.S., Tyagi, P., Mirvish, S.S., Kompella, U.B., Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose (2013) Journal of Controlled Release, 168, pp. 239-250; Wu, K., Li, J., Precipitation of a biodegradable polymer using compressed carbon dioxide as antisolvent (2008) The Journal of Supercritical Fluids, 46, pp. 211-216; Chen, A.Z., Zhao, C., Wang, S.B., Liu, Y.G., Lin, D.L., Generation of porous poly-l-lactide microspheres by emulsion-combined precipitation with a compressed CO2 antisolvent process (2013) Journal of Materials Chemistry B, 1, pp. 2967-2975; Kang, Y.Q., Zhao, C., Chen, A.Z., Wang, S.B., Liu, Y.G., Wu, W.G., Su, X.Q., Study of lysozyme-loaded poly-l-lactide (PLLA) porous microparticles in a compressed CO2 antisolvent process (2013) Materials, 6, pp. 3571-3583; Nolan, L.M., Tajber, L., McDonald, B.F., Barham, A.S., Corrigan, O.I., Healy, A.M., Excipient-free nanoporous microparticles of budesonide for pulmonary delivery (2009) European Journal of Pharmaceutical Sciences, 37, pp. 593-602; Sreerama, N., Woody, R.W., Estimation of protein secondary structure from circular dichroism spectra: Comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set (2000) Analytical Biochemistry, 287, pp. 252-260; House, Jr.J.E., Decomposition of ammonium carbonate and ammonium bicarbonate and proton affinities of the anions (1980) Inorganic and Nuclear Chemistry Letters, 16, pp. 185-187; Reverchon, E., De Marco, I., Adami, R., Caputo, G., Expanded micro-particles by supercritical antisolvent precipitation: Interpretation of results (2008) The Journal of Supercritical Fluids, 44, pp. 98-108; Khajeh-Hosseini-Dalasm, N., Longest, P.W., Deposition of particles in the alveolar airways: Inhalation and breath-hold with pharmaceutical aerosols (2015) Journal of Aerosol Science, 79, pp. 15-30; Gradon, L., Sosnowski, T.R., Formation of particles for dry powder inhalers (2014) Advanced Powder Technology, 25, pp. 43-55; Dorkoosh, F.A., Verhoef, J.C., Ambagts, M.H.C., Rafiee-Tehrani, M., Borchard, G., Junginger, H.E., Peroral delivery systems based on superporous hydrogel polymers: Release characteristics for the peptide drugs buserelin, octreotide and insulin (2002) European Journal of Pharmaceutical Sciences, 15, pp. 433-439; Innocenzi, P., Falcaro, P., Bertolo, J.M., Bearzotti, A., Amenitsch, H., Electrical responses of silica mesostructured films to changes in environmental humidity and processing conditions (2005) Journal of Non-Crystalline Solids, 351, pp. 1980-1986; Quaglia, F., De Rosa, G., Granata, E., Ungaro, F., Fattal, E., Immacolata La Rotonda, M., Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying (2003) Journal of Controlled Release, 86, pp. 267-278; Hu, X., Jiang, M., Wang, J., Zhu, L., Zheng, S., Snavely, W.K., Hong, Y., Li, J., Insulin and insulin-tripalmitin particles produced by a supercritical assisted drying process (2013) Drying Technology, 31, pp. 1837-1848; Liu, Y., Tang, J.G., Influence of A7-B7 disulfide bond deletion on the refolding and structure of proinsulin (2003) Acta Biochimica et Biophysica Sinica, 35, pp. 122-126; Chen, A.Z., Pu, X.M., Yin, G.F., Zhao, C., Wang, S.B., Liu, Y.G., Wang, G.Y., Kang, Y.Q., Study of lysozyme-polymer composite microparticles in supercritical CO2 (2012) Journal of Applied Polymer Science, 125, pp. 3175-3183; Chen, A.Z., Wang, G.Y., Wang, S.B., Li, L., Liu, Y.G., Zhao, C., Formation of methotrexate-PLLA-PEG-PLLA composite microspheres by microencapsulation through a process of suspension-enhanced dispersion by supercritical CO2 (2012) International Journal of Nanomedicine, 7, pp. 3013-3022",Article,Scopus,2-s2.0-84926647644
"Telem D.A., Talamini M., Gesten F., Patterson W., Peoples B., Gracia G., Yang J., Zhang Q., Altieri M., Pryor A.D.","Hospital Admissions Greater Than 30 Days Following Bariatric Surgery: Patient and Procedure Matter",2015,"Surgical Endoscopy and Other Interventional Techniques","29","6",,"1310","1315",,,10.1007/s00464-014-3834-x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928919993&partnerID=40&md5=aa075bbac696a20d75ddc42ef93ae6ee","Division of Bariatric and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T18-040Stony Brook, NY, United States; Office of Quality and Patient Safety, New York State Department of HealthAlbany, NY, United States; Department of Preventative Medicine, Stony Brook University Medical CenterStony Brook, NY, United States; Department of Applied Mathematics and Statistics, Stony Brook University Medical CenterStony Brook, NY, United States","Telem, D.A., Division of Bariatric and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T18-040Stony Brook, NY, United States; Talamini, M., Division of Bariatric and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T18-040Stony Brook, NY, United States; Gesten, F., Office of Quality and Patient Safety, New York State Department of HealthAlbany, NY, United States; Patterson, W., Office of Quality and Patient Safety, New York State Department of HealthAlbany, NY, United States; Peoples, B., Office of Quality and Patient Safety, New York State Department of HealthAlbany, NY, United States; Gracia, G., Division of Bariatric and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T18-040Stony Brook, NY, United States; Yang, J., Department of Preventative Medicine, Stony Brook University Medical CenterStony Brook, NY, United States; Zhang, Q., Department of Applied Mathematics and Statistics, Stony Brook University Medical CenterStony Brook, NY, United States; Altieri, M., Division of Bariatric and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T18-040Stony Brook, NY, United States; Pryor, A.D., Division of Bariatric and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T18-040Stony Brook, NY, United States","Introduction: Assessment of hospital admission in the 30-day period following bariatric surgery likely underestimates true hospital utilization. The purpose of this study is to assess hospital admissions for 2 years following bariatric surgery to identify potential differences by patient and procedure. Methods: New York State Planning and Research Cooperative System (SPARCS) longitudinal administrative data were used to identify 22,139 adult patients who underwent a primary bariatric surgery from 2006 to 2008. Bariatric operations included laparoscopic gastric banding (LGB), laparoscopic Roux-en-y gastric bypass (RYGB), and laparoscopic sleeve gastrectomy (LSG). Patients were followed for 2 years after surgery to identify all-cause hospital admissions. Statistical correlation between postoperative hospital admission and patient demographics, comorbid conditions, and bariatric procedure was performed. Results: Of the 22,139 patients, 5,718 (26 %) patients were admitted within 2 years of surgery for a total of 9,502 admissions. Thirty-day admission rate was 5 %. The number of admissions per patient ranged from 1 to 22. Assessing the number of admissions per patient demonstrated that 3,741 (17 %) patients had one, 1,575 (7 %) had 2–3, and 402 (2 %) patients had greater than 4 admissions. LSG had both the highest admission rate and percentage of patients with >4 admissions, followed by RYGB and then LGB (p < 0.001). Risk factors for admission included black race, female gender, age > 50, Medicaid/Medicare as payer, congestive heart failure, pulmonary disease, diabetes, rheumatoid arthritis, history of substance abuse, and psychoses/depression. Conclusion: One out of four bariatric patients will be admitted to the hospital within 2 years of surgery. While most patients are admitted only once, a subset of patients requiring numerous hospital admissions was identified. LSG is associated with both the highest rate as well as highest frequency of hospital admissions. Several patient factors were also identified that significantly increased admission risk. Consideration and attention to these factors are necessary for operative planning, preoperative patient education, and postoperative monitoring. © 2014, Springer Science+Business Media New York.","Bariatric surgery; Hospital admission; Long term outcomes; Outcomes; Perioperative outcomes","Ogden, C.L., CM, K.B.K., Flegal, K.M., Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief (2012) No, p. 82; Buchwald, H., Avidor, Y., Braunwald, E., Bariatric surgery: a systematic review and meta-analysis (2004) JAMA, 292, p. 1724. , COI: 1:CAS:528:DC%2BD2cXos1OjtLg%3D, PID: 15479938; Ballantyne, G.H., Measuring outcomes following bariatric surgery: weight loss parameters, improvement in co-morbid conditions, change in quality of life and patient satisfaction (2003) Obes Surg, 13, p. 954. , PID: 14738691; Wang, Y.C., McPherson, K., Marsh, T., Gortmaker, S., Brown, M., Health and economic burden of the projected obesity trends in the USA and the UK (2011) Lancet, 378 (9793), pp. 815-825. , PID: 21872750; Sjostrom, L., Peltonen, M., Jacobson, P., Bariatric surgery and long-term cardiovascular events (2012) JAMA, 307 (1), pp. 56-65. , PID: 22215166; Sjostrom, L., Narbro, K., Sjostrom, C.D., Swedish obese subjects study. Effects of bariatric surgery on mortality in Swedish obese subjects (2007) N Engl J Med, 357 (8), pp. 741-752. , PID: 17715408; Maciejewski, M.L., Livingston, E.H., Smith, V.A., Kahwati, L.C., Henderson, W.G., Arterburn, D.E., Health expenditures among high-risk patients after gastric bypass and matched controls (2012) Arch Surg, 147 (7), pp. 633-640. , PID: 22802057; Makary, M.A., Clarke, J.M., Shore, A.D., Magnuson, T.H., Richards, T., Bass, E.B., Dominici, F., Segal, J.B., Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery (2010) Arch Surg, 145 (8), pp. 726-731. , PID: 20713923; Nguyen, N.T., Paya, M., Stevens, C.M., The relationship between hospital volume and outcome in bariatric surgery at academic medical centers (2004) Am Surg, 240, pp. 586-594; Weller, W.E., R, C., Hannan, E.L., Relationship between surgeon and hospital volume and readmission after bariatric surgery (2007) J Am Coll Surg, 204, pp. 383-391. , PID: 17324771; Saunders, J.K., Ballantyne, G., Belsley, S., 30-day readmission rates at a high volume bariatric surgery center: laparoscopic adjustable gastric banding, laparoscopic gastric bypass, and vertical banded gastroplasty-Roux-en-Y gastric bypass (2007) Obes Surg, 17, pp. 1171-1177. , PID: 18074490; Nguyen, N.T., Silver, M., Robinson, M., Results of a national audit of bariatric surgery performed at academic centers: a 2004 university health system consortium benchmarking project (2006) Arch Surg, 141, pp. 445-450. , PID: 16702515; Elixhauser, A., Syeiner, C., Harris, D., Co-morbidity measures for use with administrative data (1998) Med Care, 36, pp. 8-27. , COI: 1:STN:280:DyaK1c%2FptlemtA%3D%3D, PID: 9431328; Milne, R.I.G., Clarke, A., Can readmission rates be used as an outcome indicator? (1990) BMJ, 301, pp. 1139-1140. , COI: 1:STN:280:DyaK3M%2FntVWjtg%3D%3D, PID: 2252926; Clarke, A., Are readmissions avoidable? (1990) BMJ, 301, pp. 1136-1138. , COI: 1:STN:280:DyaK3M%2FntVWjsQ%3D%3D, PID: 2252925; Chambers, M., Clarke, A., Readmissions: measuring rates (1990) BMJ, 301, pp. 1134-1136. , COI: 1:STN:280:DyaK3M%2FntVWjsA%3D%3D, PID: 2132558; Neovius, M., Narbro, K., Keating, C., Peltonen, M., Sjöholm, K., Agren, G., Sjöström, L., Carlsson Health care use during 20 years following bariatric surgery (2012) JAMA, 308 (11), pp. 1132-1141. , COI: 1:CAS:528:DC%2BC38XhsFemt7bK, PID: 22990272; Dallal, R.M., Trang, A., Analysis of perioperative outcomes, length of hospital stay, and readmission rate after gastric bypass (2012) Surg Endosc, , PID: 22011941; Kellogg, T.A., Swan, T., Leslie, D.A., Buchwald, H., Ikramuddin, S., Patterns of readmission and reoperation within 90 days after Roux-en-Y gastric bypass (2009) Surg Obes Relat Dis, 5 (4), pp. 416-423. , PID: 19540169; Hinojosa, M.W., Varela, J.E., Parikh, D., Smith, B.R., Nguyen, X.M., Nguyen, N.T., National trends in use and outcome of laparoscopic adjustable gastric banding (2009) Surg Obes Relat Dis, 5 (2), p. 150. , PID: 18849200; Saunders, J., Ballantyne, G.H., Belsley, S., Stephens, D.J., Trivedi, A., Ewing, D.R., Iannace, V.A., Schmidt, H.J., One-year readmission rates at a high volume bariatric surgery center: laparoscopic adjustable gastric banding, laparoscopic gastric bypass, and vertical banded gastroplasty-Roux-en-Y gastric bypass (2008) Obes Surg, 18 (10), pp. 1233-1240. , PID: 18452051; Zingmond, D.S., McGory, M.L., Ko, C.Y., Hospitalization before and after gastric bypass surgery (2005) JAMA, 294 (15), pp. 1918-1924. , COI: 1:CAS:528:DC%2BD2MXhtFCitLnI, PID: 16234498; DeMaria, E.J., Murr, M., Byrne, T.K., Blackstone, R., Grant, J.P., Budak, A., Wolfe, L., Validation of the obesity surgery mortality risk score in a multicenter study proves it stratifies mortality risk in patients undergoing gastric bypass for morbid obesity (2007) Ann Surg, 246 (4), pp. 578-582. , PID: 17893494; Ramanan, B., Gupta, P.K., Gupta, H., Fang, X., Forse, R.A., Development and validation of a bariatric surgery mortality risk calculator (2012) J Am Coll Surg, 214 (6), pp. 892-900. , PID: 22521443; Nguyen, N.T., Nguyen, B., Smith, B., Reavis, K.M., Elliott, C., Hohmann, S., Proposal for a bariatric mortality risk classification system for patients undergoing bariatric surgery (2013) Surg Obes Relat Dis, 9 (2), pp. 239-246. , PID: 22336492",Article,Scopus,2-s2.0-84928919993
"Manning S., Pucci A., Carter N.C., Elkalaawy M., Querci G., Magno S., Tamberi A., Finer N., Fiennes A.G., Hashemi M., Jenkinson A.D., Anselmino M., Santini F., Adamo M., Batterham R.L.","Early postoperative weight loss predicts maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass",2015,"Surgical Endoscopy and Other Interventional Techniques","29","6",,"1484","1491",,,10.1007/s00464-014-3829-7,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928892474&partnerID=40&md5=80cdd040100a33275ffdce71f6fbc310","Department of Medicine, Centre for Obesity Research, Rayne Institute, University College London, Rayne Building, 5 University StreetLondon, United Kingdom; UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom; National Institute of Health Research University College London Hospitals Biomedical Research CentreLondon, United Kingdom; Obesity Center, University Hospital of PisaPisa, Italy; Queen Alexandra Hospital, Southwick Hill RoadPortsmouth, United Kingdom; Clinical and Experimental Surgery Department, Medical Research Institute, University of Alexandria, HadaraAlexandria, Egypt; Surrey Weight Loss Centre, St Anthony’s HospitalNorth Cheam, United Kingdom; Bariatric Surgery Unit, University Hospital of PisaPisa, Italy","Manning, S., Department of Medicine, Centre for Obesity Research, Rayne Institute, University College London, Rayne Building, 5 University StreetLondon, United Kingdom, UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom, National Institute of Health Research University College London Hospitals Biomedical Research CentreLondon, United Kingdom; Pucci, A., Department of Medicine, Centre for Obesity Research, Rayne Institute, University College London, Rayne Building, 5 University StreetLondon, United Kingdom, UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom, Obesity Center, University Hospital of PisaPisa, Italy; Carter, N.C., Queen Alexandra Hospital, Southwick Hill RoadPortsmouth, United Kingdom; Elkalaawy, M., UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom, Clinical and Experimental Surgery Department, Medical Research Institute, University of Alexandria, HadaraAlexandria, Egypt; Querci, G., Obesity Center, University Hospital of PisaPisa, Italy; Magno, S., Obesity Center, University Hospital of PisaPisa, Italy; Tamberi, A., Obesity Center, University Hospital of PisaPisa, Italy; Finer, N., UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom; Fiennes, A.G., Surrey Weight Loss Centre, St Anthony’s HospitalNorth Cheam, United Kingdom; Hashemi, M., UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom; Jenkinson, A.D., UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom; Anselmino, M., Bariatric Surgery Unit, University Hospital of PisaPisa, Italy; Santini, F., Obesity Center, University Hospital of PisaPisa, Italy; Adamo, M., UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom; Batterham, R.L., Department of Medicine, Centre for Obesity Research, Rayne Institute, University College London, Rayne Building, 5 University StreetLondon, United Kingdom, UCLH Centre for Weight Loss, Metabolic and Endocrine Surgery, University College London Hospitals, Ground Floor West Wing, 250 Euston RoadLondon, United Kingdom, National Institute of Health Research University College London Hospitals Biomedical Research CentreLondon, United Kingdom","Background: Previous studies show that ‘poor responders’ to Roux-en-Y gastric bypass (RYGBP) may be identified on the basis of early postoperative weight loss. Early identification of poor responders could allow earlier provision of postoperative behavioural and/or intensive lifestyle interventions and enhance their maximal weight loss. Our aim was to investigate whether early postoperative weight loss predicts the maximal weight loss response after RYGBP and sleeve gastrectomy (SG). Methods: We undertook a retrospective cross-sectional study of 1,456 adults who underwent either RYGBP (n = 918) or SG (n = 538) as a primary procedure in one of two European centres. Postoperative weight loss was expressed as weight loss velocity (WLV) and percentage weight loss. Linear regression analyses were performed to determine the association of early postoperative weight loss with maximal %WL, including adjustment for baseline variables. Results: There was marked variability in maximal %WL following both RYGBP (mean 32.9 %, range 4.1–60.9 %) and SG (mean 26.2 %, range 1.1–58.3 %). WLV 3–6 months postoperatively was more strongly associated with maximal %WL (r2 = 0.32 for RYGBP and r2 = 0.26 for SG, P < 0.001 for both) than either WLV 0–6 weeks or 6 weeks to 3 months postoperatively (r2 = 0.14 and 0.10 for RYGBP, respectively; r2 = 0.18 and 0.21 for SG, respectively; P < 0.001 for all). Multiple linear regression analysis, including baseline variables of age, sex, preoperative BMI, type 2 diabetes, ethnicity, and bariatric centre, revealed that 3–6 month WLV was an independent predictor of maximal %WL in both SG and RYGBP groups (standardised β-coefficients 0.51 and 0.52, respectively; P < 0.001 for both). Conclusions: There is a marked variability in weight loss response following RYGBP and SG. Early postoperative weight loss can be used to identify patients whose predicted weight loss trajectories are suboptimal. Early targeting of poor responders with more intensive postoperative lifestyle and behavioural support could potentially enhance their weight loss response. © 2014, The Author(s).","% weight loss; Bariatric surgery; BMI; Obesity; Roux-en-Y gastric bypass; Sleeve gastrectomy","Sjostrom, L., Effects of bariatric surgery on mortality in Swedish obese subjects (2007) N Engl J Med, 357 (8), pp. 741-752. , PID: 17715408; Picot J et al (2009) The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 13(41):1–190, 215–357, iii–ivVidal, P., Laparoscopic gastric bypass versus laparoscopic sleeve gastrectomy as a definitive surgical procedure for morbid obesity. Mid-term results (2013) Obes Surg, 23 (3), pp. 292-299. , PID: 23196992; Buchwald, H., Oien, D.M., Metabolic/bariatric surgery worldwide 2011 (2013) Obes Surg, 23 (4), pp. 427-436. , PID: 23338049; Schauer, P.R., Bariatric surgery versus intensive medical therapy in obese patients with diabetes (2012) N Engl J Med, 366 (17), pp. 1567-1576. , COI: 1:CAS:528:DC%2BC38Xmt1OrsL8%3D, PID: 22449319; O’Brien, P.E., Intensive medical weight loss or laparoscopic adjustable gastric banding in the treatment of mild to moderate obesity: long-term follow-up of a prospective randomised trial (2013) Obes Surg, 23 (9), pp. 1345-1353. , PID: 23760764; Hatoum, I.J., Capacity for physical activity predicts weight loss after Roux-en-Y gastric bypass (2009) Obesity (Silver Spring), 17 (1), pp. 92-99; Courcoulas, A.P., Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity (2013) JAMA, 310, pp. 2416-2425. , COI: 1:CAS:528:DC%2BC2cXosFGhtQ%3D%3D, PID: 24189773; van de Laar, A.W., Acherman, Y.I., Weight loss percentile charts of large representative series: a benchmark defining sufficient weight loss challenging current criteria for success of bariatric surgery (2014) Obes Surg, 24, pp. 727-734. , PID: 24234735; Puzziferri, N., Variations of weight loss following gastric bypass and gastric band (2008) Ann Surg, 248 (2), pp. 233-242. , PID: 18650633; Still, C.D., Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery (2014) Obesity (Silver Spring), 22 (3), pp. 888-894; Contreras, J.E., Correlation between age and weight loss after bariatric surgery (2013) Obes Surg, 23 (8), pp. 1286-1289. , PID: 23462862; Ma, Y., Predictors of weight status following laparoscopic gastric bypass (2006) Obes Surg, 16 (9), pp. 1227-1231. , PID: 16989709; Ochner, C.N., Effect of preoperative body mass index on weight loss after obesity surgery (2013) Surg Obes Relat Dis, 9 (3), pp. 423-427. , PID: 23434275; Ochner, C.N., Greater short-term weight loss in women 20–45 versus 55–65 years of age following bariatric surgery (2013) Obes Surg, 23 (10), pp. 1650-1654. , PID: 23700235; Ortega, E., Predictive factors of excess body weight loss 1 year after laparoscopic bariatric surgery (2012) Surg Endosc, 26 (6), pp. 1744-1750. , PID: 22234587; Scozzari, G., Age as a long-term prognostic factor in bariatric surgery (2012) Ann Surg, 256 (5), pp. 724-726. , PID: 23095615, discussion 728–729; Piaggi, P., Artificial neural networks in the outcome prediction of adjustable gastric banding in obese women (2010) PLoS ONE, 5 (10), p. e13624. , PID: 21048960; Sczepaniak, J.P., A simpler method for predicting weight loss in the first year after Roux-en-Y gastric bypass (2012) J Obes, 2012, p. 195251. , PID: 22315671; Brown, W.A., Pre-operative weight loss does not predict weight loss following laparoscopic adjustable gastric banding (2013) Obes Surg, 23 (10), pp. 1611-1615. , PID: 23636997; Mor, A., Weight loss at first postoperative visit predicts long-term outcome of Roux-en-Y gastric bypass using Duke weight loss surgery chart (2012) Surg Obes Relat Dis, 8 (5), pp. 556-560. , PID: 22920966; Rudolph, A., Hilbert, A., Post-operative behavioural management in bariatric surgery: a systematic review and meta-analysis of randomized controlled trials (2013) Obes Rev, 14 (4), pp. 292-302. , COI: 1:STN:280:DC%2BC3s3ntlajtw%3D%3D, PID: 23294936; Nijamkin, M.P., Comprehensive nutrition and lifestyle education improves weight loss and physical activity in Hispanic Americans following gastric bypass surgery: a randomized controlled trial (2012) J Acad Nutr Diet, 112 (3), pp. 382-390. , PID: 22717198; Egberts, K., Does exercise improve weight loss after bariatric surgery? A systematic review (2012) Obes Surg, 22 (2), pp. 335-341. , PID: 22038571; Hatoum, I.J., Kaplan, L.M., Advantages of percent weight loss as a method of reporting weight loss after Roux-en-Y gastric bypass (2013) Obesity (Silver Spring), 21 (8), pp. 1519-1525; Price, H.I., Gregory, D.M., Twells, L.K., Weight loss expectations of laparoscopic sleeve gastrectomy candidates compared to clinically expected weight loss outcomes 1-year post-surgery (2013) Obes Surg, 23 (12), pp. 1987-1993. , PID: 23794118; Manning, S., Batterham, R.L., The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on (2014) Annu Rev Physiol, 76, pp. 585-608. , COI: 1:CAS:528:DC%2BC2cXlvVCmtrs%3D, PID: 24188711; Stefater, M.A., All bariatric surgeries are not created equal: insights from mechanistic comparisons (2012) Endocr Rev, 33 (4), pp. 595-622. , COI: 1:CAS:528:DC%2BC38XhtlGgtLfP, PID: 22550271; Mechanick, J.I., Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the obesity society, and American Society for Metabolic & Bariatric Surgery (2013) Surg Obes Relat Dis, 9 (2), pp. 159-191. , PID: 23537696; Hatoum, I.J., Weight loss after gastric bypass is associated with a variant at 15q26.1 (2013) Am J Hum Genet, 92 (5), pp. 827-834. , COI: 1:CAS:528:DC%2BC3sXmvF2ktb0%3D, PID: 23643386; Tam, C.S., Could the mechanisms of bariatric surgery hold the key for novel therapies? Report from a Pennington Scientific Symposium (2011) Obes Rev, 12 (11), pp. 984-994. , COI: 1:STN:280:DC%2BC38%2FhsFerug%3D%3D, PID: 21729236; Hatoum, I.J., Heritability of the weight loss response to gastric bypass surgery (2011) J Clin Endocrinol Metab, 96 (10), pp. E1630-E1633. , COI: 1:CAS:528:DC%2BC3MXhtlyiur7J, PID: 21832118; Rinella, E.S., Genome-wide association of single-nucleotide polymorphisms with weight loss outcomes after Roux-en-Y gastric bypass surgery (2013) J Clin Endocrinol Metab, 98 (6), pp. E1131-E1136. , COI: 1:CAS:528:DC%2BC3sXptlKlu78%3D, PID: 23633212; Butler, A.A., O’Rourke, R.W., Bariatric surgery in the era of personalized medicine (2013) Gastroenterology, 144 (3), pp. 497-500. , PID: 23347671; Karmali, S., Weight recidivism post-bariatric surgery: a systematic review (2013) Obes Surg, 23 (11), pp. 1922-1933. , PID: 23996349; Sjostrom, L., Review of the key results from the Swedish obese subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery (2013) J Intern Med, 273 (3), pp. 219-234. , COI: 1:STN:280:DC%2BC3s7ksFGltQ%3D%3D, PID: 23163728",Article,Scopus,2-s2.0-84928892474
"Wang Q., Li H., Xiao Y., Li S., Li B., Zhao X., Ye L., Guo B., Chen X., Ding Y., Bao C.","Locally controlled delivery of TNFα antibody from a novel glucose-sensitive scaffold enhances alveolar bone healing in diabetic conditions",2015,"Journal of Controlled Release","206",,,"232","242",,,10.1016/j.jconrel.2015.03.019,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926207179&partnerID=40&md5=b2c191ea545f4facd2e7b888e7af4f83","State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; Department of Prosthodontics, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; State Key Laboratory of Polymer Materials Engineering, Poly Research Institute of Sichuan UniversityChengdu, China; Department of Stomatology, People's Liberation Army General HospitalBeijing, China","Wang, Q., State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China, Department of Prosthodontics, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; Li, H., State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; Xiao, Y., State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; Li, S., State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China, Department of Prosthodontics, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; Li, B., State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China, Department of Prosthodontics, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; Zhao, X., State Key Laboratory of Polymer Materials Engineering, Poly Research Institute of Sichuan UniversityChengdu, China; Ye, L., State Key Laboratory of Polymer Materials Engineering, Poly Research Institute of Sichuan UniversityChengdu, China; Guo, B., Department of Stomatology, People's Liberation Army General HospitalBeijing, China; Chen, X., State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China, Department of Prosthodontics, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; Ding, Y., State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China; Bao, C., State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan UniversityChengdu, China","Diabetic patients are often accompanied with severe alveolar bone destruction and an increased local TNFα level. Bone repair is a major challenge in those with poor glycemic control. Herein, we report a glucose-sensitive TNFα-antibody-delivery system based on quaternized chitosan and collagen for local long-term control of inflammation and improving osteogenesis in diabetes. We demonstrated that the glucose-sensitive delivery system was a honeycomb-shaped scaffold with pores suitable for bone regeneration. It was capable of attenuating inflammatory response of bone marrow stromal cells under the condition of hyperglucose and TNFα. Additionally, a special diabetic rat model with fluctuation of blood glucose level was established to investigate biological effects of the scaffold. Our results showed that this TNFα-antibody-delivery strategy effectively reduced inflammation by decreasing expression of local TNFα and inflammatory factors. More importantly, with the enhancement of osteogenesis-associated proteins, promoted alveolar bone healing was achieved in the diabetic rat model. The data indicate that such a delivery system possibly provides a potential therapeutic strategy for diabetic patients with severe alveolar bone defects. © 2015 Elsevier B.V. All rights reserved.","Alveolar bone defect; Diabetes; Glucose-sensitive drug delivery; Scaffold; TNFα antibody","Wang, Q., Xie, H.H., Fu, M., Guo, B., Ding, Y., Li, W., Yu, H.Y., 25-Hydroxyvitamin D<inf>3</inf> attenuates experimental periodontitis through downregulation of TLR4 and JAK1/STAT3 signaling in diabetic mice (2013) J. Steroid Biochem. Mol. Biol., 135, pp. 43-50; Xu, F.Z., Chen, Y., Graves, T.D., Abnormal cell responses and role of TNF-alpha in impaired diabetic wound healing (2013) BioMed. Res. Int., 2013, p. 754802; Mountziaris, P.M., Lehman, E.D., Mountziaris, I., Sing, D.C., Kasper, F.K., Mikos, A.G., Effect of temporally patterned TNF-alpha delivery on in vitro osteogenic differentiation of mesenchymal stem cells cultured on biodegradable polymer scaffolds (2013) J. Biomater. Sci. Polym. Ed., 24, pp. 1794-1813; Pers, J., Saraux, A., Pierre, R., Youinou, P., Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis (2008) J. Periodontol., 799, pp. 1645-1651; Chang, P.C., Chung, M.C., Wang, Y.P., Chien, L.Y., Lim, J.C., Liang, K., Chong, L.Y., Chiang, H.C., Patterns of diabetic periodontal wound repair: A study using micro-computed tomography and immunohistochemistry (2012) J. Periodontol., 83, pp. 644-652; Losi, P., Briqanti, E., Errico, C., Lisella, A., Sanquinetti, E., Chiellini, F., Soldani, G., Fibrin-based scaffold incorporating VEGF- and bFGF-loaded nanoparticles stimulates wound healing in diabetic mice (2013) Acta Biomater., 9, pp. 7814-7821; Teich, N., Topical application of TNF-blockers [review] (2013) Dtsch. Med. Wochenschr., 138, pp. 381-385; Cornillie, F., Shealy, D., D'Haens, G., Geboes, K., Assche, G.V., Ceuppens, J., Wagner, C., Rutgeerts, P., Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease (2001) Aliment. Pharmacol. Ther., 15, pp. 463-473; Taylor, M.J., Tanna, S., Sahota, T., In vivo study of a polymeric glucose-sensitive insulin delivery system using a rat model (2010) J. Pharm. Sci., 99, pp. 4215-4227; Bhattarai, N., Gunn, J., Zhang, M., Chitosan-based hydrogels for controlled, localized drug delivery (2010) Adv. Drug Deliv. Rev., 62, pp. 83-99; Croutze, R., Jomha, N., Uludag, H., Adesida, A., Matrix forming characteristics of inner and outer human meniscus cells on 3D collagen scaffolds under normal and low oxygen tensions (2013) BMC Musculoskelet. Disord., 14, p. 353; Ji, Q.X., Zhong, D.Y., Lü, R., Zhang, W.Q., Deng, J., Chen, X.G., In vitro evaluation of the biomedical properties of chitosan and quaternized chitosan for dental applications (2009) Carbohydr. Res., 344, pp. 1297-1302; Chen, Y., Tang, C., Zhang, J., Gong, M., Su, B., Qiu, F., Self-assembling surfactant-like peptide A6K as potential delivery system for hydrophobic drugs (2015) Int. J. Nanomedicine, 10, pp. 847-858; Kim, K., Dean, D., Wallace, J., Breithaupt, R., Mikos, A.G., Fisher, J.P., The influence of stereolithographic scaffold architecture and composition on osteogenic signal expression with rat bone marrow stromal cells (2011) Biomaterials, 32, pp. 3750-3763; Li, H., Yang, H., Ding, Y., Aprecio, R., Zhang, W., Wang, Q., Li, Y.M., Experimental periodontitis induced by Porphyromonas gingivalis does not alter the onset or severity of diabetes in mice (2013) J. Periodontal Res., 48, pp. 582-590; Lane, J.M., Sandhu, H.S., Current approaches to experimental bone grafting (1987) Orthop. Clin. N. Am., 18, pp. 213-225; Prabaharan, M., Rodriguez-Perez, M.A., De Saja, J.A., Mano, J.F., Preparation and characterization of poly(l-lactic acid)-chitosan hybrid scaffolds with drug release capability (2007) J. Biomed. Mater. Res. B Appl. Biomater., 81 B, pp. 427-434; Wei, G., Jin, Q., Giannobile, W.V., Maa, P.X., Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB (2006) J. Control. Release, 112, pp. 103-110; Chen, L.Y., Tian, Z.G., Du, Y.M., Synthesis and pH sensitivity of carboxymethyl chitosan-based polyamppholyte hydrogels for protein carrier matrices (2004) Biomaterials, 25, pp. 3725-3732; Shi, H., Ma, J., Zhao, N., Chen, Y., Liao, Y., Periodontal regeneration in experimentally-induced alveolar bone dehiscence by an improved porous biphasic calcium phosphate ceramic in beagle dogs (2008) J. Mater. Sci. Mater. Med., 19, pp. 3515-3524; Prabaharan, M., Review paper: Chitosan derivatives as promising materials for controlled drug delivery (2008) J. Biomater. Appl., 23, pp. 5-36; Wu, J., Su, Z.G., Ma, G.H., A thermo- and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate (2006) Int. J. Pharm., 315, pp. 1-11; Traitel, T., Cohen, Y., Kost, J., Characterization of glucose-sensitive insulin release systems in simulated in vivo conditions (2000) Biomaterials, 21, pp. 1679-1687; Ohlrich, C.M., Leichter, J., Diabetes, periodontitis, and the subgingival microbiota (2010) J. Oral Microbiol., 2, pp. 10-34; Kim, S.H., Kim, K.H., Seo, B.M., Koo, K.T., Kim, T.I., Seol, Y.J., Ku, Y., Lee, Y.M., Alveolar bone regeneration by transplantation of periodontal ligament stem cells and bone marrow stem cells in a canine peri-implant defect model: A pilot study (2009) J. Periodontol., 80, pp. 1815-1823; Chen, X., Zhao, Y., Geng, S., Miron, R.J., Zhang, Q., Wu, C., Zhang, Y., In vivo experimental study on bone regeneration in critical bone defects using PIB nanogels/boron-containing mesoporous bioactive glass composite scaffold (2015) Int. J. Nanomedicine, 10, pp. 839-846; Baxter, M.A., The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes (2008) Acta Diabetol., 45, pp. 253-268; Pham, N.D., Barthélémy, I., Orliaguet, T., Artola, A., Mondié, J.M., Dallel, R., Etiology, distribution, treatment modalities and complications of maxillofacial fractures (2013) Med. Oral Patol. Oral Cir. Bucal, 19, pp. e261-e269; Funk, J.R., Hale, J.E., Carmines, D., Gooch, H.L., Hurwitz, S.R., Biomechanical evaluation of early fracture healing in normal and diabetic rats (2000) J. Orthop. Res., 18, pp. 126-132; Nishimura, F., Iwamoto, Y., Mineshiba, J., Shimizu, A., Soga, Y., Murayama, Y., Periodontal disease and diabetes mellitus: The role of tumor necrosis factor-alpha in a 2-way relationship (2003) J. Periodontol., 74, pp. 97-102; Li, M., Yu, L., She, T., Gan, Y., Liu, F., Hu, Z., Chen, Y., Xia, H., Astragaloside IV attenuates Toll-like receptor 4 expression via NF-kB pathway under high glucose condition in mesenchymal stem cells (2012) Eur. J. Pharmacol., 696, pp. 203-209; Yadav, A., Saini, V., Arora, S., MCP-1: Chemoattractant with a role beyond immunity: A review (2010) Clin. Chim. Acta, 411, pp. 1570-1579; Omatsu, T., Cepinskas, G., Clarson, C., Patterson, E.K., Alharfi, I.M., Summers, K., Couraud, P.O., Fraser, D.D., Canadian Critical Care Translational Biology Group, CXCL1/CXCL8 (GROalpha/IL-8) in human diabetic ketoacidosis plasma facilitates leukocyte recruitment to cerebrovascular endothelium in vitro (2014) Am. J. Physiol. Endocrinol. Metab., 306, pp. E1077-E1084; Huang, W., Yang, S.Y., Shao, J., Li, Y.P., Signaling and transcriptional regulation in osteoblast commitment and differentiation (2007) Front. Biosci., 12, pp. 3068-3092; Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J.M., Behringer, R.R., Crombrugghe, B.D., The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation (2002) Cell, 108, pp. 17-29; Neve, A., Corrado, A., Cantatore, F.P., Osteocalcin: Skeletal and extra-skeletal effects (2013) J. Cell. Physiol., 228, pp. 1149-1153; Jeong, Y., Yang, W., Ko, H., Kim, M., The effects of bone morphogenetic protein-2 and enamel matrix derivative on the bioactivity of mineral trioxide aggregate in MC3T3-E1cells (2014) Restor. Dent. Endod., 39, pp. 187-194; Genge, B.R., Sauer, G.R., Wu, L.N., McLean, F.M., Wuthier, R.E., Correlation between loss of alkaline phosphatase activity and accumulation of calcium during matrix vesicle-mediated mineralization (1988) J. Biol. Chem., 263, pp. 18513-18519; Kaneto, C.M., Lima, P.S., Zanette, D.L., Prata, K.L., Pina Neto, J.M., De Paula, F.J., Silva, W.J., COL1A1 and miR-29b show lower expression levels during osteoblast differentiation of bone marrow stromal cells from osteogenesis imperfecta patients (2014) BMC Med. Genet., 15, p. 45; Thayu, M., Leonard, M.B., Hyams, J.S., Crandall, W.V., Kugathasan, S., Otley, A.R., Olson, A., Study Group, R., Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: Results of the REACH study (2008) Clin. Gastroenterol. Hepatol., 6, pp. 1378-1384; Szentpetery, A., McKenna, M.J., Merray, B.F., Ng, C.T., Brady, J.J., Morrin, M., Radovits, B., Fitzgerald, O., Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis (2013) J. Rheumatol., 40, pp. 653-662",Article,Scopus,2-s2.0-84926207179
"Ozdemir E., Alpinar K.","An ethnobotanical survey of medicinal plants in western part of central Taurus Mountains: Aladaglar (Nigde - Turkey)",2015,"Journal of Ethnopharmacology","166",,,"53","65",,,10.1016/j.jep.2015.02.052,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925443351&partnerID=40&md5=731d2355824a7ea6dd3a72600377b6d6","Yeni YüzyIl University, Faculty of Pharmacy, Department of Pharmaceutical BotanyZeytinburnu Istanbul, Turkey; Biruni University, Faculty of Pharmacy, Department of Pharmaceutical BotanyTopkapI, Istanbul, Turkey","Özdemir, E., Yeni YüzyIl University, Faculty of Pharmacy, Department of Pharmaceutical BotanyZeytinburnu Istanbul, Turkey; Alpinar, K., Biruni University, Faculty of Pharmacy, Department of Pharmaceutical BotanyTopkapI, Istanbul, Turkey","Ethnopharmacological relevance With this study, we aimed to document traditional uses of medicinal plants in the western part of Aladaglar/Nigde. Materials and methods This study was conducted between 2003 and 2005. The research area was in the western part of the Aladaglar mountains. The settlements in Aladaglar (5 towns and 10 villages) were visited during the field work. The plants collected by the help of medicinal plant users. The plants were identified and voucher specimens prepared. These voucher specimens were kept at the Herbarium of Istanbul University Faculty of Pharmacy (ISTE). We collected the information by means of semi-structured interviews with 170 informants (90 men and 80 women). In addition, the relative importance value of the species was determined and the informant consensus factor (FIC) was calculated for the medicinal plants researched in the study. Results According to the results of the identification, among 126 plants were used by the inhabitants and 110 species belonging to 40 families were used for medicinal purposes. Most of the medicinal plants used in Aladaglar/Nigde belong to the families Lamiaceae (25 species), Asteraceae (16 species), Apiaceae (7 species), Fabaceae (6 species) and Brassicaceae (5 species). The most commonly used plant species were Hypericum perforatum Thymus sipyleus var. sipyleus, Rosa canina, Urtica dioica, Malva neglecta, Thymus leucotrichus, Salix alba, Mentha longifolia, Berberis crataegina, Juniperus oxycedrus, Viscum album subsp. abietis, Allium rotundum and Taraxacum stevenii. The most common preparations were infusion and decoction. The traditional medicinal plants have been mostly used for the treatment of cardiovascular diseases (86%), hemorrhoids (79%), urinary diseases (69%), diabetes (68%) and respiratory diseases (61%). Conclusion The use of traditional medicine was still widespread among the inhabitants of Aladaglar mountains/Nigde region. Due to the lack of medical facilities in the villages of Aladaglar mountains, local people prefer herbal treatment rather than medical treatment. This study identified not only the wild plants collected for medical purposes by local people of Aladaglar/Nigde, but also the uses and local names of these plants. This paper helps to preserve valuable information that may otherwise be lost to future generations. © 2015 Elsevier Ireland Ltd.","Aladaglar; Ethnobotany; Medicinal plants; Nigde; Traditional medicine; Turkey","Abbasi, A.M., Hkan, M.A., Ahmad, M., Zafar, M., Ethnobotanical Aspects (2012) Med. Plant Biodivers. Lesser Himal.-Pak., 13, p. 220; Abu-Irmaileh, B.E., Afifi, F.U., Herbal medicine in Jordan with special emphasis on commonly used herbs (2003) J. Ethnopharmacol., 89, pp. 193-197; Afifi, F.U., Abu-Irmaileh, B., Herbal medicine in Jordan with emphasis on less commonly used medicinal herbs (2000) J. Ethnopharmacol., 72, pp. 101-110; Akbay, P., Basaran, A., Undeger, U., Basaran, N., In vitro immunomodulatory activity flavonoid glycosides from Urtica dioica (2003) Phytother. Res., 17, pp. 34-37; Altundaʇ, E., Öztürk, M., Ethnomedicinal studies on the plant resources of east Anatolia, Turkey (2011) Proced. Soc. Behav. Sci., 19, pp. 756-777; Baʇci, Y., Ethnobotanical features of Aladaglar (YahyalI Kayseri) and its vicinity (2000) Herb J. Syst. Bot., 7, pp. 89-94; Bulut, G., Tuzlaci, E., An ethnobotanical study of medicinal plants in Turgutlu (Manisa Turkey) (2013) J. Ethnopharmacol., 149, pp. 633-647; Byfield, A., Atay, S., Özhatay, N., (2010) Important Plant Areas in Turkey: 122 Key Turkish Botanical Sites, , WWF Turkey, Istanbul; Cakilcioglu, U., Khatun, S., Turkoglu, I., Hayta, S., Ethnopharmacological survey of medicinal plants in Maden (Elazig-Turkey) (2011) J. Ethnopharmacol., 137, pp. 469-486; Cakilcioglu, U., Turkoglu, I., An ethnobotanical survey of medicinal plants in Sivrice (ElazIʇ, Turkey) (2010) J. Ethnopharmacol., 132, pp. 165-175; Davis, P.H., (1965) Flora of Turkey and the East Aegean Islands, 19 VOLS. -. , Edinburgh University Press Edinburgh; Davis, P.H., Mill, R.R., Tan, K., (1988) Flora of Turkey and the East Aegean Islands, 10 VOL.. , Edinburgh University Press Edinburgh; Demirci, S., Ozhatay, N., An ethnobotanical study in Kahramanmaraş (Turkey); Wild plants used for medicinal purpose in AndIrIn, Kahramanmaraş (2012) Turk. J. Pharm. Sci, 9 (1), pp. 75-92; Elci, B., Erik, S., An ethnobotanical study in Güdül (Ankara) (2006) J. Fac. Pharm. Hacet.E Univ., 26 (2), pp. 57-64; Ertuʇ, F., An ethnobotanical study in Central Anatolia (Turkey) (2000) J. Econ. Bot., 54, pp. 155-182; Ezer, N., Mumcu Arisan Ö., Folk Medicines in Merzifon (Amasya, Turkey) (2006) Turk. J. Bot., 30, pp. 223-230; Everest, A., Öztürk, E., Focusing on the ethnobotanical uses of plants in Mersin and Adana Provinces (Turkey) (2005) J. Ethnobiol. Ethnomed., 1, p. 6; Ghorbani, A., Studies on pharmaceutical ethnobotany in the region of Turkmen Sahra, north of Iran (part 1): General results (2005) J. Ethnopharmacol., 102, pp. 58-68; Gulcin, I., Küfrevioʇlua, O.I., Oktay, M., Büyükokuroʇlu, M.E., Antioxidant, antimicrobial, antiulcer and analgesic activities of nettle (Urtica dioica L.) (2004) J. Ethnopharmacol., 90, pp. 205-215; Gulluce, M., Sahing, F., Sokmend, M., Ozer, H., Dafereraf, D., Sokmene, A., Polissiouf, M., Ozkan, H., Antimicrobial and antioxidant properties of the essential oils and methanol extract from Mentha longifolia L. Ssp. Longifolia (2007) Food. Chem., 1034, pp. 1449-1456; Güneş, F., Özhatay, N., An Ethnobotanical study from Kars (Eastern)Turkey (2011) Biol. Divers. Conserv., 41, pp. 30-41; Gürdal, B., Kültür Ş., An Ethnobotanical Study of medicinal plants in Marmaris (Muʇla, Turkey) (2013) J. Ethnopharmacol., 146, pp. 113-126; Hayta Ş., Polat, R., Selvi, S., Traditional uses of medicinal plants in ElazIʇ (Turkey) (2014) J. Ethnopharmacol., 154, pp. 613-623; Kandemir, A., Yigit, N., Antimicrobial activity of some endemic plants (Salvia cryptantha, Origanum acutidens, Thymus sipyleus ssp. Sipyleus) (2002) Erzincan Educ. Fac., 2-4, pp. 77-81; Kargioʇlu, M., Cenkci, S., Serteser, A., Evliyaoʇlu, N., Konuk, M., Kök, M.S., Baʇci, Y., An ethnobotanical survey of inner-West Anatolia,Turkey (2008) Hum. Ecol., 36, pp. 763-777; Kaval, I., Lütfi, B., Cakilcioʇlu, U., Ethnobotanical study on medicinal plants in Geçitli and its surrounding (Hakkari-Turkey) (2014) J. Ethnopharmacol., 155 (1), pp. 171-184; Kocyiʇit, M., Özhatay, N., Wild plants used as medicinal purpose in Yalova (Northwest Turkey) (2006) Turk. J. Pharm. Sci., 3 (2), pp. 91-103; Koyuncu, O., Yaylaci Ö., K., Tokur, S., A study on Geyve (Sakarya) and its environs in terms of ethnobotanical aspects (2009) Herb J. Syst. Bot., 16, pp. 123-142; Kültür, S., Medicinal plants used in KIrklareli Province (Turkey) (2007) J. Ethnopharmacol., 111 (2), pp. 341-364; Kültür Ş., An Ethnobotanical study of KIrklareli (Turkey) (2008) Phytol. Balc., 14, pp. 279-289; Lev, E., Amar, Z., Ethnopharmacological survey of traditional drugs sold in the Kingdom of Jordan (2002) J. Ethnopharmacol., 82, pp. 131-145; Mati, E., Boer, H., Ethnobotany and trade of medicinal plants in the Qaysari Market, Kurdish Autonomous Region, Iraq (2011) J. Ethnopharmacol., 133, pp. 490-510; Mosaddegha, M., Naghibia, F., Moazzenia, H., Pirania, A., Esmaeilia, S., Ethnobotanical survey of herbal remedies traditionally used in Kohghiluyeh va Boyer Ahmad province of Iran (2012) J. Ethnopharmacol., 141, pp. 80-95; Oral, D.C., (2007) Ethnobotany of Konya, , Gazi University Institute of health Turkey M.Sc.Thesis; Özgen, U., Kaya, Y., Coskun, M., Ethnobotanical studies in the villages of the district of IlIca (Province Erzurum). Turkey (2004) Econ. Bot., 58, pp. 691-696; Özgen, U., Kaya, Y., Houghton, P., Folk medicines in the villages of IlIca district (Erzurum, Turkey) (2011) Turk. J. Biol., 35, pp. 124-140; Özgokce, F., Ozcelik, H., Ethnobotanical aspects of some taxa in East Anatolia (Turkey) (2004) Econ. Bot., 58, pp. 697-704; Özhatay, N., Koçak, S., Plants used for medicinal purpose in Karaman province (Southern Turkey) (2011) J. Fac. Pharm. Istanb., 41, pp. 75-88; Özkan, A.M.G., Koyuncu, M., Traditional medicinal plants used in PInarbaşc Area (Kayseri-Turkey) (2005) Turk. J. Pharm. Sci., 2, pp. 63-82; Öztürk, M., Dinc, M., An ethnobotanical study in Nizip (Aksaray) (2005) Ot Syst. Bot. J., 12 (1), pp. 93-102; Öztürk, F., Ölçücü, C., Ethnobotanical features of some plants in the district of Şemdinli (Hakkari - Turkey) (2011) I. J. Acad. Res., 3, pp. 120-125; Polat, R., Satil, F., Havran ve Burhaniye (Balikesir) Yörelerinde Etnobotanik AraştIrmalarI (2010) TUBA Kültür Envanter Dergisi, 8, pp. 65-100; Polat, R., Satil, F., An ethnobotanical survey of medicinal plants in Edremit Gulf (BalIkesir - Turkey) (2012) J. Ethnopharmacol., 139, pp. 626-641; Polat, R., Cakilcioʇlu, U., Satil, F., Traditional uses of medicinal plants in Solhan (Bingöl-Turkey) (2013) J. Ethnopharmacol., 148, pp. 951-963; (2003) Ravinell, Alberto and Green, Whitney., p. 126. , The Storm-god in the Ancient Near East; Rehecho, S., Uriarte-Pueyo, I., Calvo, J., Vivas, L.A., Calvo, M.I., Ethnopharmacological survey of medicinal plants in Nor-Yauyos, apart of the Landscape Reserve Nor-Yauyos-Cochas, Peru (2011) J. Ethnopharmacol., 133, pp. 75-85; Saggs, H.W.F., (1988) The Greatness That Was Babylon: A Survey of the Ancient Civilization of the Tigris-Euphrates Valley, p. 380. , 2nd Revised ed. Sidgwick & Jackson London; Sargin, S.A., Akçiçek, E., Selvi, S., An Ethnobotanical study of medicinal plants by the local people of Alaşehir (Manisa) in Turkey (2013) J. Ethnopharmacol., 150, pp. 860-874; Sarper, F., Akaydin, G., Şimşek, I., Yeşilada, E., An Ethnobotanical Field Survey in the Haymana District of Ankara Province in Turkey (2009) Turk. J. Biol., 33, pp. 79-88; Sezik, E., Tabata, M., Yeşilada, E., Honda, G., Goto, K., Ikeshiro, Y., Traditional medicine in Turkey i Folk medicine in North-East Anatolia (1991) J. Ethnopharmacol., 35, pp. 191-196; Sezik, E., Yeşilada, E., Tabata, M., Honda, G., Takaishi, Y., Fujita, T., Tanaka, T., Takeda, Y., Traditional medicine in Turkey VIII. Folk medicine in East Anatolia; Erzurum, Erzincan, AʇrI, Kars, IʇdIr provinces (1997) Econ. Bot., 51 (3), pp. 195-211; Sezik, E., Yeşilada, E., Tabata, M., Honda, G., Takaishi, Takeda, Y., Tanaka, T., Traditional medicine in Turkey X. Folk medicine in Central Anatolia (2001) J. Ethnopharmacol., 75, pp. 95-115; Sosa, S., Pace, R., Bornancin, A., Morazzoni, P., Riva, A., Tubaro, A., Della Loggia, R., Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L. (2007) J. Pharm. Pharmacol., 59 (5), pp. 703-709; Şimsek, I., Aytekin, F., Yeşilada, E., Yildirimli, S., An ethnobotanical survey of the BeypazarI, Ayas, and Güdül district towns of Ankara province (Turkey) (2004) Econ. Bot., 58, pp. 705-720; Tabata, M., Sezik, E., Honda, G., Yeşilada, E., Fukui, H., Goto, K., Ikeshiro, Y., Traditional medicine in Turkey III. Folk medicine in East Anatoli, Van and Bitlis provinces (1994) Int. J. Pharmacogn., 321, pp. 3-12; Teklehaymanot, T., Giday, M., Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, northwestern Ethiopia (2007) J. Ethnobiol. Ethnomed., 3, p. 12; Tepe, B., Sokmen, M., Akpulata, H.A., Dafererac, D., Polissiouc, M., Sokmena, A., Antioxidative activity of the essential oils of Thymus sipyleus subsp. Sipyleus var. Sipyleus and Thymus sipyleus subsp. Sipyleus var. Rosulans (2005) J. Food Eng., 66, pp. 447-454; Trotter, R.T., Logan, M.H., Informant consensus: A new approach for identifying potentially effective medicinal plants (1986) Plants in Indigenous Medicine and Diet, Behavioural Approaches, , N.L. Etkin, Redgrave Publishing Company Bredford Hills, New York; Tuzlaci, E., Alparslan Isbilen, D.F., Bulut, G., Turkish folk medicinal plants, VIII: Lalapaşa (Edirne) (2010) Marmara Pharm. J., 14, pp. 47-52; Tuzlaci, E., (2011) A Dictionary of Turkish Plants, , Alfa publishing Istanbul; Tüfekçi, S., Savran, A., Baʇci, Y., Özkurt, N., (2002) The Flora of Aladaʇ National Park, p. 206. , Ministry of Forest publication Niʇde/Turkey; Ugulu, I., Aydin, H., Yorek, N., Dogan, Y., The impact of endemism concept on environmental attitudes of secondary school students (2008) Nat. Montenegrina, 7, pp. 165-173; Uzun, E., Sariyar, G., Adsersen, A., Karakoc, B., Ötük, G., Oktayoʇlu, E., Pirildar, S., Traditional medicine in Sakarya province (Turkey) and antimicrobial activities of selected species (2004) J. Ethnopharmacol., 95, pp. 287-296; Yeşil, Y., Akalin, E., Folk medicinal plants in Kürecik area (Akçadaʇ/MalatyaTurkey) (2009) Turk. J. Pharm. Sci., 6, pp. 207-220; Yeşilada, E., Past and future contributions to traditional medicine in the health care system of the Middle-East (2005) J. Ethnopharmacol., 100, pp. 135-137; Yeşilada, E., Küpeli, E., Berberis crataegina DC. Root exhibits potent anti-inflammatory, analgesic and febrifuge effects in mice and rats (2002) J. Ethnopharmacol., 79, pp. 237-248; Yeşilada, E., Sezik, E., Honda, G., Takaishi, Y., Takeda, Y., Tanaka, T., Traditional medicine in Turkey IX. Folk medicine in North West Anatolia (1999) J. Ethnopharmacol., 64, pp. 195-210",Article,Scopus,2-s2.0-84925443351
"Oloyede H.O.B., Bello T.O., Ajiboye T.O., Salawu M.O.","Antidiabetic and antidyslipidemic activities of aqueous leaf extract of Dioscoreophyllum cumminsii (Stapf) Diels in alloxan-induced diabetic rats",2015,"Journal of Ethnopharmacology","166",,,"313","322",,,10.1016/j.jep.2015.02.049,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926158516&partnerID=40&md5=49f19e8fb9ce63e75122dca6c4dfb368","Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, P. M. B. 1515Ilorin, Nigeria; Antioxidants, Free Radicals, Functional Foods and Toxicology Research Laboratory, Department of Biological Sciences, Al-Hikmah University, P.M.B. 1601Ilorin, Nigeria","Oloyede, H.O.B., Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, P. M. B. 1515Ilorin, Nigeria; Bello, T.O., Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, P. M. B. 1515Ilorin, Nigeria; Ajiboye, T.O., Antioxidants, Free Radicals, Functional Foods and Toxicology Research Laboratory, Department of Biological Sciences, Al-Hikmah University, P.M.B. 1601Ilorin, Nigeria; Salawu, M.O., Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, P. M. B. 1515Ilorin, Nigeria","Ethnopharmacological relevance Dioscoreophyllum cumminsii (Stapf) Diels leaves are used in the management of diabetics in Nigeria. Thus, the antidiabetic activity of aqueous D. cumminsii leaf extract and its capability to halt oxidative stress and dyslipidemia in alloxan-induced diabetic rats was investigated. Methodology Antidiabetic was evaluated in alloxan-induced diabetes rats. Diabetic rats were treated with 50, 100 and 200 mg/kg body weight of the extract. Result The aqueous extract of D. cumminsii leaves significantly reduced blood glucose level in a dose dependent manner with highest dose producing 72% reduction after 21 days administration, which was compared significantly (P<0.05) with the control group and glibenclamide treated groups. Similarly, aqueous extract of D. cumminsii significantly reversed reduction in insulin in alloxan-induced diabetic rats. Alloxan-induced diabetic mediated alterations in liver and serum cholesterol, triacylglycerides, high-density lipoprotein cholesterol (HDLc), low density lipoprotein cholesterol (LDLc) and very low-density lipoprotein cholesterol (VLDLc) were significantly (P<0.05) restored by the extract. Aqueous extract of D. cumminsii leaves significantly attenuated the decrease in the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glucose 6-phosphate dehydrogenase in the liver and pancreas of alloxan-induced diabetic rats. Elevation in the concentration of malondialdehyde was significantly (P<0.05) lowered by D. cumminsii leaves extract. The diabetic-mediated alteration in the architecture of liver was alleviated by the extract. Conclusion Overall, aqueous extract of D. cumminsii leaves at all doses investigated reduced blood glucose level and prevented oxidative stress and dyslipidemia in alloxan-induced diabetic rats. © 2015 Elsevier Ireland Ltd All rights reserved.",,"Adesina, S., Harborne, J., Phillipson, J., The isolation of quaternary alkaloids from the leaves of Dioscoreophyllum cumminsii (Stapf). Diels (2009) Planta Med., 33, pp. 217-222; Aebi, H., Catalase in vitro (1984) Methods Enzymol., 105, pp. 121-126; Ajiboye, T.O., Akinpelu, S.A., Muritala, H.F., Ogunbode, S.M., Adeleye, A.O., Oladiji, A.T., Oloyede, O.B., T richosanthes Cucumerina Fruit Extenuates Dyslipidemia, Protein Oxidation, Lipid Peroxidation and DNA Fragmentation in the liver of high-fat diet-fed rats (2014) J. Food Biochem, 38 (5), pp. 480-490; Ajiboye, T.O., Salau, A.K., Yakubu, M.T., Oladiji, A.T., Akanji, M.A., Okogun, J.I., Acetaminophen perturbed redox homeostasis in wistar rat liver: Protective role of aqueous Pterocarpus osun leaf extract (2010) Drug Chem. Toxicol., 33, pp. 77-87; Ajiboye, T.O., Yakubu, M.T., Oladiji, A.T., Electrophilic and reactive oxygen species detoxification potentials of chalcone dimers is mediated by redox transcription factor Nrf-2 (2014) J. Biochem. Mol. Toxicol., (28), pp. 11-22; Altan, N., Sepici-Dinçel, A., Sahin, D., Kocamanoʇlu, N., Kosova, F., Engin, A., Oxidative DNA damage: The thyroid hormone-mediated effects of insulin on liver tissue (2010) Endocrine, 38, pp. 214-220; Dalle-Donne, I., Rossi, R., Giustarini, D., Milzani, A., Colombo, R., Protein carbonyl groups as biomarkers of oxidative stress (2003) Clin. Chim. Acta, 329, pp. 23-38; De, D., Chatterjee, K., Ali, K.M., Bera, T.K., Ghosh, D., Antidiabetic potentiality of the aqueous-methanolic extract of seed of Swietenia mahagoni (L.) Jacq. in streptozotocin-induced diabetic male albino rat: A correlative and evidence-based approach with antioxidative and antihyperlipidemic activities (2011) Evid. Based. Complement. Altern. Med., , 892807; Ellman, G.L., Tissue sulfhydryl groups (1959) Arch. Biochem. Biophys., 82, pp. 70-77; Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge (1972) Clin. Chem., 18, pp. 499-502; Garber, A.J., Attenuating CV risk factors in patients with diabetes: Clinical evidence to clinical practice (2002) Diabetes Obes. Metab., 4, pp. S5-S12; Hsu, Y.-J., Lee, T.-H., Chang, C.L.-T., Huang, Y.-T., Yang, W.-C., Anti-hyperglycemic effects and mechanism of Bidens pilosa water extract (2009) J. Ethnopharmacol., 122, pp. 379-383; Klein, G., Kim, J., Himmeldirk, K., Cao, Y., Chen, X., Antidiabetes and anti-obesity activity of Lagerstroemia speciosa. Evidence-based complement (2007) Altern. Med., 4 (4), pp. 401-407; McGillicuddy, F.C., Reilly, M.P., Rader, D.J., Adipose modulation of high-density lipoprotein cholesterol: Implications for obesity, high-density lipoprotein metabolism, and cardiovascular disease (2011) Circulation, 124, pp. 1602-1605; Misra, H.P., Fridovich, I., The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase (1972) J. Biol. Chem., 247, pp. 3170-3175; (2011) Guide for the Care and Use of Laboratory Animals, p. 118. , National Research Council eighth ed., In: Guide for the Care and Use of Laboratory Animals; Nayak, B.S., Marshall, J.R., Isitor, G., Adogwa, A., Hypoglycemic and hepatoprotective activity of fermented fruit juice of morinda citrifolia (noni) in diabetic rats (2011) Evid. Based. Complement. Altern. Med., p. 875293; Niki, E., Lipid peroxidation: Physiological levels and dual biological effects (2009) Free Radic. Biol. Med., 47, pp. 469-484; Oliver-Bever, B., (1986) Medicinal Plants in Tropical West Africa, , Cambridge University Press; Oloyede, O.B., Ajiboye, T.O., Abdussalam, A.F., Adeleye, A.O., Blighia sapida leaves halt elevated blood glucose, dyslipidemia and oxidative stress in alloxan-induced diabetic rats (2014) J. Ethnopharmacol., 157, pp. 309-319; Oselebe, H.O., Ene-Obong, E.E., Nwankiti, O.C., The biology of Dioscoreophyllum cumminsii (Stapf) Diels (2004) Nigerian J. Bot., 175, pp. 17-28; Patel, M.B., Mishra, S., Hypoglycemic activity of alkaloidal fraction of Tinospora cordifolia (2011) Phytomedicine, 18, pp. 1045-1052; Pitocco, D., Zaccardi, F., Di Stasio, E., Romitelli, F., Santini, S.A., Zuppi, C., Ghirlanda, G., Oxidative stress, nitric oxide, and diabetes (2010) Rev. Diabet. Stud., 7, pp. 15-25; Rains, J.L., Jain, S.K., Oxidative stress, insulin signaling, and diabetes (2011) Free Radic. Biol. Med., 50, pp. 567-575; Reilly, C.A., Aust, S.D., Measurement of lipid peroxidation (2001) Current Protocols in Toxicology, , http://dx.doi.org/10.1002/0471140856, Chapter 2, Unit 2.4; Roy, S., Sehgal, R., Padhy, B.M., Kumar, V.L., Antioxidant and protective effect of latex of Calotropis procera against alloxan-induced diabetes in rats (2005) J. Ethnopharmacol., 102, pp. 470-473; Sefi, M., Fetoui, H., Makni, M., Zeghal, N., Mitigating effects of antioxidant properties of Artemisia campestris leaf extract on hyperlipidemia, advanced glycation end products and oxidative stress in alloxan-induced diabetic rats (2010) Food Chem. Toxicol., 48, pp. 1986-1993; Sefi, M., Fetoui, H., Lachkar, N., Tahraoui, A., Lyoussi, B., Boudawara, T., Zeghal, N., Centaurium erythrea (Gentianaceae) leaf extract alleviates streptozotocin-induced oxidative stress and β-cell damage in rat pancreas (2011) J. Ethnopharmacol., 135, pp. 243-250; Sepici-Dincel, A., Açikgöz, S., Cevik, C., Sengelen, M., Yeşilada, E., Effects of in vivo antioxidant enzyme activities of myrtle oil in normoglycaemic and alloxan diabetic rabbits (2007) J. Ethnopharmacol., 110, pp. 498-503; Sivakumar, Rajan, Antioxidant effect of Tinospora cordifolia extract in alloxan-induced diabetic rats (2010) Indian Journal of Pharmaceutical Sciences, 72 (6), pp. 795-798; Troupin, C., (1962) Monograph des Menispermaceae Africaines, p. 218. , Academie Royale des Sciences d'Outere-Mer Bruxelles; Vickers, A.J., Which botanicals or other unconventional anticancer agents should we take to clinical trial? (2007) J. Soc. Integr. Oncol., 5 (3), pp. 125-129; Witko-Sarsat, V., Friedlander, M., Capeillère-Blandin, C., Advanced oxidation protein products as a novel marker of oxidative stress in uremia (1996) Kidney Int., 49 (5), pp. 1304-1313; Woo, M.-N., Bok, S.-H., Lee, M.-K., Kim, H.-J., Jeon, S.-M., Do, G.-M., Shin, S.K., Choi, M.-S., Anti-obesity and hypolipidemic effects of a proprietary herb and fiber combination (S&S PWH) in rats fed high-fat diets (2008) J. Med. Food, 11, pp. 169-178; (1998) Basic OECD Principles of GLP, , http://www.who/int/tdr/publications02-01-2008, World Health Organization Geneva, Switzerland: World Health Organization; Yakubu, M.T., Oladiji, A.T., Akanji, M.A., Mode of cellular toxicity of aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male rat liver and kidney (2009) Hum. Exp. Toxicol., 28, pp. 469-478",Article,Scopus,2-s2.0-84926158516
"Rashid S., Ahmad M., Zafar M., Sultana S., Ayub M., Khan M.A., Yaseen G.","Ethnobotanical survey of medicinally important shrubs and trees of Himalayan region of Azad Jammu and Kashmir, Pakistan",2015,"Journal of Ethnopharmacology","166",, 9402,"340","351",,,10.1016/j.jep.2015.03.042,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926289485&partnerID=40&md5=27a41ddff17f7567db72926e69390749","Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan","Rashid, S., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Ahmad, M., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Zafar, M., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Sultana, S., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Ayub, M., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Khan, M.A., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Yaseen, G., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan","Abstract Ethnopharmacological relevance Present study was commenced with an aim to document the indigenous knowledge of medicinally important shrubs and trees of Himalayan region of Azad Jammu and Kashmir, Pakistan. This is the first contribution to the quantitative ethnobotany of this region, as no reported data focusing on shrubs and trees from the area have been published. Study reported the ethnobotanical significance of medicinal plants for the treatment of various diseases. Method Study was conducted during 2012-2014 following standard ethnobotanical methods. The ethnomedicinal data was collected through informed consent semi- structured interviews of 160 key informants. Documented data was analyzed by using quantitative indices of informant consensus factor (ICF), fidelity level (FL), use value (UV) and relative frequency citation (RFC). Results A total of 73 shrub and tree species belonging to 56 genera and 37 families were reported to be used ethnomedicinally for the treatment of various ailments. Medicinal plant diversity showed that Rosaceae was dominating family with (9 spp.) followed by Moraceae (7 spp.), Euphorbiaceae, Mimosaceae, Pinaceae, Rhamnaceae (4 spp. each), Oleaceae (3 spp.), Apocynaceae, Caesalpinaceae, Ebenaceae, Fagaceae, Lythraceae, Papilionaceae, Acanthaceae, Verbenaceae (2 spp. each) while remaining 22 families were represented by one species each. Leaves (23%) were highly utilized plant parts, followed by fruits (22%), bark (18%), seeds (10%), roots (9%), flowers (8%), whole plant and aerial parts (4% each) and stem (2%). Modes of preparation fall into 14 categories including powder (33 reports) followed by decoction (29 reports), paste (22 reports), juice (18 reports), infusion (12 reports), raw (8 reports), extract and latex (5 reports each), gum and oil (4 reports each), fresh part and pulp (2 reports each), chewed and cooked (1 report each). The highest FIC was recorded for Gastro-intestinal disorders (0.58) followed by nail, skin and hair disorders (0.44). Maximum fidelity level (FL=100%) was expressed by Abies pindrow, Adhatoda vasica, Bauhinia variegata and Cedrela serrata. Based on use value Juglans regia (0.88) was found most significant species followed by Acacia nilotica (0.83), Phyllanthus emblica (0.81), Pinus roxburghii (0.75) and Punica granatum (0.71). Conclusion The area has a rich diversity of medicinally important shrub and tree species. The tradition of using plants for medicinal purposes is still alive in the local community but recently this tradition is gradually declining in new generation. Therefore awareness is needed to be raised among the local people on sustainable use and conservation of local flora. © 2015 Elsevier Ireland Ltd. All rights reserved.","Azad Jammu and Kashmir Pakistan; Ethnobotany; Himalayan region; Medicinal plants","Abbasi, A.M., Khan, M.A., Khan, N., Shah, M.H., Ethnobotanical survey of medicinally important wild edible fruits species used by tribal communities of Lesser Himalayas-Pakistan (2013) J. Ethnopharmacol., 148 (2), pp. 528-536; Abebe, D., Ayehu, A., (1993) Medicinal Plants and Enigmatic Health Practices of Northern Ethiopia, , B.S.P.E Addis Ababa, Ethiopia; Abu-Irmaileh, B.E., Afifi, F.U., Herbal medicine in Jordan with special emphasis on commonly used herbs (2003) J. Ethnopharmacol., 89, pp. 193-197; Ahmad, I., Ahmad, M.S.A., Hussain, M., Hameed, M., Ashraf, M.Y., Koukab, S., Spatio-temporal effects on species classification of medicinal plants in Soone valley of Pakistan (2009) Int. J. Agric. Biol., 11 (1), pp. 64-68; Ahmad, I., Ahmad, M.S.A., Hussain, M., Ashraf, M., Ashraf, M.Y., Hameed, M., Spatiotemporal aspects of plant community structure in open scrub rangelands of sub-mountainous Himalayan plateaus (2010) Pak. J. Bot., 42 (5), pp. 3431-3440; Ahmad, M., Sultana, S., Fazl-I-Hadi, S., Hadda, T.B., Rashid, S., Zafar, M., Yaseen, G., An ethnobotanical study of medicinal plants in high mountainous region of Chail valley (District Swat-Pakistan) (2014) J. Ethnobiol. Ethnomed., 10 (1), p. 36; Ajaib, M., Khan, Z.H., Khan, N., Wahab, M., Ethnobotanical studies on useful shrubs of district Kotli, Azad Jammu and Kashmir (2010) Pak. J. Bot., 42, pp. 1407-1415; Ajk Cdp, (2005) Azad Jammu and Kashmir Community Development Programme, , Azad Government of the State of Jammu and Kashmir Muzaffarabad; Akerele, O., Medicinal plants and primary healthcares: An agenda for action (1988) Fitoterapia, 59, pp. 355-363; Akerreta, S., Cavero, R.Y., Calvo, M.I., First comprehensive contribution to medical ethnobotany of Western Pyrenees (2007) J. Ethnobiol. Ethnomed., 3, p. 26; Alam, N., Shinwari, Z.K., Ilyas, M., Ullah, Z., Indigenous knowledge of medicinal plants of Chagharzai Valley, District Buner, Pakistan (2011) Pak. J. Bot., 43, pp. 773-780; Alexiades, M.N., (1996) Selected Guidelines for Ethnobotanical Research: A Field Manual, , The New York Botanical Garden Bronx, New York; Ali, S.I., Qaiser, M., (1995) Flora of Pakistan, , Botany Department,Universityof Karachi Karachi-Pakistan; Andrade-Cetto, A., Ethnobotanical study of the medicinal plants from Tlanchinol, Hidalgo, Mexico (2009) J. Ethnopharmacol., 122, pp. 163-171; Anonymous, (2006) Azad Jammu and Kashmir at a Glance, , Plan House, Azad Government of the State of Jammu and Kashmir Muzaffarabad; Arellanes, A.J., Meckes, M., Ramirez, R., Torres, J., Luna-Herrera, J., Activity against multidrug-resistant Mycobacterium tuberculosis in Mexican plants used to treat respiratory diseases (2003) Phytother. Res., 17, pp. 903-908; Bano, A., Ahmad, M., Zafar, M., Sultana, S., Rashid, S., Khan, M.A., Ethnomedicinal knowledge of the most commonly used plants from Deosai Plateau, Western Himalayas, Gilgit Baltistan, Pakistan (2014) J. Ethnopharmacol., 155 (2), pp. 1046-1052; Bibi, T., Ahmad, M., Tareen, R.B., Tareen, N.M., Jabeen, R., Rehman, S.U., Sultana, S., Yaseen, G., Ethnobotany of medicinal plants in district Mastung of Balochistan province-Pakistan (2014) J. Ethnopharmacol., 157, pp. 79-89; Cakilcioglu, U., Khatun, S., Turkoglu, I., Hayta, S., Ethnopharmacological survey of medicinal plants in Maden (Elazig-Turkey) (2011) J. Ethnopharmacol., 137, pp. 469-486; Cakilcioglu, U., Turkoglu, I., An ethnobotanical surveyof medicinal plants in Sivrice (ElazIʇ-Turkey) (2010) J. Ethnopharmacol., 132, pp. 165-175; Calixto, J.B., Twenty five years of research on medicinal plants in Latin America: a personal review (2005) J. Ethnopharmacol., 100, pp. 131-134; Cotton, C.M., (1996) Ethnobotany Principles and Applications, , John Wiley and Sons Chichester, New York; Dar, M.E.I., Ethnobotanical uses of plants of Lawat District Muzaffarabad, Azad Jammu and Kashmir (2003) Asian J. Plant Sci., 2, pp. 680-682; Dhar, U., Rawal, R.S., Upresti, J., Setting priorities for conservation of medicinal plants - a case study in Indian Himalaya (2000) Biol. Conserv., 95, pp. 57-65; Friedman, J., Yaniv, Z., Dafni, A., Palewitch, D., A preliminary classification of the healing potential of medicinal plants, based on the rational analysis of an ethnopharmacological field survey among Bedouins in Negev Desert, Israel (1986) J. Ethnopharmacol., 16, pp. 275-287; Ghimire, S.K., Gimenez, O., Pradel, R., Mckey, D., Aumeeruddy-Thomas, Y., Demographic variation and population viability in a threatened Himalayan medicinal and aromatic herb Nardostachys grandiflora: matrix modelling of harvesting effects in two contrasting habitats (2008) J. Appl. Ecol., 45, pp. 41-51; Ghorbani, A., Studies on pharmaceutical ethnobotany in the region of Turkmen Sahra, north of Iran: Part 1: General results (2005) J. Ethnopharmacol., 102 (1), pp. 58-68; Giday, M., Asfaw, Z., Elmqvist, T., Woldu, Z., An ethnobotanical study of medicinal plants used by the Zay people in Ethiopia (2003) J. Ethnopharmacol., 85, pp. 43-52; Giday, M., Asfaw, Z., Woldu, Z., Medicinal plants of the Meinit ethnic group of Ethiopia: an ethnobotanical study (2009) J. Ethnopharmacol., 124, pp. 513-521; Govaerts, R., How many species of seed plant are there? (2001) Taxon, 50, pp. 1085-1090; Hayta, S., Polat, R., Selvi, S., Traditional uses of medicinal plants in ElazIʇ (Turkey) (2014) J. Ethnopharmacol., 154, pp. 613-623; Heinrich, M., Ethnobotany and its role in drug development (2000) Phytother. Res., 14, pp. 479-488; Heinrich, M., Edwards, S., Moerman, D.E., Leonti, M., Ethnopharmacological field studies: a critical assessment of their conceptual basis and methods (2009) J. Ethnopharmacol., 124, pp. 1-17; Hill, A.F., (1952) Economic Botany, , McGraw-Hill Book Company, INC. Tokyo; Hoareau, L., Dasilva, E.J., Medicinal plants: a re-emerging health aid (1999) Electron. J. Biotechnol., 2, pp. 56-70; Hussain, F., Khaliq, A., Ethnobotanical studies on some plants of Dabargai Hills, Swat (1996) Proceedings of 1st Training Workshop on Ethnobotany and its Application to Conservation, pp. 207-215. , NARC, Islamabad; Joshi, A.R., Joshi, K., Indigenous knowledge and uses of medicinal plants by local communities of the Kali Gandaki Watershed Area, Nepal (2000) J. Ethnopharmacol., 73 (1), pp. 175-183; Kaya, G., Discussion of P&P model used for estimating option value of forest ecosystems as medicinal plant resources (2006) J. BartIn Fac. For., 8, pp. 23-32; Kayani, S., Ahmad, M., Zafar, M., Sultana, S., Khan, M.P.Z., Ashraf, M.A., Yaseen, G., Ethnobotanical uses of medicinal plants for respiratory disorders among the inhabitants of Gallies-Abbottabad, Northern Pakistan (2014) J. Ethnopharmacol., 156, pp. 47-60; Khan, A.U., History of decline and present status of natural tropical thorn forest in Punjab (1994) Biol. Conserv., 67, pp. 205-210; Kloutusos, G., Balatsouras, D.G., Kaberos, A.C., Kandiloros, D., Ferekidis, E., Economou, C., Upper airway edema resulting from use of Ecballium elaterium (2001) Laryngoscope, 111, pp. 1652-1655; Lee, S., Xiao, C., Pei, S., Ethnobotanical survey of medicinal plants at periodic markets of Honghe Prefecture in Yunnan Province, SW China (2008) J. Ethnopharmacol., 117 (2), pp. 362-377; Mahmood, A., Mahmood, A., Malik, R.N., Indigenous knowledge of medicinal plants from Leepa valley, Azad Jammu and Kashmir, Pakistan (2012) J. Ethnopharmacol., 143 (1), pp. 338-346; Mahmood, A., Mahmood, A., Tabassum, A., Ethnomedicinal survey of plants from District Sialkot, Pakistan (2011) J. Appl. Pharmacol., 2, pp. 212-220; Malik, F., Hussain, S., Dil, A.S., Hannan, A., Gilani, A.H., Islamic Republic of Pakistan (Chapter 22) (2005) WHO Global Atlas of Traditional, Complementary and Alternative Medicine (Mapvolume), pp. 165-169. , C.K. Ong, G. Bodeker, C. Grundy, G. Burford, K. Shein, World Health Organization Geneva; Mann, A., Amupitan, J.O., Oyewale, A.O., Okogun, J.I., Ibrahim, K., Oladosu, P., Lawson, L., Nnamdi, A., Evaluation of in vitro antimycobacterial activity of Nigerian plants used for treatment of respiratory diseases (2008) Afr. J. Biotechnol., 7 (11), pp. 1630-1636; Maregesi, S.M., Ngassapa, O.D., Pieters, L., Vlietinck, A.J., Ethnopharmacological survey of the Bunda district, Tanzania: plants used to treat infectious diseases (2007) J. Ethnopharmacol., 113, pp. 457-470; Martin, G.J., (1995) Ethnobotany: A Methods Manual, , Chapman and Hall London, UK; Martin, G.J., (2004) Ethnobotany: A Methods Manual, , Earths can Publications Ltd. London; Mittermeier, R.A., Gil, P.R., Hoffmann, M., Pilgrim, J., Brooks, T., Mittermeier, C.G., Lamoreux, J., Da Fonseca, G.A.B., Hotspots revised: earth's biologically richest and most threatened terrestrial ecoregions (2005) Conserv. Int., 4, pp. 1-392. , http://www.biodiversityhotspots.org; Nunkoo, D.H., Mahomoodally, M.F., Ethnopharmacological survey of native remedies commonly used against infectious diseases in the tropical island of Mauritius (2012) J. Ethnopharmacol., 143, pp. 548-564; Pardo-De-Santayana, M., Tardo, J., Blanco, E., Carvalho, A.M., Lastra, J.J., Miguel, S.E., Morales, R., Traditional knowledge of wild edible plants used in the northwest of the Iberian Peninsula (Spain and Portugal): a comparative study (2007) J. Ethnobiol. Ethnomed., 3, p. 27; Pfeiffer, J.M., Butz, R.J., Assessing cultural and ecological variation in ethnobiological research: the importance of gender (2005) J. Ethnopharmacol., 25, pp. 240-278; Poonam, K., Singh, G.S., Ethnobotanical study of medicinal plants used by the Taungya community in Terai Arc Landscape, India (2009) J. Ethnopharmacol., 123, pp. 167-176; Qureshi, R.A., Ghufran, M.A., Gilani, S.A., Ethnobotanical studies of selected medicinal plants of Sudhan Gali and Ganga Chotti Hills, district Bagh, Azad Kashmir (2007) Pak. J. Bot., 39, pp. 2275-2283; Reddy, K.N., Reddy, C.S., Trimurthulu, G., Ethnobotanical survey on respiratory disorders in Eastern Ghats of Andhra Pradesh, India (2006) Ethnobot. Leafl., 10, pp. 139-148; Rokaya, M.B., Münzbergova, Z., Timsina, B., Ethnobotanical study of medicinal plants from the Humla district of Western Nepal (2010) J. Ethnopharmacol., 130, pp. 485-504; Saghir, I.A., Awan, A.A., Majid, S., Khan, M.A., Qureshi, S.J., Ethnobotanical studies of Chikar and its allied area of District Muzaffarabad (2001) J. Biol. Sci., 1, pp. 1165-1170; Savikin, K., Zdunic, G., Menkovic, N., Zivkovic, J., Cujic, N., Terescenko, M., Bigovic, D., Ethnobotanical study on traditional use of medicinal plants in south-western Serbia, Zlatibor district (2013) J. Ethnopharmacol., 146 (3), pp. 803-810; Schippmann, U., Leaman, D.J., Cunningham, A.B., Impact of cultivation and gathering of medicinal plants on biodiversity: global trends and issues. In: Proceedings of the Biodiversity and the Ecosystem Approach in Agriculture, Forestry and Fisheries (2002) Ninth Regular Session of the Commission on Genetic Resources for Food and Agriculture, pp. 143-167. , FAO, Rome, Italy; Shahzad, K.R., Qureshi, R.A., Common Ethnomedicinal uses of plants in Jatlan Area District Mirpur, Azad Jammu and Kashmir, Pakistan (2001) Hamdard Med., 44 (3), pp. 42-45; Shil, S., Choudhury, M.D., Das, S., Indigenous knowledge of medicinal plants used by the Reang tribe of Tripura state of India (2014) J. Ethnopharmacol., 152, pp. 135-141; Shinwari, Z.K., The ethnobotany in Pakistan: sustainable and participatory approach (1996) Proceedings of 1st Traing Workshop on Ethnobotany and its Application to Conservation, pp. 14-25. , NARC, Islamabad; Shrivastava, S., Kanungo, V.K., Ethnobotanical survey of Surguja District with special reference to plants used by uraon tribe in treatment of respiratory diseases (2013) Int. J. Herb. Med., 1 (3), pp. 131-134; Singh, A., Singh, P.K., An ethnobotanical study of medicinal plants in Chandauli District of Uttar Pradesh, India (2009) J. Ethnopharmacol., 121 (2), pp. 324-329; Srithi, K., Balslevb, H., Wangpakapattanawonga, P., Srisangac, P., Trisonthia, C., Medicinal plant knowledge and its erosion among the Mien (Yao) in northern Thailand (2009) J. Ethnopharmacol., 123, pp. 335-342; Ssegawa, P., Kasenene, J.M., Medicinal plant diversity and uses in the Sango bay area, Southern Uganda (2007) J. Ethnopharmacol., 113, pp. 521-540; Sulaiman, S.F., Zahariluddin, A.S.M., Noor, S.S.M., Antituberculosis potential of some ethnobotanically selected Malaysian plants (2011) J. Ethnopharmacol., 133, pp. 1021-1026; Teklehaymanot, T., Giday, M., Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, northwestern Ethiopia (2007) J. Ethnobiol. Ethnomed., 3, p. 12; Trotter, R.T., Logan, M.H., Informant consensus: a new approach for identifying potentially effective medicinal plants (1986) Plants in Indigenous Medicine and Diet, Behavioural Approaches, pp. 91-112. , N.L. Etkin, Redgrave Publishing Company Bedford Hills, New York; Upadhyay, B., Singh, K.P., Kumar, A., Ethno-veterinary uses and informants consensus factor of medicinal plants of Sariska region, Rajasthan, India (2011) J. Ethnopharmacol., 133, pp. 14-25; Vendruscolo, G.S., Mentz, L.A., Ethnobotanical survey of the medicinal plants used by the community of Ponta Grossa neighborhood, Porto Alegre, Rio Grande do Sul, Brazil (2006) Iheringia Ser. Bot., 61 (12), pp. 83-103; Vitalini, S., Iriti, M., Puricelli, C., Ciuchi, D., Segale, A., Fico, G., Traditional knowledge on medicinal and food plants used in Val San Giacomo (Sondrio, Italy) - an alpine ethnobotanical study (2013) J. Ethnopharmacol., 145, pp. 517-529; WHO, (2002) Traditional Medicine: Growing Needs and Potentials, , Geneva; York, T., Dewet, H., Vuuren, S.F., Plants used for treating respiratory infections in rural Maputaland, KwaZulu-Natal, South Africa (2011) J. Ethnopharmacol., 135, pp. 696-710",Article,Scopus,2-s2.0-84926289485
"Abu Seman N., Wan Mohamud W.N., Ostenson C.-G., Brismar K., Gu H.F.","Increased dna methylation of the slc30a8 gene promoter is associated with type 2 diabetes in a malay population",2015,"Clinical Epigenetics","7","1",,"7","30",,,10.1186/s13148-015-0049-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927167822&partnerID=40&md5=f845f377e75cbc789f642f16d57d09f3","Department of Molecular Medicine and Surgery, Rolf Luft Research Center for Diabetes and Endocrinology, M1:03 Karolinska University Hospital, Karolinska InstitutetStockholm, Sweden; Cardiovascular, Diabetes and Nutrition Research Centre, Institute for Medical ResearchKuala Lumpur, Malaysia","Abu Seman, N., Department of Molecular Medicine and Surgery, Rolf Luft Research Center for Diabetes and Endocrinology, M1:03 Karolinska University Hospital, Karolinska InstitutetStockholm, Sweden, Cardiovascular, Diabetes and Nutrition Research Centre, Institute for Medical ResearchKuala Lumpur, Malaysia; Wan Mohamud, W.N., Cardiovascular, Diabetes and Nutrition Research Centre, Institute for Medical ResearchKuala Lumpur, Malaysia; Östenson, C.-G., Department of Molecular Medicine and Surgery, Rolf Luft Research Center for Diabetes and Endocrinology, M1:03 Karolinska University Hospital, Karolinska InstitutetStockholm, Sweden; Brismar, K., Department of Molecular Medicine and Surgery, Rolf Luft Research Center for Diabetes and Endocrinology, M1:03 Karolinska University Hospital, Karolinska InstitutetStockholm, Sweden; Gu, H.F., Department of Molecular Medicine and Surgery, Rolf Luft Research Center for Diabetes and Endocrinology, M1:03 Karolinska University Hospital, Karolinska InstitutetStockholm, Sweden","Background: Recent studies have demonstrated that DNA polymorphisms in the solute carrier family 30 member 8 (SLC30A8) gene confer the risk susceptibility to type 2 diabetes (T2D). The present study aimed to analyze DNA methylation levels of this gene in T2D and diabetic nephropathy (DN). Results: We confirmed the genetic association study of SLC30A8 in 992 Malay subjects with normal glucose tolerance and T2D patients with and without DN. Genotyping was conducted with TaqMan allelic discrimination. SNP rs11558471 (A/G) in the SLC30A8 gene was strongly associated with T2D (P = 0.002, OR= 1.334, 95% CI = 1.110 to 1.602) and moderately associated with DN (P= 0.041, OR= 1.399, 95% CI = 1.013 to 1.932). We further performed DNA methylation analysis of six CpG sites in the SLC30A8 gene promoter with bisulfite pyrosequencing protocol. The average DNA methylation levels of the SLC30A8 gene in all Malay subjects were at approximately 81.4%. DNA methylation levels of the SLC30A8 gene in T2D patients were higher compared to non-diabetic subjects (82.9% vs. 80.1%, P= 0.014). But no significant difference of DNA methylation levels of the SLC30A8 gene between T2D patients with and without DN was observed. Conclusion: The present study thus provides the first evidence that increased DNA methylation of the SLC30A8 gene promoter is associated with T2D but not DN in a Malay population. © 2015 Seman et al.; licensee BioMed Central. T","DNA methylation; SLC30A8; Type 2 diabetes","Chimienti, F., Devergnas, S., Favier, A., Seve, M., Identification and cloning of a beta-cell specific zinc transporter, ZnT-8, localized into insulin secretory granules (2004) Diabetes, 53 (9), pp. 2330-2337; Tamaki, M., Fujitani, Y., Uchida, T., Hirose, T., Kawamori, R., Watada, H., Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice (2009) Islets, 1 (2), pp. 124-128; Fu, Y., Tian, W., Pratt, E.B., Dirling, L.B., Shyng, S.L., Meshul, C.K., Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion (2009) Plos One, 4 (5), p. e5679; Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Clinical risk factors, DNA variants, and the development of type 2 diabetes (2008) N Engl J Med, 359 (21), pp. 2220-2232; Cauchi, S., Del Guerra, S., Choquet, H., D’Aleo, V., Groves, C.J., Lupi, R., Meta-analysis and functional effects of the SLC30A8 rs13266634 polymorphism on isolated human pancreatic islets (2010) Mol Genet Metab, 100 (1), pp. 77-82; Kanoni, S., Nettleton, J.A., Hivert, M.F., Ye, Z., Van Rooij, F.J., Shungin, D., Totalzinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: A 14-cohort meta-analysis (2011) Diabetes, 60 (9), pp. 2407-2416; Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., A genome-wide association study identifies novel risk loci for type 2 diabetes (2007) Nature, 445 (7130), pp. 881-885; Scott, L.J., Mohlke, K.L., Bonnycastle, L.L., Willer, C.J., Li, Y., Duren, W.L., A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants (2007) Science, 316 (5829), pp. 1341-1345; Saxena, R., Voight, B.F., Lyssenko, V., Genome-wide association analysis identifies loci for type 2diabetes and triglyceride levels (2007) Science, 316 (5829), pp. 1331-1336. , Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, Novartis Institutes of BioMedical Research; Billings, L.K., Florez, J.C., The genetics of type 2 diabetes: What have we learned from GWAS? (2010) Ann N Y Acad Sci, 1212, pp. 59-77; Ahlqvist, E., Ahluwalia, T.S., Groop, L., Genetics of type 2 diabetes (2011) Clin Chem, 57 (2), pp. 241-254; Imamura, M., Maeda, S., Genetics of type 2 diabetes: The GWAS era and future perspectives (2011) Endocr J, 58 (9), pp. 723-739; Ling, C., Groop, L., Epigenetics: A molecular link between environmental factors and type 2 diabetes (2009) Diabetes, 58 (12), pp. 2718-2725; Drong, A.W., Lindgren, C.M., Mccarthy, M.I., The genetic and epigenetic basis of type 2 diabetes and obesity (2012) Clin Pharmacol Ther, 92 (6), pp. 707-715; Kirchner, H., Osler, M.E., Krook, A., Zierath, J.R., Epigenetic flexibility in metabolic regulation: Disease cause and prevention? (2013) Trends Cell Biol, 23 (5), pp. 203-209; Flannick, J., Thorleifsson, G., Beer, N.L., Jacobs, S.B., Grarup, N., Burtt, N.P., Loss-of-function mutations in SLC30A8 protect against type 2 diabetes (2014) Nat Genet, 46 (4), pp. 357-363; Jones, P.A., Functions of DNA methylation: Islands, start sites, gene bodies and beyond (2012) Nat Rev Genet, 13 (7), pp. 484-492; Branco, M.R., Ficz, G., Reik, W., Uncovering the role of 5-hydroxymethylcytosine in the epigenome (2011) Nat Rev Genet, 13 (1), pp. 7-13; Gu, T., Gu, H.F., Hilding, A., Sjöholm, L.K., Ostenson, C.G., Ekström, T.J., Increased DNA methylation levels of the insulin-like growth factor binding protein 1 gene are associated with type 2 diabetes in Swedish men (2013) Clin Epigenetics, 5 (1), p. 21; Gu, H.F., Gu, T., Hilding, A., Zhu, Y., Kärvestedt, L., Ostenson, C.G., Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes (2013) Clin Epigenetics, 5 (1), p. 20; Gu, T., Falhammar, H., Gu, H.F., Brismar, K., Epigenetic analyses of the insulin-like growth factor binding protein 1 gene in type 1 diabetes and diabetic nephropathy (2014) Clin Epigenetics, 6 (1), p. 10; Gu, T., Gu, H.F., Hilding, A., Ostenson, C.G., Brismar, K., DNA Methylation Analysis of the Insulin-like Growth Factor-1 (IGF1) Gene in Swedish Men with Normal Glucose Tolerance and Type 2 Diabetes (2014) J Diabetes Metab, 5, p. 8; Letchuman, G.R., Wan Nazaimoon, W.M., Wan Mohamad, W.B., Chandran, L.R., Tee, G.H., Jamaiyah, H., Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006 (2010) Med J Malaysia, 65 (3), pp. 180-186; Lim, Y.N., Lim, T.O., Lee, D.G., Wong, H.S., Ong, L.M., Shaariah, W., A report of the Malaysian dialysis registry of the National Renal Registry, Malaysia (2008) Med J Malaysia, 63, pp. 5-8; Shaza, A.M., Rozina, G., Izham, M.I., Azhar, S.S., Dialysis for end stage renal disease: A descriptive study in Penang Hospital (2005) Med J Malaysia, 60 (3), pp. 320-327; Hooi, L.S., Wong, H.S., Morad, Z., Prevention of renal failure: The Malaysian experience (2005) Kidney Int Suppl, 94, pp. 4-70; Xu, X., Su, S., Barnes, V.A., De Miguel, C., Pollock, J., Ownby, D., A genome-wide methylation study on obesity: Differential variability and differential methylation (2013) Epigenetics, 8 (5), pp. 522-533; Dayeh, T.A., Olsson, A.H., Volkov, P., Almgren, P., Rönn, T., Ling, C., Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets (2013) Diabetologia, 56 (5), pp. 1036-1046; Hall, E., Volkov, P., Dayeh, T., Bacos, K., Rönn, T., Nitert, M.D., Effects of palmitate on genome-wide mRNA expression and DNA methylation patterns in human pancreatic islets (2014) BMC Med, 12, p. 103; Dick, K.J., Nelson, C.P., Tsaprouni, L., Sandling, J.K., Aïssi, D., Wahl, S., DNAmethylation and body-mass index: A genome-wide analysis (2014) Lancet, 13, pp. 62674-62674. , S0140-6736; Gu, H.F., Brismar, K., Genetic association studies in diabetic nephropathy (2012) Curr Diabetes Rev, 8 (5), pp. 336-344; Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation (1998) Diabet Med, 15 (7), pp. 539-553; Molitch, M.E., Defronzo, R.A., Franz, M.J., Keane, W.F., Mogensen, C.E., Parving, H.H., American Diabetes Association. Nephropathy in diabetes (2004) Diabetes Care, 27, pp. 79-83; Colella, S., Shen, L., Baggerly, K.A., Issa, J.P., Krahe, R., Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites (2003) Biotechniques, 35 (1), pp. 146-150; Tost, J., Dunker, J., Gut, I.G., Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing (2003) Biotechniques, 35 (1), pp. 152-156",Article,Scopus,2-s2.0-84927167822
"Behl T., Kotwani A., Kaur I., Goel H.","Mechanisms of prolonged lithium therapy-induced nephrogenic diabetes insipidus",2015,"European Journal of Pharmacology","755",, 69787,"27","33",,,10.1016/j.ejphar.2015.02.040,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925060991&partnerID=40&md5=36a3975c5aecfbcd472ab71f8b967b7a","Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of DelhiDelhi, India; Department of Pharmacy, Chandigarh College of PharmacyMohali, Punjab, India; Department of Animal HusbandryJunga, Shimla, Himachal Pradesh, India","Behl, T., Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of DelhiDelhi, India; Kotwani, A., Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of DelhiDelhi, India; Kaur, I., Department of Pharmacy, Chandigarh College of PharmacyMohali, Punjab, India; Goel, H., Department of Animal HusbandryJunga, Shimla, Himachal Pradesh, India","Abstract Nephrogenic diabetes insipidus is a clinical sub-type of a diversely expounded disorder, named diabetes insipidus. It is characterized by inability of the renal cells to sense and respond to the stimulus of vasopressin. Amongst its various etiologies, one of the most inevitable causes includes lithium-induced instigation. Numerous studies reported marked histological damage to the kidneys upon long-term treatment with lithium. The recent researches have hypothesized many lithium-mediated mechanisms to explain the damage and dysfunction caused in the kidneys following lithium exposure. These mechanisms, widely, intend to justify the lithium-induced electrolyte imbalance, its interference with some vital proteins and a specific steroidal hormone, obstruction caused to a certain imperative transducer pathway and the renal tubular acidification defect produced on its prolonged therapy. Thorough study of such mechanisms aids in better understanding of the role of lithium in the pathophysiology of this disorder. Hence, the ameliorated knowledge regarding disease-pathology might prove beneficial in developing therapies that aim on disrupting the various lithium-mediated pathways. Hence, this may effectively lead to the demonstration of a novel treatment for nephrogenic diabetes insipidus, which is, at present, limited to the use of diuretics which block lithium reuptake into the body. © 2015 Elsevier B.V. All rights reserved.","Aldosterone; Aquaporin-2 (AQP-2); Epithelial sodium channel (ENaC); GSK3-beta (Glycogen synthase kinase 3-beta); Vasopressin","Alexander, R.T., Grinstein, S., Tethering, recycling and activation of the epithelial sodium-proton exchanger, NHE3 (2009) J. Exp. Biol., 212, pp. 1630-1637; Bhalla, V., Daidie, D., Li, H., Pao, A.C., Lagrange, L.P., Wang, J., Vandewalle, A., Pearce, D., Serum- and glucocorticoid-regulated kinase 1 regulates ubiquitin ligase neural precursor cell-expressed, developmentally downregulated protein 4-2 by inducing interaction with 14-3-3 (2005) Mol. Endocrinol., 19, pp. 3073-3084; Bichet, D.G., Nephrogenic diabetes insipidus (2006) Adv. Chronic Kidney Dis., 13, pp. 96-104; Birnbaumer, L., Duran, J.M., Nakahara, T., Kaumann, A.J., Adenylyl cyclases: stimulation by hormones and regulation by nucleotides (1985) Mammalian Cell Membranes: Responses of Plasma Membranes, 5, p. 136. , G.A. Jamieson, D.M. Robinson, Butterworth-Heinemann Oxford; Burg, M.B., Ferraris, J.D., Dmitrieva, N.I., Cellular response to hyperosmotic stresses (2007) Physiol. Rev., 87, pp. 1441-1474; Choudhury, D., Ahmed, Z., Drug-associated renal dysfunction and injury (2006) Nat. Clin. Pract. Nephrol., 2, pp. 80-91; Christensen, B.M., Marples, D., Kim, Y.H., Wang, W., Frokiaer, J., Nielsen, S., Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI (2004) Am. J. Physiol. Cell Physiol., 286, pp. C952-C964; Danziger, J., Zeidel, M.L., Osmotic Homeostasis (2014) Clin J. Am. Soc. Nephrol., p. 10741013. , pii:CJN; Dell, K.M., Avner, E.D., Renal tubular acidosis (2003) Nelson Textbook of Pediatrics, pp. 1758-1762. , R.E. Behrman, R.M. Kliegman, H.B. Jenson, WB Saunders Philadelphia; Edokpolo, O., Fyyaz, M., Lithium toxicity and neurologic effects: probable neuroleptic malignant syndrome resulting from lithium toxicity (2012) Case Rep. Psychiatry, 2012, p. 271858; Elhayek, D., Perez De Nanclares, G., Chouchane, S., Hamami, S., Mlika, A., Troudi, M., Leban, N., Ariceta, G., Molecular diagnosis of distal renal tubular acidosis in Tunisian patients: proposed algorithm for Northern Africa populations for the ATP6V1B1, ATP6V0A4 and SCL4A1 genes (2013) BMC Med. Genet., 14, p. 119; Falin, R.A., Cotton, C.U., Acute downregulation of ENaC by EGF involves the PY motif and putative ERK phosphorylation site (2007) J. Gen. Physiol., 130, pp. 313-328; Goswami, R.P., Mondal, S., Karmakar, P.S., Ghosh, A., Type 3 renal tubular acidosis (2012) Indian J. Nephrol., 22, pp. 466-468; Henry, P.C., Kanelis, V., O'Brien, M.C., Kim, B., Gautschi, I., Forman-Kay, J., Schild, L., Rotin, D., Affinity and specificity of interactions between Nedd4 isoforms and the epithelial Na+ channel (2003) J. Biol. Chem., 278, pp. 20019-20028; Ichimura, T., Yamamura, H., Sasamoto, K., Tominaga, Y., Taoka, M., Kakiuchi, K., Shinkawa, T., Isobe, T., 14-3-3 Proteins modulate the expression of epithelial Na+ channels by phosphorylation-dependent interaction with Nedd4-2 ubiquitin ligase (2005) J. Biol. Chem., 280, pp. 13187-13194; John, C.A., Day, M.W., Central neurogenic diabetes insipidus, syndrome of inappropriate secretion of antidiuretic hormone, and cerebral salt-wasting syndrome in traumatic brain injury (2012) Critical Care Nurse, 32, pp. e1-e7; Kellengerger, S., Schild, L., Epithelial sodium channels/degenerin family of ion channels: a variety of functions with a shared structure (2002) Physiol. Rev., 82, pp. 735-767; Kibirige, D., Luzinda, K., Ssekitoleko, R., Spectrum of lithium induced thyroid abnormalities: a current perspective (2013) Thyroid Res., 6, p. 3; Kjaersgaard, G., Madsen, K., Marcussen, N., Jensen, B.L., Lithium induces microcysts and polyuria in adolescent rat kidney independent of cyclooxygenase-2 (2014) Physiol. Rep., 2; Kwon, T.H., Laursen, U.H., Marples, D., Maunsbach, A.B., Knepper, M.A., Frokiaer, J., Nielsen, S., Altered expression of renal AQPs and Na(+) transporters in rats with lithium-induced NDI (2000) Am. J. Physiol. Ren. Physiol., 279, pp. F552-F564; Li, Y., Shaw, S., Kamsteeg, E.J., Vandewalle, A., Deen, P.M., Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity (2006) J. Am. Soc. Nephrol., 17, pp. 1063-1072; Li, X., Friedman, A.B., Zhu, W., Wang, L., Boswell, S., May, R.S., Davis, L.L., Jope, R.S., Lithium regulates glycogen synthase kinase-3β in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder (2007) Biol. Psychiatry, 61, pp. 216-222; Loffing, J., Paradoxical antidiuretic effect of thiazides in diabetes insipidus: another piece in the puzzle (2004) J. Am. Soc. Nephrol., 15, pp. 2948-2950; Loffing, J., Korbmacher, C., Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC) (2009) Pflüg. Arch., 458, pp. 111-135; Malhi, G.S., Tanious, M., Bargh, D., Das, P., Berk, M., Safe and effective use of lithium (2013) Aust. Prescr., 36, pp. 18-21; Mann, L., Heldman, E., Bersudsky, Y., Ishikawa, Y., Almog, O., Belmaker, R.H., Agam, G., Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect (2009) Bipolar Disord., 11, pp. 885-896; Meneton, P., Comparative roles of the renal apical sodium transport systems in blood pressure control (2000) J. Am. Soc. Nephrol., 11, pp. S135-S139; Muller-Oerlinghausen, B., Bauer, M., Grof, P., Commentary on a recent review of lithium toxicity: what are its implications for clinical practice? (2012) BMC Med., 10, p. 132; Nagayama, Y., Shigeno, M., Nakagawa, Y., Suganuma, A., Takeshita, A., Fujiyama, K., Ashizawa, K., Nagataki, S., Acquired nephrogenic diabetes insipidus secondary to distal renal tubular acidosis and nephrocalcinosis associated with Sjögren's syndrome (1994) J. Endocrinol. Invest., 17, pp. 659-663; Nesterov, V., Dahlmann, A., Krueger, B., Bertog, M., Loffing, J., Korbmacher, C., Aldosterone-dependent and -independent regulation of the epithelial sodium channel (ENaC) in mouse distal nephron (2012) Am. J. Physiol. Ren. Physiol, 303, pp. F1289-F1299; Netto, I., Phutane, V.H., Reversible lithium neurotoxicity: review of the literature (2012) Prim. Care Companion CNS Disord., 14. , PCC.11r01197; Nielsen, J., Kwon, T.H., Frokiaer, J., Knepper, M.A., Nielsen, S., Lithium-induced NDI in rats is associated with loss of alpha-ENaC regulation by aldosterone in CCD (2006) Am. J Physiol. Ren. Physiol., 290, pp. F1222-F1233; Nielsen, J., Hoffert, J.D., Knepper, M.A., Agre, P., Nielsen, S., Fenton, R.A., Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: Mechanisms for aquaporin 2 down-regulation and cellular proliferation (2008) Proc. Natl. Acad. Sci. USA, 105, pp. 3634-3639; Pereira, P.C., Miranda, D.M., Oliveira, E.A., Silva, A.C., Molecular pathophysiology of renal tubular acidosis (2009) Curr. Genomics, 10, pp. 51-59; Rao, R., Patel, S., Hao, C., Woodgett, J., Harris, R., GSK3β mediates renal response to vasopressin by modulating adenylate cyclase activity (2010) J. Am. Soc. Nephrol., 21, pp. 428-437; Sasaki, S., Nephrogenic diabetes insipidus: update of genetic and clinical aspects (2004) Nephrol. Dial. Transplant., 19, pp. 1351-1353; Sasaki, S., Is Oxytocin a player in antidiuresis? (2008) J. Am. Soc. Nephrol., 19, pp. 189-190; Schrier, R.W., Body water homeostasis: clinical disorders of urinary dilution and concentration (2006) J. Am. Soc. Nephrol., 17, pp. 1820-1832; Shorter, E., The history of lithium therapy (2009) Bipolar Disord., 11, pp. 4-9; Sim, J.H., Himmel, N.J., Redd, S.K., Pulous, F.E., Rogers, R.T., Black, L.N., Hong, S.M., Blount, M.A., Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus (2014) PLoS One, 9; Soriano, J.R., Renal tubular acidosis: the clinical entity (2002) J. Am. Soc. Nephrol., 13, pp. 2160-2170; Thomsen, K., Shirley, D.G., A hypothesis linking Na and Li reabsorption in the distal nephron (2006) Nephrol. Dial. Transplant., 4, pp. 869-880; Tortora, G.J., Derrickson, B., Adrenal Glands (2006) Principles of Anatomy and Physiology, pp. 641-642. , 11th ed. John Wiley & Sons, Inc. USA; Vaisbich, M.H., Carneiro, J., Boson, W., Resende, B., De Marco, L., Honjo, R.S., Kim, C.A., Koch, V.H., (2009) Nephrogenic Diabetes Insipidus (NDI): Clinical Laboratory and Genetic Characterization of Five Brazilian Patients Clin, 64, pp. 409-414; Wright, D., Salehian, O., Brugada-type electrocardiographic changes induced by long-term lithium use (2010) Circulation, 122, pp. e418-e419; Young, A.H., Hammond, J.M., Lithium in mood disorders: increasing evidence base, declining use? (2007) Br J. Psychiatry, 191, pp. 474-476",Article,Scopus,2-s2.0-84925060991
"Dobbins R., Byerly R., Gaddy R., Gao F., Mahar K., Napolitano A., Ambery P., Le Monnier De Gouville A.-C.","GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial",2015,"European Journal of Pharmacology","755",,,"95","101",,,10.1016/j.ejphar.2015.03.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925448638&partnerID=40&md5=1ae31ea943ce98c39c425cd7b47e5b15","GlaxoSmithKline, Drug DiscoveryResearch Triangle Park, NC, United States; GlaxoSmithKline, Quantitative SciencesUpper Merion, PA, United States; GlaxoSmithKline, Immuno-Inflammation Therapeutic AreaStevenage, United Kingdom; Department of Endocrinology and Diabetes, Addenbrooke's HospitalCambridge, United Kingdom; GlaxoSmithKline, Drug Discovery, Laboratoire GSK, 27av du QuebecLes Ulis cedex, France","Dobbins, R., GlaxoSmithKline, Drug DiscoveryResearch Triangle Park, NC, United States; Byerly, R., GlaxoSmithKline, Drug DiscoveryResearch Triangle Park, NC, United States; Gaddy, R., GlaxoSmithKline, Drug DiscoveryResearch Triangle Park, NC, United States; Gao, F., GlaxoSmithKline, Quantitative SciencesUpper Merion, PA, United States; Mahar, K., GlaxoSmithKline, Quantitative SciencesUpper Merion, PA, United States; Napolitano, A., GlaxoSmithKline, Immuno-Inflammation Therapeutic AreaStevenage, United Kingdom; Ambery, P., Department of Endocrinology and Diabetes, Addenbrooke's HospitalCambridge, United Kingdom; Le Monnier De Gouville, A.-C., GlaxoSmithKline, Drug Discovery, Laboratoire GSK, 27av du QuebecLes Ulis cedex, France","This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone. Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor unblinded), placebo-controlled, parallel group trial. Participants received placebo for two weeks before being randomised (2:2:2:2:1:1) to receive doses of GSK256073 5 mg twice-daily (BID), 10 mg once-daily (QD), 25 mg BID, 50 mg QD or placebo BID or QD in addition to their current metformin treatment. The primary efficacy endpoint was change from baseline in glycosylated haemoglobin (HbA1c) at week 12. The safety profile of GSK256073 did not significantly differ from that of placebo. Decreases from baseline in HbA1c were observed in all treatment groups but were not statistically significant compared to placebo; at week 12 a maximum decrease of 0.30% from placebo was reached in the GSK256073 50 mg QD group. On day 2, GSK256073 significantly decreased non-esterified fatty acid (NEFA) (0-12 h) concentrations but pharmacological activity was lost (5 mg BID, 10 mg QD, 25 mg BID) or reduced (50 mg QD) at week 6. Drug exposure demonstrated 2-fold accumulation over 6 weeks. The primary efficacy objective of the study was not met. GSK256073 did not improve HbA1c concentrations at week 12. Despite sustained drug exposure, the ability of the HCA2 agonist to suppress plasma NEFA concentrations waned over time and targeted effects on glucose oxidation and insulin sensitivity subsided. © 2015 Elsevier B.V. All rights reserved.","GSK 256073; HbA1c; Non Esterified Fatty Acid(NEFA)-Hydroxy-carboxylicacidreceptor2(HCA2); Type 2diabetes","Bajaj, M., Suraamornkul, S., Romanelli, A., Cline, G.W., Mandarino, L.J., Shulman, G.I., Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients (2005) Diabetes, 54, pp. 3148-3153; Baldeweg, S.E., Golay, A., Natali, A., Balkau, B., Del Prato, S., Coppack, S.W., Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans (2000) Eur. J. Clin. Investig., 30, pp. 45-52; Dobbins, R.L., Shearn, S.P., Byerly, R.L., Gao, F.F., Mahar, K.M., Napolitano, A., GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus (2013) Diab. Obes. Metab., 15, pp. 1013-1021; Garg, A., Grundy, S.M., Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus (1990) J. Am. Med. Assoc., 264, pp. 723-726; Girousse, A., Tavernier, G., Valle, C., Moro, C., Mejhert, N., Dinel, A.-L., Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass (2013) PLoS Biol., 11, p. e1001485. , 10.1371/journal.pbio.1001485; Grundy, S.M., Vega, G.L., McGovern, M.E., Tulloch, B.R., Kendall, D.M., Fitz-Patrick, D., Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial (2002) Arch. Intern. Med., 162, pp. 1568-1576; Lauring, B., Taggart, A.K., Tata, J.R., Dunbar, R., Caro, L., Cheng, K., Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression (2012) Sci. Transl. Med., 4. , 148ra115; Lavezzari, M., Milanesi, G., Oggioni, E., Pamparana, F., Results of a phase IV study carried out with Acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia (1989) J. Int. Med. Res., 17, p. 373380; Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homoeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man (1985) Diabetologia, 28, pp. 412-419; McGarry, J.D., Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes (2002) Diabetes, 51, pp. 7-18; Mohan, V., Yang, W., Son, H.Y., Xu, L., Noble, L., Landon, R.B., Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea (2009) Diab. Res. Clin. Pract., 83, pp. 106-116; Paolisso, G., Tataranni, P.A., Foley, J.E., Bogardus, C., Howard, B.V., Ravussin, E., A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM (1995) Diabetologia, 38, pp. 1213-1217; Randle, P.J., Garland, P.B., Hales, C.N., Newholme, E.A., The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus (1963) Lancet, 1, pp. 785-789; Reaven, G.M., Hollenbeck, C., Jeng, C.Y., Wu, M.S., Chen, Y.D., Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM (1988) Diabetes, 37, pp. 1020-1024; Roden, M., Stingl, H., Chandramouli, V., Schumann, W.C., Hofer, A., Landau, B.R., Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans (2000) Diabetes, 49, pp. 701-707; Saloranta, C., Groop, L., Ekstrand, A., Franssila-Kallunki, A., Eriksson, J., Taskinen, M.R., Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes (1993) Diab. Med., 10, pp. 950-957; Saloranta, C., Taskinen, M.R., Widen, E., Harkonen, M., Melander, A., Groop, L., Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM (1993) Diabetes, 42, pp. 1559-1566; Santomauro Atmg, B.G., Silva, M.E.R., Rocha, D.M., Santos, R.F., Ursich, M.J.M., Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non diabetic subjects (1999) Diabetes, 48, pp. 1836-1841; Shulman, G.I., Cellular mechanism of insulin resistance (2000) J. Clin. Investig., 106, pp. 171-176; Vaag, A.A., Beck-Nielsen, H., Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus (1992) Acta Endocrinol., 127, pp. 344-350; Vosper, H., Niacin: A re-emerging pharmaceutical for the treatment of dyslipidaemia (2009) Br. J. Pharmacol., 158, pp. 429-441; Worm, D., Henricksen, J.E., Vaag, A., Thye-Rønn, P., Melander, A., Beck-Nieldsen, H., Pronounced blood glucose-lowering effect of the antilipolytic drug Acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period (1994) J. Clin. Endocrinol. Metab., 78, pp. 717-721",Article,Scopus,2-s2.0-84925448638
"Lan V.T.T., Ito K., Ohno M., Motoyama T., Ito S., Kawarasaki Y.","Analyzing a dipeptide library to identify human dipeptidyl peptidase IV inhibitor",2015,"Food Chemistry","175",,,"66","73",,,10.1016/j.foodchem.2014.11.131,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84915821684&partnerID=40&md5=fea1eb3504ca51e2e260921c5c5e6bff","Department of Food and Nutritional Sciences, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan; School of Food and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan; Food Science Research Institute, Research and Development HQ, Fuji Oil Co., Ltd., Kinunodai 4-3Tsukubamirai, Ibaraki, Japan","Lan, V.T.T., Department of Food and Nutritional Sciences, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan; Ito, K., Department of Food and Nutritional Sciences, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan, School of Food and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan; Ohno, M., School of Food and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan; Motoyama, T., Food Science Research Institute, Research and Development HQ, Fuji Oil Co., Ltd., Kinunodai 4-3Tsukubamirai, Ibaraki, Japan; Ito, S., Department of Food and Nutritional Sciences, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan, School of Food and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan; Kawarasaki, Y., Department of Food and Nutritional Sciences, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan, School of Food and Nutritional Sciences, University of Shizuoka, Yada 52-1Suruga-ku, Shizuoka, Japan","Human dipeptidyl peptidase IV (hDPPIV) inhibitors provide an effective strategy for the treatment of type 2 diabetes. Because certain peptides are known to act as hDPPIV inhibitors, a dataset of possible peptides with their inhibition intensities will facilitate the development of functional food for type 2 diabetes. In this study, we examined a total of 337 dipeptides with respect to their hDPPIV inhibitory effects. Amino acid residues at N-termini dominated their inhibition intensities. Particularly highly inhibitory dipeptides discovered included the following novel dipeptides: Thr-His, Asn-His, Val-Leu, Met-Leu, and Met-Met. Using our dataset, prime candidates contributing to the hDPPIV inhibitory effect of soy protein hydrolyzates were successfully identified. Possible dietary proteins potentially able to produce particularly highly hDPPIV inhibitory peptides are also discussed on the basis of the dataset. © 2014 Elsevier Ltd. All rights reserved.","Dipeptide; Functional food; Human dipeptidyl peptidase IV; Type 2 diabetes","Ahrén, B., Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin (2008) Vascular Health and Risk Management, 4, pp. 383-394; Ahrén, B., Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events (2009) Best Practice & Research Clinical Endocrinology & Metabolism, 23, pp. 487-498; Bella, A.M., Jr., Erickson, R.H., Kim, Y.S., Rat intestinal brush border membrane dipeptidyl-aminopeptidase IV: Kinetic properties and substrate specificities of the purified enzyme (1982) Archives of Biochemistry and Biophysics, 218 (1), pp. 156-162; Brandt, W., Lehmann, T., Thondorf, I., Born, I., Schutkowski, M., Rahfeld, J.U., A model of the active site of dipeptidyl peptidase IV predicted by comparative molecular field analysis and molecular modelling simulations (1995) International Journal of Peptide & Protein Research, 46, pp. 494-507; Gallego, M., Aristoy, M.C., Toldrá, F., Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham (2014) Meat Science, 96, pp. 757-761; Gallwitz, B., Review of sitagliptin phosphate: A novel treatment for type 2 diabetes (2007) Vascular Health and Risk Management, 3, pp. 203-210; Hatanaka, T., Inoue, Y., Arima, J., Kumagai, Y., Usuki, H., Kawakami, K., Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran (2012) Food Chemistry, 134, pp. 797-802; Hikida, A., Ito, K., Motoyama, T., Kato, R., Kawarasaki, Y., Systematic analysis of a dipeptide library for inhibitor development using human dipeptidyl peptidase IV produced by a Saccharomyces cerevisiae expression system (2013) Biochemical and Biophysical Research Communications, 430, pp. 1217-1222; Huang, S.L., Jao, C.L., Ho, K.P., Hsu, K.C., Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates (2012) Peptides, 35, pp. 114-121; Ito, K., Hikida, A., Kawai, S., Lan, V.T., Motoyama, T., Kitagawa, S., Analysing the substrate multispecificity of a proton-coupled oligopeptide transporter using a dipeptide library (2013) Nature Communications, 4, p. 2502; Iwai, K., Hasegawa, T., Taguchi, Y., Morimatsu, F., Sato, K., Nakamura, Y., Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates (2005) Journal of Agricultural and Food Chemistry, 53, pp. 6531-6536; Kim, W., Egan, J.M., The role of incretins in glucose homeostasis and diabetes treatment (2008) Pharmacological Reviews, 60, pp. 470-512; Lacroix, I.M.E., Li-Chan, E.C.Y., Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach (2012) Journal of Functional Foods, 4, pp. 403-422; Lacroix, I.M.E., Li-Chan, E.C.Y., Inhibition of dipeptidyl peptidase (DPP)-IV and α-glucosidase activities by pepsin-treated whey proteins (2013) Journal of Agricultural and Food Chemistry, 61, pp. 7500-7506; Lacroix, I.M.E., Li-Chan, E.C.Y., Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins (2014) Peptides, 54, pp. 39-48; Lan, V.T., Ito, K., Ito, S., Kawarasaki, Y., Trp-Arg-Xaa tripeptides act as uncompetitive-type inhibitors of human dipeptidyl peptidase IV (2014) Peptides, 54, pp. 166-170; Li-Chan, E.C., Hunag, S.L., Jao, C.L., Ho, K.P., Hsu, K.C., Peptides derived from Atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors (2012) Journal of Agricultural and Food Chemistry, 60, pp. 973-978; Mentlein, R., Dipeptidyl-peptidase IV. (CD26)-role in the inactivation of regulatory peptides (1999) Regulatory Peptides, 85, pp. 9-24; Nabeno, M., Akahoshi, F., Kishida, H., Miyaguchi, I., Tanaka, Y., Ishii, S., A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site (2013) Biochemical and Biophysical Research Communications, 434, pp. 191-196; Nongonierma, A.B., FitzGerald, R.J., Dipeptidyl peptidase IV inhibitory and antioxidative properties of milk protein-derived dipeptides and hydrolysates (2013) Peptides, 39, pp. 157-163; Nongonierma, A.B., FitzGerald, R.J., Inhibition of dipeptidyl peptidase IV (DPP-IV) by tryptophan containing dipeptides (2013) Food & Function, 4, pp. 1843-1849; Nongonierma, A.B., FitzGerald, R.J., Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis (2014) Food Chemistry, 145, pp. 845-852; Nongonierma, A.B., FitzGerald, R.J., An in silico model to predict the potential of dietary proteins as sources of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (2014) Food Chemistry, 165, pp. 489-498; Nongonierma, A.B., Mooney, C., Shields, D.C., FitzGerald, R.J., Inhibition of dipeptidyl peptidase IV and xanthine oxidase by amino acids and dipeptides (2013) Food Chemistry, 141, pp. 644-653; Nongonierma, A.B., Mooney, C., Shields, D.C., FitzGerald, R.J., In silico approaches to predict the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) inhibitors (2014) Peptides, 57, pp. 43-51; Ostrovskaya, R.U., Ozerova, I.V., Gudascheva, T.A., Kapitsa, I.G., Ivanova, E.A., Voronina, T.A., Comparative activity of proline-containing dipeptide noopept and inhibitor of dipeptidyl peptidase-4 sitagliptin in a rat model of developing diabetes (2014) Bulletin of Experimental Biology and Medicine, 156, pp. 342-346; Russell-Jones, D., Gough, S., Recent advances in incretin-based therapies (2012) Clinical Endocrinology (Oxf), 77, pp. 489-499; Silveira, S.T., Martínez-Maqueda, D., Recio, I., Hernández-Ledesma, B., Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin (2013) Food Chemistry, 141, pp. 1072-1077; Stöckel-Maschek, A., Stiebitz, B., Faust, J., Born, I., Kähne, T., Gorrell, M.D., Different inhibition mechanisms of dipeptidyl peptidase IV by tryptophan containing peptides and amides (2003) Advances in Experimental Medicine and Biology, 524, pp. 69-72; Tulipano, G., Sibilia, V., Caroli, A.M., Cocchi, D., Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl dipeptidase-4) inhibitors (2011) Peptides, 32, pp. 835-838; Uchida, M., Ohshiba, Y., Mogami, O., Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin (2011) Journal of Pharmaceutical Sciences, 117, pp. 63-66; Velarde-Salcedo, A.J., Barrera-Pacheco, A., Lara-González, S., Montero-Morán, G.M., Díaz-Gois, A., González De Mejia, E., In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins (2013) Food Chemistry, 136, pp. 758-764; Yan, T.R., Ho, S.C., Hou, C.L., Catalytic properties of X-prolyl dipeptidyl aminopeptidase from Lactococcus lactis subsp. Cremoris nTR (1992) Bioscience Biotechnology and Biochemistry, 56, pp. 704-707; Yoshimoto, T., Fischi, M., Orlowski, R.C., Walter, R., Postproline cleaving enzyme and post-proline dipeptidyl aminopeptidase (1978) The Journal of Biological Chemistry, 253, pp. 3708-3716",Article,Scopus,2-s2.0-84915821684
"Pugazhenthi S., Qin L., Bouchard R.","Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells",2015,"European Journal of Pharmacology","755",, 69771,"42","49",,,10.1016/j.ejphar.2015.02.024,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925004313&partnerID=40&md5=d122bb98d7c3094c449663f932ca196f","Veterans Affairs Medical CenterDenver, CO, United States; Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, 12801 E 17th AveAurora, CO, United States","Pugazhenthi, S., Veterans Affairs Medical CenterDenver, CO, United States, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, 12801 E 17th AveAurora, CO, United States; Qin, L., Veterans Affairs Medical CenterDenver, CO, United States; Bouchard, R., Veterans Affairs Medical CenterDenver, CO, United States, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, 12801 E 17th AveAurora, CO, United States","Abstract Incretin therapies are effective in controlling blood glucose levels in type 2 diabetic patients by improving the survival and function of β-cells. They include dipeptidyl peptidase-4 (DPP-4) inhibitors and long-acting glucagon-like peptide-1 (GLP-1) analogs. We have previously reported that GLP-1 enhances the survival of cultured human islets by activation of the transcription factor CREB. To test the in vivo relevance of these findings, we examined the effects of alogliptin, a DPP-4 inhibitor, in Zucker Diabetic rats, a model for type 2 diabetes. The plasma levels of GLP-1 increased in alogliptin-treated diabetic rats leading to normoglycemia. Pancreatic islets of untreated diabetic rats were characterized by decreased immunostaining for insulin and PDX-1. Elevation of GLP-1 in treated diabetic rats resulted in the improved survival of β-cells. Dual immunofluorescent staining showed phosphorylation/activation of CREB in insulin-positive β-cells of islets. This led to increases in the levels of CREB targets including Bcl-2, an antiapoptotic mitochondrial protein, BIRC3, a caspase inhibitor and IRS-2, an adapter protein needed for insulin signaling. Findings from this study suggest potential activation of cytoprotective CREB by GLP-1 in pancreatic β-cells of diabetic patients undergoing incretin-based therapies.","CREB and β-cells; Diabetes; Dipeptidyl peptidase-4; GLP-1; Insulin","Ashkenazi, A., Dixit, V.M., Death receptors: signaling and modulation (1998) Science, 281, pp. 1305-1308; Baetta, R., Corsini, A., Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences (2011) Drugs, 71, pp. 1441-1467; Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A., Butler, P.C., Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes (2003) Diabetes, 52, pp. 102-110; Campbell, R.K., Miller, S., New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy (2009) Diabetes Educ., 35, pp. 731-747; Defronzo, R.A., Fleck, P.R., Wilson, C.A., Mekki, Q., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study (2008) Diabetes Care, 31, pp. 2315-2317; Drucker, D.J., The biology of incretin hormones (2006) Cell Metab., 3, pp. 153-165; Feng, J., Zhang, Z., Wallace, M.B., Stafford, J.A., Kaldor, S.W., Kassel, D.B., Navre, M., Gwaltney, S.L., 2nd, Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV (2007) J. Med. Chem., 50, pp. 2297-2300; Inada, A., Hamamoto, Y., Tsuura, Y., Miyazaki, J., Toyokuni, S., Ihara, Y., Nagai, K., Seino, Y., Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic beta cells (2004) Mol. Cell. Biol., 24, pp. 2831-2841; Jambal, P., Masterson, S., Nesterova, A., Bouchard, R., Bergman, B., Hutton, J.C., Boxer, L.M., Pugazhenthi, S., Cytokine-mediated downregulation of the transcription factor CREB in pancreatic beta -cells (2003) J. Biol. Chem., 278, pp. 23055-23065; Jhala, U.S., Canettieri, G., Screaton, R.A., Kulkarni, R.N., Krajewski, S., Reed, J., Walker, J., Montminy, M., cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2 (2003) Genes Dev., 17, pp. 1575-1580; Kawashima, S., Matsuoka, T.A., Kaneto, H., Tochino, Y., Kato, K., Yamamoto, K., Yamamoto, T., Shimomura, I., Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice (2011) Biochem. Biophys. Res. Commun., 404, pp. 534-540; Maedler, K., Beta cells in type 2 diabetes-a crucial contribution to pathogenesis (2008) Diabetes Obes. Metab., 10, pp. 408-420; Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus (2012) Nat. Rev. Endocrinol., 8, pp. 728-742; Merry, D.E., Korsmeyer, S.J., Bcl-2 gene family in the nervous system (1997) Annu. Rev. Neurosci., 20, pp. 245-267; Montminy, M., Transcriptional regulation by cyclic AMP (1997) Annu. Rev. Biochem., 66, pp. 807-822; Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., Odaka, H., Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice (2008) Eur. J. Pharmacol., 588, pp. 325-332; Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., Odaka, H., Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice (2009) Br. J. Pharmacol., 157, pp. 415-426; Nauck, M.A., Vardarli, I., Deacon, C.F., Holst, J.J., Meier, J.J., Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? (2011) Diabetologia, 54, pp. 10-18; Pugazhenthi, S., Boras, T., O'Connor, D., Meintzer, M.K., Heidenreich, K.A., Reusch, J.E., Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells. Involvement of p38 mitogen-activated protein kinase-mediated pathway (1999) J. Biol. Chem., 274, pp. 2829-2837; Pugazhenthi, S., Miller, E., Sable, C., Young, P., Heidenreich, K.A., Boxer, L.M., Reusch, J.E.-B., Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element binding protein (1999) J. Biol. Chem., 274, pp. 27529-27535; Pugazhenthi, S., Nesterova, A., Sable, C., Heidenreich, K., Boxer, L., Heasley, L., Reusch, J., Akt/Protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein (2000) J. Biol. Chem., 275, pp. 10761-10766; Rhodes, C.J., Type 2 diabetes-a matter of beta-cell life and death? (2005) Science, 307, pp. 380-384; Sarkar, S.A., Gunter, J., Bouchard, R., Reusch, J.E., Wiseman, A., Gill, R.G., Hutton, J.C., Pugazhenthi, S., Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets (2007) Diabetologia, 50, pp. 1649-1659; Shaywitz, A.J., Greenberg, M.E., CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals (1999) Annu. Rev. Biochem., 68, pp. 821-861; Velmurugan, K., Balamurugan, A.N., Loganathan, G., Ahmad, A., Hering, B.J., Pugazhenthi, S., Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB (2012) Endocrinology, pp. 1116-1128; White, J.R., Alogliptin for the treatment of type 2 diabetes (2011) Drugs Today (Barc), 47, pp. 99-107; Zhang, X., Wang, Z., Huang, Y., Wang, J., Effects of chronic administration of alogliptin on the development of diabetes and beta-cell function in high fat diet/streptozotocin diabetic mice (2011) Diabetes Obes. Metab., 13, pp. 337-347",Article,Scopus,2-s2.0-84925004313
"Chigurupati S., Dhanaraj S.A., Balakumar P.","A step ahead of PPARγ full agonists to PPARγ partial agonists: Therapeutic perspectives in the management of diabetic insulin resistance",2015,"European Journal of Pharmacology","755",, 69790,"50","57",,,10.1016/j.ejphar.2015.02.043,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925089002&partnerID=40&md5=abedcaa95f279eb63600efcfdc0df2f4","Pharmaceutical Chemistry Unit, Faculty of Pharmacy, AIMST UniversitySemeling, Bedong, Malaysia; Pharmaceutical Technology Unit, Faculty of Pharmacy, AIMST UniversitySemeling, Bedong, Malaysia; Pharmacology Unit, Faculty of Pharmacy, AIMST UniversitySemeling, Bedong, Kedah Darul Aman, Malaysia","Chigurupati, S., Pharmaceutical Chemistry Unit, Faculty of Pharmacy, AIMST UniversitySemeling, Bedong, Malaysia; Dhanaraj, S.A., Pharmaceutical Technology Unit, Faculty of Pharmacy, AIMST UniversitySemeling, Bedong, Malaysia; Balakumar, P., Pharmacology Unit, Faculty of Pharmacy, AIMST UniversitySemeling, Bedong, Kedah Darul Aman, Malaysia","Abstract Described since long as a member of the nuclear receptor superfamily, peroxisome proliferator-activated receptors (PPARs) regulate the gene expression of proteins involved in glucose and lipid metabolism. PPARs indeed regulate several physiologic processes, including lipid homeostasis, adipogenesis, inflammation, and wound healing. PPARs bind natural or synthetic PPAR ligands can function as cellular sensors to regulate the gene transcription. Dyslipidemia, and type 2 diabetes mellitus (T2DM) with insulin resistance are treated using agonists of PPARα and PPARγ, respectively. The PPARγ is a key regulator of insulin sensitization and glucose metabolism, and therefore is considered as an imperative pharmacological target to combat diabetic metabolic disease and insulin resistance. Of note, currently available PPARγ full agonists like rosiglitazone display serious adverse effects such as fluid retention/oedema, weight gain, and increased incidence of cardiovascular events. On the other hand, PPARγ partial agonists are being suggested to devoid or having less incidence of these undesirable events, and are under developmental stages. Current research is on the way for the development of novel PPARγ partial agonists with enhanced therapeutic efficacy and reduced adverse effects. This review sheds lights on the current status of development of PPARγ partial agonists, for the management of T2DM, having comparatively less or no adverse effects to that of PPARγ full agonists. © 2015 Elsevier B.V. All rights reserved.","Adverse effects; Cardiovascular events; Diabetes mellitus; PPARγ full agonists; PPARγ partial agonists","Abbott, B.D., Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development (2009) Reprod. Toxicol., 27, pp. 246-257; Acton, J.J., 3rd, Akiyama, T.E., Chang, C.H., Colwell, L., Debenham, S., Doebber, T., Einstein, M., Wood, H.B., Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy) butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume (2009) J. Med. Chem., 52, pp. 3846-3854; Allen, T., Zhang, F., Moodie, S.A., Clemens, L.E., Smith, A., Gregoire, F., Bell, A., Gustafson, T.A., Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity (2006) Diabetes, 55, pp. 2523-2533; Amato, A.A., Rajagopalan, S., Lin, J.Z., Carvalho, B.M., Figueira, A.C., Lu, J., Ayers, S.D., Neves, F.A., GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain (2012) J. Biol. Chem., 287, pp. 28169-28179; Atanasov, A.G., Blunder, M., Fakhrudin, N., Liu, X., Noha, S.M., Malainer, C., Kramer, M.P., Bauer, R., Polyacetylenes from Notopterygium incisum - New selective partial agonists of peroxisome proliferator-activated receptor-gamma (2013) PLoS One, 8; Atanasov, A.G., Wang, J.N., Gu, S.P., Bu, J., Kramer, M.P., Baumgartner, L., Fakhrudin, N., Heiss, E.H., Honokiol: a non-adipogenic PPARγ agonist from nature (2013) Biochim. Biophys. Acta, 1830, pp. 4813-4819; Azoulay, L., Yin, H., Filion, K.B., Assayag, J., Majdan, A., Pollak, M.N., Suissa, S., The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study (2012) BMJ, 344; Balakumar, P., Arora, M.K., Singh, M., Emerging role of PPAR ligands in the management of diabetic nephropathy (2009) Pharmacol. Res., 60, pp. 170-173; Balakumar, P., Jagadeesh, G., PPAR ligands and cardiovascular disorders: friend or foe (2012) Curr. Mol. Pharmacol., 5, pp. 219-223; Balakumar, P., Kathuria, S., Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders (2012) Br. J. Pharmacol., 166, pp. 1981-1992; Balakumar, P., Mahadevan, N., Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? (2012) Br. J. Pharmacol., 165, pp. 373-379; Balakumar, P., Rose, M., Ganti, S.S., Krishan, P., Singh, M., PPAR dual agonists: are they opening Pandor's Box? (2007) Pharmacol. Res., 56, pp. 91-98; Berger, J.P., Petro, A.E., Macnaul, K.L., Kelly, L.J., Zhang, B.B., Richards, K., Elbrecht, A., Moller, D.E., Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator (2003) Mol. Endocrinol., 17, pp. 662-676; Berlie, H.D., Kalus, J.S., Jaber, L.A., Thiazolidinediones and the risk of edema: a meta-analysis (2007) Diabetes Res. Clin. Pract., 76, pp. 279-289; Bilik, D., Mcewen, L.N., Brown, M.B., Selby, J.V., Karter, A.J., Marrero, D.G., Hsiao, V.C., Herman, W.H., Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD) (2010) Pharmacoepidemiol. Drug Saf., 19, pp. 715-721; Brown, J.D., Plutzky, J., Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets (2007) Circulation, 115, pp. 518-533; Burgermeister, E., Schnoebelen, A., Flament, A., Benz, J., Stihle, M., Gsell, B., Rufer, A., Meyer, M., A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro (2006) Mol. Endocrinol., 20, pp. 809-830; Chandalia, A., Clarke, H.J., Clemens, L.E., Pandey, B., Vicena, V., Lee, P., Lavan, B.E., Gregoire, F.M., MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation (2009) PPAR Res., 2009, p. 706852; Chaudhary, S., Dube, A., Kothari, V., Sachan, N., Upasani, C.D., NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile (2012) Eur. J. Pharmacol., 684, pp. 154-160; Chetty, V.T., Sharma, A.M., Can PPARgamma agonists have a role in the management of obesity-related hypertension? (2006) Vasc. Pharmacol., 45, pp. 46-53; Cho, M.C., Lee, D.H., Kim, E.J., Lee, J.Y., Kang, J.W., Song, J.H., Chong, Y., Yoon, D.Y., Novel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening system (2011) Mol. Cell. Biochem., 358, pp. 75-83; Clyne, M., Bladder cancer: pioglitazone increases risk of bladder cancer (2012) Nat. Rev. Urol., 9, p. 353; Colhoun, H.M., Livingstone, S.J., Looker, H.C., Morris, A.D., Wild, S.H., Lindsay, R.S., Reed, C., Scottish Diabetes Research Network Epidemiology Group, Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs (2012) Diabetologia, 55, pp. 2929-2937; De Groot, J.C., Weidner, C., Krausze, J., Kawamoto, K., Schroeder, F.C., Sauer, S., Büssow, K., Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor γ (2013) J. Med. Chem., 56, pp. 1535-1543; Gallagher, A.M., Smeeth, L., Seabroke, S., Leufkens, H.G., Van Staa, T.P., Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data (2011) PLoS One, 6; Gregoire, F.M., Zhang, F., Clarke, H.J., Gustafson, T.A., Sears, D.D., Favelyukis, S., Lenhard, J., Lavan, B.E., MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema (2009) Mol. Endocrinol., 23, pp. 975-988; He, S., Tang, Y.H., Zhao, G., Yang, X., Wang, D., Zhang, Y., Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis (2014) Tumour Biol., 35, pp. 2095-2102; Henriksen, K., Byrjalsen, I., Nielsen, R.H., Madsen, A.N., Larsen, L.K., Christiansen, C., Beck-Nielsen, H., Karsdal, M.A., A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats (2009) Eur. J. Pharmacol., 616, pp. 340-345; Henriksen, K., Byrjalsen, I., Qvist, P., Beck-Nielsen, H., Hansen, G., Riis, B.J., Perrild, H., Ballet Trial Investigators, Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy (2011) Diabetes Metab. Res. Rev., 27, pp. 392-401; Hernandez, A.V., Usmani, A., Rajamanickam, A., Moheet, A., Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials (2011) Am. J. Cardiovasc. Drugs, 11, pp. 115-128; Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., Jones, N.P., Record Study Team, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009) Lancet, 373, pp. 2125-2135; http://www.diabetes.org.my/article.php?aid=837, accessed 04.10.14Jones, S.G., Momin, S.R., Good, M.W., Shea, T.K., Patric, K., Distal upper and lower limb fractures associated with thiazolidinedione use (2009) Am. J. Manag. Care, 15, pp. 491-496; Juurlink, D.N., Gomes, T., Lipscombe, L.L., Austin, P.C., Hux, J.E., Mamdani, M.M., Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study (2009) BMJ, 339, p. 2942; Kim, M.K., Chae, Y.N., Choi, S.H., Moon, H.S., Son, M.H., Bae, M.H., Choi, H.H., Shin, C.Y., PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects (2011) Eur. J. Pharmacol., 650, pp. 673-681; Kintscher, U., Goebel, M., INT-131, a PPARgamma agonist for the treatment of type 2 diabetes (2009) Curr. Opin. Investig. Drugs, 10, pp. 381-387; Konda, V.R., Desai, A., Darland, G., Grayson, N., Bland, J.S., KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes (2014) PLoS One, 9; Kouskoumvekaki, I., Petersen, R.K., Fratev, F., Taboureau, O., Nielsen, T.E., Oprea, T.I., Sonne, S.B., Kristiansen, K., Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow (2013) J. Chem. Inf. Model., 53, pp. 923-937; Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Kadowaki, T., PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance (1999) Mol. Cell, 4, pp. 597-609; Larsen, P.J., Lykkegaard, K., Larsen, L.K., Fleckner, J., Sauerberg, P., Wassermann, K., Wulff, E.M., Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone (2008) Eur. J. Pharmacol., 596, pp. 173-179; Lee, D.H., Huang, H., Choi, K., Mantzoros, C., Kim, Y.B., Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice (2012) Am. J. Physiol. Endocrinol. Metab., 302, pp. E552-E560; Lewis, J.D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W.B., Quesenberry, Jr.C.P., Vaughn, D.J., Strom, B.L., Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study (2011) Diabetes Care, 34, pp. 916-922; Li, Y., Wang, Z., Furukawa, N., Escaron, P., Weiszmann, J., Lee, G., Lindstrom, M., Chen, J.L., T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties (2008) J. Biol. Chem., 283, pp. 9168-9176; Liao, X., Wang, Y., Wong, C.W., Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein (2010) Br. J. Pharmacol., 161, pp. 771-781; Loke, Y.K., Kwok, C.S., Singh, S., Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies (2011) BMJ, 342, p. 1309; Mamtani, R., Haynes, K., Bilker, W.B., Vaughn, D.J., Strom, B.L., Glanz, K., Lewis, J.D., Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study (2012) J. Natl. Cancer Inst., 104, pp. 1411-1421; Meier, C., Kraenzlin, M.E., Bodmer, M., Jick, S.S., Jick, H., Meier, C.R., Use of thiazolidinediones and fracture risk (2008) Arch. Intern. Med., 168, pp. 820-825; Ming, Y., Hu, X., Song, Y., Liu, Z.1., Li, J., Gao, R., Zhang, Y., Xiao, X., CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo (2014) PLoS One, 9; Motani, A., Wang, Z., Weiszmann, J., Mcgee, L.R., Lee, G., Liu, Q., Staunton, J., Li, Y., INT131: a selective modulator of PPAR gamma (2009) J. Mol. Biol., 386, pp. 1301-1311; Neumann, A., Weill, A., Ricordeau, P., Fagot, J.P., Alla, F., Allemand, H., Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study (2012) Diabetologia, 55, pp. 1953-1962; Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (2007) N. Engl. J. Med., 356, pp. 2457-2471; Riche, D.M., King, S.T., Bone loss and fracture risk associated with thiazolidinedione therapy (2010) Pharmacotherapy, 30, pp. 716-727; Romero, V., Peyton, C., Gray, I., Hemal, A., Terlecki, R., Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use (2014) BMC Urol., 14, p. 10; Rosenstock, J., Flores-Losano, F., Schwartz, S., Gonzalez-Galvez, G., Karpf, D.B., MBX-102: A novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with type 2 diabetes mellitus (T2DM) on concomitant insulin therapy [abstract 44-OR] (2005) Diabetes, 54, p. A11; Schernthaner, G., Chilton, R.J., Cardiovascular risk and thiazolidinediones - What do meta-analyses really tell us? (2010) Diabetes Obes. Metab., 12, pp. 1023-1035; Seto, S., Okada, K., Kiyota, K., Isogai, S., Iwago, M., Shinozaki, T., Kitamura, Y., Murakami, K., Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone (2010) J. Med. Chem., 53, pp. 5012-5024; Singh, S., Loke, Y.K., Furberg, C.D., Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis (2007) JAMA, 298, pp. 1189-1195; Starner, C.I., Schafer, J.A., Heaton, A.H., Gleason, P.P., Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events (2008) J. Manag. Care Pharm., 14, pp. 523-531; Taygerly, J.P., Mcgee, L.R., Rubenstein, S.M., Houze, J.B., Cushing, T.D., Li, Y., Motani, A., Nakamura, M., Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity (2013) Bioorg. Med. Chem., 21, pp. 979-992; Wang, C.C., Chen, W.L., Kao, T.W., Chang, Y.W., Loh, C.H., Chou, C.C., Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population (2011) Clin. Ther., 33, pp. 1904-1913; Wang, L., Waltenberger, B., Pferschy-Wenzig, E.M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Atanasov, A.G., Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (2014) Biochem. Pharmacol., 92, pp. 73-89; Ziyadeh, N., Mcafee, A.T., Koro, C., Landon, J., Arnold Chan, K., The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database (2009) Clin. Ther., 31, pp. 2665-2677",Article,Scopus,2-s2.0-84925089002
"Navarro M., Morales F.J.","Mechanism of reactive carbonyl species trapping by hydroxytyrosol under simulated physiological conditions",2014,"Food Chemistry","175",,,"92","99",,,10.1016/j.foodchem.2014.11.117,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84919346636&partnerID=40&md5=1a72c1715d60ebff85cf5a68d56e779a","Institute of Food Science, Technology and Nutrition, ICTAN-CSICMadrid, Spain","Navarro, M., Institute of Food Science, Technology and Nutrition, ICTAN-CSICMadrid, Spain; Morales, F.J., Institute of Food Science, Technology and Nutrition, ICTAN-CSICMadrid, Spain","This investigation reveals that hydroxytyrosol (HT) could compete with lysine, arginine and histidine to bind methylglyoxal (MGO) and reducing the formation of advanced glycation end products. Kinetic of the degradation of HT in presence/absence of MGO under simulated physiological conditions is monitored by HPLC coupled to a QTOF spectrometer. HT should previously be oxidized to DOPAC (3,4-dihydroxyphenylacetic acid) which reacts with MGO by electrophilic aromatic substitution of the ortho-diphenyl ring. DOPAC was detected as the major degradation product of HT under simulated physiological conditions. Ortho-hydroxyl groups are necessary to promote the nucleophilic addition of MGO by HT and related compounds. The formation of four adducts were described by mass spectrometry, but monoDOPAC-monoMGO adduct (C11H12O6) was predominant. Results suggest that HT and its degradation product DOPAC could have a relevant role in preventing the formation of advanced glycation end products and therefore potentially mitigate the diabetic complications. © 2014 Elsevier Ltd. All rights reserved.","Antiglycative activity; Dicarbonyl trapping; Glycation; Hydroxytyrosol; Methylglyoxal","Baynes, J., Monnier, V., Ames, J., Thorpe, S., The Maillard reaction: Chemistry at the interface of nutrition, aging, and disease (2004) 8th International Symposium on the Maillard Reaction, p. 954. , J. Baynes, V. Monnier, J. Ames, S. Thorpe, Annals of the New York Academy of Science Charleston, SC; Baynes, J.W., Thorpe, S.R., Role of oxidative stress in diabetic complications: A new perspective on an old paradigm (1999) Diabetes, 48, pp. 1-9; Benzie, I.F.F., Strain, J.J., The ferric reducing ability of plasma (FRAP) as a measure of ""antioxidant power"": The FRAP assay (1996) Analytical Biochemistry, 239, pp. 70-76; Cai, W., Gao, Q.D., Zhu, L., Peppa, M., He, C., Vlassara, H., Oxidative stress-inducing carbonyl compounds from common foods: Novel mediators of cellular dysfunction (2002) Molecular Medicine, 8 (7), pp. 337-346; Cervantes-Laurean, D., Schramm, D.D., Jacobson, E.L., Halaweish, I., Bruckner, G.G., Boissonneault, G.A., Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites (2006) The Journal of Nutritional Biochemistry, 17 (8), pp. 531-540; García, P., Romero, C., Brenes, M., Garrido, A., Effect of metal cations on the chemical oxidation of olive o-diphenols in model systems (1996) Journal of Agricultural and Food Chemistry, 44 (8), pp. 2101-2105; Hamden, K., Allouche, N., Damak, M., Elfeki, A., Hypoglycemic and antioxidant effects of phenolic extracts and purified hydroxytyrosol from olive mill waste in vitro and in rats (2009) Chemico-Biological Interactions, 180 (3), pp. 421-432; Hamden, K., Allouche, N., Jouadi, B., El-Fazaa, S., Gharbi, N., Carreau, S., Inhibitory action of purified hydroxytyrosol from stored olive mill waste on intestinal disaccharidases and lipase activities and pancreatic toxicity in diabetic rats (2010) Food Science and Biotechnology, 19 (2), pp. 439-447; Hu, T., He, X.-W., Jiang, J.-G., Xu, X.-L., Hydroxytyrosol and its potential therapeutic effects (2014) Journal of Agricultural and Food Chemistry, 62 (7), pp. 1449-1455; Kawaguchi, K., Matsumoto, T., Kumazawa, Y., Effects of antioxidant polyphenols on TNF-alpha-related diseases (2011) Current Topics in Medicinal Chemistry, 11 (14), pp. 1767-1779; Lo, T.W., Westwood, M.E., McLellan, A.C., Selwood, T., Thornalley, P.J., Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin (1994) Journal of Biological Chemistry, 269 (51), pp. 32299-32305; Mesias, M., Navarro, M., Gökmen, V., Morales, F.J., Antiglycative effect of fruit and vegetable seed extracts: Inhibition of AGE formation and carbonyl-trapping abilities (2013) Journal of the Science of Food and Agriculture, 93 (8), pp. 2037-2044; Montonen, J., Knekt, P., Järvinen, R., Reunanen, A., Dietary antioxidant intake and risk of type 2 diabetes (2004) Diabetes Care, 27 (2), pp. 362-366; Nagasawa, T., Tabata, N., Ito, Y., Nishizawa, N., Aiba, Y., Kitts, D., Inhibition of glycation reaction in tissue protein incubations by water soluble rutin derivative (2003) Molecular and Cellular Biochemistry, 249 (12), pp. 3-10; Nemet, I., Vikić-Topić, D., Varga-Defterdarović, L., Spectroscopic studies of methylglyoxal in water and dimethylsulfoxide (2004) Bioorganic Chemistry, 32 (6), pp. 560-570; Pan, M.-H., Lai, C.-S., Tsai, M.-L., Wu, J.-C., Ho, C.-T., Molecular mechanisms for anti-aging by natural dietary compounds (2012) Molecular Nutrition & Food Research, 56 (1), pp. 88-115; Peng, X., Ma, J., Chen, F., Wang, M., Naturally occurring inhibitors against the formation of advanced glycation end-products (2011) Food & Function, 2 (6), pp. 289-301; Pereira-Caro, G., Sarriá, B., Madrona, A., Espartero, J.L., Escuderos, M.E., Bravo, L., Digestive stability of hydroxytyrosol, hydroxytyrosyl acetate and alkyl hydroxytyrosyl ethers (2012) International Journal of Food Science and Nutrition, 63 (6), pp. 703-707; Peyroux, J., Sternberg, M., Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes (2006) Pathologie Biologie, 54 (7), pp. 405-419; Poulsen, M.W., Hedegaard, R.V., Andersen, J.M., De Courten, B., Bügel, S., Nielsen, J., Advanced glycation endproducts in food and their effects on health (2013) Food and Chemical Toxicology, 60, pp. 10-37; Rahbar, S., Figarola, J.L., Novel inhibitors of advanced glycation endproducts (2003) Archives of Biochemistry and Biophysics, 419 (1), pp. 63-79; Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., Rice-Evans, C., Antioxidant activity applying an improved ABTS radical cation decolorization assay (1999) Free Radical Biology & Medicine, 26, pp. 1231-1237; Roche, M., Dufour, C., Mora, N., Dangles, O., Antioxidant activity of olive phenols: Mechanistic investigation and characterization of oxidation products by mass spectrometry (2005) Organic & Biomolecular Chemistry, 3, pp. 423-430; Rubio-Senent, F., Rodríguez-Gutíerrez, G., Lama-Muñoz, A., Fernández-Bolaños, J., New phenolic compounds hydrothermally extracted from the olive oil byproduct alperujo and their antioxidative activities (2012) Journal of Agricultural and Food Chemistry, 60 (5), pp. 1175-1186; Shao, X., Chen, H., Zhu, Y., Sedighi, R., Ho, C.-T., Sang, S., Essential structural requirements and additive effects for flavonoids to scavenge methylglyoxal (2014) Journal of Agricultural and Food Chemistry, 62 (14), pp. 3202-3210; Singh, R., Barden, A., Mori, T., Beilin, L., Advanced glycation endproducts: A review (2001) Diabetologia, 44 (2), pp. 129-146; Singleton, V.L., Orthofer, R., Lamuela-Raventos, R.M., Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent (1999) Methods in Enzymology, 299, pp. 152-178; Totlani, V.M., Peterson, D.G., Reactivity of epicatechin in aqueous glycine and glucose Maillard reaction models: Quenching of C2, C3, and C4 sugar fragments (2005) Journal of Agricultural and Food Chemistry, 53 (10), pp. 4130-4135; Totlani, V.M., Peterson, D.G., Epicatechin carbonyl-trapping reactions in aqueous Maillard systems: Identification and structural elucidation (2006) Journal of Agricultural and Food Chemistry, 54 (19), pp. 7311-7318; Visioli, F., Bellomo, G., Galli, C., Free radical-scavenging properties of olive oil polyphenols (1998) Biochemical and Biophysical Research Communications, 247 (1), pp. 60-64; Wang, Y., Ho, C.-T., Flavour chemistry of methylglyoxal and glyoxal (2012) Chemical Society Reviews, 41 (11), pp. 4140-4149; Wang, H., Meng, Q.H., Gordon, J.R., Khandwala, H., Wu, L., Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus (2007) Clinical Biochemistry, 40 (1617), pp. 1232-1239; Wang, W., Yagiz, Y., Buran, T.J., Nunes D. C, N., Gu, L., Phytochemicals from berries and grapes inhibited the formation of advanced glycation end-products by scavenging reactive carbonyls (2011) Food Research International, 44 (9), pp. 2666-2673; Wu, Q., Chen, H., Lv, Z., Li, S., Hu, B., Guan, Y., Oligomeric procyanidins of lotus seedpod inhibits the formation of advanced glycation end-products by scavenging reactive carbonyls (2013) Food Chemistry, 138 (23), pp. 1493-1502; Wu, C.-H., Huang, S.-M., Lin, J.-A., Yen, G.-C., Inhibition of advanced glycation endproduct formation by foodstuffs (2011) Food & Function, 2 (5), pp. 224-234; Wu, C.-H., Yen, G.-C., Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts (2005) Journal of Agricultural and Food Chemistry, 53 (8), pp. 3167-3173; Zafra-Gómez, A., Luzón-Toro, B., Capel-Cuevas, S., Morales, J.C., Stability of hydroxytyrosol in aqueous solutions at different concentration, temperature and with different ionic content: A study using UPLC-MS (2011) Food and Nutrition Sciences, 2, pp. 1114-1120",Article,Scopus,2-s2.0-84919346636
"Nassir F., Ibdah J.A.","Role of mitochondria in nonalcoholic fatty liver disease",2014,"International Journal of Molecular Sciences","15","5",,"8713","8742",,2,10.3390/ijms15058713,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84900851950&partnerID=40&md5=ab951560ba966985b468382944bfe2d1","Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, Columbia, MO 65212, United States","Nassir, F., Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, Columbia, MO 65212, United States; Ibdah, J.A., Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, Columbia, MO 65212, United States","Nonalcoholic fatty liver disease (NAFLD) affects about 30% of the general population in the United States and includes a spectrum of disease that includes simple steatosis, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Significant insight has been gained into our understanding of the pathogenesis of NALFD; however the key metabolic aberrations underlying lipid accumulation in hepatocytes and the progression of NAFLD remain to be elucidated. Accumulating and emerging evidence indicate that hepatic mitochondria play a critical role in the development and pathogenesis of steatosis and NAFLD. Here, we review studies that document a link between the pathogenesis of NAFLD and hepatic mitochondrial dysfunction with particular focus on new insights into the role of impaired fatty acid oxidation, the transcription factor peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), and sirtuins in development and progression of NAFLD. © 2014 by the authors; licensee MDPI, Basel, Switzerland.","Fatty acid oxidation; Liver; Mitochondria; NAFLD; NASH; PGC-1α; Sirtuin-1 (SIRT1); Sirtuin-3 (SIRT3); Steatosis","Milic, S., Stimac, D., Nonalcoholic fatty liver disease/steatohepatitis: Epidemiology, pathogenesis, clinical presentation and treatment (2012) Dig. Dis. (Basel, Switz.), 30, pp. 158-162; Nassir, F., Adewole, O.L., Brunt, E.M., Abumrad, N.A., CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice (2013) J. Lipid Res, 54, pp. 2988-2997; Cohen, J.C., Horton, J.D., Hobbs, H.H., Human fatty liver disease: Old questions and new insights (2011) Science, 332, pp. 1519-1523; Fabbrini, E., Sullivan, S., Klein, S., Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications (2010) Hepatology (Baltim., Md, 51, pp. 679-689; Grattagliano, I., Russmann, S., Diogo, C., Bonfrate, L., Oliveira, P.J., Wang, D.Q., Portincasa, P., Mitochondria in chronic liver disease (2011) Curr. Drug Targets, 12, pp. 879-893; Szczepaniak, L.S., Nurenberg, P., Leonard, D., Browning, J.D., Reingold, J.S., Grundy, S., Hobbs, H.H., Dobbins, R.L., Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population (2005) Am. J. Physiol. Endocrinol. Metab, 288, pp. E462-E468; Scaglioni, F., Ciccia, S., Marino, M., Bedogni, G., Bellentani, S., (2011) ASH and NASH. Dig. Dis. (Basel, Switz.), 29, pp. 202-210; Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., Sanyal, A.J., (2012) The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline By the American Association For the Study of Liver Diseases, 55, pp. 2005-2023. , American College of Gastroenterology, and the American Gastroenterological Association. Hepatology (Baltim., Md.); Adams, L.A., Lymp, J.F., Sauver, J.S., Sanderson, S.O., Lindor, K.D., Feldstein, A., Angulo, P., The natural history of nonalcoholic fatty liver disease: A population-based cohort study (2005) Gastroenterology, 129, pp. 113-121; Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults (2011) Aliment. Pharmacol. Therap, 34, pp. 274-285; Tetri, L.H., Basaranoglu, M., Brunt, E.M., Yerian, L.M., Neuschwander-Tetri, B.A., Severe NAFLD With Hepatic Necroinflammatory Changes In Mice Fed Trans Fats and A High-fructose Corn Syrup Equivalent (2008) Am. J. Physiol. Gastrointest. Liver Physiol, 295, pp. G987-G995; Alisi, A., Manco, M., Panera, N., Nobili, V., Association between type two diabetes and non-alcoholic fatty liver disease in youth (2009) Ann. Hepatol, 8 (SUPPL. 1), pp. S44-S50; Parikh, R.M., Mohan, V., Changing definitions of metabolic syndrome (2012) Indian J. Endocrinol. Metab, 16, pp. 7-12; Rahman, R., Hammoud, G.M., Almashhrawi, A.A., Ahmed, K.T., Ibdah, J.A., Primary hepatocellular carcinoma and metabolic syndrome: An update (2013) World J. Gastrointest. Oncol, 5, pp. 186-194; Clark, J.M., Brancati, F.L., Diehl, A.M., Nonalcoholic fatty liver disease (2002) Gastroenterology, 122, pp. 1649-1657; Machado, M., Marques-Vidal, P., Cortez-Pinto, H., Hepatic histology in obese patients undergoing bariatric surgery (2006) J. Hepatol, 45, pp. 600-606; Loria, P., Lonardo, A., Anania, F., Liver and diabetes: A vicious circle (2013) Hepatol. Res, 43, pp. 51-64; Takamura, T., Misu, H., Ota, T., Kaneko, S., Fatty liver as a consequence and cause of insulin resistance: Lessons from type 2 diabetic liver (2012) Endocr. J, 59, pp. 745-763; Younossi, Z.M., Gramlich, T., Matteoni, C.A., Boparai, N., McCullough, A.J., Nonalcoholic fatty liver disease in patients with type 2 diabetes (2004) Clin. Gastroenterol. Hepatol, 2, pp. 262-265; Abdelmalek, M., Ludwig, J., Lindor, K.D., Two cases from the spectrum of nonalcoholic steatohepatitis (1995) J. Clin. Gastroenterol, 20, pp. 127-130; Bacon, B.R., Farahvash, M.J., Janney, C.G., Neuschwander-Tetri, B.A., Nonalcoholic steatohepatitis: An expanded clinical entity (1994) Gastroenterology, 107, pp. 1103-1109; Teli, M.R., James, O.F., Burt, A.D., Bennett, M.K., Day, C.P., The natural history of nonalcoholic fatty liver: A follow-up study (1995) Hepatology (Baltim., Md.), 22, pp. 1714-1719; Guerrero, R., Vega, G.L., Grundy, S.M., Browning, J.D., Ethnic differences in hepatic steatosis: An insulin resistance paradox? (2009) Hepatology (Baltim., Md.), 49, pp. 791-801; Lewis, J.R., Mohanty, S.R., Nonalcoholic fatty liver disease: A review and update (2010) Dig. Dis. Sci, 55, pp. 560-578; Day, C.P., James, O.F., Steatohepatitis: A tale of two ""hits""? (1998) Gastroenterology, 114, pp. 842-845; Tilg, H., Moschen, A.R., Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis (2010) Hepatology (Baltim., Md.), 52, pp. 1836-1846; Lonardo, A., Bellentani, S., Ratziu, V., Loria, P., Insulin resistance in nonalcoholic steatohepatitis: Necessary but not sufficient-Death of a dogma from analysis of therapeutic studies? Expert (2011) Rev. Gastroenterol. Hepatol, 5, pp. 279-289; Yilmaz, Y., Review article: Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? (2012) Aliment. Pharmacol. Therap, 36, pp. 815-823; Amaro, A., Fabbrini, E., Kars, M., Yue, P., Schechtman, K., Schonfeld, G., Klein, S., Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia (2010) Gastroenterology, 139, pp. 149-153; Kantartzis, K., Machicao, F., Machann, J., Schick, F., Fritsche, A., Haring, H.U., Stefan, N., The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans (2009) Clin. Sci. (Lond., Engl.), 116, pp. 531-537; Kantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Konigsrainer, I., Konigsrainer, A., Haring, H.U., Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene (2009) Diabetes, 58, pp. 2616-2623; Stefan, N., Staiger, H., Haring, H.U., Dissociation between fatty liver and insulin resistance: The role of adipose triacylglycerol lipase (2011) Diabetologia, 54, pp. 7-9; Brumbaugh, D.E., Friedman, J.E., Developmental origins of nonalcoholic fatty liver disease (2014) Pediatr. Res, 75, pp. 140-147; Nestel, P.J., Havel, R.J., Bezman, A., Sites of initial removal of chylomicron triglyceride fatty acids from the blood (1962) J. Clin. Investig, 41, pp. 1915-1921; Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of Fatty Acids Stored In Liver and Secreted Via Lipoproteins In Patients With Nonalcoholic Fatty Liver Disease (2005) J. Clin. Investig, 115, pp. 1343-1351; Lafontan, M., Langin, D., Lipolysis and lipid mobilization in human adipose tissue (2009) Prog. Lipid Res, 48, pp. 275-297; Ferre, P., Foufelle, F., Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c (2010) Diabetes, Obes. Metab, 12 (SUPPL. 2), pp. 83-92; Horton, J.D., Goldstein, J.L., Brown, M.S., SREBPs: Transcriptional mediators of lipid homeostasis (2002) Cold Spring Harb. Symp. Quant. Biol, 67, pp. 491-498; Kazantzis, M., Stahl, A., Fatty acid transport proteins, implications in physiology and disease (2012) Biochim. Biophys. Acta, 1821, pp. 852-857; Doege, H., Baillie, R.A., Ortegon, A.M., Tsang, B., Wu, Q., Punreddy, S., Hirsch, D., Stahl, A., Targeted deletion of FATP5 reveals multiple functions in liver metabolism (2006) Alterations In Hepatic Lipid Homeostasis. Gastroenterology, 130, pp. 1245-1258; Doege, H., Grimm, D., Falcon, A., Tsang, B., Storm, T.A., Xu, H., Ortegon, A.M., Stahl, A., Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia (2008) J. Biol. Chem, 283, pp. 22186-22192; Falcon, A., Doege, H., Fluitt, A., Tsang, B., Watson, N., Kay, M.A., Stahl, A., FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase (2010) Am. J. Physiol. Endocrinol. Metab, 299, pp. E384-E393; Fernandez, M.A., Albor, C., Ingelmo-Torres, M., Nixon, S.J., Ferguson, C., Kurzchalia, T., Tebar, F., Pol, A., Caveolin-1 is essential for liver regeneration (2006) Science, 313, pp. 1628-1632; Su, X., Abumrad, N.A., Cellular fatty acid uptake: A pathway under construction (2009) Trends Endocrinol. Metab, 20, pp. 72-77; Koonen, D.P.Y., Jacobs, R.L., Febbraio, M., Young, M.E., Soltys, C.-L.M., Ong, H., Vance, D.E., Dyck, J.R.B., Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity (2007) Diabetes, 56, pp. 2863-2871; Miquilena-Colina, M.E., Lima-Cabello, E., Sanchez-Campos, S., Garcia-Mediavilla, M.V., Fernandez-Bermejo, M., Lozano-Rodriguez, T., Vargas-Castrillon, J., Aspichueta, P., Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis (2011) C. Gut, 60, pp. 1394-1402; Zhou, D., Samovski, D., Okunade, A.L., Stahl, P.D., Abumrad, N.A., Su, X., CD36 level and trafficking are determinants of lipolysis in adipocytes (2012) FASEB J, 26, pp. 4733-4742; Fabbrini, E., Magkos, F., Mohammed, B.S., Pietka, T., Abumrad, N.A., Patterson, B.W., Okunade, A., Klein, S., Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 15430-15435; Stremmel, W., Pohl, L., Ring, A., Herrmann, T., A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids (2001) Lipids, 36, pp. 981-989; Storch, J., Corsico, B., The emerging functions and mechanisms of mammalian fatty acid-binding proteins (2008) Annu. Rev. Nutr, 28, pp. 73-95; Newberry, E.P., Xie, Y., Kennedy, S., Han, X., Buhman, K.K., Luo, J., Gross, R.W., Davidson, N.O., Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene (2003) J. Biol. Chem, 278, pp. 51664-51672; Wolins, N.E., Brasaemle, D.L., Bickel, P.E., A proposed model of fat packaging by exchangeable lipid droplet proteins (2006) FEBS Lett, 580, pp. 5484-5491; Schonfeld, G., Familial hypobetalipoproteinemia: A review (2003) J. Lipid Res, 44, pp. 878-883; Sen, D., Dagdelen, S., Erbas, T., Hepatosteatosis with hypobetalipoproteinemia (2007) J. Natl. Med. Assoc, 99, pp. 284-286; Ginsberg, H.N., Fisher, E.A., The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism (2009) J. Lipid Res, 50 (SUPPL.), pp. S162-S166; Tarugi, P., Lonardo, A., Ballarini, G., Grisendi, A., Pulvirenti, M., Bagni, A., Calandra, S., Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein, B (1996) Gastroenterology, 111, pp. 1125-1133; Welty, F.K., Hypobetalipoproteinemia and abetalipoproteinemia (2014) Curr. Opin. Lipidol, 25, pp. 161-168; Wolfrum, C., Stoffel, M., Coactivation of Foxa2 through Pgc-1β promotes liver fatty acid oxidation and triglyceride/VLDL secretion (2006) Cell Metab, 3, pp. 99-110; Choi, S.H., Ginsberg, H.N., Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance (2011) Trends Endocrinol. Metab, 22, pp. 353-363; Van der Poorten, D., Samer, C.F., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L.E., Komuta, M., Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause? (2013) Hepatology (Baltim., Md.), 57, pp. 2180-2188; Begriche, K., Massart, J., Robin, M.A., Bonnet, F., Fromenty, B., Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease (2013) Hepatology (Baltim., Md.), 58, pp. 1497-1507; Eaton, S., Bartlett, K., Pourfarzam, M., Mammalian mitochondrial β-oxidation (1996) Biochem. J, 320, pp. 345-357; McGarry, J.D., Foster, D.W., Regulation of hepatic fatty acid oxidation and ketone body production (1980) Annu. Rev. Biochem, 49, pp. 395-420; Sidossis, L.S., Stuart, C.A., Shulman, G.I., Lopaschuk, G.D., Wolfe, R.R., Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria (1996) J. Clin. Investig, 98, pp. 2244-2250; Longuet, C., Sinclair, E.M., Maida, A., Baggio, L.L., Maziarz, M., Charron, M.J., Drucker, D.J., The glucagon receptor is required for the adaptive metabolic response to fasting (2008) Cell Metab, 8, pp. 359-371; Mandard, S., Muller, M., Kersten, S., Peroxisome proliferator-activated receptor α target genes (2004) Cell. Mol. Life Sci, 61, pp. 393-416; Potthoff, M.J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Kliewer, S.A., FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 10853-10858; Pellicoro, A., Ramachandran, P., Iredale, J.P., Fallowfield, J.A., Liver fibrosis and repair: Immune regulation of wound healing in a solid organ (2014) Nat. Rev. Immunol, 14, pp. 181-194; Wang, K., Molecular mechanisms of hepatic apoptosis (2014) Cell Death Dis, 5, pp. e996; Malaguarnera, M., Rosa, M., Nicoletti, F., Malaguarnera, L., Molecular mechanisms involved in NAFLD progression (2009) J. Mol. Med. (Berl., Ger.), 87, pp. 679-695; Musso, G., Gambino, R., Cassader, M., Obesity, diabetes, and gut microbiota: The hygiene hypothesis expanded? (2010) Diabetes Care, 33, pp. 2277-2284; Calvo, S.E., Mootha, V.K., The mitochondrial proteome and human disease (2010) Annu. Rev. Genomics Hum. Genet, 11, pp. 25-44; Pessayre, D., Mansouri, A., Fromenty, B., Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis (2002) Am. J. Physiol. Gastrointest. Liver Physiol, 282, pp. G193-G199; Boveris, A., Chance, B., The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen (1973) Biochem. J, 134, pp. 707-716; Begriche, K., Igoudjil, A., Pessayre, D., Fromenty, B., Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it (2006) Mitochondrion, 6, pp. 1-28; Mansouri, A., Gaou, I., de Kerguenec, C., Amsellem, S., Haouzi, D., Berson, A., Moreau, A., Pessayre, D., An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice (1999) Gastroenterology, 117, pp. 181-190; Caldwell, S.H., Chang, C.Y., Nakamoto, R.K., Krugner-Higby, L., Mitochondria in nonalcoholic fatty liver disease (2004) Clin. Liver Dis, 8, pp. 595-617; Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W.B., Contos, M.J., Sterling, R.K., Luketic, V.A., Clore, J.N., Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities (2001) Gastroenterology, 120, pp. 1183-1192; Lammens, M., Laak, H., Contribution of histopathological examination to the diagnosis of OXPHOS disorders (2005) Oxidative Phosphorylation In Health and Disease, pp. 53-78. , Springer: New York, NY, USA; Rolo, A.P., Teodoro, J.S., Palmeira, C.M., Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis (2012) Free Radic. Biol. Med, 52, pp. 59-69; Ibdah, J.A., Paul, H., Zhao, Y., Binford, S., Salleng, K., Cline, M., Matern, D., Strauss, A.W., Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death (2001) J. Clin. Investig, 107, pp. 1403-1409; Wanders, R.J., Ijist, L., Poggi, F., Bonnefont, J.P., Munnich, A., Brivet, M., Rabier, D., Saudubray, J.M., Human trifunctional protein deficiency: A new disorder of mitochondrial fatty acid beta-oxidation (1992) Biochem. Biophys. Res. Commun, 188, pp. 1139-1145; Rector, R.S., Payne, R.M., Ibdah, J.A., Mitochondrial trifunctional protein defects: Clinical implications and therapeutic approaches (2008) Adv. Drug Deliv. Rev, 60, pp. 1488-1496; Ibdah, J.A., Perlegas, P., Zhao, Y., Angdisen, J., Borgerink, H., Shadoan, M.K., Wagner, J.D., Cline, J.M., Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance (2005) Gastroenterology, 128, pp. 1381-1390; Rector, R.S., Morris, E.M., Ridenhour, S., Meers, G.M., Hsu, F.F., Turk, J., Ibdah, J.A., Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect (2013) Hepatology, 57, pp. 2213-2223; Zhou, M., Xu, A., Tam, P.K., Lam, K.S., Chan, L., Hoo, R.L., Liu, J., Wang, Y., Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury (2008) Hepatology, 48, pp. 1087-1096; Thyfault, J.P., Rector, R.S., Uptergrove, G.M., Borengasser, S.J., Morris, E.M., Wei, Y., Laye, M.J., Ridenhour, S.E., Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury (2009) J. Physiol, 587, pp. 1805-1816; Rector, R.S., Thyfault, J.P., Uptergrove, G.M., Morris, E.M., Naples, S.P., Borengasser, S.J., Mikus, C.R., Booth, F.W., Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model (2010) J. Hepatol, 52, pp. 727-736; Kawano, K., Hirashima, T., Mori, S., Saitoh, Y., Kurosumi, M., Natori, T., Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka long-evans tokushima fatty (OLETF) strain (1992) Diabetes, 41, pp. 1422-1428; Jeong, S.K., Kim, Y.K., Park, J.W., Shin, Y.J., Kim, D.S., Impact of visceral fat on the metabolic syndrome and nonalcoholic fatty liver disease (2008) J. Korean Med. Sci, 23, pp. 789-795; Wang, Y., Zhou, M., Lam, K.S., Xu, A., Protective roles of adiponectin in obesity-related fatty liver diseases: Mechanisms and therapeutic implications (2009) Arq. Bras. Endocrinol. Metabol, 53, pp. 201-212; Bajaj, M., Suraamornkul, S., Piper, P., Hardies, L.J., Glass, L., Cersosimo, E., Pratipanawatr, T., Defronzo, R.A., Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients (2004) J. Clin. Endocrinol. Metab, 89, pp. 200-206; Hui, J.M., Hodge, A., Farrell, G.C., Kench, J.G., Kriketos, A., George, J., Beyond insulin resistance in NASH: TNF-α or adiponectin? (2004) Hepatology (Baltim., Md.), 40, pp. 46-54; Jung, U.J., Choi, M.S., Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease (2014) Int. J. Mol. Sci, 15, pp. 6184-6223; Negre-Salvayre, A., Hirtz, C., Carrera, G., Cazenave, R., Troly, M., Salvayre, R., Penicaud, L., Casteilla, L., A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation (1997) FASEB J, 11, pp. 809-815; Chow, L., From, A., Seaquist, E., Skeletal muscle insulin resistance: The interplay of local lipid excess and mitochondrial dysfunction (2010) Metab. Clin. Exp, 59, pp. 70-85; Morino, K., Petersen, K.F., Dufour, S., Befroy, D., Frattini, J., Shatzkes, N., Neschen, S., Sono, S., Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents (2005) J. Clin. Investig, 115, pp. 3587-3593; Petersen, K.F., Dufour, S., Befroy, D., Garcia, R., Shulman, G.I., Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes (2004) N. Engl. J. Med, 350, pp. 664-671; Morino, K., Petersen, K.F., Sono, S., Choi, C.S., Samuel, V.T., Lin, A., Gallo, A., Goldberg, I.J., Regulation of mitochondrial biogenesis by lipoprotein lipase in muscle of insulin-resistant offspring of parents with type 2 diabetes (2012) Diabetes, 61, pp. 877-887; Petersen, K.F., Dufour, S., Morino, K., Yoo, P.S., Cline, G.W., Shulman, G.I., Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes (2012) Proc. Natl. Acad. Sci. USA, 109, pp. 8236-8240; Andersson, U., Scarpulla, R.C., Pgc-1-related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor 1-dependent transcription in mammalian cells (2001) Mol. Cell. Biol, 21, pp. 3738-3749; Vercauteren, K., Gleyzer, N., Scarpulla, R.C., Short hairpin RNA-mediated silencing of PRC (PGC-1-related coactivator) results in a severe respiratory chain deficiency associated with the proliferation of aberrant mitochondria (2009) J. Biol. Chem, 284, pp. 2307-2319; Handschin, C., Spiegelman, B.M., Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism (2006) Endocr. Rev, 27, pp. 728-735; Lin, J., Puigserver, P., Donovan, J., Tarr, P., Spiegelman, B.M., Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β), a novel PGC-1-related transcription coactivator associated with host cell factor (2002) J. Biol. Chem, 277, pp. 1645-1648; Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M., Spiegelman, B.M., A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis (1998) Cell, 92, pp. 829-839; Lai, L., Leone, T.C., Zechner, C., Schaeffer, P.J., Kelly, S.M., Flanagan, D.P., Medeiros, D.M., Kelly, D.P., Transcriptional coactivators PGC-1α and PGC-lβ control overlapping programs required for perinatal maturation of the heart (2008) Genes Dev, 22, pp. 1948-1961; Lelliott, C.J., Medina-Gomez, G., Petrovic, N., Kis, A., Feldmann, H.M., Bjursell, M., Parker, N., Hu, P., Ablation of PGC-1β results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance (2006) PLoS Biol, 4, pp. e369; Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M., Bernal-Mizrachi, C., PGC-1α deficiency causes multi-system energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis (2005) PLoS Biol, 3, pp. e101; Sonoda, J., Mehl, I.R., Chong, L.W., Nofsinger, R.R., Evans, R.M., PGC-1β controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis (2007) Proc. Natl. Acad. Sci. USA, 104, pp. 5223-5228; Vianna, C.R., Huntgeburth, M., Coppari, R., Choi, C.S., Lin, J., Krauss, S., Barbatelli, G., Cinti, S., Hypomorphic mutation of PGC-1β causes mitochondrial dysfunction and liver insulin resistance (2006) Cell Metab, 4, pp. 453-464; Horton, J.D., Shah, N.A., Warrington, J.A., Anderson, N.N., Park, S.W., Brown, M.S., Goldstein, J.L., Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes (2003) Proc. Natl. Acad. Sci. USA, 100, pp. 12027-12032; Lin, J., Yang, R., Tarr, P.T., Wu, P.-H., Handschin, C., Li, S., Yang, W., Tontonoz, P., Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP (2005) Cell, 120, pp. 261-273; Bellafante, E., Murzilli, S., Salvatore, L., Latorre, D., Villani, G., Moschetta, A., Hepatic-specific activation of peroxisome proliferator-activated receptor γ coactivator-1β protects against steatohepatitis (2013) Hepatology (Baltim., Md.), 57, pp. 1343-1356; Morris, E.M., Meers, G.M., Booth, F.W., Fritsche, K.L., Hardin, C.D., Thyfault, J.P., Ibdah, J.A., PGC-1α overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion (2012) Am. J. Physiol. Gastrointest. Liver Physiol, 303, pp. G979-G992; Laye, M.J., Rector, R.S., Borengasser, S.J., Naples, S.P., Uptergrove, G.M., Ibdah, J.A., Booth, F.W., Thyfault, J.P., Cessation of daily wheel running differentially alters fat oxidation capacity in liver, muscle, and adipose tissue (2009) J. Appl. Physiol. (Bethesda, Md.), 106, pp. 161-168; Hirschey, M.D., Shimazu, T., Jing, E., Grueter, C.A., Collins, A.M., Aouizerat, B., Stancakova, A., Schwer, B., SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome (2011) Mol. Cell, 44, pp. 177-190; Puigserver, P., Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-α (2005) Int. J. Obes. Relat. Metab. Disord, 29, pp. S5-S9; Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Scarpulla, R.C., Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1 (1999) Cell, 98, pp. 115-124; Feige, J.N., Auwerx, J., Transcriptional coregulators in the control of energy homeostasis (2007) Trends Cell Biol, 17, pp. 292-301; Wright, D.C., Geiger, P.C., Han, D.H., Jones, T.E., Holloszy, J.O., Calcium induces increases in peroxisome proliferator-activated receptor γ coactivator-1α and mitochondrial biogenesis by a pathway leading to p38 mitogen-activated protein kinase activation (2007) J. Biol. Chem, 282, pp. 18793-18799; Canto, C., Gerhart-Hines, Z., Feige, J.N., Lagouge, M., Noriega, L., Milne, J.C., Elliott, P.J., Auwerx, J., AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity (2009) Nature, 458, pp. 1056-1060; Haigis, M.C., Guarente, L.P., Mammalian sirtuins-Emerging roles in physiology, aging, and calorie restriction (2006) Genes Dev, 20, pp. 2913-2921; Haigis, M.C., Sinclair, D.A., Mammalian sirtuins: Biological insights and disease relevance (2010) Annu. Rev. Pathol, 5, pp. 253-295; Nogueiras, R., Habegger, K.M., Chaudhary, N., Finan, B., Banks, A.S., Dietrich, M.O., Horvath, T.L., Tschop, M.H., Sirtuin 1 and sirtuin 3, physiological modulators of metabolism (2012) Physiol. Rev, 92, pp. 1479-1514; Guarente, L., Calorie restriction and sirtuins revisited (2013) Genes Dev, 27, pp. 2072-2085; Banks, A.S., Kon, N., Knight, C., Matsumoto, M., Gutierrez-Juarez, R., Rossetti, L., Gu, W., Accili, D., SirT1 gain of function increases energy efficiency and prevents diabetes in mice (2008) Cell Metab, 8, pp. 333-341; Kitada, M., Kume, S., Kanasaki, K., Takeda-Watanabe, A., Koya, D., Sirtuins as possible drug targets in type 2 diabetes (2013) Curr. Drug Targets, 14, pp. 622-636; Garcia-Rodriguez, J.L., Barbier-Torres, L., Fernandez-Alvarez, S., Juan, V.G., Monte, M.J., Halilbasic, E., Herranz, D., Marin, J.J., SIRT1 controls liver regeneration by regulating BA metabolism through FXR and mTOR signaling (2014) Hepatology (Baltim., Md.), 59, pp. 1972-1983; Ruderman, N.B., Xu, X.J., Nelson, L., Cacicedo, J.M., Saha, A.K., Lan, F., Ido, Y., AMPK and SirT1, a long-standing partnership (2010) Am. J. Physiol. Endocrinol. Metab, 298, pp. E751-E760; Chen, L.L., Deng, X.Q., Li, N.X., Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: Experiment with rats (2007) Zhonghua Yi Xue Za Zhi, 87, pp. 1434-1437; Deng, X.Q., Chen, L.L., Li, N.X., The expression of SirT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats (2007) Liver Int, 27, pp. 708-715; Colak, Y., Ozturk, O., Senates, E., Tuncer, I., Yorulmaz, E., Adali, G., Doganay, L., Enc, F.Y., SirT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease (2011) Med. Sci. Monit, 17, pp. HY5-HY9; Li, Y., Xu, S., Giles, A., Nakamura, K., Lee, J.W., Hou, X., Donmez, G., Walsh, K., Hepatic overexpression of SirT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver (2011) FASEB J, 25, pp. 1664-1679; Li, Y., Wong, K., Giles, A., Jiang, J., Lee, J.W., Adams, A.C., Kharitonenkov, A., Guarente, L., Hepatic SirT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21 (2014) Gastroenterology, 146, pp. 539-549; Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X., Li, X., Hepatocyte-specific deletion of SirT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation (2009) Cell Metab, 9, pp. 327-338; Shin, S.Y., Kim, T.H., Wu, H., Choi, Y.H., Kim, S.G., SirT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of steatosis and steatohepatitis (2014) Eur. J. Pharmacol, 727 C, pp. 115-124; Lombard, D.B., Alt, F.W., Cheng, H.L., Bunkenborg, J., Streeper, R.S., Mostoslavsky, R., Kim, J., Murphy, A., Mammalian SirT2 homolog SirT3 regulates global mitochondrial lysine acetylation (2007) Mol. Cell. Biol, 27, pp. 8807-8814; Hebert, A.S., Dittenhafer-Reed, K.E., Yu, W., Bailey, D.J., Selen, E.S., Boersma, M.D., Carson, J.J., Higbee, A.J., Calorie restriction and SirT3 trigger global reprogramming of the mitochondrial protein acetylome (2013) Mol. Cell, 49, pp. 186-199; Hirschey, M.D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D.B., Grueter, C.A., Ilkayeva, O.R., SirT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation (2010) Nature, 464, pp. 121-125; Shimazu, T., Hirschey, M.D., Hua, L., Dittenhafer-Reed, K.E., Schwer, B., Lombard, D.B., Li, Y., Denu, J.M., SirT3 deacetylates mitochondrial 3-hydroxy-3- methylglutaryl CoA synthase 2 and regulates ketone body production (2010) Cell Metab, 12, pp. 654-661; Fujino, T., Kondo, J., Ishikawa, M., Morikawa, K., Yamamoto, T.T., Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate (2001) J. Biol. Chem, 276, pp. 11420-11426; Ahn, B.-H., Kim, H.-S., Song, S., Lee, I.H., Liu, J., Vassilopoulos, A., Deng, C.-X., Finkel, T., A role for the mitochondrial deacetylase SirT3 in regulating energy homeostasis (2008) Proc. Natl. Acad. Sci. USA, 105, pp. 14447-14452; Cimen, H., Han, M.-J., Yang, Y., Tong, Q., Koc, H., Koc, E.C., Regulation of succinate dehydrogenase activity by SirT3 in mammalian mitochondria (2009) Biochemistry, 49, pp. 304-311; Finley, L.W., Haas, W., Desquiret-Dumas, V., Wallace, D.C., Procaccio, V., Gygi, S.P., Haigis, M.C., Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity (2011) PLoS One, 6, pp. e23295; Zhang, D., Liu, Z.X., Choi, C.S., Tian, L., Kibbey, R., Dong, J., Cline, G.W., Shulman, G.I., Mitochondrial dysfunction due to long-chain acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance (2007) Proc. Natl. Acad. Sci. USA, 104, pp. 17075-17080; Kurtz, D.M., Rinaldo, P., Rhead, W.J., Tian, L., Millington, D.S., Vockley, J., Hamm, D.A., Pinkert, C.A., Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidatio (1998) N. Proc. Natl. Acad. Sci. USA, 95, pp. 15592-15597; Qiu, X., Brown, K., Hirschey, M.D., Verdin, E., Chen, D., Calorie restriction reduces oxidative stress by SirT3-mediated SOD2 activation (2010) Cell Metab, 12, pp. 662-667; Hirschey, M.D., Shimazu, T., Huang, J.Y., Schwer, B., Verdin, E., SirT3 regulates mitochondrial protein acetylation and intermediary metabolism (2011) Cold Spring Harb. Symp. Quant. Biol, 76, pp. 267-277; Petro, A.E., Cotter, J., Cooper, D.A., Peters, J.C., Surwit, S.J., Surwit, R.S., Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse (2004) Metab. Clin. Exp, 53, pp. 454-457; Rossmeisl, M., Rim, J.S., Koza, R.A., Kozak, L.P., Variation in type 2 diabetes-Related traits in mouse strains susceptible to diet-induced obesity (2003) Diabetes, 52, pp. 1958-1966; Surwit, R.S., Feinglos, M.N., Rodin, J., Sutherland, A., Petro, A.E., Opara, E.C., Kuhn, C.M., Rebuffe-Scrive, M., Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice (1995) Metab. Clin. Exp, 44, pp. 645-651; Kendrick, A.A., Choudhury, M., Rahman, S.M., McCurdy, C.E., Friederich, M., van Hove, J.L., Watson, P.A., Gius, D., Fatty liver is associated with reduced SirT3 activity and mitochondrial protein hyperacetylation (2011) Biochem. J, 433, pp. 505-514; Crunkhorn, S., Dearie, F., Mantzoros, C., Gami, H., da Silva, W.S., Espinoza, D., Faucette, R., Patti, M.E., Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: Potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation (2007) J. Biol. Chem, 282, pp. 15439-15450; Ji, H., Friedman, M.I., Reduced capacity for fatty acid oxidation in rats with inherited susceptibility to diet-induced obesity (2007) Metab. Clin. Exp, 56, pp. 1124-1130; Jing, E., Emanuelli, B., Hirschey, M.D., Boucher, J., Lee, K.Y., Lombard, D., Verdin, E.M., Kahn, C.R., Sirtuin-3 (SirT3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production (2011) Proc. Natl. Acad. Sci. USA, 108, pp. 14608-14613; Bao, J., Scott, I., Lu, Z., Pang, L., Dimond, C.C., Gius, D., Sack, M.N., SirT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity (2010) Free Radic. Biol. Med, 49, pp. 1230-1237; Mailloux, R.J., Beriault, R., Lemire, J., Singh, R., Chenier, D.R., Hamel, R.D., Appanna, V.D., The tricarboxylic acid cycle, an ancient metabolic network with a novel twist (2007) PLoS One, 2, pp. e690; Someya, S., Yu, W., Hallows, W.C., Xu, J., Vann, J.M., Leeuwenburgh, C., Tanokura, M., Prolla, T.A., SirT3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction (2010) Cell, 143, pp. 802-812; Yu, H.S., Oyama, T., Isse, T., Kitagawa, K., Pham, T.T., Tanaka, M., Kawamoto, T., Formation of acetaldehyde-derived DNA adducts due to alcohol exposure (2010) Chem. Biol. Interact, 188, pp. 367-375; Spitz, D.R., Oberley, L.W., An assay for superoxide dismutase activity in mammalian tissue homogenates (1989) Anal. Biochem, 179, pp. 8-18; Tao, R., Coleman, M.C., Pennington, J.D., Ozden, O., Park, S.-H., Jiang, H., Kim, H.-S., McDonald, H., SirT3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress (2010) Mol. Cell, 40, pp. 893-904; He, J., Hu, B., Shi, X., Weidert, E.R., Lu, P., Xu, M., Huang, M., Xie, W., Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase SirT 3 (2013) Mol. Cell. Biol, 33, pp. 2047-2055; Amir, M., Czaja, M.J., Autophagy in nonalcoholic steatohepatitis (2011) Expert Rev. Gastroenterol. Hepatol, 5, pp. 159-166; Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Czaja, M.J., Autophagy regulates lipid metabolism (2009) Nature, 458, pp. 1131-1135; Yang, L., Li, P., Fu, S., Calay, E.S., Hotamisligil, G.S., Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance (2010) Cell Metab, 11, pp. 467-478; Scarpulla, R.C., Vega, R.B., Kelly, D.P., Transcriptional integration of mitochondrial biogenesis (2012) Trends Endocrinol. Metab, 23, pp. 459-466; Aatsinki, S.M., Buler, M., Salomaki, H., Koulu, M., Pavek, P., Hakkola, J., Metformin induces PGC-1α expression and selectively affects hepatic PGC-1α functions (2014) Br. J. Pharmacol, 171, pp. 2351-2363; Srivastava, S., Diaz, F., Iommarini, L., Aure, K., Lombes, A., Moraes, C.T., PGC-1α/β induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders (2009) Hum. Mol. Genet, 18, pp. 1805-1812; Kong, X., Wang, R., Xue, Y., Liu, X., Zhang, H., Chen, Y., Fang, F., Chang, Y., Sirtuin 3, a new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial biogenesis (2010) PLoS One, 5, pp. e11707; St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Yang, W., Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators (2006) Cell, 127, pp. 397-408; Giralt, A., Hondares, E., Villena, J.A., Ribas, F., Díaz-Delfín, J., Giralt, M., Iglesias, R., Villarroya, F., Peroxisome proliferator-activated receptor-γ coactivator-1α controls transcription of the SirT3 Gene, an essential component of the thermogenic brown adipocyte phenotype (2011) J. Biol. Chem, 286, pp. 16958-16966; Kubli, D.A., Gustafsson, Å.B., Mitochondria and mitophagy: The yin and yang of cell death control (2012) Circ. Res, 111, pp. 1208-1221; Babbar, M., Sheikh, M.S., Metabolic stress and disorders related to alterations in mitochondrial fission or fusion (2013) Mol. Cell. Pharmacol, 5, pp. 109-133; Palikaras, K., Tavernarakis, N., Mitochondrial homeostasis: The interplay between mitophagy and mitochondrial biogenesis (2014) Exp. Gerontol, , doi.10.1016/j.exger.2014.01.021; Van der Bliek, A.M., Shen, Q., Kawajiri, S., Mechanisms of mitochondrial fission and fusion (2013) Cold Spring Harb. Perspect. Biol, , doi:10.1101/cshperspect.a011072; Geisler, S., Holmstrom, K.M., Treis, A., Skujat, D., Weber, S.S., Fiesel, F.C., Kahle, P.J., Springer, W., The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations (2010) Autophagy, 6, pp. 871-878; Geisler, S., Holmstrom, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J., Springer, W., PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM 1 (2010) Nat. Cell Biol, 12, pp. 119-131; Jin, S.M., Youle, R.J., PINK1- and Parkin-mediated mitophagy at a glance (2012) J. Cell Sci, 125, pp. 795-799; Chan, N.C., Salazar, A.M., Pham, A.H., Sweredoski, M.J., Kolawa, N.J., Graham, R.L.J., Hess, S., Chan, D.C., Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy (2011) Hum. Mol. Genet, 20, pp. 1726-1737; Poole, A.C., Thomas, R.E., Yu, S., Vincow, E.S., Pallanck, L., The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/Parkin pathway (2010) PLoS One, 5, pp. e10054; Gegg, M.E., Cooper, J.M., Chau, K.-Y., Rojo, M., Schapira, A.H.V., Taanman, J.-W., Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/Parkin-dependent manner upon induction of mitophagy (2010) Hum. Mol. Genet, 19, pp. 4861-4870; Bhat, G., Baba, C.S., Pandey, A., Kumari, N., Choudhuri, G., Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease (2012) World J. Hepatol, 4, pp. 209-217; Browning, J.D., Baker, J.A., Rogers, T., Davis, J., Satapati, S., Burgess, S.C., Short-term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction (2011) Am. J. Clin. Nutr, 93, pp. 1048-1052; Elias, M.C., Parise, E.R., de Carvalho, L., Szejnfeld, D., Netto, J.P., Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease (2010) Nutrition, 26, pp. 1094-1099; Goncalves, I.O., Oliveira, P.J., Ascensao, A., Magalhaes, J., Exercise as a therapeutic tool to prevent mitochondrial degeneration in nonalcoholic steatohepatitis (2013) Eur. J. Clin. Investig, 43, pp. 1184-1194; Goncalves, I.O., Passos, E., Rocha-Rodrigues, S., Diogo, C.V., Torrella, J.R., Rizo, D., Viscor, G., Oliveira, P.J., Physical exercise prevents and mitigates non-alcoholic steatohepatitis-induced liver mitochondrial structural and bioenergetics impairments (2014) Mitochondrion, 15, pp. 40-51; Haus, J.M., Solomon, T.P., Kelly, K.R., Fealy, C.E., Kullman, E.L., Scelsi, A.R., Lu, L., Flask, C.A., Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease (2013) J. Clin. Endocrinol. Metab, 98, pp. E1181-E1188; He, Y., Zhang, H., Fu, F., The effects of swimming exercise on high-fat-diet-induced steatohepatitis (2008) J. Sports Med. Phys. Fit, 48, pp. 259-265; Larson-Meyer, D.E., Newcomer, B.R., Heilbronn, L.K., Volaufova, J., Smith, S.R., Alfonso, A.J., Lefevre, M., Ravussin, E., Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function (2008) Obesity (Silver Spring, Md.), 16, pp. 1355-1362; Rector, R.S., Thyfault, J.P., Morris, R.T., Laye, M.J., Borengasser, S.J., Booth, F.W., Ibdah, J.A., Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in otsuka long-evans tokushima Fatty rats (2008) Am. J. Physiol. Gastrointest. Liver Physiol, 294, pp. G619-G626; Pacana, T., Sanyal, A.J., Vitamin E and nonalcoholic fatty liver disease (2012) Curr. Opin. Clin. Nutr. Metab. Care, 15, pp. 641-648; Linden, M.A., Fletcher, J.A., Morris, E.M., Meers, G.M., Kearney, M.L., Crissey, J.M., Laughlin, M.H., Ibdah, J.A., Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats (2014) Am. J. Physiol. Endocrinol. Metab, 306, pp. E300-E310; Chachay, V.S., Macdonald, G.A., Martin, J.H., Whitehead, J.P., O'Moore-Sullivan, T.M., Lee, P., Franklin, M., Ferguson, M., Resveratrol does not benefit patients with non-alcoholic fatty liver disease (2014) Clin. Gastroenterol. Hepatol, , doi:10.1016/j.cgh. 2014.02.024; Poulsen, M.M., Larsen, J.O., Hamilton-Dutoit, S., Clasen, B.F., Jessen, N., Paulsen, S.K., Kjaer, T.N., Pedersen, S.B., Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet (2012) Nutr. Res, 32, pp. 701-708; Poulsen, M.M., Vestergaard, P.F., Clasen, B.F., Radko, Y., Christensen, L.P., Stodkilde-Jorgensen, H., Moller, N., Jorgensen, J.O., High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition (2013) Diabetes, 62, pp. 1186-1195; Timmers, S., Konings, E., Bilet, L., Houtkooper, R.H., van de Weijer, T., Goossens, G.H., Hoeks, J., Kersten, S., Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans (2011) Cell Metab, 14, pp. 612-622; Teodoro, J.S., Duarte, F.V., Gomes, A.P., Varela, A.T., Peixoto, F.M., Rolo, A.P., Palmeira, C.M., Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats (2013) A Possible Role For SirT3 Activation. Mitochondrion, 13, pp. 637-646",Review,Scopus,2-s2.0-84900851950
"Kerling A., Tegtbur U., Gutzlaff E., Kuck M., Borchert L., Ates Z., Von Bohlen A., Frieling H., Huper K., Hartung D., Schweiger U., Kahl K.G.","Effects of adjunctive exercise on physiological and psychological parameters in depression: A randomized pilot trial",2015,"Journal of Affective Disorders","177",,,"1","6",,,10.1016/j.jad.2015.01.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923934453&partnerID=40&md5=86daabaf4dce06aca9403e73f6083bc7","Institute of Sports Medicine, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Institute for Radiology, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Department of Psychiatry and Psychotherapy, University of Lübeck, Ratzeburger Allee 160Lübeck, Germany","Kerling, A., Institute of Sports Medicine, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Tegtbur, U., Institute of Sports Medicine, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Gützlaff, E., Institute of Sports Medicine, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Kück, M., Institute of Sports Medicine, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Borchert, L., Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Ates, Z., Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Von Bohlen, A., Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Frieling, H., Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Hüper, K., Institute for Radiology, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Hartung, D., Institute for Radiology, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany; Schweiger, U., Department of Psychiatry and Psychotherapy, University of Lübeck, Ratzeburger Allee 160Lübeck, Germany; Kahl, K.G., Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1Hannover, Germany","Objective Major depressive disorder (MDD) is associated with decreased physical activity and increased rates of the metabolic syndrome (MetS), a risk factor for the development of type 2 diabetes and cardiovascular disorders. Exercise training has been shown to improve cardiorespiratory fitness and metabolic syndrome factors. Therefore, our study aimed at examining whether patients receiving an exercise program as an adjunct to inpatient treatment will benefit in terms of physiological and psychological factors. Method Fourty-two inpatients with moderate to severe depression were included. Twenty-two patients were randomized to additional 3x weekly exercise training (EXERCISE) and compared to treatment as usual (TAU). Exercise capacity was assessed as peak oxygen uptake (VO2peak), ventilatory anaerobic threshold (VAT) and workload expressed as Watts (W). Metabolic syndrome was defined according to NCEP ATPIII panel criteria. Results After 6 weeks of treatment, cardiorespiratory fitness (VO2peak, VAT, Watt), waist circumference and HDL cholesterol were significantly improved in EXERCISE participants. Treatment response expressed as ≥50% MADRS reduction was more frequent in the EXERCISE group. Conclusions Adjunctive exercise training in depressed inpatients improves physical fitness, MetS factors, and psychological outcome. Given the association of depression with cardiometablic disorders, exercise training is recommended as an adjunct to standard antidepressant treatment. © 2015 Elsevier B.V.","Depression; Metabolic syndrome; Physical exercise","Aberg, M.A., Waern, M., Nyberg, J., Pedersen, N.L., Bergh, Y., Aberg, N.D., Nilsson, M., Toren, K., Cardiovascular fitness in males at age 18 and risk of serious depression in adulthood: Swedish prospective population-based study (2012) Br. J. Psychiatry, 2012, pp. 352-359; Azevedo Da Silva, M., Singh-Manoux, A., Brunner, E.J., Kaffashian, S., Shipley, M.J., Kivimaki, M., Nabi, H., Bidirectional association between physical activity and symptoms of anxiety and depression: The Whitehall II study (2012) Eur. J. Epidemiol., 27, pp. 537-546; Blumenthal, J.A., Babyak, M.A., Doraiswamy, P.M., Watkins, L., Hoffman, B.M., Barbour, K.A., Herman, S., Sherwood, A., Exercise and pharmacotherapy in the treatment of major depressive disorder (2007) Psychosom. Med., 69, pp. 587-596; Boettger, S., Wetzig, F., Puta, C., Donath, L., Muller, H.J., Gabriel, H.H., Bar, K.J., Physical fitness and heart rate recovery are decreased in major depressive disorder (2009) Psychosom. Med., 71, pp. 519-523; Borg, G., Psychophysical scaling with applications in physical work and the perception of exertion (1990) Scand. J.Work Environ. Health, 16, pp. S55-S58; Cooney, G.M., Dwan, K., Greig, C.A., Lawlor, D.A., Rimer, J., Waugh, F.R., McMurdo, M., Mead, G.E., Exercise for depression (2013) Cochrane Database Syst. Rev., 12 (9), p. CD004366; Cuijpers, P., Vogelzangs, N., Twisk, J., Kleiboer, A., Li, J., Penninx, B.W., Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses (2014) Am. J. Psychiatry, 171, pp. 453-462; Cuppett, M., Latin, R.W., A survey of physical activity levels of certified athletic trainers (2002) J. Athl. Train., 37, pp. 281-285; Dhoble, A., Lahr, B.D., Allison, T.G., Kopecky, S.L., Cardiopulmonary fitness and heart rate recovery as predictors of mortality in a referral population (2014) J. Am. Heart Assoc., 24 (3), p. e000559; Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L., A meta-analysis of cytokines in major depression (2010) Biol. Psychiatry, 67, pp. 446-457; Faude, O., Kindermann, W., Meyer, T., Lactate threshold concepts: How valid are they? (2009) Sports Med., 39, pp. 469-490; Ford, E.S., Giles, W.H., Dietz, W.H., Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey (2002) JAMA, 287, pp. 356-359; Greggersen, W., Rudolf, S., Fassbinder, E., Dibbelt, L., Stoeckelhuber, B.M., Hohagen, F., Oltmanns, K.M., Schweiger, U., Major depression, borderline personality disorder, and visceral fat content in women (2011) Eur. Arch. Psychiatry Clin. Neurosci., 261, pp. 551-557; Itoh, H., Ajisaka, R., Koike, A., Makita, S., Omiya, K., Kato, Y., Adachi, H., Taniguchi, K., Heart rate and blood pressure response to ramp exercise and exercise capacity in relation to age, gender, and mode of exercise in a healthy population (2013) J. Cardiol., 61, pp. 71-78; Jacka, F.N., Pasco, J.A., Mykletun, A., Williams, L.J., Hodge, A.M., O'Reilly, S.L., Nicholson, G.C., Berk, M., Association of Western and traditional diets with depression and anxiety in women (2010) Am. J. Psychiatry, 167, pp. 305-311; Jerstad, S.J., Boutelle, K.N., Ness, K.K., Stice, E., Prospective reciprocal relations between physical activity and depression in female adolescents (2010) J. Consult. Clin. Psychol., 78, pp. 268-272; Kahl, K.G., Greggersen, W., Schweiger, U., Cordes, J., Balijepalli, C., Losch, C., Moebus, S., Prevalence of the metabolic syndrome in unipolar major depression (2012) Eur. Arch. Psychiatry Clin. Neurosci., 262, pp. 313-320; Kahl, K.G., Hueper, K., Schweiger, U., Gutberlet, M., Detlef, A.M., Weiss, C., Von Bohlen, A., Hartung, D., Pericardial, intra-abdominal and subcutaneous adipose tissue in patients with major depressive disorder (2014) Acta Psychiatr. Scand., 130, pp. 137-143; Knapen, J., Vancampfort, D., Moriën, Y., Marchal, Y., Exercise therapy improves both mental and physical health in patients with major depression (2014) Disabil. Rehabil., , ([Epub ahead of print]); Krogh, J., Nordentoft, M., Sterne, J.A., Lawlor, D.A., The effect of exercise in clinically depressed adults: Systematic review and meta-analysis of randomized controlled trials (2011) J. Clin. Psychiatry, 72, pp. 529-538; Krogh, J., Saltin, B., Gluud, C., Nordentoft, M., The DEMO trial: A randomized, parallel-group, observer-blinded clinical trial of strength versus aerobic versus relaxation training for patients with mild to moderate depression (2009) J. Clin. Psychiatry, 70, pp. 790-800; Krogh, J., Videbech, P., Thomsen, C., Gluud, C., Nordentoft, M., DEMO-II trial. Aerobic exercise versus stretching exercise in patients with major depression-a randomised clinical trial (2012) PLoS One, 7, p. e48316; Loe, H., Rognmo, O., Saltin, B., Wisloff, U., Aerobic capacity reference data in 3816 healthy men and women 20-90 years (2013) PLoS One, 8, p. e64319; Luger, T.M., Suls, J., Vander Weg, M.W., How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models (2014) Addict. Behav., 39, pp. 1418-1429; Mezuk, B., Eaton, W.W., Albrecht, S., Golden, S.H., Depression and type 2 diabetes over the lifespan: A meta-analysis (2008) Diabetes Care, 31, pp. 2383-2390; Mikkelsen, S.S., Tolstrup, J.S., Flachs, E.M., Mortensen, E.L., Schnohr, P., Flensborg-Madsen, T., A cohort study of leisure time physical activity and depression (2010) Prev. Med., 51, pp. 471-475; Oeland, A.M., Laessoe, U., Olesen, A.V., Munk-Jorgensen, P., Impact of exercise on patients with depression and anxiety (2010) Nord. J. Psychiatry, 64, pp. 210-217; Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., Albus, C., Zannad, F., European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) (2012) Eur. Heart J., 33, pp. 1635-1701. , European Association for Cardiovascular Prevention & Rehabilitation (EACPR) ESC Committee for Practice Guidelines (CPG); Robergs, R.A., Dwyer, D., Astorino, T., Recommendations for improved data processing from expired gas analysis indirect calorimetry (2010) Sports Med., 40, pp. 95-111; Roecker, K., Niess, A.M., Horstmann, T., Striegel, H., Mayer, F., Dickhuth, H.H., Heart rate prescriptions from performance and anthropometrical characteristics (2002) Med. Sci. Sports Exerc., 34, pp. 881-887; Schellenberg, E.S., Dryden, D.M., Vandermeer, B., Ha, C., Korownyk, C., Lifestyle interventions for patients with and at risk for type 2 diabetes: A systematic review and meta-analysis (2013) Ann. Intern. Med., 159, pp. 543-551; Soundy, A., Roskell, C., Stubbs, B., Vancampfort, D., Selection, use and psychometric properties of physical activity measures to assess individuals with severe mental illness: A narrative synthesis (2014) Arch. Psychiatr. Nurs., 28, pp. 135-151; Stetler, C., Miller, G.E., Depression and hypothalamic-pituitary-adrenal activation: A quantitative summary of four decades of research (2011) Psychosom. Med., 73, pp. 114-126; Vallance, J.K., Winkler, E.A., Gardiner, P.A., Healy, G.N., Lynch, B.M., Owen, N., Associations of objectively-assessed physical activity and sedentary time with depression: NHANES (2005-2006) (2011) Prev. Med., 53, pp. 284-288; Vancampfort, D., De Hert, M., Vansteenkiste, M., De Herdt, A., Scheewe, T.W., Soundy, A., Stubbs, B., Probst, M., The importance of self-determined motivation towards physical activity in patients with schizophrenia (2013) Psychiatry Res., 210, pp. 812-818; Vancampfort, D., Correll, C.U., Wampers, M., Sienaert, P., Mitchell, A.J., De Herdt, A., Probst, M., De Hert, M., Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalences and moderating variables (2013) Psychol. Med., , ([epub ahead of print]); Voderholzer, U., Dersch, R., Dickhut, H.H., Herter, A., Freyer, T., Berger, M., Physical fitness in depressive patients and impact of illness course and disability (2011) J. Affect. Disord., 128, pp. 160-164; Wasserman, K., Whipp, B.J., Koyl, S.N., Beaver, W.L., Anaerobic threshold and respiratory gas exchange during exercise (1973) J. Appl. Physiol., 35, pp. 236-243; Whiteford, H.A., Degenhardt, L., Rehm, J., Baxter, A.J., Ferrari, A.J., Erskine, H.E., Charlson, F.J., Vos, T., Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010 (2013) Lancet, 382, pp. 1575-1586; Whooley, M.A., Wong, J.M., Depression and cardiovascular disorders (2013) Ann. Rev. Clin. Psychol., 9, pp. 327-354; Wing, R.R., Bolin, P., Brancati, F.L., Bray, G.A., Clark, J.M., Coday, M., Crow, R.S., Yanovski, S.Z., Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes (2013) N. Engl. J. Med., 369, pp. 145-154; Yoon, U., Kwok, L.L., Magkidis, A., Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: A systematic review of randomized controlled trials (2013) Metabolism, 62, pp. 303-314",Article,Scopus,2-s2.0-84923934453
"Rehman K., Mashwani Z.-U.-R., Khan M.A., Ullah Z., Chaudhary H.J.","An ethno botanical perspective of traditional medicinal plants from the Khattak tribe of Chonthra Karak, Pakistan",2015,"Journal of Ethnopharmacology","165",,,"251","259",,,10.1016/j.jep.2015.02.035,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925445849&partnerID=40&md5=e7f099e31c7a27e6265a3eb34a667677","Department of Plant Sciences, Quaid.-i-Azam UniversityIslamabad, Pakistan; Department of Botany, PMAS Arid Agriculture UniversityRawalpindi, Pakistan; Department of Biotechnology, Quaid.-i-.Azam UniversityIslamabad, Pakistan; Centre of Plant Sciences and Biodiversity, University of Swat, Pakistan","Rehman, K., Department of Plant Sciences, Quaid.-i-Azam UniversityIslamabad, Pakistan; Mashwani, Z.-U.-R., Department of Botany, PMAS Arid Agriculture UniversityRawalpindi, Pakistan; Khan, M.A., Department of Biotechnology, Quaid.-i-.Azam UniversityIslamabad, Pakistan; Ullah, Z., Centre of Plant Sciences and Biodiversity, University of Swat, Pakistan; Chaudhary, H.J., Department of Plant Sciences, Quaid.-i-Azam UniversityIslamabad, Pakistan","Ethno pharmacological relevance The present study was carried out with an aim to gather, evaluate and analyze the ethno botanical information of medicinal uses of the plant species possessed by the native Khattak tribe of the Chonthra, district Karak Pakistan. The region with poor documentation of traditional knowledge, preserving the local traditional knowledge, reporting new as well as rarely reported medicinal properties of medicinal plants, to be tested experimentally for validation. Material and method The medicinal uses of existing plant species were documented by oral communication with 103 people, all over above 60 years of age, born and residing in Chonthra. Information was gathered by semi-structured interviews with further analysis by indices like Relative frequency citation RFC and Medicinal use value MUV. Results The study resulted with medicinal information on 66 plants species belonging to 34 families (using against 58 health related problems with 83 different preparations mainly administered orally and topical). The dominant families include Brasicaceae and Limiaceae. Withania coagulans and Pegnum harmala were the plant species quoted 100% by the informants with RFC values 1 each. The MUV were scattered between 1.24 and 0.03. The highest MUV were W. coagulans 1.24, Pegnum harmala 1.18, Fagonia cretica 1.14. This study for the first time include Nepeta lagopsis to the ethnobotanical wealth. Conclusions This study was an extension to the ethnobotanical research conducted in Khyber Pakhtunkhwa (KPK) Pakistan. The target area being small and less number of plants with limited traditional knowledge can serve basis for further work focusing on rarely or non- reported plant species of pharmacological and phytochemical importance with active metabolite capable of broadening the sources of new drugs. © 2015 Elsevier Ireland Ltd. All rights reserved.","Chonthra; Ethnobotany; Karak; Khattak tribe; Medicinal plants; Traditional use","Abbasi, A., Dastagir, G., Hussain, F., Sanaullah, P., Ethnobotany and marketing of crude drug plants in district Haripur, Pakistan (2005) Pak. J. Plant Sci., 11, pp. 103-114; Abbasi, A.M., Khan, M.A., Ahmad, M., Zafar, M., Khan, H., Muhammad, N., Sultana, S., Medicinal plants used for the treatment of jaundice and hepatitis based on socio-economic documentation (2009) Afr. J. Biotechnol., 8; Ahmad, S.S., Husain, S.Z., Ethno medicinal survey of plants from salt range (Kallar Kahar) of Pakistan (2008) Pak. J. Bot., 40, pp. 1005-1011; Ali, H., Qaiser, M., The ethnobotany of Chitral valley, Pakistan with particular reference to medicinal plants (2009) Pak. J. Bot., 41, pp. 2009-2041; Badshah, L., Hussain, F., Mohammad, Z., Floristic and ethno ecological studies on some plants of Pirghar Hills South Waziristan, Pakistan (1996) Pak. J. Plant Sci., 2, pp. 167-177; Badshah, L., Hussain, F., Sher, Z., Floristic inventory, ecological characteristics and biological spectrum of rangeland, district Tank, Pakistan (2013) Pak. J. Bot., 45, pp. 1159-1168; Bibi, T., Ahmad, M., Tareen, R.B., Tareen, N.M., Jabeen, R., Rehman, S.-U., Sultana, S., Yaseen, G., Ethnobotany of medicinal plants in district Mastung of Balochistan province-Pakistan (2014) J. Ethnopharmacol., 157, pp. 79-89; Chaturvedi, V., (1994) Diseases in Tribal Women and Comparative Study for Their Medical Treatment, , M.L.V. Tribal Research Institute Udaipur, India (Project Report); Cox, P.A., Balick, M.J., The ethnobotanical approach to drug discovery (1994) Sci. Am., 270, pp. 60-65; Dastagir, G., Abbasi, A., Folk medicines used for the treatment of jaundice in district Haripur, Pakistan (2004) Pak. J. Plant Sci., 10, pp. 119-123; Fabricant, D.S., Farnsworth, N.R., The value of plants used in traditional medicine for drug discovery (2001) Environ. Health Perspect., 109, p. 69; Farnsworth, N.R., Screening plants for new medicines (1988) Biodiversity, 3, pp. 81-99; Farnsworth, N.R., Akerele, O., Bingel, A.S., Soejarto, D.D., Guo, Z., Medicinal plants in therapy (1985) Bull. World Health Org., 63, p. 965; Ghimire, S.K., Gimenez, O., Pradel, R., McKey, D., Aumeeruddythomas, Y., Demographic variation and population viability in a threatened Himalayan medicinal and aromatic herb Nardostachys grandiflora: Matrix modelling of harvesting effects in two contrasting habitats (2008) J. Appl. Ecol., 45, pp. 41-51; Giday, M., Asfaw, Z., Elmqvist, T., Woldu, Z., An ethnobotanical study of medicinal plants used by the Zay people in Ethiopia (2003) J. Ethnopharmacol., 85, pp. 43-52; Goleniowski, M.E., Bongiovanni, G., Palacio, L., Nuñez, C., Cantero, J., Medicinal plants from the ""sierra de Comechingones"", Argentina (2006) J. Ethnopharmacol., 107, pp. 324-341; Gulshan, A.B., Dasti, A.A., Hussain, S., Atta, M.I., Amin-Ud-Din, M., (2006) Indigenous Uses of Medicinal Plants in Rural Areas of Dera Ghazi Khan, , Punjab, Pakistan; Hamayun, M., Ethnobotanical studies of some useful shrubs and trees of District Buner, NWFP, Pakistan (2003) Ethnobot. Leafl., 12; Hamayun, M., Ethnobotanical profile of Utror and Gabral valleys, district Swat, Pakistan (2005) Ethnobot. Leafl., 9; Hamayun, M., Khan, A., Afzal, S., Khan, M.A., Study on traditional knowledge and utility of medicinal herbs of district Buner, NWFP, Pakistan (2006) Indian J. Trad. Knowl., 5, pp. 407-412; Haq, I., Hussain, Z., Medicinal plants of Palandri district Poonch (AJK) (1995) Pak. J. Plant Sci., 1, pp. 115-126; Haq, I., Rehman, M., Medicinal plants of upper Swat (NWFP) Pakistan (1990) Hamdard Med., 33, pp. 51-68; Haq, I., Shah, M., Medicinal plants of Peshawar district,(NWFP) Pakistan (1986) Hamdard Med., 29, pp. 73-87; Hussain, K., Shahazad, A., Zia-Ul-Hussnain, S., An ethnobotanical survey of important wild medicinal plants of Hattar district Haripur, Pakistan (2008) Ethnobot. Leafl., 5; Hussain, M., Palynological and ethnobotanical studies of Chrysanthemum leucanthemum L., from Gallies (Abbottabad), Pakistan (2003) Hamdard Med., 45, pp. 13-14; Hussain, M., Shah, G.M., Khan, M.A., Traditional medicinal and economic uses of Gymnosperms of Kaghan valley, Pakistan (2006) Ethnobot. Leafl., 7; Inam, B., Sultana, K., Qureshi, R., Malik, S., A checklist of plants of Bhogarmang, Siran Valley, NWFP, Pakistan (2000) Hamdard Med., 43, pp. 62-76; Khan, M., Hussain, F., Musharaf, S., Ethnobotanical profile of Tehsil Takht-e-Nasratti, District Karak, Pakistan (2013) J. Med. Plants Res., 7, pp. 1636-1651; Khan, M.A., Khan, S.A., Qureshi, M.A., Ahmed, G., Khan, M.A., Hussain, M., Ghulam, G.M., Ethnobotany of some useful plants of Poonch valley Azad Kashmir (2011) J. Med. Plants Res., 5, pp. 6140-6151; Khan, S.W., Khatoon, S., Ethnobotanical studies on some useful herbs of Haramosh and Bugrote valleys in Gilgit, northern areas of Pakistan (2008) Pak. J. Bot., 40, p. 43; Konno, B., (2004) Integration of Traditional Medicine with Modern Medicine, pp. 3-9. , EHNRI, AddisAbaba; Mahmood, A., Malik, R.N., Shinwari, Z.K., Mahmood, A., Ethnobotanical survey of plants from Nelum, Azad Jammu and Kashmir, Pakistan (2011) Pak. J. Bot., 43, pp. 105-110; Organization, W.H., (2003) WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants, , World Health Organization Geneva; Qasim, M., Gulzar, S., Ma, K., Halophytes as medicinal plants (2011) Proceedings of the NAM Meeting, , Denizli, Turkey; Qureshi, R.A., Ghufran, M.A., Gilani, S.A., Yousaf, Z., Abbas, G., Batool, A., Indigenous medicinal plants used by local women in southern Himalayan regions of Pakistan (2009) Pak. J. Bot., 41, pp. 19-25; Saqib, Z., Sultan, A., Ethnobotany of Palas valley, Pakistan (2005) Ethnobot. Leafl., 28; Shah, G.M., Khan, M.A., Common medicinal folk recipes of Siran Valley, Mansehra, Pakistan (2006) Ethnobot. Leafl., 5; Shinwari, M.I., Khan, M.A., Folk use of medicinal herbs of Margalla hills national park, Islamabad (2000) J. Ethnopharmacol., 69, pp. 45-56; Srithi, K., Balslev, H., Wangpakapattanawong, P., Srisanga, P., Trisonthi, C., Medicinal plant knowledge and its erosion among the Mien (Yao) in Northern Thailand (2009) J. Ethnopharmacol., 123, pp. 335-342; Tardío, J., Pardo-De-Santayana, M., Cultural importance indices: A comparative analysis based on the useful wild plants of Southern Cantabria (Northern Spain) 1 (2008) Econ. Bot., 62, pp. 24-39; Ul Haq, I., Hussain, M., Medicinal plants of Mansehra (1993) Hamdard Med., 36, pp. 63-100; Upadhyay, B., Parveen, Dhaker, A.K., Kumar, A., Ethnomedicinal and ethnopharmaco-statistical studies of Eastern Rajasthan, India (2010) J. Ethnopharmacol., 4 (129), pp. 64-86; Zabihullah, Q., Rashid, A., Akhtar, N., Ethnobotanical survey in kot Manzaray Baba valley Malakand agency, Pakistan (2006) Pak. J. Plant Sci., 12, pp. 115-121; Zhang, X., (2002) WHO Traditional Medicine Strategy 2002-2005, , World Health Organization Geneva 11",Article,Scopus,2-s2.0-84925445849
"Damschroder L.J., Moin T., Datta S.K., Reardon C.M., Steinle N., Weinreb J., Billington C.J., Maciejewski M.L., Yancy W.S., Hughes M., Makki F., Richardson C.R.","Implementation and evaluation of the VA DPP clinical demonstration: Protocol for a multi-site non-randomized hybrid effectiveness-implementation type III trial",2015,"Implementation Science",,,,"","",,,10.1186/s13012-015-0250-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929000231&partnerID=40&md5=fadb276c03b12dab93116a7bda4678ea","Ann Arbor VA Center for Clinical Management Research, P.O. Box 130170, Ann Arbor, MI, 48113-0170 USA; VA Diabetes QUERI, Ann Arbor, MI, USA; VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; University of California, David Geffen School of Medicine, Los Angeles, CA, USA; Implementation and Policy, Greater Los Angeles VA Health Services Research and Development (HSR and D) Center for Healthcare Innovation, Los Angeles, CA, USA; Durham VA Medical Center, Durham, NC, USA; Duke University School of Medicine, Durham, NC, USA; Baltimore VA Medical Center, Baltimore, MD, USA; University of Maryland School of Medicine, Baltimore, MD, USA; Minneapolis VA Healthcare System, Minneapolis, MN, USA; University of Minnesota Medical Center, Minneapolis, MN, USA; University of Michigan, Department of Family Medicine, Ann Arbor, MI, USA","Damschroder, L.J., Ann Arbor VA Center for Clinical Management Research, P.O. Box 130170, Ann Arbor, MI, 48113-0170 USA, VA Diabetes QUERI, Ann Arbor, MI, USA; Moin, T., VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Implementation and Policy, Greater Los Angeles VA Health Services Research and Development (HSR and D) Center for Healthcare Innovation, Los Angeles, CA, USA; Datta, S.K., Durham VA Medical Center, Durham, NC, USA, Duke University School of Medicine, Durham, NC, USA; Reardon, C.M., Ann Arbor VA Center for Clinical Management Research, P.O. Box 130170, Ann Arbor, MI, 48113-0170 USA; Steinle, N., Baltimore VA Medical Center, Baltimore, MD, USA, University of Maryland School of Medicine, Baltimore, MD, USA; Weinreb, J., VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA, University of California, David Geffen School of Medicine, Los Angeles, CA, USA; Billington, C.J., Minneapolis VA Healthcare System, Minneapolis, MN, USA, University of Minnesota Medical Center, Minneapolis, MN, USA; Maciejewski, M.L., Durham VA Medical Center, Durham, NC, USA, Duke University School of Medicine, Durham, NC, USA; Yancy, W.S., Durham VA Medical Center, Durham, NC, USA, Duke University School of Medicine, Durham, NC, USA; Hughes, M., Ann Arbor VA Center for Clinical Management Research, P.O. Box 130170, Ann Arbor, MI, 48113-0170 USA; Makki, F., Ann Arbor VA Center for Clinical Management Research, P.O. Box 130170, Ann Arbor, MI, 48113-0170 USA; Richardson, C.R., Ann Arbor VA Center for Clinical Management Research, P.O. Box 130170, Ann Arbor, MI, 48113-0170 USA, VA Diabetes QUERI, Ann Arbor, MI, USA, University of Michigan, Department of Family Medicine, Ann Arbor, MI, USA","Background: The Diabetes Prevention Program (DPP) study showed that lifestyle intervention resulted in a 58% reduction in incidence of type 2 diabetes among individuals with prediabetes. Additional large randomized controlled trials have confirmed these results, and long-term follow-up has shown sustained benefit 10-20 years after the interventions ended. Diabetes is a common and costly disease, especially among Veterans, and despite strong evidence supporting the feasibility of type 2 diabetes prevention, the DPP has not been widely implemented. The first aim of this study will evaluate implementation of the Veterans Affairs (VA) DPP in three VA medical centers. The second aim will assess weight and hemoglobin A1c (A1c) outcomes, and the third aim will determine the cost-effectiveness and budget impact of implementation of the VA DPP from a health system perspective. Methods/Design: This partnered multi-site non-randomized systematic assignment study will use a highly pragmatic hybrid effectiveness-implementation type III mixed methods study design. The implementation and administration of the VA DPP will be funded by clinical operations while the evaluation of the VA DPP will be funded by research grants. Seven hundred twenty eligible Veterans will be systematically assigned to the VA DPP clinical demonstration or the usual care VA MOVE!® weight management program. A multi-phase formative evaluation of the VA DPP implementation will be conducted. A theoretical program change model will be used to guide the implementation process and assess applicability and feasibility of the DPP for VA. The Consolidated Framework for Implementation Research (CFIR) will be used to guide qualitative data collection, analysis, and interpretation of barriers and facilitators to implementation. The RE-AIM framework will be used to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance of the VA DPP. Twelve-month weight and A1c change will be evaluated for the VA DPP compared to the VA MOVE! program. Mediation analyses will be conducted to identify whether program design differences impact outcomes. Discussion: Findings from this pragmatic evaluation will be highly applicable to practitioners who are tasked with implementing the DPP in clinical settings. In addition, findings will determine the effectiveness and cost-effectiveness of the VA DPP in the Veteran population. © 2015 Damschroder et al.; licensee BioMed Central.","Diabetes prevention; Implementation; Pragmatic study design; Veterans",,Article in Press,Scopus,2-s2.0-84929000231
"McClintock T.R., Parvez F., Wu F., Islam T., Ahmed A., Rani Paul R., Shaheen I., Sarwar G., Rundek T., Demmer R.T., Desvarieux M., Ahsan H., Chen Y.","Major dietary patterns and carotid intima-media thickness in Bangladesh",2015,"Public Health Nutrition",,,,"","",12,,10.1017/S136898001500124X,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929000819&partnerID=40&md5=305744fc52f49f13866268237168ad5a","Departments of Population Health and Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA; Division of Urology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA; U-Chicago Research Bangladesh, Ltd, Dhaka, Bangladesh; Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; INSERM, UMR-S 707, Université Pierre et Marie Curie-Paris 6, Paris, France; École des Hautes Études en Santé Publique, Paris and Rennes, France; Departments of Health Studies, Medicine and Human Genetics and Comprehensive Cancer Center, The University of Chicago, 5841 South Maryland Avenue, Suite N102, Chicago, IL 60637, USA","McClintock, T.R., Departments of Population Health and Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA, Division of Urology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; Parvez, F., Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA; Wu, F., Departments of Population Health and Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA; Islam, T., U-Chicago Research Bangladesh, Ltd, Dhaka, Bangladesh; Ahmed, A., U-Chicago Research Bangladesh, Ltd, Dhaka, Bangladesh; Rani Paul, R., U-Chicago Research Bangladesh, Ltd, Dhaka, Bangladesh; Shaheen, I., U-Chicago Research Bangladesh, Ltd, Dhaka, Bangladesh; Sarwar, G., U-Chicago Research Bangladesh, Ltd, Dhaka, Bangladesh; Rundek, T., Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA; Demmer, R.T., Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Desvarieux, M., Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA, INSERM, UMR-S 707, Université Pierre et Marie Curie-Paris 6, Paris, France, École des Hautes Études en Santé Publique, Paris and Rennes, France; Ahsan, H., Departments of Health Studies, Medicine and Human Genetics and Comprehensive Cancer Center, The University of Chicago, 5841 South Maryland Avenue, Suite N102, Chicago, IL 60637, USA; Chen, Y., Departments of Population Health and Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA","Objective: Carotid intima-media thickness (IMT) is a validated surrogate marker of preclinical atherosclerosis and is predictive of cardiovascular morbidity and mortality. Research on the association between IMT and diet, however, is lacking, especially in low-income countries or low-BMI populations. Design: Cross-sectional analysis. Dietary intakes were measured using a validated, thirty-nine-item FFQ at baseline cohort recruitment. IMT measurements were obtained from 2010–2011. Setting: Rural Bangladesh. Subjects: Participants (n 1149) randomly selected from the Health Effects of Arsenic Longitudinal Study, an ongoing, population-based, prospective cohort study established in 2000. Average age at IMT measurement was 45·5 years. Results: Principal component analysis of reported food items yielded a ‘balanced’ diet, an ‘animal protein’ diet and a ‘gourd and root vegetable’ diet. We observed a positive association between the gourd/root vegetable diet and IMT, as each 1 sd increase in pattern adherence was related to a difference of 7·74 (95 % CI 2·86, 12·62) μm in IMT (P<0·01), controlling for age, sex, total energy intake, smoking status, BMI, systolic blood pressure and diabetes mellitus diagnoses. The balanced pattern was associated with lower IMT (−4·95 (95 % CI −9·78, −0·11) μm for each 1sd increase of adherence; P=0·045). Conclusions: A gourd/root vegetable diet in this Bangladeshi population positively correlated with carotid IMT, while a balanced diet was associated with decreased IMT. Copyright © The Authors 2015","Atherosclerosis; Bangladesh; Carotid intima-media thickness; Diet; Dietary patterns",,Article in Press,Scopus,2-s2.0-84929000819
"Olczak-Kowalczyk D., Pyrzak B., Dabkowska M., Panczyk-Tomaszewska M., Miszkurka G., Rogozinska I., Swoboda-Kopec E., Gozdowski D., Kalinska A., Pirog A., Mizerska-Wasiak M., Roszkowska-Blaim M.","Candida spp. and gingivitis in children with nephrotic syndrome or type 1 diabetes",2015,"BMC Oral Health",,,,"","",,,10.1186/s12903-015-0042-6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928966709&partnerID=40&md5=497608a1cab6ca04822f395e9149f5a0","Medical University of Warsaw, Department of Paediatric Dentistry, 18 Miodowa St, Warszawa, 00-246 Poland; Medical University of Warsaw, Department of Paediatric Endocrinology, Warszawa, Poland; Medical University of Warsaw, Department of Dental Medical Microbiology, Warszawa, Poland; Medical University of Warsaw, Department of Paediatric Nephrology, Warszawa, Poland; Warsaw University of Life Sciences, Department of Experimental Statistics and Bioinformatics, Warsaw, Poland","Olczak-Kowalczyk, D., Medical University of Warsaw, Department of Paediatric Dentistry, 18 Miodowa St, Warszawa, 00-246 Poland; Pyrzak, B., Medical University of Warsaw, Department of Paediatric Endocrinology, Warszawa, Poland; Dabkowska, M., Medical University of Warsaw, Department of Dental Medical Microbiology, Warszawa, Poland; Pańczyk-Tomaszewska, M., Medical University of Warsaw, Department of Paediatric Nephrology, Warszawa, Poland; Miszkurka, G., Medical University of Warsaw, Department of Paediatric Endocrinology, Warszawa, Poland; Rogozińska, I., Medical University of Warsaw, Department of Paediatric Endocrinology, Warszawa, Poland; Swoboda-Kopeć, E., Medical University of Warsaw, Department of Dental Medical Microbiology, Warszawa, Poland; Gozdowski, D., Warsaw University of Life Sciences, Department of Experimental Statistics and Bioinformatics, Warsaw, Poland; Kalińska, A., Medical University of Warsaw, Department of Paediatric Dentistry, 18 Miodowa St, Warszawa, 00-246 Poland; Piróg, A., Medical University of Warsaw, Department of Paediatric Dentistry, 18 Miodowa St, Warszawa, 00-246 Poland; Mizerska-Wasiak, M., Medical University of Warsaw, Department of Paediatric Nephrology, Warszawa, Poland; Roszkowska-Blaim, M., Medical University of Warsaw, Department of Paediatric Nephrology, Warszawa, Poland","Background: Diabetes and Nephrotic syndrome (NS) promote plaque-related gingivitis and yeast-like fungal infections. Methods: Body mass index (BMI), BMI standard deviation score, and oral cavity (Plaque Index - PLI, Gingival Index - GI, mucosa status, presence and Candida enzymatic activity) were assessed in 96 patients (32 with NS: 30- immunosuppressive treatment, 35 - type 1 diabetes, and 29 generally healthy), aged; 3-18 years. Laboratory included cholesterol and triglyceride measurements; in diabetic subjects- glycated haemoglobin, in NS: total protein, albumin, creatinine, haemoglobin, haematocrit, white cell count, urinary protein excretion. Medical records supplied information on disease duration and treatment. A statistical analysis was performed; Kendall Tau coefficient, chi-square test, t-test, and multiple regression analysis ( P < 0.05). Results: Candida spp. often occurred in healthy patients, but oral candidiasis was found only in the NS and diabetes groups (9.37% and 11.43%). Gingivitis occurred more frequently in patients with NS/diabetes. Gingivitis severity was correlated with PLI, age, and yeast enzyme activity in NS - to with immunosuppressive treatment with >1 drug, drug doses, treatment duration, lipid disorders, and BMI; in diabetes, with blood glucose and glycated haemoglobin >8%. Conclusion: Poor hygiene control is the main cause of gingivitis. Gingivitis severity is most likely related to age, lipid disorders and increase in body mass. Candida spp., in uncompensated diabetes and in those using immunosuppressive treatment, might intensify plaque-related gingivitis. © 2015 Olczak-Kowalczyk et al.; licensee BioMed Central.","Candida spp; Gingivitis; Hydrolytic enzyme activity; Immunosuppression; Nephrotic syndrome; Oral cavity; Type 1 diabetes",,Article in Press,Scopus,2-s2.0-84928966709
"Jinnouchi H., Morita K., Tanaka T., Kajiwara A., Kawata Y., Oniki K., Saruwatari J., Nakagawa K., Otake K., Ogata Y., Yoshida A., Hokimoto S., Ogawa H.","Interactive effects of a common γ-glutamyltransferase 1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy",2015,"Cardiovascular Diabetology",,,,"","",,,10.1186/s12933-015-0212-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928958046&partnerID=40&md5=c24954fa93d35afcc0eab6672b67ee4f","Kumamoto University Hospital, Division of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto, Japan; Diabetes Care Center, Jinnouchi Clinic, Kumamoto, Japan; Kumamoto University, Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, 5-1, Oe-honmachi, Kumamoto, 862-0973 Japan; Kumamoto University, Center for Clinical Pharmaceutical Sciences, Kumamoto, Japan; Japanese Red Cross Kumamoto Health Care Center, Kumamoto, Japan; Kumamoto University, Department of Cardiovascular Medicine, Faculty of Life Sciences, Graduate School of Medical Sciences, Kumamoto, Japan","Jinnouchi, H., Kumamoto University Hospital, Division of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto, Japan, Diabetes Care Center, Jinnouchi Clinic, Kumamoto, Japan; Morita, K., Kumamoto University, Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, 5-1, Oe-honmachi, Kumamoto, 862-0973 Japan; Tanaka, T., Kumamoto University, Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, 5-1, Oe-honmachi, Kumamoto, 862-0973 Japan; Kajiwara, A., Kumamoto University, Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, 5-1, Oe-honmachi, Kumamoto, 862-0973 Japan; Kawata, Y., Kumamoto University, Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, 5-1, Oe-honmachi, Kumamoto, 862-0973 Japan; Oniki, K., Kumamoto University, Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, 5-1, Oe-honmachi, Kumamoto, 862-0973 Japan; Saruwatari, J., Kumamoto University, Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, 5-1, Oe-honmachi, Kumamoto, 862-0973 Japan; Nakagawa, K., Kumamoto University, Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, 5-1, Oe-honmachi, Kumamoto, 862-0973 Japan, Kumamoto University, Center for Clinical Pharmaceutical Sciences, Kumamoto, Japan; Otake, K., Japanese Red Cross Kumamoto Health Care Center, Kumamoto, Japan; Ogata, Y., Japanese Red Cross Kumamoto Health Care Center, Kumamoto, Japan; Yoshida, A., Diabetes Care Center, Jinnouchi Clinic, Kumamoto, Japan; Hokimoto, S., Kumamoto University Hospital, Division of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto, Japan, Kumamoto University, Department of Cardiovascular Medicine, Faculty of Life Sciences, Graduate School of Medical Sciences, Kumamoto, Japan; Ogawa, H., Kumamoto University Hospital, Division of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto, Japan, Kumamoto University, Department of Cardiovascular Medicine, Faculty of Life Sciences, Graduate School of Medical Sciences, Kumamoto, Japan","Background: We investigated the clinical relevance of a common variant, rs4820599, in the γ-glutamyltransferase (GGT)1 gene, associated with the serum GGT level, in Japanese type 2 diabetes mellitus (T2DM) subjects. Methods: We conducted a retrospective longitudinal study (4.9 ± 2.5 years) including 352 T2DM patients (T2DM subjects) and a cross-sectional study including 796 health screening program participants (general subjects). A real-time TaqMan allelic discrimination assay was used to identify the genotypes. Risk factors for a high brachial-ankle pulse wave velocity (baPWV) (≥1750 cm/sec) or diabetic retinopathy (DR) were determined using a generalized estimating equations approach, receiver operating characteristic (ROC) analysis or Cox proportional hazards model, etc. Results: The frequency of the GGT1 G allele was 20.8% in the T2DM subjects, and no associations were found between the GGT1 genotype and risk of T2DM. The mean log GGT values in the T2DM and general subjects were significantly higher among G allele carriers than non-carriers. The G allele and a low HDL-C level were identified to be risk factors for a high baPWV in the T2DM subjects [odds ratio (OR) 1.80, P = 0.008; OR 1.71, P = 0.03; respectively), and a significant interactive effect between these factors was found on the risk of a high baPWV and DR. The HDL-C level at baseline was a significant predictor of a high baPWV only in G allele carriers according to the ROC analysis. This result regarding baPWV in the T2DM subjects was replicated in the general population. Meanwhile, the GGT1 genotype was not associated with the risk of DR, although it affected the principal factors involved in the risk of DR, and a low HDL-C level was also found to be a risk factor for DR only in G allele carriers. Conclusions: We herein describe for the first time the significant interactive effects of the GGT1 G allele and a low HDL-C level on a high baPWV and DR. These findings may encourage future clinical trials comparing the efficacy of agents increasing the HDL-C levels among the GGT1 genotypes. However, well-designed studies in larger cohorts are needed to confirm our results. © 2015 Jinnouchi et al.; licensee BioMed Central.","Brachial-Ankle Pulse Wave Velocity; Diabetic Angiopathies; Diabetic Retinopathy; High Density Lipoprotein Cholesterol; Oxidative Stress; Single Nucleotide Polymorphism; Type 2 Diabetes Mellitus; γ-Glutamyltransferase",,Article in Press,Scopus,2-s2.0-84928958046
"Nicolucci A., Buseghin G., de Portu S.","Short-term cost analysis of complications related to glycated hemoglobin in patients with type 1 diabetes in the Italian setting",2015,"Acta Diabetologica",,,,"","",6,,10.1007/s00592-015-0755-7,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928974636&partnerID=40&md5=e9e782836e466ef05c7ece832f6a9000","Mario Negri Sud InstituteSanta Maria Imbaro, Chieti, Italy; Medtronic Italia S.p.A., Via Varesina 162Milan, Italy; Medtronic International Trading SarlTolochenaz, Switzerland","Nicolucci, A., Mario Negri Sud InstituteSanta Maria Imbaro, Chieti, Italy; Buseghin, G., Medtronic Italia S.p.A., Via Varesina 162Milan, Italy; de Portu, S., Medtronic International Trading SarlTolochenaz, Switzerland","Aims: The aim of this study is to assess the impact of the diabetes-related complications on costs and to shed light on the potential savings that could be obtained by the National Healthcare System if better glycemic control was to be achieved in the type 1 diabetes population. Methods: Epidemiologic data were used to distribute diabetes type 1 patients into A1c levels, and the relative risk of diabetes-related complications associated with the level of A1c was extrapolated from published risk curves. The costs associated with all complications in the Italian settings, retrieved from published literature, were used to estimate the economic impact of complications in each A1c level from the NHS perspective and the potential savings that could be obtained should a treatment strategy allow to achieve better metabolic control. Results: The reduction in the number of complications translates into consistent monetary savings compared to current scenario. Within 5 years, €29 and €33 million would be saved if all patients reduced their A1c level by 1 % and within the range 7–8 % (53–64 mmol/mol), respectively. Conclusions: This work allows focusing on the impact of managing the diabetes-related complications on the overall costs, not yet reported in the literature. It was shown that the potential savings for the National Healthcare Service associated with a more effective glycemic control are substantial. © 2015 Springer-Verlag Italia","Budget impact; Complications; Costs; Diabetes; Glycated hemoglobin",,Article in Press,Scopus,2-s2.0-84928974636
"Lopez-de-Andres A., Jimenez-Trujillo I., Jimenez-Garcia R., Hernandez-Barrera V., de Miguel-Yanes J.M., Mendez-Bailon M., Perez-Farinos N., Salinero-Fort M., Carrasco-Garrido P.","National trends in incidence and outcomes of abdominal aortic aneurysm among elderly type 2 diabetic and non-diabetic patients in Spain (2003-2012)",2015,"Cardiovascular Diabetology",,,,"","",,,10.1186/s12933-015-0216-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928957958&partnerID=40&md5=961a43c3f5198a7edf308a3a5161db5a","Health Sciences Faculty, Rey Juan Carlos University, Preventive Medicine and Public Health Teaching and Research Unit, Avda. de Atenas s/n, Alcorcon, Comunidad deMadrid, 28922 Spain; Medicine Department, Hospital Gregorio Marañon, Comunidad de Madrid, Spain; Medicine Department, Hospital Clínico San Carlos, Madrid, Comunidad de Madrid, Spain; Health Security Agency, Ministry of Health, Madrid, Comunidad de Madrid, Spain; Dirección Técnica de Docencia e Investigación, Gerencia Atención Primaria, Madrid, Comunidad de Madrid, Spain","Lopez-de-Andrés, A., Health Sciences Faculty, Rey Juan Carlos University, Preventive Medicine and Public Health Teaching and Research Unit, Avda. de Atenas s/n, Alcorcon, Comunidad deMadrid, 28922 Spain; Jiménez-Trujillo, I., Health Sciences Faculty, Rey Juan Carlos University, Preventive Medicine and Public Health Teaching and Research Unit, Avda. de Atenas s/n, Alcorcon, Comunidad deMadrid, 28922 Spain; Jiménez-García, R., Health Sciences Faculty, Rey Juan Carlos University, Preventive Medicine and Public Health Teaching and Research Unit, Avda. de Atenas s/n, Alcorcon, Comunidad deMadrid, 28922 Spain; Hernández-Barrera, V., Health Sciences Faculty, Rey Juan Carlos University, Preventive Medicine and Public Health Teaching and Research Unit, Avda. de Atenas s/n, Alcorcon, Comunidad deMadrid, 28922 Spain; de Miguel-Yanes, J.M., Medicine Department, Hospital Gregorio Marañon, Comunidad de Madrid, Spain; Méndez-Bailón, M., Medicine Department, Hospital Clínico San Carlos, Madrid, Comunidad de Madrid, Spain; Perez-Farinos, N., Health Security Agency, Ministry of Health, Madrid, Comunidad de Madrid, Spain; Salinero-Fort, M., Dirección Técnica de Docencia e Investigación, Gerencia Atención Primaria, Madrid, Comunidad de Madrid, Spain; Carrasco-Garrido, P., Health Sciences Faculty, Rey Juan Carlos University, Preventive Medicine and Public Health Teaching and Research Unit, Avda. de Atenas s/n, Alcorcon, Comunidad deMadrid, 28922 Spain","Background: This study aims to describe trends in the rate of abdominal aortic aneurysm (AAA) and use of open surgery repair (OSR) and endovascular aneurysm repair (EVAR) in elderly patients with and without type 2 diabetes in Spain, 2003-2012. Methods: We select all patients with a discharge of AAA using national hospital discharge data. Discharges were grouped by diabetes status: type 2 diabetes and no diabetes. In both groups OSR and EVAR were identified. The incidence of discharges attributed to AAA were calculated overall and stratified by diabetes status and year. We calculated length of stay (LOHS) and in-hospital mortality (IHM). Use of OSR and EVAR were calculated stratified by diabetes status. Multivariate analysis was adjusted by age, sex, year, smoking habit and comorbidity. Results: From 2003 to 2012, 115,020 discharges with AAA were identified. The mean age was 74.91 years and 16.7% suffered type 2 diabetes. Rates of discharges due to AAA increased significantly in diabetic patients (50.09 in 2003 to 78.23 cases per 100,000 in 2012) and non diabetic subjects (69.24 to 78.66). The incidences were higher among those without than those with diabetes in all the years studied. Conclusions: Incidence rates were higher in non-diabetic patients. For diabetic and non diabetic patients the use of EVAR has increased and open repair seems to be decreasing. IHM and LOHS have improved from 2003 to 2012. Patients with diabetes had significantly lower mortality. © 2015 Lopez-de-Andrés et al.; licensee BioMed Central.","Abdominal aortic aneurysm; Elderly; Hospitalization; In-hospital mortality; Length of stay; Type 2 diabetes",,Article in Press,Scopus,2-s2.0-84928957958
"Clair C., Cohen M.J., Eichler F., Selby K.J., Rigotti N.A.","The Effect of Cigarette Smoking on Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis",2015,"Journal of General Internal Medicine",,,,"","",11,,10.1007/s11606-015-3354-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928969254&partnerID=40&md5=a3ae12f5f407259a95d7ce95c10bc29a","Department of Ambulatory Care and Community Medicine, Lausanne University HospitalLausanne, Switzerland; Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, United States; Department of Neurology, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, United States; Massachusetts General Hospital, Tobacco Research and Treatment Center, Division of General Internal Medicine, Harvard Medical SchoolBoston, MA, United States","Clair, C., Department of Ambulatory Care and Community Medicine, Lausanne University HospitalLausanne, Switzerland; Cohen, M.J., Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, United States; Eichler, F., Department of Neurology, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, United States; Selby, K.J., Department of Ambulatory Care and Community Medicine, Lausanne University HospitalLausanne, Switzerland; Rigotti, N.A., Massachusetts General Hospital, Tobacco Research and Treatment Center, Division of General Internal Medicine, Harvard Medical SchoolBoston, MA, United States","Objective: Studies suggest that smoking may be a risk factor for the development of microvascular complications such as diabetic peripheral neuropathy (DPN). The objective of this study was to assess the relationship between smoking and DPN in persons with type 1 or type 2 diabetes. Research Design and Methods: A systematic review of the PubMed, Embase, and Cochrane clinical trials databases was conducted for the period from January 1966 to November 2014 for cohort, cross-sectional and case–control studies that assessed the relationship between smoking and DPN. Separate meta-analyses for prospective cohort studies and case–control or cross-sectional studies were performed using random effects models. Results: Thirty-eight studies (10 prospective cohort and 28 cross-sectional) were included. The prospective cohort studies included 5558 participants without DPN at baseline. During follow-up ranging from 2 to 10 years, 1550 cases of DPN occurred. The pooled unadjusted odds ratio (OR) of developing DPN associated with smoking was 1.26 (95 % CI 0.86–1.85; I2 = 74 %; evidence grade: low strength). Stratified analyses of the prospective studies revealed that studies of higher quality and with better levels of adjustment and longer follow-up showed a significant positive association between smoking and DPN, with less heterogeneity. The cross-sectional studies included 27,594 participants. The pooled OR of DPN associated with smoking was 1.42 (95 % CI 1.21–1.65; I2 = 65 %; evidence grade: low strength). There was no evidence of publication bias. Conclusions: Smoking may be associated with an increased risk of DPN in persons with diabetes. Further studies are needed to test whether this association is causal and whether smoking cessation reduces the risk of DPN in adults with diabetes. © 2015 Society of General Internal Medicine","Comorbidity; Diabetes; Smoking cessation",,Article in Press,Scopus,2-s2.0-84928969254
"Mochizuki Y., Tanaka H., Matsumoto K., Sano H., Toki H., Shimoura H., Ooka J., Sawa T., Motoji Y., Ryo K., Hirota Y., Ogawa W., Hirata K.","Association of peripheral nerve conduction in diabetic neuropathy with subclinical left ventricular systolic dysfunction",2015,"Cardiovascular Diabetology",,,,"","",,,10.1186/s12933-015-0213-4,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928969496&partnerID=40&md5=f58d2a68e70faa932e7ffbc89892ac90","Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Diabetes and Endocrinology, Kobe, Japan","Mochizuki, Y., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Tanaka, H., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Matsumoto, K., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Sano, H., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Toki, H., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Shimoura, H., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Ooka, J., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Sawa, T., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Motoji, Y., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Ryo, K., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan; Hirota, Y., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Diabetes and Endocrinology, Kobe, Japan; Ogawa, W., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Diabetes and Endocrinology, Kobe, Japan; Hirata, K., Kobe University Graduate School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine, 7-5-2, Kusunoki-cho, Kobe, Chuo-ku, 650-0017 Japan","Background: Subclinical left ventricular (LV) longitudinal myocardial systolic dysfunction occurs in patients with diabetes mellitus (DM) and preserved LV ejection fraction (LVEF), and is closely related to DM-related complications. However, the association of diabetic neuropathy (DN) with subclinical LV systolic longitudinal dysfunction in such patients has not been fully clarified. Methods: The subjects of this study were 112 consecutive DM patients with preserved LVEF (all ≥50%) without coronary artery disease and overt heart failure (aged 59 ± 14 years; 60 women, 52 men). Global longitudinal strain (GLS) was determined as the average peak strain of 18 segments from the three standard apical views, and was expressed as an absolute value. DN was diagnosed by experienced diabetologists. Median, ulnar, and sural nerves were subjected to motor and sensory nerve conduction studies. F-wave latency was defined as the minimum F-wave latency after a total of 16 stimulations of the tibial nerve. Results: Forty-one (37%) patients were clinically diagnosed with DN. LV functions of DM patients with and without DN were similar except for GLS being significantly smaller in patients with than in patients without DN (18 ± 2% vs. 20 ± 2%, p < 0.001). It was noteworthy that, of the parameters for the nerve conduction study, only F-wave latency correlated with GLS (r = -0.34, p < 0.001), and also was identified as an independent determinative value of GLS in a multivariate linear regression model (β = -0.25, p = 0.001) even after adjustment for other closely related GLS factors. Conclusions: Monitoring of F-wave latency may aid early detection of not only DN but also subclinical LV dysfunction. Joint planning of assessment by diabetologists and cardiologists is therefore advisable for better management of DM patients. © 2015 Mochizuki et al.; licensee BioMed Central.","2-dimensional speckle-tracking strain; Diabetes mellitus; Diabetic neuropathy; Echocardiography; F-wave latency; Global longitudinal strain; Nerve conduction study",,Article in Press,Scopus,2-s2.0-84928969496
"Tao Z., Cheng M., Hu H., Wang S., Su J., Lv W., Guo H., Tang J., Cao B.","Altered Plasticity of Glycogen Phosphorylase in Forebrain Gliosomes Obtained from Insulinoma Patients",2015,"Journal of Molecular Neuroscience",,,,"","",7,,10.1007/s12031-015-0573-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928978718&partnerID=40&md5=0aa5d759999d854bde679fdb5aa6b4a9","Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China","Tao, Z., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China; Cheng, M., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China; Hu, H., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China; Wang, S., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China; Su, J., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China; Lv, W., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China; Guo, H., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China; Tang, J., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China; Cao, B., Department of Neurology, General Hospital of Jinan Military Command, No.25, Shifan Road, Tianqiao DistrictJinan, Shandong, China","We investigated a control model of hypoglycemia-exposed brain tissues from a small series of patients with insulinoma, immediately dissect them, and perform a differential cold centrifugation to obtain gliosomes and examine alterations of glycogenolytic mechanisms. The BB as well as MM isoforms of glycogen phosphorylase enzymatic protein expression remained unaltered between insulinoma and control subjects within the gliosomes. However, the glycogen phosphorylase remained in a form that was potentially activated several folds on placing the gliosomes in a glucose-free medium. This was examined by its increased interaction with protein kinase A. Inhibitors of glycogen phosphorylase was used as controls. Furthermore, we demonstrated that glucose-depleted medium enhanced production of both ATP and lactate by the gliosomes. It is possible that a portion of glucose obtained from glycogen breakdown was circuited through glycolytic pathways to generate ATP. It has been reported earlier that ATP within gliosomes plays a major role in glutamate uptake, thus potentially preventing seizure during active bouts of hypoglycemia. Lactate shuttle from astrocytes is a potential mechanism to balance neuronal bioenergetics during events of hypoglycemia. Newer approaches to pharmacologically modulate glycogen phosphorylase may prove to be rational approach for neuroprotective therapy in this common clinical syndrome of hypoglycemia. © 2015 Springer Science+Business Media New York","Autonomic; Diabetes; Enzyme plasticity; Metabolic brain disease; Seizure",,Article in Press,Scopus,2-s2.0-84928978718
"Robertson J., Mace C., Forte G., de Joncheere K., Beran D.","Medicines availability for non-communicable diseases: The case for standardized monitoring",2015,"Globalization and Health",,,,"","",,,10.1186/s12992-015-0105-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928975722&partnerID=40&md5=72213deaea2b93214b48577d2c87f973","World Health Organization, 20, avenue Appia, Geneva, 1211 Switzerland; University of Newcastle, Calvary Mater Hospital, Newcastle, 2298 Australia; Geneva University Hospitals (HUG), 4, rue Gabrielle-Perret-Gentil, Geneva, 1211 Switzerland; University of Geneva, 24 rue du Général-Dufour, Geneva, 1211 Switzerland","Robertson, J., World Health Organization, 20, avenue Appia, Geneva, 1211 Switzerland, University of Newcastle, Calvary Mater Hospital, Newcastle, 2298 Australia; Macé, C., World Health Organization, 20, avenue Appia, Geneva, 1211 Switzerland; Forte, G., World Health Organization, 20, avenue Appia, Geneva, 1211 Switzerland; de Joncheere, K., World Health Organization, 20, avenue Appia, Geneva, 1211 Switzerland; Beran, D., Geneva University Hospitals (HUG), 4, rue Gabrielle-Perret-Gentil, Geneva, 1211 Switzerland, University of Geneva, 24 rue du Général-Dufour, Geneva, 1211 Switzerland","Background: In response to the global burden of non-communicable diseases (NCDs), the World Health Organization (WHO) has developed a Global Action Plan that includes a voluntary medicines target of 80% availability and affordability of essential medicines for the prevention and treatment of diabetes, cardiovascular disease and respiratory disease both in public and private health facilities. Reliable measures of medicines availability are needed to track progress towards meeting this target. The results of three studies measuring the availability of medicines for hypertension and diabetes conducted in Tanzania in 2012-2013 were compared to assess the consistency of the results across the studies. Methods: Availability was defined by observation of the medicine (no minimum quantity) on the day of the survey. The three studies involved 24, 107 and 1297 health facilities. Estimates of the availability of medicines for hypertension and diabetes were compared for medicines availability overall, by managing authority (government, mission/faith-based, private-for-profit), by facility level (hospital, health centre, dispensary) and by setting (urban, rural). Results: Comparisons of the availability of medicines were limited by differences in the definitions of the medicines and the classifications of the facilities surveyed. Metformin was variously reported as available in 33%, 39%, 46%, and 57% of facilities. Glibenclamide availability ranged from 19% to 52%. One study reported low levels of insulin availability (9-16% depending on insulin type) compared to 34% in a second study. Captopril (or angiotensin converting enzyme [ACE] inhibitor) availability ranged from 13% to 48%while availability of calcium channel blockers was 29% to 57% and beta-blockers 15% to 50%. Trends were similar across studies with lower availability in government compared to mission or private facilities, in dispensary and health centres compared to hospitals, and in rural compared to urban facilities. Conclusions: All three studies showed suboptimal availability of NCD medicines, however the estimates of availability differed. Regular monitoring using reproducible methods and measuring key medicines must replace ad-hoc studies, small selected samples and differences in definitions. Low and middle-income countries need to implement monitoring and evaluation systems to track progress towards meeting the NCD medicines target and to inform country-level interventions to improve access to NCD medicines. © 2015 Robertson et al.; licensee BioMed Central.","Availability; Essential medicines; Monitoring; Non-communicable diseases",,Article in Press,Scopus,2-s2.0-84928975722
"Koike S., Yamaguchi S., Ojio Y., Shimada T., Watanabe K.-I., Ando S.","Long-term effect of a name change for schizophrenia on reducing stigma",2015,"Social Psychiatry and Psychiatric Epidemiology",,,,"","",8,,10.1007/s00127-015-1064-8,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928978453&partnerID=40&md5=6784883674db90194dd20051ae3a91a0","Division for Counseling and Support, Office for Mental Health Support, The University of Tokyo, Yasuda-Auditorium, 7-3-1 Hongo, Bunkyo-kuTokyo, Japan; Medical Research Council Unit for Lifelong Health and Ageing, University College London, 33 Bedford PlaceLondon, United Kingdom; Department of Psychiatric Rehabilitation, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-HigashiKodaira, Tokyo, Japan; Department of Physical and Health Education, The University of Tokyo, 7-3-1 Hongo, Bunkyo-kuTokyo, Japan; Department of Psychiatry and Behavioral Science, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, SetagayakuTokyo, Japan","Koike, S., Division for Counseling and Support, Office for Mental Health Support, The University of Tokyo, Yasuda-Auditorium, 7-3-1 Hongo, Bunkyo-kuTokyo, Japan, Medical Research Council Unit for Lifelong Health and Ageing, University College London, 33 Bedford PlaceLondon, United Kingdom; Yamaguchi, S., Department of Psychiatric Rehabilitation, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-HigashiKodaira, Tokyo, Japan; Ojio, Y., Department of Physical and Health Education, The University of Tokyo, 7-3-1 Hongo, Bunkyo-kuTokyo, Japan; Shimada, T., Division for Counseling and Support, Office for Mental Health Support, The University of Tokyo, Yasuda-Auditorium, 7-3-1 Hongo, Bunkyo-kuTokyo, Japan; Watanabe, K.-I., Division for Counseling and Support, Office for Mental Health Support, The University of Tokyo, Yasuda-Auditorium, 7-3-1 Hongo, Bunkyo-kuTokyo, Japan; Ando, S., Department of Psychiatry and Behavioral Science, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, SetagayakuTokyo, Japan","Background: A name change for schizophrenia was first implemented in Japan for reducing stigma in 2002; however, little is known of its long-term impact. Methods: Total 259 students from 20 universities answered an anonymous self-administered questionnaire about their mental health-related experiences, and stigma scales including feasible knowledge and negative stereotypes for four specific diseases, including schizophrenia (old and new names), depression, and diabetes mellitus. We also asked to choose the old and new names of schizophrenia and dementia among ten names for mental and physical illnesses and conditions. Results: The participants had more feasible knowledge and fewer negative stereotypes for the new name of schizophrenia than the old name, but were still significantly worse than for depression and diabetes mellitus (p < 0.01). Direct contact experiences with those who have mental health problems were associated with feasible knowledge for schizophrenia but not negative stereotypes (β = 0.13, p = 0.020). The rate of correct responses for the old and new names of schizophrenia was significantly lower than that of dementia (41 vs. 87 %, p < 0.001). Mental health-related experience from media was associated with the recognition of name change for schizophrenia (p = 0.008), which was associated with less feasible knowledge for new name of schizophrenia. Discussion: The name change of schizophrenia has reduced stigma since 12 years have passed. More effective campaigns, educational curricula, and policy making are needed to reduce stigma toward schizophrenia. © 2015 Springer-Verlag Berlin Heidelberg","Name change; Schizophrenia; Stereotyping; Stigma; Terminology",,Article in Press,Scopus,2-s2.0-84928978453
"Loppenthin K., Esbensen B.A., Ostergaard M., Jennum P., Tolver A., Aadahl M., Thomsen T., Midtgaard J.","Physical activity and the association with fatigue and sleep in Danish patients with rheumatoid arthritis",2015,"Rheumatology International",,,,"","",10,,10.1007/s00296-015-3274-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928969585&partnerID=40&md5=57b9764f94744e397b6fb109ae2f834f","Research Unit of Nursing and Health Science, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej 57Glostrup, Denmark; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Glostrup Hospital, University of CopenhagenGlostrup, Denmark; Department of Public Health, Faculty of Health and Medical Sciences, University of CopenhagenGlostrup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of CopenhagenGlostrup, Denmark; Department of Clinical Neurophysiology, Danish Center for Sleep Medicine, Glostrup Hospital, University of CopenhagenGlostrup, Denmark; Laboratory of Applied Statistics, Department of Mathematical Sciences, University of CopenhagenGlostrup, Denmark; Research Center for Prevention and Health, The Capital RegionCopenhagen, Denmark; The University Hospitals Center for Health Research, Copenhagen University Hospital, University of CopenhagenCopenhagen, Denmark","Løppenthin, K., Research Unit of Nursing and Health Science, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej 57Glostrup, Denmark, Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Glostrup Hospital, University of CopenhagenGlostrup, Denmark; Esbensen, B.A., Research Unit of Nursing and Health Science, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej 57Glostrup, Denmark, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of CopenhagenGlostrup, Denmark; Østergaard, M., Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Glostrup Hospital, University of CopenhagenGlostrup, Denmark, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of CopenhagenGlostrup, Denmark; Jennum, P., Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of CopenhagenGlostrup, Denmark, Department of Clinical Neurophysiology, Danish Center for Sleep Medicine, Glostrup Hospital, University of CopenhagenGlostrup, Denmark; Tolver, A., Laboratory of Applied Statistics, Department of Mathematical Sciences, University of CopenhagenGlostrup, Denmark; Aadahl, M., Department of Public Health, Faculty of Health and Medical Sciences, University of CopenhagenGlostrup, Denmark, Research Center for Prevention and Health, The Capital RegionCopenhagen, Denmark; Thomsen, T., Research Unit of Nursing and Health Science, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej 57Glostrup, Denmark, Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Glostrup Hospital, University of CopenhagenGlostrup, Denmark; Midtgaard, J., Department of Public Health, Faculty of Health and Medical Sciences, University of CopenhagenGlostrup, Denmark, The University Hospitals Center for Health Research, Copenhagen University Hospital, University of CopenhagenCopenhagen, Denmark","The aim of this study was to examine physical activity behavior in patients with rheumatoid arthritis and to identify potential correlates of regular physical activity including fatigue, sleep, pain, physical function and disease activity. A total of 443 patients were recruited from a rheumatology outpatient clinic and included in this cross-sectional study. Physical activity was assessed by a four-class questionnaire, in addition to the Physical Activity Scale. Other instruments included the Multidimensional Fatigue Inventory (MFI), the Pittsburgh Sleep Quality Index and the Health Assessment Questionnaire. Disease activity was obtained from a nationwide clinical database. Of the included patients, 80 % were female and mean age was 60 (range 21–88 years). Hereof, 22 % (n = 96) were regularly physically active, and 78 % (n = 349) were mainly sedentary or having a low level of physical activity. An inverse univariate association was found between moderate to vigorous physical activity, and fatigue (MFI mental, MFI activity, MFI physical and MFI general), sleep, diabetes, depression, pain, patient global assessment, HAQ and disease activity. The multivariate prediction model demonstrated that fatigue-related reduced activity and physical fatigue were selected in >95 % of the bootstrap samples with median odds ratio 0.89 (2.5–97.5 % quantiles: 0.78–1.00) and 0.91 (2.5–97.5 % quantiles: 0.81–0.97), respectively, while disease activity was selected in 82 % of the bootstrap samples with median odds ratio 0.90. Moderate to vigorous physical activity in patients with rheumatoid arthritis is associated with the absence of several RA-related factors with the most important correlates being reduced activity due to fatigue, physical fatigue and disease activity. © 2015 Springer-Verlag Berlin Heidelberg","fatigue; Physical activity; rheumatoid arthritis; sleep",,Article in Press,Scopus,2-s2.0-84928969585
"Hussen H.I., Persson M., Moradi T.","Maternal overweight and obesity are associated with increased risk of type 1 diabetes in offspring of parents without diabetes regardless of ethnicity",2015,"Diabetologia",,,,"","",10,,10.1007/s00125-015-3580-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928739005&partnerID=40&md5=fa382067868fceb48da7b7a03b137f63","Department of Environmental Medicine, Division of Epidemiology, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Nobels väg 13, Box 210Stockholm, Sweden; Department of Medicine, Clinical Epidemiology Unit, Karolinska University HospitalStockholm, Sweden; Centre for Epidemiology and Social Medicine, Health Care Services, Stockholm County CouncilStockholm, Sweden","Hussen, H.I., Department of Environmental Medicine, Division of Epidemiology, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Nobels väg 13, Box 210Stockholm, Sweden; Persson, M., Department of Medicine, Clinical Epidemiology Unit, Karolinska University HospitalStockholm, Sweden; Moradi, T., Department of Environmental Medicine, Division of Epidemiology, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Nobels väg 13, Box 210Stockholm, Sweden, Centre for Epidemiology and Social Medicine, Health Care Services, Stockholm County CouncilStockholm, Sweden","Aims/hypothesis: The incidence of type 1 diabetes in children is increasing in Sweden, as is the prevalence of maternal overweight/obesity. Therefore, the aim of this study was to investigate if maternal overweight/obesity increases the risk of type 1 diabetes in offspring of parents with and without diabetes, and of different ethnicities. Methods: The study cohort comprised 1,263,358 children, born in Sweden between 1992 and 2004. Children were followed from birth until diagnosis of type 1 diabetes, emigration, death or end of follow-up in 2009, whichever occurred first. First trimester maternal BMI was calculated (kg/m2). Poisson regression was used to calculate incidence rate ratios (IRRs) with 95% CI for type 1 diabetes in the offspring. Results: The risk of type 1 diabetes was increased in offspring of parents with any type of diabetes regardless of parental ethnicity. High first trimester maternal BMI was associated with increased risk of type 1 diabetes only in offspring of parents without diabetes (IRR 1.33 [95% CI 1.20, 1.48]). Conclusions/Interpretation: Increasing incidence of type 1 diabetes in children with non-diabetic parents may partly be explained by increasing prevalence of maternal overweight/obesity. © 2015 Springer-Verlag Berlin Heidelberg","Country of birth; Incidence; Maternal obesity; Maternal overweight; Sweden; Type 1 diabetes",,Article in Press,Scopus,2-s2.0-84928739005
"O'Connor L., Imamura F., Lentjes M.A.H., Khaw K.-T., Wareham N.J., Forouhi N.G.","Prospective associations and population impact of sweet beverage intake and type 2 diabetes, and effects of substitutions with alternative beverages",2015,"Diabetologia",,,,"","",10,,10.1007/s00125-015-3572-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928974780&partnerID=40&md5=1bde9fa8a1bba244ed3d0923beefb077","Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, PO Box 285Cambridge, United Kingdom; Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom","O’Connor, L., Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, PO Box 285Cambridge, United Kingdom; Imamura, F., Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, PO Box 285Cambridge, United Kingdom; Lentjes, M.A.H., Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Khaw, K.-T., Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Wareham, N.J., Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, PO Box 285Cambridge, United Kingdom; Forouhi, N.G., Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, PO Box 285Cambridge, United Kingdom","Aims/hypothesis: This study aimed to evaluate the association of types of sugar-sweetened beverages (SSB) (soft drinks, sweetened-milk beverages, sweetened tea/coffee), artificially sweetened beverages (ASB) and fruit juice with incident type 2 diabetes and determine the effects of substituting non-SSB for SSB and the population-attributable fraction of type 2 diabetes due to total sweet beverages. Methods: Beverage consumption of 25,639 UK-resident adults without diabetes at baseline (1993–1997) in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study was assessed using 7-day food diaries. During 10.8 years of follow-up 847 incident type 2 diabetes cases were verified. Results: In adjusted Cox regression analyses there were positive associations (HR [95% CI] per serving/day]) for soft drinks 1.21 (1.05, 1.39), sweetened-milk beverages 1.22 (1.05, 1.43) and ASB 1.22 (1.11, 1.33), but not for sweetened tea/coffee 0.98 (0.94, 1.02) or fruit juice 1.01 (0.88, 1.15). Further adjustment for adiposity attenuated the association of ASB, HR 1.06 (0.93, 1.20). There was a positive dose–response relationship with total sweet beverages: HR per 5% energy 1.18 (1.11, 1.26). Substituting ASB for any SSB did not reduce the incidence in analyses accounting for energy intake and adiposity. Substituting one serving/day of water or unsweetened tea/coffee for soft drinks and for sweetened-milk beverages reduced the incidence by 14%–25%. If sweet beverage consumers reduced intake to below 2% energy, 15% of incident diabetes might be prevented. Conclusions/interpretation: The consumption of soft drinks, sweetened-milk beverages and energy from total sweet beverages was associated with higher type 2 diabetes risk independently of adiposity. Water or unsweetened tea/coffee appear to be suitable alternatives to SSB for diabetes prevention. These findings support the implementation of population-based interventions to reduce SSB consumption and increase the consumption of suitable alternatives. © 2015 The Author(s)","Adiposity; Coffee; Fruit juice; Population impact; Sweet beverages; Tea; Type 2 diabetes; Water",,Article in Press,Scopus,2-s2.0-84928974780
"Qi L., Liu Q., Qi X., Wu N., Tang W., Xiong H.","Effectiveness of peer support for improving glycaemic control in patients with type 2 diabetes: A meta-analysis of randomized controlled trials",2015,"BMC Public Health",,,,"","",,,10.1186/s12889-015-1798-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928963959&partnerID=40&md5=ae9b5aaa23764618560a9f79d61f0269","College of Military Prevention, Third Military Medical University, Department of Military Epidemiology, Chongqing, China; Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China; Chongqing Medical University, School of Public Health and Management, Chongqing, China; Sichuan University, Department of Dental Medicine, Chengdu, China","Qi, L., College of Military Prevention, Third Military Medical University, Department of Military Epidemiology, Chongqing, China, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China; Liu, Q., Chongqing Medical University, School of Public Health and Management, Chongqing, China; Qi, X., Sichuan University, Department of Dental Medicine, Chengdu, China; Wu, N., College of Military Prevention, Third Military Medical University, Department of Military Epidemiology, Chongqing, China; Tang, W., Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China; Xiong, H., College of Military Prevention, Third Military Medical University, Department of Military Epidemiology, Chongqing, China","Background: To assess the effects of peer support at improving glycemic control in patients with type 2 diabetes. Methods: Relevant electronic databases were sought for this investigation up to Dec 2014. Randomized controlled trials involving patients with type 2 diabetes that evaluated the effect of peer support on glycated hemoglobin (HbA1c) concentrations were included. The pooled mean differences (MD) between intervention and control groups with 95% confidence interval (CI) were calculated using random-effects model. The Cochrane Collaboration's tool was used to assess the risk of bias. Results: Thirteen randomized controlled trials met the inclusion criteria. Peer support resulted in a significant reduction in HbA1c (MD -0.57 [95% CI: -0.78 to -0.36]). Programs with moderate or high frequency of contact showed a significant reduction in HbA1c levels (MD -0.52 [95% CI: -0.60 to -0.44] and -0.75 [95% CI: -1.21 to -0.29], respectively), whereas programs with low frequency of contact showed no significant reduction (MD -0.32 [95% CI: -0.74 to 0.09]). The reduction in HbA1c were greater among patients with a baseline HbA1c ≥ 8.5% (MD -0.78 [95% CI: -1.06 to -0.51]) and between 7.5 ~ 8.5% (MD -0.76 [95% CI: -1.05 to -0.47]), than patients with HbA1c < 7.5% (MD -0.08 [95% CI: -0.32 to 0.16]). Conclusions: Peer support had a significant impact on HbA<inf>1c</inf> levels among patients with type 2 diabetes. Priority should be given to programs with moderate or high frequency of contact for target patients with poor glycemic control rather than programs with low frequency of contact that target the overall population of patients. © 2015 Qi et al.; licensee BioMed Central.","Meta-analysis; Peer support; Randomized control trial; Type 2 diabetes",,Article in Press,Scopus,2-s2.0-84928963959
"Duru O.K., Turk N., Ettner S.L., Neugebauer R., Moin T., Li J., Kimbro L., Chan C., Luchs R.H., Keckhafer A.M., Kirvan A., Ho S., Mangione C.M.","Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP)",2015,"Journal of General Internal Medicine",,,,"","",6,,10.1007/s11606-015-3284-8,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928963251&partnerID=40&md5=f4d6762ac91ef615d689efee19a4ed90","David Geffen School of Medicine at UCLA, University of CaliforniaLos Angeles, CA, United States; Fielding School of Public Health, University of CaliforniaLos Angeles, CA, United States; Division of Research, Kaiser Permanente Northern CaliforniaOakland, CA, United States; VA HSR&D Center for the Study of Healthcare Innovation, Implementation, and PolicyLos Angeles, CA, United States; VA Greater Los Angeles Healthcare SystemLos Angeles, CA, United States; UnitedHealthcareMinnetonka, MN, United States","Duru, O.K., David Geffen School of Medicine at UCLA, University of CaliforniaLos Angeles, CA, United States; Turk, N., David Geffen School of Medicine at UCLA, University of CaliforniaLos Angeles, CA, United States; Ettner, S.L., David Geffen School of Medicine at UCLA, University of CaliforniaLos Angeles, CA, United States, Fielding School of Public Health, University of CaliforniaLos Angeles, CA, United States; Neugebauer, R., Division of Research, Kaiser Permanente Northern CaliforniaOakland, CA, United States; Moin, T., VA HSR&D Center for the Study of Healthcare Innovation, Implementation, and PolicyLos Angeles, CA, United States, VA Greater Los Angeles Healthcare SystemLos Angeles, CA, United States; Li, J., David Geffen School of Medicine at UCLA, University of CaliforniaLos Angeles, CA, United States; Kimbro, L., David Geffen School of Medicine at UCLA, University of CaliforniaLos Angeles, CA, United States; Chan, C., UnitedHealthcareMinnetonka, MN, United States; Luchs, R.H., UnitedHealthcareMinnetonka, MN, United States; Keckhafer, A.M., UnitedHealthcareMinnetonka, MN, United States; Kirvan, A., UnitedHealthcareMinnetonka, MN, United States; Ho, S., UnitedHealthcareMinnetonka, MN, United States; Mangione, C.M., David Geffen School of Medicine at UCLA, University of CaliforniaLos Angeles, CA, United States, Fielding School of Public Health, University of CaliforniaLos Angeles, CA, United States","Background: Reducing patient cost-sharing and engaging patients in disease management activities have been shown to increase uptake of evidence-based care. Objective: To evaluate the effect of employer purchase of a disease-specific plan with reduced cost-sharing and disease management (the Diabetes Health Plan/DHP) on medication adherence among eligible employees and dependents. Design: Employer-level “intent to treat” cohort study, including data from eligible employees and their dependents with diabetes, regardless of whether they were enrolled in the DHP. Setting: Employers that contracted with a large national health plan administrator in 2009, 2010, and/or 2011. Participants: Ten employers that purchased the DHP and 191 employers that did not (controls). Inverse probability weighting (IPW) estimation was used to adjust for inter-group differences. Intervention: The DHP includes free or low-cost medications and physician visits. Enrollment strategies and specific benefit designs are determined by the employer and vary in practice. DHP participants are notified up front that they must engage in their own health care (e.g., receiving diabetes-related screening) in order to remain enrolled. Main Outcome Measure: Mean employee adherence to metformin, statins, and ACE/ARBs at the employer level at one year post-DHP implementation, as measured by the proportion of days covered (PDC). Results: Baseline adherence to the three medications was similar across DHP and control employers, ranging from 64 to 69 %. In the first year after DHP implementation, predicted employer-level adherence for metformin (+4.9 percentage points, p = 0.017), statins (+4.8, p = 0.019), and ACE/ARBs (+4.4, p = 0.02) was higher with DHP purchase. Limitations: Non-randomized, observational study. Conclusions: The Diabetes Health Plan, an innovative health plan that combines reduced cost-sharing and disease management with an up-front requirement of enrollee participation in his or her own health care, is associated with a modest improvement in medication adherence at 12 months. © 2015 Society of General Internal Medicine",,,Article in Press,Scopus,2-s2.0-84928963251
"Shi L., Rui Y.-F., Li G., Wang C.","Alterations of tendons in diabetes mellitus: what are the current findings?",2015,"International Orthopaedics",,,,"","",9,,10.1007/s00264-015-2775-x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928964046&partnerID=40&md5=a9732de9641b700acbf26df06c9137a1","Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, 87 Ding Jia QiaoNanjing, Jiangsu, China; Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong KongHong Kong, SAR, China; Program of Stem Cell and Regeneration, School of Biomedical Science, and Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong KongHong Kong, SAR, China","Shi, L., Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, 87 Ding Jia QiaoNanjing, Jiangsu, China; Rui, Y.-F., Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, 87 Ding Jia QiaoNanjing, Jiangsu, China; Li, G., Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong KongHong Kong, SAR, China, Program of Stem Cell and Regeneration, School of Biomedical Science, and Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong KongHong Kong, SAR, China; Wang, C., Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, 87 Ding Jia QiaoNanjing, Jiangsu, China","As a connective tissue, tendon connects the muscle and bone, and plays the key role in the locomotor system. Some previous studies have shown the pathological alternations in diabetic tendons, which might result in the structural and functional changes, and even accelerate the process of diabetic foot. In this review, we examined the current findings of the diabetic tendons in the form of various aspects, and summarized the clinical presentation, imaging, biomechanical, histopathological, cellular and molecular abnormalities in the diabetic tendons. The progress of diabetic tendon damage is complicated and the main hypotheses include the excessive accumulation of AGEs, the altered inflammatory response, neovascularization and insensitive neuropathy. However, the cellular and molecular mechanisms of these alterations are still ambiguous. Tendon stem/progenitor cells (TSPCs) have been discovered to play important roles in both tendon physiology and tendon pathology. Recently, we identified TSPCs from patellar tendons in our well-established diabetic rat model and found impaired tenogenic differentiation potential of these cells. We proposed a new hypothesis that the impaired cell functions of diabetic TSPCs might be the underlying cellular and molecular mechanism of the diabetic tendon alternations. These findings should be helpful to establish a better therapeutic strategy for diabetic tendon repair and regeneration. © 2015 SICOT aisbl","Diabetes mellitus; Tendon repair and regeneration; Tendon stem/progenitor cells",,Article in Press,Scopus,2-s2.0-84928964046
"Guo C.","Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians",2015,"Acta Diabetologica",,,,"","",2,,10.1007/s00592-015-0749-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928975495&partnerID=40&md5=545d2bf75bf7af5f5bb3e6dbbc5ee786","Department of Pharmacy, Yantai Yuhuangding Hospital, School of Medicine, Qingdao UniversityYantai, China","Guo, C., Department of Pharmacy, Yantai Yuhuangding Hospital, School of Medicine, Qingdao UniversityYantai, China",[No abstract available],,,Article in Press,Scopus,2-s2.0-84928975495
"Stage T.B., Brosen K., Christensen M.M.H.","A Comprehensive Review of Drug–Drug Interactions with Metformin",2015,"Clinical Pharmacokinetics",,,,"","",14,,10.1007/s40262-015-0270-6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928974465&partnerID=40&md5=acbbbad710d13762e0372aa57c80649a","Clinical Pharmacology, Department of Public Health, University of Southern Denmark, J.B. Winsloews vej 19, 2nd FloorOdense, Denmark","Stage, T.B., Clinical Pharmacology, Department of Public Health, University of Southern Denmark, J.B. Winsloews vej 19, 2nd FloorOdense, Denmark; Brøsen, K., Clinical Pharmacology, Department of Public Health, University of Southern Denmark, J.B. Winsloews vej 19, 2nd FloorOdense, Denmark; Christensen, M.M.H., Clinical Pharmacology, Department of Public Health, University of Southern Denmark, J.B. Winsloews vej 19, 2nd FloorOdense, Denmark","Metformin is the world’s most commonly used oral glucose-lowering drug for type 2 diabetes, and this is mainly because it protects against diabetes-related mortality and all-cause mortality. Although it is an old drug, its mechanism of action has not yet been clarified and its pharmacokinetic pathway is still not fully understood. There is considerable inter-individual variability in the response to metformin, and this has led to many drug–drug interaction (DDI) studies of metformin. In this review, we describe both in vitro and human interaction studies of metformin both as a victim and as a perpetrator. We also clarify the importance of including pharmacodynamic end points in DDI studies of metformin and taking pharmacogenetic variation into account when performing these studies to avoid hidden pitfalls in the interpretation of DDIs with metformin. This evaluation of the literature has revealed holes in our knowledge and given clues as to where future DDI studies should be focused and performed. © 2015 Springer International Publishing Switzerland",,,Article in Press,Scopus,2-s2.0-84928974465
"Allen L., Thorpe K., Joski P.","The Effect of Obesity and Chronic Conditions on Medicare Spending, 1987–2011",2015,"PharmacoEconomics",,,,"","",7,,10.1007/s40273-015-0284-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928966969&partnerID=40&md5=28753e563acf3c7a7dd0f638070873fe","Emory University, 1518 Clifton RdAtlanta, GA, United States","Allen, L., Emory University, 1518 Clifton RdAtlanta, GA, United States; Thorpe, K., Emory University, 1518 Clifton RdAtlanta, GA, United States; Joski, P., Emory University, 1518 Clifton RdAtlanta, GA, United States","Background: Slowing the growth in Medicare expenditure is a key policy goal. Rising chronic disease prevalence is responsible for much of this growth. Objective: The first goal of this study is to estimate the percentage of Medicare spending growth that is attributable to increasing disease prevalence rates of diabetes, hyperlipidaemia, hypertension and heart disease. Second, we estimate how much of this prevalence-related spending growth is attributable to rising obesity rates. Methods: We employ spending decomposition equations to estimate the percentage of Medicare spending growth that is attributable to rising chronic disease prevalence, and we use two-part models to estimate the portion of prevalence-related spending that is potentially due to obesity. Results: For our four conditions of interest, growing disease prevalence accounted for between 13.6 % (in heart disease) and 58.9 % (in hyperlipidaemia) of Medicare expenditure growth. Up to 17.0 % (in diabetes) of the expenditure growth due to prevalence increases may be attributable to obesity and therefore may be modifiable. Conclusions: Rising obesity rates contribute to chronic disease prevalence, which, in turn, can lead to higher Medicare expenditures. To slow the growth in spending, policy makers should consider targeting obesity, using approaches such as improving pharmacotherapy coverage and providing intensive care coordination services to Medicare enrollees. © 2015 Springer International Publishing Switzerland",,,Article in Press,Scopus,2-s2.0-84928966969
"Nelson W.W., Desai S., Damaraju C.V., Lu L., Fields L.E., Wildgoose P., Schein J.R.","International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation",2015,"American Journal of Cardiovascular Drugs",,,,"","",7,,10.1007/s40256-015-0120-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928969294&partnerID=40&md5=6a7da09b5052bdd455ce839f43465f17","Health Economics and Outcomes Research (HECOR), Janssen Scientific Affairs, LLC, 1000 US Highway 202 SouthRaritan, NJ, United States; CTI/S2 Statistical SolutionsCincinnati, OH, United States; Janssen R&D, LLCRaritan, NJ, United States; Janssen Pharmaceuticals, Inc.Raritan, NJ, United States","Nelson, W.W., Health Economics and Outcomes Research (HECOR), Janssen Scientific Affairs, LLC, 1000 US Highway 202 SouthRaritan, NJ, United States; Desai, S., CTI/S2 Statistical SolutionsCincinnati, OH, United States; Damaraju, C.V., Janssen R&D, LLCRaritan, NJ, United States; Lu, L., Janssen R&D, LLCRaritan, NJ, United States; Fields, L.E., Janssen Pharmaceuticals, Inc.Raritan, NJ, United States; Wildgoose, P., Janssen Pharmaceuticals, Inc.Raritan, NJ, United States; Schein, J.R., Health Economics and Outcomes Research (HECOR), Janssen Scientific Affairs, LLC, 1000 US Highway 202 SouthRaritan, NJ, United States","Background: Maintaining stable levels of anticoagulation using warfarin therapy is challenging. Few studies have examined the stability of the international normalized ratio (INR) in patients with nonvalvular atrial fibrillation (NVAF) who have had ≥6 months’ exposure to warfarin anticoagulation for stroke prevention. Objective: Our objective was to describe INR control in NVAF patients who had been receiving warfarin for at least 6 months. Methods: Using retrospective patient data from the CoagClinic™ database, we analyzed data from NVAF patients treated with warfarin to assess the quality of INR control and possible predictors of poor INR control. Time within, above, and below the recommended INR range (2.0–3.0) was calculated for patients who had received warfarin for ≥6 months and had three or more INR values. The analysis also assessed INR patterns and resource utilization of patients with an INR >4.0. Logistic regression models were used to determine factors associated with poor INR control. Results: Patients (n = 9433) had an average of 1.6 measurements per 30 days. Mean follow-up time was 544 days. Approximately 39 % of INR values were out of range, with 23 % of INR values being <2.0 and 16 % being >3.0. Mean percent time with INR in therapeutic range was 67 %; INR <2.0 was 19 % and INR >3.0 was 14 %. Patients with more than one reading of INR >4.0 (~39 %) required an average of one more visit and took 3 weeks to return to an in-range INR. Male sex and age >75 years were predictive of better INR control, whereas a history of heart failure or diabetes were predictive of out-of-range INR values. However, patient characteristics did not predict the likelihood of INR >4.0. Conclusions: Out-of-range INR values remain frequent in patients with NVAF treated with warfarin. Exposure to high INR values was common, resulting in increased resource utilization. © 2015 The Author(s)",,,Article in Press,Scopus,2-s2.0-84928969294
"Sonawane R.D., Deore V.B., Patil S.D., Patil C.R., Surana S.J., Goyal R.K.","Role of 5-HT2 receptors in diabetes: Swertiamarin seco-iridoid glycoside might be a possible 5-HT2 receptor modulator",2015,"Physiology and Behavior","144",,,"66","72",,,10.1016/j.physbeh.2015.02.036,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924691841&partnerID=40&md5=1143bb8b825e29fd45d92df2f5071ec7","Department of Pharmacology, R.C. Patel Institute of Pharmaceutical Education and Research (RCPIPER)Karvand naka, Shirpur, Maharashtra, India; Medicinal Chemistry Department, Piramal Enterprises Limited, 1 Nirlon Complex, Off Western Express HighwayGoregaon (E), Mumbai, Maharashtra, India; Pharmacy Department, The M.S. University of BarodaVadodara, Gujarat, India; Department of Pharmacology, H.R. Patel Institute of Pharmaceutical Education and Research (HRPIPER)Karvand naka, Shirpur, Maharashtra, India; V ClinBio Labs, Sri Ramachandra University and HospitalPorur, Chennai, Tamil Nadu, India","Sonawane, R.D., Department of Pharmacology, R.C. Patel Institute of Pharmaceutical Education and Research (RCPIPER)Karvand naka, Shirpur, Maharashtra, India, Pharmacy Department, The M.S. University of BarodaVadodara, Gujarat, India; Deore, V.B., Medicinal Chemistry Department, Piramal Enterprises Limited, 1 Nirlon Complex, Off Western Express HighwayGoregaon (E), Mumbai, Maharashtra, India; Patil, S.D., Department of Pharmacology, H.R. Patel Institute of Pharmaceutical Education and Research (HRPIPER)Karvand naka, Shirpur, Maharashtra, India; Patil, C.R., Department of Pharmacology, R.C. Patel Institute of Pharmaceutical Education and Research (RCPIPER)Karvand naka, Shirpur, Maharashtra, India; Surana, S.J., Department of Pharmacology, R.C. Patel Institute of Pharmaceutical Education and Research (RCPIPER)Karvand naka, Shirpur, Maharashtra, India; Goyal, R.K., Pharmacy Department, The M.S. University of BarodaVadodara, Gujarat, India, V ClinBio Labs, Sri Ramachandra University and HospitalPorur, Chennai, Tamil Nadu, India","In the present review, we are focusing on modulators of 5-HT2 receptors, swertiamarin and their role in diabetes. These drugs possess both central and peripheral actions in various animal models of depression, diabetes and obesity. Swertiamarin and 5-HT2 antagonist are reported antidepressant, hypolipidemic and beneficial in peripheral vasculopathy. In contrast to this, 5-HT2C selective agonist decreases hyperglycemia, hyperlipidemia and insulin secretogogue by action. Selective serotonin reuptake inhibitors (SSRIs) are known antidepressant having weight gain as an adverse effect. Swertiamarin has similar pharmacological actions as 5-HT2 antagonist and 5-HT2C selective agonist. This warrants that swertiamarin might modulate 5-HT2 receptors rather than affecting the uptake of serotonin. In the light of present investigation, the mechanism of these drugs can correlate the role of central and peripheral 5-HT2 receptors in diabetes. © 2015 Elsevier Inc.","5-HT2 receptor; Anti-depressant; Diabetes; Serotonin; Swertiamarin and receptor modulators","Mohan, S.S., Deepa, R., Shah, B., Varghese, C., Epidemiology of type 2 diabetes: Indian scenario (2007) Indian J. Med. Res., 125, pp. 217-230; Cade, W.T., Diabetes-related microvascular and macrovascular diseases in the physical therapy setting (2008) Phys. Ther., 88 (11), pp. 1322-1335; Sonawane, R.D., Vishwakarma, S.L., Lakshmi, S., Rajani, M., Padh, H., Goyal, R.K., Amelioration of STZ-induced type 1 diabetic nephropathy by aqueous extract of Enicostemma littorale Blume and swertiamarin in rats (2010) Mol. Cell. Biochem., 340, pp. 1-6; Vishwakarma, S.L., Sonawane, R.D., Rajani, M., Goyal, R.K., Evaluation of effect of aqueous extract of Enicostemma littorale Blume in streptozotocin-induced type 1 diabetic rats (2010) IJEB, 48, pp. 26-30; Deeneya, J.T., Branstrom, R., Corkey, B.E., Larsson, O., Berggren, P., 3H-serotonin as a marker of oscillatory insulin secretion in clonal b-cells (INS-1) (2007) FEBS Lett., 581, pp. 4080-4084; Sakano, D., Shiraki, N., Kikawa, K., Yamazoe, T., Kataoka, M., Umeda, K., Araki, K., Kume, S., VMAT2 identified as a regulator of late-stage β-cell differentiation (2014) Nat. Chem. Biol., 10, pp. 141-148; Hara, K., HirowatariY, S.Y., Takahashi, H., Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease (2011) Diabetes Res. Clin. Pract., 94, pp. 167-171; Yanai, H., Hirowatari, Y., A significant association of plasma serotonin to cardiovascular risk factors and changes in pulse wave velocity in patients with type 2 diabetes (2012) Int. J. Cardiol., 157, pp. 312-313; Gupta, D., Kurhe, Y., Radhakrishnan, M., Antidepressant effects of insulin in streptozotocin induced diabetic mice: modulation of brain serotonin system (2014) Physiol. Behav., 129, pp. 73-78; Miyata, S., Hirano, S., Kamei, J., Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test (2004) Neuropsychopharmacology, 29, pp. 461-469; Abraham, P.M., Anju, T.R., Jayanarayanan, S., Paulose, C.S., Serotonergic receptor upregulation in cerebral cortex and down regulation in brainstem of streptozotocin induced diabetic rats: antagonism by pyridoxine and insulin (2010) Neurosci. Lett., 483, pp. 23-27; Iordanidou, M., TavridouA, P.I., Arvanitidis, K.I., Christakidis, D., Vargemezis, V., Manolopoulos, V.G., The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes (2010) Clin. Chim. Acta, 411, pp. 167-171; Bhattacharya, S.K., Reddy, P.K., Ghosal, S., Singh, A.K., Sharma, P.V., Chemical constituents of Gentianaceae XIX: CNS-depressant effects of swertiamarin (1976) J. Pharm. Sci., 65 (10), pp. 1547-1549; Sandoval, D.A., Obici, S.X., Seeley, R.J., Targeting the CNS to treat type 2 diabetes (2009) Nat. Rev. Drug Discov., 8, pp. 386-398; Moreau, J.L., Bos, M., Jenck, F., Martin, J.R., Mortas, P., Wichmann, J., 5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats (1996) Eur. Neuropsychopharmacol., 6 (3), pp. 169-175; Sawynok, J., Esser, M.J., Reid, A.R., Antidepressants as analgesics: an overview of central and peripheral mechanisms of action (2001) J. Psychiatry Neurosci., 26 (1), pp. 21-29; Ferguson, J.M., SSRI antidepressant medications: adverse effects and tolerability (2001) Prim Care Companion J. Clin. Psychiatry, 3 (1), pp. 22-27; Mackin, P., Hampson, L.J., Agius, L., Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs (2007) Diabetologia, 50, pp. 1743-1751; Erritzoe, D., Frokjaer, V.G., Haugbol, S., Marner, L., Svarer, C., Holst, K., Baare, W.C., Knudsen, G.M., Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use (2009) NeuroImage, 46, pp. 23-30; Granda, M.L., Carlin, S.M., Moseley, C.K., Neelamegam, R., Mandeville, J.B., Hooker, J.M., Synthesis and evaluation of methylated arylazepine compounds for PET imaging of 5-HT2c receptors (2013) ACS Chem. Neurosci., 4, pp. 261-265; MacKenzie, R.G., Hoebel, B.G., Ducret, R.P., Trulson, M.E., Hyperphagia following intraventricular p-chlorophenylalanine, leucine or tryptophan methyl esters: lack of correlation with whole brain serotonin levels (1979) Pharmacol. Biochem. Behav., 10, pp. 951-955; Kirsz, K., Zieba, D.A., A review on the effect of the photoperiod and melatonin on interactions between ghrelin and serotonin (2012) General and Comparative Endocrinology, 179, pp. 248-253; Sood, S., Liu, X., Liu, H., Hor, R.L., Genioglossus muscle activity and serotonergic modulation of hypoglossal motor output in obese Zucker rats (2007) J. Appl. Physiol., 102, pp. 2240-2250; Wurtman, R.J., Hefti, F., Melamed, E., Precursor control of neurotransmitter synthesis (1980) Pharmacol. Rev., 32, pp. 315-335; Williams, K.W., Scott, M.M., Elmquist, J.K., Modulation of the central melanocortin system by leptin, insulin, and serotonin: co-ordinated actions in a dispersed neuronal network (2011) Eur. J. Pharmacol., 660, pp. 2-12; Papazoglou, I., Berthou, F., Vicaire, N., Rouch, C., Markaki, E.M., Bailbe, D., Portha, B., Gerozissis, K., Hypothalamic serotonin-insulin signaling crosstalk and alterations in a type 2 diabetic model (2012) Mol. Cell. Endocrinol., 350, pp. 136-144; Coelho, W.S., Da Silva, D., Marinho-Carvalho, M.M., Sola-Penna, M., Serotonin modulates hepatic 6-phosphofructo-1-kinase in an insulin synergistic manner (2012) Int. J. Biochem. Cell Biol., 44, pp. 150-157; Matsumoto, T., Watanabe, S., Taguchi, K., Kobayashi, T., Mechanisms underlying increased serotonin-induced contraction incarotid arteries from chronic type 2 diabetic Goto-Kakizaki rats (2014) Pharmacol. Res., 87, pp. 123-132; James, G.M., Hodgson, W.C., Potentiation by endothelin-1 of 5-hydroxytryptamine responses in aortae from streptozotocin-diabetic rats: a role for thromboxane A2 (1995) Br. J. Pharmacol., 114, pp. 1236-1240; James, G.M., Hodgson, W.C., Davis, E.A., Haynes, J.M., Attenuated 5-hydroxytryptamine receptor-mediated responses in aortae from streptozotocin-induced diabetic rats (1994) Br. J. Pharmacol., 111, pp. 370-376; Shafizadeh, M., Rajaba, A., Khan, M.I., Ostadhadi, S., Rastegar, H., Dehpour, A., Anti-pruritic activity of pioglitazone on serotonin induced scratching in mice: possible involvement of PPAR-gamma receptor and nitric oxide (2014) Eur. J. Pharmacol., 744 (5), pp. 103-107; Kasho, M., Sakai, M., Sasahara, T., Anami, Y., Matsumura, T., Takemura, T., Matsuda, H., Shichiri, M., Serotonin enhances the production of type IV collagen by human mesangial cells (1998) Kidney Int., 54 (4), pp. 1083-1092; Mennini, T., Bizzi, A., Caccia, S., Codegoni, A., Fracasso, C., Frittoli, E., Comparative-studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea-pigs (1991) Naunyn Schmiedebergs Arch. Pharmacol., 343, pp. 483-490; Goudie, A.J., Thornton, E.W., Wheeler, T.J., Effects of Lilly 110140, a specific inhibitor of 5-hydroxytryptamine uptake, on food-intake and on 5-hydroxytryptophan-induced anorexia - evidence for serotoninergic inhibition of feeding (1976) J. Pharm. Pharmacol., 28, pp. 318-320; Gupta, D., Radhakrishnan, M., Kurhe, Y., Ondansetron, a 5-HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system (2014) Eur. J. Pharmacol., 744, pp. 59-66; Rahimian, R., Mehr, S.E., Fakhfouri, G., Dehpour, A.R., 5-HT3 receptor antagonists: new promising therapeutic agents in diabetes and its complications (2013) Acta Med., 56 (10), p. 736; Janiaka, P., Laine'e, P., Grataloup, Y., Luyt, C., Bidouard, J.P., Michel, J., Connor, S.E., Herbert, J., Serotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty Zucker rat (2002) Cardiovasc. Res., 56, pp. 293-302; Murao, S., Hosokawa, H., Serotonin 5-HT3 receptor antagonist for treatment of severe diabetic diarrhea (2010) Diabetes Care, 33 (3), p. e38; Garfield, A.S., Burke, L.K., Shaw, J., Evans, M.L., Heisler, L.K., Distribution of cells responsive to 5-HT6 receptor antagonist-induced hypophagia (2014) Behav. Brain Res., 266, pp. 201-206; Tudhope, S.J., Wang, C.C., Petrie, J.L., Potts, L., Malcomson, F., Kieswich, J., Yaqoob, M.M., Agius, L.A., Novel mechanism for regulating hepatic glycogen synthesis involving serotonin and cyclin-dependent kinase-5 (2012) Diabetes, 61, pp. 49-60; Garcia, M., Morán, A., Martín, M.L., Urbina, V.O., Román, L.S., Diabetes-induced changes in 5-hydroxytryptamine modulation of vagally induced bradycardia in rat heart (2007) Clin. Exp. Pharmacol. Physiol., 34, pp. 1199-1206; Takeshita, N., Yamaguchi, I., Meta-chloro phenyl piperazine attenuates formalin-induced nociceptive responses through 5-HT1/2 receptors in both normal and diabetic mice (1995) Br. J. Pharmacol., 116, pp. 3133-3138; James, A.N., Ryan, J.P., Crowell, M.D., Parkman, H.P., Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulation (2004) Am. J. Physiol. Gastrointest. Liver Physiol., 287, pp. G612-G619; Zarse, K., Ristow, M., Antidepressants of the serotonin-antagonist type increase body fat and decrease lifespan of adult Caenorhabditis elegans (2008) PLoS ONE, 3 (12), p. e4062; Taylor, J.R., Dietrich, E., Powell, J., Lorcaserin for weight management (2013) Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 6, pp. 209-216; Takahashi, T., Yano, M., Minami, J., Haraguchi, T., Koga, N., Higashi, K., Kobori, S., Kobori, S., Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy (2002) Diabetes Res. Clin. Pract., 58, pp. 123-129; Berglund, E.D., Liu, C., Sohn, J.W., Liu, T., Kim, M., Lee, C.E., Vianna, C.R., Elmquist, J.K., Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis (2013) J. Clin. Invest., 123 (12), pp. 5061-5070; Guenette, M.D., Giacca, A., Hahn, M., Teo, C., Lam, L., Chintoh, A., Arenovich, T., Remington, G., Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model (2013) Schizophr. Res., 146, pp. 162-169; Nelson, P.M., Harrod, J.S., Lamping, K.G., 5HT2A and 5HT2B receptors contribute to serotonin-induced vascular dysfunction in diabetes (2012) Exp. Diabetes Res., 2012, pp. 1-11; Malyszko, J., Urano, T., Knofler, R., Taminato, A., Yoshimi, T., Takada, Y., Takada, A., Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes (1994) Thromb. Res., 75 (5), pp. 569-576; Wang, Y., Beck, W., Deppisch, R., Marshall, S.M., Hoenich, N.A., Thompson, M.G., Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors (2007) Am. J. Physiol. Cell Physiol., 293, pp. C328-C336; Pietraszek, M.H., Takada, Y., Takada, A., Watanabea, F.M., Taminato, A., Yoshimi, T., Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus (1992) Thromb. Res., 66, pp. 765-774; Cameron, N.E., Cotter, M.A., The effects of 5-hydroxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats (2003) Naunyn Schmiedeberg's Arch. Pharmacol., 367, pp. 607-614; Viau, M., Lafond, J., Vaillancou, C., Expression of placental serotonin transporter and 5HT2A receptor in normal and gestational diabetes mellitus pregnancies (2009) Reprod. BioMed. Online, 19 (2), pp. 207-215; Banas, S.M., Doly, S., Boutourlinsky, K., Diaz, S.L., Belmer, A., Callebert, J., Collet, C., Maroteaux, L., Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects (2011) Neuropsychopharmacology, 36, pp. 423-433; Bhaskaran, S., Singhal, S., Banes-Berceli, A., Serotonin (5-HT) receptor expression and function in the kidney and vasculature is altered in the streptozotocin (STZ) rat model of diabetes mellitus (2013) FASEB J., 27. , 917.1; Iwabayashi, M., Taniyamaa, Y., Sanada, F., Azumaa, J., Iekushia, K., Kusunokia, H., Chatterjee, A., Morishita, R., Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT1B/Akt/eNOS pathway in diabetic mice (2012) Atherosclerosis, 220, pp. 337-342; Saunders, C., Siuta, M., Robertson, S.D., Davis, A.R., Sauer, J., Matthies, H.J.G., Gresch, P.J., Galli, A., Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function (2014) Neurochem. Int., 73, pp. 113-121; Banes, A.K., Shaw, S.M., Tawfik, A., Patel, B.P., Ogbi, S., Fulton, D., Marrero, M.B., Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin (2005) Am. J. Physiol. Cell Physiol., 288, pp. C805-C812; Oufkir, T., Arseneault, M., Sanderson, J.T., Vaillancourt, C., The 5-HT2A serotonin receptor enhances cell viability, affects cell cycle progression and activates MEK-ERK1/2 and JAK2-STAT3 signalling pathways in human choriocarcinoma cell lines (2010) Placenta, 31 (5), pp. 439-447; Zhang, Q., Zhu, Y., Zhou, W., Gao, L., Yuan, L., Serotonin receptor 2C and insulin secretion (2013) PLoS ONE, 8 (1), p. e54250; Marston, O.J., Heisler, L.K., Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes (2009) Neuropsychopharmacology, 34, pp. 252-253; Giorgetti, M., Tecott, L.H., Contributions of 5-HT2C receptors to multiple actions of central serotonin systems (2004) Eur. J. Pharmacol., 488, pp. 1-9; Tecott, L.H., Sun, L.M., Akana, S.F., Strack, A.M., Lowenstein, D.H., Dallman, M.F., Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors (1995) Nature, 374, pp. 542-546; Akana, S.F., Feeding and stress interact through the serotonin 2C receptor in developing mice (2008) Physiol. Behav., 94 (4), pp. 569-579; Vickers, S.P., Dourish, C.T., Kennett, G.A., Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors (2001) Neuropharmacology, 41 (2), pp. 200-209; Booth, R.G., Fang, L., Huang, Y., Wilczynski, A., Sivendran, S., (1R, 3S)-(-)-Trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity (2009) Eur. J. Pharmacol., 615 (1-3), pp. 1-9; Vaidya, H., Rajani, M., Sudarsanam, V., Padh, H., Goyal, R., Swertiamarin: a lead from Enicostemma littorale Blume. for antihyperlipidaemic effect (2009) Eur. J. Pharmacol., 617 (1-3), pp. 108-112; Jaishree, V., Badami, S., Kumar, M.R., Tamizhmani, T., Antinociceptive activity of swertiamarin isolated from Enicostemma axillare (2009) Phytomedicine, 16, pp. 227-232; Jaishree, V., Badami, S., Antioxidant and hepatoprotective effect of swertiamarin from Enicostemma axillare against d-galactosamine induced acute liver damage in rats (2010) J. Ethnopharmacol., 130 (1), pp. 103-106; Yamahara, J., Kobayashi, M., Matsuda, H., Aoki, S., Anticholinergic action of Swertia japonica and an active constituent (1991) J. Ethnopharmacol., 33 (1-2), pp. 31-35; Kimura, Y., Sumiyoshi, M., Effects of Swertia japonica extract and its main compound swertiamarin on gastric emptying and gastrointestinal motility in mice (2011) Fitoterapia, 82 (6), pp. 827-833; Sharma, A.N., Bauer, I.E., Sanches, M., Galvez, J.F., Zunta-Soares, G.B., Quevedo, J., Kapczinski, F., Soares, J.C., Common biological mechanisms between bipolar disorder and type 2 diabetes: focus on inflammation (2014) Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 54, pp. 289-298; Saravanan, S., Islam, V.H., Babu, N.P., Pandikumar, P., Thirugnanasambantham, K., Chellappandian, M., Raj, C.D., Ignacimuthu, S., Swertiamarin attenuates inflammation mediators via modulating NF-κB/I κB and JAK2/STAT3 transcription factors in adjuvant induced arthritis (2014) Eur. J. Pharm. Sci., 56 (2), pp. 70-86; Patel, T.P., Soni, S., Parikh, P., Gosai, J., Chruvattil, R., Gupta, S., Swertiamarin: an active lead from Enicostemma littorale regulates hepatic and adipose tissue gene expression by targeting PPAR-γ and improves insulin sensitivity in experimental NIDDM rat model (2013) Evid. Based Complement. Alternat. Med., 2013, pp. 1-11; Vaidya, H., Goyal, R.K., Cheema, S.K., Anti-diabetic activity of swertiamarin is due to an active metabolite, gentianine, that upregulates PPAR-γ gene expression in 3T3-L1 cells (2012) Phytol. Res., 27, pp. 624-627",Review,Scopus,2-s2.0-84924691841
"Chen H., Qiu Q., Zou C., Dou L., Liang J.","Regulation of hepatic carbohydrate metabolism by Selenium during diabetes",2015,"Chemico-Biological Interactions","232",, 7293,"1","6",,,10.1016/j.cbi.2015.02.017,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925341633&partnerID=40&md5=1a81ee9e908a45ac69a0086034f4ddd1","Department of Endocrinology, Xuzhou Central Hospital, Affiliated XuZhou Hospital of Medical College of Southeast University, 199# South Jiefang RoadXuzhou, Jiangsu, China; Xuzhou Institute of Medical Sciences, Xuzhou Institute of DiabetesXuzhou, Jiangsu, China; Xuzhou Medical CollegeXuzhou, Jiangsu, China","Chen, H., Department of Endocrinology, Xuzhou Central Hospital, Affiliated XuZhou Hospital of Medical College of Southeast University, 199# South Jiefang RoadXuzhou, Jiangsu, China, Xuzhou Institute of Medical Sciences, Xuzhou Institute of DiabetesXuzhou, Jiangsu, China; Qiu, Q., Xuzhou Medical CollegeXuzhou, Jiangsu, China; Zou, C., Department of Endocrinology, Xuzhou Central Hospital, Affiliated XuZhou Hospital of Medical College of Southeast University, 199# South Jiefang RoadXuzhou, Jiangsu, China, Xuzhou Institute of Medical Sciences, Xuzhou Institute of DiabetesXuzhou, Jiangsu, China; Dou, L., Department of Endocrinology, Xuzhou Central Hospital, Affiliated XuZhou Hospital of Medical College of Southeast University, 199# South Jiefang RoadXuzhou, Jiangsu, China, Xuzhou Institute of Medical Sciences, Xuzhou Institute of DiabetesXuzhou, Jiangsu, China; Liang, J., Department of Endocrinology, Xuzhou Central Hospital, Affiliated XuZhou Hospital of Medical College of Southeast University, 199# South Jiefang RoadXuzhou, Jiangsu, China, Xuzhou Institute of Medical Sciences, Xuzhou Institute of DiabetesXuzhou, Jiangsu, China, Xuzhou Medical CollegeXuzhou, Jiangsu, China","Abstract In the present study, we have tried to unravel the role of Selenium supplementation in containing hyperglycemia by regulating enzymes activities involved in carbohydrate metabolism in liver of diabetic animals. Male wistar rats were divided into four groups: normal control, diabetic, Selenium treated control and Selenium treated diabetic group. Diabetes was induced in the animals by injecting alloxan intraperitoneally at a dose level of 150 mg/kg body weight. Selenium in the form of sodium selenite was supplemented to rats at a dose level of 1 PPM in drinking water, ad libitum for two time durations of 2 and 4 weeks. Animals were sacrificed and livers were excised for the analyses of enzymes involved in carbohydrate metabolism as well as the levels of glycogen. In-vitro 14C-d glucose uptake and its turnover were also assessed in liver slices of all the treatment groups using radiorespirometry. Selenium supplementation to the diabetic rats normalized the enzyme activities of glucose-6-phosphatase, lactate dehydrogenase and glycogen phosphorylase as well as restored the glycogen levels to within the normal limits which were altered during diabetes. Interestingly, when Selenium was supplemented to diabetic rats, 14C-d glucose uptake and its turnover showed a statistically significant increase in their values which however, were decreased in diabetic rats. In conclusion, Selenium mediates insulin-like role during diabetes by tending to normalize the altered activities of glucose metabolizing enzymes and also improves the glucose uptake and its metabolism by the liver. © 2015 Elsevier Ireland Ltd. All rights reserved.","14C-d glucose uptake; Carbohydrate metabolism; Diabetes; Radiorespirometry; Selenium supplementation","Steppan, C.M., The hormone resistin links obesity to diabetes (2001) Nature, 409, pp. 307-312; Daubresse, J.C., The importance of syndrome X in daily practice (2000) Rev. Med. Bruk., 21, pp. 473-477; Ward, J.D., Diabetic neuropathy (1989) Br. Med. Bull., 45, pp. 111-126; Kohner, E.M., Diabetic retinopathy (1989) Br. Med. Bull., 45, pp. 148-173; Boel, E., Selmer, J., Flodgaard, H.J., Jensen, T., Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? (1995) J. Diabetes Complications, 9, pp. 104-129; Chausmer, A.B., Selenium, insulin and diabetes (1998) J. Am. Coll. Nutr., 17, pp. 109-115; Levinthal, G.N., Tavill, A.S., Liver Disease and Diabetes Mellitus (1999) Clin. Diab., 17; Kelkar, S.M., Determination of antidiabetic activity in Allium cepa (onion) tissue cultures (2001) Indian J. Biochem. Biophys., 38, pp. 277-279; Skyler, J., (2002) N. Engl. J. Med.; Stone, B.E., Vanthiel, D., Diabetes mellitus and the liver (1985) Sem. Liver Dis., 5, pp. 8-28; Perry, Serum insulin and incident coronary heart disease in middle aged British men (1996) Am. J. Epidemio., 144, pp. 224-234; Flodin, N.W., Artherosclerosis: an insulin dependent disease? (1986) J. Am. Coll. Nutr., 5, pp. 417-427; Margaret, P., Rayman, G.F., Combs, J.R., David, J.W., Selenium and vitamin E supplementation for chemoprevention (2009) JAMA, 301 (18), p. 1876; Ganther, H.E., Selenium metabolism, selenoproteins, and mechanisms of cancer prevention: complexities with thioredoxin reductase (1999) Carcinogenesis, 20, pp. 1657-1666; Fereshteh, S., Abdollah Dhawan, D.K., Selenium as a chemopreventive agent in experimentally induced colon carcinogenesis (2009) World J. Gastrointes. Oncol., 1 (1), pp. 74-81; Mihailović, M., Cvetković, M., Ljubić, A., Kosanović, M., Nedeljković, S., Jovanović, I., Pesut, O., Selenium and malondialdehyde content and glutathione peroxidase activity in maternal and umbilical cord blood and amniotic fluid Biol. Trac. Ele. Res., 73 (1), pp. 47-54; Chun, J.Y., Lee, S.O., Onate, S.A., Lou, W., Gao, A.C., Mechanisms of selenium downregulation of androgen receptor signaling in prostate cancer (2006) Mol. Cancer Ther., 5 (4), pp. 913-918; Zhong, W., Redox mediated effects of selenium on apoptosis and cell cycle in LNCap human prostate cancer cell line (2001) Cancer Res., 61 (19), pp. 7071-7078; Josef, L., Selenium-containing compounds attenuate peroxynitriete mediated NF-k B and Ap-1 activation and interleukin -8 gene and protein expression in human leukocytes (2003) Free Radical Biol. Med., 35 (9), pp. 1018-1027; Sharma, R., Dhawan, D., Sharma, R.R., Dash, R.J., Effects of alloxan induced diabetes mellitus on uptake and biological half-life of I-131 in rat thyroid (1985) IRCS Med. Sci., 13, p. 90; Ghadi, F., Malhotra, A., Ramzani, A., Dhawan, D.K., Chemopreventive effects of selenium on cancer marker indices and ultrastructural changes during 1,2 dimethylhydrazine induced colon carcinogenesis in rats (2013) J. Gastrointest. Cancer, 44 (1), p. 54; Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., Protein measurement with the Follin-phenol reagent (1951) J. Biol. Chem., 193, pp. 265-275; Kun, E., Abood, L.G., Colorimetric estimation of succinic dehydrogenase by triphenyl tetrazolim chloride (1949) Science, 109, pp. 144-145; Bergmeyer, H.U., Brent, E., (1971) Methods in enzymatic analyses, 2, pp. 5574-5579. , Acadamic press New York; Crane, R.K., Sols, A., The non-competitive inhibition of brain hexokinase by glucose-6-phosphate and related compounds (1954) J. Biol. Chem., 210, pp. 597-606; Swanson, M.A., Phosphatases of liver. I. Glucose-6-phosphatase (1950) J. Biol. Chem., 184, p. 647; Slein, J.M.W., (1956) Bioz Chem., 186, p. 753; Nieymer, H., Influence of diet on liver phosphorylase: effects of fasting and refeeding (1961) J. Biol. Chem., 236, p. 610; Seifter, S., Dayton, S., Novic, B., Muntwyler, E., The estimation of glycogen with the anthrone reagent (1950) Arch. Biochem., 25, pp. 191-200; Crane, R., Madelstam, P., The active transport of sugars by various preparation of hamster intestine (1960) Biochim. Biophys. Acta, 45, pp. 460-464; Malhotra, A., Nair, P., Dhawan, D., Study to evaluate molecular mechanics behind synergistic chemo preventive effects of curcumin and resveratrol during lung carcinogenesis (2014) PLoS ONE, 9 (4); Bunn, H.F., Gabbay, K.H., Gallop, P.M., The glycosylation of hemoglobin: relevance to diabetes mellitus (1978) Science, 200, pp. 21-27; Derr, R., Stacy, G.A., Christopher, E.G., Saudek, D., HbA1c affected by glycemic instability? (2003) Diabetes Care, 26, pp. 2728-2733; Ghadi, F., Malhotra, A., Ramzani, A., Dhawan, D.K., Selenium as a modulator of membrane stability parameters and surface changes during the initiation phase of 1,2 dimethylhydrazine induced colorectal carcinogenesis (2012) Mol. Cell. Biochem., 369 (1), pp. 119-126; Yechoor, V.K., Patti, M.-E., Saccone, R., Ronald Kahn, C., Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice (2002) PNAS, 99, pp. 10587-10592; Wahlberg, G., Adamson, U., Svensson, J., Pyridine nucleotides in glucose metabolism and diabetes: a review (2000) Diab. Metab. Res. Rev., 16, pp. 33-42; Andallu, B., Vardacharyulu, N.C., Effect of Mulberry leaves on diabetes (2001) Int. J. Diab. Dev. Ctries., 21, pp. 147-151; Mishra, G., Routray, R., Das, S.R., Behera, H.N., Alloxan diabetes in Swiss mice: activity of Na(+)-K(+)-ATPase and succinic dehydrogenase (1995) Indian J. Physiol. Pharmacol., 39, pp. 271-274; Singh, S.N., Vats, P., Suri, S., Radhey Shyam, M.M.L., Kumria, S., Ranganathan, K.S., Effect of an antidiabetic extract of Catharanthus roseus on enzymic activities in streptozotocin induced diabetic rats (2001) J. Ethnopharmacol., 76, pp. 269-277; Liu, Z., Barrett, E.J., Dalkin, A.C., Zwart, A.D., Chou, J.Y., Effect of acute diabetes on rat hepatic glucose-6-phosphatase activity and its messenger RNA level (1994) Biochem. Biophys. Res. Commun., 205, pp. 680-686; Floettmann, E., Gregory, L., Teague, J., Myatt, J., Hammond, C., Poucher, S.M., Jones, H.B., Prolonged inhibition of glycogen phosphorylase in livers of zucker diabetic fatty rats models human glycogen storage diseases (2010) Toxicol. Pathol., 38, pp. 393-401; Hartmann, H., Probst, I., Jungermann, K., Creutzfeldt, W., Inhibition of glycogenolysis and glycogen phosphorylase by insulin and proinsulin in rat hepatocyte cultures (1987) Diabetes, 36, pp. 551-555",Article,Scopus,2-s2.0-84925341633
"Carcone A.I., Ellis D.A., Chen X., Naar S., Cunningham P.B., Moltz K.","Multisystemic Therapy Improves the Patient-Provider Relationship in Families of Adolescents with Poorly Controlled Insulin Dependent Diabetes",2015,"Journal of Clinical Psychology in Medical Settings",,,,"","",10,,10.1007/s10880-015-9422-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928717113&partnerID=40&md5=12392a6828d681bf9eb4c25d4883c9d7","Prevention Research Center, Department of Pediatrics, Wayne State University School of MedicineDetroit, MI, United States; Department of Epidemiology, College of Public Health & Health Professions and College of Medicine, University of FloridaGainesville, FL, United States; Department of Psychiatry and Behavioral Sciences, Medical University of South CarolinaCharleston, SC, United States; Division of Endocrinology, Department of Pediatrics, Wayne State University School of MedicineDetroit, MI, United States","Carcone, A.I., Prevention Research Center, Department of Pediatrics, Wayne State University School of MedicineDetroit, MI, United States; Ellis, D.A., Prevention Research Center, Department of Pediatrics, Wayne State University School of MedicineDetroit, MI, United States; Chen, X., Department of Epidemiology, College of Public Health & Health Professions and College of Medicine, University of FloridaGainesville, FL, United States; Naar, S., Prevention Research Center, Department of Pediatrics, Wayne State University School of MedicineDetroit, MI, United States; Cunningham, P.B., Department of Psychiatry and Behavioral Sciences, Medical University of South CarolinaCharleston, SC, United States; Moltz, K., Division of Endocrinology, Department of Pediatrics, Wayne State University School of MedicineDetroit, MI, United States","The purpose of this study was to determine if multisystemic therapy (MST), an intensive, home and community-based family treatment, significantly improved patient-provider relationships in families where youth had chronic poor glycemic control. One hundred forty-six adolescents with type 1 or 2 diabetes in chronic poor glycemic control (HbA1c ≥8 %) and their primary caregivers were randomly assigned to MST or a telephone support condition. Caregiver perceptions of their relationship with the diabetes multidisciplinary medical team were assessed at baseline and treatment termination with the Measure of Process of Care-20. At treatment termination, MST families reported significant improvement on the Coordinated and Comprehensive Care scale and marginally significant improvement on the Respectful and Supportive Care scale. Improvements on the Enabling and Partnership and Providing Specific Information scales were not significant. Results suggest MST improves the ability of the families and the diabetes treatment providers to work together. © 2015 Springer Science+Business Media New York","Diabetes; Family therapy; Health care services; Randomized controlled trial",,Article in Press,Scopus,2-s2.0-84928717113
"Qian Y., Dong M., Lu F., Li H., Jin G., Hu Z., Shen C., Shen H.","Joint effect of CENTD2 and KCNQ1 polymorphisms on the risk of type 2 diabetes mellitus among Chinese Han population",2015,"Molecular and Cellular Endocrinology","407",,,"46","51",,,10.1016/j.mce.2015.02.026,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925352870&partnerID=40&md5=c7fb49b5195e411b5d3d148c0c8a45c7","Department of Chronic Non-communicable Disease Control, Wuxi Center for Disease Control and PreventionWuxi, China; Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityNanjing, China","Qian, Y., Department of Chronic Non-communicable Disease Control, Wuxi Center for Disease Control and PreventionWuxi, China; Dong, M., Department of Chronic Non-communicable Disease Control, Wuxi Center for Disease Control and PreventionWuxi, China; Lu, F., Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityNanjing, China; Li, H., Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityNanjing, China; Jin, G., Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityNanjing, China; Hu, Z., Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityNanjing, China; Shen, C., Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityNanjing, China; Shen, H., Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical UniversityNanjing, China","Genome-wide association studies (GWAS) in populations of European ancestry have identified nine single nuclear polymorphisms (SNP) on chromosome 11 related to type 2 diabetes (T2D) susceptibility. Herein, we further evaluate the association of these SNPs and T2D in a Chinese Han population. We performed a case-control study of 2925 T2D cases and 3281 controls to evaluate the association of five SNPs of KCNJ11, MTNR1B, CENTD2 and LOC387761 and T2D in addition to the previously reported four SNPs of KCNQ1. Multiple logistic regression was used to evaluate SNP's effect by adjustment for confounding factor age, sex and BMI. In the first stage, SNPs rs1552224 at CENTD2 were significantly associated with T2D and the association was statistically significant in the whole study population (P = 0.001) although it was not replicated in the second stage. rs1552224 and rs2237897 of KCNQ1 showed significant joint effect on T2D and there was a significant decreased risk of T2D with the number increase of risk alleles (P for trend = 3.81 × 10-17). Compared to those without carrying any risk allele, individuals carrying one, two, and three or four risk alleles had a 30.7%, 44.8% and 62.0% decreased risk for developing T2D, respectively. Our finding suggests that genetic variant rs1552224 of CENTD2 on chromosome 11 contributes to an independent effect as well as joint cumulative effect with rs2237897 of KCNQ1 on the risk of T2D in Chinese Han population, and further functional research would be warranted. © 2015 Elsevier Ireland Ltd.","Association study; CENTD2; Chromosome 11; KCNQ1; Type 2 diabetes","Almawi, W.Y., Nemr, R., Keleshian, S.H., Echtay, A., Saldanha, F.L., AlDoseri, F.A., A replication study of 19 GWAS-validated type 2 diabetes at-risk variants in the Lebanese population (2013) Diabetes Res. Clin. Pract, 102, pp. 117-122; Bao, X.Y., Peng, B., Yang, M.S., Replication study of novel risk variants in six genes with type 2 diabetes and related quantitative traits in the Han Chinese lean individuals (2012) Mol. Biol. Rep, 39, pp. 2447-2454; Been, L.F., Ralhan, S., Wander, G.S., Mehra, N.K., Singh, J., Mulvihill, J.J., Variants in KCNQ1 increase type II diabetes susceptibility in South Asians: a study of 3,310 subjects from India and the US (2011) BMC Med. Genet, 12, p. 18; Cauchi, S., Ezzidi, I., El Achhab, Y., Mtiraoui, N., Chaieb, L., Salah, D., European genetic variants associated with type 2 diabetes in North African Arabs (2012) Diabetes Metab, 38, pp. 316-323; Clark, C.M., Kinney, E.D., Standards for the care of diabetes. Origins, uses and implications for third-party payment (1992) Diabetes Care, 15, pp. 10-14; Cui, B., Zhu, X., Xu, M., Guo, T., Zhu, D., Chen, G., A genome-wide association study confirms previously reported loci for type 2 diabetes in Han Chinese (2011) PLoS ONE, 6, p. e22353; Saxena, R., Voight, B.F., Lyssenko, V., Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels (2007) Science, 316, pp. 1331-1336. , Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund UniversityLund University, Novartis Institutes of BioMedical ResearchNovartis Institutes of BioMedical Research; Duesing, K., Fatemifar, G., Charpentier, G., Marre, M., Tichet, J., Hercberg, S., Evaluation of the association of IGF2BP2 variants with type 2 diabetes in French Caucasians (2008) Diabetes, 57, pp. 1992-1996; Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes (2006) Nat. Genet, 38, pp. 320-323; Guo, S.W., Thompson, E.A., Performing the exact test of Hardy-Weinberg proportion for multiple alleles (1992) Biometrics, 48, pp. 361-372; Hayes, M.G., Pluzhnikov, A., Miyake, K., Sun, Y., Ng, M.C., Roe, C.A., Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies (2007) Diabetes, 56, pp. 3033-3044; Kong, A., Steinthorsdottir, V., Masson, G., Thorleifsson, G., Sulem, P., Besenbacher, S., Parental origin of sequence variants associated with complex diseases (2009) Nature, 462, pp. 868-874; Li, H., Gan, W., Lu, L., Dong, X., Han, X., Hu, C., A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans (2013) Diabetes, 62, pp. 291-298; Lin, Y.D., Qian, Y., Dong, M.H., Lu, F., Shen, C., Jin, G.F., Association of polymorphisms of potassium voltage-gated channel, KQT-like subfamily, member 1 and type 2 diabetes in Jiangsu province, China (2013) Zhonghua Yu Fang Yi Xue Za Zhi, 47, pp. 538-541; Long, J., Edwards, T., Signorello, L.B., Cai, Q., Zheng, W., Shu, X.O., Evaluation of genome-wide association study-identified type 2 diabetes loci in African Americans (2012) Am. J. Epidemiol, 176, pp. 995-1001; Lu, F., Qian, Y., Li, H., Dong, M., Lin, Y., Du, J., Genetic variants on chromosome 6p21.1 and 6p22.3 are associated with type 2 diabetes risk: a case-control study in Han Chinese (2012) J. Hum. Genet, 57, pp. 320-325; Lu, S., Xie, Y., Lin, K., Li, S., Zhou, Y., Ma, P., Genome-wide association studies-derived susceptibility loci in type 2 diabetes: confirmation in a Chinese population (2012) Clin. Invest. Med, 35, p. E327; Nielsen, T., Sparso, T., Grarup, N., Jorgensen, T., Pisinger, C., Witte, D.R., Type 2 diabetes risk allele near CENTD2 is associated with decreased glucose-stimulated insulin release (2011) Diabetologia, 54, pp. 1052-1056; Odgerel, Z., Lee, H.S., Erdenebileg, N., Gandbold, S., Luvsanjamba, M., Sambuughin, N., Genetic variants in potassium channels are associated with type 2 diabetes in a Mongolian population (2012) J Diabetes, 4, pp. 238-242; Ohshige, T., Iwata, M., Omori, S., Tanaka, Y., Hirose, H., Kaku, K., Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese (2011) PLoS ONE, 6, p. e26911; Palmer, N.D., Langefeld, C.D., Ziegler, J.T., Hsu, F., Haffner, S.M., Fingerlin, T., Candidate loci for insulin sensitivity and disposition index from a genome-wide association analysis of Hispanic participants in the Insulin Resistance Atherosclerosis (IRAS) Family Study (2010) Diabetologia, 53, pp. 281-289; Parikh, H., Lyssenko, V., Groop, L.C., Prioritizing genes for follow-up from genome wide association studies using information on gene expression in tissues relevant for type 2 diabetes mellitus (2009) BMC Med. Genomics, 2, p. 72; Rampersaud, E., Damcott, C.M., Fu, M., Shen, H., McArdle, P., Shi, X., Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations (2007) Diabetes, 56, pp. 3053-3062; Reiling, E., Jafar-Mohammadi, B., van 't Riet, E., Weedon, M.N., van Vliet-Ostaptchouk, J.V., Hansen, T., Genetic association analysis of LARS2 with type 2 diabetes (2010) Diabetologia, 53, pp. 103-110; Reiman, E.M., In this issue: entering the era of high-density genome-wide association studies (2007) J. Clin. Psychiatry, 68, pp. 611-612; Rich, S.S., Goodarzi, M.O., Palmer, N.D., Langefeld, C.D., Ziegler, J., Haffner, S.M., A genome-wide association scan for acute insulin response to glucose in Hispanic-Americans: the Insulin Resistance Atherosclerosis Family Study (IRAS FS) (2009) Diabetologia, 52, pp. 1326-1333; Richards, J.B., Waterworth, D., O'Rahilly, S., Hivert, M.F., Loos, R.J., Perry, J.R., A genome-wide association study reveals variants in ARL15 that influence adiponectin levels (2009) PLoS Genet, 5, p. e1000768; Ruchat, S.M., Rankinen, T., Weisnagel, S.J., Rice, T., Rao, D.C., Bergman, R.N., Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study (2009) Diabetologia, 53 (4), pp. 679-689; Ruchat, S.M., Elks, C.E., Loos, R.J., Vohl, M.C., Weisnagel, S.J., Rankinen, T., Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies (2009) Acta Diabetol, 46, pp. 217-226; Ruchat, S.M., Rankinen, T., Weisnagel, S.J., Rice, T., Rao, D.C., Bergman, R.N., Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study (2010) Diabetologia, 53, pp. 679-689; Saif-Ali, R., Muniandy, S., Al-Hamodi, Z., Lee, C.S., Ahmed, K.A., Al-Mekhlafi, A.M., KCNQ1 variants associate with type 2 diabetes in Malaysian Malay subjects (2011) Ann. Acad. Med. Singapore, 40, pp. 488-492; Saxena, R., Voight, B.F., Lyssenko, V., Burtt, N.P., de Bakker, P.I., Chen, H., Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels (2007) Science, 316, pp. 1331-1336; Scott, L.J., Mohlke, K.L., Bonnycastle, L.L., Willer, C.J., Li, Y., Duren, W.L., A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants (2007) Science, 316, pp. 1341-1345; Strawbridge, R.J., Dupuis, J., Prokopenko, I., Barker, A., Ahlqvist, E., Rybin, D., Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes (2011) Diabetes, 60, pp. 2624-2634; Tam, C.H., Ho, J.S., Wang, Y., Lam, V.K., Lee, H.M., Jiang, G., Use of net reclassification improvement (NRI) method confirms the utility of combined genetic risk score to predict type 2 diabetes (2013) PLoS ONE, 8, p. e83093; Tan, J.T., Ng, D.P., Nurbaya, S., Ye, S., Lim, X.L., Leong, H., Polymorphisms identified through genome-wide association studies and their associations with type 2 diabetes in Chinese, Malays, and Asian-Indians in Singapore (2010) J. Clin. Endocrinol. Metab, 95, pp. 390-397; Tsai, F.J., Yang, C.F., Chen, C.C., Chuang, L.M., Lu, C.H., Chang, C.T., A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese (2010) PLoS Genet, 6, p. e1000847; Xu, M., Bi, Y., Xu, Y., Yu, B., Huang, Y., Gu, L., Combined effects of 19 common variations on type 2 diabetes in Chinese: results from two community-based studies (2010) PLoS ONE, 5, p. e14022; Yasuda, K., Miyake, K., Horikawa, Y., Hara, K., Osawa, H., Furuta, H., Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus (2008) Nat. Genet, 40, pp. 1092-1097; Zeggini, E., Weedon, M.N., Lindgren, C.M., Frayling, T.M., Elliott, K.S., Lango, H., Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes (2007) Science, 316, pp. 1336-1341",Article,Scopus,2-s2.0-84925352870
"Bertinato J., Xiao C.W., Ratnayake W.M.N., Fernandez L., Lavergne C., Wood C., Swist E.","Lower serum magnesium concentration is associated with diabetes, insulin resistance, and obesity in South Asian and white Canadian women but not men",2015,"Food and Nutrition Research","59",, 25974,"","",,,10.3402/fnr.v59.25974,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84929011846&partnerID=40&md5=0bf31ae626909c6936093c079c54aba1","Nutrition Research Division, Health Products and Food Branch, Health CanadaOttawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of OttawaOttawa, Canada; Department of Cellular and Molecular Medicine, University of OttawaOttawa, Canada; Department of Biology, University of OttawaOttawa, Canada","Bertinato, J., Nutrition Research Division, Health Products and Food Branch, Health CanadaOttawa, Canada, Department of Biochemistry, Microbiology and Immunology, University of OttawaOttawa, Canada; Xiao, C.W., Nutrition Research Division, Health Products and Food Branch, Health CanadaOttawa, Canada, Department of Cellular and Molecular Medicine, University of OttawaOttawa, Canada; Ratnayake, W.M.N., Nutrition Research Division, Health Products and Food Branch, Health CanadaOttawa, Canada; Fernandez, L., Nutrition Research Division, Health Products and Food Branch, Health CanadaOttawa, Canada; Lavergne, C., Nutrition Research Division, Health Products and Food Branch, Health CanadaOttawa, Canada, Department of Biology, University of OttawaOttawa, Canada; Wood, C., Nutrition Research Division, Health Products and Food Branch, Health CanadaOttawa, Canada; Swist, E., Nutrition Research Division, Health Products and Food Branch, Health CanadaOttawa, Canada","Background: A large proportion of adults in North America are not meeting recommended intakes for magnesium (Mg). Women and people of South Asian race may be at higher risk for Mg deficiency because of lower Mg intakes relative to requirements and increased susceptibility to diabetes, respectively. Objective: This study compared serum Mg concentrations in South Asian (n=276) and white (n=315) Canadian women and men aged 20-79 years living in Canada's Capital Region and examined the relationship with diabetes, glucose control, insulin resistance, and body mass index. Results: Serum Mg concentration was lower in women of both races and South Asians of both genders. Racial differences in serum Mg were not significant after controlling for use of diabetes medication. A substantial proportion of South Asian (18%) and white (9%) women had serum Mg <0.75 mmol/L indicating hypomagnesemia. Use of diabetes medication and indicators of poorer glucose control, insulin resistance, and obesity were associated with lower serum Mg in women, but not in men. Conclusions: These results suggest that the higher incidence of diabetes in South Asians increases their risk for Mg deficiency and that health conditions that increase Mg requirements have a greater effect on Mg status in women than men. © 2015 Jesse Bertinato et al.","Adults; Body mass index; Glucose; Homeostatic model assessment of insulin resistance; Magnesium status; McAuley's index; Quantitative insulin sensitivity check index","Paolisso, G., Scheen, A., D'Onofrio, F., Lefebvre, P., Magnesium and glucose homeostasis (1990) Diabetologia, 33, pp. 511-514; Kao, W.H., Folsom, A.R., Nieto, F.J., Mo, J.P., Watson, R.L., Brancati, F.L., Serum and dietary magnesium and the risk for type 2 diabetes mellitus: The atherosclerosis risk in communities study (1999) Arch Intern Med, 159, pp. 2151-2159; Rumawas, M.E., McKeown, N.M., Rogers, G., Meigs, J.B., Wilson, P.W., Jacques, P.F., Magnesium intake is related to improved insulin homeostasis in the Framingham offspring cohort (2006) J Am Coll Nutr, 25, pp. 486-492; Cahill, F., Shahidi, M., Shea, J., Wadden, D., Gulliver, W., Randell, E., High dietary magnesium intake is associated with low insulin resistance in the Newfoundland population (2013) PLoS One, 8, p. e58278; Huerta, M.G., Roemmich, J.N., Kington, M.L., Bovbjerg, V.E., Weltman, A.L., Holmes, V.F., Magnesium deficiency is associated with insulin resistance in obese children (2005) Diabetes Care, 28, pp. 1175-1181; Villegas, R., Gao, Y.T., Dai, Q., Yang, G., Cai, H., Li, H., Dietary calcium and magnesium intakes and the risk of type 2 diabetes: The Shanghai Women's Health Study (2009) Am J Clin Nutr, 89, pp. 1059-1067; Larsson, S.C., Wolk, A., Magnesium intake and risk of type 2 diabetes: A meta-analysis (2007) J Intern Med, 262, pp. 208-214; Pham, P.C., Pham, P.M., Pham, S.V., Miller, J.M., Pham, P.T., Hypomagnesemia in patients with type 2 diabetes (2007) Clin J Am Soc Nephrol, 2, pp. 366-373; Ford, E.S., Mokdad, A.H., Dietary magnesium intake in a national sample of US adults (2003) J Nutr, 133, pp. 2879-2882; Health Canada, (2012) Do Canadian Adults Meet Their Nutrient Requirements through Food Intake Alone?, , http://www.hc-sc.gc.ca/fn-an/alt_formats/pdf/surveill/nutrition/commun/art-nutr-adult-eng.pdf, [cited 9 September 2014]; Statistics Canada, (2011) Immigration and Ethnocultural Diversity in Canada. National Household Survey, , http://www12.statcan.gc.ca/nhs-enm/2011/as-sa/99-010-x/99-010-x2011001-eng.pdf, [cited 9 September 2014]; Enas, E.A., Singh, V., Munjal, Y.P., Bhandari, S., Yadave, R.D., Manchanda, S.C., Reducing the burden of coronary artery disease in India: Challenges and opportunities (2008) Indian Heart J, 60, pp. 161-175; Gholap, N., Davies, M., Patel, K., Sattar, N., Khunti, K., Type 2 diabetes and cardiovascular disease in South Asians (2011) Prim Care Diabetes, 5, pp. 45-56; Gujral, U.P., Pradeepa, R., Weber, M.B., Narayan, K.M., Mohan, V., Type 2 diabetes in South Asians: Similarities and differences with white Caucasian and other populations (2013) Ann N YAcad Sci, 1281, pp. 51-63; Institute of Medicine Food and Nutrition Board, (1997) Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride., , Washington, DC: National Academy Press; Hunt, C.D., Johnson, L.K., Magnesium requirements: New estimations for men and women by cross-sectional statistical analyses of metabolic magnesium balance data (2006) Am J Clin Nutr, 84, pp. 843-852; Witkowski, M., Hubert, J., Mazur, A., Methods of assessment of magnesium status in humans: A systematic review (2011) Magnes Res, 24, pp. 163-180; Lowenstein, F.W., Stanton, M.F., Serum magnesium levels in the United States, 1971-1974 (1986) J Am Coll Nutr, 5, pp. 399-414; Elin, R.J., Re-evaluation of the concept of chronic, latent, magnesium deficiency (2011) Magnes Res, 24, pp. 225-227; Elin, R.J., Assessment of magnesium status for diagnosis and therapy (2010) Magnes Res, 23, pp. S194-S198; American Diabetes Association, (2014) Diagnosing Diabetes and Learning about Prediabetes, , http://www.diabetes.org/diabetes-basics/diagnosis/, [cited 9 September 2014]; Ascaso, J.F., Pardo, S., Real, J.T., Lorente, R.I., Priego, A., Carmena, R., Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism (2003) Diabetes Care, 26, pp. 3320-3325; Takenaka, T., Kanno, Y., Ohno, Y., Suzuki, H., Key role of insulin resistance in vascular injury among hemodialysis patients (2007) Metabolism, 56, pp. 153-159; Hung, A.M., Sundell, M.B., Egbert, P., Siew, E.D., Shintani, A., Ellis, C.D., A comparison of novel and commonly-used indices of insulin sensitivity in African American chronic hemodialysis patients (2011) Clin J Am Soc Nephrol, 6, pp. 767-774; McAuley, K.A., Williams, S.M., Mann, J.I., Walker, R.J., Lewis-Barned, N.J., Temple, L.A., Diagnosing insulin resistance in the general population (2001) Diabetes Care, 24, pp. 460-464; World Health Organization, (2006) BMI Classification, , http://apps.who.int/bmi/index.jsp?introPage=intro_3.html, [cited 9 September 2014]; WHO expert consultation, Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies (2004) Lancet, 363, pp. 157-163; Chambers, E.C., Heshka, S., Gallagher, D., Wang, J., Pi-Sunyer, F.X., Pierson, R.N., Jr., Serum magnesium and type-2 diabetes in African Americans and Hispanics: A New York cohort (2006) J Am Coll Nutr, 25, pp. 509-513; Ma, J., Folsom, A.R., Melnick, S.L., Eckfeldt, J.H., Sharrett, A.R., Nabulsi, A.A., Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: The ARIC study. Atherosclerosis risk in communities study (1995) J Clin Epidemiol, 48, pp. 927-940; Katz, A., Nambi, S.S., Mather, K., Baron, A.D., Follmann, D.A., Sullivan, G., Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans (2000) J Clin Endocrinol Metab, 85, pp. 2402-2410; Shoji, T., Emoto, M., Nishizawa, Y., HOMA index to assess insulin resistance in renal failure patients (2001) Nephron, 89, pp. 348-349; Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man (1985) Diabetologia, 28, pp. 412-419; Trikudanathan, S., Raji, A., Chamarthi, B., Seely, E.W., Simonson, D.C., Comparison of insulin sensitivity measures in South Asians (2013) Metabolism, 62, pp. 1448-1454; Takaya, J., Higashino, H., Kobayashi, Y., Intracellular magnesium and insulin resistance (2004) Magnes Res, 17, pp. 126-136; Shields, M., Carroll, M.D., Ogden, C.L., Adult obesity prevalence in Canada and the United States (2011) NCHS Data Brief, 56, pp. 1-8; Jose, B., Jain, V., Vikram, N.K., Agarwala, A., Saini, S., Serum magnesium in overweight children (2012) Indian Pediatr, 49, pp. 109-112; Kroll, M.H., Elin, R.J., Relationships between magnesium and protein concentrations in serum (1985) Clin Chem, 31, pp. 244-246",Article,Scopus,2-s2.0-84929011846
"Zhao C., Fu Y.","Statistical analysis based online sensor failure detection for continuous glucose monitoring in type I diabetes",2015,"Chemometrics and Intelligent Laboratory Systems","144",,,"128","137",,,10.1016/j.chemolab.2015.04.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928340572&partnerID=40&md5=6c9464ac24c4a7ed9b9b114b726a97a1","State Key Laboratory of Industrial Control Technology, Department of Control Science and Engineering, Zhejiang UniversityHangzhou, China; Becton Dickinson TechnologiesResearch Triangle Park, NC, United States","Zhao, C., State Key Laboratory of Industrial Control Technology, Department of Control Science and Engineering, Zhejiang UniversityHangzhou, China; Fu, Y., Becton Dickinson TechnologiesResearch Triangle Park, NC, United States","Wide use of continuous glucose monitoring (CGM) provides time-series sensor data and knowledge about the underlying correlations of glucose concentrations and their progressing dynamics over time direction. From self-monitoring of blood glucose to continuous glucose monitoring, sensor performance is key for successful clinical use. However, sensor failures have not been analyzed and detected before use of CGM data for glucose control, although they are very common problems in real-world cases and may result in unreliable CGM data and thus bad control performance. In the present work, a statistical analysis based failure detection method is proposed as a high-level glucose monitoring tool to identify sensor problems online only using CGM data. By analyzing CGM data, different types of monitoring charts (i.e., fault detection charts) are developed and sensor abnormality is indicated during online monitoring by comparing monitoring profiles against the predefined confidence limits. Comparison is also made between different monitoring charts for two important typical disturbances. Different from the conventional glucose monitoring which worked as a low-level monitoring tool and focused on direct real-time display of CGM readings, the proposed method focuses on detecting undesirable sensor disturbances by analyzing the underlying time-wise glucose autocorrelations. The feasibility of the proposed method to serve as a completely new glucose monitoring engine is successfully assessed using CGM data collected from the Food and Drug Administration (FDA)-accepted University of Virginia/University of Padova (UVa/Padova) metabolic simulator. © 2015 Elsevier B.V.","Continuous glucose monitoring (CGM); Multivariate statistical analysis; Sensor failure detection; Statistical monitoring chart; Type I diabetes mellitus (TIDM)","Rubin, R.R., Peyrot, M., Quality of life and diabetes (1999) Diabetes Metab. Res. Rev., 15, pp. 205-218; http://www.health.gov.on.ca/en/common/ministry/publications/reports/diabetes/diabetes.aspxConrad, S.C., McGrath, M.T., Gitelman, S.E., Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus (2002) J. Pediatr., 140 (2), pp. 235-240; Rabasa-Lhoret, R., Garon, J., Langelier, H., Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen (1999) Diabetes Care, 22, pp. 667-673; Boland, E., Monsod, T., Delucia, M., Brandt, C.A., Fernando, S., Tamborlane, W.V., Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes (2001) Diabetes Care, 24, pp. 1858-1862; Ellis, S.L., Bookout, T., Garg, S.K., Izuora, K.E., Use of continuous glucose monitoring to improve diabetes mellitus management (2007) Endocrinol. Metab. Clin. North Am., 36, pp. 46-68; Hermanides, J., Phillip, M., DeVries, J.H., Current application of continuous glucose monitoring in the treatment of diabetes (2011) Diabetes Care, 34, pp. S197-S201; Bremer, T., Gough, D.A., Is blood glucose predictable from previous values? A solicitation for data (1999) Diabetes, 48, pp. 445-451; Finan, D.A., Palerm, C.C., Doyle, F.J., Seborg, D.E., Zisser, H., Bevier, W.C., Jovanovič, L., Effect of input excitation on the quality of empirical dynamic models for type 1 diabetes (2009) AIChE J., 55, pp. 1135-1146; Zhao, C.H., Dassau, E., Harvey, R.A., Seborg, D.E., Doyle, F.J., Predictive glucose monitoring for type 1 diabetes using latent variable-based multivariate statistical analysis"" (2011) Proceedings of 18th IFAC, 18, pp. 7012-7017; Sparacino, G., Zanderigo, F., Corazza, S., Maran, A., Facchinetti, A., Cobelli, C., Glucose concentration can be predicted ahead in time from continuous glucose monitoring sensor time-series (2007) IEEE Trans. Biomed. Eng., 54, pp. 931-937; Zanderigo, F., Sparacino, G., Kovatchev, B., Cobelli, C., Glucose prediction algorithms from continuous monitoring data: assessment of accuracy via continuous glucose error-grid analysis (2007) J. Diabetes Sci. Technol., 1, pp. 645-651; Zhao, C.H., Dassau, E., Jovanovič, L., Predicting subcutaneous glucose concentration using latent variable (LV)-based statistical analysis method for type 1 diabetes mellitus (2012) J. Diabetes Sci. Technol., 6, pp. 617-633; Reifman, J., Rajaraman, S., Gribok, A., Ward, W.K., Predictive monitoring for improved management of glucose levels (2007) J. Diabetes Sci. Technol., 1, pp. 478-486; Zhao, C.H., Eyal, D., Zisser, H.C., Online prediction of subcutaneous glucose concentration for Type 1 Diabetes using empirical models and frequency-band separation (2014) AICHE J., 60, pp. 574-584; Eren-Qruklu, M., Cinar, A., Quinn, L., Smith, D., Estimation of future glucose concentrations with subject-specific recursive linear models (2009) Diabetes Technol. Ther., 9, pp. 438-450; Eren-Oruklu, M., Cinar, A., Quinn, L., Hypoglycemia prediction with subject-specific recursive time-series models (2010) J. Diabetes Sci. Technol., 4, pp. 25-33; Finan, D.A., Zisser, H., Zisser, H., Jovanovič, L., Bevier, W.C., Seborg, D.E., Practical issues in the identification of empirical models from simulated type 1 diabetes data (2007) Diabetes Technol. Ther., 9, pp. 438-450; Palerm, C.C., Willis, J.P., Desemone, J., Bequette, B.W., Hypoglycemia prediction and detection using optimal estimation (2005) Diabetes Technol. Ther., 7, pp. 3-14; Zhao, C.H., Sun, Y.X., Zhao, L.P., Interindividual glucose dynamics in different frequency bands for online prediction of subcutaneous glucose concentration in type 1 diabetic subjects (2013) AICHE J., 59, pp. 4228-4240; Deiss, D., Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring (2006) Diabetes Care, 29, pp. 2730-2732; Ehrhardt, N.M., Chellappa, M., Walker, M.S., Vigersky, R.A., The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus (2011) J. Diabetes Sci. Technol., 5, pp. 668-675; Facchinetti, A., Favero, S.D., Sparacino, G., Cobelli, C., An online fault detection method of the glucose sensor-insulin pump system: improved overnight safety of type-1 diabetic subjects (2013) IEEE Trans. Biomed. Eng., 60, pp. 406-416; Herrero, P., Calm, R., Vehi, J., Armengol, J., Georgiou, P., Oliver, N., Toumazou, C., Robust fault detection system for insulin pump therapy using continuous glucose monitoring (2012) J. Diabetes Sci. Technol., 6, pp. 1131-1141; Kovatchev, B.P., Breton, M., Dalla Man, C., Cobelli, C., In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes (2009) J. Diabetes Sci. Technol., 3, pp. 44-55; Wold, S., Esbensen, K., Geladi, P., Principal component analysis (1987) Chemom. Intell. Lab. Syst., 2, pp. 37-52; Jackson, J.E., (1991) A User's Guide to Principal Components, , Wiley, New York, USA; Seborg, D.E., Edgar, T.F., Mellichamp, D.A., (2003) Process Dynamic and Control, , Wiley, New York, USA; Nomikos, P., MacGregor, J.F., Multivariate SPC charts for monitoring batch processes (1995) Technometrics, 37, pp. 41-59; Burnham, A.J., Viveros, R., MacGregor, J.F., Frameworks for latent variable multivariate regression (1996) J. Chemom., 10, pp. 31-45; Burnham, A.J., MacGregor, J.F., Viveros, R., Latent variable multivariate regression modeling (1999) Chemom. Intell. Lab. Syst., 48, pp. 167-180; Yu, H., MacGregor, J.F., Post processing methods (PLS-CCA): simple alternatives to preprocessing methods (OSC-PLS) (2004) Chemom. Intell. Lab. Syst., 73, pp. 199-205; Rahaghi, F.N., Gough, D.A., Blood glucose dynamics (2008) Diabetes Technol. Ther., 10, pp. 81-94; Lu, Y.H., Gribok, A.V., Ward, W.K., The importance of different frequency bands in predicting subcutaneous glucose concentration in type 1 diabetic patients (1839) IEEE Trans. Biomed. Eng., 2010, p. 57",Article,Scopus,2-s2.0-84928340572
"Zhou J., Yan J., Bai Z., Li K., Huang K.","Hypoglycemic activity and potential mechanism of a polysaccharide from the loach in streptozotocin-induced diabetic mice",2015,"Carbohydrate Polymers","121",,,"199","206",,,10.1016/j.carbpol.2014.12.037,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920855206&partnerID=40&md5=e5fdd7225b4378954f9d528c2b36966b","Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu RoadWuhan, China","Zhou, J., Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu RoadWuhan, China; Yan, J., Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu RoadWuhan, China; Bai, Z., Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu RoadWuhan, China; Li, K., Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu RoadWuhan, China; Huang, K., Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu RoadWuhan, China","The present study was designed to investigate the hypoglycemic activity and the potential mechanisms of Misgurnus anguillicaudatus polysaccharide (MAP) in streptozotocin-induced diabetic mice. MAP oral administration significantly decreased the blood levels of glucose, TC, TG, LDL-C, and increased the blood levels of HDL-C and insulin in diabetic mice, concurrent with increases in body weights and pancreatic insulin contents. Moreover, MAP reversed the increased mRNA expressions of PEPCK and the reduced glycogen contents in the liver of diabetic mice. Concurrently, MAP exhibited potent anti-inflammatory and anti-oxidative activities, as evidenced by the decreased blood levels of TNF-α, IL-6, monocyte chemoattractant protein-1, MDA, and also the elevated SOD and GPx activities in the serum of diabetic mice. Furthermore, MAP also significantly improved the blood markers of the impaired liver function and renal function in diabetic mice. Altogether, these results suggest that MAP may be a potential therapeutic option for type 1 diabetes. © 2014 Elsevier Ltd.","Diabetes; Dyslipidemia; Inflammation; Insulin; Misgurnus anguillicaudatus polysaccharide; Oxidative stress","Agius, L., New hepatic targets for glycaemic control in diabetes (2007) Best Practice & Research Clinical Endocrinology & Metabolism, 21, pp. 587-605; Andreozzi, F., Laratta, E., Cardellini, M., Marini, M.A., Lauro, R., Hribal, M.L., Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian-Caucasian nondiabetic subjects (2006) Diabetes, 55, pp. 2021-2024; Brownlee, M., The pathogenesis of diabetic complications: A unifying mechanism (2005) Diabetes, 54, pp. 1615-1625; Castelli, W.P., Garrison, R.J., Wilson, P.W., Abbott, R.D., Kalousdian, S., Kannel, W.B., Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study (1986) JAMA, 256, pp. 2835-2838; Chen, X., Tang, J., Xie, W., Wang, J., Jin, J., Ren, J., Protective effect of the polysaccharide from Ophiopogon japonicus on streptozotocin-induced diabetic rats (2013) Carbohydrate Polymers, 94, pp. 378-385; Fu, J., Yuan, J., Tu, Y.Y., Fu, J., Zhang, N., Gao, B., A polysaccharide from Acanthopanax senticosus improves the antioxidant status in alloxan-induced diabetic mice (2012) Carbohydrate Polymers, 88, pp. 517-521; Goto-Nance, R., Watanabe, Y., Characterization of lectins from the skin mucus of the loach, Misgurnus anguillicaudatus (1995) Fish Sciences, 61, pp. 137-140; Guha, M., Bai, W., Nadler, J.L., Natarajan, R., Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways (2000) Journal of Biological Chemistry, 275, pp. 17728-17739; Hsu, F.L., Huang, C.F., Chen, Y.W., Yen, Y.P., Wu, C.T., Uang, B.J., Antidiabetic effects of pterosin A, a small-molecular-weight natural product, on diabetic mouse models (2013) Diabetes, 62, pp. 628-638; Huerta, M.G., Nadler, J.L., Oxidative stress, inflammation and diabetic complications (2004) Diabetes Mellitus: A Fundamental and Clinical Text, pp. 1485-1501. , D. LeRoith, S.I. Taylor, J.M. Olefsky, Lippincott Williams & Wilkins Philadelphia; Hurtley, S., Service, R., Szuromi, P., Cinderella's coach is ready (2001) Science, 291, pp. 2337-2343; Jain, S.K., Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells (1989) Journal of Biological Chemistry, 264, pp. 21340-21345; Jain, S.K., Kannan, K., Lim, G., Ketosis (acetoacetate) can generate oxygen radicals and cause increased lipid peroxidation and growth inhibition in human endothelial cells (1998) Free Radical Biology and Medicine, 25, pp. 1083-1088; Jain, S.K., Kannan, K., Lim, G., McVie, R., Bocchini, J.A., Hyperketonemia increases TNF-α secretion in cultured U937 monocytes and type-1 diabetic patients (2002) Diabetes, 51, pp. 2287-2293; Jain, S.K., McVie, R., Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients (1999) Diabetes, 48, pp. 1850-1855; Jain, S.K., McVie, R., Jackson, R., Levine, S.N., Lim, G., Effect of hyperketonemia on lipid peroxidation levels of plasma in diabetic patients (1999) Diabetes Care, 22, pp. 1171-1175; Jain, S.K., Rains, J.L., Croad, J.L., Effect of chromium nicinate and chromium picolinate supplementation on lipid peroxidation, TNF-α, IL-6 CRP, glycated hemoglobin, and cholesterol levels in blood of streptozotocin-treated diabetic rats (2007) Free Radical Biology and Medicine, 43, pp. 1124-1131; Jain, S.K., Rains, J., Croad, J., Larson, B., Jones, K., Curcumin supplementation lowers TNF-α, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-α IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats (2009) Antioxidants & Redox Signaling, 11, pp. 241-249; Jay, D., Hitomi, H., Griendling, K.K., Oxidative stress and diabetic cardiovascular complications (2006) Free Radical Biology and Medicine, 40, pp. 183-192; Kern, P.A., Ranganathan, S., Li, C., Wood, L., Ranganathan, G., Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance (2001) American Journal of Physiology: Endocrinology and Metabolism, 280, pp. E745-E751; Kimura, M., Hama, Y., Sumi, T., Asakawa, M., Rao, B.N., Horne, A.P., Characterization of a deaminated neuraminic acid-containing glycoprotein from the skin mucus of the loach, Misgurnus anguillicaudatus (1994) Journal of Biological Chemistry, 269, pp. 32138-32143; King, G.L., Loeken, M.R., Hyperglycemia-induced oxidative stress in diabetic complications (2004) Histochemistry and Cell Biology, 122, pp. 333-338; Kinosian, B., Glick, H., Garland, G., Cholesterol and coronary heart disease: Predicting risks by levels and ratios (1994) Annals of Internal Medicine, 121, pp. 641-647; Liu, S.H., Chang, Y.H., Chiang, M.T., Chitosan reduces gluconeogenesis and increases glucose uptake in skeletal muscle in streptozotocin-induced diabetic rats (2010) Journal of Agricultural and Food Chemistry, 58, pp. 5795-5800; Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method (2001) Methods, 25, pp. 402-408; Newsholme, E.A., Dimitriadis, G., Integration of biochemical and physiologic effects of insulin on glucose metabolism (2001) Experimental and Clinical Endocrinology & Diabetes, 109, pp. S122-S134; Noh, J.R., Hwang, J.H., Kim, Y.H., Kim, K.S., Gang, G.T., Kim, S.W., The orphan nuclear receptor small heterodimer partner negatively regulates pancreatic beta cell survival and hyperglycemia in multiple low-dose streptozotocin-induced type 1 diabetic mice (2013) International Journal of Biochemistry & Cell Biology, 45, pp. 1538-1545; Okamoto, T., Kanemoto, N., Ban, T., Sudo, T., Nagano, K., Niki, I., Establishment and characterization of a novel method for evaluating gluconeogenesis using hepatic cell lines, H4IIE and HepG2 (2009) Archives of Biochemistry and Biophysics, 491, pp. 46-52; Okutumi, T., Nakajima, Y., Sakakibara, F., Kawauchi, H., Yamazaki, M., Induction of a cytotoxin from murine bone narrow by an animal lectin (1987) Cancer Research, 47, pp. 47-50; Park, C.B., Lee, J.H., Park, I.Y., Kim, M.S., Kim, S.C., A novel antimicrobial peptide from the loach Misgurnus angullicaudatus (1997) FEBS Letters, 411, pp. 173-178; Placer, Z.A., Cushman, L.L., Johnson, B.C., Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems (1966) Analytical Biochemistry, 16, pp. 359-364; Qin, C., Ding, Y., Huang, K., Xu, H., Protective effect of Misgurnus anguillicaudatus polysaccharide on immunological liver injury in mice (2008) International Immunopharmacology, 8, pp. 607-612; Qin, C.G., Huang, K.X., Xu, H.B., Effects of Misgurnus anguillicaudatus polysaccharides on glycemia and lipidemia in experimental diabetic mice (2002) Chinese Journal of Pharmacology and Toxicology, 16, pp. 124-127; Qin, C.G., Huang, K.X., Xu, H.B., Investigation on immunomodulating activities of polysaccharide from loach mucus (2002) Chinese Pharmaceutical Journal, 37, pp. 588-591; Qin, C., Huang, K., Xu, H., Isolation and characterization of a novel polysaccharide from the mucus of the loach, Misgurnus anguillicaudatus (2002) Carbohydrate Polymers, 49, pp. 367-371; Qin, C., Huang, K., Xu, H., Protective effect of polysaccharide from the loach on the in vitro and in vivo peroxidative damage of hepatocyte (2002) Journal of Nutritional Biochemistry, 13, pp. 592-597; Qin, C.G., Zhou, J., Zhao, W., Huang, K.X., Xu, H.B., Effects of the loach polysaccharide on removal of reactive oxygen species and protection of DNA chains (2001) Acta Biochimica et Biophysica Sinica, 33, pp. 215-218; Rader, D.J., Inflammatory markers of coronary risk (2000) New England Journal of Medicine, 343, pp. 1179-1182; Shin, H., Park, Y.H., Kim, S.U., Moon, H.B., Park, D.S., Han, Y.H., Hepatitis B virus X protein regulates hepatic glucose homeostasis via activation of inducible nitric oxide synthase (2011) Journal of Biological Chemistry, 286, pp. 29872-29881; Wellen, K.E., Hotamisligil, G.S., Inflammation, stress, and oxidative stress (2005) Journal of Clinical Investigations, 115, pp. 1111-1119; Whitear, M., Biology of the integument 2 (1984) Vertebrates, pp. 8-38. , J. Bereiter-Hahn, A.G. Matoltsy, K.S. Richards, Springer-Verlag Berlin; Wilson, P.W.F., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B., Prediction of coronary heart disease using risk factor categories (1998) Circulation, 97, pp. 1837-1847; Zhang, C.X., Huang, K.X., Apoptosis induction of a novel polysaccharide from the mucus of the loach, Misgurnus anguillicaudatus on HL-60 cells (2005) Journal of Ethnopharmacology, 99, pp. 385-390; Zhang, C., Huang, K., Characteristic immunostimulation by MAP, a polysaccharide isolated from the mucus of the loach, Misgurnus anguillicaudatus (2005) Carbohydrate Polymers, 59, pp. 75-82; Zhang, C.X., Huang, K.X., Mechanism of apoptosis induced by a polysaccharide, from the loach Misgurnus anguillicaudatus (MAP) in human hepatocellular carcinoma cells (2006) Toxicology and Applied Pharmacology, 210, pp. 236-245; Zhang, W., Zheng, L., Zhang, Z., Hai, C.X., Protective effect of a water-soluble polysaccharide from Salvia miltiorrhiza Bunge on insulin resistance in rats (2012) Carbohydrate Polymers, 89, pp. 890-898; Zhou, J., He, X., Huang, K., Bidirectional regulation of insulin receptor autophosphorylation and kinase activity by peroxynitrite (2009) Archives of Biochemistry and Biophysics, 488, pp. 1-8; Zhou, J., Huang, K., Lei, X.G., Selenium and diabetes - Evidence from animal studies (2013) Free Radical Biology and Medicine, 65, pp. 1548-1556; Zhu, J., Liu, W., Yu, J., Zou, S., Wang, J., Yao, W., Characterization and hypoglycemic effect of a polysaccharide extracted from the fruit of Lycium barbarum L (2013) Carbohydrate Polymers, 98, pp. 8-16",Article,Scopus,2-s2.0-84920855206
"Zhang Y., Zhan R.-X., Chen J.-Q., Gao Y., Chen L., Kong Y., Zhong X.-J., Liu M.-Q., Chu J.-J., Yan G.-Q., Li T., He M., Huang Q.-R.","Pharmacological activation of PPAR gamma ameliorates vascular endothelial insulin resistance via a non-canonical PPAR gamma-dependent nuclear factor-kappa B trans-repression pathway",2015,"European Journal of Pharmacology","754",,,"41","51",,,10.1016/j.ejphar.2015.02.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924063164&partnerID=40&md5=2a8b79ac49b5519d5c32480a6c7ed6b7","Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China; Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; 461 Ba-Yi StreetNanchang, China","Zhang, Y., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Zhan, R.-X., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Chen, J.-Q., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Gao, Y., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Chen, L., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Kong, Y., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Zhong, X.-J., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Liu, M.-Q., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Chu, J.-J., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Yan, G.-Q., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Li, T., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; He, M., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China; Huang, Q.-R., Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang UniversityNanchang, China, Department of Pharmacology, Pharmaceutical Science College, Nanchang UniversityNanchang, China, 461 Ba-Yi StreetNanchang, China","Vascular endothelial insulin resistance (IR) is a critically initial factor in cardiocerebrovascular events resulted from diabetes and is becoming a worldwide public health issue. Thiazolidinediones (TZDs) are clinical insulin-sensitizers acting through a canonical peroxisome proliferator-activated receptor gamma (PPARγ)-dependent insulin trans-activation pathway. However, it remains elusive whether there are other mechanisms. In current study, we investigated whether TZDs improve endothelial IR induced by high glucose concentration or hyperglycemia via a non-canonical PPARγ-dependent nuclear factor-kappa B (NF-κB) trans-repression pathway. Our results showed that pre-treatment with TZDs dramatically decrease the susceptibility of endothelial cell to IR, while post-treatment notably improve the endothelial IR both in vitro and in vivo. Moreover, TZDs substantially increase the levels of endothelial nitric oxide synthase (eNOS) and inhibitory κB alpha (IκBα), whereas decrease those of the phosphorylated inhibitory κB kinase alpha/beta (phosphor-IKKα/β) and the cytokines including tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cellular adhesion molecule-1 (sVCAM-1), suggesting that TZDs act indeed through a PPARγ-dependent NF-κB trans-repression pathway. These findings highlighted a non-canonical mechanism for TZDs to ameliorate endothelial IR which might provide a potential strategy to prevent and treat the diabetic vascular complications clinically. © 2015 Elsevier B.V. All rights reserved.","Diabetes; Endothelium; Inflammation; Insulin resistance; Peroxisome proliferator-activated receptor gamma; Thiazolidinedione","Amato, A.A., Rocha, A., Neves, F., Idealized PPARγ-based therapies: Lessons from bench and bedside (2012) PPAR Res., 2012, p. 978687; Bardelli, C., Amoruso, A., Federici, C.D., Fresu, L., Balbo, P., Neri, T., Celi, A., Brunelleschi, S., Autocrine activation of human monocyte/macrophages by monocyte-derived microparticles and modulation by PPARγ ligands (2012) Br. J. Pharmacol., 165 (3), pp. 716-728; Burgermeister, E., Seger, R., PPARγ and MEK interactions in cancer (2008) PPAR Res., 2008, p. 309469; Calkin, A.C., Thomas, M.C., PPAR agonists and cardiovascular disease in diabetes (2008) PPAR Res., 2008, p. 245410; Chen, Z., Vigueira, P.A., Chambers, K.T., Hall, A.M., Mitra, M.S., Qi, N., McDonald, W.G., Finck, B.N., Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione (2012) J. Biol. Chem., 287 (28), pp. 23537-23548; Dahabreh, D.F., Medh, J.D., Activation of peroxisome proliferator activated receptor-gamma results in an atheroprotective apolipoprotein profile in HepG2 cells (2012) Adv. Biol. Chem., 2 (3), pp. 218-225; Defronzo, R.A., Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009 (2010) Diabetologia, 53 (7), pp. 1270-1287; Fontana, L., Vinciguerra, M., Longo, V.D., Growth factors, nutrient signaling, and cardiovascular aging (2012) Circ. Res., 110 (8), pp. 1139-1150; Ford, E.S., Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence (2005) Diabetes Care, 28, pp. 1769-1778; Gallagher, E.J., Leroith, D., Diabetes, antihyperglycemic medications and cancer risk: Smoke or fire? (2013) Curr. Opin. Endocrinol. Diabetes Obes., 20 (5), pp. 485-494; Gupta, D., Peshavaria, M., Monga, N., Jetton, T.L., Leahy, J.L., Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in β-cells by peroxisome proliferator-activated receptor (PPAR)-γ signaling: Possible mechanism for the gip resistance in type 2 diabetes (2010) Diabetes, 59 (6), pp. 1445-1450; He, M., Tu, C., Huang, Q., Li, P., Li, X., Peng, W., Approach on exerting Lee's index to evaluate the obese degree of mature rats (1997) Chin. J. Clin. Pharmacol. Ther., 2 (3), pp. 177-179. , (in Chinese); Hitomi, H., Kaifu, K., Fujita, Y., Sofue, T., Nakano, D., Moriwaki, K., Hara, T., Nishiyama, A., Angiotensin II shifts insulin signaling into vascular remodeling from glucose metabolism in vascular smooth muscle cells (2011) Am. J. Hypertens., 24 (10), pp. 1149-1155; Holness, M.J., Samsuddin, S., Sugden, M.C., The role of PPARs in modulating cardiac metabolism in diabetes (2009) Pharmacol. Res., 60 (3), pp. 185-194; Hou, X., Lu, J., Weng, J., Ji, L., Shan, Z., Liu, J., Ji, Q., Jia, W., Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults: A national diabetes and metabolic disorders survey (2013) PLoS One, 8 (3), p. e57319. , China National Diabetes and Metabolic Disorders Study Group; Huang, Q.R., Li, Q., Chen, Y.H., Li, L., Liu, L.L., Lei, S.H., Chen, H.P., He, M., Involvement of anion exchanger-2 in apoptosis of endothelial cells induced by high glucose through an mPTP-ROS-Caspase-3 dependent pathway (2010) Apoptosis, 15 (6), pp. 693-704; Hulsmans, M., Geeraert, B., Arnould, T., Tsatsanis, C., Holvoet, P., PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin- resistant mice depends on adiponectin-induced Irak3 expression (2013) PLoS One, 8 (4), p. e62253; Ingelsson, E., Pencina, M.J., Tofler, G.H., Benjamin, E.J., Lanier, K.J., Jacques, P.F., Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: The Framingham offspring study (2007) Circulation, 16, pp. 984-992; Jeong, K., Monica, M., Kwang, K., Michael, J.Q., Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms (2006) Circulation, 113, pp. 1888-1904; Jocken, J.W., Goossens, G.H., Boon, H., Mason, R.R., Essers, Y., Havekes, B., Watt, M.J., Blaak, E.E., Insulin-mediated suppression of lipolysis in adipose tissue and skeletal muscle of obese type 2 diabetic men and men with normal glucose tolerance (2013) Diabetologia, 56 (10), pp. 2255-2265; Karak, M., Bal, N.C., Bal, C., Sharon, A., Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug (2013) Curr. Diabetes Rev., 9 (4), pp. 275-285; Kearney, M.T., Duncan, E.R., Kahn, M., Wheatcroft, S.B., Insulin resistance and endothelial cell dysfunction: Studies in mammalian models (2008) Exp. Physiol., 93 (1), pp. 158-163; Kozakova, M., Natali, A., Dekker, J., Beck-Nielsen, H., Laakso, M., Nilsson, P., Balkau, B., Ferrannini, E., Insulin sensitivity and carotid intima-media thickness: Relationship between insulin sensitivity and cardiovascular risk study (2013) Arterioscler. Thromb. Vasc. Biol., 33 (6), pp. 1409-1417. , RISC Investigators; Liu, L.L., Yan, L., Chen, Y.H., Zeng, G.H., Zhou, Y., Chen, H.P., Peng, W.J., Huang, Q.R., A role for diallyl trisulfide in mitochondrial antioxidative stress contributes to its protective effects against vascular endothelial impairment (2014) Eur. J. Pharmacol., 725, pp. 23-31; Maniati, E., Bossard, M., Cook, N., Candido, J.B., Emami-Shahri, N., Nedospasov, S.A., Balkwill, F.R., Hagemann, T., Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits PPARγ expression and promotes pancreatic cancer progression in mice (2011) J. Clin. Investig., 121 (12), pp. 4685-4699; Mi, D., Zhang, L., Wang, C., Liu, L., Pu, Y., Zhao, X., Wang, Y., Wang, Y., Impact of metabolic syndrome on the prognosis of ischemic stroke secondary to symptomatic intracranial atherosclerosis in Chinese patients (2012) PLoS One, 7 (12), p. e51421; Montagnani, M., Ravichandran, L.V., Chen, H., Esposito, D.L., Quon, M.J., Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells (2002) Mol. Endocrinol., 6, pp. 931-942; Nguyen, M.T., Chen, A., Lu, W.J., Fan, W., Li, P.P., Oh, D.Y., Patsouris, D., Regulation of chemokine and chemokine receptor expression by PPARγ in adipocytes and macrophages (2012) PLoS One, 7 (4), p. e34976; Pershadsingh, H.A., Moorel, D.M., PPARγ agonists: Potential as therapeutics for neovascular retinopathies (2008) PPAR Res., 2008, p. 164273; Phielix, E., Szendroedi, J., Roden, M., The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact (2011) Trends Pharmacol. Sci., 32 (10), pp. 607-616; Pop-Busui, R., Lombardero, M., Lavis, V., Forker, A., Green, J., Korytkowski, M., Sobel, B.E., Jones, T.L., Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study) (2009) Am. J. Cardiol., 104 (1), pp. 52-58; Potenza, M.A., Marasciulo, F.L., Chieppa, D.M., Brigiani, G.S., Formoso, G., Quon, M.J., Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production (2005) Am. J. Physiol., 289, pp. H813-H822; Rao, J.R., Keating, D.J., Chen, C., Parkington, H.C., Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARγ-dependent and PPARγ-independent mechanisms (2012) Diabetes Obes. Metab., 14 (11), pp. 983-989; Reaven, G.M., Role of insulin resistance in human disease (syndrome X): An expanded definition (1993) Annu. Rev. Med., 44, pp. 121-131; Schmieder, R.E., Hilgers, K.F., Schlaich, M.P., Schmidt, B.M., Renin-angiotensin system and cardiovascular risk (2007) Lancet, 369, pp. 1208-1219; Schöndorf, T., Musholt, P.B., Hohberg, C., Forst, T., Lehmann, U., Fuchs, W., Löbig, M., Pfützner, A., The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: Results from the PIOfix study (2011) J. Diabetes Sci. Technol., 5 (2), pp. 426-432; Seldin, M.M., Peterson, J.M., Byerly, M.S., Wei, Z., Wong, G.W., Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis (2012) J. Biol. Chem., 287 (15), pp. 11968-11980; Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C.L., Ramarao, P., Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening (2005) Pharmacol. Res., 52, pp. 313-320; Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Arnold, S.E., Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline (2012) J. Clin. Investig., 122 (4), pp. 1316-1338; Tzoulaki, I., Molokhia, M., Va, C., Little, M.P., Millett, C.J., Ng, A., Hughes, R.I., Elliott, P., Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database (2009) BMJ, 339, p. b4731; Wang, Y., Cheng, K., Lam, K.S., Wu, D., Wang, Y., Huang, Y., Vanhoutte, P.M., Xu, A., APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice (2011) Diabetes, 60 (11), pp. 3044-3054; Wong, C., Marwick, T.H., Obesity cardiomyopathy: Pathogenesis and pathophysiology (2007) Nat. Clin. Pract. Cardiovasc. Med., 4, pp. 436-443; Wyatt, J., Nandish, S., Oliveros, R., Zion, A.S., Lujan, M.S., Chilton, R., Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients (2010) Vasc. Health Risk Manag., 6, pp. 1-8; Yin, Q.Q., Pei, J.J., Xu, S., Luo, D.Z., Dong, S.Q., Sun, M.H., You, L., Liu, X.P., Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats (2013) PLoS One, 8 (3), p. e59313; Zhang, F., Kong, D., Lu, Y., Zheng, S., Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: From bench to bedside (2013) Cell. Mol. Life Sci., 70 (2), pp. 259-276",Article,Scopus,2-s2.0-84924063164
